%PDF-1.5
1 0 obj
<</Type /Pages
/Kids [3 0 R 5 0 R 7 0 R 9 0 R 11 0 R 13 0 R 15 0 R 17 0 R 19 0 R 21 0 R 23 0 R 25 0 R 27 0 R 29 0 R 31 0 R 33 0 R 35 0 R 37 0 R 39 0 R 41 0 R 43 0 R 45 0 R 47 0 R 49 0 R 51 0 R 53 0 R 55 0 R 57 0 R 59 0 R 61 0 R 63 0 R 65 0 R 67 0 R 69 0 R 71 0 R 73 0 R 75 0 R 77 0 R 79 0 R 81 0 R 83 0 R 85 0 R 87 0 R 89 0 R 91 0 R 93 0 R 95 0 R 97 0 R 99 0 R 101 0 R 103 0 R 105 0 R 107 0 R 109 0 R 111 0 R 113 0 R 115 0 R 117 0 R 119 0 R 121 0 R 123 0 R 125 0 R 127 0 R 129 0 R 131 0 R 133 0 R 135 0 R 137 0 R 139 0 R 141 0 R 143 0 R 145 0 R 147 0 R 149 0 R 151 0 R 153 0 R 155 0 R 157 0 R 159 0 R 161 0 R 163 0 R 165 0 R 167 0 R 169 0 R 171 0 R 173 0 R 175 0 R 177 0 R 179 0 R 181 0 R 183 0 R 185 0 R 187 0 R 189 0 R 191 0 R 193 0 R 195 0 R 197 0 R 199 0 R 201 0 R 203 0 R 205 0 R 207 0 R 209 0 R 211 0 R 213 0 R 215 0 R 217 0 R 219 0 R 221 0 R 223 0 R 225 0 R 227 0 R 229 0 R 231 0 R 233 0 R 235 0 R 237 0 R 239 0 R 241 0 R 243 0 R 245 0 R 247 0 R 249 0 R 251 0 R 253 0 R 255 0 R 257 0 R 259 0 R 261 0 R 263 0 R 265 0 R 267 0 R 269 0 R 271 0 R 273 0 R 275 0 R 277 0 R 279 0 R 281 0 R 283 0 R 285 0 R 287 0 R 289 0 R 291 0 R 293 0 R 295 0 R 297 0 R 299 0 R 301 0 R 303 0 R 305 0 R 307 0 R 309 0 R 311 0 R 313 0 R 315 0 R 317 0 R 319 0 R 321 0 R 323 0 R 325 0 R 327 0 R 329 0 R 331 0 R 333 0 R 335 0 R 337 0 R 339 0 R 341 0 R 343 0 R 345 0 R 347 0 R 349 0 R 351 0 R 353 0 R 355 0 R 357 0 R 359 0 R 361 0 R 363 0 R 365 0 R 367 0 R 369 0 R 371 0 R 373 0 R 375 0 R 377 0 R 379 0 R 381 0 R 383 0 R 385 0 R 387 0 R 389 0 R 391 0 R 393 0 R 395 0 R 397 0 R 399 0 R 401 0 R 403 0 R 405 0 R 407 0 R 409 0 R 411 0 R 413 0 R 415 0 R 417 0 R 419 0 R 421 0 R 423 0 R 425 0 R 427 0 R 429 0 R 431 0 R 433 0 R 435 0 R 437 0 R 439 0 R 441 0 R 443 0 R 445 0 R 447 0 R 449 0 R 451 0 R 453 0 R 455 0 R 457 0 R 459 0 R]
/Count 229>>
endobj
3 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 4 0 R>>
endobj
4 0 obj
<</Length 15274>>
stream
BT /F1 13.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
q 0 0 0 rg BT 255.10 747.20 Td (UNITED ST) Tj ET Q
q 0 0 0 rg BT 323.85 747.20 Td (A) Tj ET Q
q 0 0 0 rg BT 332.27 747.20 Td (TES) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 166.40 731.60 Td (SECURITIES ) Tj ET Q
q 0 0 0 rg BT 247.69 731.60 Td (AND EXCHANGE COMMISSION) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 264.75 722.00 Td (W) Tj ET Q
q 0 0 0 rg BT 272.31 722.00 Td (ashington, D.C. 20549) Tj ET Q
BT /F1 3.00 Tf ET
q 0 0 0 rg BT 237.00 718.40 Td (____________________________________________________________________________________________) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 270.75 702.80 Td (FORM ) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 313.71 702.80 Td (10-K) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 341.15 702.80 Td ( ) Tj ET Q
BT /F1 3.00 Tf ET
q 0 0 0 rg BT 237.00 699.20 Td (____________________________________________________________________________________________) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 285.40 686.60 Td (\(Mark One\)) Tj ET Q
BT /F2 9.00 Tf ET
/GS0 gs
q 6.60 0 0 9.44 36.00 673.91 cm
/I1 Do Q
/GS0 gs
q 11.40 0 0 9.44 42.60 673.91 cm
/I2 Do Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 54.00 675.80 Td (ANNUAL) Tj ET Q
q 0 0 0 rg BT 87.78 675.80 Td ( REPOR) Tj ET Q
q 0 0 0 rg BT 117.50 675.80 Td (T) Tj ET Q
q 0 0 0 rg BT 122.69 675.80 Td ( PURSUANT) Tj ET Q
q 0 0 0 rg BT 168.11 675.80 Td ( ) Tj ET Q
q 0 0 0 rg BT 169.96 675.80 Td (T) Tj ET Q
q 0 0 0 rg BT 175.15 675.80 Td (O SECTION 13 OR 15\(d\) OF) Tj ET Q
q 0 0 0 rg BT 275.98 675.80 Td ( ) Tj ET Q
q 0 0 0 rg BT 277.83 675.80 Td (THE SECURITIES EXCHANGE ) Tj ET Q
q 0 0 0 rg BT 394.98 675.80 Td (ACT) Tj ET Q
q 0 0 0 rg BT 411.72 675.80 Td ( OF) Tj ET Q
q 0 0 0 rg BT 424.54 675.80 Td ( 1934) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 239.65 666.20 Td (For) Tj ET Q
q 0 0 0 rg BT 251.94 666.20 Td ( the fiscal year) Tj ET Q
q 0 0 0 rg BT 301.34 666.20 Td ( ended ) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 325.79 666.20 Td (December) Tj ET Q
q 0 0 0 rg BT 360.29 666.20 Td (�31, 2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 390.29 666.20 Td ( ) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 301.75 653.60 Td (or) Tj ET Q
BT /F2 11.00 Tf ET
/GS0 gs
q 8.07 0 0 11.32 36.00 635.09 cm
/I3 Do Q
/GS0 gs
q 9.93 0 0 11.32 44.07 635.09 cm
/I4 Do Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 54.00 637.40 Td (TRANSITION REPOR) Tj ET Q
q 0 0 0 rg BT 134.40 637.40 Td (T) Tj ET Q
q 0 0 0 rg BT 139.59 637.40 Td ( PURSUANT) Tj ET Q
q 0 0 0 rg BT 185.00 637.40 Td ( ) Tj ET Q
q 0 0 0 rg BT 186.86 637.40 Td (T) Tj ET Q
q 0 0 0 rg BT 192.05 637.40 Td (O SECTION 13 OR 15\(d\) OF) Tj ET Q
q 0 0 0 rg BT 292.88 637.40 Td ( ) Tj ET Q
q 0 0 0 rg BT 294.73 637.40 Td (THE SECURITIES EXCHANGE ) Tj ET Q
q 0 0 0 rg BT 411.88 637.40 Td (ACT) Tj ET Q
q 0 0 0 rg BT 428.62 637.40 Td ( OF) Tj ET Q
q 0 0 0 rg BT 441.43 637.40 Td ( 1934) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 233.00 627.80 Td (For) Tj ET Q
q 0 0 0 rg BT 245.29 627.80 Td ( the transition period fr) Tj ET Q
q 0 0 0 rg BT 325.59 627.80 Td (om ������������  ������������to) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 245.70 618.20 Td (Commission file number) Tj ET Q
q 0 0 0 rg BT 329.56 618.20 Td ( ) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 331.56 618.20 Td (001-36326) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 366.22 618.20 Td ( ) Tj ET Q
BT /F1 3.00 Tf ET
q 0 0 0 rg BT 237.00 611.60 Td (____________________________________________________________________________________________) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 242.75 596.00 Td (Endo International plc) Tj ET Q
BT /F1 13.00 Tf ET
q 0 0 0 rg BT 369.16 596.00 Td ( ) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 217.60 586.40 Td (\(Exact name of r) Tj ET Q
q 0 0 0 rg BT 274.55 586.40 Td (egistrant as specified in its charter\)) Tj ET Q
BT /F1 3.00 Tf ET
q 0 0 0 rg BT 237.00 579.80 Td (____________________________________________________________________________________________) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 175.40 561.38 Td (Ir) Tj ET Q
q 0 0 0 rg BT 181.99 561.38 Td (eland) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 438.65 561.38 Td (68-0683755) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 95.05 548.25 Td (State or other jurisdiction of incorporation or or) Tj ET Q
q 0 0 0 rg BT 247.61 548.25 Td (ganization) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 399.90 548.25 Td (\(I.R.S. Employer Identification No.\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 105.45 531.38 Td (First Floor) Tj ET Q
q 0 0 0 rg BT 141.81 531.38 Td (, Minerva House, Simmonscourt Road) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 110.30 518.38 Td (Ballsbridge, Dublin 4,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 193.00 518.38 Td (Ir) Tj ET Q
q 0 0 0 rg BT 199.52 518.38 Td (eland) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 432.55 518.38 Td (Not ) Tj ET Q
q 0 0 0 rg BT 446.55 518.38 Td (Applicable) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 124.50 505.25 Td (\(Address of principal executive of) Tj ET Q
q 0 0 0 rg BT 233.72 505.25 Td (fices\)) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 440.30 505.25 Td (\(Zip Code\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 268.75 487.00 Td (01) Tj ET Q
q 0 0 0 rg BT 277.25 487.00 Td (1-) Tj ET Q
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 284.75 487.00 Td (353) Tj ET Q
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 298.25 487.00 Td (-) Tj ET Q
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 301.25 487.00 Td (1-268-2000) Tj ET Q
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 343.24 487.00 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 223.95 477.40 Td (Registrant�) Tj ET Q
q 0 0 0 rg BT 259.06 477.40 Td (s telephone number) Tj ET Q
q 0 0 0 rg BT 321.38 477.40 Td (, including area code) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 208.35 464.80 Td (Securities r) Tj ET Q
q 0 0 0 rg BT 247.08 464.80 Td (egister) Tj ET Q
q 0 0 0 rg BT 269.59 464.80 Td (ed pursuant to Section 12\(b\) of the ) Tj ET Q
q 0 0 0 rg BT 388.93 464.80 Td (Act:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
109.95 444.280078125 m
170.01640625 444.280078125 l
s
q 0 0 0 rg BT 109.95 445.53 Td (T) Tj ET Q
q 0 0 0 rg BT 115.21 445.53 Td (itle of each class) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
273.15 444.280078125 m
336.790625 444.280078125 l
s
q 0 0 0 rg BT 273.15 445.53 Td (T) Tj ET Q
q 0 0 0 rg BT 278.19 445.53 Td (rading Symbol\(s\)) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
395.7 444.280078125 m
544.2703125 444.280078125 l
s
q 0 0 0 rg BT 395.70 445.53 Td (Name of each exchange on which r) Tj ET Q
q 0 0 0 rg BT 513.76 445.53 Td (egister) Tj ET Q
q 0 0 0 rg BT 536.27 445.53 Td (ed) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 60.20 432.55 Td (Ordinary shares, nominal value $0.0001 per share) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 294.70 432.55 Td (ENDP) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 415.55 432.55 Td (The Nasdaq Global Select Market) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
208.25 408.280078125 m
401.69921875 408.280078125 l
s
q 0 0 0 rg BT 208.25 409.53 Td (Securities r) Tj ET Q
q 0 0 0 rg BT 246.98 409.53 Td (egister) Tj ET Q
q 0 0 0 rg BT 269.49 409.53 Td (ed pursuant to section 12\(g\) of the ) Tj ET Q
q 0 0 0 rg BT 387.04 409.53 Td (Act:) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 296.30 396.55 Td (None) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 374.25 Td (Indicate by check mark if the registrant is a well-known seasoned issuer) Tj ET Q
q 0 0 0 rg BT 268.21 374.25 Td (, as defined in Rule 405 of the Securities ) Tj ET Q
q 0 0 0 rg BT 399.79 374.25 Td (Act.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 506.35 374.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 511.73 374.25 Td (es) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 530.10 372.30 cm
/I5 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 544.20 374.25 Td (No) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 372.30 cm
/I6 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 357.25 Td (Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15\(d\) of the ) Tj ET Q
q 0 0 0 rg BT 407.01 357.25 Td (Act.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 506.35 357.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 511.73 357.25 Td (es) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 530.10 355.30 cm
/I7 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 544.20 357.25 Td (No) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 355.30 cm
/I8 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 340.25 Td (Indicate by check mark whether the registrant \(1\) has filed all reports required to be filed by Section 13 or 15\(d\) of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 485.62 340.25 Td (Act) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 332.25 Td (of 1934 during the preceding 12 months \(or for such shorter period that the registrant was required to file such reports\), and \(2\) has been subject) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 324.25 Td (to such filing requirements for the past 90 days.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 506.35 340.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 511.73 340.25 Td (es) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 530.10 338.30 cm
/I9 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 544.20 340.25 Td (No) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 338.30 cm
/I10 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 307.25 Td (Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 299.25 Td (405 of Regulation S-T) Tj ET Q
q 0 0 0 rg BT 109.63 299.25 Td ( \(�232.405 of this chapter\) during the preceding 12 months \(or for such shorter period that the registrant was required to) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 291.25 Td (submit such files\).) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 506.35 307.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 511.73 307.25 Td (es) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 530.10 305.30 cm
/I11 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 544.20 307.25 Td (No) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 305.30 cm
/I12 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 268.25 Td (Indicate by check mark whether the registrant is a lar) Tj ET Q
q 0 0 0 rg BT 207.78 268.25 Td (ge accelerated filer) Tj ET Q
q 0 0 0 rg BT 268.30 268.25 Td (, an accelerated filer) Tj ET Q
q 0 0 0 rg BT 332.82 268.25 Td (, a non-accelerated filer) Tj ET Q
q 0 0 0 rg BT 408.00 268.25 Td (, a smaller reporting company) Tj ET Q
q 0 0 0 rg BT 503.23 268.25 Td (, or an emer) Tj ET Q
q 0 0 0 rg BT 541.29 268.25 Td (ging) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 260.25 Td (growth company) Tj ET Q
q 0 0 0 rg BT 91.47 260.25 Td (. See the definitions of "lar) Tj ET Q
q 0 0 0 rg BT 177.23 260.25 Td (ge accelerated filer) Tj ET Q
q 0 0 0 rg BT 237.75 260.25 Td (," "accelerated filer) Tj ET Q
q 0 0 0 rg BT 299.25 260.25 Td (," "smaller reporting company) Tj ET Q
q 0 0 0 rg BT 395.46 260.25 Td (," and "emer) Tj ET Q
q 0 0 0 rg BT 435.39 260.25 Td (ging growth company" in Rule 12b-2 of) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 252.25 Td (the Exchange ) Tj ET Q
q 0 0 0 rg BT 82.87 252.25 Td (Act.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 239.25 Td (Lar) Tj ET Q
q 0 0 0 rg BT 49.03 239.25 Td (ge accelerated filer) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 163.00 237.30 cm
/I13 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 219.00 239.25 Td (Accelerated filer) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 384.10 237.30 cm
/I14 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 226.25 Td (Non-accelerated filer) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 163.00 224.30 cm
/I15 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 219.00 226.25 Td (Smaller reporting company) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 384.10 224.30 cm
/I16 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 400.00 226.25 Td (Emer) Tj ET Q
q 0 0 0 rg BT 417.18 226.25 Td (ging growth company) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 224.30 cm
/I17 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 203.25 Td (If an emer) Tj ET Q
q 0 0 0 rg BT 70.79 203.25 Td (ging growth company) Tj ET Q
q 0 0 0 rg BT 140.67 203.25 Td (, indicate by check mark if the registrant has elected not to use the extended transition period for complying) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 195.25 Td (with any new or revised financial accounting standards provided pursuant to Section 13\(a\) of the Exchange ) Tj ET Q
q 0 0 0 rg BT 383.01 195.25 Td (Act.) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 201.30 cm
/I18 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 178.25 Td (Indicate by check mark whether the registrant is a shell company \(as defined in Rule 12b-2 of the ) Tj ET Q
q 0 0 0 rg BT 351.23 178.25 Td (Act\).) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 506.35 178.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 511.73 178.25 Td (es) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 530.10 176.30 cm
/I19 Do Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 544.20 178.25 Td (No) Tj ET Q
/GS0 gs
q 5.87 0 0 7.50 566.10 176.30 cm
/I20 Do Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 155.25 Td (The aggregate market value of the voting common equity \(ordinary shares\) held by non-af) Tj ET Q
q 0 0 0 rg BT 326.94 155.25 Td (filiates as of June 28, 2019 \(the last business day of the registrant�) Tj ET Q
q 0 0 0 rg BT 537.93 155.25 Td (s most) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 147.25 Td (recently completed second fiscal quarter\) was $670,135,609 based on a closing sale price of $4.12 per share as reported on the Nasdaq Global Select Market on that) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 139.25 Td (date. Ordinary shares held by each of) Tj ET Q
q 0 0 0 rg BT 157.21 139.25 Td (ficer and director and each beneficial owner of 10% or more \(as calculated on June 28, 2019\) of the outstanding ordinary shares) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 131.25 Td (of the registrant have been excluded since such persons and beneficial owners may be deemed to be af) Tj ET Q
q 0 0 0 rg BT 365.58 131.25 Td (filiates. ) Tj ET Q
q 0 0 0 rg BT 391.20 131.25 Td (This determination of af) Tj ET Q
q 0 0 0 rg BT 468.59 131.25 Td (filiate status is not necessarily a) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 123.25 Td (conclusive determination for other purposes. ) Tj ET Q
q 0 0 0 rg BT 182.78 123.25 Td (The registrant has no non-voting ordinary shares authorized or outstanding.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 107.25 Td (The number of Ordinary shares, nominal value $0.0001 per share outstanding as of February 18, 2020 was 226,833,617.) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 89.53 Td (Documents Incorporated by Refer) Tj ET Q
q 0 0 0 rg BT 154.95 89.53 Td (ence) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 66.55 Td (Portions of the registrant�) Tj ET Q
q 0 0 0 rg BT 119.54 66.55 Td (s proxy statement pursuant to Regulation 14A) Tj ET Q
q 0 0 0 rg BT 266.19 66.55 Td ( relating to its 2020 ) Tj ET Q
q 0 0 0 rg BT 329.96 66.55 Td (Annual General Meeting, to be filed with the Securities and Exchange) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 58.55 Td (Commission subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 38.00 50.55 Td (Exchange Commission not later than 120 days after the conclusion of the registrant�) Tj ET Q
q 0 0 0 rg BT 306.82 50.55 Td (s fiscal year ended December 31, 2019.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
5 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [38 685.258203125 155.48046875 694.35] /Border [0 0 0] /H /I /Dest [7 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [270.8 655.2693359375 303.1388671875 664.2] /Border [0 0 0] /H /I /Dest [9 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 640.258203125 66.3251953125 649.35] /Border [0 0 0] /H /I /Dest [9 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [83 640.258203125 118.5615234375 649.35] /Border [0 0 0] /H /I /Dest [9 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [38 625.258203125 71.046875 634.35] /Border [0 0 0] /H /I /Dest [41 0 R /XYZ 0 496.07 null]>><</Type /Annot /Subtype /Link /Rect [83 625.258203125 133.2783203125 634.35] /Border [0 0 0] /H /I /Dest [41 0 R /XYZ 0 496.07 null]>><</Type /Annot /Subtype /Link /Rect [38 610.258203125 72.9951171875 619.35] /Border [0 0 0] /H /I /Dest [99 0 R /XYZ 0 256.67 null]>><</Type /Annot /Subtype /Link /Rect [83 610.258203125 196.69140625 619.35] /Border [0 0 0] /H /I /Dest [99 0 R /XYZ 0 256.67 null]>><</Type /Annot /Subtype /Link /Rect [38 595.258203125 66.3251953125 604.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [83 595.258203125 123.546875 604.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 580.258203125 66.3251953125 589.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 436.23 null]>><</Type /Annot /Subtype /Link /Rect [83 580.258203125 157.140625 589.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 436.23 null]>><</Type /Annot /Subtype /Link /Rect [38 565.258203125 66.3251953125 574.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 388.23 null]>><</Type /Annot /Subtype /Link /Rect [83 565.258203125 181.3154296875 574.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 388.23 null]>><</Type /Annot /Subtype /Link /Rect [268.85 535.2693359375 305.08046875 544.2] /Border [0 0 0] /H /I /Dest [103 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 520.258203125 66.3251953125 529.35] /Border [0 0 0] /H /I /Dest [103 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [83 520.258203125 531.7060546875 529.35] /Border [0 0 0] /H /I /Dest [103 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [38 505.258203125 66.3251953125 514.35] /Border [0 0 0] /H /I /Dest [107 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [83 505.258203125 177.9609375 514.35] /Border [0 0 0] /H /I /Dest [107 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 490.258203125 66.3251953125 499.35] /Border [0 0 0] /H /I /Dest [109 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [83 490.258203125 441.291015625 499.35] /Border [0 0 0] /H /I /Dest [109 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 475.258203125 73.546875 484.35] /Border [0 0 0] /H /I /Dest [143 0 R /XYZ 0 254.85 null]>><</Type /Annot /Subtype /Link /Rect [83 475.258203125 324.62109375 484.35] /Border [0 0 0] /H /I /Dest [143 0 R /XYZ 0 254.85 null]>><</Type /Annot /Subtype /Link /Rect [38 460.258203125 66.3251953125 469.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 496.06 null]>><</Type /Annot /Subtype /Link /Rect [83 460.258203125 267.951171875 469.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 496.06 null]>><</Type /Annot /Subtype /Link /Rect [38 445.258203125 66.3251953125 454.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 448.06 null]>><</Type /Annot /Subtype /Link /Rect [83 445.258203125 441.8134765625 454.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 448.06 null]>><</Type /Annot /Subtype /Link /Rect [38 430.258203125 73.546875 439.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 412.06 null]>><</Type /Annot /Subtype /Link /Rect [83 430.258203125 181.3154296875 439.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 412.06 null]>><</Type /Annot /Subtype /Link /Rect [38 415.258203125 72.9951171875 424.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 142.06 null]>><</Type /Annot /Subtype /Link /Rect [83 415.258203125 156.0322265625 424.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 142.06 null]>><</Type /Annot /Subtype /Link /Rect [266.9 385.2693359375 307.0220703125 394.2] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 370.258203125 71.3251953125 379.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [83 370.258203125 310.4951171875 379.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [38 355.258203125 70.9541015625 364.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 496.23 null]>><</Type /Annot /Subtype /Link /Rect [83 355.258203125 183.25390625 364.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 496.23 null]>><</Type /Annot /Subtype /Link /Rect [38 340.258203125 71.3251953125 349.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 460.23 null]>><</Type /Annot /Subtype /Link /Rect [83 340.258203125 488.15625 349.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 460.23 null]>><</Type /Annot /Subtype /Link /Rect [38 325.258203125 71.3251953125 334.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 226.03 null]>><</Type /Annot /Subtype /Link /Rect [83 325.258203125 385.6953125 334.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 226.03 null]>><</Type /Annot /Subtype /Link /Rect [38 310.258203125 71.3251953125 319.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 190.03 null]>><</Type /Annot /Subtype /Link /Rect [83 310.258203125 241.8525390625 319.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 190.03 null]>><</Type /Annot /Subtype /Link /Rect [267.3 280.2693359375 306.77021484375 289.2] /Border [0 0 0] /H /I /Dest [149 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 265.258203125 71.3251953125 274.35] /Border [0 0 0] /H /I /Dest [149 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [83 265.258203125 244.083984375 274.35] /Border [0 0 0] /H /I /Dest [149 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [38 250.25820312500002 71.3251953125 259.35] /Border [0 0 0] /H /I /Dest [155 0 R /XYZ 0 513.40 null]>><</Type /Annot /Subtype /Link /Rect [83 250.25820312500002 169.1083984375 259.35] /Border [0 0 0] /H /I /Dest [155 0 R /XYZ 0 513.40 null]>><</Type /Annot /Subtype /Link /Rect [38 220.25820312500002 76.3251953125 229.35000000000002] /Border [0 0 0] /H /I /Dest [157 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [569.2 685.708203125 571.9783203125 694.8] /Border [0 0 0] /H /I /Dest [7 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [567 640.258203125 572 649.35] /Border [0 0 0] /H /I /Dest [9 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [562 625.258203125 572 634.35] /Border [0 0 0] /H /I /Dest [41 0 R /XYZ 0 496.07 null]>><</Type /Annot /Subtype /Link /Rect [562 610.258203125 572 619.35] /Border [0 0 0] /H /I /Dest [99 0 R /XYZ 0 256.67 null]>><</Type /Annot /Subtype /Link /Rect [562 595.258203125 572 604.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [562 580.258203125 572 589.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 436.23 null]>><</Type /Annot /Subtype /Link /Rect [562 565.258203125 572 574.35] /Border [0 0 0] /H /I /Dest [101 0 R /XYZ 0 388.23 null]>><</Type /Annot /Subtype /Link /Rect [562 520.258203125 572 529.35] /Border [0 0 0] /H /I /Dest [103 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [562 505.258203125 572 514.35] /Border [0 0 0] /H /I /Dest [107 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [562 490.258203125 572 499.35] /Border [0 0 0] /H /I /Dest [109 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [562 475.258203125 572 484.35] /Border [0 0 0] /H /I /Dest [143 0 R /XYZ 0 254.85 null]>><</Type /Annot /Subtype /Link /Rect [562 460.258203125 572 469.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 496.06 null]>><</Type /Annot /Subtype /Link /Rect [562 445.258203125 572 454.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 448.06 null]>><</Type /Annot /Subtype /Link /Rect [562 430.258203125 572 439.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 412.06 null]>><</Type /Annot /Subtype /Link /Rect [562 415.258203125 572 424.35] /Border [0 0 0] /H /I /Dest [145 0 R /XYZ 0 142.06 null]>><</Type /Annot /Subtype /Link /Rect [562 370.258203125 572 379.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [562 355.258203125 572 364.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 496.23 null]>><</Type /Annot /Subtype /Link /Rect [562 340.258203125 572 349.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 460.23 null]>><</Type /Annot /Subtype /Link /Rect [562 325.258203125 572 334.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 226.03 null]>><</Type /Annot /Subtype /Link /Rect [562 310.258203125 572 319.35] /Border [0 0 0] /H /I /Dest [147 0 R /XYZ 0 190.03 null]>><</Type /Annot /Subtype /Link /Rect [562 265.258203125 572 274.35] /Border [0 0 0] /H /I /Dest [149 0 R /XYZ 0 742.23 null]>><</Type /Annot /Subtype /Link /Rect [562 250.25820312500002 572 259.35] /Border [0 0 0] /H /I /Dest [155 0 R /XYZ 0 513.40 null]>><</Type /Annot /Subtype /Link /Rect [562 220.25820312500002 572 229.35000000000002] /Border [0 0 0] /H /I /Dest [157 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 6 0 R>>
endobj
6 0 obj
<</Length 20913>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 253.25 736.25 Td (INDEX ) Tj ET Q
q 0 0 0 rg BT 287.80 736.25 Td (T) Tj ET Q
q 0 0 0 rg BT 294.29 736.25 Td (O FORM 10-K) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 200.85 723.25 Td (FOR ) Tj ET Q
q 0 0 0 rg BT 224.28 723.25 Td (THE ) Tj ET Q
q 0 0 0 rg BT 247.52 723.25 Td (YEAR ENDED DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 391.15 723.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
1 1 1 rg
/GS0 gs
80.50 562.75 459.00 -15.00 re f
/GS0 gs
BT /F1 10.00 Tf ET
0 0 0 RG
/GS0 gs
0.95 w
0 i 
[] 0 d
1 J
1 j
3 M
551.45 700.86259765625 m
571.996875 700.86259765625 l
s
q 0 0 0 rg BT 551.45 702.43 Td (Page) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 686.0833984375 m
155.48046875 686.0833984375 l
s
q 0 0 1 rg BT 38.00 687.42 Td (Forward-Looking Statements) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.95 w
0 i 
[] 0 d
1 J
1 j
3 M
270.8 655.86259765625 m
303.1388671875 655.86259765625 l
s
q 0 0 1 rg BT 270.80 657.43 Td (P) Tj ET Q
q 0 0 1 rg BT 276.17 657.43 Td (AR) Tj ET Q
q 0 0 1 rg BT 290.26 657.43 Td (T) Tj ET Q
q 0 0 1 rg BT 296.75 657.43 Td ( I) Tj ET Q
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 641.0833984375 m
66.3251953125 641.0833984375 l
s
q 0 0 1 rg BT 38.00 642.42 Td (Item 1.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 641.0833984375 m
118.5615234375 641.0833984375 l
s
q 0 0 1 rg BT 83.00 642.42 Td (Business) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 626.0833984375 m
71.046875 626.0833984375 l
s
q 0 0 1 rg BT 38.00 627.42 Td (Item 1A) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
q 0 0 0 rg BT 71.05 627.42 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 626.0833984375 m
133.2783203125 626.0833984375 l
s
q 0 0 1 rg BT 83.00 627.42 Td (Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 611.0833984375 m
72.9951171875 611.0833984375 l
s
q 0 0 1 rg BT 38.00 612.42 Td (Item 1B.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 611.0833984375 m
196.69140625 611.0833984375 l
s
q 0 0 1 rg BT 83.00 612.42 Td (Unresolved Staf) Tj ET Q
q 0 0 1 rg BT 147.53 612.42 Td (f Comments) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 596.0833984375 m
66.3251953125 596.0833984375 l
s
q 0 0 1 rg BT 38.00 597.42 Td (Item 2.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 596.0833984375 m
123.546875 596.0833984375 l
s
q 0 0 1 rg BT 83.00 597.42 Td (Properties) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 581.0833984375 m
66.3251953125 581.0833984375 l
s
q 0 0 1 rg BT 38.00 582.42 Td (Item 3.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 581.0833984375 m
157.140625 581.0833984375 l
s
q 0 0 1 rg BT 83.00 582.42 Td (Legal Proceedings) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 566.0833984375 m
66.3251953125 566.0833984375 l
s
q 0 0 1 rg BT 38.00 567.42 Td (Item 4.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 566.0833984375 m
181.3154296875 566.0833984375 l
s
q 0 0 1 rg BT 83.00 567.42 Td (Mine Safety Disclosures) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.95 w
0 i 
[] 0 d
1 J
1 j
3 M
268.85 535.86259765625 m
305.08046875 535.86259765625 l
s
q 0 0 1 rg BT 268.85 537.43 Td (P) Tj ET Q
q 0 0 1 rg BT 274.22 537.43 Td (AR) Tj ET Q
q 0 0 1 rg BT 288.31 537.43 Td (T) Tj ET Q
q 0 0 1 rg BT 294.80 537.43 Td ( II) Tj ET Q
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 521.0833984375 m
66.3251953125 521.0833984375 l
s
q 0 0 1 rg BT 38.00 522.42 Td (Item 5.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 521.0833984375 m
531.7060546875 521.0833984375 l
s
q 0 0 1 rg BT 83.00 522.42 Td (Market for Registrant�) Tj ET Q
q 0 0 1 rg BT 172.42 522.42 Td (s Common Equity) Tj ET Q
q 0 0 1 rg BT 244.55 522.42 Td (, Related Stockholder Matters and Issuer Purchases of Equity Securities) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 506.0833984375 m
66.3251953125 506.0833984375 l
s
q 0 0 1 rg BT 38.00 507.42 Td (Item 6.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 506.0833984375 m
177.9609375 506.0833984375 l
s
q 0 0 1 rg BT 83.00 507.42 Td (Selected Financial Data) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 491.0833984375 m
66.3251953125 491.0833984375 l
s
q 0 0 1 rg BT 38.00 492.42 Td (Item 7.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 491.0833984375 m
441.291015625 491.0833984375 l
s
q 0 0 1 rg BT 83.00 492.42 Td (Management�) Tj ET Q
q 0 0 1 rg BT 137.98 492.42 Td (s Discussion and ) Tj ET Q
q 0 0 1 rg BT 207.15 492.42 Td (Analysis of Financial Condition and Results of Operations) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 476.0833984375 m
73.546875 476.0833984375 l
s
q 0 0 1 rg BT 38.00 477.42 Td (Item 7A.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 476.0833984375 m
324.62109375 476.0833984375 l
s
q 0 0 1 rg BT 83.00 477.42 Td (Quantitative and Qualitative Disclosures ) Tj ET Q
q 0 0 1 rg BT 247.40 477.42 Td (About Market Risk) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 461.0833984375 m
66.3251953125 461.0833984375 l
s
q 0 0 1 rg BT 38.00 462.42 Td (Item 8.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 461.0833984375 m
267.951171875 461.0833984375 l
s
q 0 0 1 rg BT 83.00 462.42 Td (Financial Statements and Supplementary Data) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 446.0833984375 m
66.3251953125 446.0833984375 l
s
q 0 0 1 rg BT 38.00 447.42 Td (Item 9.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 446.0833984375 m
441.8134765625 446.0833984375 l
s
q 0 0 1 rg BT 83.00 447.42 Td (Changes in and Disagreements with ) Tj ET Q
q 0 0 1 rg BT 228.81 447.42 Td (Accountants on ) Tj ET Q
q 0 0 1 rg BT 293.24 447.42 Td (Accounting and Financial Disclosure) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 431.0833984375 m
73.546875 431.0833984375 l
s
q 0 0 1 rg BT 38.00 432.42 Td (Item 9A.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 431.0833984375 m
181.3154296875 431.0833984375 l
s
q 0 0 1 rg BT 83.00 432.42 Td (Controls and Procedures) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 416.0833984375 m
72.9951171875 416.0833984375 l
s
q 0 0 1 rg BT 38.00 417.42 Td (Item 9B.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 416.0833984375 m
156.0322265625 416.0833984375 l
s
q 0 0 1 rg BT 83.00 417.42 Td (Other Information) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.95 w
0 i 
[] 0 d
1 J
1 j
3 M
266.9 385.86259765625 m
307.0220703125 385.86259765625 l
s
q 0 0 1 rg BT 266.90 387.43 Td (P) Tj ET Q
q 0 0 1 rg BT 272.27 387.43 Td (AR) Tj ET Q
q 0 0 1 rg BT 286.36 387.43 Td (T) Tj ET Q
q 0 0 1 rg BT 292.85 387.43 Td ( III) Tj ET Q
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 371.0833984375 m
71.3251953125 371.0833984375 l
s
q 0 0 1 rg BT 38.00 372.42 Td (Item 10.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 371.0833984375 m
310.4951171875 371.0833984375 l
s
q 0 0 1 rg BT 83.00 372.42 Td (Directors, Executive Of) Tj ET Q
q 0 0 1 rg BT 178.06 372.42 Td (ficers and Corporate Governance) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 356.0833984375 m
70.9541015625 356.0833984375 l
s
q 0 0 1 rg BT 38.00 357.42 Td (Item 1) Tj ET Q
q 0 0 1 rg BT 63.45 357.42 Td (1.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 356.0833984375 m
183.25390625 356.0833984375 l
s
q 0 0 1 rg BT 83.00 357.42 Td (Executive Compensation) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 341.0833984375 m
71.3251953125 341.0833984375 l
s
q 0 0 1 rg BT 38.00 342.42 Td (Item 12.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 341.0833984375 m
488.15625 341.0833984375 l
s
q 0 0 1 rg BT 83.00 342.42 Td (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 326.0833984375 m
71.3251953125 326.0833984375 l
s
q 0 0 1 rg BT 38.00 327.42 Td (Item 13.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 326.0833984375 m
385.6953125 326.0833984375 l
s
q 0 0 1 rg BT 83.00 327.42 Td (Certain Relationships and Related ) Tj ET Q
q 0 0 1 rg BT 221.68 327.42 Td (T) Tj ET Q
q 0 0 1 rg BT 227.43 327.42 Td (ransactions, and Director Independence) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 311.0833984375 m
71.3251953125 311.0833984375 l
s
q 0 0 1 rg BT 38.00 312.42 Td (Item 14.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 311.0833984375 m
241.8525390625 311.0833984375 l
s
q 0 0 1 rg BT 83.00 312.42 Td (Principal ) Tj ET Q
q 0 0 1 rg BT 121.05 312.42 Td (Accounting Fees and Services) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.95 w
0 i 
[] 0 d
1 J
1 j
3 M
267.3 280.86259765625 m
306.77021484375 280.86259765625 l
s
q 0 0 1 rg BT 267.30 282.43 Td (P) Tj ET Q
q 0 0 1 rg BT 272.67 282.43 Td (AR) Tj ET Q
q 0 0 1 rg BT 286.76 282.43 Td (T) Tj ET Q
q 0 0 1 rg BT 293.25 282.43 Td ( IV) Tj ET Q
BT /F1 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 266.0833984375 m
71.3251953125 266.0833984375 l
s
q 0 0 1 rg BT 38.00 267.42 Td (Item 15.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 266.0833984375 m
244.083984375 266.0833984375 l
s
q 0 0 1 rg BT 83.00 267.42 Td (Exhibits, Financial Statement Schedules) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 251.08339843750002 m
71.3251953125 251.08339843750002 l
s
q 0 0 1 rg BT 38.00 252.42 Td (Item 16.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 251.08339843750002 m
169.1083984375 251.08339843750002 l
s
q 0 0 1 rg BT 83.00 252.42 Td (Form 10-K Summary) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
38 221.08339843750002 m
76.3251953125 221.08339843750002 l
s
q 0 0 1 rg BT 38.00 222.42 Td (Signature) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
BT /F3 1.00 Tf ET
q 0 0 0 rg BT 36.00 217.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
569.2 686.5333984375 m
571.9783203125 686.5333984375 l
s
q 0 0 1 rg BT 569.20 687.87 Td (i) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
567 641.0833984375 m
572 641.0833984375 l
s
q 0 0 1 rg BT 567.00 642.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 626.0833984375 m
572 626.0833984375 l
s
q 0 0 1 rg BT 562.00 627.42 Td (17) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 611.0833984375 m
572 611.0833984375 l
s
q 0 0 1 rg BT 562.00 612.42 Td (46) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 596.0833984375 m
572 596.0833984375 l
s
q 0 0 1 rg BT 562.00 597.42 Td (47) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 581.0833984375 m
572 581.0833984375 l
s
q 0 0 1 rg BT 562.00 582.42 Td (47) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 566.0833984375 m
572 566.0833984375 l
s
q 0 0 1 rg BT 562.00 567.42 Td (47) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 521.0833984375 m
572 521.0833984375 l
s
q 0 0 1 rg BT 562.00 522.42 Td (48) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 506.0833984375 m
572 506.0833984375 l
s
q 0 0 1 rg BT 562.00 507.42 Td (50) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 491.0833984375 m
572 491.0833984375 l
s
q 0 0 1 rg BT 562.00 492.42 Td (51) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 476.0833984375 m
572 476.0833984375 l
s
q 0 0 1 rg BT 562.00 477.42 Td (68) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 461.0833984375 m
572 461.0833984375 l
s
q 0 0 1 rg BT 562.00 462.42 Td (69) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 446.0833984375 m
572 446.0833984375 l
s
q 0 0 1 rg BT 562.00 447.42 Td (69) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 431.0833984375 m
572 431.0833984375 l
s
q 0 0 1 rg BT 562.00 432.42 Td (69) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 416.0833984375 m
572 416.0833984375 l
s
q 0 0 1 rg BT 562.00 417.42 Td (69) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 371.0833984375 m
572 371.0833984375 l
s
q 0 0 1 rg BT 562.00 372.42 Td (70) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 356.0833984375 m
572 356.0833984375 l
s
q 0 0 1 rg BT 562.00 357.42 Td (70) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 341.0833984375 m
572 341.0833984375 l
s
q 0 0 1 rg BT 562.00 342.42 Td (70) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 326.0833984375 m
572 326.0833984375 l
s
q 0 0 1 rg BT 562.00 327.42 Td (70) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 311.0833984375 m
572 311.0833984375 l
s
q 0 0 1 rg BT 562.00 312.42 Td (70) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 266.0833984375 m
572 266.0833984375 l
s
q 0 0 1 rg BT 562.00 267.42 Td (71) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 251.08339843750002 m
572 251.08339843750002 l
s
q 0 0 1 rg BT 562.00 252.42 Td (74) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
562 221.08339843750002 m
572 221.08339843750002 l
s
q 0 0 1 rg BT 562.00 222.42 Td (75) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
endstream
endobj
7 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 8 0 R>>
endobj
8 0 obj
<</Length 6988>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.60 24.60 Td (i) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 219.50 749.25 Td (FOR) Tj ET Q
q 0 0 0 rg BT 240.26 749.25 Td (W) Tj ET Q
q 0 0 0 rg BT 249.15 749.25 Td (ARD-LOOKING ST) Tj ET Q
q 0 0 0 rg BT 337.03 749.25 Td (A) Tj ET Q
q 0 0 0 rg BT 343.51 749.25 Td (TEMENTS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Statements contained or incorporated by reference in this document contain information that includes or is based on �forward-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (looking statements� within the meaning of Section 27A) Tj ET Q
q 0 0 0 rg BT 257.91 719.25 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.96 719.25 Td (Securities ) Tj ET Q
q 0 0 0 rg BT 327.34 719.25 Td (Act of 1933, as amended \(Securities ) Tj ET Q
q 0 0 0 rg BT 474.24 719.25 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.01 719.25 Td ( and Section 21E of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 707.25 Td (Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 134.02 707.25 Td (Act of 1934, as amended \(Exchange ) Tj ET Q
q 0 0 0 rg BT 280.92 707.25 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.69 707.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 303.50 707.25 Td (These statements, including estimates of future revenues, future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (expenses, future net income and future net income per share contained in the �Management�) Tj ET Q
q 0 0 0 rg BT 404.75 695.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 473.92 695.25 Td (Analysis of Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.25 Td (Condition and Results of Operations� section of this document, as well as statements regarding future financing activities, are subject ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.25 Td (to risks and uncertainties. Forward-looking statements include the information concerning our possible or assumed results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.25 Td (operations. ) Tj ET Q
q 0 0 0 rg BT 82.47 659.25 Td (W) Tj ET Q
q 0 0 0 rg BT 91.11 659.25 Td (e have tried, whenever possible, to identify such statements by words such as �believe,� �expect,� �anticipate,� �intend,� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.25 Td (�estimate,� �plan,� �project,� �forecast,� �will,� �may� or similar expressions. ) Tj ET Q
q 0 0 0 rg BT 352.06 647.25 Td (W) Tj ET Q
q 0 0 0 rg BT 360.70 647.25 Td (e have based these forward-looking statements on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.25 Td (current expectations and projections about the growth of our business, our financial performance and the development of our industry) Tj ET Q
q 0 0 0 rg BT 569.91 635.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.25 Td (Because these statements reflect our current views concerning future events, these forward-looking statements involve risks and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.25 Td (uncertainties. Investors should note that many factors, as more fully described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.91 611.25 Td (Part I, Item 1A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.35 611.25 Td ( of this report under the caption �Risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 599.25 Td (Factors,� and as otherwise enumerated herein, could af) Tj ET Q
q 0 0 0 rg BT 255.45 599.25 Td (fect our future financial results and could cause our actual results to dif) Tj ET Q
q 0 0 0 rg BT 539.61 599.25 Td (fer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.25 Td (materially from those expressed in forward-looking statements contained or incorporated by reference in this document.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 569.25 Td (e do not undertake any obligation to update our forward-looking statements after the date of this document for any reason, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (even if new information becomes available or other events occur in the future, except as may be required under applicable securities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.25 Td (laws. ) Tj ET Q
q 0 0 0 rg BT 58.96 545.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 65.18 545.25 Td (ou are advised to consult any further disclosures we make on related subjects in our reports filed with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.11 545.25 Td (Securities and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.25 Td (Exchange Commission \(SEC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.99 533.25 Td ( and with securities regulators in Canada on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.44 533.25 Td (System for Electronic Document ) Tj ET Q
q 0 0 0 rg BT 481.74 533.25 Td (Analysis and Retrieval ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 521.25 Td (\(SEDAR\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.44 521.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 79.89 521.25 Td (Also note that in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.77 521.25 Td (Part I, Item 1A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.76 521.25 Td (, we provide a cautionary discussion of the risks, uncertainties and possibly inaccurate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.25 Td (assumptions relevant to our business. ) Tj ET Q
q 0 0 0 rg BT 187.47 509.25 Td (These are factors that, individually or in the aggregate, we think could cause our actual results to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.25 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 497.25 Td (fer materially from expected and historical results. ) Tj ET Q
q 0 0 0 rg BT 251.11 497.25 Td (W) Tj ET Q
q 0 0 0 rg BT 259.75 497.25 Td (e note these factors for investors as permitted by Section 27A) Tj ET Q
q 0 0 0 rg BT 505.24 497.25 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.29 497.25 Td (Securities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.44 485.25 Td ( and Section 21E of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.53 485.25 Td (Exchange ) Tj ET Q
q 0 0 0 rg BT 187.90 485.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.34 485.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 206.97 485.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 213.19 485.25 Td (ou should understand that it is not possible to predict or identify all such factors. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.25 Td (Consequently) Tj ET Q
q 0 0 0 rg BT 90.35 473.25 Td (, you should not consider this to be a complete discussion of all potential risks or uncertainties.) Tj ET Q
endstream
endobj
9 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 10 0 R>>
endobj
10 0 obj
<</Length 14646>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (1) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 289.80 742.25 Td (P) Tj ET Q
q 0 0 0 rg BT 295.17 742.25 Td (AR) Tj ET Q
q 0 0 0 rg BT 309.26 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 315.75 742.25 Td ( I) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 721.25 Td (Item 1.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 721.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 721.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 721.25 Td (Business) Tj ET Q
BT /F4 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 703.25 Td (Overview) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 685.25 Td (Unless otherwise indicated or required by the context, references throughout to �Endo,� the �Company) Tj ET Q
q 0 0 0 rg BT 474.16 685.25 Td (,� �we,� �our� or �us� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 673.25 Td (refer to financial information and transactions of Endo International plc and its subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 655.25 Td (Endo International plc is an Ireland-domiciled specialty branded and generics pharmaceutical company) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.24 655.25 Td (. Endo International plc ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 643.25 Td (was incorporated in Ireland in 2013 as a private limited company and re-registered ef) Tj ET Q
q 0 0 0 rg BT 376.52 643.25 Td (fective February 18, 2014 as a public limited ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 631.25 Td (company) Tj ET Q
q 0 0 0 rg BT 72.01 631.25 Td (. Endo International plc is a holding company that conducts its operations through its subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 613.25 Td (Our ordinary shares are traded on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.33 613.25 Td (Nasdaq Global Select Market \(NASDAQ\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.18 613.25 Td ( under the ticker symbol �ENDP) Tj ET Q
q 0 0 0 rg BT 512.32 613.25 Td (.� References ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 601.25 Td (throughout to �ordinary shares� refer to Endo International plc�) Tj ET Q
q 0 0 0 rg BT 289.25 601.25 Td (s ordinary shares \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.84 601.25 Td (1,000,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.34 601.25 Td ( authorized, par value of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.29 601.25 Td ($0.0001) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.79 601.25 Td ( per ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 589.25 Td (share\). In addition, we have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.57 589.25 Td (4,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.57 589.25 Td ( euro deferred shares outstanding \(par value of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.38 589.25 Td ($0.01) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.88 589.25 Td ( per share\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 571.25 Td (The address of Endo International plc�) Tj ET Q
q 0 0 0 rg BT 216.56 571.25 Td (s headquarters is Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 559.25 Td (\(telephone number: 01) Tj ET Q
q 0 0 0 rg BT 126.16 559.25 Td (1-353-1-268-2000\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 541.25 Td (Our focus is on pharmaceutical products and we tar) Tj ET Q
q 0 0 0 rg BT 268.86 541.25 Td (get areas where we believe we can build leading positions. ) Tj ET Q
q 0 0 0 rg BT 505.54 541.25 Td (W) Tj ET Q
q 0 0 0 rg BT 514.18 541.25 Td (e use a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 529.25 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 529.25 Td (ferentiated operating model based on a lean and nimble structure, the rational allocation of capital and an emphasis on high-value ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 517.25 Td (research and development \(R&D\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.22 517.25 Td ( tar) Tj ET Q
q 0 0 0 rg BT 184.09 517.25 Td (gets. ) Tj ET Q
q 0 0 0 rg BT 205.02 517.25 Td (While our primary focus is on or) Tj ET Q
q 0 0 0 rg BT 335.92 517.25 Td (ganic growth, we evaluate and, where appropriate, execute ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 505.25 Td (on opportunities to expand through the acquisition of products and companies in areas that we believe serve patients and customers ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 493.25 Td (while of) Tj ET Q
q 0 0 0 rg BT 68.87 493.25 Td (fering attractive growth characteristics and mar) Tj ET Q
q 0 0 0 rg BT 257.76 493.25 Td (gins. ) Tj ET Q
q 0 0 0 rg BT 279.25 493.25 Td (W) Tj ET Q
q 0 0 0 rg BT 287.89 493.25 Td (e believe our operating model and the execution of our corporate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 481.25 Td (strategy will enable us to create shareholder value over the long-term.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 463.25 Td (For branded products, we seek to invest in products or product candidates that have inherent scientific, regulatory) Tj ET Q
q 0 0 0 rg BT 516.66 463.25 Td (, legal and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 451.25 Td (technical complexities and market such products under recognizable brand names that are trademarked. For products we develop for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 439.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 439.25 Td (United States \(U.S.\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.26 439.25 Td ( market, after the completion of required clinical trials and testing, we seek approvals from regulatory bodies ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 427.25 Td (such as through the submission of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.33 427.25 Td (New Drug ) Tj ET Q
q 0 0 0 rg BT 218.21 427.25 Td (Applications \(NDAs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.03 427.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.36 427.25 Td (Biologics License ) Tj ET Q
q 0 0 0 rg BT 391.23 427.25 Td (Applications \(BLAs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.39 427.25 Td ( to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.88 427.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.67 427.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.17 427.25 Td (Food and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 415.25 Td (Drug ) Tj ET Q
q 0 0 0 rg BT 58.50 415.25 Td (Administration \(FDA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.22 415.25 Td (. Upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.94 415.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.72 415.25 Td ( approval, patents included in such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.07 415.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.74 415.25 Td (s are listed in a publication referred to as the Orange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 403.25 Td (Book. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.49 403.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.13 403.25 Td (e believe that our patents, the protection of discoveries in connection with our development activities, our proprietary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 391.25 Td (products, technologies, processes, trade secrets, know-how) Tj ET Q
q 0 0 0 rg BT 271.12 391.25 Td (, innovations and all of our intellectual property are important to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 379.25 Td (business and achieving a competitive position.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.07 379.25 Td ( However) Tj ET Q
q 0 0 0 rg BT 260.82 379.25 Td (, there can be no assurance that any of our patents, licenses or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 367.25 Td (intellectual property rights will af) Tj ET Q
q 0 0 0 rg BT 170.22 367.25 Td (ford us any protection from competition. ) Tj ET Q
q 0 0 0 rg BT 334.91 367.25 Td (Additional information is included throughout this Part I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 355.25 Td (Item 1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 337.25 Td (For generic products, which are the pharmaceutical and therapeutic equivalents of branded products and are generally marketed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 325.25 Td (under their generic \(chemical\) names rather than their brand names, our focus is on high-barrier) Tj ET Q
q 0 0 0 rg BT 418.70 325.25 Td (-to-entry products, including first-to-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 313.25 Td (file or first-to-market opportunities that are dif) Tj ET Q
q 0 0 0 rg BT 221.87 313.25 Td (ficult to formulate or manufacture or face complex legal and regulatory challenges. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 301.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 301.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 301.25 Td (, a first-to-file product refers to a generic product for which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.57 301.25 Td (Abbreviated New Drug ) Tj ET Q
q 0 0 0 rg BT 418.37 301.25 Td (Application \(ANDA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.63 301.25 Td ( containing a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 289.25 Td (patent challenge \(or Paragraph IV) Tj ET Q
q 0 0 0 rg BT 171.31 289.25 Td ( certification\) to the corresponding branded product�) Tj ET Q
q 0 0 0 rg BT 380.68 289.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.07 289.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.53 289.25 Td ( Orange Book-listed patents was the first ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 277.25 Td (to be filed with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.04 277.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.04 277.25 Td (. In the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.59 277.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.37 277.25 Td (, manufacturers that launch first-to-file products, after success in litigating or otherwise resolving ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 265.25 Td (related patent challenges, and receive final ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.96 265.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.42 265.25 Td ( approval have the opportunity for 180 days of generic marketing exclusivity from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 253.25 Td (competing generic products other than authorized generics. ) Tj ET Q
q 0 0 0 rg BT 274.80 253.25 Td (A) Tj ET Q
q 0 0 0 rg BT 281.47 253.25 Td ( first-to-market product refers to a product that is the first marketed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 241.25 Td (generic equivalent of a branded product for reasons apart from statutory marketing exclusivity) Tj ET Q
q 0 0 0 rg BT 412.44 241.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 417.26 241.25 Td (This can occur) Tj ET Q
q 0 0 0 rg BT 475.72 241.25 Td (, for example, when a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 229.25 Td (generic product is dif) Tj ET Q
q 0 0 0 rg BT 121.07 229.25 Td (ficult to formulate or manufacture. First-to-market products allow manufacturers to mitigate risks from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 217.25 Td (competitive pressures commonly associated with commoditized generic products. ) Tj ET Q
q 0 0 0 rg BT 365.08 217.25 Td (Additional information is included throughout this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 205.25 Td (Part I, Item 1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 187.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 187.25 Td (four) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.71 187.25 Td ( reportable business segments in which we operate are: \(1\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.29 187.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.20 187.25 Td (, \(2\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.36 187.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.27 187.25 Td (, \(3\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 175.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.67 175.25 Td ( and \(4\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.27 175.25 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.39 175.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 292.84 175.25 Td (Additional information about our reportable business segments is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 163.25 Td (included throughout this Part I. ) Tj ET Q
q 0 0 0 rg BT 163.03 163.25 Td (The results of operations of our reportable business segments are discussed in Part II, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.55 163.25 Td (Item 7 of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 151.25 Td (report �Management�) Tj ET Q
q 0 0 0 rg BT 121.80 151.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 190.97 151.25 Td (Analysis of Financial Condition and Results of Operations�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.54 151.25 Td ( under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.62 151.25 Td (RESUL) Tj ET Q
q 0 0 0 rg BT 541.38 151.25 Td (TS OF ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 139.25 Td (OPERA) Tj ET Q
q 0 0 0 rg BT 67.67 139.25 Td (TIONS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.12 139.25 Td (.� ) Tj ET Q
q 0 0 0 rg BT 106.00 139.25 Td (Across all of our reportable business segments, we generated total revenues of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.74 139.25 Td ($2.91 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.85 139.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.85 139.25 Td ($2.95 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.96 139.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.40 139.25 Td ($3.47 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 127.25 Td (billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.11 127.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.89 127.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.89 127.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.89 127.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.89 127.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.33 127.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.33 127.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 211.99 127.25 Td (.) Tj ET Q
endstream
endobj
11 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 12 0 R>>
endobj
12 0 obj
<</Length 13567>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (2) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 742.25 Td ( Strategy) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (Endo International plc is a highly focused specialty branded and generics pharmaceutical company that, through its operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (subsidiaries, seeks to deliver quality medicines to patients in need through excellence in development, manufacturing and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (commercialization. Our strategic priorities include reshaping our or) Tj ET Q
q 0 0 0 rg BT 305.73 700.25 Td (ganization for success, building our portfolio and capabilities for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (the future and driving mar) Tj ET Q
q 0 0 0 rg BT 140.79 688.25 Td (gin expansion and, over the longer term, de-levering. Specific areas of management�) Tj ET Q
q 0 0 0 rg BT 478.44 688.25 Td (s focus include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 676.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 676.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.40 676.25 Td (: ) Tj ET Q
q 0 0 0 rg BT 192.13 676.25 Td (Accelerating performance of or) Tj ET Q
q 0 0 0 rg BT 317.71 676.25 Td (ganic growth drivers in our Specialty Products portfolio and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 664.25 Td (expanding mar) Tj ET Q
q 0 0 0 rg BT 145.02 664.25 Td (gin in our Established Products portfolio. ) Tj ET Q
q 0 0 0 rg BT 311.96 664.25 Td (As further described below under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.61 664.25 Td (Select ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 652.25 Td (Development Projects) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.09 652.25 Td (,� management is also focused on investing in key pipeline life cycle management and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 640.25 Td (development opportunities, including in the areas of medical therapeutics and medical aesthetics.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 628.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 628.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.41 628.25 Td (: Focusing on developing branded injectable products with inherent scientific, regulatory) Tj ET Q
q 0 0 0 rg BT 511.95 628.25 Td (, legal and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 616.25 Td (technical complexities, expanding the product portfolio to include other dosages and technologies and developing or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 604.25 Td (acquiring high-barrier) Tj ET Q
q 0 0 0 rg BT 173.32 604.25 Td (-to-entry) Tj ET Q
q 0 0 0 rg BT 207.65 604.25 Td (, generic injectable products that are dif) Tj ET Q
q 0 0 0 rg BT 366.01 604.25 Td (ficult to manufacture.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 592.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 592.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.17 592.25 Td (: Focusing on developing or acquiring high-barrier) Tj ET Q
q 0 0 0 rg BT 387.70 592.25 Td (-to-entry products, including first-to-file or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 580.25 Td (first-to-market opportunities that are dif) Tj ET Q
q 0 0 0 rg BT 244.71 580.25 Td (ficult to formulate or manufacture or face complex legal and regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 568.25 Td (challenges.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 556.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 556.25 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.62 556.25 Td (: Operating in regulated markets where physicians play a significant role in choosing the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 544.25 Td (course of therapy and seeking to expand distribution of certain of our products outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.73 544.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 526.25 Td (Going forward, our primary focus will be on or) Tj ET Q
q 0 0 0 rg BT 251.94 526.25 Td (ganic growth. However) Tj ET Q
q 0 0 0 rg BT 345.68 526.25 Td (, we will evaluate and, where appropriate, execute on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (opportunities to expand through acquisitions of products and companies. ) Tj ET Q
q 0 0 0 rg BT 329.10 514.25 Td (There can be no assurance that we will be successful in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (executing on our strategy) Tj ET Q
q 0 0 0 rg BT 136.71 502.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 484.25 Td ( Competitive Str) Tj ET Q
q 0 0 0 rg BT 123.95 484.25 Td (engths) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 466.25 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 466.25 Td (o successfully execute our strategy) Tj ET Q
q 0 0 0 rg BT 207.16 466.25 Td (, we must continue to capitalize on our following core strengths:) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 448.25 Td (Experienced and dedicated management team.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.92 448.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 257.24 448.25 Td (W) Tj ET Q
q 0 0 0 rg BT 265.88 448.25 Td (e have a highly skilled and customer) Tj ET Q
q 0 0 0 rg BT 411.75 448.25 Td (-focused management team in critical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (leadership positions across Endo. Our senior management team has extensive experience in the pharmaceutical industry and a proven ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (track record of developing businesses and creating value. ) Tj ET Q
q 0 0 0 rg BT 267.12 424.25 Td (This experience includes improving business performance through or) Tj ET Q
q 0 0 0 rg BT 544.36 424.25 Td (ganic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (revenue growth, operational excellence and through the identification, consummation and integration of licensing and acquisition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (opportunities.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 382.25 Td (Operational excellence.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 160.20 382.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.70 382.25 Td (W) Tj ET Q
q 0 0 0 rg BT 171.33 382.25 Td (e have ef) Tj ET Q
q 0 0 0 rg BT 207.24 382.25 Td (ficient, ef) Tj ET Q
q 0 0 0 rg BT 245.37 382.25 Td (fective and high-quality manufacturing capabilities across a diversified array of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (dosage forms in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.09 370.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.88 370.25 Td ( and India. ) Tj ET Q
q 0 0 0 rg BT 179.68 370.25 Td (W) Tj ET Q
q 0 0 0 rg BT 188.32 370.25 Td (e believe our comprehensive suite of technology) Tj ET Q
q 0 0 0 rg BT 381.49 370.25 Td (, manufacturing and development competencies ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (increases the likelihood of success in commercializing high-barrier) Tj ET Q
q 0 0 0 rg BT 303.76 358.25 Td (-to-entry products and obtaining first-to-file and first-to-market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (status on future products, yielding more sustainable market share and profitability) Tj ET Q
q 0 0 0 rg BT 362.77 346.25 Td (. For example, our capabilities in the rapidly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (growing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.83 334.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.61 334.25 Td ( market for sterile products af) Tj ET Q
q 0 0 0 rg BT 208.00 334.25 Td (ford us with a broader and more diversified product portfolio and a greater selection of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (tar) Tj ET Q
q 0 0 0 rg BT 46.37 322.25 Td (gets for potential development.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 304.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 304.25 Td (e believe that our competitive advantages include our integrated team-based approach to product development that combines ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.25 Td (our formulation, regulatory) Tj ET Q
q 0 0 0 rg BT 144.49 292.25 Td (, legal, manufacturing and commercial capabilities; our ability to introduce new generic equivalents for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.25 Td (brand-name products; our quality and cost-ef) Tj ET Q
q 0 0 0 rg BT 216.04 280.25 Td (fective production; our ability to meet customer and/or patient expectations and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (breadth of our existing sterile injectables and generic product portfolio of) Tj ET Q
q 0 0 0 rg BT 329.06 268.25 Td (ferings.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 250.25 Td (Growth of our branded Specialty Products portfolio while leveraging the strength of our Established Products portfolio.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.27 250.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 557.58 250.25 Td (W) Tj ET Q
q 0 0 0 rg BT 566.22 250.25 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (have assembled a portfolio of branded prescription products of) Tj ET Q
q 0 0 0 rg BT 286.85 238.25 Td (fered by our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.22 238.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.13 238.25 Td ( segment to treat and manage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (conditions in urology) Tj ET Q
q 0 0 0 rg BT 120.90 226.25 Td (, urologic oncology) Tj ET Q
q 0 0 0 rg BT 198.29 226.25 Td (, endocrinology) Tj ET Q
q 0 0 0 rg BT 260.41 226.25 Td (, pain, bariatrics and orthopedics. ) Tj ET Q
q 0 0 0 rg BT 395.37 226.25 Td (Additional information on these product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (portfolios is included below under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.01 214.25 Td (Products Overview) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.29 214.25 Td (.�) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 196.25 Td (Focus on the dif) Tj ET Q
q 0 0 0 rg BT 130.33 196.25 Td (ferentiated products of our sterile injectables and generics portfolios.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 413.93 196.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.43 196.25 Td (By leveraging operational ef) Tj ET Q
q 0 0 0 rg BT 530.37 196.25 Td (ficiency) Tj ET Q
q 0 0 0 rg BT 561.93 196.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.83 184.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.74 184.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.18 184.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.86 184.25 Td ( segments aim to be low-cost producers of high-barrier) Tj ET Q
q 0 0 0 rg BT 462.04 184.25 Td (-to-entry products, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (including first-to-file and first-to-market opportunities that are dif) Tj ET Q
q 0 0 0 rg BT 298.80 172.25 Td (ficult to formulate or manufacture or face complex legal and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (regulatory challenges. ) Tj ET Q
q 0 0 0 rg BT 126.62 160.25 Td (W) Tj ET Q
q 0 0 0 rg BT 135.25 160.25 Td (e believe products with these characteristics will provide longer product life cycles and higher profitability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (than products without these characteristics. ) Tj ET Q
q 0 0 0 rg BT 210.77 148.25 Td (These segments also aim to manufacture products that meet the evolving needs of hospitals ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (and health systems, including ready-to-use sterile injectable products, in a cost ef) Tj ET Q
q 0 0 0 rg BT 360.44 136.25 Td (ficient manner) Tj ET Q
q 0 0 0 rg BT 417.92 136.25 Td (. ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 118.25 Td (Continuing proactive diversification of our business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.69 118.25 Td ( Our primary focus is on or) Tj ET Q
q 0 0 0 rg BT 388.38 118.25 Td (ganic growth. However) Tj ET Q
q 0 0 0 rg BT 482.12 118.25 Td (, we will evaluate and, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.25 Td (where appropriate, execute on opportunities to expand through acquisitions of products and companies in areas that will serve patients ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.25 Td (and customers and that we believe will of) Tj ET Q
q 0 0 0 rg BT 202.16 94.25 Td (fer attractive growth characteristics and mar) Tj ET Q
q 0 0 0 rg BT 378.28 94.25 Td (gins. In particular) Tj ET Q
q 0 0 0 rg BT 448.69 94.25 Td (, we will look to continue to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.25 Td (enhance our product lines by acquiring or licensing rights to additional products and regularly evaluating selective acquisition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.25 Td (opportunities.) Tj ET Q
endstream
endobj
13 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 14 0 R>>
endobj
14 0 obj
<</Length 22028>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (3) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.25 Td (R&D) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 84.67 742.25 Td ( expertise.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.33 742.25 Td ( Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.88 742.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.55 742.25 Td ( ef) Tj ET Q
q 0 0 0 rg BT 178.63 742.25 Td (forts are focused on the development of a balanced, diversified portfolio of innovative and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (clinically dif) Tj ET Q
q 0 0 0 rg BT 86.63 730.25 Td (ferentiated product candidates. ) Tj ET Q
q 0 0 0 rg BT 211.95 730.25 Td (Through our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.72 730.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.63 730.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.07 730.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.75 730.25 Td ( businesses, we seek out and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (develop high-barrier) Tj ET Q
q 0 0 0 rg BT 117.71 718.25 Td (-to-entry products, including first-to-file or first-to-market opportunities. ) Tj ET Q
q 0 0 0 rg BT 410.51 718.25 Td (W) Tj ET Q
q 0 0 0 rg BT 419.15 718.25 Td (e periodically review our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.88 718.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.55 718.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.25 Td (pipeline in order to better direct investment toward those opportunities that we expect will deliver the greatest returns. ) Tj ET Q
q 0 0 0 rg BT 510.39 706.25 Td (W) Tj ET Q
q 0 0 0 rg BT 519.03 706.25 Td (e will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (continue to evaluate strategic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.39 694.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.06 694.25 Td ( opportunities, with an aim to develop assets with inherently lower risk profiles and clearly defined ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (regulatory pathways. Our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.23 682.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.90 682.25 Td ( pipeline consists of products in various stages of development. For additional detail, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 670.25 Td (Select Development Projects) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.96 670.25 Td (.� Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.45 670.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.12 670.25 Td ( and regulatory af) Tj ET Q
q 0 0 0 rg BT 275.74 670.25 Td (fairs staf) Tj ET Q
q 0 0 0 rg BT 310.27 670.25 Td (f is based primarily in India and Pennsylvania.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 652.25 Td (T) Tj ET Q
q 0 0 0 rg BT 68.19 652.25 Td (argeted sales and marketing infrastructure.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.82 652.25 Td ( Our sales and marketing activities are based in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.86 652.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.64 652.25 Td ( and Canada and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (primarily focus on the promotion of our Specialty Products portfolio and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.56 640.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.47 640.25 Td ( segment. ) Tj ET Q
q 0 0 0 rg BT 442.12 640.25 Td (W) Tj ET Q
q 0 0 0 rg BT 450.76 640.25 Td (e market our Specialty ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (Products directly to specialty physicians, including those specializing in urology) Tj ET Q
q 0 0 0 rg BT 356.96 628.25 Td (, orthopedics, pediatric endocrinology and bariatric ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (sur) Tj ET Q
q 0 0 0 rg BT 48.04 616.25 Td (gery) Tj ET Q
q 0 0 0 rg BT 65.16 616.25 Td (. Our sales force also directs its marketing ef) Tj ET Q
q 0 0 0 rg BT 243.53 616.25 Td (forts on retail pharmacies and other healthcare professionals. ) Tj ET Q
q 0 0 0 rg BT 489.09 616.25 Td (W) Tj ET Q
q 0 0 0 rg BT 497.72 616.25 Td (e distribute our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (Specialty Products through independent wholesale distributors, but we also sell directly to retailers, clinics, government agencies, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (doctors, independent retail and specialty pharmacies and independent specialty distributors. Our marketing policy is designed to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (provide physicians, pharmacies, hospitals, public and private payers and appropriate healthcare professionals with products and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (appropriate medical information. ) Tj ET Q
q 0 0 0 rg BT 170.21 568.25 Td (W) Tj ET Q
q 0 0 0 rg BT 178.85 568.25 Td (e work to gain access to various formularies \(lists of recommended or approved medicines and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (other products\) and reimbursement lists by demonstrating the qualities and treatment benefits of our products within their approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (indications.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 526.25 Td (Our dedicated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.86 526.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.78 526.25 Td ( sales and marketing team is focused on health systems and national ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.15 526.25 Td (group purchasing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (or) Tj ET Q
q 0 0 0 rg BT 44.15 514.25 Td (ganizations \(GPOs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.75 514.25 Td (. Our customers�) Tj ET Q
q 0 0 0 rg BT 188.93 514.25 Td ( growing complexity requires us to engage directly with key stakeholders and decision makers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (Our experienced sales and marketing team is key to growing our existing portfolio and executing on new product launches.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (Pr) Tj ET Q
q 0 0 0 rg BT 46.37 484.25 Td (oducts Overview) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 448.25 Td (The following table displays the revenues from external customers of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.75 448.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.65 448.25 Td ( segment for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.85 448.25 Td (years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 436.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 412.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 412.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 412.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 412.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 412.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 412.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 382.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 382.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 382.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 382.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 382.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 382.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 352.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 352.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 352.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 352.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 352.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 352.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 322.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 322.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 322.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 322.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 322.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 322.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 292.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 292.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 292.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 292.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 292.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 292.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 262.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 262.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 262.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 262.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 262.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 262.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 412.75 m
437.5 412.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 412.75 m
506.5 412.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 412.75 m
575.5 412.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 352.75 m
437.5 352.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 352.75 m
506.5 352.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 352.75 m
575.5 352.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 337.75 m
437.5 337.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 337.75 m
506.5 337.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 337.75 m
575.5 337.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 277.75 m
437.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 277.75 m
506.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 277.75 m
575.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 277.75 m
437.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 262.75 m
437.5 262.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 277.75 m
506.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 262.75 m
506.5 262.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 277.75 m
575.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 262.75 m
575.5 262.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 248.75 m
437.5 248.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 246.75 m
437.5 246.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 248.75 m
506.5 248.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 246.75 m
506.5 246.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 248.75 m
575.5 248.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 246.75 m
575.5 246.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 398.50 416.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 467.50 416.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 536.50 416.98 Td (2017) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 402.46 Td (Specialty Pr) Tj ET Q
q 0 0 0 rg BT 86.96 402.46 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 387.42 Td (XIAFLEX�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 386.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 386.42 Td (327,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 386.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 386.42 Td (264,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 386.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 386.42 Td (213,378) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 372.42 Td (SUPPRELIN� LA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 371.42 Td (86,797) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 371.42 Td (81,707) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 371.42 Td (86,21) Tj ET Q
q 0 0 0 rg BT 566.65 371.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 357.42 Td (Other Specialty \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 356.42 Td (105,241) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 356.42 Td (98,230) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 356.42 Td (84,161) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 342.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 342.42 Td (otal Specialty Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 341.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 341.42 Td (519,676) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 341.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 341.42 Td (444,575) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 341.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 341.42 Td (383,750) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 327.46 Td (Established Pr) Tj ET Q
q 0 0 0 rg BT 96.79 327.46 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 312.42 Td (PERCOCET�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 311.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 311.42 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 311.42 Td (16,012) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 311.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 311.42 Td (122,901) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 311.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 311.42 Td (125,231) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 297.42 Td (TEST) Tj ET Q
q 0 0 0 rg BT 67.80 297.42 Td (OPEL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 296.42 Td (55,244) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 296.42 Td (58,377) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 296.42 Td (69,223) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 282.42 Td (Other Established \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 281.42 Td (164,470) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 281.42 Td (236,979) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 281.42 Td (379,321) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 267.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 267.42 Td (otal Established Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 266.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 266.42 Td (335,726) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 266.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 266.42 Td (418,257) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 266.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 266.42 Td (573,775) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 252.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 252.42 Td (otal Branded Pharmaceuticals \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 251.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 251.42 Td (855,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 251.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 251.42 Td (862,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 251.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 251.42 Td (957,525) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 240.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 230.65 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 230.65 Td (Products included within Other Specialty are NASCOBAL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 256.36 234.27 Td (� ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 261.61 230.65 Td (Nasal Spray and ) Tj ET Q
q 0 0 0 rg BT 315.60 230.65 Td (A) Tj ET Q
q 0 0 0 rg BT 320.34 230.65 Td (VEED) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 341.67 234.27 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 345.62 230.65 Td (. Beginning with our first-quarter 2019 reporting, ) Tj ET Q
q 0 0 0 rg BT 505.22 230.65 Td (TEST) Tj ET Q
q 0 0 0 rg BT 524.19 230.65 Td (OPEL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 544.19 234.27 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 548.14 230.65 Td (, which ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 221.05 Td (was previously included in Other Specialty) Tj ET Q
q 0 0 0 rg BT 204.95 221.05 Td (, has been reclassified and is now included in the Established Products portfolio for all periods presented.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 211.45 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 211.45 Td (Products included within Other Established include, but are not limited to, LIDODERM) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 349.45 215.08 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 353.40 211.45 Td (, EDEX) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 378.73 215.08 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 382.68 211.45 Td ( and ) Tj ET Q
q 0 0 0 rg BT 398.09 211.45 Td (VOL) Tj ET Q
q 0 0 0 rg BT 413.79 211.45 Td (T) Tj ET Q
q 0 0 0 rg BT 418.04 211.45 Td (AREN) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 439.82 215.08 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 443.77 211.45 Td ( Gel.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 201.85 Td (\(3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 201.85 Td (Individual products presented above represent the top two performing products in each product category for the year ended December 31, 2019 and/or any ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 192.25 Td (product having revenues in excess of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 187.91 192.25 Td ($100 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 229.02 192.25 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 231.02 192.25 Td (during any of the years ended December 31, 2019, 2018 or 2017 or) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 446.07 192.25 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 448.07 192.25 Td ($25 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 485.18 192.25 Td ( during any quarterly period ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 182.65 Td (in 2019 or 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 118.39 182.65 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 164.65 Td (Specialty Pr) Tj ET Q
q 0 0 0 rg BT 98.28 164.65 Td (oducts Portfolio) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 146.65 Td (Endo commercializes a number of products within the market served by specialty distributors and specialty pharmacies and in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 134.65 Td (which healthcare practitioners can purchase and bill payers directly \(the buy and bill market\). Our current of) Tj ET Q
q 0 0 0 rg BT 469.26 134.65 Td (ferings primarily relate to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 122.65 Td (two distinct areas: \(i\) urology treatments, which focus mainly on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.33 122.65 Td (Peyronie�) Tj ET Q
q 0 0 0 rg BT 335.65 122.65 Td (s disease \(PD\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.87 122.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.30 122.65 Td (testosterone replacement therapies ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 110.65 Td (\(TR) Tj ET Q
q 0 0 0 rg BT 51.51 110.65 Td (T\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 60.95 110.65 Td ( for hypogonadism and \(ii\) orthopedics/pediatric endocrinology treatments, which focus on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.08 110.65 Td (Dupuytren�) Tj ET Q
q 0 0 0 rg BT 473.62 110.65 Td (s contracture \(DC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.04 110.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 98.65 Td (central precocious puberty \(CPP\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.02 98.65 Td (. Key product of) Tj ET Q
q 0 0 0 rg BT 234.37 98.65 Td (ferings in this portfolio include the following:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 86.65 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 86.65 Td (XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 128.27 91.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.21 86.65 Td (, which is the first and currently the only FDA-approved non-sur) Tj ET Q
q 0 0 0 rg BT 391.58 86.65 Td (gical treatment for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.94 86.65 Td (DC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.83 86.65 Td ( \(for adult patients with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 74.65 Td (an abnormal buildup of collagen in the fingers that limits or disables hand function\). It is also the first and currently the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 62.65 Td (only FDA-approved non-sur) Tj ET Q
q 0 0 0 rg BT 199.19 62.65 Td (gical treatment for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.54 62.65 Td (PD) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.33 62.65 Td ( \(for adult men with a collagen plaque and a penile curvature deformity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 50.65 Td (of thirty degrees or greater at the start of therapy\).) Tj ET Q
endstream
endobj
15 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 16 0 R>>
endobj
16 0 obj
<</Length 17122>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (4) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (SUPPRELIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 138.84 746.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.78 742.10 Td ( LA, which is a soft, flexible 12-month hydrogel implant based on our hydrogel polymer technology that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.02 730.10 Td (CPP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.45 730.10 Td ( in children.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 718.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 718.10 Td (NASCOBAL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 139.40 722.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.33 718.10 Td ( Nasal Spray) Tj ET Q
q 0 0 0 rg BT 194.78 718.10 Td (, which is a prescription medicine used as a supplement to treat vitamin B12 deficiency and is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 706.10 Td (the only ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.50 706.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.50 706.10 Td (-approved B12 nasal spray) Tj ET Q
q 0 0 0 rg BT 246.76 706.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 694.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 694.10 Td (A) Tj ET Q
q 0 0 0 rg BT 91.43 694.10 Td (VEED) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 118.09 698.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.03 694.10 Td (, which is a novel, long-acting testosterone undecanoate for injection for the treatment of hypogonadism that is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 682.10 Td (dosed only five times per year after the first month of therapy) Tj ET Q
q 0 0 0 rg BT 331.16 682.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 664.10 Td (Established Pr) Tj ET Q
q 0 0 0 rg BT 108.29 664.10 Td (oducts Portfolio) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.10 Td (This portfolio�) Tj ET Q
q 0 0 0 rg BT 121.05 646.10 Td (s current treatment of) Tj ET Q
q 0 0 0 rg BT 206.67 646.10 Td (ferings primarily relate to two distinct areas: \(i\) pain management, including products in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (opioid analgesics and osteoarthritis pain segments and for the treatment of pain associated with post-herpetic neuralgia and \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (urology) Tj ET Q
q 0 0 0 rg BT 66.46 622.10 Td (, which focuses mainly on the treatment of hypogonadism. Key product of) Tj ET Q
q 0 0 0 rg BT 363.71 622.10 Td (ferings in this portfolio include, among others, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (following:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 598.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 598.10 Td (PERCOCET) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 136.62 602.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.56 598.10 Td (, which is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 586.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 586.10 Td (TEST) Tj ET Q
q 0 0 0 rg BT 109.21 586.10 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 134.21 590.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.14 586.10 Td (, which is a unique, long-acting implantable pellet indicated for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.00 586.10 Td (TR) Tj ET Q
q 0 0 0 rg BT 407.18 586.10 Td (T) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.10 586.10 Td ( in conditions associated with a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 574.10 Td (deficiency or absence of endogenous testosterone.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 562.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 562.10 Td (LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 138.27 566.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.21 562.10 Td (, which is a topical patch product containing lidocaine that is approved for the relief of pain associated with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 550.10 Td (post-herpetic neuralgia, a condition thought to result after nerve fibers are damaged during a case of herpes zoster ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 538.10 Td (\(commonly known as shingles\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 526.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 526.10 Td (EDEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 112.16 530.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.10 526.10 Td (, which is a penile injection used to treat erectile dysfunction caused by conditions af) Tj ET Q
q 0 0 0 rg BT 456.54 526.10 Td (fecting nerves, blood vessels, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 514.10 Td (emotions and/or a combination of factors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 502.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 502.10 Td (VOL) Tj ET Q
q 0 0 0 rg BT 105.13 502.10 Td (T) Tj ET Q
q 0 0 0 rg BT 110.44 502.10 Td (AREN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 137.66 506.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.60 502.10 Td ( Gel, which is a topical prescription treatment for the relief of joint pain associated with osteoarthritis in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 490.10 Td (knees, ankles, feet, elbows, wrists and hands.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 472.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 472.10 Td (s pain products, including opioid products, are managed as mature brands and are not and have not been actively ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (promoted for years. In December 2016, the Company announced the elimination of its entire U.S. pain product field sales force.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (Sterile Injectables) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 424.10 Td (The following table displays the revenues from external customers of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.75 424.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.66 424.10 Td ( segment for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.86 424.10 Td (years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 412.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 388.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 388.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 388.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 388.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 388.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 388.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 358.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 358.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 358.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 358.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 358.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 358.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 328.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 328.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 328.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 328.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 328.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 328.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 388.6 m
437.5 388.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 388.6 m
506.5 388.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 388.6 m
575.5 388.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 313.6 m
437.5 313.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 299.6 m
437.5 299.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 297.6 m
437.5 297.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 313.6 m
506.5 313.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 299.6 m
506.5 299.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 297.6 m
506.5 297.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 313.6 m
575.5 313.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 299.6 m
575.5 299.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 297.6 m
575.5 297.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 392.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 392.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 392.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 378.27 Td (V) Tj ET Q
q 0 0 0 rg BT 44.58 378.27 Td (ASOSTRICT�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 378.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 378.27 Td (531,737) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 378.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 378.27 Td (453,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 378.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 378.27 Td (399,909) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 363.27 Td (ADRENALIN�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 363.27 Td (179,295) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 363.27 Td (143,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 363.27 Td (76,523) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 349.17 Td (Ertapenem for injection) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 348.27 Td (104,679) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 348.27 Td (57,668) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 348.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 334.17 Td (APLISOL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 333.27 Td (61,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 333.27 Td (64,913) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 333.27 Td (66,286) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 319.17 Td (Other Sterile Injectables \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 318.27 Td (185,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 318.27 Td (209,729) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 318.27 Td (207,753) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 304.17 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 304.17 Td (otal Sterile Injectables \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 303.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 303.27 Td (1,063,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 303.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 303.27 Td (929,566) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 303.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 303.27 Td (750,471) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 291.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 281.50 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 281.50 Td (Products included within Other Sterile Injectables include ephedrine sulfate injection, treprostinil for injection and others.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 271.90 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 271.90 Td (Individual products presented above represent the top two performing products within the Sterile Injectables segment for the year ended December 31, 2019 ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 262.30 Td (and/or any product having revenues in excess of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 223.89 262.30 Td ($100 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 265.01 262.30 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 267.01 262.30 Td (during any of the years ended December 31, 2019, 2018 or 2017 or) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 482.06 262.30 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 484.06 262.30 Td ($25 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 521.17 262.30 Td ( during any ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 252.70 Td (quarterly period in 2019 or 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.70 252.70 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 234.70 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 234.70 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.96 234.70 Td ( segment includes a product portfolio of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.42 234.70 Td (approximately 30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.68 234.70 Td ( product families, including branded sterile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 222.70 Td (injectable products that are protected by certain patent rights and have inherent scientific, regulatory) Tj ET Q
q 0 0 0 rg BT 436.30 222.70 Td (, legal and technical complexities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 210.70 Td (and generic injectable products that are dif) Tj ET Q
q 0 0 0 rg BT 206.30 210.70 Td (ficult to formulate or manufacture or face complex legal and regulatory challenges. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 198.70 Td (sterile injectables products are manufactured in sterile facilities in vial dosages and are administered at hospitals, clinics and long-term ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 186.70 Td (care facilities. ) Tj ET Q
q 0 0 0 rg BT 94.39 186.70 Td (The product of) Tj ET Q
q 0 0 0 rg BT 153.64 186.70 Td (ferings in this segment include, among others, the following:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 174.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 174.70 Td (V) Tj ET Q
q 0 0 0 rg BT 91.43 174.70 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 145.89 179.23 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.82 174.70 Td (, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 162.70 Td (despite fluids and catecholamines. ) Tj ET Q
q 0 0 0 rg BT 225.00 162.70 Td (V) Tj ET Q
q 0 0 0 rg BT 230.93 162.70 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 285.38 167.23 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.32 162.70 Td ( is the first and currently the only vasopressin injection with an NDA) Tj ET Q
q 0 0 0 rg BT 565.82 162.70 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 150.70 Td (approved by the FDA.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 138.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 138.70 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 143.83 143.23 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.76 138.70 Td (, which is a non-selective alpha and beta adrener) Tj ET Q
q 0 0 0 rg BT 342.66 138.70 Td (gic agonist indicated for emer) Tj ET Q
q 0 0 0 rg BT 461.88 138.70 Td (gency treatment of certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 126.70 Td (aller) Tj ET Q
q 0 0 0 rg BT 103.08 126.70 Td (gic reactions, including anaphylaxis.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 114.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 114.70 Td (Ertapenem for injection, the authorized generic of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.63 114.70 Td (Merck Sharp & Dohme Corp.�) Tj ET Q
q 0 0 0 rg BT 409.56 114.70 Td (s \(Merck\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.71 114.70 Td ( Invanz) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 478.42 119.23 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.35 114.70 Td (, which is indicated for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 102.70 Td (the treatment of certain moderate-to-severe infections.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 90.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 90.70 Td (APLISOL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 126.61 95.23 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.55 90.70 Td (, which is a sterile aqueous solution of a purified protein derivative for intradermal administration as an aid in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 78.70 Td (the diagnosis of tuberculosis.) Tj ET Q
endstream
endobj
17 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 18 0 R>>
endobj
18 0 obj
<</Length 16539>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (Ephedrine sulfate injection, which is an alpha and beta adrener) Tj ET Q
q 0 0 0 rg BT 336.33 742.10 Td (gic agonist and a norepinephrine-releasing agent indicated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (for the treatment of clinically important hypotension occurring in the setting of anesthesia.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 718.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 718.10 Td (T) Tj ET Q
q 0 0 0 rg BT 91.26 718.10 Td (reprostinil for injection, which is used for the treatment of pulmonary arterial hypertension.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 682.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 682.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.72 682.10 Td ( segment includes a product portfolio of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.44 682.10 Td (150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.44 682.10 Td ( generic prescription product families ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches \(which are medicated adhesive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (patches designed to deliver the pharmaceutical through the skin\), powders, ophthalmics \(which are sterile pharmaceutical preparations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (administered for ocular conditions\) and sprays and includes products in the pain management, urology) Tj ET Q
q 0 0 0 rg BT 445.24 646.10 Td (, central nervous system ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (disorders, immunosuppression, oncology) Tj ET Q
q 0 0 0 rg BT 199.78 634.10 Td (, women�) Tj ET Q
q 0 0 0 rg BT 237.00 634.10 Td (s health and cardiovascular disease markets, among others.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.10 Td (Generic products are the pharmaceutical and therapeutic equivalents of branded products and are generally marketed under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (their generic \(chemical\) names rather than their brand names. Generic products are substantially the same as branded products in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (dosage form, safety) Tj ET Q
q 0 0 0 rg BT 113.93 592.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 126.52 592.10 Td (ficacy) Tj ET Q
q 0 0 0 rg BT 150.30 592.10 Td (, route of administration, quality) Tj ET Q
q 0 0 0 rg BT 279.07 592.10 Td (, performance characteristics and intended use, but are generally sold at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (prices below those of the corresponding branded products and thus represent cost-ef) Tj ET Q
q 0 0 0 rg BT 372.10 580.10 Td (fective alternatives for consumers.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 562.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 562.10 Td (ypically) Tj ET Q
q 0 0 0 rg BT 99.97 562.10 Td (, a generic product may not be marketed until the expiration of applicable patent\(s\) on the corresponding branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (product unless a resolution of patent litigation results in an earlier opportunity to enter the market. For additional detail, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 538.10 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.02 538.10 Td (.� However) Tj ET Q
q 0 0 0 rg BT 189.71 538.10 Td (, our generics portfolio also contains certain authorized generics, which are generic versions of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (branded products licensed by brand drug companies under an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.98 526.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.09 526.10 Td ( and marketed as generics. ) Tj ET Q
q 0 0 0 rg BT 412.83 526.10 Td (Authorized generics do not face the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (same regulatory barriers to introduction and are not prohibited from sale during the 180-day marketing exclusivity period granted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (the first-to-file ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.54 502.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.87 502.10 Td ( applicant. Our authorized generics include generic versions of our branded products including, for example, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (lidocaine patch 5% \(LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 171.24 494.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.18 490.10 Td (\). ) Tj ET Q
q 0 0 0 rg BT 184.33 490.10 Td (W) Tj ET Q
q 0 0 0 rg BT 192.96 490.10 Td (e also aim to be a partner of choice to lar) Tj ET Q
q 0 0 0 rg BT 356.04 490.10 Td (ge companies seeking authorized generic distributors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (for their branded products. For example, in ) Tj ET Q
q 0 0 0 rg BT 210.12 478.10 Td (April 2019, we launched albuterol sulfate HF) Tj ET Q
q 0 0 0 rg BT 390.72 478.10 Td (A) Tj ET Q
q 0 0 0 rg BT 397.39 478.10 Td ( inhalation aerosol \(the authorized generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.83 466.10 Td (Merck) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.93 466.10 Td (�) Tj ET Q
q 0 0 0 rg BT 75.71 466.10 Td (s Proventil) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 118.76 470.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.70 466.10 Td (\) and, in July 2018, we launched colchicine tablets \(the authorized generic of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.69 466.10 Td (T) Tj ET Q
q 0 0 0 rg BT 439.10 466.10 Td (akeda Pharmaceuticals U.S.A., ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (Inc.�) Tj ET Q
q 0 0 0 rg BT 54.05 454.10 Td (s \(T) Tj ET Q
q 0 0 0 rg BT 69.18 454.10 Td (akeda\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.82 454.10 Td ( Colcrys) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 129.43 458.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.37 454.10 Td (\).) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (International Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 418.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 418.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.17 418.10 Td ( segment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.49 418.10 Td (includes a variety of specialty pharmaceutical products sold outside the U.S., ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (primarily in Canada through our operating company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.33 406.10 Td (Paladin Labs Inc. \(Paladin\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.19 406.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.01 406.10 Td (The key products of this segment serve growing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (therapeutic areas, including attention deficit hyperactivity disorder) Tj ET Q
q 0 0 0 rg BT 301.89 394.10 Td (, pain, women�) Tj ET Q
q 0 0 0 rg BT 361.32 394.10 Td (s health and oncology) Tj ET Q
q 0 0 0 rg BT 448.15 394.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.10 Td (This segment also included: \(i\) our South ) Tj ET Q
q 0 0 0 rg BT 230.48 376.10 Td (African business, which was sold in July 2017 and consisted of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.00 376.10 Td (Litha Healthcare ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (Group Limited and certain assets acquired from ) Tj ET Q
q 0 0 0 rg BT 228.99 364.10 Td (Aspen Holdings in October 2015 \(Litha\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.46 364.10 Td ( and \(ii\) our Latin ) Tj ET Q
q 0 0 0 rg BT 464.50 364.10 Td (American business, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (was sold in October 2017 and consisted of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.19 352.10 Td (Grupo Farmac�utico Somar) Tj ET Q
q 0 0 0 rg BT 318.87 352.10 Td (, S.A.P) Tj ET Q
q 0 0 0 rg BT 346.11 352.10 Td (.I. de C.V) Tj ET Q
q 0 0 0 rg BT 383.98 352.10 Td (. \(Somar\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.75 352.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (Select Development Pr) Tj ET Q
q 0 0 0 rg BT 132.45 334.10 Td (ojects) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (XIAFLEX) Tj ET Q
BT /F4 10.00 Tf ET
BT /F4 6.50 Tf ET
q 0 0 0 rg BT 79.35 320.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 298.10 Td (XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 105.77 302.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.71 298.10 Td (, which contains the enzyme ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.79 298.10 Td (collagenase clostridium histolyticum \(CCH\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.70 298.10 Td (, is currently approved by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.39 298.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.84 298.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (marketed in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.70 286.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.48 286.10 Td ( for the treatment of both ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.22 286.10 Td (DC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.12 286.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.55 286.10 Td (PD) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.34 286.10 Td ( \(two separate medical therapeutic indications\). ) Tj ET Q
q 0 0 0 rg BT 458.65 286.10 Td (As further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.07 286.10 Td (Note ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (1) Tj ET Q
q 0 0 0 rg BT 40.63 274.10 Td (1. License and Collaboration ) Tj ET Q
q 0 0 0 rg BT 158.10 274.10 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.42 274.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.91 274.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.78 274.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.49 274.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 450.36 274.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.34 274.10 Td (, we in-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (licensed certain rights related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.22 262.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.79 262.10 Td ( pursuant to which we may) Tj ET Q
q 0 0 0 rg BT 294.17 262.10 Td (, among other things, develop our XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 474.14 266.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.08 262.10 Td ( product or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (product candidates containing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.46 250.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 250.10 Td ( for potential additional medical therapeutics indications.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 232.10 Td (In early 2020, we announced that we had initiated our XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 323.76 236.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.69 232.10 Td ( development programs for the treatment of plantar ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (fibromatosis and adhesive capsulitis.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (Collagenase Clostridium Histolyticum - Medical ) Tj ET Q
q 0 0 0 rg BT 237.03 202.10 Td (Aesthetics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.10 Td (Our license rights relating to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.91 184.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.48 184.10 Td ( also permit us to develop product candidates containing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.47 184.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.04 184.10 Td ( for certain medical aesthetics ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (indications. For example, we have rights to develop and globally market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.87 172.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.43 172.10 Td ( for the treatment of cellulite. ) Tj ET Q
q 0 0 0 rg BT 467.92 172.10 Td (W) Tj ET Q
q 0 0 0 rg BT 476.56 172.10 Td (e are currently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (progressing our cellulite treatment development program. ) Tj ET Q
q 0 0 0 rg BT 268.80 160.10 Td (While based on the same enzyme, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.36 160.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.92 160.10 Td ( for the treatment of cellulite is a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 148.10 Td (ferent formulation and presentation with a dif) Tj ET Q
q 0 0 0 rg BT 228.91 148.10 Td (ferent treatment regimen. In November 2019, we announced the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.98 148.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.87 148.10 Td (�) Tj ET Q
q 0 0 0 rg BT 509.65 148.10 Td (s acceptance for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (review of the original ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.86 136.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.31 136.10 Td ( for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.97 136.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.53 136.10 Td ( for the treatment of cellulite in the buttocks. ) Tj ET Q
q 0 0 0 rg BT 362.40 136.10 Td (The BLA) Tj ET Q
q 0 0 0 rg BT 399.90 136.10 Td ( is supported by the results of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (RELEASE-1 and RELEASE-2 Phase 3 studies, as well as a clinical program. ) Tj ET Q
q 0 0 0 rg BT 347.42 124.10 Td (T) Tj ET Q
q 0 0 0 rg BT 353.18 124.10 Td (rial subjects receiving ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.42 124.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.98 124.10 Td ( for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (cellulite showed highly statistically significant levels of improvement in the appearance of cellulite with treatment, as measured by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (trials�) Tj ET Q
q 0 0 0 rg BT 58.58 100.10 Td ( primary endpoint. In addition, the RELEASE-1 trial passed 8 out of 8 key secondary endpoints and the RELEASE-2 trial passed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (7 out of 8 key secondary endpoints. Finally) Tj ET Q
q 0 0 0 rg BT 208.66 88.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.66 88.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.22 88.10 Td ( for the treatment of cellulite was well-tolerated in the actively-treated subjects with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (most adverse events being mild to moderate in severity and primarily limited to the local injection area. ) Tj ET Q
q 0 0 0 rg BT 452.36 76.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.41 76.10 Td (Prescription Drug User ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.10 Td (Fee ) Tj ET Q
q 0 0 0 rg BT 52.39 64.10 Td (Act \(PDUF) Tj ET Q
q 0 0 0 rg BT 97.48 64.10 Td (A\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.03 64.10 Td ( date, or tar) Tj ET Q
q 0 0 0 rg BT 153.38 64.10 Td (get action date, for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.57 64.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.01 64.10 Td ( has been set for July 6, 2020.) Tj ET Q
endstream
endobj
19 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 20 0 R>>
endobj
20 0 obj
<</Length 14571>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Subject to certain limitations, we have the right to further develop this same and/or other product candidates containing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.58 742.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.15 742.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (for additional medical aesthetics indications.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.10 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 694.10 Td (Our remaining pipeline consists mainly of a variety of product candidates in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.97 694.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.88 694.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.32 694.10 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 682.10 Td ( segments. Our primary approach to developing generic products, including injectables, is to tar) Tj ET Q
q 0 0 0 rg BT 484.02 682.10 Td (get high-barrier) Tj ET Q
q 0 0 0 rg BT 546.29 682.10 Td (-to-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (entry generic product opportunities, including first-to-file or first-to-market opportunities that are dif) Tj ET Q
q 0 0 0 rg BT 438.48 670.10 Td (ficult to formulate or manufacture ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (or face complex legal and regulatory challenges as well as products that meet the evolving needs of hospitals and health systems. ) Tj ET Q
q 0 0 0 rg BT 554.55 658.10 Td (W) Tj ET Q
q 0 0 0 rg BT 563.19 658.10 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (expect such product opportunities to result in products that are either the exclusive generic or have two or fewer generic competitors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (when launched, which we believe tends to lead to more sustainable market share and profitability for our product portfolio. In our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.91 622.10 Td ( business, we also focus on developing branded injectable products with inherent scientific, regulatory) Tj ET Q
q 0 0 0 rg BT 516.32 622.10 Td (, legal and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (technical complexities, as well as developing other dosage forms and technologies.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 592.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 592.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 592.10 Td (, these two segments were actively pursuing approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.13 592.10 Td (120) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.13 592.10 Td ( product candidates, which included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 580.10 Td (65) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.26 580.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.21 580.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.09 580.10 Td (s pending with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.20 580.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.20 580.10 Td (. Of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.97 580.10 Td (65) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.97 580.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.92 580.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.81 580.10 Td (s, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.96 580.10 Td (half) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.50 580.10 Td ( represent first-to-file opportunities or first-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (to-market opportunities. ) Tj ET Q
q 0 0 0 rg BT 134.96 568.10 Td (These numbers do not include five sterile injectable product candidates relating to a second-quarter 2018 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (development, license and commercialization agreement with Nevakar) Tj ET Q
q 0 0 0 rg BT 314.65 556.10 Td (, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 538.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 538.10 Td (e periodically review our development projects in order to better direct investment toward those opportunities that we expect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (will deliver the greatest returns. ) Tj ET Q
q 0 0 0 rg BT 165.22 526.10 Td (This process can lead to decisions to discontinue certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.10 526.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.77 526.10 Td ( projects that may reduce the number of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (products in our previously reported pipeline.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (Major) Tj ET Q
q 0 0 0 rg BT 63.03 496.10 Td ( Customers) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 478.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 478.10 Td (e primarily sell our branded and generic products to wholesalers, retail drug store chains, supermarket chains, mass ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (products from us and, in turn, supply products to retail drug store chains, independent pharmacies and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.18 454.10 Td (managed care or) Tj ET Q
q 0 0 0 rg BT 512.07 454.10 Td (ganizations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (\(MCOs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.33 442.10 Td (. Customers in the managed care market include health maintenance or) Tj ET Q
q 0 0 0 rg BT 352.66 442.10 Td (ganizations, nursing homes, hospitals, clinics, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (pharmacy benefit management companies and mail order customers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.40 430.10 Td (Our current customer group reflects significant consolidation in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (recent years, marked by mer) Tj ET Q
q 0 0 0 rg BT 149.37 418.10 Td (gers and acquisitions and other alliances.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.21 418.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.53 418.10 Td (T) Tj ET Q
q 0 0 0 rg BT 320.94 418.10 Td (otal revenues from direct customers that accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.41 418.10 Td (10%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.74 418.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (more of our total consolidated revenues during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.38 406.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.38 406.10 Td ( are as follows:) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 383.60 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 383.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 383.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 383.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 383.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 383.60 65.00 -14.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
35.50 369.60 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 355.60 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 355.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 355.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 355.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 355.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 355.60 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 383.6 m
437.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 383.6 m
506.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 383.6 m
575.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 383.6 m
506.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 383.6 m
575.5 383.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 387.68 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 387.68 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 387.68 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 374.17 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 103.99 374.17 Td (gen Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 374.17 Td (34) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 374.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 374.17 Td (32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 374.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 374.17 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 374.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 360.17 Td (McKesson Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 360.17 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 360.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 360.17 Td (27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 360.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 360.17 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 360.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 346.17 Td (Cardinal Health, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 346.17 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 346.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 346.17 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 346.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 346.17 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 346.17 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 324.10 Td (Revenues from these customers are included within each of our segments.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 306.10 Td (Some wholesale distributors have demanded that pharmaceutical manufacturers, including us, enter into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.76 306.10 Td (distribution service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 294.10 Td (agreements \(DSAs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.59 294.10 Td ( pursuant to which the wholesale distributors provide the pharmaceutical manufacturers with specific services, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 282.10 Td (including the provision of periodic retail demand information and current inventory levels and other information. ) Tj ET Q
q 0 0 0 rg BT 490.69 282.10 Td (W) Tj ET Q
q 0 0 0 rg BT 499.33 282.10 Td (e have entered into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 270.10 Td (certain of these agreements.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 252.10 Td (Competition) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 234.10 Td (Branded Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 216.10 Td (Our branded products compete with products manufactured by many other companies in highly competitive markets throughout ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 204.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 204.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 204.10 Td ( and internationally) Tj ET Q
q 0 0 0 rg BT 145.60 204.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 186.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 186.10 Td (e compete principally through tar) Tj ET Q
q 0 0 0 rg BT 204.74 186.10 Td (geted product development and through our acquisition and in-licensing strategies, where ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 174.10 Td (we face intense competition as a result of the limited number of assets available and the number of competitors bidding on such assets. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 162.10 Td (In addition to product development and acquisitions, other competitive factors with respect to branded products include product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 150.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 150.10 Td (ficacy) Tj ET Q
q 0 0 0 rg BT 67.36 150.10 Td (, safety) Tj ET Q
q 0 0 0 rg BT 95.59 150.10 Td (, ease of use, price, demonstrated cost-ef) Tj ET Q
q 0 0 0 rg BT 257.84 150.10 Td (fectiveness, marketing ef) Tj ET Q
q 0 0 0 rg BT 357.89 150.10 Td (fectiveness, service, reputation and access to technical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 138.10 Td (information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 120.10 Td (Branded products often must compete with therapeutically similar branded or generic products or with generic equivalents. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 108.10 Td (Such competition frequently increases over time. For example, if competitors introduce new products, delivery systems or processes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 96.10 Td (with therapeutic or cost advantages, our products could be subject to progressive price reductions and/or decreased volume of sales. ) Tj ET Q
q 0 0 0 rg BT 565.37 96.10 Td (T) Tj ET Q
q 0 0 0 rg BT 570.78 96.10 Td (o ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 84.10 Td (successfully compete for business, we must often demonstrate that our products of) Tj ET Q
q 0 0 0 rg BT 365.74 84.10 Td (fer not only medical benefits, but also cost ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 72.10 Td (advantages as compared with other forms of care. ) Tj ET Q
q 0 0 0 rg BT 236.76 72.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 286.09 72.10 Td (, we face pressure to continually seek out technological innovations and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 60.10 Td (to market our products ef) Tj ET Q
q 0 0 0 rg BT 136.90 60.10 Td (fectively) Tj ET Q
q 0 0 0 rg BT 171.23 60.10 Td (.) Tj ET Q
endstream
endobj
21 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 22 0 R>>
endobj
22 0 obj
<</Length 14712>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (7) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Manufacturers of generic products typically invest far less in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.75 742.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.42 742.10 Td ( than research-based companies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.31 742.10 Td ( and can therefore price their ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (products significantly lower than branded products. ) Tj ET Q
q 0 0 0 rg BT 244.01 730.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 293.34 730.10 Td (, when a branded product loses its market exclusivity) Tj ET Q
q 0 0 0 rg BT 505.14 730.10 Td (, it normally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (faces intense price competition from generic forms of the product. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.40 718.10 Td (Due to lower prices, generic versions, where available, may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (substituted by pharmacies or required in preference to branded versions under third-party reimbursement programs.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 688.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.10 Td (This segment�) Tj ET Q
q 0 0 0 rg BT 119.38 670.10 Td (s major competitors, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.08 670.10 Td (Mylan N.V) Tj ET Q
q 0 0 0 rg BT 288.35 670.10 Td (. \(Mylan\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.12 670.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.56 670.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 350.93 670.10 Td (gan plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.08 670.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.08 670.10 Td (Jazz Pharmaceuticals plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.04 670.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.86 670.10 Td (T) Tj ET Q
q 0 0 0 rg BT 495.27 670.10 Td (akeda ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (Pharmaceutical Company Limited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.18 658.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.18 658.10 Td (Horizon ) Tj ET Q
q 0 0 0 rg BT 213.27 658.10 Td (Therapeutics plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.63 658.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.07 658.10 Td (Mallinckrodt plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 366.00 658.10 Td (, among others, vary depending on therapeutic and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (product category) Tj ET Q
q 0 0 0 rg BT 102.82 646.10 Td (, dosage strength and drug-delivery systems, among other factors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 628.10 Td (Several of this segment�) Tj ET Q
q 0 0 0 rg BT 159.37 628.10 Td (s products, such as PERCOCET) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 287.98 632.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.91 628.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 297.73 628.10 Td (TEST) Tj ET Q
q 0 0 0 rg BT 321.44 628.10 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 346.44 632.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.38 628.10 Td ( and LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 423.59 632.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.53 628.10 Td (, face generic and/or other forms of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (competition. ) Tj ET Q
q 0 0 0 rg BT 88.59 616.10 Td (The degree of generic and/or other competition facing this segment could increase in the future. ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 598.10 Td (Sterile Injectables) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 580.10 Td (This segment�) Tj ET Q
q 0 0 0 rg BT 119.38 580.10 Td (s major competitors, including Hospira, Inc. \(a subsidiary of Pfizer Inc.\), ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.20 580.10 Td (Fresenius Kabi USA, LLC \(Fresenius\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.35 580.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.11 568.10 Td ( and Hikma Pharmaceuticals PLC, vary by product. ) Tj ET Q
q 0 0 0 rg BT 270.39 568.10 Td (A) Tj ET Q
q 0 0 0 rg BT 277.06 568.10 Td ( significant portion of our sales, including sales to hospitals, clinics and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (long-term care facilities in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.00 556.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.79 556.10 Td (, are controlled by a relatively small number of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.27 556.10 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.28 556.10 Td (s, including HealthT) Tj ET Q
q 0 0 0 rg BT 468.86 556.10 Td (rust Purchasing Group, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (L.P) Tj ET Q
q 0 0 0 rg BT 49.06 544.10 Td (., Premier Inc. and ) Tj ET Q
q 0 0 0 rg BT 125.24 544.10 Td (V) Tj ET Q
q 0 0 0 rg BT 131.86 544.10 Td (izient, Inc. ) Tj ET Q
q 0 0 0 rg BT 176.29 544.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 225.63 544.10 Td (, it is important for us to have strong relationships with these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.87 544.10 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.88 544.10 Td (s and achieve on-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (time product launches in order to secure new bid opportunities.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (Generic Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 496.10 Td (Generic products generally face intense competition from branded equivalents, other generic equivalents \(including authorized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (generics\) and therapeutically similar branded or generic products. Our major competitors, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.35 484.10 Td (T) Tj ET Q
q 0 0 0 rg BT 442.76 484.10 Td (eva Pharmaceutical Industries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (Limited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.66 472.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.66 472.10 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.77 472.10 Td (, Sandoz \(a division of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.53 472.10 Td (Novartis) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.97 472.10 Td (\) and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.19 472.10 Td (Amneal Pharmaceuticals, Inc. \(Amneal\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.95 472.10 Td (, among others, vary by product.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 454.10 Td (Consolidations of our customer base described above under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.36 454.10 Td (Major Customers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.08 454.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.52 454.10 Td ( have resulted in increased pricing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (and other competitive pressures on pharmaceutical companies, including us. ) Tj ET Q
q 0 0 0 rg BT 342.86 442.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 392.76 442.10 Td (, the emer) Tj ET Q
q 0 0 0 rg BT 432.28 442.10 Td (gence of lar) Tj ET Q
q 0 0 0 rg BT 479.29 442.10 Td (ge buying groups ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (representing independent retail pharmacies and other distributors and the prevalence and influence of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.34 430.10 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.12 430.10 Td (s) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.01 430.10 Td ( and similar institutions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (have increased the negotiating power of these groups, enabling them to attempt to extract various demands, including without ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (limitation price discounts, rebates and other restrictive pricing terms. ) Tj ET Q
q 0 0 0 rg BT 313.79 406.10 Td (These competitive trends could continue in the future and could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.32 394.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 140.20 394.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.18 394.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.10 Td (Newly introduced generic products with limited or no other generic competition typically garner higher prices relative to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (commoditized generic products. ) Tj ET Q
q 0 0 0 rg BT 166.52 364.10 Td (As such, our primary strategy is to compete with a focus on high-value, first-to-file or first-to-market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (opportunities, regardless of therapeutic category) Tj ET Q
q 0 0 0 rg BT 228.33 352.10 Td (, and products that present significant barriers to entry for reasons such as complex ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (formulation or regulatory or legal challenges. For additional detail, see �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.90 340.10 Td (Our Competitive Strengths) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.67 340.10 Td ( - ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.00 340.10 Td (Focus on the dif) Tj ET Q
q 0 0 0 rg BT 506.54 340.10 Td (ferentiated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (products of our sterile injectables and generics portfolios.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.93 328.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 310.10 Td (Even if we are successful in launching generic products with statutory generic exclusivity) Tj ET Q
q 0 0 0 rg BT 421.13 310.10 Td (, competitors may enter the market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (when such exclusivity periods expire, resulting in significant price declines. Consequently) Tj ET Q
q 0 0 0 rg BT 396.38 298.10 Td (, maintaining profitable operations depends, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (in part, on our continuing ability to select, develop, procure regulatory approvals of, overcome legal challenges to, launch and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (commercialize new generic products in a timely and cost ef) Tj ET Q
q 0 0 0 rg BT 273.78 274.10 Td (ficient manner and to maintain ef) Tj ET Q
q 0 0 0 rg BT 406.60 274.10 Td (ficient, high quality manufacturing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (capabilities. For additional detail, see �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.34 262.10 Td (Our Competitive Strengths) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.11 262.10 Td ( - ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.44 262.10 Td (Operational excellence.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.83 262.10 Td (�) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (Seasonality) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 226.10 Td (Although our business is af) Tj ET Q
q 0 0 0 rg BT 172.26 226.10 Td (fected by the purchasing patterns and concentration of our customers, our business is not materially ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (impacted by seasonality) Tj ET Q
q 0 0 0 rg BT 131.43 214.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (Patents, ) Tj ET Q
q 0 0 0 rg BT 72.48 196.10 Td (T) Tj ET Q
q 0 0 0 rg BT 78.41 196.10 Td (rademarks, Licenses and Pr) Tj ET Q
q 0 0 0 rg BT 197.67 196.10 Td (oprietary Pr) Tj ET Q
q 0 0 0 rg BT 250.52 196.10 Td (operty) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 178.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 178.10 Td (e regard the protection of patents and other enforceable intellectual property rights that we own or license as critical to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (business and competitive position. ) Tj ET Q
q 0 0 0 rg BT 175.71 166.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 225.05 166.10 Td (, we rely on patent, trade secret and copyright law) Tj ET Q
q 0 0 0 rg BT 424.04 166.10 Td (, as well as nondisclosure and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (contractual arrangements, to protect our intellectual property) Tj ET Q
q 0 0 0 rg BT 278.30 154.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 283.12 154.10 Td (W) Tj ET Q
q 0 0 0 rg BT 291.76 154.10 Td (e have a portfolio of patents and patent applications owned or licensed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (by us that cover aspects of our products. ) Tj ET Q
q 0 0 0 rg BT 199.39 142.10 Td (These patents and applications generally include claims directed to the compounds and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (methods of using the compounds, formulations of the compounds, pharmaceutical salt forms of the compounds or methods of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (manufacturing the compounds. Our policy is to pursue patent applications on inventions that we believe are commercially important to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (the development and growth of our business. Certain patents relating to products that are the subject of approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.49 106.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.15 106.10 Td (s are listed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 94.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 94.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 94.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.45 94.10 Td ( publication, �Approved Drug Products with ) Tj ET Q
q 0 0 0 rg BT 270.52 94.10 Td (Therapeutic Equivalence Evaluations� \(Orange Book\). ) Tj ET Q
q 0 0 0 rg BT 491.92 94.10 Td (The table below ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (contains a list from the Orange Book of patent expiration dates for certain products we market.) Tj ET Q
endstream
endobj
23 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 24 0 R>>
endobj
24 0 obj
<</Length 15454>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (8) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (The Orange Book does not include a listing of patents related to biological products. Included in the table are certain products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (for which we own or license a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.01 730.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.46 730.10 Td ( along with the date of expiration of certain relevant patents or regulatory exclusivity) Tj ET Q
q 0 0 0 rg BT 517.42 730.10 Td (. In addition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (we may have other relevant regulatory protection or patents that may extend beyond the expiration date listed in the table below) Tj ET Q
q 0 0 0 rg BT 547.40 718.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 552.22 718.10 Td (W) Tj ET Q
q 0 0 0 rg BT 560.85 718.10 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (may also obtain further patents or additional regulatory or patent exclusivity for one or more indications for a product in the future.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 688.10 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.04 688.10 Td (, we held approximately: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.96 688.10 Td (234) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.96 688.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.46 688.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.24 688.10 Td ( issued patents, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.56 688.10 Td (36) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.56 688.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.06 688.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.85 688.10 Td ( patent applications pending, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.32 688.10 Td (454) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.32 688.10 Td ( foreign ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (issued patents and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.26 676.10 Td (71) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.26 676.10 Td ( foreign patent applications pending. In addition, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.38 676.10 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.97 676.10 Td (, we had licenses for approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.65 676.10 Td (46) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.65 676.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 664.10 Td ( issued patents, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.11 664.10 Td (1) Tj ET Q
q 0 0 0 rg BT 121.74 664.10 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.74 664.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.24 664.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.02 664.10 Td ( patent applications pending, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.49 664.10 Td (171) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.49 664.10 Td ( foreign issued patents and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.63 664.10 Td (64) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.63 664.10 Td ( foreign patent applications pending. ) Tj ET Q
q 0 0 0 rg BT 547.30 664.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (following table sets forth, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.92 652.10 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.52 652.10 Td (, the year of expiration relating to certain of our products:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 620.60 471.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 620.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 620.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 592.60 471.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 592.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 592.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 564.60 471.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 564.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 564.60 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 620.6 m
506.5 620.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 620.6 m
575.5 620.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 624.83 Td (Relevant�Pr) Tj ET Q
q 0 0 0 rg BT 78.51 624.83 Td (oduct) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 531.35 632.83 Td (Patent) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 513.70 624.83 Td (Expiration \(1\)\(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 611.17 Td (V) Tj ET Q
q 0 0 0 rg BT 43.93 611.17 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 98.39 615.70 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 611.17 Td (2035) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 597.17 Td (XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 80.77 601.70 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 597.17 Td (2028) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 583.17 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 96.33 587.70 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 583.17 Td (2035) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 569.17 Td (NASCOBAL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 91.90 573.70 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.83 569.17 Td ( Nasal Spray) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 569.17 Td (2024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 555.17 Td (A) Tj ET Q
q 0 0 0 rg BT 43.93 555.17 Td (VEED) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 70.59 559.70 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 555.17 Td (2027) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 543.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 533.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 533.50 Td (Our license agreements for the patents in the table above extend to or beyond the patent expiration dates. See ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 418.49 533.50 Td (Note 1) Tj ET Q
q 0 0 0 rg BT 439.74 533.50 Td (1. License and Collaboration ) Tj ET Q
q 0 0 0 rg BT 533.72 533.50 Td (Agreements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 572.37 533.50 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 523.90 Td (in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.50 523.90 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 198.59 523.90 Td ( included in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 238.36 523.90 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 260.66 523.90 Td (, Item 15 of this report) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 332.64 523.90 Td ( for additional discussion about certain license agreements.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 514.30 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 514.30 Td (The expiration of a basic product patent or loss of patent protection resulting from a legal challenge normally results in significant competition from generic ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 504.70 Td (products or biosimilars against the originally patented product and can result in a significant reduction in revenues for that product in a very short period of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 495.10 Td (time. In some cases, however) Tj ET Q
q 0 0 0 rg BT 161.37 495.10 Td (, we can continue to obtain commercial benefits from product manufacturing trade secrets, patents on uses for products, patents ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 485.50 Td (on processes and intermediates for the economical manufacture of the active ingredients or patents for special formulations of the product or delivery ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 475.90 Td (mechanisms.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 457.90 Td (The ef) Tj ET Q
q 0 0 0 rg BT 88.63 457.90 Td (fect of these issued patents is that they provide us with protection by virtue of our ability to exclude others from making, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 445.90 Td (using, selling, of) Tj ET Q
q 0 0 0 rg BT 102.48 445.90 Td (fering for sale and importing that which is covered by their claims. ) Tj ET Q
q 0 0 0 rg BT 371.95 445.90 Td (T) Tj ET Q
q 0 0 0 rg BT 377.36 445.90 Td (o achieve a competitive position, we also rely on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 433.90 Td (trade secrets, non-patented proprietary know-how and continuing technological innovation, where patent protection is not believed to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 421.90 Td (be appropriate or attainable. Many of our products are sold under trademarks. ) Tj ET Q
q 0 0 0 rg BT 348.49 421.90 Td (W) Tj ET Q
q 0 0 0 rg BT 357.12 421.90 Td (e also rely on confidentiality agreements with our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 409.90 Td (employees, consultants and other parties to protect, among other things, trade secrets and other proprietary information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 391.90 Td (There can be no assurance that any of our patents, licenses or other intellectual property rights will af) Tj ET Q
q 0 0 0 rg BT 467.67 391.90 Td (ford us any protection ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 379.90 Td (from competition or that our confidentiality agreements will not be breached, that we will have adequate remedies for any breach, that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 367.90 Td (others will not independently develop equivalent proprietary information or that other third parties will not otherwise gain access to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 355.90 Td (our trade secrets and other intellectual property) Tj ET Q
q 0 0 0 rg BT 224.16 355.90 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 337.90 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 112.90 337.90 Td (, any pending or future patent applications made by us or our subsidiaries, our license partners or entities we may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 325.90 Td (acquire in the future are subject to risks and uncertainties. ) Tj ET Q
q 0 0 0 rg BT 269.34 325.90 Td (The coverage claimed in any such patent applications could be significantly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 313.90 Td (reduced before the patent is issued and there can be no assurance that any such applications will result in the issuance of patents or) Tj ET Q
q 0 0 0 rg BT 557.92 313.90 Td (, if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 301.90 Td (any patents are issued, whether they will provide significant proprietary protection or will be challenged, circumvented or invalidated. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 289.90 Td (Because unissued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.32 289.90 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.10 289.90 Td ( patent applications are maintained in secrecy for a period of eighteen months and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.98 289.90 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.76 289.90 Td ( patent applications filed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 277.90 Td (prior to November 29, 2000 are not disclosed until such patents are issued, and since publication of discoveries in the scientific or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 265.90 Td (patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 253.90 Td (applications. Moreover) Tj ET Q
q 0 0 0 rg BT 128.35 253.90 Td (, we may have to participate in interference and other inter) Tj ET Q
q 0 0 0 rg BT 362.21 253.90 Td (-parties proceedings declared by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.09 253.90 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.87 253.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.37 253.90 Td (Patent and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 241.90 Td (T) Tj ET Q
q 0 0 0 rg BT 41.76 241.90 Td (rademark Of) Tj ET Q
q 0 0 0 rg BT 92.38 241.90 Td (fice \(PT) Tj ET Q
q 0 0 0 rg BT 124.69 241.90 Td (O\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.24 241.90 Td ( to determine priority of invention, or in opposition proceedings in a foreign patent of) Tj ET Q
q 0 0 0 rg BT 476.92 241.90 Td (fice, either of which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 229.90 Td (could result in substantial cost to us, even if the eventual outcome is favorable to us. ) Tj ET Q
q 0 0 0 rg BT 375.18 229.90 Td (There can be no assurance that any patents, if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 217.90 Td (issued, will be held valid by a court of competent jurisdiction. ) Tj ET Q
q 0 0 0 rg BT 285.67 217.90 Td (An adverse outcome could subject us to significant liabilities to third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 205.90 Td (parties, require disputed rights to be licensed from third parties or require us to cease using such technology) Tj ET Q
q 0 0 0 rg BT 466.34 205.90 Td (. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.28 205.90 Td (Item 1A. Risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 193.90 Td (Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.44 193.90 Td ( - �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.21 193.90 Td (Our ability to protect and maintain our proprietary and licensed third party technology) Tj ET Q
q 0 0 0 rg BT 422.46 193.90 Td (, which is vital to our business, is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 181.90 Td (uncertain) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.20 181.90 Td (.�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 163.90 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 163.90 Td (e may find it necessary to initiate litigation to enforce our patent rights, to protect our intellectual property or trade secrets or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 151.90 Td (to determine the scope and validity of the proprietary rights of others. Litigation is costly and time-consuming and there can be no ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 139.90 Td (assurance that our litigation expenses will not be significant in the future or that we will prevail in any such litigation. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.16 139.90 Td (Note 15. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 127.90 Td (Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.32 127.90 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.82 127.90 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.68 127.90 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.39 127.90 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 413.27 127.90 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.25 127.90 Td (.) Tj ET Q
endstream
endobj
25 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 26 0 R>>
endobj
26 0 obj
<</Length 15182>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.50 31.60 Td (9) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Governmental Regulation) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 724.25 Td (U.S.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 53.78 724.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 56.28 724.25 Td (FDA) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 76.29 724.25 Td ( and ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 96.85 724.25 Td (Drug Enforcement ) Tj ET Q
q 0 0 0 rg BT 177.04 724.25 Td (Administration \(DEA\)) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 706.25 Td (The pharmaceutical industry in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.89 706.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.68 706.25 Td ( is subject to extensive and rigorous government regulation. ) Tj ET Q
q 0 0 0 rg BT 464.11 706.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.16 706.25 Td (Federal Food, Drug, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (and Cosmetic ) Tj ET Q
q 0 0 0 rg BT 92.66 694.25 Td (Act \(FFDCA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.50 694.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.21 694.25 Td (Controlled Substances ) Tj ET Q
q 0 0 0 rg BT 259.87 694.25 Td (Act \(CSA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.92 694.25 Td ( and other federal and state statutes and regulations govern or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (influence the testing, manufacturing, packaging, labeling, storage, recordkeeping, approval, advertising, promotion, sale and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (distribution of pharmaceutical products. Noncompliance with applicable requirements can result in criminal prosecution, fines, civil ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (penalties, recall or seizure of products, total or partial suspension of production and/or distribution, injunctions and refusal of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (government to enter into supply contracts or to approve ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.66 646.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.33 646.25 Td (s, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.67 646.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.55 646.25 Td (s, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.45 646.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.45 646.25 Td (s and/or other similar applications.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 628.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.45 628.25 Td ( approval is typically required before any new pharmaceutical or biologic product can be marketed. ) Tj ET Q
q 0 0 0 rg BT 481.74 628.25 Td (An ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.46 628.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.58 628.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.91 628.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.35 628.25 Td ( is a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (filing submitted to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.10 616.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.56 616.25 Td ( to obtain approval of new chemical entities and other innovations for which thorough applied research is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (required to demonstrate safety and ef) Tj ET Q
q 0 0 0 rg BT 184.37 604.25 Td (fectiveness in use. ) Tj ET Q
q 0 0 0 rg BT 259.72 604.25 Td (The process generally involves, among other things:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 592.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 592.25 Td (completion of preclinical laboratory and animal testing and formulation studies in compliance with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.72 592.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.61 592.25 Td (�) Tj ET Q
q 0 0 0 rg BT 520.39 592.25 Td (s Good ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 580.25 Td (Laboratory Practice regulations;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 568.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 568.25 Td (submission to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.00 568.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.46 568.25 Td ( of an Investigational New Drug application for human clinical testing, which must become ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 556.25 Td (ef) Tj ET Q
q 0 0 0 rg BT 93.09 556.25 Td (fective before human clinical trials may begin in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.40 556.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.18 556.25 Td (;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 544.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 544.25 Td (approval by an independent institutional review board before each trial may be initiated and continuing review during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 532.25 Td (trial;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 520.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 520.25 Td (performance of human clinical trials, including adequate and well-controlled clinical trials in accordance with good ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 508.25 Td (clinical practices to establish the safety and ef) Tj ET Q
q 0 0 0 rg BT 268.85 508.25 Td (ficacy of the proposed product for each intended use;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 496.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 496.25 Td (submission to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.00 496.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.46 496.25 Td ( of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.73 496.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.84 496.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.17 496.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.62 496.25 Td ( for marketing approval, which must include data from preclinical testing and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 484.25 Td (clinical trials;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 472.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 472.25 Td (satisfactory completion of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.35 472.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.81 472.25 Td ( pre-approval inspection of the product�) Tj ET Q
q 0 0 0 rg BT 382.37 472.25 Td (s manufacturing processes and facility or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 460.25 Td (facilities to assess compliance with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.23 460.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.13 460.25 Td (�) Tj ET Q
q 0 0 0 rg BT 264.91 460.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.30 460.25 Td (current Good Manufacturing Practice \(cGMP\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.24 460.25 Td ( regulations and/or review of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 448.25 Td (the Chemistry) Tj ET Q
q 0 0 0 rg BT 141.23 448.25 Td (, Manufacturing and Controls section of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.42 448.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.53 448.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.86 448.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.31 448.25 Td ( to assess whether the facilities, methods and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 436.25 Td (controls are adequate to preserve the proposed product�) Tj ET Q
q 0 0 0 rg BT 306.80 436.25 Td (s identity) Tj ET Q
q 0 0 0 rg BT 343.10 436.25 Td (, strength, quality) Tj ET Q
q 0 0 0 rg BT 412.44 436.25 Td (, purity and potency;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 424.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 424.25 Td (satisfactory completion of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.35 424.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.81 424.25 Td ( advisory committee review) Tj ET Q
q 0 0 0 rg BT 334.51 424.25 Td (, if applicable; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 412.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 412.25 Td (approval by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.20 412.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.66 412.25 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.70 412.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.82 412.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.15 412.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.15 412.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 394.25 Td (Clinical trials are typically conducted in three sequential phases, although the phases may overlap. ) Tj ET Q
q 0 0 0 rg BT 458.81 394.25 Td (Those phases include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 382.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 382.25 Td (Phase 1 trials generally involve testing the product for safety) Tj ET Q
q 0 0 0 rg BT 327.84 382.25 Td (, adverse ef) Tj ET Q
q 0 0 0 rg BT 373.46 382.25 Td (fects, dosage, tolerance, absorption, distribution, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 370.25 Td (metabolism, excretion and other elements of clinical pharmacology) Tj ET Q
q 0 0 0 rg BT 354.20 370.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 358.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 358.25 Td (Phase 2 trials typically involve a small sample of the intended patient population to assess the ef) Tj ET Q
q 0 0 0 rg BT 470.23 358.25 Td (ficacy of the compound ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 346.25 Td (for a specific indication, to determine dose tolerance and the optimal dose range and to gather additional information ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 334.25 Td (relating to safety and potential adverse ef) Tj ET Q
q 0 0 0 rg BT 250.25 334.25 Td (fects.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 322.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 322.25 Td (Phase 3 trials are undertaken in an expanded patient population, typically at dispersed study sites, in order to determine ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 310.25 Td (the overall risk-benefit ratio of the compound and to provide an adequate basis for product labeling.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 292.25 Td (Each trial is conducted in accordance with certain standards under protocols that detail the objectives of the study) Tj ET Q
q 0 0 0 rg BT 516.36 292.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.25 Td (parameters to be used to monitor safety and the ef) Tj ET Q
q 0 0 0 rg BT 235.47 280.25 Td (ficacy criteria to be evaluated. Each protocol must be submitted to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.87 280.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.32 280.25 Td ( as part ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (of the Investigational New Drug application. Clinical trials are also subject to regulatory inspections by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.72 268.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.17 268.25 Td ( and other regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.25 Td (authorities to confirm compliance with applicable regulatory standards. ) Tj ET Q
q 0 0 0 rg BT 323.78 256.25 Td (The process of completing clinical trials for a new product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.25 Td (may take many years and require the expenditures of substantial resources. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.05 244.25 Td (Item 1A. Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.38 244.25 Td ( - �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.15 244.25 Td (The pharmaceutical industry ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (is heavily regulated, which creates uncertainty about our ability to bring new products to market and imposes substantial compliance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (costs on our business, including withdrawal or suspension of existing products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.14 220.25 Td (.� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 202.25 Td (As a condition of approval of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.91 202.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.02 202.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.35 202.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.35 202.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.07 202.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.52 202.25 Td ( may require further studies, including Phase 4 post-marketing studies ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (or post-marketing data reporting, such as evaluating known or signaled safety risks. Results of post-marketing programs may limit or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.25 Td (expand the future marketing of the products and result in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.65 178.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.10 178.25 Td ( requiring labeling changes, including the addition of risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.25 Td (information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 148.25 Td (For some products, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.16 148.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.61 148.25 Td ( may require a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.58 148.25 Td (Risk Evaluation and Mitigation Strategy \(REMS\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.62 148.25 Td ( to confirm that a drug�) Tj ET Q
q 0 0 0 rg BT 527.09 148.25 Td (s benefits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (outweigh its risks. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.56 136.25 Td (REMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.79 136.25 Td ( could include medication guides, physician communication plans or other elements. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.47 136.25 Td (Item 1A. Risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.44 124.25 Td ( - �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.21 124.25 Td (The pharmaceutical industry is heavily regulated, which creates uncertainty about our ability to bring new products to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.25 Td (market and imposes substantial compliance costs on our business, including withdrawal or suspension of existing products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.48 112.25 Td (.�) Tj ET Q
endstream
endobj
27 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 28 0 R>>
endobj
28 0 obj
<</Length 18198>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (10) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In most instances, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.43 742.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.89 742.10 Td ( approval of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.09 742.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.42 742.10 Td ( is required before a generic equivalent of an existing or reference-listed drug can ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (be marketed. ) Tj ET Q
q 0 0 0 rg BT 89.96 730.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.46 730.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.79 730.10 Td ( process is abbreviated in that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.58 730.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.03 730.10 Td ( waives the requirement of conducting complete preclinical and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (clinical studies and generally instead relies principally on bioequivalence studies. Bioequivalence generally involves a comparison of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (the rate of absorption and levels of concentration of a generic product in the body with those of the previously approved product. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (When the rate and extent of absorption of systemically acting test and reference drugs are considered the same under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (bioequivalence requirement, the two products are considered bioequivalent and are generally regarded as therapeutically equivalent, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (meaning that a pharmacist can substitute the generic product for the reference-listed drug. Under certain circumstances, an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.74 670.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.08 670.10 Td ( may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (also be submitted for a product authorized by approval of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.54 658.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.88 658.10 Td ( suitability petition. Such petitions may be submitted to secure ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (authorization to file an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.75 646.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.08 646.10 Td ( for a product that dif) Tj ET Q
q 0 0 0 rg BT 242.15 646.10 Td (fers from a previously approved product in active ingredient, route of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (administration, dosage form or strength. In September 2007 and July 2012, Congress re-authorized pediatric testing legislation, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (now requires ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.88 622.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.76 622.10 Td (s approved via the suitability petition route to conduct pediatric testing. ) Tj ET Q
q 0 0 0 rg BT 406.29 622.10 Td (The timing of final ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.61 622.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.06 622.10 Td ( approval of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.33 610.10 Td ( application depends on a variety of factors, including whether the applicant challenges any listed patents for the reference-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (listed drug and whether the manufacturer of the reference-listed drug is entitled to one or more statutory exclusivity periods during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.66 586.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.11 586.10 Td ( is prohibited from approving generic products. In certain circumstances, a regulatory exclusivity period can extend ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (beyond the life of a patent, thus blocking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.80 574.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.68 574.10 Td (s from being approved even after the patent expiration date.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.10 Td (Certain of our products are or could become regulated and marketed as biologic products pursuant to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.98 556.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.98 556.10 Td (s. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.92 556.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.92 556.10 Td (-licensed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (products were licensed based on a determination by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.09 544.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.54 544.10 Td ( of safety) Tj ET Q
q 0 0 0 rg BT 316.10 544.10 Td (, purity and potency as required under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.21 544.10 Td (Public Health Service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (Act \(PHSA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.17 532.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 89.61 532.10 Td (Although the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.06 532.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.39 532.10 Td ( framework referenced above does not apply to generics of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.07 532.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.07 532.10 Td (-licensed biologics, there is an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (abbreviated licensure pathway for products deemed to be biosimilar to, or interchangeable with, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.25 520.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.26 520.10 Td (-licensed reference biological ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (products pursuant to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.87 508.10 Td (Biologics Price Competition and Innovation ) Tj ET Q
q 0 0 0 rg BT 313.47 508.10 Td (Act of 2009 \(BPCIA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.85 508.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 404.67 508.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.71 508.10 Td (BPCIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.62 508.10 Td ( framework was enacted as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (part of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.59 496.10 Td (Patient Protection and ) Tj ET Q
q 0 0 0 rg BT 169.86 496.10 Td (Af) Tj ET Q
q 0 0 0 rg BT 180.23 496.10 Td (fordable Care ) Tj ET Q
q 0 0 0 rg BT 236.87 496.10 Td (Act \(PP) Tj ET Q
q 0 0 0 rg BT 267.34 496.10 Td (ACA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.79 496.10 Td ( and could be impacted by ongoing litigation regarding the legality of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 484.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 60.92 484.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.04 484.10 Td (. Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.24 484.10 Td (BPCIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.70 484.10 Td (, following the expiration of a 12-year reference exclusivity period, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.97 484.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.43 484.10 Td ( may license, under section ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (351\(k\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.71 472.10 Td (PHSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.27 472.10 Td (, a biological product that it determines is biosimilar to, or interchangeable with, a reference product licensed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (under section 351\(a\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.24 460.10 Td (PHSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.81 460.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 176.25 460.10 Td (Although licensure of biosimilar or interchangeable products is generally expected to require less ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (than the full complement of product-specific preclinical and clinical data required for innovator products, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.73 448.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.18 448.10 Td ( has considerable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (discretion over the kind and amount of scientific evidence required to demonstrate biosimilarity and interchangeability) Tj ET Q
q 0 0 0 rg BT 510.20 436.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 418.10 Td (Some pharmaceutical products are available in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.08 418.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.87 418.10 Td ( that are not the subject of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.16 418.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.16 418.10 Td (-approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.20 418.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.86 418.10 Td (. In 201) Tj ET Q
q 0 0 0 rg BT 518.32 418.10 Td (1, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.04 418.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.94 418.10 Td (�) Tj ET Q
q 0 0 0 rg BT 564.71 418.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (Center for Drug Evaluation and Research \(CDER\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.60 406.10 Td ( Of) Tj ET Q
q 0 0 0 rg BT 250.47 406.10 Td (fice of Compliance modified its enforcement policy with regard to the marketing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (of such �unapproved� marketed products. Under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.88 394.10 Td (CDER) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.54 394.10 Td (�) Tj ET Q
q 0 0 0 rg BT 262.32 394.10 Td (s revised guidance, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.90 394.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.36 394.10 Td ( encourages manufacturers to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.80 394.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.91 394.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (approvals for such products by requiring unapproved versions to be removed from the market after an approved version has been ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (introduced, subject to a grace period at the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.43 370.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.33 370.10 Td (�) Tj ET Q
q 0 0 0 rg BT 230.11 370.10 Td (s discretion. ) Tj ET Q
q 0 0 0 rg BT 280.75 370.10 Td (This grace period is intended to allow an orderly transition of supply to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (the market and to mitigate any potential related product shortage. Depending on the length of the grace period and the time it takes for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (subsequent applications to be approved, this may result in a period of de facto market exclusivity to the first manufacturer that has ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (obtained an approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.58 334.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.69 334.10 Td ( for the previously unapproved marketed product.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 316.10 Td (Over) Tj ET Q
q 0 0 0 rg BT 82.79 316.10 Td (-the-counter \(OTC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.81 316.10 Td ( products may) Tj ET Q
q 0 0 0 rg BT 216.82 316.10 Td (, depending on ingredients and proposed label claims, be marketed pursuant to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.12 316.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.12 316.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (monograph process or could require ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.90 304.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.01 304.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.79 304.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.13 304.10 Td ( approval. ) Tj ET Q
q 0 0 0 rg BT 287.43 304.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.48 304.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.48 304.10 Td ( monograph process allows for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.28 304.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.28 304.10 Td ( products to be marketed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (without pre-market approval and generally does not require clinical studies.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 274.10 Td (Laws and regulations impacting the pharmaceutical industry are constantly evolving. For example, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.38 274.10 Td (21st Century Cures ) Tj ET Q
q 0 0 0 rg BT 554.54 274.10 Td (Act ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (\(Cures ) Tj ET Q
q 0 0 0 rg BT 64.61 262.10 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.38 262.10 Td (, which was signed into law on December 13, 2016, includes various provisions to accelerate the development and delivery ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (of new treatments, such as those intended to expand the types of evidence manufacturers may submit to support ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.60 250.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.05 250.10 Td ( approval, to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (encourage patient-centered product development, to liberalize the communication of healthcare economic information to payers and to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (create greater transparency with regard to manufacturer expanded access programs. Central to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.14 226.10 Td (Cures ) Tj ET Q
q 0 0 0 rg BT 454.42 226.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.86 226.10 Td ( are provisions that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (enhance and accelerate the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.37 214.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.26 214.10 Td (�) Tj ET Q
q 0 0 0 rg BT 167.04 214.10 Td (s processes for reviewing and approving new products and supplements to approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.40 214.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.07 214.10 Td (s. ) Tj ET Q
q 0 0 0 rg BT 536.78 214.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (Cures ) Tj ET Q
q 0 0 0 rg BT 61.28 202.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.72 202.10 Td ( also included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.76 202.10 Td ($1 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.37 202.10 Td ( in new funding to states to supplement opioid abuse prevention and treatment activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.10 Td (More recently) Tj ET Q
q 0 0 0 rg BT 118.71 184.10 Td (, in December 2019, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.29 184.10 Td (Further Consolidated ) Tj ET Q
q 0 0 0 rg BT 303.95 184.10 Td (Appropriations ) Tj ET Q
q 0 0 0 rg BT 366.45 184.10 Td (Act, 2020 \(FCAA) Tj ET Q
q 0 0 0 rg BT 437.84 184.10 Td ( 2020\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.67 184.10 Td ( became law) Tj ET Q
q 0 0 0 rg BT 512.99 184.10 Td (. Section 610, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (titled �) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.49 172.10 Td (Actions for Delays of Generic Drugs and Biological Pr) Tj ET Q
q 0 0 0 rg BT 284.20 172.10 Td (oducts) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 310.31 172.10 Td (,� provides generic \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.94 172.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.28 172.10 Td ( and 505\(b\)\(2\)\) and biosimilar ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (developers with a private right of action to obtain suf) Tj ET Q
q 0 0 0 rg BT 248.26 160.10 Td (ficient quantities of reference product from the brand manufacturer) Tj ET Q
q 0 0 0 rg BT 516.07 160.10 Td (, or a generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (or biosimilar manufacturer) Tj ET Q
q 0 0 0 rg BT 142.78 148.10 Td (, necessary for approval of the developers�) Tj ET Q
q 0 0 0 rg BT 312.25 148.10 Td ( generic or biosimilar product. If a generic or biosimilar ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (developer is successful in its suit, the defendant manufacturer would be required to provide suf) Tj ET Q
q 0 0 0 rg BT 415.43 136.10 Td (ficient quantities of product on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (commercially-reasonable, market-based terms and may be required to pay the developer) Tj ET Q
q 0 0 0 rg BT 389.28 124.10 Td (�) Tj ET Q
q 0 0 0 rg BT 392.05 124.10 Td (s reasonable attorney�) Tj ET Q
q 0 0 0 rg BT 479.24 124.10 Td (s fees and costs as well ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (as financial compensation under certain circumstances. ) Tj ET Q
q 0 0 0 rg BT 258.78 112.10 Td (The purpose of section 610 is to promote competition by facilitating the timely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (entry of lower) Tj ET Q
q 0 0 0 rg BT 92.45 100.10 Td (-cost generic and biosimilar products.) Tj ET Q
endstream
endobj
29 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 30 0 R>>
endobj
30 0 obj
<</Length 17119>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.15 31.60 Td (1) Tj ET Q
q 0 0 0 rg BT 305.78 31.60 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 742.10 Td ( sponsor of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.55 742.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.67 742.10 Td ( is required to identify) Tj ET Q
q 0 0 0 rg BT 237.88 742.10 Td (, in its application, any patent that claims the drug or a use of the drug subject to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (application. Upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.15 730.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.26 730.10 Td ( approval, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.47 730.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.92 730.10 Td ( lists these patents in a publication referred to as the Orange Book. ) Tj ET Q
q 0 0 0 rg BT 475.62 730.10 Td (Any person that files an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.33 718.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.67 718.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.78 718.10 Td ( under Section 505\(b\)\(2\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.41 718.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.09 718.10 Td ( must make a certification in respect to any listed patents for the reference ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (drug. ) Tj ET Q
q 0 0 0 rg BT 59.15 706.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.20 706.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.65 706.10 Td ( may not approve such an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.07 706.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.40 706.10 Td ( or 505\(b\)\(2\) application until expiration of the reference drug�) Tj ET Q
q 0 0 0 rg BT 480.70 706.10 Td (s listed patents unless ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (\(i\) the applicant certifies that the listed patents are invalid, unenforceable and/or not infringed by the proposed generic drug and gives ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (notice to the holder of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.52 682.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.64 682.10 Td ( for the listed drug of the basis upon which the patents are challenged and \(ii\) the holder of the listed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (drug does not sue the later applicant for patent infringement within 45 days of receipt of notice. Under the current law) Tj ET Q
q 0 0 0 rg BT 507.14 670.10 Td (, if an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (infringement suit is filed, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.31 658.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.76 658.10 Td ( may not approve the later application until the earliest of: \(i\) 30 months after submission, \(ii\) entry ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (of an appellate court judgment holding the patent invalid, unenforceable or not infringed, \(iii\) such time as a court may order or \(iv\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (expiration of the patent.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.10 Td (One of the key motivators for challenging patents is the 180-day marketing exclusivity period granted to the developer of a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (generic version of a product that is the first to have its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.72 604.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.05 604.10 Td ( accepted for filing by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.57 604.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.02 604.10 Td ( and whose filing includes a certification ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (that the applicable patent\(s\) are invalid, unenforceable and/or not infringed \(a Paragraph IV) Tj ET Q
q 0 0 0 rg BT 402.05 592.10 Td ( certification\) and that otherwise does not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (forfeit eligibility for the exclusivity) Tj ET Q
q 0 0 0 rg BT 176.98 580.10 Td (. Under the Medicare Prescription Drug, Improvement, and Modernization ) Tj ET Q
q 0 0 0 rg BT 477.45 580.10 Td (Act of 2003, with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (accompanying amendments to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.85 568.10 Td (Drug Price Competition and Patent ) Tj ET Q
q 0 0 0 rg BT 317.70 568.10 Td (T) Tj ET Q
q 0 0 0 rg BT 323.11 568.10 Td (erm Restoration ) Tj ET Q
q 0 0 0 rg BT 389.21 568.10 Td (Act \(the Hatch-W) Tj ET Q
q 0 0 0 rg BT 460.04 568.10 Td (axman ) Tj ET Q
q 0 0 0 rg BT 488.64 568.10 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.41 568.10 Td (, this marketing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (exclusivity would begin to run upon the earlier of the commercial launch of the generic product or upon an appellate court decision in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (the generic company�) Tj ET Q
q 0 0 0 rg BT 122.07 544.10 Td (s favor or in favor of another ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.54 544.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.87 544.10 Td ( applicant who had filed with a Paragraph IV) Tj ET Q
q 0 0 0 rg BT 447.63 544.10 Td ( certification and has tentative ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (approval. In addition, the holder of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.90 532.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.01 532.10 Td ( for the listed drug may be entitled to certain non-patent exclusivity during which, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (depending on the type of exclusivity) Tj ET Q
q 0 0 0 rg BT 181.15 520.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.87 520.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.32 520.10 Td ( either cannot accept or approve an application for a competing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.94 520.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.27 520.10 Td ( generic product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (or 505\(b\)\(2\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.65 508.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.76 508.10 Td ( product with the same active moiety for a protected condition of use.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 490.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 490.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.50 490.10 Td ( also regulates pharmacies and outsourcing facilities that prepare �compounded� drugs pursuant to section 503A) Tj ET Q
q 0 0 0 rg BT 549.25 490.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (503B of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.72 478.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.95 478.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 170.61 478.10 Td (. For instance, under section 503A) Tj ET Q
q 0 0 0 rg BT 307.53 478.10 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.58 478.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.82 478.10 Td (, pharmacies may compound drugs for an identified ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (individual based on the receipt of a valid prescription order) Tj ET Q
q 0 0 0 rg BT 272.46 466.10 Td (, or notation approved by the prescribing practitioner) Tj ET Q
q 0 0 0 rg BT 483.67 466.10 Td (, that a compounded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (product is necessary for the identified patient. Similarly) Tj ET Q
q 0 0 0 rg BT 258.07 454.10 Td (, under section 503B of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.88 454.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.11 454.10 Td (, outsourcing facilities may compound ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (drugs and sell them to healthcare providers, but not wholesalers or distributors. ) Tj ET Q
q 0 0 0 rg BT 354.27 442.10 Td (Although section 503A) Tj ET Q
q 0 0 0 rg BT 447.04 442.10 Td ( pharmacies and section 503B ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (outsourcing facilities are subject to many regulatory requirements, compounded drugs are not subject to premarket review by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.89 430.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 573.34 430.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (and, therefore, may not have the same level of safety and ef) Tj ET Q
q 0 0 0 rg BT 274.33 418.10 Td (ficacy as products subject to premarket review and approval by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.50 418.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 564.51 418.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (Because they are not subject to premarket review) Tj ET Q
q 0 0 0 rg BT 232.21 406.10 Td (, compounded drugs are frequently lower cost than either branded or generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 376.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.50 376.10 Td ( enforces regulations to require that the methods used in, and the facilities and controls used for) Tj ET Q
q 0 0 0 rg BT 481.93 376.10 Td (, the manufacture, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (processing, packing and holding of drugs conform to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.13 364.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.24 364.10 Td (s. ) Tj ET Q
q 0 0 0 rg BT 284.95 364.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.00 364.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.74 364.10 Td ( regulations the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.89 364.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.34 364.10 Td ( enforces are comprehensive and cover ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (all aspects of manufacturing operations. Compliance with the regulations requires a continuous commitment of time, money and ef) Tj ET Q
q 0 0 0 rg BT 559.84 352.10 Td (fort ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (in all operational areas.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 322.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 322.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.50 322.10 Td ( conducts pre-approval inspections of facilities engaged in the development, manufacture, processing, packing, testing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (and holding of the products subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.58 310.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.25 310.10 Td (s and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.03 310.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.91 310.10 Td (s and pre-license inspections of facilities engaged in similar activities for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (biologic products subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.32 298.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.32 298.10 Td (s. In addition, manufacturers of both pharmaceutical products and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.06 298.10 Td (active pharmaceutical ingredients ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (\(APIs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.67 286.10 Td ( used to formulate such products also ordinarily under) Tj ET Q
q 0 0 0 rg BT 278.54 286.10 Td (go pre-approval inspections. Failure of any facility to pass a pre-approval ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (inspection will result in delayed approval.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 256.10 Td (Facilities that manufacture pharmaceutical or biological products must be registered with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.76 256.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.22 256.10 Td ( and all such products made ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (in such facilities must be manufactured in accordance with the latest ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.73 244.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.47 244.10 Td ( regulations. ) Tj ET Q
q 0 0 0 rg BT 389.23 244.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.27 244.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.73 244.10 Td ( conducts periodic inspections of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (facilities to assess the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.87 232.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.61 232.10 Td ( status of marketed products. Following such inspections, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.52 232.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.97 232.10 Td ( could issue a Form 483 Notice of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (Inspectional Observations, which could require modification to certain activities identified during the inspection. If the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.92 220.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.37 220.10 Td ( were to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (find serious ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.44 208.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.18 208.10 Td ( non-compliance during such an inspection, it could take regulatory actions. ) Tj ET Q
q 0 0 0 rg BT 416.75 208.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.79 208.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.25 208.10 Td ( also may issue an untitled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance for a ) Tj ET Q
q 0 0 0 rg BT 500.94 196.10 Td (W) Tj ET Q
q 0 0 0 rg BT 509.58 196.10 Td (arning Letter) Tj ET Q
q 0 0 0 rg BT 560.95 196.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 184.10 Td ( guidelines also provide for the issuance of ) Tj ET Q
q 0 0 0 rg BT 229.12 184.10 Td (W) Tj ET Q
q 0 0 0 rg BT 237.75 184.10 Td (arning Letters for violations of �regulatory significance� for which the failure to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (adequately and promptly achieve correction may be expected to result in an enforcement action.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 154.10 Td (Imported ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.60 154.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.72 154.10 Td ( and other components needed to manufacture our products could be rejected by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.66 154.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.44 154.10 Td ( Customs. In respect to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (domestic establishments, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.20 142.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.66 142.10 Td ( could initiate product seizures or request, or in some instances require, product recalls and seek to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (enjoin or otherwise limit a product�) Tj ET Q
q 0 0 0 rg BT 177.36 130.10 Td (s manufacture and distribution. In certain circumstances, violations could support civil penalties ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (and criminal prosecutions. In addition, if the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.23 118.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.69 118.10 Td ( concludes that a company is not in compliance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.86 118.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.60 118.10 Td ( requirements, sanctions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (may be imposed that include preventing that company from receiving the necessary licenses to export its products and classifying that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (company as an unacceptable supplier) Tj ET Q
q 0 0 0 rg BT 184.43 94.10 Td (, thereby disqualifying that company from selling products to federal agencies.) Tj ET Q
endstream
endobj
31 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 32 0 R>>
endobj
32 0 obj
<</Length 14647>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Certain of our subsidiaries sell products that are �controlled substances� as defined in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.34 742.10 Td (CSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.24 742.10 Td ( and implementing regulations, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (which establish certain security and recordkeeping requirements administered by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.99 730.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.54 730.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.36 730.10 Td (The DEA) Tj ET Q
q 0 0 0 rg BT 440.41 730.10 Td ( regulates chemical compounds ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (as Schedule I, II, III, IV) Tj ET Q
q 0 0 0 rg BT 131.34 718.10 Td ( or ) Tj ET Q
q 0 0 0 rg BT 144.49 718.10 Td (V) Tj ET Q
q 0 0 0 rg BT 151.53 718.10 Td ( substances, with Schedule I substances considered to present the highest risk of substance abuse and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (Schedule ) Tj ET Q
q 0 0 0 rg BT 74.97 706.10 Td (V) Tj ET Q
q 0 0 0 rg BT 82.02 706.10 Td ( substances the lowest risk.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.61 706.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.93 706.10 Td (The active ingredients in some of our products are listed by the DEA) Tj ET Q
q 0 0 0 rg BT 467.86 706.10 Td ( as Schedule II or III ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (substances under the CSA. Consequently) Tj ET Q
q 0 0 0 rg BT 200.05 694.10 Td (, their manufacture, shipment, storage, sale and use are subject to a high degree of regulation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 573.25 694.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 676.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 676.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.05 676.10 Td ( limits the availability of the active ingredients that are subject to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.91 676.10 Td (CSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.81 676.10 Td ( used in several of our products as well as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (the production of these products. ) Tj ET Q
q 0 0 0 rg BT 169.68 664.10 Td (W) Tj ET Q
q 0 0 0 rg BT 178.31 664.10 Td (e or our contract manufacturing or) Tj ET Q
q 0 0 0 rg BT 315.58 664.10 Td (ganizations must annually apply to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.21 664.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.21 664.10 Td ( for procurement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (and production quotas in order to obtain and produce these substances. ) Tj ET Q
q 0 0 0 rg BT 320.93 652.10 Td (As a result, our quotas may not be suf) Tj ET Q
q 0 0 0 rg BT 472.11 652.10 Td (ficient to meet ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (commercial demand or complete clinical trials. Moreover) Tj ET Q
q 0 0 0 rg BT 265.79 640.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.50 640.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.50 640.10 Td ( may adjust these quotas from time to time during the year) Tj ET Q
q 0 0 0 rg BT 538.66 640.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (although the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 88.21 628.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.21 628.10 Td ( has substantial discretion in whether or not to make such adjustments. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.82 628.10 Td (Item 1A. Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.14 628.10 Td ( - �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.91 628.10 Td (The DEA) Tj ET Q
q 0 0 0 rg BT 548.96 628.10 Td ( limits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (the availability of the active ingredients used in many of our products as well as the production of these products, and, as a result, our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (procurement and production quotas may not be suf) Tj ET Q
q 0 0 0 rg BT 239.38 604.10 Td (ficient to meet commercial demand or complete clinical trials) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.39 604.10 Td (.�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 586.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 586.10 Td (o meet its responsibilities, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.06 586.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.06 586.10 Td ( conducts periodic inspections of registered establishments that handle controlled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (substances. ) Tj ET Q
q 0 0 0 rg BT 83.22 574.10 Td (Annual registration is required for any facility that manufactures, tests, distributes, dispenses, imports or exports any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (controlled substance. ) Tj ET Q
q 0 0 0 rg BT 122.74 562.10 Td (The facilities must have the security) Tj ET Q
q 0 0 0 rg BT 266.76 562.10 Td (, control, accounting mechanisms and monitoring systems required by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 550.10 Td ( to prevent loss and diversion of controlled substances and to comply with reporting obligations. Failure to maintain compliance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (can result in enforcement action. ) Tj ET Q
q 0 0 0 rg BT 169.10 538.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.14 538.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.14 538.10 Td ( may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (revoke or restrict those registrations or) Tj ET Q
q 0 0 0 rg BT 190.27 526.10 Td (, with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.27 526.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.05 526.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.55 526.10 Td (Department of Justice \(DOJ\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.79 526.10 Td (, seek to impose civil penalties. In certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (circumstances, violations could result in criminal proceedings.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 496.10 Td (In October 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.25 496.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.04 496.10 Td ( Congress enacted the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.01 496.10 Td (Substance Use-Disorder Prevention that Promotes Opioid Recovery and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (T) Tj ET Q
q 0 0 0 rg BT 41.76 484.10 Td (reatment for Patients and Communities ) Tj ET Q
q 0 0 0 rg BT 200.34 484.10 Td (Act \(H.R. 6\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.33 484.10 Td (. Intended to achieve sweeping reform to combat opioid abuse, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.14 484.10 Td (H.R. 6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.53 484.10 Td (, among ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (other provisions, amends related laws administered by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.66 472.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.67 472.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.67 472.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.67 472.10 Td ( and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.82 472.10 Td (Centers for Medicare and Medicaid Services \(CMS\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.65 472.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (Among other things, the law: \(i\) amends requirements related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.81 460.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.71 460.10 Td (�) Tj ET Q
q 0 0 0 rg BT 331.49 460.10 Td (s authority to include packaging requirements in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.27 460.10 Td (REMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.50 460.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (requirements; \(ii\) increases civil and criminal penalties for manufacturers and distributors for failing to maintain ef) Tj ET Q
q 0 0 0 rg BT 495.38 448.10 Td (fective controls ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (against diversion of opioids or for failing to report suspicious opioid orders; \(iii\) requires the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.98 436.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.98 436.10 Td ( to estimate the amount of opioid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (diversion when establishing manufacturing and procurement quotas; \(iv\) implements expanded anti-kickback and financial disclosure ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (provisions; and \(v\) authorizes the Department of Health and Human Services to implement a demonstration program which would ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (award grants to hospitals and emer) Tj ET Q
q 0 0 0 rg BT 174.95 400.10 Td (gency departments to develop, implement, enhance or study alternative pain management protocols ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (and treatments that limit the use and prescription of opioids in emer) Tj ET Q
q 0 0 0 rg BT 306.59 388.10 Td (gency departments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 370.10 Td (Individual states also regulate controlled substances and we, as well as our third-party ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.46 370.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.57 370.10 Td ( suppliers and manufacturers, are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (subject to such regulation by several states with respect to the manufacture and distribution of these products.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (Government Benefit Programs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 322.10 Td (As described further in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.41 322.10 Td (Item 1A. Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.74 322.10 Td (, statutory and regulatory requirements for government healthcare programs such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (as Medicaid, Medicare and ) Tj ET Q
q 0 0 0 rg BT 146.61 310.10 Td (TRICARE govern access and provider reimbursement levels, and provide for other cost-containment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (measures such as requiring pharmaceutical companies to pay rebates or refunds for certain sales of products reimbursed by such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (programs, or subjecting products to certain price ceilings. In addition to the cost-containment measures described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.98 286.10 Td (Item 1A. Risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.44 274.10 Td (, sales to retail pharmacies under the ) Tj ET Q
q 0 0 0 rg BT 213.53 274.10 Td (TRICARE Retail Pharmacy Program are subject to certain price ceilings which require ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (manufacturers to, among other things, pay refunds for prescriptions filled based on the applicable ceiling price limits. Beginning in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (first quarter of 2017, pursuant to the Bipartisan Budget ) Tj ET Q
q 0 0 0 rg BT 257.63 250.10 Td (Act of 2015, manufacturers are required to pay additional rebates to state ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (Medicaid programs if the prices of their non-innovator products rise at a rate faster than inflation \(as continues to be the case for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (innovator products\); this requirement previously existed only as to branded or innovator products and the change in law may impact ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (our business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 196.10 Td (The federal government may continue to pursue legislation aimed at containing or reducing payment levels for prescription ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (pharmaceuticals paid for in whole or in part with government funds. State governments also may continue to enact similar cost ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (containment or transparency legislation. ) Tj ET Q
q 0 0 0 rg BT 198.82 172.10 Td (These ef) Tj ET Q
q 0 0 0 rg BT 232.79 172.10 Td (forts could have material consequences for the pharmaceutical industry and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (Company) Tj ET Q
q 0 0 0 rg BT 74.24 160.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 142.10 Td (From time to time, legislative changes are made to government healthcare programs that impact our business. Congress ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (continues to examine various Medicare and Medicaid policy proposals that may result in a downward pressure on the prices of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (prescription products in these programs. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.23 118.10 Td (Item 1A. Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.56 118.10 Td ( - �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.33 118.10 Td (The availability of third party reimbursement for our products is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (uncertain, and we may find it dif) Tj ET Q
q 0 0 0 rg BT 166.61 106.10 Td (ficult to maintain current price levels. ) Tj ET Q
q 0 0 0 rg BT 319.06 106.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 368.96 106.10 Td (, the market may not accept those products for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (which third party reimbursement is not adequately provided) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.66 94.10 Td (.�) Tj ET Q
endstream
endobj
33 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 34 0 R>>
endobj
34 0 obj
<</Length 13763>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.21 742.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 115.41 742.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.53 742.10 Td (, pharmaceutical manufacturers of branded prescription products must pay an annual fee to the federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (government. Each individual pharmaceutical manufacturer must pay a prorated share of the total industry fee based on the dollar value ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (of its branded prescription product sales to specified federal programs. ) Tj ET Q
q 0 0 0 rg BT 320.45 718.10 Td (The total industry fee was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.81 718.10 Td ($4 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.42 718.10 Td ( for 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.08 718.10 Td ($4.1 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.19 718.10 Td ( for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (2018 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.44 706.10 Td ($2.8 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.55 706.10 Td ( for 2019. ) Tj ET Q
q 0 0 0 rg BT 163.03 706.10 Td (The 2019 rate is expected to continue for future years. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.10 Td (Uncertainty continues to exist about the future of federal subsidies and of insurance coverage expansion as the current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (administration and congressional leaders continue to express interest in repealing these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.17 676.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 396.38 676.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.94 676.10 Td ( provisions and replacing them with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (alternatives that may be less costly and provide state Medicaid programs and private health plans more flexibility) Tj ET Q
q 0 0 0 rg BT 488.55 664.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 493.37 664.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.23 664.10 Td (T) Tj ET Q
q 0 0 0 rg BT 516.64 664.10 Td (ax Cuts and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (Jobs ) Tj ET Q
q 0 0 0 rg BT 55.73 652.10 Td (Act of 2017 \(TCJA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.55 652.10 Td ( repealed the requirement that individuals maintain health insurance coverage or face a penalty \(known as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (individual mandate\). ) Tj ET Q
q 0 0 0 rg BT 121.07 640.10 Td (The removal of this provision, coupled with the threat of the repeal of other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.70 640.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 435.91 640.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.47 640.10 Td ( provisions, as well as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (outcome of court challenges to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.51 628.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 186.71 628.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.27 628.10 Td ( \(including petitions for certiorari before the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.38 628.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.16 628.10 Td ( Supreme Court to review a December ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (2019 ruling in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.88 616.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.67 616.10 Td ( Court of ) Tj ET Q
q 0 0 0 rg BT 165.72 616.10 Td (Appeals for the Fifth Circuit finding the individual mandate of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.16 616.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 443.37 616.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.93 616.10 Td ( to be unconstitutional\), ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (threaten the stability of the insurance marketplace and may have consequences for the coverage and accessibility of prescription drugs.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (Healthcare Fraud and ) Tj ET Q
q 0 0 0 rg BT 130.92 586.10 Td (Abuse Laws) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 568.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 568.10 Td (e are subject to various federal, state and local laws tar) Tj ET Q
q 0 0 0 rg BT 289.97 568.10 Td (geting fraud and abuse in the healthcare industry) Tj ET Q
q 0 0 0 rg BT 483.98 568.10 Td (, violations of which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (can lead to civil and criminal penalties, including fines, imprisonment and exclusion from participation in federal healthcare programs. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (These laws are potentially applicable to us as both a manufacturer and a supplier of products reimbursed by federal healthcare ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (programs, and they also apply to hospitals, physicians and other potential purchasers of our products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 514.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 514.10 Td (federal ) Tj ET Q
q 0 0 0 rg BT 110.75 514.10 Td (Anti-Kickback Statute \(42 U.S.C. � 1320a-7b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.83 514.10 Td ( prohibits persons from knowingly and willfully soliciting, receiving, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (of) Tj ET Q
q 0 0 0 rg BT 44.15 502.10 Td (fering or providing remuneration, directly or indirectly) Tj ET Q
q 0 0 0 rg BT 262.60 502.10 Td (, to induce either the referral of an individual, or the furnishing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (Medicare and Medicaid programs. Remuneration is not defined in the federal ) Tj ET Q
q 0 0 0 rg BT 347.01 478.10 Td (Anti-Kickback Statute and has been broadly interpreted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (Under the federal ) Tj ET Q
q 0 0 0 rg BT 107.91 442.10 Td (Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.27 442.10 Td (42 U.S.C. � 1320a-7b) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.49 442.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (a person or entity need not have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (In addition, the government may assert that a claim, including items or services resulting from a violation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.44 418.10 Td (42 U.S.C. � 1320a-7b) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.67 418.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (constitutes a false or fraudulent claim for purposes of the civil False Claims ) Tj ET Q
q 0 0 0 rg BT 340.65 406.10 Td (Act \(discussed below\) or the civil monetary penalties ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (fraudulent. ) Tj ET Q
q 0 0 0 rg BT 81.91 370.10 Td (The federal ) Tj ET Q
q 0 0 0 rg BT 129.66 370.10 Td (Anti-Kickback Statute and implementing regulations provide for certain exceptions for �safe harbors� for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (certain discounting, rebating or personal services arrangements, among other things. However) Tj ET Q
q 0 0 0 rg BT 411.87 358.10 Td (, the lack of uniform court interpretation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (of the ) Tj ET Q
q 0 0 0 rg BT 61.00 346.10 Td (Anti-Kickback Statute, coupled with novel enforcement theories by government authorities, make compliance with the law ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 334.10 Td (ficult. ) Tj ET Q
q 0 0 0 rg BT 72.85 334.10 Td (V) Tj ET Q
q 0 0 0 rg BT 79.47 334.10 Td (iolations of the federal ) Tj ET Q
q 0 0 0 rg BT 171.66 334.10 Td (Anti-Kickback Statute can result in significant criminal fines, exclusion from participation in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (Medicare and Medicaid and follow-on civil litigation, among other things, for both entities and individuals.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 304.10 Td (In October 2019, the Of) Tj ET Q
q 0 0 0 rg BT 158.63 304.10 Td (fice of the Inspector General of the Department of Health and Human Services issued a Proposed Rule: ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (Revisions to Safe Harbors under the ) Tj ET Q
q 0 0 0 rg BT 183.58 292.10 Td (Anti-Kickback Statute and Civil Monetary Penalty Rules Regar) Tj ET Q
q 0 0 0 rg BT 436.20 292.10 Td (ding Beneficiary Inducements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.60 292.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (\() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.33 280.10 Td (October Proposed Rule) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.65 280.10 Td (\) to, among other things, add new safe harbors for certain value-based arrangements. ) Tj ET Q
q 0 0 0 rg BT 473.08 280.10 Td (Although the value-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (proposals would not include pharmaceutical manufacturers among the entities that could permissibly enter into such contracting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (arrangements, the general trend toward outcomes and value-based contracts in the healthcare industry may continue. It is possible that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (payers, among other customers, could push manufacturers for novel contracting approaches, including those that would incorporate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (value-based principles, and these ef) Tj ET Q
q 0 0 0 rg BT 178.26 232.10 Td (forts could af) Tj ET Q
q 0 0 0 rg BT 231.40 232.10 Td (fect our business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 214.10 Td (The civil False Claims ) Tj ET Q
q 0 0 0 rg BT 155.21 214.10 Td (Act and similar state laws impose liability on any person or entity who, among other things, knowingly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. ) Tj ET Q
q 0 0 0 rg BT 469.24 202.10 Td (The ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 487.29 202.10 Td (qui tam) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.57 202.10 Td ( provisions of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (the False Claims ) Tj ET Q
q 0 0 0 rg BT 104.61 190.10 Td (Act and similar state laws allow a private individual to bring civil actions on behalf of the federal or state government ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (and to share in any monetary recovery) Tj ET Q
q 0 0 0 rg BT 188.62 178.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 193.44 178.10 Td (The Federal Physician Payments Sunshine ) Tj ET Q
q 0 0 0 rg BT 365.37 178.10 Td (Act and similar state laws impose reporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (requirements for various types of payments to physicians and teaching hospitals. Failure to comply with reporting requirements under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (these laws could subject manufacturers and others to substantial civil money penalties. In addition, government entities and private ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical and medical device ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (products, including state investigations of the Company regarding vaginal mesh devices previously sold by certain of our operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (subsidiaries and investigations and litigation by certain government entities regarding the prior promotional practices of certain of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (operating subsidiaries with respect to opioid products.) Tj ET Q
endstream
endobj
35 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 36 0 R>>
endobj
36 0 obj
<</Length 14513>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (14) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (International Regulations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (Through our international operations, the Company is subject to laws and regulations that dif) Tj ET Q
q 0 0 0 rg BT 434.96 724.25 Td (fer from those under which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (Company operates in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.20 712.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.98 712.25 Td ( In most cases, non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.69 712.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.47 712.25 Td ( regulatory agencies evaluate and monitor the safety) Tj ET Q
q 0 0 0 rg BT 461.35 712.25 Td (, ef) Tj ET Q
q 0 0 0 rg BT 473.93 712.25 Td (ficacy and quality of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (pharmaceutical products, govern the approval of clinical trials and product registrations and regulate pricing and reimbursement. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (Certain international markets have dif) Tj ET Q
q 0 0 0 rg BT 187.43 688.25 Td (fering product preferences and requirements and operate in an environment of government-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (mandated, cost-containment programs, including price controls, such as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.36 676.25 Td (Patented Medicine Prices Review Board \(PMPRB\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.50 676.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (Canada.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.25 Td (In Canada, amendments to the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 186.85 646.25 Td (Patented Medicines Regulations \(Regulations ) Tj ET Q
q 0 0 0 rg BT 372.18 646.25 Td (Amending the Patented Medicines Regulations ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (\(Additional Factors and Information Reporting Requir) Tj ET Q
q 0 0 0 rg BT 254.78 634.25 Td (ements\)\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.21 634.25 Td ( \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.20 634.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.53 634.25 Td (\) will come into force on July 1, 2020 and will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.25 Td (introduce a number of changes to the regulation of Canadian drug prices by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.34 622.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.70 622.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 393.51 622.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.56 622.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.92 622.25 Td ( is an administrative board ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.25 Td (established by the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 110.15 610.25 Td (Patent ) Tj ET Q
q 0 0 0 rg BT 138.57 610.25 Td (Act, RSC 1985, c P-4) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.55 610.25 Td (, with a mandate to protect Canadians from excessive pricing. Pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.25 Td (manufacturers that are �patentees� are required to report applicable patents and file sales information so the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.59 598.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.94 598.25 Td ( can monitor for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (excessive pricing as long as the product is considered to be a patented medicine. If it is determined the average price for a patented ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (medicine is too high based on pricing tests developed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.56 574.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.91 574.25 Td (, a payment must be made to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.82 574.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.18 574.25 Td ( to of) Tj ET Q
q 0 0 0 rg BT 499.11 574.25 Td (fset the excessive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.25 Td (revenues that were generated, and/or the price of the medicine must be reduced. ) Tj ET Q
q 0 0 0 rg BT 357.62 562.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.67 562.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.02 562.25 Td (�) Tj ET Q
q 0 0 0 rg BT 411.80 562.25 Td (s authority to regulate the price of a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.25 Td (product is linked to patent protection, specifically when there is a patent to an invention that is �intended or capable of being used for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (medicine or for the preparation or production of medicine� \() Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 277.29 538.25 Td (Patent ) Tj ET Q
q 0 0 0 rg BT 305.72 538.25 Td (Act, Section 79\(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.64 538.25 Td (\). ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 520.25 Td (For patented medicines approved by Health Canada after ) Tj ET Q
q 0 0 0 rg BT 292.92 520.25 Td (August 21, 2019 \(the date of publication of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.33 520.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.65 520.25 Td (\), the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.33 508.25 Td ( will allow ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.60 508.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.95 508.25 Td ( to consider additional factors when assessing whether a price is excessive: pharmacoeconomic value ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (of the medicine in Canada, the size of the market for the medicine in Canada and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.98 496.25 Td (gross domestic product \(GDP\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.91 496.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.35 496.25 Td (GDP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.98 496.25 Td ( per ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (capita of Canada. For all patented medicines \(regardless of the date of marketing authorization\), the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.68 484.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.01 484.25 Td ( change the set of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.25 Td (countries that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.37 472.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.72 472.25 Td ( uses for international price comparisons when assessing whether the Canadian price is excessive. Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (current regulations, the price of a Canadian medicine is compared to the price of that medicine in seven other counties, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 448.25 Td ( and Switzerland. ) Tj ET Q
q 0 0 0 rg BT 125.80 448.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.30 448.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.63 448.25 Td ( define a new set of eleven comparator countries, and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.08 448.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.87 448.25 Td ( and Switzerland are no longer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (part of this basket. ) Tj ET Q
q 0 0 0 rg BT 112.19 436.25 Td (The implementation of the new set of comparator counties is expected to cause a decrease to permissible ceiling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (prices in Canada. Based on draft guidelines published by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.66 424.25 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.02 424.25 Td ( in November 2019 \(currently under consultation\), the ceiling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (price for a medicine is expected to be established as the median international list price of the eleven comparator countries for most ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (patented medicines. ) Tj ET Q
q 0 0 0 rg BT 117.36 400.25 Td (According to the Regulatory Impact ) Tj ET Q
q 0 0 0 rg BT 263.71 400.25 Td (Analysis Statement that accompanied the publication of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.65 400.25 Td (Amendments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.97 400.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (the Canada Gazette Part II, the Canadian government anticipates that ) Tj ET Q
q 0 0 0 rg BT 313.95 388.25 Td (Amendments will result in lower prices for patented medicines ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.25 Td (and an estimated benefit to Canadians of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.22 376.25 Td (8.8 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.34 376.25 Td ( Canadian dollars \(present value\) over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.28 376.25 Td (10 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.88 376.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.25 Td (Certain governments have placed restrictions on physician prescription levels and patient reimbursements, emphasized greater ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (use of generic products and enacted across-the-board price cuts as methods of cost control.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 328.25 Td (Whether or not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.03 328.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.49 328.25 Td ( approval has been obtained for a product, approval of the product by comparable regulatory authorities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.25 Td (other governments must be obtained prior to marketing the product in those jurisdictions. ) Tj ET Q
q 0 0 0 rg BT 395.19 316.25 Td (The approval process may be more or less ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.25 Td (rigorous than the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.26 304.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.05 304.25 Td ( process and the time required for approval may be longer or shorter than in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.94 304.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (Service ) Tj ET Q
q 0 0 0 rg BT 69.04 286.25 Td (Agr) Tj ET Q
q 0 0 0 rg BT 85.52 286.25 Td (eements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 268.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 268.25 Td (e contract with various third parties to provide certain critical services including manufacturing, supply) Tj ET Q
q 0 0 0 rg BT 483.63 268.25 Td (, warehousing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.25 Td (distribution, customer service, certain financial functions, certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.69 256.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.36 256.25 Td ( activities and medical af) Tj ET Q
q 0 0 0 rg BT 420.13 256.25 Td (fairs, among others.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 238.25 Td (Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.99 238.25 Td (Note 1) Tj ET Q
q 0 0 0 rg BT 124.55 238.25 Td (1. License and Collaboration ) Tj ET Q
q 0 0 0 rg BT 242.02 238.25 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.34 238.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.78 238.25 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.04 238.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.53 238.25 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.59 226.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 226.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 197.18 226.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.16 226.25 Td ( for additional information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 208.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 208.25 Td (e primarily purchase our raw materials for the production and development of our products in the open market from third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (party suppliers. ) Tj ET Q
q 0 0 0 rg BT 99.97 196.25 Td (W) Tj ET Q
q 0 0 0 rg BT 108.61 196.25 Td (e attempt, when possible, to mitigate our raw material supply risks through inventory management and alternative ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (sourcing strategies. However) Tj ET Q
q 0 0 0 rg BT 151.95 184.25 Td (, some raw materials are only available from one source. ) Tj ET Q
q 0 0 0 rg BT 380.57 184.25 Td (W) Tj ET Q
q 0 0 0 rg BT 389.21 184.25 Td (e are required to identify the suppliers of all ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (raw materials for our products in the drug applications that we file with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.69 172.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.70 172.25 Td (. If the raw materials from an approved supplier for a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (particular product become unavailable, we would be required to qualify a substitute supplier with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.54 160.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.55 160.25 Td (, which would likely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (interrupt manufacturing of the af) Tj ET Q
q 0 0 0 rg BT 166.88 148.25 Td (fected product. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.29 148.25 Td (Item 1A. Risk Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.61 148.25 Td ( for further discussion on the risks associated with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (sourcing of our raw materials.) Tj ET Q
endstream
endobj
37 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 38 0 R>>
endobj
38 0 obj
<</Length 16502>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (15) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (License & Collaboration ) Tj ET Q
q 0 0 0 rg BT 142.94 742.25 Td (Agr) Tj ET Q
q 0 0 0 rg BT 159.42 742.25 Td (eements and ) Tj ET Q
q 0 0 0 rg BT 214.42 742.25 Td (Acquisitions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 724.25 Td (e continue to seek to enhance our product line and develop a balanced portfolio of dif) Tj ET Q
q 0 0 0 rg BT 413.28 724.25 Td (ferentiated products through product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (acquisitions and in-licensing or acquiring licenses to products, compounds and technologies from third parties. ) Tj ET Q
q 0 0 0 rg BT 481.28 712.25 Td (The Company enters ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (into strategic alliances and collaborative arrangements with third parties, which give the Company rights to develop, manufacture, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (market and/or sell pharmaceutical products, the rights to which are primarily owned by these third parties. ) Tj ET Q
q 0 0 0 rg BT 462.91 688.25 Td (These alliances and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (arrangements can take many forms, including licensing arrangements, co-development and co-marketing agreements, co-promotion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (arrangements, research collaborations and joint ventures. Such alliances and arrangements enable us to share the risk of incurring all ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.67 652.25 Td ( expenses that do not lead to revenue-generating products; however) Tj ET Q
q 0 0 0 rg BT 326.90 652.25 Td (, because profits from alliance products are shared with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (counter) Tj ET Q
q 0 0 0 rg BT 65.79 640.25 Td (-parties to the collaborative arrangement, the gross mar) Tj ET Q
q 0 0 0 rg BT 286.63 640.25 Td (gins on alliance products are generally lower) Tj ET Q
q 0 0 0 rg BT 465.60 640.25 Td (, sometimes substantially ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (so, than the gross mar) Tj ET Q
q 0 0 0 rg BT 123.30 628.25 Td (gins that could be achieved had the Company not opted for a development partner) Tj ET Q
q 0 0 0 rg BT 450.71 628.25 Td (. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.69 628.25 Td (Note 1) Tj ET Q
q 0 0 0 rg BT 517.26 628.25 Td (1. License and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (Collaboration ) Tj ET Q
q 0 0 0 rg BT 92.94 616.25 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.25 616.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.75 616.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.62 616.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.33 616.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 385.20 616.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.18 616.25 Td ( for additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (information.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (Envir) Tj ET Q
q 0 0 0 rg BT 60.27 586.25 Td (onmental Matters) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 568.25 Td (Our operations are subject to substantial federal, state and local environmental laws and regulations concerning, among other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (matters, the generation, handling, storage, transportation, treatment and disposal of, and exposure to, hazardous substances. ) Tj ET Q
q 0 0 0 rg BT 531.51 556.25 Td (V) Tj ET Q
q 0 0 0 rg BT 538.13 556.25 Td (iolation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (of these laws and regulations, which may change, can lead to substantial fines and penalties. Many of our operations require ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (environmental permits and controls to prevent and limit pollution of the environment. ) Tj ET Q
q 0 0 0 rg BT 381.02 532.25 Td (W) Tj ET Q
q 0 0 0 rg BT 389.66 532.25 Td (e believe that our facilities and the facilities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (our third party service providers are in substantial compliance with applicable environmental laws and regulations and we do not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (believe that future compliance will have a material adverse ef) Tj ET Q
q 0 0 0 rg BT 282.09 508.25 Td (fect on our business, financial condition, results of operations or cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (flows.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (Employees) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 460.25 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.04 460.25 Td (, we have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.58 460.25 Td (3,172) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.08 460.25 Td ( employees, of which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.11 460.25 Td (365) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.11 460.25 Td ( are engaged in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.41 460.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.08 460.25 Td ( and regulatory work, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.67 460.25 Td (400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.67 460.25 Td ( in sales and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (marketing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.54 448.25 Td (1,243) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.04 448.25 Td ( in manufacturing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.13 448.25 Td (636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.13 448.25 Td ( in quality assurance and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.49 448.25 Td (528) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.49 448.25 Td ( in general and administrative capacities. ) Tj ET Q
q 0 0 0 rg BT 477.07 448.25 Td (W) Tj ET Q
q 0 0 0 rg BT 486.11 448.25 Td (ith the exception of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (certain production personnel in our Rochester) Tj ET Q
q 0 0 0 rg BT 218.60 436.25 Td (, Michigan manufacturing facility) Tj ET Q
q 0 0 0 rg BT 352.90 436.25 Td (, our employees are generally not represented by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (unions. ) Tj ET Q
q 0 0 0 rg BT 67.49 424.25 Td (W) Tj ET Q
q 0 0 0 rg BT 76.13 424.25 Td (e believe that our relations with our employees are good.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (Information about our) Tj ET Q
q 0 0 0 rg BT 132.49 406.25 Td ( Executive Officers) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 388.25 Td (The following table sets forth, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.97 388.25 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.56 388.25 Td (, information about our executive of) Tj ET Q
q 0 0 0 rg BT 425.78 388.25 Td (ficers:) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 364.75 m
141.5 364.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
145.5 364.75 m
166.5 364.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
170.5 364.75 m
575.5 364.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 364.75 m
141.5 364.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
145.5 364.75 m
166.5 364.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 368.98 Td (Name) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 148.80 368.98 Td (Age) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 173.00 368.98 Td (Position and Offices) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 355.32 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 58.19 355.32 Td (V) Tj ET Q
q 0 0 0 rg BT 64.67 355.32 Td (. Campanelli \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 354.42 Td (57) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 354.42 Td (President, Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 292.88 354.42 Td (ficer and Chairman of the Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 340.32 Td (Patrick Barry) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 340.32 Td (52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 339.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.39 339.42 Td (V) Tj ET Q
q 0 0 0 rg BT 222.22 339.42 Td (ice President and Chief Commercial Of) Tj ET Q
q 0 0 0 rg BT 379.84 339.42 Td (ficer) Tj ET Q
q 0 0 0 rg BT 397.86 339.42 Td (, U.S. Branded Business) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 325.32 Td (Domenico Ciarico) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 325.32 Td (47) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 324.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.39 324.42 Td (V) Tj ET Q
q 0 0 0 rg BT 222.22 324.42 Td (ice President and Chief Commercial Of) Tj ET Q
q 0 0 0 rg BT 379.84 324.42 Td (ficer) Tj ET Q
q 0 0 0 rg BT 397.86 324.42 Td (, Sterile and Generics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 310.32 Td (Blaise Coleman \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 309.42 Td (46) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 309.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.39 309.42 Td (V) Tj ET Q
q 0 0 0 rg BT 222.22 309.42 Td (ice President and Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 367.62 309.42 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 295.32 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 295.32 Td (errance J. Coughlin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 295.32 Td (54) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 294.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.39 294.42 Td (V) Tj ET Q
q 0 0 0 rg BT 222.22 294.42 Td (ice President and Chief Operating Of) Tj ET Q
q 0 0 0 rg BT 370.40 294.42 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 280.32 Td (Rahul Garella) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 279.42 Td (50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 279.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.39 279.42 Td (V) Tj ET Q
q 0 0 0 rg BT 222.22 279.42 Td (ice President, International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 265.32 Td (Matthew J. Maletta) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.50 265.32 Td (48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.00 264.42 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 215.30 264.42 Td (V) Tj ET Q
q 0 0 0 rg BT 221.92 264.42 Td (ice President and Chief Legal Of) Tj ET Q
q 0 0 0 rg BT 353.08 264.42 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 250.65 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 241.05 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 241.05 Td (On November 4, 2019, Mr) Tj ET Q
q 0 0 0 rg BT 152.38 241.05 Td (. Paul ) Tj ET Q
q 0 0 0 rg BT 172.46 241.05 Td (V) Tj ET Q
q 0 0 0 rg BT 177.20 241.05 Td (. Campanelli notified the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 258.74 241.05 Td (board of directors \(the Board\)) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 354.26 241.05 Td ( of his intention to retire as the Company�) Tj ET Q
q 0 0 0 rg BT 487.57 241.05 Td (s President and Chief ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 231.45 Td (Executive Of) Tj ET Q
q 0 0 0 rg BT 109.78 231.45 Td (ficer) Tj ET Q
q 0 0 0 rg BT 123.99 231.45 Td (. ) Tj ET Q
q 0 0 0 rg BT 127.85 231.45 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 142.29 231.45 Td (Board) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 161.84 231.45 Td ( appointed Mr) Tj ET Q
q 0 0 0 rg BT 206.72 231.45 Td (. Campanelli as the Chairman of the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 324.02 231.45 Td (Board) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 343.57 231.45 Td ( on November 4, 2019. On February 19, 2020, the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 505.77 231.45 Td (Board) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 525.32 231.45 Td ( appointed Mr) Tj ET Q
q 0 0 0 rg BT 570.20 231.45 Td (. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 221.85 Td (Blaise Coleman as the Company�) Tj ET Q
q 0 0 0 rg BT 174.15 221.85 Td (s President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 286.64 221.85 Td (ficer and Mr) Tj ET Q
q 0 0 0 rg BT 326.18 221.85 Td (. Mark Bradley) Tj ET Q
q 0 0 0 rg BT 374.31 221.85 Td (, Senior ) Tj ET Q
q 0 0 0 rg BT 401.05 221.85 Td (V) Tj ET Q
q 0 0 0 rg BT 406.35 221.85 Td (ice President, Corporate Development & ) Tj ET Q
q 0 0 0 rg BT 538.61 221.85 Td (T) Tj ET Q
q 0 0 0 rg BT 543.22 221.85 Td (reasurer) Tj ET Q
q 0 0 0 rg BT 568.66 221.85 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 212.25 Td (as the Company�) Tj ET Q
q 0 0 0 rg BT 121.27 212.25 Td (s Executive ) Tj ET Q
q 0 0 0 rg BT 160.22 212.25 Td (V) Tj ET Q
q 0 0 0 rg BT 165.52 212.25 Td (ice President and Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 282.01 212.25 Td (ficer) Tj ET Q
q 0 0 0 rg BT 296.22 212.25 Td (. Both appointments are ef) Tj ET Q
q 0 0 0 rg BT 380.72 212.25 Td (fective March 6, 2020 and Mr) Tj ET Q
q 0 0 0 rg BT 476.25 212.25 Td (. Campanelli and Mr) Tj ET Q
q 0 0 0 rg BT 542.01 212.25 Td (. Coleman ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 202.65 Td (will continue to serve in their current roles until such date.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.65 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 83.10 184.65 Td (V) Tj ET Q
q 0 0 0 rg BT 89.03 184.65 Td (. Campanelli was appointed Chairman of the Board of Endo in November 2019 and has served as Director) Tj ET Q
q 0 0 0 rg BT 514.07 184.65 Td (, Chief ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.65 Td (Executive Of) Tj ET Q
q 0 0 0 rg BT 88.85 172.65 Td (ficer and President since September 2016. Mr) Tj ET Q
q 0 0 0 rg BT 271.30 172.65 Td (. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.65 Td (leading Endo�) Tj ET Q
q 0 0 0 rg BT 91.82 160.65 Td (s fully integrated U.S. Generics business, following Endo�) Tj ET Q
q 0 0 0 rg BT 324.56 160.65 Td (s acquisition of Par Pharmaceutical. Prior to joining Endo, he ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.65 Td (served as Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 153.00 148.65 Td (ficer of Par Pharmaceutical Companies, Inc. following the company�) Tj ET Q
q 0 0 0 rg BT 427.91 148.65 Td (s September 2012 acquisition by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.65 Td (TPG. Prior to the ) Tj ET Q
q 0 0 0 rg BT 107.21 136.65 Td (TPG acquisition, Mr) Tj ET Q
q 0 0 0 rg BT 189.15 136.65 Td (. Campanelli served as Chief Operating Of) Tj ET Q
q 0 0 0 rg BT 359.75 136.65 Td (ficer and President of Par Pharmaceutical, Inc. from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.65 Td (2010 to 2012. ) Tj ET Q
q 0 0 0 rg BT 93.23 124.65 Td (At Par Pharmaceutical, Inc., Mr) Tj ET Q
q 0 0 0 rg BT 220.13 124.65 Td (. Campanelli had also served as Senior ) Tj ET Q
q 0 0 0 rg BT 377.13 124.65 Td (V) Tj ET Q
q 0 0 0 rg BT 383.75 124.65 Td (ice President, Business Development & ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.65 Td (Licensing; Executive ) Tj ET Q
q 0 0 0 rg BT 123.01 112.65 Td (V) Tj ET Q
q 0 0 0 rg BT 129.63 112.65 Td (ice President and President; and was named a Corporate Of) Tj ET Q
q 0 0 0 rg BT 366.88 112.65 Td (ficer by its board of directors. He also served on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.65 Td (board of directors of Sky Growth Holdings Corporation from 2012 until 2015. Prior to joining Par Pharmaceutical Companies, Inc., ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.65 Td (Mr) Tj ET Q
q 0 0 0 rg BT 47.67 88.65 Td (. Campanelli served as ) Tj ET Q
q 0 0 0 rg BT 140.52 88.65 Td (V) Tj ET Q
q 0 0 0 rg BT 147.14 88.65 Td (ice President, Business Development at Dr) Tj ET Q
q 0 0 0 rg BT 317.66 88.65 Td (. Reddy�) Tj ET Q
q 0 0 0 rg BT 351.55 88.65 Td (s Laboratories Ltd., where he was employed from 1992 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.65 Td (to 2001. Mr) Tj ET Q
q 0 0 0 rg BT 82.95 76.65 Td (. Campanelli earned his Bachelor of Science degree from Springfield College.) Tj ET Q
endstream
endobj
39 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 40 0 R>>
endobj
40 0 obj
<</Length 17177>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (16) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Patrick Barry) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.59 742.10 Td ( was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.08 742.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 221.38 742.10 Td (V) Tj ET Q
q 0 0 0 rg BT 228.00 742.10 Td (ice President and Chief Commercial Of) Tj ET Q
q 0 0 0 rg BT 385.83 742.10 Td (ficer) Tj ET Q
q 0 0 0 rg BT 403.74 742.10 Td (, U.S. Branded Business) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.96 742.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 513.55 742.10 Td (fective ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (February 2018. In this role, he has responsibility for all commercial activities for U.S. Branded Pharmaceuticals, including strategy) Tj ET Q
q 0 0 0 rg BT 560.21 730.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (new product planning, marketing, sales as well as managed care and patient access responsibilities. Mr) Tj ET Q
q 0 0 0 rg BT 446.71 718.10 Td (. Barry joined Endo in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (December 2016 as Senior ) Tj ET Q
q 0 0 0 rg BT 141.34 706.10 Td (V) Tj ET Q
q 0 0 0 rg BT 147.96 706.10 Td (ice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr) Tj ET Q
q 0 0 0 rg BT 432.91 706.10 Td (. Barry worked at Sanofi S.A. from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (Marketing, Launch Planning and ) Tj ET Q
q 0 0 0 rg BT 169.96 682.10 Td (T) Tj ET Q
q 0 0 0 rg BT 175.71 682.10 Td (raining and Leadership Development. Most recently) Tj ET Q
q 0 0 0 rg BT 383.89 682.10 Td (, he served at Sanofi S.A. as its General ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (Manager and Head of North ) Tj ET Q
q 0 0 0 rg BT 150.68 670.10 Td (America General Medicines starting in September 2015 and as ) Tj ET Q
q 0 0 0 rg BT 404.03 670.10 Td (V) Tj ET Q
q 0 0 0 rg BT 410.65 670.10 Td (ice President and Head of U.S. Specialty ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (from ) Tj ET Q
q 0 0 0 rg BT 57.39 658.10 Td (April 2014 until ) Tj ET Q
q 0 0 0 rg BT 123.78 658.10 Td (August 2015. During this time, Mr) Tj ET Q
q 0 0 0 rg BT 262.39 658.10 Td (. Barry oversaw three complex and diverse businesses with responsibility for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (experience including aesthetics and dermatology) Tj ET Q
q 0 0 0 rg BT 230.28 634.10 Td (, oncology) Tj ET Q
q 0 0 0 rg BT 271.84 634.10 Td (, urology) Tj ET Q
q 0 0 0 rg BT 307.30 634.10 Td (, orthopedics and medical device and sur) Tj ET Q
q 0 0 0 rg BT 470.12 634.10 Td (gical experience. He has ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (an M.B.A. from Cornell University) Tj ET Q
q 0 0 0 rg BT 176.72 622.10 Td (, Johnson School of Management and a B.A. in Public Relations and Marketing from McKendree ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (University) Tj ET Q
q 0 0 0 rg BT 77.57 610.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 592.10 Td (Domenico Ciarico) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.59 592.10 Td ( was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.07 592.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 241.37 592.10 Td (V) Tj ET Q
q 0 0 0 rg BT 248.00 592.10 Td (ice President and Chief Commercial Of) Tj ET Q
q 0 0 0 rg BT 405.82 592.10 Td (ficer) Tj ET Q
q 0 0 0 rg BT 423.74 592.10 Td (, Sterile and Generics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.82 592.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 522.40 592.10 Td (fective ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (August 2019. In this role, Mr) Tj ET Q
q 0 0 0 rg BT 152.39 580.10 Td (. Ciarico leads Endo�) Tj ET Q
q 0 0 0 rg BT 236.25 580.10 Td (s U.S. Generics business including responsibility and oversight of Par Generic and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (Par Sterile sales teams, commercial operations, marketing and business analytics group. Mr) Tj ET Q
q 0 0 0 rg BT 401.46 568.10 Td (. Ciarico joined Par in July 2018 as SVP) Tj ET Q
q 0 0 0 rg BT 562.47 568.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (and General Manager of Par Sterile Products, responsible for all sales, marketing, pricing and portfolio management for Par Sterile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (Products. Prior to joining Endo in 2018, Mr) Tj ET Q
q 0 0 0 rg BT 210.17 544.10 Td (. Ciarico was with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.88 544.10 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 350.79 544.10 Td (gen Corporation \(ABC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.77 544.10 Td ( for over 20 years from May ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (1996 to July 2017 where he held several roles of increasing responsibility) Tj ET Q
q 0 0 0 rg BT 330.00 532.10 Td (, including SVP) Tj ET Q
q 0 0 0 rg BT 393.25 532.10 Td ( of Health Systems, leading health systems ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (sales and commercial strategy) Tj ET Q
q 0 0 0 rg BT 155.58 520.10 Td (. Prior to that, Mr) Tj ET Q
q 0 0 0 rg BT 225.02 520.10 Td (. Ciarico was Group ) Tj ET Q
q 0 0 0 rg BT 307.88 520.10 Td (V) Tj ET Q
q 0 0 0 rg BT 314.50 520.10 Td (ice President, managing three of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.57 520.10 Td (ABC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.13 520.10 Td (�) Tj ET Q
q 0 0 0 rg BT 468.91 520.10 Td (s service businesses: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (American Health Packaging, Pharmacy Healthcare Solutions and ) Tj ET Q
q 0 0 0 rg BT 298.70 508.10 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 364.60 508.10 Td (gen ) Tj ET Q
q 0 0 0 rg BT 381.36 508.10 Td (T) Tj ET Q
q 0 0 0 rg BT 386.77 508.10 Td (echnology Group, as well as other key ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (leadership positions in operations and sales. Mr) Tj ET Q
q 0 0 0 rg BT 225.69 496.10 Td (. Ciarico holds an M.B.A. and a B.S. degree from ) Tj ET Q
q 0 0 0 rg BT 426.03 496.10 Td (The Ohio State University) Tj ET Q
q 0 0 0 rg BT 530.64 496.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 478.10 Td (Blaise Coleman was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.08 478.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 231.38 478.10 Td (V) Tj ET Q
q 0 0 0 rg BT 238.00 478.10 Td (ice President and Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 383.62 478.10 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.53 478.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 414.12 478.10 Td (fective December 2016. Mr) Tj ET Q
q 0 0 0 rg BT 524.07 478.10 Td (. Coleman ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (had been serving as Endo�) Tj ET Q
q 0 0 0 rg BT 140.97 466.10 Td (s Interim Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 254.10 466.10 Td (ficer since November 2016. He joined Endo in January 2015 as ) Tj ET Q
q 0 0 0 rg BT 509.96 466.10 Td (V) Tj ET Q
q 0 0 0 rg BT 516.58 466.10 Td (ice President ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (of Corporate Financial Planning & ) Tj ET Q
q 0 0 0 rg BT 176.81 454.10 Td (Analysis, and was then promoted to Senior ) Tj ET Q
q 0 0 0 rg BT 351.05 454.10 Td (V) Tj ET Q
q 0 0 0 rg BT 357.67 454.10 Td (ice President, Global Finance Operations in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (November 2015. Prior to joining Endo, Mr) Tj ET Q
q 0 0 0 rg BT 207.10 442.10 Td (. Coleman held numerous finance leadership roles with ) Tj ET Q
q 0 0 0 rg BT 429.54 442.10 Td (AstraZeneca, most recently having ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (served as the Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 164.95 430.10 Td (ficer of the ) Tj ET Q
q 0 0 0 rg BT 210.76 430.10 Td (AstraZeneca/Bristol-Myers Squibb US Diabetes ) Tj ET Q
q 0 0 0 rg BT 405.72 430.10 Td (Alliance from January 2013 until January ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (2015. Prior to that, he was the Head of Finance for the ) Tj ET Q
q 0 0 0 rg BT 255.39 418.10 Td (AstraZeneca Global Medicines Development or) Tj ET Q
q 0 0 0 rg BT 446.81 418.10 Td (ganization based in M�lndal, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (Sweden. Mr) Tj ET Q
q 0 0 0 rg BT 84.33 406.10 Td (. Coleman joined ) Tj ET Q
q 0 0 0 rg BT 154.88 406.10 Td (AstraZeneca in 2007 as Senior Director Commercial Finance for the US Cardiovascular Business. He ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (joined ) Tj ET Q
q 0 0 0 rg BT 62.94 394.10 Td (AstraZeneca from Centocor) Tj ET Q
q 0 0 0 rg BT 174.16 394.10 Td (, a wholly-owned subsidiary of Johnson & Johnson, where he held positions in both the Licenses & ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (Acquisitions and Commercial Finance or) Tj ET Q
q 0 0 0 rg BT 200.23 382.10 Td (ganizations. Mr) Tj ET Q
q 0 0 0 rg BT 262.44 382.10 Td (. Coleman�) Tj ET Q
q 0 0 0 rg BT 306.32 382.10 Td (s move to Centocor in early 2003 followed 7 years�) Tj ET Q
q 0 0 0 rg BT 511.36 382.10 Td ( experience ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (with the global public accounting firm, PricewaterhouseCoopers LLP) Tj ET Q
q 0 0 0 rg BT 313.16 370.10 Td (. Mr) Tj ET Q
q 0 0 0 rg BT 329.83 370.10 Td (. Coleman is a Certified Public ) Tj ET Q
q 0 0 0 rg BT 455.09 370.10 Td (Accountant; he holds a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (Bachelor of Science degree in accounting from ) Tj ET Q
q 0 0 0 rg BT 226.57 358.10 Td (W) Tj ET Q
q 0 0 0 rg BT 235.61 358.10 Td (idener University and an M.B.A. from the Fuqua School of Business at Duke ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (University) Tj ET Q
q 0 0 0 rg BT 77.57 346.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 328.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 328.10 Td (errance J. Coughlin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.44 328.10 Td ( was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.93 328.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 251.23 328.10 Td (V) Tj ET Q
q 0 0 0 rg BT 257.85 328.10 Td (ice President and Chief Operating Of) Tj ET Q
q 0 0 0 rg BT 406.23 328.10 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.15 328.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 436.74 328.10 Td (fective November 2016. In this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (role, Mr) Tj ET Q
q 0 0 0 rg BT 68.22 316.10 Td (. Coughlin has responsibility for Manufacturing and ) Tj ET Q
q 0 0 0 rg BT 278.56 316.10 Td (T) Tj ET Q
q 0 0 0 rg BT 283.97 316.10 Td (echnical Operations and R&D across the enterprise. Most recently) Tj ET Q
q 0 0 0 rg BT 548.51 316.10 Td (, Mr) Tj ET Q
q 0 0 0 rg BT 565.18 316.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (Coughlin served as ) Tj ET Q
q 0 0 0 rg BT 114.97 304.10 Td (V) Tj ET Q
q 0 0 0 rg BT 121.60 304.10 Td (ice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo�) Tj ET Q
q 0 0 0 rg BT 529.55 304.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (acquisition of Par in September 2015, Mr) Tj ET Q
q 0 0 0 rg BT 201.25 292.10 Td (. Coughlin was the Chief Operating Of) Tj ET Q
q 0 0 0 rg BT 356.32 292.10 Td (ficer of Par Pharmaceutical Companies, Inc. Prior to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (joining Par) Tj ET Q
q 0 0 0 rg BT 79.76 280.10 Td (, Mr) Tj ET Q
q 0 0 0 rg BT 96.43 280.10 Td (. Coughlin held numerous leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited, most ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (recently having served as the President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 288.79 268.10 Td (ficer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (Prior to this, Mr) Tj ET Q
q 0 0 0 rg BT 99.90 256.10 Td (. Coughlin had the overall responsibility for Glenmark�) Tj ET Q
q 0 0 0 rg BT 320.41 256.10 Td (s North ) Tj ET Q
q 0 0 0 rg BT 352.08 256.10 Td (American, ) Tj ET Q
q 0 0 0 rg BT 396.32 256.10 Td (W) Tj ET Q
q 0 0 0 rg BT 404.96 256.10 Td (estern European and Eastern European ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (Glenmark, Mr) Tj ET Q
q 0 0 0 rg BT 92.66 232.10 Td (. Coughlin served as Senior ) Tj ET Q
q 0 0 0 rg BT 205.24 232.10 Td (V) Tj ET Q
q 0 0 0 rg BT 211.86 232.10 Td (ice President at Dr) Tj ET Q
q 0 0 0 rg BT 285.45 232.10 Td (. Reddy�) Tj ET Q
q 0 0 0 rg BT 319.33 232.10 Td (s Laboratories, Inc. Mr) Tj ET Q
q 0 0 0 rg BT 410.70 232.10 Td (. Coughlin began his career in 1988 with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (W) Tj ET Q
q 0 0 0 rg BT 44.84 220.10 Td (yckof) Tj ET Q
q 0 0 0 rg BT 67.43 220.10 Td (f Chemical Company) Tj ET Q
q 0 0 0 rg BT 152.31 220.10 Td (, Inc. Mr) Tj ET Q
q 0 0 0 rg BT 186.75 220.10 Td (. Coughlin earned a B.S. in chemistry from Central Michigan University) Tj ET Q
q 0 0 0 rg BT 475.77 220.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 202.10 Td (Rahul Garella) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.81 202.10 Td ( was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.30 202.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 223.60 202.10 Td (V) Tj ET Q
q 0 0 0 rg BT 230.22 202.10 Td (ice President, International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.71 202.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 418.29 202.10 Td (fective ) Tj ET Q
q 0 0 0 rg BT 447.44 202.10 Td (August 2019. In this role, he ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (has responsibility for the overall strategic management, operations and commercial leadership of the International Pharmaceuticals ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (business, which includes Paladin Labs, Canada and Global partnerships in the international markets. Mr) Tj ET Q
q 0 0 0 rg BT 451.46 178.10 Td (. Garella joined Endo in 2014 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (as Senior ) Tj ET Q
q 0 0 0 rg BT 75.26 166.10 Td (V) Tj ET Q
q 0 0 0 rg BT 81.88 166.10 Td (ice President. Mr) Tj ET Q
q 0 0 0 rg BT 149.92 166.10 Td (. Garella has over 23 years�) Tj ET Q
q 0 0 0 rg BT 259.13 166.10 Td ( experience in the pharmaceutical industry across branded and generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (pharmaceuticals and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.85 154.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.97 154.10 Td (s with international experience across the European, ) Tj ET Q
q 0 0 0 rg BT 346.44 154.10 Td (Asian and Latin ) Tj ET Q
q 0 0 0 rg BT 412.26 154.10 Td (America markets. Prior to joining Endo, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (Mr) Tj ET Q
q 0 0 0 rg BT 47.67 142.10 Td (. Garella served as the Senior ) Tj ET Q
q 0 0 0 rg BT 167.17 142.10 Td (V) Tj ET Q
q 0 0 0 rg BT 173.79 142.10 Td (ice President for Glenmark Pharmaceuticals Europe Limited responsible for building and managing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (their ) Tj ET Q
q 0 0 0 rg BT 56.64 130.10 Td (W) Tj ET Q
q 0 0 0 rg BT 65.28 130.10 Td (estern European business from 2008 until 2014 and their European and Latin ) Tj ET Q
q 0 0 0 rg BT 375.21 130.10 Td (American ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.58 130.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.69 130.10 Td ( business from 2005 until 2008. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (Previously) Tj ET Q
q 0 0 0 rg BT 78.13 118.10 Td (, he worked with Ranbaxy in their ) Tj ET Q
q 0 0 0 rg BT 216.43 118.10 Td (Asia-Pacific division and Orchid Chemicals & Pharmaceuticals. He holds a Master of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (Business ) Tj ET Q
q 0 0 0 rg BT 73.51 106.10 Td (Administration \(PGDBM\) from the Institute of Management ) Tj ET Q
q 0 0 0 rg BT 318.57 106.10 Td (T) Tj ET Q
q 0 0 0 rg BT 323.98 106.10 Td (echnology) Tj ET Q
q 0 0 0 rg BT 364.98 106.10 Td (, India as well as a Bachelor degree in Electrical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (Engineering from the Faculty of Engineering, Jamia Millia, New Delhi, India.) Tj ET Q
endstream
endobj
41 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 42 0 R>>
endobj
42 0 obj
<</Length 14376>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Matthew J. Maletta) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.48 742.10 Td ( was appointed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.97 742.10 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 245.27 742.10 Td (V) Tj ET Q
q 0 0 0 rg BT 251.89 742.10 Td (ice President and Chief Legal Of) Tj ET Q
q 0 0 0 rg BT 383.05 742.10 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.96 742.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 413.55 742.10 Td (fective May 2015, and has global ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (responsibility for all legal matters af) Tj ET Q
q 0 0 0 rg BT 181.05 730.10 Td (fecting the Company) Tj ET Q
q 0 0 0 rg BT 264.27 730.10 Td (. Prior to joining Endo in 2015, Mr) Tj ET Q
q 0 0 0 rg BT 403.44 730.10 Td (. Maletta served as ) Tj ET Q
q 0 0 0 rg BT 480.73 730.10 Td (V) Tj ET Q
q 0 0 0 rg BT 487.35 730.10 Td (ice President, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (Associate General Counsel and Corporate Secretary of ) Tj ET Q
q 0 0 0 rg BT 256.76 718.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 277.12 718.10 Td (gan. In this position, he served as an advisor to the Chief Executive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (Of) Tj ET Q
q 0 0 0 rg BT 46.37 706.10 Td (ficer and Board of Directors and supervised several lar) Tj ET Q
q 0 0 0 rg BT 264.99 706.10 Td (ge transactions, including the $70 billion acquisition of ) Tj ET Q
q 0 0 0 rg BT 487.46 706.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 507.82 706.10 Td (gan by ) Tj ET Q
q 0 0 0 rg BT 536.71 706.10 Td (Actavis ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (in 2015. Mr) Tj ET Q
q 0 0 0 rg BT 82.95 694.10 Td (. Maletta also played a key role defending ) Tj ET Q
q 0 0 0 rg BT 252.61 694.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 272.98 694.10 Td (gan from an unsolicited takeover bid by ) Tj ET Q
q 0 0 0 rg BT 434.70 694.10 Td (V) Tj ET Q
q 0 0 0 rg BT 440.81 694.10 Td (aleant Pharmaceuticals and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (Pershing Square Capital Management in 2014. Mr) Tj ET Q
q 0 0 0 rg BT 236.80 682.10 Td (. Maletta joined ) Tj ET Q
q 0 0 0 rg BT 301.79 682.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 322.15 682.10 Td (gan in 2002 and during his tenure, held roles of increased ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (responsibility) Tj ET Q
q 0 0 0 rg BT 89.79 670.10 Td (, including serving as the lead commercial attorney for ) Tj ET Q
q 0 0 0 rg BT 310.28 670.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 330.64 670.10 Td (gan�) Tj ET Q
q 0 0 0 rg BT 347.86 670.10 Td (s aesthetics businesses for several years and as Head of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (Human Resources in 2010. Prior to joining ) Tj ET Q
q 0 0 0 rg BT 209.88 658.10 Td (Aller) Tj ET Q
q 0 0 0 rg BT 230.24 658.10 Td (gan, Mr) Tj ET Q
q 0 0 0 rg BT 261.35 658.10 Td (. Maletta was in private practice, focusing on general corporate matters, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (cum laude and Phi Beta Kappa, and a J.D. degree, cum laude, from the University of Minnesota Law School.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 616.10 Td (e have employment agreements with each of our executive of) Tj ET Q
q 0 0 0 rg BT 317.19 616.10 Td (ficers.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (A) Tj ET Q
q 0 0 0 rg BT 42.48 598.10 Td (vailable Information) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 580.10 Td (Our internet address is www) Tj ET Q
q 0 0 0 rg BT 176.77 580.10 Td (.endo.com. ) Tj ET Q
q 0 0 0 rg BT 223.24 580.10 Td (The contents of our website are not part of this ) Tj ET Q
q 0 0 0 rg BT 412.08 580.10 Td (Annual Report on Form 10-K and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (internet address is included in this document as an inactive textual reference only) Tj ET Q
q 0 0 0 rg BT 360.24 568.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 365.06 568.10 Td (W) Tj ET Q
q 0 0 0 rg BT 373.70 568.10 Td (e make our ) Tj ET Q
q 0 0 0 rg BT 420.07 568.10 Td (Annual Reports on Form 10-K, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy reports and all amendments to those reports available free of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 544.10 Td (ge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.50 544.10 Td (SEC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.84 544.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 526.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 69.22 526.10 Td (ou can access our filings through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.35 526.10 Td (SEC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.69 526.10 Td (�) Tj ET Q
q 0 0 0 rg BT 239.46 526.10 Td (s internet site: www) Tj ET Q
q 0 0 0 rg BT 319.08 526.10 Td (.sec.gov) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 351.85 526.10 Td ( \(intended to be an inactive textual r) Tj ET Q
q 0 0 0 rg BT 496.71 526.10 Td (efer) Tj ET Q
q 0 0 0 rg BT 511.89 526.10 Td (ence only\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 508.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 69.22 508.10 Td (ou may also access copies of the Company�) Tj ET Q
q 0 0 0 rg BT 243.34 508.10 Td (s filings with the Canadian Securities ) Tj ET Q
q 0 0 0 rg BT 394.43 508.10 Td (Administrators on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.43 508.10 Td (SEDAR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.21 508.10 Td ( through their ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (internet site: www) Tj ET Q
q 0 0 0 rg BT 109.22 496.10 Td (.sedar) Tj ET Q
q 0 0 0 rg BT 132.27 496.10 Td (.com ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 154.49 496.10 Td (\(intended to be an inactive textual r) Tj ET Q
q 0 0 0 rg BT 296.85 496.10 Td (efer) Tj ET Q
q 0 0 0 rg BT 312.03 496.10 Td (ence only\).) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (Item 1A.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 73.21 478.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 478.10 Td (Risk Factors) Tj ET Q
BT /F4 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 460.10 Td (e operate in a highly competitive industry) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 222.11 460.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 442.10 Td (The pharmaceutical industry is intensely competitive and we face competition in both our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.28 442.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.06 442.10 Td ( and international branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (and generic pharmaceutical business. Competitive factors include, without limitation, product development, technological ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (innovation, safety) Tj ET Q
q 0 0 0 rg BT 107.00 418.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 119.59 418.10 Td (ficacy) Tj ET Q
q 0 0 0 rg BT 143.36 418.10 Td (, commercialization, marketing, promotion, product quality) Tj ET Q
q 0 0 0 rg BT 380.15 418.10 Td (, price, cost-ef) Tj ET Q
q 0 0 0 rg BT 437.16 418.10 Td (fectiveness, reputation, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (service, patient convenience and access to scientific and technical information. Many of our competitors have, and future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (competitors may have, greater resources than we do and we cannot predict with certainty the timing or impact of competitors�) Tj ET Q
q 0 0 0 rg BT 538.97 394.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (products and commercialization strategies. Furthermore, recent trends in this industry include market consolidation, which may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (further concentrate financial, technical and market strength and increase competitive pressure in the industry) Tj ET Q
q 0 0 0 rg BT 469.62 370.10 Td (. It is possible that our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (competitors may make greater ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.84 358.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.51 358.10 Td ( investments and have more ef) Tj ET Q
q 0 0 0 rg BT 303.23 358.10 Td (ficient or superior processes and systems and more experience ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (in the development of new products that permit them to respond more quickly to new or emer) Tj ET Q
q 0 0 0 rg BT 410.72 346.10 Td (ging technologies and changes in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (customer demand which may make our products or technologies uncompetitive or obsolete. Furthermore, academic institutions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (government agencies and other public and private or) Tj ET Q
q 0 0 0 rg BT 246.02 322.10 Td (ganizations conducting research may seek patent protection and may establish ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (collaborative arrangements for competitive products or programs. If we fail to compete successfully) Tj ET Q
q 0 0 0 rg BT 435.49 310.10 Td (, it could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.58 310.10 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 298.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 298.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 280.10 Td (Many of our branded products do not currently compete with on-market generic products but are likely to face generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (competition in the future. ) Tj ET Q
q 0 0 0 rg BT 139.96 268.10 Td (While the entrance of generic competitors could occur at any time and cannot be predicted with certainty) Tj ET Q
q 0 0 0 rg BT 559.13 268.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (generic competition often follows shortly after the loss of patent protection. See �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.29 256.10 Td (Patents, ) Tj ET Q
q 0 0 0 rg BT 396.00 256.10 Td (T) Tj ET Q
q 0 0 0 rg BT 401.76 256.10 Td (rademarks, Licenses and Proprietary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (Property) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.44 244.10 Td (� in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.66 244.10 Td (Part 1, Item 1 of this report �Business�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.18 244.10 Td ( for additional information. Similarly) Tj ET Q
q 0 0 0 rg BT 391.12 244.10 Td (, generic products we currently sell with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (generic exclusivity could in the future be subject to competition from other generic competitors. Some of our other products, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (including both branded and generic products, already face generic competition. For these products, we face the risk of additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (generic competitors entering the market. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.38 208.10 Td (Manufacturers of generic products typically invest far less in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.13 208.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.80 208.10 Td ( than research-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (companies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.76 196.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 83.21 196.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 133.11 196.10 Td (, generic competitors, including ) Tj ET Q
q 0 0 0 rg BT 261.97 196.10 Td (Asian or other overseas generic competitors, may be able to produce ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (products at costs lower than us. For these reasons, competitors may be able to price their products lower than we can, and such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 172.10 Td (ferences could be material. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.15 172.10 Td (Due to lower prices, generic versions, where available, may be substituted by pharmacies or required ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (in preference to branded versions under third-party reimbursement programs.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.06 160.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 347.01 160.10 Td (As a result, generic competition could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 148.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 148.10 Td (. Legislation encouraging early and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (rapid approval of generic drugs could also increase the degree of generic competition we face. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.69 136.10 Td (If other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (pharmaceutical companies use litigation and regulatory means to obtain approval for generic, over) Tj ET Q
q 0 0 0 rg BT 429.27 124.10 Td (-the-counter or other competing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (versions of our drugs, our sales may suf) Tj ET Q
q 0 0 0 rg BT 195.24 112.10 Td (fer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.34 112.10 Td (� for more information.) Tj ET Q
endstream
endobj
43 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 44 0 R>>
endobj
44 0 obj
<</Length 18697>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In addition, our generics business faces competition from brand-name pharmaceutical companies, which have taken and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (may continue to take aggressive steps to thwart or delay competition from generic equivalents of their brand-name products, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (including bringing litigation alleging patent infringement or other violations of intellectual property rights. ) Tj ET Q
q 0 0 0 rg BT 464.61 718.10 Td (The actions taken by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (competing brand-name pharmaceutical companies may increase the costs and risks associated with our ef) Tj ET Q
q 0 0 0 rg BT 457.61 706.10 Td (forts to introduce generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (products and may delay or prevent such introduction altogether) Tj ET Q
q 0 0 0 rg BT 288.71 694.10 Td (. For example, if a brand-name pharmaceutical company�) Tj ET Q
q 0 0 0 rg BT 517.78 694.10 Td (s patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (was held to be valid and infringed by our generic products in a particular jurisdiction, we would be required to either obtain a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (license from the patent holder or delay or cease the manufacture and sale of such generic product. ) Tj ET Q
q 0 0 0 rg BT 428.61 670.10 Td (Any of these factors could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 658.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 658.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 640.10 Td (Our sales may also suf) Tj ET Q
q 0 0 0 rg BT 153.36 640.10 Td (fer as a result of changes in consumer demand for our products, including as a result of fluctuations in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (consumer buying patterns, changes in market conditions or actions taken by our competitors, including the introduction of new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (products or price reductions for existing products. ) Tj ET Q
q 0 0 0 rg BT 237.62 616.10 Td (Any of these factors could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.96 616.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 449.84 616.10 Td (fect on our business, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.28 604.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (If other) Tj ET Q
q 0 0 0 rg BT 68.31 586.10 Td ( pharmaceutical companies use litigation and r) Tj ET Q
q 0 0 0 rg BT 267.57 586.10 Td (egulatory means to obtain appr) Tj ET Q
q 0 0 0 rg BT 401.28 586.10 Td (oval for) Tj ET Q
q 0 0 0 rg BT 434.15 586.10 Td ( generic, over) Tj ET Q
q 0 0 0 rg BT 491.25 586.10 Td (-the-counter) Tj ET Q
q 0 0 0 rg BT 543.83 586.10 Td ( or) Tj ET Q
q 0 0 0 rg BT 555.58 586.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (other) Tj ET Q
q 0 0 0 rg BT 58.59 574.10 Td ( competing versions of our) Tj ET Q
q 0 0 0 rg BT 171.18 574.10 Td ( drugs, our) Tj ET Q
q 0 0 0 rg BT 217.95 574.10 Td ( sales may suffer) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 287.85 574.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 556.10 Td (V) Tj ET Q
q 0 0 0 rg BT 71.11 556.10 Td (arious manufacturers have filed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.39 556.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.28 556.10 Td (s seeking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.72 556.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.17 556.10 Td ( approval for generic versions of certain of our key pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (products including, but not limited to, LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 242.65 548.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.09 544.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 251.91 544.10 Td (V) Tj ET Q
q 0 0 0 rg BT 257.85 544.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 312.30 548.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.74 544.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 321.19 544.10 Td (ADRENALIN) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 379.52 548.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.96 544.10 Td ( and ) Tj ET Q
q 0 0 0 rg BT 402.85 544.10 Td (A) Tj ET Q
q 0 0 0 rg BT 408.78 544.10 Td (VEED) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 435.44 548.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.88 544.10 Td (. In connection with such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (filings, these manufacturers have challenged the validity and/or enforceability of one or more of the underlying patents protecting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (our products. In the case of LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 200.13 524.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.57 520.10 Td (, we no longer have patent protection in the markets where we sell these products. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (revenues from LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 148.75 512.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.19 508.10 Td ( have been negatively af) Tj ET Q
q 0 0 0 rg BT 250.19 508.10 Td (fected by multiple competing generic versions of LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 501.51 512.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.95 508.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 510.77 508.10 Td (W) Tj ET Q
q 0 0 0 rg BT 519.41 508.10 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (anticipate that these revenues could decrease further should one or more additional generic versions of LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 501.12 500.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.56 496.10 Td ( launch.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 478.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 114.90 478.10 Td (, in early 2019, we received notice from a competing pharmaceutical company that manufactures one of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (products of its intent to seek approval to launch a competing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.11 466.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.11 466.10 Td ( version of such product. ) Tj ET Q
q 0 0 0 rg BT 401.57 466.10 Td (W) Tj ET Q
q 0 0 0 rg BT 410.21 466.10 Td (e cannot predict whether this, or any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (other manufacturer) Tj ET Q
q 0 0 0 rg BT 111.95 454.10 Td (, will take similar actions with respect to other products. ) Tj ET Q
q 0 0 0 rg BT 338.56 454.10 Td (Any launch of competing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.98 454.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.98 454.10 Td ( versions of any of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (products could decrease the revenue of such products, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.50 442.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 410.38 442.10 Td (fect on our business, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.80 430.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 412.10 Td (Our practice is to vigorously defend and pursue all available legal and regulatory avenues in defense of the intellectual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (property rights protecting our products. Despite our ef) Tj ET Q
q 0 0 0 rg BT 252.43 400.10 Td (forts, litigation is inherently uncertain, and we cannot predict the timing or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (outcome of our ef) Tj ET Q
q 0 0 0 rg BT 107.18 388.10 Td (forts. If we are not successful in defending our intellectual property rights or opt to settle, or if a product�) Tj ET Q
q 0 0 0 rg BT 526.78 388.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (marketing or data exclusivity rights expire or become otherwise unenforceable, our competitors could ultimately launch generic, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (biosimilar) Tj ET Q
q 0 0 0 rg BT 76.15 364.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.15 364.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.15 364.10 Td ( or other competing versions of our products. Upon the loss or expiration of patent protection for one of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (products, or upon the �at-risk� launch \(despite pending patent infringement litigation against the generic product\) by a generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (manufacturer of a generic version of one of our patented products, our sales and revenues of the af) Tj ET Q
q 0 0 0 rg BT 429.55 340.10 Td (fected products would likely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (decline rapidly and materially) Tj ET Q
q 0 0 0 rg BT 155.02 328.10 Td (, which could require us to write of) Tj ET Q
q 0 0 0 rg BT 295.36 328.10 Td (f a portion or all of the intangible assets associated with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 316.10 Td (fected product and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.53 316.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 249.41 316.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 557.40 316.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 298.10 Td (In the case of ) Tj ET Q
q 0 0 0 rg BT 120.90 298.10 Td (V) Tj ET Q
q 0 0 0 rg BT 126.84 298.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 181.29 302.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.73 298.10 Td (, beginning in ) Tj ET Q
q 0 0 0 rg BT 242.95 298.10 Td (April 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.56 298.10 Td (Par Sterile Products, LLC \(PSP) Tj ET Q
q 0 0 0 rg BT 417.03 298.10 Td ( LLC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.74 298.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.18 298.10 Td (Par Pharmaceutical, Inc. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (\(PPI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.11 286.10 Td ( received notice letters from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.78 286.10 Td (Eagle Pharmaceuticals, Inc. \(Eagle\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.76 286.10 Td (, Sandoz, Inc., ) Tj ET Q
q 0 0 0 rg BT 373.92 286.10 Td (Amphastar Pharmaceuticals, Inc., ) Tj ET Q
q 0 0 0 rg BT 510.54 286.10 Td (Amneal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (Pharmaceuticals, LLC, ) Tj ET Q
q 0 0 0 rg BT 129.86 274.10 Td (American Regent and Fresenius advising of the filing by such companies of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.35 274.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.24 274.10 Td (s for generic versions of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (V) Tj ET Q
q 0 0 0 rg BT 41.93 262.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 96.39 266.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.83 262.10 Td ( \(vasopressin IV) Tj ET Q
q 0 0 0 rg BT 166.19 262.10 Td ( solution \(infusion\)\). ) Tj ET Q
q 0 0 0 rg BT 251.01 262.10 Td (The Paragraph IV) Tj ET Q
q 0 0 0 rg BT 322.46 262.10 Td ( notices refer to patents that we have listed in the Orange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (Book covering either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (form to increase blood pressure in humans. Beginning in May 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.23 238.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.68 238.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.68 238.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 347.00 238.10 Td ( LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.38 238.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.82 238.10 Td (Endo Par Innovation Company) Tj ET Q
q 0 0 0 rg BT 511.32 238.10 Td (, LLC ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (\(EPIC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.33 226.10 Td ( filed lawsuits against the companies in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.73 226.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.52 226.10 Td ( District Court for the District of Delaware and New Jersey within the 45-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (day deadline to invoke a 30-month stay of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.07 214.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.52 214.10 Td ( approval pursuant to the Hatch-W) Tj ET Q
q 0 0 0 rg BT 364.29 214.10 Td (axman legislative framework. ) Tj ET Q
q 0 0 0 rg BT 485.73 214.10 Td (W) Tj ET Q
q 0 0 0 rg BT 494.36 214.10 Td (e intend to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (pursue all available legal, business and regulatory avenues in defense of ) Tj ET Q
q 0 0 0 rg BT 326.27 202.10 Td (V) Tj ET Q
q 0 0 0 rg BT 332.21 202.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 386.66 206.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.10 202.10 Td (, including enforcement of our intellectual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (property rights. However) Tj ET Q
q 0 0 0 rg BT 136.41 190.10 Td (, there can be no assurance that we will be successful. If a generic version of ) Tj ET Q
q 0 0 0 rg BT 444.43 190.10 Td (V) Tj ET Q
q 0 0 0 rg BT 450.37 190.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 504.82 194.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.26 190.10 Td ( were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (introduced to the market, our revenues from ) Tj ET Q
q 0 0 0 rg BT 214.65 178.10 Td (V) Tj ET Q
q 0 0 0 rg BT 220.58 178.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 275.03 182.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.48 178.10 Td ( would decrease significantly and, depending on the timing of such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (introduction and its ef) Tj ET Q
q 0 0 0 rg BT 123.86 166.10 Td (fect on ) Tj ET Q
q 0 0 0 rg BT 153.66 166.10 Td (V) Tj ET Q
q 0 0 0 rg BT 159.59 166.10 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 214.05 170.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.49 166.10 Td ( pricing, could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.35 166.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 383.23 166.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 154.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 136.10 Td (There are currently ongoing legal proceedings brought by us and/or our subsidiaries and, in certain cases, our third party ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (partners, against manufacturers seeking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.77 124.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.22 124.10 Td ( approval for generic versions of our products. For a description of the material related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (legal proceedings, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.52 112.10 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.78 112.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.27 112.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.14 112.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.85 112.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 540.72 112.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.98 100.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 82.10 Td (W) Tj ET Q
q 0 0 0 rg BT 73.64 82.10 Td (e also believe it is likely that manufacturers may seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.23 82.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.68 82.10 Td ( approvals for generic, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.14 82.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.14 82.10 Td ( or other competing versions of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.10 Td (other of our key pharmaceutical products, either through the filing of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.69 70.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.58 70.10 Td (s, through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.79 70.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.79 70.10 Td ( monograph process or through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.10 Td (use of other means. ) Tj ET Q
q 0 0 0 rg BT 116.07 58.10 Td (W) Tj ET Q
q 0 0 0 rg BT 124.71 58.10 Td (e cannot determine what ef) Tj ET Q
q 0 0 0 rg BT 232.81 58.10 Td (fect section 610 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.17 58.10 Td (FCAA) Tj ET Q
q 0 0 0 rg BT 350.29 58.10 Td ( 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.79 58.10 Td ( may have on manufacturers developing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 46.10 Td (generic, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.42 46.10 Td (OTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.42 46.10 Td ( or other competing versions of our products.) Tj ET Q
endstream
endobj
45 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 46 0 R>>
endobj
46 0 obj
<</Length 16912>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (19) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (If pharmacies or) Tj ET Q
q 0 0 0 rg BT 106.92 742.25 Td ( outsour) Tj ET Q
q 0 0 0 rg BT 142.02 742.25 Td (cing facilities pr) Tj ET Q
q 0 0 0 rg BT 210.16 742.25 Td (oduce compounded versions of our) Tj ET Q
q 0 0 0 rg BT 358.32 742.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 370.64 742.25 Td (oducts, our) Tj ET Q
q 0 0 0 rg BT 418.25 742.25 Td ( sales may suffer) Tj ET Q
q 0 0 0 rg BT 488.15 742.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (Compounded drugs do not typically require the same ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.96 724.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.63 724.25 Td ( investments as either branded or generic drugs and, therefore, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (can compete favorably on price with both branded and generic versions of a drug. See �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.98 712.25 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.57 712.25 Td (� in Part I, Item ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (1. ) Tj ET Q
q 0 0 0 rg BT 45.82 700.25 Td (While we have successfully challenged an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.42 700.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.87 700.25 Td ( interim policy that would have permitted the compounding of vasopressin, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (active ingredient in ) Tj ET Q
q 0 0 0 rg BT 115.51 688.25 Td (V) Tj ET Q
q 0 0 0 rg BT 121.44 688.25 Td (ASOSTRICT) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 175.90 692.33 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.34 688.25 Td (, the introduction of compounded versions of our products by pharmacies or outsourcing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (facilities could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.96 676.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 201.84 676.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.83 676.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (If we fail to successfully identify and develop additional branded and generic pharmaceutical pr) Tj ET Q
q 0 0 0 rg BT 444.44 658.25 Td (oducts, obtain and ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (maintain exclusive marketing rights for) Tj ET Q
q 0 0 0 rg BT 204.69 646.25 Td ( our) Tj ET Q
q 0 0 0 rg BT 222.01 646.25 Td ( branded and generic pr) Tj ET Q
q 0 0 0 rg BT 325.17 646.25 Td (oducts or) Tj ET Q
q 0 0 0 rg BT 364.71 646.25 Td ( fail to intr) Tj ET Q
q 0 0 0 rg BT 410.36 646.25 Td (oduce branded and generic ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 634.25 Td (oducts on a timely basis, our) Tj ET Q
q 0 0 0 rg BT 166.76 634.25 Td ( r) Tj ET Q
q 0 0 0 rg BT 173.52 634.25 Td (evenues, gr) Tj ET Q
q 0 0 0 rg BT 221.11 634.25 Td (oss margin and operating r) Tj ET Q
q 0 0 0 rg BT 336.49 634.25 Td (esults may decline.) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.25 Td (Our financial results depend, to a significant extent, upon our ability) Tj ET Q
q 0 0 0 rg BT 335.61 616.25 Td (, and the ability of our partners, to identify) Tj ET Q
q 0 0 0 rg BT 504.92 616.25 Td (, develop, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (obtain regulatory approval for) Tj ET Q
q 0 0 0 rg BT 155.83 604.25 Td (, launch and commercialize a pipeline of commercially successful branded and generic products, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (including first-to-file or first-to-market opportunities. Due to the significant competition we face and the importance of being the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (first \(or one of the first\) to market, no assurances can be given that we will be able to develop, introduce and maintain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (commercially successful products in the future. For example, in the case of colchicine tablets, the authorized generic of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.37 568.25 Td (T) Tj ET Q
q 0 0 0 rg BT 520.78 568.25 Td (akeda) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.09 568.25 Td (�) Tj ET Q
q 0 0 0 rg BT 546.87 568.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (Colcrys) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 67.11 560.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.05 556.25 Td (, we could face competition from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.28 556.25 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.38 556.25 Td ( and other manufacturers. In November 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.60 556.25 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.71 556.25 Td ( launched its generic version ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (of Colcrys) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 77.94 548.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.88 544.25 Td ( but agreed to temporarily suspend its sales pending the outcome of preliminary injunction proceedings in the litigation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 48.32 532.25 Td (T) Tj ET Q
q 0 0 0 rg BT 53.73 532.25 Td (akeda) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.04 532.25 Td ( against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.37 532.25 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.48 532.25 Td (. If ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.64 532.25 Td (Mylan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.75 532.25 Td ( or other manufacturers enter the market, our revenues from colchicine tablets could decrease ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (significantly) Tj ET Q
q 0 0 0 rg BT 85.34 520.25 Td (, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.31 520.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 246.20 520.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.18 520.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 502.25 Td (Identifying and developing additional product candidates are prone to risks of failure inherent in product development. ) Tj ET Q
q 0 0 0 rg BT 540.17 502.25 Td (W) Tj ET Q
q 0 0 0 rg BT 548.81 502.25 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.25 Td (conduct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.16 490.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.83 490.25 Td ( to enable us to manufacture and market pharmaceutical products in accordance with specific government ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (regulations. Much of our product development ef) Tj ET Q
q 0 0 0 rg BT 232.71 478.25 Td (fort is focused on technically dif) Tj ET Q
q 0 0 0 rg BT 362.21 478.25 Td (ficult-to-formulate products and/or products that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (require advanced manufacturing technology) Tj ET Q
q 0 0 0 rg BT 211.66 466.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 216.48 466.25 Td (T) Tj ET Q
q 0 0 0 rg BT 221.89 466.25 Td (ypically) Tj ET Q
q 0 0 0 rg BT 253.46 466.25 Td (, expenses related to research, development and regulatory approval of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.25 Td (compounds for our branded products are significantly greater than those expenses associated with generic products. Should we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (expand our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.21 442.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.88 442.25 Td ( ef) Tj ET Q
q 0 0 0 rg BT 114.96 442.25 Td (forts, our research expenses are likely to increase. Because of the inherent risk associated with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.54 442.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.21 442.25 Td ( ef) Tj ET Q
q 0 0 0 rg BT 526.30 442.25 Td (forts in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (the healthcare industry) Tj ET Q
q 0 0 0 rg BT 126.42 430.25 Td (, particularly with respect to new products, our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.81 430.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.48 430.25 Td ( expenditures may not result in the successful ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (regulatory approval and introduction of new products and failure in the development of any new product can occur at any point in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (the process, including late in the process after substantial investment. ) Tj ET Q
q 0 0 0 rg BT 314.82 406.25 Td (Also, after we submit a regulatory application, the relevant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (governmental health authority may require that we conduct additional studies, including, for example, studies to assess the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (product�) Tj ET Q
q 0 0 0 rg BT 69.33 382.25 Td (s interaction with alcohol. ) Tj ET Q
q 0 0 0 rg BT 175.14 382.25 Td (As a result, we may be unable to reasonably predict the total ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.22 382.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.89 382.25 Td ( costs to develop a particular ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (product and there is a significant risk that the funds we invest in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.55 370.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.22 370.25 Td ( will not generate financial returns. In addition, our operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (results and financial condition may fluctuate as the amount we spend to research and develop, commercialize, acquire or license ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (new products, technologies and businesses changes.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 328.25 Td (The process of developing and obtaining regulatory approvals for new products is time-consuming, costly and inherently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.25 Td (unpredictable. Even if we are able to identify and develop additional product candidates, we may fail to obtain exclusive marketing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.25 Td (rights, such as the 180-day ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.87 304.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.21 304.25 Td ( first-filer marketing exclusivity period provided for in the Hatch-W) Tj ET Q
q 0 0 0 rg BT 444.82 304.25 Td (axman amendments to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.25 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.68 292.25 Td ( or the 180-day exclusivity for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.54 292.25 Td (competitive generic therapies \(CGT) Tj ET Q
q 0 0 0 rg BT 334.40 292.25 Td (s\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.62 292.25 Td ( established by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.27 292.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.72 292.25 Td ( Reauthorization ) Tj ET Q
q 0 0 0 rg BT 506.04 292.25 Td (Act of 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.25 Td (for such product candidates. Even if we were to secure such exclusivities, risks associated with securing timely approval, as well as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (risks of unfavorable litigation dispositions, put such exclusivities at risk of being forfeited. ) Tj ET Q
q 0 0 0 rg BT 400.48 268.25 Td (The approval of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.12 268.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.00 268.25 Td (s may also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.25 Td (be stayed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.20 256.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.66 256.25 Td ( for up to 30 months if such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.43 256.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.32 256.25 Td (s become the subject of patent litigation. Even where we are awarded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.25 Td (marketing exclusivity) Tj ET Q
q 0 0 0 rg BT 122.27 244.25 Td (, we may be required to share our exclusivity period with other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.81 244.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.15 244.25 Td ( applicants or with authorized generics ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (that are not prohibited from sale during the 180-day marketing exclusivity period. Our revenues have historically included sales of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (generic products with limited competition resulting from marketing exclusivity or other factors, and the failure to timely and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 208.25 Td (fectively file any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.83 208.25 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.50 208.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.95 208.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.83 208.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.83 208.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.28 208.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.61 208.25 Td (Supplemental Biologics License ) Tj ET Q
q 0 0 0 rg BT 337.98 208.25 Td (Application \(sBLA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.24 208.25 Td ( with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.74 208.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.19 208.25 Td ( or similar filings ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (with other regulatory agencies, or to partner with parties that have obtained marketing exclusivity) Tj ET Q
q 0 0 0 rg BT 425.78 196.25 Td (, could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.81 196.25 Td (material adverse ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 184.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.57 184.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 166.25 Td (Furthermore, the successful commercialization of a product is subject to a number of factors, including:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 154.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 154.25 Td (the ef) Tj ET Q
q 0 0 0 rg BT 107.30 154.25 Td (fectiveness, ease of use and safety of our products as compared to existing products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 142.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 142.25 Td (customer demand and the willingness of physicians and customers to adopt our products over products with which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 130.25 Td (they may have more loyalty or familiarity and overcoming any biases towards competitors�) Tj ET Q
q 0 0 0 rg BT 449.71 130.25 Td ( products or against our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 118.25 Td (products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 106.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 106.25 Td (the cost of our products compared to alternative products and the pricing and commercialization strategies of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 94.25 Td (competitors;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 82.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 82.25 Td (the success of our launch and marketing ef) Tj ET Q
q 0 0 0 rg BT 255.59 82.25 Td (forts;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 70.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 70.25 Td (adverse publicity about us, our products, our competitors and their products or the industry as a whole or favorable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 58.25 Td (publicity about competitors or their products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 46.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 46.25 Td (the advent of new and innovative alternative products; ) Tj ET Q
endstream
endobj
47 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 48 0 R>>
endobj
48 0 obj
<</Length 13449>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (20) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 742.10 Td (any unforeseen issues or adverse developments in connection with our products and any resulting litigation, regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 730.10 Td (scrutiny and/or harm to our reputation; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 718.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 718.10 Td (other risks that may be out of our control, including the decision by a collaboration partner to make substantial changes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 706.10 Td (to a product�) Tj ET Q
q 0 0 0 rg BT 135.54 706.10 Td (s formulation or design, or a collaboration partner refusing to perform its obligations under our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.00 694.10 Td (collaboration agreement, which may cause delays and additional costs in developing and marketing a product.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 676.10 Td (e have been, continue to be and may be the subject of lawsuits, pr) Tj ET Q
q 0 0 0 rg BT 323.32 676.10 Td (oduct liability claims, other) Tj ET Q
q 0 0 0 rg BT 439.80 676.10 Td ( significant legal ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 664.10 Td (oceedings, government investigations or) Tj ET Q
q 0 0 0 rg BT 215.62 664.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 227.94 664.10 Td (oduct r) Tj ET Q
q 0 0 0 rg BT 258.59 664.10 Td (ecalls) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 281.92 664.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 646.10 Td (Our business exposes us to significant potential risks from lawsuits, product liability claims, other significant legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (proceedings, government investigations or product recalls, including, but not limited to, such matters associated with the testing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (manufacturing, marketing and sale of our products. Some plaintif) Tj ET Q
q 0 0 0 rg BT 297.42 622.10 Td (fs have received substantial damage awards or settlements against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (healthcare companies based upon various legal theories, including without limitation claims for injuries allegedly caused by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (use of their products. ) Tj ET Q
q 0 0 0 rg BT 122.74 598.10 Td (W) Tj ET Q
q 0 0 0 rg BT 131.38 598.10 Td (e have been, continue to be and may be subject to various product liability cases, as well as other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (significant legal proceedings and government investigations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 568.10 Td (For example, we, along with other manufacturers of prescription opioid medications, as well as distributors and other sellers ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (of such medications, are the subject of lawsuits and have received subpoenas and other requests for information from various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (federal, state and local government agencies regarding the sale, marketing and/or distribution of prescription opioid medications. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (Numerous claims against opioid manufacturers, including us, have been and may continue to be filed by or on behalf of states, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (counties, cities, Native ) Tj ET Q
q 0 0 0 rg BT 129.03 520.10 Td (American tribes, other government-related persons or entities, hospitals, health systems, unions, health and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (welfare funds, other third-party payers and/or individuals. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.04 508.10 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.29 508.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.79 508.10 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.59 496.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 496.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 197.18 496.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.16 496.10 Td ( for more information. In these cases, plaintif) Tj ET Q
q 0 0 0 rg BT 467.75 496.10 Td (fs seek various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (remedies, including without limitation declaratory and/or injunctive relief; compensatory) Tj ET Q
q 0 0 0 rg BT 391.63 484.10 Td (, punitive and/or treble damages; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (restitution, disgor) Tj ET Q
q 0 0 0 rg BT 106.37 472.10 Td (gement, civil penalties, abatement, attorneys�) Tj ET Q
q 0 0 0 rg BT 286.95 472.10 Td ( fees, costs and/or other relief. Settlement demands may seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (significant monetary and other remedies, or otherwise be on terms that we do not consider reasonable under the circumstances. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (A) Tj ET Q
q 0 0 0 rg BT 42.30 448.10 Td (wards against and settlements by our competitors could also incentivize parties to bring additional claims against us. In addition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (to the risks of direct expenditures for defense costs, settlements and/or judgments in connection with these claims, proceedings and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (investigations, there is a possibility of loss of revenues, injunctions and disruption of business. Furthermore, we and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (manufacturers of prescription opioid medications have been, and will likely continue to be, subject to negative publicity and press, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (which could harm our brand and the demand for our products. In addition, current or future regulatory and legislative proposals ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (could impact us and other manufacturers of prescription opioid medications. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.38 388.10 Td (Our business and financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (condition may be adversely af) Tj ET Q
q 0 0 0 rg BT 156.33 376.10 Td (fected by legislation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.42 376.10 Td (� for more information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 358.10 Td (Our current and former products may cause or appear to cause serious adverse side ef) Tj ET Q
q 0 0 0 rg BT 406.90 358.10 Td (fects or potentially dangerous drug ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (interactions if misused or improperly prescribed or as a result of faulty sur) Tj ET Q
q 0 0 0 rg BT 332.96 346.10 Td (gical technique. For example, we and certain other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (manufacturers have been named as defendants in multiple lawsuits in various federal and state courts alleging personal injury ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (resulting from use of transvaginal sur) Tj ET Q
q 0 0 0 rg BT 185.51 322.10 Td (gical mesh products designed to treat ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.58 322.10 Td (pelvic or) Tj ET Q
q 0 0 0 rg BT 371.66 322.10 Td (gan prolapse \(POP\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.98 322.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.42 322.10 Td (stress urinary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (incontinence \(SUI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 112.36 310.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 117.18 310.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.23 310.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.68 310.10 Td ( held a public advisory committee meeting in February 2019 during which the members of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (Obstetrics and Gynecology Devices Panel of the Medical Devices ) Tj ET Q
q 0 0 0 rg BT 301.75 298.10 Td (Advisory Committee discussed and made recommendations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (regarding the safety and ef) Tj ET Q
q 0 0 0 rg BT 142.44 286.10 Td (fectiveness of sur) Tj ET Q
q 0 0 0 rg BT 212.23 286.10 Td (gical mesh to treat ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.31 286.10 Td (POP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.55 286.10 Td (. In ) Tj ET Q
q 0 0 0 rg BT 320.83 286.10 Td (April 2019, following the meeting, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.47 286.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.92 286.10 Td ( ordered that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (manufacturers of all remaining sur) Tj ET Q
q 0 0 0 rg BT 174.10 274.10 Td (gical mesh products indicated for the transvaginal repair of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.63 274.10 Td (POP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.60 274.10 Td ( cease selling and distributing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (their products in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.76 262.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.54 262.10 Td ( ef) Tj ET Q
q 0 0 0 rg BT 146.63 262.10 Td (fective immediately) Tj ET Q
q 0 0 0 rg BT 225.67 262.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 230.12 262.10 Td (Although we have not sold transvaginal sur) Tj ET Q
q 0 0 0 rg BT 403.79 262.10 Td (gical mesh products since March 2016, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (it is possible that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.72 250.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.61 250.10 Td (�) Tj ET Q
q 0 0 0 rg BT 142.39 250.10 Td (s order and any additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.75 250.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.20 250.10 Td ( actions based on the outcome of the advisory committee meeting could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (result in additional litigation against the Company) Tj ET Q
q 0 0 0 rg BT 235.87 238.10 Td (. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.81 238.10 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.07 238.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.57 238.10 Td (Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 226.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.59 226.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 157.46 226.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.45 226.10 Td ( for more information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 208.10 Td (Any failure to ef) Tj ET Q
q 0 0 0 rg BT 131.18 208.10 Td (fectively identify) Tj ET Q
q 0 0 0 rg BT 199.12 208.10 Td (, analyze, report and protect adverse event data and/or to fully comply with relevant laws, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (rules and regulations around adverse event reporting could expose the Company to legal proceedings, penalties, fines and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (reputational damage.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 166.10 Td (In addition, in the age of social media, plaintif) Tj ET Q
q 0 0 0 rg BT 249.77 166.10 Td (fs�) Tj ET Q
q 0 0 0 rg BT 259.58 166.10 Td ( attorneys have a wide variety of tools to advertise their services and solicit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (new clients for litigation, including using judgments and settlements obtained in litigation against us or other pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (companies as an advertising tool. For these or other reasons, any significant product liability or mass tort litigation in which we are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (a defendant could have a lar) Tj ET Q
q 0 0 0 rg BT 148.26 130.10 Td (ger number of plaintif) Tj ET Q
q 0 0 0 rg BT 236.11 130.10 Td (fs than such actions have seen historically and we could also see an increase in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (the number of cases filed against us because of the increasing use of widespread and media-varied advertising. Furthermore, a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (ruling against other pharmaceutical companies in product liability or mass tort litigation in which we are not a defendant could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (have a negative impact on pending litigation where we are a defendant.) Tj ET Q
endstream
endobj
49 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 50 0 R>>
endobj
50 0 obj
<</Length 12754>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (21) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 742.10 Td (In addition, in certain circumstances, such as in the case of products that do not meet approved specifications or for which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (subsequent data demonstrate such products may be unsafe, inef) Tj ET Q
q 0 0 0 rg BT 289.35 730.10 Td (fective or misused, it may be necessary for us to initiate voluntary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (or mandatory recalls or withdraw such products from the market. ) Tj ET Q
q 0 0 0 rg BT 298.42 718.10 Td (Any such recall or withdrawal could result in adverse publicity) Tj ET Q
q 0 0 0 rg BT 549.64 718.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (costs connected to the recall and loss of revenue. ) Tj ET Q
q 0 0 0 rg BT 233.15 706.10 Td (Adverse publicity could also result in an increased number of additional product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (liability claims, whether or not these claims have a basis in scientific fact. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.82 694.10 Td (Public concern around the abuse of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (opioids or other products, including without limitation law enforcement concerns over diversion or marketing practices, regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 670.10 Td (forts to combat abuse, and litigation could result in costs to our business) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.16 670.10 Td (� for more information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 652.10 Td (If we are found liable in any lawsuits, including product liability claims or actions related to our sales, marketing or pricing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (practices or the sale, marketing and/or distribution of prescription opioid medications, or if we are subject to government ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (investigations or product recalls, it could result in the imposition of damages, including punitive damages, fines, reputational harm, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (civil lawsuits, criminal penalties, interruptions of business, modification of business practices, equitable remedies and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (sanctions against us or our personnel as well as significant legal and other costs. ) Tj ET Q
q 0 0 0 rg BT 358.80 604.10 Td (W) Tj ET Q
q 0 0 0 rg BT 367.44 604.10 Td (e may also voluntarily settle cases even if we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (believe that we have meritorious defenses because of the significant legal and other costs that may be required to defend such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (actions. ) Tj ET Q
q 0 0 0 rg BT 68.77 580.10 Td (Any judgments, claims, settlements and related costs could be well in excess of any applicable insurance. ) Tj ET Q
q 0 0 0 rg BT 492.26 580.10 Td (As a result, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (may experience significant negative impacts on our operations. ) Tj ET Q
q 0 0 0 rg BT 291.01 568.10 Td (T) Tj ET Q
q 0 0 0 rg BT 296.42 568.10 Td (o satisfy judgments or settlements, we also may need to seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (financing, which may not be available on terms acceptable to us, or at all, when required. Judgments also could cause defaults ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (under our debt agreements and/or restrictions on our product use and we could incur losses as a result. ) Tj ET Q
q 0 0 0 rg BT 446.72 544.10 Td (Any of the risks above could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.32 532.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 140.20 532.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.18 532.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 514.10 Td (The occurrence or possibility of any such result may cause us to pursue one or more significant corporate transactions as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (well as other remedial measures, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.55 502.10 Td (internal reor) Tj ET Q
q 0 0 0 rg BT 258.51 502.10 Td (ganizations, restructuring activities, strategic corporate alignments, cost-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (saving initiatives or asset sales) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.75 490.10 Td (. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.16 490.10 Td (Our ability to fund our operations, maintain liquidity and meet our financing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (obligations is reliant on our operations, which are subject to significant risks and uncertainties) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.02 478.10 Td (� for more information. Likewise, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 466.10 Td (internal reor) Tj ET Q
q 0 0 0 rg BT 101.90 466.10 Td (ganizations, restructuring activities, strategic corporate alignments, cost-saving initiatives or asset sales) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.83 466.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.33 466.10 Td (may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (complex, could entail significant costs and char) Tj ET Q
q 0 0 0 rg BT 226.04 454.10 Td (ges or could otherwise negatively impact shareholder value and there can be no ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (their intended benefits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.41 430.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 412.10 Td (See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.94 412.10 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.20 412.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.69 412.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.56 412.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.27 412.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 494.14 412.10 Td (, Item 15 of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.88 400.10 Td ( for further discussion of the foregoing and other material legal proceedings.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 382.10 Td (e may not have and may be unable to obtain or) Tj ET Q
q 0 0 0 rg BT 245.28 382.10 Td ( maintain insurance adequate to cover) Tj ET Q
q 0 0 0 rg BT 408.15 382.10 Td ( potential liabilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 364.10 Td (W) Tj ET Q
q 0 0 0 rg BT 73.64 364.10 Td (e may not have and may be unable to obtain or maintain in the future insurance on acceptable terms or with adequate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (coverage against potential liabilities or other losses, such as the cost of a recall, if any claim is brought against us, regardless of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (success or failure of the claim. For example, we generally no longer have product liability insurance to cover the claims in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (connection with the mesh-related litigation described above. ) Tj ET Q
q 0 0 0 rg BT 279.26 328.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 329.16 328.10 Td (, we may be limited by the surviving insurance policies of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (our acquired subsidiaries, which may not be adequate to cover against potential liabilities or other losses. Even where claims are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (submitted to insurance carriers for defense and indemnity) Tj ET Q
q 0 0 0 rg BT 265.55 304.10 Td (, there can be no assurance that the claims will be fully covered by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (insurance or that the indemnitors or insurers will remain financially viable. ) Tj ET Q
q 0 0 0 rg BT 337.95 292.10 Td (The failure to generate suf) Tj ET Q
q 0 0 0 rg BT 443.28 292.10 Td (ficient cash flow or to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (other financing could af) Tj ET Q
q 0 0 0 rg BT 131.62 280.10 Td (fect our ability to pay the amounts due under those liabilities not covered by insurance.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 262.10 Td ( ability to fund our) Tj ET Q
q 0 0 0 rg BT 133.99 262.10 Td ( operations, maintain liquidity and meet our) Tj ET Q
q 0 0 0 rg BT 322.44 262.10 Td ( financing obligations is r) Tj ET Q
q 0 0 0 rg BT 430.05 262.10 Td (eliant on our) Tj ET Q
q 0 0 0 rg BT 484.32 262.10 Td ( operations, which ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (ar) Tj ET Q
q 0 0 0 rg BT 45.26 250.10 Td (e subject to significant risks and uncertainties) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 240.26 250.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 232.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 232.10 Td (e rely on cash from operations as well as access to the financial markets to fund our operations, maintain liquidity and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (meet our financial obligations. Our operations are subject to many significant risks and uncertainties described in this �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.53 220.10 Td (Risk ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (Factors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.44 208.10 Td (� section, including those related to generic competition and legal challenges that could impact our key products, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (V) Tj ET Q
q 0 0 0 rg BT 41.93 196.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 96.39 200.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.32 196.10 Td (, outstanding and future legal proceedings and governmental investigations, including those related to our sale, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (marketing and/or distribution of prescription opioid medications, and others. ) Tj ET Q
q 0 0 0 rg BT 344.00 184.10 Td (Any negative development or outcome in connection ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (with any or all of these risks and uncertainties could result in significant consequences, including one or more of the following:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 160.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 160.10 Td (causing a substantial portion of our cash flows from operations to be dedicated to the payment of legal or related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 148.10 Td (expenses and therefore unavailable for other purposes, including the payment of principal and interest on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 136.10 Td (indebtedness, our operations, capital expenditures and future business opportunities; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 124.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 124.10 Td (limiting our ability to adjust to changing market conditions, causing us to be more vulnerable to periods of negative or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 112.10 Td (slow growth in the general economy or in our business, causing us to be unable to carry out capital spending that is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 100.10 Td (important to our growth and placing us at a competitive disadvantage;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 88.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 88.10 Td (limiting our ability to attract and retain key personnel;) Tj ET Q
endstream
endobj
51 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 52 0 R>>
endobj
52 0 obj
<</Length 13674>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (22) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (causing us to be unable to maintain compliance with or making it more dif) Tj ET Q
q 0 0 0 rg BT 383.30 742.10 Td (ficult for us to satisfy our financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (obligations under certain of our outstanding debt obligations, causing a downgrade of our debt and long-term corporate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 718.10 Td (ratings \(which could increase our cost of capital\) and exposing us to potential events of default \(if not cured or waived\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 706.10 Td (under financial and operating covenants contained in our or our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 391.88 706.10 Td ( outstanding indebtedness;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 694.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 694.10 Td (limiting our ability to incur additional borrowings under the covenants in our then-existing facilities or to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 682.10 Td (additional debt or equity financing for working capital, capital expenditures, business development, debt service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 670.10 Td (requirements, acquisitions or general corporate or other purposes, or to refinance our indebtedness; and/or) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 658.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 658.10 Td (otherwise causing us to be unable to fund our operations and liquidity needs, such as future capital expenditures and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 646.10 Td (payment of our indebtedness.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 628.10 Td (The occurrence or possibility of one or more of these or similar events may cause us to pursue one or more significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (corporate transactions as well as other remedial measures, including refinancing all or part of our then-existing indebtedness, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (selling assets, reducing or delaying capital expenditures, seeking to raise additional capital or pursuing one or more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.48 604.10 Td (internal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (reor) Tj ET Q
q 0 0 0 rg BT 51.92 592.10 Td (ganizations, restructuring activities, strategic corporate alignments, cost-saving initiatives or asset sales) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.85 592.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 469.30 592.10 Td (Any refinancing of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (substantial indebtedness ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.43 580.10 Td (could be at significantly higher interest rates, which will depend on the conditions of the markets and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (financial condition at such time) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.07 568.10 Td (, and may require us to comply with more onerous covenants, which could further restrict our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (business operations. ) Tj ET Q
q 0 0 0 rg BT 118.50 556.10 Td (Any refinancing may also increase the amount of our secured indebtedness. In addition, the terms of existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (or future debt agreements may restrict us from adopting any of these alternatives. Likewise, any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.26 544.10 Td (internal reor) Tj ET Q
q 0 0 0 rg BT 471.22 544.10 Td (ganizations, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (restructuring activities, strategic corporate alignments, cost-saving initiatives or asset sales) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.39 532.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.89 532.10 Td (may be complex, could entail ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (significant costs and char) Tj ET Q
q 0 0 0 rg BT 137.18 520.10 Td (ges or could otherwise negatively impact shareholder value and there can be no assurance that we will be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in their intended benefits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.00 508.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 490.10 Td ( ability to pr) Tj ET Q
q 0 0 0 rg BT 106.47 490.10 Td (otect and maintain our) Tj ET Q
q 0 0 0 rg BT 203.79 490.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 216.11 490.10 Td (oprietary and licensed third party technology) Tj ET Q
q 0 0 0 rg BT 409.16 490.10 Td (, which is vital to our) Tj ET Q
q 0 0 0 rg BT 498.43 490.10 Td ( business, is ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (uncertain) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 77.11 478.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.10 Td (Our success, competitive position and future income will depend in part on our ability) Tj ET Q
q 0 0 0 rg BT 406.72 460.10 Td (, and the ability of our partners and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (suppliers, to obtain and protect patent and other intellectual property rights relating to our current and future technologies, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (processes and products. ) Tj ET Q
q 0 0 0 rg BT 133.02 436.10 Td (The degree of protection any patents will af) Tj ET Q
q 0 0 0 rg BT 307.49 436.10 Td (ford is uncertain, including whether the protection obtained ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (will be of suf) Tj ET Q
q 0 0 0 rg BT 88.87 424.10 Td (ficient breadth and degree to protect our commercial interests in all the jurisdictions where we conduct business. ) Tj ET Q
q 0 0 0 rg BT 540.76 424.10 Td (That ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (is, the issuance of a patent is not conclusive as to its claimed scope, validity or enforceability) Tj ET Q
q 0 0 0 rg BT 406.91 412.10 Td (. Patent rights may be challenged, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (revoked, invalidated, infringed or circumvented by third parties. For example, if an invention qualifies as a joint invention, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (joint inventor may have intellectual property rights in the invention, which it might not protect. ) Tj ET Q
q 0 0 0 rg BT 418.42 388.10 Td (A) Tj ET Q
q 0 0 0 rg BT 425.09 388.10 Td ( third party may also infringe ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (upon, design around or develop uses not covered by any patent issued or licensed to us and our patents may not otherwise be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (commercially viable. In this regard, the patent position of pharmaceutical compounds and compositions is particularly uncertain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (and involves complex legal and factual questions. Even issued patents may later be modified or revoked by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.26 352.10 Td (PT) Tj ET Q
q 0 0 0 rg BT 493.75 352.10 Td (O) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.97 352.10 Td (, by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (comparable foreign patent of) Tj ET Q
q 0 0 0 rg BT 151.60 340.10 Td (fices or by a court following legal proceedings. Laws relating to such rights may in the future also be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (changed or withdrawn.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 310.10 Td (There is no assurance that any of our patent claims in our pending non-provisional and provisional patent applications ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (relating to our technologies, processes or products will be issued or) Tj ET Q
q 0 0 0 rg BT 304.71 298.10 Td (, if issued, that any of our existing and future patent claims will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (be held valid and enforceable against third-party infringement. It is possible that we could incur significant costs and management ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (distraction if we are required to initiate litigation against others to protect or enforce our intellectual property rights. Such patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (disputes may be lengthy and a potential violator of our patents may bring a potentially infringing product to market during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (dispute, subjecting us to competition and damages due to infringement of the competitor product. Upon the expiration or loss of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (intellectual property protection for a product, others may manufacture and distribute such patented product, which may result in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (loss of a significant portion of our sales of that product.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 208.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 208.10 Td (e also rely on trade secrets and other unpatented proprietary information, which we generally seek to protect by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (confidentiality and nondisclosure agreements with our employees, consultants, advisors and partners. ) Tj ET Q
q 0 0 0 rg BT 443.50 196.10 Td (These agreements may not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 184.10 Td (fectively prevent disclosure of confidential information and may not provide us with an adequate remedy in the event of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (unauthorized disclosure. For example, in ) Tj ET Q
q 0 0 0 rg BT 201.24 172.10 Td (August 2017, we filed a complaint against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.87 172.10 Td (QuV) Tj ET Q
q 0 0 0 rg BT 391.21 172.10 Td (a Pharma, Inc. \(QuV) Tj ET Q
q 0 0 0 rg BT 473.12 172.10 Td (a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.89 172.10 Td ( and certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (individual defendants in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.86 160.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.65 160.10 Td ( District Court for the District of New Jersey alleging misappropriation in violation of the federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (Defend ) Tj ET Q
q 0 0 0 rg BT 67.75 148.10 Td (T) Tj ET Q
q 0 0 0 rg BT 73.50 148.10 Td (rade Secrets ) Tj ET Q
q 0 0 0 rg BT 124.04 148.10 Td (Act, New Jersey ) Tj ET Q
q 0 0 0 rg BT 192.17 148.10 Td (T) Tj ET Q
q 0 0 0 rg BT 197.92 148.10 Td (rade Secrets ) Tj ET Q
q 0 0 0 rg BT 248.46 148.10 Td (Act and New Jersey common law) Tj ET Q
q 0 0 0 rg BT 382.49 148.10 Td (, as well as unfair competition, breach of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (contract, breach of fiduciary duty) Tj ET Q
q 0 0 0 rg BT 168.90 136.10 Td (, breach of the duty of loyalty) Tj ET Q
q 0 0 0 rg BT 286.83 136.10 Td (, tortious interference with contractual relations and breach of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (duty of confidence in connection with ) Tj ET Q
q 0 0 0 rg BT 190.22 124.10 Td (V) Tj ET Q
q 0 0 0 rg BT 196.15 124.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 250.60 128.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.54 124.10 Td (. For more information regarding this litigation, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.83 124.10 Td (Note 15. Commitments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.15 112.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.65 112.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.51 112.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.22 112.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 354.10 112.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.08 112.10 Td (. Even if third parties ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (misappropriate or infringe upon our proprietary rights, we may not be able to discover or determine the extent of any such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (unauthorized use and we may not be able to prevent third parties from misappropriating or infringing upon our proprietary rights. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (In addition, if our employees, scientific consultants or partners develop inventions or processes that may be applicable to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.10 Td (existing products or products under development, such inventions and processes will not necessarily become our property and may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 52.10 Td (remain the property of those persons or their employers.) Tj ET Q
endstream
endobj
53 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 54 0 R>>
endobj
54 0 obj
<</Length 14607>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Any failure by us to adequately protect our technology) Tj ET Q
q 0 0 0 rg BT 281.17 742.10 Td (, trade secrets or proprietary know-how or to enforce our intellectual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (property rights could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.69 730.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 226.57 730.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.55 730.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 712.10 Td ( competitors or) Tj ET Q
q 0 0 0 rg BT 118.39 712.10 Td ( other) Tj ET Q
q 0 0 0 rg BT 143.48 712.10 Td ( third parties may allege that we ar) Tj ET Q
q 0 0 0 rg BT 292.99 712.10 Td (e infringing their) Tj ET Q
q 0 0 0 rg BT 365.58 712.10 Td ( intellectual pr) Tj ET Q
q 0 0 0 rg BT 427.62 712.10 Td (operty) Tj ET Q
q 0 0 0 rg BT 454.83 712.10 Td (, for) Tj ET Q
q 0 0 0 rg BT 472.42 712.10 Td (cing us to expend ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (substantial r) Tj ET Q
q 0 0 0 rg BT 89.44 700.10 Td (esour) Tj ET Q
q 0 0 0 rg BT 112.59 700.10 Td (ces in litigation, the outcome of which is uncertain. ) Tj ET Q
q 0 0 0 rg BT 330.08 700.10 Td (Any unfavorable outcome of such litigation, including ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (losses r) Tj ET Q
q 0 0 0 rg BT 66.65 688.10 Td (elated to �at-risk� pr) Tj ET Q
q 0 0 0 rg BT 156.18 688.10 Td (oduct launches, could have a ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 280.64 688.10 Td (material adverse effect on our) Tj ET Q
q 0 0 0 rg BT 408.19 688.10 Td ( business, financial condition, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (r) Tj ET Q
q 0 0 0 rg BT 40.26 676.10 Td (esults of operations and cash flows) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 187.22 676.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 658.10 Td (Companies that produce branded pharmaceutical products routinely bring litigation against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.01 658.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.35 658.10 Td ( or similar applicants that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (seek regulatory approval to manufacture and market generic forms of branded products, alleging patent infringement or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (violations of intellectual property rights. Patent holders may also bring patent infringement suits against companies that are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (currently marketing and selling approved generic products. Litigation often involves significant expense. ) Tj ET Q
q 0 0 0 rg BT 457.55 622.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 507.45 622.10 Td (, if the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (patents of others are held valid, enforceable and infringed by our current products or future product candidates, we would, unless ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (we could obtain a license from the patent holder) Tj ET Q
q 0 0 0 rg BT 228.31 598.10 Td (, need to delay selling our corresponding generic product and, if we are already ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (selling our product, cease selling and potentially destroy existing product stock. ) Tj ET Q
q 0 0 0 rg BT 356.77 586.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 406.67 586.10 Td (, we could be required to pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (monetary damages or royalties to license proprietary rights from third parties and we may not be able to obtain such licenses on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (commercially reasonable terms or at all.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 544.10 Td (There may be situations in which we may make business and legal judgments to market and sell products that are subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (claims of alleged patent infringement prior to final resolution of those claims by the courts based upon our belief that such patents ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (are invalid, unenforceable or are not infringed by our marketing and sale of such products. ) Tj ET Q
q 0 0 0 rg BT 399.86 520.10 Td (This is commonly referred to in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (pharmaceutical industry as an �at-risk� launch. ) Tj ET Q
q 0 0 0 rg BT 226.02 508.10 Td (The risk involved in an at-risk launch can be substantial because, if a patent holder ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (ultimately prevails against us, the remedies available to such holder may include, among other things, damages calculated based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (the profits lost by the patent holder) Tj ET Q
q 0 0 0 rg BT 175.57 484.10 Td (, which can be significantly higher than the profits we make from selling the generic version of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (the product. Moreover) Tj ET Q
q 0 0 0 rg BT 125.29 472.10 Td (, if a court determines that such infringement is willful, the damages could be subject to trebling. ) Tj ET Q
q 0 0 0 rg BT 514.45 472.10 Td (W) Tj ET Q
q 0 0 0 rg BT 523.09 472.10 Td (e could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (face substantial damages from adverse court decisions in such matters. ) Tj ET Q
q 0 0 0 rg BT 321.00 460.10 Td (W) Tj ET Q
q 0 0 0 rg BT 329.64 460.10 Td (e could also be at risk for the value of such inventory that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (we are unable to market or sell.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (Agr) Tj ET Q
q 0 0 0 rg BT 52.48 430.10 Td (eements between branded pharmaceutical companies and generic pharmaceutical companies ar) Tj ET Q
q 0 0 0 rg BT 460.31 430.10 Td (e facing incr) Tj ET Q
q 0 0 0 rg BT 512.89 430.10 Td (eased ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (government scrutiny and private litigation in the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 246.27 418.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 264.06 418.10 Td ( and abr) Tj ET Q
q 0 0 0 rg BT 300.00 418.10 Td (oad.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 400.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 400.10 Td (e are and may in the future be involved in patent litigations in which generic companies challenge the validity or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (enforceability of our products�) Tj ET Q
q 0 0 0 rg BT 157.71 388.10 Td ( listed patents and/or the applicability of these patents to the generic applicant�) Tj ET Q
q 0 0 0 rg BT 471.50 388.10 Td (s products. Likewise, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (we are and may in the future be involved in patent litigations in which we challenge the validity or enforceability of innovator ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (companies�) Tj ET Q
q 0 0 0 rg BT 81.35 364.10 Td ( listed patents and/or their applicability to our generic products. ) Tj ET Q
q 0 0 0 rg BT 337.49 364.10 Td (Therefore, settling patent litigations has been and is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (likely to continue to be part of our business. Parties to such settlement agreements in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.75 352.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.54 352.10 Td (, including us, are required by law to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (file them with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.32 340.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.10 340.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.60 340.10 Td (Federal ) Tj ET Q
q 0 0 0 rg BT 161.90 340.10 Td (T) Tj ET Q
q 0 0 0 rg BT 167.66 340.10 Td (rade Commission \(FTC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.43 340.10 Td ( and the ) Tj ET Q
q 0 0 0 rg BT 299.04 340.10 Td (Antitrust Division of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.59 340.10 Td (DOJ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.92 340.10 Td ( for review) Tj ET Q
q 0 0 0 rg BT 461.14 340.10 Td (. In some instances, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.34 328.10 Td ( has brought actions against brand and generic companies that have entered into such agreements, alleging that they violate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (antitrust laws. Even in the absence of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.56 316.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.90 316.10 Td ( challenge, other governmental or private litigants may assert antitrust or other claims ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (relating to such agreements. ) Tj ET Q
q 0 0 0 rg BT 150.13 304.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 199.47 304.10 Td (, we may receive formal or informal requests from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.55 304.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.89 304.10 Td ( or other governmental entities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (for information about any such settlement agreement we enter into, and there is a risk that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.54 292.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.88 292.10 Td ( or other governmental or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (private litigants may commence an action against us alleging violation of antitrust laws or other claims.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 262.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 262.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.83 262.10 Td ( Supreme Court, in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 177.43 262.10 Td (FTC) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 195.77 262.10 Td ( v) Tj ET Q
q 0 0 0 rg BT 201.97 262.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 206.79 262.10 Td (Actavis) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.22 262.10 Td (, determined that patent settlement agreements between generic and brand ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (companies should be evaluated under the rule of reason, but provided limited guidance beyond the selection of this standard. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (Because the Supreme Court did not articulate the full range of criteria upon which a determination of the legality of such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (settlements would be based, or provide guidance on the precise circumstances under which such settlements would qualify as legal, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (there may be extensive litigation over what constitutes a reasonable and lawful patent settlement between a brand and generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (company) Tj ET Q
q 0 0 0 rg BT 72.01 202.10 Td (. For example, certain of our subsidiaries are subject to multiple lawsuits, including proposed class actions, brought by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (direct and indirect purchasers alleging that a patent settlement agreement with Impax Laboratories, LLC \(now ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.07 190.10 Td (Amneal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.72 190.10 Td (\) regarding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (OP) Tj ET Q
q 0 0 0 rg BT 47.87 178.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 69.53 182.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.47 178.10 Td ( ER was unlawful in violation of federal antitrust laws and various state laws.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 160.10 Td (There have been federal and state legislative ef) Tj ET Q
q 0 0 0 rg BT 250.77 160.10 Td (forts to overturn the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 332.98 160.10 Td (FTC) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 351.32 160.10 Td ( v) Tj ET Q
q 0 0 0 rg BT 357.51 160.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 362.33 160.10 Td (Actavis) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.76 160.10 Td ( decision and make certain terms in patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (settlement agreements ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 127.63 148.10 Td (per se) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.79 148.10 Td ( unlawful. For example, some members of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.41 148.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.20 148.10 Td ( Congress have proposed legislation that would ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (limit the types of settlement agreements generic manufacturers and brand companies can enter into. ) Tj ET Q
q 0 0 0 rg BT 436.50 136.10 Td (The state of California recently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (enacted legislation, ef) Tj ET Q
q 0 0 0 rg BT 123.28 124.10 Td (fective January 1, 2020, that deems a settlement of a patent infringement claim to be presumptively ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (anticompetitive and allows the California ) Tj ET Q
q 0 0 0 rg BT 203.46 112.10 Td (Attorney General to seek monetary penalties if a generic company receives anything of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (value from the branded company and the generic company agrees to delay research and development, manufacturing, marketing or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (sales of the generic product for any period of time. ) Tj ET Q
q 0 0 0 rg BT 241.02 88.10 Td (The California law carves out from the definition of �anything of value� certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (types of settlement terms and it allows the settling parties to rebut the presumption of anticompetitive harm.) Tj ET Q
endstream
endobj
55 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 56 0 R>>
endobj
56 0 obj
<</Length 15999>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (24) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 742.25 Td (e have significant goodwill and other) Tj ET Q
q 0 0 0 rg BT 201.66 742.25 Td ( intangible assets. Consequently) Tj ET Q
q 0 0 0 rg BT 336.69 742.25 Td (, potential impairments of goodwill and other) Tj ET Q
q 0 0 0 rg BT 529.56 742.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (intangibles may significantly impact our) Tj ET Q
q 0 0 0 rg BT 207.49 730.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 219.81 730.25 Td (ofitability) Tj ET Q
q 0 0 0 rg BT 260.93 730.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 712.25 Td (Goodwill and other intangibles represent a significant portion of our assets. ) Tj ET Q
q 0 0 0 rg BT 366.27 712.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.71 712.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.29 712.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.73 712.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.73 712.25 Td (, goodwill ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (and other intangibles comprised approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.78 700.25 Td (66%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.11 700.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.55 700.25 Td (71%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.88 700.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 335.54 700.25 Td (, of our total assets. Goodwill and other indefinite-lived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (intangible assets are subject to impairment tests at least annually) Tj ET Q
q 0 0 0 rg BT 293.33 688.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 297.78 688.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 347.68 688.25 Td (, impairment tests must be performed for certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (assets whenever events or changes in circumstances indicate such assets�) Tj ET Q
q 0 0 0 rg BT 327.10 676.25 Td ( carrying amounts may not be recoverable.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 658.25 Td (For the years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.08 658.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.67 658.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.67 658.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.67 658.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.11 658.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.11 658.25 Td (, we recorded asset impairment char) Tj ET Q
q 0 0 0 rg BT 431.31 658.25 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.97 658.25 Td ($0.5 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.08 658.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.08 658.25 Td ($0.9 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.19 658.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 646.25 Td ($1.2 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.05 646.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 151.71 646.25 Td (, which related primarily to goodwill and other intangible assets. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.19 646.25 Td (Note 10. Goodwill and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.70 634.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.20 634.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.06 634.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.78 634.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 349.65 634.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.63 634.25 Td ( for examples and a discussion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.25 Td (of material impairment tests and impairment char) Tj ET Q
q 0 0 0 rg BT 233.53 622.25 Td (ges during the years ended years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.64 622.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.22 622.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.22 622.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.22 622.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.66 622.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.66 622.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 540.48 622.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.25 Td (procedures and assumptions used in our goodwill and other intangible assets impairment testing are discussed in Part II, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.40 610.25 Td (Item 7 of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.25 Td (this report �Management�) Tj ET Q
q 0 0 0 rg BT 138.74 598.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 207.91 598.25 Td (Analysis of Financial Condition and Results of Operations�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.49 598.25 Td ( under the caption ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 586.25 Td (CRITICAL) Tj ET Q
q 0 0 0 rg BT 86.18 586.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 88.12 586.25 Td (ACCOUNTING ESTIMA) Tj ET Q
q 0 0 0 rg BT 192.85 586.25 Td (TES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.62 586.25 Td (� and in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.78 586.25 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.64 586.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.13 586.25 Td (Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 574.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.59 574.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 157.46 574.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.45 574.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.25 Td (Events giving rise to asset impairments are an inherent risk in the pharmaceutical industry and often cannot be predicted. ) Tj ET Q
q 0 0 0 rg BT 548.41 556.25 Td (As ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (a result of the significance of goodwill and other intangible assets, our results of operations and financial position in future periods ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (could be negatively impacted should additional impairments of our goodwill or other intangible assets occur) Tj ET Q
q 0 0 0 rg BT 468.68 532.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 514.25 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 514.25 Td (e subject to various laws and r) Tj ET Q
q 0 0 0 rg BT 190.91 514.25 Td (egulations pertaining to the marketing of our) Tj ET Q
q 0 0 0 rg BT 382.94 514.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 395.26 514.25 Td (oducts and services) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 477.48 514.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 496.25 Td (The marketing and pricing of our products and services, including product promotion, educational activities, support of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (continuing medical education programs and other interactions with healthcare professionals, are governed by various laws and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.25 Td (regulations, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.71 472.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.16 472.25 Td ( regulations and the ) Tj ET Q
q 0 0 0 rg BT 225.70 472.25 Td (Anti-Kickback Statute. ) Tj ET Q
q 0 0 0 rg BT 319.84 472.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 369.75 472.25 Td (, many states have adopted laws similar to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (Anti-Kickback Statute, without identical exceptions or exemptions. Some of these state prohibitions apply to referral of patients for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (healthcare items or services reimbursed by any third-party payer) Tj ET Q
q 0 0 0 rg BT 293.28 448.25 Td (, not only the Medicare and Medicaid programs. ) Tj ET Q
q 0 0 0 rg BT 488.22 448.25 Td (Any such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (regulations or requirements could be dif) Tj ET Q
q 0 0 0 rg BT 196.05 436.25 Td (ficult and expensive for us to comply with, could delay our introduction of new products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.97 424.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 181.85 424.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.84 424.25 Td (. In addition, it is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (unclear at this time whether the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.29 412.25 Td (October Proposed Rule) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.60 412.25 Td ( revising safe harbors to the federal ) Tj ET Q
q 0 0 0 rg BT 400.60 412.25 Td (Anti-Kickback Statute to, among other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (things, add new safe harbors for certain value-based arrangements, will be adopted or) Tj ET Q
q 0 0 0 rg BT 377.69 400.25 Td (, if adopted, what ef) Tj ET Q
q 0 0 0 rg BT 457.48 400.25 Td (fect, if any) Tj ET Q
q 0 0 0 rg BT 499.87 400.25 Td (, it would have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (on the cost of complying with and our ability to comply with the federal ) Tj ET Q
q 0 0 0 rg BT 326.50 388.25 Td (Anti-Kickback Statute or on our business. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 376.25 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.02 376.25 Td (� in Part I, Item 1. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.25 Td (Sanctions for violating these laws include criminal penalties and civil sanctions and possible exclusion from federally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (funded healthcare programs such as Medicare and Medicaid as well as potential liability under the False Claims ) Tj ET Q
q 0 0 0 rg BT 485.58 346.25 Td (Act and applicable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (state false claims acts. ) Tj ET Q
q 0 0 0 rg BT 127.17 334.25 Td (There can be no assurance that our practices will not be challenged under these laws in the future, that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (changes in these laws or interpretation of these laws would not give rise to new challenges of our practices or that any such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (challenge would not have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.90 310.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 223.79 310.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.77 310.25 Td (. Law ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (enforcement agencies sometimes initiate investigations into sales, marketing and/or pricing practices based on preliminary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (information or evidence, and such investigations can be and often are closed without any enforcement action. Nevertheless, these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (types of investigations and any related litigation can result in: \(i\) lar) Tj ET Q
q 0 0 0 rg BT 307.13 274.25 Td (ge expenditures of cash for legal fees, payment of penalties and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (compliance activities; \(ii\) limitations on operations; \(iii\) diversion of management resources; \(iv\) injury to our reputation; and \(v\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.25 Td (decreased demand for our products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 232.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 232.25 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 112.73 232.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.17 232.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.62 232.25 Td ( regulations and guidance restrict the ability of healthcare companies, such as our company) Tj ET Q
q 0 0 0 rg BT 515.29 232.25 Td (, to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (communicate with patients, physicians and other third-parties about uses of prescription pharmaceuticals or devices that are not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (cleared or approved by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.12 208.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.12 208.25 Td (, which are commonly referred to as �of) Tj ET Q
q 0 0 0 rg BT 324.87 208.25 Td (f-label� uses. Prohibitions on the promotion of of) Tj ET Q
q 0 0 0 rg BT 521.88 208.25 Td (f-label ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (uses and against promotional practices deemed false or misleading are actively enforced by various parties at both the federal and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (state level. ) Tj ET Q
q 0 0 0 rg BT 80.71 184.25 Td (A) Tj ET Q
q 0 0 0 rg BT 87.38 184.25 Td ( company that is found to have improperly promoted its products under these laws may be subject to significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (liability) Tj ET Q
q 0 0 0 rg BT 66.46 172.25 Td (, including significant administrative, civil and criminal sanctions including, but not limited to, significant civil damages, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (criminal fines and exclusion from participation in Medicare, Medicaid and other federal healthcare programs. ) Tj ET Q
q 0 0 0 rg BT 475.83 160.25 Td (Applicable laws ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (governing product promotion also provide for administrative, civil and criminal liability for individuals, including, in some ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (circumstances, potential strict vicarious liability) Tj ET Q
q 0 0 0 rg BT 227.24 136.25 Td (. Conduct giving rise to such liability could also form the basis for private civil ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (litigation by third-party payers or other persons allegedly harmed by such conduct.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 106.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 106.25 Td (e have established and implemented a corporate compliance program designed to prevent, detect and correct violations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.25 Td (state and federal healthcare laws, including laws related to advertising and promotion of our products. Nonetheless, enforcement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.25 Td (agencies or private plaintif) Tj ET Q
q 0 0 0 rg BT 142.72 82.25 Td (fs may take the position that we are not in compliance with such requirements and, if such non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.25 Td (compliance is proven, the Company and, in some cases, individual employees, may be subject to significant liability) Tj ET Q
q 0 0 0 rg BT 500.80 70.25 Td (, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.25 Td (aforementioned administrative, civil and criminal sanctions.) Tj ET Q
endstream
endobj
57 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 58 0 R>>
endobj
58 0 obj
<</Length 16258>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In February 2014, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.43 742.10 Td (Endo Pharmaceuticals Inc. \(EPI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.49 742.10 Td ( entered into a Deferred Prosecution ) Tj ET Q
q 0 0 0 rg BT 415.10 742.10 Td (Agreement and a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.91 742.10 Td (Corporate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (Integrity ) Tj ET Q
q 0 0 0 rg BT 72.38 730.10 Td (Agreement \(CIA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.19 730.10 Td ( with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.68 730.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.47 730.10 Td ( Department of Health and Human Services to resolve allegations regarding the promotion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (of LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 99.60 722.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.54 718.10 Td (. In March 2013, our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.41 718.10 Td (Par Pharmaceutical Companies, Inc. \(PPCI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.92 718.10 Td ( entered into a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.34 718.10 Td (CIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.01 718.10 Td ( and plea ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (agreement with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.14 706.10 Td (DOJ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.47 706.10 Td ( to resolve allegations regarding the promotion of MEGACE) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 6.50 Tf ET
q 0 0 0 rg BT 376.20 710.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.13 706.10 Td ( ES, which was subsequently subsumed by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.00 694.10 Td (�) Tj ET Q
q 0 0 0 rg BT 53.78 694.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 60.17 694.10 Td (CIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.39 694.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 82.21 694.10 Td (Those agreements placed certain obligations on us related to the marketing of our pharmaceutical products and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (healthcare regulatory compliance program, including reporting requirements to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.76 682.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.55 682.10 Td ( government, detailed requirements for our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (compliance program, code of conduct and policies and procedures and the requirement to engage an Independent Review ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (Or) Tj ET Q
q 0 0 0 rg BT 46.37 658.10 Td (ganization. ) Tj ET Q
q 0 0 0 rg BT 92.84 658.10 Td (W) Tj ET Q
q 0 0 0 rg BT 101.48 658.10 Td (e have implemented procedures and practices to comply with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.61 658.10 Td (CIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.83 658.10 Td (s, including the engagement of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (Independent Review Or) Tj ET Q
q 0 0 0 rg BT 131.34 646.10 Td (ganization. In February 2020, Endo was notified that it had satisfied its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.95 646.10 Td (CIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.62 646.10 Td ( requirements and the 5-year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (term of Endo�) Tj ET Q
q 0 0 0 rg BT 91.54 634.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.93 634.10 Td (CIA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.60 634.10 Td ( has now concluded.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (The pharmaceutical industry is heavily r) Tj ET Q
q 0 0 0 rg BT 209.43 616.10 Td (egulated, which cr) Tj ET Q
q 0 0 0 rg BT 287.30 616.10 Td (eates uncertainty about our) Tj ET Q
q 0 0 0 rg BT 404.61 616.10 Td ( ability to bring new pr) Tj ET Q
q 0 0 0 rg BT 503.05 616.10 Td (oducts to ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (market and imposes substantial compliance costs on our) Tj ET Q
q 0 0 0 rg BT 275.56 604.10 Td ( business, including withdrawal or) Tj ET Q
q 0 0 0 rg BT 421.80 604.10 Td ( suspension of existing pr) Tj ET Q
q 0 0 0 rg BT 528.87 604.10 Td (oducts) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 556.65 604.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 586.10 Td (Governmental authorities including without limitation the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.85 586.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.30 586.10 Td ( impose substantial requirements on the development, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (manufacture, holding, labeling, marketing, advertising, promotion, distribution and sale of therapeutic pharmaceutical products. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (See �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.38 562.10 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.96 562.10 Td (� in Part I, Item 1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 544.10 Td (Regulatory approvals for the sale of any new product candidate may require preclinical studies and clinical trials that such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (product candidate is safe and ef) Tj ET Q
q 0 0 0 rg BT 162.15 532.10 Td (fective for its intended use. Preclinical and clinical studies may fail to demonstrate the safety and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 520.10 Td (fectiveness of a product candidate. Likewise, we may not be able to demonstrate through clinical trials that a product candidate�) Tj ET Q
q 0 0 0 rg BT 554.79 520.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (therapeutic benefits outweigh its risks. Even promising results from preclinical and early clinical studies do not always accurately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (predict results in later) Tj ET Q
q 0 0 0 rg BT 122.51 496.10 Td (, lar) Tj ET Q
q 0 0 0 rg BT 137.88 496.10 Td (ge-scale trials. ) Tj ET Q
q 0 0 0 rg BT 197.58 496.10 Td (A) Tj ET Q
q 0 0 0 rg BT 204.25 496.10 Td ( failure to demonstrate safety and ef) Tj ET Q
q 0 0 0 rg BT 347.89 496.10 Td (ficacy would result in our failure to obtain regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (approvals. Clinical trials can be delayed for reasons outside of our control, which can lead to increased development costs and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (delays in regulatory approval. For example, there is substantial competition to enroll patients in clinical trials, and such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (competition has delayed clinical development of our products in the past. For example, patients could enroll in clinical trials more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (slowly than expected or could drop out before or during clinical trials. In addition, we may rely on collaboration partners that may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (control or make changes in trial protocol and design enhancements, or encounter clinical trial compliance-related issues, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (may also delay clinical trials. Product supplies may be delayed or be insuf) Tj ET Q
q 0 0 0 rg BT 332.13 424.10 Td (ficient to treat the patients participating in the clinical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (trials and manufacturers or suppliers may not meet the requirements of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.46 412.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.91 412.10 Td ( or foreign regulatory authorities, such as those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (relating to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.32 400.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.33 400.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 109.14 400.10 Td (W) Tj ET Q
q 0 0 0 rg BT 117.78 400.10 Td (e also may experience delays in obtaining, or we may not obtain, required initial and continuing approval of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (our clinical trials from institutional review boards. ) Tj ET Q
q 0 0 0 rg BT 239.66 388.10 Td (W) Tj ET Q
q 0 0 0 rg BT 248.29 388.10 Td (e may experience delays or undesired results in any of our clinical trials.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 370.10 Td (Compliance with clinical trial requirements and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.27 370.10 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.01 370.10 Td ( regulations requires significant expenditures and the dedication of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (substantial resources. ) Tj ET Q
q 0 0 0 rg BT 123.85 358.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.90 358.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.35 358.10 Td ( may place a hold on a clinical trial and may cause a suspension or withdrawal of product approvals ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (if regulatory standards are not maintained. In the event an approved manufacturing facility for a particular drug is required by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 334.10 Td ( to curtail or cease operations, or otherwise becomes inoperable, or a third party contract manufacturing facility faces ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (manufacturing problems, obtaining the required ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.83 322.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.29 322.10 Td ( authorization to manufacture at the same or a dif) Tj ET Q
q 0 0 0 rg BT 445.97 322.10 Td (ferent manufacturing site ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (could result in production delays, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.05 310.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 327.94 310.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 298.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 280.10 Td (Additional delays may result if an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.30 280.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.75 280.10 Td ( advisory committee or other regulatory authority recommends non-approval or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (restrictions on approval. ) Tj ET Q
q 0 0 0 rg BT 134.87 268.10 Td (Although the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.86 268.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.32 268.10 Td ( is not required to follow the recommendations of its advisory committees, it usually ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (does. ) Tj ET Q
q 0 0 0 rg BT 58.78 256.10 Td (A) Tj ET Q
q 0 0 0 rg BT 65.45 256.10 Td ( negative advisory committee meeting could signal a lower likelihood of approval, although the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.07 256.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.52 256.10 Td ( may still end up ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (approving our application. Regardless of an advisory committee meeting outcome or the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.29 244.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.19 244.10 Td (�) Tj ET Q
q 0 0 0 rg BT 413.96 244.10 Td (s final approval decision, public ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (presentation of our data may shed positive or negative light on our application.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 214.10 Td (W) Tj ET Q
q 0 0 0 rg BT 73.64 214.10 Td (e may seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.56 214.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.01 214.10 Td ( approval for certain unapproved marketed products through the 505\(b\)\(2\) regulatory pathway) Tj ET Q
q 0 0 0 rg BT 516.18 214.10 Td (. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 202.10 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.02 202.10 Td (� in Part I, Item 1. Even if we receive approval for an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.76 202.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.88 202.10 Td ( under section 505\(b\)\(2\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.84 202.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.08 202.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 190.10 Td ( may not take timely enforcement action against companies marketing unapproved versions of the product; therefore, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (cannot be sure that that we will receive the benefit of any de facto exclusive marketing period or that we will fully recoup the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (expenses incurred to obtain an approval. In addition, certain competitors and others have objected to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.75 166.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.65 166.10 Td (�) Tj ET Q
q 0 0 0 rg BT 476.42 166.10 Td (s interpretation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (Section 505\(b\)\(2\). If the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.69 154.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.59 154.10 Td (�) Tj ET Q
q 0 0 0 rg BT 157.37 154.10 Td (s interpretation of Section 505\(b\)\(2\) is successfully challenged, this could delay or even prevent the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 142.10 Td ( from approving any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.88 142.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.99 142.10 Td ( that we submit under Section 505\(b\)\(2\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 124.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.50 124.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.83 124.10 Td ( approval process for a new product varies in time, generally requiring a minimum of 10 months following ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (submission of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.50 112.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.84 112.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.62 112.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.62 112.10 Td (, but could also take several years from the date of application. ) Tj ET Q
q 0 0 0 rg BT 422.68 112.10 Td (The timing for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.67 112.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.00 112.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (approval process for generic products is dif) Tj ET Q
q 0 0 0 rg BT 209.10 100.10 Td (ficult to estimate and can vary significantly) Tj ET Q
q 0 0 0 rg BT 381.72 100.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.17 100.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.51 100.10 Td ( approvals, if granted, may not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (include all uses \(known as indications\) for which a company may seek to market a product.) Tj ET Q
endstream
endobj
59 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 60 0 R>>
endobj
60 0 obj
<</Length 15063>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 742.10 Td (The submission of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.33 742.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.99 742.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.99 742.10 Td (Supplemental New Drug ) Tj ET Q
q 0 0 0 rg BT 281.36 742.10 Td (Application \(sNDA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.29 742.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.74 742.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.63 742.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.63 742.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.07 742.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.40 742.10 Td (sBLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.74 742.10 Td ( to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.24 742.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.69 742.10 Td ( with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (supporting clinical safety and ef) Tj ET Q
q 0 0 0 rg BT 164.11 730.10 Td (ficacy data does not guarantee that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.87 730.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.33 730.10 Td ( will grant approval to market the product. Meeting the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.90 718.10 Td (�) Tj ET Q
q 0 0 0 rg BT 57.67 718.10 Td (s regulatory requirements to obtain approval to market a drug product, which vary substantially based on the type, complexity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (and novelty of the product candidate, typically takes years, if approved at all, and is subject to uncertainty) Tj ET Q
q 0 0 0 rg BT 458.54 706.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 463.36 706.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.41 706.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.86 706.10 Td ( or foreign ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (regulatory authorities may not agree with our assessment of the clinical data or they may interpret it dif) Tj ET Q
q 0 0 0 rg BT 448.74 694.10 Td (ferently) Tj ET Q
q 0 0 0 rg BT 479.19 694.10 Td (. Such regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (authorities may require additional or expanded clinical trials. ) Tj ET Q
q 0 0 0 rg BT 281.75 682.10 Td (Any approval by regulatory agencies may subject the marketing of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (our products to certain limits on indicated use. For example, regulatory authorities may approve any of our product candidates for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (fewer or more limited indications than we may request, may grant approval contingent on conditions such as the performance and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (results of costly post-marketing clinical trials or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.12 646.10 Td (REMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.35 646.10 Td ( or may approve a product candidate with a label that does not include the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (labeling claims necessary or desirable for the successful commercialization of that product candidate. ) Tj ET Q
q 0 0 0 rg BT 443.62 634.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 493.52 634.10 Td (, reimbursement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (by government payers or other payers may not be approved at the price we intend to char) Tj ET Q
q 0 0 0 rg BT 392.36 622.10 Td (ge for our products. ) Tj ET Q
q 0 0 0 rg BT 473.17 622.10 Td (Any limitation on use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (imposed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.60 610.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.06 610.10 Td ( or delay in or failure to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.02 610.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.47 610.10 Td ( approvals or clearances of products developed by us would adversely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 598.10 Td (fect the marketing of these products and our ability to generate product revenue. ) Tj ET Q
q 0 0 0 rg BT 366.62 598.10 Td (W) Tj ET Q
q 0 0 0 rg BT 375.26 598.10 Td (e could also be at risk for the value of any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (capitalized pre-launch inventories related to products under development. ) Tj ET Q
q 0 0 0 rg BT 332.65 586.10 Td (The factors could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.44 586.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 509.32 586.10 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 574.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 556.10 Td (Once a product is approved or cleared for marketing, failure to comply with applicable regulatory requirements can result ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (in, among other things, suspensions or withdrawals of approvals or clearances; seizures or recalls of products; injunctions against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (the manufacture, holding, distribution, marketing and sale of a product; and civil and criminal sanctions. For example, any failure ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (to ef) Tj ET Q
q 0 0 0 rg BT 53.87 520.10 Td (fectively identify) Tj ET Q
q 0 0 0 rg BT 121.80 520.10 Td (, analyze, report and protect adverse event data and/or to fully comply with relevant laws, rules and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (regulations around adverse event reporting could expose the Company to legal proceedings, penalties, fines and reputational ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (damage. Furthermore, changes in existing regulations or the adoption of new regulations could prevent us from obtaining, or af) Tj ET Q
q 0 0 0 rg BT 544.85 496.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (the timing of, future regulatory approvals or clearances. Meeting regulatory requirements and evolving government standards may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (delay marketing of our new products for a considerable period of time, impose costly procedures upon our activities and result in a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (competitive advantage to other companies that compete against us.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 442.10 Td (In addition, after a product is approved or cleared for marketing, new data and information, including information about ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (product misuse or abuse at the user level, may lead government agencies, professional societies, practice management groups or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (patient or trade or) Tj ET Q
q 0 0 0 rg BT 107.18 418.10 Td (ganizations to recommend or publish guidance or guidelines related to the use of our products, which may lead to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (reduced sales of our products. For example, in May 2016, an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.49 406.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.95 406.10 Td ( advisory panel recommended mandatory training of all ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (physicians who prescribe opioids on the risks of prescription opioids. In 2016, the Centers for Disease Control and Prevention also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (issued a guideline for prescribing opioids for chronic pain that provides recommendations for primary care clinicians prescribing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (opioids for chronic pain outside of active cancer treatment, palliative care and end-of-life care. In addition, state health departments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (and boards of pharmacy have authority to regulate distribution and may modify their regulations with respect to prescription opioid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (medications in an attempt to curb abuse. ) Tj ET Q
q 0 0 0 rg BT 199.66 346.10 Td (These or any new regulations or requirements could be dif) Tj ET Q
q 0 0 0 rg BT 433.02 346.10 Td (ficult and expensive for us to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (comply with and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.74 334.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 234.63 334.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.61 334.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 316.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.05 316.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.50 316.10 Td ( scheduled a Joint Meeting of the Drug Safety and Risk Management ) Tj ET Q
q 0 0 0 rg BT 380.77 316.10 Td (Advisory Committee and the ) Tj ET Q
q 0 0 0 rg BT 498.54 316.10 Td (Anesthetic and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (Analgesic Drug Products ) Tj ET Q
q 0 0 0 rg BT 138.49 304.10 Td (Advisory Committee in March 2017 to discuss pre- and post-marketing data about the abuse of OP) Tj ET Q
q 0 0 0 rg BT 533.32 304.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 554.99 308.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.43 304.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (ER and the overall risk-benefit of this product. ) Tj ET Q
q 0 0 0 rg BT 224.94 292.10 Td (The advisory committees were also scheduled to discuss abuse of generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (oxymorphone ER and oxymorphone immediate-release products. In March 2017, the advisory committees voted 18 to eight, with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (one abstention, that the benefits of reformulated OP) Tj ET Q
q 0 0 0 rg BT 242.25 268.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 263.91 272.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.35 268.10 Td ( ER no longer outweigh its risks. ) Tj ET Q
q 0 0 0 rg BT 402.06 268.10 Td (While several of the advisory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (committee members acknowledged the role of OP) Tj ET Q
q 0 0 0 rg BT 235.58 256.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 257.24 260.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.68 256.10 Td ( ER in clinical practice, others believed its benefits were overshadowed by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (the continuing public health concerns around the product�) Tj ET Q
q 0 0 0 rg BT 266.77 244.10 Td (s misuse, abuse and diversion. In June 2017, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.74 244.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.19 244.10 Td ( requested that we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (voluntarily withdraw OP) Tj ET Q
q 0 0 0 rg BT 134.52 232.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 156.18 236.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.62 232.10 Td ( ER from the market and, in July 2017, after careful consideration and consultation with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.97 232.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.97 232.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (we decided to voluntarily remove OP) Tj ET Q
q 0 0 0 rg BT 184.76 220.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 206.43 224.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.87 220.10 Td ( ER from the market to the Company�) Tj ET Q
q 0 0 0 rg BT 362.23 220.10 Td (s financial detriment. During the second quarter ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (of 2017, we began to work with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.69 208.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.15 208.10 Td ( to coordinate an orderly withdrawal of the product from the market. By September 1, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (2017, we ceased shipments of OP) Tj ET Q
q 0 0 0 rg BT 170.06 196.10 Td (ANA) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 191.72 200.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.17 196.10 Td ( ER to customers and we expect the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.68 196.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.79 196.10 Td ( will be withdrawn. ) Tj ET Q
q 0 0 0 rg BT 442.88 196.10 Td (These actions had an adverse ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 184.10 Td (fect on our revenues and, as a result of these actions, we incurred certain char) Tj ET Q
q 0 0 0 rg BT 353.27 184.10 Td (ges. ) Tj ET Q
q 0 0 0 rg BT 371.05 184.10 Td (Actions similar to these, such as recalls or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (withdrawals, could divert management time and attention, reduce market acceptance of all of our products, harm our reputation, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (reduce our revenues, lead to additional char) Tj ET Q
q 0 0 0 rg BT 210.46 160.10 Td (ges or expenses or result in product liability claims, any of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.04 160.10 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 148.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 148.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 130.10 Td (Based on scientific developments, post-market experience, legislative or regulatory changes or other factors, the current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 118.10 Td ( standards of review for approving new pharmaceutical products, or new indications or uses for approved or cleared products, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (are sometimes more stringent than those that were applied in the past.) Tj ET Q
endstream
endobj
61 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 62 0 R>>
endobj
62 0 obj
<</Length 14799>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 742.10 Td (Some new or evolving ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.76 742.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.22 742.10 Td ( review standards or conditions for approval or clearance were not applied to many established ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (products currently on the market, including certain opioid products. ) Tj ET Q
q 0 0 0 rg BT 308.43 730.10 Td (As a result, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.92 730.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.37 730.10 Td ( does not have safety databases on these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (products that are as extensive as some products developed more recently) Tj ET Q
q 0 0 0 rg BT 325.80 718.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 330.25 718.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 379.59 718.10 Td (, we believe the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.84 718.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.29 718.10 Td ( has expressed an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (intention to develop such databases for certain of these products, including many opioids. In particular) Tj ET Q
q 0 0 0 rg BT 445.49 706.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.20 706.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.66 706.10 Td ( has expressed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (interest in specific chemical structures that may be present as impurities in a number of opioid narcotic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.48 694.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.59 694.10 Td (s, such as oxycodone, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (which, based on certain structural characteristics and laboratory tests, may indicate the potential for having mutagenic ef) Tj ET Q
q 0 0 0 rg BT 517.86 682.10 Td (fects. ) Tj ET Q
q 0 0 0 rg BT 541.56 682.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 670.10 Td ( has required, and may continue to require, more stringent controls of the levels of these or other impurities in products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 652.10 Td (Also, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.61 652.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.06 652.10 Td ( may require labeling revisions, formulation or manufacturing changes and/or product modifications for new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (or existing products containing impurities. More stringent requirements, together with any additional testing or remedial measures ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (that may be necessary) Tj ET Q
q 0 0 0 rg BT 123.37 628.10 Td (, could result in increased costs for) Tj ET Q
q 0 0 0 rg BT 262.09 628.10 Td (, or delays in, obtaining approvals. ) Tj ET Q
q 0 0 0 rg BT 402.35 628.10 Td (Although we do not believe that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 616.10 Td ( would seek to remove a currently marketed product from the market unless the ef) Tj ET Q
q 0 0 0 rg BT 383.49 616.10 Td (fects of alleged impurities are believed to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (indicate a significant risk to patient health, we cannot make any such assurance.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 586.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.05 586.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.94 586.10 Td (�) Tj ET Q
q 0 0 0 rg BT 104.72 586.10 Td (s exercise of its authority under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.73 586.10 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.42 586.10 Td ( could result in delays or increased costs during product development, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (clinical trials and regulatory review) Tj ET Q
q 0 0 0 rg BT 177.51 574.10 Td (, increased costs to comply with additional post-approval regulatory requirements and potential ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (restrictions on sales of approved products. For example, in 2015, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.61 562.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.06 562.10 Td ( sent letters to a number of manufacturers, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (Endo, requiring that a randomized, double-blind, placebo-controlled clinical trial be conducted to evaluate the ef) Tj ET Q
q 0 0 0 rg BT 485.93 550.10 Td (fect of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.06 550.10 Td (TR) Tj ET Q
q 0 0 0 rg BT 526.24 550.10 Td (T) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.17 550.10 Td ( on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (incidence of major adverse cardiovascular events in men. ) Tj ET Q
q 0 0 0 rg BT 267.67 538.10 Td (The letter received by Endo required that we include new safety ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (information in the labeling and Medication Guide for certain prescription medications containing testosterone, such as ) Tj ET Q
q 0 0 0 rg BT 511.24 526.10 Td (TESTIM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 547.35 530.18 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.79 526.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 508.10 Td (Post-marketing studies and other emer) Tj ET Q
q 0 0 0 rg BT 218.67 508.10 Td (ging data about marketed products, such as adverse event reports, may adversely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 496.10 Td (fect sales of our products. Furthermore, the discovery of significant safety or ef) Tj ET Q
q 0 0 0 rg BT 360.53 496.10 Td (ficacy concerns or problems with a product in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (same therapeutic class as one of our products that implicate or appear to implicate the entire class of products could have an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 472.10 Td (fect on sales of our product or) Tj ET Q
q 0 0 0 rg BT 196.19 472.10 Td (, in some cases, result in product withdrawals. ) Tj ET Q
q 0 0 0 rg BT 382.91 472.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.96 472.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.41 472.10 Td ( has continuing authority over the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (approval of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.25 460.10 Td (NDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.92 460.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.37 460.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.70 460.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.03 460.10 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.48 460.10 Td ( and may withdraw approval if, among other reasons, post-marketing clinical or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (experience, tests or data show that a product is unsafe for use under the conditions upon which it was approved or licensed, or if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 436.10 Td ( determines that there is a lack of substantial evidence of the product�) Tj ET Q
q 0 0 0 rg BT 332.58 436.10 Td (s ef) Tj ET Q
q 0 0 0 rg BT 346.56 436.10 Td (ficacy under the conditions described in its labeling.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 418.10 Td (In addition to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.10 418.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.55 418.10 Td ( and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.04 418.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.82 418.10 Td ( regulatory agencies, non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.67 418.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.45 418.10 Td ( regulatory agencies may have authority over various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (aspects of our business and may impose additional requirements and costs. Similar to other healthcare companies, our facilities in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (multiple countries across the full range of our business units are subject to routine and new-product related inspections by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (regulatory authorities including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.30 382.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.30 382.10 Td (, the Medicines and Healthcare products Regulatory ) Tj ET Q
q 0 0 0 rg BT 409.23 382.10 Td (Agency) Tj ET Q
q 0 0 0 rg BT 439.68 382.10 Td (, the Health Products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (Regulatory ) Tj ET Q
q 0 0 0 rg BT 82.38 370.10 Td (Authority and Health Canada. In the past, some of these inspections have resulted in inspection observations \(including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 358.10 Td ( Form 483 observations\). ) Tj ET Q
q 0 0 0 rg BT 158.32 358.10 Td (W) Tj ET Q
q 0 0 0 rg BT 166.96 358.10 Td (e have responded to all inspection observations within the required timeframe and have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (implemented, or are continuing to implement, the corrective action plans as agreed with the relevant regulatory agencies. Future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (inspections may result in additional inspection observations or other corrective actions, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.99 334.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 542.88 334.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.50 322.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 304.10 Td (Several of our core products contain controlled substances. Stringent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.70 304.10 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.70 304.10 Td ( and other governmental regulations on our use of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (controlled substances include restrictions on their use in research, manufacture, distribution and storage. ) Tj ET Q
q 0 0 0 rg BT 454.76 292.10 Td (A) Tj ET Q
q 0 0 0 rg BT 461.43 292.10 Td ( breach of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (regulations could result in imposition of civil penalties, refusal to renew or action to revoke necessary registrations, or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (restrictions on operations involving controlled substances. In addition, failure to comply with applicable legal requirements could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (subject the manufacturing facilities of our subsidiaries and manufacturing partners to possible legal or regulatory action, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (shutdown. ) Tj ET Q
q 0 0 0 rg BT 79.34 244.10 Td (Any such shutdown may adversely af) Tj ET Q
q 0 0 0 rg BT 229.40 244.10 Td (fect their ability to manufacture or supply product and thus, our ability to market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 232.10 Td (fected products. ) Tj ET Q
q 0 0 0 rg BT 109.77 232.10 Td (This could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.08 232.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 258.96 232.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 220.10 Td (. See also the risk described under the caption �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.16 220.10 Td (The DEA) Tj ET Q
q 0 0 0 rg BT 286.21 220.10 Td ( limits the availability of the active ingredients used in many of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (products as well as the production of these products, and, as a result, our procurement and production quotas may not be suf) Tj ET Q
q 0 0 0 rg BT 531.81 208.10 Td (ficient ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (to meet commercial demand or complete clinical trials) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.97 196.10 Td (.�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 178.10 Td (In addition, we are subject to the Federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.78 178.10 Td (Drug Supply Chain Security ) Tj ET Q
q 0 0 0 rg BT 346.33 178.10 Td (Act \(DSCSA\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.16 178.10 Td ( enacted by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.91 178.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.70 178.10 Td ( government, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (requires development of an electronic pedigree to track and trace each prescription product at the salable unit level through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (distribution system. ) Tj ET Q
q 0 0 0 rg BT 117.21 154.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.26 154.10 Td (DSCSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.94 154.10 Td ( will be ef) Tj ET Q
q 0 0 0 rg BT 207.03 154.10 Td (fective incrementally over a 10-year period from its enactment on November 27, 2013. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (Compliance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.10 142.10 Td (DSCSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.78 142.10 Td ( and future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.60 142.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.38 142.10 Td ( federal or state electronic pedigree requirements could require significant capital ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (expenditures, increase our operating costs and impose significant administrative burdens.) Tj ET Q
endstream
endobj
63 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 64 0 R>>
endobj
64 0 obj
<</Length 12090>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (28) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 742.10 Td (W) Tj ET Q
q 0 0 0 rg BT 73.64 742.10 Td (e cannot determine what ef) Tj ET Q
q 0 0 0 rg BT 181.74 742.10 Td (fect changes in laws, regulations or legal interpretations or requirements by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.24 742.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.25 742.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (courts or others, when and if promulgated or issued, or advisory committee meetings may have on our business in the future. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (Changes could, among other things, require expanded or dif) Tj ET Q
q 0 0 0 rg BT 275.76 718.10 Td (ferent labeling, additional testing, monitoring of patients, interaction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (with physicians, education programs for patients or physicians, curtailment of necessary supplies, limitations on product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (distribution, the recall or discontinuance of certain products and additional recordkeeping. ) Tj ET Q
q 0 0 0 rg BT 398.38 694.10 Td (Any such changes could result in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (additional litigation and may have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.07 682.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 257.95 682.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 670.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 63.04 670.10 Td (The evolving and complex nature of regulatory science and regulatory requirements, the broad authority and discretion of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 658.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.17 658.10 Td ( and the generally high level of regulatory oversight results in a continuing possibility that, from time to time, we will be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (adversely af) Tj ET Q
q 0 0 0 rg BT 84.40 646.10 Td (fected by regulatory actions despite our ongoing ef) Tj ET Q
q 0 0 0 rg BT 287.77 646.10 Td (forts and commitment to achieve and maintain full compliance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (all regulatory requirements.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (The success of our) Tj ET Q
q 0 0 0 rg BT 113.87 616.10 Td ( acquisition and licensing strategy is subject to uncertainty and acquisitions or) Tj ET Q
q 0 0 0 rg BT 446.77 616.10 Td ( licenses may r) Tj ET Q
q 0 0 0 rg BT 509.08 616.10 Td (educe our) Tj ET Q
q 0 0 0 rg BT 550.83 616.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (earnings, be difficult to integrate, not perform as expected or) Tj ET Q
q 0 0 0 rg BT 295.49 604.10 Td ( r) Tj ET Q
q 0 0 0 rg BT 302.25 604.10 Td (equir) Tj ET Q
q 0 0 0 rg BT 324.84 604.10 Td (e us to obtain additional financing.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 586.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 586.10 Td (e regularly evaluate selective acquisitions and look to continue to enhance our product line by acquiring rights to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (additional products and compounds. Such acquisitions may be carried out through corporate acquisitions, asset acquisitions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (licensing or joint venture arrangements. However) Tj ET Q
q 0 0 0 rg BT 233.87 562.10 Td (, we may not be able to complete acquisitions, obtain licenses or enter into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (arrangements that meet our tar) Tj ET Q
q 0 0 0 rg BT 157.99 550.10 Td (get criteria on satisfactory terms, if at all. For example, we may not be able to identify suitable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (acquisition candidates. In addition, any acquisition of assets and rights to products and compounds may fail to accomplish our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (strategic objective and may not perform as expected. Further) Tj ET Q
q 0 0 0 rg BT 278.56 526.10 Td (, if we are unable to maintain, on commercially reasonable terms, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (product, compound or other licenses that we have acquired, our ability to develop or commercialize our products may be inhibited. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (In order to continue to develop and broaden our product range, we must compete to acquire assets. Our competitors may have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (greater resources than us and therefore be better able to complete acquisitions or licenses, which could cause us to be unable to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (consummate acquisitions, licensing agreements or cause the ultimate price we pay to increase. If we fail to achieve our acquisition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (or licensing goals, our growth may be limited.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 448.10 Td (Acquisitions of companies may expose us to additional risks, which may be beyond our control and may have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.35 448.10 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 436.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 436.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 389.43 436.10 Td (The combination of two independent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (businesses is a complex, costly and time-consuming process. ) Tj ET Q
q 0 0 0 rg BT 281.52 424.10 Td (As a result, we may be required to devote significant management ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (attention and resources to the integration of an acquired business into our practices and operations. ) Tj ET Q
q 0 0 0 rg BT 432.55 412.10 Td (Any integration process may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (disruptive and may not achieve realization of expected benefits. ) Tj ET Q
q 0 0 0 rg BT 293.50 400.10 Td (The dif) Tj ET Q
q 0 0 0 rg BT 322.47 400.10 Td (ficulties of combining operations of companies include, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (among others:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 376.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 376.10 Td (diversion of management�) Tj ET Q
q 0 0 0 rg BT 189.91 376.10 Td (s attention to integration matters;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 364.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 364.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 364.10 Td (ficulties in achieving anticipated cost or tax savings, syner) Tj ET Q
q 0 0 0 rg BT 329.79 364.10 Td (gies, business opportunities and growth prospects from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 352.10 Td (the combination of the businesses;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 340.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 340.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 340.10 Td (ficulties in the integration of operations and systems;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 328.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 328.10 Td (the impact of pre-existing legal and/or regulatory issues;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 316.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 316.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 316.10 Td (ficulties in conforming standards, controls, procedures and accounting and other policies, business cultures and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 304.10 Td (compensation structures between the companies;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 292.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 292.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 292.10 Td (ficulties in the assimilation of employees and retention of key personnel;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 280.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 280.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 280.10 Td (ficulties in managing the expanded operations of a lar) Tj ET Q
q 0 0 0 rg BT 311.17 280.10 Td (ger and more complex company;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 268.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 268.10 Td (challenges in retaining existing customers and obtaining new customers;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 256.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 256.10 Td (potential unknown liabilities or lar) Tj ET Q
q 0 0 0 rg BT 223.63 256.10 Td (ger liabilities than projected;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 244.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 244.10 Td (unforeseen increases to expenses or other adverse consequences associated with the transaction; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 232.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 232.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 232.10 Td (ficulties in coordinating a geographically dispersed or) Tj ET Q
q 0 0 0 rg BT 311.74 232.10 Td (ganization.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 214.10 Td (In addition, any acquisitions may result in material unanticipated problems, expenses, liabilities, competitive responses and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (loss or disruption of relationships with customers, suppliers, partners, regulators and others with whom we have business or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (dealings.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 172.10 Td (The benefits of mer) Tj ET Q
q 0 0 0 rg BT 141.40 172.10 Td (gers and acquisitions are also subject to a variety of other factors, many of which are beyond our ability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (to control, such as changes in the rate of economic growth in jurisdictions in which the combined company will do business, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (financial performance of the combined business in various jurisdictions, currency exchange rate fluctuations and significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (changes in trade, monetary or fiscal policies, including changes in interest rates and tax law of the jurisdictions in which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (combined company will do business. ) Tj ET Q
q 0 0 0 rg BT 186.36 124.10 Td (The impact of these factors, individually and in the aggregate, is dif) Tj ET Q
q 0 0 0 rg BT 456.92 124.10 Td (ficult to predict, in part ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (because the occurrence of the events or circumstances relating to such factors may be interrelated, and the impact to the combined ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (company of the occurrence of any one of these events or circumstances could be compounded or) Tj ET Q
q 0 0 0 rg BT 422.40 100.10 Td (, alternatively) Tj ET Q
q 0 0 0 rg BT 476.72 100.10 Td (, reduced, of) Tj ET Q
q 0 0 0 rg BT 526.52 100.10 Td (fset or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (more than of) Tj ET Q
q 0 0 0 rg BT 86.91 88.10 Td (fset by the occurrence of one or more of the other events or circumstances relating to such factors.) Tj ET Q
endstream
endobj
65 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 66 0 R>>
endobj
66 0 obj
<</Length 11458>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In addition, based on current acquisition prices in the pharmaceutical industry) Tj ET Q
q 0 0 0 rg BT 373.64 742.10 Td (, acquisitions could decrease our net income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (per share and add significant intangible assets and related amortization or impairment char) Tj ET Q
q 0 0 0 rg BT 397.91 730.10 Td (ges. Our acquisition strategy may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (require us to obtain additional debt or equity financing, resulting in additional debt obligations, increased interest expense or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (dilution of equity ownership. ) Tj ET Q
q 0 0 0 rg BT 154.42 706.10 Td (W) Tj ET Q
q 0 0 0 rg BT 163.06 706.10 Td (e may not be able to finance acquisitions on terms satisfactory to us, or at all.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 688.10 Td (e may decide to sell assets, which could adversely affect our) Tj ET Q
q 0 0 0 rg BT 297.73 688.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 310.05 688.10 Td (ospects and opportunities for) Tj ET Q
q 0 0 0 rg BT 434.04 688.10 Td ( gr) Tj ET Q
q 0 0 0 rg BT 445.80 688.10 Td (owth.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 670.10 Td (e may from time to time consider selling certain assets if we determine that such assets are not critical to our strategy or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (we believe the opportunity to monetize the asset is attractive or for various other reasons, including for the reduction of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (indebtedness. For example, we divested both ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.18 646.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.29 646.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.72 646.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.83 646.10 Td ( in 2017 and various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.44 646.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.32 646.10 Td (s throughout 2018 and 2019. ) Tj ET Q
q 0 0 0 rg BT 514.36 646.10 Td (W) Tj ET Q
q 0 0 0 rg BT 523.00 646.10 Td (e will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (continue to explore the sale of certain non-core assets. ) Tj ET Q
q 0 0 0 rg BT 254.81 634.10 Td (Although our expectation is to engage in asset sales only if they advance or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (otherwise support our overall strategy) Tj ET Q
q 0 0 0 rg BT 186.98 622.10 Td (, we may be forced to sell assets in response to liquidation or other claims described herein, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (and any such sale could reduce the size or scope of our business, our market share in particular markets or our opportunities with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (respect to certain markets, products or therapeutic categories. ) Tj ET Q
q 0 0 0 rg BT 283.12 598.10 Td (As a result, any such sale could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.74 598.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 515.62 598.10 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 586.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (The availability of third party r) Tj ET Q
q 0 0 0 rg BT 170.54 568.10 Td (eimbursement for) Tj ET Q
q 0 0 0 rg BT 246.73 568.10 Td ( our) Tj ET Q
q 0 0 0 rg BT 264.05 568.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 276.37 568.10 Td (oducts is uncertain, and we may find it difficult to maintain ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (curr) Tj ET Q
q 0 0 0 rg BT 54.70 556.10 Td (ent price levels. ) Tj ET Q
q 0 0 0 rg BT 122.46 556.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 175.25 556.10 Td (, the market may not accept those pr) Tj ET Q
q 0 0 0 rg BT 331.15 556.10 Td (oducts for) Tj ET Q
q 0 0 0 rg BT 374.02 556.10 Td ( which third party r) Tj ET Q
q 0 0 0 rg BT 458.84 556.10 Td (eimbursement is not ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (adequately pr) Tj ET Q
q 0 0 0 rg BT 94.99 544.10 Td (ovided) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 123.33 544.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 526.10 Td (Our ability to commercialize our products depends, in part, on the extent to which reimbursement for the costs of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (products is available from government healthcare programs, such as Medicaid and Medicare, private health insurers and others. ) Tj ET Q
q 0 0 0 rg BT 548.42 514.10 Td (W) Tj ET Q
q 0 0 0 rg BT 557.05 514.10 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (cannot be certain that, over time, third party reimbursements for our products will be adequate for us to maintain price levels ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (suf) Tj ET Q
q 0 0 0 rg BT 48.04 490.10 Td (ficient for realization of an appropriate return on our investment. Government payers, private insurers and other third party ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (payers are increasingly attempting to contain healthcare costs by: \(i\) limiting both coverage and the level of reimbursement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (\(including adjusting co-pays\) for products, \(ii\) refusing, in some cases, to provide any coverage for of) Tj ET Q
q 0 0 0 rg BT 442.92 466.10 Td (f-label uses for products and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (\(iii\) requiring or encouraging, through more favorable reimbursement levels or otherwise, the substitution of generic alternatives to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (branded products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 424.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 80.87 424.10 Td (T) Tj ET Q
q 0 0 0 rg BT 86.62 424.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 109.68 424.10 Td (Administration also has been tar) Tj ET Q
q 0 0 0 rg BT 238.91 424.10 Td (geting pharmaceutical prices in ways that could af) Tj ET Q
q 0 0 0 rg BT 439.49 424.10 Td (fect reimbursement for our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (products. For example, beginning in January 2020, Medicare ) Tj ET Q
q 0 0 0 rg BT 281.78 412.10 Td (Advantage Plans are permitted to apply �step therapy� to products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (covered under Part B, which could impact our ability to negotiate for favorable product access in this sector) Tj ET Q
q 0 0 0 rg BT 466.42 400.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 470.87 400.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 520.77 400.10 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (October 2018, President ) Tj ET Q
q 0 0 0 rg BT 135.24 388.10 Td (T) Tj ET Q
q 0 0 0 rg BT 141.00 388.10 Td (rump announced a new initiative to contain costs by establishing an �international pricing index� that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (would be used as a benchmark in deciding how much to pay for Medicare Part B products. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.46 376.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.58 376.10 Td ( issued an ) Tj ET Q
q 0 0 0 rg BT 463.97 376.10 Td (Advance Notice of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (Proposed Rulemaking for the Medicare Program that would reduce Part B spending and reimbursement in part based on the prices ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (that manufacturers char) Tj ET Q
q 0 0 0 rg BT 130.21 352.10 Td (ge to customers in foreign countries \(also referred to as reference pricing\). ) Tj ET Q
q 0 0 0 rg BT 429.63 352.10 Td (This proposal tar) Tj ET Q
q 0 0 0 rg BT 497.21 352.10 Td (gets physician-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (administered products. It is possible that any final rule could adversely af) Tj ET Q
q 0 0 0 rg BT 329.07 340.10 Td (fect reimbursement for certain products that we sell, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (we cannot anticipate the adverse impact of this or similar developments on our business. ) Tj ET Q
q 0 0 0 rg BT 391.74 328.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 441.64 328.10 Td (, the Congress is considering ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (multiple proposals impacting healthcare. ) Tj ET Q
q 0 0 0 rg BT 201.05 316.10 Td (There can be no assurance as to which proposals, if any) Tj ET Q
q 0 0 0 rg BT 422.82 316.10 Td (, will be adopted, the final terms ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (of any such proposals and the ultimate impact that such proposals would have on our business, results of operations, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (condition and cash flows. ) Tj ET Q
q 0 0 0 rg BT 140.52 292.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.57 292.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.35 292.10 Td ( presidential election is also leading to significant policy proposals regarding healthcare and we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (cannot predict which policies will ultimately be adopted and how they would impact us.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (New tariffs and evolving trade policy between the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 249.31 262.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 267.09 262.10 Td ( and other) Tj ET Q
q 0 0 0 rg BT 310.80 262.10 Td ( countries, including China, could have a ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 487.22 262.10 Td (material adverse ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (effect on our) Tj ET Q
q 0 0 0 rg BT 89.69 250.10 Td ( business, financial condition, r) Tj ET Q
q 0 0 0 rg BT 221.76 250.10 Td (esults of operations and cash flows) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 368.71 250.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 232.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 232.10 Td (e conduct business globally and our operations, including third party suppliers, span numerous countries outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.66 232.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.45 232.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (There is currently significant uncertainty about the future relationship between the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.83 220.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.61 220.10 Td ( and various other countries, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (China, with respect to trade policies, treaties, government regulations and tarif) Tj ET Q
q 0 0 0 rg BT 349.33 208.10 Td (fs.) Tj ET Q
endstream
endobj
67 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 68 0 R>>
endobj
68 0 obj
<</Length 14766>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 80.87 742.10 Td (T) Tj ET Q
q 0 0 0 rg BT 86.62 742.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 109.68 742.10 Td (Administration has called for substantial changes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.35 742.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.14 742.10 Td ( foreign trade policy) Tj ET Q
q 0 0 0 rg BT 417.84 742.10 Td (, including the possibility of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (imposing greater restrictions on international trade and significant increases in tarif) Tj ET Q
q 0 0 0 rg BT 368.49 730.10 Td (fs on goods imported into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.48 730.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.26 730.10 Td ( Such tarif) Tj ET Q
q 0 0 0 rg BT 547.73 730.10 Td (fs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (could potentially disrupt our existing supply chains and impose additional costs on our business, including costs with respect to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (raw materials upon which our business depends. Furthermore, if tarif) Tj ET Q
q 0 0 0 rg BT 312.14 706.10 Td (fs, trade restrictions or trade barriers are placed on products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (such as ours by foreign governments, it could cause us to raise prices for our products, which may result in the loss of customers. If ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (we are unable to pass along increased costs to our customers, our mar) Tj ET Q
q 0 0 0 rg BT 314.34 682.10 Td (gins could be adversely af) Tj ET Q
q 0 0 0 rg BT 418.57 682.10 Td (fected. ) Tj ET Q
q 0 0 0 rg BT 447.45 682.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 497.35 682.10 Td (, it is possible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (further tarif) Tj ET Q
q 0 0 0 rg BT 82.18 670.10 Td (fs may be imposed that could af) Tj ET Q
q 0 0 0 rg BT 209.75 670.10 Td (fect imports of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.57 670.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.68 670.10 Td (s and other materials used in our products, or our business may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (adversely impacted by retaliatory trade measures taken by other countries, including restricted access to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.34 658.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.46 658.10 Td (s or other materials ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (used in our products, causing us to raise prices or make changes to our products. Further) Tj ET Q
q 0 0 0 rg BT 389.13 646.10 Td (, the continued threats of tarif) Tj ET Q
q 0 0 0 rg BT 507.24 646.10 Td (fs, trade ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (sales. For example, the ) Tj ET Q
q 0 0 0 rg BT 130.24 622.10 Td (T) Tj ET Q
q 0 0 0 rg BT 136.00 622.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 159.05 622.10 Td (Administration has placed tarif) Tj ET Q
q 0 0 0 rg BT 283.00 622.10 Td (fs on certain goods imported from China. In January 2020, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.89 622.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.67 622.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (and China agreed to roll back certain tarif) Tj ET Q
q 0 0 0 rg BT 202.69 610.10 Td (fs, expand trade purchases and renew commitments on intellectual property) Tj ET Q
q 0 0 0 rg BT 504.16 610.10 Td (, technology ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (transfer and currency practices. Nevertheless, given the volatility and uncertainty regarding the scope and duration of these tarif) Tj ET Q
q 0 0 0 rg BT 547.01 598.10 Td (fs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (and other aspects of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.19 586.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.98 586.10 Td ( foreign trade policy) Tj ET Q
q 0 0 0 rg BT 216.68 586.10 Td (, the impact on our operations and results is uncertain and could be significant. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (Further governmental action related to tarif) Tj ET Q
q 0 0 0 rg BT 208.81 574.10 Td (fs, additional taxes, regulatory changes or other retaliatory trade measures could occur ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (in the future. ) Tj ET Q
q 0 0 0 rg BT 89.32 562.10 Td (Any of these factors could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.66 562.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 301.54 562.10 Td (fect on our business, financial condition, results of operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.43 550.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 532.10 Td (e may experience pricing pr) Tj ET Q
q 0 0 0 rg BT 164.13 532.10 Td (essur) Tj ET Q
q 0 0 0 rg BT 186.17 532.10 Td (e on our) Tj ET Q
q 0 0 0 rg BT 220.99 532.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 233.30 532.10 Td (oducts due to social or) Tj ET Q
q 0 0 0 rg BT 328.12 532.10 Td ( political pr) Tj ET Q
q 0 0 0 rg BT 377.39 532.10 Td (essur) Tj ET Q
q 0 0 0 rg BT 399.43 532.10 Td (e, which would r) Tj ET Q
q 0 0 0 rg BT 469.81 532.10 Td (educe our) Tj ET Q
q 0 0 0 rg BT 511.57 532.10 Td ( r) Tj ET Q
q 0 0 0 rg BT 518.32 532.10 Td (evenue ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (and futur) Tj ET Q
q 0 0 0 rg BT 76.66 520.10 Td (e pr) Tj ET Q
q 0 0 0 rg BT 93.42 520.10 Td (ofitability) Tj ET Q
q 0 0 0 rg BT 134.54 520.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 502.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 502.10 Td (e may experience downward pricing pressure on our products due to social or political pressure, which would reduce our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (revenue and future profitability) Tj ET Q
q 0 0 0 rg BT 160.58 490.10 Td (. Price increases have resulted in increased public and governmental scrutiny of the cost of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (pharmaceutical products. For example, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.28 478.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.06 478.10 Td ( federal prosecutors have issued subpoenas to pharmaceutical companies in connection ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (with an investigation into pricing practices conducted by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.10 466.10 Td (DOJ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.44 466.10 Td (. Several state attorneys general also have commenced drug ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (pricing investigations and filed lawsuits against pharmaceutical companies, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.36 454.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.81 454.10 Td (, and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.46 454.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.25 454.10 Td ( Senate has investigated a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (number of pharmaceutical companies relating to price increases and pricing practices. Our revenue and future profitability could be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (negatively af) Tj ET Q
q 0 0 0 rg BT 87.74 430.10 Td (fected if these or other inquiries were to result in legislative or regulatory proposals limiting our ability to increase or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (maintain the prices of our products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 400.10 Td (In addition, the ) Tj ET Q
q 0 0 0 rg BT 126.14 400.10 Td (T) Tj ET Q
q 0 0 0 rg BT 131.90 400.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 154.95 400.10 Td (Administration and a number of federal legislators continue to scrutinize pharmaceutical prices and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (are seeking ways to lower prices. For example, the ) Tj ET Q
q 0 0 0 rg BT 241.03 388.10 Td (T) Tj ET Q
q 0 0 0 rg BT 246.79 388.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 269.84 388.10 Td (Administration�) Tj ET Q
q 0 0 0 rg BT 333.17 388.10 Td (s �Blueprint� on pharmaceutical prices describes a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (number of mechanisms for lowering manufacturer list prices and reducing patient out-of-pocket costs. ) Tj ET Q
q 0 0 0 rg BT 446.43 376.10 Td (Although the Blueprint ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (contains a number of policy objectives, we cannot know the form that any new requirements will take or the ef) Tj ET Q
q 0 0 0 rg BT 479.01 364.10 Td (fect that they may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (have on our business. In December 2019, the ) Tj ET Q
q 0 0 0 rg BT 218.55 352.10 Td (T) Tj ET Q
q 0 0 0 rg BT 224.31 352.10 Td (rump ) Tj ET Q
q 0 0 0 rg BT 247.36 352.10 Td (Administration, through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.24 352.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.24 352.10 Td (, released a proposed rule and draft guidance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (that set forth two pathways for the legal importation of certain pharmaceutical products in an ef) Tj ET Q
q 0 0 0 rg BT 417.63 340.10 Td (fort to control costs. Since these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (pathways are not yet ef) Tj ET Q
q 0 0 0 rg BT 128.56 328.10 Td (fective and are subject to revision pending receipt of public comments, we cannot determine what ef) Tj ET Q
q 0 0 0 rg BT 529.90 328.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (these pathways may have on our business, financial condition, results of operations and cash flows. In addition, Congress has held ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (a number of hearings related to pharmaceutical prices and a bipartisan group of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.59 304.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.38 304.10 Td ( Senators introduced legislation that would ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (require pharmaceutical manufacturers to justify certain price increases. ) Tj ET Q
q 0 0 0 rg BT 321.70 292.10 Td (A) Tj ET Q
q 0 0 0 rg BT 328.37 292.10 Td ( lar) Tj ET Q
q 0 0 0 rg BT 341.23 292.10 Td (ge number of individual states also have introduced ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (legislation aimed at pharmaceutical pricing regulation, transparency or both. For example, California, Oregon, ) Tj ET Q
q 0 0 0 rg BT 479.56 280.10 Td (V) Tj ET Q
q 0 0 0 rg BT 485.67 280.10 Td (ermont and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (Nevada have enacted such laws. Our revenue and future profitability could be negatively af) Tj ET Q
q 0 0 0 rg BT 401.78 268.10 Td (fected by the passage of these laws or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (similar federal or state legislation. Pressure from social activist groups and future government regulations may also put downward ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (pressure on the prices of pharmaceutical products in the future.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 226.10 Td ( business is highly dependent upon market per) Tj ET Q
q 0 0 0 rg BT 251.52 226.10 Td (ceptions of us, our) Tj ET Q
q 0 0 0 rg BT 329.12 226.10 Td ( brands, and the safety and quality of our) Tj ET Q
q 0 0 0 rg BT 505.36 226.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 517.68 226.10 Td (oducts ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (and similar) Tj ET Q
q 0 0 0 rg BT 84.44 214.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 96.76 214.10 Td (oducts, and may be adversely impacted by negative publicity or) Tj ET Q
q 0 0 0 rg BT 367.13 214.10 Td ( findings.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 196.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 196.10 Td (e are dependent on market perceptions, and negative publicity or findings associated with product quality) Tj ET Q
q 0 0 0 rg BT 492.25 196.10 Td (, patient illness ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (or other adverse ef) Tj ET Q
q 0 0 0 rg BT 110.50 184.10 Td (fects resulting from, or perceived to be resulting from, our products, or similar products, or our partners�) Tj ET Q
q 0 0 0 rg BT 527.42 184.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (suppliers�) Tj ET Q
q 0 0 0 rg BT 74.70 172.10 Td ( manufacturing facilities, could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.47 172.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 306.35 172.10 Td (fect on our business, financial condition, results of operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.43 160.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 142.10 Td (Market perceptions are very important to our business, especially market perceptions of our company and brands and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (safety and quality of our products. If we, our partners and suppliers or our brands suf) Tj ET Q
q 0 0 0 rg BT 375.45 130.10 Td (fer negative publicity) Tj ET Q
q 0 0 0 rg BT 460.33 130.10 Td (, or if any of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (products or similar products are subject to market withdrawal or recall or are proven to be, or are claimed to be, inef) Tj ET Q
q 0 0 0 rg BT 500.37 118.10 Td (fective or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (harmful to consumers, it could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.29 106.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 265.17 106.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 94.10 Td (.) Tj ET Q
endstream
endobj
69 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 70 0 R>>
endobj
70 0 obj
<</Length 15333>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (31) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (For example, the pharmaceutical supply chain has been increasingly challenged by the vulnerability of distribution channels ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the internet. ) Tj ET Q
q 0 0 0 rg BT 513.43 730.10 Td (Third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (parties may illegally distribute and sell counterfeit versions of our products that do not meet the rigorous manufacturing and testing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (standards that our products under) Tj ET Q
q 0 0 0 rg BT 169.12 706.10 Td (go. Counterfeit products are frequently unsafe or inef) Tj ET Q
q 0 0 0 rg BT 382.20 706.10 Td (fective and can be potentially life-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (threatening. Counterfeit medicines may contain harmful substances, the wrong dose of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.52 694.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.63 694.10 Td ( or no ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.91 694.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.02 694.10 Td ( at all. However) Tj ET Q
q 0 0 0 rg BT 505.48 694.10 Td (, to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (distributors and users, counterfeit products may be visually indistinguishable from the authentic version.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 664.10 Td (In addition, negative posts or comments about us on any social networking website could seriously damage our reputation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (The inappropriate use of certain social media vehicles could cause brand damage or information leakage or could lead to legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (implications from the improper collection and/or dissemination of personally identifiable information or the improper ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (dissemination of material non-public information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 610.10 Td (Furthermore, unfavorable media coverage about opioid abuse could negatively af) Tj ET Q
q 0 0 0 rg BT 388.25 610.10 Td (fect our business, financial condition and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (results of operations. In recent years, opioid abuse has received a high degree of media coverage. Unfavorable publicity regarding, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (for example, the use or misuse of oxycodone or other prescription opioid medications, the limitations of abuse-deterrent forms, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (public inquiries and investigations into drug abuse, including the abuse of prescription products, litigation or regulatory activity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (could adversely af) Tj ET Q
q 0 0 0 rg BT 109.12 562.10 Td (fect our reputation. ) Tj ET Q
q 0 0 0 rg BT 187.43 562.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 237.33 562.10 Td (, increased scrutiny of opioids generally) Tj ET Q
q 0 0 0 rg BT 396.63 562.10 Td (, whether focused on our products or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (otherwise, could negatively impact our relationship with healthcare providers and other members of the healthcare community) Tj ET Q
q 0 0 0 rg BT 541.29 550.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (Such negative publicity could have an adverse ef) Tj ET Q
q 0 0 0 rg BT 231.58 538.10 Td (fect on the potential size of the market for new or existing products and could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (decrease revenues and royalties, any of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.06 526.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 350.95 526.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 514.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 496.10 Td ( business and financial condition may be adversely affected by legislation) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 364.17 496.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 478.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 478.10 Td (e cannot predict with any certainty how existing laws may be applied or how laws or legal standards may change in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (future. Current or future legislation, whether state or federal, or in any of the non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.83 466.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.61 466.10 Td ( jurisdictions with authority over our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (operations, may have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.69 454.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 206.57 454.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.55 454.10 Td (. For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (example, the ef) Tj ET Q
q 0 0 0 rg BT 97.18 442.10 Td (fect of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.49 442.10 Td (H.R. 6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.88 442.10 Td (, enacted in October 2018, is still uncertain.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 424.10 Td (In addition, in ) Tj ET Q
q 0 0 0 rg BT 121.33 424.10 Td (April 2018, New ) Tj ET Q
q 0 0 0 rg BT 190.95 424.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 197.17 424.10 Td (ork enacted a statute called the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.66 424.10 Td (Opioid Stewardship ) Tj ET Q
q 0 0 0 rg BT 404.33 424.10 Td (Act \(the Stewardship ) Tj ET Q
q 0 0 0 rg BT 490.70 424.10 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.47 424.10 Td (, which, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (among other things, provided for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.42 412.10 Td (certain manufacturers and distributors of certain opioids in the state of New ) Tj ET Q
q 0 0 0 rg BT 474.95 412.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 481.17 412.10 Td (ork \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (Contributing Parties\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.16 400.10 Td ( to make payments to a newly created ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.44 400.10 Td (Opioid Stewardship Fund \(the Fund\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.65 400.10 Td (. By its terms, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 493.71 400.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 545.09 400.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.53 400.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (required ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.82 388.10 Td (Contributing Parties) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.65 388.10 Td ( to pay a combined total of up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.12 388.10 Td ($100 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.51 388.10 Td ( annually into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.71 388.10 Td (Fund) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.28 388.10 Td (, with each ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.37 388.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.09 388.10 Td (�) Tj ET Q
q 0 0 0 rg BT 552.87 388.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (share based on the total amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.68 376.10 Td (morphine milligram equivalents \(MME\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.04 376.10 Td ( of certain opioids sold or distributed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.72 364.10 Td ( in the state of New ) Tj ET Q
q 0 0 0 rg BT 190.88 364.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 197.10 364.10 Td (ork during the preceding calendar year) Tj ET Q
q 0 0 0 rg BT 351.35 364.10 Td (, subject to potential adjustments by the New ) Tj ET Q
q 0 0 0 rg BT 533.45 364.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 539.67 364.10 Td (ork ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (State Department of Health. Failure of a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.28 352.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.00 352.10 Td ( to make required reports or pay its ratable share, or a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.30 352.10 Td (Contributing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.11 340.10 Td ( passing on the cost of its ratable share to a purchaser) Tj ET Q
q 0 0 0 rg BT 269.70 340.10 Td (, could subject the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.96 340.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.68 340.10 Td ( to penalties. In December 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 328.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 328.10 Td ( District Court for the Southern District of New ) Tj ET Q
q 0 0 0 rg BT 260.59 328.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 266.82 328.10 Td (ork held the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.08 328.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 368.47 328.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.90 328.10 Td ( unconstitutional. ) Tj ET Q
q 0 0 0 rg BT 454.66 328.10 Td (This ruling is on appeal as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (of February 18, 2020. If the decision is reversed, we may be deemed to be a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.73 316.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.45 316.10 Td ( under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.94 316.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 510.33 316.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.76 316.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (even if we are not considered to be a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.10 304.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.17 304.10 Td (, or such a determination is never made, other entities may attempt to seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (reimbursement from Endo for payments made related to products manufactured by Endo and distributed in New ) Tj ET Q
q 0 0 0 rg BT 487.17 292.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 493.39 292.10 Td (ork. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (Furthermore, the application of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.18 280.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 229.56 280.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.00 280.10 Td ( may require additional regulatory guidance, which could be substantially ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (delayed, increasing the uncertainty as to the ultimate ef) Tj ET Q
q 0 0 0 rg BT 256.57 268.10 Td (fect of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.60 268.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 350.99 268.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.42 268.10 Td ( on us. If we are ultimately deemed to be a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (Contributing Party) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.72 256.10 Td ( under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.21 256.10 Td (Stewardship ) Tj ET Q
q 0 0 0 rg BT 204.59 256.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.03 256.10 Td (, or similar legislation that could be enacted by New ) Tj ET Q
q 0 0 0 rg BT 429.99 256.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 436.21 256.10 Td (ork or other jurisdictions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (compliance with those laws could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.34 244.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 278.22 244.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 232.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 214.10 Td (In the meantime, in ) Tj ET Q
q 0 0 0 rg BT 142.70 214.10 Td (April 2019, New ) Tj ET Q
q 0 0 0 rg BT 212.32 214.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 218.54 214.10 Td (ork enacted an excise tax on the first sale of every opioid unit in New ) Tj ET Q
q 0 0 0 rg BT 498.36 214.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 504.58 214.10 Td (ork at the rate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.83 202.10 Td (one quarter of a cent) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.01 202.10 Td ( per ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.78 202.10 Td (MME) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.67 202.10 Td ( where ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.10 202.10 Td (wholesale acquisition cost \(W) Tj ET Q
q 0 0 0 rg BT 319.23 202.10 Td (AC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.45 202.10 Td ( is less than ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.34 202.10 Td ($0.50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.84 202.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.28 202.10 Td (one and one half cents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.69 202.10 Td ( per ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.46 202.10 Td (MME) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.35 202.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (where ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.75 190.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.08 190.10 Td (AC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.97 190.10 Td ( is equal to or greater than ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.87 190.10 Td ($0.50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.37 190.10 Td (. For purposes of this statute, �opioid� does not include buprenorphine, methadone or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (morphine and �sale� does not include transfers of title from a manufacturer in New ) Tj ET Q
q 0 0 0 rg BT 370.51 178.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 376.73 178.10 Td (ork to a purchaser outside New ) Tj ET Q
q 0 0 0 rg BT 503.54 178.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 509.76 178.10 Td (ork when the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (opioid unit will be used or consumed outside New ) Tj ET Q
q 0 0 0 rg BT 239.21 166.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 245.43 166.10 Td (ork.) Tj ET Q
endstream
endobj
71 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 72 0 R>>
endobj
72 0 obj
<</Length 14587>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In October 2018, the Canadian province of British Columbia enacted a statute called the Opioid Damages and Health Care ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (Costs Recovery ) Tj ET Q
q 0 0 0 rg BT 101.00 730.10 Td (Act, which allows the British Columbia government to file a direct action against opioid manufacturers and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (wholesalers to recover the health care costs it has incurred, and will incur) Tj ET Q
q 0 0 0 rg BT 329.10 718.10 Td (, resulting from an �opioid-related wrong.� ) Tj ET Q
q 0 0 0 rg BT 503.31 718.10 Td (The statute ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (defines �opioid-related wrong� to include any breach of a common law) Tj ET Q
q 0 0 0 rg BT 320.24 706.10 Td (, equitable or statutory duty or obligation owed to persons in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (British Columbia who have been or might be exposed to an opioid product. ) Tj ET Q
q 0 0 0 rg BT 339.66 694.10 Td (The statute, among other ef) Tj ET Q
q 0 0 0 rg BT 449.16 694.10 Td (fects, erases limitation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (periods for certain claims, reverses certain burdens of proof as to causation, allows the use of population-based evidence and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (restricts discovery of certain documents. ) Tj ET Q
q 0 0 0 rg BT 200.21 670.10 Td (The provinces of ) Tj ET Q
q 0 0 0 rg BT 269.91 670.10 Td (Alberta, Ontario and Newfoundland enacted similar legislation in 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (and the province of Saskatchewan has announced that it expects to pass similar legislation in 2020. It is possible that these statutes, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (or similar statutes enacted by other jurisdictions, and resultant litigation, could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.63 646.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 456.52 646.10 Td (fect on our business, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.28 634.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.10 Td (In Canada, the prices of patented pharmaceutical products are subject to regulation by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.69 616.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.05 616.10 Td (. Under the Canadian ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (Patent ) Tj ET Q
q 0 0 0 rg BT 64.42 604.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.75 604.10 Td ( and ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 97.19 604.10 Td (Patented Medicines Regulations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.60 604.10 Td (, patentees of inventions that pertain to pharmaceutical products sold in Canada are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (required to file price and sales information about their patented pharmaceutical products with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.42 592.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.77 592.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 464.59 592.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.64 592.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.99 592.10 Td ( reviews ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (this information on an ongoing basis to ensure that the prices of patented pharmaceuticals sold in Canada are not excessive, based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (upon price tests established by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.41 568.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.77 568.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 213.59 568.10 Td (There is a risk that the price of our pharmaceutical products could be found to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (excessive because the price as set at launch is non-compliant with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.46 556.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.81 556.10 Td (�) Tj ET Q
q 0 0 0 rg BT 352.59 556.10 Td (s guidelines, or because our average sale prices over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (time are not compliant with the guidelines. Furthermore, amendments expected to come into force on July 1, 2020 will introduce a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (number of changes to the regulation of Canadian drug prices by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.14 532.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.49 532.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 346.31 532.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.36 532.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.71 532.10 Td ( guidelines will be updated to introduce ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (new price tests to account for changes introduced by the amendments. ) Tj ET Q
q 0 0 0 rg BT 318.50 520.10 Td (The application of the new price tests under the guidelines ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (could result in the current prices of our pharmaceutical products being deemed to be excessive. Failure by us to comply with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (current or future guidelines could ultimately result in us reducing the prices of the pharmaceutical products we sell in Canada and/) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (or making a payment to the Canadian government to of) Tj ET Q
q 0 0 0 rg BT 257.15 484.10 Td (fset revenues deemed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.93 484.10 Td (PMPRB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.29 484.10 Td ( to be excessive, which could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (ultimately reduce the revenues and cash flows of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.54 472.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.65 472.10 Td ( segment and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.95 472.10 Td (material adverse ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 460.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.57 460.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 442.10 Td (It is possible that these or other changes in law could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.43 442.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 381.32 442.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 430.10 Td (. See �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.40 430.10 Td (Governmental Regulation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.98 430.10 Td (� in Part I, Item 1.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (Public concern ar) Tj ET Q
q 0 0 0 rg BT 111.36 412.10 Td (ound the abuse of opioids or) Tj ET Q
q 0 0 0 rg BT 231.49 412.10 Td ( other) Tj ET Q
q 0 0 0 rg BT 256.58 412.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 268.90 412.10 Td (oducts, including without limitation law enfor) Tj ET Q
q 0 0 0 rg BT 463.73 412.10 Td (cement concerns over) Tj ET Q
q 0 0 0 rg BT 555.74 412.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (diversion or) Tj ET Q
q 0 0 0 rg BT 87.21 400.10 Td ( marketing practices, r) Tj ET Q
q 0 0 0 rg BT 184.22 400.10 Td (egulatory efforts to combat abuse, and litigation could r) Tj ET Q
q 0 0 0 rg BT 421.52 400.10 Td (esult in costs to our) Tj ET Q
q 0 0 0 rg BT 503.56 400.10 Td ( business) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 541.64 400.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 382.10 Td (Media stories regarding drug abuse and diversion, including the abuse and diversion of prescription opioid medications and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (other controlled substances, are commonplace. ) Tj ET Q
q 0 0 0 rg BT 225.10 370.10 Td (Aggressive enforcement and unfavorable publicity regarding, for example, the use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (or misuse of opioids, the limitations of abuse-deterrent formulations, the ability of abusers to discover previously unknown ways to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (abuse our products, public inquiries and investigations into drug abuse or litigation or regulatory or enforcement activity regarding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (sales, marketing, distribution or storage of opioids could have a material adverse ef) Tj ET Q
q 0 0 0 rg BT 368.50 334.10 Td (fect on our reputation, on the results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (litigation and on our ability to attract or maintain relationships with third-party partners, including suppliers, vendors, advisors, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (distributors, manufacturers, collaboration partners, administrators and agents.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 292.10 Td (Manufacturers of prescription opioid medications have been the subject of significant civil and criminal investigatory and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (enforcement actions even in cases where such medications have received approval from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.01 280.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.46 280.10 Td ( or similar regulatory authorities. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (Numerous governmental and private persons and entities are pursuing litigation against opioid manufacturers, including us, as well ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (as distributors and others, asserting alleged violations of various laws and regulations relating to opioids and/or other prescription ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (medicines, relying on common law theories, and seeking to hold the defendants accountable for) Tj ET Q
q 0 0 0 rg BT 418.54 244.10 Td (, among other things, societal costs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (associated with the misuse and abuse of prescription opioid medications as well as non-prescription opioids. ) Tj ET Q
q 0 0 0 rg BT 471.28 232.10 Td (There is a risk we will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (be subject to similar investigations, enforcement actions or litigations in the future, that we will suf) Tj ET Q
q 0 0 0 rg BT 432.12 220.10 Td (fer adverse decisions or verdicts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (of substantial amounts or that we will enter into monetary settlements. ) Tj ET Q
q 0 0 0 rg BT 319.28 208.10 Td (Any unfavorable outcomes as a result of such proceedings ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.03 196.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 164.92 196.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.90 196.10 Td (. In 2019, several ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (manufacturers of prescription opioid medications commenced cases under ) Tj ET Q
q 0 0 0 rg BT 335.16 184.10 Td (T) Tj ET Q
q 0 0 0 rg BT 340.92 184.10 Td (itle 1) Tj ET Q
q 0 0 0 rg BT 360.82 184.10 Td (1 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.87 184.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.65 184.10 Td ( Code in order to address the lar) Tj ET Q
q 0 0 0 rg BT 539.49 184.10 Td (ge ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (volume of claims asserted against them in such litigation. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.11 172.10 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.37 172.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.87 172.10 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.59 160.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 160.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 197.18 160.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.16 160.10 Td ( for more information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 142.10 Td (Regulatory actions at the federal, state and local level may seek to limit or restrict the manufacturing, distribution or sale of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (opioids, both directly and indirectly) Tj ET Q
q 0 0 0 rg BT 178.38 130.10 Td (, and/or to impose novel policy or regulatory mechanisms regarding the manufacturing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (distribution or sales of opioids. For example, in ) Tj ET Q
q 0 0 0 rg BT 227.65 118.10 Td (April 2019, New ) Tj ET Q
q 0 0 0 rg BT 297.27 118.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 303.49 118.10 Td (ork enacted an excise tax on opioids. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.85 118.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (business and financial condition may be adversely af) Tj ET Q
q 0 0 0 rg BT 247.14 106.10 Td (fected by legislation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.23 106.10 Td (� for more information. Many state legislatures are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (considering various bills intended to reduce opioid abuse such as by) Tj ET Q
q 0 0 0 rg BT 307.51 94.10 Td (, for example, establishing prescription drug monitoring ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (programs and mandating prescriber education.) Tj ET Q
endstream
endobj
73 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 74 0 R>>
endobj
74 0 obj
<</Length 11559>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (33) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 742.10 Td (V) Tj ET Q
q 0 0 0 rg BT 71.11 742.10 Td (arious government entities, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.19 742.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.97 742.10 Td ( Congress, state legislatures or other policy-making bodies in the U.S. or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (elsewhere may hold hearings, conduct investigations and/or issue reports calling attention to opioid misuse and abuse, and may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (mention or criticize the role of manufacturers, including us, in supplying or marketing opioid medications or failing to take ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (adequate steps to detect or report suspicious orders or to prevent abuse and diversion. Press or) Tj ET Q
q 0 0 0 rg BT 411.83 706.10 Td (ganizations have reported and likely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (will continue to report on these issues, and such reporting has and may further result in adverse publicity which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 682.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 682.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 664.10 Td ( r) Tj ET Q
q 0 0 0 rg BT 60.36 664.10 Td (eporting and payment obligations under) Tj ET Q
q 0 0 0 rg BT 231.87 664.10 Td ( the Medicaid Drug Rebate Pr) Tj ET Q
q 0 0 0 rg BT 360.27 664.10 Td (ogram and other) Tj ET Q
q 0 0 0 rg BT 431.75 664.10 Td ( governmental drug pricing ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 652.10 Td (ograms ar) Tj ET Q
q 0 0 0 rg BT 89.24 652.10 Td (e complex and may involve subjective decisions. ) Tj ET Q
q 0 0 0 rg BT 294.79 652.10 Td (Any failur) Tj ET Q
q 0 0 0 rg BT 338.78 652.10 Td (e to comply with those obligations could subject us ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (to penalties and sanctions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 622.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 622.10 Td (e are subject to federal and state laws prohibiting the presentation \(or the causing to be presented\) of claims for payment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (\(by Medicare, Medicaid or other third-party payers\) that are determined to be false or fraudulent, including presenting a claim for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (an item or service that was not provided. ) Tj ET Q
q 0 0 0 rg BT 201.05 598.10 Td (These false claims statutes include the federal civil False Claims ) Tj ET Q
q 0 0 0 rg BT 460.97 598.10 Td (Act, which permits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (private persons to bring suit in the name of the government alleging false or fraudulent claims presented to or paid by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (government \(or other violations of the statutes\) and to share in any amounts paid by the entity to the government in fines or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (settlement. Such suits, known as ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 168.49 562.10 Td (qui tam) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.77 562.10 Td ( actions, have increased significantly in the healthcare industry in recent years. ) Tj ET Q
q 0 0 0 rg BT 515.69 562.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (actions against pharmaceutical companies, which do not require proof of a specific intent to defraud the government, may result in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (payment of fines to and/or administrative exclusion from the Medicare, Medicaid and/or other government healthcare programs.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 520.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 520.10 Td (e are subject to laws that require us to enter into a Medicaid Drug Rebate ) Tj ET Q
q 0 0 0 rg BT 365.71 520.10 Td (Agreement, a 340B Pharmaceutical Pricing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (Agreement and agreements with the Department of ) Tj ET Q
q 0 0 0 rg BT 243.24 508.10 Td (V) Tj ET Q
q 0 0 0 rg BT 249.35 508.10 Td (eterans ) Tj ET Q
q 0 0 0 rg BT 279.62 508.10 Td (Af) Tj ET Q
q 0 0 0 rg BT 289.99 508.10 Td (fairs as a condition for having our products eligible for payment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (under Medicare Part B and Medicaid. ) Tj ET Q
q 0 0 0 rg BT 188.82 496.10 Td (W) Tj ET Q
q 0 0 0 rg BT 197.46 496.10 Td (e have entered into such agreements. In addition, we are required to report certain pricing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (information to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.99 484.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.11 484.10 Td (, the Health Resources and Services ) Tj ET Q
q 0 0 0 rg BT 262.35 484.10 Td (Administration and the Department of ) Tj ET Q
q 0 0 0 rg BT 417.41 484.10 Td (V) Tj ET Q
q 0 0 0 rg BT 423.52 484.10 Td (eterans ) Tj ET Q
q 0 0 0 rg BT 453.78 484.10 Td (Af) Tj ET Q
q 0 0 0 rg BT 464.15 484.10 Td (fairs on a periodic basis ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (to facilitate rebate payments to the State Medicaid Programs, to set Medicare Part B reimbursement levels and to establish the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (prices that can be char) Tj ET Q
q 0 0 0 rg BT 125.21 460.10 Td (ged to certain purchasers, including 340B-covered entities and certain government entities. ) Tj ET Q
q 0 0 0 rg BT 490.93 460.10 Td (Any failure to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (comply with these laws and agreements could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.65 448.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 326.54 448.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 436.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 418.10 Td (W) Tj ET Q
q 0 0 0 rg BT 72.04 418.10 Td (ith regard to the Medicaid Drug Rebate Program, on February 1, 2016, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.24 418.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.37 418.10 Td ( issued a Final Rule implementing the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (Medicaid Drug Rebate provisions incorporated into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.55 406.10 Td (PP) Tj ET Q
q 0 0 0 rg BT 269.76 406.10 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.87 406.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 303.46 406.10 Td (fective ) Tj ET Q
q 0 0 0 rg BT 332.61 406.10 Td (April 1, 2016 in most instances. Implementation of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (Final Rule required operational adjustments by us in order to maintain compliance with applicable law) Tj ET Q
q 0 0 0 rg BT 445.79 394.10 Td (. Ongoing compliance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (these program rules, including the requirement that we adopt reasonable assumptions where law) Tj ET Q
q 0 0 0 rg BT 419.96 382.10 Td (, regulation and guidance do not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (address specific participation issues, may impact the level of rebates that we owe under the program. ) Tj ET Q
q 0 0 0 rg BT 441.23 370.10 Td (The Final Rule also expanded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (the scope of the Medicaid Drug Rebate program to apply to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.76 358.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.54 358.10 Td ( territories and, pursuant to further rulemaking, that requirement is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (now ef) Tj ET Q
q 0 0 0 rg BT 63.31 346.10 Td (fective ) Tj ET Q
q 0 0 0 rg BT 92.46 346.10 Td (April 1, 2022, which will require operational adjustments and may result in additional rebate liability) Tj ET Q
q 0 0 0 rg BT 496.16 346.10 Td (. Finally) Tj ET Q
q 0 0 0 rg BT 528.84 346.10 Td (, despite ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (an initial proposal, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.21 334.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.33 334.10 Td ( has not defined the term �line extension� for the Medicaid Drug Rebate Program. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.06 334.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.18 334.10 Td ( has indicated that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (manufacturers should rely on the statutory definition of that term and reasonable assumptions in determining which products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (should be subject to an alternative rebate calculation. In light of the lack of clear guidance on this issue, it is possible that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.80 310.10 Td (CMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.92 310.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (could in the future disagree with a manufacturer) Tj ET Q
q 0 0 0 rg BT 228.79 298.10 Td (�) Tj ET Q
q 0 0 0 rg BT 231.57 298.10 Td (s determination of which products should be subject to higher rebates under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (�line extension� rebate calculation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 268.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 268.10 Td (e and other pharmaceutical companies have been named as defendants in a number of lawsuits filed by various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (government entities, alleging generally that we and numerous other pharmaceutical companies reported false pricing information in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (connection with certain products that are reimbursable by state Medicaid programs, which are partially funded by the federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (government. ) Tj ET Q
q 0 0 0 rg BT 88.58 232.10 Td (There is a risk we will be subject to similar investigations or litigations in the future, that we will suf) Tj ET Q
q 0 0 0 rg BT 490.55 232.10 Td (fer adverse ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (decisions or verdicts of substantial amounts or that we will enter into monetary settlements. ) Tj ET Q
q 0 0 0 rg BT 403.98 220.10 Td (Any unfavorable outcomes as a result ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (of such proceedings could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.51 208.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 247.39 208.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.38 208.10 Td (.) Tj ET Q
endstream
endobj
75 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 76 0 R>>
endobj
76 0 obj
<</Length 17155>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (34) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Decr) Tj ET Q
q 0 0 0 rg BT 56.36 742.25 Td (eases in the degr) Tj ET Q
q 0 0 0 rg BT 126.44 742.25 Td (ee to which individuals ar) Tj ET Q
q 0 0 0 rg BT 235.72 742.25 Td (e cover) Tj ET Q
q 0 0 0 rg BT 265.79 742.25 Td (ed by healthcar) Tj ET Q
q 0 0 0 rg BT 331.72 742.25 Td (e insurance could r) Tj ET Q
q 0 0 0 rg BT 412.93 742.25 Td (esult in decr) Tj ET Q
q 0 0 0 rg BT 464.96 742.25 Td (eased use of our) Tj ET Q
q 0 0 0 rg BT 532.84 742.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 730.25 Td (oducts.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 712.25 Td (Employers may seek to reduce costs by reducing or eliminating employer group healthcare plans or transferring a greater ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (portion of healthcare costs to their employees. Job losses or other economic hardships may also result in reduced levels of coverage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (for some individuals, potentially resulting in lower levels of healthcare coverage for themselves or their families. Further) Tj ET Q
q 0 0 0 rg BT 519.34 688.25 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (addition to the fact that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.79 676.25 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.13 676.25 Td ( eliminated the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.05 676.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 241.25 676.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.26 676.25 Td (�) Tj ET Q
q 0 0 0 rg BT 264.04 676.25 Td (s requirement that individuals maintain insurance or face a penalty) Tj ET Q
q 0 0 0 rg BT 529.68 676.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (additional steps by the ) Tj ET Q
q 0 0 0 rg BT 128.03 664.25 Td (T) Tj ET Q
q 0 0 0 rg BT 133.78 664.25 Td (rump ) Tj ET Q
q 0 0 0 rg BT 156.84 664.25 Td (Administration or other parties to limit or end cost-sharing subsidies to lower) Tj ET Q
q 0 0 0 rg BT 465.76 664.25 Td (-income ) Tj ET Q
q 0 0 0 rg BT 500.47 664.25 Td (Americans ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (may increase instability in the insurance marketplace and the number of uninsured ) Tj ET Q
q 0 0 0 rg BT 367.56 652.25 Td (Americans. ) Tj ET Q
q 0 0 0 rg BT 415.69 652.25 Td (These economic conditions may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 640.25 Td (fect patients�) Tj ET Q
q 0 0 0 rg BT 94.76 640.25 Td ( ability to af) Tj ET Q
q 0 0 0 rg BT 143.18 640.25 Td (ford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (existing co-pay or deductible obligations and lost healthcare insurance coverage or for other reasons. ) Tj ET Q
q 0 0 0 rg BT 441.51 628.25 Td (W) Tj ET Q
q 0 0 0 rg BT 450.15 628.25 Td (e believe such conditions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (could lead to changes in patient behavior and spending patterns that negatively af) Tj ET Q
q 0 0 0 rg BT 361.27 616.25 Td (fect usage of certain of our products, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (some patients delaying treatment, rationing prescription medications, leaving prescriptions unfilled, reducing the frequency of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (visits to healthcare facilities, utilizing alternative therapies or foregoing healthcare insurance coverage. Such changes may result in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (reduced demand for our products, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.70 580.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 329.58 580.25 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 568.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 550.25 Td (In December 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.13 550.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.91 550.25 Td ( District Court for the Northern District of ) Tj ET Q
q 0 0 0 rg BT 345.81 550.25 Td (T) Tj ET Q
q 0 0 0 rg BT 351.22 550.25 Td (exas held in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 401.48 550.25 Td (T) Tj ET Q
q 0 0 0 rg BT 406.13 550.25 Td (exas v) Tj ET Q
q 0 0 0 rg BT 430.09 550.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 434.91 550.25 Td (Azar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.80 550.25 Td ( that, because the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (provisions of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.72 538.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 115.92 538.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.48 538.25 Td ( requiring certain individuals to either obtain health insurance or pay a shared responsibility payment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (\(known as the individual mandate\) are no longer permissible under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.20 526.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.98 526.25 Td ( Congress�) Tj ET Q
q 0 0 0 rg BT 381.29 526.25 Td ( taxing power) Tj ET Q
q 0 0 0 rg BT 435.87 526.25 Td (, the entire ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.85 526.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 491.06 526.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.62 526.25 Td ( is no longer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (constitutional. ) Tj ET Q
q 0 0 0 rg BT 95.26 514.25 Td (The decision was appealed to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.21 514.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.99 514.25 Td ( Court of ) Tj ET Q
q 0 0 0 rg BT 286.05 514.25 Td (Appeals for the Fifth Circuit. In December 2019, the Fifth Circuit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (issued an opinion holding that, while the individual mandate was no longer constitutional, the case must be remanded to the district ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.25 Td (court to further evaluate whether the mandate can be severed from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.65 490.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 328.85 490.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.41 490.25 Td ( or the entire ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.72 490.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 412.93 490.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.49 490.25 Td ( must be stricken down. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (January 2020, petitions for certiorari were filed requesting that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.96 478.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.75 478.25 Td ( Supreme Court review the Fifth Circuit�) Tj ET Q
q 0 0 0 rg BT 484.50 478.25 Td (s decision and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (ultimately decide the constitutionality of the PP) Tj ET Q
q 0 0 0 rg BT 225.60 466.25 Td (ACA. ) Tj ET Q
q 0 0 0 rg BT 251.54 466.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.58 466.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.37 466.25 Td ( Supreme Court has not yet decided whether to grant the petitions. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.25 Td (Changes in law resulting from this ongoing lawsuit or other court challenges to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.82 454.25 Td (PP) Tj ET Q
q 0 0 0 rg BT 380.03 454.25 Td (ACA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.59 454.25 Td ( could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.12 454.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 532.01 454.25 Td (fect on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 442.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 424.25 Td ( customer) Tj ET Q
q 0 0 0 rg BT 95.35 424.25 Td ( concentration may adversely affect our) Tj ET Q
q 0 0 0 rg BT 264.29 424.25 Td ( financial condition and r) Tj ET Q
q 0 0 0 rg BT 371.90 424.25 Td (esults of operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 406.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 406.25 Td (e primarily sell our branded and generic products to wholesalers, retail drug store chains, supermarket chains, mass ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (products from us and, in turn, supply products to retail drug store chains, independent pharmacies and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.18 382.25 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.96 382.25 Td (s. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.86 382.25 Td (Our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (customer group reflects significant consolidation in recent years, marked by mer) Tj ET Q
q 0 0 0 rg BT 357.66 370.25 Td (gers and acquisitions and other alliances.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.49 370.25 Td ( For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (example, we understand that McKesson Corporation and ) Tj ET Q
q 0 0 0 rg BT 265.76 358.25 Td (W) Tj ET Q
q 0 0 0 rg BT 274.40 358.25 Td (al-Mart Stores, Inc. are party to an agreement to jointly source generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (pharmaceuticals and Express Scripts, through a wholly-owned subsidiary) Tj ET Q
q 0 0 0 rg BT 328.62 346.25 Td (, Innovative Product ) Tj ET Q
q 0 0 0 rg BT 411.94 346.25 Td (Alignment, LLC, participates in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (W) Tj ET Q
q 0 0 0 rg BT 44.64 334.25 Td (algreens Boots ) Tj ET Q
q 0 0 0 rg BT 105.74 334.25 Td (Alliance Development GmbH ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.21 334.25 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.21 334.25 Td (. Consolidations and joint purchasing arrangements such as these) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.44 334.25 Td ( have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (resulted in increased pricing and other competitive pressures on pharmaceutical companies, including us. ) Tj ET Q
q 0 0 0 rg BT 458.37 322.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 508.27 322.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (emer) Tj ET Q
q 0 0 0 rg BT 55.80 310.25 Td (gence of lar) Tj ET Q
q 0 0 0 rg BT 102.82 310.25 Td (ge buying groups representing independent retail pharmacies and other distributors and the prevalence and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (influence of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.53 298.25 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.32 298.25 Td (s) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.21 298.25 Td ( and similar institutions have increased the negotiating power of these groups, enabling them to attempt to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (extract various demands, including without limitation price discounts, rebates and other restrictive pricing terms. ) Tj ET Q
q 0 0 0 rg BT 489.31 286.25 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (competitive trends could continue in the future and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.64 274.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 371.52 274.25 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 262.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 244.25 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 244.25 Td (otal revenues from direct customers that accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.88 244.25 Td (10%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.21 244.25 Td ( or more of our total consolidated revenues during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.92 244.25 Td (years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.40 232.25 Td ( are as follows:) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.25 208.75 324.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
359.25 208.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
424.25 208.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
428.25 208.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.25 208.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.25 208.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.25 178.75 324.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
359.25 178.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
424.25 178.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
428.25 178.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.25 178.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.25 178.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
359.25 208.75 m
424.25 208.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
428.25 208.75 m
493.25 208.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497.25 208.75 m
562.25 208.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 383.25 212.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 452.25 212.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 521.25 212.98 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 37.75 199.32 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 103.74 199.32 Td (gen Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.40 198.42 Td (34) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.40 198.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.40 198.42 Td (32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.40 198.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.40 198.42 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.40 198.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 37.75 184.32 Td (McKesson Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.40 183.42 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.40 183.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.40 183.42 Td (27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.40 183.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.40 183.42 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.40 183.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 37.75 169.32 Td (Cardinal Health, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.40 168.42 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.40 168.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.40 168.42 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.40 168.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.40 168.42 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.40 168.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 146.25 Td (Revenues from these customers are included within each of our segments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.30 146.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 361.25 146.25 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 410.58 146.25 Td (, our revenues, financial condition or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 134.25 Td (results of operations may also be unduly af) Tj ET Q
q 0 0 0 rg BT 207.72 134.25 Td (fected by fluctuations in the buying or distribution patterns of these customers. ) Tj ET Q
q 0 0 0 rg BT 524.97 134.25 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 122.25 Td (fluctuations may result from seasonality) Tj ET Q
q 0 0 0 rg BT 195.87 122.25 Td (, pricing, wholesaler inventory objectives or other factors. In addition, if we were to lose ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 110.25 Td (the business of any of these customers, or if any were to fail to pay us on a timely basis, it could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.90 110.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 526.78 110.25 Td (fect on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 98.25 Td (our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 98.25 Td (.) Tj ET Q
endstream
endobj
77 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 78 0 R>>
endobj
78 0 obj
<</Length 15021>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (35) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 742.25 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 742.25 Td (e curr) Tj ET Q
q 0 0 0 rg BT 87.28 742.25 Td (ently dependent on outside manufactur) Tj ET Q
q 0 0 0 rg BT 254.33 742.25 Td (ers for) Tj ET Q
q 0 0 0 rg BT 282.19 742.25 Td ( the manufactur) Tj ET Q
q 0 0 0 rg BT 350.89 742.25 Td (e of a significant amount of our) Tj ET Q
q 0 0 0 rg BT 484.04 742.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 496.36 742.25 Td (oducts; ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (ther) Tj ET Q
q 0 0 0 rg BT 53.59 730.25 Td (efor) Tj ET Q
q 0 0 0 rg BT 70.61 730.25 Td (e, we have and will continue to have limited contr) Tj ET Q
q 0 0 0 rg BT 280.98 730.25 Td (ol of the manufacturing pr) Tj ET Q
q 0 0 0 rg BT 394.13 730.25 Td (ocess and r) Tj ET Q
q 0 0 0 rg BT 441.17 730.25 Td (elated costs. Certain of our) Tj ET Q
q 0 0 0 rg BT 555.68 730.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (manufactur) Tj ET Q
q 0 0 0 rg BT 86.37 718.25 Td (ers curr) Tj ET Q
q 0 0 0 rg BT 120.34 718.25 Td (ently constitute the sole sour) Tj ET Q
q 0 0 0 rg BT 241.25 718.25 Td (ce of one or) Tj ET Q
q 0 0 0 rg BT 290.22 718.25 Td ( mor) Tj ET Q
q 0 0 0 rg BT 310.31 718.25 Td (e of our) Tj ET Q
q 0 0 0 rg BT 342.89 718.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 355.21 718.25 Td (oducts.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 700.25 Td (Third party manufacturers currently manufacture a significant amount of our products pursuant to contractual arrangements. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (Certain of our manufacturers currently constitute the sole source of our products. For example, ) Tj ET Q
q 0 0 0 rg BT 417.37 688.25 Td (T) Tj ET Q
q 0 0 0 rg BT 422.78 688.25 Td (eikoku Seiyaku Co., Ltd. is our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (sole source of LIDODERM) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 146.81 680.33 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.25 676.25 Td ( and GlaxoSmithKline plc is our sole source of ) Tj ET Q
q 0 0 0 rg BT 341.32 676.25 Td (VOL) Tj ET Q
q 0 0 0 rg BT 360.95 676.25 Td (T) Tj ET Q
q 0 0 0 rg BT 366.26 676.25 Td (AREN) Tj ET Q
BT /F3 9.00 Tf ET
BT /F3 5.85 Tf ET
q 0 0 0 rg BT 393.48 680.33 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.92 676.25 Td ( Gel. Because of contractual restraints ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (and the lead-time necessary to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.05 664.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.51 664.25 Td ( approval and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.54 664.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.54 664.25 Td ( registration of a new manufacturer) Tj ET Q
q 0 0 0 rg BT 434.91 664.25 Td (, there are no readily accessible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (alternatives to these manufacturers and replacement of any of these manufacturers may be expensive and time consuming and may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (cause interruptions in our supply of products to customers. Our business and financial viability are dependent on these third party ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (manufacturers for continued manufacture of our products, the continued regulatory compliance of these manufacturers and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (strength, validity and terms of our various contracts with these manufacturers. ) Tj ET Q
q 0 0 0 rg BT 350.08 616.25 Td (Any interruption or failure by these manufacturers to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (meet their obligations pursuant to various agreements with us on schedule or in accordance with our expectations, or any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (termination by these manufacturers of our supply arrangements, which, in each case, could be the result of one or many factors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (outside of our control, could delay or prevent our ability to achieve sales expectations, cause interruptions in our supply of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (products to customers, cause us to incur failure-to-supply penalties, disrupt our operations or cause reputational harm to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (company) Tj ET Q
q 0 0 0 rg BT 72.01 556.25 Td (, any or all of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.07 556.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 283.95 556.25 Td (fect on our business, financial condition, results of operations and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.49 544.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 526.25 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 526.25 Td (e dependent on third parties to supply raw materials used in our) Tj ET Q
q 0 0 0 rg BT 335.65 526.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 347.97 526.25 Td (oducts and to pr) Tj ET Q
q 0 0 0 rg BT 417.52 526.25 Td (ovide services for) Tj ET Q
q 0 0 0 rg BT 491.21 526.25 Td ( certain cor) Tj ET Q
q 0 0 0 rg BT 539.89 526.25 Td (e ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (aspects of our) Tj ET Q
q 0 0 0 rg BT 94.70 514.25 Td ( business. ) Tj ET Q
q 0 0 0 rg BT 137.23 514.25 Td (Any interruption or) Tj ET Q
q 0 0 0 rg BT 222.04 514.25 Td ( failur) Tj ET Q
q 0 0 0 rg BT 248.25 514.25 Td (e by these suppliers, distributors and collaboration partners to meet their) Tj ET Q
q 0 0 0 rg BT 560.56 514.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (obligations pursuant to various agr) Tj ET Q
q 0 0 0 rg BT 185.84 502.25 Td (eements with us could have a ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 311.96 502.25 Td (material adverse effect on our) Tj ET Q
q 0 0 0 rg BT 439.51 502.25 Td ( business, financial ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.25 Td (condition, r) Tj ET Q
q 0 0 0 rg BT 85.27 490.25 Td (esults of operations and cash flows) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 232.23 490.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 472.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 472.25 Td (e rely on third parties to supply raw materials used in our products. In addition, we rely on third party suppliers, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (distributors and collaboration partners to provide services for certain core aspects of our business, including manufacturing, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (warehousing, distribution, customer service support, medical af) Tj ET Q
q 0 0 0 rg BT 289.92 448.25 Td (fairs services, clinical studies, sales and other technical and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (financial services. ) Tj ET Q
q 0 0 0 rg BT 110.14 436.25 Td (All third party suppliers and contractors are subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.13 436.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.58 436.25 Td ( and very often ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.34 436.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.34 436.25 Td ( requirements. Our business and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (financial viability are dependent on the continued supply of goods and services by these third parties, the regulatory compliance of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (these third parties and on the strength, validity and terms of our various contracts with these third parties. ) Tj ET Q
q 0 0 0 rg BT 458.68 412.25 Td (Any interruption or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (failure by our suppliers, distributors and collaboration partners to meet their obligations pursuant to various agreements with us on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (schedule or in accordance with our expectations, or any termination by these third parties of their arrangements with us, which, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.25 Td (each case, could be the result of one or many factors outside of our control, could delay or prevent the development, approval, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.25 Td (manufacture or commercialization of our products, result in non-compliance with applicable laws and regulations, cause us to incur ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (failure-to-supply penalties, disrupt our operations or cause reputational harm to our company) Tj ET Q
q 0 0 0 rg BT 407.46 352.25 Td (, any or all of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 340.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 340.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 424.69 340.25 Td (W) Tj ET Q
q 0 0 0 rg BT 433.32 340.25 Td (e may also be unsuccessful in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.25 Td (resolving any underlying issues with such suppliers, distributors and partners or replacing them within a reasonable time and on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.25 Td (commercially reasonable terms.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 298.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.11 298.25 Td (s imported into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.88 298.25 Td (European Union \(EU\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.19 298.25 Td ( must be certified as complying with the good manufacturing practice ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (standards established by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.42 286.25 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 163.75 286.25 Td (, as stipulated by the International Conference for Harmonization. ) Tj ET Q
q 0 0 0 rg BT 429.31 286.25 Td (These regulations place the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (certification requirement on the regulatory bodies of the exporting countries. ) Tj ET Q
q 0 0 0 rg BT 344.51 274.25 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 393.85 274.25 Td (, the national regulatory authorities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (each exporting country must: \(i\) ensure that all manufacturing plants within their borders that export ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.50 262.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.61 262.25 Td ( into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.89 262.25 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.22 262.25 Td ( comply with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.25 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 49.33 250.25 Td ( manufacturing standards and \(ii\) for each ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.99 250.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.10 250.25 Td ( exported, present a written document confirming that the exporting plant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (conforms to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.55 238.25 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.88 238.25 Td ( manufacturing standards. ) Tj ET Q
q 0 0 0 rg BT 205.78 238.25 Td (The imposition of this responsibility on the governments of the nations exporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.41 238.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.52 238.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (may cause a shortage of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.02 226.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.13 226.25 Td ( necessary to manufacture our products, as certain governments may not be willing or able to comply ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (with the regulation in a timely fashion, or at all. ) Tj ET Q
q 0 0 0 rg BT 228.73 214.25 Td (A) Tj ET Q
q 0 0 0 rg BT 235.40 214.25 Td ( shortage in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.01 214.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.12 214.25 Td ( may cause us to cease manufacturing of certain products or to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.25 Td (incur costs and delays to qualify other suppliers to substitute for those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.62 202.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.73 202.25 Td ( manufacturers unable to export. ) Tj ET Q
q 0 0 0 rg BT 465.73 202.25 Td (This could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 190.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 190.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 172.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 172.25 Td (e are dependent on third parties to provide us with various estimates as a basis for our financial reporting. ) Tj ET Q
q 0 0 0 rg BT 495.78 172.25 Td (While we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (undertake certain procedures to review the reasonableness of this information, we cannot obtain absolute assurance over the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (accounting methods and controls over the information provided to us by third parties. ) Tj ET Q
q 0 0 0 rg BT 379.82 148.25 Td (As a result, we are at risk of them providing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (us with erroneous data which could impact our reporting. Refer to �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.03 136.25 Td (CRITICAL) Tj ET Q
q 0 0 0 rg BT 352.77 136.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 354.72 136.25 Td (ACCOUNTING ESTIMA) Tj ET Q
q 0 0 0 rg BT 459.44 136.25 Td (TES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.22 136.25 Td (� in Part II, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.70 136.25 Td (Item 7 of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (this report �Management�) Tj ET Q
q 0 0 0 rg BT 138.74 124.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 207.91 124.25 Td (Analysis of Financial Condition and Results of Operations�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.49 124.25 Td ( for information about our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.25 Td (most significant accounting estimates.) Tj ET Q
endstream
endobj
79 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 80 0 R>>
endobj
80 0 obj
<</Length 15129>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (36) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (If our) Tj ET Q
q 0 0 0 rg BT 60.54 742.25 Td ( manufacturing facilities ar) Tj ET Q
q 0 0 0 rg BT 176.73 742.25 Td (e unable to manufactur) Tj ET Q
q 0 0 0 rg BT 276.27 742.25 Td (e our) Tj ET Q
q 0 0 0 rg BT 298.03 742.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 310.35 742.25 Td (oducts or) Tj ET Q
q 0 0 0 rg BT 349.89 742.25 Td ( the manufacturing pr) Tj ET Q
q 0 0 0 rg BT 444.43 742.25 Td (ocess is interrupted due to ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (failur) Tj ET Q
q 0 0 0 rg BT 59.71 730.25 Td (e to comply with r) Tj ET Q
q 0 0 0 rg BT 136.73 730.25 Td (egulations or) Tj ET Q
q 0 0 0 rg BT 191.83 730.25 Td ( for) Tj ET Q
q 0 0 0 rg BT 206.92 730.25 Td ( other) Tj ET Q
q 0 0 0 rg BT 232.01 730.25 Td ( r) Tj ET Q
q 0 0 0 rg BT 238.76 730.25 Td (easons, it could have a ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 336.00 730.25 Td (material adverse effect on our) Tj ET Q
q 0 0 0 rg BT 463.54 730.25 Td ( business, financial ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (condition, r) Tj ET Q
q 0 0 0 rg BT 85.27 718.25 Td (esults of operations and cash flows) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 232.23 718.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 700.25 Td (If any of our or our third party manufacturing facilities fail to comply with regulatory requirements or encounter other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (manufacturing dif) Tj ET Q
q 0 0 0 rg BT 107.74 688.25 Td (ficulties, it could adversely af) Tj ET Q
q 0 0 0 rg BT 226.13 688.25 Td (fect our ability to supply products. ) Tj ET Q
q 0 0 0 rg BT 365.83 688.25 Td (All facilities and manufacturing processes used ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (for the manufacture of pharmaceutical products are subject to inspection by regulatory agencies at any time and must be operated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (in conformity with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.49 664.25 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.23 664.25 Td ( and, in the case of controlled substances, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.51 664.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.51 664.25 Td ( regulations. Compliance with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.26 664.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.16 664.25 Td (�) Tj ET Q
q 0 0 0 rg BT 486.94 664.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 493.33 664.25 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.07 664.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.51 664.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.51 664.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (requirements applies to both products for which regulatory approval is being sought and to approved products. In complying with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.74 640.25 Td ( requirements, pharmaceutical manufacturing facilities must continually expend significant time, money and ef) Tj ET Q
q 0 0 0 rg BT 505.30 640.25 Td (fort in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (production, recordkeeping, quality assurance and quality control so that their products meet applicable specifications and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (requirements for product safety) Tj ET Q
q 0 0 0 rg BT 161.14 616.25 Td (, ef) Tj ET Q
q 0 0 0 rg BT 173.72 616.25 Td (ficacy and quality) Tj ET Q
q 0 0 0 rg BT 244.71 616.25 Td (. Failure to comply with applicable legal requirements subjects our or our third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (party manufacturing facilities to possible legal or regulatory action, including shutdown, which may adversely af) Tj ET Q
q 0 0 0 rg BT 487.36 604.25 Td (fect our ability to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (supply our products. ) Tj ET Q
q 0 0 0 rg BT 119.89 592.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 169.79 592.25 Td (, our or our third party manufacturing facilities may face other significant disruptions due to labor ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (strikes, failure to reach acceptable agreement with labor unions, infringement of intellectual property rights, vandalism, natural ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (disaster) Tj ET Q
q 0 0 0 rg BT 66.15 568.25 Td (, outbreak and spread of viral or other diseases, storm or other environmental damage, civil or political unrest, export or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (import restrictions or other events. ) Tj ET Q
q 0 0 0 rg BT 176.34 556.25 Td (W) Tj ET Q
q 0 0 0 rg BT 184.98 556.25 Td (ere we not able to manufacture products at our or our third party manufacturing facilities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (because of regulatory) Tj ET Q
q 0 0 0 rg BT 121.42 544.25 Td (, business or any other reasons, the manufacture and marketing of these products could be interrupted. ) Tj ET Q
q 0 0 0 rg BT 531.95 544.25 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.03 532.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 164.92 532.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.90 532.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 514.25 Td (For example, the manufacturing facilities qualified to manufacture the enzyme ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.82 514.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.38 514.25 Td (, which is included in our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 78.77 506.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.71 502.25 Td ( product and in certain product candidates under development, including for the treatment of cellulite,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.79 502.25 Td ( are subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.25 Td (such regulatory requirements and oversight. If such facilities fail to comply with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.08 490.25 Td (cGMP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.82 490.25 Td ( requirements, we may not be permitted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (sell our products or may be limited in the jurisdictions in which we are permitted to sell them. Further) Tj ET Q
q 0 0 0 rg BT 443.01 478.25 Td (, if an inspection by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (regulatory authorities indicates that there are deficiencies, including non-compliance with regulatory requirements, we could be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.25 Td (required to take remedial actions, stop production or close our facilities, which could disrupt the manufacturing processes and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (could limit the supply of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.83 442.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.39 442.25 Td ( and/or delay clinical trials and subsequent licensure and/or limit the sale of commercial supplies. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (addition, future noncompliance with any applicable regulatory requirements may result in refusal by regulatory authorities to allow ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (use of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.66 418.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.22 418.25 Td ( in clinical trials, refusal by the government to allow distribution of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.55 418.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.11 418.25 Td ( within the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.38 418.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.17 418.25 Td ( or other jurisdictions, criminal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (prosecution, fines, recall or seizure of products, total or partial suspension of production, prohibitions or limitations on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (commercial sale of products, refusal to allow the entering into of federal and state supply contracts and civil litigation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 376.25 Td (e purchase certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.76 376.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.88 376.25 Td ( and other materials used in our manufacturing operations from foreign and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.67 376.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.45 376.25 Td ( suppliers. ) Tj ET Q
q 0 0 0 rg BT 526.88 376.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.25 Td (price and availability of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.19 364.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.30 364.25 Td ( and other materials is subject to volatility for a number of reasons, many of which may be outside of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (our control. ) Tj ET Q
q 0 0 0 rg BT 84.97 352.25 Td (There is no guarantee that we will always have timely) Tj ET Q
q 0 0 0 rg BT 300.08 352.25 Td (, suf) Tj ET Q
q 0 0 0 rg BT 317.12 352.25 Td (ficient or af) Tj ET Q
q 0 0 0 rg BT 363.58 352.25 Td (fordable access to critical raw materials or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.25 Td (supplies from third parties. ) Tj ET Q
q 0 0 0 rg BT 145.71 340.25 Td (An increase in the price, or an interruption in the supply) Tj ET Q
q 0 0 0 rg BT 369.16 340.25 Td (, of any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.38 340.25 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.49 340.25 Td ( or raw material could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 328.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 328.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 310.25 Td (e have limited experience in manufacturing biologic pr) Tj ET Q
q 0 0 0 rg BT 278.30 310.25 Td (oducts and may encounter) Tj ET Q
q 0 0 0 rg BT 390.62 310.25 Td ( difficulties in our) Tj ET Q
q 0 0 0 rg BT 466.28 310.25 Td ( manufacturing ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 298.25 Td (ocesses, which could materially adversely affect our) Tj ET Q
q 0 0 0 rg BT 265.32 298.25 Td ( r) Tj ET Q
q 0 0 0 rg BT 272.07 298.25 Td (esults of operations or) Tj ET Q
q 0 0 0 rg BT 366.05 298.25 Td ( delay or) Tj ET Q
q 0 0 0 rg BT 403.09 298.25 Td ( disrupt manufactur) Tj ET Q
q 0 0 0 rg BT 489.58 298.25 Td (e of those ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 286.25 Td (oducts r) Tj ET Q
q 0 0 0 rg BT 80.36 286.25 Td (eliant upon our) Tj ET Q
q 0 0 0 rg BT 145.75 286.25 Td ( manufacturing operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 268.25 Td (The manufacture of biologic products requires significant expertise and capital investment. ) Tj ET Q
q 0 0 0 rg BT 428.99 268.25 Td (Although we manufacture ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.90 268.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.46 268.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.25 Td (which is included in our current XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 208.74 260.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.68 256.25 Td ( product and in certain product candidates under development, including for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.25 Td (treatment of cellulite, in our Horsham, Pennsylvania facility) Tj ET Q
q 0 0 0 rg BT 275.56 244.25 Td (, we have limited experience in manufacturing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.82 244.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.38 244.25 Td ( or any other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (biologic products. Biologics such as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.21 232.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.77 232.25 Td ( require processing steps that are highly complex and generally more dif) Tj ET Q
q 0 0 0 rg BT 492.66 232.25 Td (ficult than those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (required for most chemical pharmaceuticals. In addition, ) Tj ET Q
q 0 0 0 rg BT 264.90 220.25 Td (TEST) Tj ET Q
q 0 0 0 rg BT 288.61 220.25 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 313.61 224.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.54 220.25 Td ( is manufactured using a unique, proprietary process. If the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (manufacturing processes are disrupted at the facilities where our biologic products are manufactured, it may be dif) Tj ET Q
q 0 0 0 rg BT 493.71 208.25 Td (ficult to find ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (alternate manufacturing sites. ) Tj ET Q
q 0 0 0 rg BT 156.33 196.25 Td (W) Tj ET Q
q 0 0 0 rg BT 164.96 196.25 Td (e may encounter dif) Tj ET Q
q 0 0 0 rg BT 244.47 196.25 Td (ficulties with the manufacture of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.48 196.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.04 196.25 Td ( and the active ingredient of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (TEST) Tj ET Q
q 0 0 0 rg BT 59.71 184.25 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 84.71 188.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.64 184.25 Td (, which could delay) Tj ET Q
q 0 0 0 rg BT 167.30 184.25 Td (, disrupt or halt our manufacture of such products and/or product candidates, result in product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (recalls or product liability claims, require write-of) Tj ET Q
q 0 0 0 rg BT 236.02 172.25 Td (fs or otherwise have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.27 172.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 402.15 172.25 Td (fect on our business, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.80 160.25 Td (.) Tj ET Q
endstream
endobj
81 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 82 0 R>>
endobj
82 0 obj
<</Length 13144>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (37) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (The DEA) Tj ET Q
q 0 0 0 rg BT 75.73 742.25 Td ( limits the availability of the active ingr) Tj ET Q
q 0 0 0 rg BT 242.47 742.25 Td (edients used in many of our) Tj ET Q
q 0 0 0 rg BT 359.81 742.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 372.13 742.25 Td (oducts as well as the pr) Tj ET Q
q 0 0 0 rg BT 470.56 742.25 Td (oduction of these ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (pr) Tj ET Q
q 0 0 0 rg BT 45.82 730.25 Td (oducts, and, as a r) Tj ET Q
q 0 0 0 rg BT 122.88 730.25 Td (esult, our) Tj ET Q
q 0 0 0 rg BT 162.69 730.25 Td ( pr) Tj ET Q
q 0 0 0 rg BT 175.01 730.25 Td (ocur) Tj ET Q
q 0 0 0 rg BT 194.27 730.25 Td (ement and pr) Tj ET Q
q 0 0 0 rg BT 251.31 730.25 Td (oduction quotas may not be sufficient to meet commer) Tj ET Q
q 0 0 0 rg BT 482.21 730.25 Td (cial demand or) Tj ET Q
q 0 0 0 rg BT 545.92 730.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (complete clinical trials) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 132.08 718.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 700.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 700.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.05 700.25 Td ( limits the availability of the active ingredients used in many of our products and sets a quota on the production of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (these products. ) Tj ET Q
q 0 0 0 rg BT 98.30 688.25 Td (W) Tj ET Q
q 0 0 0 rg BT 106.94 688.25 Td (e, or our contract manufacturing or) Tj ET Q
q 0 0 0 rg BT 246.70 688.25 Td (ganizations, must annually apply to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.84 688.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.84 688.25 Td ( for procurement and production ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (quotas in order to obtain these substances and produce our products. In addition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.09 676.25 Td (H.R. 6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.48 676.25 Td ( amends the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.75 676.25 Td (CSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.65 676.25 Td ( with respect to quotas by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (requiring the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.87 664.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.87 664.25 Td ( to estimate the amount and impact of diversion \(including overdose deaths and abuse and overall public health ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (impact\) of fentanyl, oxycodone, hydrocodone, oxymorphone or hydromorphone and to make appropriate quota reductions. ) Tj ET Q
q 0 0 0 rg BT 529.20 652.25 Td (As a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (result, our procurement and production quotas may not be suf) Tj ET Q
q 0 0 0 rg BT 282.43 640.25 Td (ficient to meet commercial demand or to complete clinical trials. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (Moreover) Tj ET Q
q 0 0 0 rg BT 75.03 628.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.75 628.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.75 628.25 Td ( may adjust these quotas from time to time during the year) Tj ET Q
q 0 0 0 rg BT 347.75 628.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 352.20 628.25 Td (Any delay or refusal by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.83 628.25 Td (DEA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.83 628.25 Td ( in establishing our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (quotas, or modification of our quotas, for controlled substances could delay or result in the stoppage of clinical trials or product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (launches, or could cause trade inventory disruptions for those products that have already been launched, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 111.88 592.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.87 592.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (If we ar) Tj ET Q
q 0 0 0 rg BT 69.14 574.25 Td (e unable to r) Tj ET Q
q 0 0 0 rg BT 122.57 574.25 Td (etain our) Tj ET Q
q 0 0 0 rg BT 161.00 574.25 Td ( key personnel and continue to attract additional pr) Tj ET Q
q 0 0 0 rg BT 380.82 574.25 Td (ofessional staff, we may be unable to ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.25 Td (maintain or) Tj ET Q
q 0 0 0 rg BT 86.10 562.25 Td ( expand our) Tj ET Q
q 0 0 0 rg BT 137.04 562.25 Td ( business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 544.25 Td (Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (and future competitors will remain highly dependent, in lar) Tj ET Q
q 0 0 0 rg BT 272.14 532.25 Td (ge part, upon our ability to attract and retain qualified scientific, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (technical and commercial personnel. ) Tj ET Q
q 0 0 0 rg BT 184.92 520.25 Td (The loss of key scientific, technical and commercial personnel or the failure to recruit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (additional key scientific, technical and commercial personnel could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.71 508.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 412.60 508.25 Td (fect on our business, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.80 496.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 226.62 496.25 Td (While we have consulting agreements with certain key individuals and institutions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (and have employment agreements with our key executives, we may be unsuccessful in retaining personnel or their services under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.25 Td (existing agreements. ) Tj ET Q
q 0 0 0 rg BT 120.52 472.25 Td (There is intense competition for qualified personnel in the areas of our activities and we may be unable to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (continue to attract and retain the qualified personnel necessary for the development of our business.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (The trading prices of our) Tj ET Q
q 0 0 0 rg BT 143.04 442.25 Td ( securities may be volatile, and investments in our) Tj ET Q
q 0 0 0 rg BT 354.79 442.25 Td ( securities could decline in value.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 424.25 Td (The market prices for securities of Endo, and of pharmaceutical companies in general, have been highly volatile and may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (continue to be highly volatile in the future. For example, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.11 412.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.11 412.25 Td (, our ordinary shares traded between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.11 412.25 Td ($1.97) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.61 412.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.05 412.25 Td ($12.49) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.55 412.25 Td ( per share ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.22 400.25 Td (NASDAQ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.89 400.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 109.71 400.25 Td (The following factors, in addition to other risk factors described in this section, may cause the market value of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (our securities to fluctuate:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 376.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 376.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.95 376.25 Td ( approval or disapproval of any of the drug applications we have submitted;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 364.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 364.25 Td (the success or failure of our clinical trials;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 352.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 352.25 Td (new data or new analyses of older data that raise potential safety or ef) Tj ET Q
q 0 0 0 rg BT 364.37 352.25 Td (fectiveness issues concerning our approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 340.25 Td (products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 328.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 328.25 Td (product recalls or withdrawals;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 316.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 316.25 Td (competitors announcing technological innovations or new commercial products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 304.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 304.25 Td (introduction of generic or compounded substitutes for our products, including the filing of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.21 304.25 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.10 304.25 Td (s with respect to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 292.25 Td (generic versions of our branded products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 280.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 280.25 Td (developments concerning our or others�) Tj ET Q
q 0 0 0 rg BT 244.15 280.25 Td ( proprietary rights, including patents;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 268.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 268.25 Td (competitors�) Tj ET Q
q 0 0 0 rg BT 135.30 268.25 Td ( publicity regarding actual or potential products under development or other activities af) Tj ET Q
q 0 0 0 rg BT 487.78 268.25 Td (fecting our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 256.25 Td (competitors or the industry in general;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 244.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 244.25 Td (regulatory developments in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.13 244.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.91 244.25 Td ( and foreign countries, or announcements relating to these matters;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 232.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 232.25 Td (period-to-period fluctuations in our financial results;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 220.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 220.25 Td (new legislation, regulation, administrative guidance or executive orders, or changes in interpretation of existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 208.25 Td (legislation, regulation, administrative guidance or executive orders, including by virtue of new judicial decisions, that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 196.25 Td (could af) Tj ET Q
q 0 0 0 rg BT 117.80 196.25 Td (fect the development, sale or pricing of pharmaceutical products, the number of individuals with access to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 184.25 Td (af) Tj ET Q
q 0 0 0 rg BT 93.09 184.25 Td (fordable healthcare, the taxes we pay and/or other factors;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 172.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 172.25 Td (a determination by a regulatory agency that we are engaging or have engaged in inappropriate sales or marketing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 160.25 Td (activities, including promoting of) Tj ET Q
q 0 0 0 rg BT 219.19 160.25 Td (f-label uses of our products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 148.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 148.25 Td (social and political pressure to lower the cost of pharmaceutical products;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 136.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 136.25 Td (social and political scrutiny over increases in prices of shares of pharmaceutical companies that are perceived to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 124.25 Td (caused by a strategy of growth through acquisitions;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 112.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 112.25 Td (litigation against us or others;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 100.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 100.25 Td (reports of security analysts and rating agencies;) Tj ET Q
endstream
endobj
83 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 84 0 R>>
endobj
84 0 obj
<</Length 13712>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (38) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (judgments or settlements or reports of settlement negotiations concerning opioid-related litigation or claims, and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (other companies commencing cases under ) Tj ET Q
q 0 0 0 rg BT 256.65 730.10 Td (T) Tj ET Q
q 0 0 0 rg BT 262.40 730.10 Td (itle 1) Tj ET Q
q 0 0 0 rg BT 282.31 730.10 Td (1 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.35 730.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.14 730.10 Td ( Code to address opioid-related litigation liabilities; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 718.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 718.10 Td (changes in the political and regulatory environment and international relations as a result of events such as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.98 718.10 Td (the exit of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 706.10 Td (the United Kingdom from the EU \(Brexit\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.35 706.10 Td ( and full or partial shutdowns of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.88 706.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.66 706.10 Td ( federal government that may occur ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 694.10 Td (from time to time, the current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.30 694.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.08 694.10 Td ( administration and other external factors, including market speculation or disasters ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 682.10 Td (and other crises.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 664.10 Td (e have no plans to pay r) Tj ET Q
q 0 0 0 rg BT 146.39 664.10 Td (egular) Tj ET Q
q 0 0 0 rg BT 173.43 664.10 Td ( dividends on our) Tj ET Q
q 0 0 0 rg BT 247.44 664.10 Td ( ordinary shar) Tj ET Q
q 0 0 0 rg BT 308.93 664.10 Td (es or) Tj ET Q
q 0 0 0 rg BT 329.02 664.10 Td ( to conduct ordinary shar) Tj ET Q
q 0 0 0 rg BT 437.73 664.10 Td (e r) Tj ET Q
q 0 0 0 rg BT 448.92 664.10 Td (epur) Tj ET Q
q 0 0 0 rg BT 468.74 664.10 Td (chases.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 646.10 Td (e currently do not intend to pay any cash dividends in the foreseeable future on our ordinary shares. ) Tj ET Q
q 0 0 0 rg BT 471.79 646.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 521.70 646.10 Td (, while ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 634.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.16 634.10 Td ( has approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.19 634.10 Td (a share buyback program \(the 2015 Share Buyback Program\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.11 634.10 Td (, of which there is approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.80 634.10 Td ($2.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.91 634.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (available as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.25 622.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.83 622.10 Td (, we currently do not intend to conduct ordinary share repurchases in the foreseeable future. ) Tj ET Q
q 0 0 0 rg BT 543.31 622.10 Td (Any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (declaration and payment of future dividends to holders of ordinary shares as well as any repurchase of our ordinary shares under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 598.10 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.97 598.10 Td ( will be at the sole discretion of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.99 598.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.43 598.10 Td ( and will depend on many factors, including our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (payment of both cash and property dividends or share repurchases and other considerations that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.60 574.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.04 574.10 Td ( deems relevant. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (addition, our existing debt instruments restrict or prevent us from paying dividends on our ordinary shares and conducting ordinary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (share repurchases. ) Tj ET Q
q 0 0 0 rg BT 111.24 550.10 Td (Agreements governing any future indebtedness, in addition to those governing our current indebtedness, may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (not permit us to pay dividends on our ordinary shares or conduct ordinary share repurchases.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 520.10 Td ( business and operations could be negatively affected by shar) Tj ET Q
q 0 0 0 rg BT 312.60 520.10 Td (eholder) Tj ET Q
q 0 0 0 rg BT 344.64 520.10 Td ( activism, which could cause us to incur) Tj ET Q
q 0 0 0 rg BT 512.80 520.10 Td ( significant ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (expenses, hinder) Tj ET Q
q 0 0 0 rg BT 106.38 508.10 Td ( execution of our) Tj ET Q
q 0 0 0 rg BT 177.58 508.10 Td ( business strategy and impact our) Tj ET Q
q 0 0 0 rg BT 320.46 508.10 Td ( shar) Tj ET Q
q 0 0 0 rg BT 341.67 508.10 Td (e price.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 490.10 Td (In recent years, shareholder activism involving corporate governance, strategic direction and operations has become ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (increasingly prevalent. If we become the subject of such shareholder activism, their demands may disrupt our business and divert ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (the attention of our management, employees and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.16 466.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.60 466.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 262.04 466.10 Td (Also, we may incur substantial costs, including legal fees and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (expenses, related to such activist shareholder matters. Perceived uncertainties resulting from such activist shareholder matters may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (result in loss of potential business opportunities with our current and potential customers and business partners, be exploited by our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (competitors and make attracting and retaining qualified personnel more dif) Tj ET Q
q 0 0 0 rg BT 335.44 430.10 Td (ficult. In addition, such shareholder activism may cause ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (significant fluctuations in our share price based on temporary or speculative market perceptions, uncertainties or other factors that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (do not necessarily reflect the underlying fundamentals and prospects of our business.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 388.10 Td ( operations could be disrupted if our) Tj ET Q
q 0 0 0 rg BT 208.99 388.10 Td ( information systems fail, if we ar) Tj ET Q
q 0 0 0 rg BT 351.28 388.10 Td (e unsuccessful in implementing necessary ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (upgrades or) Tj ET Q
q 0 0 0 rg BT 87.21 376.10 Td ( if we ar) Tj ET Q
q 0 0 0 rg BT 121.74 376.10 Td (e subject to cyber) Tj ET Q
q 0 0 0 rg BT 196.06 376.10 Td (-attacks.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.10 Td (Our business depends on the ef) Tj ET Q
q 0 0 0 rg BT 187.52 358.10 Td (ficient and uninterrupted operation of our computer and communications systems and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (networks, hardware and software systems and our other information technology) Tj ET Q
q 0 0 0 rg BT 354.71 346.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 359.15 346.10 Td (As such, we continuously invest financial and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (other resources to maintain, enhance, further develop, replace or add to our information technology infrastructure. Such ef) Tj ET Q
q 0 0 0 rg BT 524.53 334.10 Td (forts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (carry risks such as cost overruns, project delays and business interruptions, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.40 322.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 494.29 322.10 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 310.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 302.62 310.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 352.52 310.10 Td (, these measures are not guaranteed to protect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (against all cybersecurity incidents. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 280.10 Td (In the ordinary course of our business, we collect and maintain information, which includes confidential, proprietary and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (personal information regarding our customers and employees, in digital form. Data maintained in digital form is subject to risk of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (cyber) Tj ET Q
q 0 0 0 rg BT 58.01 256.10 Td (-attacks, which are increasing in frequency and sophistication and are made by groups and individuals with a wide range of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (motives and expertise, including criminal groups, �hackers� and others. Cyber) Tj ET Q
q 0 0 0 rg BT 349.04 244.10 Td (-attacks could include the deployment of harmful ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (malware, viruses, worms, denial-of-service attacks, ransomware, social engineering and other means to af) Tj ET Q
q 0 0 0 rg BT 459.27 232.10 Td (fect service reliability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (and threaten data confidentiality) Tj ET Q
q 0 0 0 rg BT 164.46 220.10 Td (, integrity and availability) Tj ET Q
q 0 0 0 rg BT 267.12 220.10 Td (. Despite our ef) Tj ET Q
q 0 0 0 rg BT 328.58 220.10 Td (forts to monitor and safeguard our systems to prevent data ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (compromise, the possibility of a future data compromise cannot be eliminated entirely) Tj ET Q
q 0 0 0 rg BT 380.25 208.10 Td (, and risks associated with intrusion, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (tampering and theft remain. In addition, we do not have insurance coverage with respect to system failures or cyber) Tj ET Q
q 0 0 0 rg BT 497.86 196.10 Td (-attacks. If our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (systems were to fail or we are unable to successfully expand the capacity of these systems, or we are unable to integrate new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (technologies into our existing systems, our operations and financial results could suf) Tj ET Q
q 0 0 0 rg BT 373.53 172.10 Td (fer) Tj ET Q
q 0 0 0 rg BT 384.08 172.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 154.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 154.10 Td (e also have outsourced certain elements and functions of our operations, including elements of our information technology ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (infrastructure, to third parties, some of which are outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.37 142.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.15 142.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.10 142.10 Td (As a result, we are managing many independent vendor ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (relationships with third parties who may or could have access to our confidential information. ) Tj ET Q
q 0 0 0 rg BT 413.22 130.10 Td (The size and complexity of our and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (our vendors�) Tj ET Q
q 0 0 0 rg BT 86.08 118.10 Td ( systems make such systems potentially vulnerable to service interruptions. ) Tj ET Q
q 0 0 0 rg BT 388.89 118.10 Td (The size and complexity of our and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (vendors�) Tj ET Q
q 0 0 0 rg BT 70.25 106.10 Td ( systems and the lar) Tj ET Q
q 0 0 0 rg BT 148.94 106.10 Td (ge amounts of confidential information that is present on them also makes them potentially vulnerable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (to security breaches from inadvertent or intentional actions by our employees, our partners, our vendors or other third parties, or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (from attacks by malicious third parties.) Tj ET Q
endstream
endobj
85 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 86 0 R>>
endobj
86 0 obj
<</Length 14546>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (39) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (The Company and its vendors�) Tj ET Q
q 0 0 0 rg BT 185.57 742.10 Td ( information technology operations are spread across multiple, sometimes inconsistent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (platforms, which pose dif) Tj ET Q
q 0 0 0 rg BT 138.02 730.10 Td (ficulties in maintaining data integrity across systems. ) Tj ET Q
q 0 0 0 rg BT 352.80 730.10 Td (The ever) Tj ET Q
q 0 0 0 rg BT 387.85 730.10 Td (-increasing use and evolution of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (technology) Tj ET Q
q 0 0 0 rg BT 79.78 718.10 Td (, including cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (of confidential information stored in the Company�) Tj ET Q
q 0 0 0 rg BT 240.40 706.10 Td (s systems.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.10 Td (Any breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (misappropriation or misuse of trade secrets, proprietary information or other confidential information, whether as a result of theft, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (hacking, fraud, trickery or other forms of deception, or for any other cause, could enable others to produce competing products, use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (our proprietary technology or information and/or adversely af) Tj ET Q
q 0 0 0 rg BT 282.68 652.10 Td (fect our business position. Further) Tj ET Q
q 0 0 0 rg BT 418.65 652.10 Td (, any such interruption, security ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (breach, loss or disclosure of confidential information could result in financial, legal, business and reputational harm to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (company and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.13 628.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 221.01 628.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.99 628.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (Non-) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 57.11 610.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 74.90 610.10 Td ( r) Tj ET Q
q 0 0 0 rg BT 81.65 610.10 Td (egulatory r) Tj ET Q
q 0 0 0 rg BT 128.96 610.10 Td (equir) Tj ET Q
q 0 0 0 rg BT 151.56 610.10 Td (ements vary) Tj ET Q
q 0 0 0 rg BT 202.93 610.10 Td (, including with r) Tj ET Q
q 0 0 0 rg BT 276.10 610.10 Td (espect to the r) Tj ET Q
q 0 0 0 rg BT 335.62 610.10 Td (egulatory appr) Tj ET Q
q 0 0 0 rg BT 399.05 610.10 Td (oval pr) Tj ET Q
q 0 0 0 rg BT 429.14 610.10 Td (ocess, and failur) Tj ET Q
q 0 0 0 rg BT 498.13 610.10 Td (e to obtain ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (r) Tj ET Q
q 0 0 0 rg BT 40.26 598.10 Td (egulatory appr) Tj ET Q
q 0 0 0 rg BT 103.69 598.10 Td (oval or) Tj ET Q
q 0 0 0 rg BT 133.22 598.10 Td ( maintain compliance with r) Tj ET Q
q 0 0 0 rg BT 253.04 598.10 Td (equir) Tj ET Q
q 0 0 0 rg BT 275.63 598.10 Td (ements in non-) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 338.42 598.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 356.20 598.10 Td ( jurisdictions would pr) Tj ET Q
q 0 0 0 rg BT 452.98 598.10 Td (event or) Tj ET Q
q 0 0 0 rg BT 487.51 598.10 Td ( impact the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (marketing of our) Tj ET Q
q 0 0 0 rg BT 108.59 586.10 Td ( pr) Tj ET Q
q 0 0 0 rg BT 120.91 586.10 Td (oducts in those jurisdictions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 568.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 568.10 Td (e have worldwide intellectual property rights to market many of our products and product candidates and intend to seek ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (approval to market certain of our existing or potential future products outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.12 556.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.91 556.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 392.86 556.10 Td (Approval of a product by the regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (authorities of a particular country is generally required prior to manufacturing or marketing that product in that country) Tj ET Q
q 0 0 0 rg BT 512.14 544.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 516.96 544.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (approval procedure varies among countries and can involve additional testing and the time required to obtain such approval may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 520.10 Td (fer from that required to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.55 520.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.00 520.10 Td ( approval. Non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.04 520.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.82 520.10 Td ( regulatory approval processes generally include risks similar to those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (associated with obtaining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.15 508.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.60 508.10 Td ( approval, as further described herein. ) Tj ET Q
q 0 0 0 rg BT 312.87 508.10 Td (Approval by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.36 508.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.81 508.10 Td ( does not guarantee approval by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (regulatory authorities of any other country) Tj ET Q
q 0 0 0 rg BT 205.02 496.10 Td (, nor does the approval by foreign regulatory authorities in one country guarantee ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (approval by regulatory authorities in other foreign countries or by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.20 484.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.20 484.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 466.10 Td (Outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.16 466.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.94 466.10 Td (, regulatory agencies generally evaluate and monitor the safety) Tj ET Q
q 0 0 0 rg BT 390.02 466.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 402.60 466.10 Td (ficacy and quality of pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (products and devices and impose regulatory requirements applicable to manufacturing processes, stability testing, recordkeeping ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (and quality standards, among others. ) Tj ET Q
q 0 0 0 rg BT 184.96 442.10 Td (These requirements vary by jurisdiction. In certain countries, including emer) Tj ET Q
q 0 0 0 rg BT 491.62 442.10 Td (ging and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (developing markets, the applicable healthcare and drug regulatory regimes are continuing to evolve and new requirements may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (implemented. Ensuring and maintaining compliance with these varying and evolving requirements is and will continue to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 406.10 Td (ficult, time-consuming and costly) Tj ET Q
q 0 0 0 rg BT 180.70 406.10 Td (. In seeking regulatory approvals in non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.15 406.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.94 406.10 Td ( jurisdictions, we must also continue to comply ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.28 394.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.06 394.10 Td ( laws and regulations, including those imposed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.25 394.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.03 394.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.53 394.10 Td (Foreign Corrupt Practices ) Tj ET Q
q 0 0 0 rg BT 416.79 394.10 Td (Act \(FCP) Tj ET Q
q 0 0 0 rg BT 453.93 394.10 Td (A\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.49 394.10 Td (. See the risk factor ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 382.10 Td (The risks related to our global operations may adversely impact our revenues, results of operations and financial condition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.74 382.10 Td (.� If we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (fail to comply with these various regulatory requirements or fail to obtain and maintain required approvals, our tar) Tj ET Q
q 0 0 0 rg BT 492.90 370.10 Td (get market will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (be reduced and our ability to generate non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.88 358.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.66 358.10 Td ( revenue will be adversely af) Tj ET Q
q 0 0 0 rg BT 340.70 358.10 Td (fected.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 340.10 Td (e could be adversely affected by the risks associated with having operated a medical device manufacturing business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 322.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 322.10 Td (e are subject to various risks associated with having operated a medical device manufacturing business, which risks could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (have adverse ef) Tj ET Q
q 0 0 0 rg BT 98.00 310.10 Td (fects, including potential and actual product liability claims for any defective or allegedly defective goods that were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (distributed and increased government scrutiny and/or potential claims regarding the marketing of medical devices.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 280.10 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 280.10 Td (e subject to health information privacy and data pr) Tj ET Q
q 0 0 0 rg BT 279.79 280.10 Td (otection laws that include penalties for) Tj ET Q
q 0 0 0 rg BT 443.77 280.10 Td ( noncompliance. Our) Tj ET Q
q 0 0 0 rg BT 533.31 280.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (failur) Tj ET Q
q 0 0 0 rg BT 59.71 268.10 Td (e to comply with various laws pr) Tj ET Q
q 0 0 0 rg BT 197.86 268.10 Td (otecting the confidentiality of certain patient health information could r) Tj ET Q
q 0 0 0 rg BT 502.92 268.10 Td (esult in ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (penalties and r) Tj ET Q
q 0 0 0 rg BT 99.16 256.10 Td (eputational damage.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 238.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 238.10 Td (e are subject to a number of privacy and data protection laws and regulations globally) Tj ET Q
q 0 0 0 rg BT 413.65 238.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 418.47 238.10 Td (The legislative and regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (landscape for privacy and data security continues to evolve. Certain countries in which we operate have, or are developing, laws ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (protecting the confidentiality of individually identifiable personal information, including patient health information. ) Tj ET Q
q 0 0 0 rg BT 501.81 214.10 Td (This includes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (federal and state laws and regulations in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.71 202.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.50 202.10 Td ( as well as in Europe and other markets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.10 Td (For example, California recently adopted the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.88 184.10 Td (California Consumer Privacy ) Tj ET Q
q 0 0 0 rg BT 364.03 184.10 Td (Act of 2018 \(CCP) Tj ET Q
q 0 0 0 rg BT 435.61 184.10 Td (A\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.16 184.10 Td (, which provides new data ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (privacy rights for consumers and new operational requirements for businesses. ) Tj ET Q
q 0 0 0 rg BT 352.67 172.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.72 172.10 Td (CCP) Tj ET Q
q 0 0 0 rg BT 388.71 172.10 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.38 172.10 Td ( went into ef) Tj ET Q
q 0 0 0 rg BT 445.46 172.10 Td (fect on January 1, 2020 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (establishing new data privacy rights for consumers in the state of California and creating a new and potentially severe statutory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (damages framework for violations of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.50 136.10 Td (CCP) Tj ET Q
q 0 0 0 rg BT 219.49 136.10 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.16 136.10 Td ( and for businesses that fail to implement reasonable security procedures and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (practices to prevent data breaches. Because the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.46 124.10 Td (CCP) Tj ET Q
q 0 0 0 rg BT 244.44 124.10 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.11 124.10 Td ( only recently went into ef) Tj ET Q
q 0 0 0 rg BT 356.18 124.10 Td (fect, many of its requirements have not yet been ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (interpreted by courts and best practices are still being developed, all of which increase the risk of compliance failure and related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (adverse impacts.) Tj ET Q
endstream
endobj
87 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 88 0 R>>
endobj
88 0 obj
<</Length 17363>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (40) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (In addition, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.32 742.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.65 742.10 Td (�) Tj ET Q
q 0 0 0 rg BT 142.43 742.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.82 742.10 Td (General Data Protection Regulation \(GDPR\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.66 742.10 Td (, which replaced the pre-existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.94 742.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.27 742.10 Td ( Data Protection ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (Directive and became enforceable as of May 25, 2018, imposes strict restrictions on our authority to collect, analyze and transfer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (personal data regarding persons in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.39 718.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.72 718.10 Td (, including health data from clinical trials and adverse event reporting. ) Tj ET Q
q 0 0 0 rg BT 487.05 718.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.10 718.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.78 718.10 Td (, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (has extra-territorial scope and substantial fines for breaches \(up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.57 706.10 Td (4%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.90 706.10 Td ( of global annual revenue or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.85 706.10 Td (�20 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.25 706.10 Td (, whichever is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (greater\) grants individuals whose personal data \(which is very broadly defined\) is collected or otherwise processed the right to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (access the data, request its deletion and control its use and disclosure. ) Tj ET Q
q 0 0 0 rg BT 316.29 682.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.34 682.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.01 682.10 Td ( also requires notification of a breach in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (security of such data to be provided within 72 hours of discovering the breach. ) Tj ET Q
q 0 0 0 rg BT 352.31 670.10 Td (Although the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.30 670.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.98 670.10 Td ( itself is self-executing across ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (all ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 48.50 658.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.83 658.10 Td ( member states, data protection authorities from dif) Tj ET Q
q 0 0 0 rg BT 266.58 658.10 Td (ferent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.40 658.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.73 658.10 Td ( member states may interpret and apply the regulation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (somewhat dif) Tj ET Q
q 0 0 0 rg BT 89.97 646.10 Td (ferently) Tj ET Q
q 0 0 0 rg BT 120.42 646.10 Td (, which adds to the complexity of processing personal data in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.30 646.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.63 646.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 400.45 646.10 Td (T) Tj ET Q
q 0 0 0 rg BT 405.86 646.10 Td (o date, there has been very little ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (interpretation of the regulation by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.17 634.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.50 634.10 Td ( member states�) Tj ET Q
q 0 0 0 rg BT 264.07 634.10 Td ( dif) Tj ET Q
q 0 0 0 rg BT 277.50 634.10 Td (ferent data protection authorities and little time for enforcement, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (makes predicting future enforcement very dif) Tj ET Q
q 0 0 0 rg BT 217.13 622.10 Td (ficult. ) Tj ET Q
q 0 0 0 rg BT 243.06 622.10 Td (That uncertainty contributes to liability exposure risk.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 604.10 Td (As did the pre-existing Data Protection Directive, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.77 604.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.45 604.10 Td ( prohibits the transfer of personal data to countries outside of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 592.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.05 592.10 Td ( that are not considered by the European Commission to provide an adequate level of data protection, and transfers of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (personal data to such countries may be made only in certain circumstances, such as where the transfer is necessary for important ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (reasons of public interest or the individual to whom the personal data relates has given his or her explicit consent to the transfer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (after being informed of the risks involved.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 538.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 538.10 Td (e have policies and practices that we believe make us compliant with applicable privacy regulations, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.37 538.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 557.04 538.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (Nevertheless, there remains a risk of failure to comply with the rules arising from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.23 526.10 Td (GDPR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.90 526.10 Td ( or privacy laws in other countries in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (which we operate. Should a transgression be deemed to have occurred, it could lead to government enforcement actions and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (significant sanctions or penalties against us, adversely impact our results of operations and subject us to negative publicity) Tj ET Q
q 0 0 0 rg BT 524.68 502.10 Td (. Such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (liabilities could materially af) Tj ET Q
q 0 0 0 rg BT 151.06 490.10 Td (fect our operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 472.10 Td (There has also been increased enforcement activity in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.84 472.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.62 472.10 Td ( particularly related to data security breaches. ) Tj ET Q
q 0 0 0 rg BT 496.43 472.10 Td (A) Tj ET Q
q 0 0 0 rg BT 503.10 472.10 Td ( violation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (these laws or regulations by us or our third party vendors could subject us to penalties, fines, liability and/or possible exclusion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (from Medicare or Medicaid. Such sanctions could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.04 448.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 342.92 448.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 436.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 418.10 Td (e face risks r) Tj ET Q
q 0 0 0 rg BT 99.41 418.10 Td (elating to the exit of the United Kingdom fr) Tj ET Q
q 0 0 0 rg BT 283.66 418.10 Td (om the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 315.32 418.10 Td (EU) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 329.21 418.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 400.10 Td (On June 23, 2016, the United Kingdom held a remain-or) Tj ET Q
q 0 0 0 rg BT 289.14 400.10 Td (-leave referendum on the United Kingdom�) Tj ET Q
q 0 0 0 rg BT 462.14 400.10 Td (s membership within the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 49.33 388.10 Td (, the result of which favored the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.29 388.10 Td (Brexit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.28 388.10 Td (. On March 29, 2017, the Prime Minister of the United Kingdom delivered a formal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (notice of withdrawal to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.24 376.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.57 376.10 Td (. On May 22, 2017, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.84 376.10 Td (Council of the EU \(the Council\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.43 376.10 Td (, adopted a decision authorizing the opening ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.83 364.10 Td (Brexit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.83 364.10 Td ( negotiations with the United Kingdom and formally nominated the European Commission as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.43 364.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.76 364.10 Td ( negotiator) Tj ET Q
q 0 0 0 rg BT 519.25 364.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 524.07 364.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (Council) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.67 352.10 Td ( also adopted negotiating directives for the talks. On January 9, 2020, a ) Tj ET Q
q 0 0 0 rg BT 354.63 352.10 Td (W) Tj ET Q
q 0 0 0 rg BT 363.67 352.10 Td (ithdrawal ) Tj ET Q
q 0 0 0 rg BT 403.38 352.10 Td (Agreement Bill was passed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (United Kingdom House of Commons and, subject to scrutiny by the United Kingdom House of Lords, the ) Tj ET Q
q 0 0 0 rg BT 462.71 340.10 Td (W) Tj ET Q
q 0 0 0 rg BT 471.75 340.10 Td (ithdrawal ) Tj ET Q
q 0 0 0 rg BT 511.46 340.10 Td (Agreement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (Bill approves an eleven-month transition period starting on January 31, 2020 in which the United Kingdom will cease to be a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (member of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.81 316.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.14 316.10 Td (, but will continue to follow the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.01 316.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.34 316.10 Td (�) Tj ET Q
q 0 0 0 rg BT 255.12 316.10 Td (s rules and contribute to its budget. In the event a full trade deal is not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (reached between the United Kingdom and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.05 304.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.38 304.10 Td ( by the December 31, 2020 deadline and there is no further extension, trade relations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (between the United Kingdom and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.18 292.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.51 292.10 Td ( will be governed by any terms agreed within this period or by the ) Tj ET Q
q 0 0 0 rg BT 467.93 292.10 Td (W) Tj ET Q
q 0 0 0 rg BT 476.57 292.10 Td (orld ) Tj ET Q
q 0 0 0 rg BT 495.00 292.10 Td (T) Tj ET Q
q 0 0 0 rg BT 500.76 292.10 Td (rade ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (Or) Tj ET Q
q 0 0 0 rg BT 46.37 280.10 Td (ganization Rules. ) Tj ET Q
q 0 0 0 rg BT 118.12 280.10 Td (The impact on our business as a result of Brexit will depend, in part, on the outcome of tarif) Tj ET Q
q 0 0 0 rg BT 485.62 280.10 Td (f, trade, regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (and other negotiations and on the ultimate manner and timing of the United Kingdom�) Tj ET Q
q 0 0 0 rg BT 380.65 268.10 Td (s withdrawal from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.18 268.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.51 268.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 488.96 268.10 Td (As a result, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (face risks associated with the potential uncertainty and consequences that may follow Brexit, including with respect to volatility in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (financial markets, exchange rates and interest rates. ) Tj ET Q
q 0 0 0 rg BT 244.33 244.10 Td (These uncertainties could increase the volatility of, or reduce, our investment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (results in particular periods or over time. Brexit could adversely af) Tj ET Q
q 0 0 0 rg BT 302.12 232.10 Td (fect political, regulatory) Tj ET Q
q 0 0 0 rg BT 397.82 232.10 Td (, economic or market conditions in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (United Kingdom and in Europe and it could contribute to instability in global political institutions and regulatory agencies.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 202.10 Td (Similarly) Tj ET Q
q 0 0 0 rg BT 99.57 202.10 Td (, if the United Kingdom were to significantly alter its regulations af) Tj ET Q
q 0 0 0 rg BT 369.32 202.10 Td (fecting the pharmaceutical industry) Tj ET Q
q 0 0 0 rg BT 510.01 202.10 Td (, we could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (face significant new costs. It may also be time-consuming and expensive for us to alter our internal operations in order to comply ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (with new regulations. In addition, since a significant proportion of the regulatory framework in the United Kingdom is derived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.94 166.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.27 166.10 Td ( directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (our product candidates in the United Kingdom or the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.12 154.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.45 154.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 267.89 154.10 Td (Any delay in obtaining, or an inability to obtain, any regulatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (approvals, as a result of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.19 142.10 Td (Brexit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.19 142.10 Td ( or otherwise, would prevent us from commercializing our product candidates in the United ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (Kingdom and/or the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.04 130.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.37 130.10 Td ( and restrict our ability to generate revenue and achieve and sustain profitability) Tj ET Q
q 0 0 0 rg BT 451.05 130.10 Td (. If any of these outcomes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (occur) Tj ET Q
q 0 0 0 rg BT 57.81 118.10 Td (, we may be forced to restrict or delay ef) Tj ET Q
q 0 0 0 rg BT 219.77 118.10 Td (forts to seek regulatory approval in the United Kingdom and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.27 118.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.60 118.10 Td ( for our product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (candidates, which could significantly and materially harm our business. Similarly) Tj ET Q
q 0 0 0 rg BT 361.66 106.10 Td (, it is unclear at this time what ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.69 106.10 Td (Brexit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.69 106.10 Td (�) Tj ET Q
q 0 0 0 rg BT 512.46 106.10 Td (s impact ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (will have on our intellectual property rights and the process for obtaining and defending such rights. It is possible that certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (intellectual property rights, such as trademarks, granted by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.87 82.10 Td (EU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.20 82.10 Td ( will cease being enforceable in the United Kingdom absent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.10 Td (special arrangements to the contrary) Tj ET Q
q 0 0 0 rg BT 180.29 70.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 184.74 70.10 Td (Any of these factors could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.07 70.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 396.96 70.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 58.10 Td (.) Tj ET Q
endstream
endobj
89 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 90 0 R>>
endobj
90 0 obj
<</Length 15440>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (41) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (The risks r) Tj ET Q
q 0 0 0 rg BT 82.49 742.25 Td (elated to our) Tj ET Q
q 0 0 0 rg BT 136.19 742.25 Td ( global operations may adversely impact our) Tj ET Q
q 0 0 0 rg BT 325.44 742.25 Td ( r) Tj ET Q
q 0 0 0 rg BT 332.20 742.25 Td (evenues, r) Tj ET Q
q 0 0 0 rg BT 374.78 742.25 Td (esults of operations and financial condition) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 557.87 742.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.83 724.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.83 724.25 Td (, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.09 724.25 Td (4%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.42 724.25 Td ( of our total revenues were from customers outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.91 724.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.69 724.25 Td ( Some of these sales were to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (governmental entities and other or) Tj ET Q
q 0 0 0 rg BT 173.00 712.25 Td (ganizations with extended payment terms. Conducting business internationally) Tj ET Q
q 0 0 0 rg BT 487.28 712.25 Td (, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (sourcing, manufacturing, development, sale and distribution of our products and services across international borders, subjects us ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (to extensive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.54 688.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.33 688.25 Td ( and foreign governmental trade regulations, such as various anti-bribery laws, including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.16 688.25 Td (FCP) Tj ET Q
q 0 0 0 rg BT 493.04 688.25 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.26 688.25 Td (, export control ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (laws, customs and import laws, and anti-boycott laws. ) Tj ET Q
q 0 0 0 rg BT 254.95 676.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.00 676.25 Td (FCP) Tj ET Q
q 0 0 0 rg BT 289.87 676.25 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.54 676.25 Td ( and similar anti-corruption laws in other jurisdictions generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (prohibit companies and their intermediaries from making improper payments to government of) Tj ET Q
q 0 0 0 rg BT 416.00 664.25 Td (ficials for the purpose of obtaining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (or retaining business. ) Tj ET Q
q 0 0 0 rg BT 123.58 652.25 Td (W) Tj ET Q
q 0 0 0 rg BT 132.22 652.25 Td (e cannot provide assurance that our internal controls and procedures will always protect us from criminal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (acts committed by our employees or third parties with whom we work. If we are found liable for violations of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.99 640.25 Td (FCP) Tj ET Q
q 0 0 0 rg BT 508.87 640.25 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.54 640.25 Td ( or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (applicable laws and regulations, either due to our own acts or out of inadvertence, or due to the acts or inadvertence of others, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (could suf) Tj ET Q
q 0 0 0 rg BT 72.76 616.25 Td (fer significant criminal, civil and administrative penalties, including, but not limited to, imprisonment of individuals, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (fines, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (government contracting, as well as reputational harm. ) Tj ET Q
q 0 0 0 rg BT 252.88 592.25 Td (Also, the failure to comply with applicable legal and regulatory obligations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (could result in the disruption of our shipping and sales activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 562.25 Td (In addition, some countries where we source, develop, manufacture or sell products are subject to political, economic and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.25 Td (social instability) Tj ET Q
q 0 0 0 rg BT 101.18 550.25 Td (. Our non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.56 550.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.34 550.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.84 550.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.51 550.25 Td (, manufacturing and sales operations expose us and our employees, representatives, agents ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (and distributors to risks inherent in operating in non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.08 538.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.86 538.25 Td ( jurisdictions. For example, we perform certain of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.30 538.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.97 538.25 Td ( functions in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (India. ) Tj ET Q
q 0 0 0 rg BT 61.37 526.25 Td (W) Tj ET Q
q 0 0 0 rg BT 70.00 526.25 Td (e also manufacture certain of our products in India and expect that our Indian manufacturing operations could expand in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (the future. ) Tj ET Q
q 0 0 0 rg BT 79.04 514.25 Td (A) Tj ET Q
q 0 0 0 rg BT 85.71 514.25 Td ( disruption in our Indian operations could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.61 514.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 358.50 514.25 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 502.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 144.40 502.25 Td (These risks include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 490.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 490.25 Td (the imposition of additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.82 490.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.60 490.25 Td ( and non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.37 490.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.16 490.25 Td ( governmental controls or regulations;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 478.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 478.25 Td (the imposition of costly and lengthy new export licensing requirements;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 466.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 466.25 Td (the imposition of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.33 466.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.11 466.25 Td ( and/or international sanctions against a country) Tj ET Q
q 0 0 0 rg BT 365.08 466.25 Td (, company) Tj ET Q
q 0 0 0 rg BT 406.08 466.25 Td (, person or entity with whom we do ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 454.25 Td (business that would restrict or prohibit continued business with the sanctioned country) Tj ET Q
q 0 0 0 rg BT 430.63 454.25 Td (, company) Tj ET Q
q 0 0 0 rg BT 471.63 454.25 Td (, person or entity;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 442.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 442.25 Td (economic and political instability or disruptions, including local and regional instability) Tj ET Q
q 0 0 0 rg BT 435.62 442.25 Td (, or disruptions due to natural ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 430.25 Td (disasters, such as severe weather and geological events, disruptions due to civil unrest and hostilities, rioting, military ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 418.25 Td (activity) Tj ET Q
q 0 0 0 rg BT 114.84 418.25 Td (, terror attacks or armed hostilities;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 406.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 406.25 Td (changes in duties and tarif) Tj ET Q
q 0 0 0 rg BT 190.29 406.25 Td (fs, license obligations and other non-tarif) Tj ET Q
q 0 0 0 rg BT 354.50 406.25 Td (f barriers to trade;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 394.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 394.25 Td (the imposition of new trade restrictions including foreign exchange controls;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 382.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 382.25 Td (supply disruptions and increases in ener) Tj ET Q
q 0 0 0 rg BT 245.01 382.25 Td (gy and transportation costs;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 370.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 370.25 Td (the imposition of restrictions on the activities of foreign agents, representatives and distributors;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 358.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 358.25 Td (changes in global tax laws and/or the imposition by tax authorities of significant fines, penalties and additional taxes;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 346.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 346.25 Td (pricing pressure that we may experience internationally;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 334.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 334.25 Td (fluctuations in foreign currency exchange rates;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 322.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 322.25 Td (competition from local, regional and international competitors;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 310.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 310.25 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 310.25 Td (ficulties and costs of staf) Tj ET Q
q 0 0 0 rg BT 195.67 310.25 Td (fing and managing foreign operations, including cultural dif) Tj ET Q
q 0 0 0 rg BT 435.42 310.25 Td (ferences and additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 298.25 Td (employment regulations, union workforce negotiations and potential disputes in the jurisdictions in which we operate;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 286.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 286.25 Td (laws and business practices favoring local companies;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 274.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 274.25 Td (dif) Tj ET Q
q 0 0 0 rg BT 96.43 274.25 Td (ficulties in enforcing or defending intellectual property rights; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 262.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 262.25 Td (exposure to dif) Tj ET Q
q 0 0 0 rg BT 145.30 262.25 Td (ferent legal and political standards due to our conducting business in foreign countries.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 244.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 244.25 Td (e also face the risk that some of our competitors have more experience with operations in such countries or with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (international operations generally and may be able to manage unexpected crises more easily) Tj ET Q
q 0 0 0 rg BT 403.54 232.25 Td (. Furthermore, whether due to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (language, cultural or other dif) Tj ET Q
q 0 0 0 rg BT 154.94 220.25 Td (ferences, public and other statements that we make may be misinterpreted, misconstrued or taken out ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (of context in dif) Tj ET Q
q 0 0 0 rg BT 99.97 208.25 Td (ferent jurisdictions. Moreover) Tj ET Q
q 0 0 0 rg BT 219.26 208.25 Td (, the internal political stability of, or the relationship between, any country or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (countries where we conduct business operations may deteriorate, including relationships between the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.82 196.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.60 196.25 Td ( and other countries. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (Changes in other countries�) Tj ET Q
q 0 0 0 rg BT 145.51 184.25 Td ( economic conditions, product pricing, political stability or the state of relations between any such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (countries are dif) Tj ET Q
q 0 0 0 rg BT 100.79 172.25 Td (ficult to predict and could adversely af) Tj ET Q
q 0 0 0 rg BT 254.99 172.25 Td (fect our operations, payment and credit terms and our ability to collect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (foreign receivables. ) Tj ET Q
q 0 0 0 rg BT 116.80 160.25 Td (Any such changes could lead to a decline in our profitability and/or adversely impact our ability to do ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (business. ) Tj ET Q
q 0 0 0 rg BT 74.34 148.25 Td (Any meaningful deterioration of the political or social stability in and/or diplomatic relations between any countries in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (which we or our partners and suppliers do business could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.94 136.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 371.82 136.25 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 124.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 183.47 124.25 Td (A) Tj ET Q
q 0 0 0 rg BT 190.14 124.25 Td ( substantial slowdown of the global economy) Tj ET Q
q 0 0 0 rg BT 370.58 124.25 Td (, or major national economies, could negatively ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.25 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 112.25 Td (fect growth in the markets in which we operate. Such a slowdown could result in national governments making significant cuts to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.25 Td (their public spending, including national healthcare budgets, or reducing the level of reimbursement they are willing and able to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.25 Td (provide to us for our products and, as a result, adversely af) Tj ET Q
q 0 0 0 rg BT 270.47 88.25 Td (fect our revenues, financial condition or results of operations. ) Tj ET Q
q 0 0 0 rg BT 518.82 88.25 Td (W) Tj ET Q
q 0 0 0 rg BT 527.46 88.25 Td (e have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.25 Td (little influence over these factors and changes could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.23 76.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 350.12 76.25 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.25 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 64.25 Td (. ) Tj ET Q
endstream
endobj
91 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 92 0 R>>
endobj
92 0 obj
<</Length 12373>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (42) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 742.10 Td (e cannot provide assurance that one or more of these factors will not harm our business. ) Tj ET Q
q 0 0 0 rg BT 424.59 742.10 Td (Any material decrease in our non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 730.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.28 730.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.95 730.10 Td (, manufacturing or sales could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.56 730.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 305.45 730.10 Td (fect on our business, financial condition, results of operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.43 718.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 700.10 Td (e have a substantial amount of indebtedness which could adversely affect our) Tj ET Q
q 0 0 0 rg BT 373.33 700.10 Td ( financial position and pr) Tj ET Q
q 0 0 0 rg BT 480.40 700.10 Td (event us fr) Tj ET Q
q 0 0 0 rg BT 525.21 700.10 Td (om ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (fulfilling our) Tj ET Q
q 0 0 0 rg BT 89.99 688.10 Td ( obligations under) Tj ET Q
q 0 0 0 rg BT 167.05 688.10 Td ( such indebtedness, which may r) Tj ET Q
q 0 0 0 rg BT 304.67 688.10 Td (equir) Tj ET Q
q 0 0 0 rg BT 327.27 688.10 Td (e us to r) Tj ET Q
q 0 0 0 rg BT 361.25 688.10 Td (efinance all or) Tj ET Q
q 0 0 0 rg BT 421.61 688.10 Td ( part of our) Tj ET Q
q 0 0 0 rg BT 470.59 688.10 Td ( then-outstanding ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (indebtedness. ) Tj ET Q
q 0 0 0 rg BT 95.46 676.10 Td (Any r) Tj ET Q
q 0 0 0 rg BT 120.00 676.10 Td (efinancing of this substantial indebtedness could be at significantly higher) Tj ET Q
q 0 0 0 rg BT 434.04 676.10 Td ( inter) Tj ET Q
q 0 0 0 rg BT 456.90 676.10 Td (est rates. ) Tj ET Q
q 0 0 0 rg BT 496.61 676.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 549.41 676.10 Td (, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (we have a significant amount of floating rate indebtedness and an incr) Tj ET Q
q 0 0 0 rg BT 334.44 664.10 Td (ease in inter) Tj ET Q
q 0 0 0 rg BT 385.92 664.10 Td (est rates would incr) Tj ET Q
q 0 0 0 rg BT 469.33 664.10 Td (ease the cost of ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (servicing our) Tj ET Q
q 0 0 0 rg BT 91.64 652.10 Td ( indebtedness. Despite our) Tj ET Q
q 0 0 0 rg BT 203.14 652.10 Td ( curr) Tj ET Q
q 0 0 0 rg BT 224.33 652.10 Td (ent level of indebtedness, we may still be able to incur) Tj ET Q
q 0 0 0 rg BT 452.20 652.10 Td ( substantially mor) Tj ET Q
q 0 0 0 rg BT 529.25 652.10 Td (e ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (indebtedness. ) Tj ET Q
q 0 0 0 rg BT 95.83 640.10 Td (This could incr) Tj ET Q
q 0 0 0 rg BT 160.11 640.10 Td (ease the risks associated with our) Tj ET Q
q 0 0 0 rg BT 301.31 640.10 Td ( substantial indebtedness.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 622.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 622.10 Td (e currently have a substantial amount of indebtedness. ) Tj ET Q
q 0 0 0 rg BT 290.19 622.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.63 622.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.21 622.10 Td (, we have total debt of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td ($8.47 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.11 610.10 Td ( in aggregate principal amount. Our substantial indebtedness may:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 598.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 598.10 Td (make it dif) Tj ET Q
q 0 0 0 rg BT 128.64 598.10 Td (ficult for us to satisfy our financial obligations, including making scheduled principal and interest payments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 586.10 Td (on our indebtedness;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 574.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 574.10 Td (limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 562.10 Td (business purposes;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 550.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 550.10 Td (limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 538.10 Td (acquisitions or other general business purposes;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 526.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 526.10 Td (expose us to the risk of rising interest rates with respect to the borrowings under our variable rate indebtedness;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 514.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 514.10 Td (require us to use a substantial portion of our cash on hand and/or from future operations to make debt service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 502.10 Td (payments;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 490.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 490.10 Td (limit our flexibility to plan for) Tj ET Q
q 0 0 0 rg BT 205.92 490.10 Td (, or react to, changes in our business and industry;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 478.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 478.10 Td (place us at a competitive disadvantage compared to our less leveraged competitors; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 466.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 466.10 Td (increase our vulnerability to the impact of adverse economic and industry conditions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 448.10 Td (If we are unable to pay amounts due under our outstanding indebtedness or to fund other liquidity needs, such as future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (capital expenditures or contingent liabilities as a result of adverse business developments, including expenses related to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (ongoing and future legal proceedings and governmental investigations as well as increased pricing pressures or otherwise, we may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (be required to refinance all or part of our then-existing indebtedness, sell assets, reduce or delay capital expenditures or seek to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (raise additional capital, any of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.26 400.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 315.14 400.10 Td (fect on our business, financial condition, results of operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.43 388.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 100.25 388.10 Td (There can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (at all. ) Tj ET Q
q 0 0 0 rg BT 60.16 376.10 Td (Any refinancing of this substantial indebtedness ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.12 376.10 Td (could be at significantly higher interest rates, which will depend on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (conditions of the markets and our financial condition at such time) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.71 364.10 Td (. In addition, we may be able to incur substantial additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (indebtedness in the future, including secured indebtedness. If new indebtedness is added to our current debt levels, the related risks ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (that we and our subsidiaries now face could intensify) Tj ET Q
q 0 0 0 rg BT 248.07 340.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 252.52 340.10 Td (At any time and from time to time, we may also be pursuing activities to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (extend our debt maturities, lower principal balances, reduce interest expense or obtain covenant flexibility) Tj ET Q
q 0 0 0 rg BT 459.92 328.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 464.37 328.10 Td (Activities could include, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (without limitation, one or more tender of) Tj ET Q
q 0 0 0 rg BT 199.39 316.10 Td (fers, exchange of) Tj ET Q
q 0 0 0 rg BT 267.79 316.10 Td (fers, debt-for) Tj ET Q
q 0 0 0 rg BT 319.78 316.10 Td (-equity exchanges or consent solicitations. ) Tj ET Q
q 0 0 0 rg BT 491.78 316.10 Td (W) Tj ET Q
q 0 0 0 rg BT 500.42 316.10 Td (e cannot ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (predict if or when we would conduct any such activity) Tj ET Q
q 0 0 0 rg BT 252.79 304.10 Td (, whether any such activities will achieve their intended results or whether ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (any such activity could impact our financial results or be dilutive. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 274.10 Td (While interest rates have been at record low levels in recent years, this low interest rate environment likely will not continue ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (indefinitely) Tj ET Q
q 0 0 0 rg BT 81.45 262.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 85.90 262.10 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.40 262.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.98 262.10 Td (, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.24 262.10 Td ($3.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.35 262.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.79 262.10 Td ($0.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.91 262.10 Td ( of principal amounts outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.63 262.10 Td (T) Tj ET Q
q 0 0 0 rg BT 536.04 262.10 Td (erm ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.60 250.10 Td ( and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.75 250.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.97 250.10 Td ( \(each as defined in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.21 250.10 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.58 250.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.08 250.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.94 250.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.21 238.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 111.08 238.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.06 238.10 Td (\), respectively) Tj ET Q
q 0 0 0 rg BT 257.05 238.10 Td (, bear interest at variable rates. ) Tj ET Q
q 0 0 0 rg BT 381.44 238.10 Td (Any future borrowings by the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (could also have variable interest rates. ) Tj ET Q
q 0 0 0 rg BT 190.66 226.10 Td (As a result, to the extent we have not hedged against rising interest rates, an increase in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (applicable benchmark interest rates would increase our cost of servicing our indebtedness and could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.96 214.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 542.84 214.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.50 202.10 Td (.) Tj ET Q
endstream
endobj
93 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 94 0 R>>
endobj
94 0 obj
<</Length 17634>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (43) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Changes in the method of determining the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 217.94 742.25 Td (London Interbank Offer) Tj ET Q
q 0 0 0 rg BT 322.78 742.25 Td (ed Rate \(LIBOR\)) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 396.66 742.25 Td (, or) Tj ET Q
q 0 0 0 rg BT 410.92 742.25 Td ( the r) Tj ET Q
q 0 0 0 rg BT 433.50 742.25 Td (eplacement of ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 495.15 742.25 Td (LIBOR) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 527.38 742.25 Td ( with an ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (alternative r) Tj ET Q
q 0 0 0 rg BT 88.85 730.25 Td (efer) Tj ET Q
q 0 0 0 rg BT 105.32 730.25 Td (ence rate, may materially adversely affect our) Tj ET Q
q 0 0 0 rg BT 300.34 730.25 Td ( inter) Tj ET Q
q 0 0 0 rg BT 323.20 730.25 Td (est expense r) Tj ET Q
q 0 0 0 rg BT 377.45 730.25 Td (elated to our) Tj ET Q
q 0 0 0 rg BT 431.15 730.25 Td ( outstanding debt.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 712.25 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 712.25 Td ( significant portion of our outstanding indebtedness, including, at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.24 712.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.82 712.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.82 712.25 Td ($3.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.94 712.25 Td ( outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (T) Tj ET Q
q 0 0 0 rg BT 41.41 700.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.06 700.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.49 700.25 Td ($0.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.61 700.25 Td ( outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.26 700.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.82 700.25 Td (, bears interest rates in relation to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.33 700.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.33 700.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 541.78 700.25 Td (Any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (future amounts borrowed under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.39 688.25 Td (T) Tj ET Q
q 0 0 0 rg BT 184.80 688.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.44 688.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.77 688.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.99 688.25 Td ( would also bear interest rates in relation to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 66.00 676.25 Td (, depending on our interest election. On July 27, 2017, the Financial Conduct ) Tj ET Q
q 0 0 0 rg BT 376.22 676.25 Td (Authority in the United Kingdom announced ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (that it would phase out ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.60 664.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.60 664.25 Td ( as a benchmark by the end of 2021. ) Tj ET Q
q 0 0 0 rg BT 306.60 664.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.09 664.25 Td (Alternative Reference Rates Committee \(ARRC\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.14 664.25 Td (, a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (steering committee comprised of lar) Tj ET Q
q 0 0 0 rg BT 180.21 652.25 Td (ge ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.15 652.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.94 652.25 Td ( financial institutions, has proposed replacing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.06 652.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.06 652.25 Td ( with a new index calculated by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (short-term repurchase agreements \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.04 640.25 Td (Secured Overnight Financing Rate \(SOFR\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.79 640.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 372.57 640.25 Td (At this time, no consensus exists as to what ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (rate or rates may become accepted alternatives to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.34 628.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.34 628.25 Td (, and it is impossible to predict whether and to what extent banks will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (continue to provide ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.26 616.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.26 616.25 Td ( submissions to the administrator of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.81 616.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.81 616.25 Td (, whether ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.51 616.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.51 616.25 Td ( rates will cease to be published or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (supported before or after 2021 or whether any additional reforms to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.96 604.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.96 604.25 Td ( may be enacted in the United Kingdom or elsewhere. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (Such developments and any other legal or regulatory changes in the method by which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.46 592.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.46 592.25 Td ( is determined or the transition from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 66.00 580.25 Td ( to a successor benchmark may result in, among other things, a sudden or prolonged increase or decrease in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.81 580.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.81 580.25 Td (, a delay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (in the publication of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.32 568.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.32 568.25 Td ( and changes in the rules or methodologies in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.88 568.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.88 568.25 Td (, which may discourage market participants from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (continuing to administer or to participate in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.35 556.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.35 556.25 Td (�) Tj ET Q
q 0 0 0 rg BT 245.13 556.25 Td (s determination and, in certain situations, could result in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.02 556.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.02 556.25 Td ( no longer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (being determined and published. If ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.18 544.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.18 544.25 Td ( ceases to exist, we may need to renegotiate the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.05 544.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 427.00 544.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.42 544.25 Td ( \(as defined in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.84 544.25 Td (Note ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.44 532.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.93 532.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.80 532.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.51 532.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 314.38 532.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.36 532.25 Td (\) and we may not be able to do so on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (terms that are favorable to us. ) Tj ET Q
q 0 0 0 rg BT 157.16 520.25 Td (The overall financial market may be disrupted and there could be significant increases in benchmark ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (rates or borrowing costs to borrowers as a result of the phase-out or replacement of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.61 508.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.61 508.25 Td (. Disruption in the financial market, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (significant increases in benchmark rates or borrowing costs or our inability to refinance the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.10 496.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 430.05 496.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.47 496.25 Td ( with favorable terms ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.03 484.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 164.92 484.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.90 484.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (Covenants in our) Tj ET Q
q 0 0 0 rg BT 109.16 466.25 Td ( debt agr) Tj ET Q
q 0 0 0 rg BT 147.31 466.25 Td (eements r) Tj ET Q
q 0 0 0 rg BT 188.50 466.25 Td (estrict our) Tj ET Q
q 0 0 0 rg BT 232.46 466.25 Td ( business in many ways, a default of which may r) Tj ET Q
q 0 0 0 rg BT 440.37 466.25 Td (esult in acceleration of ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.25 Td (certain of our) Tj ET Q
q 0 0 0 rg BT 94.13 454.25 Td ( indebtedness.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 436.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 436.25 Td (e are subject to various covenants in the instruments governing our debt that limit our and/or our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 509.96 436.25 Td ( ability to, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (among other things:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 412.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 412.25 Td (incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 400.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 400.25 Td (issue redeemable stock and preferred stock;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 388.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 388.25 Td (pay dividends or distributions or redeem or repurchase capital stock;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 376.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 376.25 Td (prepay) Tj ET Q
q 0 0 0 rg BT 112.06 376.25 Td (, redeem or repurchase debt;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 364.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 364.25 Td (make loans, investments and capital expenditures;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 352.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 352.25 Td (enter into agreements that restrict distributions from our subsidiaries;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 340.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 340.25 Td (sell assets and capital stock of our subsidiaries;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 328.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 328.25 Td (enter into certain transactions with af) Tj ET Q
q 0 0 0 rg BT 233.87 328.25 Td (filiates; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 316.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 316.25 Td (consolidate or mer) Tj ET Q
q 0 0 0 rg BT 159.74 316.25 Td (ge with or into, or sell substantially all of our assets to, another person.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 298.25 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 298.25 Td ( breach of any of these covenants could result in a default under our indebtedness. If there were an event of default under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (any of the agreements relating to our outstanding indebtedness, the holders of the defaulted debt could cause all amounts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (outstanding with respect to that debt to be due and payable immediately) Tj ET Q
q 0 0 0 rg BT 322.77 274.25 Td (, terminate all commitments to extend further credit, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (foreclose against all the assets comprising the collateral securing or otherwise supporting the debt and pursue other legal remedies. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.25 Td (The instruments governing our debt may contain cross-default or cross-acceleration provisions that may cause all of the debt issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (under such instruments to become immediately due and payable as a result of a default under an unrelated debt instrument. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (assets and cash flows may be insuf) Tj ET Q
q 0 0 0 rg BT 175.23 226.25 Td (ficient to fully repay borrowings under our outstanding debt instruments if the obligations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (thereunder were accelerated upon an event of default. ) Tj ET Q
q 0 0 0 rg BT 252.65 214.25 Td (W) Tj ET Q
q 0 0 0 rg BT 261.28 214.25 Td (e may need to conduct asset sales or pursue other alternatives, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.25 Td (proceedings under applicable insolvency laws relating to some or all of our business. ) Tj ET Q
q 0 0 0 rg BT 377.95 202.25 Td (The covenants are also subject to a number of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (exceptions, including the ability to incur certain additional amounts of secured and unsecured indebtedness, which could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.25 Td (exacerbate any of these risks. ) Tj ET Q
q 0 0 0 rg BT 155.39 178.25 Td (Any or all of the above could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.40 178.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 379.28 178.25 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.25 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 166.25 Td (. For a description of our indebtedness, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.87 166.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.25 166.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.74 166.25 Td (Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.25 Td (Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 154.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.59 154.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 157.46 154.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.45 154.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (U.S. federal income tax r) Tj ET Q
q 0 0 0 rg BT 141.90 136.25 Td (eform could adversely affect us.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 118.25 Td (On December 22, 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.31 118.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.09 118.25 Td ( federal tax legislation, commonly referred to as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.27 118.25 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.17 118.25 Td (, was signed into law) Tj ET Q
q 0 0 0 rg BT 495.67 118.25 Td (, significantly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.25 Td (altering the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.76 106.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.54 106.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.04 106.25 Td (Internal Revenue Code \(the Code\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.21 106.25 Td ( ef) Tj ET Q
q 0 0 0 rg BT 251.30 106.25 Td (fective, in substantial part, January 1, 2018. ) Tj ET Q
q 0 0 0 rg BT 428.02 106.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.89 106.25 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.78 106.25 Td (, among other things, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.25 Td (includes:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 82.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 82.25 Td (changes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.49 82.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.27 82.25 Td ( federal tax rates;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 70.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 70.25 Td (expanded limitations on the deductibility of interest;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 58.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 58.25 Td (immediate expensing of capital expenditures;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 46.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 46.25 Td (the migration from a �worldwide� system of taxation to a �territorial� system;) Tj ET Q
endstream
endobj
95 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 96 0 R>>
endobj
96 0 obj
<</Length 16051>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (44) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (the creation of an anti-base erosion minimum tax system; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 730.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (the modification or repeal of many business deductions and credits. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 712.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 112.90 712.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.44 712.10 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.78 712.10 Td ( eliminates the ability to carry back any future net operating losses and only allows for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (carryforwards, the utilization of which is limited to 80% of taxable income in a given carryforward year) Tj ET Q
q 0 0 0 rg BT 451.13 700.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 455.95 700.10 Td (This could af) Tj ET Q
q 0 0 0 rg BT 508.53 700.10 Td (fect the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (timing of our ability to utilize net operating losses in the future.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.10 Td (The aforementioned changes could, individually or in aggregate, increase our future ef) Tj ET Q
q 0 0 0 rg BT 409.07 670.10 Td (fective tax rate and have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.23 670.10 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 658.10 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 658.10 Td (. In addition, prospective or retroactive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (regulatory and administrative guidance relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.69 646.10 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.03 646.10 Td ( could adversely impact our businesses and our current and future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (projections of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.76 634.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.55 634.10 Td ( cash taxes.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (Further) Tj ET Q
q 0 0 0 rg BT 69.70 616.10 Td ( futur) Tj ET Q
q 0 0 0 rg BT 94.24 616.10 Td (e changes to tax laws could materially adversely affect us.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 598.10 Td (Under current law) Tj ET Q
q 0 0 0 rg BT 137.09 598.10 Td (, we expect Endo International plc to be treated as a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.78 598.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.56 598.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.82 598.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.60 598.10 Td ( federal income tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (purposes. However) Tj ET Q
q 0 0 0 rg BT 112.80 586.10 Td (, changes to the rules in Section 7874 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.26 586.10 Td (Code) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.37 586.10 Td ( or regulations promulgated thereunder or other guidance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (issued by the ) Tj ET Q
q 0 0 0 rg BT 90.54 574.10 Td (T) Tj ET Q
q 0 0 0 rg BT 96.29 574.10 Td (reasury or the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.77 574.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.55 574.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.05 574.10 Td (Internal Revenue Service \(IRS\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.84 574.10 Td ( could adversely af) Tj ET Q
q 0 0 0 rg BT 375.46 574.10 Td (fect our status as a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 574.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.93 574.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 562.10 Td ( federal income tax purposes, and any such changes could have prospective or retroactive application to us, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.02 562.10 Td (Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (Solutions Inc. \(EHSI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.94 550.10 Td ( and/or their respective shareholders and af) Tj ET Q
q 0 0 0 rg BT 294.91 550.10 Td (filiates. Consequently) Tj ET Q
q 0 0 0 rg BT 381.46 550.10 Td (, there can be no assurance that there will not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (exist in the future a change in law that might cause us to be treated as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.85 538.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.63 538.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.88 538.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.67 538.10 Td ( federal income tax purposes, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (including with retroactive ef) Tj ET Q
q 0 0 0 rg BT 149.39 526.10 Td (fect.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 508.10 Td (In addition, Ireland�) Tj ET Q
q 0 0 0 rg BT 144.70 508.10 Td (s Department of Finance, Luxembour) Tj ET Q
q 0 0 0 rg BT 294.75 508.10 Td (g�) Tj ET Q
q 0 0 0 rg BT 302.53 508.10 Td (s Ministry of Finance, the Or) Tj ET Q
q 0 0 0 rg BT 418.44 508.10 Td (ganization for Economic Co-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (operation and Development, the European Commission and other government agencies in jurisdictions where we and our af) Tj ET Q
q 0 0 0 rg BT 531.51 496.10 Td (filiates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (do business have had an extended focus on issues related to the taxation of multinational corporations and there are several current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (proposals that, if enacted, would substantially change the taxation of multinational corporations. ) Tj ET Q
q 0 0 0 rg BT 422.85 472.10 Td (As a result, the tax laws in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (jurisdictions in which we operate could change on a prospective or retroactive basis, and any such changes could af) Tj ET Q
q 0 0 0 rg BT 497.61 460.10 Td (fect recorded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (deferred tax assets and liabilities and increase our ef) Tj ET Q
q 0 0 0 rg BT 244.62 448.10 Td (fective tax rate, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.99 448.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 464.88 448.10 Td (fect on our business, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.28 436.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 264.10 436.10 Td (The potential impact of changes in tax laws in such jurisdictions could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (have a material impact on the Company) Tj ET Q
q 0 0 0 rg BT 194.74 424.10 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (The ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 55.17 406.10 Td (IRS) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 71.84 406.10 Td ( may not agr) Tj ET Q
q 0 0 0 rg BT 125.82 406.10 Td (ee with the conclusion that we should be tr) Tj ET Q
q 0 0 0 rg BT 306.76 406.10 Td (eated as a non-) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 370.37 406.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 388.15 406.10 Td ( corporation for) Tj ET Q
q 0 0 0 rg BT 456.29 406.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 458.79 406.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 476.57 406.10 Td ( federal income tax ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (purposes.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.10 Td (Although Endo International plc is incorporated in Ireland, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.71 376.10 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.27 376.10 Td ( may assert that it should be treated as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.88 376.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.67 376.10 Td ( corporation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (\(and, therefore, a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.79 364.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.57 364.10 Td ( tax resident\) for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.44 364.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.22 364.10 Td ( federal income tax purposes pursuant to Section 7874 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.43 364.10 Td (Code) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.54 364.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 481.99 364.10 Td (A) Tj ET Q
q 0 0 0 rg BT 488.66 364.10 Td ( corporation is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (generally considered a tax resident in the jurisdiction of its or) Tj ET Q
q 0 0 0 rg BT 281.30 352.10 Td (ganization or incorporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.82 352.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.60 352.10 Td ( federal income tax purposes. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (Because we are an Irish incorporated entity) Tj ET Q
q 0 0 0 rg BT 208.61 340.10 Td (, we would generally be classified as a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.27 340.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.05 340.10 Td ( corporation \(and, therefore, a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.27 340.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.05 340.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (tax resident\) under these rules. Section 7874 provides an exception pursuant to which a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.62 328.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.41 328.10 Td ( incorporated entity may) Tj ET Q
q 0 0 0 rg BT 520.78 328.10 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (certain circumstances, be treated as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.75 316.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.54 316.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.79 316.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.57 316.10 Td ( federal income tax purposes.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 298.10 Td (Under Section 7874, we would be treated as a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.38 298.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.17 298.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.42 298.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.21 298.10 Td ( federal income tax purposes if the former ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (shareholders of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.87 286.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.09 286.10 Td ( owned, immediately after the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.27 286.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.26 286.10 Td ( transactions \(within the meaning of Section 7874\), less than 80% \(by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (both vote and value\) of Endo shares by reason of holding shares in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.10 274.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.32 274.10 Td ( \(the ownership test\). ) Tj ET Q
q 0 0 0 rg BT 414.07 274.10 Td (The former ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.82 274.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.04 274.10 Td ( shareholders ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (owned less than 80% \(by both vote and value\) of the shares in Endo after the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.91 262.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 262.10 Td ( mer) Tj ET Q
q 0 0 0 rg BT 393.77 262.10 Td (ger by reason of their ownership of shares ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.28 250.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 250.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 72.95 250.10 Td (As a result, under current law) Tj ET Q
q 0 0 0 rg BT 190.59 250.10 Td (, we expect Endo International plc to be treated as a non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.28 250.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.06 250.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.31 250.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.10 250.10 Td ( federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (income tax purposes. ) Tj ET Q
q 0 0 0 rg BT 123.02 238.10 Td (There is limited guidance regarding the application of Section 7874, including with respect to the provisions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (regarding the application of the ownership test. Our obligation to complete the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.30 226.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.30 226.10 Td ( transactions was conditional upon its receipt ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (of a Section 7874 opinion from our counsel, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.14 214.10 Td (Skadden, ) Tj ET Q
q 0 0 0 rg BT 254.02 214.10 Td (Arps, Slate, Meagher & Flom LLP) Tj ET Q
q 0 0 0 rg BT 392.80 214.10 Td ( \(Skadden\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.40 214.10 Td (, dated as of the closing date of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 202.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.71 202.10 Td ( transactions and subject to certain qualifications and limitations set forth therein, to the ef) Tj ET Q
q 0 0 0 rg BT 441.26 202.10 Td (fect that Section 7874 and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (regulations promulgated thereunder should not apply in such a manner so as to cause Endo to be treated as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.43 190.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.21 190.10 Td ( corporation for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 178.10 Td ( federal income tax purposes from and after the closing date. However) Tj ET Q
q 0 0 0 rg BT 334.94 178.10 Td (, an opinion of tax counsel is not binding on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.25 178.10 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.81 178.10 Td ( or a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (court. ) Tj ET Q
q 0 0 0 rg BT 61.37 166.10 Td (Therefore, there can be no assurance that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.66 166.10 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.22 166.10 Td ( will not take a position contrary to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.97 166.10 Td (Skadden) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.41 166.10 Td (�) Tj ET Q
q 0 0 0 rg BT 438.19 166.10 Td (s Section 7874 opinion or that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (a court will not agree with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.46 154.10 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.02 154.10 Td ( in the event of litigation.) Tj ET Q
endstream
endobj
97 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 98 0 R>>
endobj
98 0 obj
<</Length 14665>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (45) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (The effective rate of taxation upon our) Tj ET Q
q 0 0 0 rg BT 200.23 742.25 Td ( r) Tj ET Q
q 0 0 0 rg BT 206.99 742.25 Td (esults of operations is dependent on multi-national tax considerations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 724.25 Td (e earn a portion of our income outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.31 724.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.09 724.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 261.41 724.25 Td (That portion of our earnings is generally taxed at the rates applicable to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (activities undertaken by our subsidiaries outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.50 712.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.29 712.25 Td ( Our ef) Tj ET Q
q 0 0 0 rg BT 302.43 712.25 Td (fective income tax rate in the future could be adversely af) Tj ET Q
q 0 0 0 rg BT 532.69 712.25 Td (fected ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (by a number of factors, including changes in the mix of earnings in countries with dif) Tj ET Q
q 0 0 0 rg BT 377.40 700.25 Td (fering statutory tax rates, changes in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (valuation of deferred tax assets and liabilities, changes in tax laws, the outcome of income tax audits and the repatriation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (earnings from our subsidiaries for which we have not provided for taxes. Cash repatriations are subject to restrictions in certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (jurisdictions and may be subject to withholding and other taxes. ) Tj ET Q
q 0 0 0 rg BT 293.83 664.25 Td (W) Tj ET Q
q 0 0 0 rg BT 302.46 664.25 Td (e periodically assess our tax positions to determine the adequacy ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (of our tax provisions, which are subject to significant discretion. ) Tj ET Q
q 0 0 0 rg BT 295.39 652.25 Td (Although we believe our tax provisions are adequate, the final ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (determination of tax audits and any related disputes could be materially dif) Tj ET Q
q 0 0 0 rg BT 335.45 640.25 Td (ferent from our historical income tax provisions and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (accruals. ) Tj ET Q
q 0 0 0 rg BT 73.57 628.25 Td (The results of audits and disputes could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.69 628.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 338.58 628.25 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 616.25 Td ( for the period or periods for which the applicable final determinations are made.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.25 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 598.25 Td (e may not be able to successfully maintain our) Tj ET Q
q 0 0 0 rg BT 241.38 598.25 Td ( low tax rates or) Tj ET Q
q 0 0 0 rg BT 310.06 598.25 Td ( other) Tj ET Q
q 0 0 0 rg BT 335.15 598.25 Td ( tax positions, which could adversely affect our) Tj ET Q
q 0 0 0 rg BT 534.41 598.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (businesses and financial condition, r) Tj ET Q
q 0 0 0 rg BT 190.02 586.25 Td (esults of operations and gr) Tj ET Q
q 0 0 0 rg BT 302.63 586.25 Td (owth pr) Tj ET Q
q 0 0 0 rg BT 336.06 586.25 Td (ospects) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 366.61 586.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 568.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 568.25 Td (e are incorporated in Ireland and also maintain subsidiaries in, among other jurisdictions, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.87 568.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 568.25 Td (, Canada, India, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (United Kingdom and Luxembour) Tj ET Q
q 0 0 0 rg BT 169.41 556.25 Td (g. ) Tj ET Q
q 0 0 0 rg BT 179.23 556.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.27 556.25 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.84 556.25 Td ( and other taxing authorities may continue to challenge our tax positions. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.75 556.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.80 556.25 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.36 556.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (presently is examining certain of our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 235.20 544.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.70 544.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.49 544.25 Td ( income tax returns for fiscal years ended between December 31, 201) Tj ET Q
q 0 0 0 rg BT 532.23 544.25 Td (1 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (December 31, 2015 and, in connection with those examinations, is reviewing our tax positions related to, among other things, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (certain intercompany arrangements, including the level of profit earned by our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.99 520.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.77 520.25 Td ( subsidiaries pursuant to such arrangements, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (and a worthless stock deduction directly attributable to product liability losses. ) Tj ET Q
q 0 0 0 rg BT 352.97 508.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.02 508.25 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.58 508.25 Td ( may examine our tax returns for other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (fiscal years and/or for other tax positions. Similarly) Tj ET Q
q 0 0 0 rg BT 241.42 496.25 Td (, other tax authorities, including the Canada Revenue ) Tj ET Q
q 0 0 0 rg BT 455.80 496.25 Td (Agency) Tj ET Q
q 0 0 0 rg BT 486.25 496.25 Td (, are currently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (examining our non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.87 484.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.66 484.25 Td ( tax returns. ) Tj ET Q
q 0 0 0 rg BT 182.09 484.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 231.99 484.25 Td (, other jurisdictions where we are not currently under audit remain subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.25 Td (potential future examinations. Such examinations may lead to proposed or actual adjustments to our taxes that may be material, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (individually or in the aggregate.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 442.25 Td (Responding to or defending any challenge or proposed adjustment to our tax positions is expensive, consumes time and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (other resources and diverts management�) Tj ET Q
q 0 0 0 rg BT 199.83 430.25 Td (s attention. ) Tj ET Q
q 0 0 0 rg BT 246.03 430.25 Td (W) Tj ET Q
q 0 0 0 rg BT 254.67 430.25 Td (e cannot predict whether taxing authorities will conduct an audit challenging ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (any of our tax positions, the cost involved in responding to and defending any such audit and resulting litigation, or the outcome. If ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (we are unsuccessful in any of these matters, we may be required to pay taxes for prior periods, interest, fines or penalties, and may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (be obligated to pay increased taxes in the future or repay certain tax refunds, any of which could require us to reduce our operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (costs, decrease ef) Tj ET Q
q 0 0 0 rg BT 105.50 382.25 Td (forts in support of our products or seek to raise additional funds, all of which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.47 382.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 544.35 382.25 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.50 370.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (Our) Tj ET Q
q 0 0 0 rg BT 53.60 352.25 Td ( ability to use ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 113.05 352.25 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 130.83 352.25 Td ( tax attributes to offset ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 229.97 352.25 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 247.75 352.25 Td ( taxable income may be limited.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 334.25 Td (Existing and future tax laws and regulations may limit our ability to use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.67 334.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.45 334.25 Td ( tax attributes including, but not limited to, net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (operating losses and excess interest expense, to of) Tj ET Q
q 0 0 0 rg BT 235.76 322.25 Td (fset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.70 322.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.48 322.25 Td ( taxable income. For a period of time following the 2014 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.87 322.25 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.87 322.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (transactions, Section 7874 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 310.25 Td (Code) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.41 310.25 Td ( precludes our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.56 310.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.34 310.25 Td ( af) Tj ET Q
q 0 0 0 rg BT 277.43 310.25 Td (filiates from utilizing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.91 310.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.69 310.25 Td ( tax attributes to of) Tj ET Q
q 0 0 0 rg BT 458.05 310.25 Td (fset taxable income if we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (complete certain transactions with related non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.43 298.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.21 298.25 Td ( subsidiaries. In addition, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.25 298.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.03 298.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 379.35 298.25 Td (T) Tj ET Q
q 0 0 0 rg BT 385.11 298.25 Td (reasury Department has issued temporary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (and proposed regulations related to corporate inversions and earnings stripping. ) Tj ET Q
q 0 0 0 rg BT 356.57 286.25 Td (The limitations on the use of certain tax attributes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (and deductions in these regulations are in addition to existing rules that could impose more restrictive limitations in the event that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (cumulative changes in our stock ownership within a three-year period exceeded certain thresholds. Such changes or the adoption of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.25 Td (additional limitations could impact our overall utilization of deferred tax assets, potentially resulting in a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.00 250.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 532.88 250.25 Td (fect on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 238.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (If pharmaceutical companies ar) Tj ET Q
q 0 0 0 rg BT 171.63 220.25 Td (e successful in limiting the use of generics thr) Tj ET Q
q 0 0 0 rg BT 363.66 220.25 Td (ough their) Tj ET Q
q 0 0 0 rg BT 407.65 220.25 Td ( legislative, r) Tj ET Q
q 0 0 0 rg BT 461.62 220.25 Td (egulatory and other) Tj ET Q
q 0 0 0 rg BT 545.87 220.25 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (efforts, our) Tj ET Q
q 0 0 0 rg BT 83.58 208.25 Td ( sales of generic pr) Tj ET Q
q 0 0 0 rg BT 162.82 208.25 Td (oducts may suffer) Tj ET Q
q 0 0 0 rg BT 238.01 208.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 190.25 Td (Many pharmaceutical companies increasingly have used state and federal legislative and regulatory means to delay generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.25 Td (competition. ) Tj ET Q
q 0 0 0 rg BT 88.59 178.25 Td (These ef) Tj ET Q
q 0 0 0 rg BT 122.55 178.25 Td (forts have included:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 166.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 166.25 Td (pursuing new patents for existing products which may be granted just before the expiration of earlier patents, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 154.25 Td (could extend patent protection for additional years;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 142.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 142.25 Td (using the Citizen Petition process \(for example, under 21 C.F) Tj ET Q
q 0 0 0 rg BT 329.93 142.25 Td (.R. � 10.30\) to request amendments to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.91 142.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.36 142.25 Td ( standards;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 130.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 130.25 Td (attempting to use the legislative and regulatory process to have products reclassified or rescheduled or to set ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 118.25 Td (definitions of abuse-deterrent formulations to protect patents and profits; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 106.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 106.25 Td (engaging in state-by-state initiatives to enact legislation that restricts the substitution of some generic products.) Tj ET Q
endstream
endobj
99 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 100 0 R>>
endobj
100 0 obj
<</Length 11245>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (46) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (If pharmaceutical companies or other third parties are successful in limiting the use of generic products through these or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (other means, our sales of generic products and our growth prospects may decline, which could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.48 730.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 520.37 730.10 Td (fect on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 718.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 318.82 718.10 Td (W) Tj ET Q
q 0 0 0 rg BT 327.46 718.10 Td (e cannot determine what ef) Tj ET Q
q 0 0 0 rg BT 435.56 718.10 Td (fect Section 610 of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.58 718.10 Td (FCAA) Tj ET Q
q 0 0 0 rg BT 554.71 718.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 706.10 Td ( may have on limiting or preventing the success of pharmaceutical companies or other third parties in delaying generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (competition.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 676.10 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 676.10 Td (e incorporated in Ir) Tj ET Q
q 0 0 0 rg BT 145.62 676.10 Td (eland and Irish law differs fr) Tj ET Q
q 0 0 0 rg BT 268.50 676.10 Td (om the laws in effect in the ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 384.87 676.10 Td (U.S.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 402.65 676.10 Td ( and may afford less pr) Tj ET Q
q 0 0 0 rg BT 501.08 676.10 Td (otection to, or) Tj ET Q
q 0 0 0 rg BT 560.05 676.10 Td ( ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (otherwise adversely affect, our) Tj ET Q
q 0 0 0 rg BT 166.33 664.10 Td ( shar) Tj ET Q
q 0 0 0 rg BT 187.54 664.10 Td (eholders.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.10 Td (Our shareholders may have more dif) Tj ET Q
q 0 0 0 rg BT 209.16 646.10 Td (ficulty protecting their interests than would shareholders of a corporation incorporated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (in a jurisdiction of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.82 634.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.60 634.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 146.55 634.10 Td (As an Irish company) Tj ET Q
q 0 0 0 rg BT 228.93 634.10 Td (, we are governed by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.01 634.10 Td (Irish Companies ) Tj ET Q
q 0 0 0 rg BT 382.78 634.10 Td (Act 2014 \(the Companies ) Tj ET Q
q 0 0 0 rg BT 487.21 634.10 Td (Act\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.98 634.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 509.80 634.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (Companies ) Tj ET Q
q 0 0 0 rg BT 82.94 622.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.38 622.10 Td ( and other relevant aspects of Irish law dif) Tj ET Q
q 0 0 0 rg BT 265.47 622.10 Td (fer in some material respects from laws generally applicable to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.26 622.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.04 622.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (corporations and shareholders, including, among others, the provisions relating to interested director and of) Tj ET Q
q 0 0 0 rg BT 465.15 610.10 Td (ficer transactions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (acquisitions, takeovers, shareholder lawsuits and indemnification of directors. For example, under Irish law) Tj ET Q
q 0 0 0 rg BT 465.23 598.10 Td (, the duties of directors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (and of) Tj ET Q
q 0 0 0 rg BT 61.09 586.10 Td (ficers of a company are generally owed to the company only) Tj ET Q
q 0 0 0 rg BT 302.57 586.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 307.02 586.10 Td (As a result, shareholders of Irish companies generally do not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (have a personal right of action against the directors or of) Tj ET Q
q 0 0 0 rg BT 261.85 574.10 Td (ficers of a company and may pursue a right of action on behalf of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (company only in limited circumstances. In addition, depending on the circumstances, the acquisition, ownership and/or disposition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (of our ordinary shares may subject individuals to dif) Tj ET Q
q 0 0 0 rg BT 245.22 550.10 Td (ferent or additional tax consequences under Irish law including, but not limited ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (to, Irish stamp duty) Tj ET Q
q 0 0 0 rg BT 113.12 538.10 Td (, dividend withholding tax and capital acquisitions tax.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.70 Td (Any attempts to take us over) Tj ET Q
q 0 0 0 rg BT 158.30 514.70 Td ( will be subject to Irish ) Tj ET Q
q 0 0 0 rg BT 258.12 514.70 Td (T) Tj ET Q
q 0 0 0 rg BT 263.88 514.70 Td (akeover) Tj ET Q
q 0 0 0 rg BT 297.57 514.70 Td ( Rules and subject to r) Tj ET Q
q 0 0 0 rg BT 393.23 514.70 Td (eview by the Irish ) Tj ET Q
q 0 0 0 rg BT 471.38 514.70 Td (T) Tj ET Q
q 0 0 0 rg BT 477.13 514.70 Td (akeover) Tj ET Q
q 0 0 0 rg BT 510.82 514.70 Td ( Panel.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 496.70 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 496.70 Td (e are subject to Irish ) Tj ET Q
q 0 0 0 rg BT 155.04 496.70 Td (T) Tj ET Q
q 0 0 0 rg BT 160.45 496.70 Td (akeover Rules, under which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.29 496.70 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.73 496.70 Td ( will not be permitted to take any action which might frustrate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.70 Td (an of) Tj ET Q
q 0 0 0 rg BT 56.09 484.70 Td (fer for our ordinary shares once it has received an approach which may lead to an of) Tj ET Q
q 0 0 0 rg BT 392.43 484.70 Td (fer or has reason to believe an of) Tj ET Q
q 0 0 0 rg BT 523.03 484.70 Td (fer is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.70 Td (imminent.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.70 Td (W) Tj ET Q
q 0 0 0 rg BT 45.45 454.70 Td (e ar) Tj ET Q
q 0 0 0 rg BT 61.64 454.70 Td (e an Irish company and it may be difficult to enfor) Tj ET Q
q 0 0 0 rg BT 276.46 454.70 Td (ce judgments against us or) Tj ET Q
q 0 0 0 rg BT 389.62 454.70 Td ( certain of our) Tj ET Q
q 0 0 0 rg BT 450.25 454.70 Td ( officers and dir) Tj ET Q
q 0 0 0 rg BT 518.12 454.70 Td (ectors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 436.70 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 436.70 Td (e are incorporated in Ireland and a substantial portion of our assets are located in jurisdictions outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.84 436.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.62 436.70 Td ( In addition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.70 Td (some of our of) Tj ET Q
q 0 0 0 rg BT 94.42 424.70 Td (ficers and directors reside outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.03 424.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.81 424.70 Td (, and some or all of their respective assets are or may be located in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.70 Td (jurisdictions outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.88 412.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.66 412.70 Td ( It may be dif) Tj ET Q
q 0 0 0 rg BT 216.35 412.70 Td (ficult for investors to ef) Tj ET Q
q 0 0 0 rg BT 310.59 412.70 Td (fect service of process against us or such of) Tj ET Q
q 0 0 0 rg BT 484.24 412.70 Td (ficers or directors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.70 Td (or to enforce against us or them judgments of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.12 400.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.90 400.70 Td ( courts predicated upon civil liability provisions of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.58 400.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.37 400.70 Td ( federal securities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.70 Td (laws.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 370.70 Td (There is no treaty between Ireland and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.04 370.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.82 370.70 Td ( providing for the reciprocal enforcement of foreign judgments. ) Tj ET Q
q 0 0 0 rg BT 508.21 370.70 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.70 Td (following requirements must be met before a foreign judgment will be deemed to be enforceable in Ireland:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 346.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 346.70 Td ( the judgment must be for a definite sum;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 334.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 334.70 Td ( the judgment must be final and conclusive; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 322.70 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 322.70 Td ( the judgment must be provided by a court of competent jurisdiction.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 304.70 Td (An Irish court will also exercise its right to refuse judgment if the foreign judgment was obtained by fraud, if the judgment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.70 Td (violated Irish public policy) Tj ET Q
q 0 0 0 rg BT 143.38 292.70 Td (, if the judgment is in breach of natural justice or if it is irreconcilable with an earlier judgment. Further) Tj ET Q
q 0 0 0 rg BT 556.46 292.70 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.70 Td (an Irish court may stay proceedings if concurrent proceedings are being brought elsewhere. Judgments of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.75 280.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.53 280.70 Td ( courts of liabilities ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.70 Td (predicated upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.64 268.70 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.42 268.70 Td ( federal securities laws may not be enforced by Irish courts if deemed to be contrary to public policy in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.70 Td (Ireland.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.70 Td (Item 1B.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 72.66 238.70 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 238.70 Td (Unresolved Staf) Tj ET Q
q 0 0 0 rg BT 173.65 238.70 Td (f Comments) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 220.70 Td (None.) Tj ET Q
endstream
endobj
101 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 102 0 R>>
endobj
102 0 obj
<</Length 9929>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (47) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Item 2.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 742.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 742.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 742.25 Td (Properties) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (This section provides information about the location and general character of the Company�) Tj ET Q
q 0 0 0 rg BT 430.10 724.25 Td (s principal physical properties at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 712.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 694.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 694.25 Td (s global headquarters is located in Dublin, Ireland. ) Tj ET Q
q 0 0 0 rg BT 326.92 694.25 Td (The Company also conducts certain corporate functions at its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (Malvern, Pennsylvania location. Both properties are leased. ) Tj ET Q
q 0 0 0 rg BT 276.86 682.25 Td (The Malvern lease is described in more detail in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.07 682.25 Td (Note 8. Leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.21 682.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.87 670.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.58 670.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 252.45 670.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.43 670.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 347.25 670.25 Td (These locations support each of our reportable segments. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (For example, our global quality and supply chain functions are run from our global headquarters. ) Tj ET Q
q 0 0 0 rg BT 426.55 658.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 486.26 658.25 Td (s segments conduct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (certain additional business functions, including manufacturing, distribution, quality assurance, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.64 646.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.31 646.25 Td ( and administration, at locations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (throughout the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.10 634.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.89 634.25 Td ( and select global markets. ) Tj ET Q
q 0 0 0 rg BT 223.19 634.25 Td (Additional information about the properties of the Company�) Tj ET Q
q 0 0 0 rg BT 467.30 634.25 Td (s reportable segments is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.25 Td (set forth below:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 610.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 610.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.40 610.25 Td (: ) Tj ET Q
q 0 0 0 rg BT 192.50 610.25 Td (This segment also conducts certain operations in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.11 610.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.90 610.25 Td ( through leased and owned ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 598.25 Td (manufacturing properties in Pennsylvania, New ) Tj ET Q
q 0 0 0 rg BT 278.41 598.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 284.63 598.25 Td (ork and New Jersey) Tj ET Q
q 0 0 0 rg BT 363.12 598.25 Td (, as well as certain administrative and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.85 598.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.52 598.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 586.25 Td (functions through leased properties in Pennsylvania.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 574.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 574.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.41 574.25 Td (: ) Tj ET Q
q 0 0 0 rg BT 162.51 574.25 Td (This segment also conducts certain manufacturing, quality assurance, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.42 574.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.09 574.25 Td ( and administration) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.30 574.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 562.25 Td (functions in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.21 562.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 562.25 Td ( through owned and leased properties in Michigan, as well as certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.86 562.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.53 562.25 Td ( and administration ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 550.25 Td (functions in New ) Tj ET Q
q 0 0 0 rg BT 156.51 550.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 162.73 550.25 Td (ork and in India in the same facilities as our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.45 550.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.12 550.25 Td ( segment, as discussed below) Tj ET Q
q 0 0 0 rg BT 556.40 550.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 538.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 538.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.17 538.25 Td (: ) Tj ET Q
q 0 0 0 rg BT 190.27 538.25 Td (This segment also conducts certain manufacturing, distribution, quality assurance and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 526.25 Td (administration functions, as well as certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.06 526.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.73 526.25 Td ( functions, through owned and leased properties throughout the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.23 526.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.02 526.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 514.25 Td (including in New ) Tj ET Q
q 0 0 0 rg BT 157.06 514.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 163.28 514.25 Td (ork and California. It also conducts significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.57 514.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.24 514.25 Td ( operations, as well as certain manufacturing and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 502.25 Td (administrative functions, in India through owned and leased facilities in Chennai and Mumbai.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 490.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 490.25 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.62 490.25 Td (: ) Tj ET Q
q 0 0 0 rg BT 209.71 490.25 Td (This segment�) Tj ET Q
q 0 0 0 rg BT 266.10 490.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.49 490.25 Td (operations are currently conducted through ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.15 490.25 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.14 490.25 Td (�) Tj ET Q
q 0 0 0 rg BT 479.92 490.25 Td (s leased headquarters ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.38 490.25 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 478.25 Td (Montreal, Canada.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 460.25 Td (December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 460.25 Td (, our owned and leased properties consist of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.29 460.25 Td (1.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.19 460.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.62 460.25 Td (1.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.52 460.25 Td ( square feet, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (respectively) Tj ET Q
q 0 0 0 rg BT 83.66 448.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 88.48 448.25 Td (W) Tj ET Q
q 0 0 0 rg BT 97.12 448.25 Td (e believe our properties are suitable and adequate to support our current and projected operations in all material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (respects.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (Item 3.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 418.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 418.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 418.25 Td (Legal Proceedings) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 400.25 Td (The disclosures under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.25 400.25 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.51 400.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.01 400.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.88 400.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.59 400.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 567.46 400.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.98 388.25 Td ( are incorporated into this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.22 388.25 Td (Part I, Item 3) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.99 388.25 Td ( by reference.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (Item 4.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 370.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 370.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 370.25 Td (Mine Safety Disclosures) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 352.25 Td (Not applicable.) Tj ET Q
endstream
endobj
103 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 104 0 R>>
endobj
104 0 obj
<</Length 13144>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (48) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 287.85 742.25 Td (P) Tj ET Q
q 0 0 0 rg BT 293.22 742.25 Td (AR) Tj ET Q
q 0 0 0 rg BT 307.31 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 313.80 742.25 Td ( II ) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 724.25 Td (Item 5.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 724.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 724.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 724.25 Td (Market for Registrant�) Tj ET Q
q 0 0 0 rg BT 200.60 724.25 Td (s Common Equity) Tj ET Q
q 0 0 0 rg BT 274.13 724.25 Td (, Related Stockholder Matters and Issuer Purchases of Equity Securities) Tj ET Q
BT /F4 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 706.25 Td (Market Information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.66 706.25 Td ( Our ordinary shares are traded on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.48 706.25 Td (NASDAQ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.15 706.25 Td ( under the ticker symbol �ENDP) Tj ET Q
q 0 0 0 rg BT 469.29 706.25 Td (.�) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.25 Td (Holders) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.22 688.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 99.67 688.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.11 688.25 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.71 688.25 Td (, we estimate that there were approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.86 688.25 Td (75) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.86 688.25 Td ( holders of record of our ordinary shares.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.25 Td (Dividends.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.05 670.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 108.37 670.25 Td (W) Tj ET Q
q 0 0 0 rg BT 117.00 670.25 Td (e have never declared or paid any cash dividends on our ordinary shares and we currently have no plans to declare ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (a dividend. ) Tj ET Q
q 0 0 0 rg BT 82.75 658.25 Td (W) Tj ET Q
q 0 0 0 rg BT 91.39 658.25 Td (e are permitted to pay dividends subject to limitations imposed by Irish law) Tj ET Q
q 0 0 0 rg BT 392.35 658.25 Td (, the various agreements and indentures ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (governing our indebtedness and the existence of suf) Tj ET Q
q 0 0 0 rg BT 243.26 646.25 Td (ficient distributable reserves. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.55 646.25 Td (For example, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.53 646.25 Td (Companies ) Tj ET Q
q 0 0 0 rg BT 478.48 646.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.91 646.25 Td ( requires Irish ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (companies to have distributable reserves equal to or greater than the amount of any proposed dividend. Unless we are able to generate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.25 Td (suf) Tj ET Q
q 0 0 0 rg BT 48.04 622.25 Td (ficient distributable reserves or create distributable reserves by reducing our share premium account, we will not be able to pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.25 Td (dividends.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 592.25 Td (Performance Graph.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.32 592.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 148.64 592.25 Td (The following graph provides a comparison of the cumulative total shareholder return on the Company�) Tj ET Q
q 0 0 0 rg BT 563.53 592.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (ordinary shares with that of the cumulative total shareholder return on the \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.07 580.25 Td (NASDAQ Composite Index) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.84 580.25 Td ( and \(ii\) the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.71 580.25 Td (NASDAQ ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (Pharmaceutical Index) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.90 568.25 Td (, commencing on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.55 568.25 Td (December�31, 2014) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.14 568.25 Td ( and ending ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.29 568.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.88 568.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 405.70 568.25 Td (The graph assumes $100 invested on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (December�31, 2014) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 556.25 Td ( in the Company�) Tj ET Q
q 0 0 0 rg BT 183.74 556.25 Td (s ordinary shares and in each of the comparative indices. Our historic share price performance is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (not necessarily indicative of future share price performance.) Tj ET Q
/GS0 gs
q 436.00 0 0 297.00 88.00 236.25 cm
/I21 Do Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 199.75 142.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
177.50 199.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
240.50 199.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
244.50 199.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
307.50 199.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
311.50 199.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
374.50 199.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
378.50 199.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 199.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
445.50 199.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
508.50 199.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
512.50 199.75 63.00 -15.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
35.50 184.75 142.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 169.75 142.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
177.50 169.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
240.50 169.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
244.50 169.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
307.50 169.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
311.50 169.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
374.50 169.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
378.50 169.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 169.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
445.50 169.75 63.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
508.50 169.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
512.50 169.75 63.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
177.5 212.75 m
240.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
240.5 212.75 m
244.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
244.5 212.75 m
307.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
307.5 212.75 m
311.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
311.5 212.75 m
374.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
374.5 212.75 m
378.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
378.5 212.75 m
441.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 212.75 m
445.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
445.5 212.75 m
508.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
508.5 212.75 m
512.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
512.5 212.75 m
575.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
177.5 212.75 m
240.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
177.5 199.75 m
240.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
244.5 212.75 m
307.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
244.5 199.75 m
307.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
311.5 212.75 m
374.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
311.5 199.75 m
374.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
378.5 212.75 m
441.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
378.5 199.75 m
441.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
445.5 212.75 m
508.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
445.5 199.75 m
508.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
512.5 212.75 m
575.5 212.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
512.5 199.75 m
575.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
311.5 199.75 m
374.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
378.5 199.75 m
441.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
445.5 199.75 m
508.5 199.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
512.5 199.75 m
575.5 199.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 352.75 216.98 Td (December) Tj ET Q
q 0 0 0 rg BT 387.32 216.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 200.50 203.98 Td (2014) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 267.50 203.98 Td (2015) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 334.50 203.98 Td (2016) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 401.50 203.98 Td (2017) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 468.50 203.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 535.50 203.98 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 189.42 Td (Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.15 189.42 Td (100.00) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.15 189.42 Td (84.89) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.15 189.42 Td (22.84) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.15 189.42 Td (10.75) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.15 189.42 Td (10.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.00 189.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.15 189.42 Td (6.50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 174.42 Td (NASDAQ Composite Index) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.15 174.42 Td (100.00) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.15 174.42 Td (106.96) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.15 174.42 Td (1) Tj ET Q
q 0 0 0 rg BT 348.15 174.42 Td (16.45) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.15 174.42 Td (150.96) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.15 174.42 Td (146.67) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.00 174.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 174.42 Td (200.49) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 159.42 Td (NASDAQ Pharmaceutical Index) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.15 159.42 Td (100.00) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.15 159.42 Td (103.06) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.15 159.42 Td (81.93) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.15 159.42 Td (98.23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.15 159.42 Td (92.83) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.00 159.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 159.42 Td (109.06) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 137.25 Td (Recent sales of unr) Tj ET Q
q 0 0 0 rg BT 139.00 137.25 Td (egister) Tj ET Q
q 0 0 0 rg BT 165.85 137.25 Td (ed securities; Use of pr) Tj ET Q
q 0 0 0 rg BT 258.79 137.25 Td (oceeds fr) Tj ET Q
q 0 0 0 rg BT 294.80 137.25 Td (om r) Tj ET Q
q 0 0 0 rg BT 313.04 137.25 Td (egister) Tj ET Q
q 0 0 0 rg BT 339.88 137.25 Td (ed securities. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.15 137.25 Td (There were no unregistered sales of equity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.25 Td (securities by the Company during the three years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.65 125.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.24 125.25 Td (.) Tj ET Q
endstream
endobj
105 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 106 0 R>>
endobj
106 0 obj
<</Length 11518>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (49) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Pur) Tj ET Q
q 0 0 0 rg BT 77.63 742.10 Td (chase of Equity Securities by the issuer and affiliated pur) Tj ET Q
q 0 0 0 rg BT 306.39 742.10 Td (chasers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.94 742.10 Td (The following table reflects purchases of Endo ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (International plc ordinary shares by the Company during the three months ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.91 730.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.50 730.10 Td (:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 674.60 204.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
239.50 674.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
243.50 674.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 674.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 674.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
407.50 674.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
411.50 674.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
491.50 674.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
495.50 674.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 644.60 204.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
239.50 644.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
243.50 644.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 644.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 644.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
407.50 644.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
411.50 644.60 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
491.50 644.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
495.50 644.60 80.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 674.6 m
239.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
243.5 674.6 m
323.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 674.6 m
407.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 674.6 m
491.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 674.6 m
575.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 674.6 m
239.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
243.5 674.6 m
323.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 674.6 m
407.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 674.6 m
491.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 674.6 m
575.5 674.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
243.5 629.6 m
323.5 629.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
243.5 615.6 m
323.5 615.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
243.5 613.6 m
323.5 613.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 629.6 m
491.5 629.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 615.6 m
491.5 615.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 613.6 m
491.5 613.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 678.83 Td (Period) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 254.75 686.83 Td (T) Tj ET Q
q 0 0 0 rg BT 259.72 686.83 Td (otal Number) Tj ET Q
q 0 0 0 rg BT 302.61 686.83 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 252.55 678.83 Td (Shar) Tj ET Q
q 0 0 0 rg BT 268.93 678.83 Td (es Pur) Tj ET Q
q 0 0 0 rg BT 290.33 678.83 Td (chased) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 334.40 686.83 Td (A) Tj ET Q
q 0 0 0 rg BT 339.88 686.83 Td (verage Price Paid) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 350.35 678.83 Td (per) Tj ET Q
q 0 0 0 rg BT 361.83 678.83 Td ( Shar) Tj ET Q
q 0 0 0 rg BT 380.13 678.83 Td (e) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 422.75 702.83 Td (T) Tj ET Q
q 0 0 0 rg BT 427.72 702.83 Td (otal Number) Tj ET Q
q 0 0 0 rg BT 470.61 702.83 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 416.00 694.83 Td (Shar) Tj ET Q
q 0 0 0 rg BT 432.38 694.83 Td (es Pur) Tj ET Q
q 0 0 0 rg BT 453.78 694.83 Td (chased as) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 424.10 686.83 Td (Part of Publicly) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 422.65 678.83 Td (Announced Plan) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 500.55 710.83 Td (Appr) Tj ET Q
q 0 0 0 rg BT 518.63 710.83 Td (oximate Dollar) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 500.65 702.83 Td (V) Tj ET Q
q 0 0 0 rg BT 505.69 702.83 Td (alue of Shar) Tj ET Q
q 0 0 0 rg BT 546.88 702.83 Td (es that) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 515.80 694.83 Td (May ) Tj ET Q
q 0 0 0 rg BT 533.05 694.83 Td (Y) Tj ET Q
q 0 0 0 rg BT 537.94 694.83 Td (et be) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 498.90 686.83 Td (Pur) Tj ET Q
q 0 0 0 rg BT 511.64 686.83 Td (chased Under) Tj ET Q
q 0 0 0 rg BT 558.39 686.83 Td ( the) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 521.55 678.83 Td (Plan \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 664.27 Td (October 1, 2019 to October 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.65 664.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 664.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.65 664.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.00 664.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.15 664.27 Td (2,250,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 649.27 Td (November 1, 2019 to November 30, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.65 649.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 649.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.65 649.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.00 649.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.15 649.27 Td (2,250,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 634.27 Td (December 1, 2019 to December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.65 634.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 634.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.65 634.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.00 634.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.15 634.27 Td (2,250,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 619.27 Td (Three months ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.65 619.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 619.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.65 619.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 603.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 48.45 593.50 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 593.50 Td (Pursuant to ) Tj ET Q
q 0 0 0 rg BT 104.23 593.50 Td (Article 1) Tj ET Q
q 0 0 0 rg BT 132.15 593.50 Td (1 of the Company�) Tj ET Q
q 0 0 0 rg BT 191.91 593.50 Td (s ) Tj ET Q
q 0 0 0 rg BT 196.59 593.50 Td (Articles of ) Tj ET Q
q 0 0 0 rg BT 232.13 593.50 Td (Association, the Company has broad shareholder authority to conduct ordinary share repurchases by way ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 583.90 Td (of redemptions. ) Tj ET Q
q 0 0 0 rg BT 118.22 583.90 Td (As permitted by Irish Law and the Company�) Tj ET Q
q 0 0 0 rg BT 263.30 583.90 Td (s ) Tj ET Q
q 0 0 0 rg BT 267.97 583.90 Td (Articles of ) Tj ET Q
q 0 0 0 rg BT 303.52 583.90 Td (Association, any ordinary shares redeemed shall be cancelled upon redemption. ) Tj ET Q
q 0 0 0 rg BT 560.18 583.90 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 574.30 Td (Board) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 86.00 574.30 Td ( has approved the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 144.20 574.30 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 240.41 574.30 Td ( that authorizes the Company to redeem, in the aggregate, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 427.01 574.30 Td ($2.5 billion) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 463.90 574.30 Td ( of its outstanding ordinary shares. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 564.70 Td (Redemptions under this program may be made from time to time in open market or negotiated transactions or otherwise, as determined by the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 522.77 564.70 Td (Board) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 542.32 564.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 546.18 564.70 Td (This ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 555.10 Td (program does not obligate the Company to redeem any particular amount of ordinary shares. ) Tj ET Q
q 0 0 0 rg BT 364.66 555.10 Td (T) Tj ET Q
q 0 0 0 rg BT 368.99 555.10 Td (o date, the Company has redeemed and cancelled approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 545.50 Td (4.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 101.56 545.50 Td ( of its ordinary shares under the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 204.87 545.50 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 301.07 545.50 Td ( for ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 314.40 545.50 Td ($250.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 361.51 545.50 Td (, not including related fees. ) Tj ET Q
q 0 0 0 rg BT 450.45 545.50 Td (W) Tj ET Q
q 0 0 0 rg BT 457.36 545.50 Td (e currently do not intend to conduct ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 535.90 Td (ordinary share repurchases in the foreseeable future. Future redemptions, if any) Tj ET Q
q 0 0 0 rg BT 320.06 535.90 Td (, will depend on factors such as levels of cash generation from operations, cash ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 526.30 Td (requirements for investment in the Company�) Tj ET Q
q 0 0 0 rg BT 211.97 526.30 Td (s business, repayment of future debt, if any) Tj ET Q
q 0 0 0 rg BT 349.42 526.30 Td (, the then current share price, market conditions, legal limitations, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 516.70 Td (suf) Tj ET Q
q 0 0 0 rg BT 76.08 516.70 Td (ficient distributable reserves and other factors. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 226.47 516.70 Td (For example, the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 282.45 516.70 Td (Companies ) Tj ET Q
q 0 0 0 rg BT 320.01 516.70 Td (Act) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 331.56 516.70 Td ( requires Irish companies to have distributable reserves equal to or greater ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 507.10 Td (than the amount of any proposed ordinary share repurchase amount. Unless we are able to generate suf) Tj ET Q
q 0 0 0 rg BT 395.30 507.10 Td (ficient distributable reserves or create distributable ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 497.50 Td (reserves by reducing our share premium account, we will not be able to repurchase our ordinary shares) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 395.44 497.50 Td (. ) Tj ET Q
q 0 0 0 rg BT 399.30 497.50 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 413.74 497.50 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 509.94 497.50 Td ( may be suspended, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 66.45 487.90 Td (modified or discontinued at any time.) Tj ET Q
endstream
endobj
107 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 108 0 R>>
endobj
108 0 obj
<</Length 29177>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (50) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Item 6.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 742.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 742.25 Td (Selected Financial Data) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (The following tables present selected consolidated financial data for the periods indicated below \(in thousands, except per share ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (data\). ) Tj ET Q
q 0 0 0 rg BT 60.80 712.25 Td (This data has been derived from our financial statements and should be read in conjunction with Part II, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.18 712.25 Td (Item 7 of this report ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (�Management�) Tj ET Q
q 0 0 0 rg BT 95.42 700.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 164.59 700.25 Td (Analysis of Financial Condition and Results of Operations�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.17 700.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.61 700.25 Td (Part II, Item 8 of this report ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (�Financial Statements and Supplementary Data�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.83 688.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 234.65 688.25 Td (The selected data in this section is not intended to replace the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.34 688.25 Td (Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 676.25 Td ( and is not necessarily indicative of the results of our future operations.) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 639.75 199.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 639.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 639.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 639.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 639.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 639.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 639.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 639.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 639.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 639.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 610.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 610.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 610.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 610.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 610.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 610.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 610.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 610.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 610.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 610.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 580.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 580.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 580.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 580.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 580.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 580.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 580.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 580.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 580.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 580.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 550.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 550.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 550.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 550.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 550.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 550.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 550.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 550.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 550.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 550.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 520.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 520.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 520.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 520.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 520.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 520.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 520.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 520.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 520.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 520.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 652.75 m
299.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 652.75 m
303.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 652.75 m
368.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 652.75 m
372.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 652.75 m
437.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 652.75 m
441.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 652.75 m
506.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 652.75 m
510.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 652.75 m
575.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 639.75 m
299.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 639.75 m
368.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 639.75 m
437.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 639.75 m
506.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 639.75 m
575.5 639.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 360.20 656.98 Td (Y) Tj ET Q
q 0 0 0 rg BT 365.53 656.98 Td (ear) Tj ET Q
q 0 0 0 rg BT 376.12 656.98 Td ( Ended December) Tj ET Q
q 0 0 0 rg BT 436.85 656.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 258.50 643.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 327.50 643.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 643.98 Td (2017) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 643.98 Td (2016) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 643.98 Td (2015) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 630.48 Td (Consolidated Statement of Operations Data:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 615.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 615.42 Td (otal revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 615.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 615.42 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 615.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 615.42 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 615.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 615.42 Td (3,468,858) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 615.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 615.42 Td (4,010,274) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 615.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 615.42 Td (3,268,718) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 600.42 Td (Loss from continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 600.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.80 600.47 Td (\(360,584) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 600.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 600.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 600.47 Td (\(961,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 600.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 600.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.30 600.47 Td (\(1,232,71) Tj ET Q
q 0 0 0 rg BT 428.63 600.47 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 600.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 600.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 600.47 Td (\(3,223,772) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 600.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 600.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 600.42 Td (\(300,399) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 600.42 Td (\)) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 585.46 Td (Net loss per shar) Tj ET Q
q 0 0 0 rg BT 105.69 585.46 Td (e�continuing operations:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 570.42 Td (Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 570.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.80 570.47 Td (\(1.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 570.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 570.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 570.47 Td (\(4.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 570.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 570.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 570.47 Td (\(5.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 570.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 570.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 570.47 Td (\(14.48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 570.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 570.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 570.42 Td (\(1.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 570.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 555.42 Td (Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 555.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.80 555.47 Td (\(1.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 555.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 555.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 555.47 Td (\(4.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 555.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 555.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 555.47 Td (\(5.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 555.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 555.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 555.47 Td (\(14.48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 555.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 555.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 555.42 Td (\(1.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 555.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 540.42 Td (Shares used for net loss per share�basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 540.42 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 540.42 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 540.42 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 540.42 Td (222,651) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 540.42 Td (197,100) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 525.42 Td (Shares used for net loss per share�diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 525.42 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 525.42 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 525.42 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 525.42 Td (222,651) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 525.42 Td (197,100) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 510.42 Td (Cash dividends declared per share) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 510.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 510.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 510.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 510.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 510.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 510.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 510.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 510.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 510.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 510.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 463.75 199.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 463.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 463.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 463.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 463.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 463.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 463.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 463.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 463.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 463.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 434.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 434.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 434.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 434.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 434.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 434.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 434.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 434.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 434.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 434.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 404.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 404.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 404.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 404.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 404.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 404.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 404.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 404.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 404.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 404.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 476.75 m
299.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 476.75 m
303.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 476.75 m
368.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 476.75 m
372.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 476.75 m
437.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 476.75 m
441.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 476.75 m
506.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 476.75 m
510.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 476.75 m
575.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 476.75 m
299.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 463.75 m
299.5 463.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 476.75 m
303.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 476.75 m
368.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 463.75 m
368.5 463.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 476.75 m
372.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 476.75 m
437.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 463.75 m
437.5 463.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 476.75 m
441.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 476.75 m
506.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 463.75 m
506.5 463.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 476.75 m
510.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 476.75 m
575.5 476.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 463.75 m
575.5 463.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 371.45 480.98 Td (As of December) Tj ET Q
q 0 0 0 rg BT 425.58 480.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 258.50 467.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 327.50 467.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 467.98 Td (2017) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 467.98 Td (2016) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 467.98 Td (2015) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 454.43 Td (Consolidated Balance Sheet Data:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 439.42 Td (Cash and cash equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 439.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 439.42 Td (1,454,531) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 439.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 439.42 Td (1,149,1) Tj ET Q
q 0 0 0 rg BT 354.65 439.42 Td (13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 439.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 439.42 Td (986,605) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 439.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 439.42 Td (517,250) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 439.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 439.42 Td (272,348) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 424.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 424.42 Td (otal assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 424.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 424.42 Td (9,389,527) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 424.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.60 424.42 Td (10,132,393) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 424.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.60 424.42 Td (1) Tj ET Q
q 0 0 0 rg BT 393.60 424.42 Td (1,635,580) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 424.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 424.42 Td (14,275,109) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 424.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.60 424.42 Td (19,350,336) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 409.42 Td (Long-term debt, less current portion, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 409.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 409.42 Td (8,359,899) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 409.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 409.42 Td (8,224,269) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 409.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 409.42 Td (8,242,032) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 409.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 409.42 Td (8,141,378) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 409.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 409.42 Td (8,251,657) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 394.42 Td (Other long-term obligations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 394.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 394.42 Td (435,883) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 394.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 394.42 Td (456,31) Tj ET Q
q 0 0 0 rg BT 359.65 394.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 394.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 394.42 Td (687,759) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 394.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 394.42 Td (797,397) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 394.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 394.42 Td (1,656,391) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 372.25 Td (Based on the Company�) Tj ET Q
q 0 0 0 rg BT 158.82 372.25 Td (s adoption of certain accounting principles, including, for example, its modified retrospective adoptions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 360.25 Td (of ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 46.83 360.25 Td (Accounting Standar) Tj ET Q
q 0 0 0 rg BT 126.17 360.25 Td (ds Codification T) Tj ET Q
q 0 0 0 rg BT 194.71 360.25 Td (opic 606, Revenue fr) Tj ET Q
q 0 0 0 rg BT 277.08 360.25 Td (om Contracts with Customers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.26 360.25 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.09 360.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.05 360.25 Td (\) and ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 461.82 360.25 Td (Accounting Standar) Tj ET Q
q 0 0 0 rg BT 541.16 360.25 Td (ds ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 348.25 Td (Codification T) Tj ET Q
q 0 0 0 rg BT 93.14 348.25 Td (opic 842, Leases) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 160.08 348.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.58 348.25 Td (\() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.91 348.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.87 348.25 Td (\) on January 1, 2018 and January 1, 2019, respectively) Tj ET Q
q 0 0 0 rg BT 420.49 348.25 Td (, the accounting principles in ef) Tj ET Q
q 0 0 0 rg BT 546.38 348.25 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 336.25 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 336.25 Td (fer among the periods presented above.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 318.25 Td (The Company has recorded certain char) Tj ET Q
q 0 0 0 rg BT 222.47 318.25 Td (ges for asset impairments and litigation-related and other matters during each year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 306.25 Td (presented, portions of which are reported as Discontinued operations, net of tax in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.45 306.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.82 306.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 542.64 306.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 294.25 Td (Company has completed certain business combinations during or after ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.10 294.25 Td (2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.10 294.25 Td (, certain of which resulted in significant financing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 282.25 Td (activities. ) Tj ET Q
q 0 0 0 rg BT 76.92 282.25 Td (These business combinations had a significant impact on the Company�) Tj ET Q
q 0 0 0 rg BT 363.25 282.25 Td (s financial statements in their respective years of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 270.25 Td (acquisition and in subsequent years. ) Tj ET Q
q 0 0 0 rg BT 182.46 270.25 Td (These impacts result from the consideration transferred by the Company for the acquisitions, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 258.25 Td (initial and subsequent purchase accounting for the acquired entities�) Tj ET Q
q 0 0 0 rg BT 307.39 258.25 Td ( assets and liabilities and the post-acquisition results of operations. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 246.25 Td (The Company has also ceased operations and/or divested of certain businesses during or after ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.55 246.25 Td (2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.55 246.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 228.25 Td (Through the dates of: \(i\) the sale of the Men�) Tj ET Q
q 0 0 0 rg BT 242.67 228.25 Td (s Health and Prostate Health units of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.97 228.25 Td (American Medical Systems Holdings, Inc. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 216.25 Td (\(AMS\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.33 216.25 Td ( business in ) Tj ET Q
q 0 0 0 rg BT 112.95 216.25 Td (August 2015 and \(ii\) the wind down of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.80 216.25 Td (W) Tj ET Q
q 0 0 0 rg BT 294.44 216.25 Td (omen�) Tj ET Q
q 0 0 0 rg BT 319.44 216.25 Td (s Health unit of the ) Tj ET Q
q 0 0 0 rg BT 398.04 216.25 Td (AMS business \(Astora\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.92 216.25 Td ( in March 2016, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 204.25 Td (assets and liabilities of all of these aforementioned businesses were classified as held for sale in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.60 204.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.68 204.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 192.25 Td (except in the case of certain assets and liabilities that were to remain with the Company after sale including, among others, the mesh-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 180.25 Td (related product liability accrual, related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.92 180.25 Td (Qualified Settlement Funds \(QSFs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.30 180.25 Td ( and certain intangible and fixed assets. ) Tj ET Q
q 0 0 0 rg BT 496.70 180.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 546.60 180.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 168.25 Td (assets and liabilities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.32 168.25 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.42 168.25 Td (, which was sold in July 2017, are classified as held for sale in the Consolidated Balance Sheet as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 156.25 Td (December 31, 2016. ) Tj ET Q
q 0 0 0 rg BT 119.40 156.25 Td (The operating results of the entire ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.58 156.25 Td (AMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.26 156.25 Td ( business, which includes the Men�) Tj ET Q
q 0 0 0 rg BT 418.24 156.25 Td (s Health, Prostate Health and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.54 156.25 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.20 156.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 144.25 Td (businesses, are reported as Discontinued operations, net of tax in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.31 144.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.68 144.25 Td ( for all periods presented. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 132.25 Td (For additional information, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.36 132.25 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.77 132.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.26 132.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.13 132.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 120.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 63.87 120.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.85 120.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 102.25 Td (For further information regarding the comparability of the financial data presented in the tables above and factors that may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 90.25 Td (impact comparability of future results, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.33 90.25 Td (Item 7. Management�) Tj ET Q
q 0 0 0 rg BT 293.14 90.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 362.31 90.25 Td (Analysis of Financial Condition and Results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 78.25 Td (Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 78.25 Td ( as well as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.47 78.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.34 78.25 Td ( and related notes included in this ) Tj ET Q
q 0 0 0 rg BT 413.70 78.25 Td (Annual Report and previously filed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 66.25 Td (Annual Reports on Form 10-K.) Tj ET Q
endstream
endobj
109 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 110 0 R>>
endobj
110 0 obj
<</Length 19420>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (51) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (Item 7.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 749.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 749.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 749.25 Td (Management�) Tj ET Q
q 0 0 0 rg BT 165.04 749.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 236.63 749.25 Td (Analysis of Financial Condition and Results of Operations) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (The following ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.43 731.25 Td (Management�) Tj ET Q
q 0 0 0 rg BT 177.41 731.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 246.58 731.25 Td (Analysis of Financial Condition and Results of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.72 731.25 Td ( describes the principal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (factors af) Tj ET Q
q 0 0 0 rg BT 73.29 719.25 Td (fecting the results of operations, liquidity and capital resources and critical accounting estimates of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.22 719.25 Td (Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.63 719.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (This section omits discussions about ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.61 707.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.61 707.25 Td ( items and comparisons between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.07 707.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.07 707.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.51 707.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.51 707.25 Td (. Such discussions can be found in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.50 707.25 Td (Item 7. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (Management�) Tj ET Q
q 0 0 0 rg BT 90.98 695.25 Td (s Discussion and ) Tj ET Q
q 0 0 0 rg BT 160.15 695.25 Td (Analysis of Financial Condition and Results of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.29 695.25 Td ( in our ) Tj ET Q
q 0 0 0 rg BT 422.35 695.25 Td (Annual Report on Form 10-K for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.25 Td (year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.08 683.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.67 683.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 165.49 683.25 Td (These discussions should be read in conjunction with our audited ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.77 683.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.64 683.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.25 Td (and related notes thereto. Except for the historical information contained in this report, including the following discussion, this report ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.25 Td (contains forward-looking statements that involve risks and uncertainties. See �Forward-Looking Statements� beginning on page i of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.25 Td (this report.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 629.25 Td (Unless otherwise indicated or required by the context, references throughout to �Endo,� the �Company) Tj ET Q
q 0 0 0 rg BT 474.16 629.25 Td (,� �we,� �our� or �us� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.25 Td (refer to financial information and transactions of Endo International plc and its subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 599.25 Td (The operating results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.20 599.25 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.86 599.25 Td ( are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.25 Td (for all periods presented. For additional information, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.27 587.25 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.68 587.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.17 587.25 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 575.25 Td (Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.59 575.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 575.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 197.18 575.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.16 575.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (EXECUTIVE SUMMAR) Tj ET Q
q 0 0 0 rg BT 143.71 557.25 Td (Y) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 539.25 Td (This executive summary provides ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.74 539.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.74 539.25 Td ( highlights from the results of operations that follow:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 527.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 527.25 Td (T) Tj ET Q
q 0 0 0 rg BT 90.91 527.25 Td (otal revenues in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.72 527.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.72 527.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.22 527.25 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.63 527.25 Td (d ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.13 527.25 Td (1%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.46 527.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.24 527.25 Td ($2,914.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.63 527.25 Td ( compared to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.34 527.25 Td ($2,947.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.73 527.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.51 527.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.51 527.25 Td ( as strong performance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 515.25 Td (from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.27 515.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.18 515.25 Td ( segment and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.28 515.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.18 515.25 Td ( segment�) Tj ET Q
q 0 0 0 rg BT 406.78 515.25 Td (s Specialty Products portfolio was more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 503.25 Td (than of) Tj ET Q
q 0 0 0 rg BT 113.37 503.25 Td (fset by declines in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.18 503.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.08 503.25 Td ( segment�) Tj ET Q
q 0 0 0 rg BT 344.68 503.25 Td (s Established Products portfolio and both our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.72 503.25 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 491.25 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.03 491.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.47 491.25 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.58 491.25 Td ( segments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 479.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 479.25 Td (Gross mar) Tj ET Q
q 0 0 0 rg BT 126.70 479.25 Td (gin percentage in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.06 479.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.06 479.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.56 479.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.31 479.25 Td (d to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.09 479.25 Td (46.2%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.92 479.25 Td ( from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.36 479.25 Td (44.6%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.19 479.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.97 479.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.97 479.25 Td (, reflecting the impact of changes in product mix ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 467.25 Td (to higher mar) Tj ET Q
q 0 0 0 rg BT 139.19 467.25 Td (gin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.47 467.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.38 467.25 Td ( and Specialty Products from lower mar) Tj ET Q
q 0 0 0 rg BT 385.61 467.25 Td (gin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.89 467.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.56 467.25 Td ( and Established ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 455.25 Td (Products, as well as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.88 455.25 Td (reductions to amortization expense and expenses related to retention and separation benefits and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 443.25 Td (cost reduction initiatives, partially of) Tj ET Q
q 0 0 0 rg BT 232.78 443.25 Td (fset by the unfavorable impact of increased sales of certain lower mar) Tj ET Q
q 0 0 0 rg BT 511.09 443.25 Td (gin authorized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 431.25 Td (generic products launched in the third quarter of 2018.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 419.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 419.25 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 175.85 419.25 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.18 419.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.96 419.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.96 419.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.46 419.25 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.87 419.25 Td (d to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.65 419.25 Td ($526.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.54 419.25 Td ( from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.98 419.25 Td ($916.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.87 419.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.65 419.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.65 419.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 407.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 407.25 Td (Loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.39 407.25 Td ( from continuing operations in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.54 407.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.54 407.25 Td ( was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.09 407.25 Td ($360.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.98 407.25 Td (, compared to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.18 407.25 Td ($961.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.07 407.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.85 407.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.85 407.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 389.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 112.90 389.25 Td (, the following summary highlights certain key events that occurred during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.49 389.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.49 389.25 Td (:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 377.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 377.25 Td (In November 2019, we announced the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.73 377.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.63 377.25 Td (�) Tj ET Q
q 0 0 0 rg BT 262.40 377.25 Td (s acceptance for review of the original ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.16 377.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.61 377.25 Td ( for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.27 377.25 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.83 377.25 Td ( for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 365.25 Td (cellulite in the buttocks. ) Tj ET Q
q 0 0 0 rg BT 183.91 365.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.96 365.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.40 365.25 Td ( is supported by the results of the RELEASE-1 and RELEASE-2 Phase 3 studies, as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 353.25 Td (well as a clinical program. ) Tj ET Q
q 0 0 0 rg BT 193.61 353.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.66 353.25 Td (PDUF) Tj ET Q
q 0 0 0 rg BT 236.48 353.25 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.15 353.25 Td ( date, or tar) Tj ET Q
q 0 0 0 rg BT 288.50 353.25 Td (get action date, for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.69 353.25 Td (BLA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.13 353.25 Td ( has been set for July 6, 2020.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 341.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 341.25 Td (In March 2019, we completed a series of refinancing transactions that were intended to extend our debt maturity profile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 329.25 Td (and provide greater covenant flexibility) Tj ET Q
q 0 0 0 rg BT 243.12 329.25 Td (, which resulted in a net gain on extinguishment of debt of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.90 329.25 Td ($1) Tj ET Q
q 0 0 0 rg BT 488.53 329.25 Td (19.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.42 329.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 542.24 329.25 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 317.25 Td (transactions are collectively referred to herein as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.06 317.25 Td (March 2019 Refinancing ) Tj ET Q
q 0 0 0 rg BT 399.35 317.25 Td (T) Tj ET Q
q 0 0 0 rg BT 405.11 317.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.09 317.25 Td ( and are further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 305.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.88 305.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.37 305.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.24 305.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.95 305.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 385.82 305.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.80 305.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 293.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 293.25 Td (As a result of the Company�) Tj ET Q
q 0 0 0 rg BT 197.98 293.25 Td (s lawsuit against the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.30 293.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.75 293.25 Td ( challenging its interim policy authorizing bulk compounding of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 281.25 Td (pharmaceuticals, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.18 281.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.64 281.25 Td ( evaluated whether there is a clinical need to compound vasopressin under Section 503B of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 269.25 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.74 269.25 Td (. In March 2019, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.88 269.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.33 269.25 Td ( determined that there is no such clinical need. ) Tj ET Q
q 0 0 0 rg BT 409.05 269.25 Td (As a result, the bulk compounding of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 257.25 Td (vasopressin is impermissible under Section 503B of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 310.47 257.25 Td (FFDCA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.16 257.25 Td ( unless the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.87 257.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.33 257.25 Td ( were to add vasopressin to its drug ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 245.25 Td (shortage list. ) Tj ET Q
q 0 0 0 rg BT 138.92 245.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.97 245.25 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.87 245.25 Td (�) Tj ET Q
q 0 0 0 rg BT 178.64 245.25 Td (s decision was upheld by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.85 245.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.63 245.25 Td ( District Court for the District of Columbia in ) Tj ET Q
q 0 0 0 rg BT 497.78 245.25 Td (August 2019. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 233.25 Td (V) Tj ET Q
q 0 0 0 rg BT 91.43 233.25 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 145.89 237.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.82 233.25 Td ( remains the only vasopressin injection product with an NDA) Tj ET Q
q 0 0 0 rg BT 395.50 233.25 Td ( approved by the FDA.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 212.25 Td (CRITICAL) Tj ET Q
q 0 0 0 rg BT 85.46 212.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 87.41 212.25 Td (ACCOUNTING ESTIMA) Tj ET Q
q 0 0 0 rg BT 198.07 212.25 Td (TES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 194.25 Td (The preparation of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.74 194.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.61 194.25 Td ( in conformity with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.60 194.25 Td (accounting principles generally accepted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 182.25 Td (the U.S. \(U.S. GAAP\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.17 182.25 Td ( requires us to make estimates and assumptions that af) Tj ET Q
q 0 0 0 rg BT 341.88 182.25 Td (fect the amounts and disclosures in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.46 182.25 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 170.25 Td (Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.59 170.25 Td (, including the notes thereto, and elsewhere in this report. For example, we are required to make significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 158.25 Td (estimates and assumptions related to revenue recognition, including sales deductions, long-lived assets, goodwill, other intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 146.25 Td (assets, income taxes, contingencies, financial instruments and share-based compensation, among others. Some of these estimates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 134.25 Td (can be subjective and complex. ) Tj ET Q
q 0 0 0 rg BT 163.18 134.25 Td (Although we believe that our estimates and assumptions are reasonable, there may be other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 122.25 Td (reasonable estimates or assumptions that dif) Tj ET Q
q 0 0 0 rg BT 212.17 122.25 Td (fer significantly from ours. Further) Tj ET Q
q 0 0 0 rg BT 351.45 122.25 Td (, our estimates and assumptions are based upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 110.25 Td (information available at the time they were made. ) Tj ET Q
q 0 0 0 rg BT 236.76 110.25 Td (Actual results may dif) Tj ET Q
q 0 0 0 rg BT 325.17 110.25 Td (fer significantly from our estimates.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
111 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 112 0 R>>
endobj
112 0 obj
<</Length 10703>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 112.34 742.10 Td (, in order to understand our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.70 742.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.57 742.10 Td (, it is important to understand our critical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (accounting estimates. ) Tj ET Q
q 0 0 0 rg BT 124.40 730.10 Td (W) Tj ET Q
q 0 0 0 rg BT 133.04 730.10 Td (e consider an accounting estimate to be critical if both: \(i\) the accounting estimate requires us to make ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (assumptions about matters that were highly uncertain at the time the accounting estimate was made and \(ii\) changes in the estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (that are reasonably likely to occur from period to period, or use of dif) Tj ET Q
q 0 0 0 rg BT 313.50 706.10 Td (ferent estimates that we reasonably could have used in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (current period, would have a material impact on our financial condition, results of operations or cash flows. Our most critical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (accounting estimates are described below) Tj ET Q
q 0 0 0 rg BT 201.40 682.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (Revenue recognition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.10 Td (The Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.04 646.10 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.99 646.10 Td ( on January 1, 2018 using the modified retrospective method for all revenue-generating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (contracts, including modifications thereto, that were not completed contracts at the date of adoption.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.98 634.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.93 634.10 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.88 634.10 Td ( applies to contracts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (with commercial substance that establish the payment terms and each party�) Tj ET Q
q 0 0 0 rg BT 339.79 622.10 Td (s rights regarding the goods or services to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (transferred, to the extent collection of substantially all of the related consideration is probable. Under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.25 610.10 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.21 610.10 Td (, we recognize ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (revenue for contracts meeting these criteria when \(or as\) we satisfy our performance obligations for such contracts by transferring ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (control of the underlying promised goods or services to our customers. ) Tj ET Q
q 0 0 0 rg BT 321.32 586.10 Td (The amount of revenue we recognize reflects our estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. ) Tj ET Q
q 0 0 0 rg BT 538.42 574.10 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (amount is referred to as the transaction price.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 544.10 Td (Our revenue consists almost entirely of sales of our products to customers, whereby we ship products to a customer pursuant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (to a purchase order) Tj ET Q
q 0 0 0 rg BT 111.80 532.10 Td (. For contracts such as these, revenue is recognized when our contractual performance obligations have been ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (fulfilled and control has been transferred to the customer pursuant to the contract�) Tj ET Q
q 0 0 0 rg BT 362.55 520.10 Td (s terms, which is generally upon delivery to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (customer) Tj ET Q
q 0 0 0 rg BT 72.10 508.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 76.92 508.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.97 508.10 Td (amount of revenue) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.94 508.10 Td ( we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.60 508.10 Td (recognize) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.46 508.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.96 508.10 Td (is equal to the fixed amount of the transaction price, adjusted for) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.21 508.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.54 508.10 Td (estimates of a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (number of significant variable components including, but not limited to, estimates for char) Tj ET Q
q 0 0 0 rg BT 397.95 496.10 Td (gebacks, rebates, sales incentives and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (allowances,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.92 484.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.42 484.10 Td (DSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.88 484.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.38 484.10 Td (and other fees for services, returns and allowances, which) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.40 484.10 Td ( we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.06 484.10 Td (collectively refer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.07 484.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.57 484.10 Td (to as sales deductions.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 466.10 Td (The Company utilizes the expected value method when estimating the amount of variable consideration to include in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (not qualify for the sales- and usage-based royalty exception.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.75 430.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.07 430.10 Td (V) Tj ET Q
q 0 0 0 rg BT 285.18 430.10 Td (ariable consideration is included in the transaction price only to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (consideration is resolved.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.92 406.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 140.24 406.10 Td (The variable component of the transaction price is estimated based on factors such as our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.28 406.10 Td (direct and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (indirect customers�) Tj ET Q
q 0 0 0 rg BT 112.18 394.10 Td ( buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (inventory levels, current contract sales terms with) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.10 370.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.43 370.10 Td (direct and indirect customers and other competitive factors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.12 370.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 493.44 370.10 Td (W) Tj ET Q
q 0 0 0 rg BT 502.08 370.10 Td (e subsequently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (review our estimates for sales deductions based on new or revised information that becomes available to us and make revisions to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (our estimates if and when appropriate. Refer to �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.21 346.10 Td (Sales deductions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.14 346.10 Td (� section below for additional information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 328.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 328.10 Td (e believe that speculative buying of product, particularly in anticipation of possible price increases, has been the historical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (practice of certain of our customers. ) Tj ET Q
q 0 0 0 rg BT 182.70 316.10 Td (The timing of purchasing decisions made by wholesaler and lar) Tj ET Q
q 0 0 0 rg BT 436.06 316.10 Td (ge retail chain customers can ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (materially af) Tj ET Q
q 0 0 0 rg BT 86.63 304.10 Td (fect the level of our sales in any particular period. ) Tj ET Q
q 0 0 0 rg BT 287.38 304.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 336.72 304.10 Td (, our sales may not correlate to the number of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (prescriptions written for our products based on external third-party data.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 274.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 274.10 Td (e have entered into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.93 274.10 Td (DSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.94 274.10 Td (s with certain of our significant wholesaler customers that obligate the wholesalers, in exchange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (for fees paid by us, to: \(i\) manage the variability of their purchases and inventory levels within specified limits based on product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (demand and \(ii\) provide us with specific services, including the provision of periodic retail demand information and current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (inventory levels for our pharmaceutical products held at their warehouse locations.) Tj ET Q
endstream
endobj
113 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 114 0 R>>
endobj
114 0 obj
<</Length 20874>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (53) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Sales deductions) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (As described above, the amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (our estimates of variable consideration, including sales deductions. If the assumptions we use to calculate our estimates for sales ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (deductions do not appropriately reflect future activity) Tj ET Q
q 0 0 0 rg BT 249.16 700.25 Td (, our financial position, results of operations and cash flows could be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (materially impacted. ) Tj ET Q
q 0 0 0 rg BT 120.51 688.25 Td (The following table presents the activity and ending balances, excluding Discontinued operations, for our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (product sales provisions for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.03 676.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.03 676.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.75 642.75 185.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
220.75 642.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
285.75 642.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
289.75 642.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
354.75 642.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
358.75 642.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
423.75 642.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
427.75 642.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
492.75 642.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.75 642.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.75 613.75 185.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
220.75 613.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
285.75 613.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
289.75 613.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
354.75 613.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
358.75 613.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
423.75 613.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
427.75 613.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
492.75 613.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.75 613.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.75 584.75 185.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
220.75 584.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
285.75 584.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
289.75 584.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
354.75 584.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
358.75 584.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
423.75 584.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
427.75 584.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
492.75 584.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.75 584.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.75 554.75 185.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
220.75 554.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
285.75 554.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
289.75 554.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
354.75 554.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
358.75 554.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
423.75 554.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
427.75 554.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
492.75 554.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.75 554.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.75 525.75 185.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
220.75 525.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
285.75 525.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
289.75 525.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
354.75 525.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
358.75 525.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
423.75 525.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
427.75 525.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
492.75 525.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.75 525.75 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 642.75 m
285.75 642.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 642.75 m
354.75 642.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 642.75 m
423.75 642.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 642.75 m
492.75 642.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 642.75 m
561.75 642.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 584.75 m
285.75 584.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 569.75 m
285.75 569.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 584.75 m
354.75 584.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 569.75 m
354.75 569.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 584.75 m
423.75 584.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 569.75 m
423.75 569.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 584.75 m
492.75 584.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 569.75 m
492.75 569.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 584.75 m
561.75 584.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 569.75 m
561.75 569.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 525.75 m
285.75 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 512.75 m
285.75 512.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
220.75 510.75 m
285.75 510.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 525.75 m
354.75 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 512.75 m
354.75 512.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
289.75 510.75 m
354.75 510.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 525.75 m
423.75 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 512.75 m
423.75 512.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
358.75 510.75 m
423.75 510.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 525.75 m
492.75 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 512.75 m
492.75 512.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
427.75 510.75 m
492.75 510.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 525.75 m
561.75 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 512.75 m
561.75 512.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.75 510.75 m
561.75 510.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 231.50 654.98 Td (Returns and) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 233.40 646.98 Td (Allowances) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 308.15 646.98 Td (Rebates) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 368.30 646.98 Td (Chargebacks) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 439.90 654.98 Td (Other) Tj ET Q
q 0 0 0 rg BT 460.27 654.98 Td ( Sales) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 440.60 646.98 Td (Deductions) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 520.00 646.98 Td (T) Tj ET Q
q 0 0 0 rg BT 524.60 646.98 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 633.32 Td (Balance, January 1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.25 633.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.40 633.32 Td (291,034) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.25 633.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.40 633.32 Td (354,687) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.25 633.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.40 633.32 Td (256,708) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.25 633.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.40 633.32 Td (40,348) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.25 633.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.40 633.32 Td (942,777) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 619.32 Td (Current year provision) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.40 618.42 Td (78,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.40 618.42 Td (912,885) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.90 618.42 Td (2,268,212) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.40 618.42 Td (161,788) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.90 618.42 Td (3,421,652) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 604.32 Td (Prior year provision) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.40 603.42 Td (3,693) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.05 603.47 Td (\(1,053) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.90 603.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.90 603.42 Td (785) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.55 603.47 Td (\(664) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.90 603.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.40 603.42 Td (2,761) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 589.32 Td (Payments or credits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.05 589.32 Td (\(136,548) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.90 589.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.05 589.37 Td (\(986,803) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.90 589.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.55 589.37 Td (\(2,307,339) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.90 589.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.05 589.37 Td (\(164,169) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.90 589.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.55 589.32 Td (\(3,594,859) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 557.90 589.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 575.32 Td (Balance, December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.25 574.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.40 574.42 Td (236,946) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.25 574.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.40 574.42 Td (279,716) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.25 574.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.40 574.42 Td (218,366) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.25 574.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.40 574.42 Td (37,303) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.25 574.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.40 574.42 Td (772,331) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 560.32 Td (Current year provision) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.40 559.42 Td (90,876) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.40 559.42 Td (792,389) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.90 559.42 Td (2,144,534) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.40 559.42 Td (148,156) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.90 559.42 Td (3,175,955) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 545.32 Td (Prior year provision) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.05 544.42 Td (\(4,029) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.90 544.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.05 544.47 Td (\(5,952) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.90 544.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.40 544.42 Td (1,233) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.05 544.47 Td (\(2,060) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.90 544.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.05 544.42 Td (\(10,808) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 557.90 544.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 530.32 Td (Payments or credits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.05 530.32 Td (\(1) Tj ET Q
q 0 0 0 rg BT 254.38 530.32 Td (17,545) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.90 530.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.05 530.37 Td (\(850,363) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.90 530.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.55 530.37 Td (\(2,158,965) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.90 530.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.05 530.37 Td (\(150,268) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.90 530.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.55 530.32 Td (\(3,277,141) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 557.90 530.32 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.25 516.32 Td (Balance, December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.25 516.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.40 516.32 Td (206,248) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.25 516.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.40 516.32 Td (215,790) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.25 516.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.40 516.32 Td (205,168) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.25 516.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.40 516.32 Td (33,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.25 516.32 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.40 516.32 Td (660,337) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 494.25 Td (Returns and ) Tj ET Q
q 0 0 0 rg BT 100.43 494.25 Td (Allowances) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 476.25 Td (Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 464.25 Td (period of time both subsequent to and, in certain cases, prior to the products�) Tj ET Q
q 0 0 0 rg BT 342.12 464.25 Td ( expiration dates. Our return policy generally allows ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 452.25 Td (customers to receive credit for expired products within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.59 452.25 Td (six months) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.21 452.25 Td ( prior to expiration and within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.96 452.25 Td (one year) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.11 452.25 Td ( after expiration. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 440.25 Td (provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.58 440.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 428.25 Td (The primary factors we consider in estimating our potential product returns include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 416.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 416.25 Td (the shelf life or expiration date of each product;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 404.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 404.25 Td (historical levels of expired product returns;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 392.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 392.25 Td (external data with respect to inventory levels in the wholesale distribution channel;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 380.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 380.25 Td (external data with respect to prescription demand for our products; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 368.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 368.25 Td (the estimated returns liability to be processed by year of sale based on analysis of lot information related to actual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 356.25 Td (historical returns.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 338.25 Td (In determining our estimates for returns and allowances, we are required to make certain assumptions regarding the timing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 326.25 Td (of the introduction of new products and the potential of these products to capture market share. In addition, we make certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 314.25 Td (assumptions with respect to the extent and pattern of decline associated with generic competition. ) Tj ET Q
q 0 0 0 rg BT 428.76 314.25 Td (T) Tj ET Q
q 0 0 0 rg BT 434.17 314.25 Td (o make these assessments, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 302.25 Td (utilize market data for similar products as analogs for our estimations. ) Tj ET Q
q 0 0 0 rg BT 318.52 302.25 Td (W) Tj ET Q
q 0 0 0 rg BT 327.16 302.25 Td (e use our best judgment to formulate these assumptions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 290.25 Td (based on past experience and information available to us at the time. ) Tj ET Q
q 0 0 0 rg BT 312.11 290.25 Td (W) Tj ET Q
q 0 0 0 rg BT 320.75 290.25 Td (e continually reassess and make appropriate changes to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 278.25 Td (estimates and assumptions as new information becomes available to us.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 260.25 Td (Our estimate for returns and allowances may be impacted by a number of factors, but the principal factor relates to the level ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 248.25 Td (of inventory in the distribution channel. ) Tj ET Q
q 0 0 0 rg BT 197.18 248.25 Td (Where available, we utilize information received from our wholesaler customers about the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 236.25 Td (quantities of inventory held, including the information received pursuant to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.54 236.25 Td (DSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.54 236.25 Td (s, which we have not independently verified. For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 224.25 Td (other customers, we have estimated inventory held based on buying patterns. In addition, we evaluate market conditions for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 212.25 Td (products primarily through the analysis of wholesaler and other third party sell-through data, as well as internally-generated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 200.25 Td (information, to assess factors that could impact expected product demand at the estimate date. ) Tj ET Q
q 0 0 0 rg BT 413.66 200.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.10 200.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.68 200.25 Td (, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 188.25 Td (believe that our estimates of the level of inventory held by our customers is within a reasonable range as compared to both ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 176.25 Td (historical amounts and expected demand for each respective product.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 158.25 Td (When we are aware of an increase in the level of inventory of our products in the distribution channel, we consider the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 146.25 Td (reasons for the increase to determine whether we believe the increase is temporary or other) Tj ET Q
q 0 0 0 rg BT 399.53 146.25 Td (-than-temporary) Tj ET Q
q 0 0 0 rg BT 463.85 146.25 Td (. Increases in inventory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 134.25 Td (levels assessed as temporary will not result in an adjustment to our provision for returns and allowances. Some of the factors that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 122.25 Td (may be an indication that an increase in inventory levels will be temporary include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 110.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 110.25 Td (recently implemented or announced price increases for our products; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 98.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 98.25 Td (new product launches or expanded indications for our existing products.) Tj ET Q
endstream
endobj
115 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 116 0 R>>
endobj
116 0 obj
<</Length 11729>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (54) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Conversely) Tj ET Q
q 0 0 0 rg BT 107.90 742.10 Td (, other) Tj ET Q
q 0 0 0 rg BT 133.24 742.10 Td (-than-temporary increases in inventory levels may be an indication that future product returns could be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (higher than originally anticipated and, accordingly) Tj ET Q
q 0 0 0 rg BT 237.50 730.10 Td (, we may need to adjust our provision for returns and allowances. Some of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (factors that may be an indication that an increase in inventory levels will be other) Tj ET Q
q 0 0 0 rg BT 361.24 718.10 Td (-than-temporary include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 706.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 706.10 Td (declining sales trends based on prescription demand;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 694.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 694.10 Td (recent regulatory approvals to shorten the shelf life of our products, which could result in a period of higher returns ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 682.10 Td (related to older product still in the distribution channel;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 670.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 670.10 Td (introduction of new product or generic competition;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 658.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 658.10 Td (increasing price competition from generic competitors; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 646.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 646.10 Td (changes to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.20 646.10 Td (National Drug Codes \(NDCs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.35 646.10 Td ( of our products, which could result in a period of higher returns related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 634.10 Td (product with the old ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.82 634.10 Td (NDC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.93 634.10 Td (, as our customers generally permit only one ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.16 634.10 Td (NDC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.28 634.10 Td ( per product for identification and tracking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 622.10 Td (within their inventory systems.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 604.10 Td (Rebates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 586.10 Td (Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 574.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 574.10 Td (direct rebates;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 562.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 562.10 Td (indirect rebates;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 550.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 550.10 Td (governmental rebates, including those for Medicaid, Medicare and ) Tj ET Q
q 0 0 0 rg BT 354.11 550.10 Td (TRICARE, among others; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 538.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 538.10 Td (managed-care rebates.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 520.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 520.10 Td (e establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA) Tj ET Q
q 0 0 0 rg BT 555.11 520.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (rebates paid to direct purchasing customers based on a percentage applied to a direct customer) Tj ET Q
q 0 0 0 rg BT 413.45 496.10 Td (�) Tj ET Q
q 0 0 0 rg BT 416.22 496.10 Td (s purchases from us, including fees ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers that have purchased ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (our products from a wholesaler under a contract with us.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 454.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 454.10 Td (e are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and GPOs. For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (example, we are required to provide a discount on our brand-name products to patients who fall within the Medicare Part D ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (coverage gap, also referred to as the donut hole.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 400.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 400.10 Td (e participate in various federal and state government-managed programs whereby discounts and rebates are provided to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (requirements with public sector \(Medicaid\) benefit providers after the final dispensing of the product by a pharmacy to a benefit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (plan participant.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.98 364.10 Td ( Medicaid reserves are based on expected payments, which are driven by patient usage, contract performance and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (field inventory that will be subject to a Medicaid rebate. Medicaid rebates are typically billed up to 180 days after the product is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (shipped, but can be as much as 270 days after the quarter in which the product is dispensed to the Medicaid participant. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (Periodically) Tj ET Q
q 0 0 0 rg BT 83.67 328.10 Td (, we adjust the Medicaid rebate provision based on actual claims paid. Due to the delay in billing, adjustments to actual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (claims paid may incorporate revisions of this provision for several periods. Because Medicaid pricing programs involve ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (particularly dif) Tj ET Q
q 0 0 0 rg BT 95.52 304.10 Td (ficult interpretations of complex statutes and regulatory guidance, our estimates could dif) Tj ET Q
q 0 0 0 rg BT 452.45 304.10 Td (fer from actual experience.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 286.10 Td (In determining our estimates for rebates, we consider the terms of our contracts and relevant statutes, together with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (information about sales mix \(to determine which sales are subject to rebates and the amount of such rebates\), historical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (relationships of rebates to revenues, past payment experience, estimated inventory levels of our customers and estimated future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (trends. Our provisions for rebates include estimates for both unbilled claims for end-customer sales that have already occurred and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (future claims that will be made when inventory in the distribution channel is sold through to end-customer plan participants. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (Changes in the level of utilization of our products through private or public benefit plans and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.35 226.10 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.36 226.10 Td (s will af) Tj ET Q
q 0 0 0 rg BT 462.39 226.10 Td (fect the amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (rebates that we owe.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 196.10 Td (Char) Tj ET Q
q 0 0 0 rg BT 69.69 196.10 Td (gebacks) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 178.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 178.10 Td (e market and sell products to both: \(i\) direct customers including wholesalers, distributors, warehousing pharmacy chains ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (and other direct purchasing groups and \(ii\) indirect customers including independent pharmacies, non-warehousing chains, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.75 166.10 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.53 166.10 Td (s, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 154.10 Td (s and government entities. ) Tj ET Q
q 0 0 0 rg BT 163.30 154.10 Td (W) Tj ET Q
q 0 0 0 rg BT 171.94 154.10 Td (e enter into agreements with certain of our indirect customers to establish contract pricing for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (certain products. ) Tj ET Q
q 0 0 0 rg BT 104.96 142.10 Td (These indirect customers then independently select a wholesaler from which to purchase the products at these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (contracted prices. ) Tj ET Q
q 0 0 0 rg BT 108.47 130.10 Td (Alternatively) Tj ET Q
q 0 0 0 rg BT 160.58 130.10 Td (, we may pre-authorize wholesalers to of) Tj ET Q
q 0 0 0 rg BT 323.39 130.10 Td (fer specified contract pricing to other indirect customers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (Under either arrangement, we provide credit to the wholesaler for any dif) Tj ET Q
q 0 0 0 rg BT 329.03 118.10 Td (ference between the contracted price with the indirect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (customer and the wholesaler) Tj ET Q
q 0 0 0 rg BT 150.50 106.10 Td (�) Tj ET Q
q 0 0 0 rg BT 153.28 106.10 Td (s invoice price. Such credit is called a char) Tj ET Q
q 0 0 0 rg BT 323.86 106.10 Td (geback.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 88.10 Td (Our provision for char) Tj ET Q
q 0 0 0 rg BT 152.52 88.10 Td (gebacks consists of our estimates for the credits described above. ) Tj ET Q
q 0 0 0 rg BT 415.31 88.10 Td (The primary factors we consider in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (developing and evaluating our provision for char) Tj ET Q
q 0 0 0 rg BT 231.32 76.10 Td (gebacks include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 64.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 64.10 Td (the average historical char) Tj ET Q
q 0 0 0 rg BT 190.54 64.10 Td (geback credits;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 52.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 52.10 Td (estimated future sales trends; and) Tj ET Q
endstream
endobj
117 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 118 0 R>>
endobj
118 0 obj
<</Length 13691>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (55) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 742.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 742.10 Td (an estimate of the inventory held by our wholesalers, based on internal analysis of a wholesaler) Tj ET Q
q 0 0 0 rg BT 466.87 742.10 Td (�) Tj ET Q
q 0 0 0 rg BT 469.65 742.10 Td (s historical purchases ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 730.10 Td (and contract sales.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 712.10 Td (Other sales deductions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 694.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 694.10 Td (e of) Tj ET Q
q 0 0 0 rg BT 86.73 694.10 Td (fer prompt-pay cash discounts to certain of our customers. Provisions for such discounts are estimated and recorded at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (the time of sale. ) Tj ET Q
q 0 0 0 rg BT 102.19 682.10 Td (W) Tj ET Q
q 0 0 0 rg BT 110.82 682.10 Td (e estimate provisions for cash discounts based on contractual sales terms with customers, an analysis of unpaid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (invoices and historical payment experience. Estimated cash discounts have historically been predictable and less subjective due to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (the limited number of assumptions involved, the consistency of historical experience and the fact that we generally settle these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (amounts within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.44 646.10 Td (30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.44 646.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.22 646.10 Td (60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.22 646.10 Td ( days.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 628.10 Td (Shelf-stock adjustments are credits issued to our customers to reflect decreases in the selling prices of our products. ) Tj ET Q
q 0 0 0 rg BT 527.41 628.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (credits are customary in the industry and are intended to reduce a customer) Tj ET Q
q 0 0 0 rg BT 336.26 616.10 Td (�) Tj ET Q
q 0 0 0 rg BT 339.04 616.10 Td (s inventory cost to better reflect current market prices. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (The determination to grant a shelf-stock credit to a customer following a price decrease is generally at our discretion, rather than ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (contractually required. ) Tj ET Q
q 0 0 0 rg BT 128.83 592.10 Td (The primary factors we consider when deciding whether to record a reserve for a shelf-stock adjustment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 568.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 568.10 Td (the estimated number of competing products being launched as well as the expected launch date, which we determine ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 556.10 Td (based on market intelligence;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 544.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 544.10 Td (the estimated decline in the market price of our product, which we determine based on historical experience and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 532.10 Td (customer input; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 520.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 520.10 Td (the estimated levels of inventory held by our customers at the time of the anticipated decrease in market price, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 508.10 Td (we determine based upon historical experience and customer input.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (V) Tj ET Q
q 0 0 0 rg BT 41.56 490.10 Td (aluation of long-lived assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 472.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 472.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 472.10 Td (, our combined long-lived assets balance, including property) Tj ET Q
q 0 0 0 rg BT 407.26 472.10 Td (, plant and equipment and finite-lived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (intangible assets, is approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.25 460.10 Td ($3.0 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.36 460.10 Td (. Our finite-lived intangible assets consist of license rights and developed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (technology) Tj ET Q
q 0 0 0 rg BT 79.78 448.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 430.10 Td (Long-lived assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.76 430.10 Td (are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.78 430.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (T) Tj ET Q
q 0 0 0 rg BT 41.41 418.10 Td (o the extent any such asset is deemed to have a finite life, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.55 418.10 Td (it is then amortized over its estimated useful life using either the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (straight-line method or) Tj ET Q
q 0 0 0 rg BT 127.25 406.10 Td (, in the case of certain developed technology assets, an accelerated amortization model.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.26 406.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.58 406.10 Td (The values of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (various assets are subject to continuing scientific, medical and marketplace uncertainty) Tj ET Q
q 0 0 0 rg BT 383.28 394.10 Td (. Factors giving rise to our initial estimate of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (and an acceleration of related amortization expense, which could cause our net income and net income per share to decrease. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (Amortization expense is not recorded on assets held for sale.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 340.10 Td (Long-lived assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.76 340.10 Td (are assessed for impairment whenever events or changes in circumstances indicate the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.35 340.10 Td ( carrying amounts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.55 328.10 Td (assets may not be recoverable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.94 328.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.94 328.10 Td (Recoverability of a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.58 328.10 Td (n ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.08 328.10 Td (asset that will continue to be used in) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.33 328.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.66 328.10 Td (operations is measured by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.10 Td (comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.18 316.10 Td ( In the event the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (impairment may exist. ) Tj ET Q
q 0 0 0 rg BT 127.65 292.10 Td (An impairment loss, if any) Tj ET Q
q 0 0 0 rg BT 233.93 292.10 Td (, is measured as the excess of the asset�) Tj ET Q
q 0 0 0 rg BT 390.82 292.10 Td (s carrying amount over its fair value, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (generally based on a discounted future cash flow method, independent appraisals or of) Tj ET Q
q 0 0 0 rg BT 381.54 280.10 Td (fers from prospective buyers. ) Tj ET Q
q 0 0 0 rg BT 500.67 280.10 Td (An impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.17 268.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 488.12 268.10 Td (As a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (significance of our long-lived assets, any recognized impairment loss could have a material adverse impact on our financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (position and results of operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 226.10 Td (Our reviews of long-lived assets during the two years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.71 226.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.30 226.10 Td ( resulted in certain impairment char) Tj ET Q
q 0 0 0 rg BT 526.56 226.10 Td (ges. ) Tj ET Q
q 0 0 0 rg BT 544.71 226.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (majority of these char) Tj ET Q
q 0 0 0 rg BT 123.29 214.10 Td (ges related to finite-lived intangible assets, which are described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.58 214.10 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.44 214.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 202.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.86 202.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.57 202.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 277.45 202.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.43 202.10 Td (. Our impairment char) Tj ET Q
q 0 0 0 rg BT 456.10 202.10 Td (ges relating to long-lived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (assets were generally based on fair value estimates determined using either discounted cash flow models or of) Tj ET Q
q 0 0 0 rg BT 475.68 190.10 Td (fers from prospective ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (buyers. ) Tj ET Q
q 0 0 0 rg BT 67.48 178.10 Td (When testing a long-lived asset using a discounted cash flow model, we utilize assumptions related to the future operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (performance of the corresponding product based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.09 166.10 Td (management�) Tj ET Q
q 0 0 0 rg BT 298.96 166.10 Td (s annual and ongoing budgeting, forecasting and planning ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (processes, which represent our best estimate of future cash flows. ) Tj ET Q
q 0 0 0 rg BT 300.18 154.10 Td (These estimates are subject to many assumptions, such as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (economic environment in which our segments operate, demand for our products, competitor actions and factors which could af) Tj ET Q
q 0 0 0 rg BT 543.72 142.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (our tax rate. Estimated future pre-tax cash flows are adjusted for taxes using a market participant tax rate and discounted to present ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (value using a market participant, weighted average cost of capital. Financial and credit market volatility directly impacts certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (inputs and assumptions used to develop the weighted average cost of capital such as the risk-free interest rate, industry beta, debt ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (interest rate and our market capital structure. ) Tj ET Q
q 0 0 0 rg BT 217.41 94.10 Td (These assumptions are based on significant inputs not observable in the market and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (thus represent Level 3 measurements within the fair value hierarchy) Tj ET Q
q 0 0 0 rg BT 307.19 82.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 312.01 82.10 Td (The use of dif) Tj ET Q
q 0 0 0 rg BT 367.65 82.10 Td (ferent inputs and assumptions would increase or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.10 Td (decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of our related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.10 Td (impairments, if any) Tj ET Q
q 0 0 0 rg BT 113.39 58.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.89 58.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 118.21 58.10 Td (The discount rates applied to intangible long-lived assets impaired in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.47 58.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.47 58.10 Td ( ranged from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.62 58.10 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.45 58.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.23 58.10 Td (12.0%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.06 58.10 Td (.) Tj ET Q
endstream
endobj
119 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 120 0 R>>
endobj
120 0 obj
<</Length 14217>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (56) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Events giving rise to impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Factors that we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (consider in deciding when to perform an impairment review include significant under) Tj ET Q
q 0 0 0 rg BT 378.19 730.10 Td (-performance of a product line in relation to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (expectations, competitive events af) Tj ET Q
q 0 0 0 rg BT 176.32 718.10 Td (fecting the expected future performance of a product line, significant negative industry or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (economic trends and significant changes or planned changes in our use of the assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.10 Td (Each category of long-lived intangible assets is described further below) Tj ET Q
q 0 0 0 rg BT 348.64 688.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.10 Td (Developed T) Tj ET Q
q 0 0 0 rg BT 112.90 670.10 Td (echnology) Tj ET Q
q 0 0 0 rg BT 153.44 670.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.44 670.10 Td (Our developed technology assets subject to amortization have useful lives ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.68 670.10 Td (4 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.28 670.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (20 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.60 658.10 Td (, with a weighted average useful life of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.41 658.10 Td (1) Tj ET Q
q 0 0 0 rg BT 293.04 658.10 Td (1 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.63 658.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.13 658.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.45 658.10 Td (W) Tj ET Q
q 0 0 0 rg BT 335.09 658.10 Td (e determine amortization periods and methods of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (timing and extent of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (product \(if applicable\), contractual terms and various other competitive and regulatory issues.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.59 622.10 Td ( ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 604.10 Td (License Rights. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.60 604.10 Td (Our license rights subject to amortization have useful lives ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.03 604.10 Td (12 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.62 604.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.40 604.10 Td (15 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.00 604.10 Td (, with a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (weighted average useful life of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.59 592.10 Td (14 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.19 592.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.69 592.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.01 592.10 Td (W) Tj ET Q
q 0 0 0 rg BT 269.65 592.10 Td (e determine amortization periods for licenses based on our assessment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (various factors including the expected launch date of the product, the strength of the intellectual property protection of the product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (\(if applicable\), contractual terms and various other competitive, developmental and regulatory issues.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.42 568.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (Goodwill and indefinite-lived intangible assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 532.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 532.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 532.10 Td (, our combined goodwill and indefinite-lived intangible assets balance is approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.71 532.10 Td ($3.7 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.11 520.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 502.10 Td (Goodwill and indefinite-lived intangible assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.68 502.10 Td (are tested for impairment annually and when events or changes in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (circumstances indicate that the asset might be impaired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.76 490.10 Td (. Our annual assessment is performed as of October 1.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 472.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 472.10 Td (e perform ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.28 472.10 Td (the goodwill impairment test by comparing the fair value and carrying amount of each reporting unit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.66 472.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 520.11 472.10 Td (Any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 139.68 460.10 Td (ge we recognize for a reporting unit is equal to the lesser of \(i\) the total goodwill allocated to that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (reporting unit and \(ii\) the amount by which that reporting unit�) Tj ET Q
q 0 0 0 rg BT 286.50 448.10 Td (s carrying amount exceeds its fair value.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.83 448.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 430.10 Td (Similarly) Tj ET Q
q 0 0 0 rg BT 99.57 430.10 Td (, we perform our indefinite-lived intangible asset impairment tests by comparing the fair value of each intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (asset with its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (loss is recognized in an amount equal to that excess.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 388.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 388.10 Td (e estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.40 388.10 Td (the fair values of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.87 388.10 Td ( our reporting units and of identified indefinite-lived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.04 388.10 Td (intangible assets using an income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (approach that utilizes a discounted cash flow model or) Tj ET Q
q 0 0 0 rg BT 253.31 376.10 Td (, where appropriate, a market approach) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.62 376.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.44 376.10 Td (The discounted cash flow models ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (are dependent upon) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.30 364.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.63 364.10 Td (estimates of future cash flows and other factors including estimates of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.55 364.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.05 364.10 Td (\(i\) future operating performance, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (including future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 279.36 352.10 Td (gins, discount rates, variations in the amount and timing of cash flows ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (and the probability of achieving the estimated cash flows and \(ii\) future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.84 340.10 Td (, all of which may dif) Tj ET Q
q 0 0 0 rg BT 493.74 340.10 Td (fer from actual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (future cash flows.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 310.10 Td (Assumptions related to future operating performance are based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.85 310.10 Td (management�) Tj ET Q
q 0 0 0 rg BT 383.72 310.10 Td (s annual and ongoing budgeting, forecasting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (and planning processes, which represent our best estimate of future cash flows. ) Tj ET Q
q 0 0 0 rg BT 354.61 298.10 Td (These estimates are subject to many assumptions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (such as the economic environment in which our segments operate, demand for our products, competitor actions and factors which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (could af) Tj ET Q
q 0 0 0 rg BT 68.30 274.10 Td (fect our tax rate. Estimated future pre-tax cash flows are adjusted for taxes using a market participant tax rate and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (discounted to present value using a market participant, weighted average cost of capital. Financial and credit market volatility ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (directly impacts certain inputs and assumptions used to develop the weighted average cost of capital such as the risk-free interest ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (rate, industry beta, debt interest rate and our market capital structure. ) Tj ET Q
q 0 0 0 rg BT 314.04 238.10 Td (These assumptions are based on significant inputs not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (observable in the market and thus represent Level 3 measurements within the fair value hierarchy) Tj ET Q
q 0 0 0 rg BT 425.20 226.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 430.02 226.10 Td (The use of dif) Tj ET Q
q 0 0 0 rg BT 485.66 226.10 Td (ferent inputs and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (assumptions would increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (amounts of our related impairments, if any) Tj ET Q
q 0 0 0 rg BT 206.14 202.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.10 Td (In order to assess the reasonableness of the calculated fair values of our reporting units, we also compare the sum of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (reporting units�) Tj ET Q
q 0 0 0 rg BT 97.19 172.10 Td ( fair values to Endo�) Tj ET Q
q 0 0 0 rg BT 178.28 172.10 Td (s market capitalization and calculate an implied control premium \(the excess sum of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (reporting units�) Tj ET Q
q 0 0 0 rg BT 97.19 160.10 Td ( fair values over the market capitalization\) or an implied control discount \(the excess sum of total invested capital ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (over the sum of the reporting units�) Tj ET Q
q 0 0 0 rg BT 176.89 148.10 Td ( fair values\). ) Tj ET Q
q 0 0 0 rg BT 229.47 148.10 Td (The Company evaluates the implied control premium or discount by comparing it ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (to control premiums or discounts of recent comparable market transactions, as applicable. If the control premium or discount is not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (reasonable in light of comparable recent transactions, or recent movements in the Company�) Tj ET Q
q 0 0 0 rg BT 405.04 124.10 Td (s share price, we reevaluate the fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (value estimates of the reporting units by adjusting discount rates and/or other assumptions. ) Tj ET Q
q 0 0 0 rg BT 401.31 112.10 Td (This re-evaluation could correlate to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 100.10 Td (ferent implied fair values for certain or all of the Company�) Tj ET Q
q 0 0 0 rg BT 284.62 100.10 Td (s reporting units.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 82.10 Td (As further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.41 82.10 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.27 82.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.77 82.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.63 82.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.35 82.10 Td (Part ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.10 Td (IV) Tj ET Q
q 0 0 0 rg BT 45.26 70.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.24 70.10 Td (, we recorded pre-tax, non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 367.47 70.10 Td (ges relating to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.46 70.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.13 70.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.10 Td (reporting unit of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.04 58.10 Td ($86.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.93 58.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.37 58.10 Td ($65.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.26 58.10 Td ( during the first and second quarters of 2019, respectively) Tj ET Q
q 0 0 0 rg BT 461.10 58.10 Td (. Following the second-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 46.10 Td (quarter 2019 impairment, there was no remaining goodwill associated with this reporting unit.) Tj ET Q
endstream
endobj
121 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 122 0 R>>
endobj
122 0 obj
<</Length 13740>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (57) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Endo subsequently performed its annual goodwill and indefinite-lived intangible assets impairment tests as of October 1, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (2019. For the purpose of the 2019 annual tests, the Company had three reporting units with goodwill: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.99 730.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.90 730.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.91 718.10 Td ( and Paladin. ) Tj ET Q
q 0 0 0 rg BT 162.17 718.10 Td (The fair values of each of our reporting units and of our indefinite-lived intangible assets were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (determined using an income approach with discount rates ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.70 706.10 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.53 706.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.30 706.10 Td (13.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.13 706.10 Td (, depending on the overall risk associated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (with the particular assets and other market factors. ) Tj ET Q
q 0 0 0 rg BT 239.91 694.10 Td (W) Tj ET Q
q 0 0 0 rg BT 248.55 694.10 Td (e believe the discount rates and other inputs and assumptions are consistent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (with those that a market participant would use. ) Tj ET Q
q 0 0 0 rg BT 225.12 682.10 Td (As a result of the 2019 annual test, the Company recorded a pre-tax non-cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 139.68 670.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.45 670.10 Td ($20.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.34 670.10 Td ( during the fourth quarter of 2019 related to its Paladin reporting unit. No other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (goodwill or indefinite-lived intangible asset impairment char) Tj ET Q
q 0 0 0 rg BT 279.09 658.10 Td (ges were recorded as a result of the 2019 annual test. ) Tj ET Q
q 0 0 0 rg BT 492.34 658.10 Td (A) Tj ET Q
q 0 0 0 rg BT 499.01 658.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.51 658.10 Td (50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.51 658.10 Td ( basis point ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (increase in the assumed discount rate utilized in each test would have increased our Paladin reporting unit goodwill impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 634.10 Td (ge by approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.72 634.10 Td ($5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.12 634.10 Td ( and would not have changed the outcomes of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.73 634.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.63 634.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.07 634.10 Td (Sterile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.31 622.10 Td ( goodwill impairment tests or our indefinite-lived intangible asset impairment tests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 604.10 Td (Additional information about the impairment tests is provided in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.79 604.10 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 604.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.87 592.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.58 592.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 252.45 592.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.43 592.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (Income taxes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.10 Td (Our income tax expense, deferred tax assets and liabilities, income tax payable and reserves for unrecognized tax benefits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (reflect our best assessment of estimated current and future taxes to be paid. ) Tj ET Q
q 0 0 0 rg BT 338.49 544.10 Td (W) Tj ET Q
q 0 0 0 rg BT 347.13 544.10 Td (e are subject to income taxes in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.85 544.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.64 544.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (numerous other jurisdictions in which we operate. Significant judgments and estimates are required in determining the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (consolidated income tax expense or benefit for financial statement purposes. Deferred income taxes arise from temporary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (dif) Tj ET Q
q 0 0 0 rg BT 46.93 508.10 Td (ferences, which result in future taxable or deductible amounts, between the tax basis of assets and liabilities and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (corresponding amounts reported in our Consolidated Financial Statements. In assessing the ability to realize deferred tax assets, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (consider) Tj ET Q
q 0 0 0 rg BT 69.48 484.10 Td (, when appropriate, future taxable income by tax jurisdiction and tax planning strategies. ) Tj ET Q
q 0 0 0 rg BT 425.85 484.10 Td (Where appropriate, we record a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (valuation allowance to reduce our net deferred tax assets to equal an amount that is more likely than not to be realized. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (projecting future taxable income, we consider historical results, adjusted in certain cases for the results of discontinued operations, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (changes in tax laws or nonrecurring transactions. ) Tj ET Q
q 0 0 0 rg BT 234.09 448.10 Td (W) Tj ET Q
q 0 0 0 rg BT 242.73 448.10 Td (e incorporate assumptions about the amount of future earnings within a specific ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (jurisdiction�) Tj ET Q
q 0 0 0 rg BT 84.33 436.10 Td (s pretax income, adjusted for material changes included in business operations. ) Tj ET Q
q 0 0 0 rg BT 402.67 436.10 Td (The assumptions about future taxable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (income require significant judgment and, while these assumptions rely heavily on estimates, such estimates are consistent with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (plans we are using to manage the underlying businesses. Future changes in tax laws and rates, including further administrative or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (regulatory guidance related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.70 400.10 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.60 400.10 Td (, could af) Tj ET Q
q 0 0 0 rg BT 233.90 400.10 Td (fect recorded deferred tax assets and liabilities. ) Tj ET Q
q 0 0 0 rg BT 423.82 400.10 Td (Any adjustments to these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (estimates will generally be recorded as an income tax expense or benefit in the period the adjustment is determined.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 370.10 Td (The calculation of our tax liabilities often involves dealing with uncertainties in the application of complex tax laws and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (regulations in a multitude of jurisdictions across our global operations. ) Tj ET Q
q 0 0 0 rg BT 320.67 358.10 Td (A) Tj ET Q
q 0 0 0 rg BT 327.34 358.10 Td ( benefit from an uncertain tax position may be recognized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (when it is more likely than not that the position will be sustained on the basis of the technical merits upon examination, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (resolutions of any related appeals or litigation processes. ) Tj ET Q
q 0 0 0 rg BT 264.92 334.10 Td (W) Tj ET Q
q 0 0 0 rg BT 273.56 334.10 Td (e first record unrecognized tax benefits as liabilities and then adjust ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (these liabilities when our judgment changes as a result of the evaluation of new information not previously available at the time of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (establishing the liability) Tj ET Q
q 0 0 0 rg BT 131.45 310.10 Td (. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (potentially including interest and penalties, that is materially dif) Tj ET Q
q 0 0 0 rg BT 291.59 298.10 Td (ferent from our current estimate of the unrecognized tax benefit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (liabilities. ) Tj ET Q
q 0 0 0 rg BT 78.04 286.10 Td (These dif) Tj ET Q
q 0 0 0 rg BT 115.34 286.10 Td (ferences, along with any related interest and penalties, will generally be reflected as increases or decreases to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (income tax expense in the period in which new information becomes available.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 256.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 256.10 Td (e make an evaluation at the end of each reporting period as to whether or not some or all of the undistributed earnings of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (our subsidiaries are indefinitely reinvested. ) Tj ET Q
q 0 0 0 rg BT 210.77 244.10 Td (While we may have concluded in the past that some of such undistributed earnings are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (indefinitely reinvested, facts and circumstances may change in the future. Changes in facts and circumstances may include changes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (in the estimated capital needs of our subsidiaries or in our corporate liquidity requirements. Such changes could result in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (management determining that some or all of such undistributed earnings are no longer indefinitely reinvested. In that event, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (would be required to adjust our income tax provision in the period we determined that the earnings will no longer be indefinitely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (reinvested outside the relevant tax jurisdiction.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.10 Td (Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 148.10 Td (The Company is subject to various patent challenges, product liability claims, government investigations and other legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (proceedings in the ordinary course of business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.01 136.10 Td ( Material legal proceedings are discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.44 136.10 Td (Note 15. Commitments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.21 124.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.71 124.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.57 124.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.29 124.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 337.16 124.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.14 124.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.14 124.10 Td (Contingent accruals and legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (settlements are recorded in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.67 112.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.03 112.10 Td ( as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.36 112.10 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.01 112.10 Td ( \(or as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (Discontinued operations, net of tax in the case of vaginal mesh matters\) when the Company determines that a loss is both probable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (and reasonably estimable. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (general and administrative expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.16 76.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.53 76.10 Td ( \(or as Discontinued operations, net of tax in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.10 Td (case of vaginal mesh matters\).) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
123 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 124 0 R>>
endobj
124 0 obj
<</Length 18844>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (58) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (and amount of any such liabilities involve significant judgment regarding future events.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.47 730.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 388.79 730.10 Td (The factors we consider in developing our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (liabilities for legal proceedings include the merits and jurisdiction of the proceeding, the nature and the number of other similar ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (current and past proceedings, the nature of the product and the current assessment of the science subject to the proceeding, if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (applicable, and the likelihood of the conditions of settlement being met.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 676.10 Td (In order to evaluate whether a claim is probable of loss, we may rely on certain information about the claim. ) Tj ET Q
q 0 0 0 rg BT 498.22 676.10 Td (W) Tj ET Q
q 0 0 0 rg BT 507.26 676.10 Td (ithout access ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (to and review of such information, we may not be in a position to determine whether a loss is probable. Further) Tj ET Q
q 0 0 0 rg BT 480.49 664.10 Td (, the timing and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (extent to which we obtain any such information, and our evaluation thereof, is often impacted by items outside of our control ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (including, without limitation, the normal cadence of the litigation process and the provision of claim information to us by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (plaintif) Tj ET Q
q 0 0 0 rg BT 64.70 628.10 Td (f) Tj ET Q
q 0 0 0 rg BT 68.58 628.10 Td (�) Tj ET Q
q 0 0 0 rg BT 71.36 628.10 Td (s counsel. ) Tj ET Q
q 0 0 0 rg BT 113.12 628.10 Td (The amount of our liabilities for legal proceedings may change as we receive additional information and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (become aware of additional asserted or unasserted claims. ) Tj ET Q
q 0 0 0 rg BT 270.08 616.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 319.98 616.10 Td (, there is a possibility that we will suf) Tj ET Q
q 0 0 0 rg BT 469.50 616.10 Td (fer adverse decisions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (or verdicts of substantial amounts or that we will enter into additional monetary settlements, either of which could be in excess of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (amounts previously accrued for) Tj ET Q
q 0 0 0 rg BT 161.80 592.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 166.24 592.10 Td (Any changes to our liabilities for legal proceedings could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.44 592.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 502.32 592.10 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 580.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 562.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 562.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 562.10 Td (, our accrual for loss contingencies totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.63 562.10 Td ($513.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.53 562.10 Td (, the most significant components of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (which relate to product liability and related matters associated with vaginal mesh. ) Tj ET Q
q 0 0 0 rg BT 364.51 550.10 Td (Although we believe there is a reasonable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (excess of the amount recognized at this time.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 505.10 Td (RESUL) Tj ET Q
q 0 0 0 rg BT 68.43 505.10 Td (TS OF) Tj ET Q
q 0 0 0 rg BT 96.67 505.10 Td ( OPERA) Tj ET Q
q 0 0 0 rg BT 133.43 505.10 Td (TIONS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 487.10 Td (Consolidated Results Review) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 469.10 Td (The following table displays our revenue, gross mar) Tj ET Q
q 0 0 0 rg BT 271.10 469.10 Td (gin, gross mar) Tj ET Q
q 0 0 0 rg BT 327.86 469.10 Td (gin percentage and other pre-tax expense or income for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 457.10 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 457.10 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 420.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 420.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 420.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 420.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 420.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 420.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 390.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 390.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 390.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 390.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 390.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 390.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 360.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 360.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 360.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 360.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 360.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 360.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 330.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 330.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 330.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 330.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 330.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 330.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 300.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 300.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 300.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 300.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 300.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 300.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 270.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 270.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 270.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 270.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 270.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 270.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 240.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 240.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 240.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 240.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 240.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 240.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 433.6 m
575.5 433.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 420.6 m
437.5 420.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 420.6 m
506.5 420.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 433.6 m
575.5 433.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 420.6 m
575.5 420.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 420.6 m
437.5 420.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 420.6 m
506.5 420.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 390.6 m
437.5 390.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 375.6 m
437.5 375.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 390.6 m
506.5 390.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 375.6 m
506.5 375.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 375.6 m
437.5 375.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 375.6 m
506.5 375.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 240.60000000000002 m
437.5 240.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 226.60000000000002 m
437.5 226.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 224.60000000000002 m
437.5 224.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 240.60000000000002 m
506.5 240.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 226.60000000000002 m
506.5 226.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 224.60000000000002 m
506.5 224.60000000000002 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 526.35 437.83 Td (% Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 424.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 424.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.90 424.83 Td (2019 vs. 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 410.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 410.27 Td (otal revenues, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 410.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.60 410.27 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 410.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 410.27 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 410.32 Td (\(1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 410.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 395.27 Td (Cost of revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.60 395.27 Td (1,569,338) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 395.27 Td (1,631,682) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 395.32 Td (\(4) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 395.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 380.27 Td (Gross mar) Tj ET Q
q 0 0 0 rg BT 85.29 380.27 Td (gin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 380.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.60 380.27 Td (1,345,026) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 380.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 380.27 Td (1,315,396) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.30 380.27 Td (2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 380.27 Td (%) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 44.00 365.31 Td (Gr) Tj ET Q
q 0 0 0 rg BT 54.74 365.31 Td (oss mar) Tj ET Q
q 0 0 0 rg BT 85.77 365.31 Td (gin per) Tj ET Q
q 0 0 0 rg BT 114.00 365.31 Td (centage) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 411.15 365.31 Td (46.2) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 428.65 365.31 Td (%) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 480.15 365.31 Td (44.6) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 497.65 365.31 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 350.27 Td (Selling, general and administrative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.15 350.27 Td (632,420) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 350.27 Td (646,037) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 350.32 Td (\(2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 350.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 335.27 Td (Research and development) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.15 335.27 Td (130,732) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 335.27 Td (185,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 335.32 Td (\(30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 335.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 320.27 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 320.27 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 320.27 Td (1,21) Tj ET Q
q 0 0 0 rg BT 423.65 320.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 320.27 Td (13,809) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 320.32 Td (\(19) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 320.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 305.27 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 128.44 305.27 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.15 305.27 Td (526,082) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 305.27 Td (916,939) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 305.32 Td (\(43) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 305.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 290.27 Td (Acquisition-related and integration items, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 290.32 Td (\(46,098) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 290.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 290.27 Td (21,914) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.85 290.27 Td (NM) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 275.27 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.15 275.27 Td (538,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 275.27 Td (521,656) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.30 275.27 Td (3) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 275.27 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 260.27 Td (Gain on extinguishment of debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.80 260.32 Td (\(1) Tj ET Q
q 0 0 0 rg BT 401.13 260.32 Td (19,828) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 260.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 260.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.85 260.27 Td (NM) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 245.27 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 245.27 Td (16,677) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 245.32 Td (\(51,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 245.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.85 245.27 Td (NM) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 230.27 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 230.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.80 230.32 Td (\(344,904) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 230.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 230.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.80 230.32 Td (\(938,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 230.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 230.32 Td (\(63) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 230.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 216.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 206.90 Td (NM indicates that the percentage change is not meaningful or is greater than 100%.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 188.90 Td (T) Tj ET Q
q 0 0 0 rg BT 68.19 188.90 Td (otal revenues, net) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 140.69 188.90 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.19 188.90 Td ( Revenues from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.83 188.90 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.75 188.90 Td ( segment, including ) Tj ET Q
q 0 0 0 rg BT 377.66 188.90 Td (V) Tj ET Q
q 0 0 0 rg BT 383.60 188.90 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 438.05 193.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.99 188.90 Td ( and ) Tj ET Q
q 0 0 0 rg BT 461.87 188.90 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 520.20 193.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.14 188.90 Td (, our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 176.90 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.90 176.90 Td ( segment�) Tj ET Q
q 0 0 0 rg BT 176.51 176.90 Td (s Specialty Products portfolio, led by XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 370.10 181.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.03 176.90 Td (,) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 377.53 181.43 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.16 176.90 Td (and recent product launches, as further described ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 164.90 Td (below) Tj ET Q
q 0 0 0 rg BT 59.79 164.90 Td (, increased during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.65 164.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.65 164.90 Td (. Revenues from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.80 164.90 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.70 164.90 Td ( segment�) Tj ET Q
q 0 0 0 rg BT 378.30 164.90 Td (s Established Products portfolio and both our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 152.90 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.67 152.90 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.11 152.90 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.23 152.90 Td ( segments decreased during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.97 152.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.97 152.90 Td (. Our revenues are further disaggregated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 140.90 Td (and described below under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.27 140.90 Td (Business Segment Results Review) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.67 140.90 Td (.�) Tj ET Q
endstream
endobj
125 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 126 0 R>>
endobj
126 0 obj
<</Length 19642>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (59) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.25 Td (Cost of revenues) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 131.33 749.25 Td ( and gross margin percentage.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.06 749.25 Td ( During the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.11 749.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.11 749.25 Td (, we incurred certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.25 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 737.25 Td (ges that impact the comparability of total Cost of revenues, including those related to amortization expense and retention and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.25 Td (separation benefits and other cost reduction initiatives, including restructurings. ) Tj ET Q
q 0 0 0 rg BT 357.12 725.25 Td (The following table summarizes such amounts \(in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.25 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 689.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 689.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 689.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 689.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 689.75 m
506.5 689.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 689.75 m
575.5 689.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 689.75 m
506.5 689.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 689.75 m
575.5 689.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 693.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 693.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 679.42 Td (Amortization of intangible assets \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 679.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 679.42 Td (543,862) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 679.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 679.42 Td (622,339) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 664.42 Td (Retention and separation benefits and other cost reduction initiatives \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 664.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 664.42 Td (5,693) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 664.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 664.42 Td (60,434) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 650.65 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 641.05 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 641.05 Td (Amortization expense fluctuates based on changes in the total amount of amortizable intangible assets and the rate of amortization in ef) Tj ET Q
q 0 0 0 rg BT 500.99 641.05 Td (fect for each intangible ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 631.45 Td (asset, both of which can vary based on factors such as the amount and timing of acquisitions, dispositions, asset impairment char) Tj ET Q
q 0 0 0 rg BT 479.49 631.45 Td (ges, transfers between ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 621.85 Td (indefinite- and finite-lived intangibles assets, changes in foreign currency rates and changes in the composition of our intangible assets impacting the weighted ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 612.25 Td (average useful lives and amortization methodologies being utilized. ) Tj ET Q
q 0 0 0 rg BT 285.73 612.25 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 300.17 612.25 Td (decrease) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 327.70 612.25 Td ( in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 337.93 612.25 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 353.93 612.25 Td ( was primarily driven by asset impairment char) Tj ET Q
q 0 0 0 rg BT 504.63 612.25 Td (ges and decreases in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 602.65 Td (the rate of amortization expense for certain assets, partially of) Tj ET Q
q 0 0 0 rg BT 265.05 602.65 Td (fset by the impact of certain in-process research and development assets put into service. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 593.05 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 593.05 Td (Amounts primarily relate to certain accelerated depreciation char) Tj ET Q
q 0 0 0 rg BT 275.47 593.05 Td (ges, employee separation costs, char) Tj ET Q
q 0 0 0 rg BT 391.73 593.05 Td (ges to increase excess inventory reserves related to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 583.45 Td (restructurings and other cost reduction and restructuring char) Tj ET Q
q 0 0 0 rg BT 262.62 583.45 Td (ges. See ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 290.84 583.45 Td (Note 4. Restructuring) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 359.93 583.45 Td ( in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 381.93 583.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 493.02 583.45 Td ( included in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 532.79 583.45 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 555.09 583.45 Td (, Item ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 573.85 Td (15 of this report) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 118.82 573.85 Td ( for discussion of our material restructuring initiatives.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 555.85 Td (Reductions to amortization expense and expenses related to retention and separation benefits and other cost reduction initiatives ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 543.85 Td (resulted in�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.43 543.85 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.85 543.85 Td (d Cost of revenues�and�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.99 543.85 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.75 543.85 Td (d gross mar) Tj ET Q
q 0 0 0 rg BT 288.23 543.85 Td (gin percentage. ) Tj ET Q
q 0 0 0 rg BT 351.63 543.85 Td (The overall�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.94 543.85 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.35 543.85 Td ( in revenues described above also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 531.85 Td (contributed to the�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.04 531.85 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.45 531.85 Td ( in�Cost of revenues. Changes in product mix partially of) Tj ET Q
q 0 0 0 rg BT 370.73 531.85 Td (fset these items. ) Tj ET Q
q 0 0 0 rg BT 437.20 531.85 Td (These changes in mix included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 519.85 Td (both the favorable impact of overall shifts ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.22 519.85 Td (to higher mar) Tj ET Q
q 0 0 0 rg BT 259.92 519.85 Td (gin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.19 519.85 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.11 519.85 Td ( and Specialty Products from lower mar) Tj ET Q
q 0 0 0 rg BT 506.33 519.85 Td (gin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.61 519.85 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 507.85 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 507.85 Td ( and Established Products, as well as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.95 507.85 Td (the unfavorable impact of increased sales of certain lower mar) Tj ET Q
q 0 0 0 rg BT 499.82 507.85 Td (gin authorized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 495.85 Td (generic products launched since the third quarter of 2018.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 477.85 Td (Selling, general and administrative) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 207.46 477.85 Td ( expenses.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.12 477.85 Td ( ) Tj ET Q
q 0 0 0 rg BT 251.44 477.85 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.48 477.85 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.90 477.85 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.68 477.85 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.68 477.85 Td ( was primarily driven by decreases in long-term incentive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 465.85 Td (compensation costs related primarily to the timing of certain 2018 awards, the impact of certain separations, restructurings and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 453.85 Td (cost reduction initiatives and a lower branded prescription drug fee. ) Tj ET Q
q 0 0 0 rg BT 308.78 453.85 Td (These decreases were partially of) Tj ET Q
q 0 0 0 rg BT 441.86 453.85 Td (fset by increased costs related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 441.85 Td (our continued investment and promotional ef) Tj ET Q
q 0 0 0 rg BT 216.05 441.85 Td (forts behind XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 309.37 446.38 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.31 441.85 Td (, costs associated with our planned commercial launch of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.35 441.85 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.91 441.85 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 429.85 Td (for the treatment of cellulite in the buttocks, a third-quarter 2019 premium associated with an extended reporting period endorsement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 417.85 Td (on an expiring insurance program, increased legal costs related to certain litigation matters and costs related to retention bonuses ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 405.85 Td (awarded to certain senior management of the Company in 2019. Our material restructuring initiatives and legal proceedings and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 393.85 Td (contingent matters are described more fully in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.88 393.85 Td (Note 4. Restructuring) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.25 393.85 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.69 393.85 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.95 393.85 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 551.61 393.85 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 381.85 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 381.85 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.58 381.85 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.30 381.85 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 267.17 381.85 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.15 381.85 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 363.85 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 363.85 Td (e expect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.17 363.85 Td (Selling, general and administrative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.57 363.85 Td ( expense in 2020 to increase compared to 2019, primarily due to costs associated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 351.85 Td (with our planned commercial launch of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.95 351.85 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.51 351.85 Td ( for the treatment of cellulite in the buttocks, if approved.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 333.85 Td (R&D) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 84.67 333.85 Td ( expenses.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.33 333.85 Td ( ) Tj ET Q
q 0 0 0 rg BT 128.65 333.85 Td (The amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.02 333.85 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.69 333.85 Td ( expense we record in any period varies depending on the nature and stage of development ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 321.85 Td (of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.66 321.85 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.33 321.85 Td ( programs and can also vary in periods in which we incur significant upfront or milestone char) Tj ET Q
q 0 0 0 rg BT 461.82 321.85 Td (ges related to agreements ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 309.85 Td (with third parties.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 291.85 Td (In recent years, our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.68 291.85 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.35 291.85 Td ( ef) Tj ET Q
q 0 0 0 rg BT 174.44 291.85 Td (forts have focused primarily on developing a balanced, diversified portfolio of innovative and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 279.85 Td (clinically dif) Tj ET Q
q 0 0 0 rg BT 86.63 279.85 Td (ferentiated product candidates. ) Tj ET Q
q 0 0 0 rg BT 211.95 279.85 Td (W) Tj ET Q
q 0 0 0 rg BT 220.59 279.85 Td (e have been progressing and expect to continue to progress our cellulite treatment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 267.85 Td (development program. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.03 267.85 Td (In early 2020, we announced that we had initiated our XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 389.78 272.38 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.72 267.85 Td ( development programs for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 255.85 Td (plantar fibromatosis and adhesive capsulitis.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.46 255.85 Td ( ) Tj ET Q
q 0 0 0 rg BT 215.78 255.85 Td (W) Tj ET Q
q 0 0 0 rg BT 224.41 255.85 Td (e also expect to continue to focus investments in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.59 255.85 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.50 255.85 Td ( segment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 243.85 Td (potentially including license and commercialization agreements such as our Nevakar) Tj ET Q
q 0 0 0 rg BT 374.64 243.85 Td (, Inc. agreement, which is further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 231.85 Td (Note 1) Tj ET Q
q 0 0 0 rg BT 62.57 231.85 Td (1. License and Collaboration ) Tj ET Q
q 0 0 0 rg BT 180.04 231.85 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.35 231.85 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.85 231.85 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.72 231.85 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.43 231.85 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 472.30 231.85 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 562.28 231.85 Td (. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 219.85 Td (addition, we are conducting an open-label Phase 1 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.54 219.85 Td (pharmacokinetic \(PK\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.12 219.85 Td ( study of ) Tj ET Q
q 0 0 0 rg BT 365.44 219.85 Td (V) Tj ET Q
q 0 0 0 rg BT 371.38 219.85 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 425.83 224.38 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.77 219.85 Td ( in healthy volunteers, studying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 207.85 Td (plasma clearance with ) Tj ET Q
q 0 0 0 rg BT 127.16 207.85 Td (TT) Tj ET Q
q 0 0 0 rg BT 139.20 207.85 Td ( genotype versus ) Tj ET Q
q 0 0 0 rg BT 208.35 207.85 Td (AA/A) Tj ET Q
q 0 0 0 rg BT 231.69 207.85 Td (T) Tj ET Q
q 0 0 0 rg BT 237.62 207.85 Td ( genotype.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 189.85 Td (In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.83 189.85 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.83 189.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.83 189.85 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.50 189.85 Td ( expense ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.71 189.85 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.12 189.85 Td (d, primarily due to reduced costs associated with our clinical trials of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.65 189.85 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.21 189.85 Td ( for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 177.85 Td (cellulite, the impact of a 2018 upfront payment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.61 177.85 Td ($35.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.50 177.85 Td ( related to the Nevakar) Tj ET Q
q 0 0 0 rg BT 382.16 177.85 Td (, Inc. agreement and the impact of certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 165.85 Td (separations, restructurings and other cost reduction initiatives. Partially of) Tj ET Q
q 0 0 0 rg BT 331.30 165.85 Td (fsetting these decreases was the impact of costs associated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 153.85 Td (with certain post-marketing commitments. Our material restructuring initiatives are described more fully in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.54 153.85 Td (Note 4. Restructuring) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.91 153.85 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 141.85 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 141.85 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.58 141.85 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.30 141.85 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 267.17 141.85 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.15 141.85 Td (. ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 123.85 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 254.39 123.85 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.89 123.85 Td ( Included within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.93 123.85 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.59 123.85 Td ( are changes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 111.85 Td (our accruals for litigation-related settlement char) Tj ET Q
q 0 0 0 rg BT 231.01 111.85 Td (ges and certain settlement proceeds related to suits filed by our subsidiaries. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 99.85 Td (material legal proceedings and other contingent matters are described in more detail in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.48 99.85 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.74 99.85 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 87.85 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 87.85 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.58 87.85 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.30 87.85 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 267.17 87.85 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.15 87.85 Td (. ) Tj ET Q
q 0 0 0 rg BT 361.60 87.85 Td (As further described therein, adjustments to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 75.85 Td (corresponding liability accruals may be required in the future. ) Tj ET Q
q 0 0 0 rg BT 285.73 75.85 Td (This could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.04 75.85 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 434.93 75.85 Td (fect on our business, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 63.85 Td (condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.80 63.85 Td (.) Tj ET Q
endstream
endobj
127 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 128 0 R>>
endobj
128 0 obj
<</Length 20062>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (60) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.25 Td (Asset impairment charges) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 169.67 749.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.17 749.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 174.49 749.25 Td (The following table presents the components of our total ) Tj ET Q
q 0 0 0 rg BT 403.05 749.25 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 493.40 749.25 Td (ges for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.11 749.25 Td (years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.25 Td (ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.40 737.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 713.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 713.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 713.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 713.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 683.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 683.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 683.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 683.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 713.75 m
506.5 713.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 713.75 m
575.5 713.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 668.75 m
506.5 668.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 654.75 m
506.5 654.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 652.75 m
506.5 652.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 668.75 m
575.5 668.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 654.75 m
575.5 654.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 652.75 m
575.5 652.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 717.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 717.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 704.32 Td (Goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 143.99 704.32 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 703.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 703.42 Td (171,908) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 703.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 703.42 Td (680,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 689.32 Td (Other intangible asset impairment char) Tj ET Q
q 0 0 0 rg BT 193.41 689.32 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 688.42 Td (347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 688.42 Td (230,418) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 674.32 Td (Property) Tj ET Q
q 0 0 0 rg BT 71.79 674.32 Td (, plant and equipment impairment char) Tj ET Q
q 0 0 0 rg BT 226.56 674.32 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 673.42 Td (6,468) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 673.42 Td (6,521) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 659.32 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 659.32 Td (otal asset impairment char) Tj ET Q
q 0 0 0 rg BT 154.47 659.32 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 658.42 Td (526,082) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 658.42 Td (916,939) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 636.25 Td (The factors leading to our material goodwill and intangible asset impairment tests, as well as the results of these tests, are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 624.25 Td (further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.80 624.25 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.66 624.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.15 624.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.02 624.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.73 624.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 524.60 624.25 Td (, Item 15 of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 612.25 Td (this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 76.83 612.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 81.27 612.25 Td (A) Tj ET Q
q 0 0 0 rg BT 87.94 612.25 Td ( discussion of critical accounting estimates made in connection with certain of our impairment tests is included above ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 600.25 Td (under the caption �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 112.36 600.25 Td (CRITICAL) Tj ET Q
q 0 0 0 rg BT 158.09 600.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 160.04 600.25 Td (ACCOUNTING ESTIMA) Tj ET Q
q 0 0 0 rg BT 264.76 600.25 Td (TES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.54 600.25 Td (.�) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 582.25 Td (Acquisition-related and integration items, net) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 249.96 582.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.46 582.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.41 582.25 Td (Acquisition-related and integration items, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.75 582.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.53 582.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.53 582.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.97 582.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.97 582.25 Td ( primarily ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 570.25 Td (consist of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.83 570.25 Td (net \(benefit\) expense from changes in the fair value of acquisition-related contingent consideration) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.67 570.25 Td ( liabilities resulting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 558.25 Td (from changes to our estimates regarding the timing and amount of the future revenues of the underlying products and changes in other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 546.25 Td (assumptions impacting the probability of incurring, and extent to which we could incur) Tj ET Q
q 0 0 0 rg BT 384.13 546.25 Td (, related contingent obligations. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.93 546.25 Td (Note 6. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 534.25 Td (Fair ) Tj ET Q
q 0 0 0 rg BT 54.43 534.25 Td (V) Tj ET Q
q 0 0 0 rg BT 60.54 534.25 Td (alue Measurements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.01 534.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.51 534.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.37 534.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.09 534.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 381.96 534.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.94 534.25 Td ( for further discussion of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 522.25 Td (our acquisition-related contingent consideration.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 504.25 Td (Interest expense, net) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 147.72 504.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.72 504.25 Td (The components of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.42 504.25 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.33 504.25 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.71 504.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.70 504.25 Td ( are as follows ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 492.25 Td (\(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 468.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 468.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 468.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 468.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 438.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 438.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 438.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 438.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 468.75 m
506.5 468.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 468.75 m
575.5 468.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 438.75 m
506.5 438.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 424.75 m
506.5 424.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 422.75 m
506.5 422.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 438.75 m
575.5 438.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 424.75 m
575.5 424.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 422.75 m
575.5 422.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 472.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 472.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 458.42 Td (Interest expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 457.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 457.42 Td (558,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 457.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 457.42 Td (534,850) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 443.42 Td (Interest income) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 442.47 Td (\(19,946) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 442.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 442.42 Td (\(13,194) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 442.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 428.42 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 427.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 427.42 Td (538,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 427.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 427.42 Td (521,656) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 406.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 406.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 406.25 Td ( in interest expense in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.50 406.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.50 406.25 Td ( was primarily attributable to changes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.06 406.25 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.06 406.25 Td ( that impacted our variable-rate debt, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (increases to the weighted average interest rate applicable to our senior notes and senior secured notes following the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.17 394.25 Td (March 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (Refinancing ) Tj ET Q
q 0 0 0 rg BT 87.19 382.25 Td (T) Tj ET Q
q 0 0 0 rg BT 92.95 382.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.93 382.25 Td ( and interest expense associated with our June 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.04 382.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.26 382.25 Td ( draw of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.08 382.25 Td ($300.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.97 382.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 548.79 382.25 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (increases were partially of) Tj ET Q
q 0 0 0 rg BT 141.04 370.25 Td (fset by the reductions to the amount of our indebtedness associated with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.25 370.25 Td (March 2019 Refinancing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (T) Tj ET Q
q 0 0 0 rg BT 41.76 358.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.74 358.25 Td (. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.73 358.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.10 358.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.60 358.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.47 358.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.18 358.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 427.05 358.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.03 358.25 Td ( for further ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (discussion of these transactions. Changes in interest rates could increase our interest expense in the future, which could have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.68 346.25 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 334.25 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 334.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 316.25 Td (Interest income varies primarily based on the amounts of our interest-bearing investments, such as money market funds, as well ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.25 Td (as changes in the corresponding interest rates.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 286.25 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 218.30 286.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.80 286.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 223.12 286.25 Td (The gain on extinguishment of debt recognized in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.73 286.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.73 286.25 Td ( relates to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.82 286.25 Td (March 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (Refinancing ) Tj ET Q
q 0 0 0 rg BT 87.19 274.25 Td (T) Tj ET Q
q 0 0 0 rg BT 92.95 274.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.93 274.25 Td (. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.92 274.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.30 274.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.79 274.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.66 274.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.37 274.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 478.24 274.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.22 274.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (for further discussion.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 244.25 Td (Other expense \(income\), net) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 179.09 244.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.59 244.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 183.91 244.25 Td (The components of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.62 244.25 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.90 244.25 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.28 244.25 Td (years ended December 31, 2019 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 232.25 Td ( are as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 208.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 208.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 208.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 208.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 178.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 178.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 178.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 178.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 148.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 148.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 148.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 148.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 208.75 m
506.5 208.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 208.75 m
575.5 208.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 148.75 m
506.5 148.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 148.75 m
575.5 148.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 134.75 m
506.5 134.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 132.75 m
506.5 132.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 134.75 m
575.5 134.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 132.75 m
575.5 132.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 212.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 212.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 198.42 Td (Net gain on sale of business and other assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 198.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 198.47 Td (\(6,367) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 198.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 198.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 198.42 Td (\(45,155) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 198.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 183.42 Td (Foreign currency loss \(gain\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 183.42 Td (5,247) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 183.42 Td (\(3,762) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 183.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 168.42 Td (Net loss from our investments in the equity of other companies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 168.42 Td (2,346) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 168.42 Td (3,444) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 153.42 Td (Other miscellaneous, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 153.42 Td (15,451) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 153.42 Td (\(6,480) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 153.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 138.42 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 138.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 138.42 Td (16,677) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 138.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 138.42 Td (\(51,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 138.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 116.25 Td (For additional information on the components of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.47 116.25 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.75 116.25 Td (, refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.40 116.25 Td (Note 19. Other Expense \(Income\), Net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.07 116.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 104.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 104.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.58 104.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.30 104.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 267.17 104.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.15 104.25 Td (.) Tj ET Q
endstream
endobj
129 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 130 0 R>>
endobj
130 0 obj
<</Length 18656>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (61) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.25 Td (Income tax expense \(benefit\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.14 749.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 186.96 749.25 Td (The following table displays our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.44 749.25 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.38 749.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.38 749.25 Td (Income tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.25 Td (expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.21 737.25 Td ( and Ef) Tj ET Q
q 0 0 0 rg BT 96.90 737.25 Td (fective tax rate for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.68 737.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.68 737.25 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 713.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 713.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 713.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 713.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 683.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 683.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 683.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 683.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 713.75 m
506.5 713.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 713.75 m
575.5 713.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 717.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 717.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 703.42 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 703.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.45 703.42 Td (\(344,904) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.30 703.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 703.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.45 703.42 Td (\(938,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 703.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 688.42 Td (Income tax expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 688.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.75 688.42 Td (15,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 688.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.75 688.42 Td (22,935) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 44.00 673.46 Td (Effective tax rate) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 478.45 673.46 Td (\(4.5) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 494.30 673.46 Td (\)%) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 547.45 673.51 Td (\(2.4) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 563.30 673.46 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 651.25 Td (Our tax rate is af) Tj ET Q
q 0 0 0 rg BT 130.01 651.25 Td (fected by recurring items, such as tax rates in non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.61 651.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.39 651.25 Td ( jurisdictions as compared to the notional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.86 651.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.64 651.25 Td ( federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 639.25 Td (statutory tax rate, and the relative amount of income or loss in those various jurisdictions. It is also impacted by certain items that may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 627.25 Td (occur in any given period, but are not consistent from period to period.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 609.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 609.25 Td (income tax expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.90 609.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.68 609.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.68 609.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.18 609.25 Td (primarily related to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.38 609.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.88 609.25 Td (accrued interest on uncertain tax positions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.93 609.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 448.25 609.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.30 609.25 Td (income tax expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.15 609.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 597.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 597.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.50 597.25 Td (primarily related to the establishment of a valuation allowance against certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.44 597.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.22 597.25 Td ( deferred tax assets.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 579.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 579.25 Td (e have valuation allowances established against our deferred tax assets in most jurisdictions in which we operate, with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 567.25 Td (exception of Canada and India. ) Tj ET Q
q 0 0 0 rg BT 162.62 567.25 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 211.96 567.25 Td (, it would be unlikely for future pre-tax losses to create a tax benefit that would be more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 555.25 Td (likely than not to be realized. ) Tj ET Q
q 0 0 0 rg BT 154.57 555.25 Td (Although the Company has valuation allowances established against deferred tax assets in most major ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 543.25 Td (jurisdictions as of December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.19 543.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.19 543.25 Td (, it is possible that there could be material reversals, particularly if certain proposed law changes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 531.25 Td (were to be enacted.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 513.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 513.25 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.61 513.25 Td ( presently is examining certain of our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 298.31 513.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.81 513.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.60 513.25 Td ( income tax returns for fiscal years ended between December ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 501.25 Td (31, 201) Tj ET Q
q 0 0 0 rg BT 65.63 501.25 Td (1 and December 31, 2015 and, in connection with those examinations, is reviewing our tax positions related to, among other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 489.25 Td (things, certain intercompany arrangements, including the level of profit earned by our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.44 489.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.22 489.25 Td ( subsidiaries pursuant to such arrangements, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 477.25 Td (and a worthless stock deduction directly attributable to product liability losses. ) Tj ET Q
q 0 0 0 rg BT 352.97 477.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.02 477.25 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.58 477.25 Td ( may examine our tax returns for other fiscal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 465.25 Td (years and/or for other tax positions. Similarly) Tj ET Q
q 0 0 0 rg BT 217.26 465.25 Td (, other tax authorities, including the Canada Revenue ) Tj ET Q
q 0 0 0 rg BT 431.64 465.25 Td (Agency) Tj ET Q
q 0 0 0 rg BT 462.09 465.25 Td (, are currently examining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 453.25 Td (our non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.16 453.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.94 453.25 Td ( tax returns. ) Tj ET Q
q 0 0 0 rg BT 137.38 453.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 187.28 453.25 Td (, other jurisdictions where we are not currently under audit remain subject to potential future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 441.25 Td (examinations. Such examinations may lead to proposed or actual adjustments to our taxes that may be material, individually or in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 429.25 Td (aggregate.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.36 429.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 79.31 429.25 Td (An adverse outcome of these tax examinations could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.45 429.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 397.33 429.25 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 417.25 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 417.25 Td (. See the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.43 417.25 Td (W) Tj ET Q
q 0 0 0 rg BT 272.07 417.25 Td (e may not be able to successfully maintain our low tax rates or other tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 405.25 Td (positions, which could adversely af) Tj ET Q
q 0 0 0 rg BT 177.18 405.25 Td (fect our businesses and financial condition, results of operations and growth prospects) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.54 405.25 Td (� in Part I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 393.25 Td (Item 1A) Tj ET Q
q 0 0 0 rg BT 68.50 393.25 Td ( of this document for more information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 375.25 Td (For additional information on our income taxes, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.67 375.25 Td (Note 20. Income ) Tj ET Q
q 0 0 0 rg BT 341.92 375.25 Td (T) Tj ET Q
q 0 0 0 rg BT 347.33 375.25 Td (axes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.09 375.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.59 375.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.46 375.25 Td ( included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 363.25 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.28 363.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 74.15 363.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.13 363.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 345.25 Td (Discontinued operations, net of tax.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.24 345.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 212.56 345.25 Td (The operating results of the Company�) Tj ET Q
q 0 0 0 rg BT 366.69 345.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.53 345.25 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.19 345.25 Td ( business, which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.23 345.25 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.67 345.25 Td ( resolved to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 333.25 Td (wind-down in 2016, are reported as Discontinued operations, net of tax in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.42 333.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.78 333.25 Td ( for all periods ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 321.25 Td (presented. ) Tj ET Q
q 0 0 0 rg BT 79.13 321.25 Td (The results of our discontinued operations, net of tax, were losses of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.62 321.25 Td ($62.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.51 321.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.95 321.25 Td ($69.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.84 321.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.62 321.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.62 321.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.06 321.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.06 321.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 309.25 Td (respectively) Tj ET Q
q 0 0 0 rg BT 83.66 309.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 88.48 309.25 Td (These amounts consist of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.35 309.25 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.01 309.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.34 309.25 Td ($30.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.23 309.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.67 309.25 Td ($34.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.56 309.25 Td (, respectively) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.22 309.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 297.25 Td (mesh-related legal defense costs and certain other items) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.96 297.25 Td (. For additional discussion of mesh-related matters, refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.07 297.25 Td (Note 15. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 285.25 Td (Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.32 285.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.82 285.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.68 285.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.39 285.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 413.27 285.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.25 285.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 267.25 Td (Key T) Tj ET Q
q 0 0 0 rg BT 86.78 267.25 Td (rends. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.57 267.25 Td (W) Tj ET Q
q 0 0 0 rg BT 123.21 267.25 Td (e estimate that the following factors will impact our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.87 267.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.87 267.25 Td ( total revenues as compared to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.71 267.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.71 267.25 Td (:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 255.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 255.25 Td (growth in the Specialty Products portfolio of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.69 255.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.60 255.25 Td ( segment, primarily driven by increased ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 243.25 Td (revenues following continued investments in XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 310.18 247.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.12 243.25 Td (;) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 231.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 231.25 Td (growth in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.33 231.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.24 231.25 Td ( segment, driven by continued performance of ) Tj ET Q
q 0 0 0 rg BT 400.22 231.25 Td (V) Tj ET Q
q 0 0 0 rg BT 406.15 231.25 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 460.60 235.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.54 231.25 Td (, partially of) Tj ET Q
q 0 0 0 rg BT 514.51 231.25 Td (fset by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 219.25 Td (declines in certain other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.79 219.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.71 219.25 Td ( due to assumed competitive pressures; and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 207.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 207.25 Td (declines in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.76 207.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.43 207.25 Td ( segment, the Established Products portfolio of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.12 207.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.02 207.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 195.25 Td (segment and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.98 195.25 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.10 195.25 Td ( segment, primarily driven by competitive pressures impacting these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 183.25 Td (product portfolios. ) Tj ET Q
q 0 0 0 rg BT 162.25 183.25 Td (The expected decline in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.70 183.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.37 183.25 Td ( segment primarily relates to assumed competition ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 171.25 Td (for colchicine tablets, the authorized generic of Colcrys) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 307.63 175.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.57 171.25 Td (. For more information, see the risk factor �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.96 171.25 Td (If we fail to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 159.25 Td (successfully identify and develop additional branded and generic pharmaceutical products, obtain and maintain exclusive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 147.25 Td (marketing rights for our branded and generic products or fail to introduce branded and generic products on a timely basis, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 135.25 Td (our revenues, gross mar) Tj ET Q
q 0 0 0 rg BT 180.85 135.25 Td (gin and operating results may decline.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.02 135.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 117.25 Td (These estimated trends reflect the current expectations of the Company�) Tj ET Q
q 0 0 0 rg BT 350.39 117.25 Td (s management team based on information currently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 105.25 Td (known to them. ) Tj ET Q
q 0 0 0 rg BT 100.81 105.25 Td (These estimates are subject to risks and uncertainties that could cause our actual results to dif) Tj ET Q
q 0 0 0 rg BT 473.57 105.25 Td (fer materially from those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 93.25 Td (indicated by such estimated trends.) Tj ET Q
endstream
endobj
131 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 132 0 R>>
endobj
132 0 obj
<</Length 15117>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (62) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (Business Segment Results Review) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (During the first quarter of 2019, the Company changed the names of its reportable segments. ) Tj ET Q
q 0 0 0 rg BT 436.33 731.25 Td (This change, which was intended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (to simplify the segments�) Tj ET Q
q 0 0 0 rg BT 136.63 719.25 Td ( names, had no impact on the Company�) Tj ET Q
q 0 0 0 rg BT 297.71 719.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.11 719.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.97 719.25 Td ( or segment results for any of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (periods presented. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.24 707.25 Td (Note 5. Segment Results) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.12 707.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.62 707.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.48 707.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.20 707.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 489.07 707.25 Td (, Item 15 of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.88 695.25 Td ( for further details regarding this change, our reportable segments in general and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.65 695.25 Td (segment adjusted income from continuing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.25 Td (operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.34 683.25 Td ( \(the measure we use to evaluate segment performance\), as well as reconciliations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.86 683.25 Td (T) Tj ET Q
q 0 0 0 rg BT 498.27 683.25 Td (otal consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.25 Td (loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.62 671.25 Td (, which is determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.22 671.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.62 671.25 Td (, to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.73 671.25 Td (total segment adjusted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.25 Td (income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.49 659.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 641.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 641.25 Td (e refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.22 641.25 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.36 641.25 Td (, a financial measure not defined by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.86 641.25 Td (U.S. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.25 Td (GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.12 629.25 Td (, in making operating decisions because we believe it provides meaningful supplemental information regarding our operational ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.25 Td (performance. For instance, we believe that this measure facilitates internal comparisons to our historical operating results and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.25 Td (comparisons to competitors�) Tj ET Q
q 0 0 0 rg BT 149.13 605.25 Td ( results. ) Tj ET Q
q 0 0 0 rg BT 182.55 605.25 Td (W) Tj ET Q
q 0 0 0 rg BT 191.19 605.25 Td (e believe this measure is useful to investors in allowing for greater transparency related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.25 Td (supplemental information used in our financial and operational decision-making. Further) Tj ET Q
q 0 0 0 rg BT 391.06 593.25 Td (, we believe that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.09 593.25 Td (segment adjusted income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.25 Td (from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.55 581.25 Td ( may be useful to investors as we are aware that certain of our significant shareholders ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.25 Td (utilize ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.49 569.25 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.63 569.25 Td ( to evaluate our financial performance. Finally) Tj ET Q
q 0 0 0 rg BT 535.74 569.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.74 569.25 Td (segment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.31 557.25 Td ( is utilized in the calculation of other financial measures not determined ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.25 Td (in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.02 545.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.16 545.25 Td ( that are used by the Compensation Committee of the Company�) Tj ET Q
q 0 0 0 rg BT 418.33 545.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.72 545.25 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.16 545.25 Td ( in assessing the performance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.25 Td (and compensation of substantially all of our employees, including our executive of) Tj ET Q
q 0 0 0 rg BT 366.84 533.25 Td (ficers.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 515.25 Td (There are limitations to using financial measures such as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.10 515.25 Td (segment adjusted income from continuing operations before income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 503.25 Td (tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 48.22 503.25 Td (. Other companies in our industry may define ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.34 503.25 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.48 503.25 Td ( dif) Tj ET Q
q 0 0 0 rg BT 532.90 503.25 Td (ferently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 491.25 Td (than we do. ) Tj ET Q
q 0 0 0 rg BT 84.33 491.25 Td (As a result, it may be dif) Tj ET Q
q 0 0 0 rg BT 182.73 491.25 Td (ficult to use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.45 491.25 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.58 491.25 Td ( or similarly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 479.25 Td (named adjusted financial measures that other companies may use to compare the performance of those companies to our performance. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 467.25 Td (Because of these limitations, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.47 467.25 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.61 467.25 Td ( is not intended to represent cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 455.25 Td (flow from operations as defined by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.74 455.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.88 455.25 Td ( and should not be used as an indicator of operating performance, a measure of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 443.25 Td (liquidity or as alternative to net income, cash flows or any other financial measure determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.78 443.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.18 443.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 544.00 443.25 Td (W) Tj ET Q
q 0 0 0 rg BT 552.64 443.25 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 431.25 Td (compensate for these limitations by providing, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.85 431.25 Td (Note 5. Segment Results) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.73 431.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.23 431.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.10 431.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.81 431.25 Td (Part ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 419.25 Td (IV) Tj ET Q
q 0 0 0 rg BT 45.26 419.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.24 419.25 Td (, reconciliations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.26 419.25 Td (T) Tj ET Q
q 0 0 0 rg BT 217.67 419.25 Td (otal consolidated loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.82 419.25 Td (, which is determined ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.25 Td (in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.02 407.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.42 407.25 Td (, to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.53 407.25 Td (total segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.94 407.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 389.25 Td (Revenues, net. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.22 389.25 Td (The following table displays our revenue by reportable segment for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.07 389.25 Td (years ended December 31, 2019 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 377.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 377.25 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 340.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 340.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 340.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 340.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 340.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 340.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 310.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 310.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 310.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 310.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 310.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 310.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 280.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 280.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 280.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 280.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 280.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 280.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 353.75 m
575.5 353.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 340.75 m
437.5 340.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 340.75 m
506.5 340.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 353.75 m
575.5 353.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 340.75 m
575.5 340.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 280.75 m
437.5 280.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 266.75 m
437.5 266.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 264.75 m
437.5 264.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 280.75 m
506.5 280.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 266.75 m
506.5 266.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 264.75 m
506.5 264.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.35 357.98 Td (% Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 344.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 344.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.90 344.98 Td (2019 vs. 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 330.42 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 330.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 330.42 Td (855,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 330.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 330.42 Td (862,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 330.47 Td (\(1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 330.42 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 315.42 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 315.42 Td (1,063,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 315.42 Td (929,566) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 315.42 Td (14) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 315.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 300.42 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 300.42 Td (879,882) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 300.42 Td (1,012,215) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 300.47 Td (\(13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 300.42 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 285.42 Td (International Pharmaceuticals \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 285.42 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 285.42 Td (15,949) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 285.42 Td (142,465) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 285.47 Td (\(19) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 285.42 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 270.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 270.42 Td (otal net revenues from external customers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 270.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 270.42 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 270.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 270.42 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 270.47 Td (\(1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 270.42 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 258.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 248.65 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 248.65 Td (Revenues generated by our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 156.36 248.65 Td (International Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 251.65 248.65 Td ( segment are primarily attributable to external customers located in Canada. ) Tj ET Q
endstream
endobj
133 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 134 0 R>>
endobj
134 0 obj
<</Length 24189>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (63) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.70 749.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 172.52 749.10 Td (The following table displays the significant components of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.08 749.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.99 749.10 Td ( revenues ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (from external customers for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.56 737.10 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.56 737.10 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 700.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 700.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 700.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 700.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 700.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 700.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 670.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 670.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 670.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 670.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 670.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 670.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 640.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 640.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 640.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 640.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 640.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 640.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 610.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 610.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 610.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 610.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 610.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 610.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 580.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 580.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 580.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 580.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 580.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 580.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 550.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 550.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 550.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 550.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 550.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 550.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 713.6 m
575.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 700.6 m
437.5 700.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 700.6 m
506.5 700.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 700.6 m
575.5 700.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 700.6 m
437.5 700.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 700.6 m
506.5 700.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 640.6 m
437.5 640.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 640.6 m
506.5 640.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 625.6 m
437.5 625.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 625.6 m
506.5 625.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 565.6 m
437.5 565.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 565.6 m
506.5 565.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 565.6 m
437.5 565.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 550.6 m
437.5 550.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 565.6 m
506.5 565.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 550.6 m
506.5 550.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 536.6 m
437.5 536.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 534.6 m
437.5 534.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 536.6 m
506.5 536.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 534.6 m
506.5 534.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.35 717.83 Td (% Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 398.50 704.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 467.50 704.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.90 704.83 Td (2019 vs. 2018) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 690.31 Td (Specialty Pr) Tj ET Q
q 0 0 0 rg BT 86.96 690.31 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 675.27 Td (XIAFLEX�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 674.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 674.27 Td (327,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 674.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 674.27 Td (264,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 674.27 Td (24) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 674.27 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 660.27 Td (SUPPRELIN� LA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 659.27 Td (86,797) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 659.27 Td (81,707) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.30 659.27 Td (6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 659.27 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 645.27 Td (Other Specialty \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 644.27 Td (105,241) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 644.27 Td (98,230) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.30 644.27 Td (7) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 644.27 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 630.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 630.27 Td (otal Specialty Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 629.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 629.27 Td (519,676) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 629.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 629.27 Td (444,575) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 629.27 Td (17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 629.27 Td (%) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 615.31 Td (Established Pr) Tj ET Q
q 0 0 0 rg BT 96.79 615.31 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 600.27 Td (PERCOCET�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 599.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 599.27 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 599.27 Td (16,012) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 599.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 599.27 Td (122,901) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 599.32 Td (\(6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 599.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 585.27 Td (TEST) Tj ET Q
q 0 0 0 rg BT 67.80 585.27 Td (OPEL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 584.27 Td (55,244) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 584.27 Td (58,377) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 584.32 Td (\(5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 584.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 570.27 Td (Other Established \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 569.27 Td (164,470) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 569.27 Td (236,979) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 569.32 Td (\(31) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 569.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 555.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 555.27 Td (otal Established Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 554.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 554.27 Td (335,726) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 554.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 554.27 Td (418,257) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 554.32 Td (\(20) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 554.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 540.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 540.27 Td (otal Branded Pharmaceuticals \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 539.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 539.27 Td (855,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 539.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 539.27 Td (862,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 539.32 Td (\(1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 539.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 526.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 516.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 516.90 Td (Products included within Other Specialty are NASCOBAL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 256.36 520.52 Td (� ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 261.61 516.90 Td (Nasal Spray and ) Tj ET Q
q 0 0 0 rg BT 315.60 516.90 Td (A) Tj ET Q
q 0 0 0 rg BT 320.34 516.90 Td (VEED) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 341.67 520.52 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 345.62 516.90 Td (. Beginning with our first-quarter 2019 reporting, ) Tj ET Q
q 0 0 0 rg BT 505.22 516.90 Td (TEST) Tj ET Q
q 0 0 0 rg BT 524.19 516.90 Td (OPEL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 544.19 520.52 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 548.14 516.90 Td (, which ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 507.30 Td (was previously included in Other Specialty) Tj ET Q
q 0 0 0 rg BT 204.95 507.30 Td (, has been reclassified and is now included in the Established Products portfolio for all periods presented.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 497.70 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 497.70 Td (Products included within Other Established include, but are not limited to, LIDODERM) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 349.45 501.32 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 353.40 497.70 Td (, EDEX) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 378.73 501.32 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 382.68 497.70 Td ( and ) Tj ET Q
q 0 0 0 rg BT 398.09 497.70 Td (VOL) Tj ET Q
q 0 0 0 rg BT 413.79 497.70 Td (T) Tj ET Q
q 0 0 0 rg BT 418.04 497.70 Td (AREN) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 439.82 501.32 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 443.77 497.70 Td ( Gel.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 488.10 Td (\(3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 488.10 Td (Individual products presented above represent the top two performing products in each product category for the year ended December 31, 2019 and/or any ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 478.50 Td (product having revenues in excess of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 187.91 478.50 Td ($100 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 229.02 478.50 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 231.02 478.50 Td (during any of the years ended December 31, 2019, 2018 or 2017 or) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 446.07 478.50 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 448.07 478.50 Td ($25 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 485.18 478.50 Td ( during any quarterly period ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 468.90 Td (in 2019 or 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 118.39 468.90 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 450.90 Td (Specialty Pr) Tj ET Q
q 0 0 0 rg BT 98.28 450.90 Td (oducts) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 432.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 432.90 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 432.90 Td ( in XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 169.35 437.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.29 432.90 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.07 432.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.07 432.90 Td ( was primarily attributable to demand growth driven by the continued investment and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 420.90 Td (promotional ef) Tj ET Q
q 0 0 0 rg BT 94.97 420.90 Td (forts behind XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 188.29 425.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.23 420.90 Td (, as well as price.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 402.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 402.90 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 402.90 Td ( in SUPPRELIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 179.92 407.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.86 402.90 Td ( LA) Tj ET Q
q 0 0 0 rg BT 200.14 402.90 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.92 402.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.92 402.90 Td ( was primarily attributable to increases in both volume and price.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 384.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 384.90 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 384.90 Td ( in Other Specialty Products in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.34 384.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.34 384.90 Td ( was primarily attributable to increased volume of both NASCOBAL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 535.67 389.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.61 384.90 Td ( Nasal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 372.90 Td (Spray and ) Tj ET Q
q 0 0 0 rg BT 78.22 372.90 Td (A) Tj ET Q
q 0 0 0 rg BT 84.15 372.90 Td (VEED) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 110.81 377.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.75 372.90 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 354.90 Td (Established Pr) Tj ET Q
q 0 0 0 rg BT 108.29 354.90 Td (oducts) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 336.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 336.90 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.46 336.90 Td ( in PERCOCET) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 179.36 341.43 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.29 336.90 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.07 336.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.07 336.90 Td ( was primarily attributable to decreased volume, partially of) Tj ET Q
q 0 0 0 rg BT 456.53 336.90 Td (fset by increased price.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 318.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 318.90 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.46 318.90 Td ( in ) Tj ET Q
q 0 0 0 rg BT 128.06 318.90 Td (TEST) Tj ET Q
q 0 0 0 rg BT 151.76 318.90 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 176.76 323.43 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.33 318.90 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.61 318.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.61 318.90 Td ( was primarily attributable to both price and volume decreases.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 300.90 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 300.90 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.46 300.90 Td ( in Other Established Products in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.89 300.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.89 300.90 Td ( was primarily attributable to volume decreases as a result of ongoing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 288.90 Td (competitive pressures.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 270.90 Td (Sterile Injectables) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 135.48 270.90 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.48 270.90 Td (The following table displays the significant components of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.04 270.90 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.95 270.90 Td ( revenues from external ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 258.90 Td (customers for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.92 258.90 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.92 258.90 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 222.40 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 222.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 222.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 222.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 222.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 222.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 192.40 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 192.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 192.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 192.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 192.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 192.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 162.40 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 162.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 162.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 162.40 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 162.40 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 162.40 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 235.39999999999998 m
575.5 235.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 222.39999999999998 m
437.5 222.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 222.39999999999998 m
506.5 222.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 222.39999999999998 m
575.5 222.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 222.39999999999998 m
575.5 222.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 147.39999999999998 m
437.5 147.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 133.39999999999998 m
437.5 133.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 131.39999999999998 m
437.5 131.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 147.39999999999998 m
506.5 147.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 133.39999999999998 m
506.5 133.39999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 131.39999999999998 m
506.5 131.39999999999998 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.35 239.63 Td (% Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 226.63 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 226.63 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.90 226.63 Td (2019 vs. 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 212.07 Td (V) Tj ET Q
q 0 0 0 rg BT 44.58 212.07 Td (ASOSTRICT�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 212.07 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 212.07 Td (531,737) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 212.07 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 212.07 Td (453,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 212.07 Td (17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 212.07 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 197.07 Td (ADRENALIN�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 197.07 Td (179,295) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 197.07 Td (143,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 197.07 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 197.07 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 182.97 Td (Ertapenem for injection) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 182.07 Td (104,679) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 182.07 Td (57,668) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 182.07 Td (82) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 182.07 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 167.97 Td (APLISOL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 167.07 Td (61,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 167.07 Td (64,913) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 167.12 Td (\(5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 167.07 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 152.97 Td (Other Sterile Injectables \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 152.07 Td (185,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 152.07 Td (209,729) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 152.12 Td (\(12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 152.07 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 137.97 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 137.97 Td (otal Sterile Injectables \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 137.07 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 137.07 Td (1,063,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 137.07 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 137.07 Td (929,566) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 137.07 Td (14) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 137.07 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 124.90 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 115.30 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 115.30 Td (Products included within Other Sterile Injectables include ephedrine sulfate injection, treprostinil for injection and others.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 105.70 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 105.70 Td (Individual products presented above represent the top two performing products within the Sterile Injectables segment for the year ended December 31, 2019 ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 96.10 Td (and/or any product having revenues in excess of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 223.89 96.10 Td ($100 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 265.01 96.10 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 267.01 96.10 Td (during any of the years ended December 31, 2019, 2018 or 2017 or) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 482.06 96.10 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 484.06 96.10 Td ($25 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 521.17 96.10 Td ( during any ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 86.50 Td (quarterly period in 2019 or 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.70 86.50 Td (.) Tj ET Q
endstream
endobj
135 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 136 0 R>>
endobj
136 0 obj
<</Length 19490>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (64) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 749.10 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 749.10 Td ( in ) Tj ET Q
q 0 0 0 rg BT 126.40 749.10 Td (V) Tj ET Q
q 0 0 0 rg BT 132.33 749.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 186.78 753.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.35 749.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.63 749.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.63 749.10 Td ( was primarily attributable to changes in price, volume and mix of business. ) Tj ET Q
q 0 0 0 rg BT 528.83 749.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (December 31, 2019, we have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.12 737.10 Td (six) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.79 737.10 Td ( patents for ) Tj ET Q
q 0 0 0 rg BT 214.10 737.10 Td (V) Tj ET Q
q 0 0 0 rg BT 220.03 737.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 274.48 741.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.42 737.10 Td ( listed in the Orange Book and additional patents pending with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.14 737.10 Td (PT) Tj ET Q
q 0 0 0 rg BT 558.63 737.10 Td (O) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.85 737.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.05 725.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.50 725.10 Td ( requires any applicant seeking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.84 725.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.30 725.10 Td ( approval for vasopressin prior to patent expiry and relying on ) Tj ET Q
q 0 0 0 rg BT 469.88 725.10 Td (V) Tj ET Q
q 0 0 0 rg BT 475.81 725.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 530.27 729.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.21 725.10 Td ( as the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (reference-listed drug to notify us of its filing before the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.26 713.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.71 713.10 Td ( will issue an approval. ) Tj ET Q
q 0 0 0 rg BT 373.14 713.10 Td (As further discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.57 713.10 Td (Note 15. Commitments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.15 701.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.65 701.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.51 701.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.22 701.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 354.10 701.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.08 701.10 Td ( under the heading ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 689.10 Td (V) Tj ET Q
q 0 0 0 rg BT 46.37 689.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 100.82 693.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.39 689.10 Td (Related Matters) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.98 689.10 Td (,� we are aware of certain competitive actions taken by other pharmaceutical companies related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (V) Tj ET Q
q 0 0 0 rg BT 41.93 677.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 96.39 681.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.32 677.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 106.14 677.10 Td (W) Tj ET Q
q 0 0 0 rg BT 114.78 677.10 Td (e have taken and plan to continue to take actions in our best interest to protect our rights with respect to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (V) Tj ET Q
q 0 0 0 rg BT 41.93 665.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 96.39 669.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.32 665.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 106.14 665.10 Td (The introduction of any competing versions of ) Tj ET Q
q 0 0 0 rg BT 294.53 665.10 Td (V) Tj ET Q
q 0 0 0 rg BT 300.46 665.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 354.92 669.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.85 665.10 Td ( could result in reductions to our market share, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (revenues, profitability and cash flows.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 635.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 635.10 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.80 635.10 Td ( in ) Tj ET Q
q 0 0 0 rg BT 126.03 635.10 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 184.35 639.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.92 635.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.19 635.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.19 635.10 Td ( was primarily attributable to increased price and volume.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 617.10 Td (Ertapenem for injection, the authorized generic of Invanz) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 292.34 621.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.28 617.10 Td (, launched during the third quarter of 2018. ) Tj ET Q
q 0 0 0 rg BT 472.05 617.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.10 617.10 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.85 617.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.63 617.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.63 617.10 Td ( was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td (driven by the timing of this product�) Tj ET Q
q 0 0 0 rg BT 180.98 605.10 Td (s launch.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 587.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 587.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.46 587.10 Td ( in ) Tj ET Q
q 0 0 0 rg BT 127.69 587.10 Td (APLISOL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 168.80 591.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.36 587.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.64 587.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.64 587.10 Td ( was primarily attributable to decreased volume, partially of) Tj ET Q
q 0 0 0 rg BT 445.10 587.10 Td (fset by increased price.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 569.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.46 569.10 Td ( in Other Sterile Injectables in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.20 569.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.20 569.10 Td ( was primarily driven by certain competitive pressures impacting multiple ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (products in this portfolio.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 539.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 165.47 539.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.97 539.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 170.29 539.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.34 539.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.75 539.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.13 539.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.80 539.10 Td ( segment in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.40 539.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.40 539.10 Td ( was primarily attributable to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (continued competitive pressure on commoditized generic products. Partially of) Tj ET Q
q 0 0 0 rg BT 351.56 527.10 Td (fsetting the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.77 527.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.19 527.10 Td ( were the impacts of certain recent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 515.10 Td (product launches including, among others, the second-quarter 2019 launch of albuterol sulfate HF) Tj ET Q
q 0 0 0 rg BT 426.82 515.10 Td (A) Tj ET Q
q 0 0 0 rg BT 433.49 515.10 Td ( inhalation aerosol, the authorized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 503.10 Td (generic of Proventil) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 115.42 507.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.36 503.10 Td (, and the third-quarter 2018 launch of colchicine tablets.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 485.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.04 485.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 190.86 485.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.90 485.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.32 485.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.69 485.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.81 485.10 Td ( segment in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.41 485.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.41 485.10 Td ( was primarily attributable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (to competitive pressures in certain international markets and the impact of certain product discontinuation activities.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 455.10 Td (Segment adjusted income from continuing operations before income tax. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.23 455.10 Td (The following table displays our segment adjusted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 443.10 Td (income from continuing operations before income tax by reportable segment for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.22 443.10 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.22 443.10 Td ( \(dollars ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 431.10 Td (in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 394.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 394.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 394.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 394.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 394.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 394.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 364.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 364.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 364.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 364.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 364.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 364.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 407.6 m
575.5 407.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 394.6 m
437.5 394.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 394.6 m
506.5 394.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 394.6 m
575.5 394.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.35 411.83 Td (% Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 398.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 398.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.90 398.83 Td (2019 vs. 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 384.27 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 384.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 384.27 Td (362,71) Tj ET Q
q 0 0 0 rg BT 428.65 384.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 384.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 384.27 Td (368,790) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.95 384.32 Td (\(2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 384.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 369.27 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 369.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 369.27 Td (780,799) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 369.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 369.27 Td (695,363) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 369.27 Td (12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 369.27 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 354.27 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 354.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 354.27 Td (158,400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 354.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 354.27 Td (317,892) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 354.32 Td (\(50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 354.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 339.27 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 339.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 339.27 Td (44,758) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 339.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 339.27 Td (59,094) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 339.32 Td (\(24) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 339.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 317.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 167.70 317.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.20 317.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 172.52 317.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.57 317.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.98 317.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.76 317.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.76 317.10 Td ( was primarily attributable to increased costs related to our continued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.10 Td (investment and promotional ef) Tj ET Q
q 0 0 0 rg BT 158.29 305.10 Td (forts behind XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 251.61 309.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.17 305.10 Td (and costs associated with our planned commercial launch of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.15 305.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.71 305.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.10 Td (treatment of cellulite in the buttocks. ) Tj ET Q
q 0 0 0 rg BT 185.50 293.10 Td (This was of) Tj ET Q
q 0 0 0 rg BT 231.98 293.10 Td (fset by increased gross mar) Tj ET Q
q 0 0 0 rg BT 340.65 293.10 Td (gins resulting from changes in product mix and lower ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.67 281.10 Td ( expense resulting from reduced costs associated with our clinical trials of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.91 281.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.47 281.10 Td (, partially of) Tj ET Q
q 0 0 0 rg BT 425.44 281.10 Td (fset by increased costs associated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (with certain post-marketing commitments.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 251.10 Td (Sterile Injectables) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 135.48 251.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.48 251.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.52 251.10 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.28 251.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.05 251.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.05 251.10 Td ( was primarily driven by increased revenues and gross mar) Tj ET Q
q 0 0 0 rg BT 459.07 251.10 Td (gins resulting from strong ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 239.10 Td (performance across several products in this segment.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 221.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 165.47 221.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.97 221.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 170.29 221.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.34 221.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.75 221.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.53 221.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.53 221.10 Td ( was primarily attributable to decreased revenues as described above and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (resulting reduction to gross mar) Tj ET Q
q 0 0 0 rg BT 163.02 209.10 Td (gin. ) Tj ET Q
q 0 0 0 rg BT 180.24 209.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 230.15 209.10 Td (, gross mar) Tj ET Q
q 0 0 0 rg BT 274.13 209.10 Td (gin was negatively impacted by changes in product mix resulting from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (increased sales of certain lower mar) Tj ET Q
q 0 0 0 rg BT 179.36 197.10 Td (gin authorized generic products. ) Tj ET Q
q 0 0 0 rg BT 310.52 197.10 Td (These decreases were partially of) Tj ET Q
q 0 0 0 rg BT 443.60 197.10 Td (fset by reduced expenses ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (including the impact of certain restructuring and other cost saving initiatives and a lower branded prescription drug fee. Our material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.10 Td (restructuring initiatives are described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.33 173.10 Td (Note 4. Restructuring) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.71 173.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.20 173.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.07 173.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.78 173.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 527.65 173.10 Td (, Item 15 of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 161.10 Td (this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 76.83 161.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 143.10 Td (International Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 186.04 143.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.54 143.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 190.86 143.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.90 143.10 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.32 143.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.10 143.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.10 143.10 Td ( was primarily attributable to decreased revenues as described above and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.10 Td (the resulting reduction to gross mar) Tj ET Q
q 0 0 0 rg BT 177.73 131.10 Td (gin.) Tj ET Q
endstream
endobj
137 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 138 0 R>>
endobj
138 0 obj
<</Length 17647>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (65) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (LIQUIDITY) Tj ET Q
q 0 0 0 rg BT 90.09 749.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 92.04 749.25 Td (AND CAPIT) Tj ET Q
q 0 0 0 rg BT 146.57 749.25 Td (AL) Tj ET Q
q 0 0 0 rg BT 159.91 749.25 Td ( RESOURCES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Our principal source of liquidity is cash generated from operations. Our principal liquidity requirements are primarily for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (working capital for operations, licenses, milestone payments, capital expenditures, acquisitions, contingent liabilities, debt service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (payments and litigation-related matters, including vaginal mesh liability payments. ) Tj ET Q
q 0 0 0 rg BT 369.91 707.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 429.62 707.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.01 707.25 Td (working capital) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.49 707.25 Td ( was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.04 707.25 Td ($1,125.9 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 695.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.11 695.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.69 695.25 Td ( compared to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.39 695.25 Td (working capital) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.88 695.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.21 695.25 Td ($393.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.10 695.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.31 695.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.90 695.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 440.72 695.25 Td (The amounts at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.87 695.25 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 683.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.44 683.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.02 683.25 Td ( include restricted cash and cash equivalents of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.51 683.25 Td ($242.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.40 683.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.84 683.25 Td ($299.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.73 683.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 534.39 683.25 Td (, held in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.25 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.24 671.25 Td ( for mesh-related matters. ) Tj ET Q
q 0 0 0 rg BT 162.92 671.25 Td (Although these amounts in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.91 671.25 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.15 671.25 Td ( are included in working capital, they are required to be used for mesh ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.25 Td (product liability settlement agreements.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 641.25 Td (Cash and cash equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.25 641.25 Td (, which primarily consisted of bank deposits and money market accounts, totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.28 641.25 Td ($1,454.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.67 641.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 629.25 Td ( compared to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.29 629.25 Td ($1,149.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.68 629.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.89 629.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.48 629.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 331.30 629.25 Td (W) Tj ET Q
q 0 0 0 rg BT 339.94 629.25 Td (e expect our operating cash flows, together with our cash, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.25 Td (cash equivalents, restricted cash and restricted cash equivalents, to be suf) Tj ET Q
q 0 0 0 rg BT 328.49 617.25 Td (ficient to cover our principal liquidity requirements over the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.25 Td (next year) Tj ET Q
q 0 0 0 rg BT 72.37 605.25 Td (. However) Tj ET Q
q 0 0 0 rg BT 113.62 605.25 Td (, on a longer term basis, we may not be able to accurately predict the ef) Tj ET Q
q 0 0 0 rg BT 398.61 605.25 Td (fect of certain developments on our sales ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.25 Td (and gross mar) Tj ET Q
q 0 0 0 rg BT 91.92 593.25 Td (gins, such as the degree of market acceptance, patent protection and exclusivity of our products, pricing pressures ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.25 Td (\(including those due to the impact of competition\), the ef) Tj ET Q
q 0 0 0 rg BT 264.09 581.25 Td (fectiveness of our sales and marketing ef) Tj ET Q
q 0 0 0 rg BT 427.18 581.25 Td (forts and the outcome of our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.25 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 569.25 Td (forts to develop, receive approval for and successfully launch our product candidates. ) Tj ET Q
q 0 0 0 rg BT 387.73 569.25 Td (W) Tj ET Q
q 0 0 0 rg BT 396.37 569.25 Td (e may also face unexpected expenses in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (connection with our business operations, including expenses related to our ongoing and future legal proceedings and governmental ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.25 Td (investigations and other contingent liabilities. Furthermore, we may not be successful in implementing, or may face unexpected ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.25 Td (changes or expenses in connection with our strategic direction, including the potential for opportunistic corporate development ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 521.25 Td (transactions. ) Tj ET Q
q 0 0 0 rg BT 88.21 521.25 Td (Any of the above could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.89 521.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 288.77 521.25 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.25 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 509.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 491.25 Td (From time to time, we may seek to enter into certain transactions to reduce our leverage and/or interest expense and/or to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 479.25 Td (extend the maturities of our outstanding indebtedness. Such transactions could include, for example, transactions to exchange existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 467.25 Td (indebtedness for our ordinary shares, to issue equity \(including convertible securities\) or to repurchase, redeem, exchange or refinance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 455.25 Td (our existing indebtedness \(including the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.47 455.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 225.41 455.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.84 455.25 Td (\). In order to finance any such transactions, we may need to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 443.25 Td (additional funding and in certain circumstances we may issue additional secured indebtedness. ) Tj ET Q
q 0 0 0 rg BT 416.17 443.25 Td (Any of these transactions could impact ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 431.25 Td (our liquidity or results of operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 413.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 413.25 Td (e may also require additional financing to fund our future operational needs or for future corporate transactions, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 401.25 Td (acquisitions. ) Tj ET Q
q 0 0 0 rg BT 88.59 401.25 Td (W) Tj ET Q
q 0 0 0 rg BT 97.23 401.25 Td (e have historically had broad access to financial markets that provide liquidity; however) Tj ET Q
q 0 0 0 rg BT 448.93 401.25 Td (, we cannot be certain that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 389.25 Td (funding will be available to us in the future on terms acceptable to us, or at all. ) Tj ET Q
q 0 0 0 rg BT 352.30 389.25 Td (Any issuances of equity securities or convertible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 377.25 Td (securities, in connection with an acquisition or otherwise, could have a dilutive ef) Tj ET Q
q 0 0 0 rg BT 362.39 377.25 Td (fect on the ownership interest of our current ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 365.25 Td (shareholders and may adversely impact net income per share in future periods. ) Tj ET Q
q 0 0 0 rg BT 352.28 365.25 Td (An acquisition may be accretive or dilutive and, by its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 353.25 Td (nature, involves numerous risks and uncertainties. ) Tj ET Q
q 0 0 0 rg BT 238.18 353.25 Td (As a result of acquisition ef) Tj ET Q
q 0 0 0 rg BT 348.25 353.25 Td (forts, if any) Tj ET Q
q 0 0 0 rg BT 393.97 353.25 Td (, we are likely to experience significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 341.25 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 341.25 Td (ges to earnings for mer) Tj ET Q
q 0 0 0 rg BT 145.04 341.25 Td (ger and related expenses \(whether or not the acquisitions are consummated\) that may include transaction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 329.25 Td (costs, closure costs or costs of restructuring activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 311.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 311.25 Td (e consider the undistributed earnings from the majority of our subsidiaries as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.39 311.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.98 311.25 Td ( to be indefinitely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 299.25 Td (reinvested outside of Ireland and, accordingly) Tj ET Q
q 0 0 0 rg BT 218.62 299.25 Td (, neither income tax nor withholding taxes have been provided thereon. ) Tj ET Q
q 0 0 0 rg BT 505.48 299.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 287.25 Td (, indefinitely reinvested earnings were approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.34 287.25 Td ($1,092.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.73 287.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 401.55 287.25 Td (W) Tj ET Q
q 0 0 0 rg BT 410.19 287.25 Td (e do not anticipate incurring tax in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.25 Td (deploying funds to satisfy liquidity needs arising in the ordinary course of business.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 257.25 Td (Indebtedness) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 116.89 257.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.39 257.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 121.71 257.25 Td (The Company and/or certain of its subsidiaries are party to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.14 257.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 401.08 257.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.50 257.25 Td ( governing the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.77 257.25 Td (Credit Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.92 257.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.25 Td (\(as defined in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.92 245.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.30 245.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.80 245.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.66 245.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.38 245.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 393.25 245.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.23 245.25 Td (\) and the indentures ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.25 Td (governing our various senior secured and senior unsecured notes. ) Tj ET Q
q 0 0 0 rg BT 299.26 233.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.71 233.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.29 233.25 Td (, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.55 233.25 Td ($3.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.66 233.25 Td ( was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.25 Td (outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.97 221.25 Td (T) Tj ET Q
q 0 0 0 rg BT 130.38 221.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.38 221.25 Td (, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.63 221.25 Td ($0.3 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.75 221.25 Td ( was outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.45 221.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.66 221.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.25 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 209.25 Td ($4.8 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.37 209.25 Td ( was outstanding under the senior secured and senior unsecured notes.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 191.25 Td (After giving ef) Tj ET Q
q 0 0 0 rg BT 122.24 191.25 Td (fect to previous borrowings and issued and outstanding letters of credit, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.33 191.25 Td ($0.7 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.44 191.25 Td ( of remaining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 179.25 Td (credit was available under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.89 179.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.10 179.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.32 179.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.90 179.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 355.72 179.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 415.43 179.25 Td (s outstanding debt agreements contain a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 167.25 Td (number of restrictive covenants, including certain limitations on the Company�) Tj ET Q
q 0 0 0 rg BT 351.48 167.25 Td (s ability to incur additional indebtedness.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 149.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 149.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 107.99 149.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.41 149.25 Td ( and the indentures governing our various notes contains certain covenants. ) Tj ET Q
q 0 0 0 rg BT 455.11 149.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.55 149.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.14 149.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 137.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 137.25 Td (, the Company was in compliance with all such covenants. In addition, after each fiscal year) Tj ET Q
q 0 0 0 rg BT 482.59 137.25 Td (-end, the Company is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.25 Td (required to perform a calculation of Excess Cash Flow \(as defined in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.41 125.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 355.35 125.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.77 125.25 Td (\), which could result in certain pre-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 113.25 Td (payments of the principal relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.27 113.25 Td (T) Tj ET Q
q 0 0 0 rg BT 203.68 113.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.33 113.25 Td ( in accordance with the terms of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.82 113.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 447.77 113.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.19 113.25 Td (. No such payment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.25 Td (is required at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.70 101.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.29 101.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 83.25 Td (Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.99 83.25 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.36 83.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.86 83.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.72 83.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.44 83.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 398.31 83.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.29 83.25 Td ( for additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 71.25 Td (information about our indebtedness, including information about covenants, maturities, interest rates, security and priority) Tj ET Q
q 0 0 0 rg BT 523.84 71.25 Td (.) Tj ET Q
endstream
endobj
139 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 140 0 R>>
endobj
140 0 obj
<</Length 23262>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (66) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.25 Td (Credit ratings. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.96 749.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 184.67 749.25 Td (s corporate credit ratings assigned by Moody�) Tj ET Q
q 0 0 0 rg BT 367.40 749.25 Td (s Investors Service and Standard & Poor) Tj ET Q
q 0 0 0 rg BT 529.97 749.25 Td (�) Tj ET Q
q 0 0 0 rg BT 532.75 749.25 Td (s are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.84 749.25 Td (B3) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.51 749.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.25 Td (with a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.22 737.25 Td (stable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.54 737.25 Td ( outlook and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.04 737.25 Td (B) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.71 737.25 Td ( with a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.42 737.25 Td (negative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.30 737.25 Td ( outlook, respectively) Tj ET Q
q 0 0 0 rg BT 295.01 737.25 Td (. No report of any rating agency is being incorporated by reference ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.25 Td (herein.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 707.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.15 707.25 Td (orking capital) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 128.65 707.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.65 707.25 Td (The components of our working capital and our liquidity at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.04 707.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.63 707.25 Td ( and December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
1 1 1 rg
/GS0 gs
529.65 714.18 20.00 -8.93 re f
/GS0 gs
q 0 0 0 rg BT 529.65 707.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.65 707.25 Td ( are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (below \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 663.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 633.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 633.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 633.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 663.75 m
506.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 663.75 m
575.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 633.75 m
506.5 633.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 633.75 m
575.5 633.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 633.75 m
506.5 633.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 619.75 m
506.5 619.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 617.75 m
506.5 617.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 633.75 m
575.5 633.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 619.75 m
575.5 619.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 617.75 m
575.5 617.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 675.98 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 675.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 667.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 675.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 675.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 667.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 653.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 653.42 Td (otal current assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 653.42 Td (2,586,218) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 653.42 Td (2,343,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 638.42 Td (Less: total current liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 638.42 Td (1,460,289) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 638.42 Td (1,950,096) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 623.42 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 623.42 Td (orking capital) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 623.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 623.42 Td (1,125,929) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 623.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 623.42 Td (393,054) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 608.42 Td (Current ratio \(total current assets divided by total current liabilities\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.70 608.42 Td (1.8:1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.70 608.42 Td (1.2:1) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 586.25 Td (Net working capital ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.92 586.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.67 586.25 Td (d by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.67 586.25 Td ($732.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.56 586.25 Td ( from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.00 586.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.59 586.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.37 586.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.95 586.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 455.77 586.25 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.05 586.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.80 586.25 Td ( primarily ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (reflects the increase to cash of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.27 574.25 Td ($300.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.16 574.25 Td ( as a result of the June 2019 borrowing under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.17 574.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.38 574.25 Td ( and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.25 Td (favorable impact to net current assets resulting from operations during the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.60 562.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.19 562.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 464.01 562.25 Td (This activity was partially ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.25 Td (of) Tj ET Q
q 0 0 0 rg BT 44.15 550.25 Td (fset by certain items that occurred during the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.83 550.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.42 550.25 Td ( including, but not limited to, the impact of adopting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.95 538.25 Td (, which resulted in a net decrease to working capital of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.24 538.25 Td ($10.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.13 538.25 Td (, purchases of property) Tj ET Q
q 0 0 0 rg BT 499.12 538.25 Td (, plant and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (equipment, excluding capitalized interest, of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.21 526.25 Td ($63.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.11 526.25 Td ( and our incurrence of financing fees in connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.41 526.25 Td (March 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (Refinancing ) Tj ET Q
q 0 0 0 rg BT 87.19 514.25 Td (T) Tj ET Q
q 0 0 0 rg BT 92.95 514.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.93 514.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 496.25 Td (The following table summarizes our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.46 496.25 Td (Consolidated Statements of Cash Flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.90 496.25 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.28 496.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.27 496.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (\(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 460.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 460.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 460.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 460.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 430.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 430.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 430.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 430.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 400.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 400.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 400.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 400.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 460.75 m
506.5 460.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 460.75 m
575.5 460.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 385.75 m
506.5 385.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 371.75 m
506.5 371.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 369.75 m
506.5 369.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 385.75 m
575.5 385.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 371.75 m
575.5 371.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 369.75 m
575.5 369.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 464.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 464.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 450.42 Td (Net cash flow provided by \(used in\):) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 435.42 Td (Operating activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 435.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 435.42 Td (98,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 435.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 435.42 Td (267,270) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 420.42 Td (Investing activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 420.47 Td (\(60,198) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 420.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 420.42 Td (\(17,900) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 420.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 405.42 Td (Financing activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 405.42 Td (204,601) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 405.42 Td (\(81,572) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 405.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 390.42 Td (Ef) Tj ET Q
q 0 0 0 rg BT 47.35 390.42 Td (fect of foreign exchange rate) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 390.42 Td (1,096) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 390.42 Td (\(1,975) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 390.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 375.42 Td (Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 375.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 375.42 Td (243,551) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 375.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 375.42 Td (165,823) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 353.25 Td (Operating activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.77 353.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.27 353.25 Td (Net cash provided by operating activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.38 353.25 Td ( represents the cash receipts and cash disbursements from all of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 341.25 Td (our activities other than investing activities and financing activities. Changes in cash from operating activities reflect, among other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 329.25 Td (things, the timing of cash collections from customers, payments to suppliers, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.39 329.25 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.18 329.25 Td (s, government agencies, collaborative partners and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 317.25 Td (employees, as well as tax payments and refunds in the ordinary course of business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 299.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 299.25 Td ($169.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.94 299.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.44 299.25 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.85 299.25 Td ( in Net cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.84 299.25 Td (provided by) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.88 299.25 Td ( operating activities in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 366.53 299.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.53 299.25 Td ( compared to the prior year was primarily due ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.25 Td (to our results of operations as described above and the timing of cash collections and cash payments related to our operations. Cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.25 Td (paid for interest ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.81 275.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.56 275.25 Td (d by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.56 275.25 Td ($44.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.46 275.25 Td ( as a result of the timing and amounts of interest payments related to our indebtedness. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.25 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 85.90 263.25 Td (, we increased inventory levels during the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.38 263.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.96 263.25 Td ( in advance of certain recent and planned future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 251.25 Td (product launches, which utilized cash. ) Tj ET Q
q 0 0 0 rg BT 191.05 251.25 Td (W) Tj ET Q
q 0 0 0 rg BT 199.69 251.25 Td (e expect that payments for previously accrued legal matters, which are further discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 239.25 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.26 239.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.75 239.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.62 239.25 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.33 239.25 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 450.20 239.25 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.18 239.25 Td ( will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 227.25 Td (continue to impact our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.75 227.25 Td (Net cash provided by operating activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.87 227.25 Td ( in future periods.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 209.25 Td (Investing activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.44 209.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 144.76 209.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.80 209.25 Td ($42.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.70 209.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.20 209.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.95 209.25 Td ( in Net cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.94 209.25 Td (used in) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.54 209.25 Td ( investing activities in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.09 209.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.09 209.25 Td ( compared to the prior year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.25 Td (reflects ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.92 197.25 Td (a decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.28 197.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.05 197.25 Td (Proceeds from sale of business and other assets, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.39 197.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.72 197.25 Td ($63.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.61 197.25 Td (, of) Tj ET Q
q 0 0 0 rg BT 408.76 197.25 Td (fset in part by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.53 197.25 Td (a decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.88 197.25 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.66 197.25 Td (Purchases of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.25 Td (property) Tj ET Q
q 0 0 0 rg BT 69.23 185.25 Td (, plant and equipment, excluding capitalized interest) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.05 185.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.38 185.25 Td ($19.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.27 185.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 167.25 Td (Financing activities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.45 167.25 Td ( During ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.78 167.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.78 167.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.78 167.25 Td (Net cash provided by financing activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.89 167.25 Td ( related primarily to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 167.25 Td ($300.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.70 167.25 Td ( June 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.25 Td (borrowing under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.15 155.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.71 155.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 226.53 155.25 Td (The proceeds from this transaction were of) Tj ET Q
q 0 0 0 rg BT 397.95 155.25 Td (fset by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.39 155.25 Td (Repayments of term loans) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.08 155.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.41 155.25 Td ($34.2 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 143.25 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 143.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.89 143.25 Td (Payments for contingent consideration) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.02 143.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.35 143.25 Td ($16.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.24 143.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.24 143.25 Td (Payments of tax withholding for restricted shares) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.87 143.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.20 143.25 Td ($10.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.09 143.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.25 Td (Repayments of other indebtedness) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.47 131.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.80 131.25 Td ($9.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.69 131.25 Td ( and the net ef) Tj ET Q
q 0 0 0 rg BT 292.15 131.25 Td (fect of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.18 131.25 Td (March 2019 Refinancing ) Tj ET Q
q 0 0 0 rg BT 437.47 131.25 Td (T) Tj ET Q
q 0 0 0 rg BT 443.23 131.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.21 131.25 Td (, which resulted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 119.25 Td (Proceeds from issuance of notes, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.07 119.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.40 119.25 Td ($1,483.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.79 119.25 Td (, cash used for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.05 119.25 Td (Repayments of notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.92 119.25 Td ( totaling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.47 119.25 Td ($1,500.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.87 119.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.30 119.25 Td (Payments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 107.25 Td (for debt issuance and extinguishment costs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.35 107.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.68 107.25 Td ($6.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.57 107.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 89.25 Td (During ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.83 89.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.83 89.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.83 89.25 Td (Net cash used in financing activities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.51 89.25 Td ( related primarily to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.70 89.25 Td (Payments for contingent consideration) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.83 89.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.16 89.25 Td ($37.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.05 89.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 77.25 Td (Repayments of term loans) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.70 77.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.03 77.25 Td ($34.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.92 77.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.36 77.25 Td (Payments of tax withholding for restricted shares) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.98 77.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.31 77.25 Td ($5.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.20 77.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 59.25 Td (R&D) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 84.67 59.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.17 59.25 Td ( Over the past few years, we have incurred significant expenditures related to conducting clinical studies to develop new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 47.25 Td (products and expand the value of our existing products beyond their currently approved indications.) Tj ET Q
endstream
endobj
141 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 142 0 R>>
endobj
142 0 obj
<</Length 28651>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (67) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (For example, as further described above under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.57 749.10 Td (RESUL) Tj ET Q
q 0 0 0 rg BT 335.32 749.10 Td (TS OF OPERA) Tj ET Q
q 0 0 0 rg BT 396.45 749.10 Td (TIONS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.90 749.10 Td (,� the Company has recently incurred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.67 737.10 Td ( expense for certain indications of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.95 737.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.51 737.10 Td ( in various stages of development.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 719.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 719.10 Td (e expect to incur ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.50 719.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.17 719.10 Td ( expenditures related to the development and advancement of our current product pipeline and any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.10 Td (additional product candidates we may add via license, acquisition or or) Tj ET Q
q 0 0 0 rg BT 319.90 707.10 Td (ganically) Tj ET Q
q 0 0 0 rg BT 355.90 707.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 360.72 707.10 Td (There can be no assurance that the results of any ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.10 Td (ongoing or future nonclinical or clinical trials related to these projects will be successful, that additional trials will not be required, that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.10 Td (any compound, product or indication under development will receive regulatory approval in a timely manner or at all or that such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (compound, product or indication could be successfully manufactured in accordance with local current good manufacturing practices or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.10 Td (marketed successfully) Tj ET Q
q 0 0 0 rg BT 123.93 659.10 Td (, or that we will have suf) Tj ET Q
q 0 0 0 rg BT 222.89 659.10 Td (ficient funds to develop or commercialize any of our products.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 641.10 Td (Manufacturing, supply and other service agreements.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.29 641.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 285.61 641.10 Td (W) Tj ET Q
q 0 0 0 rg BT 294.25 641.10 Td (e contract with various third party manufacturers, suppliers and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (service providers to supply our products, or materials used in the manufacturing of our products, and to provide additional services ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (such as packaging, processing, labeling, warehousing, distribution and customer service support. ) Tj ET Q
q 0 0 0 rg BT 424.80 617.10 Td (Any interruption to the goods or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td (services provided for by these and similar contracts could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.30 605.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 373.18 605.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 593.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 575.10 Td (License and collaboration agreements.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.44 575.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 224.76 575.10 Td (W) Tj ET Q
q 0 0 0 rg BT 233.40 575.10 Td (e could become obligated to make certain contingent payments pursuant to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 563.10 Td (license, collaboration and other agreements. Payments under these agreements generally become due and payable only upon the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 551.10 Td (achievement of certain developmental, regulatory) Tj ET Q
q 0 0 0 rg BT 233.87 551.10 Td (, commercial and/or other milestones. Due to the fact that it is uncertain whether and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (when certain of these milestones will be achieved, they have not been recorded in our Consolidated Balance Sheets. In addition, we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (may be required to make sales-based royalty or similar payments under certain arrangements.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 509.10 Td (Acquisitions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.63 509.10 Td ( Going forward, our primary focus will be on or) Tj ET Q
q 0 0 0 rg BT 308.07 509.10 Td (ganic growth. However) Tj ET Q
q 0 0 0 rg BT 401.80 509.10 Td (, we may consider and, as appropriate, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (make acquisitions of other businesses, products, product rights or technologies. Our cash reserves and other liquid assets may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (inadequate to consummate such acquisitions and it may be necessary for us to issue ordinary shares or raise substantial additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (funds in the future to complete future transactions. In addition, as a result of any acquisition ef) Tj ET Q
q 0 0 0 rg BT 413.49 473.10 Td (forts, we are likely to experience ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (significant char) Tj ET Q
q 0 0 0 rg BT 97.74 461.10 Td (ges to earnings for mer) Tj ET Q
q 0 0 0 rg BT 189.75 461.10 Td (ger and related expenses \(whether or not our ef) Tj ET Q
q 0 0 0 rg BT 377.82 461.10 Td (forts are successful\) that may include transaction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (costs, closure costs, integration costs and/or costs of restructuring activities.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 431.10 Td (Legal proceedings.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.76 431.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 143.08 431.10 Td (W) Tj ET Q
q 0 0 0 rg BT 151.72 431.10 Td (e are subject to various patent challenges, product liability claims, government investigations and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 419.10 Td (legal proceedings in the ordinary course of business. Contingent accruals are recorded when we determine that a loss is both probable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.10 Td (and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our assessments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.10 Td (involve significant judgments regarding future events. For additional discussion of legal proceedings, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.51 395.10 Td (Note 15. Commitments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.10 Td (Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.21 383.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.71 383.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.57 383.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.29 383.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 337.16 383.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.14 383.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 365.10 Td (Contractual Obligations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.25 365.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 167.57 365.10 Td (The following table lists our enforceable and legally binding noncancelable obligations as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 353.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 353.10 Td (.) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 316.60 131.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
166.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
225.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
280.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
284.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
339.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
343.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
398.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
402.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
457.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
461.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
516.50 316.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
520.50 316.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 286.60 131.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
166.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
225.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
280.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
284.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
339.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
343.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
398.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
402.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
457.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
461.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
516.50 286.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
520.50 286.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 256.60 131.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
166.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
225.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
280.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
284.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
339.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
343.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
398.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
402.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
457.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
461.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
516.50 256.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
520.50 256.60 55.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 216.60 131.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
166.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
225.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
280.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
284.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
339.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
343.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
398.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
402.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
457.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
461.50 216.60 55.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
516.50 216.60 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
520.50 216.60 55.00 -25.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 329.6 m
221.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
221.5 329.6 m
225.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 329.6 m
280.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
280.5 329.6 m
284.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 329.6 m
339.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
339.5 329.6 m
343.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 329.6 m
398.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
398.5 329.6 m
402.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 329.6 m
457.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
457.5 329.6 m
461.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 329.6 m
516.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
516.5 329.6 m
520.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 329.6 m
575.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 329.6 m
221.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 316.6 m
221.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
221.5 329.6 m
225.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 329.6 m
280.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 316.6 m
280.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
280.5 329.6 m
284.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 329.6 m
339.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 316.6 m
339.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
339.5 329.6 m
343.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 329.6 m
398.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 316.6 m
398.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
398.5 329.6 m
402.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 329.6 m
457.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 316.6 m
457.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
457.5 329.6 m
461.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 329.6 m
516.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 316.6 m
516.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
516.5 329.6 m
520.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 329.6 m
575.5 329.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 316.6 m
575.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 316.6 m
280.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 316.6 m
339.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 316.6 m
398.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 316.6 m
457.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 316.6 m
516.5 316.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 191.60000000000002 m
221.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 177.60000000000002 m
221.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
166.5 175.60000000000002 m
221.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 191.60000000000002 m
280.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 177.60000000000002 m
280.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
225.5 175.60000000000002 m
280.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 191.60000000000002 m
339.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 177.60000000000002 m
339.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
284.5 175.60000000000002 m
339.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 191.60000000000002 m
398.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 177.60000000000002 m
398.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
343.5 175.60000000000002 m
398.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 191.60000000000002 m
457.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 177.60000000000002 m
457.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
402.5 175.60000000000002 m
457.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 191.60000000000002 m
516.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 177.60000000000002 m
516.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
461.5 175.60000000000002 m
516.5 175.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 191.60000000000002 m
575.5 191.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 177.60000000000002 m
575.5 177.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
520.5 175.60000000000002 m
575.5 175.60000000000002 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 304.60 333.83 Td (Payment Due by Period \(in thousands\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 184.75 320.83 Td (T) Tj ET Q
q 0 0 0 rg BT 189.72 320.83 Td (otal) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 244.50 320.83 Td (2020) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 303.50 320.83 Td (2021) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 362.50 320.83 Td (2022) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 421.50 320.83 Td (2023) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 480.50 320.83 Td (2024) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 529.20 320.83 Td (Ther) Tj ET Q
q 0 0 0 rg BT 545.94 320.83 Td (eafter) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 307.17 Td (Long-term debt obligations \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.60 306.27 Td (8,470,678) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.15 306.27 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.15 306.27 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.15 306.27 Td (247,723) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.60 306.27 Td (1,684,430) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.60 306.27 Td (3,770,225) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.00 306.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.60 306.27 Td (2,700,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 291.27 Td (Interest expense \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.60 291.27 Td (2,542,549) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.15 291.27 Td (525,976) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.15 291.27 Td (523,927) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.15 291.27 Td (510,591) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.15 291.27 Td (457,330) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 291.27 Td (265,400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 291.27 Td (259,325) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 277.17 Td (Finance lease obligations \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.15 276.27 Td (52,216) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.15 276.27 Td (7,446) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.15 276.27 Td (7,593) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.15 276.27 Td (7,743) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.15 276.27 Td (7,897) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.15 276.27 Td (8,054) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 276.27 Td (13,483) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 262.17 Td (Operating lease obligations \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.15 261.27 Td (70,578) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.15 261.27 Td (14,103) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.15 261.27 Td (13,262) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.15 261.27 Td (12,688) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.15 261.27 Td (10,017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.15 261.27 Td (5,176) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 261.27 Td (15,332) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 246.27 Td (Purchase obligations \(4\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.15 246.27 Td (37,471) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.15 246.27 Td (20,319) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.15 246.27 Td (1) Tj ET Q
q 0 0 0 rg BT 313.15 246.27 Td (1,927) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.65 246.27 Td (818) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.65 246.27 Td (941) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 246.27 Td (632) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 246.27 Td (2,834) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 232.17 Td (Mesh-related product liability) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 222.17 Td (settlements \(5\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.15 221.27 Td (54,769) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.15 221.27 Td (54,769) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.65 221.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.65 221.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.65 221.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 221.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 221.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 207.17 Td (Other obligations and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 197.17 Td (commitments \(6\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.15 196.27 Td (1,602) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.15 196.27 Td (1,602) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.65 196.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.65 196.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.65 196.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 196.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 196.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 182.17 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 182.17 Td (otal \(7\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.60 181.27 Td (1) Tj ET Q
q 0 0 0 rg BT 177.60 181.27 Td (1,229,863) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.15 181.27 Td (658,365) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.15 181.27 Td (590,859) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.15 181.27 Td (779,563) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.60 181.27 Td (2,160,615) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.60 181.27 Td (4,049,487) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.00 181.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.60 181.27 Td (2,990,974) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 167.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 157.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 157.90 Td (Includes minimum cash payments related to principal associated with our indebtedness as of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 365.42 157.90 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 428.29 157.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 431.85 157.90 Td (A) Tj ET Q
q 0 0 0 rg BT 437.18 157.90 Td ( discussion of such indebtedness is ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 148.30 Td (included above under the caption �) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 179.23 148.30 Td (Indebtedness) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 221.00 148.30 Td (.� ) Tj ET Q
q 0 0 0 rg BT 228.41 148.30 Td (The amounts in this table do not reflect any potential early or accelerated principal payments such as the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 138.70 Td (potential payments described in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.03 138.70 Td (Note 14. Debt) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 216.13 138.70 Td ( in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 238.13 138.70 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 349.22 138.70 Td ( included in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 388.99 138.70 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 411.29 138.70 Td (, Item 15 of this report) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 483.27 138.70 Td (.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 129.10 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 129.10 Td (These amounts represent future cash interest payments related to our indebtedness as of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 349.85 129.10 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 412.72 129.10 Td ( based on interest rates specified in the associated ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 119.50 Td (debt agreements. Payments related to variable-rate debt are based on applicable market rates, estimated at ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 407.57 119.50 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 470.44 119.50 Td (, plus the specified mar) Tj ET Q
q 0 0 0 rg BT 544.72 119.50 Td (gin in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 109.90 Td (associated debt agreements for each period presented.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 100.30 Td (\(3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 100.30 Td (Refer to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 95.49 100.30 Td (Note 8. Leases) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 142.80 100.30 Td ( in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 164.80 100.30 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 275.89 100.30 Td ( included in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 315.66 100.30 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 337.96 100.30 Td (, Item 15 of this report) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 409.95 100.30 Td ( for additional information about our leases. ) Tj ET Q
q 0 0 0 rg BT 552.43 100.30 Td (W) Tj ET Q
q 0 0 0 rg BT 559.34 100.30 Td (e ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 90.70 Td (have entered into agreements to sublease certain properties. Most significantly) Tj ET Q
q 0 0 0 rg BT 318.01 90.70 Td (, we sublease ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 362.44 90.70 Td (140,000) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 388.44 90.70 Td ( square feet of our Malvern, Pennsylvania facility and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 81.10 Td (substantially all of our Chesterbrook, Pennsylvania facility) Tj ET Q
q 0 0 0 rg BT 255.16 81.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 258.72 81.10 Td (As of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 278.28 81.10 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 341.14 81.10 Td (, we expect to receive approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 460.87 81.10 Td ($24.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 503.98 81.10 Td ( in future minimum ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 71.50 Td (rental payments over the remaining terms of the Malvern and Chesterbrook subleases from ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 360.52 71.50 Td (2020) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 376.52 71.50 Td ( to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 386.75 71.50 Td (2024) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 402.75 71.50 Td (. ) Tj ET Q
q 0 0 0 rg BT 406.30 71.50 Td (Amounts of expected sublease income are not ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 61.90 Td (reflected in the table above.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 52.30 Td (\(4\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 52.30 Td (Purchase obligations are enforceable and legally binding obligations for purchases of goods and services, including minimum inventory contracts.) Tj ET Q
endstream
endobj
143 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 144 0 R>>
endobj
144 0 obj
<</Length 15968>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (68) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 750.50 Td (\(5\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 750.50 Td (The amounts included above represent contractual payments for mesh-related product liability settlements and reflect the earliest date that a settlement ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 740.90 Td (payment could be due and the lar) Tj ET Q
q 0 0 0 rg BT 173.54 740.90 Td (gest amount that could be due on that date. ) Tj ET Q
q 0 0 0 rg BT 312.47 740.90 Td (These matters are described in more detail in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 458.19 740.90 Td (Note 15. Commitments and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 731.30 Td (Contingencies) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 113.27 731.30 Td ( in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 135.27 731.30 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 246.36 731.30 Td ( included in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 286.13 731.30 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 308.43 731.30 Td (, Item 15 of this report) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 380.41 731.30 Td (.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 721.70 Td (\(6\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 721.70 Td (Other obligations and commitments relate to any agreements to purchase third-party assets, products and services and other minimum royalty obligations.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 712.10 Td (\(7\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 712.10 Td (T) Tj ET Q
q 0 0 0 rg BT 71.83 712.10 Td (otal generally does not include contractual obligations already included in current liabilities on our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 389.51 712.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 482.38 712.10 Td (, except for amounts related ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 702.50 Td (to the current portion of long-term debt, accrued interest, current lease obligations, mesh-related product liabilities and certain purchase obligations, which are ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 692.90 Td (discussed below) Tj ET Q
q 0 0 0 rg BT 119.20 692.90 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 674.90 Td (For purposes of the table above, obligations for the purchase of goods or services are included only for significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 662.90 Td (noncancelable purchase orders at least one year in length that are enforceable, legally binding and specify all significant terms, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 650.90 Td (including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions and the timing of the obligation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 638.90 Td (In cases where our minimum obligations are variable based on future contingent events or circumstances, we estimate the minimum ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 626.90 Td (obligations based on information available to us at the time of disclosure. Our purchase orders are based on our current manufacturing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 614.90 Td (needs and are typically fulfilled by our suppliers within a relatively short period. ) Tj ET Q
q 0 0 0 rg BT 359.80 614.90 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.30 614.90 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.89 614.90 Td (, we have open purchase ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 602.90 Td (orders that represent authorizations to purchase, rather than binding agreements, that are not included in the table above. In addition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 590.90 Td (we do not include collaboration agreements and potential payments under those agreements or potential payments related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 578.90 Td (contingent consideration.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 560.90 Td (Information about our liability for unrecognized tax benefits is included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.20 560.90 Td (Note 20. Income ) Tj ET Q
q 0 0 0 rg BT 432.44 560.90 Td (T) Tj ET Q
q 0 0 0 rg BT 437.85 560.90 Td (axes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.62 560.90 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.11 560.90 Td (Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 548.90 Td (Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 548.90 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.59 548.90 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 157.46 548.90 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.45 548.90 Td ( under the caption �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.30 548.90 Td (Uncertain ) Tj ET Q
q 0 0 0 rg BT 368.05 548.90 Td (T) Tj ET Q
q 0 0 0 rg BT 373.46 548.90 Td (ax Positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.07 548.90 Td (.� Due to the nature and timing of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 536.90 Td (ultimate outcome of these uncertain tax positions, we cannot make a reliable estimate of the amount and period of related future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 524.90 Td (payments, if any) Tj ET Q
q 0 0 0 rg BT 101.72 524.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 106.54 524.90 Td (Therefore, our liability has been excluded from the above contractual obligations table.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 506.90 Td (Fluctuations. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.80 506.90 Td (Our quarterly results have fluctuated in the past and may continue to fluctuate. ) Tj ET Q
q 0 0 0 rg BT 437.18 506.90 Td (These fluctuations may be due to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 494.90 Td (the timing of new product launches, purchasing patterns of our customers, market acceptance of our products, the impact of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 482.90 Td (competitive products and pricing, certain actions taken by us which may impact the availability of our products, asset impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 470.90 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 470.90 Td (ges, litigation-related char) Tj ET Q
q 0 0 0 rg BT 157.52 470.90 Td (ges, restructuring costs including separation benefits, business combination transaction costs, the impact ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 458.90 Td (of financing transactions, upfront, milestone and certain other payments made or accrued pursuant to licensing agreements and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 446.90 Td (changes in the fair value of financial instruments and contingent assets and liabilities recorded as part of business combinations. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 434.90 Td (Further) Tj ET Q
q 0 0 0 rg BT 65.04 434.90 Td (, a substantial portion of our total revenues are through three wholesale drug distributors who in turn supply our products to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 422.90 Td (pharmacies, hospitals and physicians. ) Tj ET Q
q 0 0 0 rg BT 188.19 422.90 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 237.53 422.90 Td (, we are potentially subject to a concentration of credit risk with respect to our trade ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 410.90 Td (receivables.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 392.90 Td (Growth opportunities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.58 392.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 155.90 392.90 Td (W) Tj ET Q
q 0 0 0 rg BT 164.54 392.90 Td (e continue to evaluate growth opportunities including investments, licensing arrangements, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 380.90 Td (acquisitions of product rights or technologies, businesses and strategic alliances and promotional arrangements, any of which could ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 368.90 Td (require significant capital resources. ) Tj ET Q
q 0 0 0 rg BT 183.26 368.90 Td (W) Tj ET Q
q 0 0 0 rg BT 191.89 368.90 Td (e continue to focus our business development activities on further diversifying our revenue base ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 356.90 Td (through product licensing and company acquisitions, as well as other opportunities to enhance shareholder value. ) Tj ET Q
q 0 0 0 rg BT 490.98 356.90 Td (Through execution ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 344.90 Td (of our business strategy) Tj ET Q
q 0 0 0 rg BT 130.06 344.90 Td (, we focus on developing new products both internally and with contract and collaborative partners; expanding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 332.90 Td (our product lines by acquiring new products and technologies, increasing revenues and earnings through sales and marketing programs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 320.90 Td (for our innovative product of) Tj ET Q
q 0 0 0 rg BT 151.90 320.90 Td (ferings and ef) Tj ET Q
q 0 0 0 rg BT 206.69 320.90 Td (fectively using our resources; and providing additional resources to support our businesses.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 302.90 Td (Non-) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 84.11 302.90 Td (U.S.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 101.90 302.90 Td ( operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.24 302.90 Td ( Fluctuations in foreign currency rates resulted in a net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.28 302.90 Td (loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.84 302.90 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.17 302.90 Td ($5.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.06 302.90 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.84 302.90 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.84 302.90 Td ( and a net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.93 302.90 Td (gain) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.15 302.90 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.48 302.90 Td ($3.8 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 290.90 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 290.90 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.67 290.90 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.67 290.90 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 272.90 Td (Inflation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.68 272.90 Td (W) Tj ET Q
q 0 0 0 rg BT 113.32 272.90 Td (e do not believe that inflation had a material adverse ef) Tj ET Q
q 0 0 0 rg BT 333.04 272.90 Td (fect on our financial statements for the periods presented.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 254.90 Td (Of) Tj ET Q
q 0 0 0 rg BT 73.37 254.90 Td (f-balance sheet arrangements. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.59 254.90 Td (W) Tj ET Q
q 0 0 0 rg BT 209.23 254.90 Td (e have no of) Tj ET Q
q 0 0 0 rg BT 258.19 254.90 Td (f-balance sheet arrangements as defined in Item 303\(a\)\(4\) of Regulation S-K.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 236.90 Td (Item 7A.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 73.21 236.90 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 236.90 Td (Quantitative and Qualitative Disclosures ) Tj ET Q
q 0 0 0 rg BT 277.64 236.90 Td (About Market Risk) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 218.90 Td (Market risk is the potential loss arising from adverse changes in the financial markets, including interest rates and foreign ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 206.90 Td (currency exchange rates.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 188.90 Td (Inter) Tj ET Q
q 0 0 0 rg BT 68.57 188.90 Td (est Rate Risk) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 170.90 Td (Our exposure to interest rate risk relates primarily to our variable-rate indebtedness associated with our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.14 170.90 Td (Credit Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.29 170.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 546.74 170.90 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 158.90 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 158.90 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.02 158.90 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.02 158.90 Td (, the aggregate principal amounts of such variable-rate indebtedness were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.29 158.90 Td ($3,629.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.68 158.90 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.12 158.90 Td ($3,363.8 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 146.90 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 146.90 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 117.55 146.90 Td (. Borrowings under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.26 146.90 Td (Credit Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.42 146.90 Td ( may from time to time bear interest at variable rates, as further described ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 134.90 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.28 134.90 Td (Note 14. Debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.66 134.90 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.15 134.90 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.02 134.90 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.73 134.90 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 346.60 134.90 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.58 134.90 Td (, in certain cases subject to a floor) Tj ET Q
q 0 0 0 rg BT 572.09 134.90 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 122.90 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 48.50 122.90 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.08 122.90 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.52 122.90 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.52 122.90 Td (, a hypothetical 1% increase in the applicable rate over the floor would have resulted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.78 122.90 Td ($36.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.67 122.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 110.90 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 110.90 Td ($33.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.83 110.90 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 159.49 110.90 Td (, of incremental interest expense \(representing the annual rate of expense\) related to our variable-rate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 98.90 Td (debt borrowings.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 80.90 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 80.90 Td (o the extent that we utilize additional amounts under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.57 80.90 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.78 80.90 Td ( or otherwise increase the amount of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 68.90 Td (variable-rate indebtedness, we will be exposed to additional interest rate risk.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 50.90 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 50.90 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 50.90 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.47 50.90 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.47 50.90 Td (, we had no other assets or liabilities with significant interest rate sensitivity) Tj ET Q
q 0 0 0 rg BT 508.36 50.90 Td (.) Tj ET Q
endstream
endobj
145 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 146 0 R>>
endobj
146 0 obj
<</Length 13617>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (69) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 742.10 Td (For) Tj ET Q
q 0 0 0 rg BT 64.13 742.10 Td (eign Curr) Tj ET Q
q 0 0 0 rg BT 102.93 742.10 Td (ency Exchange Rate Risk) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 724.10 Td (e operate and transact business in various foreign countries and are therefore subject to risks associated with foreign currency ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.10 Td (exchange rate fluctuations. ) Tj ET Q
q 0 0 0 rg BT 145.77 712.10 Td (The Company manages this foreign currency risk, in part, through operational means including managing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (foreign currency revenues in relation to same-currency costs and foreign currency assets in relation to same-currency liabilities. ) Tj ET Q
q 0 0 0 rg BT 548.95 700.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (Company is also exposed to potential earnings ef) Tj ET Q
q 0 0 0 rg BT 232.17 688.10 Td (fects from intercompany foreign currency assets and liabilities that arise from normal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (trade receivables and payables and other intercompany loans. ) Tj ET Q
q 0 0 0 rg BT 283.40 676.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 333.30 676.10 Td (, certain of the Company�) Tj ET Q
q 0 0 0 rg BT 435.22 676.10 Td (s subsidiaries maintain their books ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (of record in currencies other than their respective functional currencies. ) Tj ET Q
q 0 0 0 rg BT 324.30 664.10 Td (These subsidiaries�) Tj ET Q
q 0 0 0 rg BT 400.48 664.10 Td ( financial statements are remeasured into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (their respective functional currencies. Such remeasurement adjustments could have a material adverse ef) Tj ET Q
q 0 0 0 rg BT 454.25 652.10 Td (fect on the Company�) Tj ET Q
q 0 0 0 rg BT 540.62 652.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (financial position and results of operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 622.10 Td (All assets and liabilities of our international subsidiaries, which maintain their financial statements in local currency) Tj ET Q
q 0 0 0 rg BT 526.66 622.10 Td (, are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (translated to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.65 610.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.43 610.10 Td ( dollars at period-end exchange rates. ) Tj ET Q
q 0 0 0 rg BT 257.13 610.10 Td (T) Tj ET Q
q 0 0 0 rg BT 262.89 610.10 Td (ranslation adjustments arising from the use of dif) Tj ET Q
q 0 0 0 rg BT 459.06 610.10 Td (fering exchange rates are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (included in ) Tj ET Q
q 0 0 0 rg BT 82.66 598.10 Td (Accumulated other comprehensive loss. Gains and losses on foreign currency transactions and short-term intercompany ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (receivables from foreign subsidiaries are included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.42 586.10 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.71 586.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.20 586.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.57 586.10 Td (. Refer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.28 574.10 Td (Note 19. Other Expense \(Income\), Net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.95 574.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.44 574.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.31 574.10 Td ( included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.02 574.10 Td (Part IV) Tj ET Q
q 0 0 0 rg BT 444.89 574.10 Td (, Item 15 of this report) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 534.87 574.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.33 562.10 Td (Foreign currency loss \(gain\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.56 562.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 544.10 Td (Based on the Company�) Tj ET Q
q 0 0 0 rg BT 158.82 544.10 Td (s significant foreign currency denominated intercompany loans, we separately considered the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (hypothetical impact of a 10% change in the underlying currencies of our foreign currency denominated intercompany loans, relative to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (the U.S. dollar) Tj ET Q
q 0 0 0 rg BT 93.92 520.10 Td (, at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.64 520.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.23 520.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.66 520.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.66 520.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 231.11 520.10 Td (A) Tj ET Q
q 0 0 0 rg BT 237.78 520.10 Td ( 10% change at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.64 520.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.23 520.10 Td ( would have resulted in approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.30 520.10 Td ($1) Tj ET Q
q 0 0 0 rg BT 545.93 520.10 Td (1 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 508.10 Td ( in incremental foreign currency losses on such date. ) Tj ET Q
q 0 0 0 rg BT 277.04 508.10 Td (A) Tj ET Q
q 0 0 0 rg BT 283.71 508.10 Td ( 10% change at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.58 508.10 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.16 508.10 Td ( would have resulted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 496.10 Td ($9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.65 496.10 Td ( in incremental foreign currency losses on such date.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (Item 8.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 65.99 478.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 478.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 478.10 Td (Financial Statements and Supplementary Data) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.10 Td (The information required by this item is contained in the financial statements set forth in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.85 460.10 Td (Item 15.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.18 460.10 Td ( under the caption ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 448.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.31 448.10 Td (� as part of this ) Tj ET Q
q 0 0 0 rg BT 242.35 448.10 Td (Annual Report on Form 10-K.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (Item 9.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 65.99 430.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 430.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 430.10 Td (Changes in and Disagreements with ) Tj ET Q
q 0 0 0 rg BT 259.05 430.10 Td (Accountants on ) Tj ET Q
q 0 0 0 rg BT 325.92 430.10 Td (Accounting and Financial Disclosure) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 412.10 Td (Not applicable.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (Item 9A.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 73.21 394.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 394.10 Td (Controls and Procedures) Tj ET Q
BT /F4 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 376.10 Td (\(a\) Evaluation of Disclosur) Tj ET Q
q 0 0 0 rg BT 158.84 376.10 Td (e Contr) Tj ET Q
q 0 0 0 rg BT 188.75 376.10 Td (ols and Pr) Tj ET Q
q 0 0 0 rg BT 230.05 376.10 Td (ocedur) Tj ET Q
q 0 0 0 rg BT 257.44 376.10 Td (es) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 358.10 Td (s management, with the participation of the Company�) Tj ET Q
q 0 0 0 rg BT 340.44 358.10 Td (s Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 424.40 358.10 Td (ficer and Principal Financial Of) Tj ET Q
q 0 0 0 rg BT 550.84 358.10 Td (ficer) Tj ET Q
q 0 0 0 rg BT 568.75 358.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (has evaluated the ef) Tj ET Q
q 0 0 0 rg BT 114.95 346.10 Td (fectiveness of the Company�) Tj ET Q
q 0 0 0 rg BT 229.08 346.10 Td (s disclosure controls and procedures, as defined in Rules 13a-15\(e\) and 15d-15\(e\) of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 334.10 Td (Exchange ) Tj ET Q
q 0 0 0 rg BT 92.09 334.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.53 334.10 Td (, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.19 334.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.77 334.10 Td (. Based on that evaluation, the Company�) Tj ET Q
q 0 0 0 rg BT 376.74 334.10 Td (s Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 460.70 334.10 Td (ficer and Principal Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (Of) Tj ET Q
q 0 0 0 rg BT 46.37 322.10 Td (ficer concluded that the Company�) Tj ET Q
q 0 0 0 rg BT 184.66 322.10 Td (s disclosure controls and procedures were ef) Tj ET Q
q 0 0 0 rg BT 361.63 322.10 Td (fective as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.00 322.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.58 322.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 304.10 Td (\(b\) Management�) Tj ET Q
q 0 0 0 rg BT 117.91 304.10 Td (s Report on Internal Contr) Tj ET Q
q 0 0 0 rg BT 224.20 304.10 Td (ol over Financial Reporting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 286.10 Td (The report of management of the Company regarding internal control over financial reporting is set forth in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.36 286.10 Td (Item 15.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.68 286.10 Td ( of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (Annual Report on Form 10-K under the caption �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.73 274.10 Td (MANAGEMENT�S REPOR) Tj ET Q
q 0 0 0 rg BT 348.97 274.10 Td (T) Tj ET Q
q 0 0 0 rg BT 354.90 274.10 Td ( ON INTERNAL) Tj ET Q
q 0 0 0 rg BT 423.96 274.10 Td ( CONTROL) Tj ET Q
q 0 0 0 rg BT 473.31 274.10 Td ( OVER FINANCIAL) Tj ET Q
q 0 0 0 rg BT 559.05 274.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (REPOR) Tj ET Q
q 0 0 0 rg BT 67.63 262.10 Td (TING) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.51 262.10 Td (� and incorporated herein by reference.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 244.10 Td (\(c\) ) Tj ET Q
q 0 0 0 rg BT 62.92 244.10 Td (Attestation Report of Independent Register) Tj ET Q
q 0 0 0 rg BT 233.62 244.10 Td (ed Public ) Tj ET Q
q 0 0 0 rg BT 273.98 244.10 Td (Accounting Firm) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 226.10 Td (The attestation report of the Company�) Tj ET Q
q 0 0 0 rg BT 218.23 226.10 Td (s independent registered public accounting firm regarding internal control over financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (reporting is set forth in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.15 214.10 Td (Item 15.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 163.48 214.10 Td ( of this ) Tj ET Q
q 0 0 0 rg BT 193.20 214.10 Td (Annual Report on Form 10-K under the caption �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.94 214.10 Td (REPOR) Tj ET Q
q 0 0 0 rg BT 422.57 214.10 Td (T) Tj ET Q
q 0 0 0 rg BT 428.50 214.10 Td ( OF INDEPENDENT) Tj ET Q
q 0 0 0 rg BT 515.53 214.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (REGISTERED PUBLIC ) Tj ET Q
q 0 0 0 rg BT 137.12 202.10 Td (ACCOUNTING FIRM) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.18 202.10 Td (� and incorporated herein by reference.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 184.10 Td (\(d\) Changes in Internal Contr) Tj ET Q
q 0 0 0 rg BT 169.12 184.10 Td (ol over Financial Reporting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 166.10 Td (There have been no changes in the Company�) Tj ET Q
q 0 0 0 rg BT 245.44 166.10 Td (s internal control over financial reporting during the fiscal quarter ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 154.10 Td ( that have materially af) Tj ET Q
q 0 0 0 rg BT 206.58 154.10 Td (fected, or are reasonably likely to materially af) Tj ET Q
q 0 0 0 rg BT 393.53 154.10 Td (fect, the Company�) Tj ET Q
q 0 0 0 rg BT 469.90 154.10 Td (s internal control over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (financial reporting.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (Item 9B.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 72.66 124.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 124.10 Td (Other Information) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 106.10 Td (None.) Tj ET Q
endstream
endobj
147 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 148 0 R>>
endobj
148 0 obj
<</Length 14694>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (70) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 285.90 742.25 Td (P) Tj ET Q
q 0 0 0 rg BT 291.27 742.25 Td (AR) Tj ET Q
q 0 0 0 rg BT 305.36 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 311.85 742.25 Td ( III ) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 724.25 Td (Item 10.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.99 724.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 724.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 724.25 Td (Directors, Executive Of) Tj ET Q
q 0 0 0 rg BT 204.74 724.25 Td (ficers and Corporate Governance) Tj ET Q
BT /F4 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 706.25 Td (Dir) Tj ET Q
q 0 0 0 rg BT 63.02 706.25 Td (ectors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.25 Td (The information concerning our directors required under this item is incorporated herein by reference from our proxy statement, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (which will be filed with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.75 676.25 Td (SEC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.09 676.25 Td (, relating to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.24 676.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.24 676.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 253.19 676.25 Td (Annual General Meeting \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.43 676.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.43 676.25 Td ( Proxy Statement\).) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 658.25 Td (Executive Officers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 640.25 Td (For information concerning Endo�) Tj ET Q
q 0 0 0 rg BT 199.91 640.25 Td (s executive of) Tj ET Q
q 0 0 0 rg BT 255.27 640.25 Td (ficers, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.74 640.25 Td (Part 1, Item 1 of this report �Business�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.27 640.25 Td ( under the caption ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 628.25 Td (Information about our Executive Of) Tj ET Q
q 0 0 0 rg BT 184.10 628.25 Td (ficers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.31 628.25 Td (� and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.01 628.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.01 628.25 Td ( Proxy Statement.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 610.25 Td (Code of Ethics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 592.25 Td (The information concerning our Code of Conduct is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.98 592.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.98 592.25 Td ( Proxy Statement and can ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (be viewed on our website, the internet address for which is www) Tj ET Q
q 0 0 0 rg BT 294.73 580.25 Td (.endo.com ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 338.88 580.25 Td (\(intended to be an inactive textual r) Tj ET Q
q 0 0 0 rg BT 481.24 580.25 Td (efer) Tj ET Q
q 0 0 0 rg BT 496.42 580.25 Td (ence only\).) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 562.25 Td (Audit Committee) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 544.25 Td (The information concerning our ) Tj ET Q
q 0 0 0 rg BT 192.96 544.25 Td (Audit Committee is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.82 544.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.82 544.25 Td ( Proxy Statement.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 526.25 Td (Audit Committee Financial Experts) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 508.25 Td (The information concerning our ) Tj ET Q
q 0 0 0 rg BT 192.96 508.25 Td (Audit Committee Financial Experts is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.58 508.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.58 508.25 Td ( Proxy ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (Statement.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (Item 1) Tj ET Q
q 0 0 0 rg BT 62.94 478.25 Td (1.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.44 478.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 478.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 478.25 Td (Executive Compensation) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.25 Td (The information required under this item is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.70 460.25 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.70 460.25 Td ( Proxy Statement.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (Item 12.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.99 442.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 442.25 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 442.25 Td (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters) Tj ET Q
BT /F4 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 424.25 Td (Equity Compensation Plan Information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.55 424.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 225.87 424.25 Td (The following table sets forth aggregate information for the fiscal year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 412.25 Td ( regarding the Company�) Tj ET Q
q 0 0 0 rg BT 214.28 412.25 Td (s compensation plans, under which equity securities of Endo may be issued to employees ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (and directors.) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 307.75 288.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 307.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 307.75 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
407.50 307.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
411.50 307.75 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
491.50 307.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
495.50 307.75 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 277.75 288.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 277.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 277.75 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
407.50 277.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
411.50 277.75 80.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
491.50 277.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
495.50 277.75 80.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 376.75 m
407.5 376.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 376.75 m
491.5 376.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 376.75 m
575.5 376.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 307.75 m
323.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 307.75 m
407.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 307.75 m
491.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 307.75 m
575.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 307.75 m
323.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 307.75 m
407.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
411.5 307.75 m
491.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 307.75 m
575.5 307.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 277.75 m
407.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 277.75 m
575.5 277.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 263.75 m
407.5 263.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 261.75 m
407.5 261.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 263.75 m
575.5 263.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
495.5 261.75 m
575.5 261.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 349.75 380.98 Td (Column ) Tj ET Q
q 0 0 0 rg BT 379.09 380.98 Td (A) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 433.55 380.98 Td (Column B) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 517.30 380.98 Td (Column C) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 311.98 Td (Plan Category) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 331.50 343.98 Td (Number) Tj ET Q
q 0 0 0 rg BT 359.87 343.98 Td ( of securities) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 337.50 335.98 Td (to be issued upon) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 349.15 327.98 Td (exer) Tj ET Q
q 0 0 0 rg BT 363.73 327.98 Td (cise of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 332.30 319.98 Td (outstanding options,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 332.95 311.98 Td (warrants and rights) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 420.10 343.98 Td (W) Tj ET Q
q 0 0 0 rg BT 427.88 343.98 Td (eighted-average) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 423.50 335.98 Td (exer) Tj ET Q
q 0 0 0 rg BT 438.08 335.98 Td (cise price of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 416.30 327.98 Td (outstanding options,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 416.95 319.98 Td (warrants and rights) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 446.30 311.98 Td (\(1\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 499.50 367.98 Td (Number) Tj ET Q
q 0 0 0 rg BT 527.80 367.98 Td ( of securities) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 501.15 359.98 Td (r) Tj ET Q
q 0 0 0 rg BT 504.56 359.98 Td (emaining available) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 503.10 351.98 Td (for) Tj ET Q
q 0 0 0 rg BT 513.17 351.98 Td ( futur) Tj ET Q
q 0 0 0 rg BT 532.80 351.98 Td (e issuance) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 513.15 343.98 Td (under) Tj ET Q
q 0 0 0 rg BT 533.45 343.98 Td ( equity) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 501.30 335.98 Td (compensation plans) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 500.20 327.98 Td (\(excluding securities) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 501.05 319.98 Td (r) Tj ET Q
q 0 0 0 rg BT 504.46 319.98 Td (eflected in Column) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 530.75 311.98 Td (A\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 298.32 Td (Equity compensation plans approved by security holders) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.65 297.42 Td (20,639,884) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.00 297.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 297.42 Td (18.93) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 297.42 Td (7,675,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 283.32 Td (Equity compensation plans not approved by security holders) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 282.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.65 282.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 282.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 268.32 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 268.32 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.65 267.42 Td (20,639,884) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.00 267.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.15 267.42 Td (18.93) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 267.42 Td (7,675,680) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 253.65 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 244.05 Td (\(1\) Excludes shares of restricted stock units, performance share units and long-term cash incentive awards which will be settled in the Company�) Tj ET Q
q 0 0 0 rg BT 512.92 244.05 Td (s ordinary shares.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 226.05 Td (The other information required under this item is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.75 226.05 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.75 226.05 Td ( Proxy Statement.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.05 Td (Item 13.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.99 208.05 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 208.05 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 208.05 Td (Certain Relationships and Related T) Tj ET Q
q 0 0 0 rg BT 257.65 208.05 Td (ransactions, and Director Independence) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 190.05 Td (The information required under this item is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.70 190.05 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.70 190.05 Td ( Proxy Statement.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 169.05 Td (Item 14.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.99 169.05 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 72.00 169.05 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 169.05 Td (Principal ) Tj ET Q
q 0 0 0 rg BT 148.46 169.05 Td (Accounting Fees and Services) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 151.05 Td (Information about the fees for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.46 151.05 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.46 151.05 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.89 151.05 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.89 151.05 Td ( for professional services rendered by our independent registered public ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 139.05 Td (accounting firm is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.73 139.05 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.73 139.05 Td ( Proxy Statement. Our ) Tj ET Q
q 0 0 0 rg BT 393.11 139.05 Td (Audit Committee�) Tj ET Q
q 0 0 0 rg BT 465.60 139.05 Td (s policy on pre-approval of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 127.05 Td (audit and permissible non-audit services of our independent registered public accounting firm is incorporated by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 115.05 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 115.05 Td ( Proxy Statement.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 97.05 Td (The information required under this item is incorporated herein by reference from our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.70 97.05 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.70 97.05 Td ( Proxy Statement.) Tj ET Q
endstream
endobj
149 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 150 0 R>>
endobj
150 0 obj
<</Length 20228>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (71) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 286.30 742.25 Td (P) Tj ET Q
q 0 0 0 rg BT 291.67 742.25 Td (AR) Tj ET Q
q 0 0 0 rg BT 305.76 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 312.25 742.25 Td ( IV) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 724.25 Td (Item 15.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 70.99 724.25 Td (  ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 724.25 Td (Exhibits, Financial Statement Schedules) Tj ET Q
BT /F4 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 706.25 Td (\(a\) The following documents ar) Tj ET Q
q 0 0 0 rg BT 175.23 706.25 Td (e filed as part of this r) Tj ET Q
q 0 0 0 rg BT 263.75 706.25 Td (eport:) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 688.25 Td (1. ) Tj ET Q
q 0 0 0 rg BT 81.00 688.25 Td (The Consolidated Financial Statements:) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 673.25 Td (Management�) Tj ET Q
q 0 0 0 rg BT 144.25 673.25 Td (s Report on Internal Contr) Tj ET Q
q 0 0 0 rg BT 250.54 673.25 Td (ol Over Financial Reporting) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 661.25 Td (Report of Independent Register) Tj ET Q
q 0 0 0 rg BT 214.87 661.25 Td (ed Public ) Tj ET Q
q 0 0 0 rg BT 255.23 661.25 Td (Accounting Firm) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 649.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 206.65 649.25 Td ( as of December 31, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 289.40 649.25 Td (2019) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 309.40 649.25 Td ( and ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 329.40 649.25 Td (2018) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 637.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 246.94 637.25 Td ( for the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 278.33 637.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 472.45 637.25 Td ( ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 625.25 Td (Consolidated Statements of Compr) Tj ET Q
q 0 0 0 rg BT 229.35 625.25 Td (ehensive Loss) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 284.62 625.25 Td ( for the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 316.01 625.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 613.25 Td (Consolidated Statements of Shar) Tj ET Q
q 0 0 0 rg BT 220.46 613.25 Td (eholders' Equity \(Deficit\)) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 322.01 613.25 Td ( for the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 353.40 613.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 601.25 Td (Consolidated Statements of Cash Flows) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 249.45 601.25 Td ( for the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 280.83 601.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F5 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 90.00 589.25 Td (Notes to Consolidated Financial Statements) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 571.25 Td (2. ) Tj ET Q
q 0 0 0 rg BT 81.00 571.25 Td (Financial Statement Schedules) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 164.20 553.25 Td (SCHEDULE II�V) Tj ET Q
q 0 0 0 rg BT 245.43 553.25 Td (ALUA) Tj ET Q
q 0 0 0 rg BT 273.02 553.25 Td (TION ) Tj ET Q
q 0 0 0 rg BT 300.53 553.25 Td (AND QUALIFYING ) Tj ET Q
q 0 0 0 rg BT 391.65 553.25 Td (ACCOUNTS) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 275.55 541.25 Td (\(in thousands\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 498.75 199.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 498.75 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 498.75 4.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 498.75 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 498.75 4.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 498.75 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 498.75 4.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 498.75 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 498.75 4.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 498.75 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 470.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 470.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 470.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 470.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 470.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 470.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 470.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 470.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 470.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 470.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 498.75 m
299.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 498.75 m
368.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 498.75 m
437.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 498.75 m
506.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 498.75 m
575.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 470.75 m
299.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 470.75 m
368.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 470.75 m
437.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 470.75 m
506.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 470.75 m
575.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 455.75 m
299.5 455.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 440.75 m
299.5 440.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 455.75 m
368.5 455.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 440.75 m
368.5 440.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 455.75 m
437.5 455.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 440.75 m
437.5 440.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 455.75 m
506.5 455.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 440.75 m
506.5 440.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 455.75 m
575.5 455.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 440.75 m
575.5 440.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 248.60 518.98 Td (Balance at) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 244.80 510.98 Td (Beginning of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 255.15 502.98 Td (Period) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 307.45 510.98 Td (Additions, Costs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 312.25 502.98 Td (and Expenses) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 384.35 510.98 Td (Deductions,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 387.00 502.98 Td (W) Tj ET Q
q 0 0 0 rg BT 394.93 502.98 Td (rite-offs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.65 502.98 Td (Other) Tj ET Q
q 0 0 0 rg BT 478.02 502.98 Td ( \(1\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 516.45 510.98 Td (Balance at End) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 526.80 502.98 Td (of Period) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 489.98 Td (V) Tj ET Q
q 0 0 0 rg BT 43.04 489.98 Td (aluation ) Tj ET Q
q 0 0 0 rg BT 72.61 489.98 Td (Allowance For) Tj ET Q
q 0 0 0 rg BT 122.45 489.98 Td ( Deferr) Tj ET Q
q 0 0 0 rg BT 146.95 489.98 Td (ed ) Tj ET Q
q 0 0 0 rg BT 156.81 489.98 Td (T) Tj ET Q
q 0 0 0 rg BT 161.41 489.98 Td (ax ) Tj ET Q
q 0 0 0 rg BT 170.97 489.98 Td (Assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 475.42 Td (Y) Tj ET Q
q 0 0 0 rg BT 44.72 475.42 Td (ear Ended December 31, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 475.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 475.42 Td (4,841,209) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 475.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 475.42 Td (3,81) Tj ET Q
q 0 0 0 rg BT 342.15 475.42 Td (1,982) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 475.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 475.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 475.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 475.47 Td (\(590,216) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 475.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 475.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 475.42 Td (8,062,975) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 460.42 Td (Y) Tj ET Q
q 0 0 0 rg BT 44.72 460.42 Td (ear Ended December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 460.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 460.42 Td (8,062,975) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 460.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 460.42 Td (2,569,175) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 460.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 460.47 Td (\(2,259) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 460.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 460.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 460.47 Td (\(752,274) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 460.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 460.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 460.42 Td (9,877,617) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 445.42 Td (Y) Tj ET Q
q 0 0 0 rg BT 44.22 445.42 Td (ear Ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 445.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.65 445.42 Td (9,877,617) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 445.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 445.42 Td (299,372) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 445.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 445.47 Td (\(9,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 445.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 445.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 445.47 Td (\(338,952) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 445.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 445.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 445.42 Td (9,828,959) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 431.65 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 422.05 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 422.05 Td (Represents the remeasurement of net deferred tax assets due to changes in statutory tax rates.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 404.05 Td (All other financial statement schedules have been omitted because they are not applicable or the required information is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 392.05 Td (included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.93 392.05 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.80 392.05 Td ( or notes thereto.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 374.05 Td (3. ) Tj ET Q
q 0 0 0 rg BT 67.50 374.05 Td (Exhibits:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 344.53007812499993 m
455.2265625 344.53007812499993 l
s
q 0 0 0 rg BT 342.00 345.78 Td (Incorporated by Refer) Tj ET Q
q 0 0 0 rg BT 418.80 345.78 Td (ence fr) Tj ET Q
q 0 0 0 rg BT 441.97 345.78 Td (om:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
39 331.53007812499993 m
67.369140625 331.53007812499993 l
s
q 0 0 0 rg BT 39.00 332.78 Td (Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
83 331.53007812499993 m
122.55078125 331.53007812499993 l
s
q 0 0 0 rg BT 83.00 332.78 Td (Description) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 331.53007812499993 m
385.251953125 331.53007812499993 l
s
q 0 0 0 rg BT 342.00 332.78 Td (File Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
397 331.53007812499993 m
435.6015625 331.53007812499993 l
s
q 0 0 0 rg BT 397.00 332.78 Td (Filing ) Tj ET Q
q 0 0 0 rg BT 418.93 332.78 Td (T) Tj ET Q
q 0 0 0 rg BT 423.90 332.78 Td (ype) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
492 331.53007812499993 m
529.99609375 331.53007812499993 l
s
q 0 0 0 rg BT 492.00 332.78 Td (Filing Date) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 319.12 Td (3.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 317.78339843749995 m
312.35546875 317.78339843749995 l
s
q 0 0 1 rg BT 83.00 319.12 Td (Certificate of Incorporation on re-registration as a public ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 307.78339843749995 m
253.2294921875 307.78339843749995 l
s
q 0 0 1 rg BT 83.00 309.12 Td (limited company of Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 319.12 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 319.12 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 309.12 Td (Form 8-K12B) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 319.12 Td (February 28, 2014) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 294.12 Td (3.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 292.78339843749995 m
287.130859375 292.78339843749995 l
s
q 0 0 1 rg BT 83.00 294.12 Td (Memorandum and ) Tj ET Q
q 0 0 1 rg BT 158.54 294.12 Td (Articles of ) Tj ET Q
q 0 0 1 rg BT 202.98 294.12 Td (Association of Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 282.78339843749995 m
338.1904296875 282.78339843749995 l
s
q 0 0 1 rg BT 83.00 284.12 Td (International plc, dated as of October 31, 2013 and as amended ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 272.78339843749995 m
155.490234375 272.78339843749995 l
s
q 0 0 1 rg BT 83.00 274.12 Td (as of June 8, 2017) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 294.12 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 294.12 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 284.12 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 294.12 Td (August 8, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 259.12 Td (4.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 257.78339843749995 m
232.6923828125 257.78339843749995 l
s
q 0 0 1 rg BT 83.00 259.12 Td (Description of Registrant�) Tj ET Q
q 0 0 1 rg BT 186.87 259.12 Td (s Securities) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 259.12 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 244.12 Td (4.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 242.78339843749995 m
295.1435546875 242.78339843749995 l
s
q 0 0 1 rg BT 83.00 244.12 Td (Specimen Share Certificate of Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 244.12 Td (333-194253) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 244.12 Td (Form S-8) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 244.12 Td (February 28, 2014) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 229.12 Td (4.3) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 227.78339843749995 m
324.8798828125 227.78339843749995 l
s
q 0 0 1 rg BT 83.00 229.12 Td (Indenture, dated January 27, 2015, among Endo Designated ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 217.78339843749995 m
323.6884765625 217.78339843749995 l
s
q 0 0 1 rg BT 83.00 219.12 Td (Activity Company \(formerly) Tj ET Q
q 0 0 1 rg BT 197.33 219.12 Td (, Endo Limited\), Endo Finance ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 207.78339843749995 m
336.6669921875 207.78339843749995 l
s
q 0 0 1 rg BT 83.00 209.12 Td (LLC, Endo Finco Inc., the guarantors named therein and ) Tj ET Q
q 0 0 1 rg BT 311.64 209.12 Td (W) Tj ET Q
q 0 0 1 rg BT 320.28 209.12 Td (ells ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 197.78339843749995 m
323.87890625 197.78339843749995 l
s
q 0 0 1 rg BT 83.00 199.12 Td (Far) Tj ET Q
q 0 0 1 rg BT 96.15 199.12 Td (go Bank, National ) Tj ET Q
q 0 0 1 rg BT 171.14 199.12 Td (Association, as trustee, relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 187.78339843749995 m
312.140625 187.78339843749995 l
s
q 0 0 1 rg BT 83.00 189.12 Td (6.00% Senior Notes due 2025 \(including Form of 6.00% ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 177.78339843749995 m
327.12109375 177.78339843749995 l
s
q 0 0 1 rg BT 83.00 179.12 Td (Senior Notes due 2025 and Form of Supplemental Indenture ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 167.78339843749995 m
264.07421875 167.78339843749995 l
s
q 0 0 1 rg BT 83.00 169.12 Td (relating to the 6.00% Senior Notes due 2025\)) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 229.12 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 229.12 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 219.12 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 229.12 Td (January 27, 2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 154.12 Td (4.4) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 152.78339843749995 m
329.884765625 152.78339843749995 l
s
q 0 0 1 rg BT 83.00 154.12 Td (Supplemental Indenture, dated March 27, 2015, among Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 142.78339843749995 m
336.466796875 142.78339843749995 l
s
q 0 0 1 rg BT 83.00 144.12 Td (Designated ) Tj ET Q
q 0 0 1 rg BT 129.93 144.12 Td (Activity Company \(formerly) Tj ET Q
q 0 0 1 rg BT 244.26 144.12 Td (, Endo Limited\), Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 132.78339843749995 m
329.0400390625 132.78339843749995 l
s
q 0 0 1 rg BT 83.00 134.12 Td (Finance LLC, Endo Finco Inc., the guarantors named therein ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 122.78339843749995 m
332.619140625 122.78339843749995 l
s
q 0 0 1 rg BT 83.00 124.12 Td (and ) Tj ET Q
q 0 0 1 rg BT 99.76 124.12 Td (W) Tj ET Q
q 0 0 1 rg BT 108.40 124.12 Td (ells Far) Tj ET Q
q 0 0 1 rg BT 137.93 124.12 Td (go Bank, National ) Tj ET Q
q 0 0 1 rg BT 212.92 124.12 Td (Association, as trustee, to the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 112.78339843749995 m
219.0693359375 112.78339843749995 l
s
q 0 0 1 rg BT 83.00 114.12 Td (Indenture, dated January 27, 2015) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 154.12 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 154.12 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 144.12 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 154.12 Td (February 29, 2016) Tj ET Q
endstream
endobj
151 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 152 0 R>>
endobj
152 0 obj
<</Length 22741>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (72) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 745.480078125 m
455.2265625 745.480078125 l
s
q 0 0 0 rg BT 342.00 746.73 Td (Incorporated by Refer) Tj ET Q
q 0 0 0 rg BT 418.80 746.73 Td (ence fr) Tj ET Q
q 0 0 0 rg BT 441.97 746.73 Td (om:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
39 732.480078125 m
67.369140625 732.480078125 l
s
q 0 0 0 rg BT 39.00 733.73 Td (Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
83 732.480078125 m
122.55078125 732.480078125 l
s
q 0 0 0 rg BT 83.00 733.73 Td (Description) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 732.480078125 m
385.251953125 732.480078125 l
s
q 0 0 0 rg BT 342.00 733.73 Td (File Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
397 732.480078125 m
435.6015625 732.480078125 l
s
q 0 0 0 rg BT 397.00 733.73 Td (Filing ) Tj ET Q
q 0 0 0 rg BT 418.93 733.73 Td (T) Tj ET Q
q 0 0 0 rg BT 423.90 733.73 Td (ype) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
492 732.480078125 m
529.99609375 732.480078125 l
s
q 0 0 0 rg BT 492.00 733.73 Td (Filing Date) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 720.07 Td (4.5) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 718.7333984375 m
322.1259765625 718.7333984375 l
s
q 0 0 1 rg BT 83.00 720.07 Td (Registration Rights ) Tj ET Q
q 0 0 1 rg BT 162.45 720.07 Td (Agreement, dated January 27, 2015, by ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 708.7333984375 m
319.5234375 708.7333984375 l
s
q 0 0 1 rg BT 83.00 710.07 Td (and among Endo Designated ) Tj ET Q
q 0 0 1 rg BT 200.20 710.07 Td (Activity Company \(formerly) Tj ET Q
q 0 0 1 rg BT 314.52 710.07 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 698.7333984375 m
312.12109375 698.7333984375 l
s
q 0 0 1 rg BT 83.00 700.07 Td (Endo Limited\), Endo Finance LLC, Endo Finco Inc., the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 688.7333984375 m
334.0498046875 688.7333984375 l
s
q 0 0 1 rg BT 83.00 690.07 Td (guarantors named therein and RBC Capital Markets, LLC and ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 678.7333984375 m
324.064453125 678.7333984375 l
s
q 0 0 1 rg BT 83.00 680.07 Td (Citigroup Global Markets Inc., relating to the 6.00% Senior ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 668.7333984375 m
302.130859375 668.7333984375 l
s
q 0 0 1 rg BT 83.00 670.07 Td (Notes due 2025 \(including Form of Counterpart to the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 658.7333984375 m
324.34765625 658.7333984375 l
s
q 0 0 1 rg BT 83.00 660.07 Td (Registration Rights ) Tj ET Q
q 0 0 1 rg BT 162.45 660.07 Td (Agreement relating to the 6.00% Senior ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 648.7333984375 m
149.0986328125 648.7333984375 l
s
q 0 0 1 rg BT 83.00 650.07 Td (Notes due 2025\)) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 720.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 720.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 710.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 720.07 Td (January 27, 2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 635.07 Td (4.6) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 633.7333984375 m
305.451171875 633.7333984375 l
s
q 0 0 1 rg BT 83.00 635.07 Td (Indenture, dated July 9, 2015, among Endo Designated ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 623.7333984375 m
323.6884765625 623.7333984375 l
s
q 0 0 1 rg BT 83.00 625.07 Td (Activity Company \(formerly) Tj ET Q
q 0 0 1 rg BT 197.33 625.07 Td (, Endo Limited\), Endo Finance ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 613.7333984375 m
336.6669921875 613.7333984375 l
s
q 0 0 1 rg BT 83.00 615.07 Td (LLC, Endo Finco Inc., the guarantors named therein and ) Tj ET Q
q 0 0 1 rg BT 311.64 615.07 Td (W) Tj ET Q
q 0 0 1 rg BT 320.28 615.07 Td (ells ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 603.7333984375 m
323.87890625 603.7333984375 l
s
q 0 0 1 rg BT 83.00 605.07 Td (Far) Tj ET Q
q 0 0 1 rg BT 96.15 605.07 Td (go Bank, National ) Tj ET Q
q 0 0 1 rg BT 171.14 605.07 Td (Association, as trustee, relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 593.7333984375 m
322.140625 593.7333984375 l
s
q 0 0 1 rg BT 83.00 595.07 Td (6.000% Senior Notes due 2023 \(including Form of 6.000% ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 583.7333984375 m
331.5546875 583.7333984375 l
s
q 0 0 1 rg BT 83.00 585.07 Td (Notes due 2023 and Form of Supplemental Indenture relating ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 573.7333984375 m
207.423828125 573.7333984375 l
s
q 0 0 1 rg BT 83.00 575.07 Td (to the 6.000% Notes due 2023\)) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 635.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 635.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 625.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 635.07 Td (July 9, 2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 560.07 Td (4.7) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 558.7333984375 m
286.2763671875 558.7333984375 l
s
q 0 0 1 rg BT 83.00 560.07 Td (Indenture, dated as of March 28, 2019, among Par ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 548.7333984375 m
330.529296875 548.7333984375 l
s
q 0 0 1 rg BT 83.00 550.07 Td (Pharmaceutical, Inc., the guarantors named therein and ) Tj ET Q
q 0 0 1 rg BT 305.50 550.07 Td (W) Tj ET Q
q 0 0 1 rg BT 314.14 550.07 Td (ells ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 538.7333984375 m
323.87890625 538.7333984375 l
s
q 0 0 1 rg BT 83.00 540.07 Td (Far) Tj ET Q
q 0 0 1 rg BT 96.15 540.07 Td (go Bank, National ) Tj ET Q
q 0 0 1 rg BT 171.14 540.07 Td (Association, as trustee, relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 528.7333984375 m
323.517578125 528.7333984375 l
s
q 0 0 1 rg BT 83.00 530.07 Td (7.500% Senior Secured Notes due 2027 \(including Form of ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 518.7333984375 m
245.744140625 518.7333984375 l
s
q 0 0 1 rg BT 83.00 520.07 Td (7.500% Senior Secured Notes due 2027\)) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 560.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 560.07 Td (Current Report on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 550.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 560.07 Td (March 28, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 505.07 Td (10.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 503.7333984375 m
319.0302734375 503.7333984375 l
s
q 0 0 1 rg BT 83.00 505.07 Td (Amended and Restated Executive Deferred Compensation ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 493.7333984375 m
100.7783203125 493.7333984375 l
s
q 0 0 1 rg BT 83.00 495.07 Td (Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 505.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 505.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 495.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 505.07 Td (August 8, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 480.07 Td (10.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 478.7333984375 m
273.791015625 478.7333984375 l
s
q 0 0 1 rg BT 83.00 480.07 Td (Amended and Restated 401\(k\) Restoration Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 480.07 Td (001-15989) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 480.07 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 470.07 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 480.07 Td (March 1, 2013) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 455.07 Td (10.3) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 453.7333984375 m
238.7861328125 453.7333984375 l
s
q 0 0 1 rg BT 83.00 455.07 Td (Directors Deferred Compensation Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 455.07 Td (001-15989) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 455.07 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 445.07 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 455.07 Td (March 1, 2013) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 430.07 Td (10.4) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 428.7333984375 m
337.931640625 428.7333984375 l
s
q 0 0 1 rg BT 83.00 430.07 Td (Endo International plc ) Tj ET Q
q 0 0 1 rg BT 174.36 430.07 Td (Amended and Restated Employee Stock ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 418.7333984375 m
139.376953125 418.7333984375 l
s
q 0 0 1 rg BT 83.00 420.07 Td (Purchase Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 430.07 Td (333-194253) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 430.07 Td (Form S-8) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 430.07 Td (February 28, 2014) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 405.07 Td (10.5) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 403.7333984375 m
321.564453125 403.7333984375 l
s
q 0 0 1 rg BT 83.00 405.07 Td (Credit ) Tj ET Q
q 0 0 1 rg BT 109.94 405.07 Td (Agreement, dated as of ) Tj ET Q
q 0 0 1 rg BT 204.63 405.07 Td (April�27, 2017, among Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 393.7333984375 m
308.859375 393.7333984375 l
s
q 0 0 1 rg BT 83.00 395.07 Td (International, plc, as parent, Endo Luxembour) Tj ET Q
q 0 0 1 rg BT 267.20 395.07 Td (g Finance ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 383.7333984375 m
325.1728515625 383.7333984375 l
s
q 0 0 1 rg BT 83.00 385.07 Td (Company I S.�.r) Tj ET Q
q 0 0 1 rg BT 148.00 385.07 Td (.l. and Endo LLC, as borrowers, the lenders ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 373.7333984375 m
285.001953125 373.7333984375 l
s
q 0 0 1 rg BT 83.00 375.07 Td (party thereto and JPMor) Tj ET Q
q 0 0 1 rg BT 179.74 375.07 Td (gan Chase Bank, N.A., as ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 363.7333984375 m
305.451171875 363.7333984375 l
s
q 0 0 1 rg BT 83.00 365.07 Td (administrative agent, issuing bank and swingline lender) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 405.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 405.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 395.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 405.07 Td (April 28, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 350.07 Td (10.5.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 348.7333984375 m
325.4560546875 348.7333984375 l
s
q 0 0 1 rg BT 83.00 350.07 Td (First ) Tj ET Q
q 0 0 1 rg BT 103.29 350.07 Td (Amendment, dated as of March 28, 2019 \(to the Credit ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 338.7333984375 m
327.3896484375 338.7333984375 l
s
q 0 0 1 rg BT 83.00 340.07 Td (Agreement, dated as of ) Tj ET Q
q 0 0 1 rg BT 177.69 340.07 Td (April 27, 2017\), by and among Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 328.7333984375 m
331.369140625 328.7333984375 l
s
q 0 0 1 rg BT 83.00 330.07 Td (International plc, Endo Luxembour) Tj ET Q
q 0 0 1 rg BT 223.89 330.07 Td (g Finance Company I Sarl ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 318.7333984375 m
319.0400390625 318.7333984375 l
s
q 0 0 1 rg BT 83.00 320.07 Td (and Endo LLC, as borrowers, the lenders and other parties ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 308.7333984375 m
282.501953125 308.7333984375 l
s
q 0 0 1 rg BT 83.00 310.07 Td (party thereto and JPMor) Tj ET Q
q 0 0 1 rg BT 179.74 310.07 Td (gan Chase Bank, N.A. as ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 298.7333984375 m
305.451171875 298.7333984375 l
s
q 0 0 1 rg BT 83.00 300.07 Td (administrative agent, issuing bank and swingline lender) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 350.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 350.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 340.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 350.07 Td (March 28, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 285.07 Td (10.6*) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 283.7333984375 m
316.5400390625 283.7333984375 l
s
q 0 0 1 rg BT 83.00 285.07 Td (Second ) Tj ET Q
q 0 0 1 rg BT 114.39 285.07 Td (Amended and Restated Development and License ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 273.7333984375 m
292.3017578125 273.7333984375 l
s
q 0 0 1 rg BT 83.00 275.07 Td (Agreement, dated ) Tj ET Q
q 0 0 1 rg BT 156.03 275.07 Td (August�31, 201) Tj ET Q
q 0 0 1 rg BT 217.05 275.07 Td (1, by and between ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 263.7333984375 m
271.818359375 263.7333984375 l
s
q 0 0 1 rg BT 83.00 265.07 Td (BioSpecifics ) Tj ET Q
q 0 0 1 rg BT 136.42 265.07 Td (T) Tj ET Q
q 0 0 1 rg BT 141.83 265.07 Td (echnologies Corp. and ) Tj ET Q
q 0 0 1 rg BT 233.48 265.07 Td (Auxilium) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 285.07 Td (000-50855) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 285.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 275.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 285.07 Td (September 1, 201) Tj ET Q
q 0 0 0 rg BT 562.08 285.07 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 250.07 Td (10.6.1*) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 248.7333984375 m
292.1357421875 248.7333984375 l
s
q 0 0 1 rg BT 83.00 250.07 Td (First ) Tj ET Q
q 0 0 1 rg BT 103.29 250.07 Td (Amendment to Second ) Tj ET Q
q 0 0 1 rg BT 196.89 250.07 Td (Amended and Restated ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 238.7333984375 m
336.5302734375 238.7333984375 l
s
q 0 0 1 rg BT 83.00 240.07 Td (Development and License ) Tj ET Q
q 0 0 1 rg BT 189.35 240.07 Td (Agreement, dated February 1, 2016, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 228.7333984375 m
322.8974609375 228.7333984375 l
s
q 0 0 1 rg BT 83.00 230.07 Td (by and between BioSpecifics ) Tj ET Q
q 0 0 1 rg BT 201.68 230.07 Td (T) Tj ET Q
q 0 0 1 rg BT 207.09 230.07 Td (echnologies Corp. and Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 218.7333984375 m
147.5263671875 218.7333984375 l
s
q 0 0 1 rg BT 83.00 220.07 Td (Global ) Tj ET Q
q 0 0 1 rg BT 112.54 220.07 Td (V) Tj ET Q
q 0 0 1 rg BT 118.65 220.07 Td (entures) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 250.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 250.07 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 240.07 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 250.07 Td (February 29, 2016) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 205.07 Td (10.6.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 203.7333984375 m
303.234375 203.7333984375 l
s
q 0 0 1 rg BT 83.00 205.07 Td (Second ) Tj ET Q
q 0 0 1 rg BT 114.39 205.07 Td (Amendment to Second ) Tj ET Q
q 0 0 1 rg BT 207.99 205.07 Td (Amended and Restated ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 193.7333984375 m
316.5302734375 193.7333984375 l
s
q 0 0 1 rg BT 83.00 195.07 Td (Development and License ) Tj ET Q
q 0 0 1 rg BT 189.35 195.07 Td (Agreement, dated February 26, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 183.7333984375 m
324.2890625 183.7333984375 l
s
q 0 0 1 rg BT 83.00 185.07 Td (2019, by and between BioSpecifics ) Tj ET Q
q 0 0 1 rg BT 226.68 185.07 Td (T) Tj ET Q
q 0 0 1 rg BT 232.09 185.07 Td (echnologies Corp. and ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 173.7333984375 m
171.134765625 173.7333984375 l
s
q 0 0 1 rg BT 83.00 175.07 Td (Endo Global ) Tj ET Q
q 0 0 1 rg BT 136.14 175.07 Td (V) Tj ET Q
q 0 0 1 rg BT 142.26 175.07 Td (entures) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 205.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 205.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 195.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 205.07 Td (May 9, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 160.07 Td (10.7*) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 158.7333984375 m
323.7958984375 158.7333984375 l
s
q 0 0 1 rg BT 83.00 160.07 Td (Supply ) Tj ET Q
q 0 0 1 rg BT 113.29 160.07 Td (Agreement, dated June�26, 2008, between ) Tj ET Q
q 0 0 1 rg BT 282.96 160.07 Td (Auxilium ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 148.7333984375 m
231.369140625 148.7333984375 l
s
q 0 0 1 rg BT 83.00 150.07 Td (and Hollister) Tj ET Q
q 0 0 1 rg BT 134.73 150.07 Td (-Stier Laboratories�LLC) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 160.07 Td (000-50855) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 160.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 150.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 160.07 Td (August 8, 2008) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 135.07 Td (10.8) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 133.7333984375 m
317.3896484375 133.7333984375 l
s
q 0 0 1 rg BT 83.00 135.07 Td (Endo International plc ) Tj ET Q
q 0 0 1 rg BT 174.36 135.07 Td (Amended and Restated 2015 Stock ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 123.7333984375 m
140.48046875 123.7333984375 l
s
q 0 0 1 rg BT 83.00 125.07 Td (Incentive Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 135.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 135.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 125.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 135.07 Td (June 1) Tj ET Q
q 0 0 0 rg BT 517.64 135.07 Td (1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 110.07 Td (10.9) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 108.7333984375 m
337.111328125 108.7333984375 l
s
q 0 0 1 rg BT 83.00 110.07 Td (Form of Stock Option ) Tj ET Q
q 0 0 1 rg BT 173.00 110.07 Td (Agreement under the Endo International ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 98.7333984375 m
297.6728515625 98.7333984375 l
s
q 0 0 1 rg BT 83.00 100.07 Td (plc ) Tj ET Q
q 0 0 1 rg BT 97.17 100.07 Td (Amended and Restated 2015 Stock Incentive Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 110.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 110.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 100.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 110.07 Td (November 8, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 85.07 Td (10.10) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 83.7333984375 m
335.0751953125 83.7333984375 l
s
q 0 0 1 rg BT 83.00 85.07 Td (Form of Stock ) Tj ET Q
q 0 0 1 rg BT 142.73 85.07 Td (A) Tj ET Q
q 0 0 1 rg BT 149.03 85.07 Td (ward ) Tj ET Q
q 0 0 1 rg BT 170.97 85.07 Td (Agreement under the Endo International ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 73.7333984375 m
297.6728515625 73.7333984375 l
s
q 0 0 1 rg BT 83.00 75.07 Td (plc ) Tj ET Q
q 0 0 1 rg BT 97.17 75.07 Td (Amended and Restated 2015 Stock Incentive Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 85.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 85.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 75.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 85.07 Td (November 8, 2018) Tj ET Q
endstream
endobj
153 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 154 0 R>>
endobj
154 0 obj
<</Length 23796>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (73) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 745.480078125 m
455.2265625 745.480078125 l
s
q 0 0 0 rg BT 342.00 746.73 Td (Incorporated by Refer) Tj ET Q
q 0 0 0 rg BT 418.80 746.73 Td (ence fr) Tj ET Q
q 0 0 0 rg BT 441.97 746.73 Td (om:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
39 732.480078125 m
67.369140625 732.480078125 l
s
q 0 0 0 rg BT 39.00 733.73 Td (Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
83 732.480078125 m
122.55078125 732.480078125 l
s
q 0 0 0 rg BT 83.00 733.73 Td (Description) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 732.480078125 m
385.251953125 732.480078125 l
s
q 0 0 0 rg BT 342.00 733.73 Td (File Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
397 732.480078125 m
435.6015625 732.480078125 l
s
q 0 0 0 rg BT 397.00 733.73 Td (Filing ) Tj ET Q
q 0 0 0 rg BT 418.93 733.73 Td (T) Tj ET Q
q 0 0 0 rg BT 423.90 733.73 Td (ype) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
492 732.480078125 m
529.99609375 732.480078125 l
s
q 0 0 0 rg BT 492.00 733.73 Td (Filing Date) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 720.07 Td (10.1) Tj ET Q
q 0 0 0 rg BT 56.31 720.07 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 718.7333984375 m
309.7919921875 718.7333984375 l
s
q 0 0 1 rg BT 83.00 720.07 Td (Form of Performance ) Tj ET Q
q 0 0 1 rg BT 171.03 720.07 Td (A) Tj ET Q
q 0 0 1 rg BT 177.34 720.07 Td (ward ) Tj ET Q
q 0 0 1 rg BT 199.27 720.07 Td (Agreement under the Endo ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 708.7333984375 m
333.4833984375 708.7333984375 l
s
q 0 0 1 rg BT 83.00 710.07 Td (International plc ) Tj ET Q
q 0 0 1 rg BT 150.75 710.07 Td (Amended and Restated 2015 Stock Incentive ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 698.7333984375 m
100.7783203125 698.7333984375 l
s
q 0 0 1 rg BT 83.00 700.07 Td (Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 720.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 720.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 710.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 720.07 Td (May 9, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 685.07 Td (10.12) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 683.7333984375 m
327.98046875 683.7333984375 l
s
q 0 0 1 rg BT 83.00 685.07 Td (Form of Long-T) Tj ET Q
q 0 0 1 rg BT 147.85 685.07 Td (erm Cash Incentive ) Tj ET Q
q 0 0 1 rg BT 227.55 685.07 Td (A) Tj ET Q
q 0 0 1 rg BT 233.85 685.07 Td (ward ) Tj ET Q
q 0 0 1 rg BT 255.79 685.07 Td (Agreement under ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 673.7333984375 m
297.6728515625 673.7333984375 l
s
q 0 0 1 rg BT 83.00 675.07 Td (the ) Tj ET Q
q 0 0 1 rg BT 97.17 675.07 Td (Amended and Restated 2015 Stock Incentive Plan) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 685.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 685.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 675.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 685.07 Td (August 8, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 660.07 Td (10.13) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 658.7333984375 m
303.78125 658.7333984375 l
s
q 0 0 1 rg BT 83.00 660.07 Td (Form of Indemnification ) Tj ET Q
q 0 0 1 rg BT 183.82 660.07 Td (Agreement with Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 648.7333984375 m
138.556640625 648.7333984375 l
s
q 0 0 1 rg BT 83.00 650.07 Td (Solutions Inc.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 660.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 660.07 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 650.07 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 660.07 Td (February 29, 2016) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 635.07 Td (10.14) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 633.7333984375 m
328.21484375 633.7333984375 l
s
q 0 0 1 rg BT 83.00 635.07 Td (Form of Indemnification ) Tj ET Q
q 0 0 1 rg BT 183.82 635.07 Td (Agreement with Endo International ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 623.7333984375 m
95.216796875 623.7333984375 l
s
q 0 0 1 rg BT 83.00 625.07 Td (plc) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 635.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 635.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 625.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 635.07 Td (May 6, 2016) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 610.07 Td (10.15*) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 608.7333984375 m
316.65234375 608.7333984375 l
s
q 0 0 1 rg BT 83.00 610.07 Td (Master Supply ) Tj ET Q
q 0 0 1 rg BT 143.56 610.07 Td (Agreement by and between Endo ) Tj ET Q
q 0 0 1 rg BT 279.16 610.07 Td (V) Tj ET Q
q 0 0 1 rg BT 285.28 610.07 Td (entures ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 598.7333984375 m
243.5322265625 598.7333984375 l
s
q 0 0 1 rg BT 83.00 600.07 Td (Limited and Jubilant HollisterStier LLC) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 610.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 610.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 600.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 610.07 Td (August 9, 2016) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 585.07 Td (10.16) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 583.7333984375 m
314.591796875 583.7333984375 l
s
q 0 0 1 rg BT 83.00 585.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 585.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 573.7333984375 m
333.244140625 573.7333984375 l
s
q 0 0 1 rg BT 83.00 575.07 Td (Solutions Inc. and Paul Campanelli, dated as of ) Tj ET Q
q 0 0 1 rg BT 274.64 575.07 Td (April 24, 2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 585.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 585.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 575.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 585.07 Td (April 26, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 560.07 Td (10.17) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 558.7333984375 m
314.591796875 558.7333984375 l
s
q 0 0 1 rg BT 83.00 560.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 560.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 548.7333984375 m
323.99609375 548.7333984375 l
s
q 0 0 1 rg BT 83.00 550.07 Td (Solutions Inc. and ) Tj ET Q
q 0 0 1 rg BT 157.81 550.07 Td (T) Tj ET Q
q 0 0 1 rg BT 163.22 550.07 Td (errance J. Coughlin, dated December 9, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 538.7333984375 m
103 538.7333984375 l
s
q 0 0 1 rg BT 83.00 540.07 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 560.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 560.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 550.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 560.07 Td (December 12, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 525.07 Td (10.18) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 523.7333984375 m
314.591796875 523.7333984375 l
s
q 0 0 1 rg BT 83.00 525.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 525.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 513.7333984375 m
300.5 513.7333984375 l
s
q 0 0 1 rg BT 83.00 515.07 Td (Solutions Inc. and Blaise Coleman, as Executive ) Tj ET Q
q 0 0 1 rg BT 279.72 515.07 Td (V) Tj ET Q
q 0 0 1 rg BT 286.34 515.07 Td (ice ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 503.7333984375 m
320.109375 503.7333984375 l
s
q 0 0 1 rg BT 83.00 505.07 Td (President and Chief Financial Of) Tj ET Q
q 0 0 1 rg BT 214.46 505.07 Td (ficer) Tj ET Q
q 0 0 1 rg BT 232.37 505.07 Td (, dated December 19, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 493.7333984375 m
103 493.7333984375 l
s
q 0 0 1 rg BT 83.00 495.07 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 525.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 525.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 515.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 525.07 Td (December 19, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 480.07 Td (10.18.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 478.7333984375 m
314.591796875 478.7333984375 l
s
q 0 0 1 rg BT 83.00 480.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 480.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 468.7333984375 m
318.7958984375 468.7333984375 l
s
q 0 0 1 rg BT 83.00 470.07 Td (Solutions Inc. and Blaise Coleman, as President and Chief ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 458.7333984375 m
313.2490234375 458.7333984375 l
s
q 0 0 1 rg BT 83.00 460.07 Td (Executive Of) Tj ET Q
q 0 0 1 rg BT 135.85 460.07 Td (ficer) Tj ET Q
q 0 0 1 rg BT 153.77 460.07 Td (, dated February 19, 2020 and ef) Tj ET Q
q 0 0 1 rg BT 283.55 460.07 Td (fective ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 448.7333984375 m
141.5986328125 448.7333984375 l
s
q 0 0 1 rg BT 83.00 450.07 Td (March 6, 2020) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 480.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 435.07 Td (10.19) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 433.7333984375 m
314.591796875 433.7333984375 l
s
q 0 0 1 rg BT 83.00 435.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 435.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 423.7333984375 m
335.353515625 423.7333984375 l
s
q 0 0 1 rg BT 83.00 425.07 Td (Solutions Inc. and Mark Bradley) Tj ET Q
q 0 0 1 rg BT 213.16 425.07 Td (, dated February 19, 2020 and ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 413.7333984375 m
178.888671875 413.7333984375 l
s
q 0 0 1 rg BT 83.00 415.07 Td (ef) Tj ET Q
q 0 0 1 rg BT 90.59 415.07 Td (fective March 6, 2020) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 435.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 400.07 Td (10.20) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 398.7333984375 m
314.591796875 398.7333984375 l
s
q 0 0 1 rg BT 83.00 400.07 Td (Executive Employment ) Tj ET Q
q 0 0 1 rg BT 179.09 400.07 Td (Agreement between Endo Health ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 388.7333984375 m
324.8896484375 388.7333984375 l
s
q 0 0 1 rg BT 83.00 390.07 Td (Solutions Inc. and Matthew J. Maletta, dated as of February ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 378.7333984375 m
118 378.7333984375 l
s
q 0 0 1 rg BT 83.00 380.07 Td (13, 2018) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 400.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 400.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 390.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 400.07 Td (February 15, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 365.07 Td (10.21) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 363.7333984375 m
337.404296875 363.7333984375 l
s
q 0 0 1 rg BT 83.00 365.07 Td (Cash Contribution Bonus ) Tj ET Q
q 0 0 1 rg BT 186.62 365.07 Td (Agreement between Endo and Blaise ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 353.7333984375 m
209.0986328125 353.7333984375 l
s
q 0 0 1 rg BT 83.00 355.07 Td (Coleman, dated ) Tj ET Q
q 0 0 1 rg BT 147.71 355.07 Td (August 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 365.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 365.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 355.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 365.07 Td (August 5, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 340.07 Td (10.22) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 338.7333984375 m
309.9091796875 338.7333984375 l
s
q 0 0 1 rg BT 83.00 340.07 Td (Cash Contribution Bonus ) Tj ET Q
q 0 0 1 rg BT 186.62 340.07 Td (Agreement between Endo and ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 328.7333984375 m
256.4375 328.7333984375 l
s
q 0 0 1 rg BT 83.00 330.07 Td (T) Tj ET Q
q 0 0 1 rg BT 88.41 330.07 Td (errance J. Coughlin, dated ) Tj ET Q
q 0 0 1 rg BT 195.05 330.07 Td (August 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 340.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 340.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 330.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 340.07 Td (August 5, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 315.07 Td (10.23) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 313.7333984375 m
334.0693359375 313.7333984375 l
s
q 0 0 1 rg BT 83.00 315.07 Td (Cash Contribution Bonus ) Tj ET Q
q 0 0 1 rg BT 186.62 315.07 Td (Agreement between Endo and Mark ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 303.7333984375 m
204.0009765625 303.7333984375 l
s
q 0 0 1 rg BT 83.00 305.07 Td (Bradley) Tj ET Q
q 0 0 1 rg BT 114.01 305.07 Td (, dated ) Tj ET Q
q 0 0 1 rg BT 142.61 305.07 Td (August 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 315.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 290.07 Td (10.24) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 288.7333984375 m
337.2578125 288.7333984375 l
s
q 0 0 1 rg BT 83.00 290.07 Td (Letter ) Tj ET Q
q 0 0 1 rg BT 108.82 290.07 Td (Agreement between Endo and Mark Bradley) Tj ET Q
q 0 0 1 rg BT 287.27 290.07 Td (, dated May ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 278.7333984375 m
118 278.7333984375 l
s
q 0 0 1 rg BT 83.00 280.07 Td (17, 2018) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 290.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 265.07 Td (10.25) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 263.7333984375 m
309.9091796875 263.7333984375 l
s
q 0 0 1 rg BT 83.00 265.07 Td (Cash Contribution Bonus ) Tj ET Q
q 0 0 1 rg BT 186.62 265.07 Td (Agreement between Endo and ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 253.7333984375 m
250.4755859375 253.7333984375 l
s
q 0 0 1 rg BT 83.00 255.07 Td (Matthew J. Maletta, dated ) Tj ET Q
q 0 0 1 rg BT 189.08 255.07 Td (August 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 265.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 265.07 Td (Quarterly Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 255.07 Td (Form 10-Q) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 265.07 Td (August 5, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 240.07 Td (10.26) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 238.7333984375 m
334.650390625 238.7333984375 l
s
q 0 0 1 rg BT 83.00 240.07 Td (Succession Planning and ) Tj ET Q
q 0 0 1 rg BT 184.75 240.07 Td (T) Tj ET Q
q 0 0 1 rg BT 190.51 240.07 Td (ransition Compensation ) Tj ET Q
q 0 0 1 rg BT 287.73 240.07 Td (Agreement ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 228.7333984375 m
324.23046875 228.7333984375 l
s
q 0 0 1 rg BT 83.00 230.07 Td (between Endo and Paul ) Tj ET Q
q 0 0 1 rg BT 179.46 230.07 Td (V) Tj ET Q
q 0 0 1 rg BT 185.39 230.07 Td (. Campanelli, dated December 12, ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 218.7333984375 m
103 218.7333984375 l
s
q 0 0 1 rg BT 83.00 220.07 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 240.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 240.07 Td (Current Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 230.07 Td (Form 8-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 240.07 Td (December 12, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 205.07 Td (14.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 203.7333984375 m
169.376953125 203.7333984375 l
s
q 0 0 1 rg BT 83.00 205.07 Td (Our Code of Conduct) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 205.07 Td (001-36326) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 205.07 Td (Annual Report on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.00 195.07 Td (Form 10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.00 205.07 Td (February 28, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 180.07 Td (21.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 178.7333984375 m
201.037109375 178.7333984375 l
s
q 0 0 1 rg BT 83.00 180.07 Td (Subsidiaries of the Registrant) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 180.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 165.07 Td (23.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 163.7333984375 m
248.615234375 163.7333984375 l
s
q 0 0 1 rg BT 83.00 165.07 Td (Consent of PricewaterhouseCoopers LLP) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 165.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 150.07 Td (24.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 148.7333984375 m
156.876953125 148.7333984375 l
s
q 0 0 1 rg BT 83.00 150.07 Td (Power of ) Tj ET Q
q 0 0 1 rg BT 121.33 150.07 Td (Attorney) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 150.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 135.07 Td (31.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 133.7333984375 m
327.453125 133.7333984375 l
s
q 0 0 1 rg BT 83.00 135.07 Td (Certification of the President and Chief Executive Of) Tj ET Q
q 0 0 1 rg BT 295.81 135.07 Td (ficer of ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 123.7333984375 m
322.951171875 123.7333984375 l
s
q 0 0 1 rg BT 83.00 125.07 Td (Endo pursuant to Section 302 of the Sarbanes-Oxley ) Tj ET Q
q 0 0 1 rg BT 295.18 125.07 Td (Act of ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 113.7333984375 m
103 113.7333984375 l
s
q 0 0 1 rg BT 83.00 115.07 Td (2002) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 135.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 100.07 Td (31.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 98.7333984375 m
328.576171875 98.7333984375 l
s
q 0 0 1 rg BT 83.00 100.07 Td (Certification of the Chief Financial Of) Tj ET Q
q 0 0 1 rg BT 236.38 100.07 Td (ficer of Endo pursuant ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 88.7333984375 m
282.404296875 88.7333984375 l
s
q 0 0 1 rg BT 83.00 90.07 Td (to Section 302 of the Sarbanes-Oxley ) Tj ET Q
q 0 0 1 rg BT 234.64 90.07 Td (Act of 2002) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 100.07 Td (Not applicable; filed herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 75.07 Td (32.1) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 73.7333984375 m
327.453125 73.7333984375 l
s
q 0 0 1 rg BT 83.00 75.07 Td (Certification of the President and Chief Executive Of) Tj ET Q
q 0 0 1 rg BT 295.81 75.07 Td (ficer of ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 63.7333984375 m
335.197265625 63.7333984375 l
s
q 0 0 1 rg BT 83.00 65.07 Td (Endo pursuant to 18 U.S.C. Section 1350, as adopted pursuant ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 53.7333984375 m
282.404296875 53.7333984375 l
s
q 0 0 1 rg BT 83.00 55.07 Td (to Section 906 of the Sarbanes-Oxley ) Tj ET Q
q 0 0 1 rg BT 234.64 55.07 Td (Act of 2002) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 75.07 Td (Not applicable; furnished herewith) Tj ET Q
endstream
endobj
155 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 156 0 R>>
endobj
156 0 obj
<</Length 6490>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (74) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 744.480078125 m
455.2265625 744.480078125 l
s
q 0 0 0 rg BT 342.00 745.73 Td (Incorporated by Refer) Tj ET Q
q 0 0 0 rg BT 418.80 745.73 Td (ence fr) Tj ET Q
q 0 0 0 rg BT 441.97 745.73 Td (om:) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
39 731.480078125 m
67.369140625 731.480078125 l
s
q 0 0 0 rg BT 39.00 732.73 Td (Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
83 731.480078125 m
122.55078125 731.480078125 l
s
q 0 0 0 rg BT 83.00 732.73 Td (Description) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
342 731.480078125 m
385.251953125 731.480078125 l
s
q 0 0 0 rg BT 342.00 732.73 Td (File Number) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
397 731.480078125 m
435.6015625 731.480078125 l
s
q 0 0 0 rg BT 397.00 732.73 Td (Filing ) Tj ET Q
q 0 0 0 rg BT 418.93 732.73 Td (T) Tj ET Q
q 0 0 0 rg BT 423.90 732.73 Td (ype) Tj ET Q
BT /F1 8.00 Tf ET
0 0 0 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
492 731.480078125 m
529.99609375 731.480078125 l
s
q 0 0 0 rg BT 492.00 732.73 Td (Filing Date) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 719.07 Td (32.2) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 717.7333984375 m
328.576171875 717.7333984375 l
s
q 0 0 1 rg BT 83.00 719.07 Td (Certification of the Chief Financial Of) Tj ET Q
q 0 0 1 rg BT 236.38 719.07 Td (ficer of Endo pursuant ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 707.7333984375 m
334.923828125 707.7333984375 l
s
q 0 0 1 rg BT 83.00 709.07 Td (to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 ) Tj ET Q
BT /F3 10.00 Tf ET
0 0 1 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
83 697.7333984375 m
222.130859375 697.7333984375 l
s
q 0 0 1 rg BT 83.00 699.07 Td (of the Sarbanes-Oxley ) Tj ET Q
q 0 0 1 rg BT 174.36 699.07 Td (Act of 2002) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 719.07 Td (Not applicable; furnished herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 684.07 Td (101.INS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 684.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 684.07 Td ( Instance Document - the instance document does not) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 674.07 Td (appear in the interactive data file because its XBRL) Tj ET Q
q 0 0 0 rg BT 289.40 674.07 Td ( tags are) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 664.07 Td (embedded within the inline XBRL) Tj ET Q
q 0 0 0 rg BT 221.13 664.07 Td ( document.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 684.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 649.07 Td (101.SCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 649.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 649.07 Td ( ) Tj ET Q
q 0 0 0 rg BT 114.49 649.07 Td (T) Tj ET Q
q 0 0 0 rg BT 120.16 649.07 Td (axonomy Extension Schema Document) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 649.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 634.07 Td (101.CAL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 634.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 634.07 Td ( ) Tj ET Q
q 0 0 0 rg BT 114.49 634.07 Td (T) Tj ET Q
q 0 0 0 rg BT 120.16 634.07 Td (axonomy Extension Calculation Linkbase Document) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 634.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 619.07 Td (101.DEF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 619.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 619.07 Td ( ) Tj ET Q
q 0 0 0 rg BT 114.49 619.07 Td (T) Tj ET Q
q 0 0 0 rg BT 120.16 619.07 Td (axonomy Extension Definition Linkbase Document) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 619.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 604.07 Td (101.LAB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 604.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 604.07 Td ( ) Tj ET Q
q 0 0 0 rg BT 114.49 604.07 Td (T) Tj ET Q
q 0 0 0 rg BT 120.16 604.07 Td (axonomy Extension Label Linkbase Document) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 604.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 589.07 Td (101.PRE) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 589.07 Td (iXBRL) Tj ET Q
q 0 0 0 rg BT 112.26 589.07 Td ( ) Tj ET Q
q 0 0 0 rg BT 114.49 589.07 Td (T) Tj ET Q
q 0 0 0 rg BT 120.16 589.07 Td (axonomy Extension Presentation Linkbase Document) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 589.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 574.07 Td (104) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 574.07 Td (Cover Page Interactive Data File, formatted in iXBRL) Tj ET Q
q 0 0 0 rg BT 299.97 574.07 Td ( and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.00 564.07 Td (contained in Exhibit 101) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.00 574.07 Td (Not applicable; submitted herewith) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 549.40 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 537.40 Td (*  ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.50 537.40 Td (Confidential portions of this exhibit \(indicated by asterisks\) have been redacted and filed separately with the Securities and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.50 525.40 Td (Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.50 513.40 Td (Act of 1934, as amended.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 495.40 Td (Item 16.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.99 495.40 Td ( ) Tj ET Q
q 0 0 0 rg BT 72.00 495.40 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 108.00 495.40 Td (Form 10-K Summary) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 477.40 Td (None.) Tj ET Q
endstream
endobj
157 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 158 0 R>>
endobj
158 0 obj
<</Length 2406>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 24.60 Td (75) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 276.60 749.25 Td (SIGNA) Tj ET Q
q 0 0 0 rg BT 307.53 749.25 Td (TURE) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Pursuant to the requirements of Section 13 or 15\(d\) of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 379.87 731.25 Td (Act of 1934, the Registrant has duly caused this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (report to be signed on its behalf by the undersigned, thereunto duly authorized.) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
240.5 693.75 m
574.5 693.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
240.5 693.75 m
574.5 693.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
240.5 650.75 m
574.5 650.75 l
s
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.00 698.42 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 316.60 698.42 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 353.07 698.42 Td ( PLC) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 243.00 685.83 Td (\(Registrant\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.00 655.42 Td (/S/ P) Tj ET Q
q 0 0 0 rg BT 261.26 655.42 Td (AUL) Tj ET Q
q 0 0 0 rg BT 281.44 655.42 Td ( ) Tj ET Q
q 0 0 0 rg BT 283.76 655.42 Td (V) Tj ET Q
q 0 0 0 rg BT 289.69 655.42 Td (. CAMP) Tj ET Q
q 0 0 0 rg BT 322.12 655.42 Td (ANELLI) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 212.00 642.70 Td (Name:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 243.00 642.83 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 260.49 642.83 Td (V) Tj ET Q
q 0 0 0 rg BT 265.68 642.83 Td (. Campanelli) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 212.00 629.70 Td (T) Tj ET Q
q 0 0 0 rg BT 216.61 629.70 Td (itle:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 243.00 629.83 Td (Pr) Tj ET Q
q 0 0 0 rg BT 251.37 629.83 Td (esident and Chief Executive Officer) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 243.00 616.83 Td (\(Principal Executive Officer\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 594.25 Td (Date: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.16 594.25 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
159 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 160 0 R>>
endobj
160 0 obj
<</Length 6477>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.00 31.60 Td (76) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Pursuant to the requirements of the Securities Exchange of 1934, this report has been signed below by the following persons on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (behalf of the Registrant and in the capacities and on the dates indicated.) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 691.6 m
183.5 691.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 648.6 m
183.5 648.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 605.6 m
183.5 605.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 562.6 m
183.5 562.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 519.6 m
183.5 519.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 476.6 m
183.5 476.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 433.6 m
183.5 433.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 433.6 m
183.5 433.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 390.6 m
183.5 390.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 390.6 m
183.5 390.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
60.5 347.6 m
183.5 347.6 l
s
BT /F1 9.00 Tf ET
0 0 0 RG
/GS0 gs
0.86 w
0 i 
[] 0 d
1 J
1 j
3 M
63 708.646337890625 m
100.34033203125 708.646337890625 l
s
q 0 0 0 rg BT 63.00 710.05 Td (Signatur) Tj ET Q
q 0 0 0 rg BT 96.43 710.05 Td (e) Tj ET Q
BT /F1 9.00 Tf ET
0 0 0 RG
/GS0 gs
0.86 w
0 i 
[] 0 d
1 J
1 j
3 M
190 708.646337890625 m
207.8330078125 708.646337890625 l
s
q 0 0 0 rg BT 190.00 710.05 Td (T) Tj ET Q
q 0 0 0 rg BT 195.92 710.05 Td (itle) Tj ET Q
BT /F1 9.00 Tf ET
0 0 0 RG
/GS0 gs
0.86 w
0 i 
[] 0 d
1 J
1 j
3 M
505 708.646337890625 m
522.9912109375 708.646337890625 l
s
q 0 0 0 rg BT 505.00 710.05 Td (Date) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 696.86 Td (/S/ P) Tj ET Q
q 0 0 0 rg BT 79.85 696.86 Td (AUL) Tj ET Q
q 0 0 0 rg BT 97.77 696.86 Td ( ) Tj ET Q
q 0 0 0 rg BT 99.77 696.86 Td (V) Tj ET Q
q 0 0 0 rg BT 105.60 696.86 Td (. CAMP) Tj ET Q
q 0 0 0 rg BT 134.62 696.86 Td (ANELLI) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 696.86 Td (Chairman, Director) Tj ET Q
q 0 0 0 rg BT 259.61 696.86 Td (, President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 384.92 696.86 Td (ficer) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 687.86 Td (\(Principal Executive Of) Tj ET Q
q 0 0 0 rg BT 275.31 687.86 Td (ficer\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 696.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 682.86 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 81.17 682.86 Td (V) Tj ET Q
q 0 0 0 rg BT 87.01 682.86 Td (. Campanelli) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 653.86 Td (/S/ BLAISE COLEMAN) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 653.86 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 228.07 653.86 Td (V) Tj ET Q
q 0 0 0 rg BT 234.03 653.86 Td (ice President, Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 352.08 653.86 Td (ficer) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 644.86 Td (\(Principal Financial Of) Tj ET Q
q 0 0 0 rg BT 272.81 644.86 Td (ficer\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 653.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 639.86 Td (Blaise Coleman) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 610.86 Td (/S/ JACK BOYLE) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 610.86 Td (Senior ) Tj ET Q
q 0 0 0 rg BT 215.58 610.86 Td (V) Tj ET Q
q 0 0 0 rg BT 221.54 610.86 Td (ice President, Controller) Tj ET Q
q 0 0 0 rg BT 308.91 610.86 Td (, Chief ) Tj ET Q
q 0 0 0 rg BT 335.16 610.86 Td (Accounting Of) Tj ET Q
q 0 0 0 rg BT 388.73 610.86 Td (ficer) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 601.86 Td (\(Principal ) Tj ET Q
q 0 0 0 rg BT 227.24 601.86 Td (Accounting Of) Tj ET Q
q 0 0 0 rg BT 280.82 601.86 Td (ficer\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 610.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 596.86 Td (Jack Boyle) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 567.86 Td (   *) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 567.86 Td (Senior Independent Director) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 567.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 553.86 Td (Roger H. Kimmel) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 524.86 Td (   *) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 524.86 Td (Director) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 524.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 510.86 Td (Shane M. Cooke) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 481.86 Td (   *) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 481.86 Td (Director) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 481.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 467.86 Td (Nancy J. Hutson, Ph.D.) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 438.86 Td (   *) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 438.86 Td (Director) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 438.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 424.86 Td (Michael Hyatt) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 395.86 Td (   *) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 395.86 Td (Director) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 395.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 381.86 Td (W) Tj ET Q
q 0 0 0 rg BT 71.31 381.86 Td (illiam P) Tj ET Q
q 0 0 0 rg BT 98.89 381.86 Td (. Montague) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 352.86 Td (*By:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 352.86 Td (/S/ MA) Tj ET Q
q 0 0 0 rg BT 89.26 352.86 Td (TTHEW) Tj ET Q
q 0 0 0 rg BT 120.17 352.86 Td ( J. MALETT) Tj ET Q
q 0 0 0 rg BT 166.47 352.86 Td (A) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 190.00 352.86 Td (Attorney-in-fact pursuant to a Power of ) Tj ET Q
q 0 0 0 rg BT 334.21 352.86 Td (Attorney filed with this Report as Exhibit 24) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 505.00 352.86 Td (February 26, 2020) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 63.00 338.86 Td (Matthew J. Maletta) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
161 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 692.26279296875 296.82177734375 700.9] /Border [0 0 0] /H /I /Dest [163 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 677.26279296875 260.15673828125 685.9] /Border [0 0 0] /H /I /Dest [165 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 662.26279296875 148.28369140625 670.9] /Border [0 0 0] /H /I /Dest [173 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 647.26279296875 186.54931640625 655.9] /Border [0 0 0] /H /I /Dest [175 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 632.26279296875 224.814453125 640.9] /Border [0 0 0] /H /I /Dest [177 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 617.26279296875 259.7080078125 625.9] /Border [0 0 0] /H /I /Dest [179 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 602.26279296875 189.4716796875 610.9] /Border [0 0 0] /H /I /Dest [181 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [38 587.26279296875 204.2333984375 595.9] /Border [0 0 0] /H /I /Dest [183 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [558.8 692.26279296875 571.997265625 700.9] /Border [0 0 0] /H /I /Dest [163 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [558.8 677.26279296875 571.997265625 685.9] /Border [0 0 0] /H /I /Dest [165 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [558.8 662.26279296875 571.997265625 670.9] /Border [0 0 0] /H /I /Dest [173 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [558.8 647.26279296875 571.997265625 655.9] /Border [0 0 0] /H /I /Dest [175 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [558.8 632.26279296875 571.997265625 640.9] /Border [0 0 0] /H /I /Dest [177 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [554.05 617.26279296875 571.997265625 625.9] /Border [0 0 0] /H /I /Dest [179 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [554.4 602.26279296875 571.9947265625 610.9] /Border [0 0 0] /H /I /Dest [181 0 R /XYZ 0 792.00 null]>><</Type /Annot /Subtype /Link /Rect [554.05 587.26279296875 571.997265625 595.9] /Border [0 0 0] /H /I /Dest [183 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 162 0 R>>
endobj
162 0 obj
<</Length 5531>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-1) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 217.55 742.25 Td (INDEX ) Tj ET Q
q 0 0 0 rg BT 252.10 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 258.59 742.25 Td (O FINANCIAL) Tj ET Q
q 0 0 0 rg BT 324.98 742.25 Td ( ST) Tj ET Q
q 0 0 0 rg BT 338.97 742.25 Td (A) Tj ET Q
q 0 0 0 rg BT 345.45 742.25 Td (TEMENTS) Tj ET Q
BT /F1 9.50 Tf ET
0 0 0 RG
/GS0 gs
0.90 w
0 i 
[] 0 d
1 J
1 j
3 M
552.45 707.8292236328125 m
571.97001953125 707.8292236328125 l
s
q 0 0 0 rg BT 552.45 709.32 Td (Page) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 693.046728515625 m
296.82177734375 693.046728515625 l
s
q 0 0 1 rg BT 38.00 694.31 Td (Management�) Tj ET Q
q 0 0 1 rg BT 90.23 694.31 Td (s Report on Internal Control Over Financial Reporting) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 678.046728515625 m
260.15673828125 678.046728515625 l
s
q 0 0 1 rg BT 38.00 679.31 Td (Report of Independent Registered Public ) Tj ET Q
q 0 0 1 rg BT 194.98 679.31 Td (Accounting Firm) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 663.046728515625 m
148.28369140625 663.046728515625 l
s
q 0 0 1 rg BT 38.00 664.31 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 648.046728515625 m
186.54931640625 648.046728515625 l
s
q 0 0 1 rg BT 38.00 649.31 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 633.046728515625 m
224.814453125 633.046728515625 l
s
q 0 0 1 rg BT 38.00 634.31 Td (Consolidated Statements of Comprehensive Loss) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 618.046728515625 m
259.7080078125 618.046728515625 l
s
q 0 0 1 rg BT 38.00 619.31 Td (Consolidated Statements of Shareholders�) Tj ET Q
q 0 0 1 rg BT 196.92 619.31 Td ( Equity \(Deficit\)) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 603.046728515625 m
189.4716796875 603.046728515625 l
s
q 0 0 1 rg BT 38.00 604.31 Td (Consolidated Statements of Cash Flows) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
38 588.046728515625 m
204.2333984375 588.046728515625 l
s
q 0 0 1 rg BT 38.00 589.31 Td (Notes to Consolidated Financial Statements) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
558.8 693.046728515625 m
571.997265625 693.046728515625 l
s
q 0 0 1 rg BT 558.80 694.31 Td (F-2) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
558.8 678.046728515625 m
571.997265625 678.046728515625 l
s
q 0 0 1 rg BT 558.80 679.31 Td (F-3) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
558.8 663.046728515625 m
571.997265625 663.046728515625 l
s
q 0 0 1 rg BT 558.80 664.31 Td (F-7) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
558.8 648.046728515625 m
571.997265625 648.046728515625 l
s
q 0 0 1 rg BT 558.80 649.31 Td (F-8) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
558.8 633.046728515625 m
571.997265625 633.046728515625 l
s
q 0 0 1 rg BT 558.80 634.31 Td (F-9) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
554.05 618.046728515625 m
571.997265625 618.046728515625 l
s
q 0 0 1 rg BT 554.05 619.31 Td (F-10) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
554.4 603.046728515625 m
571.9947265625 603.046728515625 l
s
q 0 0 1 rg BT 554.40 604.31 Td (F-1) Tj ET Q
q 0 0 1 rg BT 567.24 604.31 Td (1) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.46 w
0 i 
[] 0 d
1 J
1 j
3 M
554.05 588.046728515625 m
571.997265625 588.046728515625 l
s
q 0 0 1 rg BT 554.05 589.31 Td (F-12) Tj ET Q
BT /F3 9.50 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
endstream
endobj
163 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 164 0 R>>
endobj
164 0 obj
<</Length 6290>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-2) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 103.20 742.25 Td (MANAGEMENT�S REPOR) Tj ET Q
q 0 0 0 rg BT 224.79 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 231.28 742.25 Td ( ON INTERNAL) Tj ET Q
q 0 0 0 rg BT 303.52 742.25 Td ( CONTROL) Tj ET Q
q 0 0 0 rg BT 356.03 742.25 Td ( OVER FINANCIAL) Tj ET Q
q 0 0 0 rg BT 446.04 742.25 Td ( REPOR) Tj ET Q
q 0 0 0 rg BT 483.19 742.25 Td (TING) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (The management of Endo International plc is responsible for establishing and maintaining adequate internal control over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (financial reporting as defined in Rules 13a-15\(f\) and 15d-15\(f\) under the Exchange ) Tj ET Q
q 0 0 0 rg BT 370.88 712.25 Td (Act, as amended. Endo International plc�) Tj ET Q
q 0 0 0 rg BT 534.44 712.25 Td (s internal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (control over financial reporting was designed to provide reasonable assurance regarding the reliability of financial reporting and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.25 Td (preparation of financial statements for external purposes in accordance with generally accepted accounting principles.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 670.25 Td (Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. ) Tj ET Q
q 0 0 0 rg BT 531.20 670.25 Td (Also, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (projections of any evaluation of ef) Tj ET Q
q 0 0 0 rg BT 173.27 658.25 Td (fectiveness to future periods are subject to the risk that controls may become inadequate because of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 628.25 Td (Endo International plc�) Tj ET Q
q 0 0 0 rg BT 155.19 628.25 Td (s management assessed the ef) Tj ET Q
q 0 0 0 rg BT 273.86 628.25 Td (fectiveness of the Company�) Tj ET Q
q 0 0 0 rg BT 388.00 628.25 Td (s internal control over financial reporting as of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 574.32 628.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 616.25 Td (. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Or) Tj ET Q
q 0 0 0 rg BT 528.21 616.25 Td (ganizations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (of the ) Tj ET Q
q 0 0 0 rg BT 61.37 604.25 Td (T) Tj ET Q
q 0 0 0 rg BT 67.12 604.25 Td (readway Commission \(COSO\) in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 202.67 604.25 Td (Internal Contr) Tj ET Q
q 0 0 0 rg BT 260.36 604.25 Td (ol-Integrated Framework \(2013\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.44 604.25 Td (. Based on management�) Tj ET Q
q 0 0 0 rg BT 489.75 604.25 Td (s assessment, as of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 564.74 604.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 592.25 Td (, the Company�) Tj ET Q
q 0 0 0 rg BT 175.97 592.25 Td (s internal control over financial reporting is ef) Tj ET Q
q 0 0 0 rg BT 359.89 592.25 Td (fective based on those criteria.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 574.25 Td (Endo International plc�) Tj ET Q
q 0 0 0 rg BT 155.19 574.25 Td (s independent registered public accounting firm has issued its report on the ef) Tj ET Q
q 0 0 0 rg BT 464.92 574.25 Td (fectiveness of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.25 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 562.25 Td (s internal control over financial reporting as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.49 562.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.07 562.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 349.89 562.25 Td (This report appears on page ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.46 562.25 Td (F-3) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.35 562.25 Td (.) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
36.5 536.75 m
370.5 536.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
36.5 536.75 m
370.5 536.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
36.5 468.75 m
370.5 468.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
36.5 468.75 m
370.5 468.75 l
s
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 541.21 Td (/S/ P) Tj ET Q
q 0 0 0 rg BT 55.85 541.21 Td (AUL) Tj ET Q
q 0 0 0 rg BT 73.77 541.21 Td ( ) Tj ET Q
q 0 0 0 rg BT 75.77 541.21 Td (V) Tj ET Q
q 0 0 0 rg BT 81.60 541.21 Td (. CAMP) Tj ET Q
q 0 0 0 rg BT 110.62 541.21 Td (ANELLI) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 526.21 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 57.17 526.21 Td (V) Tj ET Q
q 0 0 0 rg BT 63.01 526.21 Td (. Campanelli) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 512.21 Td (Chairman, Director) Tj ET Q
q 0 0 0 rg BT 108.61 512.21 Td (, President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 233.92 512.21 Td (ficer ) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 503.21 Td (\(Principal Executive Of) Tj ET Q
q 0 0 0 rg BT 124.31 503.21 Td (ficer\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 473.21 Td (/S/ BLAISE COLEMAN) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 458.21 Td (Blaise Coleman) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 444.21 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 77.07 444.21 Td (V) Tj ET Q
q 0 0 0 rg BT 83.03 444.21 Td (ice President, Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 201.08 444.21 Td (ficer ) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 39.00 435.21 Td (\(Principal Financial Of) Tj ET Q
q 0 0 0 rg BT 121.81 435.21 Td (ficer\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.25 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
165 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 166 0 R>>
endobj
166 0 obj
<</Length 11643>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-3) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 135.40 742.25 Td (REPOR) Tj ET Q
q 0 0 0 rg BT 170.05 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 176.54 742.25 Td ( OF) Tj ET Q
q 0 0 0 rg BT 192.55 742.25 Td ( INDEPENDENT) Tj ET Q
q 0 0 0 rg BT 267.66 742.25 Td ( REGISTERED PUBLIC ) Tj ET Q
q 0 0 0 rg BT 377.97 742.25 Td (ACCOUNTING FIRM) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (T) Tj ET Q
q 0 0 0 rg BT 41.41 718.25 Td (o the Board of Directors and Shareholders of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.58 718.25 Td (Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (Opinions on the Financial Statements and Internal Control over Financial Reporting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.25 Td (W) Tj ET Q
q 0 0 0 rg BT 44.64 676.25 Td (e have audited the accompanying consolidated balance sheets of Endo International plc and its subsidiaries \(the �Company�\) as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 664.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.02 664.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.02 664.25 Td (, and the related consolidated statements of operations, comprehensive loss, shareholders�) Tj ET Q
q 0 0 0 rg BT 512.34 664.25 Td ( equity \(deficit\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.25 Td (and cash flows for each of the three years in the period ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.95 652.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.54 652.25 Td (, including the related notes and schedule of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.25 Td (valuation and qualifying accounts for each of the three years in the period ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.76 640.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.35 640.25 Td ( appearing under Item 15\(a\)\(2\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (\(collectively referred to as the �consolidated financial statements�\). ) Tj ET Q
q 0 0 0 rg BT 308.20 628.25 Td (W) Tj ET Q
q 0 0 0 rg BT 316.83 628.25 Td (e also have audited the Company's internal control over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (financial reporting as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.30 616.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.88 616.25 Td ( based on criteria established in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 341.17 616.25 Td (Internal Contr) Tj ET Q
q 0 0 0 rg BT 398.86 616.25 Td (ol - Integrated Framework) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.78 616.25 Td ( \(2013\) issued by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (the Committee of Sponsoring Or) Tj ET Q
q 0 0 0 rg BT 166.92 604.25 Td (ganizations of the ) Tj ET Q
q 0 0 0 rg BT 240.33 604.25 Td (T) Tj ET Q
q 0 0 0 rg BT 246.08 604.25 Td (readway Commission \(COSO\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (In our opinion, the consolidated financial statements referred to above present fairly) Tj ET Q
q 0 0 0 rg BT 371.34 586.25 Td (, in all material respects, the financial position of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (the Company as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.76 574.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.35 574.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.79 574.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.79 574.25 Td (, and the results of its operations and its cash flows for each of the three years in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.25 Td (period ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.42 562.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.01 562.25 Td ( in conformity with accounting principles generally accepted in the United States of ) Tj ET Q
q 0 0 0 rg BT 505.85 562.25 Td (America. ) Tj ET Q
q 0 0 0 rg BT 544.73 562.25 Td (Also in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.25 Td (our opinion, the Company maintained, in all material respects, ef) Tj ET Q
q 0 0 0 rg BT 295.75 550.25 Td (fective internal control over financial reporting as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.88 550.25 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 538.25 Td (, based on criteria established in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 186.79 538.25 Td (Internal Contr) Tj ET Q
q 0 0 0 rg BT 244.48 538.25 Td (ol - Integrated Framework) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.40 538.25 Td ( \(2013\) issued by the COSO.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (Change in ) Tj ET Q
q 0 0 0 rg BT 79.71 514.25 Td (Accounting Principle) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (2019.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (Basis for Opinions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (The Company's management is responsible for these consolidated financial statements, for maintaining ef) Tj ET Q
q 0 0 0 rg BT 458.89 442.25 Td (fective internal control over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (financial reporting, and for its assessment of the ef) Tj ET Q
q 0 0 0 rg BT 238.26 430.25 Td (fectiveness of internal control over financial reporting, included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 406.25 Td (s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. ) Tj ET Q
q 0 0 0 rg BT 553.60 406.25 Td (W) Tj ET Q
q 0 0 0 rg BT 562.24 406.25 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (are a public accounting firm registered with the Public Company ) Tj ET Q
q 0 0 0 rg BT 297.04 394.25 Td (Accounting Oversight Board \(United States\) \(PCAOB\) and are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (and regulations of the Securities and Exchange Commission and the PCAOB.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (W) Tj ET Q
q 0 0 0 rg BT 44.64 352.25 Td (e conducted our audits in accordance with the standards of the PCAOB. ) Tj ET Q
q 0 0 0 rg BT 334.10 352.25 Td (Those standards require that we plan and perform the audits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.25 Td (to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.25 Td (error or fraud, and whether ef) Tj ET Q
q 0 0 0 rg BT 154.09 328.25 Td (fective internal control over financial reporting was maintained in all material respects.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.25 Td (statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.25 Td (as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.25 Td (included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (testing and evaluating the design and operating ef) Tj ET Q
q 0 0 0 rg BT 234.37 238.25 Td (fectiveness of internal control based on the assessed risk. Our audits also included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (performing such other procedures as we considered necessary in the circumstances. ) Tj ET Q
q 0 0 0 rg BT 372.36 226.25 Td (W) Tj ET Q
q 0 0 0 rg BT 381.00 226.25 Td (e believe that our audits provide a reasonable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (basis for our opinions.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (Definition and Limitations of Internal Control over Financial Reporting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.25 Td (A) Tj ET Q
q 0 0 0 rg BT 42.67 172.25 Td ( company�) Tj ET Q
q 0 0 0 rg BT 84.60 172.25 Td (s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (principles. ) Tj ET Q
q 0 0 0 rg BT 79.88 148.25 Td (A) Tj ET Q
q 0 0 0 rg BT 86.55 148.25 Td ( company�) Tj ET Q
q 0 0 0 rg BT 128.49 148.25 Td (s internal control over financial reporting includes those policies and procedures that \(i\) pertain to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (company; \(ii\) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.25 Td (accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.25 Td (accordance with authorizations of management and directors of the company; and \(iii\) provide reasonable assurance regarding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.25 Td (prevention or timely detection of unauthorized acquisition, use, or disposition of the company�) Tj ET Q
q 0 0 0 rg BT 414.25 88.25 Td (s assets that could have a material ef) Tj ET Q
q 0 0 0 rg BT 559.84 88.25 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.25 Td (on the financial statements.) Tj ET Q
endstream
endobj
167 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 168 0 R>>
endobj
168 0 obj
<</Length 15742>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-4) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.10 Td (Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. ) Tj ET Q
q 0 0 0 rg BT 504.20 742.10 Td (Also, projections ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (of any evaluation of ef) Tj ET Q
q 0 0 0 rg BT 126.34 730.10 Td (fectiveness to future periods are subject to the risk that controls may become inadequate because of changes in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (conditions, or that the degree of compliance with the policies or procedures may deteriorate.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (Critical ) Tj ET Q
q 0 0 0 rg BT 69.24 694.10 Td (Audit Matters) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (statements that were communicated or required to be communicated to the audit committee and that \(i\) relate to accounts or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (disclosures that are material to the consolidated financial statements and \(ii\) involved our especially challenging, subjective, or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (complex judgments. ) Tj ET Q
q 0 0 0 rg BT 119.42 640.10 Td (The communication of critical audit matters does not alter in any way our opinion on the consolidated financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (statements, taken as a whole, and we are not, by communicating the critical audit matters below) Tj ET Q
q 0 0 0 rg BT 418.56 628.10 Td (, providing separate opinions on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (critical audit matters or on the accounts or disclosures to which they relate.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (Reserves for Sales Deductions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (As described in Note 2 to the consolidated financial statements, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.59 574.10 Td (amount of revenue) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.56 574.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.06 574.10 Td (recognize) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.92 574.10 Td (d by the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.03 574.10 Td (is equal to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (fixed amount of the transaction price, adjusted for) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.93 562.10 Td ( management�) Tj ET Q
q 0 0 0 rg BT 292.30 562.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.69 562.10 Td (estimates of a number of significant variable components including, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (but not limited to, estimates for char) Tj ET Q
q 0 0 0 rg BT 181.06 550.10 Td (gebacks, rebates, sales incentives and allowances,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.43 550.10 Td ( DSA) Tj ET Q
q 0 0 0 rg BT 402.38 550.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.88 550.10 Td (and other fees for services, returns and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (allowances, which) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.86 538.10 Td ( management ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.95 538.10 Td (collectively refer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.96 538.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.46 538.10 Td (to as sales deductions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.34 538.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 327.28 538.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.73 538.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.31 538.10 Td (, reserves for sales deductions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.71 526.10 Td ($660.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.60 526.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.42 526.10 Td (These amounts relate primarily to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.38 526.10 Td ( management�) Tj ET Q
q 0 0 0 rg BT 320.75 526.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.14 526.10 Td (estimates of unsettled obligations for returns and allowances, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.10 Td (rebates and char) Tj ET Q
q 0 0 0 rg BT 100.78 514.10 Td (gebacks. ) Tj ET Q
q 0 0 0 rg BT 137.81 514.10 Td (The most significant sales deductions relate to rebates paid under Medicaid and Medicare for the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.89 514.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.39 514.10 Td (Branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 502.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.03 502.10 Td (segment, wholesaler char) Tj ET Q
q 0 0 0 rg BT 205.19 502.10 Td (gebacks and rebates for the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.03 502.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.53 502.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.45 502.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.95 502.10 Td (and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.38 502.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.88 502.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.56 502.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.06 502.10 Td (segments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (sales returns for each of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.06 490.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.04 490.10 Td ( segments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.26 490.10 Td ( Management estimates the reserves for sales deductions based on factors such as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.21 490.10 Td (direct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (and indirect customers�) Tj ET Q
q 0 0 0 rg BT 129.12 478.10 Td ( buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (levels, current contract sales terms with) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.28 454.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.78 454.10 Td (direct and indirect customers and other competitive factors.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (The principal considerations for our determination that performing procedures relating to reserves for sales deductions is a critical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (audit matter are there was significant judgment by management due to the significant measurement uncertainty in developing these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (reserves which in turn led to significant audit ef) Tj ET Q
q 0 0 0 rg BT 226.87 412.10 Td (fort and a high degree of auditor judgment and subjectivity in performing procedures ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (related to those estimates, as the reserves are based on estimates of future claims, including assumptions related to customers�) Tj ET Q
q 0 0 0 rg BT 538.44 400.10 Td ( buying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (patterns and the estimated resulting contractual deduction rates, estimated customer inventory levels, and other competitive factors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (on the consolidated financial statements. ) Tj ET Q
q 0 0 0 rg BT 200.77 358.10 Td (These procedures included testing the ef) Tj ET Q
q 0 0 0 rg BT 361.92 358.10 Td (fectiveness of controls relating to sales deductions, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (including the Company�) Tj ET Q
q 0 0 0 rg BT 132.66 346.10 Td (s controls over the assumptions used to estimate the corresponding reserves for sales deductions. ) Tj ET Q
q 0 0 0 rg BT 521.55 346.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (procedures also included, among others, \(i\) developing an independent estimate of the reserves for sales deductions utilizing historical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (payment information, third party data as well as evaluating pricing changes, other competitive factors, and terms of the specific sales ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (deduction programs, \(ii\) comparing the independent estimates to the sales deduction reserves recorded by management, \(iii\) evaluating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (management's estimates in previous years by comparing historical reserves to rebate payments and credits processed in subsequent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (periods, and \(iv\) testing actual payments made and amounts credited to both direct and indirect customers to evaluate whether the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (payments and credits were made in accordance with the contractual and mandated terms of the Company�) Tj ET Q
q 0 0 0 rg BT 458.90 274.10 Td (s rebate programs and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (returns policy) Tj ET Q
q 0 0 0 rg BT 90.61 262.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (Intangible ) Tj ET Q
q 0 0 0 rg BT 79.42 238.10 Td (Assets Impairment ) Tj ET Q
q 0 0 0 rg BT 155.90 238.10 Td (Assessments - Developed T) Tj ET Q
q 0 0 0 rg BT 263.57 238.10 Td (echnology and In-Pr) Tj ET Q
q 0 0 0 rg BT 345.96 238.10 Td (ocess Resear) Tj ET Q
q 0 0 0 rg BT 397.51 238.10 Td (ch and Development) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (As described in Notes 2 and 10 to the consolidated financial statements, the Company�) Tj ET Q
q 0 0 0 rg BT 382.59 220.10 Td (s consolidated balance for developed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (technology finite-lived intangible assets was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.23 208.10 Td ($2,430.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.63 208.10 Td ( and for in-process research and development indefinite-lived intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (assets was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 196.10 Td ($93.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.77 196.10 Td ( as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.93 196.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.52 196.10 Td (. Finite-lived intangible assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.00 196.10 Td (are assessed for impairment whenever events or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (changes in circumstances indicate the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.49 184.10 Td ( carrying amounts of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.74 184.10 Td (assets may not be recoverable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.14 184.10 Td (. Indefinite-lived intangible assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 184.10 Td (are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (tested for impairment annually and when events or changes in circumstances indicate that the asset might be impaired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.24 172.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.24 172.10 Td (Recoverability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (of a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.27 160.10 Td ( finite-lived intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.19 160.10 Td (asset that will continue to be used in) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.44 160.10 Td ( the Company�) Tj ET Q
q 0 0 0 rg BT 347.32 160.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.71 160.10 Td (operations is measured by comparing the carrying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (amount of the asset to the forecasted undiscounted future cash flows related to the asset.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.39 148.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 390.34 148.10 Td (As part of intangible asset impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (assessments, management estimates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.63 136.10 Td (the fair values of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.10 136.10 Td ( the Company�) Tj ET Q
q 0 0 0 rg BT 308.98 136.10 Td (s indefinite-lived ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.52 136.10 Td (intangible assets using an income approach that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (utilizes a discounted cash flow model or) Tj ET Q
q 0 0 0 rg BT 196.67 124.10 Td (, where appropriate, a market approach) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.98 124.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.80 124.10 Td (The discounted cash flow models are dependent upon) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 572.46 124.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (management�) Tj ET Q
q 0 0 0 rg BT 89.87 112.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 112.10 Td (estimates of future cash flows and other factors including estimates of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.18 112.10 Td ( \(i\) future operating performance, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 239.09 100.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.02 100.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.02 100.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.32 100.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.75 100.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.61 88.10 Td (, and \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.27 88.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.68 88.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 383.50 88.10 Td (The Company recognized total impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 76.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.69 76.10 Td ($347.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.58 76.10 Td ( during the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.49 76.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.07 76.10 Td (.) Tj ET Q
endstream
endobj
169 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 170 0 R>>
endobj
170 0 obj
<</Length 12930>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.10 Td (The principal considerations for our determination that performing procedures relating to the impairment assessments for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (developed technology and in-process research and development intangible assets is a critical audit matter are there was significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (judgment and estimation by management when developing the fair value measurement of developed technology and in-process ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (research and development intangible assets. ) Tj ET Q
q 0 0 0 rg BT 213.53 706.10 Td (This in turn led to significant audit ef) Tj ET Q
q 0 0 0 rg BT 362.49 706.10 Td (fort and a high degree of auditor judgment and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (subjectivity in performing procedures to evaluate management�) Tj ET Q
q 0 0 0 rg BT 289.25 694.10 Td (s estimated cash flows, including significant assumptions related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 239.09 682.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.02 682.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.02 682.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.32 682.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.75 682.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.61 670.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.55 670.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.96 670.10 Td ( in determining the fair value of each intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (asset. In addition, the audit ef) Tj ET Q
q 0 0 0 rg BT 153.84 658.10 Td (fort included the use of professionals with specialized skill and knowledge to assist in performing these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (procedures and evaluating the audit evidence obtained from these procedures.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (on the consolidated financial statements. ) Tj ET Q
q 0 0 0 rg BT 200.77 616.10 Td (These procedures included testing the ef) Tj ET Q
q 0 0 0 rg BT 361.92 616.10 Td (fectiveness of controls relating to the valuation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (intangible assets, including controls over the identification of triggering events, and the development of assumptions used to estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (fair value. ) Tj ET Q
q 0 0 0 rg BT 78.85 592.10 Td (These procedures also included, among others, evaluating whether there were any events or circumstances indicating that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (intangible assets may be impaired and testing management�) Tj ET Q
q 0 0 0 rg BT 273.99 580.10 Td (s process for developing the estimate, which included evaluating the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (appropriateness of the cash flow projections and discounted cash flow model; testing the completeness, accuracy) Tj ET Q
q 0 0 0 rg BT 486.60 568.10 Td (, and relevance of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (underlying data used in the model; and evaluating the reasonableness of significant assumptions, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.62 556.10 Td (future sales, long-term ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 146.34 544.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.27 544.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.27 544.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.57 544.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.00 544.10 Td (the probability of achieving the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.31 532.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.25 532.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.66 532.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 255.48 532.10 Td (These procedures also included the involvement of professionals with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (specialized skill and knowledge to assist in evaluating the reasonableness of significant assumptions, including the discount rate used ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (by management. Evaluating the assumptions related to future operating performance, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.49 508.10 Td (future sales, long-term growth rates, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (operating mar) Tj ET Q
q 0 0 0 rg BT 91.63 496.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.56 496.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.56 496.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.86 496.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.30 496.10 Td (the probability of achieving the estimated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.49 484.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.43 484.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.84 484.10 Td (, involved evaluating whether the assumptions used were reasonable considering \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (historical performance, \(ii\) industry and economic forecasts and \(iii\) whether the assumptions were consistent with evidence obtained ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.10 Td (in other areas of the audit.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (Goodwill Impairment ) Tj ET Q
q 0 0 0 rg BT 124.71 436.10 Td (Assessment) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 170.26 436.10 Td ( - ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 178.59 436.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 281.06 436.10 Td ( and ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 301.06 436.10 Td (International Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 424.10 436.10 Td ( Segments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (As described in Notes 2 and 10 to the consolidated financial statements, the Company�) Tj ET Q
q 0 0 0 rg BT 382.59 418.10 Td (s consolidated goodwill balance for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.99 418.10 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 406.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.97 406.10 Td (International Pharmaceuticals) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 240.08 406.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.58 406.10 Td (segments was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.35 406.10 Td ($35.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.24 406.10 Td ( as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.40 406.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.99 406.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.42 406.10 Td ($171.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.32 406.10 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (impairment char) Tj ET Q
q 0 0 0 rg BT 101.63 394.10 Td (ges were recorded during the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.27 394.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.85 394.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.30 394.10 Td (An impairment assessment is conducted as of October ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (1, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.96 382.10 Td ( Management performs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (the goodwill impairment test by comparing the fair value and carrying amount of each reporting unit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.38 370.10 Td (. Management estimated the fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (values of its reporting units using an income approach that utilizes a discounted cash flow model. ) Tj ET Q
q 0 0 0 rg BT 427.67 358.10 Td (The discounted cash flow models ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (are dependent upon management�) Tj ET Q
q 0 0 0 rg BT 170.67 346.10 Td (s estimates of future cash flows and other factors including estimates of \(i\) future operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (performance, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.80 334.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 334.88 334.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.82 334.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.75 334.10 Td (variations in the amount and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.93 322.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.37 322.10 Td (the probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.70 322.10 Td (, and \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.36 322.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.77 322.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.10 Td (The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment - ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.67 292.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.11 292.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.23 292.10 Td ( segments is a critical audit matter are there was significant judgment and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (estimation by management when determining the fair value of the reporting units. ) Tj ET Q
q 0 0 0 rg BT 365.45 280.10 Td (This in turn led to significant audit ef) Tj ET Q
q 0 0 0 rg BT 514.40 280.10 Td (fort and a high ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (degree of auditor judgment and subjectivity in performing procedures related to management�) Tj ET Q
q 0 0 0 rg BT 411.15 268.10 Td (s cash flows, including significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (assumptions related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.93 256.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 331.01 256.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.95 256.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.95 256.10 Td (variations in the amount and timing of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.49 244.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.93 244.10 Td (the probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.26 244.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.20 244.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.61 244.10 Td (. In addition, the audit ef) Tj ET Q
q 0 0 0 rg BT 539.01 244.10 Td (fort ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (involved the use of professionals with specialized skill and knowledge to assist in performing these procedures and evaluating the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (audit evidence obtained from these procedures.) Tj ET Q
endstream
endobj
171 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 172 0 R>>
endobj
172 0 obj
<</Length 5509>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 31.60 Td (F-6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.10 Td (Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (on the consolidated financial statements. ) Tj ET Q
q 0 0 0 rg BT 200.77 730.10 Td (These procedures included testing the ef) Tj ET Q
q 0 0 0 rg BT 361.92 730.10 Td (fectiveness of controls relating to goodwill ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (impairment assessment, including controls over the identification of triggering events, determination of reporting units and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (estimation of each reporting units�) Tj ET Q
q 0 0 0 rg BT 173.00 706.10 Td ( fair value, and the development of assumptions used to estimate fair value. ) Tj ET Q
q 0 0 0 rg BT 476.89 706.10 Td (These procedures also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (included, among others, \(i\) evaluating whether there were any events or circumstances indicating that goodwill may not be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (recoverable and therefore required goodwill impairment tests in addition to the annual test, \(ii\) testing management�) Tj ET Q
q 0 0 0 rg BT 499.74 682.10 Td (s process for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (developing the fair value estimate, which included evaluating the appropriateness of the discounted cash flow model, \(iii\) testing the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (completeness, accuracy) Tj ET Q
q 0 0 0 rg BT 129.75 658.10 Td (, and relevance of underlying data used in the model, and evaluating the reasonableness of assumptions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 76.27 646.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 279.36 646.10 Td (gins, discount rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.29 646.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.29 646.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.59 646.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 634.10 Td (the probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.27 634.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.21 634.10 Td (future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.62 634.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 400.44 634.10 Td (The procedures also included evaluating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (management�) Tj ET Q
q 0 0 0 rg BT 89.87 622.10 Td (s determination of reporting units and testing the assignment of assets and liabilities to each of the respective reporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (units. ) Tj ET Q
q 0 0 0 rg BT 60.27 610.10 Td (The procedures included the involvement of professionals with specialized skill and knowledge to assist in evaluating the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (reasonableness of significant assumptions, including the discount rate and long-term growth rate calculations used by management. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (Evaluating the assumptions used to estimate fair value, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.72 586.10 Td (future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 501.81 586.10 Td (gins, discount ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (rates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.88 574.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.88 574.10 Td (variations in the amount and timing of cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.17 574.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.61 574.10 Td (the probability of achieving the estimated cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.94 574.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.88 574.10 Td (future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.04 562.10 Td (, involved evaluating whether the assumptions used were reasonable considering \(i\) historical performance, \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (industry and economic forecasts and \(iii\) whether the assumptions were consistent with evidence obtained in other areas of the audit.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 524.17 Td (/s/ PricewaterhouseCoopers LLP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 500.27 Td (Philadelphia, Pennsylvania) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 485.27 Td (February 26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 463.27 Td (W) Tj ET Q
q 0 0 0 rg BT 47.64 463.27 Td (e have served as the Company�) Tj ET Q
q 0 0 0 rg BT 171.76 463.27 Td (s auditor since 2014.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
173 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 174 0 R>>
endobj
174 0 obj
<</Length 21025>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 24.60 Td (F-7) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 219.40 737.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 279.22 737.25 Td (TED BALANCE SHEETS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 235.30 725.25 Td (DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 310.58 725.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 330.58 725.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 332.53 725.25 Td (AND ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 356.70 725.25 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 200.35 714.45 Td (\(Dollars in thousands, except shar) Tj ET Q
q 0 0 0 rg BT 330.45 714.45 Td (e and per) Tj ET Q
q 0 0 0 rg BT 366.29 714.45 Td ( shar) Tj ET Q
q 0 0 0 rg BT 385.38 714.45 Td (e data\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 682.95 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 682.95 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 682.95 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 682.95 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 653.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 653.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 653.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 653.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 623.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 623.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 623.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 623.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 593.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 593.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 593.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 593.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 563.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 563.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 563.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 563.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 533.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 533.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 533.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 533.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 503.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 503.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 503.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 503.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 473.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 473.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 473.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 473.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 443.95 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 443.95 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 443.95 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 443.95 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 414.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 414.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 414.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 414.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 384.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 384.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 384.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 384.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 354.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 354.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 354.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 354.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 324.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 324.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 324.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 324.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 294.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 294.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 294.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 294.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 264.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 264.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 264.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 264.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 234.95 406.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 234.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 234.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 234.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 174.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 174.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 174.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 174.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 144.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 144.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 144.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 144.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 114.95 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 114.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 114.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 114.95 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 682.95 m
506.5 682.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 682.95 m
575.5 682.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 682.95 m
575.5 682.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 563.95 m
506.5 563.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 548.95 m
506.5 548.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 563.95 m
575.5 563.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 548.95 m
575.5 548.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 458.95000000000005 m
506.5 458.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 458.95000000000005 m
506.5 458.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 444.95000000000005 m
506.5 444.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 442.95000000000005 m
506.5 442.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 458.95000000000005 m
575.5 458.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 444.95000000000005 m
575.5 444.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 442.95000000000005 m
575.5 442.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 339.95000000000005 m
506.5 339.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 324.95000000000005 m
506.5 324.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 339.95000000000005 m
575.5 339.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 324.95000000000005 m
575.5 324.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 324.95000000000005 m
506.5 324.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 129.95000000000005 m
506.5 129.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 114.95000000000005 m
506.5 114.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 129.95000000000005 m
575.5 129.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 114.95000000000005 m
506.5 114.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 100.95000000000005 m
506.5 100.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 98.95000000000005 m
506.5 98.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 114.95000000000005 m
575.5 114.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 100.95000000000005 m
575.5 100.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 98.95000000000005 m
575.5 98.95000000000005 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 695.18 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 695.18 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 687.18 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 695.18 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 695.18 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 687.18 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 219.35 673.63 Td (ASSETS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 658.62 Td (CURRENT) Tj ET Q
q 0 0 0 rg BT 84.58 658.62 Td ( ) Tj ET Q
q 0 0 0 rg BT 86.71 658.62 Td (ASSETS:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 643.62 Td (Cash and cash equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 643.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 643.62 Td (1,454,531) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 643.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 643.62 Td (1,149,1) Tj ET Q
q 0 0 0 rg BT 561.65 643.62 Td (13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 628.62 Td (Restricted cash and cash equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 628.62 Td (247,457) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 628.62 Td (305,368) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 613.62 Td (Accounts receivable, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 613.62 Td (467,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 613.62 Td (470,570) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 598.62 Td (Inventories, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 598.62 Td (327,865) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 598.62 Td (322,179) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 583.62 Td (Prepaid expenses and other current assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 583.62 Td (40,845) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 583.62 Td (56,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 568.62 Td (Income taxes receivable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 568.62 Td (47,567) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 568.62 Td (39,781) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 553.62 Td (T) Tj ET Q
q 0 0 0 rg BT 55.76 553.62 Td (otal current assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 553.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 553.62 Td (2,586,218) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 553.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 553.62 Td (2,343,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 538.62 Td (PROPER) Tj ET Q
q 0 0 0 rg BT 75.49 538.62 Td (TY) Tj ET Q
q 0 0 0 rg BT 87.88 538.62 Td (, PLANT) Tj ET Q
q 0 0 0 rg BT 124.36 538.62 Td ( ) Tj ET Q
q 0 0 0 rg BT 126.50 538.62 Td (AND EQUIPMENT) Tj ET Q
q 0 0 0 rg BT 207.79 538.62 Td (, NET) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 538.62 Td (504,865) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 538.62 Td (498,892) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 523.62 Td (OPERA) Tj ET Q
q 0 0 0 rg BT 70.23 523.62 Td (TING LEASE ) Tj ET Q
q 0 0 0 rg BT 129.39 523.62 Td (ASSETS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 523.62 Td (51,700) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 523.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 508.62 Td (GOODWILL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 508.62 Td (3,595,184) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 508.62 Td (3,764,636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 493.62 Td (OTHER INT) Tj ET Q
q 0 0 0 rg BT 90.09 493.62 Td (ANGIBLES, NET) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 493.62 Td (2,571,267) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 493.62 Td (3,457,306) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 478.62 Td (DEFERRED INCOME ) Tj ET Q
q 0 0 0 rg BT 134.02 478.62 Td (T) Tj ET Q
q 0 0 0 rg BT 139.64 478.62 Td (AXES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 478.62 Td (2,192) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 478.62 Td (678) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 463.62 Td (OTHER ) Tj ET Q
q 0 0 0 rg BT 73.55 463.62 Td (ASSETS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 463.62 Td (78,101) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 463.62 Td (67,731) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 448.62 Td (T) Tj ET Q
q 0 0 0 rg BT 44.02 448.62 Td (OT) Tj ET Q
q 0 0 0 rg BT 56.86 448.62 Td (AL) Tj ET Q
q 0 0 0 rg BT 69.60 448.62 Td ( ) Tj ET Q
q 0 0 0 rg BT 71.64 448.62 Td (ASSETS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 448.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 448.62 Td (9,389,527) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 448.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.60 448.62 Td (10,132,393) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 129.00 434.63 Td (LIABILITIES ) Tj ET Q
q 0 0 0 rg BT 192.65 434.63 Td (AND SHAREHOLDERS' DEFICIT) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 419.62 Td (CURRENT) Tj ET Q
q 0 0 0 rg BT 84.58 419.62 Td ( LIABILITIES:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 404.62 Td (Accounts payable and accrued expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 404.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 404.62 Td (899,949) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 404.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 404.62 Td (1,009,200) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 389.62 Td (Current portion of legal settlement accrual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 389.62 Td (513,005) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 389.62 Td (905,085) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 374.62 Td (Current portion of operating lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 374.62 Td (10,763) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 374.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 359.62 Td (Current portion of long-term debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 359.62 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 359.62 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 344.62 Td (Income taxes payable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 344.62 Td (2,422) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 344.62 Td (1,661) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 329.62 Td (T) Tj ET Q
q 0 0 0 rg BT 55.76 329.62 Td (otal current liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 329.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 329.62 Td (1,460,289) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 329.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 329.62 Td (1,950,096) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 314.62 Td (DEFERRED INCOME ) Tj ET Q
q 0 0 0 rg BT 134.02 314.62 Td (T) Tj ET Q
q 0 0 0 rg BT 139.64 314.62 Td (AXES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 314.62 Td (31,703) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 314.62 Td (34,487) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 299.62 Td (LONG-TERM DEBT) Tj ET Q
q 0 0 0 rg BT 125.12 299.62 Td (, LESS CURRENT) Tj ET Q
q 0 0 0 rg BT 202.17 299.62 Td ( POR) Tj ET Q
q 0 0 0 rg BT 223.73 299.62 Td (TION, NET) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 299.62 Td (8,359,899) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 299.62 Td (8,224,269) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 284.62 Td (OPERA) Tj ET Q
q 0 0 0 rg BT 70.23 284.62 Td (TING LEASE LIABILITIES, LESS CURRENT) Tj ET Q
q 0 0 0 rg BT 264.29 284.62 Td ( POR) Tj ET Q
q 0 0 0 rg BT 285.85 284.62 Td (TION) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 284.62 Td (48,299) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 284.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 269.62 Td (OTHER LIABILITIES) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 269.62 Td (355,881) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 269.62 Td (421,824) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 254.62 Td (COMMITMENTS ) Tj ET Q
q 0 0 0 rg BT 115.23 254.62 Td (AND CONTINGENCIES \(NOTE 15\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 239.62 Td (SHAREHOLDERS' DEFICIT) Tj ET Q
q 0 0 0 rg BT 159.28 239.62 Td (:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 224.62 Td (Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both December) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 214.62 Td (31, 2019 and December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 214.62 Td (45) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 214.62 Td (46) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 199.62 Td (Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 226,802,609 and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 189.62 Td (224,382,791 shares issued and outstanding at December 31, 2019 and December 31, 2018,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 179.62 Td (respectively) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 179.62 Td (23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 179.62 Td (22) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 164.62 Td (Additional paid-in capital) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 164.62 Td (8,904,692) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 164.62 Td (8,855,810) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 149.62 Td (Accumulated deficit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 149.67 Td (\(9,552,214) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 149.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 149.62 Td (\(9,124,932) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 149.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 134.62 Td (Accumulated other comprehensive loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 134.67 Td (\(219,090) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 134.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 134.62 Td (\(229,229) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 134.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 119.62 Td (T) Tj ET Q
q 0 0 0 rg BT 55.41 119.62 Td (otal shareholders' deficit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 119.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 119.67 Td (\(866,544) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 119.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 119.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 119.62 Td (\(498,283) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 119.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 104.62 Td (T) Tj ET Q
q 0 0 0 rg BT 43.93 104.62 Td (OT) Tj ET Q
q 0 0 0 rg BT 56.46 104.62 Td (AL) Tj ET Q
q 0 0 0 rg BT 69.42 104.62 Td ( LIABILITIES ) Tj ET Q
q 0 0 0 rg BT 131.07 104.62 Td (AND SHAREHOLDERS' DEFICIT) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 104.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 104.62 Td (9,389,527) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 104.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.60 104.62 Td (10,132,393) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.35 85.45 Td (See accompanying Notes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.21 85.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.07 85.45 Td (.) Tj ET Q
endstream
endobj
175 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 176 0 R>>
endobj
176 0 obj
<</Length 24015>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 24.60 Td (F-8) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 189.15 737.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 248.97 737.25 Td (TED ST) Tj ET Q
q 0 0 0 rg BT 283.52 737.25 Td (A) Tj ET Q
q 0 0 0 rg BT 290.00 737.25 Td (TEMENTS OF) Tj ET Q
q 0 0 0 rg BT 354.92 737.25 Td ( OPERA) Tj ET Q
q 0 0 0 rg BT 391.68 737.25 Td (TIONS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 185.85 725.25 Td (YEARS ENDED DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 335.03 725.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 355.03 725.25 Td (, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 360.03 725.25 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 380.03 725.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 381.98 725.25 Td (AND ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 406.15 725.25 Td (2017) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 198.60 714.45 Td (\(Dollars and shar) Tj ET Q
q 0 0 0 rg BT 265.45 714.45 Td (es in thousands, except per) Tj ET Q
q 0 0 0 rg BT 368.04 714.45 Td ( shar) Tj ET Q
q 0 0 0 rg BT 387.13 714.45 Td (e data\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 690.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 660.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 660.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 660.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 660.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 660.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 660.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 630.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 630.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 630.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 630.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 630.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 630.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 600.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 600.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 600.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 600.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 600.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 600.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 570.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 570.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 570.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 570.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 570.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 570.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 540.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 540.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 540.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 540.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 540.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 540.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 510.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 510.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 510.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 510.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 510.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 510.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 480.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 480.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 480.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 480.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 480.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 480.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 450.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 450.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 450.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 450.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 450.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 450.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 420.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 420.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 420.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 420.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 420.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 420.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 390.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 390.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 390.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 390.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 390.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 390.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 360.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 360.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 360.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 360.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 360.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 360.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 330.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 330.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 330.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 330.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 330.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 330.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 300.95 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 300.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 300.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 300.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 300.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 300.95 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 690.95 m
437.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 690.95 m
506.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 690.95 m
575.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 690.95 m
575.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 525.95 m
437.5 525.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 510.95 m
437.5 510.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 525.95 m
506.5 525.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 510.95 m
506.5 510.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 525.95 m
575.5 525.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 510.95 m
575.5 510.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 495.95 m
437.5 495.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 480.95 m
437.5 480.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 495.95 m
506.5 495.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 480.95 m
506.5 480.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 495.95 m
575.5 495.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 480.95 m
575.5 480.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 465.95 m
437.5 465.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 451.95 m
437.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 449.95 m
437.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 465.95 m
506.5 465.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 451.95 m
506.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 449.95 m
506.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 465.95 m
575.5 465.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 451.95 m
575.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 449.95 m
575.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 449.95 m
437.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 451.95 m
437.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 449.95 m
506.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 451.95 m
506.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 449.95 m
575.5 449.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 451.95 m
575.5 451.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 405.95 m
437.5 405.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 391.95 m
437.5 391.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 389.95 m
437.5 389.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 405.95 m
506.5 405.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 391.95 m
506.5 391.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 389.95 m
506.5 389.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 405.95 m
575.5 405.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 391.95 m
575.5 391.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 389.95 m
575.5 389.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 345.95 m
437.5 345.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 331.95 m
437.5 331.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 329.95 m
437.5 329.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 345.95 m
506.5 345.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 331.95 m
506.5 331.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 329.95 m
506.5 329.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 345.95 m
575.5 345.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 331.95 m
575.5 331.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 329.95 m
575.5 329.95 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 695.18 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 695.18 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 695.18 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 680.62 Td (T) Tj ET Q
q 0 0 0 rg BT 44.02 680.62 Td (OT) Tj ET Q
q 0 0 0 rg BT 56.86 680.62 Td (AL) Tj ET Q
q 0 0 0 rg BT 69.60 680.62 Td ( REVENUES, NET) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 680.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 680.62 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 680.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 680.62 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 680.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 680.62 Td (3,468,858) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 665.62 Td (COSTS ) Tj ET Q
q 0 0 0 rg BT 71.35 665.62 Td (AND EXPENSES:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 650.62 Td (Cost of revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 650.62 Td (1,569,338) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 650.62 Td (1,631,682) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 650.62 Td (2,228,530) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 635.62 Td (Selling, general and administrative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 635.62 Td (632,420) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 635.62 Td (646,037) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 635.62 Td (629,874) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 620.62 Td (Research and development) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 620.62 Td (130,732) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 620.62 Td (185,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 620.62 Td (172,067) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 605.62 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 605.62 Td (1) Tj ET Q
q 0 0 0 rg BT 411.15 605.62 Td (1,21) Tj ET Q
q 0 0 0 rg BT 428.65 605.62 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 605.62 Td (13,809) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 605.62 Td (185,990) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 590.62 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 134.44 590.62 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 590.62 Td (526,082) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 590.62 Td (916,939) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 590.62 Td (1,154,376) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 575.62 Td (Acquisition-related and integration items, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 575.67 Td (\(46,098) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 575.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 575.62 Td (21,914) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 575.62 Td (58,086) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 560.62 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 560.62 Td (538,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 560.62 Td (521,656) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 560.62 Td (488,228) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 545.62 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 545.67 Td (\(1) Tj ET Q
q 0 0 0 rg BT 406.13 545.67 Td (19,828) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 545.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 545.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 545.62 Td (51,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 530.62 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 530.62 Td (16,677) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 530.67 Td (\(51,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 530.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 530.62 Td (\(17,023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 530.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 515.62 Td (LOSS FROM CONTINUING OPERA) Tj ET Q
q 0 0 0 rg BT 193.30 515.62 Td (TIONS BEFORE INCOME ) Tj ET Q
q 0 0 0 rg BT 307.38 515.62 Td (T) Tj ET Q
q 0 0 0 rg BT 313.00 515.62 Td (AX) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 515.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 515.67 Td (\(344,904) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 515.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 515.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 515.67 Td (\(938,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 515.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 515.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 515.62 Td (\(1,483,004) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 515.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 500.62 Td (INCOME ) Tj ET Q
q 0 0 0 rg BT 79.85 500.62 Td (T) Tj ET Q
q 0 0 0 rg BT 85.47 500.62 Td (AX EXPENSE \(BENEFIT\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 500.62 Td (15,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 500.62 Td (22,935) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 500.62 Td (\(250,293) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 500.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 485.62 Td (LOSS FROM CONTINUING OPERA) Tj ET Q
q 0 0 0 rg BT 193.30 485.62 Td (TIONS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 485.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 485.67 Td (\(360,584) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 485.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 485.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 485.67 Td (\(961,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 485.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 485.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 485.62 Td (\(1,232,71) Tj ET Q
q 0 0 0 rg BT 566.63 485.62 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 485.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 470.62 Td (DISCONTINUED OPERA) Tj ET Q
q 0 0 0 rg BT 147.17 470.62 Td (TIONS, NET) Tj ET Q
q 0 0 0 rg BT 200.40 470.62 Td ( OF ) Tj ET Q
q 0 0 0 rg BT 218.01 470.62 Td (T) Tj ET Q
q 0 0 0 rg BT 223.63 470.62 Td (AX \(NOTE 3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 470.67 Td (\(62,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 470.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 470.67 Td (\(69,702) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 470.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 470.62 Td (\(802,722) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 470.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 455.62 Td (NET) Tj ET Q
q 0 0 0 rg BT 57.35 455.62 Td ( LOSS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 455.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 455.67 Td (\(422,636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 455.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 455.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 455.67 Td (\(1,031,469) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 455.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 455.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 455.62 Td (\(2,035,433) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 455.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 440.62 Td (NET) Tj ET Q
q 0 0 0 rg BT 57.35 440.62 Td ( LOSS PER SHARE�BASIC:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 425.62 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 425.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 425.67 Td (\(1.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 425.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 425.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 425.67 Td (\(4.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 425.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 425.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 425.62 Td (\(5.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 425.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 410.62 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 410.67 Td (\(0.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 410.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 410.67 Td (\(0.32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 410.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 410.62 Td (\(3.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 410.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 395.62 Td (Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 395.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 395.67 Td (\(1.87) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 395.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 395.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 395.67 Td (\(4.61) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 395.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 395.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 395.62 Td (\(9.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 395.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 380.62 Td (NET) Tj ET Q
q 0 0 0 rg BT 57.35 380.62 Td ( LOSS PER SHARE�DILUTED:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 365.62 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 365.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 365.67 Td (\(1.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 365.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 365.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 365.67 Td (\(4.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 365.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 365.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 365.62 Td (\(5.52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 365.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 350.62 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 350.67 Td (\(0.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 350.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 350.67 Td (\(0.32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 350.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 350.62 Td (\(3.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 350.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 335.62 Td (Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 335.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 335.67 Td (\(1.87) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 335.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 335.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 335.67 Td (\(4.61) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 335.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 335.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 335.62 Td (\(9.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 335.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 320.62 Td (WEIGHTED ) Tj ET Q
q 0 0 0 rg BT 92.98 320.62 Td (A) Tj ET Q
q 0 0 0 rg BT 99.28 320.62 Td (VERAGE SHARES:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 305.62 Td (Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 305.62 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 305.62 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 305.62 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 290.62 Td (Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 290.62 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 290.62 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 290.62 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.35 271.45 Td (See accompanying Notes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.21 271.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.07 271.45 Td (.) Tj ET Q
endstream
endobj
177 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 178 0 R>>
endobj
178 0 obj
<</Length 13797>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.05 24.60 Td (F-9) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 163.10 737.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 222.92 737.25 Td (TED ST) Tj ET Q
q 0 0 0 rg BT 257.48 737.25 Td (A) Tj ET Q
q 0 0 0 rg BT 263.95 737.25 Td (TEMENTS OF) Tj ET Q
q 0 0 0 rg BT 328.87 737.25 Td ( COMPREHENSIVE LOSS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 185.85 725.25 Td (YEARS ENDED DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 335.03 725.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 355.03 725.25 Td (, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 360.03 725.25 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 380.03 725.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 381.98 725.25 Td (AND ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 406.15 725.25 Td (2017) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 263.45 714.45 Td (\(Dollars in thousands\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 690.95 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 690.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 690.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 650.95 130.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 650.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 650.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 650.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 650.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 650.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 650.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 600.95 130.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 600.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 600.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 600.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 600.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 600.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 600.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 540.95 130.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 540.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 540.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 540.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 540.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 540.95 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 540.95 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 470.95 130.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 470.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 470.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 470.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 470.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 470.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 470.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 470.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 470.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 470.95 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 470.95 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 470.95 65.00 -25.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 690.95 m
230.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
230.5 690.95 m
234.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 690.95 m
299.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 690.95 m
368.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 690.95 m
372.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 690.95 m
437.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 690.95 m
506.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 690.95 m
510.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 690.95 m
575.5 690.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 565.95 m
230.5 565.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 565.95 m
368.5 565.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 565.95 m
506.5 565.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 565.95 m
506.5 565.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 470.95 m
230.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 470.95 m
299.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 470.95 m
368.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 470.95 m
437.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 470.95 m
506.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 470.95 m
575.5 470.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 445.95 m
299.5 445.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 431.95 m
299.5 431.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 429.95 m
299.5 429.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 445.95 m
437.5 445.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 431.95 m
437.5 431.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 429.95 m
437.5 429.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 445.95 m
575.5 445.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 431.95 m
575.5 431.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 429.95 m
575.5 429.95 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 224.00 695.18 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 362.00 695.18 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 500.00 695.18 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 680.62 Td (NET) Tj ET Q
q 0 0 0 rg BT 57.35 680.62 Td ( LOSS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 679.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.80 679.67 Td (\(422,636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 679.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 679.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.30 679.67 Td (\(1,031,469) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 679.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 679.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 679.62 Td (\(2,035,433) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 679.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 665.62 Td (OTHER COMPREHENSIVE) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 655.62 Td (INCOME \(LOSS\):) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 640.62 Td (Net unrealized loss on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 630.62 Td (securities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 615.62 Td (Unrealized loss arising) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 605.62 Td (during the period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 604.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.65 604.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 604.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 604.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 604.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.30 604.67 Td (\(515) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 604.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 590.62 Td (Less: reclassification) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 580.62 Td (adjustments for gain) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 570.62 Td (realized in net loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.65 569.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 569.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 569.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 569.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 569.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.30 569.62 Td (\(515) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 569.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 555.62 Td (Net unrealized gain \(loss\) on) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 545.62 Td (foreign currency:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 530.62 Td (Foreign currency) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 520.62 Td (translation gain \(loss\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 510.62 Td (arising during the period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 509.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.15 509.62 Td (10,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 509.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.80 509.67 Td (\(19,408) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 509.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 509.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 509.62 Td (31,202) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 495.62 Td (Less: reclassification) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 485.62 Td (adjustments for loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 475.62 Td (realized in net loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.65 474.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.15 474.62 Td (10,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 474.62 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 474.67 Td (\(19,408) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 474.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 474.62 Td (1) Tj ET Q
q 0 0 0 rg BT 475.15 474.62 Td (12,926) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 474.62 Td (144,128) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 460.62 Td (OTHER COMPREHENSIVE) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 450.62 Td (INCOME \(LOSS\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 449.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.15 449.62 Td (10,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 449.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 449.67 Td (\(19,408) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 449.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 449.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 449.62 Td (143,613) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 435.62 Td (COMPREHENSIVE LOSS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 434.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.80 434.67 Td (\(412,497) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 434.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 434.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.30 434.67 Td (\(1,050,877) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 434.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 434.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 434.62 Td (\(1,891,820) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 434.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.35 416.45 Td (See accompanying Notes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.21 416.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.07 416.45 Td (.) Tj ET Q
endstream
endobj
179 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 792.00 612.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 592.3734375 110.15625 599.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 612.00 null]>>]
/Rotate 0
/Contents 180 0 R>>
endobj
180 0 obj
<</Length 66763>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 592.848046875 m
110.15625 592.848046875 l
s
q 0 0 1 rg BT 50.00 594.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 594.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.55 31.60 Td (F-10) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 326.90 562.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 403.67 562.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 442.57 562.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 222.55 550.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 282.37 550.25 Td (TED ST) Tj ET Q
q 0 0 0 rg BT 316.93 550.25 Td (A) Tj ET Q
q 0 0 0 rg BT 323.40 550.25 Td (TEMENTS OF) Tj ET Q
q 0 0 0 rg BT 388.32 550.25 Td ( SHAREHOLDERS' EQUITY) Tj ET Q
q 0 0 0 rg BT 518.54 550.25 Td ( \(DEFICIT\)) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 275.85 538.25 Td (YEARS ENDED DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 425.03 538.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 445.03 538.25 Td (, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 450.03 538.25 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 470.03 538.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 471.98 538.25 Td (AND ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 496.15 538.25 Td (2017) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 332.45 527.45 Td (\(In thousands, except shar) Tj ET Q
q 0 0 0 rg BT 433.30 527.45 Td (e data\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 483.95 249.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 483.95 40.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 483.95 40.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 483.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 483.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 450.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 450.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 450.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 450.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 450.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 426.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 426.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 426.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 426.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 426.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 402.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 402.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 402.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 402.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 402.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 378.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 378.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 378.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 378.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 378.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 345.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 345.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 345.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 345.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 345.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 321.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 321.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 321.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 321.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 321.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 297.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 297.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 297.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 297.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 297.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 273.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 273.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 273.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 273.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 273.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 249.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 249.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 249.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 249.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 249.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 225.95 249.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 225.95 40.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 225.95 40.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 225.95 4.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 225.95 65.00 -21.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 192.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 192.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 192.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 192.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 192.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 168.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 168.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 168.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 168.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 168.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 144.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 144.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 144.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 144.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 144.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 120.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 120.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 120.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 120.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 120.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
22.00 96.95 249.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
271.00 96.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
336.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
340.00 96.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
380.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
384.00 96.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
449.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
453.00 96.95 40.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
497.00 96.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
562.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
566.00 96.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
631.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
635.00 96.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
700.00 96.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
704.00 96.95 65.00 -12.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 504.95000000000005 m
336 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
336 504.95000000000005 m
340 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 504.95000000000005 m
380 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 504.95000000000005 m
449 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
449 504.95000000000005 m
453 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 504.95000000000005 m
493 504.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 483.95000000000005 m
336 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 483.95000000000005 m
380 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 483.95000000000005 m
449 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 483.95000000000005 m
493 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 483.95000000000005 m
562 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 483.95000000000005 m
631 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 483.95000000000005 m
700 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 483.95000000000005 m
769 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 483.95000000000005 m
336 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 483.95000000000005 m
380 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 483.95000000000005 m
449 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 483.95000000000005 m
493 483.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 450.95000000000005 m
336 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 450.95000000000005 m
380 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 450.95000000000005 m
449 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 450.95000000000005 m
493 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 450.95000000000005 m
562 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 450.95000000000005 m
631 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 450.95000000000005 m
700 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 450.95000000000005 m
769 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 450.95000000000005 m
336 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 438.95000000000005 m
336 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 450.95000000000005 m
380 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 438.95000000000005 m
380 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 450.95000000000005 m
449 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 438.95000000000005 m
449 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 450.95000000000005 m
493 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 438.95000000000005 m
493 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 450.95000000000005 m
562 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 438.95000000000005 m
562 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 450.95000000000005 m
631 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 438.95000000000005 m
631 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 450.95000000000005 m
700 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 438.95000000000005 m
700 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 450.95000000000005 m
769 450.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 438.95000000000005 m
769 438.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 366.95000000000005 m
336 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 366.95000000000005 m
380 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 366.95000000000005 m
449 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 366.95000000000005 m
493 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 366.95000000000005 m
562 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 366.95000000000005 m
631 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 366.95000000000005 m
700 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 366.95000000000005 m
769 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 366.95000000000005 m
336 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 346.95000000000005 m
336 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 344.95000000000005 m
336 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 366.95000000000005 m
380 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 346.95000000000005 m
380 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 344.95000000000005 m
380 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 366.95000000000005 m
449 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 346.95000000000005 m
449 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 344.95000000000005 m
449 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 366.95000000000005 m
493 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 346.95000000000005 m
493 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 344.95000000000005 m
493 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 366.95000000000005 m
562 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 346.95000000000005 m
562 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 344.95000000000005 m
562 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 366.95000000000005 m
631 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 346.95000000000005 m
631 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 344.95000000000005 m
631 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 366.95000000000005 m
700 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 346.95000000000005 m
700 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 344.95000000000005 m
700 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 366.95000000000005 m
769 366.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 346.95000000000005 m
769 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 344.95000000000005 m
769 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 344.95000000000005 m
336 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 346.95000000000005 m
336 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 344.95000000000005 m
380 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 346.95000000000005 m
380 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 344.95000000000005 m
449 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 346.95000000000005 m
449 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 344.95000000000005 m
493 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 346.95000000000005 m
493 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 344.95000000000005 m
562 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 346.95000000000005 m
562 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 344.95000000000005 m
631 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 346.95000000000005 m
631 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 344.95000000000005 m
700 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 346.95000000000005 m
700 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 344.95000000000005 m
769 344.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 346.95000000000005 m
769 346.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 333.95000000000005 m
336 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 321.95000000000005 m
336 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 333.95000000000005 m
380 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 321.95000000000005 m
380 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 333.95000000000005 m
449 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 321.95000000000005 m
449 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 333.95000000000005 m
493 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 321.95000000000005 m
493 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 333.95000000000005 m
562 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 321.95000000000005 m
562 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 333.95000000000005 m
631 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 321.95000000000005 m
631 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 333.95000000000005 m
700 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 321.95000000000005 m
700 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 333.95000000000005 m
769 333.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 321.95000000000005 m
769 321.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 225.95000000000005 m
336 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 205.95000000000005 m
336 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 203.95000000000005 m
336 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 225.95000000000005 m
380 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 205.95000000000005 m
380 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 203.95000000000005 m
380 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 225.95000000000005 m
449 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 205.95000000000005 m
449 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 203.95000000000005 m
449 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 225.95000000000005 m
493 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 205.95000000000005 m
493 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 203.95000000000005 m
493 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 225.95000000000005 m
562 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 205.95000000000005 m
562 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 203.95000000000005 m
562 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 225.95000000000005 m
631 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 205.95000000000005 m
631 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 203.95000000000005 m
631 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 225.95000000000005 m
700 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 205.95000000000005 m
700 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 203.95000000000005 m
700 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 225.95000000000005 m
769 225.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 205.95000000000005 m
769 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 203.95000000000005 m
769 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 203.95000000000005 m
336 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 205.95000000000005 m
336 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 192.95000000000005 m
336 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 203.95000000000005 m
380 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 205.95000000000005 m
380 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 192.95000000000005 m
380 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 203.95000000000005 m
449 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 205.95000000000005 m
449 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 192.95000000000005 m
449 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 203.95000000000005 m
493 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 205.95000000000005 m
493 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 192.95000000000005 m
493 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 203.95000000000005 m
562 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 205.95000000000005 m
562 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 192.95000000000005 m
562 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 203.95000000000005 m
631 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 205.95000000000005 m
631 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 192.95000000000005 m
631 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 203.95000000000005 m
700 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 205.95000000000005 m
700 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 192.95000000000005 m
700 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 203.95000000000005 m
769 203.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 205.95000000000005 m
769 205.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 192.95000000000005 m
769 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 192.95000000000005 m
336 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 180.95000000000005 m
336 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 192.95000000000005 m
380 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 180.95000000000005 m
380 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 192.95000000000005 m
449 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 180.95000000000005 m
449 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 192.95000000000005 m
493 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 180.95000000000005 m
493 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 192.95000000000005 m
562 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 180.95000000000005 m
562 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 192.95000000000005 m
631 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 180.95000000000005 m
631 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 192.95000000000005 m
700 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 180.95000000000005 m
700 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 192.95000000000005 m
769 192.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 180.95000000000005 m
769 180.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 96.95000000000005 m
336 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 85.95000000000005 m
336 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
271 83.95000000000005 m
336 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 96.95000000000005 m
380 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 85.95000000000005 m
380 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
340 83.95000000000005 m
380 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 96.95000000000005 m
449 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 85.95000000000005 m
449 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
384 83.95000000000005 m
449 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 96.95000000000005 m
493 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 85.95000000000005 m
493 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
453 83.95000000000005 m
493 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 96.95000000000005 m
562 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 85.95000000000005 m
562 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
497 83.95000000000005 m
562 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 96.95000000000005 m
631 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 85.95000000000005 m
631 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
566 83.95000000000005 m
631 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 96.95000000000005 m
700 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 85.95000000000005 m
700 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
635 83.95000000000005 m
700 83.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 96.95000000000005 m
769 96.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 85.95000000000005 m
769 85.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
704 83.95000000000005 m
769 83.95000000000005 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 296.25 509.03 Td (Ordinary Shar) Tj ET Q
q 0 0 0 rg BT 347.07 509.03 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 400.65 509.03 Td (Eur) Tj ET Q
q 0 0 0 rg BT 413.91 509.03 Td (o Deferr) Tj ET Q
q 0 0 0 rg BT 442.41 509.03 Td (ed Shar) Tj ET Q
q 0 0 0 rg BT 468.72 509.03 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 500.65 496.18 Td (Additional Paid-) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 511.95 488.18 Td (in Capital) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 575.30 496.18 Td (Accumulated) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 586.65 488.18 Td (Deficit) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 644.30 509.03 Td (Accumulated) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 656.85 501.03 Td (Other) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 640.40 493.03 Td (Compr) Tj ET Q
q 0 0 0 rg BT 664.77 493.03 Td (ehensive) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 659.20 485.08 Td (Loss) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 727.25 504.18 Td (T) Tj ET Q
q 0 0 0 rg BT 732.22 504.18 Td (otal) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 712.25 496.18 Td (Shar) Tj ET Q
q 0 0 0 rg BT 728.63 496.18 Td (eholders') Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 709.40 488.18 Td (Equity \(Deficit\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 284.50 496.18 Td (Number) Tj ET Q
q 0 0 0 rg BT 312.87 496.18 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 291.50 488.18 Td (Shar) Tj ET Q
q 0 0 0 rg BT 307.88 488.18 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 345.45 488.18 Td (Amount) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 397.50 496.18 Td (Number) Tj ET Q
q 0 0 0 rg BT 425.87 496.18 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 404.50 488.18 Td (Shar) Tj ET Q
q 0 0 0 rg BT 420.88 488.18 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 458.45 488.18 Td (Amount) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 475.21 Td (BALANCE, DECEMBER 31, 2016, prior to the adoption of ) Tj ET Q
q 0 0 0 rg BT 244.24 475.21 Td (ASU) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 466.21 Td (2016-16) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 467.41 Td (222,954,175) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 467.41 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 467.41 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 467.41 Td (42) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 467.41 Td (8,743,240) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 467.41 Td (\(5,688,281) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 467.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 467.41 Td (\(353,434) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 467.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 467.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 729.50 467.41 Td (2,701,589) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 454.21 Td (Ef) Tj ET Q
q 0 0 0 rg BT 32.91 454.21 Td (fect of adopting ) Tj ET Q
q 0 0 0 rg BT 91.81 454.21 Td (ASU 2016-16 \(NOTE 17\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 595.25 454.21 Td (\(372,825) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 454.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 454.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 733.25 454.21 Td (\(372,825) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 454.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 442.21 Td (BALANCE, JANUAR) Tj ET Q
q 0 0 0 rg BT 106.75 442.21 Td (Y) Tj ET Q
q 0 0 0 rg BT 112.84 442.21 Td ( 1, 2017) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 442.21 Td (222,954,175) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 442.21 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 442.21 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 442.21 Td (42) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 442.21 Td (8,743,240) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 442.21 Td (\(6,061,106) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 442.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 442.21 Td (\(353,434) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 442.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 442.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 729.50 442.21 Td (2,328,764) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 430.21 Td (Net loss) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 430.21 Td (\(2,035,433) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 430.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 430.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 726.50 430.21 Td (\(2,035,433) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 430.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 418.21 Td (Other comprehensive income) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 418.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 667.25 418.21 Td (143,613) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 736.25 418.21 Td (143,613) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 406.21 Td (Compensation related to share-based awards) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.75 406.21 Td (50,149) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 406.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 740.75 406.21 Td (50,149) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 394.21 Td (Ordinary shares issued) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 303.25 394.21 Td (377,531) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 756.50 394.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 382.21 Td (T) Tj ET Q
q 0 0 0 rg BT 29.68 382.21 Td (ax withholding for restricted shares) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 535.25 382.21 Td (\(2,078) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 382.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 382.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 742.25 382.21 Td (\(2,078) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 382.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 370.21 Td (Other) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 370.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 370.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 370.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 485.00 370.21 Td (6) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.00 370.21 Td (\(141) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 370.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 370.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 370.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 749.00 370.21 Td (\(135) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 370.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 358.21 Td (BALANCE, DECEMBER 31, 2017, prior to the adoption of ) Tj ET Q
q 0 0 0 rg BT 244.24 358.21 Td (ASC) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 349.21 Td (606) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 350.41 Td (223,331,706) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 350.41 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 350.41 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 350.41 Td (48) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 350.41 Td (8,791,170) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 350.41 Td (\(8,096,539) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 350.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 350.41 Td (\(209,821) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 350.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 350.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 736.25 350.41 Td (484,880) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 337.21 Td (Ef) Tj ET Q
q 0 0 0 rg BT 32.91 337.21 Td (fect of adopting ) Tj ET Q
q 0 0 0 rg BT 91.81 337.21 Td (ASC 606 \(NOTE 17\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 607.25 337.21 Td (3,076) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 337.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 745.25 337.21 Td (3,076) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 325.21 Td (BALANCE, JANUAR) Tj ET Q
q 0 0 0 rg BT 106.75 325.21 Td (Y) Tj ET Q
q 0 0 0 rg BT 112.84 325.21 Td ( 1, 2018) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 325.21 Td (223,331,706) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 325.21 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 325.21 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 325.21 Td (48) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 325.21 Td (8,791,170) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 325.21 Td (\(8,093,463) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 325.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 325.21 Td (\(209,821) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 325.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 325.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 736.25 325.21 Td (487,956) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 313.21 Td (Net loss) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 313.21 Td (\(1,031,469) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 313.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 313.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 726.50 313.21 Td (\(1,031,469) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 313.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 301.21 Td (Other comprehensive loss) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 301.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 668.75 301.21 Td (\(19,408) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 301.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 737.75 301.21 Td (\(19,408) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 301.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 289.21 Td (Compensation related to share-based awards) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.75 289.21 Td (54,071) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 289.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 740.75 289.21 Td (54,071) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 277.21 Td (Exercise of options) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 307.75 277.21 Td (94,392) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 277.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 277.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 277.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 545.00 277.21 Td (933) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 277.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 277.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 752.00 277.21 Td (933) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 265.21 Td (Ordinary shares issued) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 303.25 265.21 Td (956,693) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 756.50 265.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 253.21 Td (L) Tj ET Q
q 0 0 0 rg BT 29.58 253.21 Td (TCI modification \(NOTE 18\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.75 253.21 Td (14,936) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 253.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 740.75 253.21 Td (14,936) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 241.21 Td (T) Tj ET Q
q 0 0 0 rg BT 29.68 241.21 Td (ax withholding for restricted shares) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 535.25 241.21 Td (\(5,375) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 241.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 241.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 742.25 241.21 Td (\(5,375) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 241.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 229.21 Td (Other) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 229.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 229.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 229.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 482.00 229.21 Td (\(2) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 489.50 229.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 229.21 Td (75) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 229.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 229.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 756.50 229.21 Td (73) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 217.21 Td (BALANCE, DECEMBER 31, 2018, prior to the adoption of ) Tj ET Q
q 0 0 0 rg BT 244.24 217.21 Td (ASC) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 208.21 Td (842) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 209.41 Td (224,382,791) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 209.41 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 209.41 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 209.41 Td (46) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 209.41 Td (8,855,810) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 209.41 Td (\(9,124,932) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 209.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 209.41 Td (\(229,229) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 209.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 209.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 733.25 209.41 Td (\(498,283) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 209.41 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 196.21 Td (Ef) Tj ET Q
q 0 0 0 rg BT 32.91 196.21 Td (fect of adopting ) Tj ET Q
q 0 0 0 rg BT 91.81 196.21 Td (ASC 842 \(NOTE 17\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 604.25 196.21 Td (\(4,646) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 196.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 196.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 742.25 196.21 Td (\(4,646) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 196.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 184.21 Td (BALANCE, JANUAR) Tj ET Q
q 0 0 0 rg BT 106.75 184.21 Td (Y) Tj ET Q
q 0 0 0 rg BT 112.84 184.21 Td ( 1, 2019) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 184.21 Td (224,382,791) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 184.21 Td (22) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 184.21 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 184.21 Td (46) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 184.21 Td (8,855,810) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 184.21 Td (\(9,129,578) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 184.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 184.21 Td (\(229,229) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 184.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 184.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 733.25 184.21 Td (\(502,929) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 184.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 172.21 Td (Net loss) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 595.25 172.21 Td (\(422,636) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 172.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 172.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 733.25 172.21 Td (\(422,636) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 172.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 160.21 Td (Other comprehensive income) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 160.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 671.75 160.21 Td (10,139) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 740.75 160.21 Td (10,139) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 148.21 Td (Compensation related to share-based awards) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.75 148.21 Td (59,142) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 148.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 740.75 148.21 Td (59,142) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 136.21 Td (Exercise of options) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 319.00 136.21 Td (557) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 136.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 136.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 136.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 554.00 136.21 Td (4) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 136.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 136.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 761.00 136.21 Td (4) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 124.21 Td (Ordinary shares issued) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 296.50 124.21 Td (2,419,261) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 549.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 756.50 124.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 112.21 Td (T) Tj ET Q
q 0 0 0 rg BT 29.68 112.21 Td (ax withholding for restricted shares) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 530.75 112.21 Td (\(10,156) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 112.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 112.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 737.75 112.21 Td (\(10,156) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 112.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 100.21 Td (Other) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 323.50 100.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 372.00 100.21 Td (1) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 436.50 100.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 482.00 100.21 Td (\(1) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 489.50 100.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.00 100.21 Td (\(108) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 100.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 618.50 100.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 687.50 100.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 749.00 100.21 Td (\(108) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 100.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 24.50 88.21 Td (BALANCE, DECEMBER 31, 2019) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 287.50 88.21 Td (226,802,609) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 342.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 367.50 88.21 Td (23) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.50 88.21 Td (4,000,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 455.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 480.50 88.21 Td (45) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 499.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 522.50 88.21 Td (8,904,692) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 568.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 588.50 88.21 Td (\(9,552,214) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 627.50 88.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 637.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 664.25 88.21 Td (\(219,090) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 696.50 88.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 706.50 88.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 733.25 88.21 Td (\(866,544) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 765.50 88.21 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.35 70.45 Td (See accompanying Notes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.21 70.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.07 70.45 Td (.) Tj ET Q
endstream
endobj
181 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 182 0 R>>
endobj
182 0 obj
<</Length 36873>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.70 24.60 Td (F-1) Tj ET Q
q 0 0 0 rg BT 310.22 24.60 Td (1) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 188.65 737.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 248.47 737.25 Td (TED ST) Tj ET Q
q 0 0 0 rg BT 283.02 737.25 Td (A) Tj ET Q
q 0 0 0 rg BT 289.50 737.25 Td (TEMENTS OF) Tj ET Q
q 0 0 0 rg BT 354.42 737.25 Td ( CASH FLOWS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 185.85 725.25 Td (YEARS ENDED DECEMBER 31, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 335.03 725.25 Td (2019) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 355.03 725.25 Td (, ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 360.03 725.25 Td (2018) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 380.03 725.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 381.98 725.25 Td (AND ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 406.15 725.25 Td (2017) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 9.00 Tf ET
q 0 0 0 rg BT 263.45 714.45 Td (\(Dollars in thousands\)) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 691.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 691.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 691.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 691.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 691.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 691.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 667.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 667.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 667.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 667.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 667.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 667.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 643.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 643.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 643.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 643.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 643.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 643.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 619.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 619.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 619.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 619.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 619.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 619.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 595.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 595.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 595.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 595.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 595.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 595.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 571.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 571.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 571.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 571.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 571.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 571.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 547.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 547.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 547.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 547.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 547.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 547.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 523.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 523.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 523.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 523.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 523.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 523.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 499.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 499.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 499.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 499.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 499.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 499.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 475.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 475.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 475.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 475.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 475.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 475.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 451.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 451.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 451.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 451.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 451.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 451.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 427.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 427.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 427.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 427.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 427.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 427.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 403.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 403.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 403.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 403.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 403.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 403.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 379.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 379.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 379.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 379.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 379.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 379.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 355.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 355.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 355.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 355.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 355.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 355.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 331.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 331.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 331.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 331.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 331.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 331.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 307.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 307.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 307.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 307.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 307.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 307.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 283.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 283.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 283.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 283.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 283.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 283.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 259.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 259.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 259.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 259.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 259.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 259.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 235.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 235.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 235.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 235.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 235.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 235.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 211.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 211.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 211.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 211.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 211.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 211.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 177.95 337.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 177.95 65.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 177.95 4.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 177.95 65.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 177.95 4.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 177.95 65.00 -22.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 133.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 133.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 133.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 133.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 133.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 133.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 109.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 109.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 109.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 109.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 109.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 109.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 85.95 337.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 85.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 85.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 85.95 65.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 85.95 4.00 -12.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 85.95 65.00 -12.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 691.95 m
437.5 691.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 691.95 m
506.5 691.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 691.95 m
575.5 691.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 691.95 m
575.5 691.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 475.95000000000005 m
437.5 475.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 463.95000000000005 m
437.5 463.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 475.95000000000005 m
506.5 475.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 463.95000000000005 m
506.5 463.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 475.95000000000005 m
575.5 475.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 463.95000000000005 m
575.5 463.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 379.95000000000005 m
437.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 379.95000000000005 m
506.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 379.95000000000005 m
575.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 379.95000000000005 m
437.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 367.95000000000005 m
437.5 367.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 379.95000000000005 m
506.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 367.95000000000005 m
506.5 367.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 379.95000000000005 m
575.5 379.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 367.95000000000005 m
575.5 367.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 235.95000000000005 m
437.5 235.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 223.95000000000005 m
437.5 223.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 235.95000000000005 m
506.5 235.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 223.95000000000005 m
506.5 223.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 235.95000000000005 m
575.5 235.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 223.95000000000005 m
575.5 223.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 199.95000000000005 m
437.5 199.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 199.95000000000005 m
506.5 199.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 199.95000000000005 m
575.5 199.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 177.95000000000005 m
437.5 177.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 177.95000000000005 m
506.5 177.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 177.95000000000005 m
575.5 177.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 155.95000000000005 m
437.5 155.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 134.95000000000005 m
437.5 134.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 132.95000000000005 m
437.5 132.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 155.95000000000005 m
506.5 155.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 134.95000000000005 m
506.5 134.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 132.95000000000005 m
506.5 132.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 155.95000000000005 m
575.5 155.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 134.95000000000005 m
575.5 134.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 132.95000000000005 m
575.5 132.95000000000005 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 696.03 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 696.03 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 696.03 Td (2017) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 683.21 Td (OPERA) Tj ET Q
q 0 0 0 rg BT 67.01 683.21 Td (TING ) Tj ET Q
q 0 0 0 rg BT 90.00 683.21 Td (ACTIVITIES:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 671.21 Td (Net loss) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 671.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 401.75 671.21 Td (\(422,636) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 671.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 671.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 464.00 671.21 Td (\(1,031,469) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 671.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 671.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.00 671.21 Td (\(2,035,433) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 671.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 659.21 Td (Adjustments to reconcile Net loss to Net cash provided by operating activities:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 647.21 Td (Depreciation and amortization) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 647.21 Td (612,862) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 647.21 Td (723,707) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 647.21 Td (983,765) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 635.21 Td (Inventory step-up) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 425.00 635.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 489.50 635.21 Td (261) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 558.50 635.21 Td (390) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 623.21 Td (Share-based compensation) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 623.21 Td (59,142) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 623.21 Td (54,071) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 623.21 Td (50,149) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 611.21 Td (Amortization of debt issuance costs and discount) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 611.21 Td (18,107) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 611.21 Td (20,514) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 611.21 Td (22,694) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 599.21 Td (Deferred income taxes) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 410.75 599.21 Td (\(5,561) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 599.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 482.75 599.21 Td (5,557) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 539.75 599.21 Td (\(156,129) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 599.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 587.21 Td (Change in fair value of contingent consideration) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 587.21 Td (\(46,098) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 587.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 587.21 Td (19,910) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 587.21 Td (49,949) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 575.21 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 401.75 575.21 Td (\(1) Tj ET Q
q 0 0 0 rg BT 409.25 575.21 Td (19,828) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 575.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 575.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 575.21 Td (51,734) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 563.21 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 131.39 563.21 Td (ges) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 563.21 Td (526,082) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 563.21 Td (916,939) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 536.00 563.21 Td (1,154,376) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 551.21 Td (Gain on sale of business and other assets) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 410.75 551.21 Td (\(6,367) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 551.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 551.21 Td (\(45,155) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 551.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 544.25 551.21 Td (\(13,809) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 551.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 539.21 Td (Changes in assets and liabilities which provided \(used\) cash:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 527.21 Td (Accounts receivable) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 527.21 Td (19,158) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 527.21 Td (17,090) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 527.21 Td (484,710) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 515.21 Td (Inventories) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 515.21 Td (\(27,139) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 515.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 515.21 Td (67,269) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 515.21 Td (147,189) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 503.21 Td (Prepaid and other assets) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 503.21 Td (1) Tj ET Q
q 0 0 0 rg BT 413.75 503.21 Td (1,370) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 503.21 Td (\(12,797) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 503.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 551.75 503.21 Td (5,345) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 491.21 Td (Accounts payable, accrued expenses and other liabilities) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 401.75 491.21 Td (\(525,746) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 491.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 470.75 491.21 Td (\(425,336) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 491.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 544.25 491.21 Td (\(87,944) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 491.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 479.21 Td (Income taxes payable/receivable, net) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 413.75 479.21 Td (4,706) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 479.21 Td (\(43,291) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 479.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 539.75 479.21 Td (\(103,001) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 479.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 56.00 467.21 Td (Net cash provided by operating activities) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 467.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 467.21 Td (98,052) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 467.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 467.21 Td (267,270) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 467.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 467.21 Td (553,985) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 455.21 Td (INVESTING ) Tj ET Q
q 0 0 0 rg BT 87.99 455.21 Td (ACTIVITIES:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 443.21 Td (Purchases of property) Tj ET Q
q 0 0 0 rg BT 122.19 443.21 Td (, plant and equipment, excluding capitalized interest) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 443.21 Td (\(63,854) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 443.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 443.21 Td (\(83,398) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 443.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 539.75 443.21 Td (\(125,654) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 443.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 431.21 Td (Capitalized interest payments) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 410.75 431.21 Td (\(3,833) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 431.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 479.75 431.21 Td (\(3,549) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 431.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 431.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 419.21 Td (Decrease in notes receivable) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 425.00 419.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 419.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 551.75 419.21 Td (7,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 407.21 Td (Product acquisition costs and license fees) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 425.00 407.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 479.75 407.21 Td (\(3,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 407.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 407.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 395.21 Td (Proceeds from sale of business and other assets, net) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 413.75 395.21 Td (6,577) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 395.21 Td (70,369) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 395.21 Td (223,237) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 383.21 Td (Other investing activities) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 420.50 383.21 Td (912) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 482.75 383.21 Td (1,678) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 383.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 371.21 Td (Net cash \(used in\) provided by investing activities) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 371.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 371.21 Td (\(60,198) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 371.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 371.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 371.21 Td (\(17,900) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 371.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 371.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 371.21 Td (104,583) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 359.21 Td (FINANCING ) Tj ET Q
q 0 0 0 rg BT 89.50 359.21 Td (ACTIVITIES:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 347.21 Td (Proceeds from issuance of notes, net) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 398.00 347.21 Td (1,483,125) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 347.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 347.21 Td (300,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 335.21 Td (Proceeds from issuance of term loans) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 425.00 335.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 335.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 536.00 335.21 Td (3,415,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 323.21 Td (Repayments of notes) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 395.00 323.21 Td (\(1,501,788) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 323.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 323.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 323.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 311.21 Td (Repayments of term loans) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 311.21 Td (\(34,152) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 311.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 311.21 Td (\(34,150) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 311.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 533.00 311.21 Td (\(3,730,951) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 311.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 299.21 Td (Proceeds from draw of revolving debt) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 299.21 Td (300,000) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 299.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 299.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 287.21 Td (Repayments of other indebtedness) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 410.75 287.21 Td (\(9,196) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 287.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 479.75 287.21 Td (\(5,222) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 287.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 548.75 287.21 Td (\(6,154) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 287.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 275.21 Td (Payments for debt issuance and extinguishment costs) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 410.75 275.21 Td (\(6,414) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 275.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 275.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 544.25 275.21 Td (\(57,773) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 275.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 263.21 Td (Payments for contingent consideration) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 263.21 Td (\(16,822) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 263.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 263.21 Td (\(37,758) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 263.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 544.25 263.21 Td (\(85,037) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 263.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 251.21 Td (Payments of tax withholding for restricted shares) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 406.25 251.21 Td (\(10,156) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 434.00 251.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 479.75 251.21 Td (\(5,375) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 251.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 548.75 251.21 Td (\(2,078) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 251.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 239.21 Td (Proceeds from exercise of options) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 429.50 239.21 Td (4) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 489.50 239.21 Td (933) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 563.00 239.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 227.21 Td (Net cash provided by \(used in\) financing activities) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 227.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 227.21 Td (204,601) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 227.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 475.25 227.21 Td (\(81,572) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 227.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 227.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 539.75 227.21 Td (\(166,993) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 572.00 227.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 215.21 Td (Ef) Tj ET Q
q 0 0 0 rg BT 46.41 215.21 Td (fect of foreign exchange rate) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 413.75 215.21 Td (1,096) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 479.75 215.21 Td (\(1,975) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 503.00 215.21 Td (\)) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 551.75 215.21 Td (2,515) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 203.21 Td (Movement in cash held for sale) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 425.00 203.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 494.00 203.21 Td (�) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 203.21 Td (1) Tj ET Q
q 0 0 0 rg BT 551.75 203.21 Td (1,744) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 191.21 Td (NET) Tj ET Q
q 0 0 0 rg BT 55.41 191.21 Td ( INCREASE IN CASH, CASH EQUIV) Tj ET Q
q 0 0 0 rg BT 197.76 191.21 Td (ALENTS, RESTRICTED CASH ) Tj ET Q
q 0 0 0 rg BT 318.94 191.21 Td (AND) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 182.21 Td (RESTRICTED CASH EQUIV) Tj ET Q
q 0 0 0 rg BT 148.42 182.21 Td (ALENTS) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 182.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 182.41 Td (243,551) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 182.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 182.41 Td (165,823) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 182.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 182.41 Td (505,834) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 169.21 Td (CASH, CASH EQUIV) Tj ET Q
q 0 0 0 rg BT 120.18 169.21 Td (ALENTS, RESTRICTED CASH ) Tj ET Q
q 0 0 0 rg BT 241.35 169.21 Td (AND RESTRICTED CASH) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 160.21 Td (EQUIV) Tj ET Q
q 0 0 0 rg BT 65.41 160.21 Td (ALENTS, BEGINNING OF PERIOD) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 398.00 160.41 Td (1,476,837) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 467.00 160.41 Td (1,31) Tj ET Q
q 0 0 0 rg BT 482.75 160.41 Td (1,014) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 160.41 Td (805,180) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 147.21 Td (CASH, CASH EQUIV) Tj ET Q
q 0 0 0 rg BT 120.18 147.21 Td (ALENTS, RESTRICTED CASH ) Tj ET Q
q 0 0 0 rg BT 241.35 147.21 Td (AND RESTRICTED CASH) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 138.21 Td (EQUIV) Tj ET Q
q 0 0 0 rg BT 65.41 138.21 Td (ALENTS, END OF PERIOD) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 138.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 398.00 138.41 Td (1,720,388) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 138.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 467.00 138.41 Td (1,476,837) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 138.41 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 536.00 138.41 Td (1,31) Tj ET Q
q 0 0 0 rg BT 551.75 138.41 Td (1,014) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 38.00 125.21 Td (SUPPLEMENT) Tj ET Q
q 0 0 0 rg BT 95.29 125.21 Td (AL) Tj ET Q
q 0 0 0 rg BT 106.95 125.21 Td ( INFORMA) Tj ET Q
q 0 0 0 rg BT 149.71 125.21 Td (TION:) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 113.21 Td (Cash paid for interest, excluding capitalized interest) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 113.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 113.21 Td (559,528) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 113.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 113.21 Td (515,042) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 113.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 113.21 Td (467,017) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 101.21 Td (Cash paid for income taxes) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 101.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 101.21 Td (14,875) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 101.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 101.21 Td (17,639) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 101.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 101.21 Td (28,675) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 89.21 Td (Cash paid into Qualified Settlement Funds for mesh legal settlements) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 89.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 89.21 Td (253,520) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 89.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 89.21 Td (336,648) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 89.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 89.21 Td (668,306) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 77.21 Td (Cash paid out of Qualified Settlement Funds for mesh legal settlements) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 77.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 404.75 77.21 Td (314,266) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 77.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 473.75 77.21 Td (353,032) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 77.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 542.75 77.21 Td (632,176) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 44.00 65.21 Td (Other cash distributions for mesh legal settlements) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 375.00 65.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 409.25 65.21 Td (15,330) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 444.00 65.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 478.25 65.21 Td (25,222) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 513.00 65.21 Td ($) Tj ET Q
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 547.25 65.21 Td (19,243) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.35 47.45 Td (See accompanying Notes to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.21 47.45 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.07 47.45 Td (.) Tj ET Q
endstream
endobj
183 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 184 0 R>>
endobj
184 0 obj
<</Length 16754>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-12) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 236.90 749.25 Td (ENDO INTERNA) Tj ET Q
q 0 0 0 rg BT 313.67 749.25 Td (TIONAL) Tj ET Q
q 0 0 0 rg BT 352.57 749.25 Td ( PLC) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 175.30 737.25 Td (NOTES ) Tj ET Q
q 0 0 0 rg BT 211.52 737.25 Td (T) Tj ET Q
q 0 0 0 rg BT 218.01 737.25 Td (O ) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 228.29 737.25 Td (CONSOLIDA) Tj ET Q
q 0 0 0 rg BT 288.11 737.25 Td (TED FINANCIAL) Tj ET Q
q 0 0 0 rg BT 367.29 737.25 Td ( ST) Tj ET Q
q 0 0 0 rg BT 381.28 737.25 Td (A) Tj ET Q
q 0 0 0 rg BT 387.76 737.25 Td (TEMENTS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 162.50 725.25 Td (FOR ) Tj ET Q
q 0 0 0 rg BT 185.93 725.25 Td (THE ) Tj ET Q
q 0 0 0 rg BT 209.17 725.25 Td (YEARS ENDED DECEMBER 31, 2019, 2018 ) Tj ET Q
q 0 0 0 rg BT 405.31 725.25 Td (AND 2017) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 698.25 Td (NOTE 1. DESCRIPTION OF) Tj ET Q
q 0 0 0 rg BT 162.31 698.25 Td ( BUSINESS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 680.25 Td (Endo International plc is an Ireland-domiciled specialty branded and generics pharmaceutical company) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.89 680.25 Td ( that conducts business ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 668.25 Td (through its operating subsidiaries. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.04 668.25 Td (Unless otherwise indicated or required by the context, references throughout to �Endo,� the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 656.25 Td (�Company) Tj ET Q
q 0 0 0 rg BT 78.68 656.25 Td (,� �we,� �our� or �us� refer to financial information and transactions of Endo International plc and its subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.84 656.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 539.16 656.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 644.25 Td (accompanying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.81 644.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.68 644.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.01 644.25 Td (Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.42 644.25 Td ( and its subsidiaries have been prepared in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 632.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.40 632.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 602.25 Td (NOTE 2. SUMMAR) Tj ET Q
q 0 0 0 rg BT 122.59 602.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 129.44 602.25 Td ( OF) Tj ET Q
q 0 0 0 rg BT 145.46 602.25 Td ( SIGNIFICANT) Tj ET Q
q 0 0 0 rg BT 214.46 602.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 216.41 602.25 Td (ACCOUNTING POLICIES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 584.25 Td (Significant ) Tj ET Q
q 0 0 0 rg BT 84.07 584.25 Td (Accounting Policies) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 566.25 Td (Consolidation and Basis of Presentation) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 229.15 566.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.15 566.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.19 566.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.06 566.25 Td ( include the accounts of wholly-owned ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 554.25 Td (subsidiaries after the elimination of intercompany accounts and transactions.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 536.25 Td (Reclassifications) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 132.44 536.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.44 536.25 Td (Certain prior period amounts have been reclassified to conform to the current period presentation.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 518.25 Td (Use of Estimates) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 131.89 518.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.89 518.25 Td (The preparation of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.63 518.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.49 518.25 Td ( in conformity with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.48 518.25 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.62 518.25 Td ( requires us to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 506.25 Td (make estimates and assumptions that af) Tj ET Q
q 0 0 0 rg BT 193.84 506.25 Td (fect the amounts and disclosures in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.41 506.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.28 506.25 Td (, including the notes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 494.25 Td (thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 482.25 Td (recognition, including sales deductions, long-lived assets, goodwill, other intangible assets, income taxes, contingencies, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 470.25 Td (instruments and share-based compensation, among others. Some of these estimates can be subjective and complex. ) Tj ET Q
q 0 0 0 rg BT 497.54 470.25 Td (Although we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 458.25 Td (believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that dif) Tj ET Q
q 0 0 0 rg BT 525.11 458.25 Td (fer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 446.25 Td (significantly from ours. Further) Tj ET Q
q 0 0 0 rg BT 161.69 446.25 Td (, our estimates and assumptions are based upon information available at the time they were made. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 434.25 Td (Actual results may dif) Tj ET Q
q 0 0 0 rg BT 124.41 434.25 Td (fer significantly from our estimates.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 416.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 416.25 Td (e regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 404.25 Td (environment. ) Tj ET Q
q 0 0 0 rg BT 90.99 404.25 Td (As future events and their ef) Tj ET Q
q 0 0 0 rg BT 204.38 404.25 Td (fects cannot be determined with precision, our estimates and assumptions may prove to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 392.25 Td (incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 380.25 Td (assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 368.25 Td (and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. ) Tj ET Q
q 0 0 0 rg BT 455.68 368.25 Td (W) Tj ET Q
q 0 0 0 rg BT 464.32 368.25 Td (e also are subject to other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 356.25 Td (risks and uncertainties that may cause actual results to dif) Tj ET Q
q 0 0 0 rg BT 266.02 356.25 Td (fer from estimated amounts, such as changes in the healthcare environment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 344.25 Td (competition, litigation, legislation and regulations. ) Tj ET Q
q 0 0 0 rg BT 240.23 344.25 Td (W) Tj ET Q
q 0 0 0 rg BT 248.87 344.25 Td (e adjust our estimates and assumptions when facts and circumstances indicate the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 332.25 Td (need for change. ) Tj ET Q
q 0 0 0 rg BT 104.67 332.25 Td (Those changes generally will be reflected in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.59 332.25 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.46 332.25 Td ( on a prospective basis.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 314.25 Td (Customer) Tj ET Q
q 0 0 0 rg BT 102.46 314.25 Td (, Product and Supplier Concentration) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 257.77 314.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.77 314.25 Td (W) Tj ET Q
q 0 0 0 rg BT 271.40 314.25 Td (e primarily sell our branded and generic products to wholesalers, retail drug ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 302.25 Td (store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 290.25 Td (wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 278.25 Td (pharmacies and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.97 278.25 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.75 278.25 Td (s) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.65 278.25 Td (. Customers in the managed care market include health maintenance or) Tj ET Q
q 0 0 0 rg BT 410.97 278.25 Td (ganizations, nursing homes, hospitals, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 266.25 Td (clinics, pharmacy benefit management companies and mail order customers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.32 266.25 Td (T) Tj ET Q
q 0 0 0 rg BT 349.73 266.25 Td (otal revenues from direct customers that accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 254.25 Td (10%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.33 254.25 Td ( or more of our total consolidated revenues during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.04 254.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.04 254.25 Td ( are as follows:) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 231.75 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 231.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 231.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 231.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 231.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 231.75 65.00 -14.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
35.50 217.75 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 203.75 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 203.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 203.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 203.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 203.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 203.75 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 231.75 m
437.5 231.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 231.75 m
506.5 231.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 231.75 m
575.5 231.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 231.75 m
506.5 231.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 231.75 m
575.5 231.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 235.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 235.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 235.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 222.32 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 103.99 222.32 Td (gen Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 222.32 Td (34) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 222.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 222.32 Td (32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 222.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 222.32 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 222.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 208.32 Td (McKesson Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 208.32 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 208.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 208.32 Td (27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 208.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 208.32 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 208.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 194.32 Td (Cardinal Health, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 194.32 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 194.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 194.32 Td (26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 194.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 194.32 Td (25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 194.32 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 172.25 Td (Revenues from these customers are included within each of our segments.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 154.25 Td (V) Tj ET Q
q 0 0 0 rg BT 68.93 154.25 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 123.39 158.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.32 154.25 Td ( accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.02 154.25 Td (18%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.35 154.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.35 154.25 Td (15%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.68 154.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.11 154.25 Td (12%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.44 154.25 Td ( of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.60 154.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.60 154.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.60 154.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.60 154.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.04 154.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.04 154.25 Td ( total revenues, respectively) Tj ET Q
q 0 0 0 rg BT 492.01 154.25 Td (. XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 539.79 158.78 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.73 154.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.25 Td (accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.19 142.25 Td (1) Tj ET Q
q 0 0 0 rg BT 97.82 142.25 Td (1%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.15 142.25 Td ( of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.31 142.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.31 142.25 Td ( total revenues. No other products accounted for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.52 142.25 Td (10%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.85 142.25 Td ( or more of our total revenues during the years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.25 Td (ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.38 130.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 130.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.96 130.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.96 130.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.29 130.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.29 130.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 112.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 112.25 Td (e have agreements with certain third parties for the manufacture, supply and processing of certain of our existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.25 Td (pharmaceutical products. See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.95 100.25 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.21 100.25 Td ( for information on material manufacturing, supply and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.25 Td (service agreements.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 70.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 70.25 Td (e are subject to risks and uncertainties associated with these concentrations that could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.56 70.25 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 520.45 70.25 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 58.25 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 58.25 Td ( in future periods, including in the near term. ) Tj ET Q
endstream
endobj
185 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 186 0 R>>
endobj
186 0 obj
<</Length 14913>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-13) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.25 Td (Revenue Recognition and Sales Deductions) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 242.45 742.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.45 742.25 Td (The Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.49 742.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.44 742.25 Td ( on January 1, 2018 using the modified ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (date of adoption.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.48 718.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.43 718.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.38 718.25 Td ( applies to contracts with commercial substance that establish the payment terms and each party�) Tj ET Q
q 0 0 0 rg BT 528.37 718.25 Td (s rights ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.25 Td (regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (Under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.94 694.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.89 694.25 Td (, we recognize revenue for contracts meeting these criteria when \(or as\) we satisfy our performance obligations for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (such contracts by transferring control of the underlying promised goods or services to our customers. ) Tj ET Q
q 0 0 0 rg BT 442.39 682.25 Td (The amount of revenue we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (such goods or services. ) Tj ET Q
q 0 0 0 rg BT 131.08 658.25 Td (This amount is referred to as the transaction price.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 640.25 Td (Our revenue consists almost entirely of sales of our products to customers, whereby we ship products to a customer pursuant to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (a purchase order) Tj ET Q
q 0 0 0 rg BT 101.52 628.25 Td (. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (and control has been transferred to the customer pursuant to the contract�) Tj ET Q
q 0 0 0 rg BT 327.84 616.25 Td (s terms, which is generally upon delivery to the customer) Tj ET Q
q 0 0 0 rg BT 556.12 616.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.05 604.25 Td (amount of revenue) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.02 604.25 Td ( we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.68 604.25 Td (recognize) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.54 604.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.04 604.25 Td (is equal to the fixed amount of the transaction price, adjusted for) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.29 604.25 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.62 604.25 Td (estimates of a number of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (significant variable components including, but not limited to, estimates for char) Tj ET Q
q 0 0 0 rg BT 354.08 592.25 Td (gebacks, rebates, sales incentives and allowances,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.44 592.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.94 592.25 Td (DSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 575.39 592.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (and other fees for services, returns and allowances, which) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.02 580.25 Td ( we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.68 580.25 Td (collectively refer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.69 580.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.19 580.25 Td (to as sales deductions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.07 580.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.38 580.25 Td (The Company utilizes the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (royalty exception.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.20 532.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.52 532.25 Td (V) Tj ET Q
q 0 0 0 rg BT 116.63 532.25 Td (ariable consideration is included in the transaction price only to the extent that it is probable that a significant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.90 520.25 Td ( Payment terms for these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (types of contracts generally fall within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.62 508.25 Td (30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.62 508.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.39 508.25 Td (90) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.39 508.25 Td ( days of invoicing.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 490.25 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 490.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 490.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.52 490.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.52 490.25 Td (, our reserves for sales deductions totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.25 490.25 Td ($660.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.14 490.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.58 490.25 Td ($772.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 498.47 490.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 551.13 490.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.25 Td (These amounts relate primarily to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.96 478.25 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.29 478.25 Td (estimates of unsettled obligations for returns and allowances, rebates and char) Tj ET Q
q 0 0 0 rg BT 500.95 478.25 Td (gebacks. ) Tj ET Q
q 0 0 0 rg BT 537.97 478.25 Td (The most ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (significant sales deductions relate to rebates paid under Medicaid and Medicare for the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.09 466.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.59 466.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.49 466.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.99 466.25 Td (segment, wholesaler ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.25 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 454.25 Td (gebacks and rebates for the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.86 454.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.36 454.25 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.28 454.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.78 454.25 Td (and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.22 454.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.72 454.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.39 454.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.89 454.25 Td (segments and sales returns for each of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.60 454.25 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.59 454.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (segments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.72 442.25 Td ( Our estimates are based on factors such as our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.65 442.25 Td (direct and indirect customers�) Tj ET Q
q 0 0 0 rg BT 384.03 442.25 Td ( buying patterns and the estimated resulting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.71 418.25 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.04 418.25 Td (direct and indirect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (customers and other competitive factors.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.45 406.25 Td ( Significant judgment and estimation is required in developing the foregoing and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (relevant assumptions. ) Tj ET Q
q 0 0 0 rg BT 124.97 394.25 Td (The most significant sales deductions are further described below) Tj ET Q
q 0 0 0 rg BT 386.46 394.25 Td (. ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 376.25 Td (Returns and ) Tj ET Q
q 0 0 0 rg BT 113.93 376.25 Td (Allowances�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.92 376.25 Td (Consistent with industry practice, we maintain a return policy that allows our customers to return ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.25 Td (products within a specified period of time both subsequent to and, in certain cases, prior to the products�) Tj ET Q
q 0 0 0 rg BT 452.65 364.25 Td ( expiration dates. Our return ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (policy generally allows customers to receive credit for expired products within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.40 352.25 Td (six months) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.02 352.25 Td ( prior to expiration and within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.77 352.25 Td (one year) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.92 352.25 Td ( after ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.25 Td (expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.25 Td (delivery errors.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 310.25 Td (Rebates�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.55 310.25 Td (Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (types:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 286.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 286.25 Td (direct rebates;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 274.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 274.25 Td (indirect rebates;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 262.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 262.25 Td (governmental rebates, including those for Medicaid, Medicare and ) Tj ET Q
q 0 0 0 rg BT 354.11 262.25 Td (TRICARE, among others; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 250.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 250.25 Td (managed-care rebates.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 232.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 232.25 Td (e establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA) Tj ET Q
q 0 0 0 rg BT 555.11 232.25 Td ( fees ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.25 Td (paid to direct purchasing customers based on a percentage applied to a direct customer) Tj ET Q
q 0 0 0 rg BT 382.63 208.25 Td (�) Tj ET Q
q 0 0 0 rg BT 385.41 208.25 Td (s purchases from us, including fees paid to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.25 Td (wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers that have purchased our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (products from a wholesaler under a contract with us.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 166.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 166.25 Td (e are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.25 Td (respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and GPOs. For example, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.25 Td (we are required to provide a discount on our brand-name products to patients who fall within the Medicare Part D coverage gap, also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.25 Td (referred to as the donut hole.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 112.25 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 112.25 Td (e participate in various federal and state government-managed programs whereby discounts and rebates are provided to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.25 Td (participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.25 Td (requirements with public sector \(Medicaid\) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.25 Td (participant.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
187 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 188 0 R>>
endobj
188 0 obj
<</Length 16835>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-14) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Char) Tj ET Q
q 0 0 0 rg BT 83.19 742.10 Td (gebacks�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.29 742.10 Td (W) Tj ET Q
q 0 0 0 rg BT 132.93 742.10 Td (e market and sell products to both: \(i\) direct customers including wholesalers, distributors, warehousing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (pharmacy chains and other direct purchasing groups and \(ii\) indirect customers including independent pharmacies, non-warehousing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (chains, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 66.55 718.10 Td (MCO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.33 718.10 Td (s, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.22 718.10 Td (GPO) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.23 718.10 Td (s and government entities. ) Tj ET Q
q 0 0 0 rg BT 225.52 718.10 Td (W) Tj ET Q
q 0 0 0 rg BT 234.16 718.10 Td (e enter into agreements with certain of our indirect customers to establish contract ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (pricing for certain products. ) Tj ET Q
q 0 0 0 rg BT 149.95 706.10 Td (These indirect customers then independently select a wholesaler from which to purchase the products at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (these contracted prices. ) Tj ET Q
q 0 0 0 rg BT 131.51 694.10 Td (Alternatively) Tj ET Q
q 0 0 0 rg BT 183.62 694.10 Td (, we may pre-authorize wholesalers to of) Tj ET Q
q 0 0 0 rg BT 346.43 694.10 Td (fer specified contract pricing to other indirect customers. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (Under either arrangement, we provide credit to the wholesaler for any dif) Tj ET Q
q 0 0 0 rg BT 329.03 682.10 Td (ference between the contracted price with the indirect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (customer and the wholesaler) Tj ET Q
q 0 0 0 rg BT 150.50 670.10 Td (�) Tj ET Q
q 0 0 0 rg BT 153.28 670.10 Td (s invoice price. Such credit is called a char) Tj ET Q
q 0 0 0 rg BT 323.86 670.10 Td (geback.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 652.10 Td (Prior to the adoption of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.27 652.10 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.22 652.10 Td (, the Company accounted for revenue recognition and sales deductions under ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 505.68 652.10 Td (Accounting ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (Standar) Tj ET Q
q 0 0 0 rg BT 67.30 640.10 Td (ds Codification T) Tj ET Q
q 0 0 0 rg BT 135.83 640.10 Td (opic 605, Revenue Recognition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.23 640.10 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.06 640.10 Td (ASC 605) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.02 640.10 Td (\).) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 622.10 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 101.25 622.10 Td (Assets and Contract Liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.10 622.10 Td (. Contract assets represent the Company�) Tj ET Q
q 0 0 0 rg BT 390.39 622.10 Td (s right to consideration in exchange for goods ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (or services that the Company has transferred when that right is conditioned on something other than the passage of time. ) Tj ET Q
q 0 0 0 rg BT 519.86 610.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (fulfill one or more additional performance obligations before being entitled to payment. Once the Company�) Tj ET Q
q 0 0 0 rg BT 469.48 586.10 Td (s right to consideration ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (becomes unconditional, the contract asset amount is reclassified as ) Tj ET Q
q 0 0 0 rg BT 304.81 574.10 Td (Accounts receivable.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.10 Td (Contract liabilities represent the Company�) Tj ET Q
q 0 0 0 rg BT 235.18 556.10 Td (s obligation to transfer goods or services to a customer) Tj ET Q
q 0 0 0 rg BT 453.19 556.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 458.00 556.10 Td (The Company records a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (obligations. Upon completing each performance obligation, the corresponding contract liability amount is reversed and revenue is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (recognized.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 502.10 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 99.61 502.10 Td (assets ) Tj ET Q
q 0 0 0 rg BT 125.11 502.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 141.72 502.10 Td (liabilities ) Tj ET Q
q 0 0 0 rg BT 181.11 502.10 Td (related ) Tj ET Q
q 0 0 0 rg BT 210.48 502.10 Td (to ) Tj ET Q
q 0 0 0 rg BT 220.43 502.10 Td (rights ) Tj ET Q
q 0 0 0 rg BT 245.38 502.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 261.99 502.10 Td (obligations ) Tj ET Q
q 0 0 0 rg BT 308.61 502.10 Td (arising ) Tj ET Q
q 0 0 0 rg BT 338.00 502.10 Td (from ) Tj ET Q
q 0 0 0 rg BT 359.61 502.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 366.22 502.10 Td (single ) Tj ET Q
q 0 0 0 rg BT 392.27 502.10 Td (contract, ) Tj ET Q
q 0 0 0 rg BT 429.15 502.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 439.65 502.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 446.26 502.10 Td (series ) Tj ET Q
q 0 0 0 rg BT 471.20 502.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 481.70 502.10 Td (contracts ) Tj ET Q
q 0 0 0 rg BT 519.97 502.10 Td (combined ) Tj ET Q
q 0 0 0 rg BT 561.57 502.10 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (accounted ) Tj ET Q
q 0 0 0 rg BT 78.93 490.10 Td (for ) Tj ET Q
q 0 0 0 rg BT 92.99 490.10 Td (as ) Tj ET Q
q 0 0 0 rg BT 103.71 490.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 110.55 490.10 Td (single ) Tj ET Q
q 0 0 0 rg BT 136.83 490.10 Td (contract, ) Tj ET Q
q 0 0 0 rg BT 173.93 490.10 Td (are ) Tj ET Q
q 0 0 0 rg BT 188.53 490.10 Td (generally ) Tj ET Q
q 0 0 0 rg BT 228.13 490.10 Td (presented ) Tj ET Q
q 0 0 0 rg BT 268.84 490.10 Td (on ) Tj ET Q
q 0 0 0 rg BT 281.24 490.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 288.07 490.10 Td (net ) Tj ET Q
q 0 0 0 rg BT 302.69 490.10 Td (basis. ) Tj ET Q
q 0 0 0 rg BT 327.58 490.10 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 364.41 490.10 Td (assets ) Tj ET Q
q 0 0 0 rg BT 390.14 490.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 406.98 490.10 Td (liabilities ) Tj ET Q
q 0 0 0 rg BT 446.59 490.10 Td (are ) Tj ET Q
q 0 0 0 rg BT 461.19 490.10 Td (further ) Tj ET Q
q 0 0 0 rg BT 490.80 490.10 Td (described ) Tj ET Q
q 0 0 0 rg BT 531.51 490.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.68 490.10 Td (Note ) Tj ET Q
q 0 0 0 rg BT 563.52 490.10 Td (12. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 72.38 478.10 Td (Assets ) Tj ET Q
q 0 0 0 rg BT 101.00 478.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 117.93 478.10 Td (Liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.48 478.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.10 Td (R&D) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 84.67 460.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.67 460.10 Td (Expenditures for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.09 460.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.76 460.10 Td ( are expensed as incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.32 460.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 286.64 460.10 Td (T) Tj ET Q
q 0 0 0 rg BT 292.05 460.10 Td (otal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.55 460.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.22 460.10 Td ( expenses include, among other things, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.68 460.10 Td (costs of discovery ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, materials, medical support ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.10 Td (of marketed products and certain upfront and milestone payments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.70 436.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.70 436.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.37 436.10 Td ( spending also includes enterprise-wide costs which support ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.10 Td (our overall ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.09 424.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.76 424.10 Td ( infrastructure. Property) Tj ET Q
q 0 0 0 rg BT 198.92 424.10 Td (, plant and equipment that are acquired or constructed for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.77 424.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.44 424.10 Td ( activities and that have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.10 Td (alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.10 Td (milestone payments made to third parties are generally: \(i\) expensed as incurred up to the point of regulatory approval and \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.10 Td (capitalized and amortized over the related product�) Tj ET Q
q 0 0 0 rg BT 239.24 388.10 Td (s remaining useful life subsequent to regulatory approval. ) Tj ET Q
q 0 0 0 rg BT 471.68 388.10 Td (Amounts capitalized for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (such payments are included in Other intangibles, net in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.44 376.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.52 376.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.10 Td (Cash and Cash Equivalents) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 177.20 358.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.20 358.10 Td (The Company considers all highly liquid money market instruments with an original maturity of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (three months or less when purchased to be cash equivalents. ) Tj ET Q
q 0 0 0 rg BT 278.44 346.10 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.94 346.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.52 346.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.96 346.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.96 346.10 Td (, cash equivalents were deposited in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (financial institutions and consisted almost entirely of immediately available fund balances. ) Tj ET Q
q 0 0 0 rg BT 401.27 334.10 Td (The Company maintains its cash deposits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (and cash equivalents with financial institutions it believes to be well-known and stable.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 304.10 Td (Restricted Cash and Cash Equivalents) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 220.81 304.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.81 304.10 Td (Cash and cash equivalents that are restricted as to withdrawal or use under the terms of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (certain contractual agreements are excluded from Cash and cash equivalents in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.64 292.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.72 292.10 Td (. For additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.10 Td (information see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.98 280.10 Td (Note 6. Fair ) Tj ET Q
q 0 0 0 rg BT 151.35 280.10 Td (V) Tj ET Q
q 0 0 0 rg BT 157.46 280.10 Td (alue Measurements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.93 280.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 262.10 Td (Accounts Receivable) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 148.26 262.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.26 262.10 Td (Accounts receivable are stated at their net realizable value and the Company maintains an allowance for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (doubtful accounts against gross accounts receivable. ) Tj ET Q
q 0 0 0 rg BT 247.69 250.10 Td (The allowance is not material to the Company�) Tj ET Q
q 0 0 0 rg BT 435.14 250.10 Td (s Consolidated Financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (Statements at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.10 238.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.68 238.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.01 238.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.01 238.10 Td (. In addition, our accounts receivable balance is reduced by certain sales deduction reserves ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (where we have the right of of) Tj ET Q
q 0 0 0 rg BT 153.55 226.10 Td (fset with the customer) Tj ET Q
q 0 0 0 rg BT 241.59 226.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 208.10 Td (Concentrations of Credit Risk) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 186.08 208.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.08 208.10 Td (Financial instruments that potentially subject the Company to significant concentrations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (credit risk consist primarily of cash equivalents, restricted cash equivalents and accounts receivable. From time to time, we invest our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (excess cash in high-quality) Tj ET Q
q 0 0 0 rg BT 143.38 184.10 Td (, liquid money market instruments maintained by major banks and financial institutions. ) Tj ET Q
q 0 0 0 rg BT 498.13 184.10 Td (W) Tj ET Q
q 0 0 0 rg BT 506.77 184.10 Td (e have not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (experienced any losses on our cash equivalents.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 154.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 154.10 Td (e perform ongoing credit evaluations of our customers and generally do not require collateral. ) Tj ET Q
q 0 0 0 rg BT 448.83 154.10 Td (W) Tj ET Q
q 0 0 0 rg BT 457.46 154.10 Td (e have no history of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.10 Td (significant losses from uncollectible accounts. ) Tj ET Q
q 0 0 0 rg BT 222.62 142.10 Td (Approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.66 142.10 Td (88%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.99 142.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.43 142.10 Td (87%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.76 142.10 Td ( of our gross trade accounts receivable balances represent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.10 Td (amounts due from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.26 130.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.25 130.10 Td ( customers \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.13 130.10 Td (Cardinal Health, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.98 130.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.98 130.10 Td (McKesson Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.58 130.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.47 130.10 Td (AmerisourceBer) Tj ET Q
q 0 0 0 rg BT 447.37 130.10 Td (gen Corporation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.64 130.10 Td (\) at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 118.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.02 118.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.02 118.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 206.68 118.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 100.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 100.10 Td (e do not expect our current or future exposures to credit risk to have a significant impact on our operations. However) Tj ET Q
q 0 0 0 rg BT 538.59 100.10 Td (, there ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (can be no assurance that any of these risks will not have an adverse ef) Tj ET Q
q 0 0 0 rg BT 315.16 88.10 Td (fect on our business.) Tj ET Q
endstream
endobj
189 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 190 0 R>>
endobj
190 0 obj
<</Length 13991>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-15) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.25 Td (Inventories) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 109.67 742.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.67 742.25 Td (Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.10 730.25 Td (Consolidated Balance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.11 718.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 66.93 718.25 Td (The Company capitalizes inventory costs associated with certain products prior to regulatory approval and product launch ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.25 Td (when it is reasonably certain, based on management�) Tj ET Q
q 0 0 0 rg BT 247.04 706.25 Td (s judgment of future commercial use and net realizable value, that the pre-launch ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (inventories will be saleable. ) Tj ET Q
q 0 0 0 rg BT 149.95 694.25 Td (The determination to capitalize is made on a product-by-product basis. ) Tj ET Q
q 0 0 0 rg BT 434.96 694.25 Td (The Company could be required to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (net realizable value.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 640.25 Td (Cost is determined by the first-in, first-out method. It includes materials, direct labor and an allocation of overhead, but ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.25 Td (excludes certain period char) Tj ET Q
q 0 0 0 rg BT 148.26 628.25 Td (ges and unallocated overheads that are char) Tj ET Q
q 0 0 0 rg BT 321.88 628.25 Td (ged to expense in the period in which they are incurred. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.25 Td (Unallocated overheads can occur as a consequence of abnormally low production or idle facilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 598.25 Td (Net realizable value is determined by the estimated selling prices in the ordinary course of business, less reasonably predictable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.25 Td (costs of completion, disposal and transportation. ) Tj ET Q
q 0 0 0 rg BT 231.90 586.25 Td (When necessary) Tj ET Q
q 0 0 0 rg BT 296.49 586.25 Td (, we write-down inventories to net realizable value based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.25 Td (forecasted demand and market and regulatory conditions, which may dif) Tj ET Q
q 0 0 0 rg BT 325.72 574.25 Td (fer from actual results. ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.25 Td (Property) Tj ET Q
q 0 0 0 rg BT 98.18 556.25 Td (, Plant and Equipment) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 191.53 556.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.53 556.25 Td (Property) Tj ET Q
q 0 0 0 rg BT 230.32 556.25 Td (, plant and equipment is generally stated at cost less accumulated depreciation. Major ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.25 Td (improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.25 Td (or development of property) Tj ET Q
q 0 0 0 rg BT 145.04 532.25 Td (, plant and equipment are capitalized as assets under construction. Once an asset has been placed into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.25 Td (service, depreciation expense is taken on a straight-line basis over the estimated useful life of the related assets or) Tj ET Q
q 0 0 0 rg BT 489.60 520.25 Td (, in the case of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.25 Td (leasehold improvements and finance lease assets, over the shorter of the estimated useful life and the lease term. Depreciation is based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (on the following estimated useful lives, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.91 496.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.49 496.25 Td (:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 472.75 396.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
431.50 472.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.50 472.75 14.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 472.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 442.75 396.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
431.50 442.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.50 442.75 14.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 442.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
431.5 472.75 m
496.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.5 472.75 m
510.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 472.75 m
575.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
431.5 472.75 m
496.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
496.5 472.75 m
510.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 472.75 m
575.5 472.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 454.05 476.98 Td (Range of Useful Lives, fr) Tj ET Q
q 0 0 0 rg BT 538.56 476.98 Td (om:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 462.42 Td (Buildings) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.40 462.42 Td (10 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.10 462.42 Td (to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 462.42 Td (30 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 447.42 Td (Machinery and equipment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.25 447.42 Td (1 year) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.10 447.42 Td (to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 447.42 Td (15 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 432.42 Td (Computer equipment and software) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.25 432.42 Td (1 year) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.10 432.42 Td (to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 432.42 Td (10 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 417.42 Td (Furniture and fixtures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.25 417.42 Td (1 year) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.10 417.42 Td (to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 417.42 Td (10 years) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 395.25 Td (Depreciation expense is not recorded on assets held for sale. Gains and losses on disposals are included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.27 395.25 Td (Other expense ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.25 Td (\(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.31 383.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.81 383.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.17 383.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 277.62 383.25 Td (As further described below under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.27 383.25 Td (Long-Lived ) Tj ET Q
q 0 0 0 rg BT 516.98 383.25 Td (Asset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.25 Td (Impairment ) Tj ET Q
q 0 0 0 rg BT 84.97 371.25 Td (T) Tj ET Q
q 0 0 0 rg BT 90.38 371.25 Td (esting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.27 371.25 Td (,� our property plant and equipment assets are also subject to impairment reviews.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 353.25 Td (Computer Software) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 143.29 353.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.29 353.25 Td (The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 341.25 Td (software, including external direct costs of material and services, and payroll costs for employees directly involved with the software ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 329.25 Td (development. Capitalized software costs are included in) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 259.54 329.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.04 329.25 Td (Property) Tj ET Q
q 0 0 0 rg BT 295.82 329.25 Td (, plant and equipment, net in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.18 329.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.27 329.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 317.25 Td (depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.25 Td (during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.25 Td (incurred.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 275.25 Td (Lease ) Tj ET Q
q 0 0 0 rg BT 89.01 275.25 Td (Accounting.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.29 275.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 141.61 275.25 Td (The Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.65 275.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.60 275.25 Td ( on January 1, 2019. For further discussion of the adoption, refer to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.25 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 40.44 263.25 Td (Recent ) Tj ET Q
q 0 0 0 rg BT 70.15 263.25 Td (Accounting Pronouncements ) Tj ET Q
q 0 0 0 rg BT 187.91 263.25 Td (Adopted or Otherwise Ef) Tj ET Q
q 0 0 0 rg BT 288.53 263.25 Td (fective as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.90 263.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.48 263.25 Td (� section below) Tj ET Q
q 0 0 0 rg BT 480.03 263.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.48 263.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.43 263.25 Td ( applies to a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 251.25 Td (number of arrangements to which the Company is party) Tj ET Q
q 0 0 0 rg BT 258.63 251.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 233.25 Td (Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.25 Td (contains a lease. ) Tj ET Q
q 0 0 0 rg BT 103.57 221.25 Td (This determination generally depends on whether the arrangement conveys to the Company the right to control the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.25 Td (use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.25 Td (conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.25 Td (from using the underlying asset.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 167.25 Td (If a lease exists, the Company must then determine the separate lease and nonlease components of the arrangement. Each right ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.25 Td (to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 143.25 Td (can benefit the Company without depending on other resources not readily available to the Company and \(ii\) does not significantly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.25 Td (af) Tj ET Q
q 0 0 0 rg BT 43.59 131.25 Td (fect and is not significantly af) Tj ET Q
q 0 0 0 rg BT 162.54 131.25 Td (fected by other rights of use conveyed by the lease. ) Tj ET Q
q 0 0 0 rg BT 369.41 131.25 Td (Aspects of a lease arrangement that transfer other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 119.25 Td (goods or services to the Company but do not meet the definition of lease components are considered nonlease components. ) Tj ET Q
q 0 0 0 rg BT 530.69 119.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 107.25 Td (consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and nonlease component for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 95.25 Td (accounting purposes. However) Tj ET Q
q 0 0 0 rg BT 159.17 95.25 Td (, the Company has elected, for all of its leases, to not separate lease and nonlease components. Each ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 83.25 Td (lease component is accounted for separately from other lease components, but together with the associated nonlease components.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 65.25 Td (For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 53.25 Td (the lease as either an operating or finance lease.) Tj ET Q
endstream
endobj
191 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 192 0 R>>
endobj
192 0 obj
<</Length 13342>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-16) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (The lease term is the period of the lease not cancellable by the Company) Tj ET Q
q 0 0 0 rg BT 352.52 742.10 Td (, together with periods covered by: \(i\) renewal options ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (the Company is reasonably certain to exercise, \(ii\) termination options the Company is reasonably certain not to exercise and \(iii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (renewal or termination options that are controlled by the lessor) Tj ET Q
q 0 0 0 rg BT 286.76 718.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 700.10 Td (The present value of lease payments is calculated based on:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 688.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 688.10 Td (Lease payments�Lease payments include fixed and certain variable payments, less lease incentives, together with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 676.10 Td (amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 664.10 Td (the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 652.10 Td (exclude consideration that is not related to the transfer of goods and services to the Company) Tj ET Q
q 0 0 0 rg BT 457.24 652.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 640.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 640.10 Td (Discount rate�The discount rate must be determined based on information available to the Company upon the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 628.10 Td (commencement of a lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 616.10 Td (however) Tj ET Q
q 0 0 0 rg BT 119.53 616.10 Td (, as the implicit rate in the Company�) Tj ET Q
q 0 0 0 rg BT 267.83 616.10 Td (s leases is generally not readily determinable, the Company generally uses ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 604.10 Td (the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 592.10 Td (collateralized basis, over a timeframe similar to the lease term.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 574.10 Td (In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (certain other factors, including the lessee's and lessor's rights, obligations and economic incentives over the term of the lease.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 532.10 Td (Generally) Tj ET Q
q 0 0 0 rg BT 101.77 532.10 Td (, upon the commencement of a lease, the Company will record a lease liability and a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.66 532.10 Td (right-of-use \(ROU\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.14 532.10 Td ( asset. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (However) Tj ET Q
q 0 0 0 rg BT 72.25 520.10 Td (, the Company has elected, for all underlying assets with initial lease terms of twelve months or less \(known as short-term ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (leases\), to not recognize a lease liability or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.99 508.10 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.10 508.10 Td ( asset. Lease liabilities are initially recorded at lease commencement as the present ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.10 Td (value of future lease payments. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 163.17 496.10 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 184.29 496.10 Td ( assets are initially recorded at lease commencement as the initial amount of the lease liability) Tj ET Q
q 0 0 0 rg BT 558.78 496.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.10 Td (together with the following, if applicable: \(i\) initial direct costs incurred by the lessee and \(ii\) lease payments made by the lessor) Tj ET Q
q 0 0 0 rg BT 549.33 484.10 Td (, net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (of lease incentives received, prior to lease commencement.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 454.10 Td (Over the lease term, the Company generally increases its lease liabilities using the ef) Tj ET Q
q 0 0 0 rg BT 401.59 454.10 Td (fective interest method and decreases its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (lease liabilities for lease payments made. For finance leases, amortization expense and interest expense are recognized separately in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (the Consolidated Statements of Operations, with amortization expense generally recorded on a straight-line basis over the lease term ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (and interest expense recorded using the ef) Tj ET Q
q 0 0 0 rg BT 203.53 418.10 Td (fective interest method. For operating leases, a single lease cost is generally recognized in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (the Consolidated Statements of Operations on a straight-line basis over the lease term unless an impairment has been recorded with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (respect to a leased asset. Lease costs for short-term leases not recognized in the Consolidated Balance Sheets are recognized in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (Consolidated Statements of Operations on a straight-line basis over the lease term. ) Tj ET Q
q 0 0 0 rg BT 368.24 382.10 Td (V) Tj ET Q
q 0 0 0 rg BT 374.35 382.10 Td (ariable lease costs not initially included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (lease liability and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.03 370.10 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.15 370.10 Td ( asset impairment char) Tj ET Q
q 0 0 0 rg BT 220.21 370.10 Td (ges are expensed as incurred. ROU assets are assessed for impairment, similar to other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (long-lived assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 340.10 Td (Prior to the adoption of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.27 340.10 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.22 340.10 Td (, the Company accounted for leases under ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 365.16 340.10 Td (Accounting Standar) Tj ET Q
q 0 0 0 rg BT 444.50 340.10 Td (ds Codification T) Tj ET Q
q 0 0 0 rg BT 513.04 340.10 Td (opic 840, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.10 Td (Leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.22 328.10 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.05 328.10 Td (ASC 840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.00 328.10 Td (\).) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 310.10 Td (Cloud Computing ) Tj ET Q
q 0 0 0 rg BT 138.77 310.10 Td (Arrangements.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.17 310.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 202.49 310.10 Td (The Company may from time to time incur costs in connection with hosting arrangements ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (that are service contracts. Subsequent to the Company�) Tj ET Q
q 0 0 0 rg BT 255.38 298.10 Td (s January 1, 2019 adoption of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.64 298.10 Td (Accounting Standards Update \(ASU\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.78 298.10 Td ( No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.33 286.10 Td (, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 74.33 286.10 Td (Customer) Tj ET Q
q 0 0 0 rg BT 113.59 286.10 Td (�) Tj ET Q
q 0 0 0 rg BT 115.63 286.10 Td (s ) Tj ET Q
q 0 0 0 rg BT 121.84 286.10 Td (Accounting for Implementation Costs Incurr) Tj ET Q
q 0 0 0 rg BT 299.23 286.10 Td (ed in a Cloud Computing ) Tj ET Q
q 0 0 0 rg BT 402.67 286.10 Td (Arrangement That Is a Service Contract) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 563.48 286.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 274.10 Td (\() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.33 274.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.33 274.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.83 274.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.17 274.10 Td (\), which is further described below) Tj ET Q
q 0 0 0 rg BT 233.92 274.10 Td (, the Company capitalizes any such implementation costs, expenses them over the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (terms of the respective hosting arrangements and subjects them to impairment testing consistent with other long-lived assets.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 244.10 Td (Finite-Lived Intangible ) Tj ET Q
q 0 0 0 rg BT 161.52 244.10 Td (Assets) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 187.08 244.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.08 244.10 Td (Our finite-lived intangible assets consist of license rights and developed technology) Tj ET Q
q 0 0 0 rg BT 526.34 244.10 Td (. Upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (acquisition, intangible assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.20 232.10 Td (are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 572.22 232.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (There are several methods that can be used to determine fair value. For intangible assets, we typically use an income approach. ) Tj ET Q
q 0 0 0 rg BT 546.19 220.10 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (approach starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (marketing exclusivity) Tj ET Q
q 0 0 0 rg BT 122.27 184.10 Td (, such as that granted by a patent. ) Tj ET Q
q 0 0 0 rg BT 257.61 184.10 Td (The pricing, mar) Tj ET Q
q 0 0 0 rg BT 324.34 184.10 Td (gins and expense levels of similar products are considered if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (available. For certain licensed assets, our estimates of future cash flows consider periods covered by renewal options to the extent we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (have the intent and ability) Tj ET Q
q 0 0 0 rg BT 139.21 160.10 Td (, at the date of the estimate, to renew the underlying license agreements. ) Tj ET Q
q 0 0 0 rg BT 430.03 160.10 Td (These cash flows are then adjusted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 130.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 130.10 Td (o the extent an intangible asset is deemed to have a finite life, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.21 130.10 Td (it is then amortized over its estimated useful life using either the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.10 Td (straight-line method or) Tj ET Q
q 0 0 0 rg BT 127.25 118.10 Td (, in the case of certain developed technology assets, an accelerated amortization model.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.26 118.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.58 118.10 Td (The values of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 106.10 Td (various assets are subject to continuing scientific, medical and marketplace uncertainty) Tj ET Q
q 0 0 0 rg BT 383.28 106.10 Td (. Factors giving rise to our initial estimate of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 94.10 Td (useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 82.10 Td (and an acceleration of related amortization expense, which could cause our net income and net income per share to decrease. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 70.10 Td (Amortization expense is not recorded on assets held for sale.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
193 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 194 0 R>>
endobj
194 0 obj
<</Length 12878>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (As further described below under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.65 742.10 Td (Long-Lived ) Tj ET Q
q 0 0 0 rg BT 302.37 742.10 Td (Asset Impairment ) Tj ET Q
q 0 0 0 rg BT 376.06 742.10 Td (T) Tj ET Q
q 0 0 0 rg BT 381.47 742.10 Td (esting) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.35 742.10 Td (,� our finite-lived intangible assets are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (also subject to impairment reviews.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 712.10 Td (Developed T) Tj ET Q
q 0 0 0 rg BT 113.44 712.10 Td (echnology) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 155.66 712.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.66 712.10 Td (Our developed technology assets subject to amortization have useful lives ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.90 712.10 Td (4 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.50 712.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.28 712.10 Td (20 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.10 700.10 Td (, with a weighted average useful life of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.91 700.10 Td (1) Tj ET Q
q 0 0 0 rg BT 280.54 700.10 Td (1 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.13 700.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.63 700.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.95 700.10 Td (W) Tj ET Q
q 0 0 0 rg BT 322.59 700.10 Td (e determine amortization periods and methods of amortization ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (for developed technology assets based on our assessment of various factors impacting estimated useful lives and the timing and extent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the product \(if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (applicable\), contractual terms and various other competitive and regulatory issues.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 646.10 Td (License Rights) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 123.83 646.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.83 646.10 Td (Our license rights subject to amortization have useful lives ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.26 646.10 Td (12 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.86 646.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.63 646.10 Td (15 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.23 646.10 Td (, with a weighted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (average useful life of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.44 634.10 Td (14 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.04 634.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.54 634.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.85 634.10 Td (W) Tj ET Q
q 0 0 0 rg BT 230.49 634.10 Td (e determine amortization periods for licenses based on our assessment of various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (factors including the expected launch date of the product, the strength of the intellectual property protection of the product \(if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (applicable\), contractual terms and various other competitive, developmental and regulatory issues.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 592.10 Td (Long-Lived ) Tj ET Q
q 0 0 0 rg BT 112.89 592.10 Td (Asset Impairment T) Tj ET Q
q 0 0 0 rg BT 193.65 592.10 Td (esting) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 218.10 592.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.10 592.10 Td (Long-lived assets, including property) Tj ET Q
q 0 0 0 rg BT 371.86 592.10 Td (, plant and equipment and finite-lived intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (assets, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.33 580.10 Td (are assessed for impairment whenever events or changes in circumstances indicate the) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.92 580.10 Td ( carrying amounts of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.16 580.10 Td (assets may not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (be recoverable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.57 568.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.57 568.10 Td (Recoverability of a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.21 568.10 Td (n ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.71 568.10 Td (asset that will continue to be used in) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.95 568.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.28 568.10 Td (operations is measured by comparing the carrying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.10 Td (amount of the asset to the forecasted undiscounted future cash flows related to the asset.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.39 556.10 Td ( In the event the carrying amount of the asset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. ) Tj ET Q
q 0 0 0 rg BT 522.80 544.10 Td (An ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (impairment loss, if any) Tj ET Q
q 0 0 0 rg BT 127.56 532.10 Td (, is measured as the excess of the asset�) Tj ET Q
q 0 0 0 rg BT 284.45 532.10 Td (s carrying amount over its fair value, generally based on a discounted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (future cash flow method, independent appraisals or of) Tj ET Q
q 0 0 0 rg BT 251.31 520.10 Td (fers from prospective buyers. ) Tj ET Q
q 0 0 0 rg BT 370.44 520.10 Td (An impairment loss would be recognized in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (Consolidated Statements of Operations in the period that the impairment occurs.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 490.10 Td (In-Process Research and Development ) Tj ET Q
q 0 0 0 rg BT 224.84 490.10 Td (Assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.40 490.10 Td (. In-process research and development acquired in an asset acquisition is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (expensed in the period it is acquired, assuming the assets have no alternative future use to the Company) Tj ET Q
q 0 0 0 rg BT 450.24 478.10 Td (. Otherwise, acquired in-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (process research and development is generally recognized as an indefinite-lived intangible asset. Such assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.79 466.10 Td (are generally initially ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (recorded at fair value if acquired in a business combination, or at cost if otherwise.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.00 454.10 Td ( Indefinite-lived intangible assets are not subject to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (amortization. Instead, they ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.13 442.10 Td (are tested for impairment annually and when events or changes in circumstances indicate that the asset ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.10 Td (might be impaired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.32 430.10 Td (. Our annual assessment is performed as of October 1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.64 430.10 Td ( If the fair value of the intangible assets is less than its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.10 Td (carrying amount, an impairment loss is recognized for the dif) Tj ET Q
q 0 0 0 rg BT 280.75 418.10 Td (ference. For those assets that reach commercialization, the assets are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.10 Td (reclassified and accounted for as finite-lived intangible assets.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 388.10 Td (Goodwill) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 100.23 388.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.23 388.10 Td (Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 376.10 Td (accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. ) Tj ET Q
q 0 0 0 rg BT 512.19 376.10 Td (Any excess of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 364.10 Td (the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. ) Tj ET Q
q 0 0 0 rg BT 432.34 364.10 Td (While amortization expense is not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.10 Td (recorded on goodwill, goodwill is subject to impairment reviews. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.01 352.10 Td (An impairment assessment is conducted as of October 1, or more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (frequently whenever events or changes in circumstances indicate that the asset might be impaired.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 322.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 322.10 Td (e perform ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.28 322.10 Td (the goodwill impairment test by comparing the fair value and carrying amount of each reporting unit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.66 322.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 520.11 322.10 Td (Any goodwill ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.10 Td (impairment char) Tj ET Q
q 0 0 0 rg BT 101.63 310.10 Td (ge we recognize for a reporting unit is equal to the lesser of \(i\) the total goodwill allocated to that reporting unit and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.10 Td (\(ii\) the amount by which that reporting unit�) Tj ET Q
q 0 0 0 rg BT 212.35 298.10 Td (s carrying amount exceeds its fair value.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.68 298.10 Td ( ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 280.10 Td (Contingencies) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 121.90 280.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.90 280.10 Td (The Company is subject to various patent challenges, product liability claims, government investigations and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.10 Td (other legal proceedings in the ordinary course of business.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.99 268.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.49 268.10 Td (Contingent accruals and legal settlements are recorded in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.23 268.10 Td (Consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.09 256.10 Td ( as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.42 256.10 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.07 256.10 Td ( \(or as Discontinued operations, net of tax in the case of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (vaginal mesh matters\) when the Company determines that a loss is both probable and reasonably estimable. Legal fees and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.36 220.10 Td ( \(or as Discontinued operations, net of tax in the case of vaginal mesh matters\).) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 202.10 Td (Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (amount of any such liabilities involve significant judgment regarding future events.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.53 190.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 371.85 190.10 Td (The Company records receivables from its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.10 Td (insurance carriers only when the realization of the potential claim for recovery is considered probable.) Tj ET Q
endstream
endobj
195 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 196 0 R>>
endobj
196 0 obj
<</Length 14125>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-18) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.25 Td (Contingent Consideration) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 169.98 742.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.98 742.25 Td (Certain of the Company�) Tj ET Q
q 0 0 0 rg BT 274.12 742.25 Td (s acquisitions involve the potential for future payment of consideration that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (is contingent upon the occurrence of a future event, such as \(i\) the achievement of specified regulatory) Tj ET Q
q 0 0 0 rg BT 445.46 730.25 Td (, operational and/or commercial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (milestones or \(ii\) royalty payments, such as those relating to future product sales. Contingent consideration liabilities related to an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.25 Td (asset acquisition are initially recorded when considered probable and reasonably estimable, which may occur subsequent to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (acquisition date. Subsequent changes in the recorded amounts are recorded as adjustments to the cost of the acquired assets. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (Contingent consideration liabilities related to a business combination are initially recorded at fair value on the acquisition date using ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (unobservable inputs. ) Tj ET Q
q 0 0 0 rg BT 121.08 670.25 Td (These inputs include the estimated amount and timing of projected cash flows, the probability of success ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (\(achievement of the contingent event\) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liabilities to their ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (current estimated fair values, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.25 Td (result in fair value adjustments that dif) Tj ET Q
q 0 0 0 rg BT 190.22 622.25 Td (fer significantly from the actual remeasurement adjustments recognized.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 604.25 Td (Share Repurchases) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 142.74 604.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.74 604.25 Td (The Company accounts for the repurchase of ordinary shares, if any) Tj ET Q
q 0 0 0 rg BT 418.93 604.25 Td (, at par value. Under applicable Irish ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (law) Tj ET Q
q 0 0 0 rg BT 49.79 592.25 Td (, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (Company records the dif) Tj ET Q
q 0 0 0 rg BT 134.96 580.25 Td (ference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (an adjustment to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.05 568.25 Td (Accumulated deficit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.40 568.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.89 568.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.98 568.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 550.25 Td (Advertising Costs) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 134.96 550.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.96 550.25 Td (Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 538.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.08 538.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 211.53 538.25 Td (Advertising costs amounted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.96 538.25 Td ($63.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.85 538.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.85 538.25 Td ($49.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.74 538.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.18 538.25 Td ($42.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.07 538.25 Td ( for the years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.38 526.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 526.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.96 526.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.96 526.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.40 526.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.40 526.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 258.06 526.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 508.25 Td (Cost of Revenues) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 134.11 508.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.11 508.25 Td (Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 496.25 Td (their final selling destination. ) Tj ET Q
q 0 0 0 rg BT 155.15 496.25 Td (Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.25 Td (supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 460.25 Td (property) Tj ET Q
q 0 0 0 rg BT 69.23 460.25 Td (, plant and equipment, amortization of intangible assets, lease costs, warehousing costs, freight char) Tj ET Q
q 0 0 0 rg BT 467.83 460.25 Td (ges, costs to operate our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.25 Td (equipment and other shipping and handling costs, among others.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 430.25 Td (Share-Based Compensation) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 177.74 430.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.74 430.25 Td (The Company grants share-based compensation awards to certain employees and non-employee ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (directors. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.99 418.25 Td (Generally) Tj ET Q
q 0 0 0 rg BT 114.76 418.25 Td (, the grant-date fair value of each award is recognized as expense over the requisite service period. However) Tj ET Q
q 0 0 0 rg BT 547.22 418.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (expense recognition dif) Tj ET Q
q 0 0 0 rg BT 129.68 406.25 Td (fers in the case of certain performance share units where the ultimate payout is performance-based. For these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (and the percent of the requisite service period that has elapsed.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.73 382.25 Td ( Share-based compensation expense is reduced for estimated future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.25 Td (forfeitures. ) Tj ET Q
q 0 0 0 rg BT 82.46 370.25 Td (These estimates are revised in future periods if actual forfeitures dif) Tj ET Q
q 0 0 0 rg BT 353.29 370.25 Td (fer from the estimates. Changes in forfeiture estimates ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (exercise of stock options or vesting of stock awards by employees and non-employee directors. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.49 346.25 Td (Note 18. Share-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (Compensation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.77 334.25 Td ( for additional discussion, including the accounting treatment for long-term cash incentive awards that will be settled in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (ordinary shares.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 304.25 Td (Foreign Currency) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 137.73 304.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.73 304.25 Td (The Company operates in various jurisdictions both inside and outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.68 304.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.46 304.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 472.78 304.25 Td (While the Company�) Tj ET Q
q 0 0 0 rg BT 556.10 304.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.25 Td (reporting currency is the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.52 292.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.30 292.25 Td ( dollar) Tj ET Q
q 0 0 0 rg BT 179.73 292.25 Td (, the Company has concluded that certain of its distinct and separable operations have functional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.25 Td (currencies other than the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.06 280.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.85 280.25 Td ( dollar) Tj ET Q
q 0 0 0 rg BT 180.12 280.25 Td (. Further) Tj ET Q
q 0 0 0 rg BT 214.16 280.25 Td (, certain of the Company�) Tj ET Q
q 0 0 0 rg BT 316.07 280.25 Td (s operations hold assets and liabilities and recognize income and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (expenses denominated in various local currencies, which may dif) Tj ET Q
q 0 0 0 rg BT 296.57 268.25 Td (fer from their functional currencies.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 250.25 Td (Assets and liabilities are first remeasured from local currency to functional currency) Tj ET Q
q 0 0 0 rg BT 399.16 250.25 Td (, generally using end-of-period exchange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (rates. Foreign currency income and expenses are generally remeasured using average exchange rates in ef) Tj ET Q
q 0 0 0 rg BT 458.68 238.25 Td (fect during the year) Tj ET Q
q 0 0 0 rg BT 536.14 238.25 Td (. In the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (case of nonmonetary assets and liabilities such as inventories, prepaid expenses, property) Tj ET Q
q 0 0 0 rg BT 392.19 226.25 Td (, plant and equipment, goodwill and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (intangible assets, and related income statement amounts, such as depreciation expense, historical exchange rates are used for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.25 Td (remeasurement. ) Tj ET Q
q 0 0 0 rg BT 101.90 202.25 Td (The net ef) Tj ET Q
q 0 0 0 rg BT 142.25 202.25 Td (fect of remeasurement is included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.53 202.25 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.81 202.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.31 202.25 Td (Consolidated Statements of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 190.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 172.25 Td (As part of the Company�) Tj ET Q
q 0 0 0 rg BT 161.87 172.25 Td (s consolidation process, assets and liabilities of entities with functional currencies other than the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.72 172.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.50 172.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.25 Td (dollar are translated into ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.96 160.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.74 160.25 Td ( dollars at end-of-period exchange rates. Income and expenses are translated using average exchange ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.25 Td (rates in ef) Tj ET Q
q 0 0 0 rg BT 75.24 148.25 Td (fect during the year) Tj ET Q
q 0 0 0 rg BT 152.71 148.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 157.53 148.25 Td (The net ef) Tj ET Q
q 0 0 0 rg BT 197.88 148.25 Td (fect of translation, as well as any foreign currency gains or losses on intercompany ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (transactions considered to be of a long-term investment nature, are recognized as foreign currency translation, a component of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.03 136.25 Td (Other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (comprehensive income \(loss\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.19 124.25 Td (. Upon the sale or liquidation of an investment in a foreign operation, the Company records a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.25 Td (reclassification adjustment out of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.52 112.25 Td (Other comprehensive income \(loss\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.97 112.25 Td ( for the corresponding accumulated amount of foreign currency ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.25 Td (translation gain or loss.) Tj ET Q
endstream
endobj
197 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 198 0 R>>
endobj
198 0 obj
<</Length 16533>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-19) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.25 Td (Income T) Tj ET Q
q 0 0 0 rg BT 101.80 742.25 Td (axes) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 120.13 742.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.13 742.25 Td (The Company accounts for income taxes under the asset and liability method, which requires the recognition of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.25 Td (deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.25 Td (statements. Under this method, deferred tax assets and liabilities are determined based on the dif) Tj ET Q
q 0 0 0 rg BT 421.25 718.25 Td (ferences between the financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.25 Td (statement and tax basis of assets and liabilities using enacted tax rates in ef) Tj ET Q
q 0 0 0 rg BT 335.45 706.25 Td (fect for the year in which the dif) Tj ET Q
q 0 0 0 rg BT 464.38 706.25 Td (ferences are expected to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.25 Td (reverse. ) Tj ET Q
q 0 0 0 rg BT 69.69 694.25 Td (The ef) Tj ET Q
q 0 0 0 rg BT 95.32 694.25 Td (fect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.25 Td (enactment date. ) Tj ET Q
q 0 0 0 rg BT 101.06 682.25 Td (The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.25 Td (In making such a determination, the Company considers all available positive and negative evidence, including projected future ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.25 Td (taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.25 Td (be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.25 Td (to the deferred tax asset valuation allowance, which would reduce the provision for income tax.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 616.25 Td (The Company records uncertain tax positions on the basis of a two-step process whereby the Company first determines whether ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.25 Td (it is more likely than not that the tax positions will be sustained based on the technical merits of the position and then measures those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.25 Td (tax positions that meet the more-likely-than-not recognition threshold. ) Tj ET Q
q 0 0 0 rg BT 319.36 592.25 Td (The Company recognizes the lar) Tj ET Q
q 0 0 0 rg BT 449.13 592.25 Td (gest amount of tax benefit that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.25 Td (is greater than ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.14 580.25 Td (50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.47 580.25 Td ( likely to be realized upon ultimate settlement with the tax authority) Tj ET Q
q 0 0 0 rg BT 384.13 580.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 388.95 580.25 Td (The Company recognizes interest and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.25 Td (penalties related to unrecognized tax benefits within the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.03 568.25 Td (Income tax expense \(benefit\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.36 568.25 Td ( line in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.35 568.25 Td (Consolidated Statements of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 556.25 Td (Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 556.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 84.33 556.25 Td (Accrued interest and penalties are included within the related tax liability line in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.54 556.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.62 556.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 538.25 Td (Comprehensive Income) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 160.50 538.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.50 538.25 Td (Comprehensive income or loss includes all changes in equity during a period except those that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.25 Td (resulted from investments by or distributions to a company�) Tj ET Q
q 0 0 0 rg BT 274.85 526.25 Td (s shareholders. Other comprehensive income or loss refers to revenues, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 514.25 Td (expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.25 Td (directly as an adjustment to shareholders�) Tj ET Q
q 0 0 0 rg BT 201.60 502.25 Td ( equity) Tj ET Q
q 0 0 0 rg BT 228.44 502.25 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 484.25 Td (Recent ) Tj ET Q
q 0 0 0 rg BT 67.38 484.25 Td (Accounting Pr) Tj ET Q
q 0 0 0 rg BT 129.13 484.25 Td (onouncements) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.25 Td (Recently Issued ) Tj ET Q
q 0 0 0 rg BT 102.85 466.25 Td (Accounting Pronouncements Not ) Tj ET Q
q 0 0 0 rg BT 242.96 466.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 247.96 466.25 Td (et ) Tj ET Q
q 0 0 0 rg BT 257.31 466.25 Td (Adopted at ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 303.97 466.25 Td (December�31, 2019) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 448.25 Td (In June 2016, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.38 448.25 Td (Financial ) Tj ET Q
q 0 0 0 rg BT 173.54 448.25 Td (Accounting Standards Board \(F) Tj ET Q
q 0 0 0 rg BT 299.72 448.25 Td (ASB\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.50 448.25 Td ( issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.95 448.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.96 448.25 Td ( No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.68 448.25 Td (2016-13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.01 448.25 Td (, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 430.01 448.25 Td (Measur) Tj ET Q
q 0 0 0 rg BT 460.19 448.25 Td (ement of Cr) Tj ET Q
q 0 0 0 rg BT 507.03 448.25 Td (edit Losses on ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 436.25 Td (Financial Instruments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.60 436.25 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.43 436.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.44 436.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.94 436.25 Td (2016-13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.27 436.25 Td (\). ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.05 436.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.05 436.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.55 436.25 Td (2016-13) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.88 436.25 Td (, together with a series of subsequently-issued related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.66 436.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.66 436.25 Td (s, establishes new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 424.25 Td (requirements for companies to estimate expected credit losses when measuring certain assets, including accounts receivables. ) Tj ET Q
q 0 0 0 rg BT 539.81 424.25 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (guidance is ef) Tj ET Q
q 0 0 0 rg BT 91.35 412.25 Td (fective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. ) Tj ET Q
q 0 0 0 rg BT 514.36 412.25 Td (W) Tj ET Q
q 0 0 0 rg BT 523.40 412.25 Td (ith certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 400.25 Td (exceptions, this guidance requires adoption using a modified retrospective approach. ) Tj ET Q
q 0 0 0 rg BT 376.83 400.25 Td (This guidance is not expected to have a material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 388.25 Td (impact on the Company�) Tj ET Q
q 0 0 0 rg BT 134.59 388.25 Td (s consolidated results of operations, financial position or disclosures.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 370.25 Td (In November 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.25 370.25 Td (F) Tj ET Q
q 0 0 0 rg BT 163.07 370.25 Td (ASB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.53 370.25 Td ( issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.97 370.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.98 370.25 Td ( No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.70 370.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.03 370.25 Td (, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 290.03 370.25 Td (Clarifying the Interaction Between T) Tj ET Q
q 0 0 0 rg BT 436.31 370.25 Td (opic 808 and T) Tj ET Q
q 0 0 0 rg BT 495.67 370.25 Td (opic 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.39 370.25 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.22 370.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.22 370.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 69.33 358.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 77.48 358.25 Td (The main provisions of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.47 358.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.47 358.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.97 358.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.30 358.25 Td ( include: \(i\) clarifying that certain transactions between collaborative arrangement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.25 Td (participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.25 Td (of account and \(ii\) precluding the presentation of transactions with collaborative arrangement participants that are not directly related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.25 Td (to sales to third parties together with revenue. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.67 322.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.68 322.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.18 322.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.51 322.25 Td ( is ef) Tj ET Q
q 0 0 0 rg BT 295.77 322.25 Td (fective for fiscal years beginning after December 15, 2019, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (interim periods within those fiscal years. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.69 310.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.69 310.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.19 310.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.52 310.25 Td ( should be applied retrospectively to the date of initial application of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.00 310.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.95 310.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 298.25 Td (which was January 1, 2018 for the Company) Tj ET Q
q 0 0 0 rg BT 214.20 298.25 Td (. Early adoption is permitted. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.79 298.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.80 298.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 355.30 298.25 Td (2018-18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.63 298.25 Td ( is not expected to have a material impact on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 286.25 Td (the Company�) Tj ET Q
q 0 0 0 rg BT 92.38 286.25 Td (s consolidated results of operations, financial position or disclosures.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (Recent ) Tj ET Q
q 0 0 0 rg BT 66.45 268.25 Td (Accounting Pronouncements ) Tj ET Q
q 0 0 0 rg BT 188.88 268.25 Td (Adopted or Otherwise Ef) Tj ET Q
q 0 0 0 rg BT 290.65 268.25 Td (fective as of ) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 342.01 268.25 Td (December�31, 2019) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 250.25 Td (In February 2016, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.15 250.25 Td (F) Tj ET Q
q 0 0 0 rg BT 156.96 250.25 Td (ASB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.42 250.25 Td ( issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.87 250.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.87 250.25 Td ( No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.59 250.25 Td (2016-02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.92 250.25 Td (, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 283.92 250.25 Td (Leases \(T) Tj ET Q
q 0 0 0 rg BT 321.62 250.25 Td (opic 842\)) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 359.67 250.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.17 250.25 Td (\() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.50 250.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.50 250.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.00 250.25 Td (2016-02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.33 250.25 Td (\) to establish a comprehensive new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.25 Td (accounting standard for leases. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.23 238.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.24 238.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.74 238.25 Td (2016-02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.07 238.25 Td (, together with a series of subsequently-issued related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.85 238.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.85 238.25 Td (s, has been codified in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.94 238.25 Td (ASC ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.25 Td (842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.00 226.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 226.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.40 226.25 Td ( supersedes the lease accounting requirements in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.72 226.25 Td (ASC 840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.68 226.25 Td ( and requires lessees to, among other things, recognize on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.25 Td (balance sheet ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.08 214.25 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.19 214.25 Td ( assets and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.46 214.25 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.57 214.25 Td ( lease liabilities, representing the present value of future minimum lease payments, for most leases.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 196.25 Td (The Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.04 196.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.99 196.25 Td ( using the modified retrospective approach with an ef) Tj ET Q
q 0 0 0 rg BT 406.07 196.25 Td (fective date of January 1, 2019 for leases ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.25 Td (that existed on that date.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 166.25 Td (The Company has elected to apply certain practical expedients permitted under the transition guidance within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.13 166.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.08 166.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.25 Td (leases that commenced before January 1, 2019, including the package of practical expedients, as well as the practical expedient ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.25 Td (permitting the Company to not assess whether certain land easements contain leases. Due to the Company's election of these practical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.25 Td (expedients, the Company has carried forward certain historical conclusions for existing contracts, including conclusions relating to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 118.25 Td (initial direct costs and to the existence and classification of leases.) Tj ET Q
endstream
endobj
199 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 200 0 R>>
endobj
200 0 obj
<</Length 19572>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-20) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (On January 1, 2019, as a result of adopting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.58 742.10 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.53 742.10 Td (, the Company recognized new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.16 742.10 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.27 742.10 Td ( assets, current lease liabilities and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (noncurrent lease liabilities associated with operating leases of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.36 730.10 Td ($59.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.25 730.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.25 730.10 Td ($1) Tj ET Q
q 0 0 0 rg BT 353.88 730.10 Td (1.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.77 730.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.21 730.10 Td ($57.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.10 730.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 523.76 730.10 Td (, which were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (recorded in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.47 718.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.55 718.10 Td ( as Operating lease assets, Current portion of operating lease liabilities and Operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (lease liabilities, less current portion, respectively) Tj ET Q
q 0 0 0 rg BT 230.57 706.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 235.38 706.10 Td (The Company also derecognized certain assets and liabilities related to existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (build-to-suit lease arrangements for which construction was completed prior to the date of transition and recognized new finance lease ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.11 682.10 Td ( assets and lease liabilities related to those lease arrangements. ) Tj ET Q
q 0 0 0 rg BT 309.34 682.10 Td (The net ef) Tj ET Q
q 0 0 0 rg BT 349.69 682.10 Td (fect of the Company�) Tj ET Q
q 0 0 0 rg BT 434.39 682.10 Td (s adoption of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.55 682.10 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.51 682.10 Td ( resulted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (a net increase to ) Tj ET Q
q 0 0 0 rg BT 102.64 670.10 Td (Accumulated deficit of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.32 670.10 Td ($4.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.21 670.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 652.10 Td (In ) Tj ET Q
q 0 0 0 rg BT 73.28 652.10 Td (August 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.39 652.10 Td (F) Tj ET Q
q 0 0 0 rg BT 149.21 652.10 Td (ASB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.66 652.10 Td ( issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.11 652.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.11 652.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.61 652.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.94 652.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.39 652.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.40 652.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.90 652.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.23 652.10 Td ( aligns the requirements for capitalizing implementation costs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 640.10 Td (incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 628.10 Td (develop or obtain internal-use software \(including hosting arrangements where a software license is deemed to exist\). ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.79 628.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.80 628.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.30 628.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.63 628.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 616.10 Td (also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 604.10 Td (the existing impairment guidance for long-lived assets to such capitalized costs. ) Tj ET Q
q 0 0 0 rg BT 357.03 604.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 406.93 604.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.38 604.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.39 604.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.89 604.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.22 604.10 Td ( sets forth required ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (within the scope of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.32 580.10 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.33 580.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.83 580.10 Td (2018-15) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.16 580.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 174.97 580.10 Td (The Company early adopted this guidance during the first quarter of 2019 on a prospective basis.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (NOTE 3. DISCONTINUED OPERA) Tj ET Q
q 0 0 0 rg BT 191.39 550.10 Td (TIONS ) Tj ET Q
q 0 0 0 rg BT 224.46 550.10 Td (AND DIVESTITURES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 514.10 Td (The operating results of the Company�) Tj ET Q
q 0 0 0 rg BT 217.13 514.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.97 514.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.63 514.10 Td ( business, which the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.68 514.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.12 514.10 Td ( resolved to wind-down in 2016, are reported as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (Discontinued operations, net of tax in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.74 502.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.10 502.10 Td ( for all periods presented.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 484.10 Td (The following table provides the operating results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.17 484.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.83 484.10 Td ( Discontinued operations, net of tax, for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.45 484.10 Td (years ended December ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 472.10 Td (31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.44 472.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 448.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 448.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 448.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 448.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 448.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 448.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 418.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 418.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 418.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 418.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 418.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 418.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 448.6 m
437.5 448.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 448.6 m
506.5 448.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 448.6 m
575.5 448.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 452.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 452.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 452.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 438.27 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 438.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 438.27 Td (30,400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 438.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 438.27 Td (34,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 438.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 438.27 Td (775,474) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 423.27 Td (Loss from discontinued operations before income taxes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 423.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 423.32 Td (\(62,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 423.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 423.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 423.32 Td (\(69,702) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 423.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 423.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 423.27 Td (\(816,426) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 423.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 408.27 Td (Income tax benefit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 408.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 408.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 408.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 408.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 408.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 408.27 Td (\(13,704) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 408.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 393.27 Td (Discontinued operations, net of tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 393.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 393.32 Td (\(62,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 393.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 393.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 393.32 Td (\(69,702) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 393.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 393.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 393.27 Td (\(802,722) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 393.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 371.10 Td (Loss from discontinued operations before income taxes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.61 371.10 Td ( includes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.93 371.10 Td (Litigation-related and other contingencies, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.58 371.10 Td (, mesh-related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (legal defense costs and certain other items) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.82 359.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 341.10 Td (The cash flows from discontinued operating activities related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.87 341.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.53 341.10 Td ( included the impact of net losses of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 493.16 341.10 Td ($62.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.05 341.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.05 341.10 Td ($69.7 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 329.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 329.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.33 329.10 Td ($802.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.22 329.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.60 329.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.60 329.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 420.26 329.10 Td (, and the impact of cash activity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 317.10 Td (related to vaginal mesh cases. ) Tj ET Q
q 0 0 0 rg BT 157.44 317.10 Td (There were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.18 317.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.18 317.10 Td ( material net cash flows related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.08 317.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.74 317.10 Td ( discontinued investing activities during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.00 305.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 233.82 305.10 Td (There was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.68 305.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.68 305.10 Td ( depreciation or amortization during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.30 305.10 Td (years ended December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.10 Td (2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.44 293.10 Td ( related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.37 293.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.03 293.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.10 Td (Litha) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 257.10 Td (During the fourth quarter of 2016, the Company initiated a process to sell ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.60 257.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.70 257.10 Td ( and, on February 27, 2017, the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.10 Td (entered into a definitive agreement to sell ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.54 245.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.65 245.10 Td ( to ) Tj ET Q
q 0 0 0 rg BT 237.88 245.10 Td (Acino Pharma ) Tj ET Q
q 0 0 0 rg BT 297.31 245.10 Td (AG. ) Tj ET Q
q 0 0 0 rg BT 316.57 245.10 Td (The sale closed on July 3, 2017 and the Company received net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.10 Td (cash proceeds of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.39 233.10 Td ($94.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.29 233.10 Td (, after giving ef) Tj ET Q
q 0 0 0 rg BT 280.75 233.10 Td (fect to cash and net working capital purchase price adjustments, as well ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.10 Td (as a short-term receivable of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.33 221.10 Td ($4.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.22 221.10 Td (, which was subsequently collected in October 2017. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.51 221.10 Td (No) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.73 221.10 Td ( additional gain or loss was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (recognized upon sale. However) Tj ET Q
q 0 0 0 rg BT 161.66 209.10 Td (, in December 2017, ) Tj ET Q
q 0 0 0 rg BT 244.97 209.10 Td (Acino Pharma ) Tj ET Q
q 0 0 0 rg BT 304.40 209.10 Td (AG became obligated to pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.31 209.10 Td ($10.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.20 209.10 Td ( of additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.10 Td (the sale of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.59 173.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.70 173.10 Td ( for this amount. ) Tj ET Q
q 0 0 0 rg BT 169.12 173.10 Td (The gain was recorded in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.69 173.10 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.98 173.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.47 173.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.83 173.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 161.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.10 161.10 Td ( was part of the Company�) Tj ET Q
q 0 0 0 rg BT 162.91 161.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.31 161.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.42 161.10 Td ( segment. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.25 161.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.35 161.10 Td ( did not meet the requirements for treatment as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 149.10 Td (discontinued operation.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.10 Td (Somar) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 113.10 Td (On June 30, 2017, the Company entered into a definitive agreement to sell ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.20 113.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.31 113.10 Td ( and all of the securities thereof, to ) Tj ET Q
q 0 0 0 rg BT 530.09 113.10 Td (AI Global ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.10 Td (Investments \(Netherlands\) PCC Limited acting for and on behalf of the Soar Cell \(the purchaser\). ) Tj ET Q
q 0 0 0 rg BT 428.49 101.10 Td (The sale closed on October 25, 2017 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 89.10 Td (and the Soar Cell paid an aggregate purchase price of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.28 89.10 Td ($124 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.67 89.10 Td ( in cash, after giving ef) Tj ET Q
q 0 0 0 rg BT 455.68 89.10 Td (fect to estimated cash, debt ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 77.10 Td (and net working capital purchase price adjustments. ) Tj ET Q
q 0 0 0 rg BT 245.75 77.10 Td (The Company recognized a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.49 77.10 Td ($1.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.38 77.10 Td ( loss upon sale. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.99 77.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.09 77.10 Td ( was part of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 65.10 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 65.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.06 65.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.17 65.10 Td ( segment. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.00 65.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.11 65.10 Td ( did not meet the requirements for treatment as a discontinued operation.) Tj ET Q
endstream
endobj
201 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 202 0 R>>
endobj
202 0 obj
<</Length 17265>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-21) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 4. RESTRUCTURING) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Set forth below are disclosures relating to restructuring initiatives that resulted in material expenses or cash expenditures during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (any of the years ended) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.96 719.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.46 719.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.04 719.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.04 719.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.04 719.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.38 719.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.38 719.25 Td ( or had material restructuring liabilities at either ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.19 719.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.78 719.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 707.25 Td (. Employee separation benefits provided under an established severance plan are expensed when a liability is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (considered both probable and estimable. One-time employee separation benefits, retention and certain other employee benefit-related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.25 Td (costs are expensed ratably over the requisite service period. Other restructuring costs are generally expensed as incurred.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.25 Td (2016 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 647.25 Td (As part of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.21 647.25 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.88 647.25 Td ( integration ef) Tj ET Q
q 0 0 0 rg BT 275.79 647.25 Td (forts initiated in connection with the acquisition of Par Pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.25 Td (Companies, Inc. in September 2015, the Company announced a restructuring initiative in May 2016 to optimize its product portfolio ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.25 Td (and rationalize its manufacturing sites to expand product mar) Tj ET Q
q 0 0 0 rg BT 280.74 623.25 Td (gins \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 317.96 623.25 Td (2016 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.66 623.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 543.81 623.25 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.25 Td (initiative included certain cost savings measures, including a reduction in headcount and the disposal of our Charlotte, North Carolina ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 599.25 Td (manufacturing facility) Tj ET Q
q 0 0 0 rg BT 124.48 599.25 Td (. On October 31, 2016, we entered into a definitive agreement to sell the Charlotte facility for cash proceeds of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.25 Td ($14 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.39 587.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 87.21 587.25 Td (The transaction closed in January 2017.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.25 Td (The Company did ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.71 569.25 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.71 569.25 Td (t incur any material pre-tax char) Tj ET Q
q 0 0 0 rg BT 276.08 569.25 Td (ges as a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.94 569.25 Td (2016 Generic Pharmaceuticals Restructuring ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.10 557.25 Td ( during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.21 557.25 Td (any of the years ended) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.17 557.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.67 557.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.25 557.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.25 557.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.25 557.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.58 557.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.58 557.25 Td ( and does not expect to incur additional material pre-tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.25 Td (restructuring-related expenses related to this initiative. Substantially all related cash payments were made by the end of 2017. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.25 Td (Payments made in 2017 included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.25 533.25 Td ($10.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.15 533.25 Td ( for previously-accrued employee separation and other benefit-related costs.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 515.25 Td (2016 Branded Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 497.25 Td (In December 2016, the Company announced that it was terminating its worldwide license and development agreement with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.25 Td (BioDelivery Sciences International, Inc. \(BDSI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.72 485.25 Td ( for BELBUCA� and returning the product to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.49 485.25 Td (BDSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.27 485.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 446.09 485.25 Td (This termination was completed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.25 Td (on January 6, 2017. ) Tj ET Q
q 0 0 0 rg BT 116.55 473.25 Td (As a result of this announcement and a comprehensive assessment of its product portfolio, the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.25 Td (restructured its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 98.20 461.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.11 461.25 Td ( segment sales or) Tj ET Q
q 0 0 0 rg BT 268.52 461.25 Td (ganization during the fourth quarter of 2016 \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.13 461.25 Td (2016 Branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.25 Td (Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.06 449.25 Td (\), which included the elimination of an approximate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.27 449.25 Td (375) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.27 449.25 Td (-member ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.87 449.25 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 562.77 449.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.25 Td (pain field sales force and the termination of certain contracts.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 419.25 Td (The Company did ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.71 419.25 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.71 419.25 Td (t incur any material pre-tax char) Tj ET Q
q 0 0 0 rg BT 276.08 419.25 Td (ges as a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.94 419.25 Td (2016 Branded Pharmaceuticals Restructuring ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.25 Td (Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.10 407.25 Td ( during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.21 407.25 Td (any of the years ended) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.17 407.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.67 407.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.25 407.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.25 407.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.25 407.25 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.58 407.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.58 407.25 Td ( and does not expect to incur additional material pre-tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.25 Td (restructuring-related expenses related to this initiative. Substantially all related cash payments were made by the end of 2017. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.25 Td (Payments made in 2017 included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.25 383.25 Td ($16.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.15 383.25 Td ( for previously-accrued employee separation and other benefit-related costs and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 546.12 383.25 Td ($5.2 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.25 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 371.25 Td ( for previously-accrued contract termination char) Tj ET Q
q 0 0 0 rg BT 261.01 371.25 Td (ges.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 353.25 Td (January 2017 Restructuring Initiative) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 335.25 Td (On January 26, 2017, the Company announced a restructuring initiative implemented as part of an or) Tj ET Q
q 0 0 0 rg BT 466.32 335.25 Td (ganizational review \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.25 Td (January 2017 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.13 323.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 193.28 323.25 Td (This restructuring was intended to further integrate, streamline and optimize the Company�) Tj ET Q
q 0 0 0 rg BT 557.06 323.25 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.25 Td (operations by aligning certain corporate and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.82 311.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.49 311.25 Td ( functions with its recently restructured ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.89 311.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.68 311.25 Td ( generics and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.93 311.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.71 311.25 Td ( branded business ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 299.25 Td (units in order to create ef) Tj ET Q
q 0 0 0 rg BT 136.05 299.25 Td (ficiencies and cost savings. ) Tj ET Q
q 0 0 0 rg BT 246.86 299.25 Td (As part of this restructuring, the Company undertook certain cost reduction ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.25 Td (initiatives, including a reduction of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.00 287.25 Td (90) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.00 287.25 Td ( positions of its workforce, primarily related to corporate and branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.58 287.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.25 287.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.25 Td (functions in Malvern, Pennsylvania and Chestnut Ridge, New ) Tj ET Q
q 0 0 0 rg BT 285.59 275.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 291.81 275.25 Td (ork, a streamlining of general and administrative expenses, an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.25 Td (optimization of commercial spend and a refocusing of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.82 263.25 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.49 263.25 Td ( ef) Tj ET Q
q 0 0 0 rg BT 286.58 263.25 Td (forts.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 245.25 Td (During the year ended December 31, 2017, the Company incurred total pre-tax char) Tj ET Q
q 0 0 0 rg BT 398.25 245.25 Td (ges of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.17 245.25 Td ($15.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.06 245.25 Td ( related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.25 Td (to employee separation and other benefit-related costs. Of the total char) Tj ET Q
q 0 0 0 rg BT 322.09 233.25 Td (ges incurred, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.24 233.25 Td ($6.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.13 233.25 Td ( was included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.61 233.25 Td (Branded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.25 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 221.25 Td ( segment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.35 221.25 Td ($4.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.24 221.25 Td ( was included in Corporate unallocated costs and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.52 221.25 Td ($3.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.41 221.25 Td ( was included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.89 221.25 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.25 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 209.25 Td ( segment. ) Tj ET Q
q 0 0 0 rg BT 142.17 209.25 Td (These char) Tj ET Q
q 0 0 0 rg BT 185.58 209.25 Td (ges were included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.55 209.25 Td (Selling, general and administrative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.95 209.25 Td ( expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.04 209.25 Td (Consolidated Statements ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.25 Td (of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.71 197.25 Td (. Of these amounts, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.69 197.25 Td ($12.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.58 197.25 Td ( was paid in 2017 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.57 197.25 Td ($2.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.46 197.25 Td ( was paid in 2018.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 179.25 Td (The Company did not incur any other material pre-tax char) Tj ET Q
q 0 0 0 rg BT 299.12 179.25 Td (ges as a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.99 179.25 Td (January 2017 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.12 179.25 Td ( and does ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 167.25 Td (not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 149.25 Td (2017 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 131.25 Td (On July 21, 2017, the Company announced that, after completing a comprehensive review of its manufacturing network, it ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 119.25 Td (would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, ) Tj ET Q
q 0 0 0 rg BT 432.04 119.25 Td (Alabama \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.68 119.25 Td (2017 Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 107.25 Td (Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.06 107.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 205.21 107.25 Td (The closure of the facilities was completed in June 2018 and the facilities were sold in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 95.25 Td (fourth quarter of 2018 for net cash proceeds of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.10 95.25 Td ($23.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.99 95.25 Td (, resulting in a net gain on disposal of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.74 95.25 Td ($12.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.63 95.25 Td (, which is included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 83.25 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.29 83.25 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.78 83.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.14 83.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 65.25 Td (As a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.82 65.25 Td (2017 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.52 65.25 Td (, the Company incurred pre-tax char) Tj ET Q
q 0 0 0 rg BT 496.28 65.25 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.94 65.25 Td ($61.6 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 53.25 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 53.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.33 53.25 Td ($286.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.22 53.25 Td ( during the years ended December 31, 2018 and 2017, respectively) Tj ET Q
q 0 0 0 rg BT 409.71 53.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 414.53 53.25 Td (The 2018 amount does not include the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 41.25 Td ($12.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 41.25 Td ( gain on sale of the Huntsville facilities described above.) Tj ET Q
endstream
endobj
203 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 204 0 R>>
endobj
204 0 obj
<</Length 18500>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-22) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (During the year ended December 31, 2018, the expenses consisted of char) Tj ET Q
q 0 0 0 rg BT 359.10 749.10 Td (ges relating to accelerated depreciation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.46 749.10 Td ($35.2 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 737.10 Td (, employee separation, retention and other benefit-related costs of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.51 737.10 Td ($9.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.40 737.10 Td (, asset impairment char) Tj ET Q
q 0 0 0 rg BT 470.97 737.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.63 737.10 Td ($2.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 546.52 737.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (certain other char) Tj ET Q
q 0 0 0 rg BT 105.78 725.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.44 725.10 Td ($14.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.33 725.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 707.10 Td (During the year ended December 31, 2017, the expenses included accelerated depreciation char) Tj ET Q
q 0 0 0 rg BT 444.87 707.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.53 707.10 Td ($123.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.42 707.10 Td (, employee ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.10 Td (separation, retention and other benefit-related costs of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.25 695.10 Td ($29.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.14 695.10 Td (, certain intangible asset and property) Tj ET Q
q 0 0 0 rg BT 457.44 695.10 Td (, plant and equipment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.10 Td (impairment char) Tj ET Q
q 0 0 0 rg BT 101.63 683.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.29 683.10 Td ($104.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.18 683.10 Td (, char) Tj ET Q
q 0 0 0 rg BT 209.20 683.10 Td (ges to increase excess inventory reserves of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.08 683.10 Td ($12.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.97 683.10 Td ( and certain other char) Tj ET Q
q 0 0 0 rg BT 529.18 683.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td ($17.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 671.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 653.10 Td (These char) Tj ET Q
q 0 0 0 rg BT 106.40 653.10 Td (ges are included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.87 653.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.54 653.10 Td ( segment. ) Tj ET Q
q 0 0 0 rg BT 338.82 653.10 Td (Accelerated depreciation, employee separation, retention ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (and other benefit-related costs and char) Tj ET Q
q 0 0 0 rg BT 193.25 641.10 Td (ges to increase excess inventory reserves are primarily included in Cost of revenues in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.36 629.10 Td (. Impairment char) Tj ET Q
q 0 0 0 rg BT 263.54 629.10 Td (ges are included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.74 629.10 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 431.08 629.10 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.41 629.10 Td (. Certain other char) Tj ET Q
q 0 0 0 rg BT 521.42 629.10 Td (ges are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (included in both Cost of revenues and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.14 617.10 Td (Selling, general and administrative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.54 617.10 Td ( expenses.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 599.10 Td (The Company did not incur any other material pre-tax char) Tj ET Q
q 0 0 0 rg BT 299.12 599.10 Td (ges as a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.99 599.10 Td (2017 Generic Pharmaceuticals Restructuring ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.10 587.10 Td ( and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (The liability related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.35 569.10 Td (2017 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.06 569.10 Td ( is primarily included in ) Tj ET Q
q 0 0 0 rg BT 485.10 569.10 Td (Accounts payable and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (accrued expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.18 557.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.26 557.10 Td (. Changes to this liability during the years ended December 31, 2019 and 2018 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.10 Td (were as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 497.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 497.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 497.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 497.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 497.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 497.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 467.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 467.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 467.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 467.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 467.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 467.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 437.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 437.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 437.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 437.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 437.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 437.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 497.6 m
437.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 497.6 m
506.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 497.6 m
575.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 497.6 m
437.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 497.6 m
506.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 497.6 m
575.5 497.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 452.6 m
437.5 452.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 437.6 m
437.5 437.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 452.6 m
506.5 452.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 437.6 m
506.5 437.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 452.6 m
575.5 452.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 437.6 m
575.5 437.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 422.6 m
437.5 422.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 408.6 m
437.5 408.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 406.6 m
437.5 406.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 422.6 m
506.5 422.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 408.6 m
506.5 408.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 406.6 m
506.5 406.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 422.6 m
575.5 422.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 408.6 m
575.5 408.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 406.6 m
575.5 406.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 387.60 525.83 Td (Employee) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 378.35 517.83 Td (Separation and) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 379.80 509.83 Td (Other) Tj ET Q
q 0 0 0 rg BT 400.17 509.83 Td ( Benefit-) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 381.05 501.83 Td (Related Costs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 463.35 517.83 Td (Other) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.50 509.83 Td (Restructuring) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 464.15 501.83 Td (Costs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.75 501.83 Td (T) Tj ET Q
q 0 0 0 rg BT 538.35 501.83 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 487.27 Td (Liability balance as of January 1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 487.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 487.27 Td (22,975) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 487.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 487.27 Td (1,610) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 487.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 487.27 Td (24,585) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 472.27 Td (Expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 472.27 Td (9,090) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 472.27 Td (1) Tj ET Q
q 0 0 0 rg BT 480.15 472.27 Td (1,294) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 472.27 Td (20,384) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 457.27 Td (Cash distributions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 457.32 Td (\(27,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 457.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 457.32 Td (\(12,856) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 457.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 457.27 Td (\(40,682) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 457.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 442.27 Td (Liability balance as of December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 442.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 442.27 Td (4,239) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 442.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 442.27 Td (48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 442.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 442.27 Td (4,287) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 427.27 Td (Cash distributions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 427.32 Td (\(4,239) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 427.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.30 427.32 Td (\(48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 427.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 427.27 Td (\(4,287) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 427.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 412.27 Td (Liability balance as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 412.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 412.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 412.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 412.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 412.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 412.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 390.10 Td (January 2018 Restructuring Initiative) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 192.42 390.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 372.10 Td (In January 2018, the Company initiated a restructuring initiative that included a reor) Tj ET Q
q 0 0 0 rg BT 399.67 372.10 Td (ganization of its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.59 372.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.27 372.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 360.10 Td (segment�) Tj ET Q
q 0 0 0 rg BT 72.10 360.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.50 360.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.17 360.10 Td ( network, a further simplification of the Company�) Tj ET Q
q 0 0 0 rg BT 302.34 360.10 Td (s manufacturing networks and a company-wide unification of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 348.10 Td (certain corporate functions \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 163.72 348.10 Td (January 2018 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.85 348.10 Td (\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 330.10 Td (As a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.82 330.10 Td (January 2018 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.95 330.10 Td (, the Company incurred pre-tax char) Tj ET Q
q 0 0 0 rg BT 427.71 330.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.37 330.10 Td ($23.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.26 330.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.70 330.10 Td ($2.6 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 318.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 318.10 Td ( during the years ended December 31, 2018 and 2017, respectively) Tj ET Q
q 0 0 0 rg BT 331.38 318.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 300.10 Td (The expenses in 2018 consisted primarily of employee separation, retention and other benefit-related costs of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.30 300.10 Td ($21.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.19 300.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 288.10 Td (certain other char) Tj ET Q
q 0 0 0 rg BT 105.78 288.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.44 288.10 Td ($1.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.33 288.10 Td (. Of the total char) Tj ET Q
q 0 0 0 rg BT 251.40 288.10 Td (ges incurred, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.54 288.10 Td ($10.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.43 288.10 Td ( are included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.57 288.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.24 288.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 276.10 Td (segment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.33 276.10 Td ($5.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.22 276.10 Td ( are included in Corporate unallocated costs, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.71 276.10 Td ($3.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.60 276.10 Td ( are included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.74 276.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.65 276.10 Td ( segment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.48 276.10 Td ($3.1 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 264.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 264.10 Td ( are included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.03 264.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.14 264.10 Td ( segment and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.41 264.10 Td ($0.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.30 264.10 Td ( are included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.43 264.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.34 264.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 252.10 Td (segment.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 234.10 Td (The expenses in 2017 consisted of certain property) Tj ET Q
q 0 0 0 rg BT 265.90 234.10 Td (, plant and equipment impairment char) Tj ET Q
q 0 0 0 rg BT 420.67 234.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.33 234.10 Td ($2.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.22 234.10 Td ( and certain other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 222.10 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 222.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.69 222.10 Td ($0.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.58 222.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 133.40 222.10 Td (These char) Tj ET Q
q 0 0 0 rg BT 176.80 222.10 Td (ges are primarily included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.98 222.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.65 222.10 Td ( segment.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 204.10 Td (Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 192.10 Td (administrative and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 112.65 192.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.32 192.10 Td ( expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.41 192.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.77 192.10 Td (. Certain other char) Tj ET Q
q 0 0 0 rg BT 433.78 192.10 Td (ges are primarily included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 180.10 Td (Selling, general and administrative expenses. Impairment char) Tj ET Q
q 0 0 0 rg BT 285.18 180.10 Td (ges are included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.38 180.10 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 452.72 180.10 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.05 180.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 162.10 Td (The Company did not incur any other material pre-tax char) Tj ET Q
q 0 0 0 rg BT 299.12 162.10 Td (ges as a result of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.99 162.10 Td (January 2018 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.12 162.10 Td ( and does ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 150.10 Td (not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. ) Tj ET Q
endstream
endobj
205 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 206 0 R>>
endobj
206 0 obj
<</Length 19500>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The liability related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.35 749.10 Td (January 2018 Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.48 749.10 Td ( is primarily included in ) Tj ET Q
q 0 0 0 rg BT 416.53 749.10 Td (Accounts payable and accrued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (expenses in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.59 737.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.68 737.10 Td (. Changes to this liability during the years ended December 31, 2019 and 2018 were as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 677.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 677.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 677.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 677.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 677.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 677.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 647.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 647.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 647.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 647.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 647.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 647.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 617.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 617.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 617.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 617.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 617.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 617.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 677.6 m
437.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 677.6 m
506.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 677.6 m
575.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 677.6 m
437.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 677.6 m
506.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 677.6 m
575.5 677.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 632.6 m
437.5 632.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 617.6 m
437.5 617.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 632.6 m
506.5 632.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 617.6 m
506.5 617.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 632.6 m
575.5 632.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 617.6 m
575.5 617.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 602.6 m
437.5 602.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 588.6 m
437.5 588.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 586.6 m
437.5 586.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 602.6 m
506.5 602.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 588.6 m
506.5 588.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 586.6 m
506.5 586.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 602.6 m
575.5 602.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 588.6 m
575.5 588.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 586.6 m
575.5 586.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 387.60 705.83 Td (Employee) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 378.35 697.83 Td (Separation and) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 379.80 689.83 Td (Other) Tj ET Q
q 0 0 0 rg BT 400.17 689.83 Td ( Benefit-) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 381.05 681.83 Td (Related Costs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 463.35 697.83 Td (Other) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.50 689.83 Td (Restructuring) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 464.15 681.83 Td (Costs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.75 681.83 Td (T) Tj ET Q
q 0 0 0 rg BT 538.35 681.83 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 667.27 Td (Liability balance as of January 1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 667.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 667.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 667.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 667.27 Td (650) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 667.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 667.27 Td (650) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 652.27 Td (Expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 652.27 Td (21,754) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 652.27 Td (1,764) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 652.27 Td (23,518) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 637.27 Td (Cash distributions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 637.32 Td (\(20,925) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 637.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 637.32 Td (\(2,094) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 637.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 637.27 Td (\(23,019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 637.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 622.27 Td (Liability balance as of December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 622.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 622.27 Td (829) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 622.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 622.27 Td (320) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 622.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 622.27 Td (1,149) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 607.27 Td (Cash distributions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.30 607.32 Td (\(829) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 607.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.30 607.32 Td (\(320) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 607.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 607.27 Td (\(1,149) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 607.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 592.27 Td (Liability balance as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 592.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 592.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 592.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 592.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 592.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 592.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 558.10 Td (NOTE 5. SEGMENT) Tj ET Q
q 0 0 0 rg BT 126.67 558.10 Td ( RESUL) Tj ET Q
q 0 0 0 rg BT 161.60 558.10 Td (TS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 540.10 Td (During the first quarter of 2019, the Company changed the names of its reportable segments. ) Tj ET Q
q 0 0 0 rg BT 436.33 540.10 Td (This change, which was intended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 528.10 Td (to simplify the segments�) Tj ET Q
q 0 0 0 rg BT 136.63 528.10 Td ( names, had no impact on the Company�) Tj ET Q
q 0 0 0 rg BT 297.71 528.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.11 528.10 Td (Consolidated Financial Statements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.97 528.10 Td ( or segment results for any of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 516.10 Td (periods presented. Following this change, the Company�) Tj ET Q
q 0 0 0 rg BT 261.52 516.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.91 516.10 Td (four) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.57 516.10 Td ( reportable business segments are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.92 516.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.82 516.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.82 516.10 Td (Sterile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 504.10 Td (Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.31 504.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.31 504.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.98 504.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.42 504.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.54 504.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 327.36 504.10 Td (These segments reflect the level at which the chief operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 492.10 Td (decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 480.10 Td (Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below) Tj ET Q
q 0 0 0 rg BT 519.37 480.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 462.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 462.10 Td (e evaluate segment performance based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.00 462.10 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.14 462.10 Td (, which we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 450.10 Td (define as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.32 450.10 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.26 450.10 Td ( and before ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.74 450.10 Td (certain upfront and milestone payments to partners; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 438.10 Td (acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 426.10 Td (reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 414.10 Td (associated with integrating an acquired company�) Tj ET Q
q 0 0 0 rg BT 233.99 414.10 Td (s operations; asset impairment char) Tj ET Q
q 0 0 0 rg BT 374.88 414.10 Td (ges; amortization of intangible assets; inventory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 402.10 Td (step-up recorded as part of our acquisitions; litigation-related and other contingent matters; certain legal costs; gains or losses from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 390.10 Td (early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 378.10 Td (intercompany financing arrangements; and certain other items) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.24 378.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 360.10 Td (Certain of the corporate expenses incurred by the Company are not directly attributable to any specific segment. ) Tj ET Q
q 0 0 0 rg BT 513.40 360.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 562.74 360.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 348.10 Td (these costs are not allocated to any of the Company�) Tj ET Q
q 0 0 0 rg BT 244.55 348.10 Td (s segments and are included in the results below as �Corporate unallocated costs.� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 336.10 Td (Interest income and expense are also considered corporate items and not allocated to any of the Company�) Tj ET Q
q 0 0 0 rg BT 460.85 336.10 Td (s segments. ) Tj ET Q
q 0 0 0 rg BT 509.28 336.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 568.99 336.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 324.10 Td (total ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.27 324.10 Td (segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.41 324.10 Td ( is equal to the combined results of each of its segments.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 306.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 288.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 288.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.96 288.10 Td ( segment includes a variety of branded prescription products to treat and manage conditions in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 276.10 Td (urology) Tj ET Q
q 0 0 0 rg BT 66.46 276.10 Td (, urologic oncology) Tj ET Q
q 0 0 0 rg BT 143.85 276.10 Td (, endocrinology) Tj ET Q
q 0 0 0 rg BT 205.97 276.10 Td (, pain and orthopedics. ) Tj ET Q
q 0 0 0 rg BT 299.10 276.10 Td (The products in this segment include XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 491.84 280.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.78 276.10 Td (, SUPPRELIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 555.12 280.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 264.10 Td (LA, NASCOBAL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 108.23 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.16 264.10 Td ( Nasal Spray) Tj ET Q
q 0 0 0 rg BT 163.61 264.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 168.06 264.10 Td (A) Tj ET Q
q 0 0 0 rg BT 173.99 264.10 Td (VEED) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 200.65 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.59 264.10 Td (, PERCOCET) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 261.71 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.65 264.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 271.47 264.10 Td (TEST) Tj ET Q
q 0 0 0 rg BT 295.17 264.10 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 320.17 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.11 264.10 Td (, LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 382.88 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.82 264.10 Td (, EDEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 419.48 268.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.42 264.10 Td ( and ) Tj ET Q
q 0 0 0 rg BT 443.68 264.10 Td (VOL) Tj ET Q
q 0 0 0 rg BT 463.31 264.10 Td (T) Tj ET Q
q 0 0 0 rg BT 468.62 264.10 Td (AREN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 495.84 268.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.40 264.10 Td (Gel, among ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 252.10 Td (others.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 234.10 Td (Sterile Injectables) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 216.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 216.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.97 216.10 Td ( segment consists primarily of branded sterile injectable products such as ) Tj ET Q
q 0 0 0 rg BT 447.43 216.10 Td (V) Tj ET Q
q 0 0 0 rg BT 453.36 216.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 507.81 220.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.75 216.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 204.10 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 94.33 208.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.26 204.10 Td ( and ) Tj ET Q
q 0 0 0 rg BT 118.15 204.10 Td (APLISOL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 159.26 208.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.20 204.10 Td (, among others, and certain generic sterile injectable products, including ertapenem for injection, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 192.10 Td (authorized generic of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.46 192.10 Td (Merck) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.55 192.10 Td (�) Tj ET Q
q 0 0 0 rg BT 152.33 192.10 Td (s Invanz) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 185.93 196.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.87 192.10 Td (, ephedrine sulfate injection and treprostinil for injection, among others.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 174.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 156.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 156.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.72 156.10 Td ( segment consists of a dif) Tj ET Q
q 0 0 0 rg BT 281.92 156.10 Td (ferentiated product portfolio including solid oral extended-release, solid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 144.10 Td (oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 132.10 Td (urology) Tj ET Q
q 0 0 0 rg BT 66.46 132.10 Td (, central nervous system disorders, immunosuppression, oncology) Tj ET Q
q 0 0 0 rg BT 329.38 132.10 Td (, women�) Tj ET Q
q 0 0 0 rg BT 366.60 132.10 Td (s health and cardiovascular disease markets, among ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 120.10 Td (others.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 102.10 Td (International Pharmaceuticals) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 84.10 Td (Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 84.10 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.17 84.10 Td ( segment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.49 84.10 Td (includes a variety of specialty pharmaceutical products sold outside the U.S., ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 72.10 Td (primarily in Canada through our operating company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.33 72.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.33 72.10 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.15 72.10 Td (The key products of this segment serve growing therapeutic areas, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 60.10 Td (including attention deficit hyperactivity disorder) Tj ET Q
q 0 0 0 rg BT 229.43 60.10 Td (, pain, women�) Tj ET Q
q 0 0 0 rg BT 288.87 60.10 Td (s health and oncology) Tj ET Q
q 0 0 0 rg BT 375.70 60.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.20 60.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 380.52 60.10 Td (This segment also included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.16 60.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.27 60.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.70 60.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.41 60.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 48.10 Td (which were sold in the second half of 2017.) Tj ET Q
endstream
endobj
207 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 208 0 R>>
endobj
208 0 obj
<</Length 29287>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-24) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 749.10 Td (The following represents selected information for the Company�) Tj ET Q
q 0 0 0 rg BT 318.43 749.10 Td (s reportable segments for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.44 749.10 Td (years ended December 31, 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.44 737.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 713.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 713.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 713.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 683.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 683.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 683.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 653.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 653.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 653.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 653.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 653.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 653.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 623.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 623.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 623.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 623.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 623.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 623.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 593.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 593.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 593.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 593.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 593.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 593.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 563.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 563.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 563.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 563.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 563.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 563.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 713.6 m
437.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 713.6 m
506.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 713.6 m
575.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 638.6 m
437.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 638.6 m
506.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 638.6 m
575.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 638.6 m
437.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 624.6 m
437.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 622.6 m
437.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 638.6 m
506.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 624.6 m
506.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 622.6 m
506.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 638.6 m
575.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 624.6 m
575.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 622.6 m
575.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 622.6 m
437.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 624.6 m
437.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 622.6 m
506.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 624.6 m
506.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 622.6 m
575.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 624.6 m
575.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 548.6 m
437.5 548.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 534.6 m
437.5 534.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 532.6 m
437.5 532.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 548.6 m
506.5 548.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 534.6 m
506.5 534.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 532.6 m
506.5 532.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 548.6 m
575.5 548.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 534.6 m
575.5 534.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 532.6 m
575.5 532.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 717.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 717.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 717.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 703.27 Td (Net revenues from external customers:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 688.27 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 688.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 688.27 Td (855,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 688.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 688.27 Td (862,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 688.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 688.27 Td (957,525) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 673.27 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 673.27 Td (1,063,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 673.27 Td (929,566) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 673.27 Td (750,471) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 658.27 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 658.27 Td (879,882) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 658.27 Td (1,012,215) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 658.27 Td (1,530,530) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 643.27 Td (International Pharmaceuticals \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 643.27 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 643.27 Td (15,949) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 643.27 Td (142,465) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 643.27 Td (230,332) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 628.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 628.27 Td (otal net revenues from external customers) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 628.27 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 628.27 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 628.27 Td (3,468,858) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 613.27 Td (Segment adjusted income from continuing operations before income tax:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 598.27 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 598.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 598.27 Td (362,71) Tj ET Q
q 0 0 0 rg BT 428.65 598.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 598.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 598.27 Td (368,790) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 598.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 598.27 Td (485,515) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 583.27 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 583.27 Td (780,799) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 583.27 Td (695,363) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 583.27 Td (563,103) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 568.27 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 568.27 Td (158,400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 568.27 Td (317,892) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 568.27 Td (501,249) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 553.27 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 553.27 Td (44,758) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 553.27 Td (59,094) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 553.27 Td (58,308) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 538.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 538.27 Td (otal segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 538.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 538.27 Td (1,346,668) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 538.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 538.27 Td (1,441,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 538.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 538.27 Td (1,608,175) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 524.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 514.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 514.90 Td (Revenues generated by our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 156.36 514.90 Td (International Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 251.65 514.90 Td ( segment are primarily attributable to external customers located in Canada and, prior to the sale of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 505.30 Td (Litha) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 84.38 505.30 Td ( in July 2017 and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 141.49 505.30 Td (Somar) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 162.38 505.30 Td ( in October 2017, South ) Tj ET Q
q 0 0 0 rg BT 240.60 505.30 Td (Africa and Latin ) Tj ET Q
q 0 0 0 rg BT 295.02 505.30 Td (America.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 487.30 Td (There were no material revenues from external customers attributed to an individual country outside of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.30 487.30 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.08 487.30 Td ( during any of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 475.30 Td (the periods presented. ) Tj ET Q
q 0 0 0 rg BT 125.79 475.30 Td (There were no material tangible long-lived assets in an individual country other than the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.23 475.30 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.02 475.30 Td ( as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 463.30 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 463.30 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.91 463.30 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.50 463.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 445.30 Td (The table below provides reconciliations of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.70 445.30 Td (T) Tj ET Q
q 0 0 0 rg BT 260.11 445.30 Td (otal consolidated loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.27 445.30 Td (, which is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 433.30 Td (determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.50 433.30 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.90 433.30 Td (, to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.01 433.30 Td (total segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 546.42 433.30 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 421.30 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.00 421.30 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 397.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 397.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 397.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 397.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 397.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 397.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 367.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 367.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 367.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 367.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 367.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 367.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 337.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 337.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 337.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 337.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 337.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 337.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 307.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 307.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 307.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 307.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 307.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 307.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 277.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 277.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 277.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 277.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 277.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 277.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 247.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 247.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 247.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 247.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 247.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 247.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 207.80 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 207.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 207.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 207.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 207.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 207.80 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 397.79999999999995 m
437.5 397.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 397.79999999999995 m
506.5 397.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 397.79999999999995 m
575.5 397.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 192.79999999999995 m
437.5 192.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 178.79999999999995 m
437.5 178.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 176.79999999999995 m
437.5 176.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 192.79999999999995 m
506.5 192.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 178.79999999999995 m
506.5 178.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 176.79999999999995 m
506.5 176.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 192.79999999999995 m
575.5 192.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 178.79999999999995 m
575.5 178.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 176.79999999999995 m
575.5 176.79999999999995 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 402.03 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 402.03 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 402.03 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 387.47 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 387.47 Td (otal consolidated loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 387.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 387.52 Td (\(344,904) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 387.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 387.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 387.52 Td (\(938,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 387.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 387.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 387.47 Td (\(1,483,004) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 387.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 372.47 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 372.47 Td (538,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 372.47 Td (521,656) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 372.47 Td (488,228) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 357.47 Td (Corporate unallocated costs \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 357.47 Td (168,136) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 357.47 Td (200,592) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 357.47 Td (165,298) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 342.47 Td (Amortization of intangible assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 342.47 Td (543,862) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 342.47 Td (622,339) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 342.47 Td (773,766) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 327.47 Td (Inventory step-up) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 327.47 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 327.47 Td (261) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 327.47 Td (390) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 312.47 Td (Upfront and milestone payments to partners) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 312.47 Td (6,623) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 312.47 Td (45,108) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 312.47 Td (9,483) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 297.47 Td (Retention and separation benefits and other cost reduction initiatives \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 297.47 Td (34,598) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 297.47 Td (86,295) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 297.47 Td (212,448) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 282.47 Td (Certain litigation-related and other contingencies, net \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 282.47 Td (1) Tj ET Q
q 0 0 0 rg BT 411.15 282.47 Td (1,21) Tj ET Q
q 0 0 0 rg BT 428.65 282.47 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 282.47 Td (13,809) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 282.47 Td (185,990) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 267.47 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 134.44 267.47 Td (ges \(4\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 267.47 Td (526,082) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 267.47 Td (916,939) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 267.47 Td (1,154,376) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 252.47 Td (Acquisition-related and integration items, net \(5\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 252.52 Td (\(46,098) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 252.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 252.47 Td (21,914) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 252.47 Td (58,086) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 237.47 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 237.52 Td (\(1) Tj ET Q
q 0 0 0 rg BT 406.13 237.52 Td (19,828) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 237.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 237.47 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 237.47 Td (51,734) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 222.47 Td (Foreign currency impact related to the remeasurement of intercompany debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 212.47 Td (instruments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 212.47 Td (4,362) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 212.52 Td (\(5,486) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 212.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 212.47 Td (\(1,403) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 212.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 197.47 Td (Other) Tj ET Q
q 0 0 0 rg BT 66.37 197.47 Td (, net \(6\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 197.47 Td (23,890) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 197.52 Td (\(43,456) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 197.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 197.47 Td (\(7,217) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 197.47 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 182.47 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 182.47 Td (otal segment adjusted income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 182.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 182.47 Td (1,346,668) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 182.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 182.47 Td (1,441,139) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 182.47 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 182.47 Td (1,608,175) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 170.30 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 160.70 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 160.70 Td (Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 151.10 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 151.10 Td (Amounts in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 107.06 151.10 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 123.06 151.10 Td ( include ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 150.61 151.10 Td ($14.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 193.72 151.10 Td ( of costs associated with retention bonuses awarded to certain senior management of the Company) Tj ET Q
q 0 0 0 rg BT 508.22 151.10 Td (. Other amounts in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 141.50 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 83.50 141.50 Td ( related primarily to our restructuring and other cost reduction initiatives. Such amounts included employee separation costs of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 490.72 141.50 Td ($8.9 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 529.84 141.50 Td ( and other ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 131.90 Td (char) Tj ET Q
q 0 0 0 rg BT 81.12 131.90 Td (ges of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 102.45 131.90 Td ($1) Tj ET Q
q 0 0 0 rg BT 110.15 131.90 Td (1.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 145.27 131.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 148.82 131.90 Td (Amounts in 2018 primarily relate to employee separation costs of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 360.77 131.90 Td ($31.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 403.89 131.90 Td (, accelerated depreciation of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 496.05 131.90 Td ($35.2 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 539.16 131.90 Td (, char) Tj ET Q
q 0 0 0 rg BT 556.79 131.90 Td (ges to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 122.30 Td (increase excess inventory reserves of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 188.11 122.30 Td ($2.9 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 227.23 122.30 Td ( and other char) Tj ET Q
q 0 0 0 rg BT 274.84 122.30 Td (ges of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 296.16 122.30 Td ($16.5 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 339.28 122.30 Td (, each of which related primarily to our restructuring initiatives. ) Tj ET Q
q 0 0 0 rg BT 544.55 122.30 Td (Amounts ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 112.70 Td (in 2017 primarily relate to employee separation costs of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 248.11 112.70 Td ($53.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 291.23 112.70 Td (, accelerated depreciation of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 383.39 112.70 Td ($123.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 430.50 112.70 Td (, char) Tj ET Q
q 0 0 0 rg BT 448.13 112.70 Td (ges to increase excess inventory ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 103.10 Td (reserves of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 104.37 103.10 Td ($13.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 147.48 103.10 Td ( and other char) Tj ET Q
q 0 0 0 rg BT 195.09 103.10 Td (ges of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 216.42 103.10 Td ($22.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 259.54 103.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 263.39 103.10 Td (These char) Tj ET Q
q 0 0 0 rg BT 298.11 103.10 Td (ges were related primarily to the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 403.85 103.10 Td (2017 Generic Pharmaceuticals Restructuring ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 93.50 Td (Initiative) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 96.38 93.50 Td (. See ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 113.93 93.50 Td (Note 4. Restructuring) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 183.03 93.50 Td ( for discussion of our material restructuring initiatives.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 83.90 Td (\(3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 83.90 Td (Amounts include adjustments to our accruals for litigation-related settlement char) Tj ET Q
q 0 0 0 rg BT 328.83 83.90 Td (ges and certain settlement proceeds related to suits filed by our subsidiaries. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 74.30 Td (Our material legal proceedings and other contingent matters are described in more detail in) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 358.72 74.30 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 360.72 74.30 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 496.93 74.30 Td (.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 64.70 Td (\(4\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 64.70 Td (Amounts primarily relate to char) Tj ET Q
q 0 0 0 rg BT 172.21 64.70 Td (ges to impair goodwill and intangible assets as further described in) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 385.94 64.70 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 387.94 64.70 Td (Note 10. Goodwill and Other Intangibles) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 519.02 64.70 Td ( as well as ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 55.10 Td (char) Tj ET Q
q 0 0 0 rg BT 81.12 55.10 Td (ges to write down certain property) Tj ET Q
q 0 0 0 rg BT 190.57 55.10 Td (, plant and equipment as further described in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 335.19 55.10 Td (Note 4. Restructuring) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 404.29 55.10 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 408.29 55.10 Td (Note 6. Fair ) Tj ET Q
q 0 0 0 rg BT 448.58 55.10 Td (V) Tj ET Q
q 0 0 0 rg BT 453.47 55.10 Td (alue Measurements) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 515.45 55.10 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 531.00 55.10 Td (Note 9. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 45.50 Td (Property) Tj ET Q
q 0 0 0 rg BT 94.53 45.50 Td (, Plant and Equipment) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 165.63 45.50 Td (.) Tj ET Q
endstream
endobj
209 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 210 0 R>>
endobj
210 0 obj
<</Length 25955>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-25) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 750.50 Td (\(5\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 750.50 Td (Amounts primarily relate to changes in the fair value of contingent consideration.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 740.90 Td (\(6\) ) Tj ET Q
q 0 0 0 rg BT 67.50 740.90 Td (Amounts in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 107.06 740.90 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 123.06 740.90 Td ( include ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 150.61 740.90 Td ($17.5 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 193.72 740.90 Td ( for ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 207.05 740.90 Td (contract termination costs incurred as a result of certain product discontinuation activities in our International ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 731.30 Td (Pharmaceuticals segment) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 148.58 731.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 164.13 731.30 Td ($14.1 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 207.25 731.30 Td ( for a ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 226.13 731.30 Td (premium associated with an extended reporting period endorsement on an expiring insurance program) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 553.13 731.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 556.99 731.30 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 721.70 Td (remaining amounts in 2019 and 2018 primarily relate to gains on sales of businesses and other assets, as further described in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 467.41 721.70 Td (Note 19. Other Expense ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 712.10 Td (\(Income\), Net) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 112.37 712.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 694.10 Td (During the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.55 694.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.54 694.10 Td (, the Company disaggregated its revenue from contracts with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (customers into the categories included in the table below \(in thousands\). ) Tj ET Q
q 0 0 0 rg BT 327.41 682.10 Td (The Company believes these categories depict how the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (nature, timing and uncertainty of revenue and cash flows are af) Tj ET Q
q 0 0 0 rg BT 288.22 670.10 Td (fected by economic factors.) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 646.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 646.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 646.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 616.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 616.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 616.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 586.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 586.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 586.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 556.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 556.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 556.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 526.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 526.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 526.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 526.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 526.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 526.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 496.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 496.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 496.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 496.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 496.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 496.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 466.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 466.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 466.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 466.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 466.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 466.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 436.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 436.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 436.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 436.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 436.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 436.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 406.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 406.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 406.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 406.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 406.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 406.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 376.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 376.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 376.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 376.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 376.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 376.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 346.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 346.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 346.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 346.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 346.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 346.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 646.6 m
437.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 646.6 m
506.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 646.6 m
575.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 571.6 m
437.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 556.6 m
437.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 571.6 m
506.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 556.6 m
506.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 571.6 m
575.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 556.6 m
575.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 496.6 m
437.5 496.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 481.6 m
437.5 481.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 496.6 m
506.5 496.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 481.6 m
506.5 481.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 496.6 m
575.5 496.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 481.6 m
575.5 481.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 466.6 m
437.5 466.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 466.6 m
506.5 466.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 466.6 m
575.5 466.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 376.6 m
437.5 376.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 376.6 m
506.5 376.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 376.6 m
575.5 376.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 361.6 m
437.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 361.6 m
506.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 361.6 m
575.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 361.6 m
437.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 361.6 m
506.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 361.6 m
575.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 346.6 m
437.5 346.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 346.6 m
506.5 346.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 346.6 m
575.5 346.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 331.6 m
437.5 331.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 317.6 m
437.5 317.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 315.6 m
437.5 315.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 331.6 m
506.5 331.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 317.6 m
506.5 317.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 315.6 m
506.5 315.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 331.6 m
575.5 331.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 317.6 m
575.5 317.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 315.6 m
575.5 315.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 650.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 650.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 650.83 Td (2017) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 636.31 Td (Branded Pharmaceuticals:) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 44.00 621.31 Td (Specialty Pr) Tj ET Q
q 0 0 0 rg BT 92.96 621.31 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 606.27 Td (XIAFLEX�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 606.27 Td (327,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 606.27 Td (264,638) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 606.27 Td (213,378) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 591.27 Td (SUPPRELIN� LA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 591.27 Td (86,797) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 591.27 Td (81,707) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 591.27 Td (86,21) Tj ET Q
q 0 0 0 rg BT 566.65 591.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 576.27 Td (Other Specialty \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 576.27 Td (105,241) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 576.27 Td (98,230) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 576.27 Td (84,161) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 561.27 Td (T) Tj ET Q
q 0 0 0 rg BT 49.76 561.27 Td (otal Specialty Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 561.27 Td (519,676) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 561.27 Td (444,575) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 561.27 Td (383,750) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 44.00 546.31 Td (Established Pr) Tj ET Q
q 0 0 0 rg BT 102.79 546.31 Td (oducts:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 531.27 Td (PERCOCET�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 531.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 531.27 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 531.27 Td (16,012) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 531.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 531.27 Td (122,901) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 531.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 531.27 Td (125,231) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 516.27 Td (TEST) Tj ET Q
q 0 0 0 rg BT 73.80 516.27 Td (OPEL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 516.27 Td (55,244) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 516.27 Td (58,377) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 516.27 Td (69,223) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 501.27 Td (Other Established \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 501.27 Td (164,470) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 501.27 Td (236,979) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 501.27 Td (379,321) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 486.27 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 486.27 Td (otal Established Products) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 486.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 486.27 Td (335,726) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 486.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 486.27 Td (418,257) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 486.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 486.27 Td (573,775) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 471.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 471.27 Td (otal Branded Pharmaceuticals \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 471.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 471.27 Td (855,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 471.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 471.27 Td (862,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 471.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 471.27 Td (957,525) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 456.31 Td (Sterile Injectables:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 441.27 Td (V) Tj ET Q
q 0 0 0 rg BT 56.58 441.27 Td (ASOSTRICT�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 441.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 441.27 Td (531,737) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 441.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 441.27 Td (453,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 441.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 441.27 Td (399,909) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 426.27 Td (ADRENALIN�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 426.27 Td (179,295) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 426.27 Td (143,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 426.27 Td (76,523) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 411.27 Td (Ertapenem for injection) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 411.27 Td (104,679) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 411.27 Td (57,668) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 411.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 396.27 Td (APLISOL�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 396.27 Td (61,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 396.27 Td (64,913) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 396.27 Td (66,286) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 381.27 Td (Other Sterile Injectables \(4\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 381.27 Td (185,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 381.27 Td (209,729) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 381.27 Td (207,753) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 366.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 366.27 Td (otal Sterile Injectables \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 366.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 366.27 Td (1,063,131) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 366.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 366.27 Td (929,566) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 366.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 366.27 Td (750,471) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 351.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 351.27 Td (otal Generic Pharmaceuticals \(5\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 351.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 351.27 Td (879,882) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 351.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 351.27 Td (1,012,215) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 351.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 351.27 Td (1,530,530) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 336.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 336.27 Td (otal International Pharmaceuticals \(6\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 336.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 336.27 Td (1) Tj ET Q
q 0 0 0 rg BT 406.15 336.27 Td (15,949) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 336.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 336.27 Td (142,465) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 336.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 336.27 Td (230,332) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 321.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 321.27 Td (otal revenues, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 321.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 321.27 Td (2,914,364) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 321.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 321.27 Td (2,947,078) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 321.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 321.27 Td (3,468,858) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 309.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 299.50 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 299.50 Td (Products included within Other Specialty are NASCOBAL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 256.36 303.13 Td (� ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 261.61 299.50 Td (Nasal Spray and ) Tj ET Q
q 0 0 0 rg BT 315.60 299.50 Td (A) Tj ET Q
q 0 0 0 rg BT 320.34 299.50 Td (VEED) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 341.67 303.13 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 345.62 299.50 Td (. Beginning with our first-quarter 2019 reporting, ) Tj ET Q
q 0 0 0 rg BT 505.22 299.50 Td (TEST) Tj ET Q
q 0 0 0 rg BT 524.19 299.50 Td (OPEL) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 544.19 303.13 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 548.14 299.50 Td (, which ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 289.90 Td (was previously included in Other Specialty) Tj ET Q
q 0 0 0 rg BT 204.95 289.90 Td (, has been reclassified and is now included in the Established Products portfolio for all periods presented.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 280.30 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 280.30 Td (Products included within Other Established include, but are not limited to, LIDODERM) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 349.45 283.92 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 353.40 280.30 Td (, EDEX) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 378.73 283.92 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 382.68 280.30 Td ( and ) Tj ET Q
q 0 0 0 rg BT 398.09 280.30 Td (VOL) Tj ET Q
q 0 0 0 rg BT 413.79 280.30 Td (T) Tj ET Q
q 0 0 0 rg BT 418.04 280.30 Td (AREN) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 5.20 Tf ET
q 0 0 0 rg BT 439.82 283.92 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 443.77 280.30 Td ( Gel.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 270.70 Td (\(3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 270.70 Td (Individual products presented above represent the top two performing products in each product category for the year ended December 31, 2019 and/or any ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 261.10 Td (product having revenues in excess of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 187.91 261.10 Td ($100 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 229.02 261.10 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 231.02 261.10 Td (during any of the years ended December 31, 2019, 2018 or 2017 or) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 446.07 261.10 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 448.07 261.10 Td ($25 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 485.18 261.10 Td ( during any quarterly period ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 251.50 Td (in 2019 or 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 118.39 251.50 Td (.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 241.90 Td (\(4\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 241.90 Td (Products included within Other Sterile Injectables include ephedrine sulfate injection, treprostinil for injection and others.) Tj ET Q
BT /F3 8.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 232.30 Td (\(5\) ) Tj ET Q
q 0 0 0 rg BT 67.50 232.30 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 81.94 232.30 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 161.68 232.30 Td ( segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 222.70 Td (the same wholesalers, generally have no intellectual property protection and are sold within the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 374.29 222.70 Td (U.S.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 388.51 222.70 Td ( During ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 415.18 222.70 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 431.18 222.70 Td (, colchicine tablets, which launched in July ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 213.10 Td (2018, made up ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 116.82 213.10 Td (6%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 127.49 213.10 Td ( of consolidated total revenue. During 2017, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 203.50 Td (marketing exclusivity during the second quarter of 2017, made up ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 280.55 203.50 Td (7%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 291.22 203.50 Td ( of consolidated total revenue. No other individual product within this segment has ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 193.90 Td (exceeded ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 99.25 193.90 Td (5%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 109.92 193.90 Td ( of consolidated total revenues for the periods presented.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 184.30 Td (\(6\) ) Tj ET Q
q 0 0 0 rg BT 67.50 184.30 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 81.94 184.30 Td (International Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 177.23 184.30 Td ( segment, which accounted for ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 277.20 184.30 Td (4%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 287.86 184.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 291.86 184.30 Td (5%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 302.52 184.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 318.07 184.30 Td (7%) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 328.74 184.30 Td ( of consolidated total revenues in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 436.71 184.30 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 452.71 184.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 456.71 184.30 Td (2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 472.71 184.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 488.26 184.30 Td (2017) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 504.26 184.30 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 546.39 184.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 174.70 Td (includes a variety of specialty pharmaceutical products sold outside the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 297.65 174.70 Td (U.S.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 311.88 174.70 Td (, primarily in Canada through our operating company ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 484.94 174.70 Td (Paladin) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 508.94 174.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 512.79 174.70 Td (This segment also ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 165.10 Td (included ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 97.05 165.10 Td (Litha) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 113.93 165.10 Td (, which was sold in July 2017, and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 226.37 165.10 Td (Somar) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 246.93 165.10 Td (, which was sold in October 2017.) Tj ET Q
endstream
endobj
211 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 212 0 R>>
endobj
212 0 obj
<</Length 16540>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 749.10 Td (The following represents depreciation expense for our reportable segments for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.71 749.10 Td (years ended December 31, 2019, 2018 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 737.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 713.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 713.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 713.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 713.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 683.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 683.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 683.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 683.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 653.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 653.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 653.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 653.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 653.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 653.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 713.6 m
437.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 713.6 m
506.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 713.6 m
575.5 713.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 638.6 m
437.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 638.6 m
506.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 638.6 m
575.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 638.6 m
437.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 624.6 m
437.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 622.6 m
437.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 638.6 m
506.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 624.6 m
506.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 622.6 m
506.5 622.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 638.6 m
575.5 638.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 624.6 m
575.5 624.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 622.6 m
575.5 622.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 717.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 717.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 717.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 703.27 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 703.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 703.27 Td (12,573) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 703.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 703.27 Td (14,542) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 703.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 703.27 Td (16,957) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 688.27 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 688.27 Td (14,287) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 688.27 Td (10,500) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 688.27 Td (8,41) Tj ET Q
q 0 0 0 rg BT 566.65 688.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 673.27 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 673.27 Td (32,689) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 673.27 Td (66,016) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 673.27 Td (174,652) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 658.27 Td (International Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 658.27 Td (4,234) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 658.27 Td (4,925) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 658.27 Td (3,332) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 643.27 Td (Corporate unallocated) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 643.27 Td (5,217) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 643.27 Td (5,385) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 643.27 Td (6,647) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 628.27 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 628.27 Td (otal depreciation expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 628.27 Td (69,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 628.27 Td (101,368) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 628.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 628.27 Td (209,999) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 606.10 Td (Asset information is not reviewed or included within our internal management reporting. ) Tj ET Q
q 0 0 0 rg BT 420.78 606.10 Td (Therefore, the Company has not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 594.10 Td (disclosed asset information for each reportable segment.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 564.10 Td (NOTE 6. F) Tj ET Q
q 0 0 0 rg BT 82.21 564.10 Td (AIR ) Tj ET Q
q 0 0 0 rg BT 102.86 564.10 Td (V) Tj ET Q
q 0 0 0 rg BT 108.79 564.10 Td (ALUE MEASUREMENTS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 546.10 Td (Financial Instruments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 528.10 Td (The financial instruments recorded in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.28 528.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.36 528.10 Td ( include cash and cash equivalents \(including money ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 516.10 Td (market funds\), restricted cash and cash equivalents, accounts receivable, equity method investments, accounts payable and accrued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 504.10 Td (expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 492.10 Td (and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities \(for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 480.10 Td (example, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.87 480.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.66 480.10 Td ( government bonds, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.31 480.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.09 480.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 194.41 480.10 Td (T) Tj ET Q
q 0 0 0 rg BT 200.17 480.10 Td (reasury Bills and commercial paper\). Money market funds pay dividends that generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 468.10 Td (reflect short-term interest rates. Due to their short-term maturity) Tj ET Q
q 0 0 0 rg BT 291.65 468.10 Td (, the carrying amounts of non-restricted and restricted cash and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 456.10 Td (equivalents \(including money market funds\), accounts receivable, accounts payable and accrued expenses approximate their fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 444.10 Td (values.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 426.10 Td (The following table presents current and noncurrent restricted cash and cash equivalent balances at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.17 426.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.76 426.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 414.10 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 414.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 382.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 382.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 382.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 382.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 352.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 352.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 352.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 352.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 382.6 m
506.5 382.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 382.6 m
575.5 382.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 352.6 m
506.5 352.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 338.6 m
506.5 338.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 336.6 m
506.5 336.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 352.6 m
575.5 352.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 338.6 m
575.5 338.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 336.6 m
575.5 336.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 394.83 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 394.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 386.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 394.83 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 394.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 386.83 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 373.17 Td (Restricted cash and cash equivalents�current portion \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 372.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 372.27 Td (247,457) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 372.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 372.27 Td (305,368) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 358.17 Td (Restricted cash and cash equivalents�noncurrent portion \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 357.27 Td (18,400) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 357.27 Td (22,356) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 343.17 Td (Restricted cash and cash equivalents�total \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 342.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 342.27 Td (265,857) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 342.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 342.27 Td (327,724) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 330.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 320.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 320.50 Td (These amounts are reported in our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 179.02 320.50 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 271.88 320.50 Td ( as Restricted cash and cash equivalents.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 310.90 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 310.90 Td (These amounts are reported in our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 179.02 310.90 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 271.88 310.90 Td ( as Other assets.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 301.30 Td (\(3\) ) Tj ET Q
q 0 0 0 rg BT 67.50 301.30 Td (Approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 117.93 301.30 Td ($242.8 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 165.05 301.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 180.60 301.30 Td ($299.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 227.71 301.30 Td ( of our restricted cash and cash equivalents are held in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 402.98 301.30 Td (QSFs) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 420.77 301.30 Td ( for mesh-related matters at ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 510.73 301.30 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 573.59 301.30 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 291.70 Td (and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 81.05 291.70 Td (December�31, 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 143.92 291.70 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 186.05 291.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 189.90 291.70 Td (The remaining restricted cash and cash equivalents primarily relates to other litigation-related matters. See ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 532.66 291.70 Td (Note 15. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 282.10 Td (Commitments and Contingencies) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 174.16 282.10 Td ( for further information.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 264.10 Td (Fair value guidance establishes a three-tier fair value hierarchy) Tj ET Q
q 0 0 0 rg BT 311.90 264.10 Td (, which prioritizes the inputs used in measuring fair value. ) Tj ET Q
q 0 0 0 rg BT 546.66 264.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 252.10 Td (tiers include:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 240.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 240.10 Td (Level 1�Quoted prices in active markets for identical assets or liabilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 228.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 228.10 Td (Level 2�Inputs other than Level 1 that are observable, either directly or indirectly) Tj ET Q
q 0 0 0 rg BT 416.12 228.10 Td (, such as quoted prices for similar ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 216.10 Td (assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 204.10 Td (by observable market data for substantially the full term of the assets or liabilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 192.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 192.10 Td (Level 3�Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 180.10 Td (the assets or liabilities.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 162.10 Td (Acquisition-Related Contingent Consideration) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 144.10 Td (The fair value of contingent consideration liabilities is determined using unobservable inputs; hence, these instruments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 132.10 Td (represent Level 3 measurements within the above-defined fair value hierarchy) Tj ET Q
q 0 0 0 rg BT 347.71 132.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 352.53 132.10 Td (These inputs include the estimated amount and timing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 120.10 Td (of projected cash flows, the probability of success \(achievement of the contingent event\) and the risk-adjusted discount rate used to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 108.10 Td (present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 96.10 Td (consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 84.10 Td (used as of the date of this report could have resulted in significant adjustments to fair value. See the �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.43 84.10 Td (Recurring Fair ) Tj ET Q
q 0 0 0 rg BT 502.35 84.10 Td (V) Tj ET Q
q 0 0 0 rg BT 508.46 84.10 Td (alue ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 72.10 Td (Measurements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.32 72.10 Td (� section below for additional information on acquisition-related contingent consideration.) Tj ET Q
endstream
endobj
213 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 214 0 R>>
endobj
214 0 obj
<</Length 20676>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-27) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (Recurring Fair) Tj ET Q
q 0 0 0 rg BT 100.52 749.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 102.84 749.25 Td (V) Tj ET Q
q 0 0 0 rg BT 109.14 749.25 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 162.01 749.25 Td (ements) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 731.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 120.71 731.25 Td (s financial assets and liabilities measured at fair value on a recurring basis at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.93 731.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.52 731.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.96 731.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 546.96 731.25 Td ( were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 682.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 682.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 682.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 682.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 682.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 682.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 682.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 682.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 653.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 653.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 653.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 653.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 653.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 653.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 653.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 653.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 624.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 624.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 624.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 624.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 624.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 624.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 624.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 624.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 695.75 m
368.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 695.75 m
372.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 695.75 m
441.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 695.75 m
506.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 695.75 m
510.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 695.75 m
575.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 695.75 m
368.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 682.75 m
368.5 682.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 682.75 m
437.5 682.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 682.75 m
506.5 682.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 682.75 m
575.5 682.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 348.10 699.98 Td (Fair) Tj ET Q
q 0 0 0 rg BT 362.69 699.98 Td ( ) Tj ET Q
q 0 0 0 rg BT 364.54 699.98 Td (V) Tj ET Q
q 0 0 0 rg BT 369.88 699.98 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 411.88 699.98 Td (ements at December) Tj ET Q
q 0 0 0 rg BT 481.04 699.98 Td ( 31, 2019 using:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 311.05 686.98 Td (Level 1 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 382.05 686.98 Td (Level 2 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 451.05 686.98 Td (Level 3 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 535.75 686.98 Td (T) Tj ET Q
q 0 0 0 rg BT 540.35 686.98 Td (otal) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 673.31 Td (Assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 658.42 Td (Money market funds) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 658.42 Td (427,033) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 658.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 658.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 658.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 658.42 Td (427,033) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 644.31 Td (Liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 629.42 Td (Acquisition-related contingent consideration�current) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 629.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 629.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 629.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 629.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 629.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 629.42 Td (6,534) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 629.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 629.42 Td (6,534) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 614.42 Td (Acquisition-related contingent consideration�noncurrent) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 614.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 614.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 614.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 614.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 614.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 614.42 Td (23,123) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 614.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 614.42 Td (23,123) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 573.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 573.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 573.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 573.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 573.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 573.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 573.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 573.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 544.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 544.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 544.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 544.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 544.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 544.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 544.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 544.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 515.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 515.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 515.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 515.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 515.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 515.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 515.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 515.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 586.75 m
368.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 586.75 m
372.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 586.75 m
437.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 586.75 m
441.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 586.75 m
506.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 586.75 m
510.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 586.75 m
575.5 586.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 573.75 m
368.5 573.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 573.75 m
437.5 573.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 573.75 m
506.5 573.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 573.75 m
575.5 573.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 346.10 590.98 Td (Fair) Tj ET Q
q 0 0 0 rg BT 360.69 590.98 Td ( ) Tj ET Q
q 0 0 0 rg BT 362.54 590.98 Td (V) Tj ET Q
q 0 0 0 rg BT 367.88 590.98 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 409.88 590.98 Td (ements at December) Tj ET Q
q 0 0 0 rg BT 479.04 590.98 Td ( 31, 2018 using:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 311.05 577.98 Td (Level 1 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 380.05 577.98 Td (Level 2 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.05 577.98 Td (Level 3 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.75 577.98 Td (T) Tj ET Q
q 0 0 0 rg BT 538.35 577.98 Td (otal) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 564.31 Td (Assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 549.42 Td (Money market funds) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 549.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 549.42 Td (137,215) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 549.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 549.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 549.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 549.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 549.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 549.42 Td (137,215) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 38.00 535.31 Td (Liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 520.42 Td (Acquisition-related contingent consideration�current) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 520.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 520.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 520.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 520.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 520.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 520.42 Td (36,514) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 520.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 520.42 Td (36,514) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 505.42 Td (Acquisition-related contingent consideration�noncurrent) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 505.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 505.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 505.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 505.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 505.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 505.42 Td (80,189) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 505.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 505.42 Td (80,189) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 483.25 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 483.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 483.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.52 483.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.11 483.25 Td (, money market funds include ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.74 483.25 Td ($70.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.63 483.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.07 483.25 Td ($86.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.96 483.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 553.63 483.25 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 471.25 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.24 471.25 Td ( to be disbursed to mesh-related or other product liability claimants. ) Tj ET Q
q 0 0 0 rg BT 331.50 471.25 Td (Amounts in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.95 471.25 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.19 471.25 Td ( are considered restricted cash equivalents. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 459.25 Td (See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 459.25 Td (Note 15. Commitments and Contingencies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.20 459.25 Td ( for further discussion of our product liability cases. ) Tj ET Q
q 0 0 0 rg BT 432.60 459.25 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.10 459.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.68 459.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 447.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 447.25 Td (, the dif) Tj ET Q
q 0 0 0 rg BT 145.23 447.25 Td (ferences between the amortized cost and the fair value of our money market funds were not material, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 435.25 Td (individually or in the aggregate.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 417.25 Td (Fair V) Tj ET Q
q 0 0 0 rg BT 62.40 417.25 Td (alue Measurements Using Significant Unobservable Inputs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 399.25 Td (The following table presents changes to the Company�) Tj ET Q
q 0 0 0 rg BT 279.00 399.25 Td (s liability for acquisition-related contingent consideration, which is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 387.25 Td (measured at fair value on a recurring basis using significant unobservable inputs \(Level 3\), for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.59 387.25 Td (years ended December 31, 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 375.25 Td (and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.94 375.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 350.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 350.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 350.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 350.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 320.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 320.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 320.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 320.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 290.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 290.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 290.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 290.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 350.75 m
506.5 350.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 350.75 m
575.5 350.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 350.75 m
506.5 350.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 350.75 m
575.5 350.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 290.75 m
506.5 290.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 290.75 m
575.5 290.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 290.75 m
506.5 290.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 276.75 m
506.5 276.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 274.75 m
506.5 274.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 290.75 m
575.5 290.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 276.75 m
575.5 276.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 274.75 m
575.5 274.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 354.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 354.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 340.42 Td (Beginning of period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 340.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 340.42 Td (1) Tj ET Q
q 0 0 0 rg BT 475.15 340.42 Td (16,703) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 340.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 340.42 Td (190,442) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 325.42 Td (Amounts settled) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 325.47 Td (\(41,448) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 325.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 325.42 Td (\(92,627) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 325.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 310.42 Td (Changes in fair value recorded in earnings) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 310.47 Td (\(46,098) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 310.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 310.42 Td (19,910) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 295.42 Td (Ef) Tj ET Q
q 0 0 0 rg BT 47.35 295.42 Td (fect of currency translation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 295.42 Td (500) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 295.42 Td (\(1,022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 295.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 280.42 Td (End of period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 280.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 280.42 Td (29,657) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 280.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 280.42 Td (1) Tj ET Q
q 0 0 0 rg BT 544.15 280.42 Td (16,703) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 258.25 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 258.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 258.25 Td (, the fair value measurements of the contingent consideration obligations were determined using risk-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 246.25 Td (adjusted discount rates ranging from approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.83 246.25 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.66 246.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.44 246.25 Td (15.0%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.27 246.25 Td ( \(weighted average rate of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.42 246.25 Td (10.9%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.25 246.25 Td (\). ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.58 246.25 Td (Changes in fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 234.25 Td (value recorded in earnings) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.79 234.25 Td ( related to acquisition-related contingent consideration are included in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.01 234.25 Td (Consolidated Statements of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 222.25 Td (Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 222.25 Td ( as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.66 222.25 Td (Acquisition-related and integration items, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.99 222.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 278.44 222.25 Td (Amounts recorded for the current and noncurrent portions of acquisition-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 210.25 Td (related contingent consideration are included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.15 210.25 Td (Accounts payable and accrued expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.64 210.25 Td ( and Other liabilities, respectively) Tj ET Q
q 0 0 0 rg BT 523.22 210.25 Td (, in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 198.25 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.08 198.25 Td (.) Tj ET Q
endstream
endobj
215 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 216 0 R>>
endobj
216 0 obj
<</Length 29511>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-28) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The following table presents changes to the Company�) Tj ET Q
q 0 0 0 rg BT 281.00 749.10 Td (s liability for acquisition-related contingent consideration during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.77 749.10 Td (the year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 737.10 Td ( by acquisition \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 697.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 697.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 697.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 697.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 697.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 697.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 697.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 697.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 667.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 667.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 667.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 667.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 667.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 667.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 667.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 667.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 637.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 637.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 637.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 637.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 637.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 637.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 637.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 637.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 697.6 m
368.5 697.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 697.6 m
437.5 697.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 697.6 m
506.5 697.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 697.6 m
575.5 697.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 637.6 m
368.5 637.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 623.6 m
368.5 623.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 621.6 m
368.5 621.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 637.6 m
437.5 637.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 623.6 m
437.5 623.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 621.6 m
437.5 621.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 637.6 m
506.5 637.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 623.6 m
506.5 623.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 621.6 m
506.5 621.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 637.6 m
575.5 637.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 623.6 m
575.5 623.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 621.6 m
575.5 621.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 313.05 717.83 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 312.25 709.83 Td (December) Tj ET Q
q 0 0 0 rg BT 346.82 709.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 327.50 701.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 377.20 717.83 Td (Changes in Fair) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 377.40 709.83 Td (V) Tj ET Q
q 0 0 0 rg BT 382.81 709.83 Td (alue Recorded) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 384.60 701.83 Td (in Earnings) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 445.15 709.83 Td (Amounts Settled) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 455.90 701.83 Td (and Other) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 520.05 717.83 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 709.83 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 709.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 701.83 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 687.27 Td (Auxilium acquisition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 687.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.15 687.27 Td (14,157) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 687.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.65 687.27 Td (777) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 687.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 687.32 Td (\(1,727) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 687.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 687.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 687.27 Td (13,207) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 672.27 Td (Lehigh ) Tj ET Q
q 0 0 0 rg BT 68.73 672.27 Td (V) Tj ET Q
q 0 0 0 rg BT 75.31 672.27 Td (alley ) Tj ET Q
q 0 0 0 rg BT 96.60 672.27 Td (T) Tj ET Q
q 0 0 0 rg BT 102.27 672.27 Td (echnologies, Inc. acquisitions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.15 672.27 Td (34,700) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 672.32 Td (\(8,614) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 672.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 672.32 Td (\(19,286) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 672.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 672.27 Td (6,800) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 657.27 Td (VOL) Tj ET Q
q 0 0 0 rg BT 58.09 657.27 Td (T) Tj ET Q
q 0 0 0 rg BT 63.34 657.27 Td (AREN� Gel acquisition \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.15 657.27 Td (56,240) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 657.32 Td (\(37,184) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 657.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 657.32 Td (\(18,870) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 657.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 657.27 Td (186) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 642.27 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.15 642.27 Td (1) Tj ET Q
q 0 0 0 rg BT 342.15 642.27 Td (1,606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 642.32 Td (\(1,077) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 642.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 642.32 Td (\(1,065) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 642.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 642.27 Td (9,464) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 627.27 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 627.27 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 627.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 627.27 Td (1) Tj ET Q
q 0 0 0 rg BT 337.15 627.27 Td (16,703) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 627.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 627.32 Td (\(46,098) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 627.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 627.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 627.32 Td (\(40,948) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 627.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 627.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 627.27 Td (29,657) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 615.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 605.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 605.50 Td (The change in fair value recorded in earnings includes the impact of certain competitive events occurring during ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 428.91 605.50 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 444.91 605.50 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 587.50 Td (The following table presents changes to the Company�) Tj ET Q
q 0 0 0 rg BT 281.00 587.50 Td (s liability for acquisition-related contingent consideration during the year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 575.50 Td (ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.38 575.50 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 575.50 Td ( by acquisition \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 536.00 264.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 536.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
365.50 536.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
369.50 536.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
435.50 536.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
439.50 536.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
505.50 536.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
509.50 536.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 506.00 264.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 506.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
365.50 506.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
369.50 506.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
435.50 506.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
439.50 506.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
505.50 506.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
509.50 506.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 476.00 264.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 476.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
365.50 476.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
369.50 476.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
435.50 476.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
439.50 476.00 66.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
505.50 476.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
509.50 476.00 66.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 536 m
365.5 536 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
369.5 536 m
435.5 536 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
439.5 536 m
505.5 536 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 536 m
575.5 536 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 476 m
365.5 476 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 462 m
365.5 462 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
299.5 460 m
365.5 460 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
369.5 476 m
435.5 476 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
369.5 462 m
435.5 462 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
369.5 460 m
435.5 460 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
439.5 476 m
505.5 476 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
439.5 462 m
505.5 462 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
439.5 460 m
505.5 460 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 476 m
575.5 476 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 462 m
575.5 462 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 460 m
575.5 460 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 309.55 556.23 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 308.75 548.23 Td (December) Tj ET Q
q 0 0 0 rg BT 343.32 548.23 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 324.00 540.23 Td (2017) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 374.70 556.23 Td (Changes in Fair) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 374.90 548.23 Td (V) Tj ET Q
q 0 0 0 rg BT 380.31 548.23 Td (alue Recorded) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 382.10 540.23 Td (in Earnings) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 443.65 548.23 Td (Amounts Settled) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 454.40 540.23 Td (and Other) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.55 556.23 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 518.75 548.23 Td (December) Tj ET Q
q 0 0 0 rg BT 553.25 548.23 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.00 540.23 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 525.67 Td (Auxilium acquisition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.00 525.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.15 525.67 Td (13,061) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.00 525.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.15 525.67 Td (2,941) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.00 525.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.80 525.72 Td (\(1,845) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 525.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.00 525.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 525.67 Td (14,157) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 510.67 Td (Lehigh ) Tj ET Q
q 0 0 0 rg BT 68.73 510.67 Td (V) Tj ET Q
q 0 0 0 rg BT 75.31 510.67 Td (alley ) Tj ET Q
q 0 0 0 rg BT 96.60 510.67 Td (T) Tj ET Q
q 0 0 0 rg BT 102.27 510.67 Td (echnologies, Inc. acquisitions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.15 510.67 Td (63,001) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.15 510.67 Td (19,146) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.80 510.72 Td (\(47,447) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 510.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 510.67 Td (34,700) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 495.67 Td (VOL) Tj ET Q
q 0 0 0 rg BT 58.09 495.67 Td (T) Tj ET Q
q 0 0 0 rg BT 63.34 495.67 Td (AREN� Gel acquisition) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.15 495.67 Td (98,124) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.65 495.67 Td (9) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.80 495.72 Td (\(41,893) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 495.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 495.67 Td (56,240) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 480.67 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.15 480.67 Td (16,256) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.80 480.72 Td (\(2,186) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.65 480.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.80 480.72 Td (\(2,464) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 480.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 480.67 Td (1) Tj ET Q
q 0 0 0 rg BT 549.15 480.67 Td (1,606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 465.67 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 465.67 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.00 465.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 329.15 465.67 Td (190,442) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.00 465.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.15 465.67 Td (19,910) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.00 465.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.80 465.72 Td (\(93,649) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 465.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.00 465.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 465.67 Td (1) Tj ET Q
q 0 0 0 rg BT 544.15 465.67 Td (16,703) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 443.50 Td (Nonr) Tj ET Q
q 0 0 0 rg BT 58.04 443.50 Td (ecurring Fair) Tj ET Q
q 0 0 0 rg BT 115.34 443.50 Td ( ) Tj ET Q
q 0 0 0 rg BT 117.66 443.50 Td (V) Tj ET Q
q 0 0 0 rg BT 123.96 443.50 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 176.83 443.50 Td (ements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 425.50 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 425.50 Td (s financial assets and liabilities measured at fair value on a nonrecurring basis during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.54 425.50 Td (years ended December ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.50 Td (31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.44 413.50 Td ( were as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 369.00 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 369.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 369.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 369.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 369.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 369.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 369.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 369.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 339.00 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 339.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 339.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 339.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 339.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 339.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 339.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 339.00 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 382 m
368.5 382 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 382 m
372.5 382 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 382 m
437.5 382 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 382 m
441.5 382 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 382 m
506.5 382 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 369 m
368.5 369 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 369 m
437.5 369 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 369 m
506.5 369 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 369 m
575.5 369 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 339 m
368.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 339 m
437.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 339 m
368.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 325 m
368.5 325 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 323 m
368.5 323 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 339 m
437.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 325 m
437.5 325 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 323 m
437.5 323 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 339 m
506.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 325 m
506.5 325 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 323 m
506.5 323 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 339 m
575.5 339 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 325 m
575.5 325 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 323 m
575.5 323 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 320.85 394.23 Td (Fair) Tj ET Q
q 0 0 0 rg BT 335.44 394.23 Td ( ) Tj ET Q
q 0 0 0 rg BT 337.29 394.23 Td (V) Tj ET Q
q 0 0 0 rg BT 342.63 394.23 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 384.63 394.23 Td (ements during the ) Tj ET Q
q 0 0 0 rg BT 448.19 394.23 Td (Y) Tj ET Q
q 0 0 0 rg BT 453.37 394.23 Td (ear) Tj ET Q
q 0 0 0 rg BT 463.96 394.23 Td ( Ended) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 355.10 386.23 Td (December) Tj ET Q
q 0 0 0 rg BT 389.67 386.23 Td ( 31, 2019 \(1\) using:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 518.50 395.08 Td (T) Tj ET Q
q 0 0 0 rg BT 523.47 395.08 Td (otal Expense) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 522.35 387.08 Td (for) Tj ET Q
q 0 0 0 rg BT 532.49 387.08 Td ( the ) Tj ET Q
q 0 0 0 rg BT 546.94 387.08 Td (Y) Tj ET Q
q 0 0 0 rg BT 552.12 387.08 Td (ear) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 513.10 379.08 Td (Ended December) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 528.50 371.13 Td (31, 2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 311.05 373.23 Td (Level 1 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 380.05 373.23 Td (Level 2 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.05 373.23 Td (Level 3 Inputs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 358.67 Td (Intangible assets, excluding goodwill \(Note 10\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 358.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 358.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 358.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 358.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 358.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 358.67 Td (229,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 358.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 358.67 Td (\(347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 358.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 343.67 Td (Certain property) Tj ET Q
q 0 0 0 rg BT 103.16 343.67 Td (, plant and equipment \(Note 9\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 343.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 343.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 343.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 343.67 Td (\(6,468) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 343.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 328.67 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 328.67 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 328.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 328.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 328.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 328.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 328.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 328.67 Td (229,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 328.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 328.67 Td (\(354,174) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 328.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 280.00 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 280.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 280.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 280.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 280.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 280.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 280.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 280.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 250.00 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 250.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 250.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 250.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 250.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 250.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 250.00 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 250.00 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 293 m
368.5 293 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 293 m
372.5 293 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 293 m
437.5 293 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 293 m
441.5 293 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 293 m
506.5 293 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 280 m
368.5 280 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 280 m
437.5 280 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 280 m
506.5 280 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 280 m
575.5 280 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 250 m
368.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 250 m
437.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 250 m
368.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 236 m
368.5 236 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 234 m
368.5 234 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 250 m
437.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 236 m
437.5 236 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 234 m
437.5 234 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 250 m
506.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 236 m
506.5 236 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 234 m
506.5 234 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 250 m
575.5 250 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 236 m
575.5 236 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 234 m
575.5 234 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 320.85 305.23 Td (Fair) Tj ET Q
q 0 0 0 rg BT 335.44 305.23 Td ( ) Tj ET Q
q 0 0 0 rg BT 337.29 305.23 Td (V) Tj ET Q
q 0 0 0 rg BT 342.63 305.23 Td (alue Measur) Tj ET Q
q 0 0 0 rg BT 384.63 305.23 Td (ements during the ) Tj ET Q
q 0 0 0 rg BT 448.19 305.23 Td (Y) Tj ET Q
q 0 0 0 rg BT 453.37 305.23 Td (ear) Tj ET Q
q 0 0 0 rg BT 463.96 305.23 Td ( Ended) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 355.10 297.23 Td (December) Tj ET Q
q 0 0 0 rg BT 389.67 297.23 Td ( 31, 2018 \(1\) using:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 518.50 306.08 Td (T) Tj ET Q
q 0 0 0 rg BT 523.47 306.08 Td (otal Expense) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 522.35 298.08 Td (for) Tj ET Q
q 0 0 0 rg BT 532.49 298.08 Td ( the ) Tj ET Q
q 0 0 0 rg BT 546.94 298.08 Td (Y) Tj ET Q
q 0 0 0 rg BT 552.12 298.08 Td (ear) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 513.10 290.08 Td (Ended December) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 528.50 282.13 Td (31, 2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 311.05 284.23 Td (Level 1 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 380.05 284.23 Td (Level 2 Inputs) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.05 284.23 Td (Level 3 Inputs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 269.67 Td (Intangible assets, excluding goodwill \(Note 10\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 269.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 269.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 269.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 269.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 269.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 269.67 Td (239,857) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 269.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 269.67 Td (\(230,418) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 269.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 254.67 Td (Certain property) Tj ET Q
q 0 0 0 rg BT 103.16 254.67 Td (, plant and equipment \(Note 9\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 254.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 254.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 254.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 254.67 Td (\(6,521) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 254.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 239.67 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 239.67 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 239.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 239.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 239.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 239.67 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 239.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 239.67 Td (239,857) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 239.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 239.67 Td (\(236,939) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 239.67 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 227.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 217.90 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 217.90 Td (The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 208.30 Td (measurements generally occur in connection with our quarter) Tj ET Q
q 0 0 0 rg BT 263.49 208.30 Td (-end financial reporting close procedures.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 190.30 Td (The Company also performed fair value measurements in connection with its goodwill impairment tests. Refer to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.72 190.30 Td (Note 10. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.30 Td (Goodwill and Other Intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.92 178.30 Td ( for additional information, including the valuation methodologies utilized.) Tj ET Q
endstream
endobj
217 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 218 0 R>>
endobj
218 0 obj
<</Length 16154>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-29) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 7. INVENT) Tj ET Q
q 0 0 0 rg BT 115.56 749.25 Td (ORIES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 731.25 Td (Inventories consist of the following at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.41 731.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.00 731.25 Td ( and December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.02 731.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.02 731.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 699.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 699.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 699.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 699.75 65.00 -15.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
35.50 684.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 669.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 669.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 669.75 65.00 -15.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
35.50 654.75 406.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 699.75 m
506.5 699.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 699.75 m
575.5 699.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 654.75 m
506.5 654.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 654.75 m
575.5 654.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 654.75 m
506.5 654.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 640.75 m
506.5 640.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 638.75 m
506.5 638.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 640.75 m
575.5 640.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 638.75 m
575.5 638.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 711.98 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 711.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 703.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 711.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 711.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 703.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 689.42 Td (Raw materials \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 689.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 689.42 Td (124,171) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 689.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 689.42 Td (122,825) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 674.42 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 674.42 Td (ork-in-process \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 674.42 Td (65,392) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 674.42 Td (70,458) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 659.42 Td (Finished goods \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 659.42 Td (138,302) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 659.42 Td (128,896) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 644.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 644.42 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 644.42 Td (327,865) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 644.42 Td (322,179) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 630.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 620.65 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 60.68 620.65 Td (The components of inventory shown in the table above are net of allowance for obsolescence.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 602.65 Td (Inventory that is in excess of the amount expected to be sold within one year is classified as noncurrent inventory and is not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 590.65 Td (included in the table above. ) Tj ET Q
q 0 0 0 rg BT 148.19 590.65 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.69 590.65 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.27 590.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.71 590.65 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.29 590.65 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.29 590.65 Td ($29.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.19 590.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.62 590.65 Td ($8.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.52 590.65 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 517.18 590.65 Td (, of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 578.65 Td (noncurrent inventory was included in Other assets in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.00 578.65 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.08 578.65 Td (. ) Tj ET Q
q 0 0 0 rg BT 384.53 578.65 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 408.97 578.65 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.56 578.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.00 578.65 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 566.65 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 566.65 Td (, the Company�) Tj ET Q
q 0 0 0 rg BT 117.38 566.65 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.77 566.65 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.86 566.65 Td ( included approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 339.55 566.65 Td ($17.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.44 566.65 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.88 566.65 Td ($12.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.77 566.65 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 519.43 566.65 Td (, of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 554.65 Td (capitalized pre-launch inventories related to products that were not yet available to be sold.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 524.65 Td (NOTE 8. LEASES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 506.65 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 506.65 Td (e have entered into contracts with third parties to lease a variety of assets, including certain real estate, machinery) Tj ET Q
q 0 0 0 rg BT 525.25 506.65 Td (, equipment, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 494.65 Td (automobiles and other assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 476.65 Td (Our leases frequently allow for lease payments that could vary based on factors such as inflation or the degree of utilization of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 464.65 Td (the underlying asset and the incurrence of contractual char) Tj ET Q
q 0 0 0 rg BT 269.60 464.65 Td (ges such as those for common area maintenance or utilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 446.65 Td (Renewal and/or early termination options are common in our lease arrangements, particularly with respect to our real estate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 434.65 Td (leases. Our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.93 434.65 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.04 434.65 Td ( assets and lease liabilities generally exclude periods covered by renewal options and include periods covered by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 422.65 Td (early termination options \(based on our conclusion that it is not reasonably certain that we will exercise such options\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 404.65 Td (Our most significant lease is for our Malvern, Pennsylvania location. ) Tj ET Q
q 0 0 0 rg BT 341.09 404.65 Td (The initial term of the lease is through 2024 and includes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 392.65 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.99 392.65 Td ( renewal options, each for an additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.48 392.65 Td (60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.48 392.65 Td (-month period. ) Tj ET Q
q 0 0 0 rg BT 288.24 392.65 Td (These renewal options are not considered reasonably certain of exercise ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 380.65 Td (and are therefore excluded from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.48 380.65 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.59 380.65 Td ( asset and lease liability) Tj ET Q
q 0 0 0 rg BT 296.91 380.65 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 362.65 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 362.65 Td (e are party to certain sublease arrangements, primarily related to our real estate leases, where we act as the lessee and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 350.65 Td (intermediate lessor) Tj ET Q
q 0 0 0 rg BT 111.25 350.65 Td (. For example, we sublease portions of our Malvern, Pennsylvania facility to multiple tenants through sublease ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 338.65 Td (arrangements ending in 2024, with certain limited renewal and early termination options.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 320.65 Td (The following table presents information about the Company's ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.86 320.65 Td (ROU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.97 320.65 Td ( assets and lease liabilities at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.16 320.65 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.75 320.65 Td ( \(in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 308.65 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 277.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 277.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 277.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 277.15 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 247.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 247.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 247.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 247.15 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 217.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 217.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 217.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 217.15 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 187.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 187.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 187.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 187.15 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 157.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 157.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 157.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 157.15 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 127.15 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 127.15 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 127.15 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 127.15 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
201.5 277.15 m
506.5 277.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 277.15 m
575.5 277.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 232.14999999999998 m
575.5 232.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 218.14999999999998 m
575.5 218.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 216.14999999999998 m
575.5 216.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 172.14999999999998 m
575.5 172.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 172.14999999999998 m
575.5 172.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 158.14999999999998 m
575.5 158.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 156.14999999999998 m
575.5 156.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 112.14999999999998 m
575.5 112.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 98.14999999999998 m
575.5 98.14999999999998 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 96.14999999999998 m
575.5 96.14999999999998 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 204.00 281.38 Td (Consolidated Balance Sheets Line Items) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 289.38 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 289.38 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 281.38 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 266.82 Td (ROU assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 251.82 Td (Operating lease ROU assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 251.82 Td (Operating lease assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 251.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 251.82 Td (51,700) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 236.82 Td (Finance lease ROU assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 236.82 Td (Property) Tj ET Q
q 0 0 0 rg BT 238.11 236.82 Td (, plant and equipment, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 236.82 Td (56,793) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 221.82 Td (T) Tj ET Q
q 0 0 0 rg BT 55.76 221.82 Td (otal ROU assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 221.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 221.82 Td (108,493) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 206.82 Td (Operating lease liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 191.82 Td (Current operating lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 191.82 Td (Current portion of operating lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 191.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 191.82 Td (10,763) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 176.82 Td (Noncurrent operating lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 176.82 Td (Operating lease liabilities, less current portion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 176.82 Td (48,299) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 161.82 Td (T) Tj ET Q
q 0 0 0 rg BT 55.76 161.82 Td (otal operating lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 161.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 161.82 Td (59,062) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 146.82 Td (Finance lease liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 131.82 Td (Current finance lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 131.82 Td (Accounts payable and accrued expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 131.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 131.82 Td (5,672) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 116.82 Td (Noncurrent finance lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 116.82 Td (Other liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 116.82 Td (31,312) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 101.82 Td (T) Tj ET Q
q 0 0 0 rg BT 55.41 101.82 Td (otal finance lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 101.82 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 101.82 Td (36,984) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
219 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 220 0 R>>
endobj
220 0 obj
<</Length 15535>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (At December 31, 2018, our lease assets and liabilities determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.83 749.10 Td (ASC 840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.78 749.10 Td (, which related primarily to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (Malvern, Pennsylvania lease that was accounted for as a build-to-suit lease arrangement, totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.81 737.10 Td ($49.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.70 737.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.14 737.10 Td ($36.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.03 737.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (respectively) Tj ET Q
q 0 0 0 rg BT 83.66 725.10 Td (. Lease assets had a cost basis of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.12 725.10 Td ($98.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 270.01 725.10 Td ( and accumulated depreciation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.23 725.10 Td ($49.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.12 725.10 Td ( and were reflected as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (Property) Tj ET Q
q 0 0 0 rg BT 69.79 713.10 Td (, plant and equipment, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.65 713.10 Td ( in the Consolidated Balance Sheets. Lease liabilities consisted of current liabilities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.67 713.10 Td ($5.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.56 713.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.66 701.10 Td (Accounts payable and accrued expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.14 701.10 Td ( and noncurrent liabilities of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.94 701.10 Td ($30.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.84 701.10 Td ( included in Other liabilities.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 683.10 Td (The following table presents information about lease costs and expenses and sublease income for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.00 683.10 Td (the year ended December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 671.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 647.60 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 647.60 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 647.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 647.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 617.60 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 617.60 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 617.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 617.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 587.60 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 587.60 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 587.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 587.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 557.60 166.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
201.50 557.60 305.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 557.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 557.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
201.5 647.6 m
506.5 647.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 647.6 m
575.5 647.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 647.6 m
575.5 647.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 204.00 651.83 Td (Consolidated Statements of Operations Line Items) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 651.83 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 637.27 Td (Operating lease cost) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 637.27 Td (V) Tj ET Q
q 0 0 0 rg BT 210.67 637.27 Td (arious \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 637.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 637.27 Td (13,648) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 622.27 Td (Finance lease cost:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 607.27 Td (Amortization of ROU assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 607.27 Td (V) Tj ET Q
q 0 0 0 rg BT 210.67 607.27 Td (arious \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 607.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 607.27 Td (9,407) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 592.27 Td (Interest on lease liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 592.27 Td (Interest expense, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 592.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 592.27 Td (1,986) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 577.27 Td (Other lease costs and income:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 562.27 Td (V) Tj ET Q
q 0 0 0 rg BT 50.67 562.27 Td (ariable lease costs \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 562.27 Td (V) Tj ET Q
q 0 0 0 rg BT 210.67 562.27 Td (arious \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 562.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 562.27 Td (9,653) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 547.27 Td (Sublease income) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.00 547.27 Td (V) Tj ET Q
q 0 0 0 rg BT 210.11 547.27 Td (arious \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 547.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 547.27 Td (\(3,689) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 547.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 533.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 523.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 523.90 Td (Amounts are included in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 160.14 523.90 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 285.23 523.90 Td ( based on the function that the underlying leased asset supports. ) Tj ET Q
q 0 0 0 rg BT 490.82 523.90 Td (The following table ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 514.30 Td (presents the components of such aggregate amounts for ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 247.00 514.30 Td (the year ended December 31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 358.51 514.30 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
68.00 490.80 444.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
512.00 490.80 65.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
68.00 464.80 444.00 -13.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
512.00 464.80 65.00 -13.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
512 490.8 m
577 490.8 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 536.00 495.03 Td (2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 70.50 482.05 Td (Cost of revenues) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 514.50 482.05 Td ($) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 551.80 482.05 Td (1) Tj ET Q
q 0 0 0 rg BT 555.80 482.05 Td (1,168) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 70.50 469.05 Td (Selling, general and administrative) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 514.50 469.05 Td ($) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 551.80 469.05 Td (17,648) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 70.50 456.05 Td (Research and development) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 514.50 456.05 Td ($) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 561.80 456.05 Td (203) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 442.70 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 442.70 Td (Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 433.10 Td (utilities costs associated with leased real estate and certain costs associated with our automobile leases.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 415.10 Td (Expenses incurred under operating leases, determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 358.44 415.10 Td (ASC 840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 395.39 415.10 Td (, were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.32 415.10 Td ($18.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.21 415.10 Td ( in both 2018 and 2017.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 397.10 Td (The following table provides the undiscounted amount of future cash flows included in our lease liabilities at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.50 397.10 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 385.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 385.10 Td ( for each of the five years subsequent to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.88 385.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.47 385.10 Td ( and thereafter) Tj ET Q
q 0 0 0 rg BT 353.81 385.10 Td (, as well as a reconciliation of such undiscounted cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 373.10 Td (flows to our lease liabilities at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.75 373.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.33 373.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 341.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 341.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 341.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 341.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 311.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 311.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 311.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 311.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 281.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 281.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 281.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 281.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 251.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 251.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 251.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 251.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 221.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 221.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 221.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 221.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 341.6 m
506.5 341.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 341.6 m
575.5 341.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 251.60000000000002 m
506.5 251.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 237.60000000000002 m
506.5 237.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 235.60000000000002 m
506.5 235.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 251.60000000000002 m
575.5 251.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 237.60000000000002 m
575.5 237.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 235.60000000000002 m
575.5 235.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 221.60000000000002 m
506.5 221.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 207.60000000000002 m
506.5 207.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 205.60000000000002 m
506.5 205.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 221.60000000000002 m
575.5 221.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 207.60000000000002 m
575.5 207.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 205.60000000000002 m
575.5 205.60000000000002 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 455.90 353.83 Td (Operating) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 462.15 345.83 Td (Leases) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 516.60 345.83 Td (Finance Leases) Tj ET Q
BT /F6 10.00 Tf ET
q 0 0 0 rg BT 38.00 331.27 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 331.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 331.27 Td (14,103) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 331.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 331.27 Td (7,446) Tj ET Q
BT /F6 10.00 Tf ET
q 0 0 0 rg BT 38.00 316.27 Td (2021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 316.27 Td (13,262) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 316.27 Td (7,593) Tj ET Q
BT /F6 10.00 Tf ET
q 0 0 0 rg BT 38.00 301.27 Td (2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 301.27 Td (12,688) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 301.27 Td (7,743) Tj ET Q
BT /F6 10.00 Tf ET
q 0 0 0 rg BT 38.00 286.27 Td (2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 286.27 Td (10,017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 286.27 Td (7,897) Tj ET Q
BT /F6 10.00 Tf ET
q 0 0 0 rg BT 38.00 271.27 Td (2024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 271.27 Td (5,176) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 271.27 Td (8,054) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 256.27 Td (Thereafter) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 256.27 Td (15,332) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 256.27 Td (13,483) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 241.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 241.27 Td (otal future lease payments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 241.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 241.27 Td (70,578) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 241.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 241.27 Td (52,216) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 226.27 Td (Less: amount representing interest) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 226.27 Td (1) Tj ET Q
q 0 0 0 rg BT 480.15 226.27 Td (1,516) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 226.27 Td (15,232) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 211.27 Td (Present value of future lease payments \(lease liability\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 211.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 211.27 Td (59,062) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 211.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 211.27 Td (36,984) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
221 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 222 0 R>>
endobj
222 0 obj
<</Length 11747>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-31) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 749.10 Td (s future minimum lease commitments as of December 31, 2018, as determined in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.32 749.10 Td (ASC 840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.27 749.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (reported in the ) Tj ET Q
q 0 0 0 rg BT 96.26 737.10 Td (Annual Report on Form 10-K for the year ended December 31, 2018, were as follows:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 705.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 705.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 705.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 705.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 675.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 675.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 675.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 675.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 645.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 645.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 645.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 645.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 615.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 615.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 615.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 615.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 585.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 585.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 585.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 585.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 555.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 555.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 555.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 555.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 705.6 m
506.5 705.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 705.6 m
575.5 705.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 615.6 m
506.5 615.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 601.6 m
506.5 601.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 599.6 m
506.5 599.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 615.6 m
575.5 615.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 601.6 m
575.5 601.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 599.6 m
575.5 599.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 585.6 m
506.5 585.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 571.6 m
506.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 569.6 m
506.5 569.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 555.6 m
506.5 555.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 541.6 m
506.5 541.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 539.6 m
506.5 539.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 448.50 717.83 Td (Capital Leases) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 468.80 709.83 Td (\(1\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.90 717.83 Td (Operating) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 531.15 709.83 Td (Leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 695.27 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 695.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 695.27 Td (6,884) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 695.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 695.27 Td (15,800) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 680.27 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 680.27 Td (6,819) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 680.27 Td (14,519) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 665.27 Td (2021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 665.27 Td (6,921) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 665.27 Td (12,883) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 650.27 Td (2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 650.27 Td (7,072) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 650.27 Td (12,454) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 635.27 Td (2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 635.27 Td (7,225) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 635.27 Td (9,945) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 620.27 Td (Thereafter) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 620.27 Td (9,127) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 620.27 Td (20,573) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 605.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 605.27 Td (otal minimum lease payments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 605.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 605.27 Td (44,048) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 605.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 605.27 Td (86,174) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 590.27 Td (Less: ) Tj ET Q
q 0 0 0 rg BT 61.33 590.27 Td (Amount representing interest) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 590.27 Td (4,084) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 575.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 575.27 Td (otal present value of minimum payments) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 575.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 575.27 Td (39,964) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 560.27 Td (Less: Current portion of such obligations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 560.27 Td (5,845) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 545.27 Td (Long-term capital lease obligations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 545.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 545.27 Td (34,1) Tj ET Q
q 0 0 0 rg BT 492.65 545.27 Td (19) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 533.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 523.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 523.50 Td (The Malvern, Pennsylvania location�) Tj ET Q
q 0 0 0 rg BT 185.69 523.50 Td (s lease arrangement is included under Capital Leases.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 505.50 Td (The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 493.50 Td (of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.83 493.50 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.41 493.50 Td (:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 462.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 462.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 432.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 432.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 402.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 402.00 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 462 m
575.5 462 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 474.23 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 474.23 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 466.23 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 451.67 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 451.67 Td (eighted average remaining lease term \(years\), weighted based on lease liability balances:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 436.67 Td (Operating leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.90 436.67 Td (5.9 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 421.67 Td (Finance leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.90 421.67 Td (9.5 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 406.67 Td (W) Tj ET Q
q 0 0 0 rg BT 46.64 406.67 Td (eighted average discount rate \(percentages\), weighted based on the remaining balance of lease payments:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 391.67 Td (Operating leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.15 391.67 Td (5.8) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 391.67 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 376.67 Td (Finance leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.15 376.67 Td (5.5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 376.67 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 354.50 Td (The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.02 354.50 Td (the year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 342.50 Td (ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 342.50 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 319.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 319.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 289.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 289.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 259.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 259.00 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 229.00 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 229.00 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 319 m
575.5 319 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 323.23 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 308.67 Td (Cash paid for amounts included in the measurement of lease liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 293.67 Td (Operating cash payments for operating leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 293.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 293.67 Td (14,940) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 278.67 Td (Operating cash payments for finance leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 278.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 278.67 Td (2,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 263.67 Td (Financing cash payments for finance leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 263.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 263.67 Td (9,196) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 248.67 Td (Lease liabilities arising from obtaining right-of-use assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 233.67 Td (Operating leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 233.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 233.67 Td (623) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 218.67 Td (Finance leases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 218.67 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 218.67 Td (5,953) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
223 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 224 0 R>>
endobj
224 0 obj
<</Length 32707>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-32) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (NOTE 9. PROPER) Tj ET Q
q 0 0 0 rg BT 117.60 742.25 Td (TY) Tj ET Q
q 0 0 0 rg BT 130.57 742.25 Td (, PLANT) Tj ET Q
q 0 0 0 rg BT 169.28 742.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 171.23 742.25 Td (AND EQUIPMENT) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 724.25 Td (Changes in the amount of Property) Tj ET Q
q 0 0 0 rg BT 200.05 724.25 Td (, plant and equipment for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.35 724.25 Td (the year ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.74 724.25 Td ( are set forth in the table below ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (\(in thousands\).) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 674.75 96.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 674.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 674.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 646.75 96.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 646.75 4.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 646.75 60.00 -33.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 589.75 96.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 589.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 589.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 551.75 96.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 551.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 551.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 523.75 96.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 523.75 4.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 523.75 60.00 -24.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 475.75 96.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 475.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 475.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 447.75 96.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
131.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
191.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
195.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
255.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
259.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
319.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
323.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
383.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
387.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
447.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
451.50 447.75 60.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
511.50 447.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
515.50 447.75 60.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 674.75 m
191.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 674.75 m
255.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 674.75 m
319.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 674.75 m
383.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 674.75 m
447.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 674.75 m
511.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 674.75 m
575.5 674.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 589.75 m
191.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 575.75 m
191.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 589.75 m
255.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 575.75 m
255.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 589.75 m
319.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 575.75 m
319.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 589.75 m
383.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 575.75 m
383.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 589.75 m
447.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 575.75 m
447.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 589.75 m
511.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 575.75 m
511.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 589.75 m
575.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 575.75 m
575.5 575.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 475.75 m
191.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 461.75 m
191.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 475.75 m
255.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 461.75 m
255.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 475.75 m
319.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 461.75 m
319.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 475.75 m
383.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 461.75 m
383.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 475.75 m
447.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 461.75 m
447.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 475.75 m
511.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 461.75 m
511.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 475.75 m
575.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 461.75 m
575.5 461.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 434.75 m
191.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 432.75 m
191.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 434.75 m
255.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 432.75 m
255.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 434.75 m
319.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 432.75 m
319.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 434.75 m
383.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 432.75 m
383.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 434.75 m
447.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 432.75 m
447.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 434.75 m
511.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 432.75 m
511.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 434.75 m
575.5 434.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 432.75 m
575.5 432.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 420.75 m
191.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
131.5 418.75 m
191.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 420.75 m
255.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
195.5 418.75 m
255.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 420.75 m
319.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
259.5 418.75 m
319.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 420.75 m
383.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
323.5 418.75 m
383.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 420.75 m
447.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
387.5 418.75 m
447.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 420.75 m
511.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
451.5 418.75 m
511.5 418.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 420.75 m
575.5 420.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
515.5 418.75 m
575.5 418.75 l
s
BT /F5 9.00 Tf ET
q 0 0 0 rg BT 38.00 679.20 Td (Cost:) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 145.45 686.37 Td (Land and) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 145.75 678.87 Td (Buildings) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 200.50 686.37 Td (Machinery and) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 207.05 678.87 Td (Equipment) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 272.70 686.37 Td (Leasehold) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 265.70 678.87 Td (Impr) Tj ET Q
q 0 0 0 rg BT 282.30 678.87 Td (ovements) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 336.60 693.87 Td (Computer) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 328.05 686.37 Td (Equipment and) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 338.65 678.87 Td (Softwar) Tj ET Q
q 0 0 0 rg BT 363.99 678.87 Td (e) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 394.25 686.37 Td (Furnitur) Tj ET Q
q 0 0 0 rg BT 422.52 686.37 Td (e and) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 403.70 678.87 Td (Fixtur) Tj ET Q
q 0 0 0 rg BT 424.05 678.87 Td (es) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 460.50 686.37 Td (Assets under) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 459.95 678.87 Td (Construction) Tj ET Q
BT /F1 7.50 Tf ET
q 0 0 0 rg BT 536.80 678.87 Td (T) Tj ET Q
q 0 0 0 rg BT 541.11 678.87 Td (otal) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 665.31 Td (At January 1, 2019) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 156.90 665.31 Td (230,035) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 220.90 665.31 Td (21) Tj ET Q
q 0 0 0 rg BT 230.40 665.31 Td (1,491) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 289.65 665.31 Td (69,256) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 348.90 665.31 Td (1) Tj ET Q
q 0 0 0 rg BT 353.65 665.31 Td (17,134) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 417.65 665.31 Td (12,495) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 476.90 665.31 Td (121,024) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 665.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 540.90 665.31 Td (761,435) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 651.31 Td (Additions \(1\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 161.65 651.31 Td (49,716) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 225.65 651.31 Td (56,888) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 294.40 651.31 Td (9,934) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 358.40 651.31 Td (8,359) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 429.55 651.31 Td (954) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 478.50 651.31 Td (\(46,715) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 507.80 651.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 545.65 651.31 Td (79,136) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 637.31 Td (Disposals, transfers,) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 627.81 Td (impairments and) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 618.31 Td (other \(2\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 166.40 618.31 Td (6,1) Tj ET Q
q 0 0 0 rg BT 178.28 618.31 Td (15) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 227.25 618.31 Td (\(6,394) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 251.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 291.25 618.31 Td (\(8,926) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 315.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 355.25 618.31 Td (\(8,951) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 379.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 426.35 618.31 Td (\(515) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 443.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 483.25 618.31 Td (\(1,096) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 507.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 542.50 618.31 Td (\(19,767) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 571.80 618.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 603.81 Td (Ef) Tj ET Q
q 0 0 0 rg BT 52.88 603.81 Td (fect of currency) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 594.31 Td (translation) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 178.30 594.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 242.30 594.31 Td (71) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 306.30 594.31 Td (60) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 365.55 594.31 Td (495) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 429.55 594.31 Td (509) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 594.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 550.40 594.31 Td (1,135) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 580.31 Td (At December 31, 2019) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 156.90 580.31 Td (285,866) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 220.90 580.31 Td (262,056) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 289.65 580.31 Td (70,324) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 348.90 580.31 Td (1) Tj ET Q
q 0 0 0 rg BT 353.65 580.31 Td (17,037) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 417.65 580.31 Td (13,443) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 481.65 580.31 Td (73,213) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 580.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 540.90 580.31 Td (821,939) Tj ET Q
BT /F5 9.50 Tf ET
q 0 0 0 rg BT 38.00 565.80 Td (Accumulated) Tj ET Q
BT /F5 9.50 Tf ET
q 0 0 0 rg BT 38.00 556.30 Td (Depr) Tj ET Q
q 0 0 0 rg BT 57.35 556.30 Td (eciation:) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 542.31 Td (At January 1, 2019) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 158.50 542.31 Td (\(69,656) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 187.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 222.50 542.31 Td (\(83,906) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 251.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 286.50 542.31 Td (\(30,600) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 315.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 350.50 542.31 Td (\(71,437) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 379.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 419.25 542.31 Td (\(6,944) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 443.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 542.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 542.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 537.75 542.31 Td (\(262,543) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 571.80 542.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 528.31 Td (Additions) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 158.50 528.31 Td (\(17,670) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 187.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 222.50 528.31 Td (\(22,012) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 251.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 291.25 528.31 Td (\(7,337) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 315.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 350.50 528.31 Td (\(20,696) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 379.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 419.25 528.31 Td (\(1,285) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 443.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 528.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 542.50 528.31 Td (\(69,000) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 571.80 528.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 513.81 Td (Disposals, transfers) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 504.31 Td (and other \(2\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 166.40 504.31 Td (2,850) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 230.40 504.31 Td (1,605) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 294.40 504.31 Td (1,1) Tj ET Q
q 0 0 0 rg BT 306.27 504.31 Td (10) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 358.40 504.31 Td (8,617) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 429.55 504.31 Td (515) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 504.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 545.65 504.31 Td (14,697) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 489.81 Td (Ef) Tj ET Q
q 0 0 0 rg BT 52.80 489.81 Td (fect of currency) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 44.00 480.31 Td (translation) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 178.30 480.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 239.10 480.31 Td (\(44) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 251.80 480.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 303.10 480.31 Td (\(31) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 315.80 480.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 362.35 480.31 Td (\(142) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 379.80 480.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 431.10 480.31 Td (\(1) Tj ET Q
q 0 0 0 rg BT 439.01 480.31 Td (1) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 443.80 480.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 480.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 554.35 480.36 Td (\(228) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 571.80 480.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 466.31 Td (At December 31, 2019) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 158.50 466.31 Td (\(84,476) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 187.80 466.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 217.75 466.31 Td (\(104,357) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 251.80 466.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 286.50 466.31 Td (\(36,858) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 315.80 466.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 350.50 466.31 Td (\(83,658) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 379.80 466.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 419.25 466.31 Td (\(7,725) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 443.80 466.31 Td (\)) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 498.30 466.31 Td (�) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 466.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 537.75 466.31 Td (\(317,074) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 571.80 466.31 Td (\)) Tj ET Q
BT /F5 9.50 Tf ET
q 0 0 0 rg BT 38.00 452.30 Td (Net Book ) Tj ET Q
q 0 0 0 rg BT 75.29 452.30 Td (Amount:) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 438.31 Td (At December 31, 2019) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 156.90 438.31 Td (201,390) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 220.90 438.31 Td (157,699) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 289.65 438.31 Td (33,466) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 353.65 438.31 Td (33,379) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 422.40 438.31 Td (5,718) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 481.65 438.31 Td (73,213) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 438.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 540.90 438.31 Td (504,865) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 38.00 424.31 Td (At December 31, 2018) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 134.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 156.90 424.31 Td (160,379) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 198.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 220.90 424.31 Td (127,585) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 262.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 289.65 424.31 Td (38,656) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 326.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 353.65 424.31 Td (45,697) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 390.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 422.40 424.31 Td (5,551) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 454.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 476.90 424.31 Td (121,024) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 518.00 424.31 Td ($) Tj ET Q
BT /F3 9.50 Tf ET
q 0 0 0 rg BT 540.90 424.31 Td (498,892) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 412.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 402.65 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 402.65 Td (Costs incurred during the construction or development of property) Tj ET Q
q 0 0 0 rg BT 279.38 402.65 Td (, plant and equipment are initially recorded as additions to ) Tj ET Q
q 0 0 0 rg BT 467.10 402.65 Td (Assets under Construction. Once ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 393.05 Td (an asset has been placed into service, the cost of that asset is transferred from ) Tj ET Q
q 0 0 0 rg BT 316.30 393.05 Td (Assets under Construction to one of the other classes of assets.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 383.45 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 383.45 Td (Amounts include the ef) Tj ET Q
q 0 0 0 rg BT 142.23 383.45 Td (fect of the Company�) Tj ET Q
q 0 0 0 rg BT 209.98 383.45 Td (s January 1, 2019 adoption of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 306.20 383.45 Td (ASC 842) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 335.76 383.45 Td (, which is further described in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 433.29 383.45 Td (Note 2. Summary of Significant ) Tj ET Q
q 0 0 0 rg BT 537.27 383.45 Td (Accounting ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 373.85 Td (Policies) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 92.83 373.85 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 355.85 Td (Depreciation expense was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.90 355.85 Td ($69.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.79 355.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.79 355.85 Td ($101.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.68 355.85 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.12 355.85 Td ($210.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 366.01 355.85 Td ( for the years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.37 355.85 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.95 355.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.95 355.85 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.95 355.85 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 343.85 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 343.85 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 108.66 343.85 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 325.85 Td (During the years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.52 325.85 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.11 325.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.11 325.85 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.11 325.85 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.54 325.85 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.54 325.85 Td (, the Company recorded property) Tj ET Q
q 0 0 0 rg BT 433.35 325.85 Td (, plant and equipment impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 313.85 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 313.85 Td (ges totaling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.91 313.85 Td ($6.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.80 313.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.80 313.85 Td ($6.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.69 313.85 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.13 313.85 Td ($65.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.02 313.85 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 330.68 313.85 Td (. ) Tj ET Q
q 0 0 0 rg BT 335.50 313.85 Td (These char) Tj ET Q
q 0 0 0 rg BT 378.91 313.85 Td (ges are included in the ) Tj ET Q
q 0 0 0 rg BT 470.82 313.85 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 561.17 313.85 Td (ges ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 301.85 Td (line item in our Consolidated Statement of Operations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 283.85 Td (In 2019 and 2018, impairment char) Tj ET Q
q 0 0 0 rg BT 203.89 283.85 Td (ges reflect the write-of) Tj ET Q
q 0 0 0 rg BT 294.50 283.85 Td (f of certain property) Tj ET Q
q 0 0 0 rg BT 374.09 283.85 Td (, plant and equipment, including amounts that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 271.85 Td (were abandoned or sold as part of our ongoing ef) Tj ET Q
q 0 0 0 rg BT 232.15 271.85 Td (forts to improve our operating ef) Tj ET Q
q 0 0 0 rg BT 362.76 271.85 Td (ficiency and consolidate certain locations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 253.85 Td (In 2017, impairment char) Tj ET Q
q 0 0 0 rg BT 164.46 253.85 Td (ges primarily relate to an aggregate char) Tj ET Q
q 0 0 0 rg BT 325.30 253.85 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.07 253.85 Td ($47.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.96 253.85 Td ( recorded in connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.59 253.85 Td (2017 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 241.85 Td (Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.21 241.85 Td (, which is described further in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.11 241.85 Td (Note 4. Restructuring) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.49 241.85 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.42 241.85 Td ($1) Tj ET Q
q 0 0 0 rg BT 471.05 241.85 Td (1.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.95 241.85 Td ( recorded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 229.85 Td (following the initiation of held-for) Tj ET Q
q 0 0 0 rg BT 173.55 229.85 Td (-sale accounting resulting from the Company�) Tj ET Q
q 0 0 0 rg BT 357.11 229.85 Td (s June 30, 2017 definitive agreement to sell ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.46 229.85 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.17 229.85 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 217.85 Td (which is described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.20 217.85 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.61 217.85 Td (.) Tj ET Q
endstream
endobj
225 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 226 0 R>>
endobj
226 0 obj
<</Length 18137>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-33) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 10. GOODWILL) Tj ET Q
q 0 0 0 rg BT 139.08 749.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 141.02 749.25 Td (AND OTHER INT) Tj ET Q
q 0 0 0 rg BT 220.85 749.25 Td (ANGIBLES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 731.25 Td (Goodwill) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 713.25 Td (Changes in the carrying amount of our goodwill for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.84 713.25 Td (years ended December 31, 2019 and 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.84 713.25 Td ( were as follows \(in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.25 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 669.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 669.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 669.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 669.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 669.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 669.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 639.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 639.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 639.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 639.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 639.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 639.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 639.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 639.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 639.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 639.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 609.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 609.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 609.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 609.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 609.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 609.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 609.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 609.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 609.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 609.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 579.75 199.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 579.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 579.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 579.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 579.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 579.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 579.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 579.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 579.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 579.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 669.75 m
299.5 669.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 669.75 m
368.5 669.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 669.75 m
437.5 669.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 669.75 m
506.5 669.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 669.75 m
575.5 669.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 609.75 m
299.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 609.75 m
368.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 609.75 m
437.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 609.75 m
506.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 609.75 m
575.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 609.75 m
299.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 595.75 m
299.5 595.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 593.75 m
299.5 593.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 609.75 m
368.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 595.75 m
368.5 595.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 593.75 m
368.5 593.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 609.75 m
437.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 595.75 m
437.5 595.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 593.75 m
437.5 593.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 609.75 m
506.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 595.75 m
506.5 595.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 593.75 m
506.5 593.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 609.75 m
575.5 609.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 595.75 m
575.5 595.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 593.75 m
575.5 593.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 564.75 m
299.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 564.75 m
368.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 564.75 m
437.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 564.75 m
506.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 564.75 m
575.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 564.75 m
299.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 550.75 m
299.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 548.75 m
299.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 564.75 m
368.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 550.75 m
368.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 548.75 m
368.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 564.75 m
437.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 550.75 m
437.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 548.75 m
437.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 564.75 m
506.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 550.75 m
506.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 548.75 m
506.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 564.75 m
575.5 564.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 550.75 m
575.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 548.75 m
575.5 548.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 251.60 681.98 Td (Branded) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 238.05 673.98 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 324.35 681.98 Td (Sterile) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 316.80 673.98 Td (Injectables) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 390.95 681.98 Td (Generic) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 376.05 673.98 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.80 681.98 Td (International) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 445.05 673.98 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.75 673.98 Td (T) Tj ET Q
q 0 0 0 rg BT 538.35 673.98 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 659.42 Td (Goodwill as of December 31, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 659.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 659.42 Td (828,818) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 659.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 659.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 659.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 659.42 Td (3,531,301) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 659.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 659.42 Td (89,963) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 659.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 659.42 Td (4,450,082) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 644.42 Td (Allocation to current segments \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 644.42 Td (2,731,193) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.30 644.47 Td (\(2,731,193) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 644.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 629.42 Td (Ef) Tj ET Q
q 0 0 0 rg BT 53.35 629.42 Td (fect of currency translation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 629.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 629.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 629.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 629.47 Td (\(5,446) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 629.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 629.42 Td (\(5,446) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 629.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 614.42 Td (Goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 149.99 614.42 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 614.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 614.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 614.47 Td (\(649,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 614.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 614.47 Td (\(31,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 614.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 614.42 Td (\(680,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 614.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 599.42 Td (Goodwill as of December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 599.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 599.42 Td (828,818) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 599.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 599.42 Td (2,731,193) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 599.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 599.42 Td (151,108) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 599.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 599.42 Td (53,517) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 599.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 599.42 Td (3,764,636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 584.42 Td (Ef) Tj ET Q
q 0 0 0 rg BT 53.35 584.42 Td (fect of currency translation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 584.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 584.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 584.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 584.42 Td (2,456) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 584.42 Td (2,456) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 569.42 Td (Goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 149.90 569.42 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 569.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 569.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 569.47 Td (\(151,108) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 569.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 569.47 Td (\(20,800) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 569.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 569.42 Td (\(171,908) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 569.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 554.42 Td (Goodwill as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 554.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 554.42 Td (828,818) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 554.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 554.42 Td (2,731,193) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 554.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 554.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 554.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 554.42 Td (35,173) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 554.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 554.42 Td (3,595,184) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 542.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 532.65 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 532.65 Td (This allocation relates to the change in segments described below under the heading �) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 341.85 532.65 Td (Impairments) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 382.29 532.65 Td (.� ) Tj ET Q
q 0 0 0 rg BT 389.69 532.65 Td (The amount of goodwill allocated was determined using a ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 523.05 Td (relative fair value methodology in accordance with ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 232.54 523.05 Td (U.S. GAAP) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 269.66 523.05 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 505.05 Td (The carrying amounts of goodwill at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.85 505.05 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.44 505.05 Td ( and December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.46 505.05 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.46 505.05 Td ( are net of the following accumulated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 493.05 Td (impairments \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 461.55 199.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 461.55 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 461.55 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 461.55 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 461.55 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 461.55 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 461.55 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 461.55 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 461.55 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 461.55 65.00 -25.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 461.55 m
299.5 461.55 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 461.55 m
368.5 461.55 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 461.55 m
437.5 461.55 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 461.55 m
506.5 461.55 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 461.55 m
575.5 461.55 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 251.60 473.78 Td (Branded) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 238.05 465.78 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 324.35 473.78 Td (Sterile) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 316.80 465.78 Td (Injectables) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 390.95 473.78 Td (Generic) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 376.05 465.78 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.80 473.78 Td (International) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 445.05 465.78 Td (Pharmaceuticals) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.75 465.78 Td (T) Tj ET Q
q 0 0 0 rg BT 538.35 465.78 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 451.22 Td (Accumulated impairment losses as of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 441.22 Td (December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 441.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 441.22 Td (855,810) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 441.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 441.22 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 441.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 441.22 Td (2,991,549) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 441.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 441.22 Td (456,408) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 441.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 441.22 Td (4,303,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 426.22 Td (Accumulated impairment losses as of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 416.22 Td (December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 416.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.15 416.22 Td (855,810) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 416.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 416.22 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 416.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.65 416.22 Td (3,142,657) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 416.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 416.22 Td (500,417) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 416.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 416.22 Td (4,498,884) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
227 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 228 0 R>>
endobj
228 0 obj
<</Length 32786>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-34) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (Other Intangible ) Tj ET Q
q 0 0 0 rg BT 107.31 749.25 Td (Assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Changes in the amount of other intangible assets from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.56 731.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.15 731.25 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.93 731.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.51 731.25 Td ( are set forth in the table below ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (\(in thousands\).) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 679.75 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 679.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 679.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 679.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 679.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 679.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 679.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 639.75 130.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 639.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 639.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 639.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 639.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 639.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 639.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 599.75 130.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 599.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 599.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 599.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 599.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 599.75 4.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 599.75 65.00 -25.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 559.75 130.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 559.75 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 559.75 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 559.75 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 559.75 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 559.75 4.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 559.75 65.00 -35.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 489.75 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 489.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 489.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 489.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 489.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 489.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 489.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 441.75 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 441.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 441.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 441.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 441.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 441.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 441.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 411.75 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 411.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 411.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 411.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 411.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 411.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 411.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 381.75 130.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
165.50 381.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
230.50 381.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
234.50 381.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
299.50 381.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 381.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 381.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 381.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 381.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 381.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 381.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 381.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 679.75 m
230.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 679.75 m
299.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 679.75 m
368.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 679.75 m
437.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 679.75 m
506.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 679.75 m
575.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 679.75 m
230.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 679.75 m
299.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 679.75 m
368.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 679.75 m
437.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 679.75 m
506.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 679.75 m
575.5 679.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 639.75 m
230.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 639.75 m
299.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 639.75 m
368.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 639.75 m
437.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 639.75 m
506.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 639.75 m
575.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 639.75 m
230.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 614.75 m
230.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 639.75 m
299.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 614.75 m
299.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 639.75 m
368.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 614.75 m
368.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 639.75 m
437.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 614.75 m
437.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 639.75 m
506.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 614.75 m
506.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 639.75 m
575.5 639.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 614.75 m
575.5 614.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 524.75 m
230.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 524.75 m
299.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 524.75 m
368.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 524.75 m
437.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 524.75 m
506.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 524.75 m
575.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 524.75 m
230.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 524.75 m
299.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 524.75 m
368.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 524.75 m
437.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 524.75 m
506.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 524.75 m
575.5 524.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 489.75 m
230.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 475.75 m
230.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 473.75 m
230.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 489.75 m
299.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 475.75 m
299.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 473.75 m
299.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 489.75 m
368.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 475.75 m
368.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 473.75 m
368.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 489.75 m
437.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 475.75 m
437.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 473.75 m
437.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 489.75 m
506.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 475.75 m
506.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 473.75 m
506.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 489.75 m
575.5 489.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 475.75 m
575.5 475.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 473.75 m
575.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 441.75 m
230.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 441.75 m
299.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 441.75 m
368.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 441.75 m
437.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 441.75 m
506.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 441.75 m
575.5 441.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 381.75 m
230.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 381.75 m
299.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 381.75 m
368.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 381.75 m
437.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 381.75 m
506.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 381.75 m
575.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 381.75 m
230.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 367.75 m
230.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 365.75 m
230.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 381.75 m
299.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 367.75 m
299.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
234.5 365.75 m
299.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 381.75 m
368.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 367.75 m
368.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 365.75 m
368.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 381.75 m
437.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 367.75 m
437.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 365.75 m
437.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 381.75 m
506.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 367.75 m
506.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 365.75 m
506.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 381.75 m
575.5 381.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 367.75 m
575.5 367.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 365.75 m
575.5 365.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 352.75 m
230.5 352.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
165.5 350.75 m
230.5 350.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 352.75 m
575.5 352.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 350.75 m
575.5 350.75 l
s
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 684.43 Td (Cost basis:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 175.05 699.98 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 174.25 691.98 Td (December) Tj ET Q
q 0 0 0 rg BT 208.82 691.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 189.50 683.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 245.35 683.98 Td (Acquisitions) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 313.25 683.98 Td (Impairments) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 388.65 683.98 Td (Other) Tj ET Q
q 0 0 0 rg BT 409.02 683.98 Td ( \(1\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 458.95 699.98 Td (Effect of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.10 691.98 Td (Curr) Tj ET Q
q 0 0 0 rg BT 474.36 691.98 Td (ency) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 453.75 683.98 Td (T) Tj ET Q
q 0 0 0 rg BT 458.79 683.98 Td (ranslation) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 520.05 699.98 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 691.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.82 691.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 683.98 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 669.42 Td (Indefinite-lived intangibles:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 654.42 Td (In-process research and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 644.42 Td (development) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.15 644.42 Td (93,900) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 644.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 644.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 644.42 Td (93,900) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 629.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.76 629.42 Td (otal indefinite-lived) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 619.42 Td (intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.15 619.42 Td (93,900) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 619.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 619.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 619.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 619.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 619.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 619.42 Td (93,900) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 604.42 Td (Finite-lived intangibles:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 589.42 Td (Licenses \(weighted average) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 579.42 Td (life of 14 years\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.15 579.42 Td (457,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 579.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 579.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 579.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 579.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 579.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 579.42 Td (457,402) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 564.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.93 564.42 Td (radenames) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.15 564.42 Td (6,409) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 564.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 564.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 564.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 564.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 564.42 Td (6,409) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 549.42 Td (Developed technology) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 539.42 Td (\(weighted average life of 1) Tj ET Q
q 0 0 0 rg BT 151.54 539.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 529.42 Td (years\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.65 529.42 Td (6,182,015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 529.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 529.47 Td (\(347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 529.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 529.47 Td (\(2,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 529.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 529.42 Td (12,327) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 529.42 Td (5,844,439) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 514.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.76 514.42 Td (otal finite-lived intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 504.42 Td (\(weighted average life of 1) Tj ET Q
q 0 0 0 rg BT 151.54 504.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 494.42 Td (years\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.65 494.42 Td (6,645,826) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 494.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 494.47 Td (\(347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 494.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 494.47 Td (\(2,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 494.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 494.42 Td (12,327) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 494.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 494.42 Td (6,308,250) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 479.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 479.42 Td (otal other intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.65 479.42 Td (6,739,726) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 479.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 479.47 Td (\(347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 479.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 479.47 Td (\(2,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 479.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 479.42 Td (12,327) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 479.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 479.42 Td (6,402,150) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 446.43 Td (Accumulated amortization:) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 175.05 461.98 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 174.25 453.98 Td (December) Tj ET Q
q 0 0 0 rg BT 208.82 453.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 189.50 445.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 243.60 445.98 Td (Amortization) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 313.25 445.98 Td (Impairments) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 388.65 445.98 Td (Other) Tj ET Q
q 0 0 0 rg BT 409.02 445.98 Td ( \(1\)) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 458.95 461.98 Td (Effect of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.10 453.98 Td (Curr) Tj ET Q
q 0 0 0 rg BT 474.36 453.98 Td (ency) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 453.75 445.98 Td (T) Tj ET Q
q 0 0 0 rg BT 458.79 445.98 Td (ranslation) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 520.05 461.98 Td (Balance as of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 453.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 453.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 445.98 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 431.42 Td (Finite-lived intangibles:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 416.42 Td (Licenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.80 416.42 Td (\(398,182) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.65 416.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.80 416.47 Td (\(12,154) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 416.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 416.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 416.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 416.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 416.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 416.42 Td (\(410,336) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 416.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 401.42 Td (T) Tj ET Q
q 0 0 0 rg BT 49.93 401.42 Td (radenames) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.80 401.42 Td (\(6,409) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.65 401.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.65 401.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 401.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 401.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 401.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 401.42 Td (\(6,409) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 401.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 386.42 Td (Developed technology) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.30 386.42 Td (\(2,877,829) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.65 386.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.80 386.47 Td (\(531,708) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 386.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 386.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 386.42 Td (2,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 386.47 Td (\(6,798) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 386.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 386.42 Td (\(3,414,138) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 386.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 371.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 371.42 Td (otal other intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.30 371.42 Td (\(3,282,420) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 226.65 371.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.80 371.47 Td (\(543,862) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.65 371.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 371.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 371.42 Td (2,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 371.47 Td (\(6,798) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 371.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 371.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 371.42 Td (\(3,830,883) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 371.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 356.42 Td (Net other intangibles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.00 356.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.65 356.42 Td (3,457,306) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 356.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 356.42 Td (2,571,267) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 342.65 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 333.05 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 333.05 Td (Other adjustments relate to the removal of certain fully amortized intangible assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 315.05 Td (Amortization expense for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.40 315.05 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.40 315.05 Td ( totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.61 315.05 Td ($543.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.51 315.05 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.51 315.05 Td ($622.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.40 315.05 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.84 315.05 Td ($773.8 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 303.05 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 303.05 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 117.55 303.05 Td (. ) Tj ET Q
q 0 0 0 rg BT 122.00 303.05 Td (Amortization expense is included in Cost of revenues in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.61 303.05 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 519.97 303.05 Td (. Estimated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 291.05 Td (amortization of intangibles for the five fiscal years subsequent to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.14 291.05 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.73 291.05 Td ( is as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 280.55 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 280.55 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 250.55 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 250.55 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 220.55 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 220.55 65.00 -15.00 re f
/GS0 gs
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 270.22 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 270.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 270.22 Td (437,420) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 255.22 Td (2021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 255.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 255.22 Td (396,864) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 240.22 Td (2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 240.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 240.22 Td (381,312) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 225.22 Td (2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 225.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 225.22 Td (351,805) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 210.22 Td (2024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 210.22 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 210.22 Td (308,986) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 188.05 Td (Impairments) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 170.05 Td (Goodwill and indefinite-lived intangible assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.68 170.05 Td (are tested for impairment annually and when events or changes in circumstances ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 158.05 Td (indicate that the asset might be impaired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 197.62 158.05 Td (. Our annual assessment is performed as of October 1.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 140.05 Td (As part of our goodwill and intangible asset impairment assessments, we estimate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.65 140.05 Td (the fair values of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.12 140.05 Td ( our reporting units and our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 128.05 Td (intangible assets using an income approach that utilizes a discounted cash flow model or) Tj ET Q
q 0 0 0 rg BT 389.67 128.05 Td (, where appropriate, a market approach) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.98 128.05 Td (. ) Tj ET Q
endstream
endobj
229 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 230 0 R>>
endobj
230 0 obj
<</Length 17119>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-35) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The discounted cash flow models are dependent upon) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.66 749.10 Td ( our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.99 749.10 Td (estimates of future cash flows and other factors including estimates of) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 575.91 749.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (\(i\) future operating performance, including future sales, long-term growth rates, operating mar) Tj ET Q
q 0 0 0 rg BT 413.46 737.10 Td (gins, discount rates, variations in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (amount and timing of cash flows and the probability of achieving the estimated cash flows and \(ii\) future economic conditions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 541.70 725.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 546.52 725.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (value hierarchy) Tj ET Q
q 0 0 0 rg BT 97.26 701.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 102.08 701.10 Td (The discount rates applied to the estimated cash flows for the Company�) Tj ET Q
q 0 0 0 rg BT 391.17 701.10 Td (s October 1, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 442.27 701.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.27 701.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.27 701.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.27 701.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.71 701.10 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.71 701.10 Td ( annual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (goodwill and indefinite-lived intangible assets impairment tests ranged from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.98 689.10 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.81 689.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.59 689.10 Td (13.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.42 689.10 Td (, from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.36 689.10 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.19 689.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.97 689.10 Td (1) Tj ET Q
q 0 0 0 rg BT 468.60 689.10 Td (1.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.43 689.10 Td ( and from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.80 689.10 Td (9.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.63 689.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (12.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.83 677.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 114.49 677.10 Td (, depending on the overall risk associated with the particular assets and other market factors. ) Tj ET Q
q 0 0 0 rg BT 486.13 677.10 Td (W) Tj ET Q
q 0 0 0 rg BT 494.77 677.10 Td (e believe the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (discount rates and other inputs and assumptions are consistent with those that a market participant would use. ) Tj ET Q
q 0 0 0 rg BT 475.91 665.10 Td (Any impairment char) Tj ET Q
q 0 0 0 rg BT 561.25 665.10 Td (ges ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.56 653.10 Td (Asset impairment char) Tj ET Q
q 0 0 0 rg BT 537.91 653.10 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.24 653.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.83 641.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.19 641.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 623.10 Td (During the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.55 623.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.54 623.10 Td (, the Company incurred the following goodwill and other intangible ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.10 Td (asset impairment char) Tj ET Q
q 0 0 0 rg BT 123.56 611.10 Td (ges \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 587.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 587.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 587.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 587.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 587.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 587.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 587.6 m
437.5 587.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 587.6 m
506.5 587.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 587.6 m
575.5 587.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 591.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 591.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 591.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 578.17 Td (Goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 143.99 578.17 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 577.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 577.27 Td (171,908) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 577.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 577.27 Td (680,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 577.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 577.27 Td (288,745) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 563.17 Td (Other intangible asset impairment char) Tj ET Q
q 0 0 0 rg BT 193.32 563.17 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 562.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 562.27 Td (347,706) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 562.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 562.27 Td (230,418) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 562.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 562.27 Td (799,955) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 540.10 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 540.10 Td ( summary of significant goodwill and other intangible asset impairment tests and related char) Tj ET Q
q 0 0 0 rg BT 442.44 540.10 Td (ges is included below) Tj ET Q
q 0 0 0 rg BT 528.17 540.10 Td (. Except as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 528.10 Td (described below) Tj ET Q
q 0 0 0 rg BT 100.60 528.10 Td (, pre-tax non-cash intangible asset impairment char) Tj ET Q
q 0 0 0 rg BT 305.07 528.10 Td (ges related primarily to certain in-process research and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 516.10 Td (development and/or developed technology intangible assets that were tested for impairment following changes in market conditions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 504.10 Td (and certain other factors impacting recoverability) Tj ET Q
q 0 0 0 rg BT 232.76 504.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 54.00 486.10 Td (Annual Goodwill Impairment T) Tj ET Q
q 0 0 0 rg BT 178.92 486.10 Td (ests) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 468.10 Td (As a result of our annual test performed as of October 1, 2019, the Company determined that the estimated carrying amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 456.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 456.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.71 456.10 Td ( reporting unit exceeded its fair value; therefore, the Company recorded a pre-tax non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 550.07 456.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 444.10 Td ($20.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 444.10 Td ( during the fourth quarter of 2019. ) Tj ET Q
q 0 0 0 rg BT 229.12 444.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.17 444.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.16 444.10 Td ( impairment was primarily a result of certain anticipated product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 432.10 Td (discontinuation activities. ) Tj ET Q
q 0 0 0 rg BT 141.08 432.10 Td (The impairment also reflects the estimated impact of Canadian pricing regulations that were issued in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 420.10 Td (second half of 2019 and that we expect will become ef) Tj ET Q
q 0 0 0 rg BT 254.07 420.10 Td (fective as early as July 2020. ) Tj ET Q
q 0 0 0 rg BT 371.91 420.10 Td (W) Tj ET Q
q 0 0 0 rg BT 380.55 420.10 Td (e did not record goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 549.76 420.10 Td (ges ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 408.10 Td (for the other reporting units as a result of the 2019 annual tests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 390.10 Td (As a result of our annual test performed as of October 1, 2018, the Company determined that the estimated carrying amounts of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 378.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 378.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.39 378.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.83 378.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.82 378.10 Td ( reporting units exceeded their respective fair values; therefore, the Company recorded pre-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 366.10 Td (tax non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 193.00 366.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.66 366.10 Td ($258.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.55 366.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.99 366.10 Td ($31.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.88 366.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 404.54 366.10 Td (, during the fourth quarter of 2018. ) Tj ET Q
q 0 0 0 rg BT 546.27 366.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 354.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.67 354.10 Td ( impairment can be primarily attributed to an increase in the discount rate used in the determination of fair ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 342.10 Td (value and unfavorable underlying business outlook assumption changes. ) Tj ET Q
q 0 0 0 rg BT 327.70 342.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.75 342.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.75 342.10 Td ( impairment was primarily a result of increased ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 330.10 Td (competition and slower than expected product launches in our Canadian market. ) Tj ET Q
q 0 0 0 rg BT 359.60 330.10 Td (W) Tj ET Q
q 0 0 0 rg BT 368.24 330.10 Td (e did not record goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 537.46 330.10 Td (ges for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 318.10 Td (the other reporting units as a result of the 2018 annual tests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 300.10 Td (As a result of our annual test performed as of October 1, 2017, the Company determined that the estimated fair values of its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 288.10 Td (Branded, Generics and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.85 288.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.85 288.10 Td ( reporting units exceeded their carrying amounts; therefore, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.03 288.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.03 288.10 Td ( related goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 545.92 288.10 Td (ges ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 276.10 Td (were required.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 54.00 258.10 Td (Other Impairment T) Tj ET Q
q 0 0 0 rg BT 133.63 258.10 Td (ests) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 240.10 Td (As a result of certain competitive events that occurred during the first quarter of 2019, we tested the goodwill of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.52 240.10 Td (Generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 228.10 Td (Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.53 228.10 Td ( reporting unit for impairment as of March 31, 2019. ) Tj ET Q
q 0 0 0 rg BT 314.08 228.10 Td (The fair value of the reporting unit was estimated using an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 216.10 Td (income approach that utilized a discounted cash flow model. ) Tj ET Q
q 0 0 0 rg BT 280.74 216.10 Td (The discount rate utilized in this test was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.82 216.10 Td (10.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.65 216.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 477.46 216.10 Td (This goodwill ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 204.10 Td (impairment test resulted in a pre-tax non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 325.45 204.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.22 204.10 Td ($86.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.11 204.10 Td ( during the three months ended March 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 192.10 Td (2019, representing the excess of this reporting unit�) Tj ET Q
q 0 0 0 rg BT 241.51 192.10 Td (s carrying amount over its estimated fair value. ) Tj ET Q
q 0 0 0 rg BT 432.10 192.10 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.38 192.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.05 192.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 180.10 Td (impairment can be primarily attributed to the impact of the competitive events referenced above and an increase in the discount rate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 168.10 Td (used in the determination of fair value.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 150.10 Td (During the second quarter of 2019, unfavorable competitive and pricing events occurred that caused us to update certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 138.10 Td (assumptions from those used in our first-quarter 2019 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.19 138.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.86 138.10 Td ( goodwill impairment test. ) Tj ET Q
q 0 0 0 rg BT 460.72 138.10 Td (The Company considered ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 126.10 Td (these events, together with the fact that this reporting unit�) Tj ET Q
q 0 0 0 rg BT 269.27 126.10 Td (s carrying amount equaled its fair value immediately subsequent to the first-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 114.10 Td (quarter 2019 goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 193.00 114.10 Td (ge, as part of its qualitative assessment of goodwill triggering events for the second quarter of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 102.10 Td (2019. ) Tj ET Q
q 0 0 0 rg BT 60.45 102.10 Td (As a result, we concluded that it was more likely than not that the fair value of this reporting unit was below its carrying amount ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 90.10 Td (as of June 30, 2019 and a goodwill impairment test was required. ) Tj ET Q
q 0 0 0 rg BT 298.72 90.10 Td (After performing this quantitative test, we determined that this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 78.10 Td (reporting unit�) Tj ET Q
q 0 0 0 rg BT 93.49 78.10 Td (s carrying amount exceeded its estimated fair value. ) Tj ET Q
q 0 0 0 rg BT 303.50 78.10 Td (The fair value of the reporting unit was estimated using an income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 66.10 Td (approach that utilized a discounted cash flow model. ) Tj ET Q
q 0 0 0 rg BT 248.81 66.10 Td (The discount rate utilized in this test was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.88 66.10 Td (10.5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 440.71 66.10 Td (. Based on the excess of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 54.10 Td (reporting unit�) Tj ET Q
q 0 0 0 rg BT 93.49 54.10 Td (s carrying amount over its estimated fair value, we recorded a pre-tax non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 515.93 54.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.70 54.10 Td ($65.1 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 42.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 42.10 Td ( during the three months ended June 30, 2019, representing the entire remaining amount of this reporting unit�) Tj ET Q
q 0 0 0 rg BT 505.07 42.10 Td (s goodwill.) Tj ET Q
endstream
endobj
231 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 232 0 R>>
endobj
232 0 obj
<</Length 16072>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-36) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (During the first quarter of 2018, a change in segments resulted in changes to our reporting units for goodwill impairment testing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (purposes, including the creation of a new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.17 737.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.09 737.10 Td ( reporting unit, which was previously part of our Generics reporting unit. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (As a result of these changes, under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.62 725.10 Td (U.S. GAAP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.02 725.10 Td (, we tested the goodwill of the former Generics reporting unit immediately before the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (segment realignment and the goodwill of both the new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.78 713.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.70 713.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.13 713.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.81 713.10 Td ( reporting units immediately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (after the segment realignment. ) Tj ET Q
q 0 0 0 rg BT 159.94 701.10 Td (These goodwill tests were performed using an income approach that utilized a discounted cash flow ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (model. ) Tj ET Q
q 0 0 0 rg BT 65.81 689.10 Td (The results of these goodwill impairment tests were as follows:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 677.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 677.10 Td (The former Generics reporting unit�) Tj ET Q
q 0 0 0 rg BT 228.78 677.10 Td (s estimated fair value exceeded its carrying amount, resulting in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.75 677.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.75 677.10 Td ( related goodwill ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 665.10 Td (impairment char) Tj ET Q
q 0 0 0 rg BT 151.13 665.10 Td (ge.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 653.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 653.10 Td (The new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.71 653.10 Td (Sterile Injectables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.62 653.10 Td ( reporting unit�) Tj ET Q
q 0 0 0 rg BT 254.61 653.10 Td (s estimated fair value exceeded its carrying amount, resulting in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.58 653.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.58 653.10 Td ( related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 641.10 Td (goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 189.18 641.10 Td (ge.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 629.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 629.10 Td (The new ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.71 629.10 Td (Generic Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.38 629.10 Td ( reporting unit�) Tj ET Q
q 0 0 0 rg BT 282.37 629.10 Td (s carrying amount exceeded its estimated fair value, resulting in a pre-tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 617.10 Td (non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 227.78 617.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.55 617.10 Td ($391.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.44 617.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 599.10 Td (In March 2017, we announced that the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.62 599.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.51 599.10 Td (�) Tj ET Q
q 0 0 0 rg BT 241.29 599.10 Td (s Drug Safety and Risk Management and ) Tj ET Q
q 0 0 0 rg BT 407.65 599.10 Td (Anesthetic and ) Tj ET Q
q 0 0 0 rg BT 469.30 599.10 Td (Analgesic Drug Products ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (Advisory Committees voted that the benefits of reformulated OP) Tj ET Q
q 0 0 0 rg BT 294.47 587.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 316.14 591.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.70 587.10 Td (ER \(oxymorphone hydrochloride extended release\) no longer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 575.10 Td (outweigh its risks. In June 2017, we became aware of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.32 575.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.22 575.10 Td (�) Tj ET Q
q 0 0 0 rg BT 289.00 575.10 Td (s request that we voluntarily withdraw OP) Tj ET Q
q 0 0 0 rg BT 456.94 575.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 478.60 579.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.17 575.10 Td (ER from the market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 563.10 Td (and, in July 2017, after careful consideration and consultation with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.64 563.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.65 563.10 Td (, we decided to voluntarily remove OP) Tj ET Q
q 0 0 0 rg BT 494.41 563.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 516.08 567.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.64 563.10 Td (ER from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 551.10 Td (market. ) Tj ET Q
q 0 0 0 rg BT 68.21 551.10 Td (As a result of our decision, the Company determined that the carrying amount of its OP) Tj ET Q
q 0 0 0 rg BT 417.22 551.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 438.88 555.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.82 551.10 Td ( ER intangible asset was no ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (longer recoverable, resulting in a pre-tax, non-cash impairment char) Tj ET Q
q 0 0 0 rg BT 307.93 539.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.70 539.10 Td ($20.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.59 539.10 Td ( in the second quarter of 2017, representing the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (remaining carrying amount.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 509.10 Td (As a result of the withdrawal of OP) Tj ET Q
q 0 0 0 rg BT 204.00 509.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 225.66 513.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.60 509.10 Td ( ER from the market and the continued erosion of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.48 509.10 Td (Branded Pharmaceuticals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.39 509.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (segment�) Tj ET Q
q 0 0 0 rg BT 72.10 497.10 Td (s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (the second quarter of 2017. ) Tj ET Q
q 0 0 0 rg BT 147.45 485.10 Td (W) Tj ET Q
q 0 0 0 rg BT 156.09 485.10 Td (e recorded a pre-tax, non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 383.04 485.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.80 485.10 Td ($180.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.70 485.10 Td ( during the three months ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (ended June 30, 2017 for the amount by which the reporting unit�) Tj ET Q
q 0 0 0 rg BT 293.72 473.10 Td (s carrying amount exceeded its fair value. ) Tj ET Q
q 0 0 0 rg BT 462.92 473.10 Td (W) Tj ET Q
q 0 0 0 rg BT 471.56 473.10 Td (e estimated the fair value ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (of the Branded reporting unit using an income approach that utilized a discounted cash flow model.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 443.10 Td (Following the announcement of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.69 443.10 Td (2017 Generic Pharmaceuticals Restructuring Initiative) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.40 443.10 Td (, which is further described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.31 443.10 Td (Note ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 431.10 Td (4. Restructuring) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.43 431.10 Td (, the Company assessed the recoverability of certain products that were discontinued as part of this initiative, resulting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 419.10 Td (in pre-tax, non-cash intangible asset impairment char) Tj ET Q
q 0 0 0 rg BT 248.25 419.10 Td (ges of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.17 419.10 Td ($57.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.06 419.10 Td ( during the second quarter of 2017.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 401.10 Td (Pursuant to an existing agreement with a wholly-owned subsidiary of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.95 401.10 Td (Novartis) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.38 401.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.38 401.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.38 401.10 Td ( licensed the Canadian rights to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 389.10 Td (commercialize serelaxin, an investigational drug for the treatment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.56 389.10 Td (acute heart failure \(AHF\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.90 389.10 Td (. In March 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.32 389.10 Td (Novartis) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.76 389.10 Td ( announced ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 377.10 Td (that a Phase 3 study of serelaxin in patients with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.97 377.10 Td (AHF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.97 377.10 Td ( failed to meet its primary endpoints. ) Tj ET Q
q 0 0 0 rg BT 400.38 377.10 Td (As a result, we concluded that the full ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 365.10 Td (carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.79 365.10 Td ($45.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.68 365.10 Td ( pre-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 353.10 Td (tax non-cash impairment char) Tj ET Q
q 0 0 0 rg BT 154.94 353.10 Td (ge during the three months ended March 31, 2017. In addition, and as a result of the serelaxin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 341.10 Td (impairment, we assessed the recoverability of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.04 341.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.04 341.10 Td ( goodwill balance and determined that the estimated fair value of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.16 341.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 574.15 341.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 329.10 Td (reporting unit was below its carrying amount. ) Tj ET Q
q 0 0 0 rg BT 220.78 329.10 Td (W) Tj ET Q
q 0 0 0 rg BT 229.42 329.10 Td (e recorded a pre-tax, non-cash goodwill impairment char) Tj ET Q
q 0 0 0 rg BT 456.37 329.10 Td (ge of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.13 329.10 Td ($82.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.03 329.10 Td ( during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 317.10 Td (the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit�) Tj ET Q
q 0 0 0 rg BT 493.36 317.10 Td (s fair value. ) Tj ET Q
q 0 0 0 rg BT 542.61 317.10 Td (W) Tj ET Q
q 0 0 0 rg BT 551.24 317.10 Td (e ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.10 Td (estimated the fair value of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.62 305.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.61 305.10 Td ( reporting unit using an income approach that utilized a discounted cash flow model.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 287.10 Td (As further discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.43 287.10 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.83 287.10 Td (, we entered into a definitive agreement to sell ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.54 287.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.65 287.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.10 Td (on June 30, 2017, which resulted in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.70 275.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.18 275.10 Td (�) Tj ET Q
q 0 0 0 rg BT 209.96 275.10 Td (s assets and liabilities being classified as held for sale. ) Tj ET Q
q 0 0 0 rg BT 428.89 275.10 Td (The initiation of held-for) Tj ET Q
q 0 0 0 rg BT 528.38 275.10 Td (-sale ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.10 Td (accounting, together with the agreed upon sale price, triggered an impairment review) Tj ET Q
q 0 0 0 rg BT 375.50 263.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 379.95 263.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 429.28 263.10 Td (, we performed an impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 251.10 Td (analysis using a market approach and determined that impairment char) Tj ET Q
q 0 0 0 rg BT 318.77 251.10 Td (ges were required. ) Tj ET Q
q 0 0 0 rg BT 394.67 251.10 Td (W) Tj ET Q
q 0 0 0 rg BT 403.30 251.10 Td (e recorded pre-tax, non-cash impairment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 239.10 Td (char) Tj ET Q
q 0 0 0 rg BT 53.03 239.10 Td (ges of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.69 239.10 Td ($25.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.58 239.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 153.02 239.10 Td ($89.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.91 239.10 Td ( related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.39 239.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.87 239.10 Td (�) Tj ET Q
q 0 0 0 rg BT 278.65 239.10 Td (s goodwill and other intangible assets, respectively) Tj ET Q
q 0 0 0 rg BT 481.56 239.10 Td (, during the second ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 227.10 Td (quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (NOTE 1) Tj ET Q
q 0 0 0 rg BT 71.29 197.10 Td (1. LICENSE ) Tj ET Q
q 0 0 0 rg BT 127.14 197.10 Td (AND COLLABORA) Tj ET Q
q 0 0 0 rg BT 215.02 197.10 Td (TION ) Tj ET Q
q 0 0 0 rg BT 242.53 197.10 Td (AGREEMENTS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 179.10 Td (Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 167.10 Td (development. ) Tj ET Q
q 0 0 0 rg BT 92.47 167.10 Td (These agreements require our subsidiaries to share in the development costs of such products and the third parties grant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.10 Td (marketing rights to our subsidiaries for such products.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 137.10 Td (Generally) Tj ET Q
q 0 0 0 rg BT 101.77 137.10 Td (, under these agreements: \(i\) we are required to make upfront payments and other payments upon successful ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.10 Td (completion of regulatory or sales milestones and/or \(ii\) we are required to pay royalties on sales of the products arising from these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 113.10 Td (agreements.) Tj ET Q
endstream
endobj
233 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 234 0 R>>
endobj
234 0 obj
<</Length 13895>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-37) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 742.10 Td (BioSpecifics T) Tj ET Q
q 0 0 0 rg BT 106.07 742.10 Td (echnologies Corp. \(BioSpecifics\)) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.10 Td (The Company) Tj ET Q
q 0 0 0 rg BT 119.28 724.10 Td (, through an af) Tj ET Q
q 0 0 0 rg BT 177.42 724.10 Td (filiate, is party to a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.17 724.10 Td (development and license agreement, as amended \(the BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 523.69 724.10 Td (Agreement\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.44 724.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.10 Td (with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.28 712.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.38 712.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 112.20 712.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.25 712.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 183.30 712.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.72 712.10 Td ( was originally entered into in June 2004 to obtain exclusive worldwide rights to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.10 Td (develop, market and sell certain products containing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.60 700.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.70 700.10 Td (�) Tj ET Q
q 0 0 0 rg BT 301.29 700.10 Td ( enzyme ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.38 700.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 357.94 700.10 Td (, which is included in our XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 504.87 704.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.80 700.10 Td ( product. ) Tj ET Q
q 0 0 0 rg BT 547.67 700.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 688.10 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 688.10 Td (s licensed rights concern the development and commercialization of products, other than dermal formulations labeled for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 676.10 Td (topical administration, and currently) Tj ET Q
q 0 0 0 rg BT 180.86 676.10 Td (, the Company�) Tj ET Q
q 0 0 0 rg BT 242.25 676.10 Td (s licensed rights cover the indications of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.81 676.10 Td (DC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.71 676.10 Td (, Dupuytren�) Tj ET Q
q 0 0 0 rg BT 470.25 676.10 Td (s nodules, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.75 676.10 Td (PD) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.54 676.10 Td (, adhesive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 664.10 Td (capsulitis, cellulite, plantar fibromatosis, lateral hip fat and other potential indications. ) Tj ET Q
q 0 0 0 rg BT 383.22 664.10 Td (The Company may further expand the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 652.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 89.05 652.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.48 652.10 Td (, at its option, to cover other indications as they are developed by the Company or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.39 652.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.50 652.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 634.10 Td (Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.21 634.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 158.26 634.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.68 634.10 Td (, we are responsible, at our own cost and expense, for developing the formulation and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (finished dosage form of products and arranging for the clinical supply of products. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.69 622.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 419.79 622.10 Td ( may from time to time conduct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (exploratory clinical trials evaluating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.17 610.10 Td (CCH) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.73 610.10 Td ( as a treatment for a number of conditions, including uterine fibroids. In certain cases, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (Company has the option to license development and marketing rights to future indications based on a full analysis of the data from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (clinical trials, which would transfer responsibility for the future development costs to the Company and trigger opt-in payments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (potential future milestone and royalty payments to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.12 574.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.22 574.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 556.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 134.10 556.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.52 556.10 Td ( extends, on a country-by-country and product-by-product basis, for the longer of the patent life, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (the expiration of any regulatory exclusivity period or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.38 544.10 Td (twelve years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 300.63 544.10 Td ( from the ef) Tj ET Q
q 0 0 0 rg BT 347.38 544.10 Td (fective date. Either party may terminate the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.41 544.10 Td (BioSpecifics ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.42 532.10 Td ( as a result of the other party�) Tj ET Q
q 0 0 0 rg BT 197.33 532.10 Td (s breach or bankruptcy) Tj ET Q
q 0 0 0 rg BT 288.03 532.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 292.85 532.10 Td (W) Tj ET Q
q 0 0 0 rg BT 301.49 532.10 Td (e may terminate the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.12 532.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 436.17 532.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.59 532.10 Td ( with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.37 532.10 Td (90) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.37 532.10 Td ( days�) Tj ET Q
q 0 0 0 rg BT 536.79 532.10 Td ( written ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 520.10 Td (notice.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 502.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 502.10 Td (e must pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.46 502.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.57 502.10 Td ( on a country-by-country and product-by-product basis a specified percentage within a range of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.32 502.10 Td (5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.65 502.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (15%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.33 490.10 Td ( of net sales for products covered by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.78 490.10 Td (BioSpecifics ) Tj ET Q
q 0 0 0 rg BT 269.83 490.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.25 490.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 319.07 490.10 Td (This royalty applies to net sales by the Company and/or any of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (its sublicensees. ) Tj ET Q
q 0 0 0 rg BT 102.75 478.10 Td (W) Tj ET Q
q 0 0 0 rg BT 111.39 478.10 Td (e are also obligated to pay a percentage of any future regulatory or commercial milestone payments received from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (any sublicensees. In addition, the Company and its af) Tj ET Q
q 0 0 0 rg BT 249.11 466.10 Td (filiates pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.76 466.10 Td (BioSpecifics) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.86 466.10 Td ( an amount equal to a specified mark-up on certain cost ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 454.10 Td (of goods related to supply of XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 195.98 458.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.91 454.10 Td ( \(which mark-up is capped at a specified percentage within the range of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.40 454.10 Td (5%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.73 454.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.51 454.10 Td (15%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.84 454.10 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.10 Td (cost of goods of XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 145.43 446.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.37 442.10 Td (\) for products sold by the Company and its af) Tj ET Q
q 0 0 0 rg BT 331.55 442.10 Td (filiates.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 424.10 Td (Nevakar) Tj ET Q
q 0 0 0 rg BT 82.27 424.10 Td (, Inc.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 406.10 Td (During the second quarter of 2018, we entered into a development, license and commercialization agreement with Nevakar) Tj ET Q
q 0 0 0 rg BT 555.19 406.10 Td (, Inc. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.10 Td (related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.98 394.10 Td (five) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.53 394.10 Td ( sterile injectable product candidates. Pursuant to this agreement, Nevakar) Tj ET Q
q 0 0 0 rg BT 387.41 394.10 Td (, Inc. will generally be responsible, at its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.10 Td (expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 370.10 Td (expense, to launch and distribute any products that are approved. ) Tj ET Q
q 0 0 0 rg BT 297.96 370.10 Td (The Company will have exclusive license rights to all of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 358.10 Td (products launched in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.53 358.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.31 358.10 Td ( and a first right of refusal for the Canadian territory) Tj ET Q
q 0 0 0 rg BT 362.47 358.10 Td (. Upon entering into this agreement, the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.10 Td (became obligated to make an upfront payment, which was recorded as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.78 346.10 Td (R&D) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.45 346.10 Td ( expense in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.66 346.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.02 346.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 334.10 Td (during the three months ended June 30, 2018. ) Tj ET Q
q 0 0 0 rg BT 220.79 334.10 Td (The Company could become obligated to make additional payments based on certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 322.10 Td (potential future milestones being achieved.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (NOTE 12. CONTRACT) Tj ET Q
q 0 0 0 rg BT 138.89 292.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 140.83 292.10 Td (ASSETS ) Tj ET Q
q 0 0 0 rg BT 180.03 292.10 Td (AND LIABILITIES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 274.10 Td (Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (customer pursuant to a purchase order) Tj ET Q
q 0 0 0 rg BT 187.89 262.10 Td (. Revenue contracts such as these do not generally give rise to contract assets or contract ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (liabilities because: \(i\) the underlying contracts generally have only a single performance obligation and \(ii\) we do not generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (receive consideration until the performance obligation is fully satisfied. ) Tj ET Q
q 0 0 0 rg BT 323.69 238.10 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.19 238.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.77 238.10 Td (, the unfulfilled performance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (obligations for these types of contracts relate to ordered but undelivered products. ) Tj ET Q
q 0 0 0 rg BT 365.44 226.10 Td (W) Tj ET Q
q 0 0 0 rg BT 374.08 226.10 Td (e generally expect to fulfill the performance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (obligations and recognize revenue within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.45 214.10 Td (one) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 217.88 214.10 Td ( week of entering into the underlying contract. Based on the short-term initial contract ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (duration, additional disclosure about the remaining performance obligations is not required.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 184.10 Td (Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (from customers when there are remaining performance obligations.) Tj ET Q
endstream
endobj
235 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 236 0 R>>
endobj
236 0 obj
<</Length 16117>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-38) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 80.23 749.10 Td (following ) Tj ET Q
q 0 0 0 rg BT 120.81 749.10 Td (table ) Tj ET Q
q 0 0 0 rg BT 141.93 749.10 Td (shows ) Tj ET Q
q 0 0 0 rg BT 168.62 749.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 182.52 749.10 Td (opening ) Tj ET Q
q 0 0 0 rg BT 216.43 749.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 232.55 749.10 Td (closing ) Tj ET Q
q 0 0 0 rg BT 263.13 749.10 Td (balances ) Tj ET Q
q 0 0 0 rg BT 299.24 749.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 309.25 749.10 Td (contract ) Tj ET Q
q 0 0 0 rg BT 343.14 749.10 Td (assets ) Tj ET Q
q 0 0 0 rg BT 368.16 749.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 384.29 749.10 Td (contract ) Tj ET Q
q 0 0 0 rg BT 418.18 749.10 Td (liabilities ) Tj ET Q
q 0 0 0 rg BT 457.08 749.10 Td (from ) Tj ET Q
q 0 0 0 rg BT 478.21 749.10 Td (contracts ) Tj ET Q
q 0 0 0 rg BT 515.99 749.10 Td (with ) Tj ET Q
q 0 0 0 rg BT 535.45 749.10 Td (customers ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (\(dollars ) Tj ET Q
q 0 0 0 rg BT 69.05 737.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 79.33 737.10 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 705.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 705.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 705.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 705.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 705.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 705.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 705.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 705.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 705.6 m
368.5 705.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 705.6 m
437.5 705.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 705.6 m
506.5 705.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 705.6 m
575.5 705.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 312.25 717.83 Td (December) Tj ET Q
q 0 0 0 rg BT 346.82 717.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 327.50 709.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 381.25 717.83 Td (December) Tj ET Q
q 0 0 0 rg BT 415.82 717.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 709.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.35 709.83 Td ($ Change) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 524.35 709.83 Td (% Change) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 695.27 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 74.93 695.27 Td (assets, ) Tj ET Q
q 0 0 0 rg BT 103.26 695.27 Td (net ) Tj ET Q
q 0 0 0 rg BT 117.98 695.27 Td (\(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 695.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.65 695.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 695.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 695.27 Td (12,065) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 695.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 695.32 Td (\(12,065) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 695.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.95 695.27 Td (\(100) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 695.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 680.27 Td (Contract ) Tj ET Q
q 0 0 0 rg BT 74.93 680.27 Td (liabilities, ) Tj ET Q
q 0 0 0 rg BT 117.15 680.27 Td (net ) Tj ET Q
q 0 0 0 rg BT 131.87 680.27 Td (\(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 680.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 342.15 680.27 Td (6,592) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 680.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 680.27 Td (19,217) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 680.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 680.32 Td (\(12,625) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 680.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.95 680.32 Td (\(66) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.30 680.27 Td (\)%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 666.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 656.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 656.90 Td (At ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 77.50 656.90 Td (December�31, 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 140.37 656.90 Td (, approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 192.57 656.90 Td ($9.3 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 231.69 656.90 Td ( of the contract asset amount is classified as a current asset and is included in Prepaid expenses and other ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 647.30 Td (current assets in the Company�) Tj ET Q
q 0 0 0 rg BT 166.14 647.30 Td (s ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.26 647.30 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 264.13 647.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 267.98 647.30 Td (The remaining amount is classified as noncurrent and is included in Other assets. ) Tj ET Q
q 0 0 0 rg BT 529.10 647.30 Td (The net ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 637.70 Td (decrease) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 95.03 637.70 Td ( in contract assets during ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 176.57 637.70 Td (the year ended December 31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 288.07 637.70 Td ( was primarily due to reclassifications to accounts receivable following the resolution of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 628.10 Td (certain conditions other than the passage of time af) Tj ET Q
q 0 0 0 rg BT 230.41 628.10 Td (fecting the Company�) Tj ET Q
q 0 0 0 rg BT 299.73 628.10 Td (s rights to consideration for the sale of certain goods, as well as certain product ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 618.50 Td (discontinuation activities in our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 170.59 618.50 Td (International Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 265.89 618.50 Td ( segment.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 608.90 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 608.90 Td (At ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 77.50 608.90 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 140.37 608.90 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 155.92 608.90 Td (December�31, 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 218.79 608.90 Td (, approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 270.99 608.90 Td ($1.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 310.11 608.90 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.66 608.90 Td ($1.7 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 364.77 608.90 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 406.90 608.90 Td (, of these contract liability amounts are classified as ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 599.30 Td (current liabilities and are included in ) Tj ET Q
q 0 0 0 rg BT 186.57 599.30 Td (Accounts payable and accrued expenses in the Company�) Tj ET Q
q 0 0 0 rg BT 370.29 599.30 Td (s ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 375.40 599.30 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 468.27 599.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 472.12 599.30 Td (The remaining amounts are ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 589.70 Td (classified as noncurrent and are included in Other liabilities. During ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 286.77 589.70 Td (the year ended December 31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 398.27 589.70 Td (, the Company entered into new contracts resulting in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 580.10 Td (an increase to contract liabilities of approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 229.88 580.10 Td ($4.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 269.00 580.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 272.85 580.10 Td (This increase was more than of) Tj ET Q
q 0 0 0 rg BT 372.45 580.10 Td (fset by approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 444.21 580.10 Td ($14.9 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 487.32 580.10 Td ( in reductions following ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 570.50 Td (certain product discontinuation activities in our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 220.79 570.50 Td (International Pharmaceuticals) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 316.09 570.50 Td ( segment and approximately ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 408.50 570.50 Td ($1.2 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 447.62 570.50 Td ( in revenue recognized during the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 560.90 Td (period.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 542.90 Td (During ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.83 542.90 Td (the year ended December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.21 542.90 Td (, we recognized ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.74 542.90 Td (revenue) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.38 542.90 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.71 542.90 Td ($10.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.60 542.90 Td ( relating to performance obligations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 530.90 Td (satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 518.90 Td (consideration.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 488.90 Td (NOTE 13. ) Tj ET Q
q 0 0 0 rg BT 81.29 488.90 Td (ACCOUNTS P) Tj ET Q
q 0 0 0 rg BT 145.27 488.90 Td (A) Tj ET Q
q 0 0 0 rg BT 151.58 488.90 Td (Y) Tj ET Q
q 0 0 0 rg BT 157.88 488.90 Td (ABLE ) Tj ET Q
q 0 0 0 rg BT 187.06 488.90 Td (AND ) Tj ET Q
q 0 0 0 rg BT 210.67 488.90 Td (ACCRUED EXPENSES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 470.90 Td (Accounts payable and accrued expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.48 470.90 Td ( include the following at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.74 470.90 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.32 470.90 Td ( and December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.34 470.90 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.34 470.90 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 439.40 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 439.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 439.40 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 439.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 411.40 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 411.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 411.40 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 411.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 383.40 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 383.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 383.40 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 383.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 355.40 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 355.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 355.40 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 355.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 327.40 406.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 327.40 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 327.40 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 327.40 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 439.4 m
506.5 439.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 439.4 m
575.5 439.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 439.4 m
506.5 439.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 439.4 m
575.5 439.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 313.4 m
506.5 313.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 300.4 m
506.5 300.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 298.4 m
506.5 298.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 313.4 m
575.5 313.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 300.4 m
575.5 300.4 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 298.4 m
575.5 298.4 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 451.63 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 451.63 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 443.63 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 451.63 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 451.63 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 443.63 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 429.97 Td (T) Tj ET Q
q 0 0 0 rg BT 43.93 429.97 Td (rade accounts payable) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 429.97 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 429.97 Td (101,532) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 429.97 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 429.97 Td (96,024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 415.97 Td (Returns and allowances) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 415.97 Td (206,248) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 415.97 Td (236,946) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 401.97 Td (Rebates) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 401.97 Td (129,056) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 401.97 Td (144,860) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 387.97 Td (Char) Tj ET Q
q 0 0 0 rg BT 57.35 387.97 Td (gebacks) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 387.97 Td (1,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 387.97 Td (2,971) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 373.97 Td (Accrued interest) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 373.97 Td (1) Tj ET Q
q 0 0 0 rg BT 475.15 373.97 Td (12,860) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 373.97 Td (130,182) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 359.97 Td (Accrued payroll and related benefits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 359.97 Td (79,869) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 359.97 Td (89,895) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 345.97 Td (Accrued royalties and other distribution partner payables) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 345.97 Td (1) Tj ET Q
q 0 0 0 rg BT 475.15 345.97 Td (15,816) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 345.97 Td (122,028) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 331.97 Td (Acquisition-related contingent consideration�current) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 331.97 Td (6,534) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 331.97 Td (36,514) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 317.97 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 317.97 Td (146,440) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 317.97 Td (149,780) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 303.97 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 303.97 Td (otal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 303.97 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 303.97 Td (899,949) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 303.97 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 303.97 Td (1,009,200) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
237 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 238 0 R>>
endobj
238 0 obj
<</Length 27138>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-39) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 14. DEBT) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (The following table presents information about the Company�) Tj ET Q
q 0 0 0 rg BT 310.45 731.25 Td (s total indebtedness at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.98 731.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.57 731.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.01 731.25 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 719.25 Td ( \(dollars in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 663.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 663.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 663.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 663.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 663.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 633.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 633.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 633.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 633.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 633.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 633.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 633.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 633.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 603.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 603.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 603.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 603.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 603.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 603.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 603.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 603.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 603.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 603.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 603.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 603.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 573.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 573.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 573.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 573.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 573.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 573.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 573.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 573.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 573.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 573.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 573.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 573.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 543.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 543.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 543.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 543.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 543.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 543.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 543.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 543.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 543.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 543.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 543.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 543.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 513.75 186.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
221.50 513.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
258.50 513.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
262.50 513.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
327.50 513.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
331.50 513.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
396.50 513.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
400.50 513.75 37.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 513.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 513.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 513.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 513.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
221.5 695.75 m
258.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
258.5 695.75 m
262.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 695.75 m
327.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
327.5 695.75 m
331.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 695.75 m
396.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
400.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 695.75 m
441.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 695.75 m
506.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 695.75 m
510.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 695.75 m
575.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
221.5 663.75 m
258.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 663.75 m
327.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 663.75 m
396.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
400.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
400.5 663.75 m
437.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 663.75 m
506.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 663.75 m
575.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 663.75 m
396.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 663.75 m
575.5 663.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 528.75 m
327.5 528.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 528.75 m
396.5 528.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 528.75 m
506.5 528.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 528.75 m
575.5 528.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 513.75 m
327.5 513.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 513.75 m
396.5 513.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 513.75 m
506.5 513.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 513.75 m
575.5 513.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 498.75 m
327.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 472.75 m
327.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
262.5 470.75 m
327.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 498.75 m
396.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 472.75 m
396.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
331.5 470.75 m
396.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 498.75 m
506.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 472.75 m
506.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 470.75 m
506.5 470.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 498.75 m
575.5 498.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 472.75 m
575.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 470.75 m
575.5 470.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 276.25 699.98 Td (December) Tj ET Q
q 0 0 0 rg BT 310.82 699.98 Td ( 31, 2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 455.25 699.98 Td (December) Tj ET Q
q 0 0 0 rg BT 489.82 699.98 Td ( 31, 2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 224.35 687.18 Td (Effective) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 226.20 677.58 Td (Inter) Tj ET Q
q 0 0 0 rg BT 243.46 677.58 Td (est) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 231.50 667.98 Td (Rate) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 278.70 677.58 Td (Principal) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 280.45 667.98 Td (Amount) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 347.70 677.58 Td (Carrying) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 349.45 667.98 Td (Amount) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 403.35 687.18 Td (Effective) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 405.20 677.58 Td (Inter) Tj ET Q
q 0 0 0 rg BT 422.46 677.58 Td (est) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 410.50 667.98 Td (Rate) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.70 677.58 Td (Principal) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 459.45 667.98 Td (Amount) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 526.70 677.58 Td (Carrying) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 528.45 667.98 Td (Amount) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 653.42 Td (7.25% Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 653.42 Td (7.25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 653.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.15 653.42 Td (8,294) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.15 653.42 Td (8,294) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 653.42 Td (7.91) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 653.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 653.42 Td (400,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 653.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 653.42 Td (392,947) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 638.42 Td (5.75% Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 638.42 Td (5.75) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 638.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.15 638.42 Td (182,479) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.15 638.42 Td (182,479) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 638.42 Td (6.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 638.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 638.42 Td (700,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 638.42 Td (694,464) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 623.42 Td (5.375% Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 623.42 Td (5.62) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 623.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.15 623.42 Td (210,440) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.15 623.42 Td (209,018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 623.42 Td (5.62) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 623.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 623.42 Td (750,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 623.42 Td (743,438) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 608.42 Td (6.00% Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 608.42 Td (6.28) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 608.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 608.42 Td (1,439,840) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 608.42 Td (1,426,998) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 608.42 Td (6.28) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 608.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 608.42 Td (1,635,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 608.42 Td (1,616,817) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 593.42 Td (5.875% Senior Secured Notes due 2024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 593.42 Td (6.14) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 593.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.15 593.42 Td (300,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.15 593.42 Td (296,647) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 593.42 Td (6.14) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 593.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 593.42 Td (300,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 593.42 Td (296,062) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 578.42 Td (6.00% Senior Notes due 2025) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 578.42 Td (6.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 578.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 578.42 Td (1,200,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 578.42 Td (1,185,726) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 578.42 Td (6.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 578.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 578.42 Td (1,200,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 578.42 Td (1,183,415) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 563.42 Td (7.50% Senior Secured Notes due 2027) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 563.42 Td (7.71) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 563.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 563.42 Td (1,500,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 563.42 Td (1,482,212) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 563.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 563.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 548.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 548.42 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 548.42 Td (6.21) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 548.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 548.42 Td (3,329,625) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 548.42 Td (3,302,675) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.10 548.42 Td (7.02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.65 548.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 548.42 Td (3,363,775) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 548.42 Td (3,331,276) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 533.42 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.10 533.42 Td (4.25) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.65 533.42 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.15 533.42 Td (300,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.15 533.42 Td (300,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 533.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 533.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 518.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 518.42 Td (otal long-term debt, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.00 518.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 518.42 Td (8,470,678) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.00 518.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 518.42 Td (8,394,049) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 518.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 518.42 Td (8,348,775) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 518.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 518.42 Td (8,258,419) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 503.42 Td (Less current portion, net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.15 503.42 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.15 503.42 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 503.42 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 503.42 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 488.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 488.42 Td (otal long-term debt, less current portion,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 476.42 Td (net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.00 476.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 283.65 476.42 Td (8,436,528) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.00 476.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.65 476.42 Td (8,359,899) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 476.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 476.42 Td (8,314,625) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 476.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 476.42 Td (8,224,269) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 454.25 Td (The Company and its subsidiaries, with certain customary exceptions, guarantee or serve as issuers or borrowers of the debt ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 442.25 Td (instruments representing substantially all of the Company�) Tj ET Q
q 0 0 0 rg BT 269.85 442.25 Td (s indebtedness at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.11 442.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.70 442.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.20 442.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 423.51 442.25 Td (The obligations under \(i\) all of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 430.25 Td (senior secured notes and \(ii\) the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.96 430.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 192.90 430.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.32 430.25 Td ( \(as defined below\) and related loan documents are secured on a ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 496.10 430.25 Td (pari passu ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.56 430.25 Td (basis by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 418.25 Td (a perfected first priority \(subject to certain permitted liens\) lien on the collateral securing such instruments, which collateral represents ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 406.25 Td (substantially all of the assets of the issuers or borrowers and the guarantors party thereto \(subject to customary exceptions\). Our senior ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 394.25 Td (unsecured notes are unsecured and ef) Tj ET Q
q 0 0 0 rg BT 184.92 394.25 Td (fectively subordinated in right of priority to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.54 394.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 403.48 394.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.90 394.25 Td ( and our senior secured notes, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 382.25 Td (in each case to the extent of the value of the collateral securing such instruments.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 364.25 Td (The aggregate estimated fair value of the Company�) Tj ET Q
q 0 0 0 rg BT 270.97 364.25 Td (s long-term debt, which was estimated using inputs based on quoted market ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 352.25 Td (prices for the same or similar debt issuances, was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.94 352.25 Td ($7.4 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.05 352.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.49 352.25 Td ($7.2 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.61 352.25 Td ( at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.82 352.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.41 352.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.85 352.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.43 352.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.25 Td (respectively) Tj ET Q
q 0 0 0 rg BT 83.66 340.25 Td (. Based on this valuation methodology) Tj ET Q
q 0 0 0 rg BT 236.88 340.25 Td (, we determined these debt instruments represent Level 2 measurements within the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 328.25 Td (fair value hierarchy) Tj ET Q
q 0 0 0 rg BT 113.64 328.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 310.25 Td (Credit Facilities) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 292.25 Td (The Company and certain of its subsidiaries are party to a credit agreement \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.99 292.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 412.93 292.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.36 292.25 Td (\), which provides for \(i\) a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.25 Td ($1,000.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.39 280.25 Td ( senior secured revolving credit facility \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.82 280.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.04 280.25 Td (\) and \(ii\) a senior secured term loan facility in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 268.25 Td (an initial principal amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.14 268.25 Td ($3,415.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.53 268.25 Td ( \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.89 268.25 Td (T) Tj ET Q
q 0 0 0 rg BT 247.30 268.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.95 268.25 Td ( and, together with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 268.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.71 268.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.43 268.25 Td (Credit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.25 Td (Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.66 256.25 Td (\). Current amounts outstanding under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.57 256.25 Td (Credit Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.73 256.25 Td ( are set forth in the table above. ) Tj ET Q
q 0 0 0 rg BT 431.74 256.25 Td (After giving ef) Tj ET Q
q 0 0 0 rg BT 490.98 256.25 Td (fect to borrowings ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.25 Td (under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.99 244.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.20 244.25 Td ( and previously issued and outstanding letters of credit, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.74 244.25 Td ($696.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.63 244.25 Td ( of remaining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.25 Td (credit is available under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.01 232.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.22 232.25 Td ( as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.38 232.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.96 232.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 358.78 232.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 418.50 232.25 Td (s outstanding debt agreements contain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.25 Td (a number of restrictive covenants, including certain limitations on the Company�) Tj ET Q
q 0 0 0 rg BT 358.42 220.25 Td (s ability to incur additional indebtedness.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 202.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.05 202.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 109.99 202.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.41 202.25 Td ( contains af) Tj ET Q
q 0 0 0 rg BT 200.33 202.25 Td (firmative and negative covenants that the Company believes to be usual and customary for a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.25 Td (senior secured credit facility of this type. ) Tj ET Q
q 0 0 0 rg BT 201.87 190.25 Td (The negative covenants include, among other things, limitations on asset sales, mer) Tj ET Q
q 0 0 0 rg BT 534.95 190.25 Td (gers and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 178.25 Td (acquisitions, indebtedness, liens, dividends and other restricted payments, investments and transactions with the Company�) Tj ET Q
q 0 0 0 rg BT 527.85 178.25 Td (s af) Tj ET Q
q 0 0 0 rg BT 541.83 178.25 Td (filiates. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 166.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 60.44 166.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.03 166.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.47 166.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.05 166.25 Td (, we were in compliance with all such covenants.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 148.25 Td (In addition, after each fiscal year) Tj ET Q
q 0 0 0 rg BT 196.40 148.25 Td (-end, the Company is required to perform a calculation of Excess Cash Flow \(as defined in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 62.94 136.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.37 136.25 Td (\), which could result in certain pre-payments of the principal relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.42 136.25 Td (T) Tj ET Q
q 0 0 0 rg BT 415.83 136.25 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.47 136.25 Td ( in accordance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.25 Td (the terms of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.98 124.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 127.92 124.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.35 124.25 Td (. No such payment is required at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.54 124.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.12 124.25 Td (.) Tj ET Q
endstream
endobj
239 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 240 0 R>>
endobj
240 0 obj
<</Length 17614>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-40) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 749.10 Td (The commitments under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.97 749.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.18 749.10 Td ( generally mature in 2024, with the exception of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.12 749.10 Td ($76.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.02 749.10 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (commitments that mature in 2022. Principal payments on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.44 737.10 Td (T) Tj ET Q
q 0 0 0 rg BT 287.85 737.10 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.50 737.10 Td ( equal to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.43 737.10 Td (0.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.26 737.10 Td ( of the initial principal amount are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (generally payable quarterly until the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.26 725.10 Td (T) Tj ET Q
q 0 0 0 rg BT 188.67 725.10 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.32 725.10 Td (�) Tj ET Q
q 0 0 0 rg BT 263.09 725.10 Td (s ultimate maturity date in 2024, at which time the remaining principal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (amount outstanding will be payable. However) Tj ET Q
q 0 0 0 rg BT 220.00 713.10 Td (, with certain exceptions set forth in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.79 713.10 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 407.73 713.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.15 713.10 Td (, maturities under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.63 713.10 Td (Credit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (Facilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.66 701.10 Td ( will be accelerated if any of the following of our senior notes are not refinanced or repaid in full at least 91 days prior to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (respective maturity dates thereof:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 663.60 461.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.50 663.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
500.50 663.60 75.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 633.60 461.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
496.50 633.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
500.50 633.60 75.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 663.6 m
496.5 663.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
500.5 663.6 m
575.5 663.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 667.83 Td (Instrument) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 512.95 667.83 Td (Maturity Date) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 653.27 Td (7.25% Senior Notes Due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.40 653.27 Td (January 15, 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 638.27 Td (5.75% Senior Notes Due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.40 638.27 Td (January 15, 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 623.27 Td (5.375% Senior Notes Due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.40 623.27 Td (January 15, 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 608.27 Td (6.00% Senior Notes Due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.80 608.27 Td (July 15, 2023) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 586.10 Td (Borrowings under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.71 586.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.92 586.10 Td ( bear interest, at the borrower) Tj ET Q
q 0 0 0 rg BT 375.01 586.10 Td (�) Tj ET Q
q 0 0 0 rg BT 377.79 586.10 Td (s election, at a rate equal to \(i\) an applicable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (mar) Tj ET Q
q 0 0 0 rg BT 51.37 574.10 Td (gin between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.46 574.10 Td (1.50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.29 574.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.73 574.10 Td (3.00%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.56 574.10 Td ( depending on the Company�) Tj ET Q
q 0 0 0 rg BT 289.10 574.10 Td (s ) Tj ET Q
q 0 0 0 rg BT 295.31 574.10 Td (T) Tj ET Q
q 0 0 0 rg BT 300.72 574.10 Td (otal Net Leverage Ratio plus ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.18 574.10 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 448.18 574.10 Td ( or \(ii\) an applicable mar) Tj ET Q
q 0 0 0 rg BT 547.12 574.10 Td (gin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 562.10 Td (between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.82 562.10 Td (0.50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.65 562.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.08 562.10 Td (2.00%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.91 562.10 Td ( depending on the Company�) Tj ET Q
q 0 0 0 rg BT 258.45 562.10 Td (s ) Tj ET Q
q 0 0 0 rg BT 264.66 562.10 Td (T) Tj ET Q
q 0 0 0 rg BT 270.07 562.10 Td (otal Net Leverage Ratio plus the ) Tj ET Q
q 0 0 0 rg BT 401.70 562.10 Td (Alternate Base Rate \(as defined in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 550.10 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 62.94 550.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.37 550.10 Td (\). In addition, borrowings under our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.27 550.10 Td (T) Tj ET Q
q 0 0 0 rg BT 258.68 550.10 Td (erm Loan Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.33 550.10 Td ( bear interest, at the borrower) Tj ET Q
q 0 0 0 rg BT 448.42 550.10 Td (�) Tj ET Q
q 0 0 0 rg BT 451.20 550.10 Td (s election, at a rate equal to \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 538.10 Td (4.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.83 538.10 Td ( plus ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.50 538.10 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.50 538.10 Td (, subject to a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.54 538.10 Td (LIBOR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.54 538.10 Td ( floor of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.81 538.10 Td (0.75%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.64 538.10 Td (, or \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.19 538.10 Td (3.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 314.02 538.10 Td ( plus the ) Tj ET Q
q 0 0 0 rg BT 349.85 538.10 Td (Alternate Base Rate, subject to an ) Tj ET Q
q 0 0 0 rg BT 487.31 538.10 Td (Alternate Base Rate ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 526.10 Td (floor of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.77 526.10 Td (1.75%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.60 526.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 508.10 Td (Senior Notes and Senior Secured Notes) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 490.10 Td (Our various senior notes and senior secured notes mature between 2022 and 2027. ) Tj ET Q
q 0 0 0 rg BT 396.40 490.10 Td (The indentures governing these notes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (generally allow for redemption prior to maturity) Tj ET Q
q 0 0 0 rg BT 228.07 478.10 Td (, in whole or in part, subject to certain restrictions and limitations described therein, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 466.10 Td (the following ways:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 454.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 454.10 Td (Until ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.56 454.10 Td (a date specified in each indenture \(the Non-Call Period\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.80 454.10 Td (, the notes may be redeemed, in whole or in part, by paying ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 442.10 Td (the sum of: \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.93 442.10 Td (100%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.26 442.10 Td ( of the principal amount being redeemed, \(ii\) an applicable make-whole premium as described in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 430.10 Td (each indenture and \(iii\) accrued and unpaid interest. ) Tj ET Q
q 0 0 0 rg BT 295.13 430.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.58 430.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.16 430.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.88 430.10 Td (Non-Call Period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.70 430.10 Td ( has expired for each ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 418.10 Td (of our notes except for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.24 418.10 Td (5.875%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.07 418.10 Td ( Senior Secured Notes due 2024, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.37 418.10 Td (6.00%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.20 418.10 Td ( Senior Notes due 2025 and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.23 418.10 Td (7.50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.06 418.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 406.10 Td (Senior Secured Notes due 2027.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 394.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 394.10 Td (After the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.82 394.10 Td (Non-Call Period) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.64 394.10 Td ( specified in each indenture, the notes may be redeemed, in whole or in part, at redemption ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 382.10 Td (prices set forth in each indenture, plus accrued and unpaid interest. ) Tj ET Q
q 0 0 0 rg BT 354.94 382.10 Td (The redemption prices for each of our notes vary over ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 370.10 Td (time. ) Tj ET Q
q 0 0 0 rg BT 108.09 370.10 Td (The redemption prices pursuant to this clause range from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.85 370.10 Td (100.000%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.68 370.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 392.46 370.10 Td (105.625%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.29 370.10 Td ( of principal at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.38 370.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 572.97 370.10 Td (; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 358.10 Td (however) Tj ET Q
q 0 0 0 rg BT 119.53 358.10 Td (, these redemption prices generally decrease to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.89 358.10 Td (100%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.22 358.10 Td ( of the principal amount of the applicable notes over time as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 346.10 Td (the notes approach maturity pursuant to a step-down schedule set forth in each of the indentures.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 334.10 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 334.10 Td (Until a date specified in each indenture, the notes may be redeemed, in part \(up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.38 334.10 Td (35%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.71 334.10 Td ( of the principal amount ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 322.10 Td (outstanding\), with the net cash proceeds from specified equity of) Tj ET Q
q 0 0 0 rg BT 344.69 322.10 Td (ferings at redemption prices set forth in each indenture, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 310.10 Td (plus accrued and unpaid interest. ) Tj ET Q
q 0 0 0 rg BT 218.79 310.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 243.23 310.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.82 310.10 Td (, this clause has expired for each of our notes except for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 298.10 Td (5.875%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.33 298.10 Td ( Senior Secured Notes due 2024 and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.07 298.10 Td (7.50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.90 298.10 Td ( Senior Secured Notes due 2027, for which the specified ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 286.10 Td (redemption premiums are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.74 286.10 Td (105.875%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.57 286.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.01 286.10 Td (107.500%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.84 286.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 344.50 286.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 268.10 Td (The indentures governing our various senior notes contain af) Tj ET Q
q 0 0 0 rg BT 306.09 268.10 Td (firmative and negative covenants that the Company believes to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 256.10 Td (usual and customary for similar indentures. Under the senior secured notes indentures, the negative covenants, among other things, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 244.10 Td (restrict the Company�) Tj ET Q
q 0 0 0 rg BT 122.65 244.10 Td (s ability and the ability of its restricted subsidiaries \(as defined in the indentures\) to incur certain additional ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 232.10 Td (indebtedness and issue preferred stock; make certain dividends, distributions, investments and other restricted payments; sell certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 220.10 Td (assets; enter into sale and leaseback transactions; agree to certain restrictions on the ability of restricted subsidiaries to make certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 208.10 Td (payments to the Company or any of its restricted subsidiaries; create certain liens; mer) Tj ET Q
q 0 0 0 rg BT 381.55 208.10 Td (ge, consolidate or sell all or substantially all of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.10 Td (the Company�) Tj ET Q
q 0 0 0 rg BT 92.38 196.10 Td (s assets; enter into certain transactions with af) Tj ET Q
q 0 0 0 rg BT 275.76 196.10 Td (filiates or designate subsidiaries as unrestricted subsidiaries. Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.10 Td (senior unsecured notes indentures, the negative covenants, among other things, restrict the ability of Endo Designated ) Tj ET Q
q 0 0 0 rg BT 508.93 184.10 Td (Activity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 172.10 Td (Company and its restricted subsidiaries \(as defined in the indentures\) to incur certain additional indebtedness and issue preferred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 160.10 Td (stock; make certain dividends, distributions, investments and other restricted payments; sell certain assets; enter into sale and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 148.10 Td (leaseback transactions; agree to certain restrictions on the ability of restricted subsidiaries to make certain payments to the issuer or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 136.10 Td (any of the restricted subsidiaries; create certain liens; mer) Tj ET Q
q 0 0 0 rg BT 266.28 136.10 Td (ge, consolidate or sell all or substantially all of Endo Designated ) Tj ET Q
q 0 0 0 rg BT 526.22 136.10 Td (Activity ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 124.10 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 124.10 Td (s, its co-issuers�) Tj ET Q
q 0 0 0 rg BT 141.08 124.10 Td ( or guarantors�) Tj ET Q
q 0 0 0 rg BT 199.21 124.10 Td ( assets; enter into certain transactions with af) Tj ET Q
q 0 0 0 rg BT 378.69 124.10 Td (filiates or designate subsidiaries as unrestricted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 112.10 Td (subsidiaries. ) Tj ET Q
q 0 0 0 rg BT 88.04 112.10 Td (These covenants are subject to a number of exceptions and qualifications, including the fall away or revision of certain of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.10 Td (these covenants and release of collateral in the case of the senior secured notes, upon the notes receiving investment grade credit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.10 Td (ratings. ) Tj ET Q
q 0 0 0 rg BT 67.67 88.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.11 88.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 170.69 88.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 190.13 88.10 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 268.71 88.10 Td (, we were in compliance with all such covenants. ) Tj ET Q
q 0 0 0 rg BT 466.71 88.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 516.61 88.10 Td (, pursuant to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.10 Td (the terms of the indentures governing certain of our senior unsecured notes, the restricted subsidiaries of Endo International plc, whose ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.10 Td (assets comprise substantially all of the Company�) Tj ET Q
q 0 0 0 rg BT 233.74 64.10 Td (s consolidated total assets after intercompany eliminations, are subject to various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 52.10 Td (restrictions limiting their ability to transfer assets in excess of certain thresholds to Endo International plc.) Tj ET Q
endstream
endobj
241 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 242 0 R>>
endobj
242 0 obj
<</Length 18216>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-41) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (Debt Financing T) Tj ET Q
q 0 0 0 rg BT 109.53 749.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (Set forth below are certain disclosures relating to debt financing transactions that occurred during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.36 731.25 Td (years ended December ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.44 719.25 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 701.25 Td (April 2017 Refinancing) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 683.25 Td (In ) Tj ET Q
q 0 0 0 rg BT 75.28 683.25 Td (April 2017, the Company executed certain transactions \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.48 683.25 Td (April 2017 Refinancing ) Tj ET Q
q 0 0 0 rg BT 412.78 683.25 Td (T) Tj ET Q
q 0 0 0 rg BT 418.54 683.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.53 683.25 Td (\) that included entry into a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.25 Td (credit agreement, which provided for a term loan facility and a revolving credit facility) Tj ET Q
q 0 0 0 rg BT 382.99 671.25 Td (, and the issuance of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.85 671.25 Td ($300.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.74 671.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.07 671.25 Td (5.875%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.90 671.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.25 Td (Senior Secured Notes due 2024 \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.63 659.25 Td (2024 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.46 659.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 236.61 659.25 Td (The Company used the net proceeds from this term loan facility) Tj ET Q
q 0 0 0 rg BT 491.44 659.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.16 659.25 Td (2024 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.99 659.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.25 Td (cash on hand to refinance certain of its prior indebtedness and to pay related fees and expenses.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 629.25 Td (In connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.65 629.25 Td (April 2017 Refinancing ) Tj ET Q
q 0 0 0 rg BT 253.95 629.25 Td (T) Tj ET Q
q 0 0 0 rg BT 259.70 629.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.69 629.25 Td (, the Company incurred new debt issuance costs of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.25 Td ($56.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 617.25 Td (, which were allocated among the new debt instruments as follows: \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.87 617.25 Td ($41.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.76 617.25 Td ( to the new term loan facility) Tj ET Q
q 0 0 0 rg BT 541.63 617.25 Td (, \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.25 Td ($10.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 605.25 Td ( to the new revolving credit facility and \(iii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.89 605.25 Td ($4.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 316.78 605.25 Td ( to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.28 605.25 Td (2024 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.11 605.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 394.93 605.25 Td (These costs, together with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.84 605.25 Td ($10.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 555.74 605.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.25 Td (the previously deferred debt issuance costs associated with our prior revolving credit facility) Tj ET Q
q 0 0 0 rg BT 405.23 593.25 Td (, were deferred to be amortized as interest ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.25 Td (expense over the terms of the respective instruments. ) Tj ET Q
q 0 0 0 rg BT 250.47 581.25 Td (The remaining ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.56 581.25 Td ($51.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.45 581.25 Td ( of deferred debt issuance costs associated with our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.25 Td (prior revolving and term loan facilities were char) Tj ET Q
q 0 0 0 rg BT 232.13 569.25 Td (ged to expense in the second quarter of 2017. ) Tj ET Q
q 0 0 0 rg BT 415.78 569.25 Td (These net expenses were included in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.25 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 557.25 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.08 557.25 Td ( line item in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.35 557.25 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.71 557.25 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 539.25 Td (Mar) Tj ET Q
q 0 0 0 rg BT 66.35 539.25 Td (ch 2019 Refinancing) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 521.25 Td (In March 2019, the Company executed certain transactions \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.58 521.25 Td (March 2019 Refinancing ) Tj ET Q
q 0 0 0 rg BT 421.87 521.25 Td (T) Tj ET Q
q 0 0 0 rg BT 427.62 521.25 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.61 521.25 Td (\) that included:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 509.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 509.25 Td (entry into an amendment \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.74 509.25 Td (Revolving Credit Facility ) Tj ET Q
q 0 0 0 rg BT 309.90 509.25 Td (Amendment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.33 509.25 Td (\) to the Company�) Tj ET Q
q 0 0 0 rg BT 431.82 509.25 Td (s existing credit agreement, which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 497.25 Td (was originally dated ) Tj ET Q
q 0 0 0 rg BT 168.54 497.25 Td (April 27, 2017 \(the amended credit agreement is described above under the heading �) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.63 497.25 Td (Credit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 485.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.92 485.25 Td (�\);) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 473.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 473.25 Td (issuance of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.71 473.25 Td ($1,500.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.10 473.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.43 473.25 Td (7.50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.26 473.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.76 473.25 Td (Senior Secured Notes due 2027) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 366.84 473.25 Td ( \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.39 473.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.22 473.25 Td (\); ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 461.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 461.25 Td (repurchase of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.14 461.25 Td ($1,642.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.53 461.25 Td ( aggregate principal amount of certain of the Company�) Tj ET Q
q 0 0 0 rg BT 430.67 461.25 Td (s senior unsecured notes for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 449.25 Td ($1,500.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.89 449.25 Td ( in cash, excluding accrued interest \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.94 449.25 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.30 449.25 Td (\); and) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 437.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 437.25 Td (solicitation of consents from the holders of the existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.51 437.25 Td (7.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.34 437.25 Td ( Senior Notes due 2022 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.66 437.25 Td (5.75%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.49 437.25 Td ( Senior Notes due 2022 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 425.25 Td (\(together) Tj ET Q
q 0 0 0 rg BT 121.19 425.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.91 425.25 Td (Consent Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.52 425.25 Td (\) to certain amendments to the indentures governing such notes, which eliminated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 413.25 Td (substantially all of the restrictive covenants, certain events of default and other provisions contained in each such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 401.25 Td (indenture.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 383.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 383.25 Td (Revolving Credit Facility ) Tj ET Q
q 0 0 0 rg BT 185.21 383.25 Td (Amendment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.64 383.25 Td ( amended the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.45 383.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 317.39 383.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.82 383.25 Td ( to, among other things, \(i\) extend the maturity of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.25 Td (commitments under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.92 371.25 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.14 371.25 Td ( from ) Tj ET Q
q 0 0 0 rg BT 259.02 371.25 Td (April ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.63 371.25 Td (2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.63 371.25 Td ( to March ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.01 371.25 Td (2024) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.01 371.25 Td ( \(with the exception of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.04 371.25 Td ($76.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.93 371.25 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.25 Td (commitments that were not extended\), \(ii\) provide greater covenant flexibility by increasing the maximum Secured Net Leverage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.25 Td (Ratio described in the Financial Covenant \(as defined in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.15 347.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 305.10 347.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.52 347.25 Td (\) from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 377.29 347.25 Td (3.50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 394.79 347.25 Td ( to 1.00 to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.85 347.25 Td (4.50) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.35 347.25 Td ( to 1.00 and \(iii\) limit the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.25 Td (scenarios under which such Financial Covenant will be tested.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 317.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 317.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.88 317.25 Td ( were issued by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.31 317.25 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.76 317.25 Td (, a wholly-owned indirect subsidiary of the Company) Tj ET Q
q 0 0 0 rg BT 418.40 317.25 Td (, in a private of) Tj ET Q
q 0 0 0 rg BT 479.03 317.25 Td (fering to �qualified ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.25 Td (institutional buyers� \(as defined in Rule 144A) Tj ET Q
q 0 0 0 rg BT 219.86 305.25 Td ( under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.34 305.25 Td (Securities ) Tj ET Q
q 0 0 0 rg BT 303.72 305.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.16 305.25 Td (\) and outside the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.04 305.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.82 305.25 Td ( to non-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.93 305.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.71 305.25 Td ( persons in compliance with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.25 Td (Regulation S under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.43 293.25 Td (Securities ) Tj ET Q
q 0 0 0 rg BT 171.81 293.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.25 293.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 191.07 293.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.12 293.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.95 293.25 Td ( are guaranteed on a senior secured basis by the Company and its subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.25 Td (that also guarantee the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.18 281.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 155.13 281.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 199.55 281.25 Td ( \(collectively) Tj ET Q
q 0 0 0 rg BT 251.38 281.25 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.09 281.25 Td (Guarantors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.52 281.25 Td (\). ) Tj ET Q
q 0 0 0 rg BT 323.67 281.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.72 281.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.55 281.25 Td ( are senior secured obligations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.50 281.25 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 536.96 281.25 Td ( and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.25 Td (Guarantors) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.43 269.25 Td ( and are secured by the same collateral that secures the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.71 269.25 Td (Credit ) Tj ET Q
q 0 0 0 rg BT 328.66 269.25 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.08 269.25 Td ( and the Company�) Tj ET Q
q 0 0 0 rg BT 448.90 269.25 Td (s existing senior secured notes. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 257.25 Td (Interest on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.70 257.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.53 257.25 Td ( is payable semiannually in arrears on ) Tj ET Q
q 0 0 0 rg BT 294.54 257.25 Td (April 1 and October 1 of each year) Tj ET Q
q 0 0 0 rg BT 433.25 257.25 Td (, beginning on October 1, 2019.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 239.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.05 239.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.88 239.25 Td ( will mature on ) Tj ET Q
q 0 0 0 rg BT 191.65 239.25 Td (April 1, 2027; however) Tj ET Q
q 0 0 0 rg BT 284.56 239.25 Td (, the indenture governing these notes generally allow for redemption ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 227.25 Td (prior to maturity) Tj ET Q
q 0 0 0 rg BT 101.45 227.25 Td (, in whole or in part, subject to certain restrictions and limitations described therein, in the following ways:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 215.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 215.25 Td (Before ) Tj ET Q
q 0 0 0 rg BT 114.66 215.25 Td (April 1, 2022, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.98 215.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.81 215.25 Td ( may be redeemed, in whole or in part, by paying the sum of: \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.35 215.25 Td (100%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.68 215.25 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 203.25 Td (principal amount being redeemed, \(ii\) an applicable make-whole premium as described in the indenture and \(iii\) accrued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 191.25 Td (and unpaid interest.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 179.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 179.25 Td (On or after ) Tj ET Q
q 0 0 0 rg BT 131.32 179.25 Td (April 1, 2022, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.64 179.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.47 179.25 Td ( may be redeemed, in whole or in part, at redemption prices set forth in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 167.25 Td (indenture, plus accrued and unpaid interest. ) Tj ET Q
q 0 0 0 rg BT 261.93 167.25 Td (The redemption prices for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.27 167.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.10 167.25 Td ( vary over time pursuant to a step-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 155.25 Td (down schedule set forth in the indenture, beginning at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 303.22 155.25 Td (105.625%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.05 155.25 Td ( of the principal amount redeemed and decreasing to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 143.25 Td (100%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.83 143.25 Td ( by ) Tj ET Q
q 0 0 0 rg BT 123.28 143.25 Td (April 1, 2025.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.00 131.25 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 131.25 Td (Before ) Tj ET Q
q 0 0 0 rg BT 114.66 131.25 Td (April 1, 2022, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.98 131.25 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.81 131.25 Td ( may be redeemed, in part \(up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 366.26 131.25 Td (35%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.59 131.25 Td ( of the principal amount outstanding\), with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 119.25 Td (net cash proceeds from specified equity of) Tj ET Q
q 0 0 0 rg BT 254.70 119.25 Td (ferings at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.68 119.25 Td (107.500%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.51 119.25 Td ( of the principal amount redeemed, plus accrued and unpaid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.50 107.25 Td (interest.) Tj ET Q
endstream
endobj
243 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 244 0 R>>
endobj
244 0 obj
<</Length 18703>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-42) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The Company used the net proceeds from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 247.39 749.10 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 293.22 749.10 Td ( and cash on hand primarily to fund the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.90 749.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.27 749.10 Td ( and to pay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (certain premiums, fees and expenses related thereto. ) Tj ET Q
q 0 0 0 rg BT 247.12 737.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.17 737.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.53 737.10 Td ( were completed by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.61 737.10 Td (Endo Finance LLC \(Endo Finance\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.69 737.10 Td (, a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (wholly-owned subsidiary of the Company) Tj ET Q
q 0 0 0 rg BT 203.66 725.10 Td (, pursuant to a tender of) Tj ET Q
q 0 0 0 rg BT 298.45 725.10 Td (fer to repurchase portions of the Company�) Tj ET Q
q 0 0 0 rg BT 470.62 725.10 Td (s outstanding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.18 725.10 Td (7.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.01 725.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.38 713.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.38 713.10 Td (5.75%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.21 713.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 160.71 713.10 Td (Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 252.08 713.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.08 713.10 Td (5.375%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.91 713.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.41 713.10 Td (Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.79 713.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.23 713.10 Td (6.00%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.06 713.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.56 713.10 Td (Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.94 713.10 Td (. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.37 701.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.73 701.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.73 701.10 Td (Endo Finance) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.00 701.10 Td ( repurchased ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.30 701.10 Td ($1,642.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.70 701.10 Td ( of senior unsecured note indebtedness, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (representing the aggregate principal amount repurchased, for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.01 689.10 Td ($1,500.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.40 689.10 Td ( in cash \(including certain cash premiums related ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (thereto\). ) Tj ET Q
q 0 0 0 rg BT 71.91 677.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.96 677.10 Td ($1,642.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.35 677.10 Td ( aggregate repurchase amount consisted of \(i\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.00 677.10 Td ($389.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.89 677.10 Td ( aggregate principal amount of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.84 677.10 Td (7.25%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.67 677.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.38 665.10 Td (, \(ii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.09 665.10 Td ($517.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.99 665.10 Td ( aggregate principal amount of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.93 665.10 Td (5.75%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.76 665.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.26 665.10 Td (Senior Notes due 2022) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.64 665.10 Td (, \(iii\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.13 665.10 Td ($539.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.03 665.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (aggregate principal amount of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.45 653.10 Td (5.375%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.28 653.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.78 653.10 Td (Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.15 653.10 Td ( and \(iv\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.53 653.10 Td ($195.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.42 653.10 Td ( aggregate principal amount of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.37 653.10 Td (6.00%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.20 653.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (Senior Notes due 2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.38 641.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 132.20 641.10 Td (The aggregate carrying amount of notes repurchased was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.21 641.10 Td ($1,624.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.60 641.10 Td (. In conjunction with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.14 641.10 Td (Notes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.54 629.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.54 629.10 Td (Endo Finance) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.80 629.10 Td ( also solicited consents from holders of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.65 629.10 Td (Consent Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 379.26 629.10 Td ( to certain proposed amendments to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (applicable indentures under which each series of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.87 617.10 Td (Consent Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.47 617.10 Td ( were issued, which would eliminate substantially all restrictive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td (covenants, certain events of default and certain other provisions contained in each such indenture. ) Tj ET Q
q 0 0 0 rg BT 429.56 605.10 Td (The proposed amendments were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 43.59 593.10 Td (fected pursuant to a supplemental indenture to each such indenture executed by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.47 593.10 Td (Endo Finance) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.73 593.10 Td ( and the guarantors of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 523.14 593.10 Td (Consent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.10 Td (Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.33 581.10 Td (, which became operative upon the repurchase of at least the requisite consent amount of the applicable series of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.82 581.10 Td (Consent Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.43 581.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.10 Td (tendered.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 551.10 Td (The dif) Tj ET Q
q 0 0 0 rg BT 91.97 551.10 Td (ference between the cash paid and the carrying amount of notes repurchased in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.61 551.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.98 551.10 Td ( resulted in a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td ($124.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.89 539.10 Td ( gain. In connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.81 539.10 Td (March 2019 Refinancing ) Tj ET Q
q 0 0 0 rg BT 314.10 539.10 Td (T) Tj ET Q
q 0 0 0 rg BT 319.85 539.10 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.84 539.10 Td (, we also incurred costs and fees totaling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.51 539.10 Td ($26.2 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 527.10 Td (, of which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.66 527.10 Td ($4.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.55 527.10 Td ( related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.75 527.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.12 527.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.12 527.10 Td ($19.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.01 527.10 Td ( related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.21 527.10 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.04 527.10 Td ( issuance and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.85 527.10 Td ($2.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.74 527.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 515.10 Td (related to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.70 515.10 Td (Revolving Credit Facility ) Tj ET Q
q 0 0 0 rg BT 194.86 515.10 Td (Amendment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.29 515.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 249.11 515.10 Td (The costs incurred in connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.12 515.10 Td (Notes Repurchases) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 493.49 515.10 Td ( were char) Tj ET Q
q 0 0 0 rg BT 534.94 515.10 Td (ged to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 503.10 Td (expense in the first quarter of 2019 and recorded as a partial of) Tj ET Q
q 0 0 0 rg BT 286.83 503.10 Td (fset to the gain. ) Tj ET Q
q 0 0 0 rg BT 350.80 503.10 Td (The costs incurred in connection with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.81 503.10 Td (2027 Notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 564.64 503.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 491.10 Td (issuance and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.03 491.10 Td (Revolving Credit Facility ) Tj ET Q
q 0 0 0 rg BT 208.19 491.10 Td (Amendment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 257.63 491.10 Td (, together with previously deferred debt issuance costs associated with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 479.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.56 479.10 Td (, have been deferred to be amortized as interest expense over the terms of the respective instruments. ) Tj ET Q
q 0 0 0 rg BT 543.06 479.10 Td (The net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 467.10 Td (gain resulting from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.87 467.10 Td (March 2019 Refinancing ) Tj ET Q
q 0 0 0 rg BT 232.16 467.10 Td (T) Tj ET Q
q 0 0 0 rg BT 237.91 467.10 Td (ransactions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.90 467.10 Td ( was included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.38 467.10 Td (\(Gain\) loss on extinguishment of debt) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.75 467.10 Td ( line item in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 455.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 455.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.08 455.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 437.10 Td (June 2019 ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 93.38 437.10 Td (Revolving Cr) Tj ET Q
q 0 0 0 rg BT 146.05 437.10 Td (edit Facility) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 194.64 437.10 Td ( Borr) Tj ET Q
q 0 0 0 rg BT 215.66 437.10 Td (owing) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 65.00 419.10 Td (In June 2019, the Company borrowed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.58 419.10 Td ($300.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.48 419.10 Td ( under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.96 419.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.52 419.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 426.34 419.10 Td (These proceeds will be used for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.10 Td (purposes consistent with the Company�) Tj ET Q
q 0 0 0 rg BT 193.21 407.10 Td (s capital allocation priorities, including for general corporate purposes.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 389.10 Td (Maturities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.00 371.10 Td (The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.36 371.10 Td (December�31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 359.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 335.60 471.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 335.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 335.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 305.60 471.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 305.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 305.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 275.60 471.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 275.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 275.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 335.6 m
575.5 335.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 518.80 339.83 Td (Maturities \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 325.27 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 325.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 325.27 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 310.27 Td (2021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 310.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 310.27 Td (34,150) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 295.27 Td (2022 \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 295.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 295.27 Td (247,723) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 280.27 Td (2023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 280.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 280.27 Td (1,684,430) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 265.27 Td (2024 \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 265.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 265.27 Td (3,770,225) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 251.50 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 241.90 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 241.90 Td (Certain amounts borrowed pursuant to the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 204.36 241.90 Td (Credit Facilities) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 255.68 241.90 Td ( will immediately mature if certain of our senior notes are not refinanced or repaid in full prior to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 232.30 Td (the date that is ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 115.93 232.30 Td (91) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 123.93 232.30 Td ( days prior to the respective stated maturity dates thereof. ) Tj ET Q
q 0 0 0 rg BT 308.98 232.30 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 348.45 232.30 Td (, we may seek to repay or refinance certain senior notes prior to their ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 222.70 Td (stated maturity dates. ) Tj ET Q
q 0 0 0 rg BT 137.56 222.70 Td (The amounts in this maturities table do not reflect any such early repayment or refinancing; rather) Tj ET Q
q 0 0 0 rg BT 450.68 222.70 Td (, they reflect stated maturity dates.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 213.10 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 213.10 Td (Based on the Company�) Tj ET Q
q 0 0 0 rg BT 144.16 213.10 Td (s borrowings under the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 219.70 213.10 Td (Revolving Credit Facility) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 301.47 213.10 Td ( that were outstanding at ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 382.11 213.10 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 444.98 213.10 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 448.98 213.10 Td ($22.8 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 492.09 213.10 Td ( will mature in 2022, with ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 203.50 Td (the remainder maturing in 2024.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.50 Td (NOTE 15. COMMITMENTS ) Tj ET Q
q 0 0 0 rg BT 163.79 173.50 Td (AND CONTINGENCIES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.50 Td (Manufacturing, Supply and Other Service ) Tj ET Q
q 0 0 0 rg BT 211.76 155.50 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 137.50 Td (Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.50 Td (in our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 111.91 125.50 Td ( products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 113.50 Td (support, warehouse and distribution services. If, for any reason, we are unable to obtain suf) Tj ET Q
q 0 0 0 rg BT 400.71 113.50 Td (ficient quantities of any of the finished ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.50 Td (goods or raw materials or components required for our products or services needed to conduct our business, it could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 530.86 101.50 Td (material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 89.50 Td (adverse ef) Tj ET Q
q 0 0 0 rg BT 76.63 89.50 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.61 89.50 Td (.) Tj ET Q
endstream
endobj
245 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 246 0 R>>
endobj
246 0 obj
<</Length 15334>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-43) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 749.10 Td (In addition to the manufacturing and supply agreements described above, we have agreements with various companies for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (clinical development services. ) Tj ET Q
q 0 0 0 rg BT 158.73 737.10 Td (Although we have no reason to believe that the parties to these agreements will not meet their ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (obligations, failure by any of these third parties to honor their contractual obligations may have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.72 725.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 502.61 725.10 Td (fect on our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.17 713.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 695.10 Td (Jubilant HollisterStier Laboratories LLC \(JHS\)) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 677.10 Td (During the second quarter of 2016, we entered into an agreement with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.96 677.10 Td (JHS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 362.63 677.10 Td ( \(the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.18 677.10 Td (JHS ) Tj ET Q
q 0 0 0 rg BT 401.80 677.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.23 677.10 Td (\). Pursuant to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.05 677.10 Td (JHS ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.42 665.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.42 665.10 Td (JHS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.10 665.10 Td ( fills and lyophilizes the XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 243.47 669.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 250.03 665.10 Td (bulk drug substance, which is manufactured by the Company) Tj ET Q
q 0 0 0 rg BT 494.05 665.10 Td (, and produces ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (sterile diluent. ) Tj ET Q
q 0 0 0 rg BT 95.53 653.10 Td (The initial term of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.78 653.10 Td (JHS ) Tj ET Q
q 0 0 0 rg BT 204.40 653.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.82 653.10 Td ( is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 260.49 653.10 Td (three years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.08 653.10 Td (, with automatic renewal provisions thereafter for subsequent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.50 653.10 Td (one) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.94 653.10 Td (-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. ) Tj ET Q
q 0 0 0 rg BT 510.67 641.10 Td (The Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (is required to purchase a specified percentage of its total forecasted volume of XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 393.37 633.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.93 629.10 Td (from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.87 629.10 Td (JHS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.54 629.10 Td ( each year) Tj ET Q
q 0 0 0 rg BT 478.67 629.10 Td (, unless ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.17 629.10 Td (JHS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.84 629.10 Td ( is unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (to supply XIAFLEX) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 118.22 621.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.78 617.10 Td (within the timeframe established under such forecasts. ) Tj ET Q
q 0 0 0 rg BT 344.16 617.10 Td (Amounts purchased pursuant to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.30 617.10 Td (JHS ) Tj ET Q
q 0 0 0 rg BT 506.93 617.10 Td (Agreement) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 551.35 617.10 Td ( were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td ($8.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.89 605.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 605.10 Td ($7.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.78 605.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.22 605.10 Td ($5.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.11 605.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.49 605.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.49 605.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 484.15 605.10 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (Milestones and Royalties) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (See ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.94 569.10 Td (Note 1) Tj ET Q
q 0 0 0 rg BT 106.51 569.10 Td (1. License and Collaboration ) Tj ET Q
q 0 0 0 rg BT 223.98 569.10 Td (Agreements) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.29 569.10 Td ( for a description of future milestone and royalty commitments pursuant to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (our material license and collaboration agreements.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (Legal Proceedings and Investigations) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 521.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 521.10 Td (e and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.10 Td (investigations \(collectively) Tj ET Q
q 0 0 0 rg BT 143.38 509.10 Td (, proceedings\) that arise from time to time, including, among others, those relating to product liability) Tj ET Q
q 0 0 0 rg BT 549.02 509.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (intellectual property) Tj ET Q
q 0 0 0 rg BT 116.15 497.10 Td (, regulatory compliance, consumer protection, tax and commercial matters. ) Tj ET Q
q 0 0 0 rg BT 418.36 497.10 Td (While we cannot predict the outcome ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (will be successful or obtain any requested relief. ) Tj ET Q
q 0 0 0 rg BT 231.21 473.10 Td (An adverse outcome in any of these proceedings could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.85 473.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 556.73 473.10 Td (fect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.50 461.10 Td (. Matters that are not being disclosed herein are, in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.10 Td (operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 425.10 Td (aggregate, we will disclose them.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 407.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 407.10 Td (e believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.10 Td (matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.10 Td (circumstances, insurance carriers reserve their rights to contest or deny coverage. ) Tj ET Q
q 0 0 0 rg BT 363.18 383.10 Td (W) Tj ET Q
q 0 0 0 rg BT 371.82 383.10 Td (e intend to contest vigorously any disputes with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (our insurance carriers and to enforce our rights under the terms of our insurance policies. ) Tj ET Q
q 0 0 0 rg BT 393.65 371.10 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 442.99 371.10 Td (, we will record receivables with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (respect to amounts due under these policies only when the realization of the potential claim for recovery is considered probable. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (Amounts recovered under our insurance policies could be materially less than stated coverage limits and may not be adequate to cover ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (damages, other relief and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.10 Td (will otherwise be available.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 305.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 305.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 305.10 Td (, our accrual for loss contingencies totaled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.63 305.10 Td ($513.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.53 305.10 Td (, the most significant components of which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.10 Td (relate to product liability and related matters associated with vaginal mesh. ) Tj ET Q
q 0 0 0 rg BT 337.57 293.10 Td (Although we believe there is a reasonable possibility that a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (recognized at this time.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.30 269.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 131.62 269.10 Td (While the timing of the resolution of certain of the matters accrued for as loss contingencies remains uncertain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 257.10 Td (and could extend beyond ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.75 257.10 Td (12 months) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.70 257.10 Td (, as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.36 257.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.94 257.10 Td (, the entire liability accrual amount is classified in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.82 257.10 Td (Current portion of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.10 Td (legal settlement accrual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.39 245.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.89 245.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.97 245.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 227.10 Td (Pr) Tj ET Q
q 0 0 0 rg BT 59.13 227.10 Td (oduct Liability and Related Matters) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 209.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 209.10 Td (e and certain of our subsidiaries have been named as defendants in numerous lawsuits in various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.86 209.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.64 209.10 Td ( federal and state courts, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (and in Canada, ) Tj ET Q
q 0 0 0 rg BT 97.65 197.10 Td (Australia and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (including the product liability and other related matters described below in more detail.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 167.10 Td (V) Tj ET Q
q 0 0 0 rg BT 68.56 167.10 Td (aginal Mesh.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.46 167.10 Td ( Since 2008, we and certain of our subsidiaries, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.08 167.10 Td (AMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.75 167.10 Td ( \(subsequently converted to ) Tj ET Q
q 0 0 0 rg BT 487.95 167.10 Td (Astora ) Tj ET Q
q 0 0 0 rg BT 516.93 167.10 Td (W) Tj ET Q
q 0 0 0 rg BT 525.57 167.10 Td (omen�) Tj ET Q
q 0 0 0 rg BT 550.56 167.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.10 Td (Health Holding LLC and mer) Tj ET Q
q 0 0 0 rg BT 154.13 155.10 Td (ged into ) Tj ET Q
q 0 0 0 rg BT 188.57 155.10 Td (Astora ) Tj ET Q
q 0 0 0 rg BT 217.55 155.10 Td (W) Tj ET Q
q 0 0 0 rg BT 226.19 155.10 Td (omen�) Tj ET Q
q 0 0 0 rg BT 251.18 155.10 Td (s Health LLC and referred to herein as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.23 155.10 Td (AMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.91 155.10 Td ( and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.90 155.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.56 155.10 Td (\), have been named as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 143.10 Td (defendants in multiple lawsuits in various state and federal courts in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.37 143.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.15 143.10 Td ( \(including a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.45 143.10 Td (multidistrict litigation \(MDL\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.33 143.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 131.10 Td ( District Court for the Southern District of ) Tj ET Q
q 0 0 0 rg BT 224.69 131.10 Td (W) Tj ET Q
q 0 0 0 rg BT 233.32 131.10 Td (est ) Tj ET Q
q 0 0 0 rg BT 246.75 131.10 Td (V) Tj ET Q
q 0 0 0 rg BT 253.37 131.10 Td (ir) Tj ET Q
q 0 0 0 rg BT 259.30 131.10 Td (ginia\), and in Canada, ) Tj ET Q
q 0 0 0 rg BT 349.28 131.10 Td (Australia and other countries, alleging personal injury ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 119.10 Td (resulting from the use of transvaginal sur) Tj ET Q
q 0 0 0 rg BT 200.22 119.10 Td (gical mesh products designed to treat ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.29 119.10 Td (POP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.27 119.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.71 119.10 Td (SUI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.82 119.10 Td (. Plaintif) Tj ET Q
q 0 0 0 rg BT 439.08 119.10 Td (fs claim a variety of personal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 107.10 Td (injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 95.10 Td (and punitive damages, where available.) Tj ET Q
endstream
endobj
247 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 248 0 R>>
endobj
248 0 obj
<</Length 19013>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-44) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 749.10 Td (e and certain plaintif) Tj ET Q
q 0 0 0 rg BT 153.92 749.10 Td (fs�) Tj ET Q
q 0 0 0 rg BT 163.73 749.10 Td ( counsel have entered into various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.57 749.10 Td (Master Settlement ) Tj ET Q
q 0 0 0 rg BT 377.56 749.10 Td (Agreements \(MSAs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.60 749.10 Td ( and other agreements to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (resolve up to approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.41 737.10 Td (71,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 177.91 737.10 Td ( filed and unfiled mesh claims handled or controlled by the participating counsel in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.54 737.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.32 737.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 547.64 737.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.67 725.10 Td (s and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries. ) Tj ET Q
q 0 0 0 rg BT 458.13 713.10 Td (All ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.41 713.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.09 713.10 Td (s are subject to a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.89 701.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.56 701.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (provide for the creation of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.46 689.10 Td (QSF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.80 689.10 Td (s into which the settlement funds will be deposited, establish participation requirements and allow for a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (reduction of the total settlement payment in the event participation thresholds are not met. Funds deposited in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.45 677.10 Td (QSF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.79 677.10 Td (s are considered ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (restricted cash and/or restricted cash equivalents. Distribution of funds to any individual claimant is conditioned upon the receipt of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (documentation substantiating product use, the dismissal of any lawsuit and the release of the claim as to us and all af) Tj ET Q
q 0 0 0 rg BT 502.65 653.10 Td (filiates. Prior to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (funds, amounts allocated to individual claimants and other terms of the agreement.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 599.10 Td (In October 2019, the Ontario Superior Court of Justice approved a class action settlement covering unresolved claims by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (Canadian women implanted with an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.36 587.10 Td (AMS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.03 587.10 Td ( vaginal mesh device. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.62 587.10 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.28 587.10 Td ( funded the settlement in February 2020.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (The following table presents the changes in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.05 569.10 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 276.29 569.10 Td ( and mesh liability accrual balances during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.84 569.10 Td (the year ended December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 557.10 Td ( \(in thousands\):) Tj ET Q
1 1 1 rg
/GS0 gs
35.50 546.60 406.00 -29.00 re f
/GS0 gs
1 1 1 rg
/GS0 gs
506.50 546.60 4.00 -29.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 517.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 517.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 517.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 517.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 487.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 487.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 487.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 487.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 457.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 457.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 457.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 457.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 427.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 427.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 427.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 427.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 517.6 m
506.5 517.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 517.6 m
575.5 517.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 427.6 m
575.5 427.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 427.6 m
506.5 427.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 413.6 m
506.5 413.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 411.6 m
506.5 411.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 427.6 m
575.5 427.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 413.6 m
575.5 413.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 411.6 m
575.5 411.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.45 537.83 Td (Qualified) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 455.25 529.83 Td (Settlement) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 462.80 521.83 Td (Funds) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 517.45 529.83 Td (Mesh Liability) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 528.90 521.83 Td (Accrual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 507.27 Td (Balance as of January 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 507.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 507.27 Td (299,733) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 507.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 507.27 Td (748,606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 492.27 Td (Additional char) Tj ET Q
q 0 0 0 rg BT 100.39 492.27 Td (ges) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 492.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 492.27 Td (30,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 477.27 Td (Cash contributions to Qualified Settlement Funds) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 477.27 Td (253,520) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 477.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 462.27 Td (Cash distributions to settle disputes from Qualified Settlement Funds) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 462.32 Td (\(314,266) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 462.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 462.27 Td (\(314,266) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 462.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 447.27 Td (Cash distributions to settle disputes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 447.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 447.27 Td (\(15,330) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 447.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 432.27 Td (Other \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 432.27 Td (3,855) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 432.27 Td (5,021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 417.27 Td (Balance as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 417.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 417.27 Td (242,842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 417.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 417.27 Td (454,031) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 405.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 395.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 395.50 Td (Amounts deposited in the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 151.49 395.50 Td (QSFs) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 169.28 395.50 Td ( may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 385.90 Td (increase to the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 115.70 385.90 Td (QSF) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 130.38 385.90 Td ( and Mesh Liability ) Tj ET Q
q 0 0 0 rg BT 194.81 385.90 Td (Accrual balances. ) Tj ET Q
q 0 0 0 rg BT 253.23 385.90 Td (Any interest remaining after all claims have been paid will generally be distributed to the claimants ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 376.30 Td (who participated in that settlement. ) Tj ET Q
q 0 0 0 rg BT 181.69 376.30 Td (Also included within this line are foreign currency adjustments for settlements not denominated in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 498.50 376.30 Td (U.S.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 512.73 376.30 Td ( dollars.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 358.30 Td (Char) Tj ET Q
q 0 0 0 rg BT 82.26 358.30 Td (ges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 346.30 Td (Discontinued operations, net of tax in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.85 346.30 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 361.21 346.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 328.30 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 328.30 Td (o date, the Company has made total mesh liability payments of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.06 328.30 Td ($3.5 billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.17 328.30 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 434.17 328.30 Td ($242.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 493.06 328.30 Td ( of which remains in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 316.30 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 316.30 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.95 316.30 Td ( as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.11 316.30 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.70 316.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 180.52 316.30 Td (W) Tj ET Q
q 0 0 0 rg BT 189.15 316.30 Td (e currently expect to fund into the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.16 316.30 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.40 316.30 Td ( during 2020 the remaining payments under all existing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 304.30 Td (settlement agreements. ) Tj ET Q
q 0 0 0 rg BT 129.58 304.30 Td (As the funds are disbursed out of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.99 304.30 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.23 304.30 Td ( from time to time, the liability accrual will be reduced accordingly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.30 Td (with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 280.30 Td (separate from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.91 280.30 Td (QSFs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.15 280.30 Td (, which will also decrease the liability accrual and decrease cash and cash equivalents.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 262.30 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 262.30 Td (e were contacted in October 2012 regarding a civil investigation initiated by various state attorneys general into mesh ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.30 Td (products, including transvaginal sur) Tj ET Q
q 0 0 0 rg BT 179.13 250.30 Td (gical mesh products designed to treat ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.19 250.30 Td (POP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.17 250.30 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.61 250.30 Td (SUI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.72 250.30 Td (. In November 2013, we received a subpoena ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.30 Td (relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.30 Td (other states. ) Tj ET Q
q 0 0 0 rg BT 86.08 226.30 Td (W) Tj ET Q
q 0 0 0 rg BT 94.72 226.30 Td (e are cooperating with the investigations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 208.30 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 208.30 Td (e will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 196.30 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 196.30 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.23 196.30 Td (W) Tj ET Q
q 0 0 0 rg BT 386.86 196.30 Td (e are unable to predict the outcome of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 184.30 Td (matters or to estimate the possible range of any additional losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 166.30 Td (Although the Company believes it has appropriately estimated the probable total amount of loss associated with all mesh-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 154.30 Td (related matters as of the date of this report, litigation is ongoing in certain cases that have not settled, trials may occur as early as ) Tj ET Q
q 0 0 0 rg BT 552.23 154.30 Td (April ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 142.30 Td (2020, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our overall liability accrual may ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 130.30 Td (be required. ) Tj ET Q
q 0 0 0 rg BT 86.07 130.30 Td (This could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.38 130.30 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 235.27 130.30 Td (fect on our business, financial condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 543.25 130.30 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 63.00 112.30 Td (T) Tj ET Q
q 0 0 0 rg BT 68.19 112.30 Td (estosterone.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.80 112.30 Td ( ) Tj ET Q
q 0 0 0 rg BT 118.75 112.30 Td (A) Tj ET Q
q 0 0 0 rg BT 125.42 112.30 Td ( federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.17 112.30 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.02 112.30 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.52 112.30 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.30 112.30 Td ( District Court for the Northern District of Illinois includes multiple lawsuits against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 100.30 Td (manufacturers of prescription medications containing testosterone, including our subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.90 100.30 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.90 100.30 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.79 100.30 Td (Auxilium Pharmaceuticals, Inc. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 88.30 Td (\(subsequently converted to ) Tj ET Q
q 0 0 0 rg BT 145.70 88.30 Td (Auxilium Pharmaceuticals, LLC and hereinafter referred to as ) Tj ET Q
q 0 0 0 rg BT 395.88 88.30 Td (Auxilium\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 437.54 88.30 Td (. Plaintif) Tj ET Q
q 0 0 0 rg BT 471.81 88.30 Td (fs in these suits have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 76.30 Td (generally alleged various personal injuries resulting from the use of such medications \(including FOR) Tj ET Q
q 0 0 0 rg BT 442.80 76.30 Td (TEST) Tj ET Q
q 0 0 0 rg BT 465.89 76.30 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 473.11 80.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.05 76.30 Td ( Gel, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 64.30 Td (DELA) Tj ET Q
q 0 0 0 rg BT 61.55 64.30 Td (TESTR) Tj ET Q
q 0 0 0 rg BT 91.56 64.30 Td (YL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 104.89 68.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.82 64.30 Td (, ) Tj ET Q
q 0 0 0 rg BT 114.64 64.30 Td (TESTIM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 150.75 68.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.69 64.30 Td (, ) Tj ET Q
q 0 0 0 rg BT 160.51 64.30 Td (TEST) Tj ET Q
q 0 0 0 rg BT 184.21 64.30 Td (OPEL) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 209.21 68.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.15 64.30 Td (, ) Tj ET Q
q 0 0 0 rg BT 218.60 64.30 Td (A) Tj ET Q
q 0 0 0 rg BT 224.53 64.30 Td (VEED) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 251.19 68.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.13 64.30 Td ( and STRIANT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 317.79 68.83 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.73 64.30 Td (\), including pulmonary embolism, stroke or other vascular and/) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 52.30 Td (or cardiac injuries, and sought compensatory and/or punitive damages, where available.) Tj ET Q
endstream
endobj
249 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 250 0 R>>
endobj
250 0 obj
<</Length 17304>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-45) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (In June 2018, counsel for plaintif) Tj ET Q
q 0 0 0 rg BT 195.57 749.10 Td (fs, on the one hand, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.77 749.10 Td (Auxilium) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.11 749.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.54 749.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.54 749.10 Td (, on the other) Tj ET Q
q 0 0 0 rg BT 417.91 749.10 Td (, executed an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.88 749.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.00 749.10 Td ( allowing for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (resolution of all known ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.36 737.10 Td (TR) Tj ET Q
q 0 0 0 rg BT 143.54 737.10 Td (T) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.47 737.10 Td ( product liability claims against our subsidiaries. ) Tj ET Q
q 0 0 0 rg BT 345.92 737.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.96 737.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.09 737.10 Td ( was solely by way of compromise and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (settlement and was not in any way an admission of liability or fault by us or any of our subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 707.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 707.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.17 707.10 Td ( established various guidelines and procedures for administering the settlement and the release of funds. ) Tj ET Q
q 0 0 0 rg BT 519.83 707.10 Td (Among other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.10 Td (things, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.17 695.10 Td (MSA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.29 695.10 Td ( provides for the creation of a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.07 695.10 Td (QSF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.42 695.10 Td ( into which the settlement funds will be deposited, establishes participation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.10 Td (requirements and allows for a reduction of the total settlement payment in the event the participation threshold is not met. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.48 683.10 Td (Auxilium) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 562.81 683.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 671.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 67.94 671.10 Td ( funded the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.42 671.10 Td (QSF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.77 671.10 Td ( in November 2019. Distribution of funds to any individual claimant is conditioned upon the receipt of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.10 Td (documentation substantiating product use and injury as determined by a third-party special master) Tj ET Q
q 0 0 0 rg BT 427.71 659.10 Td (, the dismissal of any lawsuit and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.10 Td (release of the claim as to us and all af) Tj ET Q
q 0 0 0 rg BT 186.03 647.10 Td (filiates. Prior to receiving funds, an individual claimant must represent and warrant that liens, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.10 Td (assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.10 Td (claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.10 Td (agreement.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 593.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 593.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.90 593.10 Td ( court has been dismissing cases pursuant to the settlement or for failure to comply with court orders. ) Tj ET Q
q 0 0 0 rg BT 509.19 593.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.10 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.60 581.10 Td (, we were aware of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.14 581.10 Td (5) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.14 581.10 Td ( cases \(some of which may have been filed on behalf of multiple plaintif) Tj ET Q
q 0 0 0 rg BT 542.59 581.10 Td (fs\) that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.10 Td (remained pending in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.41 569.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.26 569.10 Td ( against one or more of our subsidiaries.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 551.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 551.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.90 551.10 Td ( also included a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.81 551.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 562.81 551.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (Auxilium) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.33 539.10 Td ( and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (other third party payers. ) Tj ET Q
q 0 0 0 rg BT 134.40 527.10 Td (This lawsuit was not part of the settlement described above. ) Tj ET Q
q 0 0 0 rg BT 375.73 527.10 Td (After a series of motions to dismiss, plaintif) Tj ET Q
q 0 0 0 rg BT 551.08 527.10 Td (f filed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 515.10 Td (a third amended complaint in ) Tj ET Q
q 0 0 0 rg BT 155.14 515.10 Td (April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 503.10 Td (Or) Tj ET Q
q 0 0 0 rg BT 46.37 503.10 Td (ganizations ) Tj ET Q
q 0 0 0 rg BT 93.86 503.10 Td (Act and negligent misrepresentation based on defendants�) Tj ET Q
q 0 0 0 rg BT 324.71 503.10 Td ( marketing of certain testosterone products. In February 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 491.10 Td (the court granted defendants�) Tj ET Q
q 0 0 0 rg BT 152.15 491.10 Td ( motion for summary judgment. In November 2019, the Seventh Circuit af) Tj ET Q
q 0 0 0 rg BT 449.97 491.10 Td (firmed.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 473.10 Td (Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (related matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (our overall liability accrual may be required. ) Tj ET Q
q 0 0 0 rg BT 216.85 449.10 Td (This could have a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 290.17 449.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 366.05 449.10 Td (fect on our business, financial condition, results of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.10 Td (operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.58 437.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 419.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 419.10 Td (e will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 407.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.23 407.10 Td (W) Tj ET Q
q 0 0 0 rg BT 386.86 407.10 Td (e are unable to predict the outcome of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.10 Td (matters or to estimate the possible range of any additional losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 377.10 Td (Opioid-Related Matters) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 359.10 Td (Since 2014, multiple ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 148.55 359.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.33 359.10 Td ( states and other governmental persons or entities and private plaintif) Tj ET Q
q 0 0 0 rg BT 442.18 359.10 Td (fs in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.90 359.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.68 359.10 Td ( and Canada have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (filed suit against us and/or certain of our subsidiaries, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.89 347.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.11 347.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.11 347.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.11 347.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.11 347.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.56 347.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.56 347.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 380.69 347.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 385.69 347.10 Td (Endo Generics Holdings, Inc. \(EGHI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.31 347.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 542.13 347.10 Td (V) Tj ET Q
q 0 0 0 rg BT 548.75 347.10 Td (intage ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (Pharmaceuticals, LLC, Generics Bidco I, LLC and DA) Tj ET Q
q 0 0 0 rg BT 254.65 335.10 Td (V) Tj ET Q
q 0 0 0 rg BT 260.58 335.10 Td (A) Tj ET Q
q 0 0 0 rg BT 267.25 335.10 Td ( Pharmaceuticals, LLC, and in Canada, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.37 335.10 Td (Paladin) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.36 335.10 Td (, as well as various other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.10 Td (manufacturers, distributors, pharmacies and/or others, asserting claims relating to defendants�) Tj ET Q
q 0 0 0 rg BT 410.14 323.10 Td ( alleged sales, marketing and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.10 Td (distribution practices with respect to prescription opioid medications, including certain of our products. ) Tj ET Q
q 0 0 0 rg BT 451.18 311.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.62 311.10 Td (February�18, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.22 311.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 299.10 Td (cases in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 84.59 299.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.38 299.10 Td ( of which we were aware include, but are not limited to, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.67 299.10 Td (20) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.67 299.10 Td ( cases filed by or on behalf of states; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 287.10 Td (2,700) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.76 287.10 Td ( cases filed by counties, cities, Native ) Tj ET Q
q 0 0 0 rg BT 271.21 287.10 Td (American tribes and/or other government-related persons or entities; ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 275.10 Td (280) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.26 275.10 Td ( cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 263.10 Td (160) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.26 263.10 Td ( cases filed by individuals. Certain of the cases have been filed as putative class actions. ) Tj ET Q
q 0 0 0 rg BT 465.41 263.10 Td (The Canadian cases ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 251.10 Td (include an action filed by British Columbia on behalf of a proposed class of all federal, provincial and territorial governments and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 239.10 Td (agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids, as well as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.06 239.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.04 239.10 Td ( additional putative ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 227.10 Td (class actions, filed in Ontario, Quebec and British Columbia, seeking relief on behalf of Canadian residents who were prescribed and/) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 215.10 Td (or consumed opioid medications. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 197.10 Td (Many of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.38 197.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.16 197.10 Td ( cases have been coordinated in a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.19 197.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.04 197.10 Td ( pending in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 382.25 197.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.03 197.10 Td ( District Court for the Northern District of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (Ohio. Other cases are pending in various federal or state courts. ) Tj ET Q
q 0 0 0 rg BT 292.67 185.10 Td (The cases are at various stages. ) Tj ET Q
q 0 0 0 rg BT 419.94 185.10 Td (The first ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.60 185.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 478.45 185.10 Td ( trial, relating to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.10 Td (claims of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.43 173.10 Td (two) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 90.43 173.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.93 173.10 Td (Ohio counties \(T) Tj ET Q
q 0 0 0 rg BT 160.35 173.10 Td (rack One plaintif) Tj ET Q
q 0 0 0 rg BT 227.91 173.10 Td (fs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.47 173.10 Td (, was set for October 2019 but did not go forward after most defendants settled. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 161.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.00 161.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 161.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.22 161.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 83.22 161.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.67 161.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.11 161.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 138.24 161.10 Td ( executed a settlement agreement with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 308.26 161.10 Td (T) Tj ET Q
q 0 0 0 rg BT 314.02 161.10 Td (rack One plaintif) Tj ET Q
q 0 0 0 rg BT 381.59 161.10 Td (fs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.81 161.10 Td ( in September 2019 which provided for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 149.10 Td (payments totaling ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.88 149.10 Td ($10 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.27 149.10 Td ( and up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.49 149.10 Td ($1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.88 149.10 Td ( of ) Tj ET Q
q 0 0 0 rg BT 253.03 149.10 Td (V) Tj ET Q
q 0 0 0 rg BT 258.96 149.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 313.41 153.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.35 149.10 Td ( and/or ) Tj ET Q
q 0 0 0 rg BT 348.34 149.10 Td (ADRENALIN) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 406.67 153.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.61 149.10 Td (. Under the settlement agreement, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 137.10 Td (T) Tj ET Q
q 0 0 0 rg BT 41.76 137.10 Td (rack One plaintif) Tj ET Q
q 0 0 0 rg BT 109.33 137.10 Td (fs) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.55 137.10 Td ( may be entitled to additional payments in the event of a comprehensive resolution of government-related opioid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.10 Td (claims. ) Tj ET Q
q 0 0 0 rg BT 66.92 125.10 Td (The settlement agreement was solely by way of compromise and settlement and was not in any way an admission of liability ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 113.10 Td (or fault by us or any of our subsidiaries. Certain state court cases are scheduled for trial in 2020, with the first of these trials currently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.10 Td (scheduled to begin in March. Most other cases remain at the pleading and/or discovery stage.) Tj ET Q
endstream
endobj
251 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 252 0 R>>
endobj
252 0 obj
<</Length 14194>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-46) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (The complaints in the cases assert a variety of claims, including but not limited to statutory claims asserting violations of public ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability laws and/or common ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (law claims for public nuisance, fraud/misrepresentation, strict liability) Tj ET Q
q 0 0 0 rg BT 316.10 725.10 Td (, negligence and/or unjust enrichment. ) Tj ET Q
q 0 0 0 rg BT 471.71 725.10 Td (The claims are generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (and/or alleged failures to take adequate steps to identify and report suspicious orders and to prevent abuse and diversion. Plaintif) Tj ET Q
q 0 0 0 rg BT 550.12 701.10 Td (fs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (generally seek declaratory and/or injunctive relief; compensatory) Tj ET Q
q 0 0 0 rg BT 295.79 689.10 Td (, punitive and/or treble damages; restitution, disgor) Tj ET Q
q 0 0 0 rg BT 500.01 689.10 Td (gement, civil ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (penalties, abatement, attorneys�) Tj ET Q
q 0 0 0 rg BT 161.87 677.10 Td ( fees, costs and/or other relief.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 659.10 Td (W) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.64 659.10 Td (e will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.96 659.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 647.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.23 647.10 Td (W) Tj ET Q
q 0 0 0 rg BT 386.86 647.10 Td (e are unable to predict the outcome of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.10 Td (matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.69 635.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.64 635.10 Td (Adjustments to our overall liability accrual may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.10 Td (required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.16 623.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.66 623.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 281.54 623.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 611.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 593.10 Td (In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 518.99 593.10 Td (civil ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.10 Td (investigative demands \(CIDs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.42 581.10 Td ( and informal requests for information concerning the sale, marketing and/or distribution of prescription ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.10 Td (opioid medications, including the following:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 551.10 Td (V) Tj ET Q
q 0 0 0 rg BT 69.11 551.10 Td (arious state attorneys general have served subpoenas and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 310.14 551.10 Td (CID) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 327.36 551.10 Td (s on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.25 551.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.47 551.10 Td ( and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.02 551.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.02 551.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 418.84 551.10 Td (W) Tj ET Q
q 0 0 0 rg BT 427.48 551.10 Td (e are cooperating with the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (investigations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 521.10 Td (In January 2018, our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.87 521.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.87 521.10 Td ( received a federal grand jury subpoena from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.72 521.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.51 521.10 Td ( District Court for the Southern ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.10 Td (District of Florida seeking documents and information related to OP) Tj ET Q
q 0 0 0 rg BT 308.08 509.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 329.75 513.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.68 509.10 Td ( ER, other oxymorphone products and marketing of opioid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (medications. ) Tj ET Q
q 0 0 0 rg BT 89.14 497.10 Td (W) Tj ET Q
q 0 0 0 rg BT 97.78 497.10 Td (e are cooperating with the investigation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 479.10 Td (In September 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 144.09 479.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.09 479.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.09 479.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 186.32 479.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 191.32 479.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.77 479.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.21 479.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 246.33 479.10 Td ( received subpoenas from the New ) Tj ET Q
q 0 0 0 rg BT 387.02 479.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 393.24 479.10 Td (ork State Department of Financial Services ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 467.10 Td (seeking documents and information regarding the marketing, sale and distribution of opioid medications in New ) Tj ET Q
q 0 0 0 rg BT 487.19 467.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 493.41 467.10 Td (ork. ) Tj ET Q
q 0 0 0 rg BT 511.56 467.10 Td (W) Tj ET Q
q 0 0 0 rg BT 520.20 467.10 Td (e are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 455.10 Td (providing information responsive to these subpoenas.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 437.10 Td (Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.78 437.10 Td (W) Tj ET Q
q 0 0 0 rg BT 524.42 437.10 Td (e are unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 425.10 Td (to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.76 425.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.71 425.10 Td (Adjustments to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.10 Td (overall liability accrual may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.05 413.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.55 413.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 408.43 413.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 401.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 401.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 383.10 Td (In January 2020, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.43 383.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.43 383.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.87 383.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 181.32 383.10 Td ( executed a settlement agreement with the state of Oklahoma providing for a payment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 96.26 371.10 Td ($8.75 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.15 371.10 Td ( in resolution of potential opioid-related claims. ) Tj ET Q
q 0 0 0 rg BT 343.26 371.10 Td (The settlement agreement was solely by way of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (compromise and settlement and was not in any way an admission of liability or fault by us or any of our subsidiaries.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.00 341.10 Td (Generic Drug Pricing Matters) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 323.10 Td (Since March 2016, various private plaintif) Tj ET Q
q 0 0 0 rg BT 232.22 323.10 Td (fs and state attorneys general have filed cases against our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.85 323.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 521.30 323.10 Td ( and/or) Tj ET Q
q 0 0 0 rg BT 548.95 323.10 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.10 Td (some instances, the Company) Tj ET Q
q 0 0 0 rg BT 154.22 311.10 Td (, Generics Bidco I, LLC, DA) Tj ET Q
q 0 0 0 rg BT 269.01 311.10 Td (V) Tj ET Q
q 0 0 0 rg BT 274.95 311.10 Td (A) Tj ET Q
q 0 0 0 rg BT 281.62 311.10 Td ( Pharmaceuticals, LLC and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 404.08 311.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.20 311.10 Td (, as well as other pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 299.10 Td (manufacturers and, in some instances, other corporate and/or individual defendants, alleging price-fixing and other anticompetitive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.10 Td (conduct with respect to generic pharmaceutical products. ) Tj ET Q
q 0 0 0 rg BT 266.28 287.10 Td (These cases, which include proposed class actions filed on behalf of direct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.10 Td (purchasers, end-payers and indirect purchaser resellers, as well as non-class action suits, have generally been consolidated and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 263.10 Td (coordinated for pretrial proceedings in a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.52 263.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.37 263.10 Td ( pending in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.58 263.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.37 263.10 Td ( District Court for the Eastern District of Pennsylvania.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 245.10 Td (The various complaints and amended complaints generally assert claims under federal and/or state antitrust law) Tj ET Q
q 0 0 0 rg BT 508.31 245.10 Td (, state consumer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.10 Td (protection statutes and/or state common law regarding certain of our products, and seek damages, treble damages, civil penalties, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.10 Td (disgor) Tj ET Q
q 0 0 0 rg BT 60.82 221.10 Td (gement, declaratory and injunctive relief, costs and attorneys�) Tj ET Q
q 0 0 0 rg BT 306.93 221.10 Td ( fees. Some claims are based on alleged product-specific ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (conspiracies and other claims allege broader) Tj ET Q
q 0 0 0 rg BT 213.02 209.10 Td (, multiple-product conspiracies. Under these overarching conspiracy theories, plaintif) Tj ET Q
q 0 0 0 rg BT 554.12 209.10 Td (fs ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (seek to hold all alleged participants in a particular conspiracy jointly and severally liable for all harms caused by the alleged ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (conspiracy) Tj ET Q
q 0 0 0 rg BT 78.67 185.10 Td (, not just harms related to the products manufactured and/or sold by a particular defendant.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 167.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 167.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.90 167.10 Td ( court has issued various case management and substantive orders, including orders denying certain motions to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.10 Td (dismiss, and discovery is ongoing.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 137.10 Td (W) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.64 137.10 Td (e will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.96 137.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 125.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.23 125.10 Td (W) Tj ET Q
q 0 0 0 rg BT 386.86 125.10 Td (e are unable to predict the outcome of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 113.10 Td (matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.69 113.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.64 113.10 Td (Adjustments to our overall liability accrual may be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.10 Td (required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.16 101.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.66 101.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 281.54 101.10 Td (fect on our business, financial condition, results of operations and cash ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 89.10 Td (flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 89.10 Td (.) Tj ET Q
endstream
endobj
253 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 254 0 R>>
endobj
254 0 obj
<</Length 17224>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-47) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (In December 2014, our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.85 749.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.31 749.10 Td ( received from the ) Tj ET Q
q 0 0 0 rg BT 291.27 749.10 Td (Antitrust Division of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.82 749.10 Td (DOJ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.16 749.10 Td ( a federal grand jury subpoena issued by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 737.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 68.50 737.10 Td ( District Court for the Eastern District of Pennsylvania addressed to �Par Pharmaceuticals.� ) Tj ET Q
q 0 0 0 rg BT 436.55 737.10 Td (The subpoena requested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (documents and information focused primarily on product and pricing information relating to the authorized generic version of Lanoxin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (\(digoxin\) oral tablets and generic doxycycline products, and on communications with competitors and others regarding those products. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (W) Tj ET Q
q 0 0 0 rg BT 44.64 701.10 Td (e are cooperating with the investigation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 683.10 Td (In May 2018, we and our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.20 683.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 231.32 683.10 Td ( each received a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 297.94 683.10 Td (CID) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 315.16 683.10 Td ( from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.31 683.10 Td (DOJ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.65 683.10 Td ( in relation to a False Claims ) Tj ET Q
q 0 0 0 rg BT 489.58 683.10 Td (Act investigation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (concerning whether generic pharmaceutical manufacturers engaged in price-fixing and market allocation agreements, paid illegal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.10 Td (remuneration and caused the submission of false claims. ) Tj ET Q
q 0 0 0 rg BT 263.81 659.10 Td (W) Tj ET Q
q 0 0 0 rg BT 272.45 659.10 Td (e are cooperating with the investigation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 641.10 Td (Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.78 641.10 Td (W) Tj ET Q
q 0 0 0 rg BT 524.42 641.10 Td (e are unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.76 629.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.71 629.10 Td (Adjustments to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (overall liability accrual may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.05 617.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.55 617.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 408.43 617.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 605.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 587.10 Td (Other ) Tj ET Q
q 0 0 0 rg BT 75.15 587.10 Td (Antitrust Matters) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (Beginning in November 2013, multiple alleged purchasers of LIDODERM) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 363.21 573.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.15 569.10 Td ( sued our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 450.92 569.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.92 569.10 Td ( and other pharmaceutical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (companies alleging violations of antitrust law arising out of their settlement of certain patent infringement litigation. ) Tj ET Q
q 0 0 0 rg BT 503.75 557.10 Td (The various ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.10 Td (complaints asserted claims under Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 302.33 545.10 Td (Act, state antitrust and consumer protection statutes and/or state ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.10 Td (common law and sought damages, treble damages, disgor) Tj ET Q
q 0 0 0 rg BT 266.60 533.10 Td (gement of profits, restitution, injunctive relief and attorneys�) Tj ET Q
q 0 0 0 rg BT 508.29 533.10 Td ( fees. ) Tj ET Q
q 0 0 0 rg BT 531.70 533.10 Td (These ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 521.10 Td (cases were consolidated and/or coordinated in a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.79 521.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.64 521.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.13 521.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 326.92 521.10 Td ( District Court for the Northern District of California. ) Tj ET Q
q 0 0 0 rg BT 543.35 521.10 Td (The last ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.10 Td (cases remaining in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.64 509.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.49 509.10 Td ( were dismissed with prejudice in September 2018, when the court approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.02 509.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.02 509.10 Td (�) Tj ET Q
q 0 0 0 rg BT 475.79 509.10 Td (s settlements with direct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (and indirect purchaser classes. ) Tj ET Q
q 0 0 0 rg BT 159.94 497.10 Td (Those settlement agreements provided for aggregate payments of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.99 497.10 Td ($100 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.38 497.10 Td (. Of this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (total, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.77 485.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.77 485.10 Td ( paid approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.25 485.10 Td ($60 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.64 485.10 Td ( in 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.42 485.10 Td ($30 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.81 485.10 Td ( in the first quarter of 2019 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.00 485.10 Td ($10 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.39 485.10 Td ( in the first quarter of 2020. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (In September 2019, Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan filed a complaint against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.79 473.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.79 473.10 Td ( and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (pharmaceutical companies in the ) Tj ET Q
q 0 0 0 rg BT 169.65 461.10 Td (Third Judicial Circuit Court, ) Tj ET Q
q 0 0 0 rg BT 285.84 461.10 Td (W) Tj ET Q
q 0 0 0 rg BT 294.48 461.10 Td (ayne County) Tj ET Q
q 0 0 0 rg BT 344.66 461.10 Td (, Michigan, asserting claims substantially similar to those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (asserted in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.70 449.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.92 449.10 Td (. In October 2019, certain defendants removed the case to federal court. In November 2019, plaintif) Tj ET Q
q 0 0 0 rg BT 516.21 449.10 Td (fs moved to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.10 Td (remand the case to state court.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 419.10 Td (Beginning in June 2014, multiple alleged purchasers of OP) Tj ET Q
q 0 0 0 rg BT 298.43 419.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 320.09 423.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.03 419.10 Td ( ER sued our subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 429.19 419.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 451.41 419.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.85 419.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.85 419.10 Td ( and other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.10 Td (pharmaceutical companies \(including Impax Laboratories, LLC \(formerly Impax Laboratories, Inc. and referred to herein as Impax\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.10 Td (and Penwest Pharmaceuticals Co., which our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.34 395.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 277.34 395.10 Td ( had acquired\), alleging violations of antitrust law arising out of an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.10 Td (agreement reached by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.22 383.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.22 383.10 Td ( and Impax to settle certain patent infringement litigation and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.92 383.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.92 383.10 Td (�) Tj ET Q
q 0 0 0 rg BT 406.70 383.10 Td (s introduction of reformulated OP) Tj ET Q
q 0 0 0 rg BT 541.31 383.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 562.98 387.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 567.92 383.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (ER. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (individual retailers or health care benefit plans. ) Tj ET Q
q 0 0 0 rg BT 226.85 359.10 Td (The cases have been consolidated and/or coordinated for pretrial proceedings in a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 66.25 347.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 88.10 347.10 Td ( pending in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.32 347.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.10 347.10 Td ( District Court for the Northern District of Illinois. ) Tj ET Q
q 0 0 0 rg BT 372.33 347.10 Td (The various complaints assert claims under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 167.37 335.10 Td (Act, state antitrust and consumer protection statutes and/or state common law) Tj ET Q
q 0 0 0 rg BT 476.91 335.10 Td (. Plaintif) Tj ET Q
q 0 0 0 rg BT 511.18 335.10 Td (fs generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.10 Td (seek damages, treble damages, disgor) Tj ET Q
q 0 0 0 rg BT 186.32 323.10 Td (gement of profits, restitution, injunctive relief and attorneys�) Tj ET Q
q 0 0 0 rg BT 428.01 323.10 Td ( fees. In March 2019, direct and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.10 Td (indirect purchaser plaintif) Tj ET Q
q 0 0 0 rg BT 139.11 311.10 Td (fs filed motions for class certification, which remain pending.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 293.10 Td (Beginning in February 2009, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.76 293.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.10 293.10 Td ( and certain private plaintif) Tj ET Q
q 0 0 0 rg BT 322.20 293.10 Td (fs sued our subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.30 293.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.43 293.10 Td ( \(since June 2016, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.13 293.10 Td (EGHI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.01 293.10 Td (\) and/or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.45 281.10 Td ( as well as other pharmaceutical companies alleging violations of antitrust law arising out of the settlement of certain patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (litigation concerning the generic version of ) Tj ET Q
q 0 0 0 rg BT 210.39 269.10 Td (AndroGel) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 250.38 273.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.32 269.10 Td ( and seeking damages, treble damages, equitable relief and attorneys�) Tj ET Q
q 0 0 0 rg BT 531.96 269.10 Td ( fees and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 257.10 Td (costs. ) Tj ET Q
q 0 0 0 rg BT 60.82 257.10 Td (The cases were consolidated and/or coordinated for pretrial proceedings in a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.00 257.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.85 257.10 Td ( pending in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 483.07 257.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.85 257.10 Td ( District Court for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.10 Td (the Northern District of Geor) Tj ET Q
q 0 0 0 rg BT 152.45 245.10 Td (gia. In May 2016, plaintif) Tj ET Q
q 0 0 0 rg BT 255.03 245.10 Td (fs representing a putative class of indirect purchasers voluntarily dismissed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.10 Td (their claims with prejudice. In February 2017, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.05 233.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.39 233.10 Td ( voluntarily dismissed its claims against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.60 233.10 Td (EGHI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 441.48 233.10 Td ( with prejudice. In June 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.85 221.10 Td ( court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular) Tj ET Q
q 0 0 0 rg BT 560.08 221.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (among other things, the court rejected two of the remaining plaintif) Tj ET Q
q 0 0 0 rg BT 304.91 209.10 Td (fs�) Tj ET Q
q 0 0 0 rg BT 314.72 209.10 Td ( causation theories and rejected damages claims related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (AndroGel) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 75.99 201.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.93 197.10 Td ( 1.62%. In July 2018, the court denied certain plaintif) Tj ET Q
q 0 0 0 rg BT 294.58 197.10 Td (fs�) Tj ET Q
q 0 0 0 rg BT 304.39 197.10 Td ( motion for certification of a direct purchaser class. In November ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 185.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.45 185.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.89 185.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 116.01 185.10 Td ( entered into settlement agreements with all but one of the remaining plaintif) Tj ET Q
q 0 0 0 rg BT 422.41 185.10 Td (fs in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.12 185.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.34 185.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 484.16 185.10 Td (The settlement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.10 Td (agreements were solely by way of compromise and settlement and were not in any way an admission of liability or fault. Separately) Tj ET Q
q 0 0 0 rg BT 562.97 173.10 Td (, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 161.10 Td (August 2019, several alleged direct purchasers filed suit in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.87 161.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.65 161.10 Td ( District Court for the Eastern District of Pennsylvania asserting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 149.10 Td (claims substantially similar to those asserted in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 241.52 149.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.74 149.10 Td (, as well as additional claims against other defendants relating to other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 137.10 Td (alleged conduct. In January 2020, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 188.17 137.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.96 137.10 Td ( District Court for the Eastern District of Pennsylvania denied defendants�) Tj ET Q
q 0 0 0 rg BT 501.80 137.10 Td ( motion to transfer ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 125.10 Td (venue to the Northern District of Geor) Tj ET Q
q 0 0 0 rg BT 189.11 125.10 Td (gia.) Tj ET Q
endstream
endobj
255 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 256 0 R>>
endobj
256 0 obj
<</Length 16753>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-48) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 749.10 Td (Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 524.54 749.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.00 749.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 737.10 Td (other pharmaceutical companies alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 725.10 Td (the generic version of Zetia) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 145.95 729.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.89 725.10 Td ( \(ezetimibe\). ) Tj ET Q
q 0 0 0 rg BT 203.74 725.10 Td (The various complaints asserted claims under Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 520.05 725.10 Td (Act, state ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 713.10 Td (antitrust and consumer protection statutes and/or state common law and sought injunctive relief, damages, treble damages, attorneys�) Tj ET Q
q 0 0 0 rg BT 567.60 713.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 701.10 Td (fees and costs. In June 2018, these and other related cases, including proposed direct purchaser class actions in which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.08 701.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.53 701.10 Td ( was not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 689.10 Td (named as a defendant, were consolidated and/or coordinated for pretrial proceedings in a federal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.89 689.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.74 689.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.23 689.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 491.01 689.10 Td ( District Court for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.10 Td (the Eastern District of ) Tj ET Q
q 0 0 0 rg BT 126.35 677.10 Td (V) Tj ET Q
q 0 0 0 rg BT 132.97 677.10 Td (ir) Tj ET Q
q 0 0 0 rg BT 138.90 677.10 Td (ginia. In September 2018, the indirect purchaser plaintif) Tj ET Q
q 0 0 0 rg BT 362.81 677.10 Td (fs dismissed their claims against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.74 677.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.19 677.10 Td ( without ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 665.10 Td (prejudice. In June and July 2019, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.69 665.10 Td (MDL) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.54 665.10 Td ( court granted the direct purchaser plaintif) Tj ET Q
q 0 0 0 rg BT 375.62 665.10 Td (fs and certain retailer plaintif) Tj ET Q
q 0 0 0 rg BT 491.49 665.10 Td (fs leave to file ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 653.10 Td (amended complaints adding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 150.69 653.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.15 653.10 Td ( as a defendant. In July 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.84 653.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.29 653.10 Td ( entered into settlement agreements with both the direct purchaser ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 641.10 Td (plaintif) Tj ET Q
q 0 0 0 rg BT 64.70 641.10 Td (fs and the retailer plaintif) Tj ET Q
q 0 0 0 rg BT 165.59 641.10 Td (fs. ) Tj ET Q
q 0 0 0 rg BT 177.63 641.10 Td (The direct purchaser settlement is subject to court approval. ) Tj ET Q
q 0 0 0 rg BT 419.03 641.10 Td (The settlement agreements were solely ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 629.10 Td (by way of compromise and settlement, were not in any way an admission of liability or fault and involved no monetary payment.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 611.10 Td (Beginning in May 2018, multiple complaints were filed in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.23 611.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 331.02 611.10 Td ( District Court for the Southern District of New ) Tj ET Q
q 0 0 0 rg BT 523.11 611.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 529.33 611.10 Td (ork against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 599.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.45 599.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.45 599.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 70.45 599.10 Td ( and/or us, as well as other pharmaceutical companies, alleging violations of antitrust law arising out of the settlement of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (certain patent litigation concerning the generic version of Exfor) Tj ET Q
q 0 0 0 rg BT 290.17 587.10 Td (ge) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 299.60 591.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.54 587.10 Td ( \(amlodipine/valsartan\). Some cases were filed on behalf of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 575.10 Td (putative classes of direct and indirect purchasers; others are non-class action suits. ) Tj ET Q
q 0 0 0 rg BT 367.10 575.10 Td (The various complaints assert claims under ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 563.10 Td (Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 167.37 563.10 Td (Act, state antitrust and consumer protection statutes and/or state common law) Tj ET Q
q 0 0 0 rg BT 476.91 563.10 Td (. Plaintif) Tj ET Q
q 0 0 0 rg BT 511.18 563.10 Td (fs generally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 551.10 Td (seek damages, treble damages, equitable relief and attorneys�) Tj ET Q
q 0 0 0 rg BT 280.43 551.10 Td ( fees and costs. In September 2018, the putative class plaintif) Tj ET Q
q 0 0 0 rg BT 524.63 551.10 Td (fs stipulated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 539.10 Td (to the dismissal without prejudice of their claims against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.56 539.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.56 539.10 Td ( and us, and the retailer plaintif) Tj ET Q
q 0 0 0 rg BT 404.06 539.10 Td (fs later did the same. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.59 539.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.04 539.10 Td ( filed a partial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 527.10 Td (motion to dismiss certain claims in September 2018, which was granted in ) Tj ET Q
q 0 0 0 rg BT 335.67 527.10 Td (August 2019. ) Tj ET Q
q 0 0 0 rg BT 391.88 527.10 Td (The cases are currently in discovery) Tj ET Q
q 0 0 0 rg BT 535.34 527.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 509.10 Td (Beginning in ) Tj ET Q
q 0 0 0 rg BT 116.89 509.10 Td (August 2019, multiple complaints were filed in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.24 509.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.03 509.10 Td ( District Court for the Southern District of New ) Tj ET Q
q 0 0 0 rg BT 533.12 509.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 539.34 509.10 Td (ork ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 66.83 497.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.28 497.10 Td ( and other pharmaceutical companies alleging violations of antitrust law arising out the settlement of certain patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (litigation concerning generic versions of Seroquel XR) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 252.05 489.63 Td (� ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.62 485.10 Td (\(extended release quetiapine fumarate\). ) Tj ET Q
q 0 0 0 rg BT 418.63 485.10 Td (The claims against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.10 485.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 510.56 485.10 Td ( are based on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (allegations that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.32 473.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.77 473.10 Td ( entered into an exclusive acquisition and license agreement with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 376.45 473.10 Td (Handa Pharmaceuticals, LLC \(Handa\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.73 473.10 Td ( in 2012 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (pursuant to which ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.16 461.10 Td (Handa) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.25 461.10 Td ( assigned to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.97 461.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.42 461.10 Td ( certain rights under a prior settlement agreement between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.60 461.10 Td (Handa) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 461.70 461.10 Td ( and ) Tj ET Q
q 0 0 0 rg BT 480.59 461.10 Td (AstraZeneca resolving ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (certain patent litigation. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.10 Td (action suits. ) Tj ET Q
q 0 0 0 rg BT 86.09 437.10 Td (The various complaints assert claims under Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 392.97 437.10 Td (Act, state antitrust and consumer protection ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 425.10 Td (statutes and/or state common law) Tj ET Q
q 0 0 0 rg BT 168.65 425.10 Td (. Plaintif) Tj ET Q
q 0 0 0 rg BT 202.91 425.10 Td (fs generally seek damages, treble damages, equitable relief and attorneys�) Tj ET Q
q 0 0 0 rg BT 496.77 425.10 Td ( fees and costs. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.10 Td (October 2019, the defendants filed various motions to dismiss and, in the alternative, moved to transfer the litigation to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 529.50 413.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.28 413.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 401.10 Td (District Court for the District of Delaware. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 383.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 383.10 Td (o the extent unresolved, w) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.66 383.10 Td (e will continue to vigorously defend the foregoing matters and to explore other options as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (appropriate in our best interests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.57 371.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.07 371.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.98 371.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.30 371.10 Td (W) Tj ET Q
q 0 0 0 rg BT 517.94 371.10 Td (e are unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.76 359.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.71 359.10 Td (Adjustments to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (overall liability accrual may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.05 347.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.55 347.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 408.43 347.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 335.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 317.10 Td (In February 2015, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 137.43 317.10 Td (EGHI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.31 317.10 Td ( and af) Tj ET Q
q 0 0 0 rg BT 188.34 317.10 Td (filiates received a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.35 317.10 Td (CID) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.57 317.10 Td ( from the Of) Tj ET Q
q 0 0 0 rg BT 328.10 317.10 Td (fice of the ) Tj ET Q
q 0 0 0 rg BT 370.58 317.10 Td (Attorney General for the state of ) Tj ET Q
q 0 0 0 rg BT 502.75 317.10 Td (Alaska seeking ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 305.10 Td (documents and information regarding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.29 305.10 Td (EGHI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 213.17 305.10 Td (�) Tj ET Q
q 0 0 0 rg BT 215.95 305.10 Td (s settlement of ) Tj ET Q
q 0 0 0 rg BT 276.22 305.10 Td (AndroGel) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 316.21 309.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.15 305.10 Td ( patent litigation as well as documents produced in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.10 Td (aforementioned litigation filed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.90 293.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.24 293.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 210.69 293.10 Td (Also in February 2015, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 305.96 293.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.18 293.10 Td ( received a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 373.98 293.10 Td (CID) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.20 293.10 Td ( from ) Tj ET Q
q 0 0 0 rg BT 415.09 293.10 Td (Alaska�) Tj ET Q
q 0 0 0 rg BT 445.63 293.10 Td (s Of) Tj ET Q
q 0 0 0 rg BT 462.40 293.10 Td (fice of the ) Tj ET Q
q 0 0 0 rg BT 504.88 293.10 Td (Attorney General ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (seeking production of certain documents and information concerning agreements with ) Tj ET Q
q 0 0 0 rg BT 382.56 281.10 Td (Actavis and Impax settling OP) Tj ET Q
q 0 0 0 rg BT 504.40 281.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 526.07 285.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.01 281.10 Td ( ER patent ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (litigation. ) Tj ET Q
q 0 0 0 rg BT 76.93 269.10 Td (W) Tj ET Q
q 0 0 0 rg BT 85.57 269.10 Td (e are cooperating with the investigations.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 251.10 Td (In July 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.00 251.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.00 251.10 Td ( received a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.80 251.10 Td (CID) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.02 251.10 Td ( from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.18 251.10 Td (FTC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.52 251.10 Td ( seeking documents and information regarding oxymorphone ER and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 532.62 251.10 Td (EPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 547.62 251.10 Td (�) Tj ET Q
q 0 0 0 rg BT 550.40 251.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 239.10 Td (settlement of a contract dispute with Impax Laboratories \(now ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.31 239.10 Td (Amneal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.97 239.10 Td (\) in ) Tj ET Q
q 0 0 0 rg BT 334.53 239.10 Td (August 2017. ) Tj ET Q
q 0 0 0 rg BT 390.74 239.10 Td (W) Tj ET Q
q 0 0 0 rg BT 399.37 239.10 Td (e are cooperating with the investigation.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 221.10 Td (Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 515.78 221.10 Td (W) Tj ET Q
q 0 0 0 rg BT 524.42 221.10 Td (e are unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.25 209.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.20 209.10 Td (Adjustments to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.10 Td (our overall liability accrual may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 345.88 197.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.38 197.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 424.26 197.10 Td (fect on our business, financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (condition, results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.80 185.10 Td (.) Tj ET Q
endstream
endobj
257 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 258 0 R>>
endobj
258 0 obj
<</Length 15851>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-49) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 749.10 Td (Securities Litigation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.10 Td (In February 2017, a putative class action entitled ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 260.44 731.10 Td (Public Employees�) Tj ET Q
q 0 0 0 rg BT 334.58 731.10 Td ( Retir) Tj ET Q
q 0 0 0 rg BT 356.71 731.10 Td (ement System of Mississippi v) Tj ET Q
q 0 0 0 rg BT 474.84 731.10 Td (. Endo International plc) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.93 731.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.10 Td (was filed in the Court of Common Pleas of Chester County) Tj ET Q
q 0 0 0 rg BT 271.99 719.10 Td (, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.10 Td (public of) Tj ET Q
q 0 0 0 rg BT 71.64 707.10 Td (fering. ) Tj ET Q
q 0 0 0 rg BT 100.34 707.10 Td (The complaint alleged violations of Sections 1) Tj ET Q
q 0 0 0 rg BT 286.04 707.10 Td (1, 12\(a\)\(2\) and 15 of the Securities ) Tj ET Q
q 0 0 0 rg BT 427.67 707.10 Td (Act of 1933 against us, certain of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.10 Td (our current and former directors and of) Tj ET Q
q 0 0 0 rg BT 191.86 695.10 Td (ficers, and the underwriters who participated in the of) Tj ET Q
q 0 0 0 rg BT 406.33 695.10 Td (fering, based on certain disclosures about ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.10 Td (Endo�) Tj ET Q
q 0 0 0 rg BT 59.89 683.10 Td (s generics business. In June 2019, the parties entered into a settlement providing for) Tj ET Q
q 0 0 0 rg BT 394.68 683.10 Td (, among other things, a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.83 683.10 Td ($50 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.22 683.10 Td ( payment ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (to the investor class in exchange for a release of their claims. In December 2019, the court denied a petition to intervene filed by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.10 Td (lead plaintif) Tj ET Q
q 0 0 0 rg BT 83.86 659.10 Td (f in the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 114.68 659.10 Td (Pelletier ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 151.61 659.10 Td (litigation described below) Tj ET Q
q 0 0 0 rg BT 254.82 659.10 Td (, and granted final approval of the settlement. In December 2019, the putative ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.10 Td (intervenor appealed the denial of its petition to intervene and the final approval order to Pennsylvania Superior Court. ) Tj ET Q
q 0 0 0 rg BT 509.29 647.10 Td (That appeal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.10 Td (remains pending. ) Tj ET Q
q 0 0 0 rg BT 106.82 635.10 Td (As a result of the settlement, during the first quarter of 2019, the Company recorded an increase of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.10 Td ($50 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.39 623.10 Td ( to its accrual for loss contingencies. ) Tj ET Q
q 0 0 0 rg BT 230.13 623.10 Td (As the Company�) Tj ET Q
q 0 0 0 rg BT 300.13 623.10 Td (s insurers agreed to fund the settlement, the Company also recorded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 611.10 Td (a corresponding insurance receivable of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.13 611.10 Td ($50 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.52 611.10 Td ( during the first quarter of 2019, which was recorded as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.90 611.10 Td (Prepaid ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 599.10 Td (expenses and other current assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.73 599.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 196.22 599.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 312.31 599.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 317.13 599.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 376.84 599.10 Td (s insurers funded the settlement during the third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 587.10 Td (quarter of 2019, resulting in corresponding decreases to the Company�) Tj ET Q
q 0 0 0 rg BT 317.59 587.10 Td (s accrual for loss contingencies and insurance receivable.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 569.10 Td (In ) Tj ET Q
q 0 0 0 rg BT 73.28 569.10 Td (April 2017, a putative class action entitled ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 244.90 569.10 Td (Phaedra ) Tj ET Q
q 0 0 0 rg BT 281.66 569.10 Td (A. Makris v) Tj ET Q
q 0 0 0 rg BT 327.29 569.10 Td (. Endo International plc, Rajiv Kanishka Liyanaar) Tj ET Q
q 0 0 0 rg BT 528.57 569.10 Td (chchie de ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (Silva and Suketu P) Tj ET Q
q 0 0 0 rg BT 109.97 557.10 Td (. Upadhyay ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.57 557.10 Td (was) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 174.12 557.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.62 557.10 Td (filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.10 Td (herself and similarly-situated Canadian-based investors who purchased Endo�) Tj ET Q
q 0 0 0 rg BT 346.75 545.10 Td (s securities between January 1) Tj ET Q
q 0 0 0 rg BT 467.45 545.10 Td (1 and May 5, 2016. ) Tj ET Q
q 0 0 0 rg BT 547.53 545.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.10 Td (statement of claim sought class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 521.10 Td (Securities ) Tj ET Q
q 0 0 0 rg BT 77.38 521.10 Td (Act arising out of alleged negligent misrepresentations concerning the Company�) Tj ET Q
q 0 0 0 rg BT 402.02 521.10 Td (s revenues, profit mar) Tj ET Q
q 0 0 0 rg BT 489.03 521.10 Td (gins and earnings per ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.10 Td (share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company�) Tj ET Q
q 0 0 0 rg BT 397.03 497.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.42 497.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.21 497.10 Td ( generic pharmaceuticals business. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (January 2019, plaintif) Tj ET Q
q 0 0 0 rg BT 123.30 485.10 Td (f amended her statement of claim to add a claim on behalf of herself and similarly-situated Canadian investors ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (who purchased Endo�) Tj ET Q
q 0 0 0 rg BT 122.65 473.10 Td (s securities between January 1) Tj ET Q
q 0 0 0 rg BT 243.34 473.10 Td (1, 2016 and June 8, 2017, based on our decision to voluntarily remove ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (reformulated OP) Tj ET Q
q 0 0 0 rg BT 102.01 461.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 123.67 465.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.61 461.10 Td ( ER from the market.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 443.10 Td (In ) Tj ET Q
q 0 0 0 rg BT 73.28 443.10 Td (August 2017, an alleged individual shareholder filed a putative class action entitled ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 409.02 443.10 Td (Bier v) Tj ET Q
q 0 0 0 rg BT 432.43 443.10 Td (. Endo International plc ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.03 443.10 Td (in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.02 443.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 573.81 443.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 431.10 Td (District Court for the Eastern District of Pennsylvania, alleging violations of Sections 10\(b\) and 20\(a\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.90 431.10 Td (Exchange ) Tj ET Q
q 0 0 0 rg BT 512.27 431.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.71 431.10 Td ( against us, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 419.10 Td (EHSI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.22 419.10 Td ( and certain of our current and former directors and of) Tj ET Q
q 0 0 0 rg BT 274.06 419.10 Td (ficers, based on our decision to voluntarily remove reformulated OP) Tj ET Q
q 0 0 0 rg BT 545.84 419.10 Td (ANA) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 567.50 423.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 572.44 419.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 407.10 Td (ER from the market. In December 2017, the court appointed SEB Investment Management ) Tj ET Q
q 0 0 0 rg BT 401.73 407.10 Td (AB lead plaintif) Tj ET Q
q 0 0 0 rg BT 465.98 407.10 Td (f in the action. In ) Tj ET Q
q 0 0 0 rg BT 536.52 407.10 Td (August ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 395.10 Td (2019, the parties entered into a settlement providing for) Tj ET Q
q 0 0 0 rg BT 258.04 395.10 Td (, among other things, a payment of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.95 395.10 Td ($82.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.84 395.10 Td ( to the investor class in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.10 Td (exchange for a release of their claims. ) Tj ET Q
q 0 0 0 rg BT 190.18 383.10 Td (The settlement received preliminary court approval in September 2019 and final approval in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (December 2019. ) Tj ET Q
q 0 0 0 rg BT 104.03 371.10 Td (As a result of the settlement, during the second quarter of 2019, the Company recorded an increase of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td ($82.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 359.10 Td ( to its accrual for loss contingencies. ) Tj ET Q
q 0 0 0 rg BT 237.63 359.10 Td (As the Company�) Tj ET Q
q 0 0 0 rg BT 307.63 359.10 Td (s insurers agreed to fund the settlement, the Company also ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (recorded a corresponding insurance receivable of approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.60 347.10 Td ($82.5 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 349.50 347.10 Td ( during the second quarter of 2019, which was recorded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 46.83 335.10 Td (Prepaid expenses and other current assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.61 335.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.10 335.10 Td (Consolidated Balance Sheets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.19 335.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 361.00 335.10 Td (W) Tj ET Q
q 0 0 0 rg BT 370.04 335.10 Td (ith respect to this settlement, the Company�) Tj ET Q
q 0 0 0 rg BT 543.62 335.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.10 Td (insurers funded ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.43 323.10 Td ($20.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.32 323.10 Td ( during the third quarter of 2019 and the remainder in October 2019, resulting in corresponding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.10 Td (decreases to the Company�) Tj ET Q
q 0 0 0 rg BT 143.47 311.10 Td (s accrual for loss contingencies and insurance receivable.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 293.10 Td (In November 2017, a putative class action entitled ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 266.55 293.10 Td (Pelletier v) Tj ET Q
q 0 0 0 rg BT 307.17 293.10 Td (. Endo International plc, Rajiv Kanishka Liyanaar) Tj ET Q
q 0 0 0 rg BT 508.45 293.10 Td (chchie De Silva, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (Suketu P) Tj ET Q
q 0 0 0 rg BT 69.97 281.10 Td (. Upadhyay and Paul V) Tj ET Q
q 0 0 0 rg BT 162.28 281.10 Td (. Campanelli ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.44 281.10 Td (was filed in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.32 281.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.10 281.10 Td ( District Court for the Eastern District of Pennsylvania by an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (individual shareholder on behalf of himself and all similarly situated shareholders. ) Tj ET Q
q 0 0 0 rg BT 367.95 269.10 Td (The lawsuit alleges violations of Section 10\(b\) and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 257.10 Td (20\(a\) of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.15 257.10 Td (Exchange ) Tj ET Q
q 0 0 0 rg BT 126.52 257.10 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 140.96 257.10 Td ( relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.10 Td (Employees�) Tj ET Q
q 0 0 0 rg BT 83.02 245.10 Td ( and Retirement Board Employees�) Tj ET Q
q 0 0 0 rg BT 223.35 245.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 225.30 245.10 Td (Annuity Benefit Fund of Chicago lead plaintif) Tj ET Q
q 0 0 0 rg BT 410.08 245.10 Td (f in the action. In September 2018, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.10 Td (defendants filed a motion to dismiss, which the court granted in part and denied in part in February 2020. In particular) Tj ET Q
q 0 0 0 rg BT 508.25 233.10 Td (, the court ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.10 Td (granted the motion and dismissed the claims with prejudice insofar as they were based on an alleged price-fixing conspiracy; the court ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.10 Td (otherwise denied the motion to dismiss, allowing other aspects of lead plaintif) Tj ET Q
q 0 0 0 rg BT 347.98 209.10 Td (f) Tj ET Q
q 0 0 0 rg BT 351.86 209.10 Td (�) Tj ET Q
q 0 0 0 rg BT 354.64 209.10 Td (s claims to proceed.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 191.10 Td (T) Tj ET Q
q 0 0 0 rg BT 68.41 191.10 Td (o the extent unresolved, w) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.66 191.10 Td (e will continue to vigorously defend the foregoing matters and to explore other options as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 179.10 Td (appropriate in our best interests.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.57 179.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 167.07 179.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.98 179.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.30 179.10 Td (W) Tj ET Q
q 0 0 0 rg BT 517.94 179.10 Td (e are unable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 167.10 Td (to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.76 167.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.71 167.10 Td (Adjustments to our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.10 Td (overall liability accrual may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 330.05 155.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.55 155.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 408.43 155.10 Td (fect on our business, financial condition, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 143.10 Td (results of operations and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 143.10 Td (.) Tj ET Q
endstream
endobj
259 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 260 0 R>>
endobj
260 0 obj
<</Length 19840>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-50) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.00 749.10 Td (V) Tj ET Q
q 0 0 0 rg BT 54.37 749.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 104.93 753.63 Td (� ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 111.49 749.10 Td (Related Matters) Tj ET Q
BT /F5 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.10 Td (In July 2016, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.00 731.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.33 731.10 Td ( sued our subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.21 731.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.33 731.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.77 731.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 302.08 731.10 Td ( LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 323.47 731.10 Td ( in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.96 731.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.75 731.10 Td ( District Court for the District of New Jersey ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.10 Td (alleging an anticompetitive scheme to exclude competition for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.14 719.10 Td (PPCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 309.26 719.10 Td (�) Tj ET Q
q 0 0 0 rg BT 312.04 719.10 Td (s ) Tj ET Q
q 0 0 0 rg BT 318.25 719.10 Td (V) Tj ET Q
q 0 0 0 rg BT 324.18 719.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 378.64 723.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.57 719.10 Td (, a vasopressin-based cardiopulmonary drug. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.10 Td (particular) Tj ET Q
q 0 0 0 rg BT 73.91 707.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 78.91 707.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 117.24 707.10 Td ( alleged violations of Sections 1 and 2 of the Sherman ) Tj ET Q
q 0 0 0 rg BT 335.25 707.10 Td (Antitrust ) Tj ET Q
q 0 0 0 rg BT 372.76 707.10 Td (Act, as well as state antitrust and common law) Tj ET Q
q 0 0 0 rg BT 557.89 707.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.10 Td (based on assertions that our subsidiaries entered into exclusive supply agreements with one or more ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.74 695.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.85 695.10 Td ( manufacturers and that, as a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 683.10 Td (result, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.22 683.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.55 683.10 Td ( could not obtain vasopressin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.15 683.10 Td (API) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.26 683.10 Td ( in order to file an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 310.13 683.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.46 683.10 Td ( to obtain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.73 683.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.52 683.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.02 683.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.47 683.10 Td ( approval for its own vasopressin ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 671.10 Td (product. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.55 671.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 109.88 671.10 Td ( sought actual, treble and punitive damages, attorneys�) Tj ET Q
q 0 0 0 rg BT 327.12 671.10 Td ( fees and costs and injunctive relief. In February 2020, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 659.10 Td (court granted our subsidiaries�) Tj ET Q
q 0 0 0 rg BT 157.17 659.10 Td ( motion for summary judgment on all claims and denied ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.34 659.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 422.67 659.10 Td (�) Tj ET Q
q 0 0 0 rg BT 425.45 659.10 Td (s cross-motion for partial summary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.10 Td (judgment.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 629.10 Td (In ) Tj ET Q
q 0 0 0 rg BT 73.28 629.10 Td (August 2017, our subsidiaries ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.22 629.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 209.67 629.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.11 629.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 245.42 629.10 Td ( LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 266.81 629.10 Td ( filed a complaint for actual, exemplary and punitive damages, injunctive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 617.10 Td (relief and other relief against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.00 617.10 Td (QuV) Tj ET Q
q 0 0 0 rg BT 172.33 617.10 Td (a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 176.77 617.10 Td (, Stuart Hinchen, Peter Jenkins and Mike Rutkowski in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.96 617.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.75 617.10 Td ( District Court for the District of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 605.10 Td (New Jersey) Tj ET Q
q 0 0 0 rg BT 81.72 605.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 86.54 605.10 Td (The complaint alleges misappropriation in violation of the federal Defend ) Tj ET Q
q 0 0 0 rg BT 384.04 605.10 Td (T) Tj ET Q
q 0 0 0 rg BT 389.80 605.10 Td (rade Secrets ) Tj ET Q
q 0 0 0 rg BT 440.33 605.10 Td (Act, New Jersey�) Tj ET Q
q 0 0 0 rg BT 508.92 605.10 Td (s ) Tj ET Q
q 0 0 0 rg BT 515.13 605.10 Td (T) Tj ET Q
q 0 0 0 rg BT 520.89 605.10 Td (rade Secrets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.10 Td (Act and New Jersey common law) Tj ET Q
q 0 0 0 rg BT 170.03 593.10 Td (, as well as unfair competition, breach of contract, breach of fiduciary duty) Tj ET Q
q 0 0 0 rg BT 468.43 593.10 Td (, breach of the duty of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 581.10 Td (loyalty) Tj ET Q
q 0 0 0 rg BT 63.12 581.10 Td (, tortious interference with contractual relations and breach of the duty of confidence in connection with ) Tj ET Q
q 0 0 0 rg BT 481.40 581.10 Td (V) Tj ET Q
q 0 0 0 rg BT 487.33 581.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 541.79 585.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 546.72 581.10 Td (. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 569.10 Td (November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In March 2018, the court granted in part ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 557.10 Td (our motion for preliminary injunction and enjoined ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.90 557.10 Td (QuV) Tj ET Q
q 0 0 0 rg BT 261.23 557.10 Td (a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 265.67 557.10 Td ( from marketing and releasing its planned vasopressin product through the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.10 Td (conclusion of trial. ) Tj ET Q
q 0 0 0 rg BT 113.58 545.10 Td (W) Tj ET Q
q 0 0 0 rg BT 122.22 545.10 Td (e subsequently deposited a bond to the court�) Tj ET Q
q 0 0 0 rg BT 302.46 545.10 Td (s interest-bearing account to secure the preliminary injunction. In ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 533.10 Td (May 2018, defendants filed a notice of appeal to the ) Tj ET Q
q 0 0 0 rg BT 246.58 533.10 Td (Third Circuit Court of ) Tj ET Q
q 0 0 0 rg BT 337.13 533.10 Td (Appeals indicating intent to appeal the court�) Tj ET Q
q 0 0 0 rg BT 517.07 533.10 Td (s preliminary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 521.10 Td (injunction. In February 2019, the defendants filed counterclaims for defamation, tortious interference with contract, tortious ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 509.10 Td (interference with prospective business relations and witness interference. ) Tj ET Q
q 0 0 0 rg BT 330.43 509.10 Td (The counterclaims seek actual, exemplary and punitive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 497.10 Td (damages and other relief. In March 2019, we filed a motion to dismiss all of the defendants�) Tj ET Q
q 0 0 0 rg BT 403.49 497.10 Td ( counterclaims. In ) Tj ET Q
q 0 0 0 rg BT 477.35 497.10 Td (April 2019, the ) Tj ET Q
q 0 0 0 rg BT 540.50 497.10 Td (Third ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 485.10 Td (Circuit Court of ) Tj ET Q
q 0 0 0 rg BT 101.83 485.10 Td (Appeals af) Tj ET Q
q 0 0 0 rg BT 144.69 485.10 Td (firmed the court�) Tj ET Q
q 0 0 0 rg BT 211.88 485.10 Td (s preliminary injunction but remanded for additional fact-finding concerning the duration ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 473.10 Td (of the preliminary injunction and, if needed, consideration of the additional trade secrets raised in our motion for preliminary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 461.10 Td (injunction but not addressed by the preliminary injunction order) Tj ET Q
q 0 0 0 rg BT 291.50 461.10 Td (. In September 2019, following the decision in ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 479.80 461.10 Td (Athenex Inc. v) Tj ET Q
q 0 0 0 rg BT 535.97 461.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 540.79 461.10 Td (Azar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.68 461.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 449.10 Td (No. 19-cv-00603, 2019 ) Tj ET Q
q 0 0 0 rg BT 131.64 449.10 Td (WL) Tj ET Q
q 0 0 0 rg BT 146.82 449.10 Td ( 350181) Tj ET Q
q 0 0 0 rg BT 178.94 449.10 Td (1 \(D.D.C. ) Tj ET Q
q 0 0 0 rg BT 220.34 449.10 Td (Aug. 1, 2019\), which upheld the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 352.26 449.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.16 449.10 Td (�) Tj ET Q
q 0 0 0 rg BT 373.93 449.10 Td (s determination that there is no clinical need for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 437.10 Td (outsourcing facilities to compound drugs using bulk vasopressin \(described below\), the parties submitted a proposed consent order to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 425.10 Td (the district court agreeing to a lifting of the preliminary injunction against ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.70 425.10 Td (QuV) Tj ET Q
q 0 0 0 rg BT 352.03 425.10 Td (a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 356.47 425.10 Td ( but reserving ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 413.95 425.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 428.41 425.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 447.85 425.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 464.16 425.10 Td ( LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.55 425.10 Td (�) Tj ET Q
q 0 0 0 rg BT 488.32 425.10 Td (s right to seek return ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.10 Td (or reduction of the bond. In January 2020, the court granted our motion to dismiss the defendants�) Tj ET Q
q 0 0 0 rg BT 427.39 413.10 Td ( counterclaims and ordered the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 401.10 Td (preliminary injunction lifted while the bond remains in place pending an adjudication on the merits.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 383.10 Td (Beginning in ) Tj ET Q
q 0 0 0 rg BT 116.89 383.10 Td (April 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.50 383.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 181.81 383.10 Td ( LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.20 383.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.64 383.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.09 383.10 Td ( received notice letters from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.76 383.10 Td (Eagle) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.52 383.10 Td (, Sandoz, Inc., ) Tj ET Q
q 0 0 0 rg BT 433.68 383.10 Td (Amphastar Pharmaceuticals, Inc., ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 371.10 Td (Amneal Pharmaceuticals LLC, ) Tj ET Q
q 0 0 0 rg BT 161.52 371.10 Td (American Regent and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.21 371.10 Td (Fresenius) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.54 371.10 Td ( advising of the filing by such companies of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 467.01 371.10 Td (ANDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.89 371.10 Td (s for generic ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 359.10 Td (versions of ) Tj ET Q
q 0 0 0 rg BT 82.48 359.10 Td (V) Tj ET Q
q 0 0 0 rg BT 88.41 359.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 142.87 363.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.80 359.10 Td ( \(vasopressin IV) Tj ET Q
q 0 0 0 rg BT 213.16 359.10 Td ( solution \(infusion\)\) 20 units/ml and/or 200 units/10 ml. Beginning in May 2018, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.55 359.10 Td (PSP) Tj ET Q
q 0 0 0 rg BT 555.86 359.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 347.10 Td (LLC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 54.89 347.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 59.89 347.10 Td (PPI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.34 347.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.78 347.10 Td (EPIC) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 115.45 347.10 Td ( filed lawsuits against the companies in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.85 347.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 307.64 347.10 Td ( District Court for the District of Delaware and New Jersey within ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.10 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 335.10 Td (45) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 60.72 335.10 Td (-day deadline to invoke a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.29 335.10 Td (30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.29 335.10 Td (-month stay of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 235.12 335.10 Td (FDA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.57 335.10 Td ( approval pursuant to the Hatch-W) Tj ET Q
q 0 0 0 rg BT 392.33 335.10 Td (axman legislative scheme. ) Tj ET Q
q 0 0 0 rg BT 499.89 335.10 Td (The earliest trial is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.10 Td (scheduled for May 2020.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 305.10 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 122.71 305.10 Td (s accrual for loss contingencies includes, among other things, an estimated accrual for certain ) Tj ET Q
q 0 0 0 rg BT 498.51 305.10 Td (V) Tj ET Q
q 0 0 0 rg BT 504.44 305.10 Td (ASOSTRICT) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 558.89 309.63 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 563.83 305.10 Td (-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 293.10 Td (related matters. ) Tj ET Q
q 0 0 0 rg BT 99.96 293.10 Td (W) Tj ET Q
q 0 0 0 rg BT 108.59 293.10 Td (e will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 281.10 Td (property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 269.10 Td (Similar matters may be brought by others or the foregoing matters may be expanded.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.91 269.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.23 269.10 Td (W) Tj ET Q
q 0 0 0 rg BT 386.86 269.10 Td (e are unable to predict the outcome of these ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 257.10 Td (matters or to estimate the possible range of any additional losses that could be incurred.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 386.18 257.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.13 257.10 Td (Adjustments to our overall liability accrual ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.10 Td (may be required in the future, which could have a) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.81 245.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.31 245.10 Td (material adverse ef) Tj ET Q
q 0 0 0 rg BT 313.20 245.10 Td (fect on our business, financial condition, results of operations ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.10 Td (and cash flows) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.43 233.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 215.10 Td (Other Pr) Tj ET Q
q 0 0 0 rg BT 84.96 215.10 Td (oceedings and Investigations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 197.10 Td (Proceedings similar to those described above may also be brought in the future. ) Tj ET Q
q 0 0 0 rg BT 382.92 197.10 Td (Additionally) Tj ET Q
q 0 0 0 rg BT 432.82 197.10 Td (, we are involved in, or have been ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.10 Td (involved in, arbitrations or various other proceedings that arise from the normal course of our business. ) Tj ET Q
q 0 0 0 rg BT 451.27 185.10 Td (W) Tj ET Q
q 0 0 0 rg BT 459.91 185.10 Td (e cannot predict the timing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 173.10 Td (or outcome of these other proceedings. Currently) Tj ET Q
q 0 0 0 rg BT 231.68 173.10 Td (, neither we nor our subsidiaries are involved in any other proceedings that we expect ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 161.10 Td (to have a material ef) Tj ET Q
q 0 0 0 rg BT 117.44 161.10 Td (fect on our business, financial condition, results of operations and cash flows.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 131.10 Td (NOTE 16. OTHER COMPREHENSIVE LOSS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 113.10 Td (There were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 110.74 113.10 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.74 113.10 Td ( significant tax ef) Tj ET Q
q 0 0 0 rg BT 190.26 113.10 Td (fects allocated to any component of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.21 113.10 Td (Other comprehensive income \(loss\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.66 113.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 509.04 113.10 Td (years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 101.10 Td (December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 101.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 183.84 101.10 Td (The 2017 reclassification adjustment out of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 359.91 101.10 Td (Other comprehensive income \(loss\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.36 101.10 Td ( included in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 89.10 Td (Consolidated Statements of Comprehensive Loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.64 89.10 Td (, which relates to foreign currency translation, was recorded upon the liquidations of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 77.10 Td (Litha) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.10 77.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 76.54 77.10 Td (Somar) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.65 77.10 Td ( in 2017. Substantially all of the Company�) Tj ET Q
q 0 0 0 rg BT 274.86 77.10 Td (s ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.70 77.10 Td (Accumulated other comprehensive loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.15 77.10 Td ( balances at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.29 77.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 565.87 77.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 65.10 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 65.10 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 131.52 65.10 Td ( consist of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 175.13 65.10 Td (Foreign currency translation loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.49 65.10 Td (.) Tj ET Q
endstream
endobj
261 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 262 0 R>>
endobj
262 0 obj
<</Length 14466>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-51) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 17. SHAREHOLDERS' DEFICIT) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (The Company has issued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.76 731.25 Td (4,000,000) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.76 731.25 Td ( euro deferred shares of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 302.66 731.25 Td ($0.01) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 325.16 731.25 Td ( each at par) Tj ET Q
q 0 0 0 rg BT 370.41 731.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 375.23 731.25 Td (The euro deferred shares are held by nominees in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (order to satisfy an Irish legislative requirement to maintain a minimum level of issued share capital denominated in euro and to have at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 707.25 Td (least ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.83 707.25 Td (seven) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.59 707.25 Td ( registered shareholders. ) Tj ET Q
q 0 0 0 rg BT 179.37 707.25 Td (The euro deferred shares carry no voting rights and are not entitled to receive any dividend or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 695.25 Td (distribution.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 677.25 Td (Ef) Tj ET Q
q 0 0 0 rg BT 45.82 677.25 Td (fects of Changes in ) Tj ET Q
q 0 0 0 rg BT 127.12 677.25 Td (Accounting Principles) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 659.25 Td (The Company early adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.52 659.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 198.53 659.25 Td ( No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 218.25 659.25 Td (2016-16) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.58 659.25 Td (, ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 256.58 659.25 Td (Intra-Entity T) Tj ET Q
q 0 0 0 rg BT 311.30 659.25 Td (ransfers of ) Tj ET Q
q 0 0 0 rg BT 356.68 659.25 Td (Assets Other Than Inventory) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.39 659.25 Td ( \() Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.22 659.25 Td (ASU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.22 659.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.72 659.25 Td (2016-16) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.05 659.25 Td (\) on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 647.25 Td (January 1, 2017, resulting in, among other ef) Tj ET Q
q 0 0 0 rg BT 215.22 647.25 Td (fects, the elimination of previously recorded deferred char) Tj ET Q
q 0 0 0 rg BT 447.72 647.25 Td (ges that were established in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 635.25 Td (2016. Specifically) Tj ET Q
q 0 0 0 rg BT 108.11 635.25 Td (, ef) Tj ET Q
q 0 0 0 rg BT 120.70 635.25 Td (fective January 1, 2017, the Company eliminated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 319.81 635.25 Td ($372.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 378.70 635.25 Td ( of deferred char) Tj ET Q
q 0 0 0 rg BT 444.86 635.25 Td (ges and recorded a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 623.25 Td (corresponding increase to its ) Tj ET Q
q 0 0 0 rg BT 152.64 623.25 Td (Accumulated deficit.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 605.25 Td (As further discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.43 605.25 Td (Note 2. Summary of Significant ) Tj ET Q
q 0 0 0 rg BT 287.41 605.25 Td (Accounting Policies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.23 605.25 Td (, the Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.94 605.25 Td (ASC 606) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.89 605.25 Td ( on January 1, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 593.25 Td (2018. ) Tj ET Q
q 0 0 0 rg BT 60.82 593.25 Td (This adoption resulted in a net decrease of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.43 593.25 Td ($3.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.32 593.25 Td ( to the Company�) Tj ET Q
q 0 0 0 rg BT 350.48 593.25 Td (s ) Tj ET Q
q 0 0 0 rg BT 356.32 593.25 Td (Accumulated deficit at January 1, 2018.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 575.25 Td (As further discussed in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.43 575.25 Td (Note 2. Summary of Significant ) Tj ET Q
q 0 0 0 rg BT 287.41 575.25 Td (Accounting Policies) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 368.23 575.25 Td (, the Company adopted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.94 575.25 Td (ASC 842) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 499.89 575.25 Td ( on January 1, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 563.25 Td (2019. ) Tj ET Q
q 0 0 0 rg BT 60.82 563.25 Td (This adoption resulted in a net increase of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 230.77 563.25 Td ($4.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.66 563.25 Td ( to the Company�) Tj ET Q
q 0 0 0 rg BT 348.82 563.25 Td (s ) Tj ET Q
q 0 0 0 rg BT 354.66 563.25 Td (Accumulated deficit at January 1, 2019.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 545.25 Td (Share Repurchase Program) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 527.25 Td (Pursuant to ) Tj ET Q
q 0 0 0 rg BT 110.23 527.25 Td (Article 1) Tj ET Q
q 0 0 0 rg BT 145.12 527.25 Td (1 of the Company�) Tj ET Q
q 0 0 0 rg BT 219.83 527.25 Td (s ) Tj ET Q
q 0 0 0 rg BT 225.67 527.25 Td (Articles of ) Tj ET Q
q 0 0 0 rg BT 270.10 527.25 Td (Association, the Company has broad shareholder authority to conduct ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 515.25 Td (ordinary share repurchases by way of redemptions. ) Tj ET Q
q 0 0 0 rg BT 242.42 515.25 Td (The Company�) Tj ET Q
q 0 0 0 rg BT 302.13 515.25 Td (s authority to repurchase ordinary shares is subject to legal ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 503.25 Td (limitations and the existence of suf) Tj ET Q
q 0 0 0 rg BT 175.51 503.25 Td (ficient distributable reserves. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 293.80 503.25 Td (For example, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.78 503.25 Td (Companies ) Tj ET Q
q 0 0 0 rg BT 410.72 503.25 Td (Act) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.16 503.25 Td ( requires Irish companies to have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 491.25 Td (distributable reserves equal to or greater than the amount of any proposed ordinary share repurchase amount. Unless we are able to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 479.25 Td (generate suf) Tj ET Q
q 0 0 0 rg BT 84.40 479.25 Td (ficient distributable reserves or create distributable reserves by reducing our share premium account, we will not be able to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 467.25 Td (repurchase our ordinary shares) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.00 467.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 163.45 467.25 Td (As permitted by Irish Law and the Company�) Tj ET Q
q 0 0 0 rg BT 344.80 467.25 Td (s ) Tj ET Q
q 0 0 0 rg BT 350.64 467.25 Td (Articles of ) Tj ET Q
q 0 0 0 rg BT 395.08 467.25 Td (Association, any ordinary shares redeemed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 455.25 Td (shall be cancelled upon redemption.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 437.25 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 437.25 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.49 437.25 Td ( has approved the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 178.24 437.25 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.49 437.25 Td ( that authorizes the Company to redeem, in the aggregate, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.75 437.25 Td ($2.5 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 425.25 Td (billion) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 62.11 425.25 Td ( of its outstanding ordinary shares. ) Tj ET Q
q 0 0 0 rg BT 202.74 425.25 Td (T) Tj ET Q
q 0 0 0 rg BT 208.15 425.25 Td (o date, the Company has redeemed and cancelled approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.05 425.25 Td (4.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 511.94 425.25 Td ( of its ordinary ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 413.25 Td (shares under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 103.48 413.25 Td (2015 Share Buyback Program) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.73 413.25 Td ( for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.39 413.25 Td ($250.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 299.28 413.25 Td (, not including related fees.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 383.25 Td (NOTE 18. SHARE-BASED COMPENSA) Tj ET Q
q 0 0 0 rg BT 211.95 383.25 Td (TION) Tj ET Q
BT /F1 10.00 Tf ET
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 365.25 Td (Stock Incentive Plans) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 347.25 Td (In June 2015, the Company�) Tj ET Q
q 0 0 0 rg BT 176.04 347.25 Td (s shareholders approved ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.18 347.25 Td (the 2015 Stock Incentive Plan \(the 2015 Plan\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.31 347.25 Td (, which has subsequently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 335.25 Td (been amended, as approved by the Company�) Tj ET Q
q 0 0 0 rg BT 217.89 335.25 Td (s shareholders, on multiple occasions, including in 2017, 2018 and 2019. Under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.22 335.25 Td (2015 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 323.25 Td (Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 323.25 Td (, stock options \(including incentive stock options\), stock appreciation rights, restricted stock awards, performance awards and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 311.25 Td (other share- or cash-based awards may be issued at the discretion of the Compensation Committee of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.82 311.25 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.26 311.25 Td ( from time to time. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 560.02 311.25 Td (No) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 572.25 311.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 299.25 Td (ordinary shares are to be granted under previously approved plans, including the Company�) Tj ET Q
q 0 0 0 rg BT 401.73 299.25 Td (s 2000, 2004, 2007, 2010 and ) Tj ET Q
q 0 0 0 rg BT 522.01 299.25 Td (Assumed ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 287.25 Td (Stock Incentive Plans. ) Tj ET Q
q 0 0 0 rg BT 127.10 287.25 Td (All awards previously granted and outstanding under these prior plans remain subject to the terms of those prior ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 275.25 Td (plans.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 257.25 Td (During the third quarter of 2017, the Company issued approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.44 257.25 Td (1.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.33 257.25 Td ( stock options and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.33 257.25 Td (0.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 503.22 257.25 Td ( restricted stock ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 245.25 Td (units that were initially subject to shareholder approval and were subsequently approved by shareholders on ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.04 245.25 Td (June�7, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.87 245.25 Td ( at the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 233.25 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 233.25 Td (s ) Tj ET Q
q 0 0 0 rg BT 83.50 233.25 Td (Annual General Meeting of Shareholders. ) Tj ET Q
q 0 0 0 rg BT 253.27 233.25 Td (The options have an exercise price equal to the closing share price on their ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 221.25 Td (issuance date in ) Tj ET Q
q 0 0 0 rg BT 101.26 221.25 Td (August 2017. For accounting and disclosure purposes, these stock options and restricted stock units were considered ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.25 Td (to have been granted in 2018 upon approval by shareholders.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 191.25 Td (As further described below) Tj ET Q
q 0 0 0 rg BT 170.92 191.25 Td (, certain of the Company�) Tj ET Q
q 0 0 0 rg BT 272.84 191.25 Td (s outstanding ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.40 191.25 Td (Performance Share Units \(PSUs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.31 191.25 Td ( are ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.52 191.25 Td (measured against tar) Tj ET Q
q 0 0 0 rg BT 559.53 191.25 Td (gets ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 179.25 Td (covering ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.49 179.25 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 93.47 179.25 Td ( independent successive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.05 179.25 Td (one) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.49 179.25 Td (-year performance periods, which are generally established for each performance period ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 167.25 Td (during the first quarter of that calendar year) Tj ET Q
q 0 0 0 rg BT 210.09 167.25 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 212.59 167.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 214.91 167.25 Td (The determination of the grant-date\(s\) underlying such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.78 167.25 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 455.13 167.25 Td (s depends in part on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 155.25 Td (date\(s\) on which each of the performance tar) Tj ET Q
q 0 0 0 rg BT 214.90 155.25 Td (gets with respect to those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 318.49 155.25 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.83 155.25 Td (s are approved. ) Tj ET Q
q 0 0 0 rg BT 399.96 155.25 Td (Therefore, for certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 488.23 155.25 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 506.58 155.25 Td (s, a single unit ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 143.25 Td (may give rise to multiple grant dates depending, in part, on the dates on which the respective performance tar) Tj ET Q
q 0 0 0 rg BT 472.89 143.25 Td (gets are approved.) Tj ET Q
endstream
endobj
263 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 264 0 R>>
endobj
264 0 obj
<</Length 16494>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-52) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Beginning in 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.44 742.10 Td (long-term cash incentive \(L) Tj ET Q
q 0 0 0 rg BT 252.32 742.10 Td (TCI\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.75 742.10 Td ( awards were provided to certain employees. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.79 742.10 Td (L) Tj ET Q
q 0 0 0 rg BT 457.99 742.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.09 742.10 Td ( awards were designed to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (vest ratably) Tj ET Q
q 0 0 0 rg BT 81.72 730.10 Td (, in equal amounts, over a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 187.25 730.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.24 730.10 Td (-year service period. Upon vesting, each vested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.11 730.10 Td (L) Tj ET Q
q 0 0 0 rg BT 404.30 730.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 420.40 730.10 Td ( unit would be settled in cash in an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (amount equal to the price of Endo�) Tj ET Q
q 0 0 0 rg BT 174.85 718.10 Td (s ordinary shares on the vest date. ) Tj ET Q
q 0 0 0 rg BT 312.04 718.10 Td (As of September 30, 2018, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.00 718.10 Td (3.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 525.89 718.10 Td ( unvested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (L) Tj ET Q
q 0 0 0 rg BT 41.19 706.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.30 706.10 Td ( awards were outstanding for approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.13 706.10 Td (570) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 251.13 706.10 Td ( employees. ) Tj ET Q
q 0 0 0 rg BT 301.21 706.10 Td (The outstanding awards had a weighted average remaining requisite ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (service period of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.69 694.10 Td (2.3 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.79 694.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 146.24 694.10 Td (A) Tj ET Q
q 0 0 0 rg BT 152.91 694.10 Td ( corresponding liability of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 259.55 694.10 Td ($14.9 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 313.45 694.10 Td ( was recorded as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.13 694.10 Td (September�30, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 473.40 694.10 Td ( in ) Tj ET Q
q 0 0 0 rg BT 485.62 694.10 Td (Accounts payable and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (accrued expenses and Other liabilities in the Company�) Tj ET Q
q 0 0 0 rg BT 256.77 682.10 Td (s Consolidated Balance Sheets. On ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 398.96 682.10 Td (October�1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 463.67 682.10 Td (, the Compensation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (Committee of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.49 670.10 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 132.92 670.10 Td ( authorized the Company to settle each of the outstanding unvested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.69 670.10 Td (L) Tj ET Q
q 0 0 0 rg BT 408.88 670.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.98 670.10 Td ( awards in shares, rather than cash, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (upon vesting in accordance with the original vesting terms of the awards. ) Tj ET Q
q 0 0 0 rg BT 331.01 658.10 Td (W) Tj ET Q
q 0 0 0 rg BT 340.05 658.10 Td (ith the authorization of the Compensation Committee, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (management�) Tj ET Q
q 0 0 0 rg BT 89.87 646.10 Td (s intent to settle the awards in shares rather than cash is a modification that changes the awards�) Tj ET Q
q 0 0 0 rg BT 472.05 646.10 Td ( classification from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (liability to equity) Tj ET Q
q 0 0 0 rg BT 104.23 634.10 Td (, ef) Tj ET Q
q 0 0 0 rg BT 116.82 634.10 Td (fective ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.52 634.10 Td (October�1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 211.23 634.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 216.05 634.10 Td (The accounting for the modification occurred in the fourth quarter of 2018. Prior to this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (modification, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 92.10 622.10 Td (L) Tj ET Q
q 0 0 0 rg BT 97.29 622.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.40 622.10 Td ( awards were excluded from amounts in this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.79 622.10 Td (Note 18. Share-based Compensation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 438.87 622.10 Td (. Subsequent to this modification, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 610.10 Td (L) Tj ET Q
q 0 0 0 rg BT 41.19 610.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.30 610.10 Td ( awards are generally treated the same as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 223.32 610.10 Td (restricted stock units \(RSUs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.59 610.10 Td (, including for accounting, financial statement ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 598.10 Td (classification and disclosure purposes. However) Tj ET Q
q 0 0 0 rg BT 228.05 598.10 Td (, adjustments to pre-modification amounts of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 410.51 598.10 Td (L) Tj ET Q
q 0 0 0 rg BT 415.70 598.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.81 598.10 Td ( expense that are recorded in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 586.10 Td (Consolidated Statements of Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.36 586.10 Td ( subsequent to this modification, including adjustments related to actual or estimated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 574.10 Td (forfeitures, are excluded from the determination of share-based compensation expense.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 556.10 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 556.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 556.10 Td (, approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.34 556.10 Td (7.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 263.23 556.10 Td ( ordinary shares were reserved for future grants under the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.36 556.10 Td (2015 Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.64 556.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 540.08 556.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 544.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 544.10 Td (, stock options, restricted stock awards, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.27 544.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 292.62 544.10 Td (s, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.51 544.10 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.96 544.10 Td (s and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 344.29 544.10 Td (L) Tj ET Q
q 0 0 0 rg BT 349.48 544.10 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 365.59 544.10 Td ( awards have been granted under the stock incentive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 532.10 Td (plans.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 514.10 Td (Generally) Tj ET Q
q 0 0 0 rg BT 101.77 514.10 Td (, the grant-date fair value of each award is recognized as expense over the requisite service period. However) Tj ET Q
q 0 0 0 rg BT 534.23 514.10 Td (, expense ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 502.10 Td (recognition dif) Tj ET Q
q 0 0 0 rg BT 94.97 502.10 Td (fers in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 490.10 Td (each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 478.10 Td (percent of the requisite service period that has elapsed.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 460.10 Td (Presented below are the components of total share-based compensation as recorded in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.82 460.10 Td (Consolidated Statements of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 448.10 Td (Operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.88 448.10 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 111.25 448.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.25 448.10 Td ( \(in thousands\).) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 425.60 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 425.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 425.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 425.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 425.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 425.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 397.60 337.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 397.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 397.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 397.60 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 397.60 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 397.60 65.00 -14.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 425.6 m
437.5 425.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 425.6 m
506.5 425.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 425.6 m
575.5 425.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 383.6 m
437.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 383.6 m
506.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 383.6 m
575.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 383.6 m
437.5 383.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 370.6 m
437.5 370.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 368.6 m
437.5 368.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 370.6 m
506.5 370.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 368.6 m
506.5 368.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 370.6 m
575.5 370.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 368.6 m
575.5 368.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 429.68 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 429.68 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 429.68 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 416.17 Td (Selling, general and administrative expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 416.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 416.17 Td (44,159) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 416.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 416.17 Td (44,454) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 416.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 416.17 Td (38,292) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 402.17 Td (Research and development expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 402.17 Td (4,501) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 402.17 Td (2,251) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 402.17 Td (4,197) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 388.17 Td (Cost of revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 388.17 Td (10,482) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 388.17 Td (7,366) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 388.17 Td (7,660) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 374.17 Td (T) Tj ET Q
q 0 0 0 rg BT 49.41 374.17 Td (otal share-based compensation expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 374.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 374.17 Td (59,142) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 374.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 374.17 Td (54,071) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 374.17 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 374.17 Td (50,149) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 352.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.44 352.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.03 352.10 Td (, the total remaining unrecognized compensation cost related to all non-vested share-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 340.10 Td (compensation awards for which a grant date has been established as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 320.90 340.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 399.49 340.10 Td ( amounted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.20 340.10 Td ($48.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 508.09 340.10 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 322.10 Td (Stock Options) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 304.10 Td (From time to time, the Company grants stock options to its employees as part of their annual share compensation awards and, in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 292.10 Td (certain circumstances, on an ad hoc basis or upon their commencement of service with the Company) Tj ET Q
q 0 0 0 rg BT 438.00 292.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 274.10 Td (Employee stock options generally vest ratably) Tj ET Q
q 0 0 0 rg BT 245.02 274.10 Td (, in equal amounts, over a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 350.55 274.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.54 274.10 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 383.87 274.10 Td (four) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.33 274.10 Td (-year service period and generally expire ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 262.10 Td (ten years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.82 262.10 Td ( from the grant date. ) Tj ET Q
q 0 0 0 rg BT 155.49 262.10 Td (The fair value of option grants is estimated at the date of grant using the Black-Scholes option-pricing ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 250.10 Td (model. ) Tj ET Q
q 0 0 0 rg BT 65.81 250.10 Td (This model utilizes assumptions related to volatility) Tj ET Q
q 0 0 0 rg BT 272.36 250.10 Td (, the risk-free interest rate, the dividend yield \(which is assumed to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 553.66 250.10 Td (zero) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.87 250.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 238.10 Td (as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends\) and the expected term of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 226.10 Td (option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company�) Tj ET Q
q 0 0 0 rg BT 478.95 226.10 Td (s share price over a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 214.10 Td (period commensurate with the expected life of the share option as well as other factors. ) Tj ET Q
q 0 0 0 rg BT 387.36 214.10 Td (The risk-free interest rate is derived from the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 202.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 202.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 56.10 202.10 Td (T) Tj ET Q
q 0 0 0 rg BT 61.86 202.10 Td (reasury yield curve in ef) Tj ET Q
q 0 0 0 rg BT 158.86 202.10 Td (fect at the time of grant. ) Tj ET Q
q 0 0 0 rg BT 257.25 202.10 Td (W) Tj ET Q
q 0 0 0 rg BT 265.88 202.10 Td (e estimate the expected term of options granted based on our historical ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 190.10 Td (experience with our employees�) Tj ET Q
q 0 0 0 rg BT 163.26 190.10 Td ( exercise of stock options and other factors.) Tj ET Q
endstream
endobj
265 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 266 0 R>>
endobj
266 0 obj
<</Length 21568>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-53) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 742.10 Td (A) Tj ET Q
q 0 0 0 rg BT 67.67 742.10 Td ( summary of the activity for each of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 228.45 742.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 421.44 742.10 Td ( is presented below:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 686.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 686.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 686.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 686.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 686.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 686.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 686.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 686.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 656.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 656.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 656.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 656.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 656.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 656.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 656.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 656.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 626.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 626.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 626.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 626.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 626.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 626.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 626.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 626.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 596.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 596.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 596.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 596.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 596.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 596.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 596.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 596.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 566.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 566.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 566.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 566.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 566.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 566.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 566.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 566.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 536.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 536.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 536.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 536.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 536.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 536.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 536.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 536.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 506.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 506.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 506.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 506.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 506.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 506.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 506.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 506.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 476.60 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 476.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 476.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 476.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 476.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 476.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 476.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 476.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 686.6 m
368.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 686.6 m
437.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 686.6 m
506.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 686.6 m
575.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 686.6 m
368.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 686.6 m
437.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 686.6 m
506.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 686.6 m
575.5 686.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 626.6 m
368.5 626.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 611.6 m
368.5 611.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 551.6 m
368.5 551.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 536.6 m
368.5 536.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 491.6 m
368.5 491.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 477.6 m
368.5 477.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 475.6 m
368.5 475.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 317.00 698.83 Td (Number) Tj ET Q
q 0 0 0 rg BT 345.37 698.83 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 324.00 690.83 Td (Shar) Tj ET Q
q 0 0 0 rg BT 340.38 690.83 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 388.25 706.83 Td (W) Tj ET Q
q 0 0 0 rg BT 396.03 706.83 Td (eighted) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 375.20 698.83 Td (A) Tj ET Q
q 0 0 0 rg BT 380.68 698.83 Td (verage Exer) Tj ET Q
q 0 0 0 rg BT 421.40 698.83 Td (cise) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 395.60 690.83 Td (Price) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 457.25 722.83 Td (W) Tj ET Q
q 0 0 0 rg BT 465.03 722.83 Td (eighted) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 459.55 714.83 Td (A) Tj ET Q
q 0 0 0 rg BT 465.03 714.83 Td (verage) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 454.80 706.83 Td (Remaining) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 452.80 698.83 Td (Contractual) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 464.30 690.83 Td (T) Tj ET Q
q 0 0 0 rg BT 469.27 690.83 Td (erm) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 525.00 706.83 Td (Aggr) Tj ET Q
q 0 0 0 rg BT 542.18 706.83 Td (egate) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 517.25 698.83 Td (Intrinsic ) Tj ET Q
q 0 0 0 rg BT 548.44 698.83 Td (V) Tj ET Q
q 0 0 0 rg BT 553.48 698.83 Td (alue) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 537.80 690.83 Td (\(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 676.27 Td (Outstanding as of January 1, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 676.27 Td (4,325,209) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 676.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 676.27 Td (41.70) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 661.27 Td (Granted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 661.27 Td (5,288,675) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 661.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 661.27 Td (10.42) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 646.27 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 646.32 Td (\(623,987) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 646.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 646.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 646.27 Td (28.32) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 631.27 Td (Expired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 631.32 Td (\(741,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 631.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 631.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 631.27 Td (40.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 616.27 Td (Outstanding as of December 31, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 616.27 Td (8,248,130) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 616.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 616.27 Td (22.79) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 601.27 Td (Granted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 601.27 Td (971,590) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 601.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.15 601.27 Td (7.55) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 586.27 Td (Exercised) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.80 586.32 Td (\(94,392) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 586.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 586.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.15 586.27 Td (9.89) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 571.27 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 571.32 Td (\(605,737) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 571.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 571.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 571.27 Td (19.01) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 556.27 Td (Expired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 556.32 Td (\(446,873) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 556.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 556.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 556.27 Td (36.80) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 541.27 Td (Outstanding as of December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 541.27 Td (8,072,718) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 541.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 541.27 Td (20.62) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 526.27 Td (Exercised) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 346.30 526.32 Td (\(557) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 526.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 526.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.15 526.27 Td (7.55) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 511.27 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 511.32 Td (\(125,739) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 511.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 511.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 511.27 Td (14.38) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 496.27 Td (Expired) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 496.32 Td (\(665,883) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 496.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 496.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 496.27 Td (40.37) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 481.27 Td (Outstanding as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 481.27 Td (7,280,539) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 481.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 481.27 Td (18.93) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.50 481.27 Td (6.30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 481.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 481.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 466.27 Td (V) Tj ET Q
q 0 0 0 rg BT 44.67 466.27 Td (ested and expected to vest as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 466.27 Td (7,212,334) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 466.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 466.27 Td (19.00) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.50 466.27 Td (6.29) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 466.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 466.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 451.27 Td (Exercisable as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.65 451.27 Td (5,003,163) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 451.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 451.27 Td (21.60) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.50 451.27 Td (6.07) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 451.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 451.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 439.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 429.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 429.50 Td (The intrinsic value of a stock option is the excess, if any) Tj ET Q
q 0 0 0 rg BT 246.93 429.50 Td (, of the closing price of the Company�) Tj ET Q
q 0 0 0 rg BT 368.24 429.50 Td (s ordinary shares on the last trading day of the fiscal year over ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 419.90 Td (the exercise price. ) Tj ET Q
q 0 0 0 rg BT 127.32 419.90 Td (The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 410.30 Td (�in-the-money) Tj ET Q
q 0 0 0 rg BT 113.63 410.30 Td (,� if any) Tj ET Q
q 0 0 0 rg BT 139.10 410.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 392.30 Td (The range of exercise prices for the above stock options outstanding at ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 347.91 392.30 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 426.49 392.30 Td ( is from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 460.10 392.30 Td ($7.55) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.60 392.30 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 495.38 392.30 Td ($86.54) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.88 392.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 374.30 Td (The total intrinsic values of options exercised during the years ended December 31, 2019 and 2018 were less than ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.64 374.30 Td ($0.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 569.53 374.30 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 362.30 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 52.94 362.30 Td ($0.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 101.83 362.30 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 154.49 362.30 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.49 362.30 Td (No) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 171.71 362.30 Td ( tax benefits from stock option exercises were realized during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.23 362.30 Td (years ended December 31, 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 350.30 Td (2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.44 350.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 100.26 350.30 Td (The weighted average grant-date fair values of the stock options granted during the years ended December 31, 2018 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 338.30 Td (and 2017 were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.37 338.30 Td ($3.97) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.87 338.30 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 139.31 338.30 Td ($4.73) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.81 338.30 Td ( per option, respectively) Tj ET Q
q 0 0 0 rg BT 257.79 338.30 Td (, determined using the following weighted average assumptions:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 314.80 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 314.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 314.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 314.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 284.80 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 284.80 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 284.80 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 284.80 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 314.79999999999995 m
506.5 314.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 314.79999999999995 m
575.5 314.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 314.79999999999995 m
506.5 314.79999999999995 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 314.79999999999995 m
575.5 314.79999999999995 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 319.03 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 319.03 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 304.47 Td (Expected term \(years\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.50 304.47 Td (4.0) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 559.50 304.47 Td (4.0) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 289.47 Td (Risk-free interest rate) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.15 289.47 Td (2.7) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 289.47 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 554.15 289.47 Td (1.7) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 289.47 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 274.47 Td (Dividend yield) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 274.47 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 274.47 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 259.47 Td (Expected volatility) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 259.47 Td (63) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.65 259.47 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 259.47 Td (58) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 566.65 259.47 Td (%) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 237.30 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.44 237.30 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.03 237.30 Td (, the weighted average remaining requisite service period of non-vested stock options was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.14 237.30 Td (0.9) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.64 237.30 Td ( years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 225.30 Td (and the total remaining unrecognized compensation cost related to non-vested stock options amounted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.11 225.30 Td ($3.1 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.00 225.30 Td (.) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 49.50 207.30 Td (Restricted Stock Units and Performance Shar) Tj ET Q
q 0 0 0 rg BT 231.59 207.30 Td (e Units) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 260.20 207.30 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 189.30 Td (From time to time, the Company grants ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.54 189.30 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.99 189.30 Td (s and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.32 189.30 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.67 189.30 Td (s to its employees as part of their annual share compensation awards and, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 177.30 Td (in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company) Tj ET Q
q 0 0 0 rg BT 448.28 177.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 159.30 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.45 159.30 Td (s vest ratably) Tj ET Q
q 0 0 0 rg BT 132.57 159.30 Td (, in equal amounts, over a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 238.09 159.30 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.08 159.30 Td ( or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 271.41 159.30 Td (four) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.87 159.30 Td (-year service period. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 372.27 159.30 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 390.61 159.30 Td (s vest in full after a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.03 159.30 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 490.02 159.30 Td (-year service period ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 147.30 Td (and are conditional upon the achievement of performance and/or market conditions established by the Compensation Committee of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 135.30 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.72 135.30 Td (Board) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.16 135.30 Td (.) Tj ET Q
endstream
endobj
267 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 268 0 R>>
endobj
268 0 obj
<</Length 17930>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-54) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 742.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 79.34 742.10 Td (s awarded in 2019, 2018 and 2017 were based upon ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.02 742.10 Td (two) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.02 742.10 Td ( discrete measures: relative ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.08 742.10 Td (total shareholder return \(TSR\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.87 742.10 Td ( and an ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (adjusted free cash flow performance metric \(FCF\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 236.48 730.10 Td (, each accounting for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.83 730.10 Td (50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.16 730.10 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 369.20 730.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 387.55 730.10 Td ( awards upon issuance. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 482.06 730.10 Td (TSR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.40 730.10 Td ( performance is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (measured against the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 122.36 718.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.34 718.10 Td (-year ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.20 718.10 Td (TSR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.54 718.10 Td ( of a custom index of companies. For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.90 718.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 353.24 718.10 Td (s awarded in 2019, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 431.28 718.10 Td (FCF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.07 718.10 Td ( performance is measured ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (against a tar) Tj ET Q
q 0 0 0 rg BT 84.13 706.10 Td (get covering a single ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 169.66 706.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 189.64 706.10 Td (-year performance period, which is generally established at the grant date. For ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.52 706.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.87 706.10 Td (s awarded in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (2018 and 2017, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.44 694.10 Td (FCF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 118.23 694.10 Td ( performance is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.92 694.10 Td (measured against tar) Tj ET Q
q 0 0 0 rg BT 264.93 694.10 Td (gets covering ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.02 694.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 341.01 694.10 Td ( independent successive ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 439.59 694.10 Td (one) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 454.03 694.10 Td (-year performance periods, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 682.10 Td (which are generally established for each performance period during the first quarter of that calendar year) Tj ET Q
q 0 0 0 rg BT 454.42 682.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 456.92 682.10 Td ( Upon the completion of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 670.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 55.99 670.10 Td (-year performance period, the PSUs vest and the actual number of shares awarded is adjusted to between ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 477.50 670.10 Td (zero) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.71 670.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.15 670.10 Td (200%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 537.48 670.10 Td ( of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 658.10 Td (tar) Tj ET Q
q 0 0 0 rg BT 46.37 658.10 Td (get award amount based upon the performance criteria described above. In addition to meeting the performance conditions, grant ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.10 Td (recipients are also generally subject to being employed by the Company until the conclusion of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.67 646.10 Td (three) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 453.66 646.10 Td (-year vesting period in order ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.10 Td (to receive the awards. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.50 634.10 Td (TSR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 143.84 634.10 Td ( is considered a market condition under applicable authoritative guidance, while ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.50 634.10 Td (FCF) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.30 634.10 Td ( is considered ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.10 Td (performance condition.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 604.10 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.45 604.10 Td (s are valued based on the closing price of Endo�) Tj ET Q
q 0 0 0 rg BT 271.78 604.10 Td (s ordinary shares on the date of grant. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 424.79 604.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.13 604.10 Td (s with ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.62 604.10 Td (TSR) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.96 604.10 Td ( conditions are valued ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 592.10 Td (using a Monte-Carlo variant valuation model, while those with adjusted free cash flow conditions are valued taking into consideration ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 580.10 Td (the probability of achieving the specified performance goal. ) Tj ET Q
q 0 0 0 rg BT 277.67 580.10 Td (The Monte-Carlo variant valuation model considered a variety of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 568.10 Td (potential future share prices for Endo as well as our peer companies in a selected market index.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 550.10 Td (A) Tj ET Q
q 0 0 0 rg BT 67.67 550.10 Td ( summary of our non-vested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.92 550.10 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 202.38 550.10 Td (s and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.71 550.10 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 244.05 550.10 Td (s for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 279.32 550.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.32 550.10 Td ( is presented below:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 510.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 510.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 510.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 510.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 480.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 480.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 480.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 480.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 450.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 450.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 450.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 450.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 420.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 420.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 420.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 420.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 390.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 390.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 390.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 390.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 360.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 360.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 360.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 360.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 330.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 330.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 330.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 330.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 300.60 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 300.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 300.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 300.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 510.6 m
506.5 510.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 510.6 m
575.5 510.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 510.6 m
506.5 510.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 510.6 m
575.5 510.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 450.6 m
506.5 450.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 435.6 m
506.5 435.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 375.6 m
506.5 375.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 360.6 m
506.5 360.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 315.6 m
506.5 315.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 301.6 m
506.5 301.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 299.6 m
506.5 299.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 455.00 522.83 Td (Number) Tj ET Q
q 0 0 0 rg BT 483.37 522.83 Td ( of) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 462.00 514.83 Td (Shar) Tj ET Q
q 0 0 0 rg BT 478.38 514.83 Td (es) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 525.00 530.83 Td (Aggr) Tj ET Q
q 0 0 0 rg BT 542.18 530.83 Td (egate) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 517.25 522.83 Td (Intrinsic ) Tj ET Q
q 0 0 0 rg BT 548.44 522.83 Td (V) Tj ET Q
q 0 0 0 rg BT 553.48 522.83 Td (alue) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 537.80 514.83 Td (\(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 501.17 Td (Non-vested as of January 1, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 500.27 Td (1,685,060) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 486.17 Td (Granted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 485.27 Td (4,168,477) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 471.17 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 470.32 Td (\(552,981) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 470.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 456.17 Td (V) Tj ET Q
q 0 0 0 rg BT 50.67 456.17 Td (ested) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 455.32 Td (\(575,883) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 455.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 441.17 Td (Non-vested as of December 31, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 440.27 Td (4,724,673) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 426.17 Td (Granted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 425.27 Td (5,609,561) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 411.17 Td (L) Tj ET Q
q 0 0 0 rg BT 49.65 411.17 Td (TCI modification \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 410.27 Td (2,989,965) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 396.17 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 395.32 Td (\(753,653) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 395.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 381.17 Td (V) Tj ET Q
q 0 0 0 rg BT 50.67 381.17 Td (ested) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 380.32 Td (\(1,551,074) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 380.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 366.17 Td (Non-vested as of December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 365.27 Td (1) Tj ET Q
q 0 0 0 rg BT 462.60 365.27 Td (1,019,472) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 351.17 Td (Granted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 350.27 Td (6,687,695) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 336.17 Td (Forfeited) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 335.32 Td (\(918,425) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 335.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 321.17 Td (V) Tj ET Q
q 0 0 0 rg BT 50.11 321.17 Td (ested) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 320.32 Td (\(3,872,453) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 320.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 306.17 Td (Non-vested as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 305.27 Td (12,916,289) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 305.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.60 305.27 Td (60,577,395) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 291.17 Td (V) Tj ET Q
q 0 0 0 rg BT 44.11 291.17 Td (ested and expected to vest as of December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 290.27 Td (12,098,438) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 290.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.60 290.27 Td (56,741,674) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 278.10 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 268.50 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 268.50 Td (The aggregate intrinsic values of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 174.35 268.50 Td (RSU) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 189.91 268.50 Td (s and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 208.57 268.50 Td (PSU) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 223.25 268.50 Td (s presented in the table above are calculated by multiplying the closing price of the Company�) Tj ET Q
q 0 0 0 rg BT 523.82 268.50 Td (s ordinary ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 258.90 Td (shares on the last trading day of the fiscal year by the corresponding number of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 322.75 258.90 Td (RSU) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 338.32 258.90 Td (s and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 356.98 258.90 Td (PSU) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 371.66 258.90 Td (s.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 249.30 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 249.30 Td (As a result of the ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 124.15 249.30 Td (October�1, 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 175.92 249.30 Td ( modification to the Company�) Tj ET Q
q 0 0 0 rg BT 274.13 249.30 Td (s ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 279.24 249.30 Td (L) Tj ET Q
q 0 0 0 rg BT 283.39 249.30 Td (TCI) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 296.28 249.30 Td ( awards described above, modified ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 409.57 249.30 Td (L) Tj ET Q
q 0 0 0 rg BT 413.72 249.30 Td (TCI) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 426.61 249.30 Td ( awards are treated as ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 497.46 249.30 Td (RSU) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 513.02 249.30 Td (s for disclosure ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 239.70 Td (purposes; thus, the table above reflects an increase to the non-vested number of shares on the modification date.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 221.70 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.44 221.70 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.03 221.70 Td (, the weighted average remaining requisite service period of the units presented in the table above was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 209.70 Td (1.6) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 48.50 209.70 Td ( years and the corresponding total remaining unrecognized compensation cost amounted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.50 209.70 Td ($39.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.39 209.70 Td ( in the case of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 526.42 209.70 Td (RSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.88 209.70 Td (s and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 197.70 Td (L) Tj ET Q
q 0 0 0 rg BT 41.19 197.70 Td (TCI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 57.30 197.70 Td ( awards and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 107.56 197.70 Td ($5.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.45 197.70 Td ( in the case of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.48 197.70 Td (PSU) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 232.83 197.70 Td (s. ) Tj ET Q
q 0 0 0 rg BT 241.54 197.70 Td (The weighted average grant-date fair value of the units granted during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.19 197.70 Td (years ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 185.70 Td (ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.40 185.70 Td ( was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.95 185.70 Td ($7.72) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 248.45 185.70 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 253.45 185.70 Td ($6.88) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 275.95 185.70 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 295.39 185.70 Td ($1) Tj ET Q
q 0 0 0 rg BT 305.02 185.70 Td (1.42) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.52 185.70 Td ( per unit, respectively) Tj ET Q
q 0 0 0 rg BT 408.50 185.70 Td (.) Tj ET Q
endstream
endobj
269 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 270 0 R>>
endobj
270 0 obj
<</Length 18516>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-55) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 19. OTHER EXPENSE \(INCOME\), NET) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (The components of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.70 731.25 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.99 731.25 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 287.37 731.25 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.36 731.25 Td ( are as follows \(in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 695.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 695.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 695.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 665.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 665.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 665.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 635.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 635.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 635.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 635.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 635.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 635.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 695.75 m
506.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 695.75 m
575.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 695.75 m
506.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 695.75 m
575.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 635.75 m
437.5 635.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 635.75 m
506.5 635.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 635.75 m
575.5 635.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 621.75 m
437.5 621.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 619.75 m
437.5 619.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 621.75 m
506.5 621.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 619.75 m
506.5 619.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 621.75 m
575.5 621.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 619.75 m
575.5 619.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 699.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 699.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 699.98 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 685.42 Td (Net gain on sale of business and other assets \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 685.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 685.47 Td (\(6,367) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 685.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 685.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 685.47 Td (\(45,155) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 685.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 685.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 685.42 Td (\(13,809) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 685.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 670.42 Td (Foreign currency loss \(gain\), net \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 670.42 Td (5,247) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 670.47 Td (\(3,762) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 670.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 670.42 Td (\(2,801) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 670.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 655.42 Td (Net loss from our investments in the equity of other companies \(3\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 655.42 Td (2,346) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 655.42 Td (3,444) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 655.42 Td (898) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 640.42 Td (Other miscellaneous, net \(4\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 640.42 Td (15,451) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 640.47 Td (\(6,480) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 640.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 640.42 Td (\(1,31) Tj ET Q
q 0 0 0 rg BT 566.63 640.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 640.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 625.42 Td (Other expense \(income\), net) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 625.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 625.42 Td (16,677) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 625.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 625.47 Td (\(51,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 625.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 625.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 625.42 Td (\(17,023) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 625.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 36.00 613.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 603.65 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 67.50 603.65 Td (Amounts in 2018 include a ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 156.16 603.65 Td ($12.5 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 199.27 603.65 Td ( gain on the sale of the Company�) Tj ET Q
q 0 0 0 rg BT 307.02 603.65 Td (s Huntsville, ) Tj ET Q
q 0 0 0 rg BT 349.03 603.65 Td (Alabama facilities, as further discussed in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 484.76 603.65 Td (Note 4. Restructuring) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 553.86 603.65 Td (. ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 594.05 Td (Amounts in 2017 include a ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 156.16 594.05 Td ($10.1 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 199.27 594.05 Td ( gain resulting from the sale of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 299.46 594.05 Td (Litha) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 316.35 594.05 Td (, as further described in ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 393.65 594.05 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 553.18 594.05 Td (. ) Tj ET Q
q 0 0 0 rg BT 557.03 594.05 Td (The ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 584.45 Td (remaining amounts primarily relate to the sales of various ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 253.89 584.45 Td (ANDA) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 277.00 584.45 Td (s.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 574.85 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 67.50 574.85 Td (Amounts relate to the remeasurement of the Company�) Tj ET Q
q 0 0 0 rg BT 243.23 574.85 Td (s foreign currency denominated assets and liabilities.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 565.25 Td (\(3\) ) Tj ET Q
q 0 0 0 rg BT 67.50 565.25 Td (Amounts relate to the income statement impacts of our investments in the equity of other companies, including investments accounted for under the equity ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 555.65 Td (method.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 546.05 Td (\(4\) ) Tj ET Q
q 0 0 0 rg BT 67.50 546.05 Td (Amounts in 2019 primarily relate to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 184.81 546.05 Td ($17.5 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 227.93 546.05 Td ( of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 238.59 546.05 Td (contract termination costs incurred as a result of certain product discontinuation activities in our ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 536.45 Td (International Pharmaceuticals segment) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 191.45 536.45 Td (.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 506.45 Td (NOTE 20. INCOME ) Tj ET Q
q 0 0 0 rg BT 126.38 506.45 Td (T) Tj ET Q
q 0 0 0 rg BT 132.31 506.45 Td (AXES) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 488.45 Td (T) Tj ET Q
q 0 0 0 rg BT 41.19 488.45 Td (ax Reform) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 470.45 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 80.87 470.45 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.76 470.45 Td (, which was signed into law on December 22, 2017, has resulted in significant changes to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 479.11 470.45 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.90 470.45 Td ( corporate income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 458.45 Td (tax system, including the reduction of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 204.30 458.45 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 222.08 458.45 Td ( statutory federal corporate income tax rate from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.66 458.45 Td (35%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 436.99 458.45 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 449.76 458.45 Td (21%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.09 458.45 Td ( ef) Tj ET Q
q 0 0 0 rg BT 478.18 458.45 Td (fective ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 507.88 458.45 Td (January�1, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.48 458.45 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 446.45 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.87 446.45 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.21 446.45 Td ( also contains a broad range of domestic and international provisions, many of which dif) Tj ET Q
q 0 0 0 rg BT 430.55 446.45 Td (fer significantly from those ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 434.45 Td (contained in previous ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 124.59 434.45 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 142.37 434.45 Td ( tax law) Tj ET Q
q 0 0 0 rg BT 173.38 434.45 Td (. ) Tj ET Q
q 0 0 0 rg BT 177.83 434.45 Td (Although the rate of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 261.14 434.45 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.92 434.45 Td ( federal income tax was reduced prospectively) Tj ET Q
q 0 0 0 rg BT 463.74 434.45 Td (, changes in tax rates and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 422.45 Td (laws are accounted for in the period of enactment. ) Tj ET Q
q 0 0 0 rg BT 238.51 422.45 Td (Therefore, during the year ended December 31, 2017, we recorded a benefit of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 410.45 Td ($36.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 89.89 410.45 Td ( as our provisional estimate of the impact of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 282.99 410.45 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.33 410.45 Td ( in accordance with Staf) Tj ET Q
q 0 0 0 rg BT 402.78 410.45 Td (f ) Tj ET Q
q 0 0 0 rg BT 408.06 410.45 Td (Accounting Bulletin 1) Tj ET Q
q 0 0 0 rg BT 496.56 410.45 Td (18. ) Tj ET Q
q 0 0 0 rg BT 511.38 410.45 Td (This benefit, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 398.45 Td (which is primarily related to remeasurement of deferred tax liabilities related to tax deductible goodwill, has been recorded in our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 386.45 Td (Consolidated Statements of Operations in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 219.86 386.45 Td (Income tax expense \(benefit\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.19 386.45 Td ( line. ) Tj ET Q
q 0 0 0 rg BT 358.50 386.45 Td (The Company has completed its accounting for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 374.45 Td (tax ef) Tj ET Q
q 0 0 0 rg BT 58.30 374.45 Td (fects of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 105.05 374.45 Td (TCJA) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.39 374.45 Td ( in accordance with Staf) Tj ET Q
q 0 0 0 rg BT 224.83 374.45 Td (f ) Tj ET Q
q 0 0 0 rg BT 230.11 374.45 Td (Accounting Bulletin 1) Tj ET Q
q 0 0 0 rg BT 318.62 374.45 Td (18. ) Tj ET Q
q 0 0 0 rg BT 333.44 374.45 Td (There were ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.18 374.45 Td (no) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.18 374.45 Td ( significant subsequent adjustments to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 362.45 Td (provisional amounts recorded.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 344.45 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 326.45 Td (Our operations are conducted through our various subsidiaries in numerous jurisdictions throughout the world. ) Tj ET Q
q 0 0 0 rg BT 508.01 326.45 Td (W) Tj ET Q
q 0 0 0 rg BT 516.65 326.45 Td (e have ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 314.45 Td (provided for income taxes based upon the tax laws and rates in the jurisdictions in which our operations are conducted.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 296.45 Td (The components of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.53 296.45 Td (Loss from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 363.48 296.45 Td ( by geography for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 452.06 296.45 Td (years ended December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 284.45 Td (2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 120.44 284.45 Td ( are as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
36.50 260.95 335.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
371.50 260.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
436.50 260.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
440.50 260.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
505.50 260.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
509.50 260.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
36.50 230.95 335.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
371.50 230.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
436.50 230.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
440.50 230.95 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
505.50 230.95 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
509.50 230.95 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
371.5 260.95000000000005 m
436.5 260.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
440.5 260.95000000000005 m
505.5 260.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 260.95000000000005 m
574.5 260.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
371.5 230.95000000000005 m
436.5 230.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
440.5 230.95000000000005 m
505.5 230.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 230.95000000000005 m
574.5 230.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
371.5 216.95000000000005 m
436.5 216.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
371.5 214.95000000000005 m
436.5 214.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
440.5 216.95000000000005 m
505.5 216.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
440.5 214.95000000000005 m
505.5 214.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 216.95000000000005 m
574.5 216.95000000000005 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
509.5 214.95000000000005 m
574.5 214.95000000000005 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 395.50 265.18 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 464.50 265.18 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 533.50 265.18 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 250.62 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.00 250.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.80 250.67 Td (\(688,224) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.65 250.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.00 250.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 458.30 250.67 Td (\(1,342,860) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 250.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.00 250.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.30 250.62 Td (\(1,866,222) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.65 250.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 235.62 Td (International) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 400.15 235.62 Td (343,320) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.15 235.62 Td (404,028) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.15 235.62 Td (383,218) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 45.00 220.62 Td (T) Tj ET Q
q 0 0 0 rg BT 50.41 220.62 Td (otal \(loss\) income from continuing operations before income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 374.00 220.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 396.80 220.67 Td (\(344,904) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.65 220.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 443.00 220.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.80 220.67 Td (\(938,832) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 501.65 220.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 512.00 220.62 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 527.30 220.62 Td (\(1,483,004) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 570.65 220.62 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
271 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 272 0 R>>
endobj
272 0 obj
<</Length 22087>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-56) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (Income tax from continuing operations consists of the following for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 351.55 742.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.55 742.10 Td ( \(in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 706.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 706.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 706.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 706.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 706.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 706.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 676.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 676.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 676.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 676.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 676.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 676.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 646.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 646.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 646.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 616.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 616.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 616.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 586.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 586.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 586.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 556.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 556.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 556.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 556.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 706.6 m
437.5 706.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 706.6 m
506.5 706.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 706.6 m
575.5 706.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 646.6 m
437.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 646.6 m
506.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 646.6 m
575.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 631.6 m
437.5 631.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 631.6 m
506.5 631.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 631.6 m
575.5 631.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 571.6 m
437.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 571.6 m
506.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 571.6 m
575.5 571.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 556.6 m
437.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 556.6 m
506.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 556.6 m
575.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 542.6 m
437.5 542.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 540.6 m
437.5 540.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 542.6 m
506.5 542.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 540.6 m
506.5 540.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 542.6 m
575.5 542.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 540.6 m
575.5 540.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 710.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 710.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 710.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 696.27 Td (Current:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 681.27 Td (U.S. Federal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 681.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 681.27 Td (15,317) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 681.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 681.27 Td (6,236) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 681.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 681.27 Td (\(86,478) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 681.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 666.27 Td (U.S. State) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 666.32 Td (\(3,002) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 666.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 666.27 Td (2,864) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 666.27 Td (\(6,462) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 666.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 651.27 Td (International) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 651.27 Td (8,926) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 651.27 Td (8,278) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 651.27 Td (\(1,224) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 651.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 636.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 636.27 Td (otal current income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 636.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 636.27 Td (21,241) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 636.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 636.27 Td (17,378) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 636.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 636.27 Td (\(94,164) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 636.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 621.27 Td (Deferred:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 606.27 Td (U.S. Federal) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.30 606.32 Td (\(515) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 606.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 606.27 Td (10,084) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 606.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 606.27 Td (\(124,682) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 606.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 591.27 Td (U.S. State) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.30 591.32 Td (\(482) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 591.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.30 591.32 Td (\(778) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 591.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 591.27 Td (\(3,225) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 591.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 576.27 Td (International) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 576.32 Td (\(4,564) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 576.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 476.80 576.32 Td (\(3,749) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 576.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 576.27 Td (\(28,222) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 576.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 561.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 561.27 Td (otal deferred income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 561.32 Td (\(5,561) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 561.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 561.27 Td (5,557) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 561.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 561.27 Td (\(156,129) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 561.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 546.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 546.27 Td (otal income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 546.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 546.27 Td (15,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 546.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 546.27 Td (22,935) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 546.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 546.27 Td (\(250,293) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 546.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 524.10 Td (T) Tj ET Q
q 0 0 0 rg BT 41.19 524.10 Td (ax Rate) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 506.10 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 506.10 Td ( reconciliation of income tax from continuing operations at the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 322.93 506.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 340.71 506.10 Td ( federal statutory income tax rate to the total income tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 494.10 Td (provision from continuing operations for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.52 494.10 Td (years ended December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.52 494.10 Td ( is as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 470.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 470.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 470.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 470.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 470.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 470.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 440.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 440.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 440.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 440.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 440.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 440.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 410.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 410.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 410.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 410.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 410.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 410.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 380.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 380.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 380.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 380.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 380.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 380.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 350.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 350.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 350.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 350.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 350.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 350.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 320.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 320.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 320.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 320.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 320.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 320.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 290.60 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 290.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 290.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 290.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 290.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 290.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 470.6 m
437.5 470.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 470.6 m
506.5 470.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 470.6 m
575.5 470.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 275.6 m
437.5 275.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 275.6 m
506.5 275.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 275.6 m
575.5 275.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 261.6 m
437.5 261.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 259.6 m
437.5 259.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 261.6 m
506.5 261.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 259.6 m
506.5 259.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 261.6 m
575.5 261.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 259.6 m
575.5 259.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 474.83 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 474.83 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 474.83 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 460.27 Td (Notional U.S. federal income tax provision at the statutory rate) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 460.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 460.32 Td (\(72,430) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 460.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 460.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 460.32 Td (\(197,155) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 460.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 460.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 460.27 Td (\(519,051) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 460.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 445.27 Td (State income tax, net of federal benefit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 445.32 Td (\(4,455) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 445.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 487.65 445.27 Td (494) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 445.27 Td (\(1) Tj ET Q
q 0 0 0 rg BT 549.13 445.27 Td (1,473) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 445.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 430.27 Td (U.S. tax reform impact) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 430.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 430.27 Td (5,664) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 430.27 Td (\(36,216) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 430.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 415.27 Td (Uncertain tax positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 415.27 Td (43,273) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 415.27 Td (46,317) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 415.27 Td (58,120) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 400.27 Td (Residual tax on non-U.S. net earnings) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 400.32 Td (\(67,987) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 400.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 400.32 Td (\(638,724) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 400.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 400.27 Td (\(1,350,81) Tj ET Q
q 0 0 0 rg BT 566.63 400.27 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 400.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 385.27 Td (Non-deductible goodwill impairment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 385.27 Td (27,493) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 385.27 Td (109,189) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 385.27 Td (60,808) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 370.27 Td (Change in valuation allowance) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 370.27 Td (30,123) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 370.27 Td (748,562) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 370.27 Td (1,644,879) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 355.27 Td (Intra-entity transfers of assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 355.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 355.32 Td (\(63,335) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 355.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 355.27 Td (\(53,509) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 355.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 340.27 Td (International Pharmaceuticals segment divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 340.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 340.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 340.27 Td (\(56,092) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 340.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 325.27 Td (Base erosion minimum tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 325.27 Td (13,662) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 325.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 325.27 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 310.27 Td (Non-deductible expenses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 310.27 Td (21,299) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 310.27 Td (3,446) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 310.27 Td (3,957) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 295.27 Td (Executive compensation limitation) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 411.15 295.27 Td (4,547) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 295.27 Td (5,955) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 295.27 Td (2,178) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 280.27 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 280.27 Td (20,155) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 280.27 Td (2,522) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 280.27 Td (6,917) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 265.27 Td (Income tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 265.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 406.15 265.27 Td (15,680) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 265.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 265.27 Td (22,935) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 265.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 265.27 Td (\(250,293) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 265.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 243.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.05 243.10 Td (income tax expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.90 243.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 172.68 243.10 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.68 243.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.18 243.10 Td (primarily related to) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 272.38 243.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 274.88 243.10 Td (accrued interest on uncertain tax positions.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.93 243.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 448.25 243.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.30 243.10 Td (income tax expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.15 243.10 Td ( in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 231.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 231.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.50 231.10 Td (primarily related to the establishment of a valuation allowance against certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 371.44 231.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 389.22 231.10 Td ( deferred tax assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 468.08 231.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 470.39 231.10 Td (The income tax benefit in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 219.10 Td (2017 primarily related to pre-tax losses incurred by certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.42 219.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 291.20 219.10 Td ( subsidiaries.) Tj ET Q
endstream
endobj
273 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 274 0 R>>
endobj
274 0 obj
<</Length 18757>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-57) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (Deferred T) Tj ET Q
q 0 0 0 rg BT 80.34 742.25 Td (ax ) Tj ET Q
q 0 0 0 rg BT 92.47 742.25 Td (Assets and Liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (Deferred income taxes result from temporary dif) Tj ET Q
q 0 0 0 rg BT 257.18 724.25 Td (ferences between the amount of assets and liabilities recognized for financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (reporting and tax purposes. ) Tj ET Q
q 0 0 0 rg BT 147.18 712.25 Td (The significant components of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 286.31 712.25 Td (net deferred income tax liability) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 414.59 712.25 Td ( shown on the balance sheets as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 700.25 Td (December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 94.58 700.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 114.58 700.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 134.02 700.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.02 700.25 Td ( are as follows \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 668.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 668.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 668.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 668.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 638.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 638.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 638.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 638.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 608.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 608.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 608.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 608.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 578.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 578.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 578.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 578.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 548.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 548.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 548.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 548.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 518.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 518.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 518.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 518.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 488.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 488.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 488.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 488.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 458.75 406.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 458.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 458.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 458.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 668.75 m
506.5 668.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 668.75 m
575.5 668.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 548.75 m
506.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 548.75 m
575.5 548.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 533.75 m
506.5 533.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 533.75 m
575.5 533.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 473.75 m
506.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 473.75 m
575.5 473.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 458.75 m
506.5 458.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 458.75 m
575.5 458.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 443.75 m
506.5 443.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 443.75 m
575.5 443.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 429.75 m
506.5 429.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 427.75 m
506.5 427.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 429.75 m
575.5 429.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 427.75 m
575.5 427.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 450.25 680.98 Td (December) Tj ET Q
q 0 0 0 rg BT 484.82 680.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 672.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 680.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 680.98 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 672.98 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 658.42 Td (Deferred tax assets:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 643.42 Td (Accrued expenses and customer allowances) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 643.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 643.42 Td (1) Tj ET Q
q 0 0 0 rg BT 475.15 643.42 Td (12,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 643.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 643.42 Td (185,910) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 628.42 Td (Deferred interest expense) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 628.42 Td (317,997) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 628.42 Td (240,736) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 613.42 Td (Fixed assets and intangible assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 613.42 Td (598,730) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 613.42 Td (604,385) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 598.42 Td (Loss on capital assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 598.42 Td (61,971) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 598.42 Td (62,033) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 583.42 Td (Net operating loss carryforward) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 583.42 Td (9,743,763) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 583.42 Td (8,751,544) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 568.42 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 568.42 Td (89,501) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 568.42 Td (65,266) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 553.42 Td (Research and development and other tax credit carryforwards) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 553.42 Td (16,620) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 553.42 Td (9,551) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 538.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 538.42 Td (otal gross deferred income tax assets) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 538.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.60 538.42 Td (10,941,071) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 538.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 538.42 Td (9,919,425) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 523.42 Td (Deferred tax liabilities:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 508.42 Td (Other) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 508.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 508.47 Td (\(10,086) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 508.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 508.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 508.42 Td (\(1,965) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 508.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 493.42 Td (Outside basis dif) Tj ET Q
q 0 0 0 rg BT 111.13 493.42 Td (ference) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 493.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 493.42 Td (\(73,652) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 493.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 478.42 Td (Intercompany notes) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 478.47 Td (\(1,131,537) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 478.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 478.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 463.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 463.42 Td (otal gross deferred income tax liabilities) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 463.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 463.47 Td (\(1,141,623) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 463.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 463.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 463.42 Td (\(75,617) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 463.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 448.42 Td (V) Tj ET Q
q 0 0 0 rg BT 50.11 448.42 Td (aluation allowance) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 448.47 Td (\(9,828,959) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 448.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 448.42 Td (\(9,877,617) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 448.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 433.42 Td (Net deferred income tax liability) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 433.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 433.47 Td (\(29,51) Tj ET Q
q 0 0 0 rg BT 497.63 433.47 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 433.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 433.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 433.42 Td (\(33,809) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 433.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 411.25 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 411.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 411.25 Td (, the Company had the following significant deferred tax assets for tax credits, net operating and capital ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 399.25 Td (loss carryforwards, net of unrecognized tax benefits \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 375.75 402.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 375.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 375.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 375.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 375.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 345.75 402.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 345.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 345.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 345.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 345.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 315.75 402.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 315.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 315.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 315.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 315.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 285.75 402.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 285.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 285.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 285.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 285.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 255.75 402.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 255.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 255.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 255.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 255.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 375.75 m
437.5 375.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 375.75 m
506.5 375.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 375.75 m
575.5 375.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 379.98 Td (Jurisdiction) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 459.45 379.98 Td (Amount) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 515.90 379.98 Td (Begin to Expir) Tj ET Q
q 0 0 0 rg BT 565.54 379.98 Td (e) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 365.42 Td (Ireland) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 365.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 365.42 Td (16,862) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 533.10 365.42 Td (Indefinite) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 350.42 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 84.56 350.42 Td (g) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 350.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.65 350.42 Td (9,336,61) Tj ET Q
q 0 0 0 rg BT 497.65 350.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 350.42 Td (2034) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 335.42 Td (U.S.:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 320.42 Td (Federal-ordinary losses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 320.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 320.42 Td (200,671) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 320.42 Td (2021) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 305.42 Td (Federal-capital losses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 305.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 305.42 Td (34,740) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 305.42 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 290.42 Td (Federal-tax credits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 290.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 290.42 Td (7,305) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 290.42 Td (2026) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 275.42 Td (State-ordinary losses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 275.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 275.42 Td (186,21) Tj ET Q
q 0 0 0 rg BT 497.65 275.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 275.42 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 260.42 Td (State-capital losses) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 260.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 475.15 260.42 Td (26,459) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 260.42 Td (2026) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 245.42 Td (State-tax credits) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 245.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 480.15 245.42 Td (6,643) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 552.00 245.42 Td (2020) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 223.25 Td (A) Tj ET Q
q 0 0 0 rg BT 69.67 223.25 Td ( valuation allowance is required when it is more likely than not that all or a portion of a deferred tax asset will not be realized. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 211.25 Td (The Company assesses the available positive and negative evidence to estimate whether the existing deferred tax assets will be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 199.25 Td (realized. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 181.25 Td (The Company has recorded a valuation allowance against certain jurisdictional net operating loss carryforwards and other tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 169.25 Td (attributes. ) Tj ET Q
q 0 0 0 rg BT 77.66 169.25 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 102.10 169.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 180.69 169.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 200.13 169.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.13 169.25 Td (, the total valuation allowance was ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 360.91 169.25 Td ($9,829.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.30 169.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 446.74 169.25 Td ($9,877.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.13 169.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 565.79 169.25 Td (. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 157.25 Td (During the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 127.63 157.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 206.21 157.25 Td (, the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 267.32 157.25 Td (decrease) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 301.73 157.25 Td (d its valuation allowance by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.42 157.25 Td ($48.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.32 157.25 Td (, which was primarily ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 145.25 Td (driven by statutory rate changes in Luxembour) Tj ET Q
q 0 0 0 rg BT 222.99 145.25 Td (g. During the year ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.62 145.25 Td (December�31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 403.20 145.25 Td (, the Company ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.31 145.25 Td (increase) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 497.06 145.25 Td (d its valuation ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 133.25 Td (allowance by ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 91.53 133.25 Td ($1,814.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.92 133.25 Td (, which was primarily driven by losses within jurisdictions unable to support recognition of a deferred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 121.25 Td (tax asset, of which the lar) Tj ET Q
q 0 0 0 rg BT 138.01 121.25 Td (gest jurisdiction was Luxembour) Tj ET Q
q 0 0 0 rg BT 269.19 121.25 Td (g, where the Company had significant interest expense and losses on its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 109.25 Td (investments in the equity of consolidated subsidiaries.) Tj ET Q
endstream
endobj
275 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 276 0 R>>
endobj
276 0 obj
<</Length 7423>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-58) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (At ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.50 742.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.08 742.10 Td (, the Company had the following significant valuation allowances \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 710.60 471.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 710.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 710.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 680.60 471.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 680.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 680.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
35.5 710.6 m
506.5 710.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 710.6 m
575.5 710.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 38.00 714.83 Td (Jurisdiction) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 722.83 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 722.83 Td ( 31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 714.83 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 700.27 Td (Ireland) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 700.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 700.27 Td (189,581) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 685.27 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 84.56 685.27 Td (g) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 685.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 685.27 Td (8,205,074) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 670.27 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 670.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 531.65 670.27 Td (1,430,762) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 648.10 Td (W) Tj ET Q
q 0 0 0 rg BT 71.64 648.10 Td (e have provided income taxes for earnings that are currently distributed as well as the taxes associated with certain earnings ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 636.10 Td (that are expected to be distributed in the future. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 227.60 636.10 Td (No) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 239.82 636.10 Td ( additional provision has been made for Irish and non-Irish income taxes on the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 624.10 Td (undistributed earnings of subsidiaries or for unrecognized deferred tax liabilities for temporary dif) Tj ET Q
q 0 0 0 rg BT 428.47 624.10 Td (ferences related to basis dif) Tj ET Q
q 0 0 0 rg BT 537.68 624.10 Td (ferences ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 612.10 Td (in investments in subsidiaries as such earnings are expected to be indefinitely reinvested. ) Tj ET Q
q 0 0 0 rg BT 393.68 612.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 418.12 612.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.71 612.10 Td (, certain ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 600.10 Td (subsidiaries had approximately ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 162.91 600.10 Td ($1,092.0 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.31 600.10 Td ( of cumulative undistributed earnings that have been permanently reinvested because ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 588.10 Td (our plans do not demonstrate a need to repatriate such earnings. ) Tj ET Q
q 0 0 0 rg BT 292.59 588.10 Td (A) Tj ET Q
q 0 0 0 rg BT 299.26 588.10 Td ( liability could arise if our intention to indefinitely reinvest such ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 576.10 Td (earnings were to change and amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 564.10 Td (practicable to estimate the additional income taxes related to indefinitely reinvested earnings or the basis dif) Tj ET Q
q 0 0 0 rg BT 468.17 564.10 Td (ferences related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 552.10 Td (investments in subsidiaries.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 534.10 Td (Uncertain T) Tj ET Q
q 0 0 0 rg BT 85.36 534.10 Td (ax Positions) Tj ET Q
BT /F4 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 516.10 Td (The Company and its subsidiaries are subject to income taxes in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 336.82 516.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 354.61 516.10 Td (, various states and numerous foreign jurisdictions ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 504.10 Td (with varying statutes as to which tax years are subject to examination by the tax authorities. ) Tj ET Q
q 0 0 0 rg BT 404.89 504.10 Td (The Company has taken positions on its ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 492.10 Td (tax returns that may be challenged by various tax authorities. ) Tj ET Q
q 0 0 0 rg BT 282.13 492.10 Td (The Company believes it has appropriately established reserves for tax-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 480.10 Td (related uncertainties. ) Tj ET Q
q 0 0 0 rg BT 121.61 480.10 Td (The Company endeavors to resolve matters with a tax authority at the examination level and could reach ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 468.10 Td (agreement with a tax authority at any time. ) Tj ET Q
q 0 0 0 rg BT 209.93 468.10 Td (The accruals for tax-related uncertainties are based on the Company�) Tj ET Q
q 0 0 0 rg BT 485.08 468.10 Td (s best estimate of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 456.10 Td (potential tax exposures. ) Tj ET Q
q 0 0 0 rg BT 133.02 456.10 Td (When particular matters arise, a number of years may elapse before such matters are audited and finally ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 444.10 Td (resolved, and the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in our financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 432.10 Td (statements. Favorable resolution of such matters could be recognized as a reduction of the Company�) Tj ET Q
q 0 0 0 rg BT 440.05 432.10 Td (s ef) Tj ET Q
q 0 0 0 rg BT 454.03 432.10 Td (fective tax rate in the year of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 420.10 Td (resolution, while a resolution that is not favorable could increase the ef) Tj ET Q
q 0 0 0 rg BT 319.62 420.10 Td (fective tax rate and may require the use of cash, including in the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 408.10 Td (year of resolution. Uncertain tax positions are reviewed quarterly and adjusted as necessary when events occur that af) Tj ET Q
q 0 0 0 rg BT 506.20 408.10 Td (fect potential tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 396.10 Td (liabilities, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, identification of new issues ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 384.10 Td (and issuance of new legislation, regulations or case law) Tj ET Q
q 0 0 0 rg BT 257.23 384.10 Td (.) Tj ET Q
endstream
endobj
277 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 278 0 R>>
endobj
278 0 obj
<</Length 17081>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-59) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 742.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 742.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 742.10 Td (, the Company had total ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 264.34 742.10 Td (unrecognized income tax benefits \(UTBs\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 432.06 742.10 Td ( of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.39 742.10 Td ($530.2 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 504.28 742.10 Td (. If recognized in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 730.10 Td (future years, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 88.48 730.10 Td ($320.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.37 730.10 Td ( of such amounts would impact the income tax provision and ef) Tj ET Q
q 0 0 0 rg BT 401.30 730.10 Td (fective tax rate. ) Tj ET Q
q 0 0 0 rg BT 465.15 730.10 Td (As of December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 548.18 730.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 568.18 730.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 718.10 Td (the Company had total ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 129.32 718.10 Td (UTB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.32 718.10 Td (s of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.54 718.10 Td ($479.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 225.43 718.10 Td (. If recognized in future years, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 348.71 718.10 Td ($304.3 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.60 718.10 Td ( of such amounts would have impacted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 706.10 Td (the income tax provision and ef) Tj ET Q
q 0 0 0 rg BT 162.17 706.10 Td (fective tax rate. ) Tj ET Q
q 0 0 0 rg BT 226.40 706.10 Td (The following table summarizes the activity related to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.21 706.10 Td (UTB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 465.21 706.10 Td (s during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 514.93 706.10 Td (years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 694.10 Td (December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 694.10 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 646.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 646.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 616.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 616.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 586.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 586.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 556.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 556.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 526.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 526.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 496.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 496.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 466.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 466.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 436.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 436.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 406.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 406.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 376.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 376.60 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 346.60 475.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 346.60 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 646.6 m
575.5 646.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 556.6 m
575.5 556.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 541.6 m
575.5 541.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 466.6 m
575.5 466.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 451.6 m
575.5 451.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 376.6 m
575.5 376.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 361.6 m
575.5 361.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 346.6 m
575.5 346.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 332.6 m
575.5 332.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 330.6 m
575.5 330.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.00 674.83 Td (Unr) Tj ET Q
q 0 0 0 rg BT 532.63 674.83 Td (ecognized) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 522.95 666.83 Td (T) Tj ET Q
q 0 0 0 rg BT 527.55 666.83 Td (ax Benefit) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 517.70 658.83 Td (Federal, State,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 514.55 650.83 Td (and For) Tj ET Q
q 0 0 0 rg BT 541.74 650.83 Td (eign ) Tj ET Q
q 0 0 0 rg BT 557.82 650.83 Td (T) Tj ET Q
q 0 0 0 rg BT 562.42 650.83 Td (ax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 636.27 Td (UTB Balance at January 1, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 636.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 636.27 Td (424,601) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 621.27 Td (Gross additions for current year positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 621.27 Td (44,293) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 606.27 Td (Gross reductions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 606.27 Td (\(64,887) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 606.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 591.27 Td (Gross additions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 591.27 Td (22,765) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 576.27 Td (Decrease due to lapse of statute of limitations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 576.27 Td (\(13,151) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 576.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 561.27 Td (Currency translation adjustment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 561.27 Td (2,330) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 546.27 Td (UTB Balance at December 31, 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 546.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 546.27 Td (415,951) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 531.27 Td (Gross additions for current year positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 531.27 Td (36,088) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 516.27 Td (Gross reductions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 516.27 Td (\(3,570) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 516.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 501.27 Td (Gross additions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 501.27 Td (7,950) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 486.27 Td (Decrease due to lapse of statute of limitations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 486.27 Td (\(2,129) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 486.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 471.27 Td (Currency translation adjustment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 471.27 Td (\(2,600) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 471.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 456.27 Td (UTB Balance at December 31, 2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 456.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 456.27 Td (451,690) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 441.27 Td (Gross additions for current year positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 441.27 Td (35,766) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 426.27 Td (Gross reductions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 426.27 Td (\(2,377) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 426.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 411.27 Td (Gross additions for prior period positions) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 556.65 411.27 Td (880) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 396.27 Td (Decrease due to lapse of statute of limitations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 545.80 396.27 Td (\(1,006) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 396.27 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 381.27 Td (Currency translation adjustment) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 549.15 381.27 Td (1,528) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 366.27 Td (UTB Balance at December 31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 366.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 366.27 Td (486,481) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 351.27 Td (Accrued interest and penalties) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 544.15 351.27 Td (43,710) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 336.27 Td (T) Tj ET Q
q 0 0 0 rg BT 43.41 336.27 Td (otal UTB balance including accrued interest and penalties) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 336.27 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 336.27 Td (530,191) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 314.10 Td (The Company records accrued interest as well as penalties related to uncertain tax positions as part of the provision for income ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 302.10 Td (taxes. ) Tj ET Q
q 0 0 0 rg BT 61.00 302.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 85.44 302.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.02 302.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 183.46 302.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 203.46 302.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 208.46 302.10 Td ($43.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.35 302.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 281.79 302.10 Td ($27.7 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 335.68 302.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 388.34 302.10 Td (, of corresponding accrued interest and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 290.10 Td (penalties is included in the Consolidated Balance Sheets, all of which is recorded in income taxes.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 272.10 Td (During the years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.52 272.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.11 272.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 242.11 272.10 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 262.11 272.10 Td (, and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 284.04 272.10 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 304.04 272.10 Td (, we recognized expense of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 415.10 272.10 Td ($13.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 469.00 272.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.00 272.10 Td ($8.6 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 522.89 272.10 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 542.33 272.10 Td ($1.4 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 260.10 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 260.10 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 117.55 260.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 122.37 260.10 Td (The expense is primarily related to interest. ) Tj ET Q
q 0 0 0 rg BT 298.24 260.10 Td (The current portion of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.15 260.10 Td (UTB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 425.15 260.10 Td ( liability of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 472.09 260.10 Td ($6.8 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.98 260.10 Td ( is included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 248.10 Td (in our Consolidated Balance Sheet as ) Tj ET Q
q 0 0 0 rg BT 187.08 248.10 Td (Accounts payable and accrued expenses. ) Tj ET Q
q 0 0 0 rg BT 352.38 248.10 Td (The noncurrent portion of our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 474.29 248.10 Td (UTB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 494.29 248.10 Td ( liability is included ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 236.10 Td (in our Consolidated Balance Sheet as Other liabilities or) Tj ET Q
q 0 0 0 rg BT 260.55 236.10 Td (, if and to the extent appropriate, as a reduction to Deferred tax assets.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 218.10 Td (Our subsidiaries file income tax returns in the countries in which they have operations. Generally) Tj ET Q
q 0 0 0 rg BT 451.40 218.10 Td (, these countries have statutes ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 206.10 Td (of limitations ranging from ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.09 206.10 Td (3) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 152.09 206.10 Td ( to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 164.87 206.10 Td (5 years) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 193.47 206.10 Td (. Certain subsidiary tax returns are currently under examination by taxing authorities, including ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 194.10 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.78 194.10 Td ( tax returns for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 130.15 194.10 Td (201) Tj ET Q
q 0 0 0 rg BT 144.77 194.10 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 149.77 194.10 Td ( through ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 185.88 194.10 Td (2015) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 205.88 194.10 Td ( tax years by the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.92 194.10 Td (IRS) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.48 194.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 176.10 Td (It is expected that the amount of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.35 176.10 Td (UTB) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 214.35 176.10 Td (s will change during the next twelve months; however) Tj ET Q
q 0 0 0 rg BT 430.56 176.10 Td (, the Company does not currently ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 164.10 Td (anticipate any adjustments that would lead to a material impact on our results of operations or our financial position.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 146.10 Td (As of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.44 146.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 166.03 146.10 Td (, we may be subject to examination in the following major tax jurisdictions:) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
36.50 122.60 453.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
489.50 122.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.50 122.60 83.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
36.50 92.60 453.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
489.50 92.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.50 92.60 83.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
36.50 62.60 453.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
489.50 62.60 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
493.50 62.60 83.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
36.5 122.60000000000002 m
489.5 122.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
493.5 122.60000000000002 m
576.5 122.60000000000002 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 39.00 126.83 Td (Jurisdiction) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 514.75 126.83 Td (Open ) Tj ET Q
q 0 0 0 rg BT 535.13 126.83 Td (Y) Tj ET Q
q 0 0 0 rg BT 540.02 126.83 Td (ears) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 112.27 Td (Canada) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.85 112.27 Td (2013 through 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 97.27 Td (India) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.85 97.27 Td (2012 through 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 82.27 Td (Ireland) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.85 82.27 Td (2014 through 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 67.27 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 85.56 67.27 Td (g) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.85 67.27 Td (2014 through 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 39.00 52.27 Td (U.S. - federal, state and local) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 496.85 52.27 Td (2006 through 2019) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
279 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 280 0 R>>
endobj
280 0 obj
<</Length 14312>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 24.60 Td (F-60) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 749.25 Td (NOTE 21. NET) Tj ET Q
q 0 0 0 rg BT 102.22 749.25 Td ( LOSS PER SHARE) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 731.25 Td (The following is a reconciliation of the numerator and denominator of basic and diluted net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 430.94 731.25 Td (loss per share) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 485.37 731.25 Td ( for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 516.75 731.25 Td (years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 719.25 Td (December 31, 2019, 2018 and 2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.02 719.25 Td ( \(in thousands\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 695.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 695.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 695.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 695.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 665.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 665.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 665.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 665.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 635.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 635.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 635.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 635.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 635.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 635.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 605.75 337.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 605.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 605.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 605.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 605.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 605.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 695.75 m
437.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 695.75 m
506.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 695.75 m
575.5 695.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 650.75 m
437.5 650.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 650.75 m
506.5 650.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 650.75 m
575.5 650.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 636.75 m
437.5 636.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 634.75 m
437.5 634.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 636.75 m
506.5 636.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 634.75 m
506.5 634.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 636.75 m
575.5 636.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 634.75 m
575.5 634.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 590.75 m
437.5 590.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 576.75 m
437.5 576.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 574.75 m
437.5 574.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 590.75 m
506.5 590.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 576.75 m
506.5 576.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 574.75 m
506.5 574.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 590.75 m
575.5 590.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 576.75 m
575.5 576.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 574.75 m
575.5 574.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 396.50 699.98 Td (2019) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 465.50 699.98 Td (2018) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 534.50 699.98 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 685.42 Td (Numerator:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 670.42 Td (Loss from continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 670.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 670.47 Td (\(360,584) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 670.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 670.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 670.47 Td (\(961,767) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 670.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 670.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 670.42 Td (\(1,232,71) Tj ET Q
q 0 0 0 rg BT 566.63 670.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 670.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 655.42 Td (Loss from discontinued operations, net of tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 655.47 Td (\(62,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 655.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 655.47 Td (\(69,702) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 655.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 655.42 Td (\(802,722) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 655.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 640.42 Td (Net loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 640.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 640.47 Td (\(422,636) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 640.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 640.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 459.30 640.47 Td (\(1,031,469) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 640.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 640.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 528.30 640.42 Td (\(2,035,433) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 640.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 625.42 Td (Denominator:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 610.42 Td (For basic per share data�weighted average shares) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 610.42 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 610.42 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 610.42 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 595.42 Td (Dilutive ef) Tj ET Q
q 0 0 0 rg BT 86.95 595.42 Td (fect of ordinary share equivalents) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 423.65 595.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 492.65 595.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 561.65 595.42 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 580.42 Td (For diluted per share data�weighted average shares) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 580.42 Td (226,050) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 580.42 Td (223,960) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 580.42 Td (223,198) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 558.25 Td (Basic net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 100.43 558.25 Td (loss per share) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 154.86 558.25 Td ( amounts are computed based on the weighted average number of ordinary shares outstanding during the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 546.25 Td (period. Diluted net ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 113.76 546.25 Td (loss per share) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 168.19 546.25 Td ( amounts are computed based on the weighted average number of ordinary shares outstanding and, if ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 534.25 Td (there is net income from continuing operations during the period, the dilutive ef) Tj ET Q
q 0 0 0 rg BT 354.90 534.25 Td (fect of ordinary share equivalents outstanding during ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 522.25 Td (the period.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 504.25 Td (The dilutive ef) Tj ET Q
q 0 0 0 rg BT 119.69 504.25 Td (fect of ordinary share equivalents is measured using the treasury stock method. Stock options and awards that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 492.25 Td (have been issued but for which a grant date has not yet been established are not considered in the calculation of basic or diluted ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 480.25 Td (weighted average shares.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 61.00 462.25 Td (All) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 73.78 462.25 Td ( potentially dilutive items were excluded from the diluted share calculation for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 405.06 462.25 Td (years ended December 31, 2019, 2018 and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 450.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 56.00 450.25 Td ( because their ef) Tj ET Q
q 0 0 0 rg BT 121.06 450.25 Td (fect would have been anti-dilutive, as the Company was in a loss position.) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 420.25 Td (NOTE 22. SA) Tj ET Q
q 0 0 0 rg BT 93.33 420.25 Td (VINGS ) Tj ET Q
q 0 0 0 rg BT 126.96 420.25 Td (AND INVESTMENT) Tj ET Q
q 0 0 0 rg BT 218.18 420.25 Td ( PLAN ) Tj ET Q
q 0 0 0 rg BT 249.85 420.25 Td (AND DEFERRED COMPENSA) Tj ET Q
q 0 0 0 rg BT 388.00 420.25 Td (TION PLANS) Tj ET Q
BT /F1 10.00 Tf ET
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 402.25 Td (Savings and Investment Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 384.25 Td (The Company maintains a defined contribution ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.62 384.25 Td (Savings and Investment Plan \(the Endo 401\(k\) Plan\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 464.87 384.25 Td ( covering all ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 517.35 384.25 Td (U.S.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.13 384.25 Td (-based ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 372.25 Td (eligible employees. ) Tj ET Q
q 0 0 0 rg BT 116.07 372.25 Td (The Company matches ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 210.77 372.25 Td (100%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.10 372.25 Td ( of the first ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 280.76 372.25 Td (3%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.09 372.25 Td ( of eligible cash compensation that a participant contributes to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 360.25 Td (Endo 401\(k\) Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 106.55 360.25 Td ( plus ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 128.22 360.25 Td (50%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.55 360.25 Td ( of the next ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.31 360.25 Td (2%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 207.64 360.25 Td ( for a total of up to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 285.12 360.25 Td (4%) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 298.45 360.25 Td (, subject to statutory limitations. Participants are immediately vested ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 348.25 Td (with respect to their own contributions and the Company�) Tj ET Q
q 0 0 0 rg BT 266.51 348.25 Td (s matching contributions, except that, for employees hired after 2017, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 336.25 Td (Company�) Tj ET Q
q 0 0 0 rg BT 77.67 336.25 Td (s matching contributions will vest ratably over a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 273.18 336.25 Td (two) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 288.18 336.25 Td (-year period.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 318.25 Td (Costs incurred for contributions made by the Company to the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 310.73 318.25 Td (Endo 401\(k\) Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 381.28 318.25 Td ( amounted to ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 435.99 318.25 Td ($7.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 484.88 318.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 489.88 318.25 Td ($6.4 million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 538.78 318.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 558.21 318.25 Td ($9.4 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 306.25 Td (million) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 64.89 306.25 Td ( for the years ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 146.24 306.25 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.83 306.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 229.83 306.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 249.83 306.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 269.27 306.25 Td (2017) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 289.27 306.25 Td (, respectively) Tj ET Q
q 0 0 0 rg BT 341.93 306.25 Td (.) Tj ET Q
BT /F4 10.00 Tf ET
q 0 0 0 rg BT 36.00 288.25 Td (Directors Stock Election Plan) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 270.25 Td (The Company maintains a directors stock election plan. ) Tj ET Q
q 0 0 0 rg BT 288.03 270.25 Td (The purpose of this plan is to provide non-employee directors the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 258.25 Td (opportunity to have their cash retainer fees, or a portion thereof, delivered in the form of Endo ordinary shares. ) Tj ET Q
q 0 0 0 rg BT 481.78 258.25 Td (The amount of shares ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 246.25 Td (will be determined by dividing the portion of cash fees elected to be received as shares by the closing price of the shares on the day the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 234.25 Td (payment would have otherwise been paid in cash.) Tj ET Q
endstream
endobj
281 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 282 0 R>>
endobj
282 0 obj
<</Length 40268>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-61) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 36.00 742.25 Td (NOTE 23. QUAR) Tj ET Q
q 0 0 0 rg BT 110.93 742.25 Td (TERL) Tj ET Q
q 0 0 0 rg BT 137.25 742.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 144.10 742.25 Td ( FINANCIAL) Tj ET Q
q 0 0 0 rg BT 202.71 742.25 Td ( DA) Tj ET Q
q 0 0 0 rg BT 218.92 742.25 Td (T) Tj ET Q
q 0 0 0 rg BT 224.84 742.25 Td (A) Tj ET Q
q 0 0 0 rg BT 231.51 742.25 Td ( \(UNAUDITED\)) Tj ET Q
BT /F1 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 724.25 Td (The following table presents select unaudited financial data for each of the three-month periods ending March 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.62 724.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.62 724.25 Td (, June ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 712.25 Td (30, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 51.00 712.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 71.00 712.25 Td (, September 30, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 136.26 712.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 156.26 712.25 Td ( and December 31, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 234.29 712.25 Td (2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 254.29 712.25 Td (, as well as the comparable ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.52 712.25 Td (2018) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 384.52 712.25 Td ( periods \(in thousands, except per share data\):) Tj ET Q
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 675.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 675.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 675.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 675.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 675.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 675.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 675.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 675.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 646.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 646.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 646.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 646.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 646.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 646.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 646.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 646.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 616.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 616.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 616.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 616.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 616.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 616.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 616.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 616.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 586.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 586.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 586.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 586.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 586.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 586.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 586.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 586.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 556.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 556.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 556.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 556.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 556.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 556.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 556.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 556.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 526.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 526.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 526.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 526.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 526.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 526.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 526.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 526.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 496.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 496.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 496.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 496.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 496.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 496.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 496.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 496.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 466.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 466.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 466.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 466.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 466.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 466.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 466.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 466.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 436.75 268.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 436.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 436.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 436.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 436.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 436.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 436.75 4.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 436.75 65.00 -14.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 407.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 407.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 407.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 407.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 407.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 407.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 407.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 407.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 377.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 377.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 377.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 377.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 377.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 377.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 377.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 377.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 347.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 347.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 347.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 347.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 347.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 347.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 347.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 347.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 317.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 317.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 317.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 317.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 317.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 317.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 317.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 317.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 287.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 287.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 287.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 287.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 287.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 287.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 287.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 287.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 257.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 257.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 257.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 257.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 257.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 257.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 257.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 257.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
35.50 227.75 268.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
303.50 227.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
368.50 227.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
372.50 227.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
437.50 227.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
441.50 227.75 65.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
506.50 227.75 4.00 -15.00 re f
/GS0 gs
0.8 0.9333333333333333 1 rg
/GS0 gs
510.50 227.75 65.00 -15.00 re f
/GS0 gs
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 688.75 m
368.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
368.5 688.75 m
372.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 688.75 m
437.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
437.5 688.75 m
441.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 688.75 m
506.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
506.5 688.75 m
510.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 688.75 m
575.5 688.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 675.75 m
368.5 675.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 675.75 m
437.5 675.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 675.75 m
506.5 675.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 675.75 m
575.5 675.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 541.75 m
368.5 541.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 527.75 m
368.5 527.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 525.75 m
368.5 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 541.75 m
437.5 541.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 527.75 m
437.5 527.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 525.75 m
437.5 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 541.75 m
506.5 541.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 527.75 m
506.5 527.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 525.75 m
506.5 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 541.75 m
575.5 541.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 527.75 m
575.5 527.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 525.75 m
575.5 525.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 481.75 m
368.5 481.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 467.75 m
368.5 467.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 465.75 m
368.5 465.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 481.75 m
437.5 481.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 467.75 m
437.5 467.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 465.75 m
437.5 465.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 481.75 m
506.5 481.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 467.75 m
506.5 467.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 465.75 m
506.5 465.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 481.75 m
575.5 481.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 467.75 m
575.5 467.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 465.75 m
575.5 465.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 302.75 m
368.5 302.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 288.75 m
368.5 288.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 286.75 m
368.5 286.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 302.75 m
437.5 302.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 288.75 m
437.5 288.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 286.75 m
437.5 286.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 302.75 m
506.5 302.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 288.75 m
506.5 288.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 286.75 m
506.5 286.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 302.75 m
575.5 302.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 288.75 m
575.5 288.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 286.75 m
575.5 286.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 242.75 m
368.5 242.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 228.75 m
368.5 228.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
303.5 226.75 m
368.5 226.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 242.75 m
437.5 242.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 228.75 m
437.5 228.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
372.5 226.75 m
437.5 226.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 242.75 m
506.5 242.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 228.75 m
506.5 228.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
441.5 226.75 m
506.5 226.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 242.75 m
575.5 242.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 228.75 m
575.5 228.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
510.5 226.75 m
575.5 226.75 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 412.95 692.98 Td (Quarter) Tj ET Q
q 0 0 0 rg BT 440.87 692.98 Td ( Ended) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 318.00 679.98 Td (Mar) Tj ET Q
q 0 0 0 rg BT 333.03 679.98 Td (ch�31,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 390.25 679.98 Td (June�30,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 449.10 679.98 Td (September) Tj ET Q
q 0 0 0 rg BT 485.91 679.98 Td (�30,) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 519.25 679.98 Td (December) Tj ET Q
q 0 0 0 rg BT 553.75 679.98 Td (�31,) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 666.43 Td (2019 \(1\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 651.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 651.42 Td (otal revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 651.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 651.42 Td (720,41) Tj ET Q
q 0 0 0 rg BT 359.65 651.42 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 651.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 651.42 Td (699,727) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 651.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 651.42 Td (729,426) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 651.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 651.42 Td (764,800) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 636.42 Td (Gross profit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 636.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 636.42 Td (328,502) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 636.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 636.42 Td (31) Tj ET Q
q 0 0 0 rg BT 411.15 636.42 Td (1,519) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 636.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 636.42 Td (340,261) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 636.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 636.42 Td (364,744) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 621.42 Td (Loss from continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 621.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.80 621.47 Td (\(12,612) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 621.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 621.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 621.47 Td (\(98,052) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 621.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 621.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 621.47 Td (\(41,431) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 621.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 621.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 621.42 Td (\(208,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 621.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 606.42 Td (Discontinued operations, net of tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 606.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.80 606.47 Td (\(5,961) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 606.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 606.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 606.47 Td (\(7,953) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 606.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 606.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 606.47 Td (\(37,984) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 606.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 606.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 606.42 Td (\(10,154) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 606.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 591.42 Td (Net loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 591.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 333.80 591.47 Td (\(18,573) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 591.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 591.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 397.80 591.47 Td (\(106,005) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 591.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 591.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 591.47 Td (\(79,415) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 591.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 591.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 591.42 Td (\(218,643) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 591.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 576.42 Td (Net loss per share�Basic:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 561.42 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 561.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 561.47 Td (\(0.06) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 561.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 561.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 561.47 Td (\(0.43) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 561.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 561.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 561.47 Td (\(0.18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 561.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 561.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 561.42 Td (\(0.92) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 561.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 546.42 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 546.47 Td (\(0.02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 546.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 546.47 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 546.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 546.47 Td (\(0.17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 546.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 546.42 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 546.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 531.42 Td (Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 531.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 531.47 Td (\(0.08) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 531.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 531.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 531.47 Td (\(0.47) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 531.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 531.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 531.47 Td (\(0.35) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 531.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 531.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 531.42 Td (\(0.96) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 531.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 516.42 Td (Net loss per share�Diluted:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 501.42 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 501.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 501.47 Td (\(0.06) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 501.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 501.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 501.47 Td (\(0.43) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 501.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 501.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 501.47 Td (\(0.18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 501.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 501.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 501.42 Td (\(0.92) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 501.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 486.42 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 486.47 Td (\(0.02) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 486.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 486.47 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 486.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 486.47 Td (\(0.17) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 486.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 486.42 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 486.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 471.42 Td (Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 471.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 471.47 Td (\(0.08) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 471.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 471.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 471.47 Td (\(0.47) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 471.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 471.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 471.47 Td (\(0.35) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 471.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 471.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 471.42 Td (\(0.96) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 471.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 456.42 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 456.42 Td (eighted average shares�Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 456.42 Td (224,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 456.42 Td (226,221) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 456.42 Td (226,598) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 456.42 Td (226,787) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 441.42 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 441.42 Td (eighted average shares�Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 441.42 Td (224,594) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 441.42 Td (226,221) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 441.42 Td (226,598) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 441.42 Td (226,787) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 38.00 427.43 Td (2018 \(2\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 412.42 Td (T) Tj ET Q
q 0 0 0 rg BT 43.76 412.42 Td (otal revenues) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 412.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 412.42 Td (700,527) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 412.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 412.42 Td (714,696) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 412.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 412.42 Td (745,466) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 412.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 412.42 Td (786,389) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 397.42 Td (Gross profit) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 397.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 397.42 Td (296,929) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 397.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 397.42 Td (332,791) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 397.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 397.42 Td (332,501) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 397.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 397.42 Td (353,175) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 382.42 Td (Loss from continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 382.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 382.47 Td (\(497,738) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 382.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 382.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 382.47 Td (\(52,479) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 382.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 382.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 382.47 Td (\(146,071) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 382.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 382.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 382.42 Td (\(265,479) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 382.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 367.42 Td (Discontinued operations, net of tax) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 367.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 338.80 367.47 Td (\(7,751) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 367.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 367.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 407.80 367.47 Td (\(8,388) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 367.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 367.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 471.80 367.47 Td (\(27,134) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 367.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 367.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.80 367.42 Td (\(26,429) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 367.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 352.42 Td (Net loss) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 352.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 328.80 352.47 Td (\(505,489) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 352.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 352.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.80 352.47 Td (\(60,867) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 352.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 352.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 466.80 352.47 Td (\(173,205) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 352.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 352.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 535.80 352.42 Td (\(291,908) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 352.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 337.42 Td (Net loss per share�Basic:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 322.42 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 322.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 322.47 Td (\(2.23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 322.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 322.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 322.47 Td (\(0.23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 322.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 322.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 322.47 Td (\(0.65) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 322.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 322.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 322.42 Td (\(1.18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 322.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 307.42 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 307.47 Td (\(0.03) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 307.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 307.47 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 307.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 307.47 Td (\(0.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 307.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 307.42 Td (\(0.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 307.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 292.42 Td (Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 292.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 292.47 Td (\(2.26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 292.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 292.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 292.47 Td (\(0.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 292.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 292.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 292.47 Td (\(0.77) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 292.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 292.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 292.42 Td (\(1.30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 292.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 277.42 Td (Net loss per share�Diluted:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 262.42 Td (Continuing operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 262.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 262.47 Td (\(2.23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 262.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 262.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 262.47 Td (\(0.23) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 262.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 262.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 262.47 Td (\(0.65) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 262.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 262.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 262.42 Td (\(1.18) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 262.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 247.42 Td (Discontinued operations) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 247.47 Td (\(0.03) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 247.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 247.47 Td (\(0.04) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 247.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 247.47 Td (\(0.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 247.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 247.42 Td (\(0.12) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 247.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 44.00 232.42 Td (Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 306.00 232.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.80 232.47 Td (\(2.26) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 364.65 232.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 375.00 232.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.80 232.47 Td (\(0.27) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 433.65 232.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 444.00 232.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 481.80 232.47 Td (\(0.77) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 502.65 232.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 513.00 232.42 Td ($) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 550.80 232.42 Td (\(1.30) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 571.65 232.42 Td (\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 217.42 Td (W) Tj ET Q
q 0 0 0 rg BT 47.04 217.42 Td (eighted average shares�Basic) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 217.42 Td (223,521) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 217.42 Td (223,834) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 217.42 Td (224,132) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 217.42 Td (224,353) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 38.00 202.42 Td (W) Tj ET Q
q 0 0 0 rg BT 46.64 202.42 Td (eighted average shares�Diluted) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 332.15 202.42 Td (223,521) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 401.15 202.42 Td (223,834) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 470.15 202.42 Td (224,132) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 539.15 202.42 Td (224,353) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 188.25 Td (__________) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 178.65 Td (\(1\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 178.65 Td (Loss from continuing operations) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.71 178.65 Td ( for the year ended ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 233.68 178.65 Td (December�31, 2019) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 296.54 178.65 Td ( was impacted by \(i\) acquisition-related and integration items, net of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 517.36 178.65 Td ($\(37.5\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 565.80 178.65 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 169.05 Td ($\(5.5\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 111.94 169.05 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 115.94 169.05 Td ($16.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 159.05 169.05 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 174.61 169.05 Td ($\(19.1\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 223.05 169.05 Td ( during the first, second, third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 422.91 169.05 Td (, which related primarily to changes in the fair ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 159.45 Td (value of contingent consideration, \(ii\) asset impairment char) Tj ET Q
q 0 0 0 rg BT 260.18 159.45 Td (ges of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 281.51 159.45 Td ($165.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 328.62 159.45 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 332.62 159.45 Td ($88.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 375.73 159.45 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 379.73 159.45 Td ($4.8 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 418.85 159.45 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 434.40 159.45 Td ($267.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 481.51 159.45 Td ( during the first, second, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 149.85 Td (third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 187.61 149.85 Td (, \(iii\) certain retention and separation benefits and other cost reduction initiatives incurred in connection with continued ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 140.25 Td (ef) Tj ET Q
q 0 0 0 rg BT 73.57 140.25 Td (forts to enhance the Company�) Tj ET Q
q 0 0 0 rg BT 171.77 140.25 Td (s operations of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 220.87 140.25 Td ($2.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 259.98 140.25 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 263.98 140.25 Td ($2.1 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 303.09 140.25 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 307.09 140.25 Td ($1) Tj ET Q
q 0 0 0 rg BT 314.80 140.25 Td (1.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 349.91 140.25 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 365.46 140.25 Td ($19.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 408.57 140.25 Td ( during the first, second, third and fourth quarters, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 130.65 Td (respectively) Tj ET Q
q 0 0 0 rg BT 105.63 130.65 Td (, \(iv\) amounts related to litigation-related and other contingent matters totaling ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 359.33 130.65 Td ($10.3 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 402.45 130.65 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 406.45 130.65 Td ($\(14.4\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 454.89 130.65 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 470.44 130.65 Td ($15.3 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 513.55 130.65 Td ( during the second, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 121.05 Td (third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 187.61 121.05 Td (, and \(v\) amounts related to sales of businesses and other assets of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 400.89 121.05 Td ($1.3 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 440.00 121.05 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 444.00 121.05 Td ($\(2.5\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 488.44 121.05 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 492.44 121.05 Td ($\(1.9\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 536.88 121.05 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 552.43 121.05 Td ($\(3.3\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 111.45 Td (million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 90.61 111.45 Td ( during the first, second, third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 290.48 111.45 Td (.) Tj ET Q
endstream
endobj
283 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Annots [<</Type /Annot /Subtype /Link /Rect [50 772.3734375 110.15625 779.51796875] /Border [0 0 0] /H /I /Dest [5 0 R /XYZ 0 792.00 null]>>]
/Rotate 0
/Contents 284 0 R>>
endobj
284 0 obj
<</Length 6074>>
stream
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
0 0 1 RG
/GS0 gs
0.76 w
0 i 
[] 0 d
1 J
1 j
3 M
50 772.848046875 m
110.15625 772.848046875 l
s
q 0 0 1 rg BT 50.00 774.10 Td (T) Tj ET Q
q 0 0 1 rg BT 54.60 774.10 Td (able of Contents) Tj ET Q
BT /F1 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 296.55 31.60 Td (F-62) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 49.50 743.50 Td (\(2\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 743.50 Td (Loss from continuing operations) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 171.71 743.50 Td ( for the year ended ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 233.68 743.50 Td (December�31, 2018) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 296.54 743.50 Td ( was impacted by \(i\) acquisition-related and integration items, net of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 517.36 743.50 Td ($6.8 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 556.48 743.50 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 560.48 743.50 Td ($5.2 ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 733.90 Td (million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 90.61 733.90 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 94.61 733.90 Td ($1.3 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 133.73 733.90 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 149.28 733.90 Td ($8.6 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 188.39 733.90 Td ( during the first, second, third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 388.26 733.90 Td (, which related primarily to changes in the fair value of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 724.30 Td (contingent consideration, \(ii\) asset impairment char) Tj ET Q
q 0 0 0 rg BT 232.19 724.30 Td (ges of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 253.52 724.30 Td ($448.4 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 300.63 724.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 304.63 724.30 Td ($22.8 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 347.75 724.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 351.75 724.30 Td ($142.2 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 398.86 724.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 414.41 724.30 Td ($303.5 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 461.52 724.30 Td ( during the first, second, third and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 714.70 Td (fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 156.95 714.70 Td (, \(iii\) certain retention and separation benefits and other cost reduction initiatives incurred in connection with continued ef) Tj ET Q
q 0 0 0 rg BT 547.34 714.70 Td (forts to ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 705.10 Td (enhance the Company�) Tj ET Q
q 0 0 0 rg BT 140.81 705.10 Td (s operations of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 189.91 705.10 Td ($49.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 233.02 705.10 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 237.02 705.10 Td ($29.2 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 280.14 705.10 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 284.14 705.10 Td ($4.0 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 323.25 705.10 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 338.80 705.10 Td ($4.2 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 377.91 705.10 Td ( during the first, second, third and fourth quarters, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 695.50 Td (respectively) Tj ET Q
q 0 0 0 rg BT 105.63 695.50 Td (, \(iv\) amounts related to litigation-related and other contingent matters totaling ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 359.33 695.50 Td ($\(2.5\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 403.77 695.50 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 407.77 695.50 Td ($19.6 million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 450.89 695.50 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 454.89 695.50 Td ($\(1.8\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 499.33 695.50 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 514.88 695.50 Td ($\(1.6\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 559.32 695.50 Td ( ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 685.90 Td (during the first, second, third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 265.37 685.90 Td (, and \(v\) amounts related to sales of businesses and other assets of ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 478.65 685.90 Td ($\(2.4\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 523.09 685.90 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 527.09 685.90 Td ($\(24.6\) ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 67.50 676.30 Td (million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 90.61 676.30 Td (, ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 94.61 676.30 Td ($\(2.9\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 139.05 676.30 Td ( and ) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 154.61 676.30 Td ($\(15.3\) million) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 203.05 676.30 Td ( during the first, second, third and fourth quarters, respectively) Tj ET Q
q 0 0 0 rg BT 402.91 676.30 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 63.00 658.30 Td (The operating results of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 174.91 658.30 Td (Astora) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 201.57 658.30 Td ( business are reported as Discontinued operations, net of tax in the Consolidated Statements ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 646.30 Td (of Operations for all periods presented. For additional information, see ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 321.48 646.30 Td (Note 3. Discontinued Operations and Divestitures) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 520.88 646.30 Td (. Quarterly ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 634.30 Td (and year) Tj ET Q
q 0 0 0 rg BT 69.95 634.30 Td (-to-date computations of per share amounts are made independently; therefore, the sum of the per share amounts for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 36.00 622.30 Td (quarters may not equal the per share amounts for the year) Tj ET Q
q 0 0 0 rg BT 265.36 622.30 Td (.) Tj ET Q
endstream
endobj
285 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 286 0 R>>
endobj
286 0 obj
<</Length 7302>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 483.95 711.90 Td (Exhibit 4.1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 156.25 684.80 Td (DESCRIPTION OF) Tj ET Q
q 0 0 0 rg BT 258.82 684.80 Td ( ) Tj ET Q
q 0 0 0 rg BT 261.60 684.80 Td (THE REGISTRANT�S SECURITIES) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 162.95 671.20 Td (REGISTERED PURSUANT) Tj ET Q
q 0 0 0 rg BT 309.76 671.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 312.55 671.20 Td (T) Tj ET Q
q 0 0 0 rg BT 320.33 671.20 Td (O SECTION 12 OF) Tj ET Q
q 0 0 0 rg BT 420.90 671.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 423.69 671.20 Td (THE) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 196.60 657.65 Td (SECURITIES EXCHANGE ) Tj ET Q
q 0 0 0 rg BT 343.98 657.65 Td (ACT) Tj ET Q
q 0 0 0 rg BT 369.09 657.65 Td ( OF) Tj ET Q
q 0 0 0 rg BT 388.31 657.65 Td ( 1934) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 632.70 Td (As of the date of our annual report on Form 10-K of which this exhibit is a part, we have the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 619.75 Td (following class of securities registered pursuant to Section 12 of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 500.89 619.75 Td (Act ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 606.80 Td (of 1934, as amended \(the �Exchange ) Tj ET Q
q 0 0 0 rg BT 250.93 606.80 Td (Act�\): ordinary shares of Endo International plc \(the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 593.80 Td (�Company�\), par value $0.0001 per share \(the �Ordinary Shares�\), which is the only security ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 580.85 Td (of the Company registered under the Exchange ) Tj ET Q
q 0 0 0 rg BT 300.26 580.85 Td (Act.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 555.90 Td (Except as otherwise indicated or the context otherwise requires, the terms �Company) Tj ET Q
q 0 0 0 rg BT 479.75 555.90 Td (,� �we,� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 542.95 Td (�us� and �our� mean Endo International plc and all entities included in its consolidated ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 530.00 Td (financial statements. ) Tj ET Q
BT /F5 12.00 Tf ET
q 0 0 0 rg BT 72.00 505.00 Td (Set forth below is a summary description of the material terms of our Or) Tj ET Q
q 0 0 0 rg BT 419.88 505.00 Td (dinary Shar) Tj ET Q
q 0 0 0 rg BT 476.43 505.00 Td (es, which ) Tj ET Q
BT /F5 12.00 Tf ET
q 0 0 0 rg BT 72.00 492.05 Td (does not purport to be complete. For mor) Tj ET Q
q 0 0 0 rg BT 270.87 492.05 Td (e information, please see our certificate of ) Tj ET Q
BT /F5 12.00 Tf ET
q 0 0 0 rg BT 72.00 479.10 Td (incorporation and memorandum and articles of association, each of which ar) Tj ET Q
q 0 0 0 rg BT 444.53 479.10 Td (e incorporated ) Tj ET Q
BT /F5 12.00 Tf ET
q 0 0 0 rg BT 72.00 466.15 Td (by r) Tj ET Q
q 0 0 0 rg BT 90.55 466.15 Td (efer) Tj ET Q
q 0 0 0 rg BT 108.76 466.15 Td (ence as an exhibit to our annual r) Tj ET Q
q 0 0 0 rg BT 270.63 466.15 Td (eport on Form 10-K.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 441.60 Td (General) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 417.15 Td (The Company is authorized to issue 1,000,000,000 Ordinary Shares, par value $0.0001 per ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 403.70 Td (share, of which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 148.64 403.70 Td (226,833,617) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 208.64 403.70 Td ( shares were issued and outstanding as of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 409.26 403.70 Td (February�18, 2020) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 497.58 403.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 503.36 403.70 Td (There ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 390.25 Td (are no sinking fund rights with respect to our Ordinary Shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 365.80 Td (W) Tj ET Q
q 0 0 0 rg BT 82.37 365.80 Td (e may issue shares subject to the maximum authorized share capital contained in our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 352.40 Td (memorandum and articles of association. ) Tj ET Q
q 0 0 0 rg BT 271.72 352.40 Td (The authorized share capital may be increased or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 338.95 Td (reduced by a resolution approved by a simple majority of the votes cast at a general meeting of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 325.50 Td (our shareholders at which a quorum is present \(referred to under Irish law as an �ordinary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 312.05 Td (resolution�\). ) Tj ET Q
q 0 0 0 rg BT 135.10 312.05 Td (The shares comprising our authorized share capital may be divided into shares of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.60 Td (such nominal value as the resolution shall prescribe. ) Tj ET Q
q 0 0 0 rg BT 324.94 298.60 Td (As a matter of Irish company law) Tj ET Q
q 0 0 0 rg BT 484.78 298.60 Td (, the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 285.20 Td (directors of a company may issue new Ordinary Shares without shareholder approval once ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 271.75 Td (authorized to do so by the memorandum and articles of association or by an ordinary resolution ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 258.30 Td (adopted by the shareholders at a general meeting. ) Tj ET Q
q 0 0 0 rg BT 312.02 258.30 Td (The authorization must include the maximum ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 244.85 Td (amount that may be allotted and may be granted for a maximum period of five years, at which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 231.40 Td (point it must be renewed by the shareholders by an ordinary resolution. Our shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 218.00 Td (adopted an ordinary resolution at the 2019 annual general meeting of the Company on June 1) Tj ET Q
q 0 0 0 rg BT 519.10 218.00 Td (1, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 204.55 Td (2019 authorizing our directors to issue up to an aggregate nominal amount of $7,464 ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 191.10 Td (\(74,639,777 Ordinary Shares\) \(being equivalent to approximately 33% of the aggregate nominal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 177.65 Td (value of the issued ordinary share capital of the Company as of ) Tj ET Q
q 0 0 0 rg BT 377.24 177.65 Td (April 12, 2019\), for a period of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 164.20 Td (18 months from June 1) Tj ET Q
q 0 0 0 rg BT 182.21 164.20 Td (1, 2019.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 139.80 Td (The rights and restrictions to which our Ordinary Shares are subject are prescribed in our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 126.35 Td (articles of association. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 101.90 Td (W) Tj ET Q
q 0 0 0 rg BT 82.37 101.90 Td (e may) Tj ET Q
q 0 0 0 rg BT 110.57 101.90 Td (, by ordinary resolution and without obtaining any vote or consent of the holders of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 88.45 Td (class or series of shares, unless expressly provided by the terms of that class or series of shares, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 75.00 Td (provide from time to time for the issuance of other classes or series of shares and to establish the ) Tj ET Q
endstream
endobj
287 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 288 0 R>>
endobj
288 0 obj
<</Length 6951>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (characteristics of each class or series, including the number of shares, designations, relative ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 684.80 Td (rights and any other preferences and relative, participating, optional or other rights and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 671.40 Td (limitations not inconsistent with applicable law) Tj ET Q
q 0 0 0 rg BT 298.18 671.40 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 646.95 Td (Irish law does not recognize fractional shares held of record. ) Tj ET Q
q 0 0 0 rg BT 364.89 646.95 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 424.09 646.95 Td (, our articles of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 633.50 Td (association do not provide for the issuance of fractional shares and our of) Tj ET Q
q 0 0 0 rg BT 423.67 633.50 Td (ficial Irish register will ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 620.05 Td (not reflect any fractional shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 595.60 Td (Whenever an issuance, alteration, reor) Tj ET Q
q 0 0 0 rg BT 255.69 595.60 Td (ganization, consolidation, division or subdivision of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 582.20 Td (share capital would result in any shareholder becoming entitled to fractions of a share, no such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 568.75 Td (fractions shall be issued or delivered to any shareholder) Tj ET Q
q 0 0 0 rg BT 338.58 568.75 Td (. ) Tj ET Q
q 0 0 0 rg BT 343.92 568.75 Td (All such fractions of a share will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 555.30 Td (aggregated into whole shares and sold in the open market at prevailing market prices and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 541.85 Td (aggregate cash proceeds from such sale \(net of tax, commissions, costs and other expenses\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 528.40 Td (shall be distributed on a pro rata basis, rounding down to the nearest cent, to each shareholder ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 515.00 Td (who would otherwise have been entitled to receive fractions of a share.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 490.40 Td (Ordinary Shar) Tj ET Q
q 0 0 0 rg BT 148.13 490.40 Td (es ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 466.00 Td (V) Tj ET Q
q 0 0 0 rg BT 78.67 466.00 Td (oting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 441.55 Td (Each of our shareholders is entitled to one vote for each Ordinary Share that he or she holds as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 428.10 Td (of the record date for the meeting. ) Tj ET Q
q 0 0 0 rg BT 238.38 428.10 Td (V) Tj ET Q
q 0 0 0 rg BT 245.50 428.10 Td (oting rights may be exercised by shareholders registered in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 414.65 Td (our share register as of the record date for the meeting or by a duly appointed proxy) Tj ET Q
q 0 0 0 rg BT 473.08 414.65 Td (, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 401.20 Td (proxy need not be a Company shareholder) Tj ET Q
q 0 0 0 rg BT 274.61 401.20 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 376.80 Td (Irish law requires special resolutions of our shareholders at a general meeting to approve certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 363.35 Td (matters. ) Tj ET Q
q 0 0 0 rg BT 112.66 363.35 Td (A) Tj ET Q
q 0 0 0 rg BT 120.66 363.35 Td ( special resolution requires the approval of three-quarters of the votes of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 349.90 Td (shareholders cast at a general meeting at which a quorum is present. Ordinary resolutions, by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 336.45 Td (contrast, require the approval of a simple majority of shareholders at a general meeting at which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 323.00 Td (a quorum is present.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.60 Td (Examples of matters requiring special resolutions include: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 285.15 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 285.15 Td (amending the objects or our memorandum of association;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 271.70 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 271.70 Td (amending our articles of association;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 258.25 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 258.25 Td (approving a change in our name;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 244.80 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 244.80 Td (authorizing the entering into of a guarantee or provision of security in connection with a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 231.40 Td (loan, quasi-loan or credit transaction to a director or connected person; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 217.95 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 217.95 Td (opting out of pre-emption rights on the issuance of new shares; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 204.50 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 204.50 Td (our re-registration from a public limited company to a private company; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 191.05 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 191.05 Td (variation of class rights attaching to classes of shares \(where our articles of association ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 177.60 Td (do not provide otherwise\); ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 164.20 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 164.20 Td (purchase of our Ordinary Shares of) Tj ET Q
q 0 0 0 rg BT 276.73 164.20 Td (f market; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 150.75 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 150.75 Td (reduction of issued share capital; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 137.30 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 137.30 Td (resolving that we be wound up by the Irish courts; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 123.85 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 123.85 Td (resolving in favor of a shareholders�) Tj ET Q
q 0 0 0 rg BT 281.38 123.85 Td ( voluntary winding-up;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 110.40 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 110.40 Td (re-designation of shares into dif) Tj ET Q
q 0 0 0 rg BT 260.41 110.40 Td (ferent share classes; and ) Tj ET Q
BT /F5 12.00 Tf ET
q 0 0 0 rg BT 90.00 97.00 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 97.00 Td (setting the re-issue price of treasury shares.) Tj ET Q
endstream
endobj
289 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 290 0 R>>
endobj
290 0 obj
<</Length 6582>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (3) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.90 Td (V) Tj ET Q
q 0 0 0 rg BT 78.67 711.90 Td (ariation of Rights ) Tj ET Q
q 0 0 0 rg BT 168.59 711.90 Td (Attaching to a Class or Series of Shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 687.45 Td (Neither Irish company law nor any of our constitutional documents place limitations on the right ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 674.00 Td (of non-resident or foreign owners to vote or hold our Ordinary Shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 649.60 Td (Under our articles of association and the Irish Companies ) Tj ET Q
q 0 0 0 rg BT 350.26 649.60 Td (Act 2014 \(the �Companies ) Tj ET Q
q 0 0 0 rg BT 480.90 649.60 Td (Act�\), any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 636.15 Td (variation of class rights attaching to our issued shares must be approved by a special resolution ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 622.70 Td (of the shareholders of the af) Tj ET Q
q 0 0 0 rg BT 206.06 622.70 Td (fected class or with the consent in writing of the holders of three-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 609.25 Td (quarters of all the votes of that class of shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.80 Td (The provisions of our articles of association relating to general meetings apply to general ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 571.40 Td (meetings of the holders of any class of shares except that the necessary quorum is determined in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 557.95 Td (reference to the shares of the holders of the class. ) Tj ET Q
q 0 0 0 rg BT 310.90 557.95 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 370.11 557.95 Td (, for general meetings of holders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 544.50 Td (of a particular class of shares, a quorum consists of one or more persons holding or representing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 531.05 Td (by proxy at least one-half of the issued shares of the class.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 506.60 Td (Dividends) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 482.20 Td (Our memorandum and articles of association authorize our board of directors to declare ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 468.75 Td (dividends without shareholder approval to the extent they appear justified by profits. Our board ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 455.30 Td (of directors may also recommend a dividend to be approved and declared by the shareholders at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 441.85 Td (a general meeting. No dividend issued may exceed the amount recommended by our board of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 428.40 Td (directors. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 404.00 Td (Dividends may be declared and paid in the form of cash or non-cash assets, including shares, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 390.55 Td (and may be paid in dollars or any other currency) Tj ET Q
q 0 0 0 rg BT 304.14 390.55 Td (. Our board of directors may deduct from any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 377.10 Td (dividend payable to any shareholder any amounts payable by such shareholder to us in relation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 363.65 Td (to our shares.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 339.20 Td (Under Irish law) Tj ET Q
q 0 0 0 rg BT 146.53 339.20 Td (, dividends and distributions may only be made from distributable reserves. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 325.80 Td (Distributable reserves generally means accumulated realized profits, so far as not previously ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 312.35 Td (utilized by distribution or capitalization, less accumulated, realized losses, so far as not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.90 Td (previously written of) Tj ET Q
q 0 0 0 rg BT 172.43 298.90 Td (f in a reduction or reor) Tj ET Q
q 0 0 0 rg BT 280.50 298.90 Td (ganization of capital duly made. In addition, no ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 285.45 Td (distribution or dividend may be made unless our net assets are equal to, or in excess of, the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 272.00 Td (aggregate of our called up share capital plus undistributable reserves and the distribution does ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 258.60 Td (not reduce our net assets below such aggregate. Undistributable reserves include the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 245.15 Td (undenominated capital \(ef) Tj ET Q
q 0 0 0 rg BT 197.06 245.15 Td (fectively the share premium account and capital redemption reserve\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 231.70 Td (and the amount by which our accumulated unrealized profits, so far as not previously utilized by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 218.25 Td (any capitalization, exceed our accumulated unrealized losses, so far as not previously written of) Tj ET Q
q 0 0 0 rg BT 531.28 218.25 Td (f ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 204.80 Td (in a reduction or reor) Tj ET Q
q 0 0 0 rg BT 173.07 204.80 Td (ganization of capital. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 180.40 Td (The determination as to whether or not we have suf) Tj ET Q
q 0 0 0 rg BT 318.70 180.40 Td (ficient distributable reserves to fund a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 166.95 Td (dividend must be made by reference to our �relevant financial statements.� Our �relevant ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 153.50 Td (financial statements� will be either our last set of unconsolidated annual audited financial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 140.05 Td (statements or other financial statements properly prepared in accordance with the Companies ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 126.60 Td (Act \(not in accordance with U.S. GAAP\), which give a �true and fair view� of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 113.20 Td (unconsolidated financial position and accord with accepted accounting practice. Our relevant ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 99.75 Td (financial statements must be filed in the Companies Registration Of) Tj ET Q
q 0 0 0 rg BT 397.38 99.75 Td (fice \(the of) Tj ET Q
q 0 0 0 rg BT 449.79 99.75 Td (ficial public ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 86.30 Td (registry for companies in Ireland\).) Tj ET Q
endstream
endobj
291 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 292 0 R>>
endobj
292 0 obj
<</Length 7190>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (4) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.90 Td (Bonus Shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 688.45 Td (Under our memorandum and articles of association, our board of directors may resolve to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 675.00 Td (capitalize any amount credited to any reserve available for distribution or the share premium ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 661.60 Td (account or other of our undistributable reserves for issuance and distribution to shareholders as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 648.15 Td (fully paid up bonus shares on the same basis of entitlement as would apply in respect of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 634.70 Td (dividend distribution. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 611.25 Td (Preemption Rights and Share Options ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 587.80 Td (Under Irish law) Tj ET Q
q 0 0 0 rg BT 146.53 587.80 Td (, certain statutory pre-emption rights apply automatically in favor of shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 574.40 Td (where shares are to be issued for cash. However) Tj ET Q
q 0 0 0 rg BT 302.43 574.40 Td (, we initially opted out of these pre-emption ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 560.95 Td (rights on incorporation in our articles of association as permitted under Irish company law) Tj ET Q
q 0 0 0 rg BT 504.11 560.95 Td (. ) Tj ET Q
q 0 0 0 rg BT 509.44 560.95 Td (As ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 547.50 Td (Irish law requires this opt-out to be renewed every five years by a special resolution of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 534.05 Td (shareholders, our memorandum and articles of association provided that this opt-out must be so ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 520.60 Td (renewed. If the opt-out is not renewed, shares issued for cash must be of) Tj ET Q
q 0 0 0 rg BT 418.68 520.60 Td (fered to our existing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 507.20 Td (shareholders on a pro rata basis to their existing shareholding before the shares can be issued to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 493.75 Td (any new shareholders. ) Tj ET Q
q 0 0 0 rg BT 181.75 493.75 Td (The statutory pre-emption rights do not apply where shares are issued for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 480.30 Td (non-cash consideration \(such as in a share-for) Tj ET Q
q 0 0 0 rg BT 291.68 480.30 Td (-share acquisition\) and do not apply to the issue of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 466.85 Td (non-equity shares \(that is, shares that have the right to participate only up to a specified amount ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 453.40 Td (in any income or capital distribution\) or where shares are issued pursuant to an employee option ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 440.00 Td (or similar equity plan. Our shareholders passed a special resolution at the 2019 annual general ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 426.55 Td (meeting of the Company on June�1) Tj ET Q
q 0 0 0 rg BT 239.53 426.55 Td (1, 2019 authorizing the directors of the Company to opt out of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 413.10 Td (pre-emption rights with respect to equity securities with up to an aggregate nominal value of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 399.65 Td ($2,262 \(22,618,1) Tj ET Q
q 0 0 0 rg BT 153.55 399.65 Td (14 Ordinary Shares\) \(being equivalent to approximately 10% of the aggregate ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 386.20 Td (nominal value of the issued ordinary share capital of the Company as of ) Tj ET Q
q 0 0 0 rg BT 419.57 386.20 Td (April�12, 2019\) for a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 372.80 Td (period of 18 months from June�1) Tj ET Q
q 0 0 0 rg BT 228.87 372.80 Td (1, 2019 \(provided that with respect to 1) Tj ET Q
q 0 0 0 rg BT 417.71 372.80 Td (1,309,057 of such shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 359.35 Td (\(being equivalent to approximately 5% of the issued ordinary share capital as of ) Tj ET Q
q 0 0 0 rg BT 458.21 359.35 Td (April�12, 2019\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 345.90 Td (such allotment is to be used for the purposes of an acquisition or a specified capital investment\). ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 322.45 Td (Our memorandum and articles of association provide that, subject to any shareholder approval ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 309.00 Td (requirement under any laws, regulations or the rules of any stock exchange to which we are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 295.60 Td (subject, our board of directors is authorized, from time to time, in its discretion, to grant such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 282.15 Td (persons, for such periods and upon such terms as our board of directors deems advisable, options ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 268.70 Td (to purchase such number of shares of any class or classes or of any series of any class as our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 255.25 Td (board of directors may deem advisable and to cause warrants or other appropriate instruments ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 241.80 Td (evidencing such options to be issued. ) Tj ET Q
q 0 0 0 rg BT 253.42 241.80 Td (The Companies ) Tj ET Q
q 0 0 0 rg BT 331.41 241.80 Td (Act provides that directors may issue share ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 228.40 Td (warrants or options without shareholder approval once authorized to do so by the articles of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 214.95 Td (association or an ordinary resolution of shareholders. ) Tj ET Q
q 0 0 0 rg BT 329.71 214.95 Td (W) Tj ET Q
q 0 0 0 rg BT 340.08 214.95 Td (e are subject to the rules of NASDAQ ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 201.50 Td (and the United States Internal Revenue Code of 1986 that require shareholder approval of certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 188.05 Td (equity plans and share issuances. Our board of directors may issue shares upon exercise of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 174.60 Td (warrants or options without shareholder approval or authorization \(up to the relevant authorized ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 161.20 Td (share capital limit\).) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 137.75 Td (Share Repurchases, Redemptions and Conversions ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 114.30 Td (Our memorandum and articles of association provide that any Ordinary Share that we have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 100.85 Td (agreed to acquire shall be deemed to be a redeemable share, unless our board of directors ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 87.40 Td (resolves otherwise. ) Tj ET Q
q 0 0 0 rg BT 166.31 87.40 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 225.52 87.40 Td (, for Irish company law purposes, our repurchase of Ordinary ) Tj ET Q
endstream
endobj
293 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 294 0 R>>
endobj
294 0 obj
<</Length 7046>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (5) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (Shares will technically be ef) Tj ET Q
q 0 0 0 rg BT 207.73 711.70 Td (fected as a redemption of those shares as described below under ��) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (Repurchases and Redemptions by Endo.� If our memorandum and articles of association did not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 684.80 Td (contain such provision, all repurchases we undertake would be subject to many of the same rules ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 671.40 Td (that apply to purchases of our Ordinary Shares by our subsidiaries as described below under ��) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 657.95 Td (Purchases by Subsidiaries of Endo, � including the shareholder approval requirements described ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 644.50 Td (below and the requirement that any purchases on market be ef) Tj ET Q
q 0 0 0 rg BT 369.67 644.50 Td (fected on a �recognized stock ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 631.05 Td (exchange,� which, for purposes of the Companies ) Tj ET Q
q 0 0 0 rg BT 313.60 631.05 Td (Act, includes NASDAQ. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 607.60 Td (Repurchases and Redemptions by Endo ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.20 Td (Under Irish law) Tj ET Q
q 0 0 0 rg BT 146.53 584.20 Td (, a company may issue redeemable shares and redeem them out of distributable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 570.75 Td (reserves or the proceeds of a new issue of shares for that purpose. ) Tj ET Q
q 0 0 0 rg BT 389.67 570.75 Td (W) Tj ET Q
q 0 0 0 rg BT 400.04 570.75 Td (e may only issue redeemable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 557.30 Td (shares if the nominal value of our issued share capital that is not redeemable is not less than 10% ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 543.85 Td (of the nominal value of our total issued share capital. ) Tj ET Q
q 0 0 0 rg BT 328.93 543.85 Td (All redeemable shares must also be fully-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 530.40 Td (paid and the terms of redemption of the shares must provide for payment on redemption. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 517.00 Td (Redeemable shares may) Tj ET Q
q 0 0 0 rg BT 187.17 517.00 Td (, upon redemption, be cancelled or held in treasury) Tj ET Q
q 0 0 0 rg BT 430.31 517.00 Td (. Based on the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 503.55 Td (provisions of our memorandum and articles of association described above, shareholder approval ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 490.10 Td (will not be required to redeem our Ordinary Shares.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 466.65 Td (W) Tj ET Q
q 0 0 0 rg BT 82.37 466.65 Td (e may also be given an additional general authority to purchase our own shares on market by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 453.20 Td (way of ordinary resolution, which would take ef) Tj ET Q
q 0 0 0 rg BT 303.05 453.20 Td (fect on the same terms and be subject to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 439.80 Td (same conditions as applicable to purchases by our subsidiaries as described below) Tj ET Q
q 0 0 0 rg BT 464.78 439.80 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 416.35 Td (Repurchased and redeemed shares may be cancelled or held as treasury shares. ) Tj ET Q
q 0 0 0 rg BT 453.28 416.35 Td (The nominal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 402.90 Td (value of treasury shares held by us at any time must not exceed 10% of the nominal value of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 389.45 Td (issued share capital. ) Tj ET Q
q 0 0 0 rg BT 171.08 389.45 Td (W) Tj ET Q
q 0 0 0 rg BT 181.45 389.45 Td (e may not exercise any voting rights in respect of any shares held as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 376.00 Td (treasury shares. ) Tj ET Q
q 0 0 0 rg BT 149.42 376.00 Td (W) Tj ET Q
q 0 0 0 rg BT 159.79 376.00 Td (e may cancel or re-issue treasury shares subject to certain conditions. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 352.60 Td (Purchases by Subsidiaries of Endo ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 329.15 Td (Under Irish law) Tj ET Q
q 0 0 0 rg BT 146.53 329.15 Td (, an Irish or non-Irish subsidiary of the Company may purchase our shares either ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 315.70 Td (on market or of) Tj ET Q
q 0 0 0 rg BT 146.09 315.70 Td (f market. For one of our subsidiaries to make purchases on market of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 302.25 Td (Ordinary Shares, our shareholders must provide general authorization for such purchase by way ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 288.80 Td (of ordinary resolution. However) Tj ET Q
q 0 0 0 rg BT 226.14 288.80 Td (, as long as this general authority has been granted, no specific ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 275.40 Td (shareholder authority for a particular on-market purchase by one of our subsidiaries of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 261.95 Td (Ordinary Shares is required. For an of) Tj ET Q
q 0 0 0 rg BT 254.07 261.95 Td (f-market purchase by one of our subsidiaries, the proposed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 248.50 Td (purchase contract must be authorized by special resolution of our shareholders before the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 235.05 Td (contract is entered into. ) Tj ET Q
q 0 0 0 rg BT 187.41 235.05 Td (The person whose shares are to be bought back cannot vote in favor of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 221.60 Td (the special resolution and from the date of the notice of the meeting at which the resolution ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 208.20 Td (approving the contract is proposed, the purchase contract must be on display or must be available ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 194.75 Td (for inspection by our shareholders at our registered of) Tj ET Q
q 0 0 0 rg BT 329.70 194.75 Td (fice.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 171.30 Td (The number of shares held by our subsidiaries at any time will count as treasury shares and will ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 157.85 Td (be included in any calculation of the permitted treasury share threshold of 10% of the nominal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 144.40 Td (value of our issued share capital. ) Tj ET Q
q 0 0 0 rg BT 232.06 144.40 Td (While a subsidiary holds our shares, it cannot exercise any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 131.00 Td (voting rights in respect of those shares. ) Tj ET Q
q 0 0 0 rg BT 262.41 131.00 Td (The acquisition of our Ordinary Shares by a subsidiary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 117.55 Td (must be funded out of distributable reserves of the subsidiary) Tj ET Q
q 0 0 0 rg BT 364.82 117.55 Td (. ) Tj ET Q
endstream
endobj
295 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 296 0 R>>
endobj
296 0 obj
<</Length 6662>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (6) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.90 Td (Lien on Shares, Calls on Shares and Forfeiture of Shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 688.45 Td (Our memorandum and articles of association provide that we have a first and paramount lien on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 675.00 Td (every share that is not a fully paid up share for all amounts payable at a fixed time or called in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 661.60 Td (respect of that share. Subject to the terms of their allotment, our board of directors may call for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 648.15 Td (any unpaid amounts in respect of any shares to be paid, and if payment is not made, the shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 634.70 Td (may be forfeited. ) Tj ET Q
q 0 0 0 rg BT 157.08 634.70 Td (These provisions are standard inclusions in the memorandum and articles of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 621.25 Td (association of an Irish public limited company such as the Company and are only applicable to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 607.80 Td (our shares that have not been fully paid up. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.40 Td (Consolidation and Division; Subdivision ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 560.95 Td (Under our articles of association, we may) Tj ET Q
q 0 0 0 rg BT 270.82 560.95 Td (, by ordinary resolution, consolidate and divide all or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 547.50 Td (any of our share capital into shares of lar) Tj ET Q
q 0 0 0 rg BT 267.71 547.50 Td (ger nominal value than our existing shares or subdivide ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 534.05 Td (our shares into smaller amounts than is fixed by our memorandum of association. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 510.60 Td (Reduction of Share Capital ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 487.20 Td (W) Tj ET Q
q 0 0 0 rg BT 82.37 487.20 Td (e may) Tj ET Q
q 0 0 0 rg BT 110.57 487.20 Td (, by ordinary resolution, reduce our authorized share capital in any way) Tj ET Q
q 0 0 0 rg BT 452.00 487.20 Td (. ) Tj ET Q
q 0 0 0 rg BT 457.79 487.20 Td (W) Tj ET Q
q 0 0 0 rg BT 468.15 487.20 Td (e also may) Tj ET Q
q 0 0 0 rg BT 518.69 487.20 Td (, by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 473.75 Td (special resolution and subject to confirmation by the Irish High Court, reduce or cancel our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 460.30 Td (issued share capital in any manner permitted by the Companies ) Tj ET Q
q 0 0 0 rg BT 377.92 460.30 Td (Act.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 436.85 Td (Election of Directors ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 413.40 Td (The Companies ) Tj ET Q
q 0 0 0 rg BT 149.99 413.40 Td (Act provides for a minimum of two directors on the board of an Irish public ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 400.00 Td (limited company) Tj ET Q
q 0 0 0 rg BT 152.20 400.00 Td (. Our memorandum and articles of association provide that the number of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 386.55 Td (directors shall not be less than five \(5\) nor more than twelve \(12\) with the exact number of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 373.10 Td (directors being fixed from time to time by resolution of our board of directors. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 349.65 Td (At each annual general meeting, all of our directors shall retire from of) Tj ET Q
q 0 0 0 rg BT 411.98 349.65 Td (fice and be re-eligible for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 336.20 Td (re-election. Each director shall hold of) Tj ET Q
q 0 0 0 rg BT 256.37 336.20 Td (fice until the next annual general meeting or until his or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 322.80 Td (her earlier resignation or removal. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 299.35 Td (Directors are elected by ordinary resolution at a general meeting. Irish law requires majority ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 285.90 Td (voting for the election of directors, which could result in the number of directors falling below ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 272.45 Td (the prescribed minimum number of directors due to the failure of nominees to be elected.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 249.00 Td (Removal of Directors; V) Tj ET Q
q 0 0 0 rg BT 190.99 249.00 Td (acancies ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 225.60 Td (Under the Companies ) Tj ET Q
q 0 0 0 rg BT 178.98 225.60 Td (Act and notwithstanding anything contained in our memorandum and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 212.15 Td (articles of association or in any agreement between us and a director) Tj ET Q
q 0 0 0 rg BT 399.72 212.15 Td (, our shareholders may) Tj ET Q
q 0 0 0 rg BT 508.24 212.15 Td (, by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 198.70 Td (an ordinary resolution, remove a director from of) Tj ET Q
q 0 0 0 rg BT 307.70 198.70 Td (fice before the expiration of his or her term at a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 185.25 Td (meeting held on no less than 28 days�) Tj ET Q
q 0 0 0 rg BT 252.08 185.25 Td ( notice and at which the director is entitled to be heard. ) Tj ET Q
q 0 0 0 rg BT 518.77 185.25 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 171.80 Td (power of removal is without prejudice to any claim for damages for breach of contract \(e.g., ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 158.40 Td (employment contract\) that the director may have against us in respect of his or her removal. Our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 144.95 Td (memorandum and articles of association provide that our board of directors may fill any vacancy ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 131.50 Td (occurring on our board of directors. If our board of directors fills a vacancy) Tj ET Q
q 0 0 0 rg BT 433.08 131.50 Td (, the director) Tj ET Q
q 0 0 0 rg BT 494.50 131.50 Td (�) Tj ET Q
q 0 0 0 rg BT 497.84 131.50 Td (s term ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 118.05 Td (expires at the next annual general meeting. ) Tj ET Q
q 0 0 0 rg BT 279.92 118.05 Td (A) Tj ET Q
q 0 0 0 rg BT 287.92 118.05 Td ( vacancy on our board of directors created by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 104.60 Td (removal of a director may be filled by our shareholders at the meeting at which such director is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 91.20 Td (removed. ) Tj ET Q
endstream
endobj
297 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 298 0 R>>
endobj
298 0 obj
<</Length 6819>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (7) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.90 Td (Annual General Meetings of Shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 688.45 Td (W) Tj ET Q
q 0 0 0 rg BT 82.37 688.45 Td (e are required to hold an annual general meeting at intervals of no more than 15 months from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 675.00 Td (the previous annual general meeting, provided that an annual general meeting is held in each ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 661.60 Td (calendar year following our first annual general meeting. Each general meeting will be held at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 648.15 Td (such time and place as designated by our board of directors and as specified in the notice of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 634.70 Td (meeting. Subject to section 176 of the Companies ) Tj ET Q
q 0 0 0 rg BT 312.96 634.70 Td (Act, all general meetings may be held outside ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 621.25 Td (of Ireland. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 597.80 Td (The only matters that must, as a matter of Irish law) Tj ET Q
q 0 0 0 rg BT 316.15 597.80 Td (, be transacted at an annual general meeting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.40 Td (are the consideration of the statutory financial statements, the report of the directors and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 570.95 Td (report of the auditors on those statements and that report, the review by the members of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 557.50 Td (Company�) Tj ET Q
q 0 0 0 rg BT 122.00 557.50 Td (s af) Tj ET Q
q 0 0 0 rg BT 138.77 557.50 Td (fairs, the appointment of new auditors and the fixing of the auditor) Tj ET Q
q 0 0 0 rg BT 459.13 557.50 Td (�) Tj ET Q
q 0 0 0 rg BT 462.47 557.50 Td (s remuneration ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 544.05 Td (\(or delegation of same\). ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 520.60 Td (If no resolution is made in respect of the reappointment of an existing auditor at an annual ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 507.20 Td (general meeting, the existing auditor will be deemed to have continued in of) Tj ET Q
q 0 0 0 rg BT 437.34 507.20 Td (fice. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 483.75 Td (The provisions of our memorandum and articles of association relating to general meetings will ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 470.30 Td (apply to every such general meeting of the holders of any class of shares except that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 456.85 Td (necessary quorum shall be one person holding or representing by proxy at least one-half of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 443.40 Td (issued shares of such class. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 420.00 Td (Our memorandum and articles of association provide that a resolution may only be put to vote at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 406.55 Td (a general meeting or of the holders of any class of shares if \(i\) it is specified in the notice of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 393.10 Td (meeting; \(ii\) it is proposed by or at the direction of the board of directors; \(iii\) it is proposed at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 379.65 Td (the direction of a court of competent jurisdiction; \(iv\) it is proposed on the requisition in writing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 366.20 Td (of the holder of shares as is prescribed by) Tj ET Q
q 0 0 0 rg BT 270.49 366.20 Td (, and is made in accordance with, section 178\(3\) of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 352.80 Td (Companies ) Tj ET Q
q 0 0 0 rg BT 128.33 352.80 Td (Act; \(v\) the chairman of the meeting in his or her absolute discretion decides that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 339.35 Td (resolution may properly be regarded as within the scope of the meeting; or \(vi\) it is proposed in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 325.90 Td (accordance with the procedures and requirements set out in our articles with respect to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 312.45 Td (nominations of directors.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 289.00 Td (Extraordinary General Meetings of Shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 265.60 Td (Extraordinary general meetings of the Company may be convened by \(i\) our board of directors; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 252.15 Td (\(ii\) on requisition of our shareholders holding not less than 10% of our paid up share capital ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 238.70 Td (carrying voting rights; \(iii\) on requisition of our auditors; or \(iv\) in exceptional cases, by order of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 225.25 Td (the Irish High Court. Extraordinary general meetings are generally held for the purpose of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 211.80 Td (approving shareholder resolutions as may be required from time to time. ) Tj ET Q
q 0 0 0 rg BT 421.91 211.80 Td (At any extraordinary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 198.40 Td (general meeting, only such business shall be conducted as is set forth in the notice thereof. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 174.95 Td (In the case of an extraordinary general meeting convened by our shareholders, the purpose of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 161.50 Td (meeting must be set out in the requisition notice. Upon receipt of any such valid requisition ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 148.05 Td (notice, our board of directors) Tj ET Q
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 211.62 148.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 214.37 148.05 Td (has 21 days to convene a meeting of our shareholders to vote on the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 134.60 Td (matters set out in the requisition notice. ) Tj ET Q
q 0 0 0 rg BT 264.41 134.60 Td (This meeting must be held within two months of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 121.20 Td (receipt of the requisition notice. If our board of directors does not convene the meeting within ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 107.75 Td (such 21-day period, the requisitioning shareholders, or any of them representing more than one ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 94.30 Td (half of the total voting rights of all of them, may themselves convene a meeting, which meeting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 80.85 Td (must be held within three months of our receipt of the requisition notice. ) Tj ET Q
endstream
endobj
299 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 300 0 R>>
endobj
300 0 obj
<</Length 5931>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (8) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (If our board of directors becomes aware that our net assets are not greater than half of the amount ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (of our called-up share capital, it must convene an extraordinary general meeting of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 684.80 Td (shareholders not later than 28 days from the date that the directors learn of this fact to consider ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 671.40 Td (how to address the situation.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 647.95 Td (Record Date; Notice Provisions ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 624.50 Td (Our memorandum and articles of association provide that our board of directors may fix in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 611.05 Td (advance a record date \(i\) to determine the shareholders entitled to notice of or to vote at a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 597.60 Td (meeting of the shareholders that is no more than 60 days and no less than 10 days before the date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.20 Td (of the meeting and \(ii\) for the purpose of determining the shareholders entitled to receive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 570.75 Td (payment of any dividend, or in order to make a determination of shareholders for any other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 557.30 Td (proper purpose that is no more than 60 days prior to the date of payment of the dividend or the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 543.85 Td (date of any other action to which the determination of shareholders is relevant. ) Tj ET Q
q 0 0 0 rg BT 452.32 543.85 Td (The record date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 530.40 Td (may not precede the date upon which the resolution fixing the record date is adopted by our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 517.00 Td (directors. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 493.55 Td (If the register of our shareholders is closed in connection with a meeting, it must be closed for at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 480.10 Td (least five days preceding the meeting and the record date for determination of the shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 466.65 Td (entitled to receive notice of, and to vote at, that meeting will be the date of the closing of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 453.20 Td (register of our shareholders. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 429.80 Td (Notice of an annual or extraordinary general meeting must be given to all of our shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 416.35 Td (and to our auditors. Our memorandum and articles of association provide for a minimum notice ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 402.90 Td (period of 21 days for an annual general meeting, which is the minimum permitted under Irish ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 389.45 Td (law) Tj ET Q
q 0 0 0 rg BT 88.55 389.45 Td (. In addition, under Irish law and our memorandum and articles of association, the minimum ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 376.00 Td (notice periods are 21 days�) Tj ET Q
q 0 0 0 rg BT 200.40 376.00 Td ( notice in writing for an extraordinary general meeting to approve a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 362.60 Td (special resolution and 14 days�) Tj ET Q
q 0 0 0 rg BT 219.74 362.60 Td ( notice in writing for any other extraordinary general meeting. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 339.15 Td (Advance Notice of Director Nominations and Other Proposals ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 315.70 Td (The Companies ) Tj ET Q
q 0 0 0 rg BT 149.99 315.70 Td (Act provides that shareholders holding not less than 10% of the total voting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 302.25 Td (rights may call an extraordinary general meeting for the purpose of considering director ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 288.80 Td (nominations or other proposals, as described under ��Extraordinary General Meetings of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 275.40 Td (Shareholders.� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 251.95 Td (Our memorandum and articles of association provide that shareholder nominations of persons to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 238.50 Td (be elected to our board of directors at an annual general meeting must be made following written ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 225.05 Td (notice to our secretary executed by a shareholder accompanied by certain background and other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 211.60 Td (information specified in our memorandum and articles of association. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 188.20 Td (Such written notice and information must be received by our secretary not less than 60 days nor ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 174.75 Td (more than 90 days before the anniversary date of the prior year) Tj ET Q
q 0 0 0 rg BT 374.65 174.75 Td (�) Tj ET Q
q 0 0 0 rg BT 377.99 174.75 Td (s annual general meeting, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 161.30 Td (provided, however) Tj ET Q
q 0 0 0 rg BT 161.49 161.30 Td (, that in the event that the annual general meeting is called for a date that is not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 147.85 Td (within 30 days before or after such anniversary date, notice must be received not later than the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 134.40 Td (close of business on the 10th day following the day on which notice of the annual general ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 121.00 Td (meeting is published. ) Tj ET Q
endstream
endobj
301 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 302 0 R>>
endobj
302 0 obj
<</Length 8172>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 303.25 59.90 Td (9) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.90 Td (Quorum for General Meetings ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 688.45 Td (Our memorandum and articles of association provide that no business shall be transacted at any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 675.00 Td (general meeting unless a quorum is present. One or more shareholders present in person or by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 661.60 Td (proxy holding not less than a majority of our issued and outstanding shares entitled to vote at the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 648.15 Td (meeting in question constitute a quorum.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 624.70 Td (Anti-T) Tj ET Q
q 0 0 0 rg BT 105.57 624.70 Td (akeover) Tj ET Q
q 0 0 0 rg BT 146.00 624.70 Td ( Pr) Tj ET Q
q 0 0 0 rg BT 161.44 624.70 Td (ovisions ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 601.25 Td (Irish T) Tj ET Q
q 0 0 0 rg BT 105.25 601.25 Td (akeover Rules and Substantial ) Tj ET Q
q 0 0 0 rg BT 258.16 601.25 Td (Acquisition Rules ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 577.80 Td (A) Tj ET Q
q 0 0 0 rg BT 80.00 577.80 Td ( transaction in which a third party seeks to acquire 30% or more of our voting rights will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 564.40 Td (governed by the Irish ) Tj ET Q
q 0 0 0 rg BT 177.09 564.40 Td (T) Tj ET Q
q 0 0 0 rg BT 183.58 564.40 Td (akeover Panel ) Tj ET Q
q 0 0 0 rg BT 253.55 564.40 Td (Act 1997, which is referred to in this exhibit as the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 550.95 Td (�T) Tj ET Q
q 0 0 0 rg BT 83.82 550.95 Td (akeover Panel ) Tj ET Q
q 0 0 0 rg BT 153.79 550.95 Td (Act,� and the Irish ) Tj ET Q
q 0 0 0 rg BT 245.21 550.95 Td (T) Tj ET Q
q 0 0 0 rg BT 251.70 550.95 Td (akeover Rules made thereunder and will be regulated by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 537.50 Td (Irish ) Tj ET Q
q 0 0 0 rg BT 96.78 537.50 Td (T) Tj ET Q
q 0 0 0 rg BT 103.27 537.50 Td (akeover Panel, which is referred to in this exhibit as the �Panel.� ) Tj ET Q
q 0 0 0 rg BT 416.29 537.50 Td (The �General Principles� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 524.05 Td (of the Irish ) Tj ET Q
q 0 0 0 rg BT 127.44 524.05 Td (T) Tj ET Q
q 0 0 0 rg BT 133.93 524.05 Td (akeover Rules and certain important aspects of the Irish ) Tj ET Q
q 0 0 0 rg BT 403.95 524.05 Td (T) Tj ET Q
q 0 0 0 rg BT 410.44 524.05 Td (akeover Rules are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 510.60 Td (described below) Tj ET Q
q 0 0 0 rg BT 149.53 510.60 Td (.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 487.20 Td (General Principles ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 463.75 Td (The ) Tj ET Q
q 0 0 0 rg BT 93.44 463.75 Td (T) Tj ET Q
q 0 0 0 rg BT 99.93 463.75 Td (akeover Rules are built on the following General Principles which will apply to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 450.30 Td (transaction regulated by the Panel: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 436.85 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 436.85 Td (in the event of an of) Tj ET Q
q 0 0 0 rg BT 204.08 436.85 Td (fer) Tj ET Q
q 0 0 0 rg BT 216.92 436.85 Td (, all holders of securities of the tar) Tj ET Q
q 0 0 0 rg BT 380.65 436.85 Td (get company should be af) Tj ET Q
q 0 0 0 rg BT 503.73 436.85 Td (forded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 423.40 Td (equivalent treatment and, if a person acquires control of a company) Tj ET Q
q 0 0 0 rg BT 430.76 423.40 Td (, the other holders of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 410.00 Td (securities must be protected;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 396.55 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 396.55 Td (the holders of securities in the tar) Tj ET Q
q 0 0 0 rg BT 267.73 396.55 Td (get company must have suf) Tj ET Q
q 0 0 0 rg BT 398.82 396.55 Td (ficient time and information ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 383.10 Td (to enable them to reach a properly informed decision on the of) Tj ET Q
q 0 0 0 rg BT 407.34 383.10 Td (fer; where it advises the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 369.65 Td (holders of securities, the board of the tar) Tj ET Q
q 0 0 0 rg BT 301.72 369.65 Td (get company must give its views on the ef) Tj ET Q
q 0 0 0 rg BT 503.46 369.65 Td (fects of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 356.20 Td (implementation of the of) Tj ET Q
q 0 0 0 rg BT 226.75 356.20 Td (fer on employment, conditions of employment and the locations ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 342.80 Td (of the tar) Tj ET Q
q 0 0 0 rg BT 151.10 342.80 Td (get company�) Tj ET Q
q 0 0 0 rg BT 216.08 342.80 Td (s places of business; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 329.35 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 329.35 Td (the board of the tar) Tj ET Q
q 0 0 0 rg BT 199.08 329.35 Td (get company must act in the interests of the company as a whole and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 315.90 Td (must not deny the holders of securities the opportunity to decide on the merits of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 302.45 Td (of) Tj ET Q
q 0 0 0 rg BT 117.78 302.45 Td (fer; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 289.00 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 289.00 Td (false markets must not be created in the securities of the tar) Tj ET Q
q 0 0 0 rg BT 392.68 289.00 Td (get company) Tj ET Q
q 0 0 0 rg BT 453.54 289.00 Td (, the bidder or of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 275.60 Td (any other company concerned by the of) Tj ET Q
q 0 0 0 rg BT 297.71 275.60 Td (fer in such a way that the rise or fall of the prices ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 262.15 Td (of the securities becomes artificial and the normal functioning of the markets is distorted; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 248.70 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 248.70 Td (a bidder must announce an of) Tj ET Q
q 0 0 0 rg BT 249.40 248.70 Td (fer only after ensuring that he or she can fulfill in full, any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 235.25 Td (cash consideration, if such is of) Tj ET Q
q 0 0 0 rg BT 259.08 235.25 Td (fered and after taking all reasonable measures to secure ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 221.80 Td (the implementation of any other type of consideration; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 208.40 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 208.40 Td (a tar) Tj ET Q
q 0 0 0 rg BT 128.77 208.40 Td (get company must not be hindered in the conduct of its af) Tj ET Q
q 0 0 0 rg BT 404.81 208.40 Td (fairs for longer than is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 194.95 Td (reasonable by an of) Tj ET Q
q 0 0 0 rg BT 201.41 194.95 Td (fer for its securities; and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 90.00 181.50 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 181.50 Td ( a substantial acquisition of securities \(whether such acquisition is to be ef) Tj ET Q
q 0 0 0 rg BT 463.69 181.50 Td (fected by one ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 168.05 Td (transactions or a series of transaction\) shall take place only at an acceptable speed and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 154.60 Td (shall be subject to adequate and timely disclosure.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 131.20 Td (Mandatory Bid ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 107.75 Td (Under certain circumstances, a person who acquires our shares or other voting rights in Endo ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 94.30 Td (may be required under the ) Tj ET Q
q 0 0 0 rg BT 200.73 94.30 Td (T) Tj ET Q
q 0 0 0 rg BT 207.22 94.30 Td (akeover Rules to make a mandatory cash of) Tj ET Q
q 0 0 0 rg BT 416.60 94.30 Td (fer for our remaining ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 80.85 Td (outstanding shares at a price not less than the highest price paid for the shares by the acquirer \(or ) Tj ET Q
endstream
endobj
303 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 304 0 R>>
endobj
304 0 obj
<</Length 7650>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 300.50 59.90 Td (10) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (any parties acting in concert with the acquirer\) during the previous 12 months. ) Tj ET Q
q 0 0 0 rg BT 451.01 711.70 Td (This mandatory ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (bid requirement is triggered if an acquisition of shares would increase the aggregate holding of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 684.80 Td (an acquirer \(including the holdings of any parties acting in concert with the acquirer\) to shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 671.40 Td (representing 30% or more of the voting rights in Endo, unless the Panel otherwise consents. ) Tj ET Q
q 0 0 0 rg BT 514.92 671.40 Td (An ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 657.95 Td (acquisition of shares by a person holding \(together with its concert parties\) shares representing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 644.50 Td (between 30% and 50% of the voting rights in Endo would also trigger the mandatory bid ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 631.05 Td (requirement if, after giving ef) Tj ET Q
q 0 0 0 rg BT 214.05 631.05 Td (fect to the acquisition, the percentage of the voting rights held by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 617.60 Td (that person \(together with its concert parties\) would increase by 0.05% within a 12-month period. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 604.20 Td (Any person \(excluding any parties acting in concert with the holder\) holding shares representing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 590.75 Td (more than 50% of the voting rights of a company is not subject to these mandatory of) Tj ET Q
q 0 0 0 rg BT 481.69 590.75 Td (fer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 577.30 Td (requirements in purchasing additional securities. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 553.85 Td (V) Tj ET Q
q 0 0 0 rg BT 78.67 553.85 Td (oluntary Bid; Requirements to Make a Cash Of) Tj ET Q
q 0 0 0 rg BT 312.81 553.85 Td (fer and Minimum Price Requirements ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 530.40 Td (If a person makes a voluntary of) Tj ET Q
q 0 0 0 rg BT 227.06 530.40 Td (fer to acquire our outstanding Ordinary Shares, the of) Tj ET Q
q 0 0 0 rg BT 483.77 530.40 Td (fer price ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 517.00 Td (must be no less than the highest price paid for our Ordinary Shares by the bidder or its concert ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 503.55 Td (parties during the three-month period prior to the commencement of the of) Tj ET Q
q 0 0 0 rg BT 430.00 503.55 Td (fer period. ) Tj ET Q
q 0 0 0 rg BT 482.76 503.55 Td (The Panel ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 490.10 Td (has the power to extend the �look back� period to 12 months if the Panel, taking into account the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 476.65 Td (General Principles, believes it is appropriate to do so. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 453.20 Td (If the bidder or any of its concert parties has acquired our Ordinary Shares \(i\)�during the period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 439.80 Td (of 12 months prior to the commencement of the of) Tj ET Q
q 0 0 0 rg BT 314.06 439.80 Td (fer period which represent more than 10% of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 426.35 Td (our total Ordinary Shares or \(ii\)�at any time after the commencement of the of) Tj ET Q
q 0 0 0 rg BT 445.65 426.35 Td (fer period, the of) Tj ET Q
q 0 0 0 rg BT 526.06 426.35 Td (fer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 412.90 Td (must be in cash \(or accompanied by a full cash alternative\) and the price per Ordinary Share ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 399.45 Td (must not be less than the highest price paid by the bidder or its concert parties during, in the case ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 386.00 Td (of \(i\), the 12-month period prior to the commencement of the of) Tj ET Q
q 0 0 0 rg BT 379.03 386.00 Td (fer period and, in the case of \(ii\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 372.60 Td (the of) Tj ET Q
q 0 0 0 rg BT 99.44 372.60 Td (fer period. ) Tj ET Q
q 0 0 0 rg BT 152.20 372.60 Td (The Panel may apply this rule to a bidder who, together with its concert parties, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 359.15 Td (has acquired less than 10% of our total Ordinary Shares in the 12-month period prior to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 345.70 Td (commencement of the of) Tj ET Q
q 0 0 0 rg BT 191.40 345.70 Td (fer period if the Panel, taking into account the General Principles, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 332.25 Td (considers it just and proper to do so. ) Tj ET Q
q 0 0 0 rg BT 248.31 332.25 Td (An of) Tj ET Q
q 0 0 0 rg BT 275.76 332.25 Td (fer period will generally commence from the date of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 318.80 Td (the first announcement of the of) Tj ET Q
q 0 0 0 rg BT 225.40 318.80 Td (fer or proposed of) Tj ET Q
q 0 0 0 rg BT 311.48 318.80 Td (fer) Tj ET Q
q 0 0 0 rg BT 324.14 318.80 Td (. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 295.40 Td (Substantial ) Tj ET Q
q 0 0 0 rg BT 130.58 295.40 Td (Acquisition Rules ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 271.95 Td (The Irish ) Tj ET Q
q 0 0 0 rg BT 118.44 271.95 Td (T) Tj ET Q
q 0 0 0 rg BT 124.93 271.95 Td (akeover Rules also contain rules governing substantial acquisitions of shares which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 258.50 Td (restrict the speed at which a person may increase his or her holding of shares and rights over ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 245.05 Td (shares to an aggregate of between 15% and 30% of the voting rights of Endo. Except in certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 231.60 Td (circumstances, an acquisition or series of acquisitions of shares or rights over shares representing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 218.20 Td (10% or more of the voting rights of Endo is prohibited, if such acquisition\(s\), when aggregated ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 204.75 Td (with shares or rights already held, would result in the acquirer holding 15% or more but less than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 191.30 Td (30% of the voting rights of Endo and such acquisitions are made within a period of seven days. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 177.85 Td (These rules also require accelerated disclosure of acquisitions of shares or rights over shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 164.40 Td (relating to such holdings. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 141.00 Td (Frustrating ) Tj ET Q
q 0 0 0 rg BT 131.92 141.00 Td (Action ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 117.55 Td (Under the ) Tj ET Q
q 0 0 0 rg BT 122.43 117.55 Td (T) Tj ET Q
q 0 0 0 rg BT 128.92 117.55 Td (akeover Rules, our board of directors is not permitted to take any action which might ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 104.10 Td (frustrate an of) Tj ET Q
q 0 0 0 rg BT 139.08 104.10 Td (fer for our shares once our board of directors has received an approach which may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 90.65 Td (lead to an of) Tj ET Q
q 0 0 0 rg BT 131.43 90.65 Td (fer or has reason to believe an of) Tj ET Q
q 0 0 0 rg BT 288.14 90.65 Td (fer is or may be imminent, subject to certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 77.20 Td (exceptions. ) Tj ET Q
endstream
endobj
305 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 306 0 R>>
endobj
306 0 obj
<</Length 7345>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 300.70 59.90 Td (1) Tj ET Q
q 0 0 0 rg BT 305.79 59.90 Td (1) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (Potentially frustrating actions such as \(i\)�the issue of shares, options or convertible securities; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (\(ii\)�material acquisitions or disposals; \(iii\)�entering into contracts other than in the ordinary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 684.80 Td (course of business; or \(iv\)�any action, other than seeking alternative of) Tj ET Q
q 0 0 0 rg BT 409.68 684.80 Td (fers, which may result in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 671.40 Td (frustration of an of) Tj ET Q
q 0 0 0 rg BT 162.09 671.40 Td (fer) Tj ET Q
q 0 0 0 rg BT 174.93 671.40 Td (, are prohibited during the course of an of) Tj ET Q
q 0 0 0 rg BT 374.31 671.40 Td (fer or at any time during which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 657.95 Td (the board has reason to believe an of) Tj ET Q
q 0 0 0 rg BT 247.38 657.95 Td (fer is or may be imminent. Exceptions to this prohibition are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 644.50 Td (available where: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 92.00 631.05 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 110.00 631.05 Td (the action is approved by our shareholders at a general meeting; or) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 92.00 617.60 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 110.00 617.60 Td (the Panel has given its consent, where: ) Tj ET Q
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 128.00 604.20 Td (o) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.50 604.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 604.20 Td (it is satisfied the action would not constitute frustrating action; ) Tj ET Q
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 128.00 590.75 Td (o) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.50 590.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 590.75 Td (our shareholders that hold 50% of the voting rights in Endo state in writing that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 577.30 Td (they approve the proposed action and would vote in favor of it at a general ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 563.85 Td (meeting; ) Tj ET Q
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 128.00 550.40 Td (o) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.50 550.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 550.40 Td (the action is taken in accordance with a contract entered into prior to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 537.00 Td (announcement of the of) Tj ET Q
q 0 0 0 rg BT 259.41 537.00 Td (fer; or) Tj ET Q
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 128.00 523.55 Td (o) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 133.50 523.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 523.55 Td (the decision to take such action was made before the announcement of the of) Tj ET Q
q 0 0 0 rg BT 514.65 523.55 Td (fer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 510.10 Td (and either has been at least partially implemented or is in the ordinary course of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 146.00 496.65 Td (business.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 473.20 Td (Rights ) Tj ET Q
q 0 0 0 rg BT 106.57 473.20 Td (Agreement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 449.80 Td (Our memorandum and articles of association expressly authorize the adoption of a shareholders�) Tj ET Q
q 0 0 0 rg BT 534.29 449.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 436.35 Td (rights plan. Irish law does not expressly authorize or prohibit companies from issuing share ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 422.90 Td (purchase rights or adopting a shareholder rights plan as an anti-takeover measure. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 399.45 Td (However) Tj ET Q
q 0 0 0 rg BT 115.50 399.45 Td (, there is no directly relevant case law on the validity of such plans under Irish law and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 386.00 Td (their interaction with the Irish ) Tj ET Q
q 0 0 0 rg BT 218.07 386.00 Td (T) Tj ET Q
q 0 0 0 rg BT 224.57 386.00 Td (akeover Rules and the General Principles underlying the Irish ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 372.60 Td (T) Tj ET Q
q 0 0 0 rg BT 78.49 372.60 Td (akeover Rules. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 349.15 Td (Subject to the Irish ) Tj ET Q
q 0 0 0 rg BT 165.77 349.15 Td (T) Tj ET Q
q 0 0 0 rg BT 172.26 349.15 Td (akeover Rules described above, our board of directors also has power to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 335.70 Td (issue any authorized and unissued shares on such terms and conditions as it may determine and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 322.25 Td (any such action should be taken in our best interests. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.80 Td (Duration; Dissolution; Rights upon Liquidation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 278.40 Td (Our duration is unlimited. ) Tj ET Q
q 0 0 0 rg BT 199.44 278.40 Td (W) Tj ET Q
q 0 0 0 rg BT 209.80 278.40 Td (e may be dissolved and wound up at any time by way of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 264.00 Td (shareholders�) Tj ET Q
q 0 0 0 rg BT 135.75 264.00 Td ( voluntary winding up or a creditors�) Tj ET Q
q 0 0 0 rg BT 311.48 264.00 Td ( winding up. In the case of a shareholders�) Tj ET Q
q 0 0 0 rg BT 514.20 264.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 249.60 Td (voluntary winding-up, a special resolution of shareholders is required. ) Tj ET Q
q 0 0 0 rg BT 411.36 249.60 Td (W) Tj ET Q
q 0 0 0 rg BT 421.73 249.60 Td (e may also be dissolved ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 235.20 Td (by way of court order on the application of a creditor) Tj ET Q
q 0 0 0 rg BT 326.09 235.20 Td (, or by the Companies Registration Of) Tj ET Q
q 0 0 0 rg BT 508.85 235.20 Td (fice as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 220.80 Td (an enforcement measure where we have failed to file certain returns. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 194.40 Td (The rights of the shareholders to a return of our assets on dissolution or winding up, following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 180.00 Td (the settlement of all claims of creditors are prescribed in our articles of association. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 156.60 Td (Acquisitions ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 133.15 Td (An Irish public limited company may be acquired in a number of ways, including: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 93.00 119.70 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 119.70 Td (a court-approved scheme of arrangement under the Companies ) Tj ET Q
q 0 0 0 rg BT 414.88 119.70 Td (Act. ) Tj ET Q
q 0 0 0 rg BT 437.55 119.70 Td (A) Tj ET Q
q 0 0 0 rg BT 445.55 119.70 Td ( scheme of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 106.25 Td (arrangement requires a court order from the Irish High Court and the approval of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 92.80 Td (majority in number representing 75% in value of the shareholders present and voting in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 79.40 Td (person or by proxy at a meeting called to approve the scheme;) Tj ET Q
endstream
endobj
307 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 308 0 R>>
endobj
308 0 obj
<</Length 7333>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 300.50 59.90 Td (12) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 93.00 711.70 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 711.70 Td (through a tender or takeover of) Tj ET Q
q 0 0 0 rg BT 259.72 711.70 Td (fer by a third party for all of our shares. ) Tj ET Q
q 0 0 0 rg BT 452.44 711.70 Td (Where the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 698.25 Td (holders of 80% or more of our Ordinary Shares have accepted an of) Tj ET Q
q 0 0 0 rg BT 436.00 698.25 Td (fer for their shares in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 684.80 Td (us, the remaining shareholders may also be statutorily required to transfer their shares. If ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 671.40 Td (the bidder does not exercise its �squeeze out� right, then the non-accepting shareholders ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 657.95 Td (also have a statutory right to require the bidder to acquire their shares on the same terms. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 644.50 Td (If our shares were to be listed on the Irish Stock Exchange or another regulated stock ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 631.05 Td (exchange in the European Union, this threshold would be increased to 90%; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 93.00 617.60 Td (� ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 617.60 Td (by way of a mer) Tj ET Q
q 0 0 0 rg BT 188.75 617.60 Td (ger with a company incorporated in the European Economic ) Tj ET Q
q 0 0 0 rg BT 480.32 617.60 Td (Area ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 604.20 Td (\(�EEA�\) under the EU Directive 2017/1) Tj ET Q
q 0 0 0 rg BT 303.48 604.20 Td (132 of the European Parliament and of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 590.75 Td (Council of 14 June 2017 as implemented in Ireland by the European Communities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 577.30 Td (\(Cross- Border Mer) Tj ET Q
q 0 0 0 rg BT 205.43 577.30 Td (gers\) Regulations 2008 \(as amended\) or with another Irish company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 563.85 Td (under the Companies ) Tj ET Q
q 0 0 0 rg BT 215.31 563.85 Td (Act. Such a mer) Tj ET Q
q 0 0 0 rg BT 292.41 563.85 Td (ger must be approved by a special resolution. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 550.40 Td (Shareholders also may be entitled to have their shares acquired for cash. See �Appraisal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 111.00 537.00 Td (Rights.�) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 513.55 Td (Irish law does not generally require shareholder approval for a sale, lease or exchange of all or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 500.10 Td (substantially all of a company�) Tj ET Q
q 0 0 0 rg BT 219.30 500.10 Td (s property and assets. ) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 476.65 Td (Appraisal Rights ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 453.20 Td (Generally) Tj ET Q
q 0 0 0 rg BT 118.53 453.20 Td (, under Irish law) Tj ET Q
q 0 0 0 rg BT 196.39 453.20 Td (, shareholders of an Irish company do not have dissenters�) Tj ET Q
q 0 0 0 rg BT 474.76 453.20 Td ( or appraisal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 439.80 Td (rights. If we are being mer) Tj ET Q
q 0 0 0 rg BT 199.07 439.80 Td (ged as the transferor company with an EEA) Tj ET Q
q 0 0 0 rg BT 408.00 439.80 Td ( company the EU Directive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 426.35 Td (2017/1) Tj ET Q
q 0 0 0 rg BT 104.89 426.35 Td (132 of the European Parliament and of the Council of 14 June 2017 as implemented in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 412.90 Td (Ireland by the European Communities \(Cross- Border Mer) Tj ET Q
q 0 0 0 rg BT 352.72 412.90 Td (gers\) Regulations 2008 \(as amended\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 399.45 Td (or if we are being mer) Tj ET Q
q 0 0 0 rg BT 178.07 399.45 Td (ged with another Irish company under the Irish Companies ) Tj ET Q
q 0 0 0 rg BT 463.00 399.45 Td (Act, \(i\)�any of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 386.00 Td (our shareholders who voted against the special resolution approving the transaction or \(ii\)�if 90% ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 372.60 Td (of our shares are held by the successor company) Tj ET Q
q 0 0 0 rg BT 303.14 372.60 Td (, any of our other shareholders, may be entitled ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 359.15 Td (to require that the successor company acquire its shares for cash at a price determined in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 345.70 Td (accordance with the share exchange ratio set out in the mer) Tj ET Q
q 0 0 0 rg BT 355.66 345.70 Td (ger agreement.) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 322.25 Td (Stock Exchange Listing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.80 Td (Our Ordinary Shares are traded on NASDAQ under the ticker symbol �ENDP) Tj ET Q
q 0 0 0 rg BT 445.58 298.80 Td (.�) Tj ET Q
BT /F4 12.00 Tf ET
q 0 0 0 rg BT 72.00 275.40 Td (T) Tj ET Q
q 0 0 0 rg BT 78.88 275.40 Td (ransfer and Registration of Shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 251.95 Td (An af) Tj ET Q
q 0 0 0 rg BT 98.77 251.95 Td (filiate of our transfer agent, Computershare Investor Services Inc., Computershare Investor ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 238.50 Td (Services \(Ireland\) Limited, maintains the share register) Tj ET Q
q 0 0 0 rg BT 335.75 238.50 Td (, registration in which will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 225.05 Td (determinative of membership in Endo. Each of our shareholders who holds shares beneficially ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 211.60 Td (will not be the holder of record of such shares. Instead, the depository or other nominee will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 198.20 Td (the holder of record of those shares. ) Tj ET Q
q 0 0 0 rg BT 246.61 198.20 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 305.81 198.20 Td (, a transfer of shares from a person who holds ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 184.75 Td (such shares beneficially to a person who also holds such shares beneficially through a depository ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 171.30 Td (or other nominee will not be registered in our of) Tj ET Q
q 0 0 0 rg BT 302.72 171.30 Td (ficial share register) Tj ET Q
q 0 0 0 rg BT 394.19 171.30 Td (, as the depository or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 157.85 Td (nominee will remain the record holder of any such shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 134.40 Td (A) Tj ET Q
q 0 0 0 rg BT 80.00 134.40 Td ( written instrument of transfer is required under Irish law in order to register on our of) Tj ET Q
q 0 0 0 rg BT 492.33 134.40 Td (ficial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 121.00 Td (share register any transfer of shares \(i\)�from a person who holds such shares directly to any other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 107.55 Td (person; \(ii\)�from a person who holds such shares beneficially to a person who holds such shares ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 94.10 Td (directly; or \(iii\)�from a person who holds such shares beneficially to another person who holds ) Tj ET Q
endstream
endobj
309 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 310 0 R>>
endobj
310 0 obj
<</Length 6223>>
stream
BT /F3 11.00 Tf ET
q 0 0 0 rg BT 300.50 59.90 Td (13) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (such shares beneficially where the transfer involves a change in the depository or other nominee ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 698.25 Td (that is the record owner of the transferred shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 674.80 Td (An instrument of transfer is also required for a shareholder who directly holds shares to transfer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 661.40 Td (those shares into his or her own broker account \(or vice versa\). Such instruments of transfer may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 647.95 Td (give rise to Irish stamp duty) Tj ET Q
q 0 0 0 rg BT 205.54 647.95 Td (, which must be paid prior to registration of the transfer on our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 634.50 Td (of) Tj ET Q
q 0 0 0 rg BT 81.78 634.50 Td (ficial Irish share register) Tj ET Q
q 0 0 0 rg BT 198.06 634.50 Td (. However) Tj ET Q
q 0 0 0 rg BT 247.56 634.50 Td (, a shareholder who directly holds shares may transfer those ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 621.05 Td (shares into his or her own broker account \(or vice versa\) without giving rise to Irish stamp duty) Tj ET Q
q 0 0 0 rg BT 528.78 621.05 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 607.60 Td (provided there is no change in the ultimate beneficial ownership of the shares as a result of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 594.20 Td (transfer and the transfer is not made in contemplation of a sale of the shares. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 570.75 Td (Any transfer of our Ordinary Shares that is subject to Irish stamp duty will not be registered in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 557.30 Td (the name of the buyer unless an instrument of transfer is duly stamped and provided to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 543.85 Td (transfer agent. Our articles of association allow us, in our absolute discretion, to create an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 530.40 Td (instrument of transfer and pay \(or procure the payment of\) any stamp duty) Tj ET Q
q 0 0 0 rg BT 427.78 530.40 Td (, which is the legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 517.00 Td (obligation of a buyer) Tj ET Q
q 0 0 0 rg BT 171.64 517.00 Td (. In the event of any such payment, we are \(on our own behalf or on behalf ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 503.55 Td (of our af) Tj ET Q
q 0 0 0 rg BT 113.10 503.55 Td (filiates\) entitled to \(i\)�seek reimbursement from the buyer or seller \(at our discretion\); ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 490.10 Td (\(ii\) set-of) Tj ET Q
q 0 0 0 rg BT 116.77 490.10 Td (f the amount of the stamp duty against future dividends payable to the buyer or seller ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 476.65 Td (\(at our discretion\); and \(iii\)�claim a lien against our Ordinary Shares on which we have paid ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 463.20 Td (stamp duty) Tj ET Q
q 0 0 0 rg BT 124.22 463.20 Td (. Parties to a share transfer may assume that any stamp duty arising in respect of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 449.80 Td (transaction in our Ordinary Shares has been paid unless one or both of such parties is otherwise ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 436.35 Td (notified by us.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 412.90 Td (Our memorandum and articles of association delegate to our secretary \(or duly appointed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 399.45 Td (nominee\) the authority to execute an instrument of transfer on behalf of a transferring party) Tj ET Q
q 0 0 0 rg BT 509.72 399.45 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 376.00 Td (In order to help ensure that the of) Tj ET Q
q 0 0 0 rg BT 232.06 376.00 Td (ficial share register is regularly updated to reflect trading of our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 362.60 Td (Ordinary Shares occurring through normal electronic systems, we intend to regularly produce ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 349.15 Td (any required instruments of transfer in connection with any transactions for which we pay stamp ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 335.70 Td (duty \(subject to the reimbursement and set-of) Tj ET Q
q 0 0 0 rg BT 289.72 335.70 Td (f rights described above\). In the event that we ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 322.25 Td (notify one or both of the parties to a share transfer that we believe stamp duty is required to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 308.80 Td (paid in connection with the transfer and that we will not pay the stamp duty) Tj ET Q
q 0 0 0 rg BT 433.80 308.80 Td (, the parties may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 295.40 Td (either themselves arrange for the execution of the required instrument of transfer \(and may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 281.95 Td (request a form of instrument of transfer from us for this purpose\) or request that we execute an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 268.50 Td (instrument of transfer on behalf of the transferring party in a form determined by us. In either ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 255.05 Td (event, if the parties to the share transfer have the instrument of transfer duly stamped \(to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 241.60 Td (extent required\) and then provide it to our transfer agent, the buyer will be registered as the legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 228.20 Td (owner of the relevant shares on our of) Tj ET Q
q 0 0 0 rg BT 254.05 228.20 Td (ficial Irish share register \(subject to the matters described ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 214.75 Td (below\). ) Tj ET Q
q 0 0 0 rg BT 111.11 214.75 Td (The directors may suspend registration of transfers from time to time, not exceeding 30 ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 201.30 Td (days in aggregate each year) Tj ET Q
q 0 0 0 rg BT 203.93 201.30 Td (.) Tj ET Q
endstream
endobj
311 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 312 0 R>>
endobj
312 0 obj
<</Length 8139>>
stream
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 462.95 771.40 Td (Exhibit 10.18.1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 409.85 711.90 Td (EXECUTION ) Tj ET Q
q 0 0 0 rg BT 485.31 711.90 Td (VERSION) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 216.20 654.80 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 283.42 654.80 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 191.20 626.20 Td (EXECUTIVE EMPLOYMENT) Tj ET Q
q 0 0 0 rg BT 344.63 626.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 346.97 626.20 Td (AGREEMENT) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 597.65 Td (THIS ) Tj ET Q
q 0 0 0 rg BT 137.00 597.65 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 210.78 597.65 Td ( \(this �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
243.439453125 596.050390625 m
296.748046875 596.050390625 l
s
q 0 0 0 rg BT 243.44 597.65 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.75 597.65 Td (�\) is hereby entered into as of February 19, 2020, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 581.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 81.11 581.10 Td (fective as of March 6, 2020 \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
243.041015625 579.500390625 m
312.4453125 579.500390625 l
s
q 0 0 0 rg BT 243.04 581.10 Td (Ef) Tj ET Q
q 0 0 0 rg BT 254.15 581.10 Td (fective Date) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 312.45 581.10 Td (�\), by and between Endo Health Solutions Inc. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 564.55 Td (\(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
98.982421875 562.950390625 m
145.646484375 562.950390625 l
s
q 0 0 0 rg BT 98.98 564.55 Td (Company) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 145.65 564.55 Td (�\), a wholly-owned subsidiary of Endo International plc \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
426.5625 562.950390625 m
451.892578125 562.950390625 l
s
q 0 0 0 rg BT 426.56 564.55 Td (Endo) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 451.89 564.55 Td (�\), and Blaise ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 548.00 Td (Coleman \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
127.646484375 546.400390625 m
175.623046875 546.400390625 l
s
q 0 0 0 rg BT 127.65 548.00 Td (Executive) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 175.62 548.00 Td (�\) \(hereinafter collectively referred to as �the parties�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 519.40 Td (In consideration of the respective agreements of the parties contained herein, it is agreed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 502.85 Td (as follows: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 474.30 Td (1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 474.30 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 472.700390625 m
133.1484375 472.700390625 l
s
q 0 0 0 rg BT 108.00 474.30 Td (T) Tj ET Q
q 0 0 0 rg BT 114.49 474.30 Td (erm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 133.15 474.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 138.93 474.30 Td (The term of this ) Tj ET Q
q 0 0 0 rg BT 218.25 474.30 Td (Agreement shall be for the period commencing on the Ef) Tj ET Q
q 0 0 0 rg BT 491.61 474.30 Td (fective ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 457.75 Td (Date and ending, subject to earlier termination as set forth in Section 7, on the third ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 441.20 Td (anniversary thereof \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
230.935546875 439.600390625 m
320.859375 439.600390625 l
s
q 0 0 0 rg BT 230.94 441.20 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 295.71 441.20 Td (T) Tj ET Q
q 0 0 0 rg BT 302.20 441.20 Td (erm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 320.86 441.20 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 412.60 Td (2.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 412.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 411.000390625 m
169.9921875 411.000390625 l
s
q 0 0 0 rg BT 108.00 412.60 Td (Employment) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 169.99 412.60 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 295.42 412.60 Td (T) Tj ET Q
q 0 0 0 rg BT 301.92 412.60 Td (erm:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 384.05 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 384.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 384.05 Td (Executive shall serve as President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 423.02 384.05 Td (ficer of Endo and shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 367.50 Td (be assigned with the customary duties and responsibilities of such position. In ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 350.95 Td (addition, as of the Ef) Tj ET Q
q 0 0 0 rg BT 244.09 350.95 Td (fective Date, Executive shall serve as a member of the board ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 334.40 Td (of directors of Endo \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
270.287109375 332.800390625 m
299.61328125 332.800390625 l
s
q 0 0 0 rg BT 270.29 334.40 Td (Board) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 299.61 334.40 Td (�\). For as long as Executive is the Chief ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 317.80 Td (Executive Of) Tj ET Q
q 0 0 0 rg BT 207.42 317.80 Td (ficer of Endo, Endo shall nominate Executive for re-election to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 301.25 Td (Board. ) Tj ET Q
q 0 0 0 rg BT 178.66 301.25 Td (At the time of Executive�) Tj ET Q
q 0 0 0 rg BT 299.96 301.25 Td (s termination of employment with the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 284.70 Td (for any reason, Executive shall resign from the Board and the board of directors ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 268.15 Td (of any of Endo�) Tj ET Q
q 0 0 0 rg BT 218.98 268.15 Td (s af) Tj ET Q
q 0 0 0 rg BT 235.76 268.15 Td (filiates. Executive shall not receive any compensation in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 251.60 Td (addition to the compensation described in Sections 3, 4 and 5 of this ) Tj ET Q
q 0 0 0 rg BT 473.95 251.60 Td (Agreement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 235.00 Td (for serving as a director of Endo or as a director or of) Tj ET Q
q 0 0 0 rg BT 399.69 235.00 Td (ficer of any of Endo�) Tj ET Q
q 0 0 0 rg BT 499.65 235.00 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 218.45 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 218.45 Td (filiates, but shall be covered under the indemnification and directors�) Tj ET Q
q 0 0 0 rg BT 483.43 218.45 Td ( and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 201.90 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 201.90 Td (ficers�) Tj ET Q
q 0 0 0 rg BT 183.53 201.90 Td ( liability insurance provisions of Section 15\(d\) for any such services.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 173.35 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 173.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 173.35 Td (Executive shall report directly to the Board. Executive shall perform the duties, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 156.80 Td (undertake the responsibilities and exercise the authority customarily performed, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 140.20 Td (undertaken and exercised by persons situated in a similar executive capacity) Tj ET Q
q 0 0 0 rg BT 509.08 140.20 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 111.65 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 111.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 111.65 Td (Executive shall devote substantially full-time attention to the business and af) Tj ET Q
q 0 0 0 rg BT 512.36 111.65 Td (fairs ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 95.10 Td (of the Company and its af) Tj ET Q
q 0 0 0 rg BT 268.09 95.10 Td (filiates. Executive may \(i\) serve on corporate, civic, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 78.55 Td (charitable or non-profit boards or committees, subject in all cases to the prior ) Tj ET Q
endstream
endobj
313 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 314 0 R>>
endobj
314 0 obj
<</Length 8544>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (approval of the Board and other applicable written policies of the Company and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (its af) Tj ET Q
q 0 0 0 rg BT 167.44 695.15 Td (filiates as in ef) Tj ET Q
q 0 0 0 rg BT 237.53 695.15 Td (fect from time to time, and \(ii\) manage personal and family ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (investments, participate in industry or) Tj ET Q
q 0 0 0 rg BT 325.41 678.60 Td (ganizations and deliver lectures at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (educational institutions or events, so long as no such service or activity ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (unreasonably interferes, individually or in the aggregate, with the performance of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 628.90 Td (s responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 325.95 628.90 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 600.35 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (Executive shall be subject to and shall abide by each of the personnel and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (compliance policies of the Company and its af) Tj ET Q
q 0 0 0 rg BT 366.72 583.80 Td (filiates applicable and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (communicated in writing to senior executives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 538.65 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 538.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (Executive shall provide services at the Company�) Tj ET Q
q 0 0 0 rg BT 381.26 538.65 Td (s U.S. headquarters in Malvern, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (Pennsylvania, and will travel to the Company�) Tj ET Q
q 0 0 0 rg BT 366.29 522.10 Td (s Chestnut Ridge, New ) Tj ET Q
q 0 0 0 rg BT 479.51 522.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 486.97 522.10 Td (ork ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (location and Endo�) Tj ET Q
q 0 0 0 rg BT 234.64 505.55 Td (s headquarters in Ireland to the extent reasonably necessary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (and appropriate to fulfill Executive�) Tj ET Q
q 0 0 0 rg BT 315.94 489.00 Td (s duties.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 460.40 Td (3.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 460.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 458.800390625 m
323.765625 458.800390625 l
s
q 0 0 0 rg BT 108.00 460.40 Td (Special Long-T) Tj ET Q
q 0 0 0 rg BT 182.14 460.40 Td (erm Incentive Compensation.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 323.77 460.40 Td (  On March 6, 2020 \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
447.732421875 458.800390625 m
500.70703125 458.800390625 l
s
q 0 0 0 rg BT 447.73 460.40 Td (Grant Date) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 500.71 460.40 Td (�\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 443.85 Td (Executive shall receive a grant of performance share units \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
416.51953125 442.250390625 m
474.861328125 442.250390625 l
s
q 0 0 0 rg BT 416.52 443.85 Td (Initial PSUs) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 474.86 443.85 Td (�\) under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 427.30 Td (Endo�) Tj ET Q
q 0 0 0 rg BT 136.66 427.30 Td (s ) Tj ET Q
q 0 0 0 rg BT 143.67 427.30 Td (Amended and Restated 2015 Stock Incentive Plan \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
414.263671875 425.700390625 m
435.59765625 425.700390625 l
s
q 0 0 0 rg BT 414.26 427.30 Td (Plan) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 435.60 427.30 Td (�\) with a tar) Tj ET Q
q 0 0 0 rg BT 493.02 427.30 Td (geted ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 410.75 Td (grant date fair market value equal to $2,000,000, with the number of such Initial PSUs as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 394.20 Td (determined by the Compensation Committee of the Board \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
416.255859375 392.600390625 m
469.58203125 392.600390625 l
s
q 0 0 0 rg BT 416.26 394.20 Td (Committee) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 469.58 394.20 Td (�\) in its good ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 377.60 Td (faith discretion \(rounded down to the nearest whole share\).  ) Tj ET Q
q 0 0 0 rg BT 396.69 377.60 Td (The Initial PSUs shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 361.05 Td (eligible to vest on the third anniversary of the grant date, provided Executive is then ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 344.50 Td (employed by the Company and subject to the achievement of the applicable performance ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 327.95 Td (goals, as determined by the Committee. On the Grant Date, Executive will also receive a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 311.40 Td (Long-T) Tj ET Q
q 0 0 0 rg BT 143.82 311.40 Td (erm Cash award \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
251.771484375 309.800390625 m
304.9921875 309.800390625 l
s
q 0 0 0 rg BT 251.77 311.40 Td (Initial L) Tj ET Q
q 0 0 0 rg BT 289.66 311.40 Td (TC) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 304.99 311.40 Td (�\) under the Plan, with a grant value equal to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.80 Td ($2,000,000.  ) Tj ET Q
q 0 0 0 rg BT 170.78 294.80 Td (The Initial L) Tj ET Q
q 0 0 0 rg BT 230.33 294.80 Td (TC award shall be eligible to vest ratably over a three-year ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 278.25 Td (period, at a rate of one-sixth of the total award on each 6-month anniversary of the Grant ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 261.70 Td (Date, provided Executive is employed in good standing on such dates by the Company) Tj ET Q
q 0 0 0 rg BT 523.80 261.70 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 245.15 Td (All such Initial PSUs and Initial L) Tj ET Q
q 0 0 0 rg BT 270.88 245.15 Td (TC shall be subject to the terms and conditions of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 228.60 Td (Plan and applicable award agreements.     ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 200.00 Td (4.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 200.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 198.400390625 m
215.654296875 198.400390625 l
s
q 0 0 0 rg BT 108.00 200.00 Td (Annual Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.65 200.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 171.45 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 171.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 169.85039062500005 m
200.5927734375 169.85039062500005 l
s
q 0 0 0 rg BT 144.00 171.45 Td (Base Salary) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 200.20 171.45 Td (. ) Tj ET Q
q 0 0 0 rg BT 205.99 171.45 Td (The Company agrees to pay or cause to be paid to Executive during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 154.90 Td (the Employment ) Tj ET Q
q 0 0 0 rg BT 226.44 154.90 Td (T) Tj ET Q
q 0 0 0 rg BT 232.93 154.90 Td (erm a base salary at the rate of $850,000 per annum or such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 138.35 Td (increased amount in accordance with this Section 4\(a\) \(hereinafter referred to as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
166.986328125 120.20039062499995 m
223.96875 120.20039062499995 l
s
q 0 0 0 rg BT 166.99 121.80 Td (Base Salary) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 223.97 121.80 Td (�\). Such Base Salary shall be payable in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 105.20 Td (s customary practices applicable to its executives. Such Base Salary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (shall be reviewed at least annually by the Committee, with the first such planned ) Tj ET Q
endstream
endobj
315 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 316 0 R>>
endobj
316 0 obj
<</Length 7962>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (3) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (review to occur in February 2021, and may be increased in the sole discretion of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (the Committee, but not decreased.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 665.000390625 m
299.296875 665.000390625 l
s
q 0 0 0 rg BT 144.00 666.60 Td (Annual Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 299.30 666.60 Td (. For each fiscal year of the Company ending ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 260.77 650.00 Td (T) Tj ET Q
q 0 0 0 rg BT 267.26 650.00 Td (erm, ef) Tj ET Q
q 0 0 0 rg BT 301.02 650.00 Td (fective as of the 2020 fiscal year) Tj ET Q
q 0 0 0 rg BT 456.47 650.00 Td (, Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (be eligible to receive a tar) Tj ET Q
q 0 0 0 rg BT 268.05 633.45 Td (get annual cash bonus of 100% of Executive�) Tj ET Q
q 0 0 0 rg BT 484.99 633.45 Td (s Base ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (Salary \(such tar) Tj ET Q
q 0 0 0 rg BT 219.09 616.90 Td (get bonus, as may hereafter be increased, the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
442.318359375 615.300390625 m
506.25 615.300390625 l
s
q 0 0 0 rg BT 442.32 616.90 Td (T) Tj ET Q
q 0 0 0 rg BT 448.81 616.90 Td (ar) Tj ET Q
q 0 0 0 rg BT 457.92 616.90 Td (get Bonus) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 506.25 616.90 Td (�\) with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (the opportunity to receive a maximum annual cash bonus in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (terms of the applicable annual cash bonus plan as in ef) Tj ET Q
q 0 0 0 rg BT 405.70 583.80 Td (fect from time to time, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (subject to the achievement of performance tar) Tj ET Q
q 0 0 0 rg BT 363.68 567.20 Td (gets set by the Committee. Such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (annual cash bonus \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
244.30078125 549.050390625 m
361.271484375 549.050390625 l
s
q 0 0 0 rg BT 244.30 550.65 Td (Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 361.27 550.65 Td (�\) shall be paid in no event later than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (the 15th day of the third month following the end of the taxable year \(of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (Company or Executive, whichever is later\) in which the performance tar) Tj ET Q
q 0 0 0 rg BT 491.31 517.55 Td (gets have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (been achieved.  If the parties \(following good faith negotiation\) fail to enter into a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (new employment agreement following expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 479.70 484.40 Td (T) Tj ET Q
q 0 0 0 rg BT 486.19 484.40 Td (erm and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (Executive terminates Executive�) Tj ET Q
q 0 0 0 rg BT 299.27 467.85 Td (s employment within ninety \(90\) days following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 291.08 451.30 Td (T) Tj ET Q
q 0 0 0 rg BT 297.57 451.30 Td (erm under circumstances that would have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (constituted Good Reason had such termination occurred during the Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 418.20 Td (erm or if, during such 90-day period, the Company terminates Executive�) Tj ET Q
q 0 0 0 rg BT 502.39 418.20 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (employment under circumstances that would not have constituted Cause had such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (termination occurred during the Employment ) Tj ET Q
q 0 0 0 rg BT 364.05 385.05 Td (T) Tj ET Q
q 0 0 0 rg BT 370.55 385.05 Td (erm, then the Company shall pay ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (Executive a Pro-Rata Bonus \(as defined in Section 9\(b\)\(ii\) below\) in a lump sum ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (at the time bonuses are payable to other senior executives of the Company) Tj ET Q
q 0 0 0 rg BT 499.78 351.95 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 323.40 Td (5.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 323.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 321.800390625 m
282.4453125 321.800390625 l
s
q 0 0 0 rg BT 108.00 323.40 Td (Long-T) Tj ET Q
q 0 0 0 rg BT 143.82 323.40 Td (erm Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 282.45 323.40 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 407.88 323.40 Td (T) Tj ET Q
q 0 0 0 rg BT 414.37 323.40 Td (erm and beginning with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 306.80 Td (grants made in 2021, Executive shall be eligible to receive long-term incentive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 290.25 Td (compensation to be awarded, in the sole discretion of the Committee \(at a level ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 273.70 Td (commensurate with his position as Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 370.06 273.70 Td (ficer) Tj ET Q
q 0 0 0 rg BT 391.56 273.70 Td (, as compared to other senior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 257.15 Td (executives of the Company\), which may be subject to the achievement of certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 240.60 Td (performance tar) Tj ET Q
q 0 0 0 rg BT 184.07 240.60 Td (gets set by the Committee. Notwithstanding the foregoing, to the extent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 224.00 Td (the shares available under the Company�) Tj ET Q
q 0 0 0 rg BT 302.94 224.00 Td (s shareholder approved incentive plans are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 207.45 Td (insuf) Tj ET Q
q 0 0 0 rg BT 131.78 207.45 Td (ficient to make such grant \(after taking into account the totality of grants to be made ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 190.90 Td (by the Company in a given year\), in the Committee�) Tj ET Q
q 0 0 0 rg BT 357.94 190.90 Td (s sole discretion, all or a portion of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 174.35 Td (the long-term incentive compensation may be issued in the form of a cash-based award ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 157.80 Td (on terms determined by the Committee.  ) Tj ET Q
q 0 0 0 rg BT 303.96 157.80 Td (All such equity-based or cash-based awards shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 141.20 Td (be subject to the terms and conditions set forth in the applicable plan and award ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 124.65 Td (agreements, and in all cases shall be as determined by the Committee; provided, that, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 108.10 Td (such terms and conditions shall be no less favorable than those provided for other senior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 91.55 Td (executives of the Company) Tj ET Q
q 0 0 0 rg BT 238.18 91.55 Td (.  If the parties \(following good faith negotiation\) fail to enter ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 75.00 Td (into a new employment agreement following expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 473.69 75.00 Td (T) Tj ET Q
q 0 0 0 rg BT 480.18 75.00 Td (erm and ) Tj ET Q
endstream
endobj
317 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 318 0 R>>
endobj
318 0 obj
<</Length 7359>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (4) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (Executive terminates Executive�) Tj ET Q
q 0 0 0 rg BT 263.27 711.70 Td (s employment within ninety \(90\) days following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 695.15 Td (expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 255.08 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 261.57 695.15 Td (erm under circumstances that would have constituted ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 678.60 Td (Good Reason had such termination occurred during the Employment ) Tj ET Q
q 0 0 0 rg BT 441.37 678.60 Td (T) Tj ET Q
q 0 0 0 rg BT 447.86 678.60 Td (erm or if, during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 662.00 Td (such 90-day period, the Company terminates Executive�) Tj ET Q
q 0 0 0 rg BT 377.59 662.00 Td (s employment under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 645.45 Td (circumstances that would not have constituted Cause had such termination occurred ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 628.90 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 224.77 628.90 Td (T) Tj ET Q
q 0 0 0 rg BT 231.26 628.90 Td (erm, then such termination of employment shall be treated as a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 612.35 Td (termination of employment for �Good Reason� or without Cause, as applicable, for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 595.80 Td (purposes of the performance share units held by Executive as of the date of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 579.20 Td (termination of employment \(and such awards shall be treated in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 562.65 Td (terms of the applicable award agreements\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 534.10 Td (6.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 534.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 532.500390625 m
178.3125 532.500390625 l
s
q 0 0 0 rg BT 108.00 534.10 Td (Other Benefits) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 178.31 534.10 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 505.55 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 505.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 503.950390625 m
235.640625 503.950390625 l
s
q 0 0 0 rg BT 144.00 505.55 Td (Employee Benefits) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 235.64 505.55 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 361.07 505.55 Td (T) Tj ET Q
q 0 0 0 rg BT 367.56 505.55 Td (erm, Executive shall be entitled to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (participate in all employee benefit plans, practices and programs maintained by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (the Company or its af) Tj ET Q
q 0 0 0 rg BT 247.76 472.40 Td (filiates and made available to similarly situated employees ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (generally) Tj ET Q
q 0 0 0 rg BT 187.86 455.85 Td (, including all pension, retirement, profit sharing, savings, medical, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (hospitalization, disability) Tj ET Q
q 0 0 0 rg BT 264.54 439.30 Td (, dental, life or travel accident insurance benefit plans, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (the extent Executive is eligible under the terms of such plans. Executive�) Tj ET Q
q 0 0 0 rg BT 493.22 422.75 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (participation in such plans, practices and programs shall be on the same basis and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (terms as are applicable to employees of the Company generally) Tj ET Q
q 0 0 0 rg BT 447.45 389.60 Td (.  During the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 373.05 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 373.05 Td (erm, Executive shall also be entitled to participate in all executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (benefit plans and entitled to all fringe benefits and perquisites generally made ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (available by the Company or its af) Tj ET Q
q 0 0 0 rg BT 309.07 339.95 Td (filiates to its senior executives in accordance ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (with current Company policy now maintained or hereafter established by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (Company or its af) Tj ET Q
q 0 0 0 rg BT 230.10 306.80 Td (filiates for the purpose of providing executive benefits or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 290.25 Td (perquisites to comparable executive employees of the Company including, but not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 273.70 Td (limited to, the Company�) Tj ET Q
q 0 0 0 rg BT 263.99 273.70 Td (s supplemental retirement, deferred compensation, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 257.15 Td (supplemental medical or life insurance plans. Unless otherwise provided herein, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 240.60 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 240.60 Td (s participation in such plans and programs shall be on the same basis ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 224.00 Td (and terms as other senior executives of the Company) Tj ET Q
q 0 0 0 rg BT 397.15 224.00 Td (. No additional compensation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (provided under any of such plans shall be deemed to modify or otherwise af) Tj ET Q
q 0 0 0 rg BT 508.68 207.45 Td (fect ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 190.90 Td (the terms of this ) Tj ET Q
q 0 0 0 rg BT 223.99 190.90 Td (Agreement or any of Executive�) Tj ET Q
q 0 0 0 rg BT 377.93 190.90 Td (s entitlements hereunder) Tj ET Q
q 0 0 0 rg BT 494.56 190.90 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 174.35 Td (Executive is responsible for any taxes \(other than taxes that are the Company�) Tj ET Q
q 0 0 0 rg BT 517.88 174.35 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 157.80 Td (responsibility\) that may be due based upon the value of the benefits or perquisites ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 141.20 Td (provided pursuant to this ) Tj ET Q
q 0 0 0 rg BT 265.99 141.20 Td (Agreement whether provided during or following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 124.65 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 124.65 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 124.65 Td (erm.  For the avoidance of doubt, Executive shall not be entitled to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 108.10 Td (any excise tax gross-up under Section 280G or Section 4999 of the Internal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 91.55 Td (Revenue Code of 1986, as amended \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
346.599609375 89.95039062499995 m
371.9296875 89.95039062499995 l
s
q 0 0 0 rg BT 346.60 91.55 Td (Code) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 371.93 91.55 Td (�\) \(or any successor provision\), or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 75.00 Td (any other tax gross-up.) Tj ET Q
endstream
endobj
319 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 320 0 R>>
endobj
320 0 obj
<</Length 8706>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (5) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
234.99609375 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Business Expenses) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 235.00 711.70 Td (. Upon submission of proper invoices in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 695.15 Td (s normal procedures, Executive shall be entitled to receive prompt ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (reimbursement of all reasonable out-of-pocket business, entertainment and travel ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (expenses \(including travel in first-class\) incurred by Executive in connection with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 289.59 645.45 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 376.24 645.45 Td (. Such reimbursement shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (made in no event later than the end of the calendar year following the calendar ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (year in which the expenses were incurred.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 582.200390625 m
241.74609375 582.200390625 l
s
q 0 0 0 rg BT 144.00 583.80 Td (Of) Tj ET Q
q 0 0 0 rg BT 156.45 583.80 Td (fice and Facilities) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 241.75 583.80 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 367.18 583.80 Td (T) Tj ET Q
q 0 0 0 rg BT 373.67 583.80 Td (erm, Executive shall be provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (with appropriate of) Tj ET Q
q 0 0 0 rg BT 235.75 567.20 Td (fices at the Company�) Tj ET Q
q 0 0 0 rg BT 340.72 567.20 Td (s U.S. headquarters in Malvern, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (Pennsylvania and the Company�) Tj ET Q
q 0 0 0 rg BT 298.97 550.65 Td (s Chestnut Ridge, New ) Tj ET Q
q 0 0 0 rg BT 412.19 550.65 Td (Y) Tj ET Q
q 0 0 0 rg BT 419.65 550.65 Td (ork location, with such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (secretarial and other support facilities as are commensurate with Executive�) Tj ET Q
q 0 0 0 rg BT 506.85 534.10 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (status with the Company and its af) Tj ET Q
q 0 0 0 rg BT 309.76 517.55 Td (filiates, which facilities shall be adequate for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 289.59 501.00 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 376.24 501.00 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 472.40 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 472.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 470.800390625 m
262.951171875 470.800390625 l
s
q 0 0 0 rg BT 144.00 472.40 Td (V) Tj ET Q
q 0 0 0 rg BT 151.34 472.40 Td (acation and Sick Leave) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 262.95 472.40 Td (. Executive shall be entitled, without loss of pay) Tj ET Q
q 0 0 0 rg BT 492.79 472.40 Td (, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (absent himself voluntarily from the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 444.23 455.85 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 439.30 Td (Agreement, pursuant to the following:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 410.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 410.75 Td (Executive shall be entitled to annual vacation in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 394.20 Td (vacation policies of the Company as in ef) Tj ET Q
q 0 0 0 rg BT 378.73 394.20 Td (fect from time to time, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 377.60 Td (shall in no event be less than four weeks per year; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 349.05 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 349.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 349.05 Td (Executive shall be entitled to sick leave \(without loss of pay\) in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 332.50 Td (accordance with the Company�) Tj ET Q
q 0 0 0 rg BT 328.95 332.50 Td (s policies as in ef) Tj ET Q
q 0 0 0 rg BT 411.38 332.50 Td (fect from time to time.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 303.95 Td (7.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 303.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 302.350390625 m
166.4765625 302.350390625 l
s
q 0 0 0 rg BT 108.00 303.95 Td (T) Tj ET Q
q 0 0 0 rg BT 114.49 303.95 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 166.48 303.95 Td (. ) Tj ET Q
q 0 0 0 rg BT 172.26 303.95 Td (The Employment ) Tj ET Q
q 0 0 0 rg BT 258.69 303.95 Td (T) Tj ET Q
q 0 0 0 rg BT 265.18 303.95 Td (erm and Executive�) Tj ET Q
q 0 0 0 rg BT 358.48 303.95 Td (s employment hereunder may be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 287.40 Td (terminated under the circumstances set forth below; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
359.578125 285.800390625 m
402.234375 285.800390625 l
s
q 0 0 0 rg BT 359.58 287.40 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 402.23 287.40 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
408.234375 285.800390625 m
449.30859375 285.800390625 l
s
q 0 0 0 rg BT 408.23 287.40 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 449.07 287.40 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 270.80 Td (notwithstanding anything contained herein to the contrary) Tj ET Q
q 0 0 0 rg BT 385.15 270.80 Td (, Executive shall not be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 254.25 Td (considered to have terminated employment with the Company for purposes of this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 237.70 Td (Agreement unless Executive would be considered to have incurred a �separation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 221.15 Td (service� from the Company within the meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 417.60 221.15 Td ( of the Code.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 192.60 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 192.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 191.00039062500002 m
190.9423828125 191.00039062500002 l
s
q 0 0 0 rg BT 144.00 192.60 Td (Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 190.55 192.60 Td (. ) Tj ET Q
q 0 0 0 rg BT 196.34 192.60 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 390.94 192.60 Td (s employment, on written ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 176.00 Td (notice to Executive after having reasonably established Executive�) Tj ET Q
q 0 0 0 rg BT 462.88 176.00 Td (s Disability) Tj ET Q
q 0 0 0 rg BT 517.10 176.00 Td (. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 159.45 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 222.33 159.45 Td (Agreement, Executive will be deemed to have a �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
460.564453125 157.85039062500005 m
507.896484375 157.85039062500005 l
s
q 0 0 0 rg BT 460.56 159.45 Td (Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 507.90 159.45 Td (� if, as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 142.90 Td (a result of any medically determinable physical or mental impairment that can be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 126.35 Td (expected to result in death or can be expected to last for a continuous period of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 109.80 Td (not less than twelve \(12\) months, Executive is unable to perform the core ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 93.20 Td (functions of Executive�) Tj ET Q
q 0 0 0 rg BT 255.97 93.20 Td (s position \(with or without reasonable accommodation\) or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 76.65 Td (is receiving income replacement benefits for a period of six \(6\) months or more ) Tj ET Q
endstream
endobj
321 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 322 0 R>>
endobj
322 0 obj
<</Length 7774>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (6) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (under the Company�) Tj ET Q
q 0 0 0 rg BT 241.98 711.70 Td (s long-term disability plan. Executive shall be entitled to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (compensation and benefits provided for under this ) Tj ET Q
q 0 0 0 rg BT 387.61 695.15 Td (Agreement for any period prior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (to Executive�) Tj ET Q
q 0 0 0 rg BT 207.64 678.60 Td (s termination by reason of Disability during which Executive is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (unable to work due to a physical or mental infirmity in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 645.45 Td (s policies for similarly situated executives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 616.90 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 616.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 615.300390625 m
172.65234375 615.300390625 l
s
q 0 0 0 rg BT 144.00 616.90 Td (Death) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 172.65 616.90 Td (. Executive�) Tj ET Q
q 0 0 0 rg BT 229.96 616.90 Td (s employment shall be terminated as of the date of Executive�) Tj ET Q
q 0 0 0 rg BT 525.87 616.90 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (death.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 571.80 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 571.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 570.200390625 m
173.326171875 570.200390625 l
s
q 0 0 0 rg BT 144.00 571.80 Td (Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 173.33 571.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 179.11 571.80 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 373.71 571.80 Td (s employment for Cause \(as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 555.20 Td (defined below\), ef) Tj ET Q
q 0 0 0 rg BT 231.41 555.20 Td (fective as of the date of the Notice of ) Tj ET Q
q 0 0 0 rg BT 412.11 555.20 Td (T) Tj ET Q
q 0 0 0 rg BT 418.61 555.20 Td (ermination \(as defined in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (Section 8 below\) that notifies Executive of Executive�) Tj ET Q
q 0 0 0 rg BT 403.59 538.65 Td (s termination for Cause and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (as evidenced by a resolution adopted by two-thirds of the independent members ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (of the Board. �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
215.30859375 503.950390625 m
244.634765625 503.950390625 l
s
q 0 0 0 rg BT 215.31 505.55 Td (Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 244.63 505.55 Td (� shall mean, for purposes of this ) Tj ET Q
q 0 0 0 rg BT 405.94 505.55 Td (Agreement: \(i\) the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (continued failure by Executive to use good faith ef) Tj ET Q
q 0 0 0 rg BT 387.04 489.00 Td (forts in the performance of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 472.40 Td (s duties under this ) Tj ET Q
q 0 0 0 rg BT 284.64 472.40 Td (Agreement \(other than any such failure resulting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (from Disability) Tj ET Q
q 0 0 0 rg BT 216.88 455.85 Td (, illness or other allowable leave of absence\); \(ii\) the criminal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (felony indictment \(or non-U.S. equivalent\) of Executive by a court of competent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (jurisdiction; \(iii\) the engagement by Executive in misconduct that has caused, or) Tj ET Q
q 0 0 0 rg BT 529.41 422.75 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (is reasonably likely to cause, material harm \(financial or otherwise\) to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (Company) Tj ET Q
q 0 0 0 rg BT 189.88 389.60 Td (, including \(A\) the unauthorized disclosure of material secret or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (Confidential Information \(as defined in Section 1) Tj ET Q
q 0 0 0 rg BT 380.16 373.05 Td (1\(d\) below\) of the Company) Tj ET Q
q 0 0 0 rg BT 516.02 373.05 Td (, \(B\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (the debarment of the Company by the U.S. Food and Drug ) Tj ET Q
q 0 0 0 rg BT 427.62 356.50 Td (Administration or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (successor agency \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
256.9453125 338.350390625 m
280.951171875 338.350390625 l
s
q 0 0 0 rg BT 256.95 339.95 Td (FDA) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 280.95 339.95 Td (�\) or any non-U.S. equivalent, or \(C\) the registration ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (of the Company with the U.S. Drug Enforcement ) Tj ET Q
q 0 0 0 rg BT 382.62 323.40 Td (Administration of any successor ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (agency \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
207.9609375 305.200390625 m
232.623046875 305.200390625 l
s
q 0 0 0 rg BT 207.96 306.80 Td (DEA) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 232.62 306.80 Td (�\) being revoked; \(iv\) the debarment of Executive by the FDA; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 290.25 Td (\(v\) the continued material breach by Executive of this ) Tj ET Q
q 0 0 0 rg BT 404.91 290.25 Td (Agreement; \(vi\) any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 273.70 Td (material breach by Executive of a Company policy; \(vii\) any material breach by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 257.15 Td (Executive of a Company policy related to sexual or other types of harassment or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 240.60 Td (abusive conduct, which breach is injurious to the Company; or \(viii\) Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 224.00 Td (making, or being found to have made, a certification relating to the Company�) Tj ET Q
q 0 0 0 rg BT 518.55 224.00 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (financial statements and public filings that is known to Executive to be false. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 190.90 Td (Notwithstanding the foregoing, prior to having Cause for Executive�) Tj ET Q
q 0 0 0 rg BT 472.26 190.90 Td (s termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 174.35 Td (\(other than as described in clauses \(ii\) , \(iv\) and \(vii\) above\), the Company must ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 157.80 Td (deliver a written demand to Executive which specifically identifies the conduct ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 141.20 Td (that may provide grounds for Cause within ninety \(90\) calendar days of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 124.65 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 124.65 Td (s actual knowledge of such conduct, events or circumstances.  During ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 108.10 Td (the thirty \(30\) day period after receipt of such demand, Executive shall have an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 91.55 Td (opportunity to cure or remedy such conduct, events or circumstances and present ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 75.00 Td (his case to the full Board \(with the assistance of counsel chosen by Executive\) ) Tj ET Q
endstream
endobj
323 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 324 0 R>>
endobj
324 0 obj
<</Length 7170>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (7) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (before any termination for Cause is finalized by a vote by at least two-thirds of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (the independent members of the Board at a meeting of the Board called and held ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (for such purpose. References to the Company in subsections \(i\) through \(viii\) of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (this paragraph shall also include af) Tj ET Q
q 0 0 0 rg BT 310.73 662.00 Td (filiates of the Company) Tj ET Q
q 0 0 0 rg BT 422.92 662.00 Td (.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 633.45 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 633.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 631.850390625 m
215.173828125 631.850390625 l
s
q 0 0 0 rg BT 144.00 633.45 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 633.45 Td (ithout Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.17 633.45 Td (. ) Tj ET Q
q 0 0 0 rg BT 220.96 633.45 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 415.56 633.45 Td (s employment without ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (Cause. ) Tj ET Q
q 0 0 0 rg BT 179.11 616.90 Td (The Company shall deliver to Executive a Notice of ) Tj ET Q
q 0 0 0 rg BT 431.81 616.90 Td (T) Tj ET Q
q 0 0 0 rg BT 438.30 616.90 Td (ermination \(as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (defined in Section 8 below\) not less than thirty \(30\) days prior to the termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (of Executive�) Tj ET Q
q 0 0 0 rg BT 208.31 583.80 Td (s employment without Cause and the Company shall have the option ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 266.63 567.20 Td (s duties and responsibilities prior to the expiration of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (such thirty-day notice period, provided the Company pays Base Salary through ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (the end of such notice period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 505.55 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 505.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 503.950390625 m
208.9921875 503.950390625 l
s
q 0 0 0 rg BT 144.00 505.55 Td (Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 208.99 505.55 Td (. Executive may terminate employment with the Company for Good ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (Reason \(as defined below\) by delivering to the Company a Notice of ) Tj ET Q
q 0 0 0 rg BT 477.02 489.00 Td (T) Tj ET Q
q 0 0 0 rg BT 483.52 489.00 Td (ermination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (not less than thirty \(30\) days prior to the termination of Executive�) Tj ET Q
q 0 0 0 rg BT 462.93 472.40 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (for Good Reason. ) Tj ET Q
q 0 0 0 rg BT 231.77 455.85 Td (The Company shall have the option of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 528.36 455.85 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (duties and responsibilities prior to the expiration of such thirty-day notice period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (provided the Company pays Base Salary through the end of such notice period. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (For purposes of this ) Tj ET Q
q 0 0 0 rg BT 242.00 406.20 Td (Agreement, �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
306.638671875 404.600390625 m
371.630859375 404.600390625 l
s
q 0 0 0 rg BT 306.64 406.20 Td (Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 371.63 406.20 Td (� means any of the following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (without Executive�) Tj ET Q
q 0 0 0 rg BT 234.98 389.60 Td (s written consent: \(i\) a diminution in Executive�) Tj ET Q
q 0 0 0 rg BT 464.60 389.60 Td (s Base Salary) Tj ET Q
q 0 0 0 rg BT 528.47 389.60 Td (, a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (material diminution in ) Tj ET Q
q 0 0 0 rg BT 254.10 373.05 Td (T) Tj ET Q
q 0 0 0 rg BT 260.59 373.05 Td (ar) Tj ET Q
q 0 0 0 rg BT 269.70 373.05 Td (get Bonus \(provided that failure to earn a bonus equal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (to or in excess of the ) Tj ET Q
q 0 0 0 rg BT 246.42 356.50 Td (T) Tj ET Q
q 0 0 0 rg BT 252.91 356.50 Td (ar) Tj ET Q
q 0 0 0 rg BT 262.02 356.50 Td (get Bonus by reason of failure to achieve applicable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (performance goals shall not be deemed Good Reason\) or material diminution in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (benefits; \(ii\) a material diminution of Executive�) Tj ET Q
q 0 0 0 rg BT 376.59 323.40 Td (s position, responsibilities, duties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (or authorities from those in ef) Tj ET Q
q 0 0 0 rg BT 286.75 306.80 Td (fect as of the Ef) Tj ET Q
q 0 0 0 rg BT 362.49 306.80 Td (fective Date; \(iii\) any change in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 290.25 Td (reporting structure such that Executive is required to report to someone other than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 273.70 Td (the Board; \(iv\) any material breach by the Company of its obligations under this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 257.15 Td (Agreement \(including the material failure to pay any amounts due hereunder ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 240.60 Td (when due or the failure of the Company to abide by the requirements of Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 224.00 Td (15\(a\)\(i\) below with respect to successors or permitted assigns\); or \(v\) the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (Company requiring Executive to be based at any of) Tj ET Q
q 0 0 0 rg BT 390.38 207.45 Td (fice or location that increases ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 190.90 Td (the length of Executive�) Tj ET Q
q 0 0 0 rg BT 258.96 190.90 Td (s commute by more than fifty \(50\) miles.  Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 174.35 Td (provide notice of the existence of the Good Reason condition within ninety \(90\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 157.80 Td (days of the date Executive learns of the condition, and the Company shall have a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 141.20 Td (period of thirty \(30\) days during which it may remedy the condition, and in case ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 124.65 Td (of full remedy such condition shall not be deemed to constitute Good Reason ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 108.10 Td (hereunder) Tj ET Q
q 0 0 0 rg BT 191.31 108.10 Td (. ) Tj ET Q
endstream
endobj
325 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 326 0 R>>
endobj
326 0 obj
<</Length 7379>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (8) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
250.83984375 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 711.70 Td (ithout Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 250.84 711.70 Td (. Executive may voluntarily terminate Executive�) Tj ET Q
q 0 0 0 rg BT 486.76 711.70 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (employment without Good Reason by delivering to the Company a Notice of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 678.60 Td (ermination not less than thirty \(30\) days prior to the termination of Executive�) Tj ET Q
q 0 0 0 rg BT 524.40 678.60 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (employment and the Company shall have the option of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 519.91 662.00 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (duties and responsibilities prior to the expiration of such thirty-day notice period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (provided the Company shall not be obligated to pay any amount through the end ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (of such notice period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 583.80 Td (8.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 582.200390625 m
214.2421875 582.200390625 l
s
q 0 0 0 rg BT 108.00 583.80 Td (Notice of ) Tj ET Q
q 0 0 0 rg BT 155.77 583.80 Td (T) Tj ET Q
q 0 0 0 rg BT 162.26 583.80 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 214.24 583.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 219.58 583.80 Td (Any purported termination by the Company or by Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 567.20 Td (be communicated by written Notice of ) Tj ET Q
q 0 0 0 rg BT 295.72 567.20 Td (T) Tj ET Q
q 0 0 0 rg BT 302.21 567.20 Td (ermination to the other party hereto. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 550.65 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 186.33 550.65 Td (Agreement, a �Notice of ) Tj ET Q
q 0 0 0 rg BT 307.06 550.65 Td (T) Tj ET Q
q 0 0 0 rg BT 313.55 550.65 Td (ermination� shall mean a notice that indicates ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 534.10 Td (a termination date, the specific termination provision in this ) Tj ET Q
q 0 0 0 rg BT 397.27 534.10 Td (Agreement relied upon and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (sets forth in reasonable detail the facts and circumstances claimed to provide a basis for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 501.00 Td (termination of Executive�) Tj ET Q
q 0 0 0 rg BT 230.63 501.00 Td (s employment under the provision so indicated. For purposes of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 484.40 Td (this ) Tj ET Q
q 0 0 0 rg BT 127.68 484.40 Td (Agreement, no such purported termination of Executive�) Tj ET Q
q 0 0 0 rg BT 399.26 484.40 Td (s employment hereunder ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 467.85 Td (shall be ef) Tj ET Q
q 0 0 0 rg BT 157.10 467.85 Td (fective without such Notice of ) Tj ET Q
q 0 0 0 rg BT 305.17 467.85 Td (T) Tj ET Q
q 0 0 0 rg BT 311.66 467.85 Td (ermination \(unless waived by the party entitled ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 451.30 Td (to receive such notice\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 422.75 Td (9.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 422.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 421.150390625 m
268.25390625 421.150390625 l
s
q 0 0 0 rg BT 108.00 422.75 Td (Compensation Upon ) Tj ET Q
q 0 0 0 rg BT 209.78 422.75 Td (T) Tj ET Q
q 0 0 0 rg BT 216.27 422.75 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 268.25 422.75 Td (. Upon termination of Executive�) Tj ET Q
q 0 0 0 rg BT 426.54 422.75 Td (s employment during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 406.20 Td (the Employment ) Tj ET Q
q 0 0 0 rg BT 190.44 406.20 Td (T) Tj ET Q
q 0 0 0 rg BT 196.93 406.20 Td (erm, Executive shall be entitled to the following benefits:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 377.60 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 377.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 376.000390625 m
522.71484375 376.000390625 l
s
q 0 0 0 rg BT 144.00 377.60 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 377.60 Td (ermination by the Company for Cause or by Executive ) Tj ET Q
q 0 0 0 rg BT 415.88 377.60 Td (W) Tj ET Q
q 0 0 0 rg BT 426.72 377.60 Td (ithout Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 522.71 377.60 Td (. If ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 361.05 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 361.05 Td (s employment is terminated by the Company for Cause or by Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (without Good Reason, the Company shall pay Executive: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 315.95 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 315.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 315.95 Td (any accrued and unpaid Base Salary) Tj ET Q
q 0 0 0 rg BT 352.82 315.95 Td (, payable on the next payroll date; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 287.40 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 287.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 287.40 Td (any Incentive Compensation earned but unpaid in respect of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 270.80 Td (completed fiscal year preceding the termination date, payable at the time ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 254.25 Td (annual incentive compensation is paid to other senior executives; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 225.70 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 225.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 225.70 Td (reimbursement for any and all monies advanced or expenses incurred in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 209.15 Td (connection with Executive�) Tj ET Q
q 0 0 0 rg BT 311.29 209.15 Td (s employment for reasonable and necessary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 192.60 Td (expenses incurred by Executive on behalf of the Company for the period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 176.00 Td (ending on the termination date, which amount shall be reimbursed within ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 159.45 Td (thirty \(30\) days of the Company�) Tj ET Q
q 0 0 0 rg BT 337.64 159.45 Td (s receipt of proper documentation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 142.90 Td (Executive; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 114.35 Td (\(iv\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 114.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 114.35 Td (any accrued and unpaid vacation pay) Tj ET Q
q 0 0 0 rg BT 356.81 114.35 Td (, payable on the next payroll date;) Tj ET Q
endstream
endobj
327 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 328 0 R>>
endobj
328 0 obj
<</Length 6723>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (9) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (\(v\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (any previous compensation that Executive has previously deferred ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (\(including any interest earned or credited thereon\), in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (terms and conditions of the applicable deferred compensation plans or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (arrangements then in ef) Tj ET Q
q 0 0 0 rg BT 292.73 662.00 Td (fect, to the extent vested as of Executive�) Tj ET Q
q 0 0 0 rg BT 489.99 662.00 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (termination date, paid pursuant to the terms of such plans or arrangements; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (\(vi\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 600.35 Td (any amount or benefit as provided under any benefit plan or program in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 583.80 Td (accordance with the terms thereof \(the foregoing items in Sections 9\(a\)\(i\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 567.20 Td (through 9\(a\)\(vi\) being collectively referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
437.888671875 565.600390625 m
481.529296875 565.600390625 l
s
q 0 0 0 rg BT 437.89 567.20 Td (Accrued ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 549.050390625 m
249.328125 549.050390625 l
s
q 0 0 0 rg BT 180.00 550.65 Td (Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 249.33 550.65 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 522.10 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 522.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 520.500390625 m
351.7353515625 520.500390625 l
s
q 0 0 0 rg BT 144.00 522.10 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 522.10 Td (ermination by the Company for Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 351.35 522.10 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 419.65 522.10 Td (s employment is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (terminated by the Company for Disability) Tj ET Q
q 0 0 0 rg BT 344.18 505.55 Td (, the Company shall pay Executive:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 477.00 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 477.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 477.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 477.00 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 448.40 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 448.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 448.40 Td (an amount equal to the Incentive Compensation that Executive would have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 431.85 Td (been entitled to receive in respect of the fiscal year in which Executive�) Tj ET Q
q 0 0 0 rg BT 523.18 431.85 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 415.30 Td (termination date occurs, had Executive continued in employment until the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 398.75 Td (end of such fiscal year) Tj ET Q
q 0 0 0 rg BT 287.47 398.75 Td (, which amount, determined based on actual ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 382.20 Td (performance for such year relative to the performance goals applicable to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 365.60 Td (Executive \(but without any exercise of negative discretion with respect to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 349.05 Td (Executive in excess of that applied to either senior executives of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 332.50 Td (Company generally or in accordance with the Company�) Tj ET Q
q 0 0 0 rg BT 451.58 332.50 Td (s historical past ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 315.95 Td (practice\), shall be multiplied by a fraction \(A\) the numerator of which is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 299.40 Td (the number of days in such fiscal year through the termination date and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 282.80 Td (\(B\) the denominator of which is 365 \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
384.615234375 281.20039062499995 m
460.9453125 281.20039062499995 l
s
q 0 0 0 rg BT 384.62 282.80 Td (Pro-Rata Bonus) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 460.95 282.80 Td (�\) and shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 266.25 Td (payable in a lump sum payment at the time such bonus or annual incentive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 249.70 Td (awards are payable to other participants. Further) Tj ET Q
q 0 0 0 rg BT 411.76 249.70 Td (, upon Executive�) Tj ET Q
q 0 0 0 rg BT 496.07 249.70 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 233.15 Td (Disability \(irrespective of any termination of employment related thereto\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 216.60 Td (the Company shall pay Executive for twenty-four \(24\) consecutive months ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 200.00 Td (thereafter regular payments in the amount by which Executive�) Tj ET Q
q 0 0 0 rg BT 482.55 200.00 Td (s monthly ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 183.45 Td (Base Salary exceeds Executive�) Tj ET Q
q 0 0 0 rg BT 332.27 183.45 Td (s monthly Disability insurance benefit; and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 154.90 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 154.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 154.90 Td (continued coverage for Executive and Executive�) Tj ET Q
q 0 0 0 rg BT 416.23 154.90 Td (s dependents under any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 138.35 Td (health, medical, dental, vision and basic life insurance \(but not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 121.80 Td (supplemental life insurance\) program or policy in which Executive was ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 105.20 Td (eligible to participate as of the time of Executive�) Tj ET Q
q 0 0 0 rg BT 417.25 105.20 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 88.65 Td (termination \(as may be amended by the Company from time to time in the ) Tj ET Q
endstream
endobj
329 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 330 0 R>>
endobj
330 0 obj
<</Length 7264>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (10) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (ordinary course\), for twenty-four \(24\) months following such termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (on the same basis as active employees, which such twenty-four month ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (period shall run concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 404.63 678.60 Td ( period; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
444.62109375 677.000390625 m
487.27734375 677.000390625 l
s
q 0 0 0 rg BT 444.62 678.60 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 487.28 678.60 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
493.27734375 677.000390625 m
534.3515625 677.000390625 l
s
q 0 0 0 rg BT 493.28 678.60 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 534.11 678.60 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (that \(x\) the Company may instead, in its discretion, provide substantially ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (similar benefits or payment outside of the Company�) Tj ET Q
q 0 0 0 rg BT 432.95 645.45 Td (s benefit plans if the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (Company reasonably determines that providing such alternative benefits ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 612.35 Td (or payment is appropriate to minimize potential adverse tax consequences ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 595.80 Td (and penalties; and \(y\) the coverage provided hereunder shall become ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 579.20 Td (secondary to any coverage provided to Executive by a subsequent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 562.65 Td (employer and to any Medicare coverage for which Executive becomes ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 546.10 Td (eligible, and it shall be the obligation of Executive to inform the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 529.55 Td (if Executive becomes eligible for such subsequent coverage \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
496.875 527.950390625 m
539.865234375 527.950390625 l
s
q 0 0 0 rg BT 496.88 529.55 Td (Benefits ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 511.400390625 m
242.666015625 511.400390625 l
s
q 0 0 0 rg BT 180.00 513.00 Td (Continuation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 242.67 513.00 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 484.40 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 484.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 482.800390625 m
302.455078125 482.800390625 l
s
q 0 0 0 rg BT 144.00 484.40 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 484.40 Td (ermination By Reason of Death) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 302.46 484.40 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 370.76 484.40 Td (s employment is terminated by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (reason of Executive�) Tj ET Q
q 0 0 0 rg BT 242.63 467.85 Td (s death, the Company shall pay Executive�) Tj ET Q
q 0 0 0 rg BT 446.91 467.85 Td (s beneficiaries:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 439.30 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 439.30 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 439.30 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 410.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 410.75 Td (the Pro-Rata Bonus; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 382.20 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 382.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 382.20 Td (continued coverage for Executive�) Tj ET Q
q 0 0 0 rg BT 344.92 382.20 Td (s dependents under any health, medical, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 365.60 Td (dental, vision and basic life insurance \(but not supplemental life ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 349.05 Td (insurance\) program or policy in which Executive was eligible to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 332.50 Td (participate as of the time of Executive�) Tj ET Q
q 0 0 0 rg BT 365.92 332.50 Td (s employment termination \(as may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 315.95 Td (be amended or replaced by the Company from time to time in the ordinary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 299.40 Td (course\), for twenty-four \(24\) months following such termination on the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 282.80 Td (same basis as the dependents of active employees, which such twenty-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 266.25 Td (four) Tj ET Q
q 0 0 0 rg BT 199.75 266.25 Td (-month period shall run concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 462.05 266.25 Td ( period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 237.70 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 237.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 236.10039062500005 m
525.71484375 236.10039062500005 l
s
q 0 0 0 rg BT 144.00 237.70 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 237.70 Td (ermination by the Company ) Tj ET Q
q 0 0 0 rg BT 287.58 237.70 Td (W) Tj ET Q
q 0 0 0 rg BT 298.43 237.70 Td (ithout Cause or by Executive for Good Reason ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 219.55039062499998 m
393.73828125 219.55039062499998 l
s
q 0 0 0 rg BT 144.00 221.15 Td (Other ) Tj ET Q
q 0 0 0 rg BT 174.11 221.15 Td (Than in Connection with a Change in Control) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 393.74 221.15 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 462.04 221.15 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 204.60 Td (is terminated by the Company without Cause \(other than on account of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 188.00 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 188.00 Td (s Disability or death\) or by Executive for Good Reason, in either case ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 171.45 Td (other than where such termination would entitle Executive to the benefits ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 154.90 Td (provided in Section 9\(e\) of this ) Tj ET Q
q 0 0 0 rg BT 295.97 154.90 Td (Agreement, then, subject to Section 15\(f\), the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 138.35 Td (Company shall pay Executive:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 109.80 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 109.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 109.80 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 109.80 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 81.20 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 81.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 81.20 Td (the Pro-Rata Bonus;) Tj ET Q
endstream
endobj
331 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 332 0 R>>
endobj
332 0 obj
<</Length 6683>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.22 59.20 Td (1) Tj ET Q
q 0 0 0 rg BT 305.78 59.20 Td (1) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (in lieu of any further Base Salary or other compensation and benefits for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (periods subsequent to the termination date, an amount in cash, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (amount shall be payable in a lump sum payment within sixty \(60\) days ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (following such termination \(subject to Section 10\(c\)\), equal to two \(2\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (times the sum of \(A\) Executive�) Tj ET Q
q 0 0 0 rg BT 333.63 645.45 Td (s Base Salary and \(B\) the ) Tj ET Q
q 0 0 0 rg BT 458.04 645.45 Td (T) Tj ET Q
q 0 0 0 rg BT 464.54 645.45 Td (ar) Tj ET Q
q 0 0 0 rg BT 473.64 645.45 Td (get Bonus; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (\(iv\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 616.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 616.90 Td (accelerated vesting and non-forfeitability) Tj ET Q
q 0 0 0 rg BT 376.80 616.90 Td (, as of the termination date, of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 600.35 Td (Initial L) Tj ET Q
q 0 0 0 rg BT 217.89 600.35 Td (TC and Initial PSUs, with performance and other terms ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 583.80 Td (determined in accordance with the applicable award agreements, except ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 567.20 Td (that with respect to the Initial PSUs, the number of Initial PSUs that are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 550.65 Td (earned and vested will not be subject to proration for any partial period of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 534.10 Td (service during the performance period; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (\(v\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.99 505.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 505.55 Td (the Benefits Continuation.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 477.00 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 477.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 475.400390625 m
525.71484375 475.400390625 l
s
q 0 0 0 rg BT 144.00 477.00 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 477.00 Td (ermination by the Company ) Tj ET Q
q 0 0 0 rg BT 287.58 477.00 Td (W) Tj ET Q
q 0 0 0 rg BT 298.43 477.00 Td (ithout Cause or by Executive for Good Reason ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 458.800390625 m
293.326171875 458.800390625 l
s
q 0 0 0 rg BT 144.00 460.40 Td (Following a Change in Control) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 293.33 460.40 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 361.63 460.40 Td (s employment by the Company shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 443.85 Td (be terminated by the Company without Cause \(other than on account of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 427.30 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 427.30 Td (s Disability or death\) or by Executive for Good Reason within twenty-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (four \(24\) months following a Change in Control, then, in lieu of the amounts due ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 394.20 Td (under Section 9\(d\) above and subject to Section 15\(f\) of this ) Tj ET Q
q 0 0 0 rg BT 436.27 394.20 Td (Agreement, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 377.60 Td (Executive shall be entitled to the benefits provided in this Section 9\(e\):) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 349.05 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 349.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 349.05 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 349.05 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 320.50 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 320.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 320.50 Td (the Pro-Rata Bonus;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 291.95 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 291.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 291.95 Td (in lieu of any further Base Salary or other compensation and benefits for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 275.40 Td (periods subsequent to the termination date, an amount in cash, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 258.80 Td (amount shall be payable in a lump sum payment within sixty \(60\) days ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 242.25 Td (following such termination \(subject to Section 10\(c\)\), equal to three \(3\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 225.70 Td (times the sum of \(A\) Executive�) Tj ET Q
q 0 0 0 rg BT 333.63 225.70 Td (s Base Salary and \(B\) the ) Tj ET Q
q 0 0 0 rg BT 458.04 225.70 Td (T) Tj ET Q
q 0 0 0 rg BT 464.54 225.70 Td (ar) Tj ET Q
q 0 0 0 rg BT 473.64 225.70 Td (get Bonus; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 197.15 Td (\(iv\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 197.15 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 197.15 Td (accelerated vesting and non-forfeitability) Tj ET Q
q 0 0 0 rg BT 376.80 197.15 Td (, as of the termination date, of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 180.60 Td (Initial L) Tj ET Q
q 0 0 0 rg BT 217.89 180.60 Td (TC and Initial PSUs, with performance and other terms ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 164.00 Td (determined in accordance with the applicable award agreements; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 135.45 Td (\(v\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.99 135.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 135.45 Td (continued coverage for Executive and Executive�) Tj ET Q
q 0 0 0 rg BT 416.23 135.45 Td (s dependents under any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 118.90 Td (health, medical, dental, vision and basic life insurance \(but not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 102.35 Td (supplemental life insurance\) program or policy in which Executive was ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 85.80 Td (eligible to participate as of the time of Executive�) Tj ET Q
q 0 0 0 rg BT 417.25 85.80 Td (s employment ) Tj ET Q
endstream
endobj
333 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 334 0 R>>
endobj
334 0 obj
<</Length 7468>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (12) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (termination \(as may be amended by the Company from time to time in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (ordinary course\), for three \(3\) years following such termination on the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (same basis as active employees, which such three year period shall run ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 326.31 662.00 Td ( period; provided, however) Tj ET Q
q 0 0 0 rg BT 455.79 662.00 Td (, that \(x\) the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (Company may instead, in its discretion, provide substantially similar ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (benefits or payment outside of the Company�) Tj ET Q
q 0 0 0 rg BT 396.62 628.90 Td (s benefit plans if the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 612.35 Td (Company reasonably determines that providing such alternative benefits ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 595.80 Td (or payment is appropriate to minimize potential adverse tax consequences ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 579.20 Td (and penalties; and \(y\) the coverage provided hereunder shall become ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 562.65 Td (secondary to any coverage provided to Executive by a subsequent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 546.10 Td (employer and to any Medicare coverage for which Executive becomes ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 529.55 Td (eligible, and it shall be the obligation of Executive to inform the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 513.00 Td (if Executive becomes eligible for such subsequent coverage; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (\(vi\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 484.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 484.40 Td (For purposes of this ) Tj ET Q
q 0 0 0 rg BT 278.00 484.40 Td (Agreement, �Change in Control� shall have the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 467.85 Td (meaning set forth in the award agreement governing the Initial PSUs and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 451.30 Td (Initial L) Tj ET Q
q 0 0 0 rg BT 217.89 451.30 Td (TC. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 422.75 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 422.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 421.150390625 m
212.33203125 421.150390625 l
s
q 0 0 0 rg BT 144.00 422.75 Td (No Mitigation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 212.33 422.75 Td (. Executive shall not be required to mitigate the amount of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (payment provided for under this Section 9 by seeking other employment or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (otherwise and, except as provided in Sections 9\(b\)\(iii\), 9\(d\)\(v\), and 9\(e\)\(v\) above, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (no such payment shall be of) Tj ET Q
q 0 0 0 rg BT 278.09 373.05 Td (fset or reduced by the amount of any compensation or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (benefits provided to Executive in any subsequent employment. Further) Tj ET Q
q 0 0 0 rg BT 483.77 356.50 Td (, the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 339.95 Td (s obligations to make any payments hereunder shall not be subject to or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 323.40 Td (fected by any set-of) Tj ET Q
q 0 0 0 rg BT 247.85 323.40 Td (f, counterclaim or defense which the Company may have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (against Executive. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 278.25 Td (10.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 278.25 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 276.650390625 m
215.58984375 276.650390625 l
s
q 0 0 0 rg BT 108.00 278.25 Td (Certain ) Tj ET Q
q 0 0 0 rg BT 146.10 278.25 Td (T) Tj ET Q
q 0 0 0 rg BT 152.60 278.25 Td (ax ) Tj ET Q
q 0 0 0 rg BT 166.71 278.25 Td (T) Tj ET Q
q 0 0 0 rg BT 173.61 278.25 Td (reatment) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.59 278.25 Td (.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 249.70 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 249.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 248.10039062500005 m
250.236328125 248.10039062500005 l
s
q 0 0 0 rg BT 144.00 249.70 Td (Golden Parachute ) Tj ET Q
q 0 0 0 rg BT 232.42 249.70 Td (T) Tj ET Q
q 0 0 0 rg BT 238.91 249.70 Td (ax) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 250.24 249.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 256.02 249.70 Td (T) Tj ET Q
q 0 0 0 rg BT 262.51 249.70 Td (o the extent that the payments and benefits provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 233.15 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 233.15 Td (Agreement and benefits provided to, or for the benefit of, Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 216.60 Td (under any other plan or agreement of the Company or any of its af) Tj ET Q
q 0 0 0 rg BT 462.01 216.60 Td (filiates \(such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 200.00 Td (payments or benefits are collectively referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
412.875 198.400390625 m
459.5390625 198.400390625 l
s
q 0 0 0 rg BT 412.88 200.00 Td (Payments) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 459.54 200.00 Td (�\) would be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 183.45 Td (subject to the excise tax \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
288.609375 181.85039062500005 m
341.197265625 181.85039062500005 l
s
q 0 0 0 rg BT 288.61 183.45 Td (Excise ) Tj ET Q
q 0 0 0 rg BT 323.38 183.45 Td (T) Tj ET Q
q 0 0 0 rg BT 329.87 183.45 Td (ax) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 341.20 183.45 Td (�\) imposed under Section 4999 of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (Code or any successor provision thereto, or any similar tax imposed by state or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 150.35 Td (local law) Tj ET Q
q 0 0 0 rg BT 186.87 150.35 Td (, then Executive may) Tj ET Q
q 0 0 0 rg BT 287.38 150.35 Td (, in Executive�) Tj ET Q
q 0 0 0 rg BT 357.03 150.35 Td (s sole discretion \(except as provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 133.80 Td (herein below\) waive the right to receive any payments or distributions \(or a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 117.20 Td (portion thereof\) by the Company in the nature of compensation to or for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 100.65 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 100.65 Td (s benefit if and to the extent necessary so that no Payment to be made ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 84.10 Td (or benefit to be provided to Executive shall be subject to the Excise ) Tj ET Q
q 0 0 0 rg BT 470.68 84.10 Td (T) Tj ET Q
q 0 0 0 rg BT 477.18 84.10 Td (ax \(such ) Tj ET Q
endstream
endobj
335 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 336 0 R>>
endobj
336 0 obj
<</Length 7495>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (13) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (reduced amount is hereinafter referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
379.212890625 710.100390625 m
503.87109375 710.100390625 l
s
q 0 0 0 rg BT 379.21 711.70 Td (Limited Payment ) Tj ET Q
q 0 0 0 rg BT 464.54 711.70 Td (Amount) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 503.87 711.70 Td (�\), but ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (only if such reduction results in a higher after) Tj ET Q
q 0 0 0 rg BT 362.36 695.15 Td (-tax payment to Executive after ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (taking into account the Excise ) Tj ET Q
q 0 0 0 rg BT 291.40 678.60 Td (T) Tj ET Q
q 0 0 0 rg BT 297.90 678.60 Td (ax and any additional taxes \(including federal, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (state and local income taxes, employment, social security and Medicare taxes and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (all other applicable taxes\) Executive would pay if such Payments were not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (reduced. If so waived, the Company shall reduce or eliminate the Payments, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (ef) Tj ET Q
q 0 0 0 rg BT 153.11 612.35 Td (fect the provisions of this Section 10 based upon Section 10\(b\) below) Tj ET Q
q 0 0 0 rg BT 485.94 612.35 Td (. ) Tj ET Q
q 0 0 0 rg BT 491.72 612.35 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (determination of the amount of Payments that would be required to be reduced to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (the Limited Payment ) Tj ET Q
q 0 0 0 rg BT 246.98 579.20 Td (Amount pursuant to this ) Tj ET Q
q 0 0 0 rg BT 365.65 579.20 Td (Agreement and the amount of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (Limited Payment ) Tj ET Q
q 0 0 0 rg BT 229.32 562.65 Td (Amount shall be made, at the Company�) Tj ET Q
q 0 0 0 rg BT 422.95 562.65 Td (s expense, by a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (reputable accounting firm selected by Executive and reasonably acceptable to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (Company \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
220.646484375 527.950390625 m
302.970703125 527.950390625 l
s
q 0 0 0 rg BT 220.65 529.55 Td (Accounting Firm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 302.97 529.55 Td (�\).  ) Tj ET Q
q 0 0 0 rg BT 321.08 529.55 Td (The ) Tj ET Q
q 0 0 0 rg BT 342.07 529.55 Td (Accounting Firm shall provide its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (determination \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
240.626953125 511.400390625 m
309.9375 511.400390625 l
s
q 0 0 0 rg BT 240.63 513.00 Td (Determination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 309.94 513.00 Td (�\), together with detailed supporting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (calculations and documentation to the Company and Executive within ten \(10\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (days of the date of termination, if applicable, or such other time as specified by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (mutual agreement of the Company and Executive, and if the ) Tj ET Q
q 0 0 0 rg BT 435.57 463.30 Td (Accounting Firm ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (determines that no Excise ) Tj ET Q
q 0 0 0 rg BT 270.41 446.75 Td (T) Tj ET Q
q 0 0 0 rg BT 276.90 446.75 Td (ax is payable by Executive with respect to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (Payments, it shall furnish Executive with an opinion reasonably acceptable to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (Executive that no Excise ) Tj ET Q
q 0 0 0 rg BT 265.74 413.60 Td (T) Tj ET Q
q 0 0 0 rg BT 272.23 413.60 Td (ax will be imposed with respect to any such Payments. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (The Determination shall be binding, final and conclusive upon the Company and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 380.50 Td (Executive, absent manifest error) Tj ET Q
q 0 0 0 rg BT 298.61 380.50 Td (. For purposes of making the calculations required ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 363.95 Td (by this Section 10\(a\), the ) Tj ET Q
q 0 0 0 rg BT 266.65 363.95 Td (Accounting Firm may make reasonable assumptions and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 347.40 Td (approximations concerning applicable taxes and rates, and rely on reasonable, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 330.80 Td (good faith interpretations concerning the application of the Code, and other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 314.25 Td (applicable legal authority) Tj ET Q
q 0 0 0 rg BT 265.17 314.25 Td (. In furtherance of the above, to the extent requested by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 297.70 Td (Executive, the Company shall cooperate in good faith in valuing, and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 281.15 Td (Accounting Firm shall value, services to be provided by Executive \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 264.60 Td (Executive refraining from performing services pursuant to any covenant not to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 248.00 Td (compete\) before, on or after the date of the transaction which causes the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 231.45 Td (application of Section 4999 of the Code, such that payments in respect of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 214.90 Td (services may be considered to be �reasonable compensation� within the meaning ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 198.35 Td (of the regulations under Section 4999 of the Code.     ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 169.80 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 169.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 168.20039062499995 m
252.638671875 168.20039062499995 l
s
q 0 0 0 rg BT 144.00 169.80 Td (Ordering of Reduction) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 252.64 169.80 Td (.  In the case of a reduction in the Payments pursuant to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 153.20 Td (Section 10\(a\), the Payments will be reduced in the following order: \(i\) payments ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 136.65 Td (that are payable in cash that are valued at full value under ) Tj ET Q
q 0 0 0 rg BT 423.66 136.65 Td (T) Tj ET Q
q 0 0 0 rg BT 430.56 136.65 Td (reasury Regulation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 120.10 Td (Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 260.66 120.10 Td ( 24\(a\) will be reduced \(if necessary) Tj ET Q
q 0 0 0 rg BT 429.13 120.10 Td (, to zero\), with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 103.55 Td (amounts that are payable last reduced first; \(ii\) payments and benefits due in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 87.00 Td (respect of any equity valued at full value under ) Tj ET Q
q 0 0 0 rg BT 372.70 87.00 Td (T) Tj ET Q
q 0 0 0 rg BT 379.61 87.00 Td (reasury Regulation Section ) Tj ET Q
endstream
endobj
337 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 338 0 R>>
endobj
338 0 obj
<</Length 7092>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (14) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 221.67 711.70 Td ( 24\(a\), with the highest values reduced first \(as such values are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (determined under ) Tj ET Q
q 0 0 0 rg BT 231.08 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 237.99 695.15 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 448.62 695.15 Td ( 24\) will next be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (reduced; \(iii\) payments that are payable in cash that are valued at less than full ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (value under ) Tj ET Q
q 0 0 0 rg BT 203.09 662.00 Td (T) Tj ET Q
q 0 0 0 rg BT 210.00 662.00 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 420.63 662.00 Td ( 24, with amounts that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (are payable last reduced first, will next be reduced; \(iv\) payments and benefits due ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (in respect of any equity valued at less than full value under ) Tj ET Q
q 0 0 0 rg BT 429.69 628.90 Td (T) Tj ET Q
q 0 0 0 rg BT 436.60 628.90 Td (reasury Regulation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 260.66 612.35 Td ( 24, with the highest values reduced first \(as such values ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (are determined under ) Tj ET Q
q 0 0 0 rg BT 248.73 595.80 Td (T) Tj ET Q
q 0 0 0 rg BT 255.64 595.80 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 466.27 595.80 Td ( 24\) will next ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (be reduced; and \(v\) all other non-cash benefits not otherwise described in clauses ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (\(ii\) or \(iv\) will be next reduced pro-rata.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 534.10 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 534.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 532.500390625 m
209.66015625 532.500390625 l
s
q 0 0 0 rg BT 144.00 534.10 Td (Section 409A) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 209.66 534.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 215.44 534.10 Td (The parties intend for the payments and benefits under this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (Agreement to be exempt from Section 409A) Tj ET Q
q 0 0 0 rg BT 356.61 517.55 Td ( of the Code or) Tj ET Q
q 0 0 0 rg BT 428.12 517.55 Td (, if not so exempt, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (be paid or provided in a manner which complies with the requirements of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (section, and intend that this ) Tj ET Q
q 0 0 0 rg BT 277.98 484.40 Td (Agreement shall be construed and administered in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (accordance with such intention. In the event the Company determines that a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (payment or benefit under this ) Tj ET Q
q 0 0 0 rg BT 287.63 451.30 Td (Agreement may not be in compliance with Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (409A) Tj ET Q
q 0 0 0 rg BT 170.00 434.75 Td ( of the Code, subject to Section 6\(a\) herein, the Company shall reasonably ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (confer with Executive in order to modify or amend this ) Tj ET Q
q 0 0 0 rg BT 411.26 418.20 Td (Agreement to comply ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (with Section 409A) Tj ET Q
q 0 0 0 rg BT 233.33 401.60 Td ( of the Code and to do so in a manner to best preserve the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (economic benefit of this ) Tj ET Q
q 0 0 0 rg BT 262.63 385.05 Td (Agreement.  Notwithstanding anything contained herein ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (to the contrary) Tj ET Q
q 0 0 0 rg BT 213.19 368.50 Td (, to the extent required in order to avoid accelerated taxation and/or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (tax penalties under Section 409A) Tj ET Q
q 0 0 0 rg BT 302.63 351.95 Td ( of the Code, \(i\) no amounts shall be paid to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 335.40 Td (Executive under Section 9 of this ) Tj ET Q
q 0 0 0 rg BT 305.96 335.40 Td (Agreement until Executive would be considered ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 318.80 Td (to have incurred a �separation from service� from the Company within the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 302.25 Td (meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 266.31 302.25 Td ( of the Code; \(ii\) amounts that would otherwise be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (payable and benefits that would otherwise be provided pursuant to this ) Tj ET Q
q 0 0 0 rg BT 485.59 285.70 Td (Agreement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (during the six-month period immediately following Executive�) Tj ET Q
q 0 0 0 rg BT 445.27 269.15 Td (s separation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 252.60 Td (service shall instead be paid on the first business day after the date that is six \(6\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 236.00 Td (months following Executive�) Tj ET Q
q 0 0 0 rg BT 283.31 236.00 Td (s separation from service \(or death, if earlier\), with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 219.45 Td (interest for any cash payments so delayed, from the date such cash amounts would ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 202.90 Td (otherwise have been paid at the short-term applicable federal rate, compounded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 186.35 Td (semi-annually) Tj ET Q
q 0 0 0 rg BT 211.20 186.35 Td (, as determined under Section 1274 of the Code for the month in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 169.80 Td (which the payment would have been made but for the delay in payment required ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 153.20 Td (to avoid the imposition of an additional rate of tax on Executive; \(iii\) each amount ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 136.65 Td (to be paid or benefit to be provided under this ) Tj ET Q
q 0 0 0 rg BT 365.95 136.65 Td (Agreement shall be construed as a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 120.10 Td (separately identified payment for purposes of Section 409A) Tj ET Q
q 0 0 0 rg BT 429.59 120.10 Td ( of the Code; \(iv\) any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 103.55 Td (payments that are due within the �short term deferral period� as defined in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 87.00 Td (Section 409A) Tj ET Q
q 0 0 0 rg BT 209.00 87.00 Td ( of the Code shall not be treated as deferred compensation unless ) Tj ET Q
endstream
endobj
339 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 340 0 R>>
endobj
340 0 obj
<</Length 7446>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (15) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (applicable law requires otherwise; and \(v\) amounts reimbursable to Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 695.15 Td (Agreement shall be paid to Executive on or before the last day of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (year following the year in which the expense was incurred and the amount of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (expenses eligible for reimbursement \(and in-kind benefits provided to Executive\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (during any one \(1\) year may not af) Tj ET Q
q 0 0 0 rg BT 310.72 645.45 Td (fect amounts reimbursable or provided in any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (subsequent year) Tj ET Q
q 0 0 0 rg BT 220.31 628.90 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 600.35 Td (1) Tj ET Q
q 0 0 0 rg BT 77.55 600.35 Td (1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.55 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 598.750390625 m
256.2890625 598.750390625 l
s
q 0 0 0 rg BT 108.00 600.35 Td (Records and Confidential Data) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 256.29 600.35 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 571.80 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 571.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 571.80 Td (Executive acknowledges that in connection with the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 524.85 571.80 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 555.20 Td (duties during the Employment ) Tj ET Q
q 0 0 0 rg BT 292.43 555.20 Td (T) Tj ET Q
q 0 0 0 rg BT 298.92 555.20 Td (erm, the Company and its af) Tj ET Q
q 0 0 0 rg BT 434.67 555.20 Td (filiates will make ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (available to Executive, or Executive will develop and have access to, certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (Confidential Information \(as defined below\) of the Company and its af) Tj ET Q
q 0 0 0 rg BT 483.69 522.10 Td (filiates. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (Executive acknowledges and agrees that any and all Confidential Information ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (learned or obtained by Executive during the course of Executive�) Tj ET Q
q 0 0 0 rg BT 456.22 489.00 Td (s employment by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (the Company or otherwise, whether developed by Executive alone or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (conjunction with others or otherwise, shall be and is the property of the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (and its af) Tj ET Q
q 0 0 0 rg BT 187.77 439.30 Td (filiates.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 410.75 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 410.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (During the Employment ) Tj ET Q
q 0 0 0 rg BT 263.43 410.75 Td (T) Tj ET Q
q 0 0 0 rg BT 269.92 410.75 Td (erm and thereafter) Tj ET Q
q 0 0 0 rg BT 357.39 410.75 Td (, Confidential Information will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 394.20 Td (kept confidential by Executive, will not be used in any manner that is detrimental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 377.60 Td (to the Company or its af) Tj ET Q
q 0 0 0 rg BT 260.10 377.60 Td (filiates, will not be used other than in connection with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 361.05 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 361.05 Td (s dischar) Tj ET Q
q 0 0 0 rg BT 237.42 361.05 Td (ge of Executive�) Tj ET Q
q 0 0 0 rg BT 316.05 361.05 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 402.87 361.05 Td (, and will be safeguarded by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (Executive from unauthorized disclosure; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
341.935546875 342.900390625 m
384.591796875 342.900390625 l
s
q 0 0 0 rg BT 341.94 344.50 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 384.59 344.50 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
390.591796875 342.900390625 m
431.666015625 342.900390625 l
s
q 0 0 0 rg BT 390.59 344.50 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 431.43 344.50 Td (, that Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (Information may be disclosed by Executive \(i\) to the Company and its af) Tj ET Q
q 0 0 0 rg BT 493.69 327.95 Td (filiates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (or to any authorized agent or representative of any of them, \(ii\) in connection with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (performing Executive�) Tj ET Q
q 0 0 0 rg BT 252.29 294.80 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 339.12 294.80 Td (, \(iii\) without limiting Section 1) Tj ET Q
q 0 0 0 rg BT 491.33 294.80 Td (1\(g\) of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 278.25 Td (Agreement, when required to do so by law or requested by a court, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (governmental agency) Tj ET Q
q 0 0 0 rg BT 246.18 261.70 Td (, legislative body) Tj ET Q
q 0 0 0 rg BT 327.71 261.70 Td (, arbitrator or other person with apparent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (jurisdiction to order Executive to divulge, disclose or make accessible such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (information, provided that Executive, to the extent legally permitted, notifies the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (Company prior to such disclosure, \(iv\) in the course of any proceeding under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (Sections 12 or 13 of this ) Tj ET Q
q 0 0 0 rg BT 263.33 195.45 Td (Agreement or Section 6 of the Release, subject to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (prior entry of a confidentiality order) Tj ET Q
q 0 0 0 rg BT 317.12 178.90 Td (, or \(v\) in confidence to an attorney or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (professional advisor for the purpose of securing professional advice, so long as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (such attorney or advisor is subject to confidentiality restrictions no less restrictive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (than those applicable to Executive hereunder) Tj ET Q
q 0 0 0 rg BT 358.92 129.20 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 100.65 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 100.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 100.65 Td (On Executive�) Tj ET Q
q 0 0 0 rg BT 212.98 100.65 Td (s last day of employment with the Company) Tj ET Q
q 0 0 0 rg BT 424.50 100.65 Td (, or at such earlier date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 84.10 Td (as requested by the Company) Tj ET Q
q 0 0 0 rg BT 284.52 84.10 Td (, \(i\) Executive will return to the Company all written ) Tj ET Q
endstream
endobj
341 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 342 0 R>>
endobj
342 0 obj
<</Length 6211>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (16) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (Confidential Information that has been provided to, or prepared by) Tj ET Q
q 0 0 0 rg BT 463.13 711.70 Td (, Executive; \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (at the election of the Company) Tj ET Q
q 0 0 0 rg BT 290.84 695.15 Td (, Executive will return to the Company or destroy ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (all copies of any analyses, compilations, studies or other documents prepared by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (Executive or for Executive�) Tj ET Q
q 0 0 0 rg BT 276.28 662.00 Td (s use containing or reflecting any Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (Information; and \(iii\) Executive will return all Company property) Tj ET Q
q 0 0 0 rg BT 457.80 645.45 Td (.  Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (shall deliver to the Company a document certifying Executive�) Tj ET Q
q 0 0 0 rg BT 445.24 628.90 Td (s compliance with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (this Section 1) Tj ET Q
q 0 0 0 rg BT 208.89 612.35 Td (1\(c\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (For the purposes of this ) Tj ET Q
q 0 0 0 rg BT 259.66 583.80 Td (Agreement, �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
324.298828125 582.200390625 m
444.603515625 582.200390625 l
s
q 0 0 0 rg BT 324.30 583.80 Td (Confidential Information) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 444.60 583.80 Td (� shall mean all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (confidential and proprietary information of the Company and its af) Tj ET Q
q 0 0 0 rg BT 464.69 567.20 Td (filiates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (including:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 522.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 522.10 Td (trade secrets concerning the business and af) Tj ET Q
q 0 0 0 rg BT 389.70 522.10 Td (fairs of the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 505.55 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 505.55 Td (filiates, product specifications, data, know-how) Tj ET Q
q 0 0 0 rg BT 415.93 505.55 Td (, formulae, compositions, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 489.00 Td (processes, non-public patent applications, designs, sketches, photographs, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 472.40 Td (graphs, drawings, samples, inventions and ideas, past, current, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 455.85 Td (planned research and development, current and planned manufacturing or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 439.30 Td (distribution methods and processes, customer lists, current and anticipated ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 422.75 Td (customer requirements, price lists, market studies, business plans, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 406.20 Td (computer software and programs \(including object code and source code\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 389.60 Td (computer software and database technologies, systems, structures, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 373.05 Td (architectures \(and related formulae, compositions, processes, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 356.50 Td (improvements, devices, know-how) Tj ET Q
q 0 0 0 rg BT 347.19 356.50 Td (, inventions, discoveries, concepts, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 339.95 Td (ideas, designs, methods and information\); ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 311.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 311.40 Td (information concerning the business and af) Tj ET Q
q 0 0 0 rg BT 386.72 311.40 Td (fairs of the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 294.80 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 294.80 Td (filiates \(which includes unpublished financial statements, financial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 278.25 Td (projections and budgets, unpublished and projected sales, capital spending ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 261.70 Td (budgets and plans, the names and backgrounds of key personnel, to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 245.15 Td (extent not publicly known, personnel training and techniques and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 228.60 Td (materials\) however documented; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 200.00 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 200.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 200.00 Td (notes, analysis, compilations, studies, summaries, and other material ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 183.45 Td (prepared by or for the Company or its af) Tj ET Q
q 0 0 0 rg BT 373.72 183.45 Td (filiates containing or based, in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 166.90 Td (whole or in part, on any information included in the foregoing. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 150.35 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 258.33 150.35 Td (Agreement, Confidential Information shall not include ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 133.80 Td (and Executive�) Tj ET Q
q 0 0 0 rg BT 251.64 133.80 Td (s obligations shall not extend to \(A\) information that is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 117.20 Td (generally available to the public, \(B\) information obtained by Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 100.65 Td (other than pursuant to or in connection with this employment, \(C\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 84.10 Td (information that is required to be disclosed by law or legal process, and ) Tj ET Q
endstream
endobj
343 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 344 0 R>>
endobj
344 0 obj
<</Length 6986>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (17) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (\(D\) Executive�) Tj ET Q
q 0 0 0 rg BT 250.97 711.70 Td (s rolodex and similar address books, including electronic ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (address books, containing contact information.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 666.60 Td (Nothing herein or elsewhere shall preclude Executive from retaining and using \(i\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 650.00 Td (s personal papers and other materials of a personal nature, including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (photographs, contacts, correspondence, personal diaries, and personal files \(so ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (long as no such materials are covered by any Company hold order\), \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (documents relating to Executive�) Tj ET Q
q 0 0 0 rg BT 302.29 600.35 Td (s personal entitlements and obligations, and \(iii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (information that is necessary for Executive�) Tj ET Q
q 0 0 0 rg BT 353.60 583.80 Td (s personal tax purposes.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 555.20 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 555.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 555.20 Td (Pursuant to 18 U.S.C. � 1833\(b\), Executive understands that Executive will not be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (held criminally or civilly liable under any Federal or State trade secret law for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (disclosure of a trade secret of the Company or its af) Tj ET Q
q 0 0 0 rg BT 391.70 522.10 Td (filiates that \(i\) is made \(A\) in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (confidence to a Federal, State, or local government of) Tj ET Q
q 0 0 0 rg BT 401.68 505.55 Td (ficial, either directly or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (indirectly) Tj ET Q
q 0 0 0 rg BT 189.21 489.00 Td (, or to Executive�) Tj ET Q
q 0 0 0 rg BT 271.85 489.00 Td (s attorney and \(B\) solely for the purpose of reporting or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (investigating a suspected violation of law; or \(ii\) is made in a complaint or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (document that is filed under seal in a lawsuit or other proceeding.� Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (understands that if Executive files a lawsuit for retaliation by the Company for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (reporting a suspected violation of law) Tj ET Q
q 0 0 0 rg BT 324.17 422.75 Td (, Executive may disclose the trade secret to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 406.20 Td (s attorney and use the trade secret information in the court proceeding ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (if Executive \(x\) files any document containing the trade secret under seal, and \(y\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (does not disclose the trade secret, except pursuant to court order) Tj ET Q
q 0 0 0 rg BT 450.90 373.05 Td (.� Nothing in this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (Agreement, or any other agreement that Executive has with the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 339.95 Td (filiates, is intended to conflict with 18 U.S.C. � 1833\(b\) or create liability for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (disclosures of trade secrets that are expressly allowed by such section.�) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.80 Td (\(g\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 294.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (Notwithstanding anything set forth in this ) Tj ET Q
q 0 0 0 rg BT 346.66 294.80 Td (Agreement or any other agreement that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (Executive has with the Company or its af) Tj ET Q
q 0 0 0 rg BT 342.07 278.25 Td (filiates to the contrary) Tj ET Q
q 0 0 0 rg BT 446.92 278.25 Td (, Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (not be prohibited from reporting possible violations of federal or state law or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (regulation to any governmental agency or entity) Tj ET Q
q 0 0 0 rg BT 373.81 245.15 Td (, legislative body) Tj ET Q
q 0 0 0 rg BT 455.35 245.15 Td (, or any self-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (regulatory or) Tj ET Q
q 0 0 0 rg BT 206.09 228.60 Td (ganization, or making other disclosures that are protected under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (whistleblower provisions of federal or state law or regulation, nor is Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (required to notify the Company regarding any such reporting, disclosure or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (cooperation with the government.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 150.35 Td (12.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 150.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 148.75039062500002 m
525.603515625 148.75039062500002 l
s
q 0 0 0 rg BT 108.00 150.35 Td (Covenant Not to Solicit, Not to Compete, Not to Disparage, to Cooperate in Litigation ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 132.20039062499995 m
396.71484375 132.20039062499995 l
s
q 0 0 0 rg BT 108.00 133.80 Td (and Not to Cooperate with Non-Governmental ) Tj ET Q
q 0 0 0 rg BT 334.39 133.80 Td (Third Parties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 396.71 133.80 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 105.20 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 105.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 103.60039062500005 m
257.66015625 103.60039062500005 l
s
q 0 0 0 rg BT 144.00 105.20 Td (Covenant Not to Solicit) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 257.66 105.20 Td (. ) Tj ET Q
q 0 0 0 rg BT 263.44 105.20 Td (T) Tj ET Q
q 0 0 0 rg BT 269.94 105.20 Td (o protect the Confidential Information and other trade ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (secrets of the Company and its af) Tj ET Q
q 0 0 0 rg BT 303.74 88.65 Td (filiates as well as the goodwill and competitive ) Tj ET Q
endstream
endobj
345 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 346 0 R>>
endobj
346 0 obj
<</Length 7098>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (18) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (business of the Company and its af) Tj ET Q
q 0 0 0 rg BT 311.76 711.70 Td (filiates, Executive agrees, during the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 695.15 Td (erm and for a period of twenty-four \(24\) months after Executive�) Tj ET Q
q 0 0 0 rg BT 526.49 695.15 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (cessation of employment with the Company) Tj ET Q
q 0 0 0 rg BT 354.85 678.60 Td (, not to solicit or participate in or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (assist in any way in the solicitation of any \(i\) customers or clients of the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (or its af) Tj ET Q
q 0 0 0 rg BT 180.44 645.45 Td (filiates whom Executive first met or about whom learned Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Information through Executive�) Tj ET Q
q 0 0 0 rg BT 295.96 628.90 Td (s employment with the Company and \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (suppliers, employees or agents of the Company or its af) Tj ET Q
q 0 0 0 rg BT 411.06 612.35 Td (filiates. For purposes of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (this covenant, �solicit� or �solicitation� means directly or indirectly influencing or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (attempting to influence any customers, clients, suppliers, employees or agents of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (the Company or its af) Tj ET Q
q 0 0 0 rg BT 247.76 562.65 Td (filiates to cease doing business with, or to reduce the level ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (of business with, the Company and its af) Tj ET Q
q 0 0 0 rg BT 339.09 546.10 Td (filiates or) Tj ET Q
q 0 0 0 rg BT 384.26 546.10 Td (, with respect to employees or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (exclusive agents, to become employed or engaged by any other person, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (partnership, firm, corporation or other entity) Tj ET Q
q 0 0 0 rg BT 356.16 513.00 Td (. Executive agrees that the covenants ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (contained in this Section 12\(a\) are reasonable and desirable to protect the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (Confidential Information of the Company and its af) Tj ET Q
q 0 0 0 rg BT 391.39 479.85 Td (filiates; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
430.3828125 478.250390625 m
473.0390625 478.250390625 l
s
q 0 0 0 rg BT 430.38 479.85 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 473.04 479.85 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (solicitation through general advertising not tar) Tj ET Q
q 0 0 0 rg BT 366.06 463.30 Td (geted at the Company�) Tj ET Q
q 0 0 0 rg BT 474.36 463.30 Td (s or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 446.75 Td (filiates�) Tj ET Q
q 0 0 0 rg BT 188.87 446.75 Td ( employees or the provision of references shall not constitute a breach of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (such obligations.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 401.60 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 401.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 400.000390625 m
269.6484375 400.000390625 l
s
q 0 0 0 rg BT 144.00 401.60 Td (Covenant Not to Compete) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 269.65 401.60 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 373.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 373.05 Td (The Company and its af) Tj ET Q
q 0 0 0 rg BT 295.09 373.05 Td (filiates are currently engaged in the business of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 356.50 Td (branded and generic pharmaceuticals, with a focus on product ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 339.95 Td (development, clinical development, manufacturing, distribution and sales ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 323.40 Td (& marketing.  ) Tj ET Q
q 0 0 0 rg BT 249.77 323.40 Td (T) Tj ET Q
q 0 0 0 rg BT 256.26 323.40 Td (o protect the Confidential Information and other trade ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 306.80 Td (secrets of the Company and its af) Tj ET Q
q 0 0 0 rg BT 339.74 306.80 Td (filiates as well as the goodwill and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 290.25 Td (competitive business of the Company and its af) Tj ET Q
q 0 0 0 rg BT 407.41 290.25 Td (filiates, Executive agrees, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 273.70 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 296.77 273.70 Td (T) Tj ET Q
q 0 0 0 rg BT 303.26 273.70 Td (erm and for a period of twenty-four \(24\) months ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 257.15 Td (after Executive�) Tj ET Q
q 0 0 0 rg BT 256.29 257.15 Td (s cessation of employment with the Company) Tj ET Q
q 0 0 0 rg BT 474.81 257.15 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 240.60 Td (Executive will not, unless otherwise agreed to by the Board, anywhere in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 224.00 Td (the world where, at the time of Executive�) Tj ET Q
q 0 0 0 rg BT 381.93 224.00 Td (s termination of employment, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 207.45 Td (the Company develops, manufactures, distributes, markets or sells its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 190.90 Td (products, except in the course of Executive�) Tj ET Q
q 0 0 0 rg BT 390.26 190.90 Td (s employment hereunder) Tj ET Q
q 0 0 0 rg BT 508.41 190.90 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 174.35 Td (directly or indirectly manage, operate, control, or participate in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 157.80 Td (management, operation, or control of, be employed by) Tj ET Q
q 0 0 0 rg BT 440.47 157.80 Td (, associated with, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 141.20 Td (in any manner connected with, lend Executive�) Tj ET Q
q 0 0 0 rg BT 405.59 141.20 Td (s name to, or render ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 124.65 Td (services or advice to, any third party or any business whose products or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 108.10 Td (services compete in whole or in part with the products or services \(both on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 91.55 Td (the market and in development\) material to the Company or any business ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 75.00 Td (unit on the termination date that constitutes more than 5% of the ) Tj ET Q
endstream
endobj
347 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 348 0 R>>
endobj
348 0 obj
<</Length 7399>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (19) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (Company�) Tj ET Q
q 0 0 0 rg BT 230.00 711.70 Td (s revenue on the termination date \(a �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
410.255859375 710.100390625 m
509.26171875 710.100390625 l
s
q 0 0 0 rg BT 410.26 711.70 Td (Competing Business) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 509.26 711.70 Td (�\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 693.550390625 m
222.65625 693.550390625 l
s
q 0 0 0 rg BT 180.00 695.15 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 222.66 695.15 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
228.65625 693.550390625 m
269.73046875 693.550390625 l
s
q 0 0 0 rg BT 228.66 695.15 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 269.49 695.15 Td (, that Executive may in any event \(x\) own up to a 5% ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (passive ownership interest in any public or private entity and \(y\) serve on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (the board of any Competing Business that competes with the business of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (the Company and its af) Tj ET Q
q 0 0 0 rg BT 291.09 645.45 Td (filiates as an immaterial part of its overall business, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (provided that Executive recuses himself fully and completely from all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 612.35 Td (matters relating to such business.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 583.80 Td (For purposes of this Section 12\(b\), any third party or any business whose ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 567.20 Td (products compete includes any entity with which the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 550.65 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 550.65 Td (filiates has had a product\(s\) licensing agreement during the Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 534.10 Td (T) Tj ET Q
q 0 0 0 rg BT 186.49 534.10 Td (erm and any entity with which the Company or any of its af) Tj ET Q
q 0 0 0 rg BT 472.88 534.10 Td (filiates is at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 517.55 Td (the time of termination actively negotiating, and eventually concludes ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 501.00 Td (within twelve \(12\) months of the Employment ) Tj ET Q
q 0 0 0 rg BT 405.42 501.00 Td (T) Tj ET Q
q 0 0 0 rg BT 411.91 501.00 Td (erm, a commercial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 484.40 Td (agreement. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 455.85 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 455.85 Td (Notwithstanding the foregoing, it shall not be a violation of this Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 439.30 Td (12\(b\), for Executive to provide services to \(or engage in activities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 422.75 Td (involving\): \(A\) a subsidiary) Tj ET Q
q 0 0 0 rg BT 312.87 422.75 Td (, division or af) Tj ET Q
q 0 0 0 rg BT 382.64 422.75 Td (filiate of a Competing Business ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 406.20 Td (where such subsidiary) Tj ET Q
q 0 0 0 rg BT 285.86 406.20 Td (, division or af) Tj ET Q
q 0 0 0 rg BT 355.63 406.20 Td (filiate is not engaged in a Competing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 389.60 Td (Business and Executive does not provide services to, or have any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 373.05 Td (responsibilities regarding, the Competing Business; \(B\) any entity that is, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 356.50 Td (or is a general partner in, or manages or participates in managing, a private ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 339.95 Td (or public fund \(including a hedge fund\) or other investment vehicle, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 323.40 Td (is engaged in venture capital investments, leveraged buy-outs, investments ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 306.80 Td (in public or private companies, other forms of private or alternative equity ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 290.25 Td (transactions, or in public equity transactions, and that might make an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 273.70 Td (investment which Executive could not make directly) Tj ET Q
q 0 0 0 rg BT 431.81 273.70 Td (, provided that in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 257.15 Td (connection therewith, Executive does not provide services to, engage in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 240.60 Td (activities involved with, or have any responsibilities regarding a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 224.00 Td (Competing Business; and \(C\) an af) Tj ET Q
q 0 0 0 rg BT 348.09 224.00 Td (filiate of a Competing Business if ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 207.45 Td (Executive does not provide services, directly or indirectly) Tj ET Q
q 0 0 0 rg BT 456.46 207.45 Td (, to such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 190.90 Td (Competing Business and the basis of the af) Tj ET Q
q 0 0 0 rg BT 386.75 190.90 Td (filiation is solely due to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 174.35 Td (common ownership by a private equity or similar investment fund; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 156.20039062499995 m
222.65625 156.20039062499995 l
s
q 0 0 0 rg BT 180.00 157.80 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 222.66 157.80 Td (, that, in each case, Executive shall remain bound by all other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 141.20 Td (post-employment obligations under this ) Tj ET Q
q 0 0 0 rg BT 373.32 141.20 Td (Agreement including Executive�) Tj ET Q
q 0 0 0 rg BT 529.27 141.20 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 124.65 Td (obligations under Sections 1) Tj ET Q
q 0 0 0 rg BT 315.87 124.65 Td (1, 12\(a\), \(c\) and \(d\) herein; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
449.14453125 123.05039062499998 m
491.80078125 123.05039062499998 l
s
q 0 0 0 rg BT 449.14 124.65 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 491.80 124.65 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
497.80078125 123.05039062499998 m
530.208984375 123.05039062499998 l
s
q 0 0 0 rg BT 497.80 124.65 Td (further) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 529.97 124.65 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 108.10 Td (that Executive�) Tj ET Q
q 0 0 0 rg BT 252.30 108.10 Td (s provision of services to \(or engagement in activities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 91.55 Td (involving\) any entity described in clauses \(A\) or \(B\) of this Section 12\(b\)) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 75.00 Td (\(iii\) shall be subject to the prior approval of the Board.  ) Tj ET Q
endstream
endobj
349 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 350 0 R>>
endobj
350 0 obj
<</Length 7812>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (20) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
234.638671875 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Nondisparagement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 234.64 711.70 Td (. Executive covenants that during and following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 695.15 Td (erm, Executive will not disparage or encourage or induce others to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (disparage the Company or its af) Tj ET Q
q 0 0 0 rg BT 296.74 678.60 Td (filiates, together with all of their respective past ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (and present directors and of) Tj ET Q
q 0 0 0 rg BT 277.07 662.00 Td (ficers, as well as their respective past and present ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (managers, of) Tj ET Q
q 0 0 0 rg BT 205.76 645.45 Td (ficers, shareholders, partners, employees, agents, attorneys, servants ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (and customers and each of their predecessors, successors and assigns ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (\(collectively) Tj ET Q
q 0 0 0 rg BT 203.19 612.35 Td (, the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
232.177734375 610.750390625 m
379.166015625 610.750390625 l
s
q 0 0 0 rg BT 232.18 612.35 Td (Company Entities and Persons) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 379.17 612.35 Td (�\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
394.822265625 610.750390625 m
437.478515625 610.750390625 l
s
q 0 0 0 rg BT 394.82 612.35 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 437.48 612.35 Td (, that such limitation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (shall extend to past and present managers, of) Tj ET Q
q 0 0 0 rg BT 359.05 595.80 Td (ficers, shareholders, partners, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (employees, agents, attorneys, servants and customers only in their capacities as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (such or in respect of their relationship with the Company and its af) Tj ET Q
q 0 0 0 rg BT 464.37 562.65 Td (filiates. ) Tj ET Q
q 0 0 0 rg BT 502.81 562.65 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (Company shall instruct its of) Tj ET Q
q 0 0 0 rg BT 282.44 546.10 Td (ficers and directors not to, during and following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 529.55 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 529.55 Td (erm, make or issue any statement that disparages Executive to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (third parties or otherwise encourage or induce others to disparage Executive. ) Tj ET Q
q 0 0 0 rg BT 514.98 513.00 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (term �disparage� includes, without limitation, comments or statements adversely ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 479.85 Td (fecting in any manner \(i\) the conduct of the business of the Company Entities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (and Persons or Executive, or \(ii\) the business reputation of the Company Entities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (and Persons or Executive. Nothing in this ) Tj ET Q
q 0 0 0 rg BT 345.98 446.75 Td (Agreement is intended to or shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (prevent either party from providing, or limiting testimony in any judicial, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (administrative or legal process or otherwise as required by law) Tj ET Q
q 0 0 0 rg BT 444.12 413.60 Td (, prevent either ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (party from engaging in truthful testimony pursuant to any proceeding under this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 380.50 Td (Section 12 or Section 13 below or Section 6 of the Release or prevent Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 363.95 Td (from making statements in the course of doing Executive�) Tj ET Q
q 0 0 0 rg BT 421.93 363.95 Td (s normal duties for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 347.40 Td (Company) Tj ET Q
q 0 0 0 rg BT 189.88 347.40 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 318.80 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 318.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 317.200390625 m
514.951171875 317.200390625 l
s
q 0 0 0 rg BT 144.00 318.80 Td (Cooperation in ) Tj ET Q
q 0 0 0 rg BT 217.99 318.80 Td (Any Investigations and Litigation; No Cooperation with Non-) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 300.650390625 m
277.74609375 300.650390625 l
s
q 0 0 0 rg BT 144.00 302.25 Td (Governmental ) Tj ET Q
q 0 0 0 rg BT 215.43 302.25 Td (Third Parties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 277.75 302.25 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 403.18 302.25 Td (T) Tj ET Q
q 0 0 0 rg BT 409.67 302.25 Td (erm and thereafter) Tj ET Q
q 0 0 0 rg BT 497.13 302.25 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (Executive shall provide truthful information and otherwise assist and cooperate ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (with the Company and its af) Tj ET Q
q 0 0 0 rg BT 279.43 269.15 Td (filiates, and its counsel, \(i\) in connection with any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 252.60 Td (investigation, inquiry) Tj ET Q
q 0 0 0 rg BT 245.88 252.60 Td (, administrative, regulatory or judicial proceedings, or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 236.00 Td (connection with any dispute or claim of any kind that may be made against, by) Tj ET Q
q 0 0 0 rg BT 521.46 236.00 Td (, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 219.45 Td (with respect to the Company) Tj ET Q
q 0 0 0 rg BT 281.19 219.45 Td (, as reasonably requested by the Company \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 202.90 Td (Executive being available to the Company upon reasonable notice for interviews ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 186.35 Td (and factual investigations, appearing at the Company�) Tj ET Q
q 0 0 0 rg BT 402.26 186.35 Td (s request to give testimony ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 169.80 Td (without requiring service of a subpoena or other legal process, volunteering to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 153.20 Td (Company all pertinent information and turning over to the Company all relevant ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 136.65 Td (documents which are in or may come into Executive�) Tj ET Q
q 0 0 0 rg BT 399.92 136.65 Td (s possession\), and \(ii\) in all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 120.10 Td (matters concerning requests for information about the services or advice ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 103.55 Td (Executive provides or provided to the Company during Executive�) Tj ET Q
q 0 0 0 rg BT 463.25 103.55 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 87.00 Td (with Endo, its af) Tj ET Q
q 0 0 0 rg BT 223.11 87.00 Td (filiates and their predecessors. Such cooperation shall be subject ) Tj ET Q
endstream
endobj
351 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 352 0 R>>
endobj
352 0 obj
<</Length 7277>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (21) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (to Executive�) Tj ET Q
q 0 0 0 rg BT 207.64 711.70 Td (s business and personal commitments and shall not require ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Executive to cooperate against Executive�) Tj ET Q
q 0 0 0 rg BT 345.25 695.15 Td (s own legal interests or the legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (interests of any future employer of Executive. Executive shall use the Company�) Tj ET Q
q 0 0 0 rg BT 530.55 678.60 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (counsel for all matters in connection with this Section 12\(d\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
437.935546875 660.400390625 m
480.591796875 660.400390625 l
s
q 0 0 0 rg BT 437.94 662.00 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 480.59 662.00 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
486.591796875 660.400390625 m
527.666015625 660.400390625 l
s
q 0 0 0 rg BT 486.59 662.00 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 527.43 662.00 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (that if there exists an actual conflict of interest between Executive and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 628.90 Td (s counsel, Executive may retain separate counsel reasonably acceptable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (to the Company) Tj ET Q
q 0 0 0 rg BT 219.88 612.35 Td (. ) Tj ET Q
q 0 0 0 rg BT 225.66 612.35 Td (The existence of an actual conflict of interest, and whether such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (conflict may be waived, shall be determined pursuant to the rules of attorney ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (professional conduct and applicable law) Tj ET Q
q 0 0 0 rg BT 335.82 579.20 Td (. ) Tj ET Q
q 0 0 0 rg BT 341.60 579.20 Td (The Company agrees to promptly ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (reimburse Executive for reasonable expenses reasonably incurred by Executive, in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (connection with Executive�) Tj ET Q
q 0 0 0 rg BT 275.29 546.10 Td (s cooperation pursuant to this Section 12\(d\) \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (travel expenses at the level of travel permitted by this ) Tj ET Q
q 0 0 0 rg BT 403.25 529.55 Td (Agreement and reasonable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (attorney fees in the event separate legal counsel for Executive is required due to a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (conflict of interest\). Such reimbursements shall be made as soon as practicable, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (and in no event later than the calendar year following the year in which the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (expenses are incurred.  Executive also shall not support \(financially or otherwise\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (counsel or assist any attorneys or their clients or any other non-governmental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (person in the presentation or prosecution of, encourage any non-governmental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (person to raise, or suggest or recommend to any non-governmental person that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (such person could or should raise, in each case, any disputes, dif) Tj ET Q
q 0 0 0 rg BT 453.04 397.05 Td (ferences, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 380.50 Td (grievances, claims, char) Tj ET Q
q 0 0 0 rg BT 259.06 380.50 Td (ges, or complaints against the Company and/or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 363.95 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 363.95 Td (filiates that \(x\) arises out of, or relates to, any period of time on or prior to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 347.40 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 347.40 Td (s last day of employment with the Company or \(y\) involves any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 330.80 Td (information Executive learned during Executive�) Tj ET Q
q 0 0 0 rg BT 378.58 330.80 Td (s employment with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 314.25 Td (Company; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
196.998046875 312.650390625 m
239.654296875 312.650390625 l
s
q 0 0 0 rg BT 197.00 314.25 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 239.65 314.25 Td (, that, following the second anniversary of Executive�) Tj ET Q
q 0 0 0 rg BT 496.58 314.25 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 297.70 Td (termination of employment with the Company) Tj ET Q
q 0 0 0 rg BT 366.18 297.70 Td (, such prohibition shall not extend ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 281.15 Td (to any such actions taken by Executive on behalf of \(A\) Executive�) Tj ET Q
q 0 0 0 rg BT 465.56 281.15 Td (s then current ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 264.60 Td (employer) Tj ET Q
q 0 0 0 rg BT 188.84 264.60 Td (, \(B\) any entity with respect to which Executive is then a member of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 248.00 Td (board of directors or managers \(as applicable\), or \(C\) any non-publicly traded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 231.45 Td (entity with respect to which Executive is a 5% or more equity owner \(or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 214.90 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 214.90 Td (filiate of any such entities referenced in clauses \(A\), \(B\) or \(C\)\). Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 198.35 Td (agrees that, in the event Executive is subpoenaed by any person or entity ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 181.80 Td (\(including any government agency\) to give testimony \(in a deposition, court ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 165.20 Td (proceeding or otherwise\) which in any way relates to Executive�) Tj ET Q
q 0 0 0 rg BT 452.89 165.20 Td (s employment by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 148.65 Td (the Company) Tj ET Q
q 0 0 0 rg BT 207.54 148.65 Td (, Executive will, to the extent not legally prohibited from doing so, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 132.10 Td (give prompt notice of such request to the Chief Legal Of) Tj ET Q
q 0 0 0 rg BT 415.71 132.10 Td (ficer of the Company so ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 115.55 Td (that the Company may contest the right of the requesting person or entity to such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 99.00 Td (disclosure before making such disclosure. Nothing in this provision shall require ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 82.40 Td (Executive to violate Executive�) Tj ET Q
q 0 0 0 rg BT 294.28 82.40 Td (s obligation to comply with valid legal process.) Tj ET Q
endstream
endobj
353 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 354 0 R>>
endobj
354 0 obj
<</Length 7742>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (22) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
199.658203125 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Blue Pencil) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 199.66 711.70 Td (. It is the intent and desire of Executive and the Company that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (provisions of this Section 12 be enforced to the fullest extent permissible under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (the laws and public policies as applied in each jurisdiction in which enforcement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (is sought. If any particular provision of this Section 12 shall be determined to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (invalid or unenforceable, such covenant shall be amended, without any action on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (the part of either party hereto, to delete therefrom the portion so determined to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (invalid or unenforceable, such deletion to apply only with respect to the operation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (of such covenant in the particular jurisdiction in which such adjudication is made.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 567.20 Td (13.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 567.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 565.600390625 m
431.466796875 565.600390625 l
s
q 0 0 0 rg BT 108.00 567.20 Td (Remedies for Breach of Obligations under Sections 1) Tj ET Q
q 0 0 0 rg BT 363.83 567.20 Td (1 or 12 hereof) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 431.47 567.20 Td (. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 550.65 Td (acknowledges that the Company and its af) Tj ET Q
q 0 0 0 rg BT 311.06 550.65 Td (filiates will suf) Tj ET Q
q 0 0 0 rg BT 382.83 550.65 Td (fer irreparable injury) Tj ET Q
q 0 0 0 rg BT 482.00 550.65 Td (, not readily ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 534.10 Td (susceptible of valuation in monetary damages, if Executive breaches Executive�) Tj ET Q
q 0 0 0 rg BT 491.19 534.10 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (obligations under Sections 1) Tj ET Q
q 0 0 0 rg BT 243.87 517.55 Td (1 or 12 hereof. ) Tj ET Q
q 0 0 0 rg BT 316.85 517.55 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 376.05 517.55 Td (, Executive agrees that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 501.00 Td (Company and its af) Tj ET Q
q 0 0 0 rg BT 201.43 501.00 Td (filiates will be entitled, in addition to any other available remedies, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 484.40 Td (obtain injunctive relief against any breach or prospective breach by Executive of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 467.85 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 159.31 467.85 Td (s obligations under Sections 1) Tj ET Q
q 0 0 0 rg BT 302.85 467.85 Td (1 or 12 hereof in any Federal or state court ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 451.30 Td (sitting in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 269.47 451.30 Td (, at the Company�) Tj ET Q
q 0 0 0 rg BT 354.79 451.30 Td (s election, in any other state in which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 434.75 Td (Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 259.95 434.75 Td (s principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 425.88 434.75 Td (s principal place of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 418.20 Td (business) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 148.67 418.20 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 151.67 418.20 Td ( Executive hereby submits to the non-exclusive jurisdiction of all those courts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 401.60 Td (for the purposes of any actions or proceedings instituted by the Company or its af) Tj ET Q
q 0 0 0 rg BT 499.03 401.60 Td (filiates ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 385.05 Td (to obtain that injunctive relief, and Executive agrees that process in any or all of those ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 368.50 Td (actions or proceedings may be served by registered mail, addressed to the last address ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 351.95 Td (provided by Executive to the Company) Tj ET Q
q 0 0 0 rg BT 295.51 351.95 Td (, or in any other manner authorized by law) Tj ET Q
q 0 0 0 rg BT 499.00 351.95 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 323.40 Td (14.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 323.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 321.800390625 m
259.4296875 321.800390625 l
s
q 0 0 0 rg BT 108.00 323.40 Td (Representations and ) Tj ET Q
q 0 0 0 rg BT 207.76 323.40 Td (W) Tj ET Q
q 0 0 0 rg BT 218.12 323.40 Td (arranties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 259.43 323.40 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.80 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 294.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (The Company represents and warrants that \(i\) it is fully authorized by action of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (the Board \(and of any other person or body whose action is required\) to enter into ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 261.70 Td (Agreement and to perform its obligations under it, \(ii\) the execution, delivery ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (and performance of this ) Tj ET Q
q 0 0 0 rg BT 260.63 245.15 Td (Agreement by it does not violate any applicable law) Tj ET Q
q 0 0 0 rg BT 509.77 245.15 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (regulation, order) Tj ET Q
q 0 0 0 rg BT 223.49 228.60 Td (, judgment or decree or any agreement, arrangement, plan or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (corporate governance document \(x\) to which it is a party or \(y\) by which it is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (bound, and \(iii\) upon the execution and delivery of this ) Tj ET Q
q 0 0 0 rg BT 410.94 195.45 Td (Agreement by the parties, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 178.90 Td (Agreement shall be its valid and binding obligation, enforceable against it in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (accordance with its terms, except to the extent that enforceability may be limited ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (by applicable bankruptcy) Tj ET Q
q 0 0 0 rg BT 264.51 145.80 Td (, insolvency or similar laws af) Tj ET Q
q 0 0 0 rg BT 408.93 145.80 Td (fecting the enforcement of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (creditors�) Tj ET Q
q 0 0 0 rg BT 189.09 129.20 Td ( rights generally) Tj ET Q
q 0 0 0 rg BT 266.29 129.20 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 100.65 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 100.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 100.65 Td (Executive represents and warrants to the Company that the execution and delivery ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 84.10 Td (by Executive of this ) Tj ET Q
q 0 0 0 rg BT 242.65 84.10 Td (Agreement do not, and the performance by Executive of ) Tj ET Q
endstream
endobj
355 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 356 0 R>>
endobj
356 0 obj
<</Length 6792>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (23) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 711.70 Td (s obligations hereunder will not, with or without the giving of notice or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (the passage of time, or both: \(a\) violate any judgment, writ, injunction, or order of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (any court, arbitrator) Tj ET Q
q 0 0 0 rg BT 239.14 678.60 Td (, or governmental agency applicable to Executive; or \(b\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (conflict with, result in the breach of any provisions of or the termination of, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (constitute a default under) Tj ET Q
q 0 0 0 rg BT 265.14 645.45 Td (, any agreement to which Executive is a party or by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (which Executive is or may be bound.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 600.35 Td (15.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 598.750390625 m
177.31640625 598.750390625 l
s
q 0 0 0 rg BT 108.00 600.35 Td (Miscellaneous) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 177.32 600.35 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 571.80 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 571.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 570.200390625 m
257.33203125 570.200390625 l
s
q 0 0 0 rg BT 144.00 571.80 Td (Successors and ) Tj ET Q
q 0 0 0 rg BT 219.32 571.80 Td (Assigns) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 257.33 571.80 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 543.20 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 543.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 543.20 Td (This ) Tj ET Q
q 0 0 0 rg BT 203.67 543.20 Td (Agreement shall be binding upon and shall inure to the benefit of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 526.65 Td (Company) Tj ET Q
q 0 0 0 rg BT 225.88 526.65 Td (, its successors and permitted assigns and the Company shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 510.10 Td (require any successor or permitted assign to expressly assume and agree to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 493.55 Td (perform this ) Tj ET Q
q 0 0 0 rg BT 241.32 493.55 Td (Agreement in the same manner and to the same extent that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 477.00 Td (the Company would be required to perform if no such succession or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 460.40 Td (assignment had taken place. ) Tj ET Q
q 0 0 0 rg BT 317.40 460.40 Td (The Company may not assign or delegate any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 443.85 Td (rights or obligations hereunder except to any of its af) Tj ET Q
q 0 0 0 rg BT 434.04 443.85 Td (filiates, or to a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 427.30 Td (successor \(whether direct or indirect, by purchase, mer) Tj ET Q
q 0 0 0 rg BT 442.68 427.30 Td (ger) Tj ET Q
q 0 0 0 rg BT 457.52 427.30 Td (, consolidation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 410.75 Td (or otherwise\) to all or substantially all of the business and/or assets of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 394.20 Td (Company) Tj ET Q
q 0 0 0 rg BT 225.88 394.20 Td (. ) Tj ET Q
q 0 0 0 rg BT 231.67 394.20 Td (The term the �Company� as used herein shall include a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 377.60 Td (corporation or other entity acquiring all or substantially all the assets and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 361.05 Td (business of the Company \(including this ) Tj ET Q
q 0 0 0 rg BT 375.99 361.05 Td (Agreement\) whether by operation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 344.50 Td (of law or otherwise.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 315.95 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 315.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 315.95 Td (Neither this ) Tj ET Q
q 0 0 0 rg BT 238.66 315.95 Td (Agreement nor any right or interest hereunder shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 299.40 Td (assignable or transferable by Executive, Executive�) Tj ET Q
q 0 0 0 rg BT 425.90 299.40 Td (s beneficiaries or legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 282.80 Td (representatives, except by will or by the laws of descent and distribution. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 266.25 Td (This ) Tj ET Q
q 0 0 0 rg BT 203.67 266.25 Td (Agreement shall inure to the benefit of and be enforceable by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 249.70 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 231.31 249.70 Td (s legal personal representatives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 222.60 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 222.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 221.00039062500002 m
234.64453125 221.00039062500002 l
s
q 0 0 0 rg BT 144.00 222.60 Td (Fees and Expenses) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 234.64 222.60 Td (. ) Tj ET Q
q 0 0 0 rg BT 240.43 222.60 Td (The Company shall pay reasonable and documented legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (fees and related expenses, up to a maximum amount of $10,000, incurred by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 192.35 Td (Executive in connection with the negotiation of this ) Tj ET Q
q 0 0 0 rg BT 394.61 192.35 Td (Agreement and related ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 177.20 Td (employment arrangements. Such reimbursement shall be made as soon as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.10 Td (practicable, but in no event later than sixty \(60\) days from the execution of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 147.00 Td (Agreement. Executive is responsible for any taxes that may be due based upon ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 131.85 Td (the value of the fees and expenses reimbursed by the Company) Tj ET Q
q 0 0 0 rg BT 445.79 131.85 Td (. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 116.75 Td (acknowledges that Executive has had the opportunity to consult with legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 101.60 Td (counsel of Executive's choice in connection with the drafting, negotiation and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 86.50 Td (execution of this ) Tj ET Q
q 0 0 0 rg BT 226.32 86.50 Td (Agreement and related employment arrangements.) Tj ET Q
endstream
endobj
357 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 358 0 R>>
endobj
358 0 obj
<</Length 8856>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (24) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
175.986328125 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Notice) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 175.99 711.70 Td (. For the purposes of this ) Tj ET Q
q 0 0 0 rg BT 297.65 711.70 Td (Agreement, notices and all other communications ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (provided for in the ) Tj ET Q
q 0 0 0 rg BT 235.98 695.15 Td (Agreement \(including the Notice of ) Tj ET Q
q 0 0 0 rg BT 410.04 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 416.53 695.15 Td (ermination\) shall be in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (writing and shall be deemed to have been duly given when personally delivered or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (sent by Certified mail, return receipt requested, postage prepaid, addressed to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (respective addresses last given by each party to the other; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
422.56640625 643.850390625 m
465.22265625 643.850390625 l
s
q 0 0 0 rg BT 422.57 645.45 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 465.22 645.45 Td (, that all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (notices to the Company shall be directed to the attention of the Chief Legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (Of) Tj ET Q
q 0 0 0 rg BT 156.45 612.35 Td (ficer of the Company with a copy to the Chairman of the Committee. ) Tj ET Q
q 0 0 0 rg BT 490.37 612.35 Td (All ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (notices and communications shall be deemed to have been received on the date of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (delivery thereof or on the third business day after the mailing thereof, except that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (notice of change of address shall be ef) Tj ET Q
q 0 0 0 rg BT 327.38 562.65 Td (fective only upon receipt.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 534.10 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 534.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 532.500390625 m
220.640625 532.500390625 l
s
q 0 0 0 rg BT 144.00 534.10 Td (Indemnification) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 220.64 534.10 Td (. Executive shall be indemnified by the Company as, and to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (extent, to the maximum extent permitted by applicable law as provided in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (memorandum and articles of association of Endo. In addition, the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (agrees to continue and maintain, at the Company�) Tj ET Q
q 0 0 0 rg BT 381.93 484.40 Td (s sole expense, a directors�) Tj ET Q
q 0 0 0 rg BT 509.99 484.40 Td ( and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 467.85 Td (ficers�) Tj ET Q
q 0 0 0 rg BT 183.53 467.85 Td ( liability insurance policy covering Executive both during and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 451.30 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 451.30 Td (erm and while the potential liability exists \(but in no event longer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (than six \(6\) years, if such limitation applies to all other individuals covered by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (such policy\) after the Employment ) Tj ET Q
q 0 0 0 rg BT 313.40 418.20 Td (T) Tj ET Q
q 0 0 0 rg BT 319.89 418.20 Td (erm, that is no less favorable than the policy ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (covering Board members and other executive of) Tj ET Q
q 0 0 0 rg BT 375.03 401.60 Td (ficers of the Company from time ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (to time. ) Tj ET Q
q 0 0 0 rg BT 183.45 385.05 Td (The obligations under this paragraph shall survive any termination of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 368.50 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 368.50 Td (erm.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 339.95 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 339.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 338.350390625 m
204.181640625 338.350390625 l
s
q 0 0 0 rg BT 144.00 339.95 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 339.95 Td (ithholding) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 204.18 339.95 Td (. ) Tj ET Q
q 0 0 0 rg BT 209.96 339.95 Td (The Company shall be entitled to withhold the amount, if any) Tj ET Q
q 0 0 0 rg BT 504.80 339.95 Td (, of all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (taxes of any applicable jurisdiction required to be withheld by an employer with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (respect to any amount paid to Executive hereunder) Tj ET Q
q 0 0 0 rg BT 386.91 306.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 392.70 306.80 Td (The Company) Tj ET Q
q 0 0 0 rg BT 460.24 306.80 Td (, in its sole and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 290.25 Td (absolute discretion, shall make all determinations as to whether it is obligated to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 273.70 Td (withhold any taxes hereunder and the amount thereof.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 245.15 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 245.15 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 243.55039062499998 m
231.310546875 243.55039062499998 l
s
q 0 0 0 rg BT 144.00 245.15 Td (Release of Claims) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 231.31 245.15 Td (. ) Tj ET Q
q 0 0 0 rg BT 237.09 245.15 Td (The termination benefits described in Sections 9\(d\)\(ii\) � \(v\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (and 9\(e\)\(ii\) � \(v\) of this ) Tj ET Q
q 0 0 0 rg BT 259.97 228.60 Td (Agreement shall be conditioned on Executive delivering ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (to the Company) Tj ET Q
q 0 0 0 rg BT 219.88 212.00 Td (, a signed release of claims in the form of Exhibit ) Tj ET Q
q 0 0 0 rg BT 459.15 212.00 Td (A) Tj ET Q
q 0 0 0 rg BT 467.15 212.00 Td ( hereto within ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (forty-five \(45\) days or twenty-one \(21\) days, as may be applicable under the ) Tj ET Q
q 0 0 0 rg BT 512.54 195.45 Td (Age ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (Discrimination in Employment ) Tj ET Q
q 0 0 0 rg BT 295.65 178.90 Td (Act of 1967, as amended by the Older ) Tj ET Q
q 0 0 0 rg BT 481.05 178.90 Td (W) Tj ET Q
q 0 0 0 rg BT 491.41 178.90 Td (orkers ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (Benefit Protection ) Tj ET Q
q 0 0 0 rg BT 233.98 162.35 Td (Act, following Executive�) Tj ET Q
q 0 0 0 rg BT 358.28 162.35 Td (s termination date, and not revoking ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 145.80 Td (s consent to such release of claims within seven \(7\) days of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (execution; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
196.98046875 127.60039062500005 m
239.63671875 127.60039062500005 l
s
q 0 0 0 rg BT 196.98 129.20 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 239.64 129.20 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
245.63671875 127.60039062500005 m
286.7109375 127.60039062500005 l
s
q 0 0 0 rg BT 245.64 129.20 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 286.47 129.20 Td (, that Executive shall not be required to release any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 112.65 Td (rights Executive may have to be indemnified by) Tj ET Q
q 0 0 0 rg BT 373.49 112.65 Td (, or be covered under any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 96.10 Td (directors�) Tj ET Q
q 0 0 0 rg BT 189.09 96.10 Td ( and of) Tj ET Q
q 0 0 0 rg BT 222.19 96.10 Td (ficers�) Tj ET Q
q 0 0 0 rg BT 251.95 96.10 Td ( liability insurance of, the Company under Section 15\(d\) of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 79.55 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 79.55 Td (Agreement, and provided further that, following a Change in Control, ) Tj ET Q
endstream
endobj
359 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 360 0 R>>
endobj
360 0 obj
<</Length 8260>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (25) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 711.70 Td (s requirement to deliver a release shall be contingent on the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (delivering to Executive a release of claims in the form of Exhibit ) Tj ET Q
q 0 0 0 rg BT 457.90 695.15 Td (A) Tj ET Q
q 0 0 0 rg BT 465.90 695.15 Td ( hereto. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(g\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 665.000390625 m
307.3916015625 665.000390625 l
s
q 0 0 0 rg BT 144.00 666.60 Td (Resignation as Of) Tj ET Q
q 0 0 0 rg BT 229.77 666.60 Td (ficer or Director) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 307.06 666.60 Td (. Upon a termination of employment for any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (reason, Executive shall, resign each position \(if any\) that Executive then holds as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (an of) Tj ET Q
q 0 0 0 rg BT 168.11 633.45 Td (ficer or director of the Company and any of its af) Tj ET Q
q 0 0 0 rg BT 403.80 633.45 Td (filiates. Executive�) Tj ET Q
q 0 0 0 rg BT 493.77 633.45 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (execution of this ) Tj ET Q
q 0 0 0 rg BT 226.32 616.90 Td (Agreement shall be deemed the grant by Executive to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 600.35 Td (ficers of the Company of a limited power of attorney to sign in Executive�) Tj ET Q
q 0 0 0 rg BT 509.35 600.35 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (name and on Executive�) Tj ET Q
q 0 0 0 rg BT 259.62 583.80 Td (s behalf any such documentation as may be required to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (executed solely for the limited purposes of ef) Tj ET Q
q 0 0 0 rg BT 360.71 567.20 Td (fectuating such resignations.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 538.65 Td (\(h\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 538.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 537.050390625 m
284.953125 537.050390625 l
s
q 0 0 0 rg BT 144.00 538.65 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 194.31 538.65 Td (Acknowledgement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 284.95 538.65 Td (. Executive acknowledges the Common Stock ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (Ownership Guidelines for Non-Employee Directors and Executive Management ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (of Endo International plc, as may be amended from time to time, and Endo�) Tj ET Q
q 0 0 0 rg BT 506.89 505.55 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (compensation recoupment policy) Tj ET Q
q 0 0 0 rg BT 302.51 489.00 Td (, as may be amended from time to time.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 460.40 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 460.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 458.800390625 m
206.654296875 458.800390625 l
s
q 0 0 0 rg BT 144.00 460.40 Td (Modification) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 206.65 460.40 Td (. No provision of this ) Tj ET Q
q 0 0 0 rg BT 311.33 460.40 Td (Agreement may be modified, waived or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 443.85 Td (dischar) Tj ET Q
q 0 0 0 rg BT 178.44 443.85 Td (ged unless such waiver) Tj ET Q
q 0 0 0 rg BT 288.93 443.85 Td (, modification or dischar) Tj ET Q
q 0 0 0 rg BT 406.68 443.85 Td (ge is agreed to in writing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 427.30 Td (and signed by Executive and the Company) Tj ET Q
q 0 0 0 rg BT 348.50 427.30 Td (. No waiver by either party hereto at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (any time of any breach by the other party hereto of, or compliance with, any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 394.20 Td (condition or provision of this ) Tj ET Q
q 0 0 0 rg BT 286.33 394.20 Td (Agreement to be performed by such other party ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 377.60 Td (shall be deemed a waiver of similar or dissimilar provisions or conditions at the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 361.05 Td (same or at any prior or subsequent time. No agreement or representations, oral or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (otherwise, express or implied, with respect to the subject matter hereof have been ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (made by either party which are not expressly set forth in this ) Tj ET Q
q 0 0 0 rg BT 437.26 327.95 Td (Agreement.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 299.40 Td (\(j\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 299.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 297.800390625 m
240.3427734375 297.800390625 l
s
q 0 0 0 rg BT 144.00 299.40 Td (Ef) Tj ET Q
q 0 0 0 rg BT 155.11 299.40 Td (fect of Other Law) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 239.95 299.40 Td (. ) Tj ET Q
q 0 0 0 rg BT 245.29 299.40 Td (Anything herein to the contrary notwithstanding, the terms ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 282.80 Td (of this ) Tj ET Q
q 0 0 0 rg BT 176.67 282.80 Td (Agreement shall be modified to the extent required to meet the provisions ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 266.25 Td (of the Sarbanes-Oxley ) Tj ET Q
q 0 0 0 rg BT 253.63 266.25 Td (Act of 2002, Section 409A) Tj ET Q
q 0 0 0 rg BT 381.96 266.25 Td ( of the Code, or other federal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 249.70 Td (law applicable to the employment arrangements between Executive and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 233.15 Td (Company) Tj ET Q
q 0 0 0 rg BT 189.88 233.15 Td (. ) Tj ET Q
q 0 0 0 rg BT 195.22 233.15 Td (Any delay in providing benefits or payments, any failure to provide a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 216.60 Td (benefit or payment, or any repayment of compensation that is required under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 200.00 Td (preceding sentence shall not in and of itself constitute a breach of this ) Tj ET Q
q 0 0 0 rg BT 480.90 200.00 Td (Agreement; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 181.85039062500005 m
186.65625 181.85039062500005 l
s
q 0 0 0 rg BT 144.00 183.45 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 186.66 183.45 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
192.65625 181.85039062500005 m
233.73046875 181.85039062500005 l
s
q 0 0 0 rg BT 192.66 183.45 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 233.49 183.45 Td (, that the Company shall provide economically equivalent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (payments or benefits to Executive to the extent permitted by law) Tj ET Q
q 0 0 0 rg BT 453.13 166.90 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 138.35 Td (\(k\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 138.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 136.75039062500002 m
219.2548828125 136.75039062500002 l
s
q 0 0 0 rg BT 144.00 138.35 Td (Governing Law) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 218.87 138.35 Td (. ) Tj ET Q
q 0 0 0 rg BT 224.65 138.35 Td (This ) Tj ET Q
q 0 0 0 rg BT 248.32 138.35 Td (Agreement shall be governed by and construed and enforced ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (in accordance with the laws of the State of Delaware applicable to contracts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (executed in and to be performed entirely within such State, without giving ef) Tj ET Q
q 0 0 0 rg BT 512.68 105.20 Td (fect ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (to the conflict of law principles thereof.  ) Tj ET Q
q 0 0 0 rg BT 339.60 88.65 Td (Any dispute hereunder may be ) Tj ET Q
endstream
endobj
361 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 362 0 R>>
endobj
362 0 obj
<</Length 7771>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (26) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (adjudicated in any Federal or state court sitting in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 501.06 711.70 Td (, at the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 695.15 Td (s election, in any other state in which Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 527.56 695.15 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 302.26 678.60 Td (s principal place of business. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 650.00 Td (\(l\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 650.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 648.400390625 m
205.6640625 648.400390625 l
s
q 0 0 0 rg BT 144.00 650.00 Td (No Conflicts) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 205.66 650.00 Td (. \(A\) Executive represents and warrants to the Company that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (Executive is not a party to or otherwise bound by any agreement or arrangement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (\(including any license, covenant, or commitment of any nature\), or subject to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (judgment, decree, or order of any court or administrative agency) Tj ET Q
q 0 0 0 rg BT 452.77 600.35 Td (, that would ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (conflict with or will be in conflict with or in any way preclude, limit or inhibit ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 567.20 Td (s ability to execute this ) Tj ET Q
q 0 0 0 rg BT 308.29 567.20 Td (Agreement or to carry out Executive�) Tj ET Q
q 0 0 0 rg BT 487.22 567.20 Td (s duties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (and responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 287.30 550.65 Td (. \(B\) ) Tj ET Q
q 0 0 0 rg BT 312.08 550.65 Td (The Company represents and warrants to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (Executive that the Company is not a party to or otherwise bound by any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (agreement or arrangement \(including any license, covenant, or commitment of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (any nature\), or subject to any judgment, decree, or order of any court or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (administrative agency) Tj ET Q
q 0 0 0 rg BT 248.85 484.40 Td (, that would conflict with or will be in conflict with or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (any way preclude, limit or inhibit the Company�) Tj ET Q
q 0 0 0 rg BT 375.29 467.85 Td (s ability to execute this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (Agreement or to carry out the Company�) Tj ET Q
q 0 0 0 rg BT 339.28 451.30 Td (s duties and responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 521.91 451.30 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 422.75 Td (\(m\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.33 422.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 421.150390625 m
201.5947265625 421.150390625 l
s
q 0 0 0 rg BT 144.00 422.75 Td (Severability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 201.21 422.75 Td (. ) Tj ET Q
q 0 0 0 rg BT 206.99 422.75 Td (The provisions of this ) Tj ET Q
q 0 0 0 rg BT 314.32 422.75 Td (Agreement shall be deemed severable and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (invalidity or unenforceability of any provision shall not af) Tj ET Q
q 0 0 0 rg BT 422.38 406.20 Td (fect the validity or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (enforceability of the other provisions hereof.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 361.05 Td (\(n\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 361.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 359.450390625 m
217.3125 359.450390625 l
s
q 0 0 0 rg BT 144.00 361.05 Td (Inconsistencies) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 217.31 361.05 Td (. In the event of any inconsistency between any provision of this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (Agreement and any provision of any employee handbook, personnel manual, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (program, policy) Tj ET Q
q 0 0 0 rg BT 219.87 327.95 Td (, or arrangement of the Company or its af) Tj ET Q
q 0 0 0 rg BT 418.59 327.95 Td (filiates \(including any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (provisions relating to notice requirements and post-employment restrictions\), the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (provisions of this ) Tj ET Q
q 0 0 0 rg BT 229.68 294.80 Td (Agreement shall control, unless Executive otherwise agrees in a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (writing that expressly refers to the provision of this ) Tj ET Q
q 0 0 0 rg BT 392.29 278.25 Td (Agreement whose control ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (Executive is waiving.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 233.15 Td (\(o\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 233.15 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 231.55039062499998 m
263.9296875 231.55039062499998 l
s
q 0 0 0 rg BT 144.00 233.15 Td (Beneficiaries/References) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 263.93 233.15 Td (. In the event of Executive�) Tj ET Q
q 0 0 0 rg BT 393.88 233.15 Td (s death or a judicial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 216.60 Td (determination of Executive�) Tj ET Q
q 0 0 0 rg BT 277.95 216.60 Td (s incompetence, references in this ) Tj ET Q
q 0 0 0 rg BT 442.55 216.60 Td (Agreement to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 200.00 Td (Executive shall be deemed, where appropriate, to refer to Executive�) Tj ET Q
q 0 0 0 rg BT 472.85 200.00 Td (s beneficiary) Tj ET Q
q 0 0 0 rg BT 533.71 200.00 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 183.45 Td (estate or other legal representative.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 154.90 Td (\(p\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 154.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 153.30039062499998 m
184.6640625 153.30039062499998 l
s
q 0 0 0 rg BT 144.00 154.90 Td (Survival) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 184.66 154.90 Td (. Except as otherwise set forth in this ) Tj ET Q
q 0 0 0 rg BT 364.29 154.90 Td (Agreement, the respective rights ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 138.35 Td (and obligations of the parties hereunder shall survive the Employment ) Tj ET Q
q 0 0 0 rg BT 483.70 138.35 Td (T) Tj ET Q
q 0 0 0 rg BT 490.19 138.35 Td (erm and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (any termination of Executive�) Tj ET Q
q 0 0 0 rg BT 286.95 121.80 Td (s employment.  ) Tj ET Q
q 0 0 0 rg BT 363.39 121.80 Td (W) Tj ET Q
q 0 0 0 rg BT 374.24 121.80 Td (ithout limiting the generality of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (the for) Tj ET Q
q 0 0 0 rg BT 175.44 105.20 Td (going, the provisions of Sections 9, 1) Tj ET Q
q 0 0 0 rg BT 353.65 105.20 Td (1, 12, and 13 shall survive the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (termination of the Employment ) Tj ET Q
q 0 0 0 rg BT 297.75 88.65 Td (T) Tj ET Q
q 0 0 0 rg BT 304.24 88.65 Td (erm.) Tj ET Q
endstream
endobj
363 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 364 0 R>>
endobj
364 0 obj
<</Length 5753>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (27) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(q\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
228.966796875 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Entire ) Tj ET Q
q 0 0 0 rg BT 175.66 711.70 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 228.97 711.70 Td (. ) Tj ET Q
q 0 0 0 rg BT 234.75 711.70 Td (This ) Tj ET Q
q 0 0 0 rg BT 258.42 711.70 Td (Agreement constitutes the entire agreement between the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (parties hereto and, as of the Ef) Tj ET Q
q 0 0 0 rg BT 290.06 695.15 Td (fective Date, supersedes all prior agreements, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (understandings and arrangements, oral or written, between the parties hereto with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (respect to the subject matter hereof, including the employment agreement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (between Executive and the Company dated December 19, 2019; provided, that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (contribution retention bonus arrangement dated ) Tj ET Q
q 0 0 0 rg BT 374.27 628.90 Td (August 1, 2019 shall remain in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (ef) Tj ET Q
q 0 0 0 rg BT 153.11 612.35 Td (fect in accordance with its terms.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (\(r\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 582.200390625 m
205.986328125 582.200390625 l
s
q 0 0 0 rg BT 144.00 583.80 Td (Counterparts) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 205.99 583.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 211.77 583.80 Td (This ) Tj ET Q
q 0 0 0 rg BT 235.44 583.80 Td (Agreement may be executed in one or more counterparts, each ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (of which will be deemed to be an original copy of this ) Tj ET Q
q 0 0 0 rg BT 405.94 567.20 Td (Agreement and all of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (which, when taken together) Tj ET Q
q 0 0 0 rg BT 276.14 550.65 Td (, will be deemed to constitute one and the same ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (agreement.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 505.55 Td (16.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 505.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 503.950390625 m
251.6484375 503.950390625 l
s
q 0 0 0 rg BT 108.00 505.55 Td (Certain Rules of Construction) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 251.65 505.55 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 477.00 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 477.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 477.00 Td (The headings and subheadings set forth in this ) Tj ET Q
q 0 0 0 rg BT 368.63 477.00 Td (Agreement are inserted for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 460.40 Td (convenience of reference only and are to be ignored in any construction of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 443.85 Td (terms set forth herein.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 415.30 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 415.30 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 415.30 Td (Wherever applicable, the neuter) Tj ET Q
q 0 0 0 rg BT 296.77 415.30 Td (, feminine or masculine pronoun as used herein ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 398.75 Td (shall also include the masculine or feminine, as the case may be.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 370.20 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 370.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 370.20 Td (The term �including� is not limiting and means �including without limitation.�) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 341.60 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 341.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 341.60 Td (References in this ) Tj ET Q
q 0 0 0 rg BT 232.31 341.60 Td (Agreement to any statute or statutory provisions include a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 325.05 Td (reference to such statute or statutory provisions as from time to time amended, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 308.50 Td (modified, reenacted, extended, consolidated or replaced \(whether before or after ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 291.95 Td (the date of this ) Tj ET Q
q 0 0 0 rg BT 217.32 291.95 Td (Agreement\) and to any subordinate legislation made from time to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 275.40 Td (time under such statute or statutory provision.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 246.80 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 246.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 246.80 Td (References to �writing� or �written� include any non-transient means of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 230.25 Td (representing or copying words legibly) Tj ET Q
q 0 0 0 rg BT 325.85 230.25 Td (, including by facsimile or electronic mail.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 201.70 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 201.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 201.70 Td (References to �$� are to United States Dollars.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.00 175.90 Td ( ) Tj ET Q
endstream
endobj
365 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 366 0 R>>
endobj
366 0 obj
<</Length 2257>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 256.00 59.20 Td (SIGNA) Tj ET Q
q 0 0 0 rg BT 291.34 59.20 Td (TURE P) Tj ET Q
q 0 0 0 rg BT 331.24 59.20 Td (AGE) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td ( IN ) Tj ET Q
q 0 0 0 rg BT 126.45 711.70 Td (WITNESS ) Tj ET Q
q 0 0 0 rg BT 181.22 711.70 Td (WHEREOF) Tj ET Q
q 0 0 0 rg BT 238.26 711.70 Td (, the Company has caused this ) Tj ET Q
q 0 0 0 rg BT 385.90 711.70 Td (Agreement to be executed by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 695.15 Td (its duly authorized of) Tj ET Q
q 0 0 0 rg BT 174.09 695.15 Td (ficer and Executive has executed this ) Tj ET Q
q 0 0 0 rg BT 354.69 695.15 Td (Agreement as of the day and year first ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 678.60 Td (above written.) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 612.1 m
540.5 612.1 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 612.1 m
540.5 612.1 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 496.1 m
540.5 496.1 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 496.1 m
540.5 496.1 l
s
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 645.47 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 327.13 645.47 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 616.47 Td (By:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 616.28 Td (/s/ Paul ) Tj ET Q
q 0 0 0 rg BT 339.56 616.28 Td (V) Tj ET Q
q 0 0 0 rg BT 347.35 616.28 Td (. Campanelli) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 601.47 Td (Name:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 601.28 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 325.23 601.28 Td (V) Tj ET Q
q 0 0 0 rg BT 333.01 601.28 Td (. Campanelli) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 586.47 Td (T) Tj ET Q
q 0 0 0 rg BT 263.90 586.47 Td (itle:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 586.28 Td (Chairman of the Board of Directors) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 529.47 Td (EXECUTIVE) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 500.47 Td (By:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 500.28 Td (/s/ Blaise Coleman) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 485.47 Td (Name:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 485.28 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
367 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 368 0 R>>
endobj
368 0 obj
<</Length 9969>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 274.90 711.90 Td (EXHIBIT) Tj ET Q
q 0 0 0 rg BT 326.03 711.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 328.37 711.90 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.04 711.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 208.15 671.55 Td (FORM OF) Tj ET Q
q 0 0 0 rg BT 264.02 671.55 Td ( RELEASE ) Tj ET Q
q 0 0 0 rg BT 325.38 671.55 Td (AGREEMENT) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 632.75 Td (THIS RELEASE ) Tj ET Q
q 0 0 0 rg BT 192.67 632.75 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 266.44 632.75 Td ( \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
296.42578125 631.150390625 m
333.73828125 631.150390625 l
s
q 0 0 0 rg BT 296.43 632.75 Td (Release) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 333.74 632.75 Td (�\) is made by and between Blaise ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 618.35 Td (Coleman \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
127.646484375 616.750390625 m
175.623046875 616.750390625 l
s
q 0 0 0 rg BT 127.65 618.35 Td (Executive) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 175.62 618.35 Td (�\) and Endo Health Solutions, Inc. \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
371.23828125 616.750390625 m
417.90234375 616.750390625 l
s
q 0 0 0 rg BT 371.24 618.35 Td (Company) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 417.90 618.35 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 589.55 Td (1. ) Tj ET Q
q 0 0 0 rg BT 108.00 589.55 Td (FOR ) Tj ET Q
q 0 0 0 rg BT 133.68 589.55 Td (AND IN CONSIDERA) Tj ET Q
q 0 0 0 rg BT 245.68 589.55 Td (TION of the payments and benefits provided in [Section 9\(d\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 575.15 Td (\(excluding clause \(i\)\)] [Section 9\(e\) \(excluding clause \(i\)\)]) Tj ET Q
BT /F3 12.00 Tf ET
BT /F3 7.80 Tf ET
q 0 0 0 rg BT 389.54 580.59 Td (1) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 393.44 575.15 Td ( of the Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 560.75 Td (Agreement between Executive and the Company dated as of March 6, 2020, \(the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 546.35 Td (�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
113.326171875 544.750390625 m
230.96484375 544.750390625 l
s
q 0 0 0 rg BT 113.33 546.35 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 177.66 546.35 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 230.96 546.35 Td (�\), Executive, for Executive, his successors and assigns, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 531.95 Td (executors and administrators, now and forever hereby releases and dischar) Tj ET Q
q 0 0 0 rg BT 464.98 531.95 Td (ges the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (Company) Tj ET Q
q 0 0 0 rg BT 153.88 517.55 Td (, together with all of its past and present parents, subsidiaries, and af) Tj ET Q
q 0 0 0 rg BT 481.92 517.55 Td (filiates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 503.15 Td (together with each of their of) Tj ET Q
q 0 0 0 rg BT 247.39 503.15 Td (ficers, directors, stockholders, partners, employees, agents, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 488.75 Td (representatives and attorneys, and each of their subsidiaries, af) Tj ET Q
q 0 0 0 rg BT 408.33 488.75 Td (filiates, estates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 474.35 Td (predecessors, successors, and assigns \(hereinafter collectively referred to as the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 459.95 Td (�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
113.326171875 458.350390625 m
160.634765625 458.350390625 l
s
q 0 0 0 rg BT 113.33 459.95 Td (Releasees) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 160.63 459.95 Td (�\) from any and all rights, claims, char) Tj ET Q
q 0 0 0 rg BT 346.02 459.95 Td (ges, actions, causes of action, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 445.55 Td (complaints, sums of money) Tj ET Q
q 0 0 0 rg BT 239.21 445.55 Td (, suits, debts, covenants, contracts, agreements, promises, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 431.15 Td (obligations, damages, demands or liabilities of every kind whatsoever) Tj ET Q
q 0 0 0 rg BT 442.77 431.15 Td (, in law or in equity) Tj ET Q
q 0 0 0 rg BT 535.97 431.15 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 416.75 Td (whether known or unknown, suspected or unsuspected, which Executive or Executive�) Tj ET Q
q 0 0 0 rg BT 523.89 416.75 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 402.35 Td (executors, administrators, successors or assigns ever had, now has or may hereafter claim ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 387.95 Td (to have by reason of any matter) Tj ET Q
q 0 0 0 rg BT 258.80 387.95 Td (, cause or thing whatsoever; arising from the beginning of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 373.55 Td (time up to the date Executive executes the Release: \(i\) relating in any way to Executive�) Tj ET Q
q 0 0 0 rg BT 530.17 373.55 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 359.15 Td (employment relationship with the Company or any of the Releasees, or the termination of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 344.75 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 159.31 344.75 Td (s employment relationship with the Company or any of the Releasees; \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 330.35 Td (arising under or relating to the Employment ) Tj ET Q
q 0 0 0 rg BT 320.95 330.35 Td (Agreement; \(iii\) arising under any federal, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 315.95 Td (local or state statute or regulation, including, without limitation, the ) Tj ET Q
q 0 0 0 rg BT 434.94 315.95 Td (Age Discrimination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 301.55 Td (in Employment ) Tj ET Q
q 0 0 0 rg BT 184.66 301.55 Td (Act of 1967, as amended by the Older ) Tj ET Q
q 0 0 0 rg BT 370.06 301.55 Td (W) Tj ET Q
q 0 0 0 rg BT 380.43 301.55 Td (orkers Benefit Protection ) Tj ET Q
q 0 0 0 rg BT 503.40 301.55 Td (Act, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 287.15 Td (T) Tj ET Q
q 0 0 0 rg BT 114.91 287.15 Td (itle ) Tj ET Q
q 0 0 0 rg BT 133.02 287.15 Td (VII of the Civil Rights ) Tj ET Q
q 0 0 0 rg BT 244.02 287.15 Td (Act of 1964, the ) Tj ET Q
q 0 0 0 rg BT 324.34 287.15 Td (Americans with Disabilities ) Tj ET Q
q 0 0 0 rg BT 460.65 287.15 Td (Act of 1990, the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 272.75 Td (Employee Retirement Income Security ) Tj ET Q
q 0 0 0 rg BT 297.28 272.75 Td (Act of 1974, the Equal Pay ) Tj ET Q
q 0 0 0 rg BT 429.59 272.75 Td (Act, Sections 1981 ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 258.35 Td (through 1988 of ) Tj ET Q
q 0 0 0 rg BT 188.11 258.35 Td (T) Tj ET Q
q 0 0 0 rg BT 195.02 258.35 Td (itle 42 of the United States Code, the Immigration Reform and Control ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 243.95 Td (Act, the ) Tj ET Q
q 0 0 0 rg BT 148.77 243.95 Td (W) Tj ET Q
q 0 0 0 rg BT 159.13 243.95 Td (orkers ) Tj ET Q
q 0 0 0 rg BT 191.46 243.95 Td (Adjustment and Retraining Notification ) Tj ET Q
q 0 0 0 rg BT 384.76 243.95 Td (Act, the Occupational Safety ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 229.55 Td (and Health ) Tj ET Q
q 0 0 0 rg BT 162.65 229.55 Td (Act, the Family and Medical Leave ) Tj ET Q
q 0 0 0 rg BT 334.93 229.55 Td (Act, the Fair Labor Standards ) Tj ET Q
q 0 0 0 rg BT 479.56 229.55 Td (Act of 1938, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 215.15 Td (Executive Order 1) Tj ET Q
q 0 0 0 rg BT 195.52 215.15 Td (1246, the Pennsylvania Human Relations ) Tj ET Q
q 0 0 0 rg BT 396.16 215.15 Td (Act, the Pennsylvania ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 200.75 Td (Whistleblower Law) Tj ET Q
q 0 0 0 rg BT 202.19 200.75 Td (, the New ) Tj ET Q
q 0 0 0 rg BT 251.06 200.75 Td (Y) Tj ET Q
q 0 0 0 rg BT 258.53 200.75 Td (ork State Human Rights Law) Tj ET Q
q 0 0 0 rg BT 397.73 200.75 Td (, the New ) Tj ET Q
q 0 0 0 rg BT 446.60 200.75 Td (Y) Tj ET Q
q 0 0 0 rg BT 454.07 200.75 Td (ork Labor Law ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 186.35 Td (and the New ) Tj ET Q
q 0 0 0 rg BT 171.20 186.35 Td (Y) Tj ET Q
q 0 0 0 rg BT 178.66 186.35 Td (ork Civil Rights Law and/or the applicable state or local  law or ordinance ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 171.95 Td (against discrimination, each as amended; \(iv\) relating to wrongful employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 157.55 Td (termination or breach of contract; or \(v\) arising under or relating to any policy) Tj ET Q
q 0 0 0 rg BT 482.75 157.55 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 143.15 Td (agreement, understanding or promise, written or oral, formal or informal, between the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 128.75 Td (Company and any of the Releasees and Executive; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
353.91796875 127.150390625 m
396.57421875 127.150390625 l
s
q 0 0 0 rg BT 353.92 128.75 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 396.57 128.75 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
402.57421875 127.150390625 m
443.6484375 127.150390625 l
s
q 0 0 0 rg BT 402.57 128.75 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 443.41 128.75 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 114.35 Td (____________________) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 72.00 106.88 Td (1 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 76.87 102.35 Td (As applicable based upon whether the termination is in connection with a change in control under the terms of the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.00 90.35 Td (Agreement.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 75.95 Td ( ) Tj ET Q
endstream
endobj
369 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 370 0 R>>
endobj
370 0 obj
<</Length 7811>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td ( ) Tj ET Q
q 0 0 0 rg BT 108.00 711.70 Td (notwithstanding the foregoing, nothing contained in the Release shall in any way ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 697.30 Td (diminish or impair: \(a\) any rights Executive may have, from and after the date the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 682.90 Td (Release is executed; \(b\) any rights to indemnification that may exist from time to time ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 668.50 Td (under the Company�) Tj ET Q
q 0 0 0 rg BT 205.98 668.50 Td (s certificate of incorporation or bylaws, or state law or any other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 654.10 Td (indemnification agreement entered into between Executive and the Company; \(c\) any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 639.70 Td (rights Executive may have under any applicable general liability and/or directors and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 625.30 Td (of) Tj ET Q
q 0 0 0 rg BT 117.78 625.30 Td (ficers insurance policy maintained by the Company; \(d\) any rights Executive may have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 610.90 Td (to payments and benefits specified under Sections 9\(a\)\(i\) and \(iii\) of the definition of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 596.50 Td (Accrued Compensation under the Employment ) Tj ET Q
q 0 0 0 rg BT 336.28 596.50 Td (Agreement; \(e\) the right to receive the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 582.10 Td (following payments and benefits: [SPECIFIC LIST) Tj ET Q
q 0 0 0 rg BT 354.76 582.10 Td ( OF COMPENSA) Tj ET Q
q 0 0 0 rg BT 440.12 582.10 Td (TION ) Tj ET Q
q 0 0 0 rg BT 471.12 582.10 Td (AND ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 567.70 Td (BENEFITS P) Tj ET Q
q 0 0 0 rg BT 172.58 567.70 Td (A) Tj ET Q
q 0 0 0 rg BT 180.14 567.70 Td (Y) Tj ET Q
q 0 0 0 rg BT 187.48 567.70 Td (ABLE UNDER SECTIONS 9\(a\)\(ii\), \(iv\), \(v\) ) Tj ET Q
q 0 0 0 rg BT 406.11 567.70 Td (AND \(vi\) OF ) Tj ET Q
q 0 0 0 rg BT 473.56 567.70 Td (THE ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 553.30 Td (EMPLOYMENT) Tj ET Q
q 0 0 0 rg BT 191.12 553.30 Td ( ) Tj ET Q
q 0 0 0 rg BT 193.45 553.30 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 267.23 553.30 Td ( ) Tj ET Q
q 0 0 0 rg BT 270.01 553.30 Td (T) Tj ET Q
q 0 0 0 rg BT 277.13 553.30 Td (O BE INCLUDED]; \(f\) Executive�) Tj ET Q
q 0 0 0 rg BT 445.08 553.30 Td (s ability to bring ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 538.90 Td (appropriate proceedings to enforce the Release; and \(g\) any rights or claims Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 524.50 Td (may have that cannot be waived under applicable law \(collectively) Tj ET Q
q 0 0 0 rg BT 427.42 524.50 Td (, the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
456.404296875 522.900390625 m
504.720703125 522.900390625 l
s
q 0 0 0 rg BT 456.40 524.50 Td (Excluded ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 508.500390625 m
142.001953125 508.500390625 l
s
q 0 0 0 rg BT 108.00 510.10 Td (Claims) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 142.00 510.10 Td (�\). Executive further acknowledges and agrees that, except with respect to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 495.70 Td (Excluded Claims, the Company and the Releasees have fully satisfied any and all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 481.30 Td (obligations whatsoever owed to Executive arising out of Executive�) Tj ET Q
q 0 0 0 rg BT 432.58 481.30 Td (s employment with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 466.90 Td (the Company or any of the Releasees, and that no further payments or benefits are owed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 452.50 Td (to Executive by the Company or any of the Releasees. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 423.70 Td (2. ) Tj ET Q
q 0 0 0 rg BT 108.00 423.70 Td ([Upon the Release becoming ef) Tj ET Q
q 0 0 0 rg BT 259.06 423.70 Td (fective, the Company hereby dischar) Tj ET Q
q 0 0 0 rg BT 435.11 423.70 Td (ges and generally ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 409.30 Td (releases Executive from all claims, causes of action, suits, agreements, and damages ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 394.90 Td (which the Company may have now or in the future against Executive for any act, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 380.50 Td (omission or event relating to his employment with the Company or termination of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 366.10 Td (employment therefrom occurring up to and including the date on which the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 351.70 Td (signs the Release \(excluding any acts or omissions constituting fraud, theft, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 337.30 Td (embezzlement or breach of fiduciary duty by Executive\) to the extent that such claim, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 322.90 Td (cause of action, suit, agreement or damages is based on facts, acts, omissions, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 308.50 Td (circumstances or events actually known, or which should have been reasonably known, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.10 Td (on the date on which the Company signs the Release by any of) Tj ET Q
q 0 0 0 rg BT 409.05 294.10 Td (ficer or member of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 279.70 Td (Board of Directors of the Company) Tj ET Q
q 0 0 0 rg BT 277.51 279.70 Td (.]) Tj ET Q
BT /F3 12.00 Tf ET
BT /F3 7.80 Tf ET
q 0 0 0 rg BT 284.51 285.14 Td (2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 265.30 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 250.90 Td (3. ) Tj ET Q
q 0 0 0 rg BT 108.00 250.90 Td (Executive acknowledges and agrees that Executive has been advised to consult with an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 236.50 Td (attorney of Executive�) Tj ET Q
q 0 0 0 rg BT 214.62 236.50 Td (s choosing prior to signing the Release. Executive understands and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 222.10 Td (agrees that Executive has the right and has been given the opportunity to review the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 207.70 Td (Release with an attorney of Executive�) Tj ET Q
q 0 0 0 rg BT 293.60 207.70 Td (s choice should Executive so desire. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 193.30 Td (also agrees that Executive has entered into the Release freely and voluntarily) Tj ET Q
q 0 0 0 rg BT 476.07 193.30 Td (. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 178.90 Td (further acknowledges and agrees that Executive has had at least [twenty-one \(21\)][forty-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 164.50 Td (five \(45\)] calendar days to consider the Release, although Executive may sign it sooner if ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 150.10 Td (Executive wishes, but in any case, not prior to the termination date. In addition, once ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 135.70 Td (Executive has signed the Release, Executive shall have seven \(7\) additional days from the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 121.30 Td (date of execution to revoke Executive�) Tj ET Q
q 0 0 0 rg BT 292.92 121.30 Td (s consent and may do so by writing to:  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 106.90 Td (____________________) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 72.00 99.43 Td (2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.25 94.90 Td ( Insert upon a qualifying termination following a Change in Control.) Tj ET Q
endstream
endobj
371 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 372 0 R>>
endobj
372 0 obj
<</Length 6214>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-3) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td ( ) Tj ET Q
q 0 0 0 rg BT 108.00 711.70 Td (___________.  ) Tj ET Q
q 0 0 0 rg BT 182.78 711.70 Td (The Release shall not be ef) Tj ET Q
q 0 0 0 rg BT 312.18 711.70 Td (fective, and no payments shall be due ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 697.30 Td (hereunder) Tj ET Q
q 0 0 0 rg BT 155.49 697.30 Td (, earlier than the eighth \(8th\) day after Executive shall have executed the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 682.90 Td (Release and returned it to the Company) Tj ET Q
q 0 0 0 rg BT 297.16 682.90 Td (, assuming that Executive had not revoked ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 668.50 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 159.31 668.50 Td (s consent to the Release prior to such date.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 639.70 Td (4. ) Tj ET Q
q 0 0 0 rg BT 108.00 639.70 Td (It is understood and agreed by Executive that any payment made to Executive is not to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 625.30 Td (construed as an admission of any liability whatsoever on the part of the Company or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 610.90 Td (of the other Releasees, by whom liability is expressly denied.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.26 610.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 584.50 Td (5. ) Tj ET Q
q 0 0 0 rg BT 108.00 584.50 Td (The Release is executed by Executive voluntarily and is not based upon any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 570.10 Td (representations or statements of any kind made by the Company or any of the other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 555.70 Td (Releasees as to the merits, legal liabilities or value of Executive�) Tj ET Q
q 0 0 0 rg BT 417.56 555.70 Td (s claims. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 541.30 Td (further acknowledges that Executive has had a full and reasonable opportunity to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 526.90 Td (consider the Release and that Executive has not been pressured or in any way coerced ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 512.50 Td (into executing the Release.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.29 512.50 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 486.10 Td (6. ) Tj ET Q
q 0 0 0 rg BT 108.00 486.10 Td (The exclusive venue for any disputes arising hereunder shall be the state or federal courts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 471.70 Td (located in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 274.11 471.70 Td (, at the Company�) Tj ET Q
q 0 0 0 rg BT 359.43 471.70 Td (s election, in any other state in which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 457.30 Td (Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 259.95 457.30 Td (s principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 425.88 457.30 Td (s principal place of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 442.90 Td (business, and each of the parties hereto irrevocably waives, to the fullest extent permitted ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 428.50 Td (by law) Tj ET Q
q 0 0 0 rg BT 139.55 428.50 Td (, any objection which it may now or hereafter have to the laying of the venue of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 414.10 Td (any such proceeding brought in such a court and any claim that any such proceeding ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 399.70 Td (brought in such a court has been brought in an inconvenient forum. Each of the parties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 385.30 Td (hereto also agrees that any final and unappealable judgment against a party hereto in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 370.90 Td (connection with any action, suit or other proceeding may be enforced in any court of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 356.50 Td (competent jurisdiction, either within or outside of the United States.  ) Tj ET Q
q 0 0 0 rg BT 439.61 356.50 Td (A) Tj ET Q
q 0 0 0 rg BT 447.61 356.50 Td ( certified or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 342.10 Td (exemplified copy of such award or judgment shall be conclusive evidence of the fact and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 327.70 Td (amount of such award or judgment. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 313.30 Td (  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 298.90 Td (7. ) Tj ET Q
q 0 0 0 rg BT 108.00 298.90 Td (The Release and the rights and obligations of the parties hereto shall be governed and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 284.50 Td (construed in accordance with the laws of the State of Delaware. If any provision hereof is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 270.10 Td (unenforceable or is held to be unenforceable, such provision shall be fully severable, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 255.70 Td (this document and its terms shall be construed and enforced as if such unenforceable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 241.30 Td (provision had never comprised a part hereof, the remaining provisions hereof shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 226.90 Td (remain in full force and ef) Tj ET Q
q 0 0 0 rg BT 233.39 226.90 Td (fect, and the court construing the provisions shall add as a part ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 212.50 Td (hereof a provision as similar in terms and ef) Tj ET Q
q 0 0 0 rg BT 319.05 212.50 Td (fect to such unenforceable provision as may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 198.10 Td (be enforceable, in lieu of the unenforceable provision.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.56 198.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 171.70 Td (8. ) Tj ET Q
q 0 0 0 rg BT 108.00 171.70 Td (The Release shall inure to the benefit of and be binding upon the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 157.30 Td (successors and assigns. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 108.00 117.10 Td ( ) Tj ET Q
endstream
endobj
373 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 374 0 R>>
endobj
374 0 obj
<</Length 3054>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (IN ) Tj ET Q
q 0 0 0 rg BT 123.45 711.70 Td (WITNESS ) Tj ET Q
q 0 0 0 rg BT 178.22 711.70 Td (WHEREOF) Tj ET Q
q 0 0 0 rg BT 235.26 711.70 Td (, Executive and the Company have executed the Release as of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 695.15 Td (the date and year provided below) Tj ET Q
q 0 0 0 rg BT 230.82 695.15 Td (.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 666.60 Td (IMPOR) Tj ET Q
q 0 0 0 rg BT 112.90 666.60 Td (T) Tj ET Q
q 0 0 0 rg BT 120.02 666.60 Td (ANT) Tj ET Q
q 0 0 0 rg BT 145.14 666.60 Td ( NOTICE:  BY) Tj ET Q
q 0 0 0 rg BT 221.70 666.60 Td ( SIGNING BELOW) Tj ET Q
q 0 0 0 rg BT 324.84 666.60 Td ( ) Tj ET Q
q 0 0 0 rg BT 327.40 666.60 Td (YOU RELEASE ) Tj ET Q
q 0 0 0 rg BT 415.42 666.60 Td (AND GIVE UP) Tj ET Q
q 0 0 0 rg BT 493.43 666.60 Td ( ) Tj ET Q
q 0 0 0 rg BT 495.77 666.60 Td (ANY) Tj ET Q
q 0 0 0 rg BT 521.32 666.60 Td ( ) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 650.00 Td (AND ) Tj ET Q
q 0 0 0 rg BT 100.34 650.00 Td (ALL) Tj ET Q
q 0 0 0 rg BT 124.35 650.00 Td ( LEGAL) Tj ET Q
q 0 0 0 rg BT 168.70 650.00 Td ( CLAIMS, KNOWN ) Tj ET Q
q 0 0 0 rg BT 276.04 650.00 Td (AND UNKNOWN, ) Tj ET Q
q 0 0 0 rg BT 376.15 650.00 Td (THA) Tj ET Q
q 0 0 0 rg BT 401.27 650.00 Td (T) Tj ET Q
q 0 0 0 rg BT 409.05 650.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 411.61 650.00 Td (YOU MA) Tj ET Q
q 0 0 0 rg BT 460.17 650.00 Td (Y) Tj ET Q
q 0 0 0 rg BT 468.39 650.00 Td ( HA) Tj ET Q
q 0 0 0 rg BT 487.84 650.00 Td (VE ) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 633.45 Td (AGAINST) Tj ET Q
q 0 0 0 rg BT 126.46 633.45 Td ( ) Tj ET Q
q 0 0 0 rg BT 129.25 633.45 Td (THE COMP) Tj ET Q
q 0 0 0 rg BT 193.35 633.45 Td (ANY) Tj ET Q
q 0 0 0 rg BT 218.91 633.45 Td ( ) Tj ET Q
q 0 0 0 rg BT 221.24 633.45 Td (AND RELA) Tj ET Q
q 0 0 0 rg BT 282.69 633.45 Td (TED P) Tj ET Q
q 0 0 0 rg BT 316.80 633.45 Td (AR) Tj ET Q
q 0 0 0 rg BT 333.71 633.45 Td (TIES.) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
72.5 554 m
122.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 554 m
288.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
302.5 554 m
352.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 554 m
518.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
72.5 554 m
122.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 554 m
288.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
302.5 554 m
352.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 554 m
518.5 554 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 510 m
288.5 510 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 510 m
518.5 510 l
s
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 75.00 543.18 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 142.77 543.18 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 305.00 543.18 Td (Blaise Coleman) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 75.00 514.18 Td (Dated:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 305.00 514.18 Td (Dated:) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
375 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 376 0 R>>
endobj
376 0 obj
<</Length 7895>>
stream
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 471.95 771.40 Td (Exhibit 10.19) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 409.85 711.90 Td (EXECUTION ) Tj ET Q
q 0 0 0 rg BT 485.31 711.90 Td (VERSION) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 216.20 650.20 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 283.42 650.20 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 191.20 621.65 Td (EXECUTIVE EMPLOYMENT) Tj ET Q
q 0 0 0 rg BT 344.63 621.65 Td ( ) Tj ET Q
q 0 0 0 rg BT 346.97 621.65 Td (AGREEMENT) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 593.10 Td (THIS ) Tj ET Q
q 0 0 0 rg BT 137.00 593.10 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 210.78 593.10 Td ( \(this �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
243.439453125 591.500390625 m
296.748046875 591.500390625 l
s
q 0 0 0 rg BT 243.44 593.10 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.75 593.10 Td (�\) is hereby entered into as of February 19, 2020, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 576.55 Td (ef) Tj ET Q
q 0 0 0 rg BT 81.11 576.55 Td (fective as of March 6, 2020 \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
243.041015625 574.950390625 m
312.4453125 574.950390625 l
s
q 0 0 0 rg BT 243.04 576.55 Td (Ef) Tj ET Q
q 0 0 0 rg BT 254.15 576.55 Td (fective Date) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 312.45 576.55 Td (�\), by and between Endo Health Solutions Inc. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 560.00 Td (\(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
98.982421875 558.400390625 m
145.646484375 558.400390625 l
s
q 0 0 0 rg BT 98.98 560.00 Td (Company) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 145.65 560.00 Td (�\), a wholly-owned subsidiary of Endo International plc \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
426.5625 558.400390625 m
451.892578125 558.400390625 l
s
q 0 0 0 rg BT 426.56 560.00 Td (Endo) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 451.89 560.00 Td (�\), and Mark ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 543.40 Td (Bradley \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
122.30859375 541.800390625 m
170.28515625 541.800390625 l
s
q 0 0 0 rg BT 122.31 543.40 Td (Executive) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 170.29 543.40 Td (�\) \(hereinafter collectively referred to as �the parties�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 514.85 Td (In consideration of the respective agreements of the parties contained herein, it is agreed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 498.30 Td (as follows: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 469.75 Td (1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 469.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 468.150390625 m
133.1484375 468.150390625 l
s
q 0 0 0 rg BT 108.00 469.75 Td (T) Tj ET Q
q 0 0 0 rg BT 114.49 469.75 Td (erm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 133.15 469.75 Td (. ) Tj ET Q
q 0 0 0 rg BT 138.93 469.75 Td (The term of this ) Tj ET Q
q 0 0 0 rg BT 218.25 469.75 Td (Agreement shall be for the period commencing on the Ef) Tj ET Q
q 0 0 0 rg BT 491.61 469.75 Td (fective ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 453.20 Td (Date and ending, subject to earlier termination as set forth in Section 6, on the third ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 436.60 Td (anniversary thereof \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
230.935546875 435.000390625 m
320.859375 435.000390625 l
s
q 0 0 0 rg BT 230.94 436.60 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 295.71 436.60 Td (T) Tj ET Q
q 0 0 0 rg BT 302.20 436.60 Td (erm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 320.86 436.60 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 408.05 Td (2.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 408.05 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 406.450390625 m
169.9921875 406.450390625 l
s
q 0 0 0 rg BT 108.00 408.05 Td (Employment) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 169.99 408.05 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 295.42 408.05 Td (T) Tj ET Q
q 0 0 0 rg BT 301.92 408.05 Td (erm:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 379.50 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 379.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 379.50 Td (Executive shall serve as Executive ) Tj ET Q
q 0 0 0 rg BT 312.71 379.50 Td (V) Tj ET Q
q 0 0 0 rg BT 320.66 379.50 Td (ice President and Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 495.39 379.50 Td (ficer of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 362.95 Td (Endo and shall be assigned with the customary duties and responsibilities of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 346.40 Td (position. If Executive serves as a director of Endo or as a director or of) Tj ET Q
q 0 0 0 rg BT 484.00 346.40 Td (ficer of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 329.80 Td (of Endo�) Tj ET Q
q 0 0 0 rg BT 185.66 329.80 Td (s af) Tj ET Q
q 0 0 0 rg BT 202.44 329.80 Td (filiates, then Executive will fulfill Executive�) Tj ET Q
q 0 0 0 rg BT 419.03 329.80 Td (s duties as such director ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 313.25 Td (or of) Tj ET Q
q 0 0 0 rg BT 166.78 313.25 Td (ficer without additional compensation.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 284.70 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 284.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 284.70 Td (Executive shall report directly to Endo�) Tj ET Q
q 0 0 0 rg BT 332.94 284.70 Td (s Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 433.69 284.70 Td (ficer) Tj ET Q
q 0 0 0 rg BT 455.01 284.70 Td (. Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 268.15 Td (perform the duties, undertake the responsibilities and exercise the authority ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 251.60 Td (customarily performed, undertaken and exercised by persons situated in a similar ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 235.00 Td (executive capacity) Tj ET Q
q 0 0 0 rg BT 232.17 235.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 206.45 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 206.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 206.45 Td (Executive shall devote substantially full-time attention to the business and af) Tj ET Q
q 0 0 0 rg BT 512.36 206.45 Td (fairs ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 189.90 Td (of the Company and its af) Tj ET Q
q 0 0 0 rg BT 268.09 189.90 Td (filiates. Executive may \(i\) serve on corporate, civic, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 173.35 Td (charitable or non-profit boards or committees, subject in all cases to the prior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 156.80 Td (approval of the board of directors of Endo \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
376.248046875 155.20039062499995 m
405.57421875 155.20039062499995 l
s
q 0 0 0 rg BT 376.25 156.80 Td (Board) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 405.57 156.80 Td (�\) and other applicable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 140.20 Td (written policies of the Company and its af) Tj ET Q
q 0 0 0 rg BT 345.40 140.20 Td (filiates as in ef) Tj ET Q
q 0 0 0 rg BT 415.49 140.20 Td (fect from time to time, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 123.65 Td (and \(ii\) manage personal and family investments, participate in industry ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 107.10 Td (or) Tj ET Q
q 0 0 0 rg BT 153.78 107.10 Td (ganizations and deliver lectures at educational institutions or events, so long as ) Tj ET Q
endstream
endobj
377 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 378 0 R>>
endobj
378 0 obj
<</Length 8122>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (no such service or activity unreasonably interferes, individually or in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (aggregate, with the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 366.56 695.15 Td (s responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 497.20 695.15 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 666.60 Td (Executive shall be subject to and shall abide by each of the personnel and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (compliance policies of the Company and its af) Tj ET Q
q 0 0 0 rg BT 366.72 650.00 Td (filiates applicable and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (communicated in writing to senior executives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 604.90 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 604.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 604.90 Td (Executive shall primarily provide services at the Company�) Tj ET Q
q 0 0 0 rg BT 428.92 604.90 Td (s U.S. headquarters in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 588.35 Td (Malvern, Pennsylvania, and will travel to the Company�) Tj ET Q
q 0 0 0 rg BT 412.95 588.35 Td (s Chestnut Ridge, New ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 571.80 Td (Y) Tj ET Q
q 0 0 0 rg BT 151.46 571.80 Td (ork location to the extent reasonably necessary and appropriate to fulfill ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 555.20 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 555.20 Td (s duties.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 526.65 Td (3.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 526.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 525.050390625 m
215.654296875 525.050390625 l
s
q 0 0 0 rg BT 108.00 526.65 Td (Annual Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.65 526.65 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 498.10 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 498.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 496.500390625 m
200.5927734375 496.500390625 l
s
q 0 0 0 rg BT 144.00 498.10 Td (Base Salary) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 200.20 498.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 205.99 498.10 Td (The Company agrees to pay or cause to be paid to Executive during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 481.55 Td (the Employment ) Tj ET Q
q 0 0 0 rg BT 226.44 481.55 Td (T) Tj ET Q
q 0 0 0 rg BT 232.93 481.55 Td (erm a base salary at the rate of $575,000 per annum or such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 465.00 Td (increased amount in accordance with this Section 3\(a\) \(hereinafter referred to as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 448.40 Td (the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
166.986328125 446.800390625 m
223.96875 446.800390625 l
s
q 0 0 0 rg BT 166.99 448.40 Td (Base Salary) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 223.97 448.40 Td (�\). Such Base Salary shall be payable in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 431.85 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 431.85 Td (s customary practices applicable to its executives. Such Base Salary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 415.30 Td (shall be reviewed at least annually by the Compensation Committee of the Board ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 398.75 Td (\(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
170.982421875 397.150390625 m
224.30859375 397.150390625 l
s
q 0 0 0 rg BT 170.98 398.75 Td (Committee) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 224.31 398.75 Td (�\), with the first such planned review to occur in Februrary 2021, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 382.20 Td (and may be increased in the sole discretion of the Committee, but not decreased.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 353.60 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 353.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 352.000390625 m
299.296875 352.000390625 l
s
q 0 0 0 rg BT 144.00 353.60 Td (Annual Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 299.30 353.60 Td (. For each fiscal year of the Company ending ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 337.05 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 260.77 337.05 Td (T) Tj ET Q
q 0 0 0 rg BT 267.26 337.05 Td (erm, ef) Tj ET Q
q 0 0 0 rg BT 301.02 337.05 Td (fective as of the 2020 fiscal year) Tj ET Q
q 0 0 0 rg BT 456.47 337.05 Td (, Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 320.50 Td (be eligible to receive a tar) Tj ET Q
q 0 0 0 rg BT 268.05 320.50 Td (get annual cash bonus of 55% of Executive�) Tj ET Q
q 0 0 0 rg BT 478.99 320.50 Td (s Base ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 303.95 Td (Salary \(such tar) Tj ET Q
q 0 0 0 rg BT 219.09 303.95 Td (get bonus, as may hereafter be increased, the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
442.318359375 302.350390625 m
506.25 302.350390625 l
s
q 0 0 0 rg BT 442.32 303.95 Td (T) Tj ET Q
q 0 0 0 rg BT 448.81 303.95 Td (ar) Tj ET Q
q 0 0 0 rg BT 457.92 303.95 Td (get Bonus) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 506.25 303.95 Td (�\) with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 287.40 Td (the opportunity to receive a maximum annual cash bonus in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 270.80 Td (terms of the applicable annual cash bonus plan as in ef) Tj ET Q
q 0 0 0 rg BT 405.70 270.80 Td (fect from time to time, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 254.25 Td (subject to the achievement of performance tar) Tj ET Q
q 0 0 0 rg BT 363.68 254.25 Td (gets set by the Committee. Such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 237.70 Td (annual cash bonus \(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
244.30078125 236.10039062500005 m
361.271484375 236.10039062500005 l
s
q 0 0 0 rg BT 244.30 237.70 Td (Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 361.27 237.70 Td (�\) shall be paid in no event later than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 221.15 Td (the 15th day of the third month following the end of the taxable year \(of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 204.60 Td (Company or Executive, whichever is later\) in which the performance tar) Tj ET Q
q 0 0 0 rg BT 491.31 204.60 Td (gets have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 188.00 Td (been achieved.  If the parties \(following good faith negotiation\) fail to enter into a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 171.45 Td (new employment agreement following expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 479.70 171.45 Td (T) Tj ET Q
q 0 0 0 rg BT 486.19 171.45 Td (erm and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 154.90 Td (Executive terminates Executive�) Tj ET Q
q 0 0 0 rg BT 299.27 154.90 Td (s employment within ninety \(90\) days following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 138.35 Td (expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 291.08 138.35 Td (T) Tj ET Q
q 0 0 0 rg BT 297.57 138.35 Td (erm under circumstances that would have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (constituted Good Reason had such termination occurred during the Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 105.20 Td (erm or if, during such 90-day period, the Company terminates Executive�) Tj ET Q
q 0 0 0 rg BT 502.39 105.20 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (employment under circumstances that would not have constituted Cause had such ) Tj ET Q
endstream
endobj
379 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 380 0 R>>
endobj
380 0 obj
<</Length 7514>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (3) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (termination occurred during the Employment ) Tj ET Q
q 0 0 0 rg BT 364.05 711.70 Td (T) Tj ET Q
q 0 0 0 rg BT 370.55 711.70 Td (erm, then the Company shall pay ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Executive a Pro-Rata Bonus \(as defined in Section 8\(b\)\(ii\) below\) in a lump sum ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (at the time bonuses are payable to other senior executives of the Company) Tj ET Q
q 0 0 0 rg BT 499.78 678.60 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 650.00 Td (4.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 650.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 648.400390625 m
282.4453125 648.400390625 l
s
q 0 0 0 rg BT 108.00 650.00 Td (Long-T) Tj ET Q
q 0 0 0 rg BT 143.82 650.00 Td (erm Incentive Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 282.45 650.00 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 407.88 650.00 Td (T) Tj ET Q
q 0 0 0 rg BT 414.37 650.00 Td (erm, Executive shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 633.45 Td (eligible to receive long-term incentive compensation, which may be subject to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 616.90 Td (achievement of certain performance tar) Tj ET Q
q 0 0 0 rg BT 296.34 616.90 Td (gets set by the Committee. Beginning with grants ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 600.35 Td (made in 2021, Executive shall be eligible to receive long-term incentive compensation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (awards with a tar) Tj ET Q
q 0 0 0 rg BT 190.08 583.80 Td (geted grant date fair market value \(as determined in the sole discretion ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 567.20 Td (of the Committee\) equal to 250% of Executive�) Tj ET Q
q 0 0 0 rg BT 335.60 567.20 Td (s Base Salary) Tj ET Q
q 0 0 0 rg BT 399.47 567.20 Td (. Notwithstanding the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 550.65 Td (foregoing, to the extent the shares available under the Company's shareholder approved ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 534.10 Td (incentive plans are insuf) Tj ET Q
q 0 0 0 rg BT 224.74 534.10 Td (ficient to make such grant \(after taking into account the totality ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (of grants to be made by the Company in a given year\), in the Committee's sole discretion, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 501.00 Td (all or a portion of the long-term incentive compensation may be issued in the form of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 484.40 Td (cash-based award on terms determined by the Committee. ) Tj ET Q
q 0 0 0 rg BT 388.92 484.40 Td (All such equity-based or cash-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 467.85 Td (based awards shall be subject to the terms and conditions set forth in the applicable plan ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 451.30 Td (and award agreements, and in all cases shall be as determined by the Committee; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 434.75 Td (provided, that, such terms and conditions shall be no less favorable than those provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 418.20 Td (for other senior executives of the Company) Tj ET Q
q 0 0 0 rg BT 315.16 418.20 Td (. If the parties \(following good faith ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 401.60 Td (negotiation\) fail to enter into a new employment agreement following expiration of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 385.05 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 172.78 385.05 Td (T) Tj ET Q
q 0 0 0 rg BT 179.27 385.05 Td (erm and Executive terminates Executive�) Tj ET Q
q 0 0 0 rg BT 376.52 385.05 Td (s employment within ninety \(90\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 368.50 Td (days following expiration of the Employment ) Tj ET Q
q 0 0 0 rg BT 329.74 368.50 Td (T) Tj ET Q
q 0 0 0 rg BT 336.23 368.50 Td (erm under circumstances that would have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 351.95 Td (constituted Good Reason had such termination occurred during the Employment ) Tj ET Q
q 0 0 0 rg BT 497.03 351.95 Td (T) Tj ET Q
q 0 0 0 rg BT 503.52 351.95 Td (erm or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 335.40 Td (if, during such 90-day period, the Company terminates Executive�) Tj ET Q
q 0 0 0 rg BT 425.25 335.40 Td (s employment under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 318.80 Td (circumstances that would not have constituted Cause had such termination occurred ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 302.25 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 224.77 302.25 Td (T) Tj ET Q
q 0 0 0 rg BT 231.26 302.25 Td (erm, then such termination of employment shall be treated as a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 285.70 Td (termination of employment for �Good Reason� or without Cause, as applicable, for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 269.15 Td (purposes of the performance-based restricted stock units held by Executive as of the date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 252.60 Td (of such termination of employment \(and such awards shall be treated in accordance with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 236.00 Td (the terms of the applicable award agreements\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 332.23 236.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 207.45 Td (5.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 207.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 205.85039062500005 m
178.3125 205.85039062500005 l
s
q 0 0 0 rg BT 108.00 207.45 Td (Other Benefits) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 178.31 207.45 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 178.90 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 178.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 177.30039062499998 m
235.640625 177.30039062499998 l
s
q 0 0 0 rg BT 144.00 178.90 Td (Employee Benefits) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 235.64 178.90 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 361.07 178.90 Td (T) Tj ET Q
q 0 0 0 rg BT 367.56 178.90 Td (erm, Executive shall be entitled to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (participate in all employee benefit plans, practices and programs maintained by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (the Company or its af) Tj ET Q
q 0 0 0 rg BT 247.76 145.80 Td (filiates and made available to similarly situated employees ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (generally) Tj ET Q
q 0 0 0 rg BT 187.86 129.20 Td (, including all pension, retirement, profit sharing, savings, medical, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 112.65 Td (hospitalization, disability) Tj ET Q
q 0 0 0 rg BT 264.54 112.65 Td (, dental, life or travel accident insurance benefit plans, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 96.10 Td (the extent Executive is eligible under the terms of such plans. Executive�) Tj ET Q
q 0 0 0 rg BT 493.22 96.10 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 79.55 Td (participation in such plans, practices and programs shall be on the same basis and ) Tj ET Q
endstream
endobj
381 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 382 0 R>>
endobj
382 0 obj
<</Length 7125>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (4) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (terms as are applicable to employees of the Company generally) Tj ET Q
q 0 0 0 rg BT 447.45 711.70 Td (. During the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 695.15 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 695.15 Td (erm, Executive shall also be entitled to participate in all executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (benefit plans and entitled to all fringe benefits and perquisites generally made ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (available by the Company or its af) Tj ET Q
q 0 0 0 rg BT 309.07 662.00 Td (filiates to its senior executives in accordance ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (with current Company policy now maintained or hereafter established by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Company or its af) Tj ET Q
q 0 0 0 rg BT 230.10 628.90 Td (filiates for the purpose of providing executive benefits or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (perquisites to comparable executive employees of the Company including, but not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (limited to, the Company�) Tj ET Q
q 0 0 0 rg BT 263.99 595.80 Td (s supplemental retirement, deferred compensation, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (supplemental medical or life insurance plans. Unless otherwise provided herein, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 562.65 Td (s participation in such plans and programs shall be on the same basis ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (and terms as other senior executives of the Company) Tj ET Q
q 0 0 0 rg BT 397.15 546.10 Td (. No additional compensation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (provided under any of such plans shall be deemed to modify or otherwise af) Tj ET Q
q 0 0 0 rg BT 508.68 529.55 Td (fect ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (the terms of this ) Tj ET Q
q 0 0 0 rg BT 223.99 513.00 Td (Agreement or any of Executive�) Tj ET Q
q 0 0 0 rg BT 377.93 513.00 Td (s entitlements hereunder) Tj ET Q
q 0 0 0 rg BT 494.56 513.00 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (Executive is responsible for any taxes \(other than taxes that are the Company�) Tj ET Q
q 0 0 0 rg BT 517.88 496.40 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (responsibility\) that may be due based upon the value of the benefits or perquisites ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (provided pursuant to this ) Tj ET Q
q 0 0 0 rg BT 265.99 463.30 Td (Agreement, whether provided during or following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 446.75 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 446.75 Td (erm. For the avoidance of doubt, Executive shall not be entitled to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (any excise tax gross-up under Section 280G or Section 4999 of the Internal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (Revenue Code of 1986, as amended \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
346.599609375 412.000390625 m
371.9296875 412.000390625 l
s
q 0 0 0 rg BT 346.60 413.60 Td (Code) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 371.93 413.60 Td (�\) \(or any successor provision\), or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (any other tax gross-up. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 368.50 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 368.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 366.900390625 m
234.99609375 366.900390625 l
s
q 0 0 0 rg BT 144.00 368.50 Td (Business Expenses) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 235.00 368.50 Td (. Upon submission of proper invoices in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 351.95 Td (s normal procedures, Executive shall be entitled to receive prompt ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 335.40 Td (reimbursement of all reasonable out-of-pocket business, entertainment and travel ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 318.80 Td (expenses incurred by Executive in connection with the performance of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 302.25 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 302.25 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 281.95 302.25 Td (. Such reimbursement shall be made in no event later ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (than the end of the calendar year following the calendar year in which the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (expenses were incurred.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 240.60 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 240.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 239.00039062500002 m
241.74609375 239.00039062500002 l
s
q 0 0 0 rg BT 144.00 240.60 Td (Of) Tj ET Q
q 0 0 0 rg BT 156.45 240.60 Td (fice and Facilities) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 241.75 240.60 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 367.18 240.60 Td (T) Tj ET Q
q 0 0 0 rg BT 373.67 240.60 Td (erm, Executive shall be provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 224.00 Td (with an appropriate of) Tj ET Q
q 0 0 0 rg BT 250.08 224.00 Td (fice, with such secretarial and other support facilities as are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (commensurate with Executive�) Tj ET Q
q 0 0 0 rg BT 292.62 207.45 Td (s status with the Company and its af) Tj ET Q
q 0 0 0 rg BT 466.05 207.45 Td (filiates, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 190.90 Td (facilities shall be adequate for the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 436.53 190.90 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 523.17 190.90 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 162.35 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 162.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 160.75039062500002 m
262.951171875 160.75039062500002 l
s
q 0 0 0 rg BT 144.00 162.35 Td (V) Tj ET Q
q 0 0 0 rg BT 151.34 162.35 Td (acation and Sick Leave) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 262.95 162.35 Td (. Executive shall be entitled, without loss of pay) Tj ET Q
q 0 0 0 rg BT 492.79 162.35 Td (, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (absent himself voluntarily from the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 444.23 145.80 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 129.20 Td (Agreement, pursuant to the following:) Tj ET Q
endstream
endobj
383 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 384 0 R>>
endobj
384 0 obj
<</Length 8376>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (5) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (Executive shall be entitled to annual vacation in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (vacation policies of the Company as in ef) Tj ET Q
q 0 0 0 rg BT 378.73 695.15 Td (fect from time to time, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (shall in no event be less than four weeks per year; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 650.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 650.00 Td (Executive shall be entitled to sick leave \(without loss of pay\) in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 633.45 Td (accordance with the Company�) Tj ET Q
q 0 0 0 rg BT 328.95 633.45 Td (s policies as in ef) Tj ET Q
q 0 0 0 rg BT 411.38 633.45 Td (fect from time to time.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 604.90 Td (6.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 604.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 603.300390625 m
166.4765625 603.300390625 l
s
q 0 0 0 rg BT 108.00 604.90 Td (T) Tj ET Q
q 0 0 0 rg BT 114.49 604.90 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 166.48 604.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 172.26 604.90 Td (The Employment ) Tj ET Q
q 0 0 0 rg BT 258.69 604.90 Td (T) Tj ET Q
q 0 0 0 rg BT 265.18 604.90 Td (erm and Executive�) Tj ET Q
q 0 0 0 rg BT 358.48 604.90 Td (s employment hereunder may be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 588.35 Td (terminated under the circumstances set forth below) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
353.244140625 586.750390625 m
449.30859375 586.750390625 l
s
q 0 0 0 rg BT 353.24 588.35 Td (; provided, however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 449.07 588.35 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 571.80 Td (notwithstanding anything contained herein to the contrary) Tj ET Q
q 0 0 0 rg BT 385.15 571.80 Td (, Executive shall not be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 555.20 Td (considered to have terminated employment with the Company for purposes of this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 538.65 Td (Agreement unless Executive would be considered to have incurred a �separation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 522.10 Td (service� from the Company within the meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 417.60 522.10 Td ( of the Code.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 493.55 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 493.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 491.950390625 m
190.9423828125 491.950390625 l
s
q 0 0 0 rg BT 144.00 493.55 Td (Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 190.55 493.55 Td (. ) Tj ET Q
q 0 0 0 rg BT 196.34 493.55 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 390.94 493.55 Td (s employment, on written ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 477.00 Td (notice to Executive after having reasonably established Executive�) Tj ET Q
q 0 0 0 rg BT 462.88 477.00 Td (s Disability) Tj ET Q
q 0 0 0 rg BT 517.10 477.00 Td (. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 460.40 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 222.33 460.40 Td (Agreement, Executive will be deemed to have a �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
460.564453125 458.800390625 m
507.896484375 458.800390625 l
s
q 0 0 0 rg BT 460.56 460.40 Td (Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 507.90 460.40 Td (� if, as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 443.85 Td (a result of any medically determinable physical or mental impairment that can be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 427.30 Td (expected to result in death or can be expected to last for a continuous period of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 410.75 Td (not less than twelve \(12\) months, Executive is unable to perform the core ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 394.20 Td (functions of Executive�) Tj ET Q
q 0 0 0 rg BT 255.97 394.20 Td (s position \(with or without reasonable accommodation\) or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 377.60 Td (is receiving income replacement benefits for a period of six \(6\) months or more ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 361.05 Td (under the Company�) Tj ET Q
q 0 0 0 rg BT 241.98 361.05 Td (s long-term disability plan. Executive shall be entitled to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (compensation and benefits provided for under this ) Tj ET Q
q 0 0 0 rg BT 387.61 344.50 Td (Agreement for any period prior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (to Executive�) Tj ET Q
q 0 0 0 rg BT 207.64 327.95 Td (s termination by reason of Disability during which Executive is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (unable to work due to a physical or mental infirmity in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 294.80 Td (s policies for similarly situated executives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 266.25 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 266.25 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 264.650390625 m
172.65234375 264.650390625 l
s
q 0 0 0 rg BT 144.00 266.25 Td (Death) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 172.65 266.25 Td (. Executive�) Tj ET Q
q 0 0 0 rg BT 229.96 266.25 Td (s employment shall be terminated as of the date of Executive�) Tj ET Q
q 0 0 0 rg BT 525.87 266.25 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 249.70 Td (death.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 221.15 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 221.15 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 219.55039062499998 m
173.326171875 219.55039062499998 l
s
q 0 0 0 rg BT 144.00 221.15 Td (Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 173.33 221.15 Td (. ) Tj ET Q
q 0 0 0 rg BT 179.11 221.15 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 373.71 221.15 Td (s employment for Cause \(as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 204.60 Td (defined below\), ef) Tj ET Q
q 0 0 0 rg BT 231.41 204.60 Td (fective as of the date of the Notice of ) Tj ET Q
q 0 0 0 rg BT 412.11 204.60 Td (T) Tj ET Q
q 0 0 0 rg BT 418.61 204.60 Td (ermination \(as defined in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 188.00 Td (Section 7 below\) that notifies Executive of Executive�) Tj ET Q
q 0 0 0 rg BT 403.59 188.00 Td (s termination for Cause. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 171.45 Td (�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
149.326171875 169.85039062500005 m
178.65234375 169.85039062500005 l
s
q 0 0 0 rg BT 149.33 171.45 Td (Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 178.65 171.45 Td (� shall mean, for purposes of this ) Tj ET Q
q 0 0 0 rg BT 339.96 171.45 Td (Agreement: \(i\) the continued failure by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 154.90 Td (Executive to use good faith ef) Tj ET Q
q 0 0 0 rg BT 287.40 154.90 Td (forts in the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 470.33 154.90 Td (s duties under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 138.35 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 138.35 Td (Agreement \(other than any such failure resulting from Disability or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (allowable leave of absence\); \(ii\) the criminal felony indictment \(or non-U.S. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (equivalent\) of Executive by a court of competent jurisdiction; \(iii\) the engagement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (by Executive in misconduct that has caused, or) Tj ET Q
q 0 0 0 rg BT 368.79 88.65 Td (, is reasonably likely to cause, ) Tj ET Q
endstream
endobj
385 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 386 0 R>>
endobj
386 0 obj
<</Length 8065>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (6) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (material harm \(financial or otherwise\) to the Company) Tj ET Q
q 0 0 0 rg BT 405.46 711.70 Td (, including \(A\) the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (unauthorized disclosure of material secret or Confidential Information \(as defined ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (in Section 10\(d\) below\) of the Company) Tj ET Q
q 0 0 0 rg BT 337.18 678.60 Td (, \(B\) the debarment of the Company by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (the U.S. Food and Drug ) Tj ET Q
q 0 0 0 rg BT 261.00 662.00 Td (Administration or any successor agency \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
482.9296875 660.400390625 m
506.935546875 660.400390625 l
s
q 0 0 0 rg BT 482.93 662.00 Td (FDA) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 506.94 662.00 Td (�\) or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (any non-U.S. equivalent, or \(C\) the registration of the Company with the U.S. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Drug Enforcement ) Tj ET Q
q 0 0 0 rg BT 235.97 628.90 Td (Administration of any successor agency \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
457.8984375 627.300390625 m
482.560546875 627.300390625 l
s
q 0 0 0 rg BT 457.90 628.90 Td (DEA) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 482.56 628.90 Td (�\) being ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (revoked; \(iv\) the debarment of Executive by the FDA; \(v\) the continued material ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (breach by Executive of this ) Tj ET Q
q 0 0 0 rg BT 277.62 595.80 Td (Agreement; \(vi\) any material breach by Executive of a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (Company policy; \(vii\) any breach by Executive of a Company policy related to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (sexual or other types of harassment or abusive conduct; or \(viii\) Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (making, or being found to have made, a certification relating to the Company�) Tj ET Q
q 0 0 0 rg BT 518.55 546.10 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (financial statements and public filings that is known to Executive to be false. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (Notwithstanding the foregoing, prior to having Cause for Executive�) Tj ET Q
q 0 0 0 rg BT 472.26 513.00 Td (s termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (\(other than as described in clauses \(ii\), \(iv\) and \(vii\) above\), the Company must ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (deliver a written demand to Executive which specifically identifies the conduct ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (that may provide grounds for Cause within ninety \(90\) calendar days of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 446.75 Td (s actual knowledge of such conduct, events or circumstances, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (Executive must have failed to cure such conduct \(if curable\) within thirty \(30\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (days after such demand. References to the Company in subsections \(i\) through ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (\(viii\) of this paragraph shall also include af) Tj ET Q
q 0 0 0 rg BT 350.72 397.05 Td (filiates of the Company) Tj ET Q
q 0 0 0 rg BT 462.91 397.05 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 368.50 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 368.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 366.900390625 m
215.173828125 366.900390625 l
s
q 0 0 0 rg BT 144.00 368.50 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 368.50 Td (ithout Cause) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.17 368.50 Td (. ) Tj ET Q
q 0 0 0 rg BT 220.96 368.50 Td (The Company may terminate Executive�) Tj ET Q
q 0 0 0 rg BT 415.56 368.50 Td (s employment without ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (Cause. ) Tj ET Q
q 0 0 0 rg BT 179.11 351.95 Td (The Company shall deliver to Executive a Notice of ) Tj ET Q
q 0 0 0 rg BT 431.81 351.95 Td (T) Tj ET Q
q 0 0 0 rg BT 438.30 351.95 Td (ermination \(as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 335.40 Td (defined in Section 7 below\) not less than thirty \(30\) days prior to the termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 318.80 Td (of Executive�) Tj ET Q
q 0 0 0 rg BT 208.31 318.80 Td (s employment without Cause and the Company shall have the option ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 302.25 Td (of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 266.63 302.25 Td (s duties and responsibilities prior to the expiration of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (such thirty-day notice period, provided the Company pays Base Salary through ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (the end of such notice period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 240.60 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 240.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 239.00039062500002 m
208.9921875 239.00039062500002 l
s
q 0 0 0 rg BT 144.00 240.60 Td (Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 208.99 240.60 Td (. Executive may terminate employment with the Company for Good ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 224.00 Td (Reason \(as defined below\) by delivering to the Company a Notice of ) Tj ET Q
q 0 0 0 rg BT 477.02 224.00 Td (T) Tj ET Q
q 0 0 0 rg BT 483.52 224.00 Td (ermination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 207.45 Td (not less than thirty \(30\) days prior to the termination of Executive�) Tj ET Q
q 0 0 0 rg BT 462.93 207.45 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 190.90 Td (for Good Reason. ) Tj ET Q
q 0 0 0 rg BT 231.77 190.90 Td (The Company shall have the option of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 528.36 190.90 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 174.35 Td (duties and responsibilities prior to the expiration of such thirty-day notice period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 157.80 Td (provided the Company pays Base Salary through the end of such notice period. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 141.20 Td (For purposes of this ) Tj ET Q
q 0 0 0 rg BT 242.00 141.20 Td (Agreement, �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
306.638671875 139.60039062500005 m
371.630859375 139.60039062500005 l
s
q 0 0 0 rg BT 306.64 141.20 Td (Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 371.63 141.20 Td (� means any of the following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 124.65 Td (without Executive�) Tj ET Q
q 0 0 0 rg BT 234.98 124.65 Td (s written consent: \(i\) a diminution in Executive�) Tj ET Q
q 0 0 0 rg BT 464.60 124.65 Td (s Base Salary) Tj ET Q
q 0 0 0 rg BT 528.47 124.65 Td (, a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 108.10 Td (material diminution in ) Tj ET Q
q 0 0 0 rg BT 254.10 108.10 Td (T) Tj ET Q
q 0 0 0 rg BT 260.59 108.10 Td (ar) Tj ET Q
q 0 0 0 rg BT 269.70 108.10 Td (get Bonus \(provided that failure to earn a bonus equal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 91.55 Td (to or in excess of the ) Tj ET Q
q 0 0 0 rg BT 246.42 91.55 Td (T) Tj ET Q
q 0 0 0 rg BT 252.91 91.55 Td (ar) Tj ET Q
q 0 0 0 rg BT 262.02 91.55 Td (get Bonus by reason of failure to achieve applicable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 75.00 Td (performance goals shall not be deemed Good Reason\) or material diminution in ) Tj ET Q
endstream
endobj
387 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 388 0 R>>
endobj
388 0 obj
<</Length 7800>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (7) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (benefits; \(ii\) a material diminution of Executive�) Tj ET Q
q 0 0 0 rg BT 376.59 711.70 Td (s position, responsibilities, duties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (or authorities from those in ef) Tj ET Q
q 0 0 0 rg BT 286.75 695.15 Td (fect as of the Ef) Tj ET Q
q 0 0 0 rg BT 362.49 695.15 Td (fective Date; \(iii\) any change in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (reporting structure such that Executive is required to report to someone other than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (Endo�) Tj ET Q
q 0 0 0 rg BT 172.66 662.00 Td (s Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 273.42 662.00 Td (ficer; \(iv\) any material breach by the Company of its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (obligations under this ) Tj ET Q
q 0 0 0 rg BT 250.33 645.45 Td (Agreement; or \(v\) the Company requiring Executive to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (based at any of) Tj ET Q
q 0 0 0 rg BT 216.09 628.90 Td (fice or location that increases the length of Executive�) Tj ET Q
q 0 0 0 rg BT 474.65 628.90 Td (s commute ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (by more than fifty \(50\) miles. Executive shall provide notice of the existence of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (the Good Reason condition within ninety \(90\) days of the date Executive learns of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (the condition, and the Company shall have a period of thirty \(30\) days during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (which it may remedy the condition, and in case of full remedy such condition ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (shall not be deemed to constitute Good Reason hereunder) Tj ET Q
q 0 0 0 rg BT 419.93 546.10 Td (. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 517.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 515.950390625 m
250.83984375 515.950390625 l
s
q 0 0 0 rg BT 144.00 517.55 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 517.55 Td (ithout Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 250.84 517.55 Td (. Executive may voluntarily terminate Executive�) Tj ET Q
q 0 0 0 rg BT 486.76 517.55 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (employment without Good Reason by delivering to the Company a Notice of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 484.40 Td (ermination not less than thirty \(30\) days prior to the termination of Executive�) Tj ET Q
q 0 0 0 rg BT 524.40 484.40 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (employment and the Company shall have the option of terminating Executive�) Tj ET Q
q 0 0 0 rg BT 519.91 467.85 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (duties and responsibilities prior to the expiration of such thirty-day notice period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (provided the Company shall not be obligated to pay any amount through the end ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (of such notice period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 389.60 Td (7.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 389.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 388.000390625 m
214.2421875 388.000390625 l
s
q 0 0 0 rg BT 108.00 389.60 Td (Notice of ) Tj ET Q
q 0 0 0 rg BT 155.77 389.60 Td (T) Tj ET Q
q 0 0 0 rg BT 162.26 389.60 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 214.24 389.60 Td (. ) Tj ET Q
q 0 0 0 rg BT 219.58 389.60 Td (Any purported termination by the Company or by Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 373.05 Td (be communicated by written Notice of ) Tj ET Q
q 0 0 0 rg BT 295.72 373.05 Td (T) Tj ET Q
q 0 0 0 rg BT 302.21 373.05 Td (ermination to the other party hereto. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 356.50 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 186.33 356.50 Td (Agreement, a �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
259.294921875 354.900390625 m
365.537109375 354.900390625 l
s
q 0 0 0 rg BT 259.29 356.50 Td (Notice of ) Tj ET Q
q 0 0 0 rg BT 307.06 356.50 Td (T) Tj ET Q
q 0 0 0 rg BT 313.55 356.50 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 365.54 356.50 Td (� shall mean a notice that indicates ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 339.95 Td (a termination date, the specific termination provision in this ) Tj ET Q
q 0 0 0 rg BT 397.27 339.95 Td (Agreement relied upon and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 323.40 Td (sets forth in reasonable detail the facts and circumstances claimed to provide a basis for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 306.80 Td (termination of Executive�) Tj ET Q
q 0 0 0 rg BT 230.63 306.80 Td (s employment under the provision so indicated. For purposes of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 290.25 Td (this ) Tj ET Q
q 0 0 0 rg BT 127.68 290.25 Td (Agreement, no such purported termination of Executive�) Tj ET Q
q 0 0 0 rg BT 399.26 290.25 Td (s employment hereunder ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 273.70 Td (shall be ef) Tj ET Q
q 0 0 0 rg BT 157.10 273.70 Td (fective without such Notice of ) Tj ET Q
q 0 0 0 rg BT 305.17 273.70 Td (T) Tj ET Q
q 0 0 0 rg BT 311.66 273.70 Td (ermination \(unless waived by the party entitled ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 257.15 Td (to receive such notice\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 228.60 Td (8.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 228.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 227.00039062500002 m
268.25390625 227.00039062500002 l
s
q 0 0 0 rg BT 108.00 228.60 Td (Compensation Upon ) Tj ET Q
q 0 0 0 rg BT 209.78 228.60 Td (T) Tj ET Q
q 0 0 0 rg BT 216.27 228.60 Td (ermination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 268.25 228.60 Td (. Upon termination of Executive�) Tj ET Q
q 0 0 0 rg BT 426.54 228.60 Td (s employment during ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 212.00 Td (the Employment ) Tj ET Q
q 0 0 0 rg BT 190.44 212.00 Td (T) Tj ET Q
q 0 0 0 rg BT 196.93 212.00 Td (erm, Executive shall be entitled to the following benefits:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 183.45 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 183.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 181.85039062500005 m
522.71484375 181.85039062500005 l
s
q 0 0 0 rg BT 144.00 183.45 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 183.45 Td (ermination by the Company for Cause or by Executive ) Tj ET Q
q 0 0 0 rg BT 415.88 183.45 Td (W) Tj ET Q
q 0 0 0 rg BT 426.72 183.45 Td (ithout Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 522.71 183.45 Td (. If ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 166.90 Td (s employment is terminated by the Company for Cause or by Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 150.35 Td (without Good Reason, the Company shall pay Executive: ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 121.80 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 121.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 121.80 Td (any accrued and unpaid Base Salary) Tj ET Q
q 0 0 0 rg BT 352.82 121.80 Td (, payable on the next payroll date; ) Tj ET Q
endstream
endobj
389 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 390 0 R>>
endobj
390 0 obj
<</Length 6644>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (8) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (any Incentive Compensation earned but unpaid in respect of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (completed fiscal year preceding the termination date, payable at the time ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (annual incentive compensation is paid to other senior executives; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 650.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 650.00 Td (reimbursement for any and all monies advanced or expenses incurred in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 633.45 Td (connection with Executive�) Tj ET Q
q 0 0 0 rg BT 311.29 633.45 Td (s employment for reasonable and necessary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 616.90 Td (expenses incurred by Executive on behalf of the Company for the period ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 600.35 Td (ending on the termination date, which amount shall be reimbursed within ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 583.80 Td (thirty \(30\) days of the Company�) Tj ET Q
q 0 0 0 rg BT 337.64 583.80 Td (s receipt of proper documentation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 567.20 Td (Executive; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (\(iv\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 538.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 538.65 Td (any accrued and unpaid vacation pay) Tj ET Q
q 0 0 0 rg BT 356.81 538.65 Td (, payable on the next payroll date;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 510.10 Td (\(v\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 157.99 510.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 510.10 Td (any previous compensation that Executive has previously deferred ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 493.55 Td (\(including any interest earned or credited thereon\), in accordance with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 477.00 Td (terms and conditions of the applicable deferred compensation plans or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 460.40 Td (arrangements then in ef) Tj ET Q
q 0 0 0 rg BT 292.73 460.40 Td (fect, to the extent vested as of Executive�) Tj ET Q
q 0 0 0 rg BT 489.99 460.40 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 443.85 Td (termination date, paid pursuant to the terms of such plans or arrangements; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 427.30 Td (and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 398.75 Td (\(vi\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 398.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 398.75 Td (any amount or benefit as provided under any benefit plan or program in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 382.20 Td (accordance with the terms thereof \(the foregoing items in Sections 8\(a\)\(i\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 365.60 Td (through 8\(a\)\(vi\) being collectively referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
437.888671875 364.000390625 m
481.529296875 364.000390625 l
s
q 0 0 0 rg BT 437.89 365.60 Td (Accrued ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 347.450390625 m
249.328125 347.450390625 l
s
q 0 0 0 rg BT 180.00 349.05 Td (Compensation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 249.33 349.05 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 320.50 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 320.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 318.900390625 m
351.7353515625 318.900390625 l
s
q 0 0 0 rg BT 144.00 320.50 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 320.50 Td (ermination by the Company for Disability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 351.35 320.50 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 419.65 320.50 Td (s employment is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 303.95 Td (terminated by the Company for Disability) Tj ET Q
q 0 0 0 rg BT 344.18 303.95 Td (, the Company shall pay Executive:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 275.40 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 275.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 275.40 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 275.40 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 246.80 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 246.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 246.80 Td (an amount equal to the Incentive Compensation that Executive would have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 230.25 Td (been entitled to receive in respect of the fiscal year in which Executive�) Tj ET Q
q 0 0 0 rg BT 523.18 230.25 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 213.70 Td (termination date occurs, had Executive continued in employment until the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 197.15 Td (end of such fiscal year) Tj ET Q
q 0 0 0 rg BT 287.47 197.15 Td (, which amount, determined based on actual ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 180.60 Td (performance for such year relative to the performance goals applicable to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 164.00 Td (Executive \(but without any exercise of negative discretion with respect to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 147.45 Td (Executive in excess of that applied to either senior executives of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 130.90 Td (Company generally or in accordance with the Company�) Tj ET Q
q 0 0 0 rg BT 451.58 130.90 Td (s historical past ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 114.35 Td (practice\), shall be multiplied by a fraction \(A\) the numerator of which is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 97.80 Td (the number of days in such fiscal year through the termination date and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 81.20 Td (\(B\) the denominator of which is 365 \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
384.615234375 79.60039062500005 m
460.9453125 79.60039062500005 l
s
q 0 0 0 rg BT 384.62 81.20 Td (Pro-Rata Bonus) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 460.95 81.20 Td (�\) and shall be ) Tj ET Q
endstream
endobj
391 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 392 0 R>>
endobj
392 0 obj
<</Length 6684>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 303.00 59.20 Td (9) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (payable in a lump sum payment at the time such bonus or annual incentive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (awards are payable to other participants. Further) Tj ET Q
q 0 0 0 rg BT 411.76 695.15 Td (, upon Executive�) Tj ET Q
q 0 0 0 rg BT 496.07 695.15 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (Disability \(irrespective of any termination of employment related thereto\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (the Company shall pay Executive for twenty-four \(24\) consecutive months ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (thereafter regular payments in the amount by which Executive�) Tj ET Q
q 0 0 0 rg BT 482.55 645.45 Td (s monthly ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (Base Salary exceeds Executive�) Tj ET Q
q 0 0 0 rg BT 332.27 628.90 Td (s monthly Disability insurance benefit; and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 600.35 Td (continued coverage for Executive and Executive�) Tj ET Q
q 0 0 0 rg BT 416.23 600.35 Td (s dependents under any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 583.80 Td (health, medical, dental, vision and basic life insurance \(but not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 567.20 Td (supplemental life insurance\) program or policy in which Executive was ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 550.65 Td (eligible to participate as of the time of Executive�) Tj ET Q
q 0 0 0 rg BT 417.25 550.65 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 534.10 Td (termination \(as may be amended by the Company from time to time in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 517.55 Td (ordinary course\), for twenty-four \(24\) months following such termination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 501.00 Td (on the same basis as active employees, which such twenty-four month ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 484.40 Td (period shall run concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 404.63 484.40 Td ( period; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
444.62109375 482.800390625 m
487.27734375 482.800390625 l
s
q 0 0 0 rg BT 444.62 484.40 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 487.28 484.40 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
493.27734375 482.800390625 m
534.3515625 482.800390625 l
s
q 0 0 0 rg BT 493.28 484.40 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 534.11 484.40 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 467.85 Td (that \(x\) the Company may instead, in its discretion, provide substantially ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 451.30 Td (similar benefits or payment outside of the Company�) Tj ET Q
q 0 0 0 rg BT 432.95 451.30 Td (s benefit plans if the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 434.75 Td (Company reasonably determines that providing such alternative benefits ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 418.20 Td (or payment is appropriate to minimize potential adverse tax consequences ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 401.60 Td (and penalties; and \(y\) the coverage provided hereunder shall become ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 385.05 Td (secondary to any coverage provided to Executive by a subsequent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 368.50 Td (employer and to any Medicare coverage for which Executive becomes ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 351.95 Td (eligible, and it shall be the obligation of Executive to inform the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 335.40 Td (if Executive becomes eligible for such subsequent coverage \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
496.875 333.800390625 m
539.865234375 333.800390625 l
s
q 0 0 0 rg BT 496.88 335.40 Td (Benefits ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 317.200390625 m
242.666015625 317.200390625 l
s
q 0 0 0 rg BT 180.00 318.80 Td (Continuation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 242.67 318.80 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 290.25 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 290.25 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 288.650390625 m
302.455078125 288.650390625 l
s
q 0 0 0 rg BT 144.00 290.25 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 290.25 Td (ermination By Reason of Death) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 302.46 290.25 Td (. If Executive�) Tj ET Q
q 0 0 0 rg BT 370.76 290.25 Td (s employment is terminated by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 273.70 Td (reason of Executive�) Tj ET Q
q 0 0 0 rg BT 242.63 273.70 Td (s death, the Company shall pay Executive�) Tj ET Q
q 0 0 0 rg BT 446.91 273.70 Td (s beneficiaries:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 245.15 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 245.15 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 245.15 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 216.60 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 216.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 216.60 Td (the Pro-Rata Bonus; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 188.00 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 188.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 188.00 Td (continued coverage for Executive�) Tj ET Q
q 0 0 0 rg BT 344.92 188.00 Td (s dependents under any health, medical, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 171.45 Td (dental, vision and basic life insurance \(but not supplemental life ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 154.90 Td (insurance\) program or policy in which Executive was eligible to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 138.35 Td (participate as of the time of Executive�) Tj ET Q
q 0 0 0 rg BT 365.92 138.35 Td (s employment termination \(as may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 121.80 Td (be amended or replaced by the Company from time to time in the ordinary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 105.20 Td (course\), for twenty-four \(24\) months following such termination on the ) Tj ET Q
endstream
endobj
393 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 394 0 R>>
endobj
394 0 obj
<</Length 7899>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (10) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (same basis as the dependents of active employees, which such twenty-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (four) Tj ET Q
q 0 0 0 rg BT 199.75 695.15 Td (-month period shall run concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 462.05 695.15 Td ( period.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 665.000390625 m
522.71484375 665.000390625 l
s
q 0 0 0 rg BT 144.00 666.60 Td (T) Tj ET Q
q 0 0 0 rg BT 150.49 666.60 Td (ermination by the Company ) Tj ET Q
q 0 0 0 rg BT 287.58 666.60 Td (W) Tj ET Q
q 0 0 0 rg BT 298.43 666.60 Td (ithout Cause or by Executive for Good Reason) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 522.71 666.60 Td (. If ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 650.00 Td (s employment is terminated by the Company without Cause \(other than ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (on account of Executive�) Tj ET Q
q 0 0 0 rg BT 263.62 633.45 Td (s Disability or death\) or by Executive for Good Reason, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (then, subject to Section 14\(e\), the Company shall pay Executive:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 588.35 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 588.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 588.35 Td (the ) Tj ET Q
q 0 0 0 rg BT 197.00 588.35 Td (Accrued Compensation;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 559.80 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 559.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 559.80 Td (the Pro-Rata Bonus;) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 531.20 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 531.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 531.20 Td (in lieu of any further Base Salary or other compensation and benefits for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 514.65 Td (periods subsequent to the termination date, an amount in cash, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 498.10 Td (amount shall be payable in a lump sum payment within sixty \(60\) days ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 481.55 Td (following such termination \(subject to Section 9\(c\)\), equal to two \(2\) times ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 465.00 Td (the sum of \(A\) Executive�) Tj ET Q
q 0 0 0 rg BT 304.63 465.00 Td (s Base Salary and \(B\) the ) Tj ET Q
q 0 0 0 rg BT 429.05 465.00 Td (T) Tj ET Q
q 0 0 0 rg BT 435.54 465.00 Td (ar) Tj ET Q
q 0 0 0 rg BT 444.64 465.00 Td (get Bonus; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 436.40 Td (\(iv\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.33 436.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 436.40 Td (the Benefits Continuation.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 407.85 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 407.85 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 406.250390625 m
212.33203125 406.250390625 l
s
q 0 0 0 rg BT 144.00 407.85 Td (No Mitigation) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 212.33 407.85 Td (. Executive shall not be required to mitigate the amount of any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 391.30 Td (payment provided for under this Section 8 by seeking other employment or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 374.75 Td (otherwise and, except as provided in Section 8\(b\)\(iii\) and 8\(d\)\(iv\) above, no such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 358.20 Td (payment shall be of) Tj ET Q
q 0 0 0 rg BT 238.09 358.20 Td (fset or reduced by the amount of any compensation or benefits ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 341.60 Td (provided to Executive in any subsequent employment. Further) Tj ET Q
q 0 0 0 rg BT 442.79 341.60 Td (, the Company�) Tj ET Q
q 0 0 0 rg BT 516.45 341.60 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 325.05 Td (obligations to make any payments hereunder shall not be subject to or af) Tj ET Q
q 0 0 0 rg BT 491.69 325.05 Td (fected by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 308.50 Td (any set-of) Tj ET Q
q 0 0 0 rg BT 191.43 308.50 Td (f, counterclaim or defense which the Company may have against ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 291.95 Td (Executive. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 263.40 Td (9.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 81.00 263.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 261.800390625 m
215.58984375 261.800390625 l
s
q 0 0 0 rg BT 108.00 263.40 Td (Certain ) Tj ET Q
q 0 0 0 rg BT 146.10 263.40 Td (T) Tj ET Q
q 0 0 0 rg BT 152.60 263.40 Td (ax ) Tj ET Q
q 0 0 0 rg BT 166.71 263.40 Td (T) Tj ET Q
q 0 0 0 rg BT 173.61 263.40 Td (reatment) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 215.59 263.40 Td (.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 234.80 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 234.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 233.20039062499995 m
250.236328125 233.20039062499995 l
s
q 0 0 0 rg BT 144.00 234.80 Td (Golden Parachute ) Tj ET Q
q 0 0 0 rg BT 232.42 234.80 Td (T) Tj ET Q
q 0 0 0 rg BT 238.91 234.80 Td (ax) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 250.24 234.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 256.02 234.80 Td (T) Tj ET Q
q 0 0 0 rg BT 262.51 234.80 Td (o the extent that the payments and benefits provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 218.25 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 218.25 Td (Agreement and benefits provided to, or for the benefit of, Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 201.70 Td (under any other plan or agreement of the Company or any of its af) Tj ET Q
q 0 0 0 rg BT 462.01 201.70 Td (filiates \(such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 185.15 Td (payments or benefits are collectively referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
412.875 183.55039062499998 m
459.5390625 183.55039062499998 l
s
q 0 0 0 rg BT 412.88 185.15 Td (Payments) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 459.54 185.15 Td (�\) would be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 168.60 Td (subject to the excise tax \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
288.609375 167.00039062500002 m
341.197265625 167.00039062500002 l
s
q 0 0 0 rg BT 288.61 168.60 Td (Excise ) Tj ET Q
q 0 0 0 rg BT 323.38 168.60 Td (T) Tj ET Q
q 0 0 0 rg BT 329.87 168.60 Td (ax) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 341.20 168.60 Td (�\) imposed under Section 4999 of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 152.00 Td (Code or any successor provision thereto, or any similar tax imposed by state or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 135.45 Td (local law) Tj ET Q
q 0 0 0 rg BT 186.87 135.45 Td (, then Executive may) Tj ET Q
q 0 0 0 rg BT 287.38 135.45 Td (, in Executive�) Tj ET Q
q 0 0 0 rg BT 357.03 135.45 Td (s sole discretion \(except as provided ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 118.90 Td (herein below\) waive the right to receive any payments or distributions \(or a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 102.35 Td (portion thereof\) by the Company in the nature of compensation to or for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 85.80 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 85.80 Td (s benefit if and to the extent necessary so that no Payment to be made ) Tj ET Q
endstream
endobj
395 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 396 0 R>>
endobj
396 0 obj
<</Length 7537>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.22 59.20 Td (1) Tj ET Q
q 0 0 0 rg BT 305.78 59.20 Td (1) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (or benefit to be provided to Executive shall be subject to the Excise ) Tj ET Q
q 0 0 0 rg BT 470.68 711.70 Td (T) Tj ET Q
q 0 0 0 rg BT 477.18 711.70 Td (ax \(such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (reduced amount is hereinafter referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
379.212890625 693.550390625 m
503.87109375 693.550390625 l
s
q 0 0 0 rg BT 379.21 695.15 Td (Limited Payment ) Tj ET Q
q 0 0 0 rg BT 464.54 695.15 Td (Amount) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 503.87 695.15 Td (�\), but ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (only if such reduction results in a higher after) Tj ET Q
q 0 0 0 rg BT 362.36 678.60 Td (-tax payment to Executive after ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (taking into account the Excise ) Tj ET Q
q 0 0 0 rg BT 291.40 662.00 Td (T) Tj ET Q
q 0 0 0 rg BT 297.90 662.00 Td (ax and any additional taxes \(including federal, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (state and local income taxes, employment, social security and Medicare taxes and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (all other applicable taxes\) Executive would pay if such Payments were not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (reduced. If so waived, the Company shall reduce or eliminate the Payments to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (ef) Tj ET Q
q 0 0 0 rg BT 153.11 595.80 Td (fect the provisions of this Section 9 based upon Section 9\(b\) below) Tj ET Q
q 0 0 0 rg BT 473.94 595.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 479.72 595.80 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (determination of the amount of Payments that would be required to be reduced to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (the Limited Payment ) Tj ET Q
q 0 0 0 rg BT 246.98 562.65 Td (Amount pursuant to this ) Tj ET Q
q 0 0 0 rg BT 365.65 562.65 Td (Agreement and the amount of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (Limited Payment ) Tj ET Q
q 0 0 0 rg BT 229.32 546.10 Td (Amount shall be made, at the Company�) Tj ET Q
q 0 0 0 rg BT 422.95 546.10 Td (s expense, by a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (reputable accounting firm selected by Executive and reasonably acceptable to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (Company \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
220.646484375 511.400390625 m
302.970703125 511.400390625 l
s
q 0 0 0 rg BT 220.65 513.00 Td (Accounting Firm) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 302.97 513.00 Td (�\).  ) Tj ET Q
q 0 0 0 rg BT 321.08 513.00 Td (The ) Tj ET Q
q 0 0 0 rg BT 342.07 513.00 Td (Accounting Firm shall provide its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (determination \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
240.626953125 494.800390625 m
309.9375 494.800390625 l
s
q 0 0 0 rg BT 240.63 496.40 Td (Determination) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 309.94 496.40 Td (�\), together with detailed supporting ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (calculations and documentation to the Company and Executive within ten \(10\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (days of the date of termination, if applicable, or such other time as specified by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (mutual agreement of the Company and Executive, and if the ) Tj ET Q
q 0 0 0 rg BT 435.57 446.75 Td (Accounting Firm ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (determines that no Excise ) Tj ET Q
q 0 0 0 rg BT 270.41 430.20 Td (T) Tj ET Q
q 0 0 0 rg BT 276.90 430.20 Td (ax is payable by Executive with respect to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (Payments, it shall furnish Executive with an opinion reasonably acceptable to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (Executive that no Excise ) Tj ET Q
q 0 0 0 rg BT 265.74 397.05 Td (T) Tj ET Q
q 0 0 0 rg BT 272.23 397.05 Td (ax will be imposed with respect to any such Payments. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 380.50 Td (The Determination shall be binding, final and conclusive upon the Company and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 363.95 Td (Executive, absent manifest error) Tj ET Q
q 0 0 0 rg BT 298.61 363.95 Td (. For purposes of making the calculations required ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 347.40 Td (by this Section 9\(a\), the ) Tj ET Q
q 0 0 0 rg BT 260.65 347.40 Td (Accounting Firm may make reasonable assumptions and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 330.80 Td (approximations concerning applicable taxes and rates, and rely on reasonable, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 314.25 Td (good faith interpretations concerning the application of the Code, and other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 297.70 Td (applicable legal authority) Tj ET Q
q 0 0 0 rg BT 265.17 297.70 Td (. In furtherance of the above, to the extent requested by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 281.15 Td (Executive, the Company shall cooperate in good faith in valuing, and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 264.60 Td (Accounting Firm shall value, services to be provided by Executive \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 248.00 Td (Executive refraining from performing services pursuant to any covenant not to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 231.45 Td (compete\) before, on or after the date of the transaction which causes the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 214.90 Td (application of Section 4999 of the Code, such that payments in respect of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 198.35 Td (services may be considered to be �reasonable compensation� within the meaning ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 181.80 Td (of the regulations under Section 4999 of the Code.     ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 153.20 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 153.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 151.60039062500005 m
252.638671875 151.60039062500005 l
s
q 0 0 0 rg BT 144.00 153.20 Td (Ordering of Reduction) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 252.64 153.20 Td (.  In the case of a reduction in the Payments pursuant to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 136.65 Td (Section 9\(a\), the Payments will be reduced in the following order: \(i\) payments ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 120.10 Td (that are payable in cash that are valued at full value under ) Tj ET Q
q 0 0 0 rg BT 423.66 120.10 Td (T) Tj ET Q
q 0 0 0 rg BT 430.56 120.10 Td (reasury Regulation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 103.55 Td (Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 260.66 103.55 Td ( 24\(a\) will be reduced \(if necessary) Tj ET Q
q 0 0 0 rg BT 429.13 103.55 Td (, to zero\), with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 87.00 Td (amounts that are payable last reduced first; \(ii\) payments and benefits due in ) Tj ET Q
endstream
endobj
397 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 398 0 R>>
endobj
398 0 obj
<</Length 7134>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (12) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (respect of any equity valued at full value under ) Tj ET Q
q 0 0 0 rg BT 372.70 711.70 Td (T) Tj ET Q
q 0 0 0 rg BT 379.61 711.70 Td (reasury Regulation Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 221.67 695.15 Td ( 24\(a\), with the highest values reduced first \(as such values are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (determined under ) Tj ET Q
q 0 0 0 rg BT 231.08 678.60 Td (T) Tj ET Q
q 0 0 0 rg BT 237.99 678.60 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 448.62 678.60 Td ( 24\) will next be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (reduced; \(iii\) payments that are payable in cash that are valued at less than full ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (value under ) Tj ET Q
q 0 0 0 rg BT 203.09 645.45 Td (T) Tj ET Q
q 0 0 0 rg BT 210.00 645.45 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 420.63 645.45 Td ( 24, with amounts that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (are payable last reduced first, will next be reduced; \(iv\) payments and benefits due ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (in respect of any equity valued at less than full value under ) Tj ET Q
q 0 0 0 rg BT 429.69 612.35 Td (T) Tj ET Q
q 0 0 0 rg BT 436.60 612.35 Td (reasury Regulation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 260.66 595.80 Td ( 24, with the highest values reduced first \(as such values ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (are determined under ) Tj ET Q
q 0 0 0 rg BT 248.73 579.20 Td (T) Tj ET Q
q 0 0 0 rg BT 255.64 579.20 Td (reasury Regulation Section 1.280G-1, Q&A) Tj ET Q
q 0 0 0 rg BT 466.27 579.20 Td ( 24\) will next ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (be reduced; and \(v\) all other non-cash benefits not otherwise described in clauses ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (\(ii\) or \(iv\) will be next reduced pro-rata.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 517.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 515.950390625 m
209.66015625 515.950390625 l
s
q 0 0 0 rg BT 144.00 517.55 Td (Section 409A) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 209.66 517.55 Td (. ) Tj ET Q
q 0 0 0 rg BT 215.44 517.55 Td (The parties intend for the payments and benefits under this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (Agreement to be exempt from Section 409A) Tj ET Q
q 0 0 0 rg BT 356.61 501.00 Td ( of the Code or) Tj ET Q
q 0 0 0 rg BT 428.12 501.00 Td (, if not so exempt, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (be paid or provided in a manner which complies with the requirements of such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (section, and intend that this ) Tj ET Q
q 0 0 0 rg BT 277.98 467.85 Td (Agreement shall be construed and administered in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (accordance with such intention. In the event the Company determines that a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (payment or benefit under this ) Tj ET Q
q 0 0 0 rg BT 287.63 434.75 Td (Agreement may not be in compliance with Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (409A) Tj ET Q
q 0 0 0 rg BT 170.00 418.20 Td ( of the Code, subject to Section 5\(a\) herein, the Company shall reasonably ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (confer with Executive in order to modify or amend this ) Tj ET Q
q 0 0 0 rg BT 411.26 401.60 Td (Agreement to comply ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (with Section 409A) Tj ET Q
q 0 0 0 rg BT 233.33 385.05 Td ( of the Code and to do so in a manner to best preserve the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (economic benefit of this ) Tj ET Q
q 0 0 0 rg BT 262.63 368.50 Td (Agreement.  Notwithstanding anything contained herein ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (to the contrary) Tj ET Q
q 0 0 0 rg BT 213.19 351.95 Td (, to the extent required in order to avoid accelerated taxation and/or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 335.40 Td (tax penalties under Section 409A) Tj ET Q
q 0 0 0 rg BT 302.63 335.40 Td ( of the Code, \(i\) no amounts shall be paid to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 318.80 Td (Executive under Section 8 of this ) Tj ET Q
q 0 0 0 rg BT 305.96 318.80 Td (Agreement until Executive would be considered ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 302.25 Td (to have incurred a �separation from service� from the Company within the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 266.31 285.70 Td ( of the Code; \(ii\) amounts that would otherwise be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (payable and benefits that would otherwise be provided pursuant to this ) Tj ET Q
q 0 0 0 rg BT 485.59 269.15 Td (Agreement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 252.60 Td (during the six-month period immediately following Executive�) Tj ET Q
q 0 0 0 rg BT 445.27 252.60 Td (s separation from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 236.00 Td (service shall instead be paid on the first business day after the date that is six \(6\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 219.45 Td (months following Executive�) Tj ET Q
q 0 0 0 rg BT 283.31 219.45 Td (s separation from service \(or death, if earlier\), with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 202.90 Td (interest for any cash payments so delayed, from the date such cash amounts would ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 186.35 Td (otherwise have been paid at the short-term applicable federal rate, compounded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 169.80 Td (semi-annually) Tj ET Q
q 0 0 0 rg BT 211.20 169.80 Td (, as determined under Section 1274 of the Code for the month in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 153.20 Td (which the payment would have been made but for the delay in payment required ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 136.65 Td (to avoid the imposition of an additional rate of tax on Executive; \(iii\) each amount ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 120.10 Td (to be paid or benefit to be provided under this ) Tj ET Q
q 0 0 0 rg BT 365.95 120.10 Td (Agreement shall be construed as a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 103.55 Td (separately identified payment for purposes of Section 409A) Tj ET Q
q 0 0 0 rg BT 429.59 103.55 Td ( of the Code; \(iv\) any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 87.00 Td (payments that are due within the �short term deferral period� as defined in ) Tj ET Q
endstream
endobj
399 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 400 0 R>>
endobj
400 0 obj
<</Length 7047>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (13) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (Section 409A) Tj ET Q
q 0 0 0 rg BT 209.00 711.70 Td ( of the Code shall not be treated as deferred compensation unless ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (applicable law requires otherwise; and \(v\) amounts reimbursable to Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (under this ) Tj ET Q
q 0 0 0 rg BT 194.00 678.60 Td (Agreement shall be paid to Executive on or before the last day of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (year following the year in which the expense was incurred and the amount of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (expenses eligible for reimbursement \(and in-kind benefits provided to Executive\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (during any one \(1\) year may not af) Tj ET Q
q 0 0 0 rg BT 310.72 628.90 Td (fect amounts reimbursable or provided in any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (subsequent year) Tj ET Q
q 0 0 0 rg BT 220.31 612.35 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 583.80 Td (10.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 582.200390625 m
256.2890625 582.200390625 l
s
q 0 0 0 rg BT 108.00 583.80 Td (Records and Confidential Data) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 256.29 583.80 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 555.20 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 555.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 555.20 Td (Executive acknowledges that in connection with the performance of Executive�) Tj ET Q
q 0 0 0 rg BT 524.85 555.20 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 538.65 Td (duties during the Employment ) Tj ET Q
q 0 0 0 rg BT 292.43 538.65 Td (T) Tj ET Q
q 0 0 0 rg BT 298.92 538.65 Td (erm, the Company and its af) Tj ET Q
q 0 0 0 rg BT 434.67 538.65 Td (filiates will make ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (available to Executive, or Executive will develop and have access to, certain ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (Confidential Information \(as defined below\) of the Company and its af) Tj ET Q
q 0 0 0 rg BT 483.69 505.55 Td (filiates. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (Executive acknowledges and agrees that any and all Confidential Information ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (learned or obtained by Executive during the course of Executive�) Tj ET Q
q 0 0 0 rg BT 456.22 472.40 Td (s employment by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (the Company or otherwise, whether developed by Executive alone or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (conjunction with others or otherwise, shall be and is the property of the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (and its af) Tj ET Q
q 0 0 0 rg BT 187.77 422.75 Td (filiates.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 394.20 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 394.20 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 394.20 Td (During the Employment ) Tj ET Q
q 0 0 0 rg BT 263.43 394.20 Td (T) Tj ET Q
q 0 0 0 rg BT 269.92 394.20 Td (erm and thereafter) Tj ET Q
q 0 0 0 rg BT 357.39 394.20 Td (, Confidential Information will be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 377.60 Td (kept confidential by Executive, will not be used in any manner that is detrimental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 361.05 Td (to the Company or its af) Tj ET Q
q 0 0 0 rg BT 260.10 361.05 Td (filiates, will not be used other than in connection with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 344.50 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 344.50 Td (s dischar) Tj ET Q
q 0 0 0 rg BT 237.42 344.50 Td (ge of Executive�) Tj ET Q
q 0 0 0 rg BT 316.05 344.50 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 402.87 344.50 Td (, and will be safeguarded by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (Executive from unauthorized disclosure; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
341.935546875 326.350390625 m
384.591796875 326.350390625 l
s
q 0 0 0 rg BT 341.94 327.95 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 384.59 327.95 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
390.591796875 326.350390625 m
431.666015625 326.350390625 l
s
q 0 0 0 rg BT 390.59 327.95 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 431.43 327.95 Td (, that Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (Information may be disclosed by Executive \(i\) to the Company and its af) Tj ET Q
q 0 0 0 rg BT 493.69 311.40 Td (filiates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (or to any authorized agent or representative of any of them, \(ii\) in connection with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (performing Executive�) Tj ET Q
q 0 0 0 rg BT 252.29 278.25 Td (s duties hereunder) Tj ET Q
q 0 0 0 rg BT 339.12 278.25 Td (, \(iii\) without limiting Section 10\(g\) of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 261.70 Td (Agreement, when required to do so by law or requested by a court, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (governmental agency) Tj ET Q
q 0 0 0 rg BT 246.18 245.15 Td (, legislative body) Tj ET Q
q 0 0 0 rg BT 327.71 245.15 Td (, arbitrator or other person with apparent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (jurisdiction to order Executive to divulge, disclose or make accessible such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (information, provided that Executive, to the extent legally permitted, notifies the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (Company prior to such disclosure, \(iv\) in the course of any proceeding under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (Section 1) Tj ET Q
q 0 0 0 rg BT 188.55 178.90 Td (1 or 12 of this ) Tj ET Q
q 0 0 0 rg BT 258.22 178.90 Td (Agreement or Section 6 of the Release, subject to the prior ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (entry of a confidentiality order) Tj ET Q
q 0 0 0 rg BT 290.79 162.35 Td (, or \(v\) in confidence to an attorney or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (professional advisor for the purpose of securing professional advice, so long as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (such attorney or advisor is subject to confidentiality restrictions no less restrictive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 112.65 Td (than those applicable to Executive hereunder) Tj ET Q
q 0 0 0 rg BT 358.92 112.65 Td (.) Tj ET Q
endstream
endobj
401 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 402 0 R>>
endobj
402 0 obj
<</Length 6445>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (14) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (On Executive�) Tj ET Q
q 0 0 0 rg BT 212.98 711.70 Td (s last day of employment with the Company) Tj ET Q
q 0 0 0 rg BT 424.50 711.70 Td (, or at such earlier date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (as requested by the Company) Tj ET Q
q 0 0 0 rg BT 284.52 695.15 Td (, \(i\) Executive will return to the Company all written ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (Confidential Information that has been provided to, or prepared by) Tj ET Q
q 0 0 0 rg BT 463.13 678.60 Td (, Executive; \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (at the election of the Company) Tj ET Q
q 0 0 0 rg BT 290.84 662.00 Td (, Executive will return to the Company or destroy ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (all copies of any analyses, compilations, studies or other documents prepared by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Executive or for Executive�) Tj ET Q
q 0 0 0 rg BT 276.28 628.90 Td (s use containing or reflecting any Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (Information; and \(iii\) Executive will return all Company property) Tj ET Q
q 0 0 0 rg BT 457.80 612.35 Td (.  Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (shall deliver to the Company a document certifying Executive�) Tj ET Q
q 0 0 0 rg BT 445.24 595.80 Td (s compliance with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (this Section 10\(c\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 550.65 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 550.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (For the purposes of this ) Tj ET Q
q 0 0 0 rg BT 259.66 550.65 Td (Agreement, �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
324.298828125 549.050390625 m
444.603515625 549.050390625 l
s
q 0 0 0 rg BT 324.30 550.65 Td (Confidential Information) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 444.60 550.65 Td (� shall mean all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (confidential and proprietary information of the Company and its af) Tj ET Q
q 0 0 0 rg BT 464.69 534.10 Td (filiates, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (including:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 489.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 489.00 Td (trade secrets concerning the business and af) Tj ET Q
q 0 0 0 rg BT 389.70 489.00 Td (fairs of the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 472.40 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 472.40 Td (filiates, product specifications, data, know-how) Tj ET Q
q 0 0 0 rg BT 415.93 472.40 Td (, formulae, compositions, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 455.85 Td (processes, non-public patent applications, designs, sketches, photographs, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 439.30 Td (graphs, drawings, samples, inventions and ideas, past, current, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 422.75 Td (planned research and development, current and planned manufacturing or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 406.20 Td (distribution methods and processes, customer lists, current and anticipated ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 389.60 Td (customer requirements, price lists, market studies, business plans, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 373.05 Td (computer software and programs \(including object code and source code\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 356.50 Td (computer software and database technologies, systems, structures, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 339.95 Td (architectures \(and related formulae, compositions, processes, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 323.40 Td (improvements, devices, know-how) Tj ET Q
q 0 0 0 rg BT 347.19 323.40 Td (, inventions, discoveries, concepts, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 306.80 Td (ideas, designs, methods and information\); ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 278.25 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 278.25 Td (information concerning the business and af) Tj ET Q
q 0 0 0 rg BT 386.72 278.25 Td (fairs of the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 261.70 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 261.70 Td (filiates \(which includes unpublished financial statements, financial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 245.15 Td (projections and budgets, unpublished and projected sales, capital spending ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 228.60 Td (budgets and plans, the names and backgrounds of key personnel, to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 212.00 Td (extent not publicly known, personnel training and techniques and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 195.45 Td (materials\) however documented; and) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 166.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 166.90 Td (notes, analysis, compilations, studies, summaries, and other material ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 150.35 Td (prepared by or for the Company or its af) Tj ET Q
q 0 0 0 rg BT 373.72 150.35 Td (filiates containing or based, in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 133.80 Td (whole or in part, on any information included in the foregoing. For ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 117.20 Td (purposes of this ) Tj ET Q
q 0 0 0 rg BT 258.33 117.20 Td (Agreement, Confidential Information shall not include ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 100.65 Td (and Executive�) Tj ET Q
q 0 0 0 rg BT 251.64 100.65 Td (s obligations shall not extend to \(A\) information that is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 84.10 Td (generally available to the public, \(B\) information obtained by Executive ) Tj ET Q
endstream
endobj
403 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 404 0 R>>
endobj
404 0 obj
<</Length 5833>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (15) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (other than pursuant to or in connection with this employment, \(C\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (information that is required to be disclosed by law or legal process, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (\(D\) Executive�) Tj ET Q
q 0 0 0 rg BT 250.97 678.60 Td (s rolodex and similar address books, including electronic ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (address books, containing contact information.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 633.45 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 633.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (Nothing herein or elsewhere shall preclude Executive from retaining and using \(i\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 616.90 Td (s personal papers and other materials of a personal nature, including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (photographs, contacts, correspondence, personal diaries, and personal files \(so ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (long as no such materials are covered by any Company hold order\), \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (documents relating to Executive�) Tj ET Q
q 0 0 0 rg BT 302.29 567.20 Td (s personal entitlements and obligations, and \(iii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (information that is necessary for Executive�) Tj ET Q
q 0 0 0 rg BT 353.60 550.65 Td (s personal tax purposes.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 522.10 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 522.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 522.10 Td (Pursuant to 18 U.S.C. � 1833\(b\), Executive understands that Executive will not be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 505.55 Td (held criminally or civilly liable under any Federal or State trade secret law for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (disclosure of a trade secret of the Company or its af) Tj ET Q
q 0 0 0 rg BT 391.70 489.00 Td (filiates that \(i\) is made \(A\) in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (confidence to a Federal, State, or local government of) Tj ET Q
q 0 0 0 rg BT 401.68 472.40 Td (ficial, either directly or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (indirectly) Tj ET Q
q 0 0 0 rg BT 189.21 455.85 Td (, or to Executive�) Tj ET Q
q 0 0 0 rg BT 271.85 455.85 Td (s attorney and \(B\) solely for the purpose of reporting or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (investigating a suspected violation of law; or \(ii\) is made in a complaint or other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (document that is filed under seal in a lawsuit or other proceeding.� Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (understands that if Executive files a lawsuit for retaliation by the Company for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (reporting a suspected violation of law) Tj ET Q
q 0 0 0 rg BT 324.17 389.60 Td (, Executive may disclose the trade secret to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 373.05 Td (s attorney and  use the trade secret information in the court proceeding ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (if Executive \(x\) files any document containing the trade secret under seal, and \(y\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (does not disclose the trade secret, except pursuant to court order) Tj ET Q
q 0 0 0 rg BT 450.90 339.95 Td (.� Nothing in this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (Agreement, or any other agreement that Executive has with the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 306.80 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 306.80 Td (filiates, is intended to conflict with 18 U.S.C. � 1833\(b\) or create liability for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 290.25 Td (disclosures of trade secrets that are expressly allowed by such section.�) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 261.70 Td (\(g\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 261.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (Notwithstanding anything set forth in this ) Tj ET Q
q 0 0 0 rg BT 346.66 261.70 Td (Agreement or any other agreement that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (Executive has with the Company or its af) Tj ET Q
q 0 0 0 rg BT 342.07 245.15 Td (filiates to the contrary) Tj ET Q
q 0 0 0 rg BT 446.92 245.15 Td (, Executive shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (not be prohibited from reporting possible violations of federal or state law or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (regulation to any governmental agency or entity) Tj ET Q
q 0 0 0 rg BT 373.81 212.00 Td (, legislative body) Tj ET Q
q 0 0 0 rg BT 455.35 212.00 Td (, or any self-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (regulatory or) Tj ET Q
q 0 0 0 rg BT 206.09 195.45 Td (ganization, or making other disclosures that are protected under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 178.90 Td (whistleblower provisions of federal or state law or regulation, nor is Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (required to notify the Company regarding any such reporting, disclosure or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (cooperation with the government.) Tj ET Q
endstream
endobj
405 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 406 0 R>>
endobj
406 0 obj
<</Length 7868>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (16) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (1) Tj ET Q
q 0 0 0 rg BT 77.55 711.70 Td (1.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 86.55 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 710.100390625 m
525.603515625 710.100390625 l
s
q 0 0 0 rg BT 108.00 711.70 Td (Covenant Not to Solicit, Not to Compete, Not to Disparage, to Cooperate in Litigation ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 693.550390625 m
396.71484375 693.550390625 l
s
q 0 0 0 rg BT 108.00 695.15 Td (and Not to Cooperate with Non-Governmental ) Tj ET Q
q 0 0 0 rg BT 334.39 695.15 Td (Third Parties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 396.71 695.15 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 666.60 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 666.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 665.000390625 m
257.66015625 665.000390625 l
s
q 0 0 0 rg BT 144.00 666.60 Td (Covenant Not to Solicit) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 257.66 666.60 Td (. ) Tj ET Q
q 0 0 0 rg BT 263.44 666.60 Td (T) Tj ET Q
q 0 0 0 rg BT 269.94 666.60 Td (o protect the Confidential Information and other trade ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 650.00 Td (secrets of the Company and its af) Tj ET Q
q 0 0 0 rg BT 303.74 650.00 Td (filiates as well as the goodwill and competitive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (business of the Company and its af) Tj ET Q
q 0 0 0 rg BT 311.76 633.45 Td (filiates, Executive agrees, during the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 616.90 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 616.90 Td (erm and for a period of eighteen \(18\) months after Executive�) Tj ET Q
q 0 0 0 rg BT 510.49 616.90 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (cessation of employment with the Company) Tj ET Q
q 0 0 0 rg BT 354.85 600.35 Td (, not to solicit or participate in or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (assist in any way in the solicitation of any \(i\) customers or clients of the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (or its af) Tj ET Q
q 0 0 0 rg BT 180.44 567.20 Td (filiates whom Executive first met or about whom learned Confidential ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (Information through Executive�) Tj ET Q
q 0 0 0 rg BT 295.96 550.65 Td (s employment with the Company and \(ii\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (suppliers, employees or agents of the Company or its af) Tj ET Q
q 0 0 0 rg BT 411.06 534.10 Td (filiates. For purposes of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (this covenant, �solicit� or �solicitation� means directly or indirectly influencing or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (attempting to influence any customers, clients, suppliers, employees or agents of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (the Company or its af) Tj ET Q
q 0 0 0 rg BT 247.76 484.40 Td (filiates to cease doing business with, or to reduce the level ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (of business with, the Company and its af) Tj ET Q
q 0 0 0 rg BT 339.09 467.85 Td (filiates or) Tj ET Q
q 0 0 0 rg BT 384.26 467.85 Td (, with respect to employees or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (exclusive agents, to become employed or engaged by any other person, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (partnership, firm, corporation or other entity) Tj ET Q
q 0 0 0 rg BT 356.16 434.75 Td (. Executive agrees that the covenants ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (contained in this Section 1) Tj ET Q
q 0 0 0 rg BT 270.87 418.20 Td (1\(a\) are reasonable and desirable to protect the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (Confidential Information of the Company and its af) Tj ET Q
q 0 0 0 rg BT 391.39 401.60 Td (filiates; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
430.3828125 400.000390625 m
473.0390625 400.000390625 l
s
q 0 0 0 rg BT 430.38 401.60 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 473.04 401.60 Td (, that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (solicitation through general advertising not tar) Tj ET Q
q 0 0 0 rg BT 366.06 385.05 Td (geted at the Company�) Tj ET Q
q 0 0 0 rg BT 474.36 385.05 Td (s or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 368.50 Td (filiates�) Tj ET Q
q 0 0 0 rg BT 188.87 368.50 Td ( employees or the provision of references shall not constitute a breach of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (such obligations.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 323.40 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 323.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 321.800390625 m
269.6484375 321.800390625 l
s
q 0 0 0 rg BT 144.00 323.40 Td (Covenant Not to Compete) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 269.65 323.40 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 294.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 294.80 Td (The Company and its af) Tj ET Q
q 0 0 0 rg BT 295.09 294.80 Td (filiates are currently engaged in the business of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 278.25 Td (branded and generic pharmaceuticals, with a focus on product ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 261.70 Td (development, clinical development, manufacturing, distribution and sales ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 245.15 Td (& marketing.  ) Tj ET Q
q 0 0 0 rg BT 249.77 245.15 Td (T) Tj ET Q
q 0 0 0 rg BT 256.26 245.15 Td (o protect the Confidential Information and other trade ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 228.60 Td (secrets of the Company and its af) Tj ET Q
q 0 0 0 rg BT 339.74 228.60 Td (filiates as well as the goodwill and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 212.00 Td (competitive business of the Company and its af) Tj ET Q
q 0 0 0 rg BT 407.41 212.00 Td (filiates, Executive agrees, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 195.45 Td (during the Employment ) Tj ET Q
q 0 0 0 rg BT 296.77 195.45 Td (T) Tj ET Q
q 0 0 0 rg BT 303.26 195.45 Td (erm and for a period of twelve \(12\) months after ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 178.90 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 231.31 178.90 Td (s cessation of employment with the Company) Tj ET Q
q 0 0 0 rg BT 449.83 178.90 Td (, that Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 162.35 Td (will not, unless otherwise agreed to by the Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 478.71 162.35 Td (ficer of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 145.80 Td (Endo \(following approval by the Chairman of the Committee\), anywhere ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 129.20 Td (in the world where, at the time of Executive�) Tj ET Q
q 0 0 0 rg BT 394.26 129.20 Td (s termination of employment, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 112.65 Td (the Company develops, manufactures, distributes, markets or sells its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 96.10 Td (products, except in the course of Executive�) Tj ET Q
q 0 0 0 rg BT 390.26 96.10 Td (s employment hereunder) Tj ET Q
q 0 0 0 rg BT 508.41 96.10 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 79.55 Td (directly or indirectly manage, operate, control, or participate in the ) Tj ET Q
endstream
endobj
407 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 408 0 R>>
endobj
408 0 obj
<</Length 6736>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (17) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 711.70 Td (management, operation, or control of, be employed by) Tj ET Q
q 0 0 0 rg BT 440.47 711.70 Td (, associated with, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (in any manner connected with, lend Executive�) Tj ET Q
q 0 0 0 rg BT 405.59 695.15 Td (s name to, or render ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (services or advice to, any third party or any business whose products or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (services compete in whole or in part with the products or services \(both on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (the market and in development\) material to the Company or any business ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (unit on the termination date that constitutes more than 5% of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 612.35 Td (Company�) Tj ET Q
q 0 0 0 rg BT 230.00 612.35 Td (s revenue on the termination date \(a �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
410.255859375 610.750390625 m
509.26171875 610.750390625 l
s
q 0 0 0 rg BT 410.26 612.35 Td (Competing Business) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 509.26 612.35 Td (�\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 594.200390625 m
222.65625 594.200390625 l
s
q 0 0 0 rg BT 180.00 595.80 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 222.66 595.80 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
228.65625 594.200390625 m
269.73046875 594.200390625 l
s
q 0 0 0 rg BT 228.66 595.80 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 269.49 595.80 Td (, that Executive may in any event \(x\) own up to a 5% ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 579.20 Td (passive ownership interest in any public or private entity and \(y\) serve on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 562.65 Td (the board of any Competing Business that competes with the business of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 546.10 Td (the Company and its af) Tj ET Q
q 0 0 0 rg BT 291.09 546.10 Td (filiates as an immaterial part of its overall business, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 529.55 Td (provided that Executive recuses himself fully and completely from all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 513.00 Td (matters relating to such business.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 484.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 484.40 Td (For purposes of this Section 1) Tj ET Q
q 0 0 0 rg BT 323.21 484.40 Td (1\(b\), any third party or any business whose ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 467.85 Td (products compete includes any entity with which the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 451.30 Td (af) Tj ET Q
q 0 0 0 rg BT 189.11 451.30 Td (filiates has had a product\(s\) licensing agreement during the Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 434.75 Td (T) Tj ET Q
q 0 0 0 rg BT 186.49 434.75 Td (erm and any entity with which the Company or any of its af) Tj ET Q
q 0 0 0 rg BT 472.88 434.75 Td (filiates is at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 418.20 Td (the time of termination actively negotiating, and eventually concludes ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 401.60 Td (within twelve \(12\) months of the Employment ) Tj ET Q
q 0 0 0 rg BT 405.42 401.60 Td (T) Tj ET Q
q 0 0 0 rg BT 411.91 401.60 Td (erm, a commercial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 385.05 Td (agreement. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (\(iii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 161.99 356.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 356.50 Td (Notwithstanding the foregoing, it shall not be a violation of this Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 339.95 Td (1) Tj ET Q
q 0 0 0 rg BT 185.55 339.95 Td (1\(b\), for Executive to provide services to \(or engage in activities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 323.40 Td (involving\): \(A\) a subsidiary) Tj ET Q
q 0 0 0 rg BT 312.87 323.40 Td (, division or af) Tj ET Q
q 0 0 0 rg BT 382.64 323.40 Td (filiate of a Competing Business ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 306.80 Td (where such subsidiary) Tj ET Q
q 0 0 0 rg BT 285.86 306.80 Td (, division or af) Tj ET Q
q 0 0 0 rg BT 355.63 306.80 Td (filiate is not engaged in a Competing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 290.25 Td (Business and Executive does not provide services to, or have any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 273.70 Td (responsibilities regarding, the Competing Business; \(B\) any entity that is, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 257.15 Td (or is a general partner in, or manages or participates in managing, a private ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 240.60 Td (or public fund \(including a hedge fund\) or other investment vehicle, which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 224.00 Td (is engaged in venture capital investments, leveraged buy-outs, investments ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 207.45 Td (in public or private companies, other forms of private or alternative equity ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 190.90 Td (transactions, or in public equity transactions, and that might make an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 174.35 Td (investment which Executive could not make directly) Tj ET Q
q 0 0 0 rg BT 431.81 174.35 Td (, provided that in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 157.80 Td (connection therewith, Executive does not provide services to, engage in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 141.20 Td (activities involved with, or have any responsibilities regarding a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 124.65 Td (Competing Business; and \(C\) an af) Tj ET Q
q 0 0 0 rg BT 348.09 124.65 Td (filiate of a Competing Business if ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 108.10 Td (Executive does not provide services, directly or indirectly) Tj ET Q
q 0 0 0 rg BT 456.46 108.10 Td (, to such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 91.55 Td (Competing Business and the basis of the af) Tj ET Q
q 0 0 0 rg BT 386.75 91.55 Td (filiation is solely due to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 75.00 Td (common ownership by a private equity or similar investment fund; ) Tj ET Q
endstream
endobj
409 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 410 0 R>>
endobj
410 0 obj
<</Length 8537>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (18) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
180 710.100390625 m
222.65625 710.100390625 l
s
q 0 0 0 rg BT 180.00 711.70 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 222.66 711.70 Td (, that, in each case, Executive shall remain bound by all other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 695.15 Td (post-employment obligations under this ) Tj ET Q
q 0 0 0 rg BT 373.32 695.15 Td (Agreement including Executive�) Tj ET Q
q 0 0 0 rg BT 529.27 695.15 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 678.60 Td (obligations under Sections 10, 1) Tj ET Q
q 0 0 0 rg BT 333.87 678.60 Td (1\(a\), \(c\) and \(d\) herein; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
449.14453125 677.000390625 m
491.80078125 677.000390625 l
s
q 0 0 0 rg BT 449.14 678.60 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 491.80 678.60 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
497.80078125 677.000390625 m
530.208984375 677.000390625 l
s
q 0 0 0 rg BT 497.80 678.60 Td (further) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 529.97 678.60 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 662.00 Td (that Executive�) Tj ET Q
q 0 0 0 rg BT 252.30 662.00 Td (s provision of services to \(or engagement in activities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 645.45 Td (involving\) any entity described in clauses \(A\) or \(B\) of this Section 1) Tj ET Q
q 0 0 0 rg BT 512.15 645.45 Td (1\(b\)) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 628.90 Td (\(iii\) shall be subject to the prior approval of the Board.  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 600.35 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 598.750390625 m
234.638671875 598.750390625 l
s
q 0 0 0 rg BT 144.00 600.35 Td (Nondisparagement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 234.64 600.35 Td (. Executive covenants that during and following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 583.80 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 583.80 Td (erm, Executive will not disparage or encourage or induce others to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (disparage the Company or its af) Tj ET Q
q 0 0 0 rg BT 296.74 567.20 Td (filiates, together with all of their respective past ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (and present directors and of) Tj ET Q
q 0 0 0 rg BT 277.07 550.65 Td (ficers, as well as their respective past and present ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (managers, of) Tj ET Q
q 0 0 0 rg BT 205.76 534.10 Td (ficers, shareholders, partners, employees, agents, attorneys, servants ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (and customers and each of their predecessors, successors and assigns ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (\(collectively) Tj ET Q
q 0 0 0 rg BT 203.19 501.00 Td (, the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
232.177734375 499.400390625 m
379.166015625 499.400390625 l
s
q 0 0 0 rg BT 232.18 501.00 Td (Company Entities and Persons) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 379.17 501.00 Td (�\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
394.822265625 499.400390625 m
437.478515625 499.400390625 l
s
q 0 0 0 rg BT 394.82 501.00 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 437.48 501.00 Td (, that such limitation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (shall extend to past and present managers, of) Tj ET Q
q 0 0 0 rg BT 359.05 484.40 Td (ficers, shareholders, partners, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (employees, agents, attorneys, servants and customers only in their capacities as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (such or in respect of their relationship with the Company and its af) Tj ET Q
q 0 0 0 rg BT 464.37 451.30 Td (filiates. ) Tj ET Q
q 0 0 0 rg BT 502.81 451.30 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (Company shall instruct its of) Tj ET Q
q 0 0 0 rg BT 282.44 434.75 Td (ficers and directors not to, during and following the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 418.20 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 418.20 Td (erm, make or issue any statement that disparages Executive to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 401.60 Td (third parties or otherwise encourage or induce others to disparage Executive. ) Tj ET Q
q 0 0 0 rg BT 514.98 401.60 Td (The ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 385.05 Td (term �disparage� includes, without limitation, comments or statements adversely ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 368.50 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 368.50 Td (fecting in any manner \(i\) the conduct of the business of the Company Entities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 351.95 Td (and Persons or Executive, or \(ii\) the business reputation of the Company Entities ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 335.40 Td (and Persons or Executive. Nothing in this ) Tj ET Q
q 0 0 0 rg BT 345.98 335.40 Td (Agreement is intended to or shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 318.80 Td (prevent either party from providing, or limiting testimony in any judicial, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 302.25 Td (administrative or legal process or otherwise as required by law) Tj ET Q
q 0 0 0 rg BT 444.12 302.25 Td (, prevent either ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 285.70 Td (party from engaging in truthful testimony pursuant to any proceeding under this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 269.15 Td (Section 1) Tj ET Q
q 0 0 0 rg BT 188.55 269.15 Td (1 or Section 12 below or Section 6 of the Release or prevent Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 252.60 Td (from making statements in the course of doing Executive�) Tj ET Q
q 0 0 0 rg BT 421.93 252.60 Td (s normal duties for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 236.00 Td (Company) Tj ET Q
q 0 0 0 rg BT 189.88 236.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 207.45 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 207.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 205.85039062500005 m
514.951171875 205.85039062500005 l
s
q 0 0 0 rg BT 144.00 207.45 Td (Cooperation in ) Tj ET Q
q 0 0 0 rg BT 217.99 207.45 Td (Any Investigations and Litigation; No Cooperation with Non-) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 189.30039062499998 m
277.74609375 189.30039062499998 l
s
q 0 0 0 rg BT 144.00 190.90 Td (Governmental ) Tj ET Q
q 0 0 0 rg BT 215.43 190.90 Td (Third Parties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 277.75 190.90 Td (. During the Employment ) Tj ET Q
q 0 0 0 rg BT 403.18 190.90 Td (T) Tj ET Q
q 0 0 0 rg BT 409.67 190.90 Td (erm and thereafter) Tj ET Q
q 0 0 0 rg BT 497.13 190.90 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 174.35 Td (Executive shall provide truthful information and otherwise assist and cooperate ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 157.80 Td (with the Company and its af) Tj ET Q
q 0 0 0 rg BT 279.43 157.80 Td (filiates, and its counsel, \(i\) in connection with any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 141.20 Td (investigation, inquiry) Tj ET Q
q 0 0 0 rg BT 245.88 141.20 Td (, administrative, regulatory or judicial proceedings, or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 124.65 Td (connection with any dispute or claim of any kind that may be made against, by) Tj ET Q
q 0 0 0 rg BT 521.46 124.65 Td (, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 108.10 Td (with respect to the Company) Tj ET Q
q 0 0 0 rg BT 281.19 108.10 Td (, as reasonably requested by the Company \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 91.55 Td (Executive being available to the Company upon reasonable notice for interviews ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 75.00 Td (and factual investigations, appearing at the Company�) Tj ET Q
q 0 0 0 rg BT 402.26 75.00 Td (s request to give testimony ) Tj ET Q
endstream
endobj
411 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 412 0 R>>
endobj
412 0 obj
<</Length 7326>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (19) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (without requiring service of a subpoena or other legal process, volunteering to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Company all pertinent information and turning over to the Company all relevant ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (documents which are in or may come into Executive�) Tj ET Q
q 0 0 0 rg BT 399.92 678.60 Td (s possession\), and \(ii\) in all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (matters concerning requests for information about the services or advice ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (Executive provides or provided to the Company during Executive�) Tj ET Q
q 0 0 0 rg BT 463.25 645.45 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (with Endo, its af) Tj ET Q
q 0 0 0 rg BT 223.11 628.90 Td (filiates and their predecessors. Such cooperation shall be subject ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (to Executive�) Tj ET Q
q 0 0 0 rg BT 207.64 612.35 Td (s business and personal commitments and shall not require ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (Executive to cooperate against Executive�) Tj ET Q
q 0 0 0 rg BT 345.25 595.80 Td (s own legal interests or the legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (interests of any future employer of Executive. Executive shall use the Company�) Tj ET Q
q 0 0 0 rg BT 530.55 579.20 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (counsel for all matters in connection with this Section 1) Tj ET Q
q 0 0 0 rg BT 411.16 562.65 Td (1\(d\); ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
437.490234375 561.050390625 m
480.146484375 561.050390625 l
s
q 0 0 0 rg BT 437.49 562.65 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 480.15 562.65 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
486.146484375 561.050390625 m
527.220703125 561.050390625 l
s
q 0 0 0 rg BT 486.15 562.65 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 526.98 562.65 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (that if there exists an actual conflict of interest between Executive and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 529.55 Td (s counsel, Executive may retain separate counsel reasonably acceptable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (to the Company) Tj ET Q
q 0 0 0 rg BT 219.88 513.00 Td (. ) Tj ET Q
q 0 0 0 rg BT 225.66 513.00 Td (The existence of an actual conflict of interest, and whether such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 496.40 Td (conflict may be waived, shall be determined pursuant to the rules of attorney ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 479.85 Td (professional conduct and applicable law) Tj ET Q
q 0 0 0 rg BT 335.82 479.85 Td (. ) Tj ET Q
q 0 0 0 rg BT 341.60 479.85 Td (The Company agrees to promptly ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 463.30 Td (reimburse Executive for reasonable expenses reasonably incurred by Executive, in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 446.75 Td (connection with Executive�) Tj ET Q
q 0 0 0 rg BT 275.29 446.75 Td (s cooperation pursuant to this Section 1) Tj ET Q
q 0 0 0 rg BT 464.15 446.75 Td (1\(d\) \(including ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 430.20 Td (travel expenses at the level of travel permitted by this ) Tj ET Q
q 0 0 0 rg BT 403.25 430.20 Td (Agreement and reasonable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 413.60 Td (attorney fees in the event separate legal counsel for Executive is required due to a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 397.05 Td (conflict of interest\). Such reimbursements shall be made as soon as practicable, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 380.50 Td (and in no event later than the calendar year following the year in which the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 363.95 Td (expenses are incurred.  Executive also shall not support \(financially or otherwise\), ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 347.40 Td (counsel or assist any attorneys or their clients or any other non-governmental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 330.80 Td (person in the presentation or prosecution of, encourage any non-governmental ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 314.25 Td (person to raise, or suggest or recommend to any non-governmental person that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 297.70 Td (such person could or should raise, in each case, any disputes, dif) Tj ET Q
q 0 0 0 rg BT 453.04 297.70 Td (ferences, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 281.15 Td (grievances, claims, char) Tj ET Q
q 0 0 0 rg BT 259.06 281.15 Td (ges, or complaints against the Company and/or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 264.60 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 264.60 Td (filiates that \(x\) arises out of, or relates to, any period of time on or prior to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 248.00 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 248.00 Td (s last day of employment with the Company or \(y\) involves any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 231.45 Td (information Executive learned during Executive�) Tj ET Q
q 0 0 0 rg BT 378.58 231.45 Td (s employment with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 214.90 Td (Company; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
196.998046875 213.30039062499998 m
239.654296875 213.30039062499998 l
s
q 0 0 0 rg BT 197.00 214.90 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 239.65 214.90 Td (, that, following the second anniversary of Executive�) Tj ET Q
q 0 0 0 rg BT 496.58 214.90 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 198.35 Td (termination of employment with the Company) Tj ET Q
q 0 0 0 rg BT 366.18 198.35 Td (, such prohibition shall not extend ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 181.80 Td (to any such actions taken by Executive on behalf of \(A\) Executive�) Tj ET Q
q 0 0 0 rg BT 465.56 181.80 Td (s then current ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 165.20 Td (employer) Tj ET Q
q 0 0 0 rg BT 188.84 165.20 Td (, \(B\) any entity with respect to which Executive is then a member of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 148.65 Td (board of directors or managers \(as applicable\), or \(C\) any non-publicly traded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 132.10 Td (entity with respect to which Executive is a 5% or more equity owner \(or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 115.55 Td (af) Tj ET Q
q 0 0 0 rg BT 153.11 115.55 Td (filiate of any such entities referenced in clauses \(A\), \(B\) or \(C\)\). Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 99.00 Td (agrees that, in the event Executive is subpoenaed by any person or entity ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 82.40 Td (\(including any government agency\) to give testimony \(in a deposition, court ) Tj ET Q
endstream
endobj
413 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 414 0 R>>
endobj
414 0 obj
<</Length 7665>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (20) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (proceeding or otherwise\) which in any way relates to Executive�) Tj ET Q
q 0 0 0 rg BT 452.89 711.70 Td (s employment by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (the Company) Tj ET Q
q 0 0 0 rg BT 207.54 695.15 Td (, Executive will, to the extent not legally prohibited from doing so, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (give prompt notice of such request to the Chief Legal Of) Tj ET Q
q 0 0 0 rg BT 415.71 678.60 Td (ficer of the Company so ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (that the Company may contest the right of the requesting person or entity to such ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (disclosure before making such disclosure. Nothing in this provision shall require ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Executive to violate Executive�) Tj ET Q
q 0 0 0 rg BT 294.28 628.90 Td (s obligation to comply with valid legal process.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 600.35 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 600.35 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 598.750390625 m
199.658203125 598.750390625 l
s
q 0 0 0 rg BT 144.00 600.35 Td (Blue Pencil) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 199.66 600.35 Td (. It is the intent and desire of Executive and the Company that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (provisions of this Section 1) Tj ET Q
q 0 0 0 rg BT 274.89 583.80 Td (1 be enforced to the fullest extent permissible under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (the laws and public policies as applied in each jurisdiction in which enforcement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (is sought. If any particular provision of this Section 1) Tj ET Q
q 0 0 0 rg BT 399.52 550.65 Td (1 shall be determined to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (invalid or unenforceable, such covenant shall be amended, without any action on ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (the part of either party hereto, to delete therefrom the portion so determined to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (invalid or unenforceable, such deletion to apply only with respect to the operation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (of such covenant in the particular jurisdiction in which such adjudication is made.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 455.85 Td (12.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 455.85 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 454.250390625 m
431.466796875 454.250390625 l
s
q 0 0 0 rg BT 108.00 455.85 Td (Remedies for Breach of Obligations under Sections 10 or 1) Tj ET Q
q 0 0 0 rg BT 391.82 455.85 Td (1 hereof) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 431.47 455.85 Td (. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 439.30 Td (acknowledges that the Company and its af) Tj ET Q
q 0 0 0 rg BT 311.06 439.30 Td (filiates will suf) Tj ET Q
q 0 0 0 rg BT 382.83 439.30 Td (fer irreparable injury) Tj ET Q
q 0 0 0 rg BT 482.00 439.30 Td (, not readily ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 422.75 Td (susceptible of valuation in monetary damages, if Executive breaches Executive�) Tj ET Q
q 0 0 0 rg BT 491.19 422.75 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 406.20 Td (obligations under Sections 10 or 1) Tj ET Q
q 0 0 0 rg BT 271.87 406.20 Td (1 hereof. ) Tj ET Q
q 0 0 0 rg BT 316.85 406.20 Td (Accordingly) Tj ET Q
q 0 0 0 rg BT 376.05 406.20 Td (, Executive agrees that the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 389.60 Td (Company and its af) Tj ET Q
q 0 0 0 rg BT 201.43 389.60 Td (filiates will be entitled, in addition to any other available remedies, to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 373.05 Td (obtain injunctive relief against any breach or prospective breach by Executive of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 356.50 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 159.31 356.50 Td (s obligations under Sections 10 or 1) Tj ET Q
q 0 0 0 rg BT 330.85 356.50 Td (1 hereof in any Federal or state court ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 339.95 Td (sitting in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 269.47 339.95 Td (, at the Company�) Tj ET Q
q 0 0 0 rg BT 354.79 339.95 Td (s election, in any other state in which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 323.40 Td (Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 259.95 323.40 Td (s principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 425.88 323.40 Td (s principal place of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 306.80 Td (business) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 148.67 306.80 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 151.67 306.80 Td ( Executive hereby submits to the non-exclusive jurisdiction of all those courts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 290.25 Td (for the purposes of any actions or proceedings instituted by the Company or its af) Tj ET Q
q 0 0 0 rg BT 499.03 290.25 Td (filiates ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 273.70 Td (to obtain that injunctive relief, and Executive agrees that process in any or all of those ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 257.15 Td (actions or proceedings may be served by registered mail, addressed to the last address ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 240.60 Td (provided by Executive to the Company) Tj ET Q
q 0 0 0 rg BT 295.51 240.60 Td (, or in any other manner authorized by law) Tj ET Q
q 0 0 0 rg BT 499.00 240.60 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 212.00 Td (13.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 212.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 210.400390625 m
259.4296875 210.400390625 l
s
q 0 0 0 rg BT 108.00 212.00 Td (Representations and ) Tj ET Q
q 0 0 0 rg BT 207.76 212.00 Td (W) Tj ET Q
q 0 0 0 rg BT 218.12 212.00 Td (arranties) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 259.43 212.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 183.45 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 183.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 183.45 Td (The Company represents and warrants that \(i\) it is fully authorized by action of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (the Board \(and of any other person or body whose action is required\) to enter into ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 150.35 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 150.35 Td (Agreement and to perform its obligations under it, \(ii\) the execution, delivery ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 133.80 Td (and performance of this ) Tj ET Q
q 0 0 0 rg BT 260.63 133.80 Td (Agreement by it does not violate any applicable law) Tj ET Q
q 0 0 0 rg BT 509.77 133.80 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 117.20 Td (regulation, order) Tj ET Q
q 0 0 0 rg BT 223.49 117.20 Td (, judgment or decree or any agreement, arrangement, plan or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 100.65 Td (corporate governance document \(x\) to which it is a party or \(y\) by which it is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 84.10 Td (bound, and \(iii\) upon the execution and delivery of this ) Tj ET Q
q 0 0 0 rg BT 410.94 84.10 Td (Agreement by the parties, ) Tj ET Q
endstream
endobj
415 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 416 0 R>>
endobj
416 0 obj
<</Length 6995>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (21) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 711.70 Td (Agreement shall be its valid and binding obligation, enforceable against it in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (accordance with its terms, except to the extent that enforceability may be limited ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (by applicable bankruptcy) Tj ET Q
q 0 0 0 rg BT 264.51 678.60 Td (, insolvency or similar laws af) Tj ET Q
q 0 0 0 rg BT 408.93 678.60 Td (fecting the enforcement of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (creditors�) Tj ET Q
q 0 0 0 rg BT 189.09 662.00 Td ( rights generally) Tj ET Q
q 0 0 0 rg BT 266.29 662.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 633.45 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 633.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 633.45 Td (Executive represents and warrants to the Company that the execution and delivery ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 616.90 Td (by Executive of this ) Tj ET Q
q 0 0 0 rg BT 242.65 616.90 Td (Agreement do not, and the performance by Executive of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 600.35 Td (s obligations hereunder will not, with or without the giving of notice or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (the passage of time, or both: \(a\) violate any judgment, writ, injunction, or order of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (any court, arbitrator) Tj ET Q
q 0 0 0 rg BT 239.14 567.20 Td (, or governmental agency applicable to Executive; or \(b\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (conflict with, result in the breach of any provisions of or the termination of, or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (constitute a default under) Tj ET Q
q 0 0 0 rg BT 265.14 534.10 Td (, any agreement to which Executive is a party or by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (which Executive is or may be bound.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 489.00 Td (14.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 489.00 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 487.400390625 m
177.31640625 487.400390625 l
s
q 0 0 0 rg BT 108.00 489.00 Td (Miscellaneous) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 177.32 489.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 460.40 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 460.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 458.800390625 m
257.33203125 458.800390625 l
s
q 0 0 0 rg BT 144.00 460.40 Td (Successors and ) Tj ET Q
q 0 0 0 rg BT 219.32 460.40 Td (Assigns) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 257.33 460.40 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 431.85 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.33 431.85 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 431.85 Td (This ) Tj ET Q
q 0 0 0 rg BT 203.67 431.85 Td (Agreement shall be binding upon and shall inure to the benefit of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 415.30 Td (Company) Tj ET Q
q 0 0 0 rg BT 225.88 415.30 Td (, its successors and permitted assigns and the Company shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 398.75 Td (require any successor or permitted assign to expressly assume and agree to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 382.20 Td (perform this ) Tj ET Q
q 0 0 0 rg BT 241.32 382.20 Td (Agreement in the same manner and to the same extent that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 365.60 Td (the Company would be required to perform if no such succession or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 349.05 Td (assignment had taken place. ) Tj ET Q
q 0 0 0 rg BT 317.40 349.05 Td (The Company may not assign or delegate any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 332.50 Td (rights or obligations hereunder except to any of its af) Tj ET Q
q 0 0 0 rg BT 434.04 332.50 Td (filiates, or to a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 315.95 Td (successor \(whether direct or indirect, by purchase, mer) Tj ET Q
q 0 0 0 rg BT 442.68 315.95 Td (ger) Tj ET Q
q 0 0 0 rg BT 457.52 315.95 Td (, consolidation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 299.40 Td (or otherwise\) to all or substantially all of the business and/or assets of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 282.80 Td (Company) Tj ET Q
q 0 0 0 rg BT 225.88 282.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 231.67 282.80 Td (The term the �Company� as used herein shall include a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 266.25 Td (corporation or other entity acquiring all or substantially all the assets and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 249.70 Td (business of the Company \(including this ) Tj ET Q
q 0 0 0 rg BT 375.99 249.70 Td (Agreement\) whether by operation ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 233.15 Td (of law or otherwise.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 204.60 Td (\(ii\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 158.66 204.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 204.60 Td (Neither this ) Tj ET Q
q 0 0 0 rg BT 238.66 204.60 Td (Agreement nor any right or interest hereunder shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 188.00 Td (assignable or transferable by Executive, his beneficiaries or legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 171.45 Td (representatives, except by will or by the laws of descent and distribution. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 154.90 Td (This ) Tj ET Q
q 0 0 0 rg BT 203.67 154.90 Td (Agreement shall inure to the benefit of and be enforceable by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 180.00 138.35 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 231.31 138.35 Td (s legal personal representatives.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 109.80 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 109.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 108.20039062499995 m
175.986328125 108.20039062499995 l
s
q 0 0 0 rg BT 144.00 109.80 Td (Notice) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 175.99 109.80 Td (. For the purposes of this ) Tj ET Q
q 0 0 0 rg BT 297.65 109.80 Td (Agreement, notices and all other communications ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 93.20 Td (provided for in the ) Tj ET Q
q 0 0 0 rg BT 235.98 93.20 Td (Agreement \(including the Notice of ) Tj ET Q
q 0 0 0 rg BT 410.04 93.20 Td (T) Tj ET Q
q 0 0 0 rg BT 416.53 93.20 Td (ermination\) shall be in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 76.65 Td (writing and shall be deemed to have been duly given when personally delivered or ) Tj ET Q
endstream
endobj
417 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 418 0 R>>
endobj
418 0 obj
<</Length 8398>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (22) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (sent by Certified mail, return receipt requested, postage prepaid, addressed to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (respective addresses last given by each party to the other; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
422.56640625 693.550390625 m
465.22265625 693.550390625 l
s
q 0 0 0 rg BT 422.57 695.15 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 465.22 695.15 Td (, that all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (notices to the Company shall be directed to the attention of the Chief Legal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (Of) Tj ET Q
q 0 0 0 rg BT 156.45 662.00 Td (ficer of the Company) Tj ET Q
q 0 0 0 rg BT 257.96 662.00 Td (. ) Tj ET Q
q 0 0 0 rg BT 263.30 662.00 Td (All notices and communications shall be deemed to have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (been received on the date of delivery thereof or on the third business day after the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (mailing thereof, except that notice of change of address shall be ef) Tj ET Q
q 0 0 0 rg BT 462.32 628.90 Td (fective only ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (upon receipt.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 582.200390625 m
220.640625 582.200390625 l
s
q 0 0 0 rg BT 144.00 583.80 Td (Indemnification) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 220.64 583.80 Td (. Executive shall be indemnified by the Company as, and to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (extent, to the maximum extent permitted by applicable law as provided in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (memorandum and articles of association of Endo. In addition, the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (agrees to continue and maintain, at the Company�) Tj ET Q
q 0 0 0 rg BT 381.93 534.10 Td (s sole expense, a directors�) Tj ET Q
q 0 0 0 rg BT 509.99 534.10 Td ( and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 517.55 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 517.55 Td (ficers�) Tj ET Q
q 0 0 0 rg BT 183.53 517.55 Td ( liability insurance policy covering Executive both during and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 501.00 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 501.00 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 501.00 Td (erm and while the potential liability exists \(but in no event longer ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 484.40 Td (than six \(6\) years, if such limitation applies to all other individuals covered by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (such policy\) after the Employment ) Tj ET Q
q 0 0 0 rg BT 313.40 467.85 Td (T) Tj ET Q
q 0 0 0 rg BT 319.89 467.85 Td (erm, that is no less favorable than the policy ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (covering Board members and other executive of) Tj ET Q
q 0 0 0 rg BT 375.03 451.30 Td (ficers of the Company from time ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 434.75 Td (to time. ) Tj ET Q
q 0 0 0 rg BT 183.45 434.75 Td (The obligations under this paragraph shall survive any termination of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 418.20 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 208.78 418.20 Td (T) Tj ET Q
q 0 0 0 rg BT 215.27 418.20 Td (erm.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 389.60 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 389.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 388.000390625 m
204.181640625 388.000390625 l
s
q 0 0 0 rg BT 144.00 389.60 Td (W) Tj ET Q
q 0 0 0 rg BT 154.85 389.60 Td (ithholding) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 204.18 389.60 Td (. ) Tj ET Q
q 0 0 0 rg BT 209.96 389.60 Td (The Company shall be entitled to withhold the amount, if any) Tj ET Q
q 0 0 0 rg BT 504.80 389.60 Td (, of all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (taxes of any applicable jurisdiction required to be withheld by an employer with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (respect to any amount paid to Executive hereunder) Tj ET Q
q 0 0 0 rg BT 386.91 356.50 Td (. ) Tj ET Q
q 0 0 0 rg BT 392.70 356.50 Td (The Company) Tj ET Q
q 0 0 0 rg BT 460.24 356.50 Td (, in its sole and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (absolute discretion, shall make all determinations as to whether it is obligated to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (withhold any taxes hereunder and the amount thereof.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.80 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 294.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 293.200390625 m
231.310546875 293.200390625 l
s
q 0 0 0 rg BT 144.00 294.80 Td (Release of Claims) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 231.31 294.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 237.09 294.80 Td (The termination benefits described in Section 8\(d\)\(ii\) � \(iv\) of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (this ) Tj ET Q
q 0 0 0 rg BT 163.68 278.25 Td (Agreement shall be conditioned on Executive delivering to the Company) Tj ET Q
q 0 0 0 rg BT 513.13 278.25 Td (, a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (signed release of claims in the form of Exhibit ) Tj ET Q
q 0 0 0 rg BT 368.94 261.70 Td (A) Tj ET Q
q 0 0 0 rg BT 376.95 261.70 Td ( hereto within forty-five \(45\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (days or twenty-one \(21\) days, as may be applicable under the ) Tj ET Q
q 0 0 0 rg BT 440.57 245.15 Td (Age Discrimination ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 228.60 Td (in Employment ) Tj ET Q
q 0 0 0 rg BT 220.66 228.60 Td (Act of 1967, as amended by the Older ) Tj ET Q
q 0 0 0 rg BT 406.06 228.60 Td (W) Tj ET Q
q 0 0 0 rg BT 416.43 228.60 Td (orkers Benefit Protection ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (Act, following Executive�) Tj ET Q
q 0 0 0 rg BT 268.30 212.00 Td (s termination date, and not revoking Executive�) Tj ET Q
q 0 0 0 rg BT 495.90 212.00 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 195.45 Td (consent to such release of claims within seven \(7\) days of such execution; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 177.30039062499998 m
186.65625 177.30039062499998 l
s
q 0 0 0 rg BT 144.00 178.90 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 186.66 178.90 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
192.65625 177.30039062499998 m
233.73046875 177.30039062499998 l
s
q 0 0 0 rg BT 192.66 178.90 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 233.49 178.90 Td (, that Executive shall not be required to release any rights ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 162.35 Td (Executive may have to be indemnified by) Tj ET Q
q 0 0 0 rg BT 343.15 162.35 Td (, or be covered under any directors�) Tj ET Q
q 0 0 0 rg BT 513.19 162.35 Td ( and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 145.80 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 145.80 Td (ficers�) Tj ET Q
q 0 0 0 rg BT 183.53 145.80 Td ( liability insurance of, the Company under Section 14\(c\) of this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 129.20 Td (Agreement, and provided further that, following a Change in Control \(as defined ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 112.65 Td (in Endo�) Tj ET Q
q 0 0 0 rg BT 185.00 112.65 Td (s ) Tj ET Q
q 0 0 0 rg BT 192.01 112.65 Td (Amended and Restated 2015 Stock Incentive Plan\), Executive�) Tj ET Q
q 0 0 0 rg BT 493.92 112.65 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 96.10 Td (requirement to deliver a release shall be contingent on the Company delivering to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 79.55 Td (Executive a release of claims in the form of Exhibit ) Tj ET Q
q 0 0 0 rg BT 393.91 79.55 Td (A) Tj ET Q
q 0 0 0 rg BT 401.92 79.55 Td ( hereto.) Tj ET Q
endstream
endobj
419 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 420 0 R>>
endobj
420 0 obj
<</Length 8436>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (23) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
307.3916015625 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (Resignation as Of) Tj ET Q
q 0 0 0 rg BT 229.77 711.70 Td (ficer or Director) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 307.06 711.70 Td (. Upon a termination of employment for any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (reason, Executive shall, resign each position \(if any\) that Executive then holds as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (an of) Tj ET Q
q 0 0 0 rg BT 168.11 678.60 Td (ficer or director of the Company and any of its af) Tj ET Q
q 0 0 0 rg BT 403.80 678.60 Td (filiates. Executive�) Tj ET Q
q 0 0 0 rg BT 493.77 678.60 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (execution of this ) Tj ET Q
q 0 0 0 rg BT 226.32 662.00 Td (Agreement shall be deemed the grant by Executive to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (of) Tj ET Q
q 0 0 0 rg BT 153.78 645.45 Td (ficers of the Company of a limited power of attorney to sign in Executive�) Tj ET Q
q 0 0 0 rg BT 509.35 645.45 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (name and on Executive�) Tj ET Q
q 0 0 0 rg BT 259.62 628.90 Td (s behalf any such documentation as may be required to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (executed solely for the limited purposes of ef) Tj ET Q
q 0 0 0 rg BT 360.71 612.35 Td (fectuating such resignations.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 583.80 Td (\(g\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 583.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 582.200390625 m
284.953125 582.200390625 l
s
q 0 0 0 rg BT 144.00 583.80 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 194.31 583.80 Td (Acknowledgement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 284.95 583.80 Td (. Executive acknowledges the Common Stock ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (Ownership Guidelines for Non-Employee Directors and Executive Management ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 550.65 Td (of Endo International plc, as may be amended from time to time, and Endo�) Tj ET Q
q 0 0 0 rg BT 506.89 550.65 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 534.10 Td (compensation recoupment policy) Tj ET Q
q 0 0 0 rg BT 302.51 534.10 Td (, as may be amended from time to time.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 505.55 Td (\(h\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 505.55 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 503.950390625 m
206.654296875 503.950390625 l
s
q 0 0 0 rg BT 144.00 505.55 Td (Modification) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 206.65 505.55 Td (. No provision of this ) Tj ET Q
q 0 0 0 rg BT 311.33 505.55 Td (Agreement may be modified, waived or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 489.00 Td (dischar) Tj ET Q
q 0 0 0 rg BT 178.44 489.00 Td (ged unless such waiver) Tj ET Q
q 0 0 0 rg BT 288.93 489.00 Td (, modification or dischar) Tj ET Q
q 0 0 0 rg BT 406.68 489.00 Td (ge is agreed to in writing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 472.40 Td (and signed by Executive and the Company) Tj ET Q
q 0 0 0 rg BT 348.50 472.40 Td (. No waiver by either party hereto at ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 455.85 Td (any time of any breach by the other party hereto of, or compliance with, any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 439.30 Td (condition or provision of this ) Tj ET Q
q 0 0 0 rg BT 286.33 439.30 Td (Agreement to be performed by such other party ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 422.75 Td (shall be deemed a waiver of similar or dissimilar provisions or conditions at the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (same or at any prior or subsequent time. No agreement or representations, oral or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (otherwise, express or implied, with respect to the subject matter hereof have been ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (made by either party which are not expressly set forth in this ) Tj ET Q
q 0 0 0 rg BT 437.26 373.05 Td (Agreement.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 344.50 Td (\(i\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 344.50 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 342.900390625 m
240.3427734375 342.900390625 l
s
q 0 0 0 rg BT 144.00 344.50 Td (Ef) Tj ET Q
q 0 0 0 rg BT 155.11 344.50 Td (fect of Other Law) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 239.95 344.50 Td (. ) Tj ET Q
q 0 0 0 rg BT 245.29 344.50 Td (Anything herein to the contrary notwithstanding, the terms ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 327.95 Td (of this ) Tj ET Q
q 0 0 0 rg BT 176.67 327.95 Td (Agreement shall be modified to the extent required to meet the provisions ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 311.40 Td (of the Sarbanes-Oxley ) Tj ET Q
q 0 0 0 rg BT 253.63 311.40 Td (Act of 2002, Section 409A) Tj ET Q
q 0 0 0 rg BT 381.96 311.40 Td ( of the Code, or other federal ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 294.80 Td (law applicable to the employment arrangements between Executive and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (Company) Tj ET Q
q 0 0 0 rg BT 189.88 278.25 Td (. ) Tj ET Q
q 0 0 0 rg BT 195.22 278.25 Td (Any delay in providing benefits or payments, any failure to provide a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (benefit or payment, or any repayment of compensation that is required under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (preceding sentence shall not in and of itself constitute a breach of this ) Tj ET Q
q 0 0 0 rg BT 480.90 245.15 Td (Agreement; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 227.00039062500002 m
186.65625 227.00039062500002 l
s
q 0 0 0 rg BT 144.00 228.60 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 186.66 228.60 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
192.65625 227.00039062500002 m
233.73046875 227.00039062500002 l
s
q 0 0 0 rg BT 192.66 228.60 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 233.49 228.60 Td (, that the Company shall provide economically equivalent ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 212.00 Td (payments or benefits to Executive to the extent permitted by law) Tj ET Q
q 0 0 0 rg BT 453.13 212.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 183.45 Td (\(j\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 183.45 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 181.85039062500005 m
219.2548828125 181.85039062500005 l
s
q 0 0 0 rg BT 144.00 183.45 Td (Governing Law) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 218.87 183.45 Td (. ) Tj ET Q
q 0 0 0 rg BT 224.65 183.45 Td (This ) Tj ET Q
q 0 0 0 rg BT 248.32 183.45 Td (Agreement shall be governed by and construed and enforced ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (in accordance with the laws of the State of Delaware applicable to contracts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 150.35 Td (executed in and to be performed entirely within such State, without giving ef) Tj ET Q
q 0 0 0 rg BT 512.68 150.35 Td (fect ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 133.80 Td (to the conflict of law principles thereof.  ) Tj ET Q
q 0 0 0 rg BT 339.60 133.80 Td (Any dispute hereunder may be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 117.20 Td (adjudicated in any Federal or state court sitting in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 501.06 117.20 Td (, at the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 100.65 Td (Company�) Tj ET Q
q 0 0 0 rg BT 194.00 100.65 Td (s election, in any other state in which Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 527.56 100.65 Td (s ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 84.10 Td (principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 302.26 84.10 Td (s principal place of business. ) Tj ET Q
endstream
endobj
421 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 422 0 R>>
endobj
422 0 obj
<</Length 8065>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (24) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (\(k\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 711.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 710.100390625 m
205.6640625 710.100390625 l
s
q 0 0 0 rg BT 144.00 711.70 Td (No Conflicts) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 205.66 711.70 Td (. \(A\) Executive represents and warrants to the Company that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (Executive is not a party to or otherwise bound by any agreement or arrangement ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (\(including any license, covenant, or commitment of any nature\), or subject to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (judgment, decree, or order of any court or administrative agency) Tj ET Q
q 0 0 0 rg BT 452.77 662.00 Td (, that would ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (conflict with or will be in conflict with or in any way preclude, limit or inhibit ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 628.90 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 195.31 628.90 Td (s ability to execute this ) Tj ET Q
q 0 0 0 rg BT 308.29 628.90 Td (Agreement or to carry out Executive�) Tj ET Q
q 0 0 0 rg BT 487.22 628.90 Td (s duties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 612.35 Td (and responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 287.30 612.35 Td (. \(B\) ) Tj ET Q
q 0 0 0 rg BT 312.08 612.35 Td (The Company represents and warrants to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 595.80 Td (Executive that the Company is not a party to or otherwise bound by any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 579.20 Td (agreement or arrangement \(including any license, covenant, or commitment of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 562.65 Td (any nature\), or subject to any judgment, decree, or order of any court or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 546.10 Td (administrative agency) Tj ET Q
q 0 0 0 rg BT 248.85 546.10 Td (, that would conflict with or will be in conflict with or in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 529.55 Td (any way preclude, limit or inhibit the Company�) Tj ET Q
q 0 0 0 rg BT 375.29 529.55 Td (s ability to execute this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 513.00 Td (Agreement or to carry out the Company�) Tj ET Q
q 0 0 0 rg BT 339.28 513.00 Td (s duties and responsibilities hereunder) Tj ET Q
q 0 0 0 rg BT 521.91 513.00 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 484.40 Td (\(l\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.33 484.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 482.800390625 m
201.5947265625 482.800390625 l
s
q 0 0 0 rg BT 144.00 484.40 Td (Severability) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 201.21 484.40 Td (. ) Tj ET Q
q 0 0 0 rg BT 206.99 484.40 Td (The provisions of this ) Tj ET Q
q 0 0 0 rg BT 314.32 484.40 Td (Agreement shall be deemed severable and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 467.85 Td (invalidity or unenforceability of any provision shall not af) Tj ET Q
q 0 0 0 rg BT 422.38 467.85 Td (fect the validity or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 451.30 Td (enforceability of the other provisions hereof.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 422.75 Td (\(m\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 125.33 422.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 421.150390625 m
217.3125 421.150390625 l
s
q 0 0 0 rg BT 144.00 422.75 Td (Inconsistencies) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 217.31 422.75 Td (. In the event of any inconsistency between any provision of this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 406.20 Td (Agreement and any provision of any employee handbook, personnel manual, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 389.60 Td (program, policy) Tj ET Q
q 0 0 0 rg BT 219.87 389.60 Td (, or arrangement of the Company or its af) Tj ET Q
q 0 0 0 rg BT 418.59 389.60 Td (filiates \(including any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 373.05 Td (provisions relating to notice requirements and post-employment restrictions\), the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 356.50 Td (provisions of this ) Tj ET Q
q 0 0 0 rg BT 229.68 356.50 Td (Agreement shall control, unless Executive otherwise agrees in a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 339.95 Td (writing that expressly refers to the provision of this ) Tj ET Q
q 0 0 0 rg BT 392.29 339.95 Td (Agreement whose control ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 323.40 Td (Executive is waiving.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.80 Td (\(n\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 294.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 293.200390625 m
263.9296875 293.200390625 l
s
q 0 0 0 rg BT 144.00 294.80 Td (Beneficiaries/References) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 263.93 294.80 Td (. In the event of Executive�) Tj ET Q
q 0 0 0 rg BT 393.88 294.80 Td (s death or a judicial ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 278.25 Td (determination of Executive�) Tj ET Q
q 0 0 0 rg BT 277.95 278.25 Td (s incompetence, references in this ) Tj ET Q
q 0 0 0 rg BT 442.55 278.25 Td (Agreement to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 261.70 Td (Executive shall be deemed, where appropriate, to refer to Executive�) Tj ET Q
q 0 0 0 rg BT 472.85 261.70 Td (s beneficiary) Tj ET Q
q 0 0 0 rg BT 533.71 261.70 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 245.15 Td (estate or other legal representative.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 216.60 Td (\(o\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 216.60 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 215.00039062500002 m
184.6640625 215.00039062500002 l
s
q 0 0 0 rg BT 144.00 216.60 Td (Survival) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 184.66 216.60 Td (. Except as otherwise set forth in this ) Tj ET Q
q 0 0 0 rg BT 364.29 216.60 Td (Agreement, the respective rights ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 200.00 Td (and obligations of the parties hereunder shall survive the Employment ) Tj ET Q
q 0 0 0 rg BT 483.70 200.00 Td (T) Tj ET Q
q 0 0 0 rg BT 490.19 200.00 Td (erm and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 183.45 Td (any termination of Executive�) Tj ET Q
q 0 0 0 rg BT 286.95 183.45 Td (s employment.  ) Tj ET Q
q 0 0 0 rg BT 363.39 183.45 Td (W) Tj ET Q
q 0 0 0 rg BT 374.24 183.45 Td (ithout limiting the generality of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 166.90 Td (the for) Tj ET Q
q 0 0 0 rg BT 175.44 166.90 Td (going, the provisions of Section 8, 10, 1) Tj ET Q
q 0 0 0 rg BT 366.98 166.90 Td (1, and 12 shall survive the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 150.35 Td (termination of the Employment ) Tj ET Q
q 0 0 0 rg BT 297.75 150.35 Td (T) Tj ET Q
q 0 0 0 rg BT 304.24 150.35 Td (erm.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 121.80 Td (\(p\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 121.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 120.20039062499995 m
228.966796875 120.20039062499995 l
s
q 0 0 0 rg BT 144.00 121.80 Td (Entire ) Tj ET Q
q 0 0 0 rg BT 175.66 121.80 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 228.97 121.80 Td (. ) Tj ET Q
q 0 0 0 rg BT 234.75 121.80 Td (This ) Tj ET Q
q 0 0 0 rg BT 258.42 121.80 Td (Agreement constitutes the entire agreement between the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 105.20 Td (parties hereto and, as of the Ef) Tj ET Q
q 0 0 0 rg BT 290.06 105.20 Td (fective Date, supersedes the Executive Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 88.65 Td (Agreement between the parties hereto dated November 6, 2018 and all prior ) Tj ET Q
endstream
endobj
423 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 424 0 R>>
endobj
424 0 obj
<</Length 4941>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 59.20 Td ( ) Tj ET Q
q 0 0 0 rg BT 300.00 59.20 Td (25) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 711.70 Td (agreements, understandings and arrangements, oral or written, between the parties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 695.15 Td (hereto with respect to the subject matter hereof, other than the Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 678.60 Td (Retention Bonus arrangement dated May 17, 2018 and the contribution retention ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 662.00 Td (bonus arrangement dated ) Tj ET Q
q 0 0 0 rg BT 266.96 662.00 Td (August 1, 2019, which shall remain in ef) Tj ET Q
q 0 0 0 rg BT 462.38 662.00 Td (fect in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 645.45 Td (accordance with its terms.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 616.90 Td (\(q\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 616.90 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
144 615.300390625 m
205.986328125 615.300390625 l
s
q 0 0 0 rg BT 144.00 616.90 Td (Counterparts) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 205.99 616.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 211.77 616.90 Td (This ) Tj ET Q
q 0 0 0 rg BT 235.44 616.90 Td (Agreement may be executed in one or more counterparts, each ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 600.35 Td (of which will be deemed to be an original copy of this ) Tj ET Q
q 0 0 0 rg BT 405.94 600.35 Td (Agreement and all of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 583.80 Td (which, when taken together) Tj ET Q
q 0 0 0 rg BT 276.14 583.80 Td (, will be deemed to constitute one and the same ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 567.20 Td (agreement.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 538.65 Td (15.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 87.00 538.65 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
108 537.050390625 m
251.6484375 537.050390625 l
s
q 0 0 0 rg BT 108.00 538.65 Td (Certain Rules of Construction) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 251.65 538.65 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 510.10 Td (\(a\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 510.10 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 510.10 Td (The headings and subheadings set forth in this ) Tj ET Q
q 0 0 0 rg BT 368.63 510.10 Td (Agreement are inserted for the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 493.55 Td (convenience of reference only and are to be ignored in any construction of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 477.00 Td (terms set forth herein.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 448.40 Td (\(b\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 448.40 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 448.40 Td (Wherever applicable, the neuter) Tj ET Q
q 0 0 0 rg BT 296.77 448.40 Td (, feminine or masculine pronoun as used herein ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 431.85 Td (shall also include the masculine or feminine, as the case may be.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 403.30 Td (\(c\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 403.30 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 403.30 Td (The term �including� is not limiting and means �including without limitation.�) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 374.75 Td (\(d\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.99 374.75 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 374.75 Td (References in this ) Tj ET Q
q 0 0 0 rg BT 232.31 374.75 Td (Agreement to any statute or statutory provisions include a ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 358.20 Td (reference to such statute or statutory provisions as from time to time amended, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 341.60 Td (modified, reenacted, extended, consolidated or replaced \(whether before or after ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 325.05 Td (the date of this ) Tj ET Q
q 0 0 0 rg BT 217.32 325.05 Td (Agreement\) and to any subordinate legislation made from time to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 308.50 Td (time under such statute or statutory provision.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 279.95 Td (\(e\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.32 279.95 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 279.95 Td (References to �writing� or �written� include any non-transient means of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 263.40 Td (representing or copying words legibly) Tj ET Q
q 0 0 0 rg BT 325.85 263.40 Td (, including by facsimile or electronic mail.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 234.80 Td (\(f\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 119.99 234.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 144.00 234.80 Td (References to �$� are to United States Dollars.) Tj ET Q
endstream
endobj
425 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 426 0 R>>
endobj
426 0 obj
<</Length 2377>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 256.00 59.20 Td (SIGNA) Tj ET Q
q 0 0 0 rg BT 291.34 59.20 Td (TURE P) Tj ET Q
q 0 0 0 rg BT 331.24 59.20 Td (AGE) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td ( IN ) Tj ET Q
q 0 0 0 rg BT 126.45 711.70 Td (WITNESS ) Tj ET Q
q 0 0 0 rg BT 181.22 711.70 Td (WHEREOF) Tj ET Q
q 0 0 0 rg BT 238.26 711.70 Td (, the Company has caused this ) Tj ET Q
q 0 0 0 rg BT 385.90 711.70 Td (Agreement to be executed by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 695.15 Td (its duly authorized of) Tj ET Q
q 0 0 0 rg BT 174.09 695.15 Td (ficer and Executive has executed this ) Tj ET Q
q 0 0 0 rg BT 354.69 695.15 Td (Agreement as of the day and year first ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 678.60 Td (above written.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 324.00 640.80 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 324.00 624.20 Td ( ) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 559.7 m
540.5 559.7 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 559.7 m
540.5 559.7 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 443.7 m
540.5 443.7 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
298.5 443.7 m
540.5 443.7 l
s
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 593.07 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 327.13 593.07 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 564.07 Td (By:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 563.88 Td (/s/ Paul ) Tj ET Q
q 0 0 0 rg BT 339.56 563.88 Td (V) Tj ET Q
q 0 0 0 rg BT 347.35 563.88 Td (. Campanelli) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 549.07 Td (Name:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 548.88 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 325.23 548.88 Td (V) Tj ET Q
q 0 0 0 rg BT 333.01 548.88 Td (. Campanelli) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 534.07 Td (T) Tj ET Q
q 0 0 0 rg BT 263.90 534.07 Td (itle:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 533.88 Td (Chairman of the Board of Directors) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 477.07 Td (EXECUTIVE) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 448.07 Td (By:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 447.88 Td (/s/ Mark Bradley) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 256.00 433.07 Td (Name:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 301.00 432.88 Td (Mark Bradley) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
427 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 428 0 R>>
endobj
428 0 obj
<</Length 9864>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-1) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 274.90 711.90 Td (EXHIBIT) Tj ET Q
q 0 0 0 rg BT 326.03 711.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 328.37 711.90 Td (A) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 337.04 711.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 208.15 671.55 Td (FORM OF) Tj ET Q
q 0 0 0 rg BT 264.02 671.55 Td ( RELEASE ) Tj ET Q
q 0 0 0 rg BT 325.38 671.55 Td (AGREEMENT) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 632.75 Td (THIS RELEASE ) Tj ET Q
q 0 0 0 rg BT 192.67 632.75 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 266.44 632.75 Td ( \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
296.42578125 631.150390625 m
333.73828125 631.150390625 l
s
q 0 0 0 rg BT 296.43 632.75 Td (Release) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 333.74 632.75 Td (�\) is made by and between Mark Bradley ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 618.35 Td (\(�) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
81.322265625 616.750390625 m
129.298828125 616.750390625 l
s
q 0 0 0 rg BT 81.32 618.35 Td (Executive) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 129.30 618.35 Td (�\) and Endo Health Solutions, Inc. \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
324.9140625 616.750390625 m
371.578125 616.750390625 l
s
q 0 0 0 rg BT 324.91 618.35 Td (Company) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 371.58 618.35 Td (�\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 589.55 Td (1. ) Tj ET Q
q 0 0 0 rg BT 108.00 589.55 Td (FOR ) Tj ET Q
q 0 0 0 rg BT 133.68 589.55 Td (AND IN CONSIDERA) Tj ET Q
q 0 0 0 rg BT 245.68 589.55 Td (TION of the payments and benefits provided in Section 8\(d\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 575.15 Td (\(excluding clause \(i\)\) of the Employment ) Tj ET Q
q 0 0 0 rg BT 308.61 575.15 Td (Agreement between Executive and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 560.75 Td (Company dated as of March 6, 2020, \(the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
315.943359375 559.150390625 m
433.58203125 559.150390625 l
s
q 0 0 0 rg BT 315.94 560.75 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 380.27 560.75 Td (Agreement) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 433.58 560.75 Td (�\), Executive, for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 546.35 Td (Executive, his successors and assigns, executors and administrators, now and forever ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 531.95 Td (hereby releases and dischar) Tj ET Q
q 0 0 0 rg BT 239.38 531.95 Td (ges the Company) Tj ET Q
q 0 0 0 rg BT 321.93 531.95 Td (, together with all of its past and present ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 517.55 Td (parents, subsidiaries, and af) Tj ET Q
q 0 0 0 rg BT 240.74 517.55 Td (filiates, together with each of their of) Tj ET Q
q 0 0 0 rg BT 418.79 517.55 Td (ficers, directors, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 503.15 Td (stockholders, partners, employees, agents, representatives and attorneys, and each of their ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 488.75 Td (subsidiaries, af) Tj ET Q
q 0 0 0 rg BT 179.77 488.75 Td (filiates, estates, predecessors, successors, and assigns \(hereinafter ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 474.35 Td (collectively referred to as the �) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
256.25390625 472.750390625 m
303.5625 472.750390625 l
s
q 0 0 0 rg BT 256.25 474.35 Td (Releasees) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 303.56 474.35 Td (�\) from any and all rights, claims, char) Tj ET Q
q 0 0 0 rg BT 488.95 474.35 Td (ges, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 459.95 Td (actions, causes of action, complaints, sums of money) Tj ET Q
q 0 0 0 rg BT 361.83 459.95 Td (, suits, debts, covenants, contracts, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 445.55 Td (agreements, promises, obligations, damages, demands or liabilities of every kind ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 431.15 Td (whatsoever) Tj ET Q
q 0 0 0 rg BT 162.16 431.15 Td (, in law or in equity) Tj ET Q
q 0 0 0 rg BT 255.37 431.15 Td (, whether known or unknown, suspected or unsuspected, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 416.75 Td (which Executive or Executive�) Tj ET Q
q 0 0 0 rg BT 255.61 416.75 Td (s executors, administrators, successors or assigns ever had, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 402.35 Td (now has or may hereafter claim to have by reason of any matter) Tj ET Q
q 0 0 0 rg BT 413.40 402.35 Td (, cause or thing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 387.95 Td (whatsoever; arising from the beginning of time up to the date Executive executes the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 373.55 Td (Release: \(i\) relating in any way to Executive�) Tj ET Q
q 0 0 0 rg BT 324.92 373.55 Td (s employment relationship with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 359.15 Td (Company or any of the Releasees, or the termination of Executive�) Tj ET Q
q 0 0 0 rg BT 428.23 359.15 Td (s employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 344.75 Td (relationship with the Company or any of the Releasees; \(ii\) arising under or relating to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 330.35 Td (the Employment ) Tj ET Q
q 0 0 0 rg BT 189.99 330.35 Td (Agreement; \(iii\) arising under any federal, local or state statute or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 315.95 Td (regulation, including, without limitation, the ) Tj ET Q
q 0 0 0 rg BT 323.31 315.95 Td (Age Discrimination in Employment ) Tj ET Q
q 0 0 0 rg BT 497.95 315.95 Td (Act of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 301.55 Td (1967, as amended by the Older ) Tj ET Q
q 0 0 0 rg BT 260.07 301.55 Td (W) Tj ET Q
q 0 0 0 rg BT 270.44 301.55 Td (orkers Benefit Protection ) Tj ET Q
q 0 0 0 rg BT 393.41 301.55 Td (Act, ) Tj ET Q
q 0 0 0 rg BT 416.52 301.55 Td (T) Tj ET Q
q 0 0 0 rg BT 423.43 301.55 Td (itle ) Tj ET Q
q 0 0 0 rg BT 441.54 301.55 Td (VII of the Civil ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 287.15 Td (Rights ) Tj ET Q
q 0 0 0 rg BT 141.68 287.15 Td (Act of 1964, the ) Tj ET Q
q 0 0 0 rg BT 222.00 287.15 Td (Americans with Disabilities ) Tj ET Q
q 0 0 0 rg BT 358.31 287.15 Td (Act of 1990, the Employee ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 272.75 Td (Retirement Income Security ) Tj ET Q
q 0 0 0 rg BT 245.63 272.75 Td (Act of 1974, the Equal Pay ) Tj ET Q
q 0 0 0 rg BT 377.94 272.75 Td (Act, Sections 1981 through 1988 ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 258.35 Td (of ) Tj ET Q
q 0 0 0 rg BT 120.78 258.35 Td (T) Tj ET Q
q 0 0 0 rg BT 127.69 258.35 Td (itle 42 of the United States Code, the Immigration Reform and Control ) Tj ET Q
q 0 0 0 rg BT 469.96 258.35 Td (Act, the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 243.95 Td (W) Tj ET Q
q 0 0 0 rg BT 118.37 243.95 Td (orkers ) Tj ET Q
q 0 0 0 rg BT 150.69 243.95 Td (Adjustment and Retraining Notification ) Tj ET Q
q 0 0 0 rg BT 343.99 243.95 Td (Act, the Occupational Safety and Health ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 229.55 Td (Act, the Family and Medical Leave ) Tj ET Q
q 0 0 0 rg BT 280.28 229.55 Td (Act, the Fair Labor Standards ) Tj ET Q
q 0 0 0 rg BT 424.91 229.55 Td (Act of 1938, Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 215.15 Td (Order 1) Tj ET Q
q 0 0 0 rg BT 144.54 215.15 Td (1246, the Pennsylvania Human Relations ) Tj ET Q
q 0 0 0 rg BT 345.18 215.15 Td (Act, the Pennsylvania ) Tj ET Q
q 0 0 0 rg BT 452.94 215.15 Td (Whistleblower ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 200.75 Td (Law) Tj ET Q
q 0 0 0 rg BT 128.54 200.75 Td (, the New ) Tj ET Q
q 0 0 0 rg BT 177.42 200.75 Td (Y) Tj ET Q
q 0 0 0 rg BT 184.88 200.75 Td (ork State Human Rights Law) Tj ET Q
q 0 0 0 rg BT 324.08 200.75 Td (, the New ) Tj ET Q
q 0 0 0 rg BT 372.96 200.75 Td (Y) Tj ET Q
q 0 0 0 rg BT 380.42 200.75 Td (ork Labor Law and the New ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 186.35 Td (Y) Tj ET Q
q 0 0 0 rg BT 115.46 186.35 Td (ork Civil Rights Law and/or the applicable state or local law or ordinance against ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 171.95 Td (discrimination, each as amended; \(iv\) relating to wrongful employment termination or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 157.55 Td (breach of contract; or \(v\) arising under or relating to any policy) Tj ET Q
q 0 0 0 rg BT 411.44 157.55 Td (, agreement, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 143.15 Td (understanding or promise, written or oral, formal or informal, between the Company and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 128.75 Td (any of the Releasees and Executive; ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
283.927734375 127.150390625 m
326.583984375 127.150390625 l
s
q 0 0 0 rg BT 283.93 128.75 Td (provided) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 326.58 128.75 Td (, ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
332.583984375 127.150390625 m
373.658203125 127.150390625 l
s
q 0 0 0 rg BT 332.58 128.75 Td (however) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 373.42 128.75 Td (, that notwithstanding the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 114.35 Td (foregoing, nothing contained in the Release shall in any way diminish or impair: \(a\) any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 99.95 Td (rights Executive may have, from and after the date the Release is executed; \(b\) any rights ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 85.55 Td (to indemnification that may exist from time to time under the Company�) Tj ET Q
q 0 0 0 rg BT 454.93 85.55 Td (s certificate of ) Tj ET Q
endstream
endobj
429 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 430 0 R>>
endobj
430 0 obj
<</Length 7560>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-2) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (incorporation or bylaws, or state law or any other indemnification agreement entered into ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 697.30 Td (between Executive and the Company; \(c\) any rights Executive may have under any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 682.90 Td (applicable general liability and/or directors and of) Tj ET Q
q 0 0 0 rg BT 347.69 682.90 Td (ficers insurance policy maintained by ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 668.50 Td (the Company; \(d\) any rights Executive may have to payments and benefits under ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 654.10 Td (Sections 8\(a\)\(i\) and \(iii\) of the Employment ) Tj ET Q
q 0 0 0 rg BT 321.62 654.10 Td (Agreement; \(e\) the right to receive the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 639.70 Td (following payments and benefits: [SPECIFIC LIST) Tj ET Q
q 0 0 0 rg BT 354.76 639.70 Td ( OF COMPENSA) Tj ET Q
q 0 0 0 rg BT 440.12 639.70 Td (TION ) Tj ET Q
q 0 0 0 rg BT 471.12 639.70 Td (AND ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 625.30 Td (BENEFITS P) Tj ET Q
q 0 0 0 rg BT 172.58 625.30 Td (A) Tj ET Q
q 0 0 0 rg BT 180.14 625.30 Td (Y) Tj ET Q
q 0 0 0 rg BT 187.48 625.30 Td (ABLE UNDER SECTIONS 8\(a\)\(ii\), \(iv\), \(v\) ) Tj ET Q
q 0 0 0 rg BT 406.11 625.30 Td (AND \(vi\) OF ) Tj ET Q
q 0 0 0 rg BT 473.56 625.30 Td (THE ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 610.90 Td (EMPLOYMENT) Tj ET Q
q 0 0 0 rg BT 191.12 610.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 193.45 610.90 Td (AGREEMENT) Tj ET Q
q 0 0 0 rg BT 267.23 610.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 270.01 610.90 Td (T) Tj ET Q
q 0 0 0 rg BT 277.13 610.90 Td (O BE INCLUDED]; \(f\) Executive�) Tj ET Q
q 0 0 0 rg BT 445.08 610.90 Td (s ability to bring ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 596.50 Td (appropriate proceedings to enforce the Release; and \(g\) any rights or claims Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 582.10 Td (may have that cannot be waived under applicable law \(collectively) Tj ET Q
q 0 0 0 rg BT 427.42 582.10 Td (, the �Excluded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 567.70 Td (Claims�\). Executive further acknowledges and agrees that, except with respect to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 553.30 Td (Excluded Claims, the Company and the Releasees have fully satisfied any and all ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 538.90 Td (obligations whatsoever owed to Executive arising out of Executive�) Tj ET Q
q 0 0 0 rg BT 432.58 538.90 Td (s employment with ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 524.50 Td (the Company or any of the Releasees, and that no further payments or benefits are owed ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 510.10 Td (to Executive by the Company or any of the Releasees.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 495.70 Td ( ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 481.30 Td (2. ) Tj ET Q
q 0 0 0 rg BT 108.00 481.30 Td ([Upon the Release becoming ef) Tj ET Q
q 0 0 0 rg BT 259.06 481.30 Td (fective, the Company hereby dischar) Tj ET Q
q 0 0 0 rg BT 435.11 481.30 Td (ges and generally ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 466.90 Td (releases Executive from all claims, causes of action, suits, agreements, and damages ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 452.50 Td (which the Company may have now or in the future against Executive for any act, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 438.10 Td (omission or event relating to his employment with the Company or termination of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 423.70 Td (employment therefrom occurring up to and including the date on which the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 409.30 Td (signs the Release \(excluding any acts or omissions constituting fraud, theft, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 394.90 Td (embezzlement or breach of fiduciary duty by Executive\) to the extent that such claim, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 380.50 Td (cause of action, suit, agreement or damages is based on facts, acts, omissions, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 366.10 Td (circumstances or events actually known, or which should have been reasonably known, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 351.70 Td (on the date on which the Company signs the Release by any of) Tj ET Q
q 0 0 0 rg BT 409.05 351.70 Td (ficer or member of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 337.30 Td (Board of Directors of the Company) Tj ET Q
q 0 0 0 rg BT 277.51 337.30 Td (.]) Tj ET Q
BT /F3 12.00 Tf ET
BT /F3 7.80 Tf ET
q 0 0 0 rg BT 284.51 342.74 Td (1) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 308.50 Td (3. ) Tj ET Q
q 0 0 0 rg BT 108.00 308.50 Td (Executive acknowledges and agrees that Executive has been advised to consult with an ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 294.10 Td (attorney of Executive�) Tj ET Q
q 0 0 0 rg BT 214.62 294.10 Td (s choosing prior to signing the Release. Executive understands and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 279.70 Td (agrees that Executive has the right and has been given the opportunity to review the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 265.30 Td (Release with an attorney of Executive�) Tj ET Q
q 0 0 0 rg BT 293.60 265.30 Td (s choice should Executive so desire. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 250.90 Td (also agrees that Executive has entered into the Release freely and voluntarily) Tj ET Q
q 0 0 0 rg BT 476.07 250.90 Td (. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 236.50 Td (further acknowledges and agrees that Executive has had at least [twenty-one \(21\)][forty-) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 222.10 Td (five \(45\)] calendar days to consider the Release, although Executive may sign it sooner if ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 207.70 Td (Executive wishes, but in any case, not prior to the termination date. In addition, once ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 193.30 Td (Executive has signed the Release, Executive shall have seven \(7\) additional days from the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 178.90 Td (date of execution to revoke Executive�) Tj ET Q
q 0 0 0 rg BT 292.92 178.90 Td (s consent and may do so by writing to:  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 164.50 Td (___________.  ) Tj ET Q
q 0 0 0 rg BT 182.78 164.50 Td (The Release shall not be ef) Tj ET Q
q 0 0 0 rg BT 312.18 164.50 Td (fective, and no payments shall be due ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 150.10 Td (hereunder) Tj ET Q
q 0 0 0 rg BT 155.49 150.10 Td (, earlier than the eighth \(8th\) day after Executive shall have executed the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 135.70 Td (Release and returned it to the Company) Tj ET Q
q 0 0 0 rg BT 297.16 135.70 Td (, assuming that Executive had not revoked ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 121.30 Td (Executive�) Tj ET Q
q 0 0 0 rg BT 159.31 121.30 Td (s consent to the Release prior to such date.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 106.90 Td (______________________) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 6.50 Tf ET
q 0 0 0 rg BT 72.00 99.43 Td (1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 75.25 94.90 Td ( Insert upon a qualifying termination following a Change in Control.) Tj ET Q
endstream
endobj
431 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 432 0 R>>
endobj
432 0 obj
<</Length 5356>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 296.65 59.20 Td (A-3) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 711.70 Td (4. ) Tj ET Q
q 0 0 0 rg BT 108.00 711.70 Td (It is understood and agreed by Executive that any payment made to Executive is not to be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 697.30 Td (construed as an admission of any liability whatsoever on the part of the Company or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 682.90 Td (of the other Releasees, by whom liability is expressly denied.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 402.26 682.90 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 656.50 Td (5. ) Tj ET Q
q 0 0 0 rg BT 108.00 656.50 Td (The Release is executed by Executive voluntarily and is not based upon any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 642.10 Td (representations or statements of any kind made by the Company or any of the other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 627.70 Td (Releasees as to the merits, legal liabilities or value of Executive�) Tj ET Q
q 0 0 0 rg BT 417.56 627.70 Td (s claims. Executive ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 613.30 Td (further acknowledges that Executive has had a full and reasonable opportunity to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 598.90 Td (consider the Release and that Executive has not been pressured or in any way coerced ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 584.50 Td (into executing the Release.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 237.29 584.50 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 558.10 Td (6. ) Tj ET Q
q 0 0 0 rg BT 108.00 558.10 Td (The exclusive venue for any disputes arising hereunder shall be the state or federal courts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 543.70 Td (located in the State of Delaware or) Tj ET Q
q 0 0 0 rg BT 274.11 543.70 Td (, at the Company�) Tj ET Q
q 0 0 0 rg BT 359.43 543.70 Td (s election, in any other state in which ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 529.30 Td (Executive maintains Executive�) Tj ET Q
q 0 0 0 rg BT 259.95 529.30 Td (s principal residence or Executive�) Tj ET Q
q 0 0 0 rg BT 425.88 529.30 Td (s principal place of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 514.90 Td (business, and each of the parties hereto irrevocably waives, to the fullest extent permitted ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 500.50 Td (by law) Tj ET Q
q 0 0 0 rg BT 139.55 500.50 Td (, any objection which it may now or hereafter have to the laying of the venue of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 486.10 Td (any such proceeding brought in such a court and any claim that any such proceeding ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 471.70 Td (brought in such a court has been brought in an inconvenient forum. Each of the parties ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 457.30 Td (hereto also agrees that any final and unappealable judgment against a party hereto in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 442.90 Td (connection with any action, suit or other proceeding may be enforced in any court of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 428.50 Td (competent jurisdiction, either within or outside of the United States.  ) Tj ET Q
q 0 0 0 rg BT 439.61 428.50 Td (A) Tj ET Q
q 0 0 0 rg BT 447.61 428.50 Td ( certified or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 414.10 Td (exemplified copy of such award or judgment shall be conclusive evidence of the fact and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 399.70 Td (amount of such award or judgment. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 385.30 Td (  ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 370.90 Td (7. ) Tj ET Q
q 0 0 0 rg BT 108.00 370.90 Td (The Release and the rights and obligations of the parties hereto shall be governed and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 356.50 Td (construed in accordance with the laws of the State of Delaware. If any provision hereof is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 342.10 Td (unenforceable or is held to be unenforceable, such provision shall be fully severable, and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 327.70 Td (this document and its terms shall be construed and enforced as if such unenforceable ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 313.30 Td (provision had never comprised a part hereof, the remaining provisions hereof shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 298.90 Td (remain in full force and ef) Tj ET Q
q 0 0 0 rg BT 233.39 298.90 Td (fect, and the court construing the provisions shall add as a part ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 284.50 Td (hereof a provision as similar in terms and ef) Tj ET Q
q 0 0 0 rg BT 319.05 284.50 Td (fect to such unenforceable provision as may ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 270.10 Td (be enforceable, in lieu of the unenforceable provision.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 367.56 270.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 243.70 Td (8. ) Tj ET Q
q 0 0 0 rg BT 108.00 243.70 Td (The Release shall inure to the benefit of and be binding upon the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 229.30 Td (successors and assigns. ) Tj ET Q
endstream
endobj
433 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 434 0 R>>
endobj
434 0 obj
<</Length 3112>>
stream
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 108.00 711.70 Td (IN ) Tj ET Q
q 0 0 0 rg BT 123.45 711.70 Td (WITNESS ) Tj ET Q
q 0 0 0 rg BT 178.22 711.70 Td (WHEREOF) Tj ET Q
q 0 0 0 rg BT 235.26 711.70 Td (, Executive and the Company have executed the Release as of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 72.00 695.15 Td (the date and year provided below) Tj ET Q
q 0 0 0 rg BT 230.82 695.15 Td (.) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 666.60 Td (IMPOR) Tj ET Q
q 0 0 0 rg BT 112.90 666.60 Td (T) Tj ET Q
q 0 0 0 rg BT 120.02 666.60 Td (ANT) Tj ET Q
q 0 0 0 rg BT 145.14 666.60 Td ( NOTICE:  BY) Tj ET Q
q 0 0 0 rg BT 221.70 666.60 Td ( SIGNING BELOW) Tj ET Q
q 0 0 0 rg BT 324.84 666.60 Td ( ) Tj ET Q
q 0 0 0 rg BT 327.40 666.60 Td (YOU RELEASE ) Tj ET Q
q 0 0 0 rg BT 415.42 666.60 Td (AND GIVE UP) Tj ET Q
q 0 0 0 rg BT 493.43 666.60 Td ( ) Tj ET Q
q 0 0 0 rg BT 495.77 666.60 Td (ANY) Tj ET Q
q 0 0 0 rg BT 521.32 666.60 Td ( ) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 650.00 Td (AND ) Tj ET Q
q 0 0 0 rg BT 100.34 650.00 Td (ALL) Tj ET Q
q 0 0 0 rg BT 124.35 650.00 Td ( LEGAL) Tj ET Q
q 0 0 0 rg BT 168.70 650.00 Td ( CLAIMS, KNOWN ) Tj ET Q
q 0 0 0 rg BT 276.04 650.00 Td (AND UNKNOWN, ) Tj ET Q
q 0 0 0 rg BT 376.15 650.00 Td (THA) Tj ET Q
q 0 0 0 rg BT 401.27 650.00 Td (T) Tj ET Q
q 0 0 0 rg BT 409.05 650.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 411.61 650.00 Td (YOU MA) Tj ET Q
q 0 0 0 rg BT 460.17 650.00 Td (Y) Tj ET Q
q 0 0 0 rg BT 468.39 650.00 Td ( HA) Tj ET Q
q 0 0 0 rg BT 487.84 650.00 Td (VE ) Tj ET Q
BT /F1 12.00 Tf ET
q 0 0 0 rg BT 72.00 633.45 Td (AGAINST) Tj ET Q
q 0 0 0 rg BT 126.46 633.45 Td ( ) Tj ET Q
q 0 0 0 rg BT 129.25 633.45 Td (THE COMP) Tj ET Q
q 0 0 0 rg BT 193.35 633.45 Td (ANY) Tj ET Q
q 0 0 0 rg BT 218.91 633.45 Td ( ) Tj ET Q
q 0 0 0 rg BT 221.24 633.45 Td (AND RELA) Tj ET Q
q 0 0 0 rg BT 282.69 633.45 Td (TED P) Tj ET Q
q 0 0 0 rg BT 316.80 633.45 Td (AR) Tj ET Q
q 0 0 0 rg BT 333.71 633.45 Td (TIES.) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
72.5 568.15 m
122.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 568.15 m
288.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
302.5 568.15 m
352.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 568.15 m
518.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
72.5 568.15 m
122.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 568.15 m
288.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
302.5 568.15 m
352.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 568.15 m
518.5 568.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
122.5 524.15 m
288.5 524.15 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
352.5 524.15 m
518.5 524.15 l
s
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 75.00 557.33 Td (ENDO HEAL) Tj ET Q
q 0 0 0 rg BT 142.77 557.33 Td (TH SOLUTIONS INC.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 305.00 557.33 Td (Mark Bradley) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 75.00 528.33 Td (Dated:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 305.00 528.33 Td (Dated:) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
435 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 436 0 R>>
endobj
436 0 obj
<</Length 33513>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 505.30 772.75 Td (Exhibit 10.23) Tj ET Q
BT /F7 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 743.20 Td (Endo) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 733.60 Td (1400 ) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 506.22 733.60 Td (Atwater Drive) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 724.00 Td (Malvern, P) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 524.14 724.00 Td (A) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 529.18 724.00 Td ( 19355) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 714.40 Td (484.216.0000) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 695.20 Td (endo.com) Tj ET Q
/GS0 gs
q 84.00 0 0 23.00 50.00 655.20 cm
/I22 Do Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 500.60 641.40 Td (August 1, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 613.80 Td (Mark ) Tj ET Q
q 0 0 0 rg BT 74.16 613.80 Td (Bradley) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 601.80 Td (9 ) Tj ET Q
q 0 0 0 rg BT 57.50 601.80 Td (Dillon ) Tj ET Q
q 0 0 0 rg BT 85.56 601.80 Td (Court) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 589.80 Td (Exton, ) Tj ET Q
q 0 0 0 rg BT 78.89 589.80 Td (Pennsylvania, ) Tj ET Q
q 0 0 0 rg BT 137.21 589.80 Td (19341) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 558.00 Td (Dear ) Tj ET Q
q 0 0 0 rg BT 71.93 558.00 Td (Mark,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 540.00 Td (As ) Tj ET Q
q 0 0 0 rg BT 90.69 540.00 Td (we ) Tj ET Q
q 0 0 0 rg BT 104.92 540.00 Td (continue ) Tj ET Q
q 0 0 0 rg BT 141.93 540.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 152.28 540.00 Td (execute ) Tj ET Q
q 0 0 0 rg BT 185.39 540.00 Td (on ) Tj ET Q
q 0 0 0 rg BT 197.97 540.00 Td (our ) Tj ET Q
q 0 0 0 rg BT 213.87 540.00 Td (corporate ) Tj ET Q
q 0 0 0 rg BT 254.20 540.00 Td (strategy) Tj ET Q
q 0 0 0 rg BT 285.21 540.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 290.28 540.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 311.18 540.00 Td (leadership ) Tj ET Q
q 0 0 0 rg BT 354.85 540.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 371.87 540.00 Td (expertise ) Tj ET Q
q 0 0 0 rg BT 410.53 540.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 419.78 540.00 Td (essential ) Tj ET Q
q 0 0 0 rg BT 456.79 540.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 467.14 540.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 481.93 540.00 Td (Company) Tj ET Q
q 0 0 0 rg BT 520.17 540.00 Td (. ) Tj ET Q
q 0 0 0 rg BT 525.24 540.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 527.63 540.00 Td (W) Tj ET Q
q 0 0 0 rg BT 536.67 540.00 Td (ith ) Tj ET Q
q 0 0 0 rg BT 549.80 540.00 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 528.00 Td (progress ) Tj ET Q
q 0 0 0 rg BT 86.47 528.00 Td (made ) Tj ET Q
q 0 0 0 rg BT 110.72 528.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 121.09 528.00 Td (date, ) Tj ET Q
q 0 0 0 rg BT 142.84 528.00 Td (we ) Tj ET Q
q 0 0 0 rg BT 157.09 528.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 171.89 528.00 Td (positioning ) Tj ET Q
q 0 0 0 rg BT 219.49 528.00 Td (ourselves ) Tj ET Q
q 0 0 0 rg BT 259.85 528.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 274.11 528.00 Td (continued ) Tj ET Q
q 0 0 0 rg BT 316.13 528.00 Td (growth ) Tj ET Q
q 0 0 0 rg BT 347.06 528.00 Td (in ) Tj ET Q
q 0 0 0 rg BT 357.43 528.00 Td (Branded ) Tj ET Q
q 0 0 0 rg BT 393.90 528.00 Td (Pharmaceuticals ) Tj ET Q
q 0 0 0 rg BT 462.02 528.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 479.05 528.00 Td (U.S. ) Tj ET Q
q 0 0 0 rg BT 499.42 528.00 Td (Branded ) Tj ET Q
q 0 0 0 rg BT 535.89 528.00 Td (Sterile ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 516.00 Td (Injectables, ) Tj ET Q
q 0 0 0 rg BT 98.25 516.00 Td (while ) Tj ET Q
q 0 0 0 rg BT 122.90 516.00 Td (continuing ) Tj ET Q
q 0 0 0 rg BT 168.11 516.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 178.32 516.00 Td (stabilize ) Tj ET Q
q 0 0 0 rg BT 214.08 516.00 Td (our ) Tj ET Q
q 0 0 0 rg BT 229.84 516.00 Td (Retail ) Tj ET Q
q 0 0 0 rg BT 256.16 516.00 Td (Generics ) Tj ET Q
q 0 0 0 rg BT 294.13 516.00 Td (segment. ) Tj ET Q
q 0 0 0 rg BT 332.39 516.00 Td (O) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
1 1 1 rg
/GS0 gs
339.62 522.93 224.89 -9.09 re f
/GS0 gs
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 339.62 516.00 Td (ur ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 350.38 516.00 Td (capabilities ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 398.35 516.00 Td (in ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 408.57 516.00 Td (these ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 431.55 516.00 Td (core ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 451.19 516.00 Td (growth ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 481.96 516.00 Td (areas ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 504.93 516.00 Td (will ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 522.92 516.00 Td (be ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 534.80 516.00 Td (further ) Tj ET Q
BT /F3 10.00 Tf ET
1 1 1 rg
/GS0 gs
50.00 510.93 512.00 -9.09 re f
/GS0 gs
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 50.00 504.00 Td (enhanced ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 89.84 504.00 Td (by ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 101.92 504.00 Td (the ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 116.23 504.00 Td (expected ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 153.84 504.00 Td (emer) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 173.65 504.00 Td (gence ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 199.05 504.00 Td (of ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 209.46 504.00 Td (the ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 223.76 504.00 Td (Company�) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 265.43 504.00 Td (s ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 270.95 504.00 Td (Aesthetics ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 314.69 504.00 Td (segment ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 350.10 504.00 Td (as ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 360.51 504.00 Td (we ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 374.26 504.00 Td (transition ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 414.12 504.00 Td (to ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 423.98 504.00 Td (the ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 438.28 504.00 Td (crucial ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 467.57 504.00 Td (next ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 486.87 504.00 Td (phase ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 511.72 504.00 Td (of ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 522.14 504.00 Td (our ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 537.55 504.00 Td (multi-) Tj ET Q
BT /F3 10.00 Tf ET
1 1 1 rg
/GS0 gs
50.00 498.93 85.80 -9.09 re f
/GS0 gs
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 50.00 492.00 Td (year ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 69.71 492.00 Td (turnaround ) Tj ET Q
q 0.0392156862745098 0.0392156862745098 0.0392156862745098 rg BT 116.08 492.00 Td (plan.) Tj ET Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
q 0 0 0 rg BT 77.00 474.00 Td (Based ) Tj ET Q
q 0 0 0 rg BT 104.75 474.00 Td (upon ) Tj ET Q
q 0 0 0 rg BT 128.06 474.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 143.58 474.00 Td (impact ) Tj ET Q
q 0 0 0 rg BT 174.11 474.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 185.75 474.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 207.38 474.00 Td (leadership ) Tj ET Q
q 0 0 0 rg BT 251.79 474.00 Td (across ) Tj ET Q
q 0 0 0 rg BT 280.09 474.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 295.61 474.00 Td (enterprise ) Tj ET Q
q 0 0 0 rg BT 338.35 474.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 356.10 474.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 371.62 474.00 Td (criticality ) Tj ET Q
q 0 0 0 rg BT 413.25 474.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 424.89 474.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 446.53 474.00 Td (ongoing ) Tj ET Q
q 0 0 0 rg BT 482.61 474.00 Td (contributions ) Tj ET Q
q 0 0 0 rg BT 538.70 474.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 549.79 474.00 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 462.00 Td (planning ) Tj ET Q
q 0 0 0 rg BT 87.82 462.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 105.09 462.00 Td (execution ) Tj ET Q
q 0 0 0 rg BT 146.79 462.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 157.95 462.00 Td (Endo�) Tj ET Q
q 0 0 0 rg BT 181.84 462.00 Td (s ) Tj ET Q
q 0 0 0 rg BT 188.56 462.00 Td (\(�Endo� ) Tj ET Q
q 0 0 0 rg BT 224.70 462.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 235.86 462.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 250.91 462.00 Td (�Company�\) ) Tj ET Q
q 0 0 0 rg BT 304.83 462.00 Td (transformation ) Tj ET Q
q 0 0 0 rg BT 366.53 462.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 383.80 462.00 Td (turnaround ) Tj ET Q
q 0 0 0 rg BT 430.50 462.00 Td (plan, ) Tj ET Q
q 0 0 0 rg BT 453.05 462.00 Td (I ) Tj ET Q
q 0 0 0 rg BT 459.21 462.00 Td (am ) Tj ET Q
q 0 0 0 rg BT 474.25 462.00 Td (pleased ) Tj ET Q
q 0 0 0 rg BT 507.06 462.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 517.67 462.00 Td (of) Tj ET Q
q 0 0 0 rg BT 525.82 462.00 Td (fer ) Tj ET Q
q 0 0 0 rg BT 539.75 462.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 557.58 462.00 Td (a ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 450.00 Td (special ) Tj ET Q
q 0 0 0 rg BT 81.44 450.00 Td (compensation ) Tj ET Q
q 0 0 0 rg BT 140.66 450.00 Td (arrangement ) Tj ET Q
q 0 0 0 rg BT 194.30 450.00 Td (that ) Tj ET Q
q 0 0 0 rg BT 212.97 450.00 Td (demonstrates ) Tj ET Q
q 0 0 0 rg BT 269.41 450.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 291.42 450.00 Td (importance ) Tj ET Q
q 0 0 0 rg BT 340.08 450.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 351.53 450.00 Td (our ) Tj ET Q
q 0 0 0 rg BT 368.54 450.00 Td (Company) Tj ET Q
q 0 0 0 rg BT 406.77 450.00 Td (. ) Tj ET Q
q 0 0 0 rg BT 412.95 450.00 Td (Specifically) Tj ET Q
q 0 0 0 rg BT 460.06 450.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 466.23 450.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 484.91 450.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 500.79 450.00 Td (eligible ) Tj ET Q
q 0 0 0 rg BT 534.46 450.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 549.79 450.00 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 438.00 Td (contribution ) Tj ET Q
q 0 0 0 rg BT 101.38 438.00 Td (retention ) Tj ET Q
q 0 0 0 rg BT 139.42 438.00 Td (bonus ) Tj ET Q
q 0 0 0 rg BT 165.82 438.00 Td (arrangement ) Tj ET Q
q 0 0 0 rg BT 218.29 438.00 Td (described ) Tj ET Q
q 0 0 0 rg BT 259.10 438.00 Td (in ) Tj ET Q
q 0 0 0 rg BT 269.38 438.00 Td (this ) Tj ET Q
q 0 0 0 rg BT 286.33 438.00 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 312.15 438.00 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 359.07 438.00 Td (\(�Letter ) Tj ET Q
q 0 0 0 rg BT 392.66 438.00 Td (Agreement�\).) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 420.00 Td (Y) Tj ET Q
q 0 0 0 rg BT 83.22 420.00 Td (our ) Tj ET Q
q 0 0 0 rg BT 99.66 420.00 Td (total ) Tj ET Q
q 0 0 0 rg BT 120.54 420.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 174.76 420.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 216.75 420.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 245.42 420.00 Td (amount ) Tj ET Q
q 0 0 0 rg BT 278.52 420.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 288.30 420.00 Td (700,000 ) Tj ET Q
q 0 0 0 rg BT 323.91 420.00 Td (USD ) Tj ET Q
q 0 0 0 rg BT 347.02 420.00 Td (\(the ) Tj ET Q
q 0 0 0 rg BT 365.68 420.00 Td (�Contribution ) Tj ET Q
q 0 0 0 rg BT 424.34 420.00 Td (Bonus�\), ) Tj ET Q
q 0 0 0 rg BT 463.27 420.00 Td (subject ) Tj ET Q
q 0 0 0 rg BT 494.71 420.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 505.59 420.00 Td (applicable ) Tj ET Q
q 0 0 0 rg BT 549.79 420.00 Td (tax ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 408.00 Td (withholdings. ) Tj ET Q
q 0 0 0 rg BT 107.05 408.00 Td (This ) Tj ET Q
q 0 0 0 rg BT 127.32 408.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 180.94 408.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 209.00 408.00 Td (will ) Tj ET Q
q 0 0 0 rg BT 227.06 408.00 Td (be ) Tj ET Q
q 0 0 0 rg BT 238.99 408.00 Td (paid ) Tj ET Q
q 0 0 0 rg BT 258.71 408.00 Td (in ) Tj ET Q
q 0 0 0 rg BT 268.99 408.00 Td (installments ) Tj ET Q
q 0 0 0 rg BT 319.82 408.00 Td (within ) Tj ET Q
q 0 0 0 rg BT 347.88 408.00 Td (thirty ) Tj ET Q
q 0 0 0 rg BT 372.04 408.00 Td (\(30\) ) Tj ET Q
q 0 0 0 rg BT 391.20 408.00 Td (days ) Tj ET Q
q 0 0 0 rg BT 412.03 408.00 Td (following ) Tj ET Q
q 0 0 0 rg BT 453.42 408.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 468.13 408.00 Td (end ) Tj ET Q
q 0 0 0 rg BT 485.07 408.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 495.90 408.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 510.62 408.00 Td (first, ) Tj ET Q
q 0 0 0 rg BT 531.73 408.00 Td (second, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 396.00 Td (third ) Tj ET Q
q 0 0 0 rg BT 71.26 396.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 88.07 396.00 Td (fourth ) Tj ET Q
q 0 0 0 rg BT 114.88 396.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 156.13 396.00 Td (Period ) Tj ET Q
q 0 0 0 rg BT 184.61 396.00 Td (\(each ) Tj ET Q
q 0 0 0 rg BT 208.63 396.00 Td (a ) Tj ET Q
q 0 0 0 rg BT 215.44 396.00 Td (�Retention ) Tj ET Q
q 0 0 0 rg BT 261.13 396.00 Td (Period� ) Tj ET Q
q 0 0 0 rg BT 294.05 396.00 Td (as ) Tj ET Q
q 0 0 0 rg BT 304.76 396.00 Td (defined ) Tj ET Q
q 0 0 0 rg BT 337.11 396.00 Td (below\), ) Tj ET Q
q 0 0 0 rg BT 369.75 396.00 Td (provided ) Tj ET Q
q 0 0 0 rg BT 407.67 396.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 425.04 396.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 439.62 396.00 Td (employed ) Tj ET Q
q 0 0 0 rg BT 481.43 396.00 Td (on ) Tj ET Q
q 0 0 0 rg BT 493.80 396.00 Td (such ) Tj ET Q
q 0 0 0 rg BT 514.50 396.00 Td (dates ) Tj ET Q
q 0 0 0 rg BT 537.42 396.00 Td (by ) Tj ET Q
q 0 0 0 rg BT 549.79 396.00 Td (the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 384.00 Td (Company ) Tj ET Q
q 0 0 0 rg BT 91.26 384.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 101.96 384.00 Td (one ) Tj ET Q
q 0 0 0 rg BT 118.77 384.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 129.48 384.00 Td (its ) Tj ET Q
q 0 0 0 rg BT 141.30 384.00 Td (af) Tj ET Q
q 0 0 0 rg BT 148.89 384.00 Td (filiates. ) Tj ET Q
q 0 0 0 rg BT 180.97 384.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 183.17 384.00 Td (The ) Tj ET Q
q 0 0 0 rg BT 201.09 384.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 242.35 384.00 Td (Periods ) Tj ET Q
q 0 0 0 rg BT 274.72 384.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 291.53 384.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 306.12 384.00 Td (associated ) Tj ET Q
q 0 0 0 rg BT 349.59 384.00 Td (installment ) Tj ET Q
q 0 0 0 rg BT 396.40 384.00 Td (amounts ) Tj ET Q
q 0 0 0 rg BT 432.66 384.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 447.24 384.00 Td (as ) Tj ET Q
q 0 0 0 rg BT 457.94 384.00 Td (follows: ) Tj ET Q
q 0 0 0 rg BT 493.10 384.00 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 507.13 384.00 Td (175,000 ) Tj ET Q
q 0 0 0 rg BT 542.00 384.00 Td (USD ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 372.00 Td (following ) Tj ET Q
q 0 0 0 rg BT 91.36 372.00 Td (September ) Tj ET Q
q 0 0 0 rg BT 136.60 372.00 Td (30, ) Tj ET Q
q 0 0 0 rg BT 151.58 372.00 Td (2019; ) Tj ET Q
q 0 0 0 rg BT 176.83 372.00 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 190.97 372.00 Td (175,000 ) Tj ET Q
q 0 0 0 rg BT 225.94 372.00 Td (USD ) Tj ET Q
q 0 0 0 rg BT 248.42 372.00 Td (following ) Tj ET Q
q 0 0 0 rg BT 289.79 372.00 Td (December ) Tj ET Q
q 0 0 0 rg BT 333.34 372.00 Td (31, ) Tj ET Q
q 0 0 0 rg BT 348.32 372.00 Td (2019; ) Tj ET Q
q 0 0 0 rg BT 373.57 372.00 Td (\(3\) ) Tj ET Q
q 0 0 0 rg BT 387.71 372.00 Td (175,000 ) Tj ET Q
q 0 0 0 rg BT 422.69 372.00 Td (USD ) Tj ET Q
q 0 0 0 rg BT 445.17 372.00 Td (following ) Tj ET Q
q 0 0 0 rg BT 486.53 372.00 Td (June ) Tj ET Q
q 0 0 0 rg BT 507.33 372.00 Td (30, ) Tj ET Q
q 0 0 0 rg BT 522.31 372.00 Td (2020; ) Tj ET Q
q 0 0 0 rg BT 547.56 372.00 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 360.00 Td (\(4\) ) Tj ET Q
q 0 0 0 rg BT 63.66 360.00 Td (175,000 ) Tj ET Q
q 0 0 0 rg BT 98.15 360.00 Td (USD ) Tj ET Q
q 0 0 0 rg BT 120.15 360.00 Td (following ) Tj ET Q
q 0 0 0 rg BT 161.04 360.00 Td (December ) Tj ET Q
q 0 0 0 rg BT 204.12 360.00 Td (31, ) Tj ET Q
q 0 0 0 rg BT 218.61 360.00 Td (2020. ) Tj ET Q
q 0 0 0 rg BT 243.11 360.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 244.96 360.00 Td (T) Tj ET Q
q 0 0 0 rg BT 250.37 360.00 Td (o ) Tj ET Q
q 0 0 0 rg BT 257.37 360.00 Td (qualify ) Tj ET Q
q 0 0 0 rg BT 287.69 360.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 301.34 360.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 315.56 360.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 368.67 360.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 396.22 360.00 Td (payments, ) Tj ET Q
q 0 0 0 rg BT 439.04 360.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 456.04 360.00 Td (must ) Tj ET Q
q 0 0 0 rg BT 477.49 360.00 Td (maintain ) Tj ET Q
q 0 0 0 rg BT 514.47 360.00 Td (strong ) Tj ET Q
q 0 0 0 rg BT 541.47 360.00 Td (work ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 348.00 Td (performance ) Tj ET Q
q 0 0 0 rg BT 103.02 348.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 119.96 348.00 Td (remain ) Tj ET Q
q 0 0 0 rg BT 150.22 348.00 Td (actively ) Tj ET Q
q 0 0 0 rg BT 184.38 348.00 Td (employed ) Tj ET Q
q 0 0 0 rg BT 226.31 348.00 Td (with ) Tj ET Q
q 0 0 0 rg BT 246.59 348.00 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 270.20 348.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 281.03 348.00 Td (one ) Tj ET Q
q 0 0 0 rg BT 297.96 348.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 308.79 348.00 Td (its ) Tj ET Q
q 0 0 0 rg BT 320.74 348.00 Td (af) Tj ET Q
q 0 0 0 rg BT 328.33 348.00 Td (filiates ) Tj ET Q
q 0 0 0 rg BT 358.04 348.00 Td (through ) Tj ET Q
q 0 0 0 rg BT 391.65 348.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 406.37 348.00 Td (applicable ) Tj ET Q
q 0 0 0 rg BT 449.96 348.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 491.34 348.00 Td (Periods.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 330.00 Td (Payment ) Tj ET Q
q 0 0 0 rg BT 115.63 330.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 127.59 330.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 143.44 330.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 198.19 330.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 227.39 330.00 Td (will ) Tj ET Q
q 0 0 0 rg BT 246.58 330.00 Td (be ) Tj ET Q
q 0 0 0 rg BT 259.65 330.00 Td (accelerated ) Tj ET Q
q 0 0 0 rg BT 308.24 330.00 Td (if ) Tj ET Q
q 0 0 0 rg BT 317.98 330.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 339.95 330.00 Td (employment ) Tj ET Q
q 0 0 0 rg BT 393.57 330.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 403.88 330.00 Td (terminated ) Tj ET Q
q 0 0 0 rg BT 450.27 330.00 Td (by ) Tj ET Q
q 0 0 0 rg BT 463.91 330.00 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 488.65 330.00 Td (without ) Tj ET Q
q 0 0 0 rg BT 522.84 330.00 Td (cause ) Tj ET Q
q 0 0 0 rg BT 548.68 330.00 Td (\(no ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 318.00 Td (misconduct ) Tj ET Q
q 0 0 0 rg BT 98.30 318.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 108.83 318.00 Td (rule ) Tj ET Q
q 0 0 0 rg BT 126.57 318.00 Td (violation; ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 167.10 318.00 Td (i.e.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 179.32 318.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 184.01 318.00 Td (restructuring, ) Tj ET Q
q 0 0 0 rg BT 239.80 318.00 Td (reor) Tj ET Q
q 0 0 0 rg BT 255.72 318.00 Td (ganization ) Tj ET Q
q 0 0 0 rg BT 299.57 318.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 310.10 318.00 Td (RIF\) ) Tj ET Q
q 0 0 0 rg BT 331.19 318.00 Td (before ) Tj ET Q
q 0 0 0 rg BT 358.92 318.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 373.33 318.00 Td (end ) Tj ET Q
q 0 0 0 rg BT 389.97 318.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 400.50 318.00 Td (any ) Tj ET Q
q 0 0 0 rg BT 417.13 318.00 Td (applicable ) Tj ET Q
q 0 0 0 rg BT 460.42 318.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 501.50 318.00 Td (Period ) Tj ET Q
q 0 0 0 rg BT 529.80 318.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 546.44 318.00 Td (will ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 306.00 Td (be ) Tj ET Q
q 0 0 0 rg BT 61.80 306.00 Td (paid ) Tj ET Q
q 0 0 0 rg BT 81.38 306.00 Td (within ) Tj ET Q
q 0 0 0 rg BT 109.29 306.00 Td (30 ) Tj ET Q
q 0 0 0 rg BT 121.66 306.00 Td (days ) Tj ET Q
q 0 0 0 rg BT 142.35 306.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 153.04 306.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 173.73 306.00 Td (termination ) Tj ET Q
q 0 0 0 rg BT 222.19 306.00 Td (date. ) Tj ET Q
q 0 0 0 rg BT 243.70 306.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 245.54 306.00 Td (Any ) Tj ET Q
q 0 0 0 rg BT 265.13 306.00 Td (unpaid ) Tj ET Q
q 0 0 0 rg BT 294.70 306.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 348.18 306.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 376.10 306.00 Td (amounts ) Tj ET Q
q 0 0 0 rg BT 412.35 306.00 Td (will ) Tj ET Q
q 0 0 0 rg BT 430.27 306.00 Td (be ) Tj ET Q
q 0 0 0 rg BT 442.06 306.00 Td (forfeited ) Tj ET Q
q 0 0 0 rg BT 478.85 306.00 Td (if ) Tj ET Q
q 0 0 0 rg BT 487.32 306.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 504.68 306.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 519.25 306.00 Td (terminated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 294.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 64.16 294.00 Td (cause ) Tj ET Q
q 0 0 0 rg BT 88.87 294.00 Td (\() Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 92.20 294.00 Td (i.e.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 104.41 294.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 109.41 294.00 Td (misconduct, ) Tj ET Q
q 0 0 0 rg BT 160.52 294.00 Td (violation ) Tj ET Q
q 0 0 0 rg BT 198.57 294.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 209.40 294.00 Td (rule ) Tj ET Q
q 0 0 0 rg BT 227.45 294.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 238.28 294.00 Td (policy) Tj ET Q
q 0 0 0 rg BT 262.62 294.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 267.62 294.00 Td (etc.\) ) Tj ET Q
q 0 0 0 rg BT 287.61 294.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 298.44 294.00 Td (if ) Tj ET Q
q 0 0 0 rg BT 307.05 294.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 324.55 294.00 Td (resign ) Tj ET Q
q 0 0 0 rg BT 351.48 294.00 Td (before ) Tj ET Q
q 0 0 0 rg BT 379.52 294.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 394.24 294.00 Td (end ) Tj ET Q
q 0 0 0 rg BT 411.18 294.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 422.01 294.00 Td (a ) Tj ET Q
q 0 0 0 rg BT 428.95 294.00 Td (Retention ) Tj ET Q
q 0 0 0 rg BT 470.33 294.00 Td (Period.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 276.00 Td (The ) Tj ET Q
q 0 0 0 rg BT 95.71 276.00 Td (of) Tj ET Q
q 0 0 0 rg BT 103.86 276.00 Td (fer ) Tj ET Q
q 0 0 0 rg BT 118.13 276.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 129.62 276.00 Td (this ) Tj ET Q
q 0 0 0 rg BT 147.24 276.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 201.51 276.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 230.24 276.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 240.08 276.00 Td (being ) Tj ET Q
q 0 0 0 rg BT 265.46 276.00 Td (made ) Tj ET Q
q 0 0 0 rg BT 290.28 276.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 301.22 276.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 319.39 276.00 Td (with ) Tj ET Q
q 0 0 0 rg BT 340.33 276.00 Td (the ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 355.72 276.00 Td (highest ) Tj ET Q
q 0 0 0 rg BT 387.77 276.00 Td (confidentiality) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 445.53 276.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 451.20 276.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 468.80 276.00 Td (it ) Tj ET Q
q 0 0 0 rg BT 477.52 276.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 487.36 276.00 Td (important ) Tj ET Q
q 0 0 0 rg BT 529.41 276.00 Td (that ) Tj ET Q
q 0 0 0 rg BT 547.57 276.00 Td (this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 264.00 Td (information ) Tj ET Q
q 0 0 0 rg BT 99.56 264.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 116.36 264.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 130.92 264.00 Td (terms ) Tj ET Q
q 0 0 0 rg BT 155.49 264.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 166.18 264.00 Td (this ) Tj ET Q
q 0 0 0 rg BT 182.98 264.00 Td (of) Tj ET Q
q 0 0 0 rg BT 191.13 264.00 Td (fer ) Tj ET Q
q 0 0 0 rg BT 204.58 264.00 Td (remain ) Tj ET Q
q 0 0 0 rg BT 234.69 264.00 Td (confidential. ) Tj ET Q
q 0 0 0 rg BT 287.14 264.00 Td (W) Tj ET Q
q 0 0 0 rg BT 295.77 264.00 Td (e ) Tj ET Q
q 0 0 0 rg BT 302.56 264.00 Td (therefore ) Tj ET Q
q 0 0 0 rg BT 341.00 264.00 Td (request ) Tj ET Q
q 0 0 0 rg BT 372.23 264.00 Td (that ) Tj ET Q
q 0 0 0 rg BT 389.58 264.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 406.93 264.00 Td (not ) Tj ET Q
q 0 0 0 rg BT 422.06 264.00 Td (disclose ) Tj ET Q
q 0 0 0 rg BT 456.63 264.00 Td (this ) Tj ET Q
q 0 0 0 rg BT 473.43 264.00 Td (information ) Tj ET Q
q 0 0 0 rg BT 523.00 264.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 533.13 264.00 Td (anyone ) Tj ET Q
BT /F5 10.00 Tf ET
q 0 0 0 rg BT 50.00 252.00 Td (other ) Tj ET Q
q 0 0 0 rg BT 73.26 252.00 Td (than ) Tj ET Q
q 0 0 0 rg BT 93.19 252.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 113.67 252.00 Td (immediate ) Tj ET Q
q 0 0 0 rg BT 157.48 252.00 Td (family ) Tj ET Q
q 0 0 0 rg BT 184.63 252.00 Td (members ) Tj ET Q
q 0 0 0 rg BT 222.88 252.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 233.93 252.00 Td (legal ) Tj ET Q
q 0 0 0 rg BT 256.08 252.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 267.12 252.00 Td (tax ) Tj ET Q
q 0 0 0 rg BT 281.49 252.00 Td (pr) Tj ET Q
q 0 0 0 rg BT 290.01 252.00 Td (ofessionals) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.46 252.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 339.11 252.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 355.70 252.00 Td (we ) Tj ET Q
q 0 0 0 rg BT 369.51 252.00 Td (ask ) Tj ET Q
q 0 0 0 rg BT 385.00 252.00 Td (that ) Tj ET Q
q 0 0 0 rg BT 402.14 252.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 419.30 252.00 Td (direct ) Tj ET Q
q 0 0 0 rg BT 444.21 252.00 Td (any ) Tj ET Q
q 0 0 0 rg BT 460.80 252.00 Td (questions ) Tj ET Q
q 0 0 0 rg BT 500.73 252.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 510.51 252.00 Td (T) Tj ET Q
q 0 0 0 rg BT 516.27 252.00 Td (racy ) Tj ET Q
q 0 0 0 rg BT 535.62 252.00 Td (Basso, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 240.00 Td (Chief ) Tj ET Q
q 0 0 0 rg BT 74.64 240.00 Td (Human ) Tj ET Q
q 0 0 0 rg BT 106.49 240.00 Td (Resources ) Tj ET Q
q 0 0 0 rg BT 150.01 240.00 Td (Of) Tj ET Q
q 0 0 0 rg BT 160.38 240.00 Td (ficer) Tj ET Q
q 0 0 0 rg BT 178.30 240.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 183.22 240.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 193.79 240.00 Td (V) Tj ET Q
q 0 0 0 rg BT 200.41 240.00 Td (ito ) Tj ET Q
q 0 0 0 rg BT 213.39 240.00 Td (Romano, ) Tj ET Q
q 0 0 0 rg BT 252.20 240.00 Td (SVP) Tj ET Q
q 0 0 0 rg BT 269.43 240.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 274.18 240.00 Td (T) Tj ET Q
q 0 0 0 rg BT 279.59 240.00 Td (otal ) Tj ET Q
q 0 0 0 rg BT 297.00 240.00 Td (Rewards ) Tj ET Q
q 0 0 0 rg BT 334.41 240.00 Td (& ) Tj ET Q
q 0 0 0 rg BT 344.61 240.00 Td (HR ) Tj ET Q
q 0 0 0 rg BT 360.92 240.00 Td (Operations. ) Tj ET Q
q 0 0 0 rg BT 409.72 240.00 Td ( ) Tj ET Q
q 0 0 0 rg BT 412.14 240.00 Td (By ) Tj ET Q
q 0 0 0 rg BT 426.23 240.00 Td (signing ) Tj ET Q
q 0 0 0 rg BT 458.09 240.00 Td (this ) Tj ET Q
q 0 0 0 rg BT 474.96 240.00 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 500.72 240.00 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 547.56 240.00 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 228.00 Td (returning ) Tj ET Q
q 0 0 0 rg BT 89.16 228.00 Td (one ) Tj ET Q
q 0 0 0 rg BT 106.09 228.00 Td (copy ) Tj ET Q
q 0 0 0 rg BT 128.03 228.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 138.13 228.00 Td (V) Tj ET Q
q 0 0 0 rg BT 144.75 228.00 Td (ito ) Tj ET Q
q 0 0 0 rg BT 157.81 228.00 Td (Romano ) Tj ET Q
q 0 0 0 rg BT 194.19 228.00 Td (\() Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
197.5244140625 226.6669921875 m
294.4921875 226.6669921875 l
s
q 0 0 0 rg BT 197.52 228.00 Td (romano.vito@endo.com) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 294.49 228.00 Td (\), ) Tj ET Q
q 0 0 0 rg BT 302.82 228.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 320.32 228.00 Td (are ) Tj ET Q
q 0 0 0 rg BT 335.03 228.00 Td (agreeing ) Tj ET Q
q 0 0 0 rg BT 371.95 228.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 382.23 228.00 Td (these ) Tj ET Q
q 0 0 0 rg BT 405.28 228.00 Td (terms.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 210.00 Td (The ) Tj ET Q
q 0 0 0 rg BT 95.01 210.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 148.59 210.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 176.61 210.00 Td (will ) Tj ET Q
q 0 0 0 rg BT 194.63 210.00 Td (not ) Tj ET Q
q 0 0 0 rg BT 209.87 210.00 Td (become ) Tj ET Q
q 0 0 0 rg BT 243.43 210.00 Td (part ) Tj ET Q
q 0 0 0 rg BT 261.44 210.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 272.23 210.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 293.03 210.00 Td (remuneration, ) Tj ET Q
q 0 0 0 rg BT 351.30 210.00 Td (salary) Tj ET Q
q 0 0 0 rg BT 374.53 210.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 379.49 210.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 390.29 210.00 Td (compensation ) Tj ET Q
q 0 0 0 rg BT 448.29 210.00 Td (\(other ) Tj ET Q
q 0 0 0 rg BT 474.63 210.00 Td (than ) Tj ET Q
q 0 0 0 rg BT 494.31 210.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 508.44 210.00 Td (tax ) Tj ET Q
q 0 0 0 rg BT 523.12 210.00 Td (purposes\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 198.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 63.51 198.00 Td (purposes ) Tj ET Q
q 0 0 0 rg BT 100.91 198.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 111.08 198.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 125.15 198.00 Td (calculation ) Tj ET Q
q 0 0 0 rg BT 170.86 198.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 181.04 198.00 Td (any ) Tj ET Q
q 0 0 0 rg BT 197.32 198.00 Td (severance, ) Tj ET Q
q 0 0 0 rg BT 241.09 198.00 Td (notice ) Tj ET Q
q 0 0 0 rg BT 267.37 198.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 277.54 198.00 Td (redundancy ) Tj ET Q
q 0 0 0 rg BT 326.04 198.00 Td (pay) Tj ET Q
q 0 0 0 rg BT 339.83 198.00 Td (, ) Tj ET Q
q 0 0 0 rg BT 344.17 198.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 354.35 198.00 Td (any ) Tj ET Q
q 0 0 0 rg BT 370.64 198.00 Td (other ) Tj ET Q
q 0 0 0 rg BT 393.03 198.00 Td (amount ) Tj ET Q
q 0 0 0 rg BT 424.87 198.00 Td (that ) Tj ET Q
q 0 0 0 rg BT 441.71 198.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 458.56 198.00 Td (may ) Tj ET Q
q 0 0 0 rg BT 477.63 198.00 Td (be ) Tj ET Q
q 0 0 0 rg BT 488.91 198.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 499.09 198.00 Td (become ) Tj ET Q
q 0 0 0 rg BT 532.03 198.00 Td (entitled ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 186.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 60.13 186.00 Td (in ) Tj ET Q
q 0 0 0 rg BT 70.27 186.00 Td (relation ) Tj ET Q
q 0 0 0 rg BT 103.16 186.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 113.30 186.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 133.98 186.00 Td (employment ) Tj ET Q
q 0 0 0 rg BT 186.33 186.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 197.01 186.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 211.58 186.00 Td (termination ) Tj ET Q
q 0 0 0 rg BT 260.04 186.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 270.72 186.00 Td (your ) Tj ET Q
q 0 0 0 rg BT 291.41 186.00 Td (employment. ) Tj ET Q
q 0 0 0 rg BT 346.25 186.00 Td (Nor ) Tj ET Q
q 0 0 0 rg BT 364.16 186.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 373.18 186.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 387.76 186.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 441.22 186.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 469.14 186.00 Td (an ) Tj ET Q
q 0 0 0 rg BT 480.93 186.00 Td (acquired ) Tj ET Q
q 0 0 0 rg BT 517.71 186.00 Td (right, ) Tj ET Q
q 0 0 0 rg BT 541.46 186.00 Td (since ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 174.00 Td (it ) Tj ET Q
q 0 0 0 rg BT 58.01 174.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 67.13 174.00 Td (part ) Tj ET Q
q 0 0 0 rg BT 85.12 174.00 Td (of ) Tj ET Q
q 0 0 0 rg BT 95.90 174.00 Td (a ) Tj ET Q
q 0 0 0 rg BT 102.79 174.00 Td (global ) Tj ET Q
q 0 0 0 rg BT 130.24 174.00 Td (employee ) Tj ET Q
q 0 0 0 rg BT 171.56 174.00 Td (retention ) Tj ET Q
q 0 0 0 rg BT 209.55 174.00 Td (program ) Tj ET Q
q 0 0 0 rg BT 245.88 174.00 Td (implemented ) Tj ET Q
q 0 0 0 rg BT 300.54 174.00 Td (by ) Tj ET Q
q 0 0 0 rg BT 312.99 174.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 327.65 174.00 Td (Company) Tj ET Q
q 0 0 0 rg BT 365.89 174.00 Td (. ) Tj ET Q
q 0 0 0 rg BT 370.66 174.00 Td (This ) Tj ET Q
q 0 0 0 rg BT 390.89 174.00 Td (Contribution ) Tj ET Q
q 0 0 0 rg BT 444.46 174.00 Td (Bonus ) Tj ET Q
q 0 0 0 rg BT 472.47 174.00 Td (is ) Tj ET Q
q 0 0 0 rg BT 481.59 174.00 Td (a ) Tj ET Q
q 0 0 0 rg BT 488.48 174.00 Td (one-time ) Tj ET Q
q 0 0 0 rg BT 526.47 174.00 Td (retention ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 162.00 Td (award ) Tj ET Q
q 0 0 0 rg BT 76.93 162.00 Td (and ) Tj ET Q
q 0 0 0 rg BT 93.87 162.00 Td (will ) Tj ET Q
q 0 0 0 rg BT 111.92 162.00 Td (not ) Tj ET Q
q 0 0 0 rg BT 127.20 162.00 Td (create ) Tj ET Q
q 0 0 0 rg BT 153.56 162.00 Td (any ) Tj ET Q
q 0 0 0 rg BT 170.50 162.00 Td (legal ) Tj ET Q
q 0 0 0 rg BT 192.44 162.00 Td (claim ) Tj ET Q
q 0 0 0 rg BT 217.15 162.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 231.31 162.00 Td (you ) Tj ET Q
q 0 0 0 rg BT 248.81 162.00 Td (in ) Tj ET Q
q 0 0 0 rg BT 259.09 162.00 Td (respect ) Tj ET Q
q 0 0 0 rg BT 289.90 162.00 Td (to ) Tj ET Q
q 0 0 0 rg BT 300.18 162.00 Td (its ) Tj ET Q
q 0 0 0 rg BT 312.13 162.00 Td (cause ) Tj ET Q
q 0 0 0 rg BT 336.84 162.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 347.67 162.00 Td (amount, ) Tj ET Q
q 0 0 0 rg BT 382.66 162.00 Td (either ) Tj ET Q
q 0 0 0 rg BT 407.92 162.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 422.08 162.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 436.80 162.00 Td (past ) Tj ET Q
q 0 0 0 rg BT 455.41 162.00 Td (or ) Tj ET Q
q 0 0 0 rg BT 466.24 162.00 Td (for ) Tj ET Q
q 0 0 0 rg BT 480.40 162.00 Td (the ) Tj ET Q
q 0 0 0 rg BT 495.12 162.00 Td (future.) Tj ET Q
endstream
endobj
437 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 438 0 R>>
endobj
438 0 obj
<</Length 17400>>
stream
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 742.10 Td (This ) Tj ET Q
q 0 0 0 rg BT 96.85 742.10 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 122.34 742.10 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 168.83 742.10 Td (does ) Tj ET Q
q 0 0 0 rg BT 189.23 742.10 Td (not ) Tj ET Q
q 0 0 0 rg BT 204.08 742.10 Td (change ) Tj ET Q
q 0 0 0 rg BT 234.47 742.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 248.76 742.10 Td (at-will ) Tj ET Q
q 0 0 0 rg BT 276.94 742.10 Td (employment ) Tj ET Q
q 0 0 0 rg BT 329.00 742.10 Td (relationship ) Tj ET Q
q 0 0 0 rg BT 378.28 742.10 Td (between ) Tj ET Q
q 0 0 0 rg BT 413.67 742.10 Td (you ) Tj ET Q
q 0 0 0 rg BT 430.74 742.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 447.25 742.10 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 470.43 742.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 480.83 742.10 Td (alter ) Tj ET Q
q 0 0 0 rg BT 500.67 742.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 517.18 742.10 Td (other ) Tj ET Q
q 0 0 0 rg BT 539.80 742.10 Td (terms ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 730.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 67.18 730.10 Td (conditions ) Tj ET Q
q 0 0 0 rg BT 111.59 730.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 122.67 730.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 143.75 730.10 Td (employment. ) Tj ET Q
q 0 0 0 rg BT 198.57 730.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 204.79 730.10 Td (ou ) Tj ET Q
q 0 0 0 rg BT 217.54 730.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 228.62 730.10 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 252.47 730.10 Td (may ) Tj ET Q
q 0 0 0 rg BT 272.43 730.10 Td (terminate ) Tj ET Q
q 0 0 0 rg BT 312.94 730.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 334.01 730.10 Td (employment ) Tj ET Q
q 0 0 0 rg BT 386.75 730.10 Td (at ) Tj ET Q
q 0 0 0 rg BT 396.71 730.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 413.90 730.10 Td (time, ) Tj ET Q
q 0 0 0 rg BT 436.91 730.10 Td (for ) Tj ET Q
q 0 0 0 rg BT 451.32 730.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 468.50 730.10 Td (reason, ) Tj ET Q
q 0 0 0 rg BT 499.85 730.10 Td (with ) Tj ET Q
q 0 0 0 rg BT 520.37 730.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 531.45 730.10 Td (without ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 718.10 Td (Cause. ) Tj ET Q
q 0 0 0 rg BT 79.25 718.10 Td (T) Tj ET Q
q 0 0 0 rg BT 84.66 718.10 Td (o ) Tj ET Q
q 0 0 0 rg BT 92.15 718.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 106.86 718.10 Td (extent ) Tj ET Q
q 0 0 0 rg BT 133.78 718.10 Td (permitted ) Tj ET Q
q 0 0 0 rg BT 174.59 718.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 187.08 718.10 Td (applicable ) Tj ET Q
q 0 0 0 rg BT 230.66 718.10 Td (law) Tj ET Q
q 0 0 0 rg BT 244.45 718.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 249.44 718.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 266.37 718.10 Td (controversy ) Tj ET Q
q 0 0 0 rg BT 316.06 718.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 326.89 718.10 Td (claim ) Tj ET Q
q 0 0 0 rg BT 351.59 718.10 Td (arising ) Tj ET Q
q 0 0 0 rg BT 381.29 718.10 Td (out ) Tj ET Q
q 0 0 0 rg BT 396.56 718.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 407.38 718.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 418.20 718.10 Td (relating ) Tj ET Q
q 0 0 0 rg BT 451.24 718.10 Td (to ) Tj ET Q
q 0 0 0 rg BT 461.50 718.10 Td (this ) Tj ET Q
q 0 0 0 rg BT 478.44 718.10 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 504.26 718.10 Td (Agreement, ) Tj ET Q
q 0 0 0 rg BT 553.67 718.10 Td (or ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 706.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 56.68 706.10 Td (breach ) Tj ET Q
q 0 0 0 rg BT 85.57 706.10 Td (thereof, ) Tj ET Q
q 0 0 0 rg BT 118.63 706.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 120.87 706.10 Td (including, ) Tj ET Q
q 0 0 0 rg BT 163.39 706.10 Td (but ) Tj ET Q
q 0 0 0 rg BT 178.41 706.10 Td (not ) Tj ET Q
q 0 0 0 rg BT 193.44 706.10 Td (limited ) Tj ET Q
q 0 0 0 rg BT 224.01 706.10 Td (to, ) Tj ET Q
q 0 0 0 rg BT 236.53 706.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 253.21 706.10 Td (claims ) Tj ET Q
q 0 0 0 rg BT 281.56 706.10 Td (arising ) Tj ET Q
q 0 0 0 rg BT 311.02 706.10 Td (out ) Tj ET Q
q 0 0 0 rg BT 326.04 706.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 336.62 706.10 Td (federal, ) Tj ET Q
q 0 0 0 rg BT 369.11 706.10 Td (state, ) Tj ET Q
q 0 0 0 rg BT 392.18 706.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 402.76 706.10 Td (local ) Tj ET Q
q 0 0 0 rg BT 424.43 706.10 Td (laws, ) Tj ET Q
q 0 0 0 rg BT 447.51 706.10 Td (rules, ) Tj ET Q
q 0 0 0 rg BT 471.69 706.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 482.26 706.10 Td (regulations, ) Tj ET Q
q 0 0 0 rg BT 531.44 706.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 552.57 706.10 Td (be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 694.10 Td (exclusively ) Tj ET Q
q 0 0 0 rg BT 98.68 694.10 Td (settled ) Tj ET Q
q 0 0 0 rg BT 127.92 694.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 141.05 694.10 Td (an ) Tj ET Q
q 0 0 0 rg BT 153.62 694.10 Td (arbitration ) Tj ET Q
q 0 0 0 rg BT 198.41 694.10 Td (proceeding ) Tj ET Q
q 0 0 0 rg BT 245.97 694.10 Td (conducted ) Tj ET Q
q 0 0 0 rg BT 290.20 694.10 Td (through ) Tj ET Q
q 0 0 0 rg BT 324.44 694.10 Td (Judicial ) Tj ET Q
q 0 0 0 rg BT 357.98 694.10 Td (Arbitration ) Tj ET Q
q 0 0 0 rg BT 405.55 694.10 Td (& ) Tj ET Q
q 0 0 0 rg BT 416.47 694.10 Td (Mediation ) Tj ET Q
q 0 0 0 rg BT 460.70 694.10 Td (Services ) Tj ET Q
q 0 0 0 rg BT 497.72 694.10 Td (\(�JAMS�\). ) Tj ET Q
q 0 0 0 rg BT 544.23 694.10 Td (This ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 682.10 Td (means ) Tj ET Q
q 0 0 0 rg BT 77.93 682.10 Td (that ) Tj ET Q
q 0 0 0 rg BT 95.31 682.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 109.91 682.10 Td (Company ) Tj ET Q
q 0 0 0 rg BT 151.18 682.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 168.00 682.10 Td (you ) Tj ET Q
q 0 0 0 rg BT 185.38 682.10 Td (are ) Tj ET Q
q 0 0 0 rg BT 199.97 682.10 Td (waiving ) Tj ET Q
q 0 0 0 rg BT 234.57 682.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 255.28 682.10 Td (right ) Tj ET Q
q 0 0 0 rg BT 276.55 682.10 Td (to ) Tj ET Q
q 0 0 0 rg BT 286.71 682.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 293.54 682.10 Td (have ) Tj ET Q
q 0 0 0 rg BT 314.79 682.10 Td (jury ) Tj ET Q
q 0 0 0 rg BT 333.29 682.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 344.00 682.10 Td (judge ) Tj ET Q
q 0 0 0 rg BT 368.60 682.10 Td (adjudicate ) Tj ET Q
q 0 0 0 rg BT 412.07 682.10 Td (such ) Tj ET Q
q 0 0 0 rg BT 432.78 682.10 Td (claims ) Tj ET Q
q 0 0 0 rg BT 461.27 682.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 471.98 682.10 Td (controversies, ) Tj ET Q
q 0 0 0 rg BT 530.18 682.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 547.00 682.10 Td (that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 670.10 Td (such ) Tj ET Q
q 0 0 0 rg BT 71.16 670.10 Td (claims ) Tj ET Q
q 0 0 0 rg BT 100.10 670.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 111.26 670.10 Td (controversies ) Tj ET Q
q 0 0 0 rg BT 167.41 670.10 Td (will ) Tj ET Q
q 0 0 0 rg BT 185.80 670.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 198.08 670.10 Td (exclusively ) Tj ET Q
q 0 0 0 rg BT 246.45 670.10 Td (decided ) Tj ET Q
q 0 0 0 rg BT 280.38 670.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 293.21 670.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 300.48 670.10 Td (single ) Tj ET Q
q 0 0 0 rg BT 327.20 670.10 Td (arbitrator) Tj ET Q
q 0 0 0 rg BT 363.85 670.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 368.98 670.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 387.36 670.10 Td (arbitration ) Tj ET Q
q 0 0 0 rg BT 431.85 670.10 Td (will ) Tj ET Q
q 0 0 0 rg BT 450.24 670.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 462.51 670.10 Td (conducted ) Tj ET Q
q 0 0 0 rg BT 506.44 670.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 517.05 670.10 Td (accordance ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 658.10 Td (with ) Tj ET Q
q 0 0 0 rg BT 69.42 658.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 83.28 658.10 Td (then-current ) Tj ET Q
q 0 0 0 rg BT 133.79 658.10 Td (JAMS ) Tj ET Q
q 0 0 0 rg BT 161.00 658.10 Td (Employment ) Tj ET Q
q 0 0 0 rg BT 213.94 658.10 Td (Arbitration ) Tj ET Q
q 0 0 0 rg BT 260.01 658.10 Td (Rules ) Tj ET Q
q 0 0 0 rg BT 284.43 658.10 Td (& ) Tj ET Q
q 0 0 0 rg BT 293.86 658.10 Td (Procedures ) Tj ET Q
q 0 0 0 rg BT 339.93 658.10 Td (\(and ) Tj ET Q
q 0 0 0 rg BT 359.34 658.10 Td (no ) Tj ET Q
q 0 0 0 rg BT 370.98 658.10 Td (other ) Tj ET Q
q 0 0 0 rg BT 393.17 658.10 Td (JAMS ) Tj ET Q
q 0 0 0 rg BT 420.38 658.10 Td (rules\). ) Tj ET Q
q 0 0 0 rg BT 447.29 658.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 448.82 658.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 466.01 658.10 Td (decision ) Tj ET Q
q 0 0 0 rg BT 500.98 658.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 510.95 658.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 524.81 658.10 Td (arbitrator ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 646.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 71.42 646.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 83.40 646.10 Td (final ) Tj ET Q
q 0 0 0 rg BT 104.26 646.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 121.24 646.10 Td (binding. ) Tj ET Q
q 0 0 0 rg BT 156.83 646.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 159.37 646.10 Td (Judgment ) Tj ET Q
q 0 0 0 rg BT 200.79 646.10 Td (on ) Tj ET Q
q 0 0 0 rg BT 213.33 646.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 228.08 646.10 Td (award ) Tj ET Q
q 0 0 0 rg BT 255.04 646.10 Td (rendered ) Tj ET Q
q 0 0 0 rg BT 292.56 646.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 305.09 646.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 319.85 646.10 Td (arbitrator\(s\) ) Tj ET Q
q 0 0 0 rg BT 370.14 646.10 Td (may ) Tj ET Q
q 0 0 0 rg BT 389.89 646.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 401.87 646.10 Td (entered ) Tj ET Q
q 0 0 0 rg BT 433.83 646.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 444.14 646.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 461.12 646.10 Td (court ) Tj ET Q
q 0 0 0 rg BT 484.20 646.10 Td (having ) Tj ET Q
q 0 0 0 rg BT 513.95 646.10 Td (jurisdiction. ) Tj ET Q
q 0 0 0 rg BT 564.50 646.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 634.10 Td (Y) Tj ET Q
q 0 0 0 rg BT 56.22 634.10 Td (ou ) Tj ET Q
q 0 0 0 rg BT 68.84 634.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 85.89 634.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 100.73 634.10 Td (Company ) Tj ET Q
q 0 0 0 rg BT 142.23 634.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 163.74 634.10 Td (each ) Tj ET Q
q 0 0 0 rg BT 184.67 634.10 Td (bear ) Tj ET Q
q 0 0 0 rg BT 204.49 634.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 225.44 634.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 242.50 634.10 Td (its ) Tj ET Q
q 0 0 0 rg BT 254.56 634.10 Td (own ) Tj ET Q
q 0 0 0 rg BT 274.40 634.10 Td (legal ) Tj ET Q
q 0 0 0 rg BT 296.45 634.10 Td (expenses, ) Tj ET Q
q 0 0 0 rg BT 337.67 634.10 Td (except ) Tj ET Q
q 0 0 0 rg BT 366.38 634.10 Td (where ) Tj ET Q
q 0 0 0 rg BT 393.42 634.10 Td (otherwise ) Tj ET Q
q 0 0 0 rg BT 434.92 634.10 Td (required ) Tj ET Q
q 0 0 0 rg BT 470.85 634.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 483.47 634.10 Td (law) Tj ET Q
q 0 0 0 rg BT 497.26 634.10 Td (. ) Tj ET Q
q 0 0 0 rg BT 502.18 634.10 Td (The ) Tj ET Q
q 0 0 0 rg BT 520.35 634.10 Td (arbitration ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 622.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 71.76 622.10 Td (take ) Tj ET Q
q 0 0 0 rg BT 91.28 622.10 Td (place ) Tj ET Q
q 0 0 0 rg BT 115.25 622.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 125.89 622.10 Td (Chester ) Tj ET Q
q 0 0 0 rg BT 159.31 622.10 Td (County) Tj ET Q
q 0 0 0 rg BT 188.11 622.10 Td (, ) Tj ET Q
q 0 0 0 rg BT 193.48 622.10 Td (Pennsylvania, ) Tj ET Q
q 0 0 0 rg BT 252.18 622.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 269.48 622.10 Td (no ) Tj ET Q
q 0 0 0 rg BT 282.35 622.10 Td (dispute ) Tj ET Q
q 0 0 0 rg BT 314.11 622.10 Td (under ) Tj ET Q
q 0 0 0 rg BT 339.75 622.10 Td (this ) Tj ET Q
q 0 0 0 rg BT 357.07 622.10 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 383.18 622.10 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 430.47 622.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 452.23 622.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 464.54 622.10 Td (adjudicated ) Tj ET Q
q 0 0 0 rg BT 513.50 622.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 524.14 622.10 Td (any ) Tj ET Q
q 0 0 0 rg BT 541.45 622.10 Td (other ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 610.10 Td (venue ) Tj ET Q
q 0 0 0 rg BT 76.20 610.10 Td (or ) Tj ET Q
q 0 0 0 rg BT 86.85 610.10 Td (forum. ) Tj ET Q
q 0 0 0 rg BT 115.94 610.10 Td (This ) Tj ET Q
q 0 0 0 rg BT 136.04 610.10 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 161.72 610.10 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 208.46 610.10 Td (shall ) Tj ET Q
q 0 0 0 rg BT 229.67 610.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 241.43 610.10 Td (governed ) Tj ET Q
q 0 0 0 rg BT 280.96 610.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 293.28 610.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 307.82 610.10 Td (laws ) Tj ET Q
q 0 0 0 rg BT 328.47 610.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 339.12 610.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 353.66 610.10 Td (State ) Tj ET Q
q 0 0 0 rg BT 375.97 610.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 386.62 610.10 Td (Pennsylvania, ) Tj ET Q
q 0 0 0 rg BT 444.77 610.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 461.53 610.10 Td (it ) Tj ET Q
q 0 0 0 rg BT 469.41 610.10 Td (may ) Tj ET Q
q 0 0 0 rg BT 488.94 610.10 Td (not ) Tj ET Q
q 0 0 0 rg BT 504.04 610.10 Td (be ) Tj ET Q
q 0 0 0 rg BT 515.80 610.10 Td (modified ) Tj ET Q
q 0 0 0 rg BT 554.23 610.10 Td (in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 598.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 64.72 598.10 Td (absence ) Tj ET Q
q 0 0 0 rg BT 98.86 598.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 109.69 598.10 Td (a ) Tj ET Q
q 0 0 0 rg BT 116.63 598.10 Td (written ) Tj ET Q
q 0 0 0 rg BT 147.46 598.10 Td (document ) Tj ET Q
q 0 0 0 rg BT 189.39 598.10 Td (signed ) Tj ET Q
q 0 0 0 rg BT 218.00 598.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 230.50 598.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 245.21 598.10 Td (parties.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 77.00 580.10 Td (Thank ) Tj ET Q
q 0 0 0 rg BT 104.19 580.10 Td (you ) Tj ET Q
q 0 0 0 rg BT 120.83 580.10 Td (for ) Tj ET Q
q 0 0 0 rg BT 134.13 580.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 154.11 580.10 Td (ongoing ) Tj ET Q
q 0 0 0 rg BT 188.53 580.10 Td (contributions ) Tj ET Q
q 0 0 0 rg BT 242.94 580.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 259.02 580.10 Td (commitment ) Tj ET Q
q 0 0 0 rg BT 311.21 580.10 Td (to ) Tj ET Q
q 0 0 0 rg BT 320.63 580.10 Td (our ) Tj ET Q
q 0 0 0 rg BT 335.60 580.10 Td (Company ) Tj ET Q
q 0 0 0 rg BT 376.13 580.10 Td (as ) Tj ET Q
q 0 0 0 rg BT 386.10 580.10 Td (we ) Tj ET Q
q 0 0 0 rg BT 399.41 580.10 Td (execute ) Tj ET Q
q 0 0 0 rg BT 431.58 580.10 Td (our ) Tj ET Q
q 0 0 0 rg BT 446.55 580.10 Td (strategic ) Tj ET Q
q 0 0 0 rg BT 482.07 580.10 Td (vision ) Tj ET Q
q 0 0 0 rg BT 508.16 580.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 524.24 580.10 Td (operating ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 568.10 Td (plans ) Tj ET Q
q 0 0 0 rg BT 73.68 568.10 Td (at ) Tj ET Q
q 0 0 0 rg BT 83.46 568.10 Td (the ) Tj ET Q
q 0 0 0 rg BT 98.24 568.10 Td (highest ) Tj ET Q
q 0 0 0 rg BT 129.70 568.10 Td (performance ) Tj ET Q
q 0 0 0 rg BT 182.79 568.10 Td (level ) Tj ET Q
q 0 0 0 rg BT 204.79 568.10 Td (in ) Tj ET Q
q 0 0 0 rg BT 215.13 568.10 Td (support ) Tj ET Q
q 0 0 0 rg BT 247.70 568.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 258.60 568.10 Td (our ) Tj ET Q
q 0 0 0 rg BT 274.50 568.10 Td (customers ) Tj ET Q
q 0 0 0 rg BT 317.61 568.10 Td (and ) Tj ET Q
q 0 0 0 rg BT 334.62 568.10 Td (patients. ) Tj ET Q
q 0 0 0 rg BT 370.79 568.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 373.36 568.10 Td (Please ) Tj ET Q
q 0 0 0 rg BT 401.47 568.10 Td (indicate ) Tj ET Q
q 0 0 0 rg BT 435.69 568.10 Td (your ) Tj ET Q
q 0 0 0 rg BT 456.58 568.10 Td (acceptance ) Tj ET Q
q 0 0 0 rg BT 503.00 568.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 515.57 568.10 Td (signing ) Tj ET Q
q 0 0 0 rg BT 547.58 568.10 Td (and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 556.10 Td (returning ) Tj ET Q
q 0 0 0 rg BT 89.16 556.10 Td (one ) Tj ET Q
q 0 0 0 rg BT 106.09 556.10 Td (copy ) Tj ET Q
q 0 0 0 rg BT 128.03 556.10 Td (of ) Tj ET Q
q 0 0 0 rg BT 138.86 556.10 Td (this ) Tj ET Q
q 0 0 0 rg BT 155.81 556.10 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 181.63 556.10 Td (Agreement ) Tj ET Q
q 0 0 0 rg BT 228.55 556.10 Td (to ) Tj ET Q
q 0 0 0 rg BT 238.65 556.10 Td (V) Tj ET Q
q 0 0 0 rg BT 245.27 556.10 Td (ito ) Tj ET Q
q 0 0 0 rg BT 258.33 556.10 Td (Romano ) Tj ET Q
q 0 0 0 rg BT 294.72 556.10 Td (by ) Tj ET Q
q 0 0 0 rg BT 306.67 556.10 Td (August ) Tj ET Q
q 0 0 0 rg BT 338.06 556.10 Td (9, ) Tj ET Q
q 0 0 0 rg BT 348.06 556.10 Td (2019.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 528.50 Td (Sincerely) Tj ET Q
q 0 0 0 rg BT 87.11 528.50 Td (,) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 500.90 Td (/S/ ) Tj ET Q
q 0 0 0 rg BT 63.62 500.90 Td (P) Tj ET Q
q 0 0 0 rg BT 68.26 500.90 Td (AUL) Tj ET Q
q 0 0 0 rg BT 88.44 500.90 Td ( ) Tj ET Q
q 0 0 0 rg BT 90.76 500.90 Td (V) Tj ET Q
q 0 0 0 rg BT 96.69 500.90 Td (. ) Tj ET Q
q 0 0 0 rg BT 101.69 500.90 Td (CAMP) Tj ET Q
q 0 0 0 rg BT 129.12 500.90 Td (ANELLI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 473.30 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 70.10 473.30 Td (V) Tj ET Q
q 0 0 0 rg BT 76.03 473.30 Td (. ) Tj ET Q
q 0 0 0 rg BT 81.03 473.30 Td (Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 459.50 Td (President ) Tj ET Q
q 0 0 0 rg BT 89.72 459.50 Td (& ) Tj ET Q
q 0 0 0 rg BT 100.00 459.50 Td (Chief ) Tj ET Q
q 0 0 0 rg BT 124.71 459.50 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 167.19 459.50 Td (Of) Tj ET Q
q 0 0 0 rg BT 177.56 459.50 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 419.90 Td (Signed ) Tj ET Q
q 0 0 0 rg BT 80.28 419.90 Td (and ) Tj ET Q
q 0 0 0 rg BT 97.22 419.90 Td (agreed ) Tj ET Q
q 0 0 0 rg BT 126.36 419.90 Td (by:) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 380.6 m
245.5 380.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
252.5 380.6 m
447.5 380.6 l
s
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 385.27 Td (/S/ MARK BRADLEY) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.00 385.27 Td (August 6, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 370.27 Td (Mark Bradley) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 255.00 370.27 Td (Date) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
439 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 440 0 R>>
endobj
440 0 obj
<</Length 8075>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 505.30 772.75 Td (Exhibit 10.24) Tj ET Q
BT /F7 8.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 743.20 Td (Endo) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 733.60 Td (1400 ) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 506.22 733.60 Td (Atwater Drive) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 724.00 Td (Malvern, P) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 524.14 724.00 Td (A) Tj ET Q
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 529.18 724.00 Td ( 19355) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 714.40 Td (484.216.0000) Tj ET Q
BT /F7 8.00 Tf ET
q 0.25882352941176473 0.25882352941176473 0.25882352941176473 rg BT 486.50 695.20 Td (endo.com) Tj ET Q
/GS0 gs
q 84.00 0 0 23.00 50.00 667.20 cm
/I23 Do Q
BT /F3 10.00 Tf ET
0 Tr
/GS0 gs
0 Tw 0 Tc 100 Tz 0 TL 
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 486.50 655.20 Td (May 17, 2018) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 620.65 Td (Mark ) Tj ET Q
q 0 0 0 rg BT 78.99 620.65 Td (Bradley) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 606.25 Td (9 ) Tj ET Q
q 0 0 0 rg BT 59.00 606.25 Td (Dillon ) Tj ET Q
q 0 0 0 rg BT 92.67 606.25 Td (Court) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 591.85 Td (Exton, ) Tj ET Q
q 0 0 0 rg BT 84.66 591.85 Td (P) Tj ET Q
q 0 0 0 rg BT 90.24 591.85 Td (A) Tj ET Q
q 0 0 0 rg BT 98.24 591.85 Td ( ) Tj ET Q
q 0 0 0 rg BT 101.24 591.85 Td (19341) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 554.90 Td (Dear ) Tj ET Q
q 0 0 0 rg BT 76.31 554.90 Td (Mark:) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 525.50 Td (Based upon your outstanding achievements in 2017 and the criticality of your ongoing contributions to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 511.10 Td (planning and execution of Endo's \("Endo" or the "Company"\) transformation and turnaround, I am ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 496.70 Td (pleased to provide you with a special employment arrangement that demonstrates your importance to our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 482.30 Td (Company) Tj ET Q
q 0 0 0 rg BT 95.88 482.30 Td (. Included in this special arrangement is your eligibility for retention incentive compensation and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 467.90 Td (a special severance commitment, collectively described in this Letter ) Tj ET Q
q 0 0 0 rg BT 383.21 467.90 Td (Agreement \("Letter ) Tj ET Q
q 0 0 0 rg BT 479.39 467.90 Td (Agreement"\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 447.50 Td (The total Retention Bonus amount is $450,000 \(the "Retention Bonus"\), subject to applicable tax ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 433.10 Td (withholdings. ) Tj ET Q
q 0 0 0 rg BT 118.46 433.10 Td (This Retention Bonus will be paid in three installments within thirty \(30\) days following ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 418.70 Td (each of the payment dates \("Payment Dates"\), provided you are employed on such dates by the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 404.30 Td (or one of its af) Tj ET Q
q 0 0 0 rg BT 119.76 404.30 Td (filiates. ) Tj ET Q
q 0 0 0 rg BT 158.20 404.30 Td (The Payment Dates and the associated amounts are as follows: $100,000 payable as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 389.90 Td (of September 30, 2018; $150,000 payable as of September 30, 2019; and $200,000 payable as of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 375.50 Td (September 30, 2020. Payment of the Retention Bonus will be accelerated if your employment is ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 361.10 Td (terminated by the Company without cause \("Cause"\), with payment of any remaining amount of the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 346.70 Td (Retention Bonus payable within thirty \(30\) days of a without Cause employment termination by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 332.30 Td (Company) Tj ET Q
q 0 0 0 rg BT 95.88 332.30 Td (. Payment of the Retention Bonus will be forfeited if you are terminated for Cause or resign for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 317.90 Td (any reason.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 297.50 Td (This of) Tj ET Q
q 0 0 0 rg BT 84.11 297.50 Td (fer of a Retention Bonus is being made to you with the ) Tj ET Q
BT /F3 12.00 Tf ET
0 0 0 RG
/GS0 gs
0.59 w
0 i 
[] 0 d
1 J
1 j
3 M
350.064453125 295.900390625 m
457.70703125 295.900390625 l
s
q 0 0 0 rg BT 350.06 297.50 Td (highest confidentiality) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 457.71 297.50 Td ( and it is important ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 283.10 Td (that this information and the terms of the contents remain confidential. ) Tj ET Q
q 0 0 0 rg BT 391.69 283.10 Td (W) Tj ET Q
q 0 0 0 rg BT 402.05 283.10 Td (e therefore expect that you will ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 268.70 Td (NOT) Tj ET Q
q 0 0 0 rg BT 74.45 268.70 Td ( disclose this information to any other persons and that you direct any questions to Larry ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 254.30 Td (Cunningham, EVP) Tj ET Q
q 0 0 0 rg BT 140.22 254.30 Td ( of Human Resources or me. ) Tj ET Q
BT /F4 12.00 Tf ET
0 0 0 RG
/GS0 gs
1.14 w
0 i 
[] 0 d
1 J
1 j
3 M
280.51953125 252.42207031249995 m
544.548828125 252.42207031249995 l
s
q 0 0 0 rg BT 280.52 254.30 Td (Any disclosure to persons other than your immediate ) Tj ET Q
BT /F4 12.00 Tf ET
0 0 0 RG
/GS0 gs
1.14 w
0 i 
[] 0 d
1 J
1 j
3 M
50 238.02207031249998 m
560.369140625 238.02207031249998 l
s
q 0 0 0 rg BT 50.00 239.90 Td (family members \(or legal counsel or financial advisor\) will result in forfeiture of this Retention Bonus. ) Tj ET Q
BT /F4 12.00 Tf ET
0 0 0 RG
/GS0 gs
1.14 w
0 i 
[] 0 d
1 J
1 j
3 M
50 223.6220703125 m
446.94921875 223.6220703125 l
s
q 0 0 0 rg BT 50.00 225.50 Td (By signing this Letter ) Tj ET Q
q 0 0 0 rg BT 158.90 225.50 Td (Agreement and returning one copy to Larry Cunningham ) Tj ET Q
BT /F4 12.00 Tf ET
0 0 0 RG
/GS0 gs
1.14 w
0 i 
[] 0 d
1 J
1 j
3 M
50 209.22207031250002 m
330.998046875 209.22207031250002 l
s
q 0 0 0 rg BT 50.00 211.10 Td (\(Cunningham.larry@endo.com\) you agree to these terms) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 331.00 211.10 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 190.70 Td (Further) Tj ET Q
q 0 0 0 rg BT 84.85 190.70 Td (, in the event that your employment is terminated by the Company without Cause \(as defined in the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 176.30 Td (Endo International PLC ) Tj ET Q
q 0 0 0 rg BT 166.98 176.30 Td (Amended and Restated 2015 Stock Incentive Plan\) or the Company requires you ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 161.90 Td (to be based at any of) Tj ET Q
q 0 0 0 rg BT 148.75 161.90 Td (fice or location that increases the length of your commute by more than fifty \(50\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 147.50 Td (miles, you will receive a severance payment \("Severance Payment"\) in lieu of any further Base Salary or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 133.10 Td (other compensation and benefits for periods subsequent to the ) Tj ET Q
q 0 0 0 rg BT 350.04 133.10 Td (T) Tj ET Q
q 0 0 0 rg BT 356.53 133.10 Td (ermination Date, payable in cash as either ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 118.70 Td (pay continuation or in a lump sum within sixty \(60\) days following such termination, equal to one \(1.5\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 104.30 Td (times your Final Base Salary) Tj ET Q
q 0 0 0 rg BT 187.87 104.30 Td (, plus the greater of one times \(1x\) the Final ) Tj ET Q
q 0 0 0 rg BT 401.26 104.30 Td (T) Tj ET Q
q 0 0 0 rg BT 407.75 104.30 Td (ar) Tj ET Q
q 0 0 0 rg BT 416.86 104.30 Td (get Bonus or an amount) Tj ET Q
endstream
endobj
441 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 442 0 R>>
endobj
442 0 obj
<</Length 8548>>
stream
/GS0 gs
q 84.00 0 0 23.00 478.00 726.00 cm
/I24 Do Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 702.60 Td (equivalent to your last IC payment under the Company's annual incentive plan \(excluding any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 688.20 Td (supplemental performance incentive not part of the standard and customary annual IC plan\), payable in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 673.80 Td (cash in a lump sum within sixty \(60\) days following such termination, and the Company shall provide ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 659.40 Td (continued coverage for you and your dependents under any health, medical, dental and vision program or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 645.00 Td (policy in which you were eligible to participate as of the time of your employment termination, for twelve ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 630.60 Td (\(12\) months following such termination on the same basis as active employees, which such twelve month ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 616.20 Td (period shall run concurrently with the COBRA) Tj ET Q
q 0 0 0 rg BT 274.63 616.20 Td ( period, and which coverage shall become secondary to any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 601.80 Td (coverage provided to you by a subsequent employer and to any Medicare coverage for which you become ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 587.40 Td (eligible; provided, however) Tj ET Q
q 0 0 0 rg BT 181.81 587.40 Td (, the parties agree to cooperate such that the continued coverage is, to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 573.00 Td (extent practicable, provided in a manner so as to minimize adverse tax consequences to the Company \(in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 558.60 Td (aggregate "Benefit Coverage Continuation"\).) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 535.20 Td (In order to receive the Severance Payment, any Benefit Coverage Continuation or any remaining Special ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 520.80 Td (Cash ) Tj ET Q
q 0 0 0 rg BT 76.34 520.80 Td (A) Tj ET Q
q 0 0 0 rg BT 83.90 520.80 Td (ward \(detailed in the letter to you dated January 27, 2017\) following the ) Tj ET Q
q 0 0 0 rg BT 432.25 520.80 Td (T) Tj ET Q
q 0 0 0 rg BT 438.75 520.80 Td (ermination Date, you are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 506.40 Td (required to sign a general release releasing any and all claims against the Company and its af) Tj ET Q
q 0 0 0 rg BT 495.62 506.40 Td (filiates within ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 492.00 Td (21 days following your ) Tj ET Q
q 0 0 0 rg BT 164.44 492.00 Td (T) Tj ET Q
q 0 0 0 rg BT 170.93 492.00 Td (ermination Date and to not revoke your consent to such release of claims. For the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 477.60 Td (purposes of this Letter ) Tj ET Q
q 0 0 0 rg BT 159.98 477.60 Td (Agreement: \(i\) "Final Base Salary" shall mean your annual base salary rate as of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 463.20 Td (the ) Tj ET Q
q 0 0 0 rg BT 67.44 463.20 Td (T) Tj ET Q
q 0 0 0 rg BT 73.94 463.20 Td (ermination Date; \(ii\) "Final ) Tj ET Q
q 0 0 0 rg BT 207.92 463.20 Td (T) Tj ET Q
q 0 0 0 rg BT 214.41 463.20 Td (ar) Tj ET Q
q 0 0 0 rg BT 223.51 463.20 Td (get Bonus" shall mean your annual incentive compensation tar) Tj ET Q
q 0 0 0 rg BT 523.45 463.20 Td (get as ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 448.80 Td (of the ) Tj ET Q
q 0 0 0 rg BT 80.44 448.80 Td (T) Tj ET Q
q 0 0 0 rg BT 86.93 448.80 Td (ermination Date; and \(iii\) "T) Tj ET Q
q 0 0 0 rg BT 223.61 448.80 Td (ermination Date" shall mean the date of termination of your ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 434.45 Td (employment for any reason, provided that such termination constitutes a "separation from service" from ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 420.05 Td (the Company within the meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 290.97 420.05 Td ( of the Internal Revenue Code of 1986, as amended \(the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 405.65 Td ("Code"\). If the Company terminates your employment for Cause or you resign for any reason, you will ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 391.25 Td (not be eligible to receive the Severance Payment, any Benefit Coverage Continuation, or any remaining ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 376.85 Td (payment under any retention compensation plan, including the Special Cash ) Tj ET Q
q 0 0 0 rg BT 417.58 376.85 Td (A) Tj ET Q
q 0 0 0 rg BT 425.14 376.85 Td (ward.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 353.45 Td (The parties intend for the payments and benefits under this Letter ) Tj ET Q
q 0 0 0 rg BT 366.24 353.45 Td (Agreement to be exempt from Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 339.05 Td (409A) Tj ET Q
q 0 0 0 rg BT 76.00 339.05 Td ( of the Code or) Tj ET Q
q 0 0 0 rg BT 147.51 339.05 Td (, if not so exempt, to be paid or provided in a manner which complies with the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 324.65 Td (requirements of such section, and intend that the Letter ) Tj ET Q
q 0 0 0 rg BT 316.58 324.65 Td (Agreement shall be construed and administered in ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 310.25 Td (accordance with such intention. In the event the Company determines that a payment or benefit under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 295.85 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 80.98 295.85 Td (Agreement may not be in compliance with Section 409A) Tj ET Q
q 0 0 0 rg BT 353.59 295.85 Td ( of the Code, the Company shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 281.45 Td (reasonably confer with you in order to modify or amend the Letter ) Tj ET Q
q 0 0 0 rg BT 371.23 281.45 Td (Agreement to comply with Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 267.05 Td (409A) Tj ET Q
q 0 0 0 rg BT 76.00 267.05 Td ( of the Code and to do so in a manner to best preserve the economic benefit of the Letter ) Tj ET Q
q 0 0 0 rg BT 502.53 267.05 Td (Agreement. ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 252.65 Td (Notwithstanding anything contained herein to the contrary) Tj ET Q
q 0 0 0 rg BT 329.81 252.65 Td (, to the extent required in order to avoid ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 238.25 Td (accelerated taxation and/or tax penalties under Section 409A) Tj ET Q
q 0 0 0 rg BT 340.89 238.25 Td ( of the Code, \(i\) the Severance Payment and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 223.85 Td (the Benefit Coverage Continuation shall not be paid to you until you would be considered to have ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 209.45 Td (incurred a "separation from service" from the Company within the meaning of Section 409A) Tj ET Q
q 0 0 0 rg BT 494.01 209.45 Td ( of the Code, ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 195.05 Td (\(ii\) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 180.65 Td (the Letter ) Tj ET Q
q 0 0 0 rg BT 98.64 180.65 Td (Agreement during the six-month period immediately following your separation from service ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 166.25 Td (shall instead be paid on the first business day after the date that is six \(6\) months following your ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 151.85 Td (separation from service \(or death, if earlier\), with interest for any cash payments so delayed, from the date ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 137.45 Td (such cash amounts would otherwise have been paid at the short-term applicable federal rate, compounded ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 123.05 Td (semi-annually) Tj ET Q
q 0 0 0 rg BT 117.20 123.05 Td (, as determined under Section 1274 of the Code for the month in which the payment would ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 108.65 Td (have been made but for the delay in payment required to avoid the imposition of an additional rate of tax ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 94.25 Td (on you, \(iii\) each amount to be paid or benefit to be provided under the Letter ) Tj ET Q
q 0 0 0 rg BT 424.88 94.25 Td (Agreement shall be ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 79.85 Td (construed as a separately identified payment for purposes of Section 409A) Tj ET Q
q 0 0 0 rg BT 406.57 79.85 Td ( of the) Tj ET Q
endstream
endobj
443 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 444 0 R>>
endobj
444 0 obj
<</Length 8778>>
stream
/GS0 gs
q 84.00 0 0 23.00 478.00 726.00 cm
/I25 Do Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 702.60 Td (Code, \(iv\) any payments that are due within the "short term deferral period" as defined in Section 409A) Tj ET Q
q 0 0 0 rg BT 546.32 702.60 Td ( of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 688.20 Td (the Code shall not be treated as deferred compensation unless applicable law requires otherwise and \(v\) ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 673.80 Td (amounts reimbursable to you under the Letter ) Tj ET Q
q 0 0 0 rg BT 271.61 673.80 Td (Agreement shall be paid to you on or before the last day of ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 659.40 Td (the year following the year in which the expense was incurred and the amount of expenses eligible for ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 645.00 Td (reimbursement \(and in-kind benefits provided to you\) during any one \(1\) year may not af) Tj ET Q
q 0 0 0 rg BT 477.66 645.00 Td (fect amounts ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 630.60 Td (reimbursable or provided in any subsequent year) Tj ET Q
q 0 0 0 rg BT 283.27 630.60 Td (.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 607.20 Td (Pursuant to Section 1833\(b\) of the Defend ) Tj ET Q
q 0 0 0 rg BT 256.07 607.20 Td (T) Tj ET Q
q 0 0 0 rg BT 262.98 607.20 Td (rade Secrets ) Tj ET Q
q 0 0 0 rg BT 323.62 607.20 Td (Act of 2016, you acknowledge that you shall not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 592.80 Td (have criminal or civil liability under any federal or State trade secret law for the disclosure of a trade ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 578.40 Td (secret that \(i\) is made \(A\) in confidence to a federal, state, or local government of) Tj ET Q
q 0 0 0 rg BT 441.28 578.40 Td (ficial, either directly or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 564.00 Td (indirectly) Tj ET Q
q 0 0 0 rg BT 95.21 564.00 Td (, or to an attorney and \(B\) solely for the purpose of reporting or investigating a suspected ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 549.60 Td (violation of law; or \(ii\) is made in a complaint or other document filed in a lawsuit or other proceeding, if ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 535.20 Td (such filing is made under seal. Nothing in this Letter ) Tj ET Q
q 0 0 0 rg BT 304.95 535.20 Td (Agreement is intended to conflict with Section ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 520.80 Td (1833\(b\) of the Defend ) Tj ET Q
q 0 0 0 rg BT 159.75 520.80 Td (T) Tj ET Q
q 0 0 0 rg BT 166.65 520.80 Td (rade Secrets ) Tj ET Q
q 0 0 0 rg BT 227.29 520.80 Td (Act of 2016 or create liability for disclosures of trade secrets that are ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 506.40 Td (expressly allowed by such Section. Notwithstanding anything set forth in the Letter ) Tj ET Q
q 0 0 0 rg BT 452.93 506.40 Td (Agreement to the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 492.00 Td (contrary) Tj ET Q
q 0 0 0 rg BT 89.20 492.00 Td (, you shall not be prohibited from reporting possible violations of federal or state law or ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 477.60 Td (regulation to any governmental agency or entity or making other disclosures that are protected under the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 463.20 Td (whistleblower provisions of federal or state law or regulation, nor are you required to notify the Company ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 448.80 Td (regarding any such reporting, disclosure or cooperation with the government.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 425.45 Td (T) Tj ET Q
q 0 0 0 rg BT 56.49 425.45 Td (o protect the Confidential Information \(as defined in the Letter ) Tj ET Q
q 0 0 0 rg BT 359.73 425.45 Td (Agreement hereto\) and other trade secrets ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 411.05 Td (of the Company and its af) Tj ET Q
q 0 0 0 rg BT 174.09 411.05 Td (filiates as well as the goodwill and competitive business of the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 396.65 Td (af) Tj ET Q
q 0 0 0 rg BT 59.11 396.65 Td (filiates, you agree, during the term of your employment with the Company and for a period of twelve ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 382.25 Td (\(12\) months after your cessation of employment with the Company) Tj ET Q
q 0 0 0 rg BT 372.15 382.25 Td (, not to solicit or participate in or assist ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 367.85 Td (in any way in the solicitation of any customer) Tj ET Q
q 0 0 0 rg BT 268.80 367.85 Td (, client, supplier) Tj ET Q
q 0 0 0 rg BT 345.63 367.85 Td (, employee or agent of the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 353.45 Td (af) Tj ET Q
q 0 0 0 rg BT 59.11 353.45 Td (filiates. For purposes of this covenant, "solicit" or "solicitation" means directly or indirectly influencing ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 339.05 Td (or attempting to influence any customers, clients, suppliers, employees or agents of the Company or its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 324.65 Td (af) Tj ET Q
q 0 0 0 rg BT 59.11 324.65 Td (filiates to cease doing business with, or to reduce the level of business with, the Company and its ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 310.25 Td (af) Tj ET Q
q 0 0 0 rg BT 59.11 310.25 Td (filiates or) Tj ET Q
q 0 0 0 rg BT 104.28 310.25 Td (, with respect to employees or exclusive agents, to become employed or engaged by any other ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 295.85 Td (person, partnership, firm, corporation or other entity) Tj ET Q
q 0 0 0 rg BT 300.15 295.85 Td (. ) Tj ET Q
q 0 0 0 rg BT 305.70 295.85 Td (Y) Tj ET Q
q 0 0 0 rg BT 313.17 295.85 Td (ou agree that this covenant is reasonable and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 281.45 Td (desirable to protect the Confidential Information of the Company and its af) Tj ET Q
q 0 0 0 rg BT 410.02 281.45 Td (filiates; provided that ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 267.05 Td (solicitation is not tar) Tj ET Q
q 0 0 0 rg BT 148.10 267.05 Td (geted at the Company's or its af) Tj ET Q
q 0 0 0 rg BT 299.35 267.05 Td (filiates' employees or the provision of references shall ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 252.65 Td (not constitute a breach of such obligations. In addition, the terms and conditions of your Proprietary ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 238.25 Td (Information, Nondisclosure and Non-Solicitation ) Tj ET Q
q 0 0 0 rg BT 288.29 238.25 Td (Agreement in full force and ef) Tj ET Q
q 0 0 0 rg BT 433.68 238.25 Td (fect.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 214.85 Td (This Letter ) Tj ET Q
q 0 0 0 rg BT 105.32 214.85 Td (Agreement does not change the at-will employment relationship between you and Endo or any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 200.45 Td (other terms and conditions of your employment. ) Tj ET Q
q 0 0 0 rg BT 284.18 200.45 Td (Y) Tj ET Q
q 0 0 0 rg BT 291.64 200.45 Td (ou or Endo may terminate your employment at any ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 186.05 Td (time, for any reason, with or without Cause. ) Tj ET Q
q 0 0 0 rg BT 263.63 186.05 Td (Any controversy or claim arising out of or relating to this ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 171.65 Td (Letter ) Tj ET Q
q 0 0 0 rg BT 80.98 171.65 Td (Agreement, or a breach thereof, including but not limited to any claims arising out of federal, state ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 157.25 Td (or local laws, rules or regulations, shall be exclusively settled by an arbitration proceeding conducted ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 142.85 Td (through Judicial ) Tj ET Q
q 0 0 0 rg BT 129.99 142.85 Td (Arbitration & Mediation Services \(JAMS\). ) Tj ET Q
q 0 0 0 rg BT 339.08 142.85 Td (The arbitration shall take place in Chester ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 128.45 Td (County) Tj ET Q
q 0 0 0 rg BT 84.56 128.45 Td (, Pennsylvania, and no dispute under this Letter ) Tj ET Q
q 0 0 0 rg BT 315.18 128.45 Td (Agreement shall be adjudicated in any other venue ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 114.05 Td (or forum. ) Tj ET Q
q 0 0 0 rg BT 98.11 114.05 Td (The arbitration will be conducted in accordance with the then-current JAMS Employment ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 99.65 Td (Arbitration Rules & Procedures \(and no other JAMS rules\). ) Tj ET Q
q 0 0 0 rg BT 339.07 99.65 Td (The decision of the arbitrator shall be final ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 85.25 Td (and binding. Judgment on the award rendered by the arbitrator\(s\) may be entered in any court having) Tj ET Q
endstream
endobj
445 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 446 0 R>>
endobj
446 0 obj
<</Length 3371>>
stream
/GS0 gs
q 84.00 0 0 23.00 478.00 726.00 cm
/I26 Do Q
BT /F3 10.00 Tf ET
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 702.60 Td (jurisdiction thereof. ) Tj ET Q
q 0 0 0 rg BT 147.20 702.60 Td (Y) Tj ET Q
q 0 0 0 rg BT 154.66 702.60 Td (ou and the Company shall split the cost of the arbitration services, and you and the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 688.20 Td (Company shall each bear your and its own legal expenses. ) Tj ET Q
q 0 0 0 rg BT 332.70 688.20 Td (This Letter ) Tj ET Q
q 0 0 0 rg BT 388.02 688.20 Td (Agreement shall be governed by the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 673.80 Td (laws of the State of Pennsylvania, and no modification\(s\) hereof may be made in the absence of a written ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 659.40 Td (document signed by the parties. ) Tj ET Q
q 0 0 0 rg BT 205.08 659.40 Td (This Letter ) Tj ET Q
q 0 0 0 rg BT 260.40 659.40 Td (Agreement constitutes the entire agreement between the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 645.00 Td (parties and supersede all prior agreements, understandings and arrangements, oral or written, between the ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 630.60 Td (parties with respect to the subject matter hereof; provided, however) Tj ET Q
q 0 0 0 rg BT 373.40 630.60 Td (, that this Letter ) Tj ET Q
q 0 0 0 rg BT 451.72 630.60 Td (Agreement shall not ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 616.20 Td (supersede the Special Cash ) Tj ET Q
q 0 0 0 rg BT 182.63 616.20 Td (A) Tj ET Q
q 0 0 0 rg BT 190.20 616.20 Td (ward letter agreement by and between you and Endo dated January 17, 2017; ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 601.80 Td (which shall remain in full force and ef) Tj ET Q
q 0 0 0 rg BT 233.38 601.80 Td (fect.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 578.40 Td (Mark, thank you for your ongoing contributions and commitment to our Company as we execute our ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 564.00 Td (strategic vision and operating plans at the highest performance level in support of our customers and ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 549.60 Td (patients. Please indicate your acceptance by signing and returning one copy of this Letter ) Tj ET Q
q 0 0 0 rg BT 480.20 549.60 Td (Agreement to ) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 535.20 Td (Larry Cunningham.) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 511.80 Td (Sincerely) Tj ET Q
q 0 0 0 rg BT 94.54 511.80 Td (,) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 488.40 Td (/S/ BLAISE COLEMAN) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 465.00 Td (Blaise Coleman) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 450.60 Td (EVP) Tj ET Q
q 0 0 0 rg BT 72.22 450.60 Td ( & Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 177.32 450.60 Td (ficer) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 50.00 421.85 Td (Signed and agreed by:) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 380.95 m
245.5 380.95 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
252.5 380.95 m
447.5 380.95 l
s
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 53.00 386.08 Td (/S/ MARK BRADLEY) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 255.00 386.08 Td (May 22, 2018) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 53.00 370.08 Td (Mark Bradley) Tj ET Q
BT /F3 12.00 Tf ET
q 0 0 0 rg BT 255.00 370.08 Td (Date) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
447 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 448 0 R>>
endobj
448 0 obj
<</Length 11573>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 21.1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 221.30 742.10 Td (SUBSIDIARIES OF ) Tj ET Q
q 0 0 0 rg BT 306.69 742.10 Td (THE REGISTRANT) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 727.10 Td (The following is a list of significant subsidiaries of the Company as of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 334.12 727.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 412.71 727.10 Td (.) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 695.6 m
264.5 695.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
268.5 695.6 m
413.5 695.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
417.5 695.6 m
562.5 695.6 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
268.5 695.6 m
413.5 695.6 l
s
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 138.50 699.83 Td (Subsidiary) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 286.00 707.83 Td (Jurisdiction of Incorporation or) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 317.80 699.83 Td (Organization) Tj ET Q
BT /F1 8.00 Tf ET
q 0 0 0 rg BT 425.45 699.83 Td (Ownership by Endo International plc) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 109.45 686.85 Td (Actient Pharmaceuticals LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 686.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 686.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 114.05 673.85 Td (Actient ) Tj ET Q
q 0 0 0 rg BT 139.52 673.85 Td (Therapeutics, LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 673.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 673.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 106.20 660.85 Td (Anchen Pharmaceuticals 2, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 660.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 660.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 109.15 647.85 Td (Astora ) Tj ET Q
q 0 0 0 rg BT 132.41 647.85 Td (W) Tj ET Q
q 0 0 0 rg BT 139.56 647.85 Td (omen�) Tj ET Q
q 0 0 0 rg BT 159.46 647.85 Td (s Health, LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 647.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 647.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 104.90 634.85 Td (Auxilium Pharmaceuticals, LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 634.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 634.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 99.10 621.85 Td (Endo Designated ) Tj ET Q
q 0 0 0 rg BT 155.75 621.85 Td (Activity Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 621.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 479.50 621.85 Td (Direct) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 101.55 608.85 Td (Endo Eurofin Unlimited Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 608.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 608.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 97.45 595.85 Td (Endo Finance II Unlimited Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 595.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 595.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 95.95 582.85 Td (Endo Finance IV) Tj ET Q
q 0 0 0 rg BT 150.53 582.85 Td ( Unlimited Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 582.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 582.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 101.10 569.85 Td (Endo Finance Unlimited Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 569.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 569.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 126.30 556.85 Td (Endo Finance LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 556.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 556.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 107.75 543.85 Td (Endo Finance Operations LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 543.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 543.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 106.65 530.85 Td (Endo Global Biologics Limited) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 530.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 530.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 113.65 517.85 Td (Endo Health Solutions Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 517.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 517.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 88.75 504.85 Td (Endo Ireland Finance Unlimited Company) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 504.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 504.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 83.15 491.85 Td (Endo Luxembour) Tj ET Q
q 0 0 0 rg BT 139.29 491.85 Td (g Finance Company I S.a r) Tj ET Q
q 0 0 0 rg BT 224.76 491.85 Td (.l.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 319.90 491.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 357.15 491.85 Td (g) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 491.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 81.85 478.85 Td (Endo Luxembour) Tj ET Q
q 0 0 0 rg BT 137.99 478.85 Td (g Finance Company II S.a r) Tj ET Q
q 0 0 0 rg BT 226.12 478.85 Td (.l.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 319.90 478.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 357.15 478.85 Td (g) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 478.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 85.05 465.85 Td (Endo Luxembour) Tj ET Q
q 0 0 0 rg BT 141.19 465.85 Td (g Holding Company S.a r) Tj ET Q
q 0 0 0 rg BT 222.89 465.85 Td (.l.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 319.90 465.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 357.15 465.85 Td (g) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 465.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 113.00 452.85 Td (Endo Management Limited) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 452.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 452.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 98.00 439.85 Td (Endo Par Innovation Company) Tj ET Q
q 0 0 0 rg BT 197.06 439.85 Td (, LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 439.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 439.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 114.20 426.85 Td (Endo Pharmaceuticals Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 426.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 426.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 103.05 413.85 Td (Endo Pharmaceuticals ) Tj ET Q
q 0 0 0 rg BT 176.29 413.85 Td (V) Tj ET Q
q 0 0 0 rg BT 181.55 413.85 Td (alera Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 413.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 413.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 122.45 400.85 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 141.26 400.85 Td (T) Tj ET Q
q 0 0 0 rg BT 145.80 400.85 Td (opFin Limited) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 400.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 400.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 133.30 387.85 Td (Endo U.S. Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 387.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 387.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 118.20 374.85 Td (Endo U.S. Finance LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 374.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 374.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 91.60 361.85 Td (Endo US Holdings Luxembour) Tj ET Q
q 0 0 0 rg BT 191.30 361.85 Td (g I S.a r) Tj ET Q
q 0 0 0 rg BT 216.34 361.85 Td (.l.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 319.90 361.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 357.15 361.85 Td (g) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 361.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 119.95 348.85 Td (Endo ) Tj ET Q
q 0 0 0 rg BT 138.76 348.85 Td (V) Tj ET Q
q 0 0 0 rg BT 144.03 348.85 Td (entures Limited) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 348.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 348.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 56.65 335.85 Td (Generics Bidco I, LLC \(doing business as Par Pharmaceutical\)) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 335.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 335.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 93.20 322.85 Td (Generics International \(US Parent\), Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 322.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 322.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 101.45 309.85 Td (Generics International \(US\) 2, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 309.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 309.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 102.00 296.85 Td (Hawk ) Tj ET Q
q 0 0 0 rg BT 122.88 296.85 Td (Acquisition Ireland Limited) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 329.15 296.85 Td (Ireland) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 296.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 112.45 283.85 Td (JHP) Tj ET Q
q 0 0 0 rg BT 125.64 283.85 Td ( Group Holdings 2, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 283.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 283.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 56.20 270.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 93.45 270.85 Td (g Endo Specialty Pharmaceuticals Holding I S.a r) Tj ET Q
q 0 0 0 rg BT 251.79 270.85 Td (.l.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 319.90 270.85 Td (Luxembour) Tj ET Q
q 0 0 0 rg BT 357.15 270.85 Td (g) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 270.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 98.90 257.85 Td (Paladin Labs Canadian Holding Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 328.50 257.85 Td (Canada) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 257.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 129.10 244.85 Td (Paladin Labs Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 328.50 244.85 Td (Canada) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 244.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 114.90 231.85 Td (Par Pharmaceutical 2, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 231.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 231.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 98.90 218.85 Td (Par Pharmaceutical Companies, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 218.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 218.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 102.20 205.85 Td (Par Pharmaceutical Holdings, Inc.) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 205.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 205.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 54.25 192.85 Td (Par Pharmaceutical, Inc. \(doing business as Par Pharmaceutical\)) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 324.25 192.85 Td (New ) Tj ET Q
q 0 0 0 rg BT 341.21 192.85 Td (Y) Tj ET Q
q 0 0 0 rg BT 346.44 192.85 Td (ork) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 192.85 Td (Indirect) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 115.65 179.85 Td (Par Sterile Products, LLC) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 325.15 179.85 Td (Delaware) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 477.05 179.85 Td (Indirect) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
449 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 450 0 R>>
endobj
450 0 obj
<</Length 1522>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 23.1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.15 742.10 Td (CONSENT) Tj ET Q
q 0 0 0 rg BT 187.08 742.10 Td ( OF INDEPENDENT) Tj ET Q
q 0 0 0 rg BT 274.12 742.10 Td ( REGISTERED PUBLIC ) Tj ET Q
q 0 0 0 rg BT 377.74 742.10 Td (ACCOUNTING FIRM) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 718.10 Td (W) Tj ET Q
q 0 0 0 rg BT 58.64 718.10 Td (e hereby consent to the incorporation by reference in the Registration Statements on Form S-8 \(No. 333-194253, No. ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 706.10 Td (333-204958, No. 333-219806, No. 333-226677 and No. 333-233029\) and Form S-3 \(No. 333-226676\) of Endo International ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 694.10 Td (plc of our report�dated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 141.91 694.10 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 215.51 694.10 Td (�relating to the financial statements and financial statement schedule and the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 682.10 Td (ef) Tj ET Q
q 0 0 0 rg BT 57.59 682.10 Td (fectiveness of internal control over financial reporting, which appears in this Form 10-K.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 646.10 Td (/s/ PricewaterhouseCoopers LLP) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 622.10 Td (Philadelphia, Pennsylvania) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 610.10 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 123.60 610.10 Td ( ) Tj ET Q
endstream
endobj
451 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 452 0 R>>
endobj
452 0 obj
<</Length 5330>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 760.75 Td (Exhibit 24.1) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 250.40 742.25 Td (POWER OF) Tj ET Q
q 0 0 0 rg BT 304.19 742.25 Td ( ) Tj ET Q
q 0 0 0 rg BT 306.14 742.25 Td (A) Tj ET Q
q 0 0 0 rg BT 312.62 742.25 Td (TT) Tj ET Q
q 0 0 0 rg BT 325.78 742.25 Td (ORNEY) Tj ET Q
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 361.52 742.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 721.25 Td (Each of the undersigned, hereby constitutes and appoints each of ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 311.86 721.25 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 331.96 721.25 Td (V) Tj ET Q
q 0 0 0 rg BT 337.89 721.25 Td (. Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 388.99 721.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 393.99 721.25 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 457.59 721.25 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 462.59 721.25 Td (Matthew J. Maletta) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 540.07 721.25 Td ( and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 709.25 Td (Y) Tj ET Q
q 0 0 0 rg BT 56.22 709.25 Td (oon ) Tj ET Q
q 0 0 0 rg BT 73.17 709.25 Td (Ah Oh to be his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, and to sign for ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 697.25 Td (the undersigned and in each of their respective names in any and all capacities stated below) Tj ET Q
q 0 0 0 rg BT 415.04 697.25 Td (, this ) Tj ET Q
q 0 0 0 rg BT 436.44 697.25 Td (Annual Report on Form 10-K ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 685.25 Td (\(and any amendments hereto\) and to file the same, with exhibits hereto and thereto and other documents in connection herewith ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 673.25 Td (and therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 661.25 Td (in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 409.36 661.25 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 640.25 Td (Pursuant to the requirements of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 276.05 640.25 Td (Act of 1934, this Power of ) Tj ET Q
q 0 0 0 rg BT 384.10 640.25 Td (Attorney has been signed by the following ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 628.25 Td (persons in the capacities and on the dates indicated.) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 256.32 628.25 Td ( ) Tj ET Q
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 589.75 m
167.5 589.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 550.75 m
167.5 550.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 511.75 m
167.5 511.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 472.75 m
167.5 472.75 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 433.75 m
167.5 433.75 l
s
BT /F1 8.50 Tf ET
0 0 0 RG
/GS0 gs
0.81 w
0 i 
[] 0 d
1 J
1 j
3 M
53 607.7629638671875 m
88.26708984375 607.7629638671875 l
s
q 0 0 0 rg BT 53.00 609.09 Td (Signatur) Tj ET Q
q 0 0 0 rg BT 84.57 609.09 Td (e) Tj ET Q
BT /F1 8.50 Tf ET
0 0 0 RG
/GS0 gs
0.81 w
0 i 
[] 0 d
1 J
1 j
3 M
170 607.7629638671875 m
186.84326171875 607.7629638671875 l
s
q 0 0 0 rg BT 170.00 609.09 Td (T) Tj ET Q
q 0 0 0 rg BT 175.59 609.09 Td (itle) Tj ET Q
BT /F1 8.50 Tf ET
0 0 0 RG
/GS0 gs
0.81 w
0 i 
[] 0 d
1 J
1 j
3 M
490 607.7629638671875 m
506.9921875 607.7629638671875 l
s
q 0 0 0 rg BT 490.00 609.09 Td (Date) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 594.11 Td (/s/ Roger H. Kimmel) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 170.00 594.11 Td (Senior Independent Director) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 490.00 594.11 Td (February 19, 2020) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 581.11 Td (Roger H. Kimmel) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 555.11 Td (/s/ Shane M. Cooke) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 170.00 555.11 Td (Director) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 490.00 555.11 Td (February 19, 2020) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 542.11 Td (Shane M. Cooke) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 516.11 Td (/s/ Nancy J. Hutson, Ph.D.) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 170.00 516.11 Td (Director) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 490.00 516.11 Td (February 19, 2020) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 503.11 Td (Nancy J. Hutson, Ph.D.) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 477.11 Td (/s/ Michael Hyatt) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 170.00 477.11 Td (Director) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 490.00 477.11 Td (February 19, 2020) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 464.11 Td (Michael Hyatt) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 438.11 Td (/s/ ) Tj ET Q
q 0 0 0 rg BT 63.08 438.11 Td (W) Tj ET Q
q 0 0 0 rg BT 70.86 438.11 Td (illiam P) Tj ET Q
q 0 0 0 rg BT 96.90 438.11 Td (. Montague) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 170.00 438.11 Td (Director) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 490.00 438.11 Td (February 19, 2020) Tj ET Q
BT /F3 8.50 Tf ET
q 0 0 0 rg BT 53.00 425.11 Td (W) Tj ET Q
q 0 0 0 rg BT 60.68 425.11 Td (illiam P) Tj ET Q
q 0 0 0 rg BT 86.42 425.11 Td (. Montague) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
453 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 454 0 R>>
endobj
454 0 obj
<</Length 8736>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 31.1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.60 742.10 Td (CER) Tj ET Q
q 0 0 0 rg BT 213.45 742.10 Td (TIFICA) Tj ET Q
q 0 0 0 rg BT 244.56 742.10 Td (TION OF CHIEF EXECUTIVE OFFICER) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.34 742.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.20 730.10 Td (PURSUANT) Tj ET Q
q 0 0 0 rg BT 285.81 730.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 288.13 730.10 Td (T) Tj ET Q
q 0 0 0 rg BT 294.05 730.10 Td (O SECTION 302 OF) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.70 718.10 Td (THE SARBANES-OXLEY) Tj ET Q
q 0 0 0 rg BT 331.72 718.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 333.66 718.10 Td (ACT) Tj ET Q
q 0 0 0 rg BT 353.48 718.10 Td ( OF 2002) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 697.10 Td (I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.33 697.10 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 78.43 697.10 Td (V) Tj ET Q
q 0 0 0 rg BT 84.36 697.10 Td (. Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 135.46 697.10 Td (, certify that:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 680.10 Td (1. I have reviewed this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.80 680.10 Td (annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.46 680.10 Td ( report on Form ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.00 680.10 Td (10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.55 680.10 Td ( of Endo International plc;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 663.10 Td (2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 651.10 Td (fact necessary to make the statements made, in light of the circumstances under which such statements were made, not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 639.10 Td (misleading with respect to the period covered by this report;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 622.10 Td (3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 610.10 Td (in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for) Tj ET Q
q 0 0 0 rg BT 523.90 610.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 598.10 Td (periods presented in this report;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 581.10 Td (4. ) Tj ET Q
q 0 0 0 rg BT 82.32 581.10 Td (The registrant�) Tj ET Q
q 0 0 0 rg BT 140.91 581.10 Td (s other certifying of) Tj ET Q
q 0 0 0 rg BT 219.87 581.10 Td (ficer and I are responsible for establishing and maintaining disclosure controls and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 569.10 Td (procedures \(as defined in Exchange ) Tj ET Q
q 0 0 0 rg BT 217.16 569.10 Td (Act Rules 13a-15\(e\) and 15d-15\(e\)\) and internal control over financial reporting \(as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 557.10 Td (defined in Exchange ) Tj ET Q
q 0 0 0 rg BT 156.64 557.10 Td (Act Rules 13a-15\(f\) and 15d-15\(f\)\) for the registrant and have:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 540.10 Td (a\) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 528.10 Td (designed under our supervision, to ensure that material information relating to the registrant, including its consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 516.10 Td (subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 504.10 Td (being prepared;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 487.10 Td (b\) Designed such internal control over financial reporting, or caused such internal control over financial reporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 475.10 Td (to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 463.10 Td (the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 446.10 Td (c\) Evaluated the ef) Tj ET Q
q 0 0 0 rg BT 174.55 446.10 Td (fectiveness of the registrant�) Tj ET Q
q 0 0 0 rg BT 287.57 446.10 Td (s disclosure controls and procedures and presented in this report our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 434.10 Td (conclusions about the ef) Tj ET Q
q 0 0 0 rg BT 169.24 434.10 Td (fectiveness of the disclosure controls and procedures, as of the end of the period covered by this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 422.10 Td (report based on such evaluation; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 405.10 Td (d\) Disclosed in this report any change in the registrant�) Tj ET Q
q 0 0 0 rg BT 319.16 405.10 Td (s internal control over financial reporting that occurred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 393.10 Td (during the registrant�) Tj ET Q
q 0 0 0 rg BT 156.37 393.10 Td (s most recent fiscal quarter \(the registrant�) Tj ET Q
q 0 0 0 rg BT 325.19 393.10 Td (s fourth fiscal quarter in the case of an annual report\) that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 381.10 Td (has materially af) Tj ET Q
q 0 0 0 rg BT 138.96 381.10 Td (fected, or is reasonably likely to materially af) Tj ET Q
q 0 0 0 rg BT 320.37 381.10 Td (fect, the registrant�) Tj ET Q
q 0 0 0 rg BT 395.62 381.10 Td (s internal control over financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 369.10 Td (reporting; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 352.10 Td (5. ) Tj ET Q
q 0 0 0 rg BT 82.32 352.10 Td (The registrant�) Tj ET Q
q 0 0 0 rg BT 140.91 352.10 Td (s other certifying of) Tj ET Q
q 0 0 0 rg BT 219.87 352.10 Td (ficer and I have disclosed, based on our most recent evaluation of internal control ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 340.10 Td (over financial reporting, to the registrant�) Tj ET Q
q 0 0 0 rg BT 237.44 340.10 Td (s auditors and the audit committee of registrant�) Tj ET Q
q 0 0 0 rg BT 428.78 340.10 Td (s Board of Directors \(or persons ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 328.10 Td (performing the equivalent functions\):) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 311.10 Td (a\) ) Tj ET Q
q 0 0 0 rg BT 109.22 311.10 Td (All significant deficiencies and material weaknesses in the design or operation of internal control over financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 299.10 Td (reporting which are reasonably likely to adversely af) Tj ET Q
q 0 0 0 rg BT 283.07 299.10 Td (fect the registrant�) Tj ET Q
q 0 0 0 rg BT 355.82 299.10 Td (s ability to record, process, summarize and report ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 287.10 Td (financial information; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 270.10 Td (b\) ) Tj ET Q
q 0 0 0 rg BT 109.78 270.10 Td (Any fraud, whether or not material, that involves management or other employees who have a significant role in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 258.10 Td (the registrant�) Tj ET Q
q 0 0 0 rg BT 127.76 258.10 Td (s internal control over financial reporting.) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 218.60000000000002 m
85.5 218.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
85.5 218.60000000000002 m
260.5 218.60000000000002 l
s
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 223.17 Td (/S/ P) Tj ET Q
q 0 0 0 rg BT 71.26 223.17 Td (AUL) Tj ET Q
q 0 0 0 rg BT 91.44 223.17 Td ( ) Tj ET Q
q 0 0 0 rg BT 93.76 223.17 Td (V) Tj ET Q
q 0 0 0 rg BT 99.69 223.17 Td (. CAMP) Tj ET Q
q 0 0 0 rg BT 132.12 223.17 Td (ANELLI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 209.17 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 73.19 209.17 Td (V) Tj ET Q
q 0 0 0 rg BT 79.67 209.17 Td (. Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 195.17 Td (President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 187.22 195.17 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 185.17 Td (\(Principal Executive Of) Tj ET Q
q 0 0 0 rg BT 147.79 185.17 Td (ficer\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 156.17 Td (Date:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 88.00 156.17 Td (February 26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
455 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 456 0 R>>
endobj
456 0 obj
<</Length 8577>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 31.2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.90 742.10 Td (CER) Tj ET Q
q 0 0 0 rg BT 214.75 742.10 Td (TIFICA) Tj ET Q
q 0 0 0 rg BT 245.86 742.10 Td (TION OF CHIEF FINANCIAL) Tj ET Q
q 0 0 0 rg BT 372.43 742.10 Td ( OFFICER) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.06 742.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 233.20 730.10 Td (PURSUANT) Tj ET Q
q 0 0 0 rg BT 285.81 730.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 288.13 730.10 Td (T) Tj ET Q
q 0 0 0 rg BT 294.05 730.10 Td (O SECTION 302 OF) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 220.70 718.10 Td (THE SARBANES-OXLEY) Tj ET Q
q 0 0 0 rg BT 331.72 718.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 333.66 718.10 Td (ACT) Tj ET Q
q 0 0 0 rg BT 353.48 718.10 Td ( OF 2002) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 391.27 718.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 697.10 Td (I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 58.33 697.10 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 121.93 697.10 Td (, certify that:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 173.30 697.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 680.10 Td (1. I have reviewed this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 165.80 680.10 Td (annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 192.46 680.10 Td ( report on Form ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 258.00 680.10 Td (10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 278.55 680.10 Td ( of Endo International plc;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 663.10 Td (2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 651.10 Td (fact necessary to make the statements made, in light of the circumstances under which such statements were made, not ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 639.10 Td (misleading with respect to the period covered by this report;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 622.10 Td (3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 610.10 Td (in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for) Tj ET Q
q 0 0 0 rg BT 523.90 610.10 Td (, the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 598.10 Td (periods presented in this report;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 581.10 Td (4. ) Tj ET Q
q 0 0 0 rg BT 82.32 581.10 Td (The registrant�) Tj ET Q
q 0 0 0 rg BT 140.91 581.10 Td (s other certifying of) Tj ET Q
q 0 0 0 rg BT 219.87 581.10 Td (ficer and I are responsible for establishing and maintaining disclosure controls and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 569.10 Td (procedures \(as defined in Exchange ) Tj ET Q
q 0 0 0 rg BT 217.16 569.10 Td (Act Rules 13a-15\(e\) and 15d-15\(e\)\) and internal control over financial reporting \(as ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 557.10 Td (defined in Exchange ) Tj ET Q
q 0 0 0 rg BT 156.64 557.10 Td (Act Rules 13a-15\(f\) and 15d-15\(f\)\) for the registrant and have:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 540.10 Td (a\) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 528.10 Td (designed under our supervision, to ensure that material information relating to the registrant, including its consolidated ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 516.10 Td (subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 504.10 Td (being prepared;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 487.10 Td (b\) Designed such internal control over financial reporting, or caused such internal control over financial reporting ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 475.10 Td (to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 463.10 Td (the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 446.10 Td (c\) Evaluated the ef) Tj ET Q
q 0 0 0 rg BT 174.55 446.10 Td (fectiveness of the registrant�) Tj ET Q
q 0 0 0 rg BT 287.57 446.10 Td (s disclosure controls and procedures and presented in this report our ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 434.10 Td (conclusions about the ef) Tj ET Q
q 0 0 0 rg BT 169.24 434.10 Td (fectiveness of the disclosure controls and procedures, as of the end of the period covered by this ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 422.10 Td (report based on such evaluation; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 405.10 Td (d\) Disclosed in this report any change in the registrant�) Tj ET Q
q 0 0 0 rg BT 319.16 405.10 Td (s internal control over financial reporting that occurred ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 393.10 Td (during the registrant�) Tj ET Q
q 0 0 0 rg BT 156.37 393.10 Td (s most recent fiscal quarter \(the registrant�) Tj ET Q
q 0 0 0 rg BT 325.19 393.10 Td (s fourth fiscal quarter in the case of an annual report\) that ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 381.10 Td (has materially af) Tj ET Q
q 0 0 0 rg BT 138.96 381.10 Td (fected, or is reasonably likely to materially af) Tj ET Q
q 0 0 0 rg BT 320.37 381.10 Td (fect, the registrant�) Tj ET Q
q 0 0 0 rg BT 395.62 381.10 Td (s internal control over financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 369.10 Td (reporting; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 352.10 Td (5. ) Tj ET Q
q 0 0 0 rg BT 82.32 352.10 Td (The registrant�) Tj ET Q
q 0 0 0 rg BT 140.91 352.10 Td (s other certifying of) Tj ET Q
q 0 0 0 rg BT 219.87 352.10 Td (ficer and I have disclosed, based on our most recent evaluation of internal control ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 340.10 Td (over financial reporting, to the registrant�) Tj ET Q
q 0 0 0 rg BT 237.44 340.10 Td (s auditors and the audit committee of registrant�) Tj ET Q
q 0 0 0 rg BT 428.78 340.10 Td (s Board of Directors \(or persons ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 328.10 Td (performing the equivalent functions\):) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 311.10 Td (a\) ) Tj ET Q
q 0 0 0 rg BT 109.22 311.10 Td (All significant deficiencies and material weaknesses in the design or operation of internal control over financial ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 299.10 Td (reporting which are reasonably likely to adversely af) Tj ET Q
q 0 0 0 rg BT 283.07 299.10 Td (fect the registrant�) Tj ET Q
q 0 0 0 rg BT 355.82 299.10 Td (s ability to record, process, summarize and report ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 287.10 Td (financial information; and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 99.50 270.10 Td (b\) ) Tj ET Q
q 0 0 0 rg BT 109.78 270.10 Td (Any fraud, whether or not material, that involves management or other employees who have a significant role in ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 258.10 Td (the registrant�) Tj ET Q
q 0 0 0 rg BT 127.76 258.10 Td (s internal control over financial reporting.) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
50.5 218.60000000000002 m
85.5 218.60000000000002 l
s
0 0 0 RG
/GS0 gs
1.00 w
0 i 
[] 0 d
0 J
0 j
3 M
85.5 218.60000000000002 m
260.5 218.60000000000002 l
s
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 223.17 Td (/S/ BLAISE COLEMAN) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 209.17 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 195.17 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 95.30 195.17 Td (V) Tj ET Q
q 0 0 0 rg BT 101.92 195.17 Td (ice President, Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 233.09 195.17 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 185.17 Td (\(Principal Financial Of) Tj ET Q
q 0 0 0 rg BT 145.02 185.17 Td (ficer\)) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 156.17 Td (Date:) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 88.00 156.17 Td (February 26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
457 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 458 0 R>>
endobj
458 0 obj
<</Length 5165>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 32.1) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 194.60 742.10 Td (CER) Tj ET Q
q 0 0 0 rg BT 213.45 742.10 Td (TIFICA) Tj ET Q
q 0 0 0 rg BT 244.56 742.10 Td (TION OF CHIEF EXECUTIVE OFFICER) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 417.34 742.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.10 730.10 Td (PURSUANT) Tj ET Q
q 0 0 0 rg BT 268.71 730.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 271.03 730.10 Td (T) Tj ET Q
q 0 0 0 rg BT 276.95 730.10 Td (O 18 U.S.C. SECTION 1350,) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.00 718.10 Td (AS ) Tj ET Q
q 0 0 0 rg BT 254.73 718.10 Td (ADOPTED PURSUANT) Tj ET Q
q 0 0 0 rg BT 356.50 718.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 358.82 718.10 Td (T) Tj ET Q
q 0 0 0 rg BT 364.75 718.10 Td (O) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.05 706.10 Td (SECTION 906 OF ) Tj ET Q
q 0 0 0 rg BT 259.37 706.10 Td (THE SARBANES-OXLEY) Tj ET Q
q 0 0 0 rg BT 370.39 706.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 372.34 706.10 Td (ACT) Tj ET Q
q 0 0 0 rg BT 392.16 706.10 Td ( OF 2002) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.00 685.10 Td (I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.33 685.10 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 102.43 685.10 Td (V) Tj ET Q
q 0 0 0 rg BT 108.36 685.10 Td (. Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 159.46 685.10 Td (, as President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 309.51 685.10 Td (ficer of Endo International plc \(the Company\), hereby certify) Tj ET Q
q 0 0 0 rg BT 553.49 685.10 Td (, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 673.10 Td (pursuant to 18 U.S.C. Section�1350, as adopted pursuant to Section�906 of the Sarbanes-Oxley ) Tj ET Q
q 0 0 0 rg BT 430.22 673.10 Td (Act of 2002, that:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.00 656.10 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 108.98 656.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.47 656.10 Td (Annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.91 656.10 Td ( Report on Form ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.80 656.10 Td (10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.35 656.10 Td ( of the Company for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.66 656.10 Td (annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.32 656.10 Td ( period ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.24 656.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.83 656.10 Td ( \(the Report\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 644.10 Td (fully complies with the requirements of Section�13\(a\) or�15\(d\) of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 432.95 644.10 Td (Act of 1934 \(15 U.S.C. 78m\); ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 632.10 Td (and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.00 615.10 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 108.98 615.10 Td (The information contained in the Report fairly presents, in all material respects, the financial condition and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 603.10 Td (results of operations of the Company) Tj ET Q
q 0 0 0 rg BT 219.88 603.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 592.30 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 557.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
97 556.0333984375 m
212.2197265625 556.0333984375 l
s
q 0 0 0 rg BT 97.00 557.37 Td (/S/ P) Tj ET Q
q 0 0 0 rg BT 115.26 557.37 Td (AUL) Tj ET Q
q 0 0 0 rg BT 135.44 557.37 Td ( ) Tj ET Q
q 0 0 0 rg BT 137.76 557.37 Td (V) Tj ET Q
q 0 0 0 rg BT 143.69 557.37 Td (. CAMP) Tj ET Q
q 0 0 0 rg BT 176.12 557.37 Td (ANELLI) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 543.37 Td (Name:) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 543.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 543.37 Td (Paul ) Tj ET Q
q 0 0 0 rg BT 117.19 543.37 Td (V) Tj ET Q
q 0 0 0 rg BT 123.67 543.37 Td (. Campanelli) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 529.37 Td (T) Tj ET Q
q 0 0 0 rg BT 58.76 529.37 Td (itle:) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 519.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 529.37 Td (President and Chief Executive Of) Tj ET Q
q 0 0 0 rg BT 231.22 529.37 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 519.37 Td (\(Principal Executive Of) Tj ET Q
q 0 0 0 rg BT 191.79 519.37 Td (ficer\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 494.30 Td (Date: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.16 494.30 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.75 494.30 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.00 473.30 Td (A) Tj ET Q
q 0 0 0 rg BT 80.67 473.30 Td ( signed original of this written statement required by Section�906 has been provided to, and will be retained by) Tj ET Q
q 0 0 0 rg BT 522.13 473.30 Td (, Endo ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 461.30 Td (International plc and furnished to the Securities and Exchange Commission or its staf) Tj ET Q
q 0 0 0 rg BT 391.41 461.30 Td (f upon request.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
459 0 obj
<</Type /Page
/Parent 1 0 R
/MediaBox [0 0 612.00 792.00]
/Resources 2 0 R
/Rotate 0
/Contents 460 0 R>>
endobj
460 0 obj
<</Length 4899>>
stream
BT /F1 10.00 Tf ET
q 0 0 0 rg BT 510.30 772.75 Td (Exhibit 32.2) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 195.90 742.10 Td (CER) Tj ET Q
q 0 0 0 rg BT 214.75 742.10 Td (TIFICA) Tj ET Q
q 0 0 0 rg BT 245.86 742.10 Td (TION OF CHIEF FINANCIAL) Tj ET Q
q 0 0 0 rg BT 372.43 742.10 Td ( OFFICER) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 416.06 742.10 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 216.10 730.10 Td (PURSUANT) Tj ET Q
q 0 0 0 rg BT 268.71 730.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 271.03 730.10 Td (T) Tj ET Q
q 0 0 0 rg BT 276.95 730.10 Td (O 18 U.S.C. SECTION 1350,) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 240.00 718.10 Td (AS ) Tj ET Q
q 0 0 0 rg BT 254.73 718.10 Td (ADOPTED PURSUANT) Tj ET Q
q 0 0 0 rg BT 356.50 718.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 358.82 718.10 Td (T) Tj ET Q
q 0 0 0 rg BT 364.75 718.10 Td (O) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 182.05 706.10 Td (SECTION 906 OF ) Tj ET Q
q 0 0 0 rg BT 259.37 706.10 Td (THE SARBANES-OXLEY) Tj ET Q
q 0 0 0 rg BT 370.39 706.10 Td ( ) Tj ET Q
q 0 0 0 rg BT 372.34 706.10 Td (ACT) Tj ET Q
q 0 0 0 rg BT 392.16 706.10 Td ( OF 2002) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.00 685.10 Td (I, ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 82.33 685.10 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 145.93 685.10 Td (, as Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 236.56 685.10 Td (ficer of Endo International plc \(the Company\), hereby certify) Tj ET Q
q 0 0 0 rg BT 480.53 685.10 Td (, pursuant to 18 ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 673.10 Td (U.S.C. Section�1350, as adopted pursuant to Section�906 of the Sarbanes-Oxley ) Tj ET Q
q 0 0 0 rg BT 370.51 673.10 Td (Act of 2002, that:) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.00 656.10 Td (\(1\) ) Tj ET Q
q 0 0 0 rg BT 108.98 656.10 Td (The ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 126.47 656.10 Td (Annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 155.91 656.10 Td ( Report on Form ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 224.80 656.10 Td (10-K) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 245.35 656.10 Td ( of the Company for the ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 343.66 656.10 Td (annual) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 370.32 656.10 Td ( period ended ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 427.24 656.10 Td (December�31, 2019) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 505.83 656.10 Td ( \(the Report\) ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 644.10 Td (fully complies with the requirements of Section�13\(a\) or�15\(d\) of the Securities Exchange ) Tj ET Q
q 0 0 0 rg BT 432.95 644.10 Td (Act of 1934 \(15 U.S.C. 78m\); ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 632.10 Td (and) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 95.00 615.10 Td (\(2\) ) Tj ET Q
q 0 0 0 rg BT 108.98 615.10 Td (The information contained in the Report fairly presents, in all material respects, the financial condition and ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 72.50 603.10 Td (results of operations of the Company) Tj ET Q
q 0 0 0 rg BT 219.88 603.10 Td (.) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 9.00 Tf ET
q 0 0 0 rg BT 50.00 592.30 Td (�) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 557.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
0 0 0 RG
/GS0 gs
0.49 w
0 i 
[] 0 d
1 J
1 j
3 M
97 556.0333984375 m
197.5615234375 556.0333984375 l
s
q 0 0 0 rg BT 97.00 557.37 Td (/S/ BLAISE COLEMAN) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 543.37 Td (Name:) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 543.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 543.37 Td (Blaise Coleman) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 53.00 529.37 Td (T) Tj ET Q
q 0 0 0 rg BT 58.76 529.37 Td (itle:) Tj ET Q
BT /F3 8.00 Tf ET
q 0 0 0 rg BT 87.00 519.05 Td (�) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 529.37 Td (Executive ) Tj ET Q
q 0 0 0 rg BT 139.30 529.37 Td (V) Tj ET Q
q 0 0 0 rg BT 145.92 529.37 Td (ice President, Chief Financial Of) Tj ET Q
q 0 0 0 rg BT 277.09 529.37 Td (ficer) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 97.00 519.37 Td (\(Principal Financial Of) Tj ET Q
q 0 0 0 rg BT 189.02 519.37 Td (ficer\)) Tj ET Q
BT /F3 10.00 Tf ET
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 494.30 Td (Date: ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.16 494.30 Td (February�26, 2020) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 147.75 494.30 Td ( ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 74.00 473.30 Td (A) Tj ET Q
q 0 0 0 rg BT 80.67 473.30 Td ( signed original of this written statement required by Section�906 has been provided to, and will be retained by) Tj ET Q
q 0 0 0 rg BT 522.13 473.30 Td (, Endo ) Tj ET Q
BT /F3 10.00 Tf ET
q 0 0 0 rg BT 50.00 461.30 Td (International plc and furnished to the Securities and Exchange Commission or its staf) Tj ET Q
q 0 0 0 rg BT 391.41 461.30 Td (f upon request.) Tj ET Q
BT /F3 10.00 Tf ET
endstream
endobj
461 0 obj
<</Type /OCG /Name (print)
/Usage <</Print <</PrintState /ON>> /View <</ViewState /OFF>>>>>>
endobj
462 0 obj
<</Type /OCG /Name (view)
/Usage <</Print <</PrintState /OFF>> /View <</ViewState /ON>>>>>>
endobj
463 0 obj
<</Type /ExtGState
/SA true
/CA 1
/BM /Normal
/ca 1
/n 463
>>
endobj
464 0 obj
<</Length 124548
/Filter /FlateDecode
/Length1 193400>>
stream
x��y�\U�7�N�өs�N��繫�����t�;=&�t:�$bHB�
�!(\0�DqPQT:/�I����(8# � ��[��;�˽�����=����k�{����k�}�I""��F&�._���+�𳧉��V�[;��7ξ�ȵ�Ȱ焵���ܹ�H�&fmZ=�r�[W���G������k?w����"�{�8o�m;
o#:�Dd���K/N�x��'���D���g��=��E�-���?s���#;ֻ�g���m��۪�D{V�����[�{Çn}�{Dɷ
]�}��-?��_����v4���6�~%����]��p��Y�^$r���z���}���dx_�^�gl6<�M�Q�w���
;���&0�v�O�����[�]�G2|��=;.�y�rQq���C���h�s�_�����(1-͆�O��O�������?ٳ��o��󙗯~�:�ݶ��#Ib�5��$��nx�ꗯ��=׾�q��4H����R���)��P3�����豙o2wa�\+7�B�^�l0،V��`4�B��F�
/ί�9�v���|�`>��R�5%ݷ����?����L�$��H�
L��t��B�c�H'���Ak��:�wP����"Ə�^G~2�
h_�t5R)�ԅ4��r.�BZ�{ }k��:"��X/���I5�De�'"EPn3=IU�"Z�T6��X?�U���6�����9G=o�Ig��5^��"w#yў��?f����>E7�����X{#斍�U�O@~���>��R�)�h>���e�f%�����*̙�'��v��i�׃�Ƀ~�X�OJ_����bj#�87ƈs�t�Lȗ	�^%1��߱�q2,j��gHO����$���Dt���#߅���
��kHB���Z��F͗p�����-���[�y�����u$�H�%Ӈ�ӟi�ʖ�S��	�چ�V��Ȏ���qH;�ܱl�u�E�l�%�їEʃw��He��μ�ٚ���1�D��,WB��������w�t�ː��o��:��p��H��?�A��|��xN�r$��cR�q�Ọ�Ԓґ|s���U�+�ލ�i=���%�g9kN��f�`��Z̃sr�l�	�jݗ�@�HA$ł{5�d���������{���r��2��l������d~�Ġh-� ��:&ϳ�qn<@%���}������>����}����������L9��,�9�(�b!P֜�|���^k*�
�94j:��g�{^���0=J�3|���BfpF��_r����Jg��ݠe��݈<czԐ6=*��w6k��pY+͗���5IZ}�s:��x��O����;iʿ3?���(��-���R
)9������d+K��#�������H�Fp�G��t�@��)���X��;�
X�%�}�o@��	�{~]���#�9F�^!s�"K"���W��s�$r�g����s�3��JlX7�m`��4� ��rY�v������r:'��������sv�����)����ٍ�YDZ~d=�:n~�������	���u���>�C��W
]��y�ui�S�y�eQ���oo^jxs�[j��9=�����~�O�y�i>�v��3����ŰI-�)�e8lv�u?�Aq��%��͠i��>�f�"��`/�n�@s߅�5>CQ�;��nh>m|7
	{9E[��h�56H1_A)�Oa���|N��v
9�1��m4�z�|���g���v��B.��
b�C�K���g4XAiA�{\9�e�-%L���Ĝ�����4z-Z6y�X��en��a��-:��%A+��/y��h��@E������尣ˍ����Ų���}��\:����
�������C�;�����Z#��{;��/�2N�;(kYݸz��Zb��:��^���˅_�6���+C�l�|�	��^�M�v9�s��]9����U�$I�X,������*�V��D[n*l��'�-K|�y͒�;�{[�k�[���+�+�����Ε=a������7�hyA�c��/j�G7i�
^�Y^�H֥\�]�ԴZ=7��X�-	�%�!Z�SN�~�by��s��,[q*�"�!�"8ڟ_�23Z{K��~w��u���Q�jA-��qK�7�+�=�w8.�%�?����,II)#5���
�B�1I�0���e�҉����Kh
�@Nq8:�G�+�K�s"vH�%��|=Օ�dLOq��
�_FE�Jn�vGԏ���(U�$��d�i]U��k���]"��KR@��
51:�RǑ�oJ���&�w��%���$I;CJ&%i]KT��_K�\��
0hǰ�x��%
���_��M���/j�$I��ȅ���-� �d$�(��F� I4?�<@�5�F���x�9:�	�"W�%�t�PP%��O��%P#O�E�]��:i�~�
�� `��P0Ja���q�6�A	�
&LQ0M	�%��,�s��S��7*R���%*���NmͿR�J�U*vX���_��*�u�vQ`7՚���:`������z���'Z,� �
Q?ఀKh��<��b�Q
�hp����	��%�Kip�6��)
��8�
���I�����泴��
�@˛��j�g�DZ���\+�:�
|
�<�Nh��^+�zZ
��N<����4m�u�����*�i����i��LO�:pml������	x&�
��N<�t6m<�N<��<�7t>m
���
�3���
C�v�w�Y�x	���]J��z:�7�F:�M���ta��
�J
^F;
/��
w�%ͧ�
��m�z��x%�
�*zS�I�z3��^Co
|����M�
^K�^G��IW4N��zz����tU��G��?���t5��k�O�@�h7��Z�����<D�w��a���Q�x3��zO�g�1�
���^�O��o����)� �mt#��~�n��>�<Hw�G?#�g����st3�]��ǚ?���q��	��	�y��?�S�w�m�_|�����Ч
��>�����>�}��~�>x�f
�L{�?���Uj~��
~�Q��'��t7�7����۴��#���]��!
�G�7H����
�O_j��~@P�!}�	�(}�
��������
���A���M�'�[�G�g�m�C���������|�~A>)�S��/���Ŀ�4�G�������[���w�����Ƕİ��c����>#��x���#=
�<����B��t��W�9�����'�ߦ�=�"���+�����o����&���:��:��:��=���������uz���:���������?��?����	�{�.;�&���Mȍ&���G<nA��f�Y,v��b�:l$��fsYmV�5�@@��d59�S��l��m��1�bs�,s�Ų��wI���lj��lN���ύ�ف��&
N���Y�-��f@���
��֪�����\����x�ш~�݂f;"fq�16<�dù��f��׭�	��`<�N�p��۪�8���
gw����8�D2Z�&AD`(��`oE��:&��8��dL�f��qta=׉�L.G�K���6��;@>�^:�@sQ������8���fc�N@K9�"V�aw;J;�`&[�6���d,�xʼ���8Ϲ�O²a5CJL&ԅH8AM"�[�#��#����ȟ�!�eey�[�v�Ghfy��O�h6�Y���Aͭo�v�l2[]������mm}Ne.��%в�RYd��Dž`3�X�,���X����c���T<��`-yD��9y���,�cr�,���n?�`uq�D��:�
�j7Z�c�Q����($������l�#��8�䑷ez8]|L,N�G��ab~:X�37�T��ڒG�]H���"���r�Y
y	�k�<�>��#垗G3�����,�Ĵ�����<:q� ��^qy�Z'	ˣi�V!�,"s�M�7\첽u��	��0�ֹڼ<2%�ʣ���Q 0uCe������贳Ҳ񑬲���VY����B��̚W�G��7!���<b��&،��B����#7�����;Z�C�,�V��3���G��
��n��N���	�¿��ɣu>���`�<:�<��-ȣ��g��P�&�Ƒ��
�!o�ǜ<��B!�,����B��|�,�� �&3��D�0,%ˬ��W�]�������v�Iv�.~(gqy��֚�G����"�!���)^�L��6��!�G���ۺٸ8p���P`�]NXN��ᰛMf;����r`��`�idK�j�Ɠ�.眈�ٍc6�s	}�T���Ź��h6˨��I�N�Kq�F�h�V�lS����'��aj���n1:�-��т~x+�1s�(b��9��.�c��C���m���1+��#p��<�`W8`�����~;���&C1B3
��%[Kɱ�	�fr���V#c�x:��+V���e3�Vf,o˧w�m.�*@��❊粳�B�;X1�)Sm|�Ł�.�WZŦ�E�'�܁�PQ\l�N����z����a���sV�6��.lž�؝�De�j
EmDjKA���G�hb�G��
�|�9y[���<���Ւ21���5���x}�z6����j�#�+���R]6U������Ȟ��Ŭ�y��}A�۰AB!������B�vf�QTG�
J���)��"�S�(��`�lw��2��E\�yt-�c���0-tϣ�a�� �ͬ88:�NvXe�.�ݐGGKU��%�N6��’CGۄ<Z�ʣEyTU�Ef]eҁ+�.7��z]`���*�f���B����2��6g�\��{-�j�<z4Yȣݮ���;p\�Q��m�)�w��2��S�
�I�
�'^�,04n��������v�L.�u�;/t�1�T+ɲxd�����@���q:e���a�X��b<<�˼*� p�sS�#��y��r8����!s	�X��QpS�|��\Cd��݌'{,�c�h��-�r|��ဉ�
tp�!$,��yy�����e��3�͠�����)�eoE&��|[T���ߢv�n��V�Iȓl�$�‚��xLB��}�4vV(��X$\N����qc��S�\�K@��f�W�8]����U��
<�4�a��簄�~�qnVV�I��
�q8�*x�p�ʱ�usxe�(٥�����VPr
���J��
����G7.:f�nEn�(P(���d����탏�)n�hw��K�"�2������X2��3��p���D���c�e�LWKfݠ�ⰶ��d�{�	Κ��l�X"7�AݲC�!Ea�nw�q�����
���S〉���f+>�Nh-j��ќ����c��ˉ��Ȼ�n�\�1x�
'1s�8,��#2S����z��G����V����/W��|'�$���
>��f��q�B�IXz�
�Ƥ�XL�@Nt]
�tf"�B�	�*�q� �������N�U5���
y��U>��??𷃣���������[�<n
.�
��2|�����@��_4>����Ɋ��V�s!���&�KUu�ͥ���)�
y���໮(��8u��á�zN3��n7�#� �c�v.��.�DhiNթbQ��Ş�"Pd���e����!ƀE\��z\L:\F��;9'�E9� ��Rݯ
7����k�G�4'�ncۊ���@���\3�)������b�S8��Y�2;|a=>����Ņ�P�¥�/E�x�
4,sw$f-,����������{�	����	��8��*�R�@@���Ҳ犰�nV��@������ۅ�egyT=�Y�6]w9�����B>6�n��qԮ���v����Q�fwij��)�G�
8?�
��0�8�l]4���aO&�I�h�֊��xK���2{��=��ă3����<>����4+t3�+��hA�+�ha��]UV�6W��@���vV�}�5Pa����nYȬ��m����a�.��#xkE���ȚK��=x�q]�"���9d�)��tqN ��W	r�`�B~8
�듽Vه}��#�o�c�ui0G��l�
�${�'c�#�<r+�p+���x8z\�X�zx4����Tͮ�_�X�8���p�7((C0���̎��EOgW,�j 8�d�����U��x���Iw9=����=�����ӭ�`rYi��
���eeQ$��Wh��7
^�{!��!�i^����u�[��|�G�)^��|�A�x�ل�Ê
t����
�%5�K�h����}���/SQʂm	6��"�B�ձ[�5?�R�fc�
�G4M�����,��=8���j^/k^h��w����Ո���ɸ�x�����e4�����&
m��6��u�N�ݢ��{�\g���8
�`G��af��j�|j��J4:^((�_����֖�oI�.���J�}〣
S�
K�ɘ2�-]�S�٦�#>�m�j}"��#����Cn=�i^���C�B>/����>0�M�Y��P�^�EB��q�`�#�ϧ���v3�C �Lj�/�#^o|S f>'[,�0�.�U���?]:K�q� *�\�3Q�D�T��F.���x����]q��D�=��JP��
�_W��/$@���9���؛_:�(� �
#���<�x����V�)vRU�?�p����G�� �p?(o��U�����J���l�,�S,%��|�8�@��uN5<�=.sΫ��l�����9�ͪ
��:+ 
�Ԝ���
���aX|��uV�^�"H��U��XLምY�y���h�x"t4\P�mjЉk�u���e�������P��Qqa#m����)�����Ȃh�cz@qD|ٗS<8����J ��B7:�zT��κ��K�w�Tz�7��A�F�i
��E��Ez��ZF��>��(��սzlN&��)�[�1UXG8��ɇ,������1��3S�d.Dx�zU5���z�ۆ��p�z�x��]}��S
�@���@�p/4�/\Z��;=��W���%�=<�d�H�ZqN�Bq�*[�}85�`�){�X{bzo���OU�_(P�-8*f�6����Z^gO 
a�c��v�0�S�y���T�l��^�ɜf�it(]xސ�4�:u�Y<|���I���3�T9�	f���3hIД�t���ހ�qᕣ1N,h"2�A5�
yAlUg�����x2��'c�TR�R �:�
�
�r����<�h��CDŽ��@"��恟�0q{���^�^�8�w�!��a�ߋ���0C}~=�
��	��DМ��?�y����a��	7�{��<� ��f5��-K&�*Q*���Y=��QG��y�r0���²'�OþP���hdy���HTK=,bX��k�c�[�8�!��myR�z���
� ��p��45ay���dz(�SAO�т4-=� O��g��A�c��o��~�%�	���CA;O�}��!�<b�PCv$9�
z��+��~��n�[�<B_�I�Ly8z�Ahf���A_�,h:��~��dy���a��fdlC��7��^��G�=y{SƓ�䘄��<��a�3������p쐐Ǹ'cy����&��0
�^�����X58�^�� �I���^Y����`��Oy@�Pd���1�9�%��\P�q�T������&�c������ow��^\p��Jy=D�R�ШkZ!�g��󷶣���Ŗ,	E"�@,&k�P6�":Zr�HO#?|j6p�.�������  �M
���V����Y����N�O�Fs.ٗ���'
��v�+�ix�i>���/��h9F�.b�i6�@0by��v�<�"9�aܶ��%G�Ѩ�d�Q#����%P��	9�zx�=���+�q=�E������ ��8jY��{|!��q����(X�iѸ/��%ܸV~a{���D�c��'WL�C�lm�˘2��%�n�T��4W.�1�c�8v���Z,w���`L�E��p�����ߠT���>�J$������.�Z.'"�P0��@�hd�	4��l0T�K�R�(�ᐐ	
�G�	LS�>��#����;�󾱶٥�9�հ����O�?���s�p�B<�GC������x*����x)���i�Q	h

W:m��n�/��c���O�[+Ή��`��^
�G�)H$Jn%PJ��z�x�.������z)O��z���	+�
~d�c�h�%Z۹��Ȣ�5Q��z8�7�,�P�)x�j\�k0�q1��+�z�x ��j����7���xK�2*��Qo�	�ď/$B%�X��;\x$3��+�QCxt+�۷�#)]�@*�NDݝ
��8lq�ǘ2�q+�+�T�Å+�9&@'=��O���lZ����hJMŋ�h*�D�T�ݏ�쇺�e�//�ׯA�6Ǣ�HfX/���D*A�E�� x�����D.�Jtt$�bю8�R����bA_0����/L��)^$ƫ���J�zЯ�J
��ڝ%�K�CP�ˊ��#5,���(��T"��z�D9��dSa�Tө8a���K�s�.%��p&���[ڽA �HeS~��&�,��
��U�M�	��.����V¸˱@��Je��@�т���!�l��`�D��m6��v�|L�ao\�3;�88��d��7�2PR~�t*�Ct%�	o*�
f����y\g�e� ޒ�@T�T�s8ʌ=���V9@cu�J�L0	2�PZ�=�VQa{��/1�
����P��p•
f����3lEP) ���T6�TSS�S �cg@�T��s�T"��g�����F `�\Β/���Aw8�W҂z2���D.���T��T:�ǒ�� �.��T"]Hg�]]�J"�
��u�K�_��hO�?��G��b$�e 1��뒕l.�ޠ�Z
����K
�:Kn81Q�#�C��
�B�4v�
Z���e�B6��f��lni6.���P���m�P4
�
Am�>�/�2�-d[+
��KTيط�D��\���Y��p�܊'�ij�MA(��
�l��h�<gm������k�B����G=��;�%ug6�
%�8���C�O֟�f�pW6�b)Cn}�h6Ze����I�����hX�����^quf������l�މM��S��#�x8�o�f�ђǣ����@�_�-D[?n��!O1M��h>�]-<K��R�
*e!O=�1:��8v��+�B��fӉT����l�P��g�E-գ*4�
��������j8Φ��tT�B�z1�+d��d:U���Ϧr��B��?ߙN��ox��3��P��P,�gS&��+D���?�kn��P��7���Q�P��n/����,�?��,�7�H��`�T[I���]�R�����B!�4�FbPɞHL�Ɣr,�uo,�G�K���J�֊�������P�����^-ދ��q�"�v��m�4-����
��B����<������`�l��
XAl����V���e�B��'0�mmm���t!X�f�rW�X�
f�^�b���աA�\�2�t��b�t$���F8Fz�$LE��B!�ۃMٷ��$����xA�W|�V)
a{�R��m��b����b�,�'c�x2�{�*JoO�c
t�$q�6УP:��S6���UȕJ��Y.�3$���p["	<[b�h(_����t�S���\(�@�t.���] {��-vJ�ŋ�z��!�-�~P<�'bA�8‰x��(E�sbx�+��T�%"�����
�VHQ�d,6P��'����h�J� "�5[�b�B�����+J�RO�4��d8����Pk�(���h,p�,#�J����B��X[E��6��Q,�K$��
MOT����R�����x��Jƒp��_e�`��p�!Ћ��� 6(��W*l����V(��@>�bvf�)��=����J��2Ӹ�T.ˆ*!PJ����
�B���`>��t$�d$��
�8���2�L���B)3�
�r�PO{{"����kɒ���3����M�JL�D%!�L!ƴJ"YP�%�dLOƒ�@[)��J�JLh�X�b��(U{�z�~�@��_*T*�<�	�����h0�&��p8���-�ya�
�\!���r��/䊅E	���gK�R��dI��|a|K�_
�RLES�p4V�cS��+�P;$4��J�(����t7y<�\:=֯�������
�|>=\��j����p�������]ˡe���������&�s�?��������\�3�����L
�kݵ֊ŸgAɉ*?3�\�>��Ʊx.�.�j}���y,ٖN��j���8����<����ؠRaI����v�i�����ݵt-ݖ������tw��Z�ϥ��U�U�`t%R��r�i���+��������\&�M�����x�cz��/�Ŏ����1�b�8�l�^϶��z_�S�����`1X����isݹ�֊iw&Wрe��Zx2��:ki
T�u��c�k�S�ȿJ���e�z�Z�Ti�wז�*��m�ZGWo�����L&�g�\*����L��SϤ3���r%���{;;�k�r�2����/
��j�΁����˻��+��[6���"0W�j!]�[']M�����l<�'����{r�̈́��si��u����/��|/k!M?jX�,��K{�z{�Ձ�X~q}�w����T��Y����C��P�-Ֆ�����`[��-����T�/�br�@��đ�<[�6Qem�a�&�V���ۦzі/�z����@o>,�����ٴ����ٴǴʚтl���K��7����:�߁�
����������3�����q���H?<��<�bo�7Uʇzs�}���^���m�m9���X�z'nWm`�TH�e��Jx�t�c~yO�R�Tz�/�U�W @�̜0��_�����m}z�p��T"�b{�Rj /bL�ފ���b������1��'c�qEo^��M��C+�9��N�
��z�NF�]�΁��ީ�.(�N�s`�0Y��Df"WN�r�d!��(�
}��Z�^~zz��o���U뮯(���S {���7�3зf͢��u��|[:��C�J]�\�-��wʥ����bv��N�t=40X*�˅��t[�h��F	.A�TZ;�³Уz�����(���u��&K�}�G�F�}��k{�֬���j��D+��j	�d�Zj+A{�ʃ�<8:�ZQH![֪��3��B!V���F�kG�V��-��7=�i�,	���,�e��m�A�@�싖�a��>��1::��х��&{r���`����
��FJ�jr07�����584ؗC��R����hI�&��}e���G'��L%�U��֬-q,�8�Q��_��]����׮�z;K���P�:�����
��J�����h���8��J�/0X
��)��Xr\;4X
�J�����!���S��c��c��ѩ��`w_�hrtp�`��hW/�9:��f:���B����u�r��L9�h0\.���z���di�ڱ�������E}'���ëA�����e��C��2����u�[%_�-�}�u,��j�\����ֱlYm�=����䳰��ѱ*z�ɵk+%��ۧ(HtU��̄�jw W���ՓƆ�Ɔ-��V��^;6�hj�khll��� ܀�j����Ֆ�v�]᙮jWW[KNT�Ŭ/[�e�k�(�'��]�څО��]��鮍X����S[�ƗaZ�K.�V7��Mm�nd��*�qE��HTO�CCxXg����]���0��}c��jWw78299Y]V�ve���ں���*���Pbx�<��뚪���Pb�����`q��ʮZ�^ZT�On�X�X=y����=�0޿�h�S7������N��w�d�S��Ԙ�^�Զ��q�k�+n�jb��k(<ֵx2��'c�q��x5*�MU'8��N�>{�[��6�zEllx`hp*;5�ڱᩩE�C�c�Vdǻ
ݱZ���ź*�mm��B�<2�Uk�C+we�ՍW�OL�
/^2��sjj|� �����UcSg��������[���6��9�^�S��j�T�*=�33�S�ť���R1'��w���ݸ�^%�r�*
�R���ֵp6�B�P��R)����M�c���U�����S�WM��exGuF����=]��k�����,��^o/�n ;>�j��"������E��H�}�to����T�o˪�����@�5�xj�ҋ��}��:�[�e������Oy8��
�꛰��8<�ªU��]4����7�/���S���P��Ep^����3�Ba�}����⮩�S������T�T����-��ƻ�>�>�>�j]w��:\�l�R�X?}��E��ˎ/,�r4���6NO��-�O��[�[��d3Sb{�R�L���U��͇c=5��?��
��)��Xrܲ|���V�S[�s���8�4�1����U'�NL�/[U��:ujbժ�Q��Յ���DwOGۢ�D�J��[�.]��w�_=2�_(ԷlY�|�*|dr|KϪU˧O��Ɨ�4�j���Ϝ>>q!��[�j_{>�?1P�o��'��Y3��������R.D��U����[����/
7Υh�7��gQ�D�d~/�{iYh�.�.��#5
�e���2�n�uƏ�gr�N0m4�fzw�����z2�L'��Z�+9�L''��'oMޖ�Lʜ�ħ�|��:5����iCڒV�޴���t9=�ޜޚ1d�L*G9CΕSs�\0�es�p�s��v��]��.wC�c����{s�羖�N���Os���G�c�M�3����hh6�o1���`�p�_	��e��I2�M'�N5��?��`��zr���/���ڳ������9�7��ܓ�
�pߓ�%w����
��ܷ��~Qj6�O5��A���D����̥��^.�\x9��_�����Z���ȕG��󓏼���~ۑK�܍��(G�q�-?�y���o8rϑw��������]Kt�<��ЎC��V;��P�P��'&�X�D�=Oԟ�x��D���t�w���:�s�u���x��������z�s'�9�9�:�<3? $h����ͥ7!��~�o���W���%�N�C0�d82W{�����y����;�H�+�*õ�~�%��������	Ri75��t=K��;�t
z����Ч�y�#��>Fw҃�u��Ng��Bߢ��
�&=Dߦ��w�W�������Y:��@�&�M?������Φ��:�Υ��f��.�t��K�b��^O��7Л��fz+���[�r���
�-���K��/I�A2J&z�^�> }P�Q���I/If�"Y�e�C҇��H�n�n�l�]rHN�c���/�W�ҭ�'�OI�I�K����>#}V��t�4+��7���i��O�������$�$K��{$��H���tD�J�t�t��t�Z�~�
�җ�җ%����]RP
I_��*����b�פ�����s���RRJIߐ��)}K�����CRZ�HY)'}OzXzD����t���
RQj�'�)�G�(����8��~LOH�����J�I����,�E���7��RI������O�,�$��F�`0
&��`1X
6��`78N�� �Š<�T1h�T�:��o���!l����!n�mH�RM�4���!m����!o(��6����k�.�<�'}Ez����Jo�t5�Y��HOӗ�Vz�4L�K#�%����^���7IZ�@��'�
�4������K�[Q=^ͧ��P8���T:���ŶR��R��uֻ�{z��
,^22:6>1�t����+gV����5k׽�׮�p�)_w�i�6��glٺ���g�}ι���/�y�%���
o|ӛ����.�u���~�U�q�5��}�u�|��{���������7�D��G>z�-��'n��n���w���g?w���ƾ����_�Ͻ�����t���կ}�~�[���w��������=�cz짏|�g��#c�Y7�dxhp�������zg��Zi/�ڊ�|.�I���x,	��
��ӼUq��ج��h��}2�tSr6�i֔�LMU��ٌ���4l�M�i�+��&7�a�W���m�2r�5rda��&i�Ҟ��$g��$�K'���wNd6$g� �3��G�e�S)LHN�O$g�M��٥�n�=�i��u:�3�[�v��p��Di6�ٱW
K�`L�5�MR�����l(3��s���̮>q��D$��Pi����Ȝ>K��Y�,�и�f�2>k�$���еɽ�v_�_��7�][2[6o\?kܼ�����l�MO�V��w|����F��'�g%��{����[N\lo��
Xs
���v/��ׁ��k���pՆ���U�2�'�S�η53�-��N��3c�����քw�Қ7����=�#�L�^�>�����l�<���k޸/4����ҾW���׭�\򱅭}�$�siz�e%�(�1�<#	L�gp�~[�i���?o�0kv8r֬}|�nu��y��9�b�_���ӯl�<�bɩ!.��,���˳��,���8x
�E���~�~�͙j�G�A��:@�T�|��:��]'�oՓtz�A#�
��M�s`�G
���Y��)I��P`��-��OQ�����Y��?tom�O��L�x�����Ms��^��Z���o�4���7Fs%C�(z!�se�k֔�?��-��6H�h��Kg�MS-���J�/'�o>dzDvt����W����
�\��@ؔ7L�;y�n�+��B�޽4�\�{������N�$���{�ca���M��߼������6�ۥ
H����f�kN�;"]�������Y��
[8�il��,��ߓ�����V�%�F�$�a����=#D�D�I4���%m��6���oh���
�/����DzP܋
����M�}.w����79��	eT5yi���%H�!�h��m��kd?��Z�����V��k�~\A]�&�@������.�mv�{'w���M:I����V�X�%�gx-k�l�k5�
�J�fQO"� �@��9$��P��&�I�x��H�#݂t�NJ�l]�hĤ�GgW)�ԁd�M&�+S�*&�b��n6Y�dr4���=XĸoR`j�W���Ql���F8Z��F*P
R�=��+���
�J���Q�s�"Ld��ؚ��X�?�%�%�ˤH���O�a7�K��>2��A��4k�K�t��/t9�
��jT:y#�]���Ri��n
�D}��?�O���n(1�p���*�S��գ>���[�P��_ �#y�7��$Y�y�>�����~���O�H������ѰճҴʻ�2����?�������Q,�G�یo�䱹/�n���i������<��gw2~O7T�����sȇQOaT �<`<�:��$������Q�q?��dIG�np����~�6�"?�6^A:�;�ok���&���W�~��p�Ov��ڍg	1>�?/����|�F��먆d�ϟD�I�����g�ʳ������y�y��<�%�����0�ƃ��f�MX�
P�Q����j|(���Ih�l��͘����İ��_��'t�
�?�7����Gٳ/�	?j�] ݛ[���710�2�MP�
A��/�
�7�]Ln�syꗃ��P��z�G��E2a�:�a��d�����J]��x������J<`��ѧ��zZ�l�`R�x��\�����m�4:'�g����`\�ؒ�'6�.O\���^�ϸJ�bU#�i57��(,m�[r5���aL&��r����+i,���	��8m�x�}}`M�I�`F}���o1�ʼn�	��Y$x\��:x\�#�E1�⸽�D2����T���� ]��%�#HfѺ	ɀ�v��ɀ;PW
G�6!�B���sHVz�X�>��
�B�E:�d�ځG;���$�d#J��G���r�r����M��/W/��Fzr����T
�6�w�wٍ5��}�ݨړv��恆u�و�2�����f^�1z��X�X
�����,���T�T�ԑ��~v�����gg�:|��CƇ+�+�V�#3��z�i������)!uHK�$�i����7���Ȃi�s�s��Xs�8W;��3�4�q��up>�4�ZX��B�ڲɲò˲�r�Œ�vX�XG,��F�
A�[g��p�(����#��G�7
���բ�
�q	)��Ǹ]�{�x�3�5�#e�����{����Dӵ�H֠f�Ye���#�#Y�l�@�p`t����1`����1�|L���E	)l"���~"����jm�w���jQ�ָd�I#ӧ�Š�
ތt�H�K�.��0|p�pӾB;��F:Y���[YTd�B��i���&,y��	�p-���k��<���P+�:<�+ʨ�Hw!���E�p�(�%�(�Y�#���y��Rp~��p�()�7��M#N�������o��q�7����FQE���58�F�^���s�,�{|��ʈ3#�##=#ߖ�G��E�s�V��G�Y�7Y�Y�Y��Y�>�IJ�#5N˿L�?K�_H�w����ƴ|bZ^�楊�$�c(�*`t$�������������?��7$�$�K�Þ�҇���=_��r�[���$��P�~�� �B���(
'��"3�39d���(�Hcf
�pc�"dZc�ĨݠH{�$ni��sW�t�����(����(-J�^n�2�^ll�!{��-�쯍m������ҟh�
�Hll�(��~GE^V�5�
w"�ߘY��_h�.}�����b,��4J@N��Q*"��Q�"�T+�D��@��ƶ*��6�݀�#�mO!��Q<�׻��b�R^�;3t_ؘ�v4f:�]И�AvNc�!dg5���gJ{%H���J�͍m%t�6w��QQto�����d)/2*K�s�����Ƥ�b��F��aÍR�P�r��med��"h,�5��z�6hc��/e�/�i��ĠDc[�xc�$��R�ܮ^Hy%�6J��%'m+:(/�tw�%����~�F⅑�6���[�݉�gNO�~f?<���p��;qC
�8�L<Qz*qp[:��F�D�*U_Ϳ1��x_b�L<���n;=q�6�����H�^�o�0��m+,���gރ�W�X��o�_���p��;;K�Ď⩉���Q qViMb;r&�l�vfbs�Ħ�񩥇k{����-S��$�t,�`�rY��j�}L#x*��J���~���频��
�e�ӭ�c�7kΚ�ƭ>�צ���{�į�3�6�����yd�̟}�3���I�UCC�ˤA��КՌӆ�c�}����������m�)��Jһ6HӳΠ�ӓ�]��/9�
6gƤY�4M�b��<'׭�/5y�U��tIR�U�p���wn�@�K��x�=��N�
�4''�GC�\~E-6����g�m��s��0=�Ɵ��1�k8{r��9�mX���p��n��Ol���b
��0���i���}�1ä�h��;<�t����Ҝ ��4~� �Ҹ4n�V�hk����#�a��\*�
K�sŰ ۛ�c�my���ǀ����>�hw����V�g�{�$��ɷ�-R^�71��1l�?�$�������pSfr+Ҧ�k/���uz2���K�'�7�~�v�7o��4�ub���Dr���W�^��C����~r����G�N4�F�&3�'6�[uE�����{�_�*�]����^�.|���{�u!�u!�jd��kz͘4�z�^�m�����ܖM�Ԇ1��cX\�ũ�e�{M�ׯ��
���ج��]���(w�Js��?
�u/[���+�>ץ�ٓ����gM��N��/�
4޹s�J�:..O�~���E�H�9��s��%GC��K;������LϚ�����~wy�N*�[�˄=qj������������_f��������w��x�q��G���<2sc=r��!��#�#c���	���w^��eI�V��
�(��ɰSt\,��jS�X��0�|����y���j�yT����_|ɫ��\+�t�]�0�)j|/E��?Gz
�7/�h��|e^>�yĨA]g[i.��J8z���ӗ�u����R�֓I
R�}M�|
2ü�5N�jҡ�)�tu�拉t��	�a����H�w�-Ҳ�o�
��t݉ٷK#T���T�0�H��_�D��t�䆱Z)9�L�V�IWӽ�cj���A�-Xe5���_���}�d�f������{FUe����7ozy�{��$�d&=�$d$
��Re�HQ �����R��'H���ZQp��OYWD�5�~�2���&Aܯ��������=��{ߛ����<F^"�a5��=�I5�J��P�-��A���U�z��� ����-���|GD�zf�x�I%~���~rP�5=���7��\!�8�����a'��ي��%W�[Q����4���г���U��Z�����J���
�˸kr���#�$NZ�N��J6JJ���( m����3���˝���$��,�
a�B�t_�}[�>���FK�&�BD��}�.��`���;)+�}�S��*�L��2�4��]�>��5��O�n���F�7Ifb/��m� �xP�,��J�Ş���s�!:������칡�.@Yɐ�x�lr;YA�;'���+�xeF�]�"�ǹ��D�A�({P����<o���˝B��v�H;~2dY�����U�	p��l���&��	���l���:��o�{�u�;����z���\1��=��d���)�t{s������{*{��<��iO��J|�4�t�!K�������^����/��4�
yp�(MNĈ�OǠ{7��bX��Vx
>�ӱ�������:�N����<��B\�zn�G��
|~����?�O+"�c���,Gr�r��FY���Q����!��i�?��
K�s;��N��&/�7�1��q�)9)��>l�@�&9��O����^��iFi�ӑ��ύ���F�<��ǐ�Ҹ;����O����t�h$��f�3�^Io�wн�y���~J�J�������]ŭ��r����܇����l�l��u�{���|?�������?¿ş�{����g�_+Ԋ�HK�(�R��8��Q�P���������eI�zh��2]ȽM�g.&��"�0��r/�GnZ���{�.#D�"}���1�"9ƿ/��_�ש�|���~n
}Sm�p
��chun@<���
��`�A3��'�/��=��8�i:�~���0uΐ��V����L�Z�n�G~!��A��Q�n%'ȷ�ԯ�ʒ�hZ��ȡ�0��uZ��w���a���e�$�N�@�U���dn�Z��J�Wd��[�0jЏ� WE&�N!ϓ�o�Z����p��Gv�%�=�Yc���V1;�';QЊH�w�����?!��:r�����.�=�2?�����]oF��*l�2���9�ۊ-�&u���҂�&=� ����={6���8y������ˁT|�W�:�̽�����pٓ�F�_q@*P�:�E�z�i~/�2����\�Z�r����DZ�����>����?��1���ճ�<�i��6���������2r'��6�!�@���e�1j���J���JF#ׯ%��:�{��4R@��N����B�����=�8�$g�r�Hx�@��c����.�j�H�H�~�BO��#_�0z�
��[��(z�%)���$7�����^zC=J�e���Aba�~t+� չA��3h�F������3X�U6��x���]��glV�\����	�'��9�
!J��.���%D7���"�����K1"�B�y!�{	�N#Ďх�u6��v<>!��;B
F"&�w!����J	�}��R8����	��AH)╼���T\AHe!Ոg�`B��zl���I�KH�?Ҍx��L��!���
YN�0\?J��b<oJ��݄\2
��%x�h<>�a���a?.��Ǥ��<��6&�e��2B��I�t�n&�}�s5�ϳ2�]��/��ao�v��7a[��o�K�r��V~FȚa��݋�_��9���
��w��w�$�n��n�������uH�ux�u��z̴�#�#���>��F�=H�{�f� �ُ�8�[��
�p��h2�?�MD؁�WB��#�@@<�@8K�F�ތt|�G����h��Ǜy�-�ꋀ�َ�|��i������9��B�N��.��n�v�s��Ez�;B�~��9B��!��6B^�I�a���#� ?� �^����2���u!o _ߔ# ���>��2���1����傰��������<A��H����~X���|������iB>���x�g(K��es$	9e"��H�/�~��ӈ�i<�4��K5��ȧ/��g�uH�3ȷ���_��|������|���i�
��ߐ�G]�;�÷x�oQF:���!ͿG��G������?�����x�?��.l�Gl�싄������3�ҿ��P.��F=���Hlt����,�g��l&�����(.C���J�F���^$��K@;�A��y0vխD�O��" 0����؎Q�Є��-&9^c�
�7kpߌ�0?���,x��a6��>!`�vlW d~ `G���pb�\����#P���!����b߂���D�l#�mF�1�?��c�f(�{�%P��c?�O�#��q�E��ޫ�T�@@ڕ`[%O#`J~!PE�
�S��$��	
qO ��G�
��"��s�c�"���#PV��aҠ�-���/E��W �*�!��G׊�*U��Z�>��JaSx�z�c=���S����g
����.���M5�]qH#�"�'^��<쏴������
�O�ՊxD��G�{D><A`�:��4�tt
�8x��`�q����!�9mH�6��l�m5C�ۑ��H�(g��ߣPnF!��P&.�㗠\]�m_��^jC@����q4�4���5v�g����ˑw��~\�<��29y4q
����2(;W�&a&!~����.��ޓ������xl
��)x��~
�c���ӕ���Ex�+�%0
����MCY��r3�3ei:��t������؇�(G���s�.sq��������k���B�f1��d0��'7���"Oo�"�y�Ԃ��y�
�x��m��ۆX��i�yz;���x�ۑO����
����+PgW!W#�k��5(�k�^k��k�>k�Ok�?w�}�Dy��_�����˽���x��x�ވ�݈:�i+�ͨ�=L�l�w([��[��[����c��ch�C�{�x���i��
�
y��w�.?��?�x<�m��<��j'�h'�a��(G{�f��{�G��"
������{
����%��K�ߗІ��:�2��a���اߣN��<���������xy���1�>��~i��~ie�=����PO��������u��(/��}Oṧ�O���~�|�i�W��_��_�����%���_�����iډ������ԭ ~�@��'�q��G��G���Q�~D��	��e�~��@7�X�홏YB=�lB�B����> ����͠W�
{)�*Wd9�h&��U���W�8�r�Uʽ��
�1��6v7�ۻI���(/c�d�|�GF�����E��#~�a6�ygϗ��Uf근Dw�i���z��
H�s�.c�]��`K
-��]ZK���N_9 
��6h
.���JZ��j�`U��A��~|�G�2흙�S*���Å��-g2$��}&]^[���@(�E��j*+lV�B!��Z
�cpu�"V��8d�jO�yҤ��IW���rtt��چ��da�I-�7������C�3-f)�D7U�,UT�����e:�݈�Y���>KD�Ţ�y�G���r�W�e s�~E�p6�ލt:;��M�D?��+��ɔϴ��7p��VLw�o4�E߃ۆ���^^]zE�6X:��~�塙��=�����lF���5n�] ��,��8OTr����ƭVZ�N!�z�`���F�]�Ylv=�::jŞP�ǭ�,^���8tr�ϭ��nw��0�V���]o���F������yy���F���\�ө�*��d{+�%m��lN��EEp;v;Q[-�Q
�*���'T���"��A?ZI;�+u;�zл�n�J��$&���Sq�筑�Gz�NK$���D�������$3��?�}�鋖���*>�Y8�*�`��?�1c7��+%���֐!s�3́	cV?����.�1��ݹ���_Ƭ�����}�+ ��ύ`�,wrEn�ȍ��Fmѳ�{�� Q� �0Z�@S�w�F��Z����nU)XTnk��f9��VY�֪R�V�\�*k�Jeq�"�@@�e�.�^t�Te����˘�H6��0�ƽ��Ժ���%1ظ�����n����)#x`�^�{Ϟ�]���R��PF�HE��=x�"K�)zُ�$��՘>F�^�J�Fa�$������DQp��e����n�����8�!�d����N��.�+�-���Bg�4.�~�)�l�f����#F�=�J���{�Y^F2`c*��Pu43VP�1�Ա���j�Cx͌\!����kj���1Z���q'���uv�e��S���o�}�٘w�X>���������KƎ9��׼�}�]�?���������<wu��۰��e�;�Im&�����l�<X=4qŨ�{-S��s1����=�+�5�
�_A�`�Wɫ�g{~���V){�I\�z��+]��rZ-<��\�_�z�(bG�l���J˾Rᆜʴ΀��줜�=�Yθ�4�8�*��J445�$Ju����[��f���7���h�O�*��Y�΁��Nԝ��u��W<\eY��Ov�Ë�*`�H�c'�T��	|t�z�J��-��N��9d��	�%�@g�F�{����n�E ��vug\��p�PЕ��t
��э�VW�3�K~3��
A�"�a*��e�V�ʊښZd5�>
�ﳧ����հ���΋�ɿz����/�ۦw:�j������5����ʊ�y��;�x���,����˸鬴ڭS��ٵ�����2����O�}��˶�ɪu������/����5;�V94ݳ��쉳�Ƕ<�V��v�歃+�Z������WY5��_��|�K�G�@�x�&��[�5om��r�BQ����Z�����������ɧ�4�i��K&�e�6�P�,M&�$��$��E��r����X,��\�m�6�Ydq���թ,mM^Yh =eG�cݎ����u�v�*��l��;�D���)zJ�G:r�W���B�cҘ�QE�����I6�F4p�h��_D�����݆
�
t@����3���lg�+ә�Z��LwW��~����Ì����o����e�����LV=U�lG�G���쯍^p�r<E��IBAf ����k�\�ݰe�ȥg���!�E�d]>���7�\��?s�>�y׶�t|r_}]n���
�T�ٿwd y���褺p�:}��a��c-��/��~6��M�[>�늎ǚ_?�mQq���������!������Ѻ�+�~b3?��=RL�C�2���O�J�"�]�j!�X�L"!~���fYF7
j�c3�j�?vbM���Kr3�خ��W�h�l#�_��nS�p�p�#:�N��s�,�=ɡ�? �D
�1�y��"�0ͻhd�d�3`�~"ӈ��n��@�3�[�ec�Ve��{��s-�'ܵ3�Z��\v���Q�Oh
��q/�v�����W�كt�j;}J%C�̈�ʂ�ߋ�q�
�
�jue�K�Xu��D�"���5L�E���1�3˛cy�`D��܌Dk�	w�z(�Ar9]����slp�,�ӹ����Q�v�48��f0g��N��?�D�����4�Bθ�T	�R��xB
�,�y=�mOl'Gnm��4B���̈;u�*u�����)�Olb}��[�"����n"귓��#�G"xlI�j}"Y �jE�{�j_�
�O��#�aq�p�չ �����X\N�;��L���/�FG�T��BWg��B_$[$���+j�~��6��]n���E��)zխ��Ƃ�^��+�6�������&#_W�Lח4i�T:<���E.s}Q�U�4�6�n@IQC�
��9g�-5��4����N�7�J�_U��_�=X�\_���<�t��
�.o��������.V�n�0BbK�댌{�d���DC��aj,�v�;e;��`٫�����
N��~��I�<�W�=��^r��vd��Pu7�ΐdW����Ly�9`�4�
c�(��o��s��s>�5������p�a2 �	^B��I�h��$��LmZ�l��������w1q�tu35�BE��&ʽ��"#f,��~hX�7��6h̒��m*�x�R�J�0Nl0m��u�1*`��6��q�Z�)!.�2v���i�I���@�:@o�>H����	=_��P��%mr
�r?�_U��*�6ϟ�(�0����8ejk�)P%�Z[�J3�z>�i)N�����|�B8��v2�v�ً��,)cMcx�kX�QM皗�+��kYV5��}�U�H��N�[�GTEv��m�[#�"�B	���,�w�����u&{�S�"��UD�'pQY���~U"I�0J��A_�ٙ�u:Љfk��Y�b_D.����q�=(�cUA�H�5d��B�\���F{'�~gǐO���8x���K�z^5��{U�k�A�
���/@�����p(�r��\��"er��
T�t�n'�hN^/�Sy�18�D���S���E@�
!ml*q�p+�%EXl�����t�E��������&�ռ����շ���/���1Sׯ$o�<�p�;e͹c2u�YwF\C]��Y,����u��Q�2-�����MO<����0��r�#�|���SS���c��
�+��vr��D�
�D	��')�)(��IG�/"6؆��OĊGl��z���J�����������y��N@5s:�/SB��5�v���WO�R@��-"�BӦԏ���G�=�(xF(TZ�-�T����}�6���];�e*�W������s���Z�\J_�"��OK:�=z{�!_����9�,�ŴpT�Qk��n��^�y(��(1뚼ߔ��S{����d��ab����yТBv�n�<�O��7x�x\�W0{wz�8XO$-�t��h�B�O��N6�K4+E�.��z\8
�Х$�C"4O�W<C�S<IZ�i��cLK�6J)�I2Ɣ)��›�h�L PMLx1ZI�"9��W*����
�Yv��ё���zz��g!ru��`�� �~��u����l[��`n�)������[�t���Oa�f�o�����=d~���i��YS�I{�E�1�1��G�H@�_����1��b"�����j�$=K��/�y��X�Լ����D��y2�18`|�	E����vW��
�y(p�\Dst�g;�Jta���mL%���F�H�]��8z�4���N)�CrAu��ZR�K���$�c�,$�o�p�������u`���ݘ{'�{vDj@<�^=d�a�#H]�x���uO�x�ڡwT�����G��t��^��u�|���D������M�#��J�ȨB��:-�)�ϢI5d���B�с���1�USA�*�WjuD)(��N�
+`��H��2j��dT�2F"���-�iV�[m�4.�Q�����)�*��S�<m�Pi����o�Ԣӥ˗�tS�3g�k���u~���	(;N�(!�����HF�	�Tj���3�Emu[=\��M~��4<��j��+��+����b/�h���
���FY�~��Ͻ�Q<1��̕�͢�`�����VG��=𞒼@�$H����#�[����[� �A��Ӡ��i�Nt�]�����t��|��Q�8��c�1]�4.�!)��ϐ�*��WI�5��ֻ-Z�����H,�F��� k4�
b���&n||��%�0f`A�\@!�b@Y�O*m��2*���8��o�0�Ц�s����7���FN�W�]rmnK��]���V���՛�����.>��R,h��l�I6~��d�c��*3l�lTͪ'V�<����u+�V�A��ǫ�֗�[O<@Q��}Ѩ@x:���.xR����W�#K�ܗ/e3��X#,��>F��J1��a��Ob*zZ��|���8Ꭸ����uS�)��F���P`tM%~n�4ѩ�6�����ϱƋ��F2�K0eŒ�BT��%TyS05�(0����魡o�
ߞ�ֵ7��S�/���:(Mn���3=�{�o*PY����SKր�Ӱ��kŵ�\Ud�V��j�Ն�
j�!*'O�JTm�'�
�©�T0�5��+�*P�Asp�J���<K��*�v=�5g5?�{��<�a4c.��F^p)�1�d�2���)/N�$��ny@��+B����}����ht*W�Kyd���¶_6���`�I���"��`�����F��ܪ��!��@�}L�b��t�s���Ӻ��Y�~��y9{d^��8���<��FD[U�V2{2�E�	\=/�I���w��8I�*-w�vd�J����	��t�p�h
�Hy�X��I���anXu<�\�BWnЅ�B&��6��:w�/wg9"z�e�'En$���8WU>�<i(+U��bv�~&'L`U�J&�,��3�����;.a�G:_@e5�U��/�tДR��Uz��Q� ����m�F��{���\R]E����o�����.���#�u�	�i�bV�Og�O�M��Y�����k���r��W�>~`����7
Y�Z=ep�#�7<��ʶ+n���9�Z�F����BrXt�9W�qU;TY�ZY����x���$MW��=�ad�������N��&��8tR�0���肒��� (����
WTe
DtQc���.N������@pN��
��Z�Tp�pV�.��b�萱�+��+E1z��*��$���S����V��Ɩm~g޻�p�;��P�.v$���؀x[������~�g�_��W�r��������?z�#c�l������K�}_�y�fkvRq�8Y��d�����ͤ1pm��W�`u:.|uu�Us0�(3_�ˍ��)SZzs:�Ȕ|N7�{���%s��Y���?H"x?��_z0[Cè��+hs��2�04�r_������_qsngx���ub(%��|�K��A��_�b�:yJK�ɗ�{z����x�/��DH9(�Fv���b����cyN��i �e��q�%���r2L\�r�{�8���
?��9+��QwE9�]J)P������R�|)
�����μUT&R�sa��8�`�]s�EY��=\�Axy��6�hnS�Wds���x�Q-S^�z.��`���\b.�i�f'a�<:,F=�`��y2K���ͣB��s�p���a�o(t���ǡ7�?裐��҇��>j��Jn�� 
$jT�*j����:��,	W]��ieFJU�Zνȵ��#�#�|I��0.GZ���%w?�Y.�n��nЁ�9l���!�IBв�H��K��"�HT�R��G�FeѕD.ȩ�}��y�޴��W���̘��>b0Yc��do)N
�X]�+�эֆ��Ϥ3�Ʊ�?�������k��r�Śx��:gf��x��抺a�y{��Ҧ�+�hF�C�����1+n��B���|����v�}�cS\uOa��W %&�*Z��dlx�E�
���gJ_(U��l��\��;��!��%n�YesY)K��KA#s8ce�-��g$��D������,*<�Z�[��h�����ޚ�G��#�^��C�#�+E�l���Db�������;]�*���yȊ�nSj���c�]��B�
�4���ΰAcf�R��Ǝ�$��_
�]i
�h&ý����*A�(Y�T��4_:�mP��6N�P�X߯��^&/��"B$�DZ�Cn!�j���D �b�K`�">K���Yz\N��d�D/х���[`h]{��Q*^"��t�ݕ_�z\�mT�\�B��d������ۘan��c���Z�PF����J�VF�T�$�"�G�T���Ja9+�*��2A�Eeu�%�����=���ln�pF�^���>W�;��5����g�}O���W�t\�H7V���}�5um�뢑�Ԍ���\8�e�Qw�9�ʟ|bO���*7�|n{n$���$�:�n9��_���>�{����5c�V
X;����K���]�Z��=%e�ء/&���̣�]�H�����Ɣ�!,�V	+CO��u{t�!J��P@��x����k�`�D�^��h���K���ڐA��H@�@�Jُ��
h���~��.҃^��
�`��B
�}�=d�Qf
N�`���g�UJ�
l�`���e��h!�DODOE�f/��H<�>�+�Xw
�!�%�q�Mfp�zS7�BΌ)���7�4��
72G�̒J9��	���2s�BhlT46��tq�m��@7Y�I�-��JvR�`�\ �I�g���]�
_�ᛁ������~��zf�u�-O�e$���!Y���+��M(0�U�	��J��đWz�2����h�v0Mw/��ʞt<Sr��P�1���%ՅP���=��wO�+���z�%g
��-�9��t�2��1�߫

~�%*�pa���HA؃��œ�DT�pŠJP�P*UJ��������U.7�|1+5��Y��	�'
O7��Y��q�IBH�D�7�����]l�Q�d�M��w����ʅ<�FhV�"^���	F�y�$���d��"���#�!<*勓22��>����|���'Ӓ�oJi�$^�
�/YY�'t�,X��������
��&�+��Q�Ѩ����ǭ����7nȝ�qE��ݒ�k�92�����^5x��{��f���6�����l�vC$T7��?7�\�-3u�I\8aµ���p����vЪK'mhd5�Q=�ch4��{��z��Q��<��Z޻��Z�Z��]cnw����Z�^�Q�1�1�`������|�n��u��n�=m���g�m�}�{���u2:ӷX�H�Ƚ�|Ƞ��Ma/�@�Ԁ���SF��������*��4��5?
QSd�A���p��D�A�SSu�����'��9~��9�a�+��R�o�P�бV�z�
�W(��a�G��"c�*����Q�M!r.4}��\|��,f��L�tH�6'(��&i��ʒ����r;ď���������>���E~�����ކ�G�=:��O*�9����{m8�?���k�[<�9�=7����V���;$���F��Z�����q���<�qUdsQ����8w67ڶ��W�~/	�~�>�$z�v���T�1x}^�mR�)`$��7��ۗ�;�
5�3�
R�m'�Rf�,5HR$��h{FUl�s|�Ju��y�^�;$\&��L共�Xq����G�6+�R�U&G�B4�lr�"f��E��#�`�"uʏ`H��v+Yž�WY���Y*���)9��wn�Q�p�6�
*[s��N����^�x�+k��>A0�+�w�%�g�D��Y�M3�b�
�r������$�V�s�ˢjÂ����KJ|R�Ld� ?�a��i�9U�_YV9�r}��G���g�?�U7�ZoJ����k������;�j���j+GV���jN����@w��a�V�s��^D1J�}[�U��^G0U^�y�7.�6��ޢ`�D���`�V[�b�qv�ݶǔp�AB�uQ�R�0(F(h�;�Q�
l�EQQ�3�J�&�����������u�G����m�m�����Js��C�~gE�xH�ѫ\�62б Ɋ���[��l�Kd�Z�["t���v9��ui�i�GC+��
�Ge�.��k��Y���	�m�hT�>c���~��_VD�����!��kx�;:�T6/�5�n�,�����_xen��
����Q�>���4�B��ͻoi
{cb���[
�]!S�K��f����r5*���:��jGp�#43ԋ�+��%E��d�ԯ�^S���Q��Ϫ�zɽy�^k0UR�����7jP��1Y�UT�Q��-�*
��p0�T(�T;BGG@��D\�0�&�3�}z�o��mBSA��Yj���i!ju��E�M�R	S��4�"`8I���M�be<Ɵ�.iZ^c��G���U�|��3��^^����5�uf�,�x�t𢡴ڋ5��]��	FhC!�SsbvT��<��bʮ/�_{M��Ȩ�k�^�=��7�0u����ݸf�ۀ<���<�_M*�jѦ�0�]�[�[^��hu�:�뫴�滊��jƍ����Ś���˲��@�@�@��%4�H,^U�����P���	��"o)����9�
ox�v)��#������U^侂dB�S�>�����qNWTalo��&(pU��UZ���T謪~.E^ͅS�Iv,z1�|*�������g�{���'U��ͧ�|��jf�[�!���
$$F#��hC���
��y1�c�1�u��H�whn{s�|u:$��������>���a+�/b5���j���h��+"͹�G7�u��w�*����Z��
mT�r_m�}ϫ�
]��Q%0y�,��G�=�{��Ws���Z�52��������7�zf��g��ʡE)�`|*���6CZ451�Hѫl���謯���Cplqp̪f�V����`�T����E<�P��Y�
�{���AkAq���آ���U�BF?c{Q_ERE���E\�4�#^��{S�P0P�L��Y9�������TJ�T(Cd�0�h�0T�OB�{3i��J�֑�[Zw��Z����&#�G
 ���oQ��^��3g�v��3�M)��ݍ�l�{�mJ�X`��7����1�ߎ�����5���m4�[K��-i���n�o�;s�]��۹���׽��݆�$��w�d�X`P��4t���`���bT��{����H)(]�I�Mi��c`(}J
ejQ=_}X-���v��K��[u*���, &�v�\�;:.�>�Gﴔ�zk��  #��"�-�?P@�3����9ׅ=-&cEu��Q�^�~ :BV��
TTQ"4Ҥ~T�,L�S�Ey�{L#��J�E8ۙJ
h���3��l	�є_\��m��	��J�N�f��w>����~�*d��h�x����!�=����f���)�U=��2{J2�Y��V>��S�~=����1�?,����i���6h���-"��fج��//i��
���'�-���D4�.M^�0�J(����`04$�R�W�R�`���N�6�yk倱�	�Đ��C��IV{k^OB2�H,�
{7�dP��Y�ziб���h�Hb\���'\ش��D#�fUȕr������+����R��~/��$��������J�>��M7�
�q��D<��c�V��Z�
|Q��w'#(��R+X�|K1+��AuU�$���+��y�΍�?Oo�n�nj�M̽Y�h�}�E�D+
�~�����A���Z�������l�aUq���U�&�}�yUnl]�i84�E�P&����P&"d�X3Í��1������0��r�����	�����->�����R�yPRe��T����W�wF�bblK�ce��޸����$6��ؕid�FF�xo�����.����t��]D��$�v���;�^?+	's��A˷�L�Uön��4�L�@
��ʘ�T7в�֚�uO�7���b�سػ����n�������W;�����|f�E�`2�
&U��b㘨�F��T��3H���A��V������z���Mjj)�X��5^���F��x=&����:��W����/�q�I񍧠j~�1��TV[U]��0�`��w�S	z8q"A�ں,\�'��U��'
$�Z_ga)2H��8$�kIo�F�*�Q-�LA�F߻�I�X�N:P�w�!�~�^���\�e�̧�y{���v�ώ�x��L�L_:�PC��8-�w�[��
����.�j���c�[��+ґ����˹	WU�"�z{>�7 �б�dB���n]����ڔ����k�ճ���Ž ��*�,�
�|b�<v0x�M���;H�=��`O
j�)
*`UQLҁ��h�c���a��{�����Т#â	Y��o�$�/��̓i@Zv�Q�}V)_%4�|t�p�IҳK����A0Ԓ�������{�z�z���^�7���e�bYL4��B�����j\m����gS�� ��-�]�.��0������m�����{���H�ޜ&ٞz���!���<ן�������3`����=q`521�Ksvl*t5��#��8<�!<?gN�?�?���;�Z����&4b�
�Y���d������5Aa/�F����!:Rψ�3����L9?v}�����I�p(
�ԡ��잘3�,�.u
+����ڛ�.*������4�ݰ��-L�A�I�I��v�n;ݮ}�]���#�H��2�R����`�v�]g�f8gx��k9y7�;�{?r��Ԍ��	g�V�L�o�8I0)��-����p��?��~��g�&�SX������L�1L�Ug��W���b�I#o�UE����pQ�Ag� ���*q�.�-�V
����j[��d����sax>�
P�Y�u�RnJ�ٞ.QcJQ�)�E�ٞ�wS�~�+���R*�{^��0l3�B�E˜�)h�����Xf1L��rvh�6���/w������ДKFo��u��i񓴹��?�rGs�>
:H�}�^~8w2�m��
��c����WE�lj����ďگM���OԤFDa�����_AY��C@��G0�Y�<�1Sr'L$����&�
���g�mKm��8��d��|�P�#ZAKGj'k���H�7�
fn��V��H!m��ӗ$H%�_��r؝v*YI�p������7�Ho����յ��!P��;�1D�ܭ/�G@8�u����%˗�Ng�V�����/1����{6n��Qpd�n��a6�7�V�f�s�窈̤1��m�6�*��5���UVu4�g��l�m6�6Y�;��o��exˬ�1�/��pPлz��si܈J����Tj�V�k�ڤ����VV�������m���"w�78^��ԪQ��Հ��c�a0Vi
q�^Z���#���^m�X��'RR��B�^�\^�ga�h���H��&�3Vxu`:��#!6��nq.�Bi�]g�*̇:�Z�3g�Z��}�7SL�e�xV(o<ˊ�S2иf�:�)j�6@EuF"Q�-��;�5.�&�
Z}$�G�+��e�G l�a�������t�m���EA'SVj���51�K�Э���A�G	\����˽�8roa�Ňr�9�{6B=���ܑ�ܽS/�q̆��ol��]�R�/�W,
9��}��s��~�-���}�ۺ�k��Px/��	��'�d����bz�k�k��S����A�A�)�+�
�\���,y�{�{qpu���Љ�r��׿��\|R����JZ+m0��
1Ŕ�+ɤ����P(xk�d&)��K���]AN��r'��{��h$���_E{ӧpiŒj��c b����xQ�%�B1-�̞�hӆ#f�Z
�v$���~��e�����U���HY��$ogwc�YǂL�
i�2��K��C��PH����qF#%��$�\���J�P�&�����X�>䧢���h����6�q���ѐw�l����<z��+z=�3�����G��^+�����W��EwQMntn���kG����[�[{�r���6�r��m>.�����M�ϱ������,2�ݲ�����˒�R1�(�ڴ8����2(��2��/5ą"��2��K��k�W�)�ܳ��T�����ʕ9�ܡ&�&����䍯��<U�q������/��5�`q	.�z�Z7(�����x�E�EE�i�i���"�F�˹P�U5�~f����a�,���j@��j0(}��ࡽ��>��{���Nf�J�v���S�I�Y1�Mi�*c��f�,K?��4R����2,��`XY�"���Y���4ot�����̖����c�vi|S&=t��B�ʾ���X�si��B������^1��w�^��阸`L��Uo�DJ��3E����ݾ
M�UnW����k|��5�JC�D��f�\�􏮰������X2�l¨��/�ݤ�O���~��CP����~��AD{�pU��lLU���*w8(+�
V(�#~���^�Kv��x}
W!�S��$��d,(��|ٶ�)8���X��~�~�H߭��>��}n�dÅ�l�M@`�go!���o��o��)�ﭤ��J��ք��6���4��\_�]��,M]�4����u^�t�o�&%2[��a�HY�)~+R$
�����R�:,��Kwhg�POH%�˜@�7��[m����(����B=�ꅠ?
�&G?��v�~=�T*X!.����	/	���S��ئvvX�Y��VL������2�ld���-e|��=�JMEE#����d_�3�D��t䳓μ���`�PePG�}DQ&I�P0Z	�b�$1q�H,y�^�Ա�3K�ib��E���2�$��(�/�F48ko�<�������Гfԥ���5���]�~X$P��{��Eï|�cZt�p���D�iw���N�o<E7^�
���x�vK٠� 	�Tֻ�U'BP)�`�B�쐲ϲ?e��e6���p:٫��ĉ�ݪ��J�WpbB(f{�k�
�_���T�(��Jڭ�\^hw�ӪT�eZމ!�U��NK0�T�P��U��v9	b�e�ɯ��d-h���Ձu�����]���n����$��*��eO�"�<K��Ҽ�o���f���� oy8�Jc�-��1�Lœ>�H3��T��ϵ��D�����w�/�4W�%/K��km��v!

Ж���� d�����.Yͫ-�H�f���tg��k��
Z����z>W�*s9��{֩~.�m�YΧY��o��)RP��I�Ԑ�*FV����B�d#��+�V���R��Ru�W|A�Iz*�kU�:�P���B���"���Y���L�6���d
����K	��N��N���Rj���K�;?�d7y��B��	j���|.�M��e�rQV$#�l��=�3��YE�����<�ҢBKQQ��h
�hJv��aW�UJu�É�N�BQXT�'۵�L(t9ُ�:�Q���
�o�j1�Ԕ�}�!q�Z�PU2�鯆����F"��K��sx�`�؜z՞��G����애��>!Z����o����D]$[q",��C�.��1��MY��2�^�+��tU��^�c�'�� :���wA��9�љI�a�����M%Պ�Uy*76�ە�;��R#�a�����.Q�?M�i-�:J�sH��RɅ#�u��f�Pv���y�7vϥt����Z��u�B['�%�$�z�kQR�p����M7Xh+�[��'/�-�W��������K�����%�J���h,�2���!��̗��%����ח���@���z�W�,py��cKzc�t�7Ń��8���c�PW^�+�����QgZ
�-吼S�&���dž˓�AJ��V������z��_�XF���Ѹhp:�T],J�9��g��^I*^�ƹ�*�,������ʋ�4+Az����M���,�������~s��%D��2>�iH�E�ޜ�ɑ�5���NٓJ�\�X�k���
���.��hs����*�)�(3��{Έ�B_���LY�ڿ����׃.��h��*A�'�;������6.r�����m@	��]&}�%龶�[��#�P�^�n�<�H$�	3{��U5�E�q�,�?i��0̄.?H�=_��!V]ۡK�"%�Gq8�-������n��糎��ltW�*��WL--
�SFda>��DKkH
TȔ�p�1?�I~�����^���^�t�B�<��#�Bi��[�")�;,�H��F"�r�"���<v�NJK�^��eQ�иf���؛�IQ�����VW��U}�]}���=�=�L��0��)�`8DQ��Q��bT�
xu
�1�ǀ�'��11+�]��,�Y"I�M�������a0��?|����z߮z��}����!���(k�赢k�a���v'�v�pȎA�~��q}$��yK��]�H�!�d�%amjj: �MS�uӘ��"]@J���u�x2c���j�'R�(���r����/�f����}��KgMBw�[����.�`F�
�_�ګ#�׏�
���v����oW+��E���R��#]�G���
�@�����@�%P2B=�~hֳ��g���Y�jw=w���������
������K�1�,��@k��î�B	���} ��i�B�-uʪWk,V��5H Df_�tz����,�9���2͠f���\FЯe�M�_5:`H�l!ܰm��6���8Fl+`�ū�	uƬـHP���b(��0{��Aݫ�Y���V͝�n��j�1�0!uĪ��W�ё��%��3������4<vƗ�}����Ej���߀��^~�z";<����3�t�,�5�J���XI�9� �E�%�"U��?�<I&
�28U�e�0ç��`�|���ؖ�x�>�y�:)����u�*m�7W��{-�-�����L�p�M��AVc������eY�dU/e�Fu��Y-��b�Z#���7IDB]��w�w�{/�m��C����U�	y[ɚJD�U^���{�*.��4�M��^�	�u߭^=��쌿t�=
+X�2S$����zDecW�֩l?{9�|?BAF�
�`1Vb�A���jC(x$"	U�
-�䂕�$��}�C��z�����/�
���H��(ƽ�	|x>:>�����o�#�G���
>w�ڣ�V�R�z�
=�]մ��z0!{Ȫ����[$�g\%�7�q�f�D�R��H��Md�
XH��
�=J��������05�h‚;�]����z!]|�O�o��"hC�d;'ͪ��\'�u��U~@�h�� �v����fx�zO���#�7r���}P�(�-���ӬӜSˋ��4;��������P���;V=�{��}��:�9w���ﶼOv�4���k[�^
�[������Y+���`��&3�X&�j��^�K�����~f���{�w�����X������$rZ�MҬ�\�Q!M�f��F�6�n�͏5��h�/�$�͢a\Ƹ��-�VI���n�$�S��]K]k]�]�\���������]�I(�^=�|V�J�JV��JM�cb�>@�V����hUA\ ��,�/ɂܱ���:P�3vh'N�r�/Y9��hQc+Gb���X��c��*��޴/\ŭ�d��<=tv(��00tv``Q�}A�:�O�*b�7z���hz�Q�ͱ`��[����F|��)����w!@�H�YS�/��
](��7�M
s��GZ��|�ԅ�I��yM�;�x�Q3E�C@����}I��ܸ�IJ�<�IߍNj��0s�
���;���e�������S[+ֽ}��G�&������t�-�mhM�ܹ��v]>{����Ɣ�ⲋ�d�{F}�m=C��]�rH���M��6O��И�P�̹S*/�UN��sd�ң�.`��6GE����ķ0�@\�7��yA�@ A��	;0�LMÚZ�K}�)THɩ��`�����:e¼�-��;m��,��'N��N�RU�b�i�"ۛLJ]AZp��񺟨��%a`]&CoM)��j��&���X9E\�$`�<P󌍩�l,'~���b�S��op��$��y��'����&��`��m��Erd#;�n����e�h��4�j�j�&�&�&qSl'�+��-�~h��Q�V�;Q���׍y�}�߽�e7�}ی�
�u�z����h��ZlHt.dg���8t�·�z[�a��s�>/��>]]�)�:���������gֹS�R��"��U�s0����=������H���,J�.Wi/��^�[�e}���m���x'�Wj�0&�	p��	x"�ACV���:c��߹�zu�W��MД!��u�
���j�%��=
���}��0��}���Ե�Hy8�)�c�B�TR��M��"��pCt����<���'��
5QU�B";���A$��X������b'���b��k_:������֙Z�������Ӌ���y���ʷ�ݿ��k֊��]?s��?�f�d���s�ϕ�n�#�15q�,�F

�sZ��)1�zD��x��Oq">YrD��b0h�$���vn�mj�P@@��m"W�v�	�gC�B葔YF�a<�$j����O:!�A�		I"��2�/��T�e'���7}�5�DI��9��B�tZ��e��P����I��Fk4�!�W�LS� mć�9��c>��m��Y���D4ZÃ���q�4m�\��Lݔ��yW�!�.ǣ�=��e�eM��mfDFq���nI��RmvK��
i`�
e�8�lYQN�1R
��Jp�ڐ72?�4���uS��������ɫ[��B����\1��s&������l��*4���O���]��X�=k~_z��{m�cO��\�z�B��cv�eyg�n������tm��c���
�����?1?�����Q�ɮMYȬbֆ�3�·1��>5~lצ5�P��f5�f�
:�q���AoܪfG``ؠ�R�D�G�!��%��� 2؀l�֛J�{���#�+���ªp0�l��	��GˀE)��&�ܡ���-�����!�LFq�?;�ȅ���0�l�����U
�90`��ӎ��r�%�!�<C�lTV<2�<~���d�3�紋�/m�FSx�Ȇk�>w�?�>�GJ�V���+�M����7���+�B�'O=y�h��4B"�a�މ�|f�e	rV1�x�ENP��,S�̂�`�`��xCTT��Q��s�+z+^f�&u�[�0g�-�o��N"a@xI�>�	f��[�ޒ+�
˸ߗ�~�!�� U������N`���hIj
nH)K��R�p€0�0�
��0p�ta==a8cP�A� �����1�rĄah5��l�qC��HDr���E�쫙Z��1���Q<�O6J�$��%u�S�d�S�?2��0ށ��H���(�g������p����C[p��/*e۝w�>����������������������+��аژ��}�[���ŲѹΆ��g��:�P޷�$�����+<�H��myNL��l�흹R�TG�R��g��w�t��2�̵g�<mSڔ�$��wk�����희�{��!c�%�E�u����"v&����!��9 ��U*t�5�U�aT�ݦ���7�2�bd�X�b�O6`
.���q?�K����K����{ao��e��	�z�-��εN��:Q
%��1���vʸ>��*Qe{C�(ЋTgGV��K�*A�$�PI�3Y�{"�����R�f>�6�=��eOdQv�L�)����To������с!,��:M/g�`+g�F3�I�4��5Ll��P)�:C9@MA|t[
�}����õ0-��Z���f�2�Q�uMf8��R�X��&4�Dj��E���Jc��	���q�:\��־2�[�ko����g�^��gn9����[����N����7���/�nU�����n�{����dC�汭�h���*/*䧺�uݷ�O\�����Fv��z��—0���y�&��
AT=����ԇG
w��
}35딦�KlB}ĪSͲ���s*�� +����,�L���kT4��_��p"*�#amT4F"��A���G�Q1�@/�
\�T�p(d2uQ�i�UM�X��)%��^�ʓ�_s�P(�C"��>������*��;V�[a���	$�+�,��P���#)?Hz��L^d7EK�-q���-�2���l“#�N&�%�`gPJO�H0��pcK��x��?�U����,���J�����Y�_��6����e��.��T���W�'��f����!�du�'�lM$.��85���l��Fp>�#�y�d͵��YQV��$rj��r
���ܽhc*�^�׹-��79#�[[��V�9с���ϙ��'��)��Quȳ>ymk����_�k�Q.�X����!��i/#�@|�W�#����f`
>�,X猊&�ƨh&'WT����>G��K
�}�d
>�b�iI��UE�����x9�]N7O# ��i@�`D	�iu�R�r��~'��J<���@_��e�'�*)P	l�'�'��q�x��}1P�x"���
T9]s���=�3�����Kdy���ꎀ-��^I/��j�wy�*Ea�rƧ��νY큣x�׃"�W"@��W	��U�U�k���Z������x��d��f6��%P�(�D�5E\��wY���#�H�a��Hg�GF��%�;@����
��Z���g2�����?�f���I(a�z%s2��m!�2/��@������{L8U"!�2��N�zm`|���_s\���(Q̍�;W���+���o��;n���T<� ��!N��f��WH�V��m_5�9�u+�d'�r�����ɘ�}��4�,U$u��.�o���%OFA{�Q����W#��z�q_8�4�W�1�7o6����q'�Sx�s�x��@�X�!���%iak���S�TA�
?��irb�1��l�pL�:�:�F_������͚���6�|
��������L"|u&��s���#���"ܪ]��v1*F"�tT�G"�*�X�8��0�pE��/��l�-���ބ�� �<�i9�:#��%
��eW4q�u>+�MX���ޥ��Ԏ����Ѽ�i�p
o@v��������(-��4U��EJ����)U�-^��Y�T�n5���(�FO�=;0���l�

��@�L��Y��)2��xL���O�$��D_�	�ԟ�n���jd)������Kw���ZJn����i��/&��2���ŷ���V,�T�A�h[���qǯ��;���jb1�~�����+�����|�3�gN`���#�R�:fk��Y�~�Y�
AdN8=��Kb<�R.��@f�#�kr��
s=�z��b8W*�k���r3��z�]���D���F�T,�-�-'-���_,�Hy8�/�)+$K��p�iNYm�����=6|������q6�����ᷟ
wF�=h�,NA�be]�Q�[A��x���`C�;*�F��ù���'�-<)*�E�|T�F"r��bb}p$"��ƨ؊��t�3*�D"�p�!���@[�*U`�������Z�	�U�+c�Ia�@�z����{�WՋ)���"���Ǎ
������W��ٽݍܟ���|��_�^ɽ�c����}�F�5�;'Q����M:9	=1i���	NLb&���y�!2�λ#R��6:V�)���;N��+��[��T�	��*�F��ׯ7�\!��|rj��������P��1*�d��
�Ej�AM ���PC5��Y@QF����E�!j(�����lv�f�v��x/ۄfs�
�TDZ��>zI�S?��a�^�H�ih���ό�f�r��3�W>��Z=\��/�'�$��.Ů�N�o�C$Ú[�7����f-�1��@ߥ��x�7{-��?�(gvN��9�&y�!���P��i�����o�Y��%��؄�Rx�ƮP�Rխ���,����7�Q�8��[^�([�	�-(�ϋRt��!}���9���^��A#����Ǽ�a�\cv�=��Yx��$���>����>�ڰ�����<�a�N�z� u{��L$
yޤs�b��;���1��]e�
�����n��nô��`���
���ao# �&��
co�6�m����$/ؠ��w^���!)7��
��v�%n$W��f�հ|���i����|�e'�����8����'�L���5W�{�wgσw�݅	�=Cve�����0���ml/@�A��<O|p��T�B<O<�u��uD�4��췌Q��!俥��n�����I2Qv
��g�D�����YSVNo~���������״�n��/oR_@���G0AΗ]oz`�-iLq#jg\�����jL������*OD���b�RTh1��^"�MfJ�#'"D�Ȳ9e����(I�	�
���h��&�a���w?���!�9��S��5I����I
�� Qv�CĹZ��Y�V�qq���s�ⷔ �
��Z���'��RSZu���Ą���4�8�̰���p*�*l0���&�&aн��n�.lv��!�6����&�v�f�f~�KCv�����R��*�-ΰ�]K�D�Va�Ɵ_�������'��Ou����\ a��c懷||כ�?�?|f�������2�n_
C�m���&��T�F,�K�Z�m�4Di�Dm(�9���U�(�/�k�š,&{#�-N�ق�..���$�`J�z,Ee|�5�}�j
�,�+�(�BQ.�����K����g8n8a`
��;dE1n�)�
_�!�)��E��b��������iE>#��0�uܱL�OIJ�T�����0鋍k�3���֨\�R���&צ������Z�&�����`bSf����N�.�Á�ÏF�؞
?=l{9j�C��'~�1���+Q�ǴH�c,���p���3�;�������/{vђ�_1sr]��o4DJ�qy夥է{K�X��˘_��ޠt�l��w7�=O��<�����z?��Y��a
�c��r�f��hx'p�N��
������]���q�:�E�w9M�:A0�y�,��/`p�6[Ʒq,�-�T����B�F
��m�‰"� &�HA�Ct����@�����-�vr2��C�Q�
��٦�]��̰$�w<��s��>���&>���6��AS4S�����L�����`f�x�ÓX�)>��)�-�|�},��/?¾�+o��9�5R,L�ΉQ}��M���1�A
\�c�fE�EG��=3���s��7�m�=<�GOu4�#�+6#�ٜ�.���>��o�����/�/v�`,��O�?��|ru�:�����_�ZG��t���`B����f�� (�/�z�M�In;��q���X��
�2/�RN�%!w��� =Ɍ��A�D�R�;�N~JP
����J$*�Y�#�:^��u��X�/#����_��1����#��I;s�c��x��D�t$��V�b����O��Q:��c�~���`L�(X�<}Z8�hk�H�3�Ԕ%�
��y_62��
7Xk��v��)���v���{R��I��,������A�6HMUu{F��������ݕ�ӺT�#\���������P��F��9|6Fc��B��Ǩ='_�/؅�J0�l�?��l��7�>�"�SB,�$4�����>���Ȉ�`D�X�&e7L�O7p�^6 K�E"�m@���M=[�e+x�"�%�O��~�+z<d9ŷ�灞�F�u��ba��%��k�[��Kp	�j?yPk��Y�����:����%�S�h#�<�E�p�/A�4���������ĕ,� i����Iƕ���'����9C�tד����!N��Y
i�<QN��U4�-TѴ�#������jx��/��2V5T4�'e-n#t	�Oބ����BK�)����?��~�n(']��}f|��@��e����
TN�
|%0r���R�;HI��������@ۂ�e�F6��bmc�� Q�1�.�"��d��"�Z�l$DfF���r,�
O��J�_�XCO��e->��0�����0�\�<u���>���˰��`���31������&8��Ɨ0<["̸O����a,�"z���6)�b����{N�C���=�Sho[�p�s�=3�x���y��꽫�^w��o-���/���}[���=S�h����}1��?�'�S5
��!ٴ]�݀�Ao�x���fc�!����g��+Mz�"�$�Y�a��U*��"�ش�a�`�Ye��VEq.I���V����l c�l���j����GP=5@<��r�J�5{d��2�I¾���7|\���s��&���[^�T�V�[>��ɿ�q|y{x'�K��GȻVΝR�� �'6���=X���"��kH�T͆G|��F|��Կנ0�:
Q�SXEV��>T�sjHTH���7	�m�˱:�J�^��0�p�npD�㰜�aю#�G�:�t�8"�qD����y�w84��%Y%�bKwњt�IuњTG�i�k�r�&�Ei2>+�G��ERt0��6��i�0�aܰ�&ۙj��Ii��!+�Θ�d:n:abL�Ȭq��JН���3_۫�����Ѹ�,Aaq����X7���-@��F�YK�������&�>o�M�D�hMy��d��F�D/��oꥷ>�!���7W�����lM`�r�������cAA�@U!���w��N������� /����c�c!ǨMQ�rB��>eT +r�.:F�m����/���zx����ބ�L>*Nb!nI�o��u�^�7AևF���|@��oaC���>��L�B�W�.AA�D��ށ�#O6�6�D��I���/	t��d@%�~�ȏ�3zu��n��Q!ޓ��g]��-�����+%s	��gk����y�����D�����"�X�����lʹ�����|e�	��%�	%�ҘQ����U_o:s��ٕ}�r��e���?��wo�x�������>	�[��Ÿ�-�a2���N��8g�E-��$��^�R�
*�C���*�d���b�8*�ٶَ��E�"���U�*�
�j����*�z�F�F���k�7$���|�}>2}��3�\���ӗ�8����I%�fU@����"��l���uXh]�Ld�bB�RiD���Ofu��x0&��s��9w�|���L6�#m��-�D.�c@�h�\����|���[�T�l�j��3��w�/�(�I�������eq�S���<������ؤl�C�֮��)�eb@��	��ü��I\G`�<hF�`�v��L�I{N����O�hݹ�ZH)q�Kr�z�
LtuP��<�(i�D���۸�ې�o�(�^�P����;�^I�2�̄(|�;I,8H�Z�g�[���1�e"��*ě��
w!)3�΁/KiJ����hp�] '���-7x�Оo�T��C/��E{��&,�X����\�Sd��tL��z=��
Sz��Q7�t	�'bJoA?��'����Z�eo�o(ma,&�ף��G�o��4�Z�Dju95j�?�}�3XjPs�R9�$���|%���,6[ݕG�5�|J��h��&��ƒl��F��~���bb���Ql8�A�]XqEİ)K%���0+�Lj{����.��^�ɿ�����▻[��g.���w�0���Ж\M���˷c ��98/�9�|�s���x
��cp��m���-2�����gD�?m���|>���/0���(ڌ��E�D*<䍼ķ�D(EIlQ�H9����?s7����Rs�'ڎ��6�
̛Kmx2�>:�!'^�9��a��t��0rh=hm�g8�GˆϞ�b��;x��0w�桡��G�
)��	�$��)�-��|��5�g?��Ì�:��&���ͳ��9�}ݱo�T��]:S�'9�
��t�d�4�jk�
�5�,
d\���!�)�S�tg��r�e�+�{�������O��u���H����Cj��P�e���~c#�L1u-�q�,CW?5��F�����-qk([��k�ʙOΞU@���a��x_$��_щګo?�q",M:����Vv��X�ht��u0}'�fТxA-��pu��gc14e]_�=�i<�$����7������AOӌ��~�b���+���ۼ#�{MIk���<=��xw��2�C�3���n#n�(
��3�E��v�v��,T�Xx����=��fL���q�<��hta��x		qf$�<n���������'�i��4`�a��<@��x�x��P]�і,1
�v�$����dS�`���J0��B�����](���h�S�+T�nJ�����\	�h!�l2���5
jva�K����e–X�?rVtAFf%N#�c��]����d�W�;`s������b��y�M)յC���.o�!�=ދ�-
�����wWk,��������Wm�Nn�!O�����N2�v�o��#oAi,��|�|ɨ�#�>���X�	z�$.��Á )�����R��V3���w�����/���t���e\�,4����Q#
W���G�$��
������
�i�o�F�T/�T�y�4 �U�<h#�B,2B�`7\g�j8f`
����q����z�!��J�=
,xܛͺ�Fk���+���k�[��64�a<�Y��x���A���� ӣ׎0q٨�
�`���8��4�t@��l�Dm*�0e�5��Z��\�OY2�Y�5��
8�Zb��b���q�&��j�����7��9J������M8�X�f�Z����ߓ��B��?��tpή�\Ԉ�%�0�kbn��cdy���R����&�x�ȍ?"m�G@w�W���%�0�+jy��*k1�E.|����E4���P��ϡ:b١�}�W?Gh��K�c�"��s�����
ޯ^}?���V/E'�5�ޕ����E�Vm=?]���k��kW�������޻�;����X[4
�m.؆�.�.�\�eq�ai�R�P������∀/�I3�b1�#W!�`m�F.�C��]
���^���
FOF�D٨��mc�HN�=�!�J���˥�D���(ќt�5�b:��O5���ڋD�xͮOu��h�ЉKsf����iڴ��"����˖�p����i`�䬗uN~sZ�=u1������Ӧ\f��]S�o�Vh��׵`}Ǥ��[y�ϻ�=0D�<#�����T�WkTćQ��D��H��Vs�y���u�Ͽ"��T��ng�£�;����jK�6�K;�_���Wi/��3�k7��m�ާ�G�oz-�h�n�y&#�Nj����\lX~�9�����C��m�-�&(�1��f��Wi\�c� y��!<L�z��w*�6�,�(�˓b����ؘ�~-��������A���ġ;%c;��mh$>���Wc��fs���h�#�d��B�L2tӧ_Y9��n���.wf⡫~#�����i��ԅ����ڻʞ�x�z���
�cc׹�6v	x�j5zx�E���Y���x���0��>̲T#�$k]�T����lZK	z|F��D͡�a&@:�y�W�gI�`<��9�|Ȧ���%�UI���W�����I]K�-�./ׯ<��>�r)z}�����=��䟑6i.9wN�����A?���[@�!����1�0Ha		s
���</���{����H/�����񶎍��K���l�]>���&�ԈҸ��֙S����u�ί�[���a��ƽr�`.��#�N�Ͱ�Ӥ���̰���4�ڋ��'���{��$����]�<��/
���P���H�������A����
oY�ř��$C�k,C�qC��u�>�)lg��$�����$����±�C�iD'Z�iB��d����Ң*O�x����/{#�ե�)x�S�
�gd$�#�NĿ;��Gp�"�9��jN�5�u?���(u�ח'��dh/+-<0�»�܂gߍ����Չ���x���:�����()t5y��������`O�VK)��{P�8OYJk��� >�Qيֶ�`{_��v�]����ĶI���~|��/i$�!*E����^�N�,��מ.�����-�O�УP)�F�T��u�ա�u��^�c�0�/J�Q�J*�Xtzqm�s�(j���Q�t���~2b��_���ʖ����H��x=J�J����k&�����w���^������iħ�4J[����uktLl���S���V?�.k�Ͱ�t���:�j1~���?%�-h���Ar�����߿���r��? Cf��3�Ml�0g�J6�8�ᗛ���	I��m|����ƽoC9����՗<��9�!焞�}C-�(�ͩQ�/1�I/B��b6
�J���
f?̪�`�G_�nB7)�Lmm�ϝ0s#�
��	��v��@4�֞�ŵEٌ�T"��|�jl������x�w�^@FH��2g��������|S�[6`�]��Udj$�҄߸x��{�i�Ku�����w�(�#9i�����!h���	�o���O'�7�1��*�N�
:��G_�9`�
�a��{\��mƋI�V�O�>^��������t
ʱ5$�
eQq�'��������r/�-��9��B���S��p;GA�yM�XW�Cr����KV��u��2�˫k���@
j� ���l"�@��S�ھ��Յ93�a_�
h���`ٙԖG����ג/�a`c�@b��"hIj��#��u���
���9ͷ;ə����F↜:Eb|D�VΞ:;z�Hԧ��f�����&p�D���D=�
17���Y�a���j�ັἿ3�P:���ً{]���9�7%�z���w����0��4Ch3jY�Q���rOw���o���ٽյ����vܝ�|���t���u�+:���3:���s��5�Vq]u�N
;�{h���y�z/��Vt}ƮF�ߒ�:}Z��^���ò��K����<cT�kl��#�æ�:�c��t�<]��|�%T��Q�1�X���G1�h
7t��U���>����1�`�ڵ����øݙ'������1���<�g�;.�3����:���o���vu����������J��?b��zs�B 
;���w�ѯ����I1����wS��)rk`Wz/��)�|�C���;�L����?���N�S�%aIZRL�f�oFxO����i���Q�#a,��}�0��X�6��eUg�i�F�V�I8���q[8�Gm��K}f��&�r$-f��]4�M�`/R1zN
��'>)&Qrrڑ��l�S���#�;s>
����-d��uCTR�
OW�t6(��A-�2�"�uS[K�~�O�6DžGK�%�x,fL@�%f�PI)H��
�u����&o��X����Zό
S�!��X�f0x�_.��p��-��X�qg�w��u5�M���]6�ꗃI)R
����L����č�S*���<����]h�^2g�aci�����HF0�}��إ|(��9���p2FO3i�"�D&FЏd}1L,��-�ǘ0�
����pP%��>������<�֭/}XY�g����7�f[�qM'FuS	���f���I'�Y�2�03�>�m���9�מ�!�b����sHi��v��g���D ���Ȑ�Ar��%~C4���X�oL5sT���G��V�a�W��S_�R�r}���	=~m�f�@����GT,_�tEsҖz�+�eRMrߪ��:�������[�Mmi�����J�&��R�.�a���=�?h0���$u��C+:{�h��{hm�Sw=zqnj���/:�-S�gG'��RH��+Y���������w黼]���yG}#����:F�i�M�m��y�*����Meͻ�wy��w�uOg����z�4�yn��>&%7���L\���Ҍ������ŵ�g����w���g��Lfn�s��-�;�;���Ǭ�]?oks=��s���`�����ԩ$̵Vn��r���#�Z�ۜ9�]n����\sf1���@�%���D��,FI��D�Rch\����8�AՃZ��-#蜬�n��E��]�#���� f��"�M�3r�/�6g�ˠ̂���-4E �`��Ѡ�w.��/DJ��������;$)�1uI���s/s������}��Wmj��DҘ�
��',[
�ќኖ_E�C�AR��;�\3�i��W0�����]G'�;���R�p����*�[����5��VYti(��CW,X��Җnh)g���&1uӔ_z����#cm�&/i��
�|x���7M�������S�s�ӛ_�29ۺh�-��^�d��%ŕMo祥���#xb&��ɼ� .[����tz��n��th�=D����Q�I�=��hV]����{�^�~�浽��|Jڄ���Q�`�
�\��d���0�y�^�M���9�A�k��A 
!4_=�v{N����gIj�/�p�Ĉ���	�0G�$5M�=�7bF�V��
uW������H����/g�_z��4W��U[7t-�h�}�_�����r����n�;y����>��g	m�n-��J[-(fXoE�������
#���z��1׵qfhn�74�'���"�|�����Q%3D��e�D~�W�1%����v�$���G��q�umu���Fd\"a�S`�vϔn���SNf��,ú{f[�ƒP��gF���я��Qj��?D��*��Z"HJ͡��cØ��:�.�^�]=�3^���4��b��qvx�zgcnُ�����u�_v�y-�du9���<o�F�ĺ�z[J:�#4;����L���\�̭7tJ6��cW����W�
�<��5�^ךFC�e���9U{6��[Y���_��ܿ�o�"]#�i�Q�[b×�$u7t�l����Ĕ(%ϥ�+M+�H˩,*��c�)^r#7���Š�(6��jRö�A�A�1�1��O���������r�Aj��$�X.6L*k5I����I=+q�����vgI
�2��'��#Lǡp���?��dS4�O����
��I�4I%�#��-H�BAJ���*V��%��bgq�σx��A��Rهϋ
�~5��$���i�gt=����!M�gb`1hڤI�b]{��k�)��Ǵe�=��̰=cpO�Ԗ��<$��pZYyۄ��ӧƒV�k+2ըfFO�TBfeˌ0N�N)�aJZ:X�"�Ru*�݆Tc���a�E����Z�%eC�X
TQi�0��f]�x���0`����##�}/��x���ާa�'a��=��G?�W����@����g���j��i�b�9i��qv͑����T_x�%8w�(\p����O>Y���O�ēO��'���)k�m��0|cA�	�������9������/"1?&Ra;��,��?W6S���H��[YR�	��բ9!�
�¡܆7-s��Rp>0.�Bǐ��Z�j���3����qϴF��l��_�Bb�'!\I>T��;Bƹ���ܪ������xh��G�lg&��V,>��1s�#���1�����q�K�~��W>8����?���[�6h����cs�������O���gӿ|��I���~;7�b=]e��������[z�����9�E���=w������
�U���&�{��qc�\B�p3�cJ��Qɴ;���d�q�l�s�ܑ�J����G���p�R���QWɳ;�������Լ;��'�:[��/��}�����y��o�'R�t�Xlnni1M#h�,N����?
����xHH��~"��.��|������`VFЋ�]����j�'6���׀{O�	"��F����=�FE��0d��B1���C
�����7;��%	Ɍ�3�|�I-�*��a����V�"Ӡ;d�!�Z����t̘~,e�D/L��FT�W�-�J����G�-Q���p�?�.)Dͼ��Z?5U=�i���l����Fv�o-=����UBz:�{�o�f�Yܖ�VMΰ�U�0�΃]�����Ì5=�˔�
���T"�J�o���<3}��&�Gbvdn@n�<�����"���F�hk���kI�M�Ww�f���"����A�q[�e��������j��o��]sw��y�5{,�:u�Y�&�#s��Y���fU_����h1��_�5F]k�|_�
kD*���30Ak`�����x���Y������,c0T��f�@�� ���ϲ���;�� \�_���2������������Z��	y�{I:M"���n�𦦛��jʢf���X�������_�*��!-:q�����%7!��w�S}>����)��)���<^}���? �1�J8�'�IV�N�
w�L!g���ą�:�nq�$��1�ز��1�͢�V��C��w�6��蟳��jC$���Ǭy�<#�k�%�F�������C�9v{?�7����ᆖF�q�F�o�˹����:����Ғ�u�r��֖��	CL�
���҈C��C��w�^�q`F��5y�=�	:��H6���DM-��R�Z|�� n%x�`�>�x��y��@���t!
�S�=#��i6�SD6:�Oe��40���":�u���22ğ_�'��(O���ߺC���6����
�=��D�#�3j���1RKȩ$���s!���Ά�}-�:4CuW³��=WD/�������QVS��w���x����3u�Tթ����)K��
KzQ�Kl�vT�ggT�޲�a�W[������8��|�U.���ꂘ�����;Sl>O����N����J�+c��v�+G$���s��g��x�?�oʺ��4ia�_R�i�L��� �Ƭ�Ӄc	�v��Ö=h���4����B��`b�:4@�D%)��A�!�\n��!CtuF�Bc4��Ρ�Fmqw�����7N
#�#.I�	f���*��Jm�_�}e'	waB�@��e&�)�A1��4�?v�^
րb�X�!�j�Fc�P��$��'R5h�>g��Ş~�$���y�Ԅ�D"��N�V4�Yi�h���@�g�t2�8�5	.����iU<6��n,B-��
%.�3�,�:����>�l���j�Q�=�Ȼ�V�{q���o|�!9ހ̱G�?/��]�s������UW>�����Y3�����;?���k�p���%�<x�<��է7I���Vw���܍+6=}�[k����(�5�-�~�qP^�+��n�8,��Tiv�Զ��8�����1�ƣ	6w
[�)e!����),�}�h�˴#�S62���yʹ6��TAs�C߿G	���Ѧ0G4i��Q|&�2�U��=7�T�|(��_�ϲ��|d��a�R�j�|p^�L{��;6LP�'&���1 *{�' �tO�Sw?���._�t��Е��9r��-ߛ~�����•ݗ�]?+�r����_:UB�>~��G���Z���W��?|�'��g[������Ϳz���[w/ �qߩZ��1)e�z#�jtI{��j��W��s,bG�����M�
� �G<�G�*����a��LVSAA�������P����bHu����R}��8�g�aM�D.s�������9$��
�[U���/A�۪�>�'��-�g������tn�j!
t�;r.�6�S؋XDz�!�AV�
��6�C��
���i��j�KHHh�������eS��P�*�
��B��y���7!:ך�#��@r{FO�>��h�*�VUc0����eh�"�n�_S�|u/��ˣ��/G~
߾��\�!�������,��އ����5y��_�d4Y��*oC�� �{������6(o�Qy#\�U������VVh��	��U=_c����K��Z��Zz������1@2���QE�W�r���iJ�e�U9N̊��9�YD����S^X��|}�-K�R9���4<�p���ؠԐ�&K	�$��(�'=7�у�`>��Qyi8h��R��-��<^/�r��j�����}�1���'��`?c�ϋy)_�����sy!�!C"G�Y���F<�
�*d]N�����0c1�P.۞E��+�=�W��Pi4ڴ����\}N��W��^���4��C��n<-\��Q�Svk�h�䎙c2��Z�yL=���]���$@4�ă��ヽ�#��O���c9�c�k��~'U�6�˫�4&yFt�%<o��z4U���Fix�=���D���$�|F���%�l>KNZ��qgr�w��Y�3��F
u����l��s
����)�
�^�������S��(�T6��"�P�5�3�:�U>�C���l@����8-��N�!ݧ��I�����PVC�'P�K]��
�����W8%a7q���Z�ni̟q��m<b�Y�
Hz�OW�(W;�'�J�
����9dv�j�0���r�9&�4���%�Z<O���i�j2���^�~׬d[Q_�,׵��ff����
�����9eWt�=�̘3o�=�>�{᎞���%��O�L�	�� ����K�k��ө-�S�8�q6f)[z,���������{��U]��{�S��>��H3��Qi�-[���q
�m��
v�dL�
�
ӋM	�P�B	�^�!�� 8$���KLI�B�|�����gF�
�����s����̙3���g���Z{��ݮTX�
W� c�m�� cN���a�b�y޶]��ӞL�8��6�B�>�-�W��ʟ�(#2��l�Kk�|����t�(Zkd~���`A;P&m��>ApUgFx^,���-7�a�W��yҺ��J��HWw_6})|��7�k���m��>�^v�u�������9S��5���wͻ}F�#Z#ٲy��*�=pf��\�Jw�HM�<�)!k4	n�WP(�N�J�R+ᙂ�e�,˨�*�:"�N��B�5�4jr�@�d��:3�v2ı,B�f>O�$�S��L$�I�}��$~]K��ZbٱV]"l�b���Ҥbo����M��}tOy1[qD���+סt�z&�5�e�-R�
2W2+;�����v�C�r)�*]�r��A�Th���u_����\�C/d%��U/d����/d
��m/d����nĚ��Q5ڂ�ډ���ѻj��!�Zy�0�=>t�u��O5BM�q��G��l��g�q��o?�87P~�?w��y~��?w�Ĺ~�y"���K3{B��Y�s3{����_���	�Hy8��%ݸ������"�N��bX�`	�/�*Mʒ����2��Ɵ�Dg�vn�./�
�ܓH_��|�x6u�A����Q���¨ޒ�M�O�n�-�����_��9�-�c��C�c�)�z)���X�X�lau�Ld��#�:�q��p_��uQ/�q/��C^�GZ�	m���q~�N).��MFft�����szi̱�!=)�G-:�E�Jg4Mˎ̈́#�F�Y��)��h�O�v��$[F�?����ۮ�?.���o꼱)����ȓƅ.䖃���B�d�|�J酾�wK�J&0[���ϼ�z�+}������{���[���T�B[�m�m�m�m�Mbd��:-(���a����x�"�k�E�.r�?�G���y�W���8�	F�7����� z ���R<0�@bL`}ɲ��e�t���PӸ�5�ϙ���.�D�J|���{�H���'&a)YK?&��(���3���ɘ���=s�����)�����4�Çm��ޥ���q�nk2>�}L U����_A��77�o��:��i
ֆp<�6c�̕.^%���Y��Ԑ-��1k���ַ-h.z��Zi�[\���9��ҽ�AnV�V����]���̘�*ܞ�m�y�����(R?���uPG�S���{��D"�n5Jg���⫕��!8����^zٶ�]殗�sQWB�Js����q�Ƈ�`aǥSB�և���e��^��wI��`�<�?�8��)Z-��D�
����C7����%\�\�Dʃ�(��t�.q�v#�����������,%�,�#�(��L1M��P�E[�0:�>B��&Qr�mNdN�>��WX_`
��R!@��0��G"��j�4���5�?|��L�VQ�W@�
���~}��RIK6�S����5�L�A��ɐht</�j�ӥ&�4e�|o���i�h��-f�X�n�&�{Τ)sU�]�r�>(<�8akogz����'On6]:�|��ݹ7n�k�ES�^}./�CJ��g�߆��?P�������ҡ�+SK+[^��\��mp,4�����ӕ7�H����G��g@3��%�CD�����
捩MeB�秢���?Q�ذ�<�'�e�ɖ��z*욪n�K�$���3|��k|!B(��$� t	�rE4JȈp�Euu��dr�N1�Fr`�tu%�w�p�r��Un�A�F pKhq���&�`��6��S��5�B6�k��hi�k|�彁x���NyHS�j�DeR�b.�)��o��;Ǎ7f÷�\�Ơ=$�ƻ@�#����8RVLg�e�.��\tAw}���u.Ft(P,q6��ɒ���'h�F9FQ
Q���Y
tꐌ,C�_�X��|�tעx��iŬb����8k�/�Rnj\[�%�|���ܼtFc���i?{��0�k���7�|�e���o^������;-�.jL�6}eϼ�ֻ���m�I��`C�+:��ok������v���	�F�عG���Nu�\cn"��q�G�_1v��4�Y$���=2-��x�.�
�h�:��͎�u�'�W��Ɛ
kyvGP����QWҏ�;����38��F6�O�����23=u�,&�$��e���م�h�n?�)�`�f�l8b��t��
�w��^y�	�2�	�B\~�\��:�(5���#��y�����gE�`qO��K��>���z}�%���DC����&�ĤI�].��G]#��-���K%#�����a�3b"=�T��#p��cr����s���"ٗ1X?���K:���w%cOT7%Wo����y�WnZ��.q���^��d~C���Ԙn�}��%ƺ������Js�
����b�Ed��xO�Mz�Ǵ=�Q)۞$A��P��U�(C�X){ �$e�d��8�U"F"�R��z��(�2�$v��va+H��v���C�V�H�d�t�@bA�~4wƬ�Y%����MXEC���v.\�E�����M�:C�3��}��ᗗݾ��yeAg����;��̾�2�٪����Nsў�W,ܶx�2R3;*]�[�U����ǍH��:�a��&�f�6r=���"J�;�<��J6���1*�0Z1�Z�t�l�fE�G��>��6,aW"q�CZ��R�6Y>..؝��Q���f�[���s�†z>�MΟس0��c^]8����Xu�;ϞֻpфI�{g5�A����\80n7��;�ZP0lB�( �ie����.�|�`�e������nE\rd�����$�u\����m�U�8
�����.��	�N�+�f�G
�I���&
�ј��F��YH$3��@	ϰ�
��� �B00<����e�M*���w{
���#\cVP,��<�	�6Y�֨�GvhUf ����uN��X�>���'��/�2�3�;�}	[4Õ.r+A'DB��� <d����È�^���0v�ըײ
spL{>b��&�MB���ˣ��GH�dcĄ�Zw-Y\��9�i��eI#�~�-�����xg�5�gӿy�q_ɻ�wh�R2���m�>��v ����q�;�8��P�4p����Qx�αc�ipL�h)^$�.ދc��"Ʃ���ֶP�5Rp�p�-��t�Æ!��Q���ê�C���O7��Zu���3�����8s�B<�4�2����gT��d;kɊ	=˦��h��Vl��je�ee��n�l�Ja��v��Dh�yW!��i���2!��^S�����DžW���%�U��s�	x�ʁ݂6���P�j�dV1��=zK6G���x�I���t�.�\�Fr�O�=����;ط�u�E|G�|�GHΣ<��
�C�vXG�Y/�g��y�v�*�=bk�:��`�B<�'g@j��ʅ�R5���Hÿɕ���.h^��Mc�������<�(��[ �_�n���ǎ���_]Ԛ]���$�����^����3ܩ��UI�WN�Gf�/z`��19���:u��ʭ�{�D���1P����p3!2B�X<v�w
2�8����o!��,�h�%�p��[Ga�b-����r�h�����+c�W���V�i��J��동�m!t@ʼ�l�%T���V��<�?
�����KDxp�@�n*t�0Q���Q�`�g���{
�o��
٤!�ȐL��l^��v˟c_�<'�l�[$/�Q!�
/�9�َjA�Oc����=�>�Ʈ�߮Pȶ���>-��r|� �,��%ʪP-���x�83����"ӭ�3�"�.a�	B�a^�en���C=�{���y����}&����T�*��Vi��µ�j�� ���fy�#��!}���\B!)³�Č̄�Tx�N~�$�n���y��E0XVl�C��P ��h���XȮ�C�k�b�A�
ߩNl�Y�#/՞q��J��x��|x_e^�������ʼ�������4���W��s�u����P2fi����g��RN����&�$[ȥpL�•�5Ld}�� ��~��R>�C��H}���W���i]g�5~��g�⍸ӵ���,�b������Ι��S�$�y�b&q'��D��IY
��=M6��IL'�/[�Z�����7�Up��E��7�V��w���w<u�d1�=�3����WG�?��Rߗ��&|^B�y�)7���܌��{��y��R�z��!��[��~!�/�F�&��6ս�;��'�W=f��������}�9��v?{���R!��W��\�maW*W.c�+�׸�c7)oP]o�Ʒ�}g�Ά�;���$���������w�������#�cXъ�`�<;��^��'I$C�d�f���j%f�����Mp+�
��c?�D'�Y=��:�b�����V�l�j�P�O> �m�qE�(5Y� �L�^���D���9�fQ۹)�3�i^��_��4:(�?t���O�鑈���\W�vu��������k��"*���]Xә'.L�"b�ū�$ĜZ����o(^*`U2ٔF�A�/�H�ZI�BcB�x4��B�c#x�Q��B���`1͋�ˎ��;
���1�ׄzG|"�0�i�M$x6�dk�:��-)Dgݾ�g��T(��B{tGO����:�פk/;|ݮ�mO�š
��q�`fʦ��?�}òӸɕ��T,��f�\;�������w����Vf�ʞ<�)(}��j�r`�3��rE��ͫ�L�I��Q�&����X�q�c#s�e��!�s��Y�[�Y�4�e���l�̀ff[PXSR�T�H��A�&B�pӨݾ��5��$����O�:�B�Vú���BJ�ڐBBjg
yR�J���`N��e��v�P�)q��
`��Ӛ�P�c5aw�S�yb��9�<!�0q�6Q��^��E�(�
:O]�ked
H[��P"I�
|�E���؎3÷�pֵx�.Xt���fok�Kk�1��)E7HS�>�dNP�
���lBP�)�wSŨ�eV�Ҭgڮ��.��ɺ���kθZh[7��׾]W�'�
{}V��uh�w9Z;���ݳ,w]�4�;�����;{z:��K����>{�Ӕ����׸,���ۖ����ד���=��q�;*�
�sp4���(��yY�7�^x�|է�n��?�Jj���0�{-����k�cXo��$֛t��q;�� �����a@MA�+�[c�@=��j2�؍rv��M_�36��T7�^0ٲ�ꡦ�]��g��VQaJ���D�/å s�ۆF���S!6�hc9�Ǚ�_��2N�il���g��*��z�[���\���XJB��׭���1�9B�Ǚ�vTka���
}eG^w�M"cɓ����6^��8ďI�ޖфa�Kv��|4���>��|7�S���÷��H+/#���c���u������#�ԷѾ������م<�q
O�uΒ	3�=N=�^K��*ŏ:n��Q�~������!}��DZq���Dd�W�#�[��S�Z��ۄL6�ڟV�|{�F�>пkJ���s$	�t���,鞽w�Dz�L�T&������՛�;�Dc�פHl�򫵭'�MJC�ztih
�����5��eA��e���IG�����K�4v>��4�
�<��q`�{�r���X�LP�����H��0�d61�h=C>id�~��������H�c��Ư��5�S���&�h�e�,�
�
ώ��	����Bů�
�m���Io&��/p7a�,O���H��5Y��������]�^+�e�L��(9^����$�,gd%R��Iqw�'~�A<�����M*�`Y�K����,�8<��)�W��+��I��U�XWiu![Z����CZ��ʐB�� ֺ�U���[*��YpwS9_nCϡ��,o)߉�aM���QL��UL�����	�t*&��g��E{��e�xyj�}�ϊ�0ޓ�Lqkz�<�A?��S���<
7�&�.�SPpҝ��"h�0/���<?8���&�Z�X�z�9�[n9�i��z���k��"�[H�� r|*�Q"a�r-2�+����j�<D���}#�����s2��u�(�>Y��%�yu����%zA�zk=j��U�2Qm�,yZd�,]I�!�V��B��ƥ!_$"`c@�F"F"�s'UYU(�TJ�=b��*����U��E�TP~�d�~X�ȀR*&���TR)&2�O��*%$����t��2V�3���M���.daL.������l��:�����Ɠ�?�k�pAI���ݪ�-����>���U����h%_}�U¦�����"��֢��L�Ł��Z��C���y|��`��	�������+��/�R����\6����b�f�`���̨$���r�~h��poô¹]�gXj��[f�6���fX�W^��n�F��N��	�K�75���m�LѺ�S>޶�%�쬼���/���x5�����&3�?�'�݊�"��<��n�ϱ��`�
,"1�?�#�	�0��2஋�3��`�d6�w�H�S�	o@�b�N�
�1����7	|�\�U�π��8Sh	
Q�a^�fv"{;|�e$���3��5��%f�D�	�A���8z��DBJ�K��qA�ĔqK���#�畹�̽�l%_���zj��³L+�����#�x��.��ȓ��#칁�>	0�@4����5<0�y��%,?~�=�6Q�$r

3���wi���(��-�AUݠ�儀'^Iy}:�R"��P�WM�s���ʍ�Hڡݶ���£"�]�4� �Q��j
����h�V���U���?a��ԌZyO"���2٦sNU>�ⲵ���+*���E����<�b_���?�[κ�s�آ��ً�7�S1���l  	��5�ϰ�U�6-Fk��T_v^<=��
9�j�Bo�4�. �S��1��C �*h�D��J�.6)�q(���n?eR��m
����B���f4�x&d�!��&k���rI�9V�-�0�WB���5�J���'%q�۶��\��-�SťZ�@�W)�CGO�J�QK�)դ3��Pc(kȻ@ڔtAlT�2.�2�MmqVD����BH4B2⾚���zs�h�h��D�z�JXzamhQ�ۚh�R���J2���l�s1B��3�>X1��.Zv��U�7��J�Q �z����
��1�tJø�
x�W9����V�6A}g��/����v��|���;BBm(rZ��K
�������̵����W�eǎ��<�-TΖTr(*a�R[����>R 5��ɳ%�p''��
La��y�uvN��s�ZdOW�={[䇣v��4��@�]�?t�:<s�A�Let�u����~�%��%�{�C��������W�'W�Zt�k&
�|��'a��
f(��Q��w�#�I��.��;��݉Ŗ�@A�R�[����▮N�
��@Q��f���(����e��Y3�n	��b(��9��Q`>4��į�5��
u�����gCԚn�"���e��3Ԟ�tLU���Y��BGԚ�,(�-�fgC��Q��ˆ�B1nK_/(f�mH�Q�h�zw"�,4:̊��\=׀>̟{��c���δ��l�'Z6��-��i�t�=�x��ᤶ`K,֡��q
���%�碽M���X�]]��w���Ǥ�電X혀#k摩N+�O��o����^�a��	<�G��="��{��'�s�|��wP�����u�YL�Y]�.��[*w"l��V�W#V�~�R�ZC�7��ʝԢ9Ɋ��e�Nf���}���
��ؾ��.��o_V�<Ŕ��1�9$�m�ɳ]U�u�<��5�P� �@D͚
"A�:�	���œ�i�e`�����Ax��hú

}
����(�����񼪼�@��mًp��$,�~�
�����g7����X겂Δ�nh�e7䚲���,����%R��D��!�ƨ����Ҋ�T��.��]X��'*ǐ�ت!����������d�LZt*��-�%z;�uH��{�3���@�y}?�C�Y��\�h1����t���K>�<�w��m�������~���b�0�6d�9lu6��c�c��3�{B��烡`8	2����^�r6�,,-�s��͔�D/l�wx�G�B���N%�t���)�m��_̼��N[���X��K����za{���2�X4z/��\^P̌�	I�	J�4B�$f����2@��t��X�RK�{
0�?��=�����b�팫�]��[&��p�Ywtk�^��Z���+����~��_��ѳS2٠0r:�Ġ4���J�����>�rկ�m��W�8�F��2�
�F-1ʹ_���?��Ż~������V��g����7���p�C{��E��3Z����V�rVJ�
l�gRX�PC��03��5̻ɳ;��q�#��
Cp�7�
�r]x�7N��߳���^\����h)�hkE'�����
8_�9S�
��yl~| ����'�Zr�s��*�KP���5d#��:i�h�Ԣ�T-�9آ�u.ꆩn�{C���#�t�;G�P�I0�߇M�I�i-{��h���!̍\U���^��" ��Sӧ0�B�	��;�
��5Cqk�^�WH�$�Zz>}�D�����#z
B������'��v(	�B�!��
��:���I��p�:��*���u�,y���g'
L���3��4zE��F/�+<�i|}�|�K�<'��W�
_�OO�-}@N�-'���w�;��= ���Χ8����j�����+L&K6M ӂR�M+\��R'�A�s��o��q�l��w����T�M��.-8ȏ+��Ci�)}(��O�QZA')��������'�;�L��)�R$(,�I�j �����gģ�N����L_�Z~43�"E����"!�O$�W��*=e5�Y�~�	NzF��OCWV}�|����G��ˎ�y�#\���5�;�[�4��a |�q��4<��A
��g��`.,�l$�"9��4j��K���˽��|�ܭ���"���oFv,��;X���(U$�e��|�+l�����1	v8�&���ە��	��f���ܑ&]��[��o�j:����f�
T	UU����d�缮���]_r��-K�#�\����D����K=ɀX�Nt;��l��d��6vF
�A�TI��]^����������XR�y$f�KAesd�[)$�W�L��)��J�K�����U���Ħ�QK�*�K�!�^=J���(!g5
GdD�c$�W��W6ֶ⬾s�7��}SQ� O���������`�{�n�x��Û@�&߃K6�}��v����7�"v�F�k��QA�_���E����f�l��Њ49�����$��p~�k�͙�n�\��4���g�9��͙���7��/�7W.�%�-O�:�L��K�:�m2��T�@��GԸ&?>�m���I`���g��L��>���Q퉥�x0#��Ix�� �s�&Ŏ��.�N&�佭��:L�-iW��C?�E��(�r��J������P�C�h���#�+h�ܮ�Uv�ȩ{�M����'���������7��2TJ��������c�V#��L]ŭ�<�����.�
(p*��s�-�Z%�
�L��N���{�j_I7��j�dt����*|<0�	��ɞ4s+R�q)[�邾0qz�.V�6hmc���6oӹ��$Ѷ�ˈ��|���d9�+��QrbhDNQAa`2�|�y�7�?�|ƛ�	^��+�Q�r�(�ܛc�m�����r��^�ףv��*���Q��{���s>��N`F>�Ao
�	��.��5��*UD�1*��*���
s�g��qA�է�#�	!i�up$�|z�F����>����}�5~�8DiN.q�4x�z��YI��j���⋒h���g�8XDR����$�<��f�X��Ir"��Sd��Q_��T�'����գ#cƷ˘O>�����ߴ�w+��Q㱮*߱�N��僉Dc@���վ�*ƕ�*~ϟ(/(��.\�V���s�a�^�o��?m���kd@�n�V�����#����X�	��tJ�n�Ҍ
��Lij�^�������!+�����er��Y��1�QC��t��̢��|��y���E/�:۔j|i<>TS����NoIliˈ����3���_
M�a<����kSQw8���P�&��<}����!s�ǺN,�*!��<j������^�kMT3x���[��|��}a{_;�ޘ&���(����	{1�ÞMQ��K
���~�`pf�M�&�W�[N����~���l�	g�{6m�q�vir	��~�:lEV� <�ky���r���e��!�c;u��h�+�z���Q�͸�����?Fd�	.	���cm��,���V��_�
�`�TRd!~v��.R��jҺ�dH>���+%]��rt3z��fz�$h����>�ƺ�KX�̴���O�)������?`y�ιJL�l�d�!��j��	|>�ǩ��}�_��	�~�+�y29�A�b9�H�S�~6���sœ��ʧ%G$Hb˶ϭ�ވ�N$J�m��P
b(T����$p�P52�@|ȓf�ٵ@������E,yħ���t��O|B�h�;m,�f�
A�&��o��d�L�-���j�1�W
��b$S����25���ɨ&���l0�&�NKß�ۊ��O[:[�Ѣ��m��3n=t]��!���j�u��]4C8�'���ç&��˳������6��=�Jv��?+�Y!�f�O�8�ݽ6�3�	��
�r��N"�`m�`�_��fuR�aN&���(�*�2<@r��x�˩�
�!��(e`��9�a�!9V�P�"Wh2r��r�ѐA� h�Ĝ�;�B�"X�4�����I�)W�Fg���}iMd�p���K	����(%E��4�7�-y���4�f����PHB�ܴ5�(�o���Ye�zΔOݿ{|���n��+f.?�>ۛ�ꅠA9.��6�:�oh��w����te���+{^�Ee��
\��������qݎ��g����g@p��Tm��/���u�/AA
A#l�lcppx��I���q ���Ya�|�%�O0���M��_k�@c#g�z�	yE�0�}~����(4naf�2[j|��

I����4�|�g�K����8>�AC��C��-
�
i�2J�����z����κK[���RΦ�$3/*�J$�����-G�E� D���b��s���A��Vd��U3W�a��y|����W��.�/�l,lr�d���z��?ܰ��nK�d]6���{O�(���}P?��������A�חwe�֝{��Ħ�p�����I�!vW���
��.���~5<�:7��hu<Y*{�_]@��S�:2����g[��J��B`@�	
z���k��n֑^��M-8�����<��*[j�@M�ik�Y���?3Y�?P+�QkŊ%�c���e�C�P8��F�0�›��>#u�p5XS\�RPW�z1?���|m�R\�ɨ­
wXR]�S�^Ә�0{��s�x����t~�YM�lKHX:fa���9k(����ܶ�Ml���O��7���u>��k[f}��ym�o-���?B�๫q?(R��b��v'�X��:�~8a�Eh|�'�o�g�e�euDc���&�d)���
^�P�g��
	�"!�H&#,�u����(e�R��y�G��+p(d� c��#�c�eT��=R^�D{?�c����`�q�
�G�HP��)+D��Q�Y�FB/�B�[�+�-Hle�c��
��;��M��T�����
Bh�Pa�/��1k~�18�Ty��}>�^y��[yΜ�??Z��*;�Ax���h2rˁ��=��j�s�>���
:�Tn�[=:�ۚ�
�_
j��R��,�������x�/ޫ߀��'�}ؔ飆��rK�������/
I�B
�	u��ljC�t�p�+�qWe�7kTq2�YW���Fny������K��pY�Ymt���a�ϑ���O���bg~md�5����_���.�.���E�r9���4r��3
�8@��!»���I�%I-���@�~X『w.�*p\P�+Rp���u3��±��б

+��CԴ�
��*(���u3'�LL?}��8�[`�ms�<��z�-��f���D��Tt�1.{Zc�s����=�eB@�1
h�����3TK�����}z����a�Z�u
La����ȋ�?E�"�Do�#=����I��"��
P�9���E:	P4�˰]��*<��6� �r�V��"� z]p�*�*v(�W|���x�O9<!��!|��Kc�q��M�Fd���P�xܸ́2m�#��>Z5@"��D?�=6@f��ri�`2�,��t�NL��Q]F4���He��ޣ�'�"�-v̱4td&�FO߳��̫���?�K�Lfŏ���
�s���FZ���.l��-^p�ϼ�-$c���;�'��=��q��Q���Sp
���g3̢�����3o�?L��},},#�H���I�f��:��z:���]���N���tYe6�ݮW*V�:���s�j�k�s1�H2B
�CS����V�eZj��gfG�Pe�@�c���8�ۓ�x�o*z8v�A7��`*�r�5�qC��	�!1�����w�87p#��a�e
� �%b��qs-�NM&��K�Ŧs5썀Y�!^:���qg�T;����^��n ���W60�|�~-�,d��$=y���� Ay_�c��O���%KƷ?t��OFK���j�GA�Vܾ�@4���c!o<��#$���\�n�������q'b�
��X�WwWԑ�����=dօ�>_<��G��@0x(#��p��O�����D<���ք��1A�/�khz(J������T%DA8N"��� %S }ܼ�рe#�*�Q�^3ܫmOw��$�nt/�t��V֓�J��eL~V���5�3$��P�|�ĉ{+o�|�ߴ�7��+�w�5�iIU�%# 
�x�-�|A!���O�R��DF~),�賬�H�c*�ll�d�y,FZ����\k"��'��x�������X_������R��G��qG�jH���h��O�/�����Y,_뛓��@��\c*���ܟ�7�3�CM��;����x����UK�������֖<$H�:���1�d*��n�#r��t��5⬆��'� �fF	c����j\o�d��Pv���~}���X���(
�=�Rs�PE��K��&J�d�dh;�φ�5!Q�#���	�����
�!@�D�(����u������N�����S;��8�{l7���£
�Ɔ��w7�<ʮ��]۰!�r2�� s�YK�K����K|nw�]tOu/t��׻����'ПA�QA�ɺ-��K����x�
"�v��?�H�SB��Θ�v��9�vrA׽�N��0n1z�!��
��oL��zC����Rq��PlZlކ��Y�	wpatB0�=\O
�0���012�4�}�1:eryp���t9Ѵ��8J����Ј�H$�!q[CU�e��K a�=6Bv��A}�V)�)d6�D*�p�K5��B2�,4r�<%$���&^9F�W_�v6ח���
�!�%a����Ϟظ���u~���?���s2�`�f�;哙N���+��U�����~R�s�
jb]���H��cԺ~~�6�`�9.%v���o�؋m�w)��D�*���u�t��u:�����8]�٬�W�X�~wd��� �VA	A�,GC
��~�RN\�>�r�wk�2s~J��v�V���Ž�uS+�B���T#�l�t�E�����S�y��� �z2���rk6C�N�ٌ��#�*�ȳ:}���9ԗ��2^�?X�	͜X�����o�2|�YH}]U��N*h�6�	�Ma������QL��Qw����=�>6A��F{]��Ъ��"ⶍ����Kp�H	��p	pɷ�w�7��2l�F;P"���x,	� ��~�z��X���]����e�>���k�����Ɵj�����?�
<�����'#��3���>�eِ]�r��+�Ӊ����v"����E�ި�(hM0(.Q�d�y��}�D�ckΣؤ@���
F\�>�^MoD���7mk���49�t�k����㯎��
�\�E�����P[�/��Jj��C��h��[F<s5C�LaL�q_)mԚ�X�P�!Հx]0j��F-�$��0lЧG�Gt��UJ.wr� �@���9/�2�T]������Y�rAw_מ峖�[޹���N���q�Z�d⊠5���["s��w���w?2z=������.����͎�jVA㩋������g�~2\����5�-�6�<����4��Tq#���rc�zq��7��-W���w���t
0?��dP��Ar&N]�=-�;�)���t���|S�Hf7�K��\�^�K(*��٨���FO�K"�����*������{IȘSX���.n'�5�;Y���Y��~b1�Y�ư�����h���ς��5wn0X;ˁK=@Gi�:J��(�	J$$aR�E��ңe�ݙ�G�h�YB�?��o��p���q_!�@h}l}���;�\^�̏�z@��	��s7=�w��e���v��e����΍�����fm�h�N@�95���$�h�#ۧ���V��mC��'�L����{�S=P�)z6x^���å<��߳ͳ��yQ���t�;P��u5�V[>F�;���
+$0�X�L#H�!a�G�)>�H��`��">"���[�a06�7�і0,�;O3$��@)������Qd8y�}���%^匷�^�sں�*O~wPɔ��W�Lb�N:*�u��w���0;O^?����a�`J"�$1��*���V��S�b��&cYe
z���Xh�ao:m���2ˌ�=U�a�ʌ|H�ND��_S��ʌ�]B�:g6'x�YM��{?�^�
���ܡJ��r�9�k�*Gki��t��1�����,	i����=|K4�08�r�Um�Qˉ�՚�}p�~���O��qܭ��uS�����%���U���+�>T�݂�,ۺ���*|�8��i���gl�A���=Ψ�_hke2m�+h׶��oh��ε��KssK��"��.=9iw�d4�ȸ/������Hk2n��u�}���P ��d(#�[Giش�5]���	��%���10'{F���L4噭D�H�A�=��}���7���v��L:����Fa��
��|N�{2�+oUA��g=���t^q��m�[Բ��o#u��z���#`�`�
aM�@��Ժ��p��ʍ-�vҀ�@�!K8z��
.g-{���3�YW�2����H��Z%��$�(OǏ�5X���p���'�
�^ZA�(�|p$0�{*�Gb��ʳ�Z_�c�ڗ!�����
���5�	8����'�l�E`QMӂHBQ��Z<*��L��jǿ6c�/�"( ��~�k��o��	�ƒ��w�1�X�����:�>�)�~�
�`�J3K�$rӯᦿ��&���ƅdžN?����������=x7�(b̰x��I1��n��{��^���Vu.���,�1��I�WQ�u��9�H�����6�5n%�}^��~�EZ�Nj�`pغko�[��W�׎���x���>P_����2Ur5��GZ׹j]_��aB0yrl���{S)��F�Lm\؈
czj�)�p+�G�p�o<PK����*]v&*��'UĉRxGJ�֗oqR�쩥xcoC6å8 4�FCZ�
#e��Z�&W�z �=�q�S��g�

�I���F��#���M\a�
�I�i�m�7&s���C����>�t�v�R�1 F-l�kBM����,�4;r��Z���e��Όy:�:�A�Ye�/T��Ζ�Ys�Yf�K<��b�Ι�kQIk1_���p-�ɸ
@ؤ��	�������SY��
,���!�8�[]"���x�*�Ґ�*ՌD�m����|��p���v%mp���q��ꬢ��7ԯI$����t����[��P�ϐ�7[�ĉT�:)
��wb�ځ�0�CD��zb��={����ｧ	iǴ��N'_{ٮ�����/�MO:��^��~�����cGb�߁��_��@4��n
�u��+�����Q���_1W���0�p H�L.�'��Q��������`@pa�/�6aa�$���NJ���ڑ������.,��ѫ�n8���Q���# Gb�̧ƨY�X�R@9պЊ4V�YX�R��Xc�֎Ī�.�e(��3��f2�,�=c�i؄>#�M�m&D8������40�D4���%�#\	��}�V+��%>(�&;�+�*�ܑ�܅���(�栙�q�1������g�j����<2`m'd��s�K�7(��b�qe�Gc���FlN�TZ�F�8i��[��"�P�d6��"��:��pM3B�v���j�t���L��“4�r:Ir])���:5��e_�����Vn�|�9�_n�r�T[�|M��?�*���1���s/�k�h4��7GA��X�����h���M��_���J*���E����
?�e�H�(o��s���!m�&HUY�-��2����P>�A�)>F�0�yu0�/���@OA
�h�=eGv���+c�&t�2�yX�!Ti��
9i�ܝ��A?��(���F�DBށR��N���8�
j&%0=@���V���3i�N��������~�3^�7U�V���c��	/�����U��P��������s+*�*��J���_��;'W��<U�}e6�<���+�zZ[{*ꍦ"�IL
�'\����z�}R�T!1K�V�Ua1[�o�
�8��ü����AŃ��/I�W<o~�._�Xn^j[�>ۻ<�Er�B:G2W1�<�>�=�;7�D*5�����l"���d:�����^�$���9弲�ѳ۞��������"��2����&(�������w�O<�Đ�%h�X�V����C��w�I]�W�S*$i�'����b"|� Hm&/a�h��Y���by�
��˅��`e_�S�����=�7���0R���N��W>�6�u��ʇ�`v,���c�„~zk0�t���ց�W��lTZ9��V��}�!!��,�&1�;��>l�S�ޥ��6��bc#uP��w�A���8�6_hި�h�&$w�k���j���'˂"�����oyW�"�
2q�)9[�PB:��f����0 �7����&Wd!��5r8L��H�R��ˣ�+p�<؉�%���3T"��40D�C�L	�I��g��7T�dt�Y��Hp�D-��
�X�&Ԑt��	$a�BU�o��N'B��a�_���Z\ӹ ������������-���h[dR=�`�k�i���v]��K��&l=g�%�Xq}e����j��i�[< ��Y��s��ձ=h<7���8�_��\�_XwE��'�ʰ�6�-h�f��"�K���ۤ~��Y\E�6R�B*	����PV`s($���
�ˆ�#^�AJ���\O�,��Rb�&02Il]�@ю�k��u��|D�4á�h�U���P��/�;f1_������xխ�?_�v͘6'3����^]���ݕ2|}ΜIb�\�<?3���������MSV���#�O�y�Lo�o����a��^�#;������f��?����h���ȢI���Af�f��Ȓ������&<��N��
�O��J����L�-��h�E
�u�%�[j�K�T��O
�j���,��}Y�.�e�lS��P�l�B�)�B�R�ER�D�X?�
�$�D�R�t�Co�~I���4�u���)�`�d�t�F��U1�3i�Q�|����IPc[+�=���曲y�_rS[�#�W��g��tK|<��MmOny��-������t�[36�ݮh|je'#A���h�\���R��i?9&�N��
wn����Z�~�v�͒�S.���\-�Xy�Lj
I��<��r�1AC�	�n�+���~�9�1�ql�ړ7�I���"�����O)�E\��!�77M^�>.��M
��I�b�+A�O����O��o��m�L?�y���߽�=8楛_\�)���[�����ށpߺ?���g��-Ȃ{�
�)k4��= Se�Z�L���D��8<��J�JF�2Q刲	����H�
�����I���ː� �qƥk%��-E�C`�IzK�e�&ԭf&ORя���f�B�/�f���D�����w\��gn����t�[hZe"���~�0��m�v�]�y�9�96���Zs_(�P~��z��l�l�9�s�kt�.r}!��(k�M��ffK���Zy���� sK%uȎP-�k^Vgփ';6�ap �N�<Ȥ�&IZܟ$}Lj�R8B$���T�`%�\U(�>�mL҃��F5��3�������M4P\G����H�8>�ȃG??����/���n���\�₴�T��6�����
�y�r��:�����6��6����}�̟~�Jk���l�*I�æXX-IIc�BSt<f�	<��־<�"k�����ޗ,��������H��EȪ BP��\qTpFAGǠDDA�g�q
�q�\Ƒ���WU���(�޼�=Hߵ�{�ԩs�΂��
��e�CA�K�՘�0N�Cwa�hAi7���z�{��`#���9e9`�{I�5C�d��\�Mh����j�B?Z�[�C��w�#�`��:bmy�םF_�炊Wx��P�+��\����\(���t�^xh7�~
�0R>g)x��#W<`��.
 t�(4Da���fd�G3*'�/���ݿNgM�~H�,�%�f2ٳ�C��L\����H�D�;)1ܫP���-*��eN�Z"��ej~�^�>�=�x�J��42g��V�i��I�[
)t�FX۠�*��Ѿ/�Ob^p���9/]��ܷ�1�x~]���{�V�C�1���62���ƫ�m+*�:mZi��|�`ǫ�x�-��*߲2dtje�Θ0_3�bښi��1ӴV[ܶ*�-�U*P�`<	l�U�T���[��{�,�Z�2�ZY��ʙӈ†�T�����vW�|�Ra;hM�9�9h��YL��	n"q1�
!8?v��⚃Ӿ��/���Ҹ 8�x�A�R�?~B/��Ĭ�Wa�/`�G����7�PC/|��v���^4mw`9��.�SM�4�%��'���&~�z!�<��h�Sje$y#=��7�(~��z��Y�4�橜����eG�� UE|�͐EB�h(>�x�� �2��2Ya�q>�pF��[rEJ�X�&yܩ&�;����F$��.�^g�C����xS�?'7�X2jv�&�p�@YmӬ�Q?[V\��~���l���m�<m,:���:�Gl�C�8����
�^=c�Jq�U��k��j_A��+/�Y���Rev
���[@����CU�k�;�����Ѓ[�O�U�5�FQ��o�N�{��&c|$x\�����)#eB#lv�N�;~;��a���C�Nq�3&d�_<uڬ��ݴ��,�ɿU�\�5��f��C�����|��["��͛޽~ִ���'�88~ƫ��2�B�;8�������2���l�Ge�\��p�z\dY-�)�/�ߞ��������n]2Ejl�<��0��qw�BjΔ��[��j�~ٛ�٪s��g>y��l�wMٻ�sЪ_�Թv��s�;TP{��ׯ��be��o&������1s�}��,`r�+L�ƒY��
�z�
�{��RR�|��7e��_�2p��}S��ȁ�p�[p����H��L��C��O�M���Ӊ�mM�?N|7��X���
��Eb@ù3��/��}g��ߺN�m
���.wX��q�6�Ɉ�R/�����&D���h4lF
Ѓ0g0�9@��Sj!��5�?��gw�k���z�^D�22Fΰ2
��,v�����
�-��2����h��䁜n����@��פ�D��mV��|a9
��R+��U�i��ޒ�#[[U���j��'��R���0`�����s��g�К|"uÚ���Wm�Y}��D�����謭��Z�ge�R�8VA3��D^b����WѬ�ܚE�o͢��5�I+����$˖���������	O��go�3���Bc$��[���.�E?������H��!}�($�ω�p�!����F��x	�(?{Ip�f���*��gq�h�6�V����N��ܼ �4fI��Z#��u���0w�A�>�6�L����w
�8�]�'�e������О�xݦ�ݨS��tZn���-�E�^5X�0���t�Δ�0Z�"�d}	��TR�W`*�J����i�$��C����Ϭ�ƽ�� ݘqo\(�N [����y}�i<Г~P���P�-����|dlXi`���y=�P��U\)7� S�y ��hU�zf@.��H~\�A\6'����[z�f�����]Li�=ɟ`J/��"��۲����l������Gڈ˸�*ۊl*Z�����~��
��?���0�KuY3��N�/������ʔ%E�Eڴ��*[#M��O�-����$�I���op"�s?R�\/О��'�a@�/��Ӿ�~1�Gn$o�N���.OI�X/2���<	8�ٞ��\j��/��lZ܋!��,�{~��U�&�7]���i;9�e!J
������pe���.�~����'�L[4nw�Dܔ�L�o2-1�d�%��X�B��W�@!������^�0�i����%����`��@�Ù��2�/�����g/5���d0�������^�kx\�P��{K�Y��ǘ@���PK��w\��C+`o��'R�̇K�)�P�0�2�����Rk�o.��c8I��x�xDSJ-I���L2
=�����=��!���9tqCO�R��$7��c��#��Ҙ�ϑ�Cx\,��"Em�N0�<����Lsf�u�B5�݉�SD�Z؛p��c$�x�ř1U(AB¤͐�,3\iCr�4�'a]n�gڙ˓�N	����x�^
�e�Kq��!R�bH�t$gڙ�%�h���,E�C�|Z?�ɶӚ���	i���!�W���L=�P��S��H�	W�J�]� �3Cqr��Ш,ա4*Cx�C��ɣ}�|<��'\�����Q���<0W������^���#m��짣��1�C���TJW3(������Âˠ�i~�ُ��|�+�|��I{��F�{�2��=��ET��"�K��EG�	���D�i�t�5fg���'9ܘ�;�Ə��c0H��Eff&�Їy�з�����h$�ʈ��^z�lQ�)SN{͌����!Pb �4�f0���X�&���T0�
��p#X�塄5����k������~��U��V�-�r%��a�*Q��U��?��ʕ�����?\��)����U��ʼ㪕�ߪ��9h�����W���6����`��~
v��@�
����~�&x�
�����+�
���z��
?����l�����+�'�����r�����\����x�^_x��d����m?Iu�%	��BY-r�.�1�M��I���U?�r��&�l�(��k	�V�!��{z�����cS�@��`&�.p
���A7�,����p7��6cY�q�$x<~^{�+�u�8�������s��8
��P��5��#$6��/a��/d�\�R����
�8������/��d��$����w����tܱ,�/��~�*�#^���rt�!���#�ripz�'"h�rU^A�w?~ƽ'޳R�g�t\	o^���������7�(�ÿI���R���y�������"s��{0�.u�Y��Iއ��w����}�~�̵W �5� ��&:�s�/�L����rw�wJ��s�qw�Kӥ$~�k�z�����t=w���qI��F(�-�va"���5��fC���+]�;�v����~�Q4����}����]/L?�eˇ�_`.,�`~Ѿ�_4lʮ)[�ۂO��5c��W��:��<�a>mc/3v�b�K����c�,!�8}	��+�6��ڗˋ3�D ��_惸��-���/�h�>���ઞ�ny���
"M�q/i��?�M왶���L��[�{; ^�bx�@���Bl(���"���&�¦$���V>����Қ����(�������<����>���[���&��{/d7=(^���`�������H�ܺuDsՃ�L���i��;��y���w���]���WLo��{{ŗi�@�|��7m
O�9�������x&N�������{��(u�B��G_16S!|;�鷪�~̓U�#�n��F�~�Fܾ���?}
y�l�#���f�vHV�1g*�C9���%�Fa!�G̤VW�����̆��2w��m"��_{�v�/�WBO�����
[��S�8
=���.ةl$����Y�_�������qǹ��9/'�ț�aAR���!Ӻ����itu�i�8J�j�I@�ا���m,�Չ_�5)���~.��ɘ:'���_��ZKe�t�`SwU�h!����ѥA����������}�����^��-�|�Mh��s�{�q0����↻.ܳ����(���`�_��)���7��e��x�['Ԧ�n�30���4�h���|Y���/��}�{~ U��'#&�k�_9�yM��5�g�Ѡ4*���q>�Un��K��^�L���(��G�En����Ev{����P��F�A���uȚɣ;��p�Sw�/}-��-[vǘ�k�e��2�=r�//�4uM]�U�j�29��ԩk'
i��z�ZRg
�
\'��@�� }�����
'��xj�A<vȥ]���ǴM=W���4�)q>���'�5��3|�;uGU�g']�z2
&޹��[���oږ�Q|��/�8��S<~��_4%"���T�íj�������.�!'2��\+��)����e���0TS��8���[&�~jh�c񑏷��nn\����6�zh�U���:����5s�n$p&Q3pQ�)'�}��!��5������m��#[~�Μ'�n�-�z�����D�>a>��`	
@Ɂ�͊g}�e�ђC�e�����e������
�Ǯ����#�qct�������Nu�/��lݨ3��XN�e\���;CK��f���JG6��y���k]^�4(��\��w�_|~�-�W͘y�΃>x�ү���\1��@��,w/�a����V@t�W�*U/|G0u�P�i����*F5��IW�L(ۘx��a4�p�	�_'���t��8���;`��y+������v�
vd��C�����Z$i?�g�tw~-s��2G!�O�L!�Z�ڔڕ:�:��u������)ΐ�)}/�v�b��B/����9�ޯ_�g�{��/��ս���>��Cj\�
T��'�傝���kVLS,T�U�@aP �K��z�F\8��5<MUV�C挳��
�_�4�oٸ�!V�	.�!��Q��Z�l��_���i��¿j�֩D�m�*`AM�۲%ԃeT�&�	��p(�e��%O�>]�j���=�{*T��*,�a�˘�XA����@�b�b�b���B��+��QF�EA��ra%Sً��j ";覚Ƙ��@�����ϔ��^��}�����ԣz|-XG�"W3���\�Q�I#2�7��~ܩ�zOz�?٣v�2�*����J/:w�IB���Qy��"`��C����y�)/�rK���N�;��B
����4�)���h�������\�_j��9���^q��[v���y�E��r.h;���ΰ��{^۷~}�+��M����S�������ol{�ȼ��Dݐx8Rw���ڂs�|��C�x�������z酧�d&s��BƽW�1�/B��q2�D;+��x�Z�6�.���\�����~�@m)(P{=>�V�
5��b6����B	
=vu�A�{!�hV �‡����T�~�cqE=
	X<.]n7l���a�
�m��l0������]��!޻���3��ST� �ۄxg[����P-�.s�1;
d�z���;�����Z]����VUE�l,+m�
�b��-3���҂v?��ܞ�Ӯ�7�M�[G������?��Zx�O�n*kx�@�_:�K��TF�8��0��׌���f��y9�ֵ"�9�r�sD�����v��.������R�a"���9����q�������.� �C���yKv�\�d玥����+��;�,~��h�
����\\�u9����>�$(�H(���P����<����;�e�F�8�ljf�
Y�f7Fv���~�/ɧ�P���?�C�k�+ى�`��7�<;���j�C�>\
��X��a_qDM�z�Z���\���p;p����"R���w���bb���2�|�����SrY=R,�u9{��p<��P�Ɋ$�'7%w%$O&9܏$��>�1k����Y�R�u�o;�-A�C �8?�Qn��x׸T��h�y5O�:3=�['�/�����d�;/W󉕙���������\�ᚷ�RA
�
��6�l`������D_ks_+a�T�Ĝe�G3��v�(A�$L�.�3-����q����7��
.�[S���A�s�n���XL�����+�Y�Cph�T�%��x�
7����������}�G�R�����̺$+3�
���b���mM���41�}TM5�
�zX�#��s-��Zb�3`|g��8�2��'���������w��A�J�B��e3�̠c�hx�p�W��_�|g���}��nםu[];���^�;�>��Q�H8Ů�xQ���6�^�W��N�42��^լj�rm���;���S�@ V�H	���yT�
�0��`4z�2UE۫�
�B��o�>|�:��v�N�����{V�G���h��uKAA��h��.�+y;	Qb�5mi�wtV
��W���A�EN'��Ji�AUj�Ɲ����c�
��������
�2��� (k��b��D���.��X�t��E�K�HQ<�
���\�cԟ�!�՝����m�>c�3���N��X�5�w'�8U��W
zbW���o��6XC���'j��Kj2?�CN_b
n�_@ӟԱ*�7^?��eL†�W_�EV_�JS7������g���k?��X��֎;Z��3i�����{���z�nFN���a�M��bPC�h^9�g��pm����ǟz����]}������]����T]$Y"�,�v�2c��,�<�X����������C3��NO�)A�+/$��U��S�:�����IP;^��p{ymo�׻}a��g��/�������Oz1��CH�TD±7�1e�$�1f��%mf��cQ�P4Q�"IEDo�Yz0'Ӌ>������ʫ�ٻ�<tU��M�B��2�	-�-�[v��<P�ە��ds�*��S
J��  ��l�
�j��x��*��(���:����Mߜ:GԞ�̴2�As�+M���#��ED#���q�:}�F;���$�fT�@�uֆ3c�&ECͿ'<�7�wæ�e�PٸF?�ץ�R|��nàTi��T�b�8����l����c��"����q�'�֔E"%
S�S���kf��8�A����6�+�X�EV�(��s_rr�¡(Rg�v�<�P�Jv��2�:l	���_g��
�_��S���E��͒QMu��Ս<�:f��1_)�1짞S?�`1Ţ	���
?eZ���E��[�
���_$��be�PX��0>`
f!�-��5���w�Q����$1Lߍ��3.��q)�\Z.�qY�K�gL�������$�,�X�S�J��/���Άa<| |4̄I�z��1q$�=�0Qn8O��t7^j�u5�cV�l|9��5/�&h�8�v}�q�p�+c��-�>�L-�\��&z��&Q�Ȳ�����,&���3�]��j�&4�g׭��� F��U��hst�,h��؟��~h����g�+�aE�t���+E��|+���Y9��WDr��d�T��R�c�n��L�Ֆ��S��c8}7����2������]�e�ע�8��r�B�e]�����#\(H=…`(�#\�'�ʭI��ḞM��t�r҂��`Aʅxz�ؤ�'Hς�8��Y�<3�L�-ʋ�fʵ�n�N�%��
�"P(`�AF8���\C)?'��n[ы�Ag`�u��<p�h�ּ���w�jC/��)ؘ��o��Y���*D��a��O��g�Z�V�Mc���9Gi~Yf���4��k�
8�bM���Q�xPQU	ԙ@�P�۸��i�(�JP�"x��@��"����ȫz���9�2�cE�����Ia \�Ee�o\[4�lX�m\���3��NqԼG��9!����m�М丅�5�]Q&�:��\��`�
�}�|�PS|��S����C�7���O�Y�+�(��1���)�;m���82交P?��|�x�:��x�Z8ѵ�lx���6"���+0������gΌ>
5�/�۶��x4�ٳܵJ�:�Ż�y.-�j���a�������U1�󸵫��+��/�')���:���ǗK�%��!�G����)ԙ�)�����<u*e�	����r����4�)78E<a޴.�
q�7���g�av�Rx���yX��tp�z��1�c�-���}jyw�P(GP.`x�����lv �\�˥���2}�5顾��9��éAZ�r:�
��	����JYI�O^$3�-�������9�!۠���3ͳ�WgwcUCj7c<�%iY�K��T(�:L��J+y�����.����\E�PH�����B�!�d!�=�t�F{�XwW�0�e�ԈItc�L����į�)-6d&L��yGA��I�ul�CrQoL8�Ă� N-�f�F'3
2�\n���O�5C�31px裙�ç��kf��&^�4���(zf¿�O�~8=٤
���U3��h�"����ᙙ��HD9
�A���V򫱚�����n.�#��s	h_Q���(D�و�Q�� �ll�[�|f,Knro�VIRIn��ҷд�������P���)%��F�e�o����uBPBU��
cj
��5*S]/Bb���J�s�eOu5&B�R�0֖�}���
|'��Պ
,S�\��a:�t��,�M~
��}�R�̟��
T �55
S�I �i�J�뭂R�[�V�2\��

����v��X����dP6�:
���!�=�+r �	h�tF�E6��A0�a?
�/���u���UI�[�P�!6�!H�e
�O��hI%�Q3�XW<�q� M���d5��PI��#3�l
U>�N�\��f�2�&5�$�]0���~>Ҁ��vBw����x�ʑ�#Ƨʛ�֣�'{�ҥ9Nr%�"��P,�g����]�?4B^��i%澅J-��C���:��p�c�/]�]l0X-�ð*,c�>�
`r�Q#�cy�`v$������ruXG��|Q�KN7�f� qts��e,#,cf��XFX�2�2������e�e,#,ca�(����]<��y�c��ϰ�|�e�3,#�a���gXF>�2R6ׁ��
`�J���Ϊ`\u@uTŨ2�F�aUVQ5"�a/屉�b�	�H8C��O���\��/�(Y����q���dşN\���k���h` \����U�ۗ,_�XB殰��bzs���Hs��@�̲�c��K?s�/�_34�2Qc2����ԯ���Dy�����;�@0�f���wy�|��'ʻ��p{��"a5��/ɳ�)W�	,���G����p�9R�r��/�8Dˏ^V>��Q���е'qz�`�̔�V���=[ˁ�Zy@(阮C���
����(g7��/�Q!��&��&���U|	�ǒY?y��&—Ugd�b���$n�55UVbf)u�G���m��+�
|XG��Y`����R��Z�.��歘:J})Q�/�
q�.��4��`���Bag�B�_ +*�A�������l�9������6��tI�j���&o��HE�F�KJ�j.�D������M�!]����D�>}
�6���.�d��x�k�XBb,'�x%�� ��2J�c�-����?����������󺩳`B�����,]_��j@?��L���W/�J?VwMKE$R�p���'�̦�<!6�7:P
a*�+B�-x����!�!d崷){�ޗT2;u����}�u�Km�+8����>J�ҙJ�J�-c)Ӣ��G�{�{��xG��b���EH2O��ӨX�t#�%���2
ĺ��A���$��$�p�:C�UT4�m����V����"B�w�މ+]H7毡g�!�r�_Lj���u�����g�2Q�V���Y鮱2Ƙ�x�Ȓ|1�nbF��4� ����O�������?�f�*Z��
V]Fh
�6L�І/�@V���/B+�^.=JޥL�ZN��0}�&���H5:S
Au��D�s������v��$�/�5%���lI	e%���.	����5�~��{�ҏڌ7�⌼6�'�Jc�Ylc+�����S�BfS��>���R�z�2�_b�@�����a@M�~��w�{�҆�I�^ Q}�P����U��B!�u��W��F�l����P#CbM�D�&�x�\T6R��F��W0��IOB���%�<NZ$�Qa����^�	ae���� ̯Y,��22�i�v����v���یۍ��dB(Qr!�ܮܥ<�d
�t@yV��wHI�F�x� $�q*������K�"�B�K��2^�"jM'��+8�ÝU���%�޸��5���
[5�zJ}8\7��X�y�������aW��=��`�Hb͠�އ^����E"R����5)&�:0χ���A���/�b��&�'"�ĉMM���<a�3X>m��L�A�¾�
 ���I*�.���tJ��8O�y\q͓1m���\۲-��ǎu8~�32�o7w��r&�;��݌�����WYi��LU�c�@<?�Nkٞ�>�9A�Pw���/�z��ۗL�	���1HcPZ/a>T
</�9�͂R)D���J��w�c?q2>h��A�����9}����j��m��6=��O�YBf���4ʖ�F�
���r���ri�U�7�
��K�!TMOJ�V�_iD��%�ц
��XP������/~��d���
ׂ��Fpa;4�OmG��{���3��V���<Ҙ�ɑZ01ׂ�h*���ud��V��*�~���񩯕
��55�5'S�Dc�s4f|C����
���WQ!�I�Je����+Q��VB�e�Fd���.����GD<BZAž�h%� {���eP���U����b�ۈ"
��I��$
�����?�{~ل���6�y4�m�B���/��٩��Fy`���
�;�@���ƽ`��َ"�����4G�WQx4��f0*�NV��$ R�Y��h淪�Ҡ��$~��������iZ. �	걐*8=�LV{�x$�|���D�{�̠��2����XwHT�`��Ʊ���/UUu�2.�Y�f8��c@�$�+U���SQ�k�MP0(m.�6���-,:B����W�TH��+?�9TK-��9��� N0����]u��1�,��aI�dv��:G#��bݘ�!ޘ���]��KV��zv!9H��~쏉���A&�~/,�aY�Ey�CV�
�}�Խ���{׷BpԘ�o����?��k����\zǨ�^{}I�l�-O��&"v}�m�߸ʶLK
�W��S�:�!U���Վ�������54�d�iEy0T��rrߟٕl�v'�X(.f���� ��X�d�|�na��v�;u;
�Y9�d_�Yo�^���@����]ñ�:�y^hw�y�q�U�D�Eik�3mJ%�V'&�Z6_���w�Oe�e�ݲC�edS��˦���1Ff>c�3!u����&��9�8
4�4HCvl5x>L�H6db$���ԑ�,���uژ�uw�CWvQ˜��TK��t?����xoǬ#�N��ѿ���<߳��{����w'��L��į���e�������>��eX&��B�,dEC̊�a]lKlGho�p�p��-���k>404�p�0�p^ْ�e�՜+WM.��W8.6�`�V�ؒ�
�ǂj��f�;,v��܏��$�9�;C5lC�/��$����j��f�r
��y�����M��6�D�4[�P�&U�,-�HZ�q�PB�QEwl��F�5���|c�{M�&���4�Jw�S0��w����*��j��hn�@��*=�S"G8h��AP$�зx��.� Ow��:�{���T�q�oI
,MPWܧI�;��<̎v�")^��.9����y;�yZ�d$�����yHH�
~�'/^�/oھbنG�	.�e����@���?��6��C�pN—
j���7t�8g���Uc�͛-L��t��E&�U5鞪x�_|_���%��Sh��ka�,aKD̊�%���4���H�MN��>	fؔ-�ng���������k�5-�Y��Z���jr��q5��έ�U3�aI͆�Ǫ�!2MEB����i�
E��z"QK$M*&�9�����V^O�`0.y����H-ԎTLU,P�V�
�Uf 1��.ͷ���%�m�Y��KT��\ܘE��� 	��wl�m0Lq�V���6	H�8ո�?��i_6�"�Td�
�Ul��h��!��K6������˂���k�~�A���\���7����4Ҵڴ�ęz�=�1��()hZ?��/Su�2QԈ
F���5]�k	��ye��M�8��mN^1jZFC�?f����KUu�O�=�k����[q�ß���V�f������5�����o�������qkɴHr.�/�g6
�vujߴd�S�a}�0I-�w�{T.��2��X�,%A
t��	+d1[,��bW�,�X��*ߒxV�#��|o�p�p����U��>606>>�c����������������sժ���E������s�f�g%��7�<V�J��h��T5��9�ȡ:kf��z�[��
|T"-Y��m0��W�F���%�<	�Wg�
�%�Dt��XtPGbz�Cy/�Q��l����%�W�6
��7��M�	�۾�[����Ӕ���7��vS-�ŏ%�����6�x�@�1V{1V�f�HmT�Y��8�ۭWC�������_=bB�A�n)ܟ����GXx��`a�n����h$�,̀�yVU�@�%�?D;.|����K�pc�xع���l��0i,*�?􄭈lڶ�Jx�]KpKw�i�ܟ�Qw(n,{Jw_}��7��Ѝ�9lӂ ��$�O!s�Q�¾$�οſñ�q�q�W�xv�2�c�c|����y�%+�����&'[����5ε�*��_R����]ͱl/�$�j5�6��l�#�|u�R����{��`���7g0N�ⴀ��x��vYx�⒆u�J�@(R�@��&�4��;6�o#Z��l�Fpɰ&�)�"�;�	�0
��8���3k Rq�}K�Z��]�G4��Q�MsD�i�����
s��9r�	as�	�'�KS��ʘEb�R]�<�f�B�	����>B��_���#c�9�R�_�FĄk�}[�
[�W�|;4)Pe�L���
���"�*5{�!m:�\a�ż���j�E߻�7^L�?q��S�(	�d2
B���Qh�����tc��xb%RU-���=�@����E�^����j�쎳�u`���Cw`��F�~���Y�S�H7��G�I�7b
w�l*r�a6#���7^�����Z-�������n)BET8ڗ��МDD�\W���+��sP_��FCp7��c��F�/��	��9��fĈ�6�b$�\|^�9��f�H|O�#jkFdW���+��� �r(�I|I��{���"�PH@��FA�y32��
�]��j�M��vh'j�S,�*�
�����R|��+����_W~x���'�?�z�}E��������?*'����V�x���[�'p�#@�D_�OE�3,S
J'�UN3ʠ�!q�_�wV8��Q�I'�$��Q��w:mEO��tTEQ���J�G���p��D�P��s���j��5���`g��xpd�H�L�
��

�B>����Fnw�U����Nk���M�-���m�m�)b�9=]G\���.�Z��=Ud]Y���*�d�1�@Fiע��Xc�z�����ђev�ĕ�=��Q�К���
��'H�-��.�As��!������e)��-	�ʨ�{�G[�t#��=�obƸo���joX�6�֍:~�0�t��2A0e삈w�G%�Z�>��t�-��kg���8Jڢ�\��6��gpF�8���̀\w���)(�+�!��o�;+�)?�7�5�"�e��>�M�`����b'��Si=�Ő(�T��D��'Ȃ����PB�E�/nW3j�)�p)�ҩ	���W%OВ�z��$������Κdq|����<j:C��+����ڞZ����R�ʒ�`%�J_�����+�+GV����Vn�D�Be��\��B��[�
w7aC���7V�Qܵ��D��\���w/"ZĮK$\Q��g��	w�:M��2��x�."�
��Ot@eVc�G����v��'�Bo�+�٭G������Myz�+�W��&{}��~��F0"�x3#h;p��Z��j�ۯ��X�G&�����S�~t1�0���'
��*CP�r+�l�-4&�x����G܌޽ڽ��LuC���j,
�^
�%����s���)uEnO�Ǜ�sc	��5OہB�W��~=
1<��E#KH���)^k����,{X��v���w��<�I�I�	�	�k����1B
G
��9�2�$�"�k�Ƌ�`Ç�
����4-@*�P1�MF��J=I�'��7x}��Gn(F�d��i��I�E	`ģl?��ZM�4�eL���������`������Kބ�?�ƾ�^zY��5q�[������{0�b��VCwf�(�J�]B�&k�������Q�c4�x����c"f,}$"=�Ry��9���c@R��E��h�JiQE#*e$����(Z�tY��B��B:�!ͫx'r���ˆK�1����`��\���z�&2�E0�
|5�Gq
y�q$7�3��<ZcK���Ǯ��X�������#�"��
�����)S�V�B�[���}��M���)T�Q�)�4UJ���n���b��
J�%�z�e�Wp�1���E�N�w!��=ɞeY'fI:��c���=��˙r2Rb4��E4&m,FU����i	�M$<Ñ����O���!�k]9�X�(�� �B�cè�������aT{�Ǥ
Ja1���L�ܤq&�{統���e@GCZ�h�p�&��u�<n���G�k�ՉV�wzC�:M3�

zrp$R�_l�[.��\Z�q�Kq�
���j6XY���
�WM{l��NT~]���CQ8\�3�gL��0e3����SӖa��A��3N-/�If=�K'��x�Ӹ5
��W�L�e
�+�P��eq���/�ZbC���J�{~���	~-(�|0��d��>V�e�r�Tn#�r���s\�p��=�GF��Hi���Q�����ʗ�1*�.r�?�a���
�4=�hO��NCZ�j�XKM5cT��$:`LxQ"PH<���`z ��hd�9�$G��U��nEOҏ�	ȿ�΄�8��o�uhq!���
�u<���-#'H�|�x\�s�*�ޗO����?��R<�QY/�F���W�-���ͧ������;�p�/F�C����f,�,،<(s�@�H[��uR�S���k����j�"��q��=F#���"��u1����ZT˶���.���2vT���rw�Lr;_��!��8VV��{�K�( `dX=$,�l�q$� ���K�d4mń)��F�A�scc��xf6�0#cHH�t�ȏi*�����
%� U.���RdDB�0���F.Ne���ĭX�{���p��\�P��E Q��7e�Blx�}�t��})�/��;�}9�������Ps�w�"%�ȟE߳�R�dc������2�mU,�@�f�f���h�J���;�Yo����L&�����l1�,E,gaY��ZLr]F�u@��gs�ewpw�6s�e��q�d*�|�|7�&�>˱3'3��DW�!Y���uw��4I1W�%g]9��(ݒ�\���ƀ��q�i8�Dv�*����?�RSӋ�:��?��j1���UVy����(#oط�"���u	~�k)�*@.�#��$�*�Q��ƼVxK0-�,w/�>�����95���k�����<6���:|+8S�	�L=k<(����a<����L-P��^%B�@0�K.�
����ej0K82�aG�� (�eeq�ޣ#�U`d�G
~�/:�>w^�=�-]���q5�ۦH�W]�p�s1�!M���T�
��@P���g�@N��ϠDZ$Z�+�N�r��]C��2��pҰY$¦F���<PLG����Љ�)aށ��+[jk�/�35��m�q@�:}
��舤&�� �
���0����D`���=�a�4��a
��
���^l�)ꌃ�����8���4"�\�d���B�h
��P*��"��b0S��hT2��HH�Ub�^�A���n��Z�JP��E��Z��FP��db� �H��J>R�&��'��$̊�����S*�Hl���
I��vmI��_���0q��fU0�X���0�ϊ%�OǬ��l,E
��ۍ����^��_��
~>:_
�`��N0֐C����Ă�`�w'`{��z�U
&X�ws�
|��W�Q�7٢TFP����X�6�0� �K_�A5�u��Ը6ޚx%�L�n<҈�B��]���m��l#Kb�����F����&�Ti+	�
��[��"��0�uW+��u[��V�����'驙�[{�U2����P��LwR�t���N��ue�r�q��1�EOt%`~�ew����ݴD�4�~%uECF,�^(C�1N�r$��HVK��I��d��I�D��ZH��tHNY/vm��3`�m��yx�:������r�Gh�I.����Q3t��e+]�H�x�{�o7�`��q&�:pÓ;ok�Qݐ��|=��mLD"�UW�e������`�.
�/�}�֫��SJ��7�}7S�
Ō^c4����氽��czWw�t����4�-��tϘ��t}��ዒ�<�MEX*�JaWxc`��L�9�H��_����|��5>��W��+�,YƯK1���ƁRE��p#d!a� �
Wj�c���I$V.�S����u"{L���rJ���}�E��h��"��k8N��g��_r8��H���Ezb�Ç����y��S�u�y�ϥ?⍎�g��F�&���}��E/���6��3y!����vx�kYuKQ0�(�%4f�w��%`���
�0�
�v�*\t�P��pf�,�����uI��.�y`�q�h����9W�1�����������VDl�[.��"���N��2u��<��� �yv_0h2����>K�N����Gp�_%]T��f04�g^U��'i����x�z<�av��Plb)��H�X@��0_�@����*e�JntȬ*�q��.�BkP���I!��^�z��?��&��[�x:��N�:U��Ck�b�=J���Z^�2Eq���+�EE%�^��x��+�U��WBh��(;�ĈX�5hy6�7g�̈�.�\ۉV�����1)H4iT,c!k��S{��4�@��b̸ѡ۫�:I;\2+\)~N����߽U�0oV]�Q�c�cFU{�G
L�Cn;Ü�y���o�Ռ��S/�Gn9��z����u���;s'�4��Ƽȼ	��G0��1 [�nea�(8So_Z(v&��3����h�uZ�a�m���*�A����E����V.��m\("vk<=[���4fIH�A�Oo��K�8]�\y,��LŘ�Ĉ#;8�+�X3���0Ȭ�����‡���f��U�oo�8����Ԥꇷ�b�̚2yV�U�0;շ�K���9w�8���W}��{|���?��>�V���ZP� �+\��
�*�
��rF�J2�ܡ��ջ!����		AQT8Zu�
UU�N�Ӫ�+�^/'(��r_Y��A���W��r���d�TWD�XН_�'a��at@d�Ő>��6@,RK7���0e��� vӈ�qj7�����H\=5���=�ԕh!c6���Os��Mt����oI�E2x���3�X�z�ַV6NH���u�V����ܢ
'��5�7�v�a[�߈�����]��ʃ	���i�\������=�1
w��eæ��jw;�5�>}`�O��M��Vj��,�v��Ā�)t^��
�'�).�=�h)�=���#�EE��J���R��O�o�3d/\�i���s�2�B@��J�X>� b/XvYX•�-�,}��b���L{"n�����jn�{j1���))n!̚��Ѭ]x@:St���Ĥ���U$�3D�:���Z�$���e����?>sݹzԊt3���n��_9f����6<��ÓyI
r���c|Fd	��<��JgW�w��y�]fW���ѵI���rw��Q94�=Swp[:�6�
ل�R�B�hlm@
��H�X^�\��IvH	s���l �gF��@�@gd��@�\�ȶ��
�x��ga�Ķ�qW
�
�<k�
��׊�[��8:�
Ǽ�_��{��>?f?��I����f�v�2�]Z�"_����F�6��LNp�cJ^V��>�]��B% �ן�#�ٮߥ?�g��@��R*IOҩ3��gLϿ�L�7��)@�M�p����c�vsa)��S8PY�t�Ѫ������o^��u�
�޴f���r�r��A8I(i3�7#%R��N'r���*vբ:sl���k~�y}�8H�ɘ*�Gf��n73΄�l���.��hv9
N�b5[�V3t���0�tOs/t�qou?�~�-g��c݌��.��Q<T���CGc|
ޠ1�q���>�ӣj������3�$���w��$�޲ԻR�i�v��ɍ<5�q�����<t�(�z`�G������)�'c��ɘ�yF�2�xy6����U,�F�hL6��<[�M]���2q��NaxK!���2&��y��"�����a��{^j�7.�@C�QZ�l�r���
�F��D�S,�zj눂�*�vg�Dqdzc��=J|�n���X��OV�Ǣ�{M�2oУ�_zer��m�^X��
m�BX�Izy'��\W�ٻ��=�=�9�=��R��+����ll`�V��xp�yt-��2��c�DXBr�T
kR��*<�g�=ȴy�23���C$A���#/��yd�ŷ�
�V�§T����.)�a����E�
tM:F|`$����j �ຬL`)����V+�PM ��	����k³�Y�ț�:	d`��)|Igmz�5b�uo�;ޡ��1(��L5"<�ٗ�bv�җKF
k��o��	��'��s�菀��Ϗ�
�P\ʫF��LD�)X�0��zf�
��!>
��ke��>vWc2����H�/�M�g�LP��RPhH��*�]�3�]%���N�4�B;� ��T�3�+�9��J䶮O�e�ݒ���"�S2,�bxv�٘�Ѱ��8˅6{V�&�SrNT��"��k�U/ߖ�k}���5V/tD#FAGC�������(�����������43�FI-�eْ|ˇ����el���m��$�p%���@N��9‘��.w�Bv
!o�1$�Z����ac���?/��̴��y����>@sǭwߝ�w�"�c���9�LGFw��^�vm���GH�C�'H}� E�}���)�].�JMw9N'M94E3*Paڃ�=��h��a�.c�)ʤ]�\������>�>�>�#����w; ��v1�5h0 ���Xh��� �	2Au��Ȕ�+=H�gAt�gA�5���T��;�ob@u�������B��J�ˬ����4���8��g����nkj�W.l����/��#<�:I�t��nA��\P��!_(�a��i�;ӡX<���tn�\��bڥ�S�\�����R竆�=�X�!mΒ�����DZ|ђ=0�vn@٧�����VI�V#�^6����>3@�9�m{l��YK��
���ls��z�N���]�c\���\��N��^�P�\7�c�0��NG���5�=��o�i8��c�}�C�����VQ��瘊ج�R����Eb2fHI�k������T��ly�=n���v������"k|�-{.Y����/ؒ��1z��ߚݹ�9eZ{��}�����_4{�j�:)�Vu�dZ�pC������9b�с9�X�{߾t�y3��z�mfGS�6(w���������d�Y���'���_�1:*L�~	xX3b.�D7kA�h����/Yo���ⴻqJ���@\���e3q��<"l���hw����1b���xl�1��T�r��A��p�#Dd�BO��W(�D����ڏ���w�d�f=ԋܾ�
�^{�kK6�sן����O�w/}�
���q��N�,�;�!k�E#��>;�Ҿu�-�E���ȑ��F����ά���N���L��U�D�q�3�7d�~�d�
pD��c��^ݎ�̄�B&X�>��j~ɤ3�Y_�:c�:�l0������޿&\��Θ�#�,��[���+�K���3�#o�c����оo=ۓ[h��W6i�C�6,-������`MpT�UD��]6��^��Ɔ�J+r9\.��`\k��
��`@���6~���V�>#8bF\��o�ybR�=��lM��u�S��GHP�XU�$�@�A�6�/ՓSC�	��n��7?����`j�Q��ڰ趖�e篡�1���U^���M���wݷy�r�#'���b�[�_������^/��
��gQH��zK�Ŷ�p-������[���&�L��:���
�Ҽ
<m�N��络V��i���n��mO�~f{��ښ�ol��4�v�iGy+�h����� �4ȖћR6��H3Υ�"���j��ܤ��(;�ꀎ�V���~@/��2Q
�X���}���^��Ndݱq3tl�VC��j�Dñ1k��Q��z�՞�l&�t�y�U��qT!t	z�Y��	��|���_o��򡞅�iǕ��;��s�7Y���g/HV��O��ͯ����}W��	��~rYӝ`���~��Qf�+�ԋ���cIX�F���bz�lw�^�6�IPOY܎x
#zA�a�I۟ݞ���`8�N��,�qЩ�N�rA�({�	�!���s;\rzOZ��Ci:�6X9���,h�Fc���VC�a������3���S�:�`�r�g�6� ����d`�����c�%��mǃq'b���Bkmp���^Rg7�R�ڗ_��s��o��]>�U��y�#w�3��
y��V(��~��ǔ���=�F\s�_�Yf�`��_y���2Sw�({:���t�� ����-�����3z�)�7p1I	]���„�E{[.��
��z4R��i��^d?Hٻl3p��ػ���	�1(#��lX�?��
0�E�/G�*������
:���h�h+tW��Y�H�$�A��j3�܀}�!\�P ���V�6�z��X��k�
#C�qDuT9��&F�d�2��#�$�yH�v,
�l��('���T�Lo����.��o�n�q�o�ý{���}�e`���~&����E�w�[�f���fx�n{�mM(��������� >66�����'"÷�E�ϋ�`%�3���V"Ͼ��,$�g�8�Tל<�ZS�Lӧ<V�����@���ʉ'�Z��Ǒ����64�B�D��pJ/���*V�UX%j/4�cRL�t52!O��L�W'���'����6� �=
���+��rZ0ٽ�g�Zo�]��q@�ʰ<�O��Ţv&O��� ~k��6�\G��u�r���ۻ�t�ۭ!�����&�|�Du@���B
@u���*X��Z�n�͊l2��ֺ�]dsyJ�"�e���z�U���6������� �!�@��J4mЦ�ԅ
���h��r8\eN�B��#5;��f'l���s�ؒ��CV�
�w�q�rP@�6
�6,F�T����q
���7���5�p.t{�q�{aJQ��#�6A����L|�Tԧ�d#m�,/�yH�!R8��O��0��]=5�I��$I1N0j��N��xh�w��{�����93s�j�
�W\h�]=8��R;Gyz���#�?Vy��Rz��7�PI�I�KR�2�i�y���j��k���v`�cO�:��	Nv�#���
kb/��ԓ�t��u?�f�=�;������:m]��&~3�ų�q���_���;�x����u��?�>�8���\�;[��n�ݥ��z�E�4���K!Ŗ��^o��Hms�6Hv���y#4��^�N"��m�����c�+*|��8���eH�`�G!���#I��Z3��M,���������o^{���.�_��;�_*��;h���ow����Eʜ{+�T�P^Iޱ|�=�T��'�H=C�Ykr��?��H�1G�
��q�s�tQ-�s5g+A����Ti6�JZ�V����k#��#�����&U�h*e�%�/*oj~U�@����J
)=2�
��>��Y"ݮ�X�y�>/�E!e�eCH�㒩i�ڒ�xX������P:Jյ��8���n��e�Z�E��5���2�e�!
y�g�����<3���5�Ȑ��	R2�LZ�*{�58��
��h����AQ`��)�C���鞣݆��*L�˦�42<��ݣ�Z��|��Թ]a�?��q�yM�n1���[�����E3{�j]���/��|	:�Q9OyF���>�K��E��`SOJl_��u����,��u$��4$�3�[
T;�S̨^*�[m�[�4�$���i�꭯��uh	�</�cӣ�����W�R�̋mof�h� ��6M*��T�͕�,� @�,hE�/x�`E��,��t�X�
!�-���k*�Br^��	koЇ�r���g�,������E�*����`m��0�r�\CjPvh�>����#���3�Q
i�C��!l�x`�Yo�F)3@�
�fh��A�ħ���4>��ʝ����Ѧ�5r�Ϧ`La4�cǸ�p�d��x5?��jq��� a0��Vk���ڵ�l�;��9O��^����uv�����������Wvԭ��ӣ��t����s[.�	oU���'I�s;}Ӧx?L_���/w�kmX�\^�F���(�.���	ҙ�)�IDG�S�
�#i����0[���3c
+�p08�]X%:E�6�^��-�%���q1���v���l�"���a�����O<���6�>�>A�Y�#u�D��Wxt���~/�����.q�`��h�(�͡	L��hL�3�1T�C����;���>5�Y�!�Y ֗9ɻp��o=v�s�i��O�k��dU�gt�U3��d��h�������r�–�$u/#�Z����Al�<�at=��HO�?�N�i�/��:�6y�)Y��g ��snGZ�_4��\�����f����UV�<g���u�-N:��~�Vp�V
�%�1N��]���.�#��A�
ɤ�;���\�Xq�[[Z*�l.�mm���2gVr��3�ϵf��P�
��X���@K.ҥ�r�>�n�IJ����������<�ͅZ�]��gZC��v���Fj'�1����iu\UW%%��)��8�IfΠ7��w?fF��&^���/��
����ʸ	�2���2v&A����Jf ��i��
��eZ~
��]K��e���f���Jc����%;�@��%����n��r�v��9��*�|��|���K�e��z��{Z�6�,�1I�l����fWj���s�,��4:�e�-��j��
�Xoi`��I
6�]/�BH����4�M!`�eS^W(�Pԇؐ�ф�i>�r�q�SNl��g�Q+����[����MPnh�״��q�.]��=�'��v=�
�����4ң��yF���!�ڄ�dOi}B�9���G��a�Ij$!|�|M�C�
�H���i(���_]`�=�ݣܓ9�\Y��?����׾���1�V4�:�}p�޹҂��-�l��v겕Bb-�m�tI����kf�Y��OϰC��S���biċЌ��I��dw�'-)Ol��������
���E�[�{*���);M���2�$�C2����\�F��V�*���nYlw�)G�r�p���g���(���k=F�
�Er�(��d��8��i�L���Q�+qDzk�����$um������s���w"�u�����k*��Bzߥ3F����77#�qf�����_ck�>U.c�#��8�����@��Wx���v�����+����bi]������Q�c�8��KrW�Ӆ��	 ������!�����u^����T���x��B��fk��\��p�G9E��p�ȱ�l�!�K����b�lT[��2��u�����d-�v���r� ��+��Y�u�i�d���ʞuJ���=�V���M��΍�s$f��S���(�����C����~}i7(^vB�S>Y�}f��Z9�}�]A����u>�,�]�w����3�ϟyK��7�o�^���2�&�M�gz�6���]�t|�����~�w3O?I�y�^W����hkjz����n\vU�d��d�,gW׬�j7bVq��C���i�.�9
_2�>A�'���Q��
�.Ò@�o��3#���Z�BR��a��2+4	
��d�n��3��
�>����4���DC�TW�
�Y8(u-g/1���%K���9>
�4��/`�1Y3�9
>7�꾱�ʮN���ڍB���Ŀ��%�h����2�۩���9�ȹ��a�����ҵ��δ���/�b�ٷ������հ��ϳܰ���2����,�f���s��9�����ë�+���ܶ���0��8�����ٹ��Q5���&ס��/#��׊���v�鲵���ռ��)�ڥb�E��'�D�����>�E�ٱճ��z���H�⡞�6���4?�8���h����ϸ�P����d������\������ݵ�Ҟ�K�lʦ�K4�ճ��5.��4�������s<�����m�D��V������inH��Yְ�m��5��͎��]5g���<e5��⮻����^?������ms���p^����^��%��2�������@��雽Ӯ�m�=��;��qm'�}��'�G�"�@}U��ѻ�KC���9�%7;w9u:M��b2sg�:��&e$Yef��C
���(kj��h������P4Bq���#����Q�
Ldw������b���!�7U��-�?�����_M�"wJ�E��H2f�
;�<�_�]_{s���=����ҷ�}�W\�=���+�o�EG��;�Y��;.H�/oY�������5�P��׿v��a�CJ@|��z�{��E��@&�H%P{�c�CV���T}}��u�|^�C	c�'�Io��r=�����P�(`�#mB��(�#$��N��R!6
�V�gbi�u2�m7�5\�j�1l��E�����@q_q�I�Q1C���0&���>dq�=D nm8���ϵ9�!Of�L6ZsG�qS�B06��
���g��U�����(����紵FS��V%Zw!���]�?Y��\|�\I�uթ�vKR���Q��E����Y��tԇ�!��ѻ�
پ�蟚il��:�0��(O������[���1�[����d!�,��Q7�h
s�=�Qw���;"B��*�Q!'��x��J"��?�#�a����Qw�=�ƣ�(@��(�n��zV�@�g�g_��F.G[:�W�W�K������-�e���9J���X�5��즿��|��/Z��2ޞ��]�B_��������ƭ��B���?~��N0���Ư��$�HK+�2�.��Y�¯0�¼9|�yW������%]��^6����gKe��_�#Y65-��);���NQ�L���b4M��Y��Hs�ɇr�r0���S���YiXE�W���/�����B�3�)�V�s���7�1M3���c�'���>����&�5��a��j�1����֏�}���Y�Q�6�����@5�6rl�"��ѡӔ&�
Rz�1w[|
�Y���K�g<k�ߺpV�ŕ���l�3�,��:yf󊛅�J����y�G�/�iYBJ�g�r�c�uX�
�Ϻa��v��r��l*KP7(�J��F��_D߲e>�.;�>�dv�: ;v9^p�����Z�A0�j�P2�&K���3�E��X"kՀh�J��0=="ҷ#1�$a�J���y=�G-�>S��Z��`��:� ���P|�NX>ĝC������2�PBk��&ϸ��e�g�@mj���%�|������ʓ���/>��i헚�\�m����L?��>5�b�o��~&�\�('?�bݜ�y{�@��G:��=yfw�i�~�zP;�����A�5v\."��ph��EXA'8/8m���|P&kH�,:\�n�.5�.��b�*���5A%V& �ߗ؟`|���2q�}&�D\j����w_ȥ��UaL@���q5q�}��"��}��uJDL��f��4e�߉+�3V��������髯�-Is��ډ^��9>}��2N^���+�q�	�6M�w~/~0�$�	�`�[�n�M&h2yB�EI��=^�$�D��9c0��z�^�Gr��Z֩ղ84!xhoLbE�[�s�t9�A�G8�N����]������
���a�)a�/0b�_4<4�Ńh�?�UD��l�z� eFڠ9����{�q��^&��6tyi$׌z�>�ֺ�Ȫ�z�K<�63��"ۢŲi�{��ݎt�̒�8)���v
#Hē�����_��x��݀!{)G4\t#�pQ6jB�>\h��{�.�/)q'3��ȁ�����c��� ��H���au$Cs����e�$V�#G���1$Q\,"ʂZD<�@���?]&k�?�}�����lt�5�Gʟny��z.�p���s�ޠ<y��i;�E�M�^��݇��������snx��=dž��ÿo{��]ON̢�o����,}�㑹<��1��S�l
R<�.�YJ��M�Ƹ��h$N\I*
B�.6B2o�8|�O�İ���B6$���8@��8�o���V�A�n�n_��:�HE���	��ح\�rvA�?V�"��#5A���p�E��l1I�kK-K3�g�sg�׽�1ڼ,,�[��V��r��+{$I���U�E�k�[j�n�f��O����j�QD�:ꕃT^�`rnF�|��V�p��
zS�?{
ά�ENH@��e���dR)�����:X	#q�C,qmEe�=0a�k����>���ݠ H�z�/���~�/L�7 ux���).<:���
��ը���Z����G
xC���D���ħM���N�/]���h7FG;VL�p�¯u\o�6���~�M�j;����NM��Ȉ𶷃ǯ���жI���%�W������d<"Ov�]���A��;꽱x��K �ӏ�BU�+(X��kyc���j�e�'M����M�K�5��^'@��Nй5�$]������Ż�ߢ��[�1�� ]|�U�O��V
�U��|ևgW�������C��?z���n�5\~u�%�ӣj����k*�����Y5�&]/�ήK-�vK���C^�6�r�xz���<���g�P?�MH��+N]�(��G�
�J{�<�cu�~}��9���rjǦ~IZu	=r%�	X�\Fx3X䞗:���t�`�tz�ڔe�"�	y҂��q�B��Ti�R�ܠʕ",E̥"&�3�H��c�tmm�C%̍�*$� OX�}nr��q�*V6R�UHਬ2V�.qf�.q�ʪ8���bׄ �_���<�-&<��}�I�[~��Ɣ/�@����#?[?o�r�ʅ�&%T4�?Ӱ���%�M�[��ߋ���
g�I��u`�R$�	�Ȕ�T2p�K�rB��ت׹�~�]��n3�yC-e���s
�`���Ѐc�c��v�z�ɨ�_�𶱼�,8��Ź3$�
N��$���$
q���A����%��s���=�_q�
2b�-C`���T�Md�5�L>�#�n^t�A�E.N�'��%Y�R��F�Ii�ኦf^Ҽ�y#�(eI�l� Z�"@��GË�
��ϧ/78m����z1�h��Jb��k�[���<�	��������Q�`�Q����
��P��U����A��t:�	
{$�O����U"!J��
�̴�x)�$��&�O�شn�O��Ԓ6�3������;o��k
B����v�Y1̱'��Y��k}N��p�	g�4/F���A,�db�
�����f�l�Oo n�g��g��}u�����t��7�}.M�.��G�
y@�"����u��)ʉ$�W��_�dЛ��N��p�>9����E�O����*�λ类�w����<��s�F�^�&tEm#s�p~���u�u��wJ
od>�� 8�X�a��(N���`��rÆrJ�>�k	�s�<%��q-�)`�@�O
Sۨ=�!�e��c��s�2�?�=�h�[�nD~+@�
�fmm�LF�3S(I�&\/3�M�!���
���3�-����E;�h�F��@����3�OD��`/��~�\�T�S���<�ď~��9(�q��9��R�P�
�҇��"T�/���s��̾P�jXF��I6�c�$�]W8R����Ry6R1G�.��$�3v����,��A�;vO���s>��+	���^�\����r��:��'�/J/dMX���d���hLn4:� �����.OI �ә%���x�a4b;�htS<i��
7�p#�����'�yR$�̔���_�?�?�ge�w���`L>��Ւnw���ݜ��t�D0���K��q���n�,����`�D�6��쵘�q�N�
Qý��
i϶g�;�;�߼�����7~1�hQ�iQk��b������E�~�?)����P~
b �
��#H+u/|�(�-��ɯ� ME1:�~�I���z�1��J4&�bt�HX���Z��{���A�S�}T���x�y������G�״��>��������Я��D�I�ո��~�M�81�e�M_���4�о����0��Qf6`�"I�F$���@��L��(p��#���ĹZ�1Wk0��ĉY����$�6�xSK��@�8�D��Fp�SE��A�	)���I!��o��5��G?��:���C�a�����/����#�^+iz`n��Un�>�#ZV���ؼ|%4�'?��"���[�Q��Gh�e$��d�Y���N�x���[
�j(:�a��S;7Ҵ�;N�}�>B�t�t�t�t�{*>�N�I2d���v�=Ռi���H��ߚՒϴэ�g`�`�K1IL���nb����vt�@	�'��g�o�"�3��Z0X��#�3&�H��
yB���ux
zk��+ufk��3"Ŋf�`��:o6�|���4mv`w��A8���N���px'�������������6v�b�ZF�=��򔍳A�W��~'kjC�S���Df�֜J�-�DR���٘��F���ӤzD�]忕C��/�S�`�'��U��Ҍ�����C当'A���iv�H����`�V��CD��GGc���������#/i�hL��YNwi�nкĶl���3t�}�^վ�{k�y��@����•gUz��Z���c��&ul����@ϣ/h�nLen�F���z�O.� ��E������Z9�$���t��N�.��t�ф�+��lu��֦r��k���7�~'�a�C��n��q������X�}�S7���-��RG7h���
fko���^L�م"�
����
�[,�R�B����pW"�|��jt��o	�e�`�a��g�]�.�kFS�Y�I�)'g眒��;c�e�N+|�F;"W�֒Yg�2���聿�
=�����{�@�<fa߆�m�������*�V���e�,����)�}{�`_���`la���oHŒLZ__X�w!\�p�w�z�Gp6Cj:j)wbD��E�'����H,���"�Lt�<B28��3�"�����jǠڌ��:$5���c��T�ػ�o�����A��Tmj�Ǜ9k
�g�(<͞fP�<2��ʌ�|-��M�>�V15��.�'�u]8�49�1A:�n7�!IC������T���+���:i`q9�;}��O�X6�gY�~���8ږj��ɕ��ִ�
C_2�).�K_��ʁ�R\�@k?�?WF$_
hg�կ,��g�t̔W��r�'=HzILi�t�����j鹱��/7�+����C	�i�k�)����c���W}U.�
/�M��7����X��Z�s
d#ںT��E4:�ޘ��]9D�<�R(��pw�?���q�$���E���}� ���M���cR�/��;4�G
�����adc�������
lMN]�>�����I'?GfV�	?�H�E
�槌WY$�
��Sǔz�??:�'����t��_~lA���%n�����!�$�������G֯������5�b�����߭������1�7��h5<"�J�)�*3i|����2N�e<덈^U+�K^�-ZD[T��CX��-%�:D}����MC�%�5�zCp��K�r�:ߒ%/�,�t4,����{t8�-�'�DAk�h_Ү�w�=��i�M�����ff�����X���}	�м�fX ^�3�+�wW��x��XfH���Ɋ�yG�`�HO2xQQ4H�*�F�/�����k�Ϫ[t�+�)'�2E��]�.%�	����R�U��\i���$yv�*I�y����nA~Wi��4c�Mx��G�H����`�~�����]����1)����L���Cn����G.X,�C˕2-�r�=4���]B���\�+�w��?�o��͋YQ͢O<
�р��T)�7$4n��x��0���>�~�͸	G��������f`m�on�ּ��h͘��}��0�h�f4�|L�
�6b���8;�L�Gc}m܉�+GI�[f���g�Zc)�t�z
��zѾgKb���6?ϥ����W}.���5�r�k����b~њ��������~�Y"Ep���1al2�:nzW)�/��!�u�7{܉P��Y�������Π�u�<N��#�Zb�e��CN��>������I�/FX�N��bA�h��q�2r�Iǘ���n��O�DRY>��àc�|C��ա[B�
��C��$�v��y-��� �|,$2�Sv�JN��N�պO�Cf��[��Ol�H�L:O��RJ��T&V`Ud���8L�њI]��ԅ�I]�+�Lj�V�"��7f2*���&F֘Z�1tf
F�(�̄::�zqd2H�
t��T���@1�Q�b���F;Aڸ ^^N��M#D����8o��]s�����zE,���b�����Y��
K{��/��{cK�9��=�4xA958mPw.L�T�-�,ǩS�C�7��/�
��CԚ�S"υf�,_��油��(6�"輇$�SMW��!M(��������wX(��K�$��hZ��me+�sq����Q�gv�yz��+-袌����ђɡ%�DKTDK�Gg+1�S�%��B!�M���D�b���C�!��>S�Q��'�=C*�#�)'����$��No�T>�^�=����"O����n^�n�@a>|ZY���-[��6��֯��3��5����Pqj��&�E����
����+\w�{�{�����I`r�EjFHx
04���@x���tA��֋v�#
bP'FD�@��&�?�[����y��ל��~�fݖ�#��3��~��zh������{�,�c��*%}_����K��1Y6
�f'�	��##![)	}Ҥ�<:ĝRE�d~�{���$ek���Z~����@�z<F6
���(2?�T�O�D�u��ڔϴ(���ɢ�\VV>h.�+���?�3$�u��S�U���pɩ�pl�۝-�#��࢙�4U�b"�d��_�!��E&Vcxk[��q�i��x�^#P�Hosװ���eL��lz�'��@`��ea�D'З3d���X|&Ҍ���\<��f�!�
=��ӗ�_��)
u��+��d���Hyjfu��j^WK!�
�nH
S�
~�_)RCR9�j�Z���
�VݢO>�ꔤ����p�7���?,-K�Eޙ�y�r����݌�.�y^cp�N�6�^60L�g
�4�����}!���A[�ϻc���ѿ����!�?��h���uG�P����N+S��D
Ѥ.3��%���TN�M�ؖ�oF�V[Y1����������z.,�(⚡�2���, 5B}�Z��u��K�Z��;�����
hg;�eԸ��4þ
�m�w|�
:/����ٽȒed�ɉ3f�sP1u�B������8�`dǻH��6��� �G"���\"�`"���c�Cp����WIB��Q��:w�[��-ٻ.�U�����
'N��7�d��=B������z���f�I�Y�j�>�9��G:��Y2�%��T���V�\tq��F�n����iL�>���Mq_*��ױ�KX��1u�׬m���E�G91��줨
���d}�]/;)q�h�p��䮋����3��r�kA^Cs�ԁ��m�-C�*V/q����l9�q�ب����zl��Z����ͤBs`<=U�L
 Pi�G=۸bm�bQ�o��ޅ�������{���廟�����Ʀ+�y3��N��`v��Ye�����<��WA`!�0�[��?�����ze'�`�3�lP������
�-�-WO񘁜��S�.!�Ġh5q1$:E�h��ۥ���,G�1�f�v8�7r(�r����A0��A���Ok�<ߖؓ` ��s�/é癔J�
ML66��a8d8b���y6���r����xډ.&�h�Jj�R��N�)��w�EqÞ��Ws
M��b2��ؑ�����BJR޻�:�c��+�2�܊ѷ�-֭��0.]m�}qE��,#�ᚿ�RǕ��O���F��<rz��8Aɣ��j�!f��uF�`H�A*����������i��˕�A��VCmiT��Fv;����*+�
|�]�
���n�}t��Gܴ�4�.?::���Uj�;C�2S�w2#�t�\֌#Y�G�Py͔��D��!��i���
�=U�:[.�b�ɖ���~Q� I���/�]��pQ'I���M�2�ɒ��XK�{�\�h��Ӌb9nъOu��Bf�GU�H�P�XH��B6�7�x��P�pR�2P�X�^a���hDs"N��ؘ�sxLZS7�IU��\&Ӆ��",��"6E�����E�Z�(�D�{�cEM���1E�K�K���t
��#t!���8�X#���rOd,������DT��[��Zӌ�L��02	�I��y�IpTuO6
��d���9F,��Kt�0kU~��RT��3�7�quw�R2x�^�k�R�^(Ţ��":d���l�,ͭ��ڑ��k�}�%o���d=~�x��v)V�=���kXY5���%��c��V�J��|n77��߭�Cm�� �&�
�ml����9�xP7"_[_��o��ӫ��S�n+~��5��g=�������k�Ks[�/�~��Ey�kqV#*_DrOQ�e�k���G���\$�ryK7
��0*�+/Z��f��D�Y�Sq�_�t����>�nީ	�q0ٌ�r�bd/��D
�Md�#rE!rK�qY�8ml�Ȃ:���=�����1<[qd(��R>��;�h��83����D�ࢆ������Ԃ"�4����٭hZR�E�l�ܒ
�.��M����*�����wB�w,P�C�u�p��EՇ<��nv��@� Ŏ��r��܄�h���U@W��K�$o�ƺ�
�L�^�x1=�#"z�`4�N;�-��A�>wh
N�a(�il��:��f��3c����
���ʹ{�f�ћ�3o�~�{�f�V�0��S����8fA��ɑLڣ:bu�m�C�Þ#ve
������>��<}E��4��D��F�q'�&BS>Dfڦ��9v��t:s2�u���7>�R�\-XC�s�=q^�Y�˅l�֖T��G51�ħo��='�]�������d$��Ά�3�Y��R���*����E��r�e7��)��!`NBj.��N!N�������uN���1��א�ċ/6�-l�b�h�{<���8��84&1d��#aف)�d1��E�'r@���ŘZ\����!.��gHM���,,����wh6��t��A�i�LY�Y�^M_^�7���b>�����RJ�Qk��e_!��9�|���7���V�:�uƟ�/�^��x

AZ�vq��2���d\o����Z���F�
o6�c��M�M����&v�	�䖲	��RȀ�,k�$�w4P3R�c�e|[�-M{j��Ԉ��!=}����e��Cvghd��gj	��86!k�q�&�@4N80;c[�`�D56Rkb���|����ɏ_x�c;\�"�
�]���,n�����7_U��W�O��h��W~KS����7�D*�����T
�e��X�'�?{i����n����:pF����b��x胉 H���'�BM�L��A�kw8��x����8Kd�vKW*�t
>��]�lp8
����]^����̎���'��^��q
c���&ޜf�����ٗϰ�7��fEgD�/[%���c.�"����R��0HZyh�DU/: ���V!�!��-j�mm��&05,CL����8�X����خf4�b�Q��Y��W�m}��W6�yxCkrђ+�]H�4����^���7!T�I�j����k"s-��V���Z���k�٭����&R�"Ga4��=$j���߲s�4�{��!����S�lΒ�8�8��_��tx���S�K"b�I�K�x�x�Q�_	@lB8��
0,;>֎��!�����Z����������L�����z������3lj���P��0��Y0��6�^��2���#����l�f1�����,$9#��Ң>�< �
�b��"(�}�b�H��#)֎�ؗ���������٤��t<x��
��$�'���[!�=�.�!5 �K����dwq,:��I0��+K���T�>熵7�+`�P2�8Н�*��Ժu���ӡ|�i���OF}�������k�n}f.�����􁎙,MI���\�Nu���j����>�j+Q>��*�������bo)��?���7�ӳ3𼕽���N2���m&;�t�L� Wv�B(jU�@�	�R<���X[!�$���� ��&�M�$�k5w�Z8��%5w5�A���H����;84<h#��j�1u�j�Ct�<��:[�V�H�:V^{
�C[v��������e\�~Vy��%7�>s�7����п�
��
x�B�y��J����s��_���i{E�I}����`c�k8��Nj�@x
�w�(�9虊��	�P���t�Q�q8wu�UH����\��6�Ngp鼆�w#��	ux1Kn����qO���������Ւ<�Z���㝃�@����v�ˆ	q)�B��[�.
�yJC�\]*�L�>��H�"m%K��e�M�����N۱�a.4t4�٪��r
hp��|�l
���1%a���(I抎��v���p&0~�BW��a�goRؖ�r�d<��m$Lo>1���l^G�>n{C�� .�f`�W��x�w7k�1���XË3���mh���H�
�yQS�1�L&ɳ)M).�]�)4�zvع���1N,�,�k��A}��-x���]hM��f-�
��n.�%`J��M�A"�r+dH5C0�p����F0���::�o�C�|�)8�MS�j���NxB��
�L��xt�/�*lkR9�3���\�]��"_�2X�|��xӵ�W4a~
���`�$M[
W�$�
����Z�����E���C���r�a���6�/����Pk`�l�}0��$��X<ky\����:цܢ�2Za>�L
�������ú%FpE���p���I>E=d>��M��ٶl�f��:t0l��	��m�
yN6�-ِ�d�qv�l8�i�~�
�?m8�i��
�?m���_�_���F���e�ٮ�2��+�s���~$�W��w�g�M���R�Bx�}lO�La5�
Ť�P���Бڞ���L��&#��Y��dVvj�	��7�����LMq�z��n���Q��8����35�چq�wݲ���ة�[bbS_�E�O��whʁ�`s���WW��}��5"��ز
�{��k����T\G�cA���݁�;�� ���"��H
�e/��ƍ����w�igc#�"��x� F�fAHuNX#Ǜ��c���q��.�;��}O���'���?�����`�`;��Z>�B��V��q'�\��`2�F#�6��-�Z�|F�q{��h�퉵�u���m�
�W��!�:��l�mL'B~>�4}��
Zo���=�d<Tޝ�����_�����k���'s�_�~���6O��i+;��8�Aw�8��R�"k�ORt��eO@��UfT��K|	�2T������e?�{�F���l����	6��=�A�'z�'�OO�MoP'�|�FGu�
�Z�:�s�p�ڸ3��I3;�>�Kt�-m���X��_(�V��
�{iþ�-��Jc���i��z7�l\O�p��D��Բ���x�_��l��Ki����2��$�����}mpv����_Oɷ�w��S:�ޭ}>�c2�OD��
8(c,�2�<0$GBt�y�fX�+�^�	e='!�ax�CԛK,+��������m�=v;��Dg��j"Fta�� ��e�e����C�#2X
JZ�
gK�(�c��W������#1��c8+�aH��ϧ�+��Je$��h���]b6
ި���_��WK�%p�`	Iz���� �_�+;�8;0����PE��G5(u:��IК��C%q��iu�65eތlM_@6mO���2
���-~��sl9�$$;Y}O|p���>�������h[fY�q���vy�WbN�����Ի����R��j��3��rS����OiF��h�m6s���I�n3�5��w�����X-3N��_���sz+��9F�����I@~	WD��=ӤR<2؝�H��	Y�K��e�iE
J�޹'F/m���N�s�a�kДG6@m�"���U�=����n?��)�2��F�4�YS�H���\������z��3�.	0>�H��.�
ni�(�o:�I��f���f�G�Nu۴jc�ju{ݾ:X��z!��8d�&cɐ~֬^���f�ٮ�!�D��z�M�%���&���I�{֬��b��x��c&z���"("�ܛ��\V�d�Ͳ٬PPkyѮ���6<=Sa�Ʉ6Χ�����6O�c�zL-E�r�q�GL��%uc$D`�2g�q ��1H�� PO-���^R���
��מ{�ƙ��
��3������֏t��vc]s��9�o����W��YO0����`n���9�
��+߽蒁j��Dx�S�6��K���<��9}N���ץh��u�S}u�K��{���������L�;���嗏��쬜�d�8�¢�"sgSH���.�(��=i�qz,
Ӳ�[J�>�t��}7p��@�L��QN$(t^�@�R�\2�p56�R�q�F�#+R���^
���k�i�hn���h4�O�(��������듁�<�gH-�D�2ժ������
5��v؄���vX��bt-�Sk��hXtI�����?�M���
���
IJ=&i��+��%���˴j�8oɿ^��Zw}=���+[�����Ǜ�
m�[���?07SaD��˝w��>~���~O�����{�����S�^�^0Ig*��U"������E�Ͻ�]���N��=
r �k/���No��pmt��b\�3z�a��]G��z���GA�_��{
��8��οË��}t��(Y
:����G!��+�H�c�G�۴<ڄ��M��&M�&<�L;e��ƛ�޺dɎ�
�t;|�����ٛ�v^����{����x��w-����w]�}���X��c���oﺵq׊]ˮ{�qݎ'(R�@9R�^e�(��I(qlZ��~��
Y[�Z{�����S�	Y�L�1�B-���=ЌV'�D�M֦���ZQ>Ek�X�ձh]J�_F�d}�)�S��Պ�IQ6��������h�����U�� �>�����"��"��"��2��h�����U��@��k�K��*����;{:{���Ix�=!�Y���!a	�K���#��KB@"�.��8
��"�����ࠣ�!��+.�
Ją�n�W�4��7�����������nݭn�W��h.�:�8sIW��s9����819K�g<bb�� ]��S���X�=��|ԕO�@L�A�G:	8�A�Aؓx�{�� >��%���|�\J
Pr
�^��
�#�1)��*�LN�!V��됞�8$���B�L!�,Dk��B�ɱ$�L�U8��)8Z��t�g]N���m�C�uhsʯ����2��Z���
2�o
��G��YH�Bz����9N��1����L�,�
�Ig���G���^݋�{�(Σ
�%	ϑ�&7��=	x&�4��IG�~�x��a��
hL�щ4z>4�����4����:"p=`*����8
;.0��O�Ą�R�Ā
0%���B-�P��4-�0QB�@<M��gO�	tp���Q�5�	0����D�7b�~`��,9�����<´mnG����v��mnG����v��m>����W���:`D`
`d �xF7
�f
�
�#J�a.�����1	1q��a�
�9����Z��2^��3^�v2^���f���¸�]�
�9BT�	�NM��X�v@�3�]�3���$�d�`	����8�8p$�b�i���<p8�P�A�㜬b����7��C:���g@�v��������P�#��H�?���9r	�`����&@�=�tD	1rrr0�i����qN������	�H������Ґ�����Ȣ���ʲh��z�tD	1�#��؋��\NB�80��M@؛̀~�/�e@��
�2�_�ˀ~�/�e@��
�2�_����`D�
=2�G=@�N�tD	��fpdr�x	0
,�
29��{^샘����?q�0�>��%�tD	1�#���+�1`2�F�A�C�
�e݀�/d���C
�@�&�tD	1�#H��5pv+`O���`2��,mKA�Rж�-mK�ݽ0i#� �!�ܶA(g�0�Tx
��)�ps���P��a��y�U,����<6���	H�#]����U '���g:�O��p6�X�V����큭,��
>+Dz���񁓀��Sx
�*p�y&��|x[���ga����.�K
���_�9�e��z�j���
@��Ӑ���M��@tA�(�	}�y$Ga$Ga$G��
���Ql,�,9�*`)H~q�r����ӑ��y��p���fAZA�"����x�ib3X>����B�^�*I�*�X��g6��z4��
,��1��c��1`!NJ��J��1��
�c��2��
�ƀ%6��pH2���ۭ��ga_�b�U�����]�*�����G���b̨bеp.�V�^�Uű	��%�i	X�q6�O	��<�8Z
���M�.�_���q<��=���<gƃ/�.����M�UHW�
NB�i�3��gs`���#&�*�d���2�o�2�r���2\�2Ȗ��P� >��c"�gxq�r����ޭ�ܯ2��|�ZZ���G��Q9�r��)`5�Nž�
Z�1Cʙ�8���Dž4�Rx�	��	$W�.x�U��
е�i����*�x�	�K���g6��ÞD3�[��66"�
QElB���"�C��H�@%T?��Iؓ��	vS%X����JX�V�€	p,�\	+r�W�J��J�u���r���3gF
���%C���y�2�7 �ww%��iъ���!���@ډ�F\�،����Ua婂�[
��JU�.>X	;�
֚���W㮯��,۪�����j��@^g&�
^Ś@f
�#������"]�7
¹�����Y�`�c���|���~�����p����
r�� �vVr�w_�:��p<�U$�l�������W��`�V�B�?$,�y8�N�hL���
'!�,왃�\�tf&���Y="p�����3p�̀���lV���j]��i
���T�r�A�K�f����	'
����V�vڡԣ�z�V�>e3�}4�G3A�=�ܶ� �.@Ҽ&�D�����
��a6֫٨k6���̎�|���9h��9��Ais 3j<���A�sA�ǀV�|.���ͅY�z��؃����g��<94`�o�x6`�o	ڑv��o��'
�H��d��xp�֊kd�[��C���kdO��l���-�c������
����M��w�M+���S�w��<*X�сȽVQ�|X5�V
%�G��1����w>�5�ٰGEl����1��7a5n���{����	ߡM��M�e)�l��M�õ4a�4��6A���i�3v�U;r�1O���>@�݁�X	�v\;H�=*��3ف1w���
�
� ��щ^��s+������\?h?h	��{�Q��mh�
�Z7����Q3���f\�f�Ռ��q��������X�a��'01	䬂Hr�o�U��
o
B�L}���3Q��6&���I����!�
ZO���F���N�ゎ ��XAG���}AG�U�	ڠ;ɮ�o���E���K��fD���u��A�IB�
A�C�1A��n�'A#��#IBD���Ƞ�ł�f#�tI�.t,I��+h;}����@�<���u`[��ZA�I�a-�a�m�-h=n؇t8�N	ZO� ���_�۸!HG�oN�M�����D:J��Fk���zi��^���Fk���zi��^���FG�2v������V:��u]бdVB��
a[̂�#���@:�Ǫ�LAC���H����a�;�'}7#�}�{X�`ߏ������b�'R�~Hw�r�U
����tw�~�b����=��4��O[�ПЯ]�z��������
�����g���ł����~<�
r ��I���I������]���D��s i��!�r���d4�'�	i����N�]�\Ο8�Ȑ�G���WlllȺ��e31�"���j��(�Vq�?i%n�)�'�e�W�#F���I
�5�|����̀ଅq��Dh[��}2H*�|E0n�Q'�|����]�7��1{*��
�$�J�\������:f_J��#2��a��|�C���E��A�T'J�����
O<fF2(�4�<*#Q�e�D����Qn�������-�����9[��Fx�>Z�Ɍ�i:!~
����`���T虊�>au�˂v���D�I&d ��_+��c^����9J�
c��v�[&
��V{`����=ڪ\n,Ώ�*��Z��׎����F'����p���"A���4�Lm]�!�����5�y��E��B����(��<N�"�.7z�J��fW�Ś��1���6߃��ň��X4���%���1�$���Y�,��|ifܓn���1��~�#�ZNw��]V�4Khqp�,���X������`t��f��
���o��3�q��"eA���(�#�ˍ��"{��f���]+vk�'��`���?���ړ���q6��k��H�o6fHR��֦�]N��խK\��#�T�3�Xd�k�F��k�Q���Y��ת�k���k\�Y�[��f�iQ<�4�y�F><U�xA�1;]2���8�Ƈϟ�z����-�C�4]��4Ш:�>�s�>�b��} IvZF�<F�x�f����7���
0�iWZA�G����Ʃ��s�d�Eq����̌Z�A[��b�FXe�b����(�݊�
�`g�-�W�
��r9-`�Si�e��I5ZAC�M5ی���"{�ū6:!�Fc��h�����,��
�Vc�bv9�˩py����n�.0��7���귣iF�GA߼ ��5�N�n�x����5�(������0R=�#��z~Ld_���`��:9�q�m�Fe�Oqz�f�Tx��r{\�TQ�����~.8�\�Z�E�f�q�ժ��S,{!�..�ʝ���b�V�i�y��|�d��V|~��q�]v�TX`U�/�Y�r����š�m�G�� ͧ�����0�Evs�>���;�,4+v;�Ԯ4�
�]���sہ�E�ٌ�.����t9Z��i�E��{�ip��0A��Fy��T�Z:xHI<��_��e�k.rf��u!�E���r��iiV<>���n���#G�����"�͐��7#o�'�H>��8��Vx�uY}-��|?�ei��~�����8$��6Up�>��n�]�h2�P�ju��`���K�B�X��h�H8�]n�(
�F����	F\'.�_�0B��~H����Ӆg%���n.&�8�
+>Ө�����朌3����
*��ճ����<|�����\97�&C��|2�c	���q9:�,.P�n��
	av+fG�C�����iq�!rRQI�n���z��
�rk�5|�@�bAI5B��6�lmV�\���\#��C
�Ş�PKj0G`��`�]t���1\s`o��b����r1tA�+~�l�0���|�\T.~	9��G���_\r^'�_���׸ƣ�%���:ݳ�u�
��Ԝ�x�GOȥ��`��X��,F*��c�G��v�
^.����Y�e�Q�
*q�s����$�#Rj�A�m5j�#j�xS���(�t�@f$��c�8���+~�Z�v��c
xHs�e�AT�/xkA�e�+��^q���\�8nZ��5~8�`|��v��-��ֈqҎ��s�~^ԭ�C�C\~Ͻ���Up����2�!�����D�����#�������k#����
�}�P<ԫ��Ũ9�:i�8��X4��Wb+^z:���
5]p���K��O1抖ɮ��LT;.~�b�e�E����1��K��C�d���]�NjG�:;��Q�*.��9���^�jm�^�3��3��,�j���;����n����Ыhc�
(�:cG�ښڱ� K��v��>q�5�{.�-(�,>�p�-�ӀςZ;.���
�6�s�w�%\&�:�������/�6�:�Cf���UJ�;�+���4�ύk�z�E|��Cm]���7������c�C��fq�O�f�</Xaέ|ڕ��t�������}���N6���qʰ��>���,���z.�Q1�h�W��a|�o�D�
9����v<�hQ��q������K�z��"V��w����zA-1^��w�;�32%�I(�'m�9B���r�s�����;��o
ϛ2����������{��]��.��_r��3&`4����w#;��O��/���w�s��r����l͝3�"u�yW��f��]zιܓa�Gۏ�(��]J��愮�뿵�.}��(}�>G���R?Z_�Ͽ��ߘs�w�N�J
j�Rs:9+�ٮ�2<
���#�@�Ĝ�*<����"���]�@����ak(�:�'��a$�D�H%"��B��#]HWO���$�� =I/қ�!}I?�H�H2�
�2�"W��p�
���d�4��#�D�ಝI��E�CrI\��(RHF�1d,�JW1�Rxu���/�2W
���k�D�M&W�{S��:H�id:����L2��&s�\2��f,CV�Щd>��
q�+i��H�����V8�/&W�%���,#�I��� +�*��\G�'7��r���Bn%k�m�v�rYG��]�nr�����G#�z��<@$�C�a�gI6�Gȣ��1�8�B� [ɓ�����7�y��$ϐ]4�<Gv���d�̋�%�w�2y��#�ɫ��y��N�I� �[�m�y��G���a�/r�|@���1���|B>%���ɱ���/�W�k�o���|��%ߑ�����娝���ΐ�����+9���г��䳦����.�+���h�ɚ@��О��M�о��ѤI4���F:�ĦЁt���C�P:��#��*�ѣ��$���f�L�E�iͥ��4��ϴ������X��%-�Ŵ��ұ��<�@�h9�����VӉt�L��5t
��ut*�F����Τ��l:�Υ�L��Z�B���ڨJ��&j��.���z���i3m�i+]Dӫ�z
]J��崍^KWЕt]M�����t
���Lo��ҵ�6z;�����wһ����Gz/����O��
�
� �H��?�Mt3}�>J�B�J���-�	��>I���t�}�>Mw�g�.�,}��������H_����'�����5�:�'}��Iҷ����.}������_�����c�#�1��~J?������%��~M�MO�o��;z������i�N�g�O�g�����
Fe�阞��p�"Y�f1,��V�º�x֍ug	��W���������K���3#�R�@6�]A�d��6�
c�����X:�$fb,�e�l��rY�g�w�h�m~v%+bŬ���ql<���I�*�w�Y5��&���*Væ�o޲�l��f�z�R6�ӓ�c2k`ffa
��Ffc*��!�3s2s��ü����������-b���l	��-e��r�Ʈe+�J���fױ��
�F����nf��[�Zv����<�w��miW����:=���qF5�[�6�)?Wc)��m�)#'G��\�8�Dž�&�I�*/�sË<J�.cQ�jt9��Yk�KͲ���`#dH��"��i\��T�f�O	�kM��i�F_eq��v���ڰSk&j\�=ْhM�5�Gkj4^��L�:��h3r2D�^�1��	��@���5�\�#�^��Y"'�X�%ad�C��)>��7٦�ɱ����(��������{�䇬�ɴʝۦ�'7���ˣX�Q�B�]��������ӹ<�n��d���bW�����hl=���ڠ���Ԩ��%�,�����D�<>_��:��P��T�(�j�lW�f%���{�����*�t��9s�G���d��([�;h3D[��&�o�m�h�x���ϙ�9S<g���&�
�ٙ���٢�m�h���|���X�A=��'��Z�#���9B�П#���9B�П#���9B�П��
v��)ֆ�aړݪ��x�ym�E	C��4aeU�v���h��?s��yT����Z�x�8��n
7��]�R��
~�����:T;�h���A��;í�RC�!���z���fSdPaQe��i�q��"Y�����W0u~�Sv��>��mS���#�Y�E�E��I&�"�"�"����.����(r�f^d��)���V��0��Ik[T*mq�81O���qZ�S�������L��x��Q2L��%#3�,d���֗5��
 �ܧ�-J��MD��JV�kV��U墠�ZS"}��Ve
�3sc��O�v�iQ͢S�,m�I��l����9u
T�I��0e�f�+$@�BEvn̔S�!��rG}��:�Q��h�����4�~Mz�p�/�"�%��B�v�aPg��E��c��Z$#��i��`3�k�aC!�ꤣd��vE�çA��Z�f��hѸ�YTţxUoTK�
��1�bcX�9�+(�Z�K���v�#G�;d�"Q��+�-�g���ho����c� �)������F6��/��r����	�]��>HƎ�^>�9Χ�F��;ɡ�e��B��'9�F�)^�s4��}1���J�%'�����蹊�J����h�Ȭ��&��t5B�d�U]��6ߋ��?B�ו�T�d�[���>G˝N*�N*A'ՠ�	�s�b��������E�h���/p=�ք��5ӝ~�P�
�v�<6W8��a���`1�a.���xu9Oy�+4��Ј�:"��+K2�6C����m�hsD�+�<�拶H�Ţ-�8�j��,��
��kzMB�I�5	��Lf��^��kzMB�I�5	��R�
�&�_��,QN�D9���3���?C���3���?C���3���?C���3��L�?S���3��L�_ڬL�?S���3�~Qs�D����3��L�?K������,�?K�5;+K������,�?K������,�?K������l�7[��z��^Q�����l�7[��z���l�7[�������^2�
9D��
�M��]n�-�j��xFt&�8,�
�ŷ�-F��?dl�lm��bIґUD�V�ߡ�=Z�Mк{���M�Q�W��j7�����,��(5�I���#Ҽ���TO�rկ��&K�!=�$/K$��w~E…��V��%���]ﭯ��O��y����pļ��->Aj�-��X�z�wͻ�ݟ~����[?�����%C����4�#E������Y�S/���7.PU���r�9�4B�t�S�7��E���o��iV�Ȓ")��Aʕr�z��{���c�M����_/ͺL�P�4�#.�t
~�Θf��!-�?�IFt�o"���������'kz�nռa=+f��\۴z������_��3���檬{[������G��=t�o���۲�y�w�+��&�7��6�rĚ�+n|+⓾�?�=2�Ё�Si��?��їoN��^yG���i<��S��y��>z���j�⿦1�у�_��� e�G�⇅EP�*
��%�������u�7��F����S������L"R&�O��KC�^?hU��h��ϙ7������t�z�IWp�RtP�.R���]x�^�Ÿ���s��gcw)��Š�^;�Ȕ�q^*��(%�_�|eв������؆���b���<7�-.uK}/y�{ag�;��ڵON�{��_��\^����I������w'my���7M��-�����z�R�Ȑ�O[U��]��_�|�Շ᫏l\wߜػ>����m+��;�������{������/������#�ΰ������������Ā������ە�A���.�j���ض��k����ಳ۲������,���}�%��ڒѧ�<5��!G����̙�}�'�uq�����ޱ>��/�\6�dz��U������7�^:�5�����'3���������ڻ��ҴǪ���~����0��<�-�1d'��zH��Cd��ip�S<Nc��VL	R7��=���i�����\�hX���SLIR?��=A�0��/��&�K������_O1��/��Ķ̈́��չm�cfp���Ԋ6�r�vm�]�G3�Q��o����ǣ�\����o�M���]v7��>�������3�3��!��?��5�����ױ����/<���5��ݷ?n�i������֤=Z6��oϞۏ���Ȧ����p�Wر�U5������k�6|0��mGW?;w�|S�����7M0�f���X��yG���=��m�#�}��5���8`���k�Os�w>2x���]{޿�����/�}�����w�\}x̐7�~}�i�w���9��J��;w}�������-y����Cu��L����]��؉��S�TZ��m�c	��\��3�b����V�n#R
��Q"iu�@ʓr�g��X%�V��r%4UJ���t�*�{%����XB 37��z�[�=J$Z^�)-;��Bu���̗���&��o�{ĺ�m��$V�r�t���a�ye���?����0d$���ɾ�'��VJC����&�M˾�1o��Ǐ�Iξ^�n�77��豿�E������Cs�<3b���~�ش�s�^���c���γ#����/oH��
�M��
��h����G_/W�yIU�=��㹗�3r�lm����]�k�4N�7�U�q��r��sw���ﳹ<���&��M9�[�?f���m�i�(1�{v�M���3NT|�
L��|�!�6�mp�5k�g����='E<n�8�<��p�����Cz���E��4/��u9���]'v]�͵_}�;�g]׼�"�\��O?ݶ�O잦�5k>8�X���/_0/:s�r��#�~���������A��p��O~ή>���2d�=o퐏V�?��
�^і�U:��ѡ�[*����?~[�����ѷz�r�yk��!�WƝu|<��VN�:m����n�k�̌�ݍ�l�p�cϊ�f������t�a���֎���U�tdm;z�i֎w=��׹��i��?S~�<�X�zs��]���2��/S�n���uG�S�g����'�r��VVS���r�q���b����{/��Ky�Q?Z��3oU]��8�K�O���h���[=ɤ��"�!b}�*�o��Y��ퟤm��RB��g��B�W��ŗԆɸ1YJ4��zk��)�Y,p�Beq������:���ѣ-9W�^��p�ѧ_ʕ�/����R��F�|;�uu��$��aY;��/��c���
z=U���'K��Wn�wyѭw�{���ӓ�/x&�O��_�ve�.��=x���O���nc���>���Ա�������ˢ�<�ػ�q��y������w�����=h����_w�Δ�o~Y�n��nIrm�3��Z���9�m���Ц�F��y�
���]#�5�X�sr�G������)��!I����¸�\��.�	+��nW�.�L������M�	W�b�
',���H��p��|0��
5W�K�F�'ۍ������4��.�S���2U��-��3����'��w9}ޠ:���������M���ͳ��ޱ]��Е�ny�ug��o�?Z8=��9F�����v�ϼ�~������^>lN�z�ኸ�
��跻����9����7��b�u�Kw(��^�Yk`�5���5�:e�mu��=f�8���⼇D����'����ƻ��j)�����xE9�D,���jM>���g�7�
��Tɔ��4��iT��!,=�oj�E�/:�r�R���<a���b�2/�FV����̊G�կ�R�e�p�O}W��u~v�O{#���ne�w=�]�{�iQ����^9�!cRe����^]8��g
�{��ȩw[z����O�2��yC��6K/�*zv¿諭궛����o*�f��ܴs����׼�Ø�W��?�sߑ�G���5�2���ẘ�c5����]�%�7-~a���n
���Y3��9�b����_��=�ti���w[�u�@�񁝧��"}����ռ}�/���>��F��35ujL��w���t�!ٶb�y����ڃ3��~>őrÖ.=V>�o�Fe���vd�M6��G�5?O1�X���M�6��P
�2J����������s>Z��5xG��JM�0��H}:2"Jg�
�JJy��r���Ҳc���M�u�����]�+�`v�'rH�B�cM���×
���Zņ�e������:��e�>�uj����o^���şW�����4����O)%?��j��#����fծ�~���Q�����'Om�ϻ�ǿ�y����?�	i�㗌[�����ªy�L�T�����������WM~�6���E�gn���~��W�\Z��W?t/� �[gX�Mm�]6�Z��#7�|�6"N��¢φ�W���t~Iaq;F�L]�E�/�dd���s2r륁��'���u�N���aؼ#�����.\��i)�c���~1�h�ˆù�b��ҭr�G��gŠ^m�<wd��}�<wkO���W�0Go�H�����������3cVN�]~���ɫ�G]��{N�ꖬ)~�Ч&>kl�|������ֱ�U��S붎�����s�06祮�l&�뷖
endstream
endobj
465 0 obj
<</Type /Font
/BaseFont /TimesNewRoman-Bold
/Subtype /TrueType
/FirstChar 32
/LastChar 255
/Widths 466 0 R
/FontDescriptor 467 0 R
/Encoding /WinAnsiEncoding
>>
endobj
466 0 obj
[ 250 333 555 500 500 1000 833 278 333 333 500 570 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 570 570 570 500 930 722 667 722 722 667 611 778 778 389 500 778 667 944 722 778 611 778 722 556 667 722 722 1000 722 722 667 333 278 333 581 500 333 500 556 444 556 444 333 500 556 278 333 556 278 833 556 500 556 556 444 389 333 556 500 722 500 500 444 394 220 394 520 778 500 778 333 500 500 1000 500 500 333 1000 556 333 1000 778 667 778 778 333 333 500 500 350 500 1000 333 1000 389 333 722 778 444 722 250 333 500 500 500 500 220 500 333 747 300 500 570 333 747 333 400 549 300 300 333 567 540 250 333 300 330 500 750 750 750 500 722 722 722 722 722 722 1000 722 667 667 667 667 389 389 389 389 722 722 778 778 778 778 778 570 778 722 722 722 722 722 611 556 500 500 500 500 500 500 722 444 444 444 444 444 278 278 278 278 500 556 500 500 500 500 500 549 500 556 556 556 556 500 556 500 ]
endobj
467 0 obj
<</Type /FontDescriptor
/FontName /TimesNewRoman-Bold
/FontWeight /Bold
/Descent -216
/Ascent 891
/AvgWidth 778
/Flags 32
/FontBBox [-184 -307 1089 1026]
/ItalicAngle 0
/StemV 70
/MissingWidth 778
/CapHeight 662
/FontFile2 464 0 R
>>
endobj
468 0 obj
<</Type /Font
/BaseFont /ArialUnicodeMS
/Subtype /Type1
/Encoding /WinAnsiEncoding
>>
endobj
469 0 obj
<</Length 140367
/Filter /FlateDecode
/Length1 215152>>
stream
x��y�\E�7~n���{{��w�޻����'�d�'�52� �H�aG�
�PPA!��"����"�	b�-��&�h�,�+����T�L���y���?���:uk?uΩo���H""?�������W�~����.X�v��3��&rm 2\�jMg�w�m'��C�ڴzl������y����cǏ\���� r�B�j����x���\D����sV�@���{������t�wo�c�m�C{�I�wl��1�1�z���:1��m!�t-�\q�3������D���.:yz�'�W������ɨp�[_F�=������>�ȧ"ǢӦ���/���K&��������������=!������ɲԷ�-�a���z��3���¦��h�$�7����,�ؑ2���������dz�����S�F�L�ұ����k���F�������F>�|�;����<p�.�ymn��/��V��g;���n�y����2�
}��t&��@*uұX��ߠd ��R�
��̟2wc�\;7^G'���`��&��h��w�;�1?w�Ț1��?�K,������MD�>�$F_efɦ���RLp2�n���t��(�t����,�)�mt��"�P�郔C����������h�+H�5H)�-H�V"��t�� }��O��h���l��T�FZ���y*�v���I.c�nc���N��d��ｭ��Ң߱���G���H^�eE� �P�<73�ȧ��潶���s�����e�u�Jԯ����1M���V|{�=�x��B���������6��Q6p_�+#�r_�Y2>)���O���'���i-�ž�%7��<�'�y�/�2�����O$��p����oH��n������3�i��֫��X�4���$%���"-6m��5��x<�|'��lC
��s~�>d�
���r5�]��i�fx�-9Z��B�T����`Y�]#�n���E��{�N�KB>�4	�O!��o���0�'�s7ҷ1^�ڝ�ֹt�[��e��i�#����a�������
�������iN7��9���o)��!�!�W#}
�MHq�y���c{a�d�`��[��:�
ٰ}���
��"$?R�B���TF_qVX��3�����e>G{~����d{:$Ϙ+bmq�خ�Kl����J�����ږ�|.x����a>��Ϧ8ȍ���e�z���e��_G9��4������8��a��y��9q��`�8�`��ֽT�.��^������K�b���e�� ]#��
i���|k�e�������������9�C����$�0�J'�����[-���Q������H����H�#�m�'m�I{�ǐ
��ҙ�a0S�i/-5Ĺˡ���i:�1�(�������-��"���#�2<A���#߾`Go���lK"�������sq����jq�Yq&��sj���,��왷���,�>�>�`���� Ʃo��7�s��<N1&���_`��<	�C��|�7��o�=�[Z�?H�ϟk�.�ڿ;�#�`���Z,�hm0�hm�>�|���݆Bk��}����E��Q���A�-ܡ9Z5�g9�KM7��nߡ>qw��B�W�5�|�v�
����z�䥷/���s�������d���9`�
:����c�+M�zc�0�Bf!��b�q���q�\��[L�OƂI���y\f�[^#�`�=��X��E�5'p���e9��g�^�\���1�''Ɯ
_A�x�,���%<��ha����z
~�bN�����Z�4`[Ly����Ko2�Kux�I|G��wT	w�$|*$��H`�j�,�i���.����]�2w�q—�6%,%�q2eж���1ϙ������VK�?'���es�	�q^Ÿ���g�y�
��)��Ô�;��y����a�c�J�t�ɶ���-�e�M{�m(���l��~�=1�mY�dzz�thxx�p�⣇�~26��5��U���	K'�^ضvpv��?�=�:��k7o�z��OV�b�Y-��`��.lݼeK�7o�6�ښ�)a����'�~ ����I6)"���1�;`����)��f�8z���b����0��2-MK'�C�[n�m��ӄ�b[�d�Z7[����mӋ���.����p���MM/���ᵈ'ttvt.NǤ�%.o��<-
{�@Dr9��K�L���g�k�)�'�Z��R!�	;$����.IrE¿��G}�_/�&���Z��㒵K�N���[�$���������飻׈[�<�sy�qSg�C��f��?��-sk�S���ʼnI)�y��V)4,
/Y�B���a��藜Y)\T�R0������?�!)����+��[^2ᚔ$T-Y�VBK0��h9<�$Y�IiH1�{*(y���=�{�R�籭a@�d��
x�����Rl������~�����($	X�[�^���E6���]�u�$g�_�"�,��dP��x�)�A����@�A~��$?��޶
�0i�A�j��b
���(h�b�)п�Nq�4%A3�͂��r���)
Z�H��_�D9�2�A;�Z�b��T�h�ʠ��֩��'�
h���݂.�����꠽��Qh?5Z��b���AA��:����@�R?(���Wh�AǨ	:NC���e�t9
�N
z��~O+ht��@W�8�4��������堫=�&[���i�A���1������=N�u�
t=�=��j���,�:�-��Z�z�6�1���X��t��_�VZ�����7���K:�6��Lo
=E�Sic�%:�6��N�A������"��[A��6з�4�������N=Kг�d�s��w�i��靂��N}7�
�zk�t���������Oo}?����A:���.�s@/�w�~��	�a�g�"z���Н�^B綞�K齠���@?"��t~��t��J��G�}�*���4}�.��>�	�0F}�.B�5�~�.�4]��}>+���2�k�#�ׁ���
��ӕ�_���~�gt}�F�
�&��fПҗ����'Ao�kP���ӧQ�e�����gAw��ZO�,]�������
}��$�E_���{苠wӍ�'�A�F7�~�n�}��8}S�oѭ�{�6�o�����w�.}�{4�}�����^�
�C��>A璘�~L�]�?���>H{@��[���t�#�>J_�1}��=F������	��z���o�>%�O黠?���}�>M��9����� =K?�O��>G����h��������K���n=@��G@_�GA-�o����[�	���q���z�z�?�)�W駠����?�>�?�z���L��7z�F�A�Aϵ�
�/z��ڢ[?�L�o��������k����k��/LY`���_��������,0�e����+����+����K����K��/	LI`�K�_�������(0�E��/
LA`��_�������?/0�y���L����_L����_LN`�sӟ��������L�/0}���g�?+0�Y���
LV`�3ӟ��������9L����?%0�)��O	LJ`�Sӟ�����'�?)0�I��O
LR`�ӟ�����'�?.0�'�"0�'�"0�1��	LL`�c�,0���,0��������G��X`��������G�?"0���LD`���������?$0�!��	LH`�C��������H`��������? 0�
��L�����? 0�
��L�_`�����~������'0�>���	L��#L��L�L�o�������'�_��;���?�t��
��NF��l�����b1��ƃ?��o��f�ڬ��d�Y6
fP'��ǚ����F;�0�P���l0[l6����`0�i��fL����`���Y�ls�,N�ނi
f��̒��ڿ?M���e��h6Y���6�!Li�X���f0o3#��V���}�_�c���
[X�b6:���V�Pi;��r��NV���r0;V�*x���
�܂�FfIlJDl�Y�95�l�m :�6����r����m	�!Z��&~�5�H�sB��b��m��9dm���Џg29��A�C��a[�†V6f5�ZY�fk[�l!~0��&���2��\�=:�=Z�h�`��cV��n2ۭ.��j��6��p,�Gf��=ZQ�j;�a`K�a����c�(-���vأՉ��S���/v�Gk��i�lw�-.�G>�����h�m�s�h�.�������jg)����F`����
�-���Q�X�`�7
VL.��#x��'��&a�6�K�~-v+������m�&��&��,��{��{���n�V�أ�h�2�+	�f���¨쐆���1q���h1Ϋ�M�m�va�f������d��\�ȕvl
�hs��P!b��C��&�|c?�^av�X��b{���Gp:`�V�G�!�hb��3�b�(�d�8q8����(��%;c��b��do��`����8��w�Qkw�Q��{�9�H��u�=�	��vX��G�9�mF�b���7g���kۘ��8,l��	X�i���he�����0Ta��l�h��Vl�m�2���Ʈ K@f2��l�66K�@^cGf�P{���|2���|If�sXX�&�Α��
�r8LB�N���0:^o��Ŏ|M���ʙ�mI0f��1)�#> �
Tk��ۣCأ�iŲ<�%>lm=�I@�V؂�m��ܘe��J��"ߕV�edfU4#_�V�����p8�ئ����8�nT2*��xF��)���lGF�
��۷�´��G+�s���)��o��u�p�o��A�$�Ӧ�G��s�lQ�{�il��G؍"F�
2j;
h�
h����C�VX�P��Ծ�f�@a.	��@�b�cV+G�dcu:'��
(QQݘ�oZ��23/�̵
�!"3a6�#_����9�-p턲�Vd��fr;9:��xe���8]Nt
��,RT�od�UV'o'�}�-�f�����{VCP@�Y��]ħӡ(N��P�Y�_us�fTⷰ9���-���F�g�m�q`,�NX�c�W��]�OnH��[q�>��-	�a�X��QH�����6;0c.�
]�.&t���0��7�
U��6��tp�j��=��]�ۣy�ٔ��9�n{�
涝�{��p�q���pg�]�1����Z9�'֊��Q��R=
��r�=Ze\��6k�9{t.�{4��EFx���9�b�ʜ=:]6���(���B����\���r
��ș1ቛھ��})�jN�	hb�=��,da�v��?ݰp�
`�l�n�Se�Z��9��.���#l��v�p7�oa���
��㕅=��n>��
{4�Z��vc`�	�]ܙ�����T]N��m��,[l⪁D���~������8���`Ä���_�pHe�F��E���Gvbv��l6�P\v�#
{Q���^�|.s��ro�>�-63�eL?��ࢴû��m���]��p�
�@��!y<W0�=�9���}1��mf�c�h���t�38<0��Ue@v(��0[�6\dN��&Ft-�y��jv�j4��dN�!��S�gb7�N��<(�
δ��������W�%���b��ن������oD�UQ`�.�9́�s`
ث����RN�Gl}B�|��5@�P3ta�m�w1�L؄ţ����+�ÀU��N�2ڣI�n���;U� 3�^T�;�����e�nr.�+��׌BN�-�WX ��](�q�߁����É���܀���(2��1=$�e����-�ܶG8��|2yV��-�>����ab��Y\HЈ[q;�0C�V`U�!2�"�:��-2�@a��he�` ��������sȓ'�A�8T|~f��L�B*�-\��s���mb����9e>۾�l�V�/^f�̑:�����L�l�[u��t�ؤ[��6��8��k���ױ��cu���3���a(z���(����ze�S���Ȗ�,N��3�Q�v%L
��v�`>��A��*������bq`���Z,8���.E���WQ\
N���܊��O�*��*C���H
#�Yr�[��כ���eܦU
Z�.�‡
x�x�ý`����Oq��\+&�}]�=�fI��/S,mׇ]�,�Qu*v>�肋ҩ����eƙ��A�.�˪�s�9V7@J���w��̞0nV���s�V�p�'8@����6 ʩb&����="[ڠl�8��Y@.K�O�<Y�w����7����
���A`���]���̋�3O�[U�'հ7ia��D7�pbT[,�����M�}N|���-�K�����B���yۿd����	�
��*c�n
��N
�}�p��}&�#�Yw�^
�0�G��#{<6�G	�tx���j��:�)0e�����q��ry�f7�0NU��X���^�����
Ymr��aq�<~��^)'Cb!\q
�+�nN���(���Тx��] wK�v`�Da�H
n >7,�뷡����2,�������ݛ������Q����t�.��8䆲��w��%۴���3�ᳪ��'������8��<����Ȋ��w�܂qѶ
�ӎ`i�G�s(�6��)��\r�V\V�3���U�p�@(���P<����Z�����H�>v��Gv���]�׮�A@xg����x�*{���W�>���t����NjB(�	��0d�����4����?]��:��@�N
i.Ec
��`���.�¿���y�>����>5�Ù�*����Tܳ.��U
�ږm~�;������2�y=��1@v$.�f�w�p�"V���D�ʾ��bx11�
��b���eS�e�@�&p�y|8-��ۄ�c������Ɋ�6k���n&ux]8�@����,
���k��<6��%�k����T1(�9���*��;��#�F9�5���Sb۪ũ�x�N���k����~w��</�>\�6�S�Sl�����Vd�������IV�m?�T������#l�g��C�O����,�[�7@�K��/�d�ǯz!AG(��b�W�zBn�@���U}
�:�To��,.��=(�wL��
5��Y~�A���>,�v٣���IMأ��4�]p^g�6����|8~����D~�^�h ���݊C 7P�fsۂ�qB�pI�n��y���-���v�"�q����`0�"�`M @�=}
\t�ne����U�r���;^���{!�Q����M��/|�l(
E��l��_J��
$�]
o�=-�
F�����C��E
�=2�?�KJuy�=�9ʱ���
NЀ q@�D2
vQJ0�z-�����/l�����,9�^8N>�s��2��%Ǩ?Pp��2�E�2����,�_s�CA��a���"
���=�?�^�s�1(�R`�^���
z|8.N��/���ވ��#��
-k
�/�=�d�\��~�}(ŵ��D
*>��������a����R�0���"�۷��b��#�ٰ�!3��<!���攃���y�������-��Fnx�jT�����ri�kf�D��i�C�.~y�����]:O(���aV����E�����_US�����Wx����#s�SI�A��=

���6����o�:}n��j8�l�6\�(8�N���Ѱ?�Y?"
�kj�@?�2�@��=��^��yɔ�QMj^�B;�|Iq��}z:���D�0�U�*>��
�ۇ��`G��?�8�S
g�tPžT��gg.9B~�=�4��8b�S����B	#�	١S�Os�H9�
4;��-{d�5U�U7�e�((
���c���
�l\մ@F����QH���7�C�
��]S�p�`�J�k8�	*nvV�2�!hl1�3�TU�3a�O�}l�]< 
�	�
ve��yC�EӒZ����
��=��z�a63��H
�fv�BZۙ_�Ƕ��"�G�ӄú��������Pϡp�2ۣ��C�
أ�x�l��G]�km{��!��ۣ��6�<�Cp/
7�H��bC�¬�P $�{�;C*Ǡ3�>~����
�Q�^���:R���=��C���4ǐ_���ә���OX����*������f��=����8Vs���m_Q�@+
�`�cOjC|n��v���iQw(�k@	?"
@�@H���=��� �)l�J`�þ �c<
j!��i�`$��B�`@�h���kq_0��=nM����w��m�a�/��v;�
謸���C�B�𘂏���-��o�]�(������D�J$�G��hدE��h4�����bOBuy}�S{��M��>oԋY�,	���Ca���W�� �=�X,�t�RQ�H��p������a�9p�G}9�����%��ra>�l��/��$�޸f����5�zp)�%��"@>wN7�Z΢Z��&Ș#��/�
��0d͡�\�A5����8I�lΗ�e}�l4r'@w� y����|��|��?hS�^x�A�y
��Ԉ�#31o��=����6�^��\#B+GXM��>G:�1
���!��HB�&b8�!-uF �TdŜQ��sx}*�Р��8�W���
i1[�V*
G������Q	��G��\.�
��-�*��^���^���Ǚ�]ed�T�>�G�e|>*Wtr:ݞ@ ����O�]<ja��D4��h��[M�s����b�D!�û��>?�_���p�Axp���8���D"I$�mV�~d�l�X�c}Y�y������)�b~�;�b$('�\"P��ܸ`}	+�t���D$�0�3��&�#.M
�l�@�
�Bp^qQ@=5�'��$�	Vz��݉ �?�DqkG\o<� �H�x�'r����/% �p8q8!x*sG��؉��TB۽XQ"���k[b"�1��/,��3�]�`<��3��'sɱ����c	��瘀�avX(�xړH'��h4��Y�Q�<%�ػ7�|��0�A�Ў/C!��B1
(��%c��h(���X.�)�e=���ˉ\(���	��]��p�@>��T0��&��
b.g2�x'�����Y�#
wj>�wl �R\����%�<�˩DR�Et]�걒�G�d$�Ju��ߠ���„� �̕��T��L�ڂ�D2�멶��}sO�����"S�Z&S��Ხ@��\�L�]�k��^ҵZ��(aLo�kp)�Z*�����-���/u��jj��t-����f�M*oҟ�E������c>D��9&�$�)&��)
�?���P��F���ZrV�H4��ҙl��!�u�˙L(մ���}� '`�K�6;!l�8�Z$��9ř��K�з����5�#�1�/� (�p���|ڕb;�!�6�]�Sz:����4͏��҂8&A���
Z"���Uo��NBΑD4+i��L�(�H2�gu=Q����Dg2��>���x�h�p0�*�3��~�����tf�wB��i��)�,��S�y���uwx!���Ռ�g��l���$*�l,�ǒ�l-�M����j0�pȅ;.��C�Ņr�����������w�X��.]0��w)j������p��ռ���h8���L��
7A~}iY[^o4,{�L2�L�/���{���_���%��l8���l��|>Ά=mEc�L0̦��`2�p%�e�y6�{t�I��
�
3fƳ�H(���Q��quec	`E�p�1��BH$�=�|>�'"�|&�p�!��#�ʹ����<"��,��
$���L8aN��2�-�h�J6�e9f�m��v��d2�@���3z*��zX�)�4�r�l$�aA�HH��Z0���I]���|\�y<�J%�g���O'��lVO�(�1=�)��hd*q��
���WxNX4�K�j("i-��m�a�,n���m��a�]\&���F�%���	�׭D��0.7��lAO
�@!U/�l\/��E8�rGC��G����h�N"�H<�Ϣw!t00�\$�Dy�R���M��@�d�С(�R6�yPL�
����B����mS�G��x<p���y]g{,���j��i���z�Q��|/�y-�J�B����p>�2=��R
0��}Ѭ7���q�[��B,�Ń�hܳ�7�1�SH�/��	8Vzo����w�J�\*-��3X��~ڗ�#�E,DD|�8�B$�R
����g��BZ�*�P=�����9ES�v	�Do>W	*E%�� �:6_�X(��BL�A5�`,
�¯�P:����d6��:;��|!��&sz=Z(dsPZ!����B��7ߙ��C�� ��@<����x�e��˱lX+�C���!�?�s�׻(���*A�Z<^��-��������=�|��I�K>������.�ʅT�\�+�3>���"��ټG0��鈲���Y��E����T*�w����1&��/;������R�x�����԰�����ձ��յ�<��S�T6(�ʋ��
~�Ⱳ.)z�}сR��ɰ' �����d�䌒�2G9^��qa���

���j��H)RΗ3�L$�dBi���_
}2j&�e�
�(Jjz<���s�/.è2����cf`1�rp��RI҉x���8C�X���$l0#�`'VBl���b)O+��c_�6��n��SK��B9���9b��x����y|�bg��١��9��c�� �4T���+'B	5���15KF  -���&�J:��������[��Y�z�J���)�ʥ��@�[�7��C�HQK&c�\2��G±|,�V8�psBax\*�:G�}�8�-_D�?�N�wå��Ǘ^^�s|Ig�Z/e;��Hg�Y����\�^_R��]$��D:����ϗ�.J�	F|i���ȕ�vvVK�z}Λg+d�I�})dZ"���.1.�.��>�7�]M���\:#��7��x"�驺�*zz���Rg��>�a�^���7)��z���
�Х�h�;u.RMT`�3љ�w�K�R��tj蛮��`5���|�8���b�P�ʤb�h!�	�����z��/;'�j���(B�\_>�hd��t�љ+ʱ�TI�J��3�,��:Gf�OLj�3�.x��F]gN�E��qIg=��LV�iߒN��T0�.�S	B(���X�����v��ugW���
PhW�_��2^=
W1�M��	`TO�+^�Rj*9�?20Шv�;��B��L���*����;{����x�@�2
٦����p��ճ8sxrdӋe��x#OE�BW�M�Ɔ�i�Z5@>���%�2��#�<j�e}���譕{z����XooGo�\��[��[��#�|H��2�C�\`1���\O\��ROO����{�G��C.�x#ҹŋW��ő���|G�gI��
4��]���L�������S�e{�<�R�֧zj=����"�ޯ��õ@9^��|o�#W.�B���{r�r��7`���G�����^
��Ho�c#�@�Z����v��2�b�#_1��=��\-W�=�`����Z��U����j>��S���K��h�3ң3s5{r�	�b<Л�W��v5�ɥv\�ӛ
��#��|`Y��l8���#�ápϢ�d�P���Q��z!�1l�������{��?�ד��?�-��|.��;�P���w4��p|d��������讍�{{�0�ގF�g���k�ʞ��Ƒ�m&��%��l��U�+W~�TO�T��כ�����d>Ok��@ 
��v�b��@4�����<�W��5�k�fLo6V4��;ڢfsU�وc�r4�����B%mi	�b)�T(sE�X��n6����_�%��_e)�+/]z4.��� ���zip\Ӣ�}���V��
Z38�\�,����Z��t��r �]3�=���wS
7
!�|��Z��S��f �	+]�tI�Y��R}�>�ݳ��07�k�6�sݹ����ě%�r��������.7���\�9�Q�T�z�3�z�����ڲ����<�00�l�9���8渕K�T����%���73Ql�c��`���Q�#"|;�P�TnhMH�*3����N��Em07��,k�86��X�������ts|Ip����ф�V4{��::�$���tK�\��,�y\�z)��u���%��哓K���������f��F���[48�l��];8Y�;�-�˹�z�R,�Tʕr.[�-U������|��Φ4-�l���J.�fU�L6O��%�ڑ˕d��H�k��B�D-ZTZ;:44��=:ύ�=:�=:Խxt츱Ѿd8�QK�j��j-�F��d6R��֪Ŋ�����t��>��E:� �Rmٲ7'��՘����S]ŗՊ�Eݵ�ŕ�Lr�hmC��LvW��J-�l4:�di�h�h?{�"D��T2�wG2��������jwmѢX,:11�B�;;T*�����h	1ҟ�O�/�Pr(ٝ�,.p���W��w��ڢ��
�
�7�jǏ.�[��?r8
�ط��@�6���h,��M�t���GV��X(1s���hUD0��c.:V��GFk#s�vgG�\�֎�FFK��Fk��F9�V��>����"�L$�һ��G��ã�䰪ӣ���������/:>���ܲ�)�寄��ծ2����±��P�D�P��<�[�z|hdt�g�gi��5�w	�b�{h��c�ͷ�edu��ơRgG��4�����j]��j����%��D�T���Htl�V�u�R��j��7Q8�ûXs�G��a=k,�X2�m��ꛜL'�ON�O��MNn��l�#��F��@Իн{���d���Z��{''��{�r00�\��}�L��r�T�����}}}����GGc�#�U����7T�m�$�'�*]����4t�EX�n���&'E��1E�'u}(�_hV��������~8�SSS�ɮda�2V
��đɡ�Pe06TL�/"������P���fu`�E����@cqj�.�][&������-�lnۊ�j�xʆ��ޱ����򾦿����f�d'+�ܐ��]"��d���I@2Ȳ�6��g�������;6وm��8�	�6�mx:)}r����+����C�����'���
�hŊ���h��RZT�6��j�QlT��F��ѡ����d�x�q+ƖON.:�
���(&�dž������^~��ѓ�*ݝ���D��������ۨT:G�{G�h��1U��K����Fo5�mc����x�k�r�J�(��W!���'
����J-ý��?7�ϸ�x��z�C&�i�i�i���ą�?��D*�ʧ���@��Z�O���b��m�Y������+:A��~sڐ����7�]'ӥtGz2�9=�1�]��(gȹrjΟ�b�l��[�k�Nϝ�� wQ����r��n�����}=�����s?ͽ�o���M�������j��f~x����x�����dr��2�`�"q~��ީx�3���޿�x�~����s�����6�{��}��W��ݲ�����)�>���t����u|���k�#:�&��u�Of-((((���o��+�?r����W=w�����s7�?g�]��|������>wֳ�>���w��ٛ���3W?s�3�=s�z6���gN@����g�d��xz�������y��t��ŧ��#O���}����}���¾�xԾ����o���������o|�Ⱦ�}�}��Ծ��‚�������n����ܿj��q�7������'�������w�Z���/���t
]h�����C���>C7�H��Ԣ����
]F�����}�{�,}�^���?��t+�Kߧ�hm�+h�G���!=H���?�Dz����v:�~GW�c���d���.�S�:�Π��t-�Io���v�Ag�Yt��~I�wӻ�=�^:����<zN���e�
�>.]-I�A2J&z��!}B��t��)�'�K2K�J�OK��>+}N�V�N�Iv�!9���ӟ�/��/J7H7J7I7K_�n�n�n�n��,�!�H��Y�+�D�X�)�"�%}UrI��G�[rK��Jz��K^�'�#}M�K
����7�oJߒ�Jߖ��F_�;����#}W�HQ)&ť�Iߧ����9�����RJҥH�J?����~$=(�����r�C���#ңҏ���n)/��T����'�8=CO�O�g�sz���~/�AzE�'�����G���_��J��.��פH���%uH�ld���`2�
��`3إ��ap\��6(��1x
>�j�RM�4
�!d"��!f����CʠKu�ː���!k�򆂡h(�4C�K�t'}��#�@����K���a���]C��o��Q����Ұt�t�t%�����"�B�����O3����j�;�.٭��3c ��‘h,�H���r�B�Tƫ��Y�jt/����_<0�}��<��e�'�X1���7�Z}��k�s�q����
o9a�ʹe��O:��SO;������mo�q�����z�{�}���;����~��]��K/���W\�я]��?��k>E���g?w�u��_��ƛn��-�[o���w���}�W��ꞻ���׿��o���|�{����?���~��C�#�����<�=�ӟ�{��8�ãǬ^�d�98�����gQw���Y�V:ʥb!��f���+�X4������Q7���6��l2$�Ld�mJ��7͘���*�3�Q����M3)T-{}���&�-�����y�z�{/���T���Jj"��yp<��#�:|_6�Y�����>R|_!�e|�:�&B'��f�M���e眼sb�8���t�eƦ�
�r8���׌�پKҖH�àM�2�MS3����L83��s��ͬ>j��xT��W+3���̖ʌ�(���ef,c3V�L��
]��Uٻ��=*m���ږٶyú��������h�~!t��ɽc�>|hkԸs"tJ��;w~85s�Q�mՙ�_�9f�e�v.�—B�Sk�L�.\�nF��x����3\���Ԍ=3�9y穛����:�]�l$2|wk?E&R;׮��3K�����c�����w��¯o�Vv���Xw����|���B����k���J�Q���Ljk
���`O�L��i�����am��Q3۠�Sf�c�v��Wy��9�b�	�����<Wcɩ&�d+Y04���tt̔�l �1h<.�j�=���v5��Ր�������z/�3L[P�9��u�r��Dgi��c��a��o	�-�Ϸ,ߔ��)�+0c�/�OQ����f����y��>�&3u���R;7��vj��J������/���Ϙr�����ǯ�
�Ϝ[��8e�$�x��3F
��_��QL�ݰ03ֹx.S�"���
,j�Բu�d��w���[���^�Q";8lnO3�/���:�\;�`ؔ7L�=~�N��ږ
�v�\�I-۹i��=��dRjf���u�u;�Ol�W���=�Dg�]��8Y�ihtWF��]��Ek�_w�
�����fqq�m]�+��uw��Ϣ���\ɅhJ©������w�/ZM�B���H����$ں�ЮS���3��EF�����
q��WaSw�Z�ow�ɥ#
����2]k|��E2��_K��㻅dn�5>�{b�1�yGM��R�nn����0>g��
�Dų���hyfvtt����\m<;�0>C@2�1>K�����Z���}�H%�:��i�@�Ɵ����~��#��o��$�oV�40�Ư���ƻ�_�k��n��A#;��ߏ���~�W�Lt��&:�r�;�L��&�:�Vq��V����W@;��D��ނ�Әo6���o��(����D�E��G}��(s~�\��ȹ�Ss�נD�ɹ���"�e�?>W>�x�w�\~�q�l"��$ОB�#�u�����w-�d���t��.�
�g�s�뽳zF�轻�p�:����{!��Br�%�Ν�sn�O�x.���>�Ϲ�Jݸ��`_TEJ!!��;�π�EzD�_z�u\2�r,�������0��v/n,���D�z�x��p�q��������=�+�wZ�Nﶻ�vzw$�����q+��@~�,�"�q$�q�l�3y��Mt��������3�g6��%﷌
Zm#���X�&:���R�&�v��v�jO���a�j��L�y�ˍƤ�ӸԸʸ�h���;k�F6��2�}��:�s���yƲ��e���9e�[�-�-�,�-�[��\g�_a��j����<�iT�)g�9�\�4'��u#��vd��t���Ÿ�)�	H����	�'PBIEz����QR�OA?�
j�(��Fڄ�}�ղ�2?����-H��"q��
��}���V�$�$�$��#��C4���(��#��υ��\�&$�hE��o汆o.�-I3%麒tEIn.i�A�^��������Lgf�̝Y<�Ӫ̪ܪ�LK3KsK�Ko0uf:s���L�L2�,&o0]���Z��J�ƕg�<o����=�Qo�<���+��H�O4܁�l��Y$#%A;��"��d2�
�4܎��Q{;�Bڈdƈ�^@�sm\�h�/n7��݈��6;нjd w#ҵHF�}�o��_w�����~�\��D}t~�w����q���O��#��a�q���A�Hۑ�@2�G<�x��v���+�rW I� ��Ǧ��l@�n���^,�RA����_V��\!h�\���H#h�JP}�9"�9"��K#2f�H'���T���o�2�����u�?t����6]�y\gW6�u2��t���agR�AR>.)�%�Y����iTЄ�Q�ҫw*�
ٿ&�J�I�m����E&�f�#��6�#��l�s�^�m~,�u��ŕ&�e6�Br$ �I:���?���!A�"�I�o���C�������0�S(��6�=�㮕������������ʻ�ꧨ"V��l��~l�r1���VNGv�l�<u�YN�x��(k�[)g`NVέ8��OG��=xb�£�y�=��l�Y�������b��lFl2N1E�2��(�D���Li��f3��,�;s/$���o��,)��K>�u���!1�����ѻY���ɇ+���ܱ�ɇ2�尭��?�G:��6���dž��DZ����$�ɴ��3�k��Q9)�����ސA+�հ������t���59�g°�|�٠3�㳦Ѽ��$�������۲ԏ���&��$2�ǰ�.�����ݷ&������:�����+�3������1����:���b=˺�z��(렵۴ܵ��q����y������E�y�͸�#������p�lᷨ��۳������[505��0��6����8��Z3*�x�h���賢�������������7��%���ۏҌ�"��k�������(�?�&����(�����������ޭ4�%5�5؇�ʴ93��9���䰭��<�����i�v��CC(>s�Ԛu3����4��_?5��_�w�f8sb�n�v�֯�[z��mGs������(m؎n�䌻��4w���[t[)��L����v��HGp'��wD���se��Z���se
	�{hO�:��$EL��HL�N�r9t��ˮ�:�����[6grmv�SN���֋u$�`�b��`����>�O�����,������������4Ҧ�K�994��������׶��ʳ��oڲ�d�7���<���ٖO�ڼ��4o��͙�]�ub��][���g7o��l_����Ʀ^���k���o&;�'�n��7�S�|#�5�kM�Z7�(֚:zT�Z�n��F��
*����aST_?T�/�cP�/z���c�N<�]�����#�n���&7�B4�zߠ�G�y�IE�'3J�8e|�;v�8���gw��uvHԝ�C����Y����Lsbfx��z��q�\[7�~��p�pf����k�w4�g����o�N6��L���<}m����6��k�ym�i�ٰ&�,��q�����?.�u��v ���8�cl�H���ە��Wɇ�A�FZ�d��>��<��L�AЏ!}
i7����D�q^q}�N���]�i��A���v���v>�v�i���.�v�(p�%��~��!��5$��al���n[����C���YLvt�%u�Cbq�����8��C��!���I�q6AP2t�;x�ٜ�n�!��JJ"���Z�!����+Z�4�F����}�|�\"���t-e����C{��7��YMW�rz�� 7�Kz���øx��/#M2�5�S�@o�i?^�S���<���ŭ�A������1�2�#�.��N|O*�D�.o�%���[O��YzQʶv�$�^"����J<�O��[����4m���s���[m�KL�L;[�� }����u$�����+���/H����l��MܥӘ�t8�����q�|�(OC�&ڌ���O%��enZ��kP{�j�0��htm���zH�	z
��Sꁇs+����O��):��M��1�6�[꒺�CvX�c�v9� �U�iJZ���b��\?���oZ�l��L��������������UwO=3;9��8�;����%�]� +"  �""�k\�z�0� �d� �����;�;�=�y�
v���gA����4�������˯���qRx
>�q�y�X��{8�<B�����#��C~�"�>���+z&�l��qQa�PC.!S�By^�1���E�/8G�x�[�K�rỞ{��1�qo«�b�w �v�,n�a/M�^��h�a5��,|P
��������}�W	BO�dc�<J�D29�;�����-�%�*X!�أ���������-�w�Vn5^�-w2�u�\�*�D)�t��<�T�'��B�W�!�k����\����q�d�v�>����"~��0L�.lSN�-Ƚ�3��9>Q ^qRB2��gJ�<įM�����HV��Q^�%1�͒��U�.��9@��]�O�
��V��a;</���)�e
ᖠU�����lz+n����=z��p�c�݁�zn�
Zi��*p*�!<�x]�PU�P�q����{r��s$��]�[�{>���	=��()%e�i'b� ��&ܞBI�G^&o��e\�
J��(
%ȵ���0��6��0��0��:�&�n���~ycs��`+�g��.|_�W�=���Ci��8M�Z��:�6�1�ͦqk����Гt7=@��,\��t��{�{�{�{����|	����	�l�f�-�m�N���9�z��[�Q�W�U�S<�8�8�T(�1\�^���GEk�'����̩%o��B
��~�z��ڄN�S�q�|�n�/�,�����������87���-�	�(�8�P��"w��F?�g�?x+��_B���Ӆ���]�+o�oNc��>��7�1�w3ws�s�NX����$����	ju'}o�3���A&����UX���Go�"�~=���cv��ƛ0����h-lC��
>���
�'��Ac�-ܓ0��[;��1�~��;��L�'c�
��;:�;�8�Ub�s���,R(;���Ԁ�hm� �&�
� ��?�;�,�pB���Q���!)�B_'u���6��F*�A��(H��#��t�L����~R�yI���q[���FCh��SD��Z��-��Y�H�g���B�Ԋ���f�<z�ܫ�+��4��>�[�R�1�}���]��B�K�Z�v���P"�vy(�
q�z��E˻�g.��J�Q#�'�J��y�@ލ鹹�2��ў�����ق�wI�.RE:��t�P�g�ƾ
/�?��@�=�|��(
�n� ���Cd�>�Ά�;{�%V�G)4��)r��6�;Fҹ�tg�`�
=�'䒞'{��!sz��=L6)�=�'lBٽ��ES�o!�A�N6\�ߒ�������(�����Y��=F|���GB��	1l$��a�w��31�G�y)!C	�����x�^�����?⿌�@	!�����#���8>��[�"��J�?w��0};!�7R}����RWAH�-H�#�4��2����s	�x���Q����i�����	�؟�K�/-��exn^�Z��mLߌ���@|ga�s��s�!�*<�~!�5�,}����B�������Ӊ���۾yw�rB��}bt��W��#�ل�yj!�`_w>E�nlw�C��U!�LȾ,!����ۏ�ۏ�܏t�"��H�,�����U�ہ'��>�x� �q�9��;4	a
�pq9\���=�
m�sț�Z�"|Lȑ!GQ��!_@�����?!O���~i��B������~qx�¿D�+��]��}��G�`=!"^�5G���|jC������!�O 䋁����5ҭk&!����A��w����F~�A���G��vg��ا�(??`�~�6�c�ȃn|~n4�b�K�/=/��ی.+/��AXCe�)	(}ԃ	hOХ���" �C�
�C&�$��0���̎������7X���-E�C��m�Wp<A�����t�%��4x����-������'h�0L@��x_q
�'�k��vH�C��NEO(>N�����(I �8��#`҈G��4#��įR�PO��]�4�����3��[mҡ��@_�E_���{��H��  ���\�}k�F���=���H���"��4��ŀ�� �A�
�2y2�?�-��o	
  �C�C_&0L�����6#$0�l¾_b@�㱘Ŏ���1����	S	LF�N)B��.E�LE�� ��s�}E��;�&3�˱~9�gf���\�x^���i6˃�
�<�3ei6�=�
�t�h��\���W�C��þ���|��Ux�U��(��H��x܆�i�@�l�˫��Wc��Q~��B@Y^�Ϲ�_��/þ-Cz/þ.w!���#��܆���Ww!w#��Fy��t7��j���������ț��wk�� ��!>"��>>����<�����������
(/P~��Cy~�{�c??F����/lB9߄tل�l�67�n��6#7#/7��<��{e�Iԧ'��[�w[�-(_[�g[��[Q�B\�F<�F�e���g�g�gQW�E|e�Ylg'�|g+�s7�`�	{��{P�� ��b��Q��#}�#
����8�Kq�"��`����s#�#c��Cz?��y�}y�>�9��������ף��G�����<��=����u�=�}y��y���H�瑷���/��/ �/<D�����/���B��>�/����P�շ��o#�������������y��=��=����6�c{�#�N�̝�{O >'P�O �'�����>B�~�t�x;��߰��!��v

m�'�����"]>EZ~���q�������)��r����×(�_c�ߠ.~���'��_�����#� ����vv�Q~��~ƾ����Q�~F���x��v�#-�#��Q^�цu#�r(w9ԭ���%�V�B�B�n"T��BUU߂p��zB�'56jJj~�P��Բ�0�#|�p���Vl�A��suf	uo$ԋ��Nh%48	�^BCg
�a�6����y��W��Z�Fh�qB�vZ� 4� 4s=�U/Z���tZ�����a�����Ch_l��@B���PB�:�?���!�����j���������g	mB\�g!`�oCx
�/����{�Љ�~�NF:\:
�3Ϸ�s/{���q��X�4��@�iṰG��p���XI��"��G�pD�d��@�*�p���B��ypq�g��G�g�Guד���(O�OAD�O��c�%���L�����,�#:�/��O'Q���U5"I��.�3׏��UD*��<I�#�Yn�~���K-�+%=Ƴ�(�2���)��:�e2�&�HCW��Ey
�屲b<�\�2S���Y�+�;sb���F~AYcc��*]
#G�p�O5��ӥ�l�歘�F���k<�?�|�����e{~��f�}i*ٞӻe��yE�b����U��:P��:��܊�cf4n��sp���#إ=z��7���\.�Is�G�U��[ݞ��s�;��϶t��w�����
������;(����z�uשTe�5eŵ��܌j[eiI���Cd���PWW>���G�X^"��)�ߝ���;�s����&~�L���f�`7�f�]a2*E�ݧw(L:����5n�I��AM&��(E��A���n��
���
z��5��+��V�+ j�۝�⒚�1ZU�vv�m8z���t�\���s{ן��J���>U$
�[�Rd_�fdF�0 A5jbg�A �d*(�6:�O�;[m��R�d�t�՝n6k�T(8#:50�	&����b�x��x�l˩�3g�!u��u)oݿT��og;����;�l�߿���b��+Ӗ`eВ���a� �9K���eۡA=�^:�R�d��iOܓ���KsOO[c��y�Oc`b3�)Wˠ9�uL�F�0u}~�L�A��%�V��Tg�~i��ʪ�+Y}����ʔP�����U�̾�yMɒԲʕ�Z�ӊ���<k}>�r�O�ϕ�$��<&�|�����6kE����9,6�C7�{��:��`���{�=�턇�I�
��p�b����@A�H���6z��"����[�OV�Ն�,#zl
��`��w}���W�NĴYHx�:���B��2�Lי�R���m�]bc⩮.,���j����dg%�;;ة`��g�w���L,��NJ bQ�
"�藧,�����^�F�*O�SE��b$�E3H��t���J5q<���b�����io��bK�f��b��VW��6;�c����S����0)�������2��/Ѯ���������x������J�=6f̜>����Ʀ?�����;捼꺬e�T���{w��
9~Ǔׯ����������=l��5zG�]��@��yEq9Z
��H���F$�Ѻrt�b�n��5��dk�b��x ���@Jw������� 7�����W��1�da�>�|��0V%W��"J
�6^��窚�2ˤ2Z������5���5g�qSd��BC(�mi�ih�5�Y�ۅe<�e�)�\yʁj3�T,�b5��h}T�cv�cL�B�F��U^����b��)Ě�d������K�5�k��
/4�.��	,
�f/X��n/� g*��)�X�� �
����۫�!d.�ݖ�`��1����w�|�����������w޿eI�-M�wN7�L�?�(p[��5���V65��
���Re�T*(���Ex��=�����+wN�Yz�a�>sfԞ#����l���Д'�]�̄ʪ��=$]=l��i��=�
�P�I_2y##N���P�nm�fp���!E���/w+�
��%�2l/�̙B)O���l���V\ѷ�bq�:��آ�W�X���i�B���R����_?Ǘ����JH{�%��,�ju9Fb�P���%{j�9u����␷l6Q[�"H�&�b���Q���!G!}y���?�nw�p�dq�c���*�ٹ����,�J��Ӝ�+�����:�:�r~���S�t���2a,}&oU��"�{��+~1
�����a�L6t���h[�� �&���*�ʼ-�,j��U��J���ڮ`W�F.�L��~]���eQ�Ge���!Ʈ�
��[቉cw,�|�A���W��:��?�oz��͸�ڵ�dW����n�����'N�yˬ�K������ʨ�!�ª9cGs�u����X��_7ι��)��=w���eMY�-h���:��eu�˺�{6_7h��y�U�ٖK0�p�q�%�[c��ͮҲ�H�B����	�i-�cQ�~��ߥf!�����Wq�q�C�˜g��LF���"Y~⬯�gJK��aM�b�dR�{X$d\n8�^��XH�^kz�Doӭ4Q�:���`@��b5+@�Q0�2�����z��Ƚ򔬰V4ϴR$Ռ9��>J���5�@���֏��ߐ[9�X�TAς����־�޳���̐�!dj�H!_�*p�p"a!j
"�_d�):��0�H@���ƾ�,eeU��Fr��ɽ��uF�#�f��uo��ws��`At��0�ww���0��6sm���t�uܭ�K���v�?�-�����`U���Pc�s��UVW
N�QxŐX_�Xп`@��dP_w�A�ݣMsO��q���
ˆ���s뀕C�9�z��n�S�͞M�
{-�Zu��aj�����U��8��EޯѓxU�)��
eׇ곰_
�3M�+	Y�ך�_W�nCC`dj�[#���G�:���H����g����9�]
��ޫF��BU����%&V(���2ݹ`^Q��wuX]���Z����
�6vIo;6��w��#��JEu����`i�[F�3#��(����+�K���;곖�>%â.O(UX�n�קj�u�E����AgD�I��W4�J��:���6���}%E�ʋk,)NT{�e��tE<5�&�y��f]���6������h����/��H�d��J�$P�|���"�]Hj�(ٍF����D�{-�F�F�
kj�}Z-i@xO��Xr��Ъ�!���s�Њ�;�)*�6z�

3�&�5�]�N��$��[�Z��}�%�BQ����)h
��=g���LNw�{�+g�ӳ�,�m�u�b'c��d:����S�[�ǝ����*3�g�tZ��h�[;��5E��o�f�F��'z����2�B^$P��-�U���.08/f���Jm�\P^7����չm%�����@]�.|���;vc��N�v�
R�
ޙU+y�8G���
k`#:��^��3g����r�K��[�c��}��`-߃�B��X�I��$�TW��*��a��Y5Uߪ˫A;�?ַ�T��Y-IJr2��\�%%�.�s��C���L�����]0��)W@)���R��/��ʵq����;O���,,���l��0�b�ӛѰ���/gm����� <�2��=����"�9�k�*��.A���^�ʂQ2�]$&Ũk�m����1;m`q�
��l���=�_��.9���k1�	�p$�
�
-U(����ss
K���N��*��i�+\3���5�k��
�h�A�,.�kE2�hɘ����LT6
բ]v�U&�se���\<�������3^��նW-���"��u+�f����4�q�K�g�������ȝ�y��Eۡ���W��}��A}�
�@���R��hult�t��!9�r��F\	�D
1
��
�ad���W�!�d���)j��r� ������Q2U��+�k����i?H#p������0�#��zS�Z�����^Kj��M��X���h%#��w0<h�����56�2�������E5>�Ro�r��}�+�LK��۰�>�#ݤthk�OߌC���
��f+T�+�)�*R�R~��R��<�b�b�#�?4m�n7�*�j������O�Ov���Sp[٧\��ڮuh���J������r�
=礂�����c�7GR��]C��Y.����Z��Q�A#^�J��|Y�K��gM�i���ޒ�da�;�H@
t����
8�O�gz���it!]AWӣ�-�	�'UQ�� ���<�����L/$�]�-��
����s�j5U�����}r�^''8T�_���]N�}���Snx��"�ZԂ��q�JB�2���еQe���m���0����:�zx��R�7��f̟8�B�\�ú�7n�����﬙=�����j�r��n,j��g�<@4='w�j�,į��6�ikG����PXXS(eZ3oeNf~�(I�+��˞��,{���'яʾ
}�
Sf��݉�H�����)He��^Nm`�†�^�8��fa�nQ_�8sH
Q�������F�
rr���P�������)�XJK���i���,�\�Hؘ9���{��K��jq���9}�A2w��c��x�Eb�]��Z�� �l��ʒ����+B�p0�y�5�b4.I�t��Xj�3@�.S�f�_�e�&?P|a���"ҎAm�ls�O6�Y�^'e�ɩa>�g#ez�8��S���'�?xCG۽��W^�:]���hѬ�.��с�
Col}x?|��s��ܷ�|�u;n�20�-Q	
���M#j��F��[�f���lx��rWC��})aӃ��KFN2B��J4����:���:=���Q�<�Y�*`��
�����?���I/���y7���t�!����Y�V�6r��{��\~�� ��Z�^�4rF�����+j��9T�
��/D6�P�̏	�݋�M�&Ya:ˊ�ޔKq#�0i_ְ)�1	�q܁}��_��,ؔ����s����w�G��1�5�}�0��'
x��dߕ��
�
��]^e%����&�y��<�t�k��qn�zc�d�H� ��o��U�y9F*S �.�]n�t��ݰ;Z�%qp	i
��Y0�Q�A�G�0do�r#�c��q�pk��QA~�'ҍA�F$u@7�Tt�ؘؗ2�N���[ud�>u1C��>�2���b
�E�A��H�E��.
�7ћ
�8�Р�0u����/4���	m^�e2Yʠ���iůb�^�e�4p�F��L�÷N�咫�-_Xvœ#F]�s�W^�Ծ��۳��uī�Vx��`f��ޭ+UR#��Iȋ�(�� 祢k�K4�nR�2�Ppp��_n���׫
�;N���,ڎ}
L�cF���� Nv��ĕ�$��E��"*�m,:Y�9�tǟ�E�,)�dYc�hQZ����(�1�<��Ȧ
:R��kK����­�2	�~�x�j����P�)��E�a��{	���f���AB:,��!��^�
V��`�Y�bʘ#Ui`������������"k���׿q��#����y�o��N����b�9Q}�cZy��O�������Cs��v�m���u�~���9�mB-В����n��� ���
�HݟH�V�F�k�*=
'�I=��@�������%G8��^��T
��w���<�ۨ�S'��	G�!�/���o��0���z�β�S��^�A�Ů�||�i���^�U/+nnQ𽂋r�#p6
�a�2�g�~��
���ў��
#c?�_r��j�L��(o�Pޜ$FҰ\:8S��?]_�^��v�:\�U魎M�'��u{\�c��/i^Ҿ��)�z�R�mz�+��F��p��V�Vb�C�`
�������\2���cs�s�����%%קW�e��&�M���m�����Lk��6Ǟ�?����T_j��}i�2�eE�R��בZ�������B�˱�B(e;��ۨF��F�g�º��X$�R%�*[+7V���+Ç�u�u@��K�5v����o{
�<&��Sg�:x`Y
yEq�2�x�5��+�3���h)3�G��"},/��� ISi^�{e��Gfl��b�J����z�n�0&���|�卭O�2ێڑ�|~��eP�TZ2kVGey��滮�Sl�v��	�ݵh��y���վ��eӯ����74]y풦̜d��7�����Ck�
�5aʄ��A'��� �� ���	7�����-�/�\�Cu�E�V�.�}TB��;��R8�H{�����2I�dta#g�c�1h���c���Y ��h�9s�@kT(vrRak��“�|!0��$�Q
�8��g��
Mw��7�'Q�>5�mTm�_E�ʤ��QO,��3����&�Z�N&,B��Mc���lt�:o��{���	���M���N�]���ߘu��O^{��_~�M��/5��ɍ��~��k ��ۿ뎭����,��ƹ��M���t���^;��eݘ5��v�=���;9'{Ϋ�]�ƹ�?�(uhЍ�����F+��(����[�3r��;�V�J�-�N�����%���l�����e�ݖ��Z���m��z'�&�K�`�y�쪗�/��N�XE�n�C��*�r�%�Or`�oT�1��r�uƠ?�䂯������șw7b�O�|�Y��A����m������ �S��.�����'��K��0v���j�ġ��FU��$�>I&�e�ܻxl���U
�*�?V( O@q�C:q�wq
��g �,�~�6�9y(�I4�B���'�$�54�m��T���[�� Ƣi��d#F�q��X��+T1U)L�i���|�'��dK{�����r�N���x�!LJ+�Y�-�����3���ޠ/�_&���N���r���*'@I�ߩPbG�	M�4��G��l�g/D�tH}�0� ����89I�P�"�q�H�8"���j%��$SU����L�Y���ީ�������-��6�Ķ(_}�U��cΌ������4bW�b����B«�c��?XH2�^
YH���@,��)�A�����հ
��FH�i���%�粎!]�DZ�$��uS���F�!�~�F��2O���
�{@%��O>����t>C�ʕM�{a���"�ѩ=�s}�y$D���j�1E)njR��d�!Ք���^}�z�n��q�:���
�hㄠ����a������(Ya
K���v"c����
����X�r�'^0z����}Q���U�cR�$UBKQ=I�;��|dJ~���Pj{���g�1jo����S~�w�����Q��Q�C�%j��:��*$o��^��k�pU�r�{^�'yӍA�B�kS�r��|T}�s�ę�e��A/l��������h��� �n��ۗ�[�vL*:�);������
{h�+�4&�Iym���`e�p7�O��ߤ�����o9�<���iv��,�)A$���Ɠ��'5o�n������Ls�A����9�
:��I�ed9���T5�o��1��)ᵼ���1M�
n���Kj���C�<���88F�+=�P����
�;��*�`{��D�R.�Ti���k���O�.jp=p�ܒ�s�&���u�öX��TH
5���s��,|��̑��[{gі���2#�?'
g����������t�|.;c�)
��N�P/�����}�Ԑ����)����QEIL��QS4K`
1���dD�0/Q$y/Q�j�͏�x�n��p�<n�K��s���x�к
�ax�H/RJ/�+���]������a#����и~=�-�h�Ϳ��|����Ԑ�v�.�d����C<���t�XҔCZ)�I��7[��V;��yʣ�6{��꽍T�9��qM��80��{7�������x��
%l]\7%˽�mn�g?��so��g?�r�(�}�Y��#W_:`�|aĨ��>CJ�:�����O.�J��A����2?~���y��+�mn����A�l��?�?��Ck.�=w��{`N��A�X���fRCӤ�S7��?%\d_jE��!~��Ie�k�����>���~G�ψA���>��*��qF���%�6���UF�"���y��d��Z�o���?� ����"B9�L��hԋ���TXٟ4��n�ë�O�D+�nwjRF����]��ӁX��˗?m�O��;�
ђ���x�q�q�8���l�(�/��k�-��-;�N�*c��i^�����a�A�þ��s��׍���x_�}d<!~m<-���d�Q�����Dm�~��H���y��[m���6U�UVS�ۺ�g���	��S�	�g
Y��d��J}~�&t2ᲰWҩD#g��T*�ʓ��%��)KS��|���o$C@24�3p�'�Vɾ��B�u�ؐI�/+�ΰ��z6��FJ:[�h:�^,v��c���ox�^Y��塓_^f_�2��\��u6�iȏ��᜖r[��=5�gFn�xg��-'j[�vyImb�����5��Ie4jt�~�O=���K�h�/�L=�t�2�!����H1��7H�)d�o%�ݷ2��������/]_����Ր��e�*Lo�<�>�:?���u�������޳ܳ�*<��K�e�g�R��/S!�X������ѕ��ȇ�ϣJ>�ϰ��ȳ��԰��%�������ᙉ0�9%���D"֍�)�庶������*���U�LЗ�"��3�+(���ҷ���|�Vꤺ������Ъh�����(�v�պ��-�\�垸�����6��ٳ��k��_�Ҵʎ8'���ʷ:�n��0����,����*��.�ճݳ����B�ʴ���0���۳�ۂIʚ���ױ�ʻ�lױ����;�{�`��/����<��<�3�/�ה���A�f��ȣ��ȟ�9����Mt<�Yx[��(,:�Dg4�R��2��l�xc������I�L���׏�B���(�����^Ε~�w]���3	]�%آ|�� ���))��t,��L8�����v��B�`��%�4$��i�bi.�i.�.LCJ(K��7�&�
�2
@�
��z��<�
h�-ZD�_L�	���'�p�R^��f����`E~F>*/|��#JS� �<����k��O>��H��ڽ�Qi:���׮������{?���3���=2���&��_���^q`|�*�����`I����G�Je�M���b;����Ҧ{�����`D[
*�W���fӓ���}�7�3�7kU>�nள.��ŭ���[�����:��S�Pn2'$U�)�1{�� F#�������"�Y�q�j�=�g���,P��*��Ϛ�oj0Q�KB
T�`t��!��cXt��rfXܲH�=���v��i9�EC�7g���We��n�NuŴ1[T�V���S(�]_J�E��s�E�-`	�Dgn�w!��s���s���~�/����%]�nym�V�C�g��
��~u��]��
�r���̽�I6����-{��|���0��P���^Yd�[�� p�d�[�M�_|W��K
:�u����_��#�&s���)����G*�ߍ�������ӟ0�ԙ�و�S�d���I�,�s����
���L�5TJa��-���p�.k�]�F�Ln��N'�6*�
;�X������r)bvV|Vf�/*W{A�<.��*Fb>�g��XxM�	�8'\ ?�E�iiO�V1�JE0�T'h+Q/��	��i@�Ǿ�o>w�G+&���ܟ��ru�:x57E�$�*w䯹Ϗ�3���N�e����)��*�A������pj�c{�P�d�j��MѦ\�Z��Pt(W�V����E���`X%1����_�V))��2H�_�VzD7�0��4�T\FJE6
G�����j��}�����U*��6+G���I�a[_H�r[Kʶ��K�x�|��F4�`�=����rc%WID�U��Qf��FdVE��U�����S�al�y�:Ö��Fv�t���w9ٵ���Ԛe�b�7D�O1��{g�1�
2
H���t\�͎���
�i.o�~a �%��v(Z�(�Q��<f|�=1Q���sR�ל�:�*�]�q)�j�[��+�}:\�8���N����d�rۣvQ��k�ї��ޟ�l52����[�P�3�̂O��άR�j͎$���`���p-���Rs�?�Q�	m����C�y�Rj�ET����*���wۃ!2��)�
��;}~w,..IhT:^��j$����c$!&h�q:�Ǩͮ�'��B ��B����/\�P��Ф����^��dNd�dNB>��I�|�+sһ��(�yD�->%�]�m�ȼ�r0���^�u_�#�R��b01�!�h8l�/�M[�.���ߤ�F!>h�z
����S�b�ƏB��Kv
�b.2��s�Mã�	��N�#-,������MN0~
Eo�z��H�4��2ꌻTt�N���Z����mΥEkk�;;����m��sT����ڪ���OV�:�6��*n�
���w�̸���g��`7F�#�
�����"Q�!5�}:Fy�Ld���2���k��hn2Sf;W�{̼�g�0�
=�G6�Y�����7���Ǩ�D^d��D�{lX��U��B��z�,�Y%s�<�ʸ$^�T�V2(V��h"^/�s
"Ơ���IY�)%�0b�Ї��R�F
��7IhQޅ�:�B�Ȑ�
b�=����A+'��0��[�wa�����>nّ\wg��w�����8�ꝣ�W�\����'��u��×-��X���q/��ͧ��B����(�>�!�e�W���;��������p9ϼ�PS����p���D�=g�2�D3ٞ�U3��gde,x�da�-�y��%��9-�
�/�E�$�%I�2��R�ЀP�9��/�D���2������Y��	�7��$�K:�f1����Xy��-��
�8����Cxː����%N��nO0��˂�A~w�`��ݚ`��w��at��p���7F
�#w��}�Z
-+-�x�*�%D�|6���::R��4 ��!�C�
�C`Ƞh��9Ӛ������(%�Y�^D��Ơ�����M���4?���_t[��������9�6�%h�S):P6�hJR��é�1g�*����C�&����Ƚ�����8����X	�C��_ٌy���ٌ4KK�7���� 셃���D�38�4�J�w�`��w��!��
����6�fj��I��8ULJ�<��R��:T'U\�
R�fU����:�:��T<�L%K�*���v/Vr�W�ڂ��A.l��c��Aʘ29!�iT��E��Z6�y.�2���NХ��tHT�����SV?�\�㚞O9R(L���2�4˴:��f�U��x,*���JQ�R�	�IdsxD��MH�����i�:z�ד��Y�7V��a�`)�h�	��)��Z�ڠzV%U}��A��^2}%�d���sE?���d$��廃'c�ܩ9(ii�豗F]]-�
��u+bG����\:O�j�Zg�~�^�sl�W���)~�v����2
�X|�|g�$���#�LO!.������R_��]Z���"MCh�N M�R�:��O`��^g`�-�:�9�W]E��*C�������������=����տ_�7k�3P*� ���v�hx�B�%l	���}�"���Aݤ������|�1��Nm
*iZ�/5���M�>�O�����crޡ�q_���;���;��z�-m�d*R�q� �O������w�#�4�|��A�Ě�������P8T�1w�O�2����\��]fD���-�*�J��y�`(�w'���ƾ�z��݂Q��~�;��Թ�!!����FB��ԸT� ���g�A)Ҙ���@ٟ�P*
m��j�)y��fsnw���H����ƶ�v�B!ĩ���=oH��|�mYZ#�$}��v�a��Y��T�4��Q�F�CC��4�:{Y�}�:��Ђ���…�
��ElA�<�t�»V�y���
R�%����.�����Cb�
�=`�2���E&I�d��1ٿt�2����,�T9l�M���"�sr�X+��Z���.C-�3��c�Dvtl'�.IOί�ޑ���#�5馪j"-���-��	g�{fb�uuiKe�DV���#�2M�˒%~G�5P��]T��K��i�K������~��e�܈�D�!G޲K3s�-�A�4᳇1��5.8�ZW���~Ժ�!�E"B�@
M���tU�������BY�[JfV��S}m=٪ݦ�!��-�
?�E�G��1����
�n>�����Kx�j�,*��F�����_�Ｕ:sF^��^�laƪX~1�.;�߆v��^+�HU����s_�'D�r
;k�Ā�����G~7�U��Dk��y,}�B������~kA�5y[�����W��F��np��Bc�R��B��d�B��*���<�|���4|�����+R�S\��*5���RqG,�)B�n�I!�!u�ZG��2�P�T1�,'K˜�S��Jǭ����dsjcŎ�7�:�U|l��q������+�Ɋ��g���Pf�����s�K�/;^J��x/����!?
�]�P�lE0NR��qɠlAX�Φ[NN����~�dA�aO%IH"�v��i�j���T*�P�.����,���A�O��RTeM�Ec�hb#�岓F^��iˆY�N2��U�|Ŧ/.	�'TY��K<��5X^
�N���b��a�u��Z�r�ڳ=���k������d&:������J��*"����
�>�6�r�Ԅ���0b,t�7p
:�#6O�9�},51l����%7����L`�dJ������ϯ��êsw������+��F�8</�Xe�j*5U��`�R��RK�e�e���P�%2�,�
Y��_���a����̡�9���d�o�Z
��R�՜��y��S�$r"��=&d�x!�`y�J\_(�&7TJ�`�?YH-�	k0�
��fr�/�`!��i��������Gǩ�ֿ���y���ٻ���Z��J��
ia�9�6;ͅ�@j�Md�y�b^H暗���p��_����O
,�L0�n��hL{����(2Gk�)��}(T���Uw����n��cTV=!͵f����Vg-�>'vik����ݏ{j�d�`�/=3�"-
U�7Qe��K�<$�6�/�8�d)r�&w�	�	R��}�}��畜Ⴈ�[�<��E�yvP�EM���/��rt��R��-ʭ��"-,Sv��J~�J� �5�P;���^��9����	�0/㯫�2����k�g���
����a�Qb{�����w`*���uq�,1��TJ��(�%�l�D�����ZJ켵�����Q�ѳ�Dde����I~��l�1�*�9�<�u�t�描��o�ʻ��}���0�]�{'�zn�
�0����:��������n�������b9g)��Hv��u�ɲk�݋=�'����(�9�G&>r��0�p�ŲD�6Z�H�M�_o+�(ӾL��)�����-lI�k��F>��H|Qx��7�20S�[�����()�&�Ma+�E	��JUJ���DW�%��\�kXY�x0)�lG�Pv��xWV����� !d4���;b%�G��Ҳ,\�;Ȇ�~G��[�(6O�����<M~�J��a/Ԛ���G
�G4+����`w�!��5V<l�>4?�>|��,���AHq~��"X�Ա������W m�̳(�	OlT����7�g�׾�����E��c�sz˸t3�.wM��s�17��F�Z���a�F�hǤFX�V�
�P+�$F���A0Iy?p
L��,X���V�'��D�%��	*�
>K�KI�-!rķ]�b�[ē1*��+��-I�e-�`���A	)A�zQ�S�ޯ��a��M�N���ԣ����LvID=1�N��
G4����o
��W�B�1b3�a��W��r�p�V9
�R������bG{��w����X$�}���Z
�����,��6��U��s���f��NX����{��-���{_�9��9�ͺ�p��+����yH����ro�������s;r�w�\���{sDz�+sP$C��+�`b���3�[c/�_*�E�,���lV�S�:�!�`!]���W��,	-�������m�-�?v��'bUn�;#���l�'��ȳ�GKO��Y�S�7��9�ZV^WV���2�)RQ��~�1"ф�`n����%Z�DB
(��v�ʢ�M��������V%�F~
���{2Y�G2V$�^5�F���R�I��
��*I�� m ���U U�U��2*Y�U2T�f�B6���V��U�l�������7#�bo*����ku�W�{�'�=
L�%�Y��t�]2"0׺�)P���V�C��r_�-
'�P�â,T�&�H*P�rA�0�_�����kT~�
��v�&X�T ;L�~�W�M�Ft������W�A�U���$(Y�� P
srks���'zb#+e� ���7W?�
����k�_xi��u��� ��&�a�57dc��n�������Vl��񅎞Oy
�D
�(9�����T�#� �Bq4Q��.���U5U.��OsLsNsMs+�` E�������ņ%�6_��-ٖZ��M۩�4�b�,��oI�f}Z��Wz�ތ��M��
_�_XX���h�r�|)*�7ӷr�~h�8��DqB�b��ԝ�W���9�9ǹ&WLMO�L��Z5���i����0�
��)L�-2/����S�K>�ڒ<�x�������{��Q݉���l��m�}V۵UҮ���w�{�W�+`:�eQ�
ǺP�C.V)@.r
5��c��H!�88��#����#p����ßh��7�����?'{�ySvʷ�7�w��}��������eD�]��6l�:B��h0y:#�nL<��v��j�Y��lJ"
G�X�t0�x��i� U,�P�PJ����N�;�;_w2�)z���?Fr
�8���E�\��3��K�F�e��PE�X��-~-�jh1	4�9�ێ���iHM���r��A�V3��}��緬��7���3M�ڝ(�Lʒ��������2ޔ�.�b���
fq{�=�b6'�x���GJ�4���a�\f��v�rY��Xj���d�h�[vԺ�"!��iX��ͬ
3-���[�I�T+��̷���?^|�ݹ�o���޼J�
XH&��n��{�ҍoݻ��\�����X"���wɮ�w��y������%�)����#wl�"��
�]�����%���X6:@d�?}��&zSxS�Zt-}m�ڈX��c�c_�|�{8(�(�N�&
��Z��ҊC�M�ӆKB9����_n���4t���s!i�sR���E�>��*�D�D�E���t��yװ����WR�:l:PO��`k��Z��s'���C�eX�xi�z��:`�Gʏ�b'԰�I�n�9t�b�����#eqE�\���K�σx��-��r!�p+?X�����tKg�v�u���V-g����o��n?J����^��IT[���Zo���������'ӝ�������Ci!������
�[��K�������8
�cm��`�#`��O�ɌMj�:ڟ�[Ý7�G:����)�$֚h`!E,��Vd��
���!�؊A�3���N֫J������(��N>�N>�N>�ަ��\h���r�a�+�\���s��p�nYjD�
�3搌�V$gGyŅ;��1�b�	٭4�H��	�^�gʚ- �S�*cI�V�L����a���v@Y�7��t
󚏘�	�59�s�F�`�s��O�fY_!>��	x�ޫ���*�q�\� �}�7?������_hu��d516��꟎-��W��.=��@�Z�w
�h���ࣴ�m;�E�6����=J{;$��UWfO��F%���JyEK�1/"҄f�EvUͰ�|����z�����b�Ӿ��3���
�c�|�;��ǹG�DŽ�=�x��	DŽ��w"�]��껁�!�ǸM�
�������Y7˗؇<���2�5<��*l�g1���%���3����d����qM�v���t��{�`�G�1Ĩl��ae��^S��o�))�G	:�">8��SgvN��� `iȍ�
��
��^�:��E�/}�C�?���w�{��z�*{Ϡ�甇�=#�Qϸ��L���c_�A4%&����'�)�iq �z�;p����@i����#
�lƀ�K����Zc����D�U�b㫇]59��W�p�ZZ�d�z���C��T�
%�0w@���Z徻4Y�6���V�������2J}�8+�2i�u\�����orG�\2)��|�o��B�j�D
(Q��kLĄ���ͦ�N}`��tH*Y�J[D
\��Z��YP�K�M���$�r��	�]sլx	 �R%1��
��xw��ji�4�n�����5�����L����*�%�Ba�eip-�Q�(���k;��
�Y�
\���&�&�&�&�f˭�[7w�n�o,��~V�L�����=_���W�?��}�/��+?*>.=ny<�h����GJO
O�G������j�0�W}�U���Wu����u�m�O�˅�ū$f��2�4���7�.,3� ��°%c1+�-�����fi�s”:�/X�B��i�٠*
dki��}?
�^8��4�R($J��rW$"R<FW�teJ�`F�⫤#�`����M�}2h���3�wYt����G�PD�eb���@��6�ԖK� ��P�ov��t&��|��Ȳ(
Ҽ��u�ovШv�A�$h4U(W����-#�d㍎Sb�[���,����i�
��4,�u�z��X�7E_�h��WNj��i���f�<��̩J	9���uĝsp�FƹkA��������<����`��8��d��zVz���j�SMW���5ѱ��&{ (�J�S�9�M<�W����#�\�L�'����V��y�=�ڛG��et�Ź�~W�V��b�{S�aNU�w|�sه��^�)_*�L��⟚��c�;S.�*�x(۵k6J�s[ٗ��X�ޏ������
Z��!��'��VR�UdS�^:E�E^�������Q><���'���T���d�S��pdw�J���9c����Wn�nv��6����@������c����?\x��L���3��{�_R^���T����+���S!���j���e���yJY-��b��rn	���
}�<pb�}��n(�V�3���.�
Y�b��ǽ��+Ҽ�.�D���C���l�����u������`^E0�Dx�To��Q}�f/�ŃV�*�����T��:�
j�W� ��U҅F�z_��!6��U-�O��UK=��B��������*��%����1'Œj���B,Z���yN����9
2�tTF�4��i�:�d4E���X��ѷ��I��k�ۦ�6��B���X�,ln�I3�!�I�&J���g�
�B��0���7��ھ`��ʶ��3X�
	����ܶ���"��,s\����n�i\����-�e��5K����Ro-U����ao�-����Ao
fw<l!���V�Z���z�<逸�L���&g6�?�^�MXf應�g��5��0>3�����݃�N�r�G�#�0Q|Ǎ�f��y��P~�q��v�lD���G�"���2���y�jwYť�w�D����?6.8��hd��.�Ϲ]ܸ�/��ۙd�S7�������S%�4~�:�3��q"<��]p5���cD���!�B*���W��%�%��2����ۑڑ�Ƿ'��9?OSe������2�q�)2�$�%�L:�I����(_�6
�"3������3׷����8�pGf�}�<��M�Mz_�X�W�7����naw�AD�BM��(�))S5�h�`$��|>��1���і�ୌ��2BY���EDQ�hTI����m���c8�&�f�M�H<v�h�����-����.���`z4=��H�)�+O�i�P`*�u���v.�,ޜ���6EA��~�Zk�̍ �f)��T_�,�A��`@c(G�b�Q�(�V���Bh����Z	� ���S�
����	��@`�E�����E��i�P�=��ܝ�FJ��CA$����1�)����l�[�*�{�v��d2�O\�X��qI1��S��
ł҉�C�
9���^�
Tz��Bn��.v���TR]@-B�[�K��
�0꺋�]w=F=&?d{��B��S6�C���1��x�i�d7�$E��GI	,��eK�� �W��$�$�򁒫�Z�b\�N]A��D����v�x;Va�+�o�b�H�l��f���Y��t,�#s�9�Q��8��)O�y�	�K�iFR�X��L���I���Tc��+\��.O*ĭ���6߸?ɾR���o���5�w-%Pgh��K1�"�)����`@�2��)�1 C�{���e�v��`�}bvs�
�����\�BO�~a�5ݪ|����H���r��`��=��#��h��[�ָF@����f���H���O n
1�%���*t�C*�9�V�C�!�T�]!�E�-*����Y�>���W��:��G+�A�A,b�A�>��6K�!jE�j�!o�#aH�$zDB�]�B
Q
ǦhF�c�/!�ϙ�#�_�s���?�Mp�>��˴ʊ����Ӳ��Z��ԁ���/��冷�5<�e5��b�Rdl~SK��-w�����V�h�d䮢x�{F7ڷv�J��v�bv17�����z�jt5}{gm
)V��h��
/'
�P���-1,C�$���ݘH7��m�tw�ei,<eH<�QW�W2���B�aS^X��)n#�5�ff��8��A�>8�i��JDߎH�D��g��ōo4�q	��]5�E/�=L�X�?6�j�
�Q�&��`�n�FW�K�j9�/�fA2|A��X����xc�Z� 7���	|�<�=ʝ��2�xǯH��;��=嵾�rS��d쫯���j�w�������k��'��iٙf����c�53Y�:�>��1<A��-�-�h��v���J����!x���H�L�����UH+�#V��)�.*�f��Ր�E�F8k'�e�:�K#Y��.
idT#GhJ2"��Y�4S��:̰Z#���K����;�Jx��&�ӯ�rǔ_��Ԡ���L���F�����ˌ�SwR;����S�ê�O���Y)��[�/����3�{¢lt�mZ!/�,���Yз�
�+-wJw�wXk��{�h}K���J1[�<��N+e�˜T�f,5+�b�U��Ѡ؍X�47YYk�aYKm��Eۦ1%m�Fk������o����G��]������p���t
F�T��j�T���
~]�30�:��_�רd49��H�F�T�O��%��`�����y�ЕF$X�u����¸�(:% (`�`��O�N��cc9�p�)��97�x����!���2��>�9gͤ�%W2V�9�L��/�,���9WOow/�K�,�|�Mo�����Sΰ+D�.G�Bm�y\-D��U+5����
����E�v�HhZ*��4�1�%�}����y5G�ԁ��"�B���Z�n�$45��uK͇�@{�R����@+�Vƭ�[�l�J�o?g�U#
`���{|s+0���[�F�q�0Ƀ���}���-�F�?ywÚz2E�R�ҁ�[.�Re�C�z�G���C_ί^��w�w�?}͂��7�O칢�-�W��Od����l���yn���������~~��t��3�9����K%�/L�"�
+�˜�Ji$�H����
`C�xn��mp�ժ�(��\�';݆�s{�`R�Ćh�����L���r�ʋi���$�X��|	|��F8.�� G�_���p;��m���#0d���NB0�OC�x�����3��%�����=�����n=u#s{��}���(,P��N�\�B�g�ؠ�Rb��tD�B���ýc�b旰Z۠m�6ac��ꀍ�l�P��i�	�`����jI�`E3�b�����1��6Vw�j�6+A��_g,BJg":
�Z��kkH�[Q6�#�%��|Pojj��a�	DrdƆ�й�q���t�����s��hޝ��/�qϷZ�еP��
]�m���Z�f�����秿8���<�ե
%>:����ή��;�lЍY�bC�1����Y��t�#ɕ��ޤC`���$!&����M�Ý:%��`��wn�~l��q�|��Jr;�o/T�8|=�mG�\k�5�~��1�1$\��čS�C���ԿqRZ��k�B[�#�H�&m,��s�	��0��?�$z�H���m�d����H�������=�x�T\p��{gޠt�D1����2����x��bJL'i���9��b������#oR Q�k��j
?�%�Ө����֒BbyG�Qj�:@A�	h�����������)Q�›<�/h[p����օ|����ۇOn'`���gf��}Rm���&|Y��0soAZ����������*b��r���S�]5NQZ����pl���|?t�Buu���5K(B�i�<���_}�C��ۑ�qZ���[ϻ��{.����.~ꇈ�Ud߻*UJyn�F�_��o}���?��3'YS�(U�W4a+U"�1Y^#@%�F����^B������t����x�}���ip�zҩ�QCRbT%&>�!��u.7��.�g��
���Ԕ0^���4
NH�j�ۋT|�[N
���	��_��%4����w�Vg��a����p�:�/	U;�3��m�\�6<|�9���a�8J��ưdI�(r~�X)����}�/�/M��4^����ݓ[ǭ��$K��z�%�z�+�#��J�t�T��uJ�=��݂��~}�~�~�|�~�>IM�G��-)ѕ���BO8�E���4����ͣ|>�X��%f�A�P=#�q�~/�Nxi�;�A��L��%U~Aq���O��cP� }?2&�
���r�LR9VL'SbV�r,^e���ڹ�N�-�D
��C�؀�(�*A�q�e4ٱ��W�VЄa�GƗ���c5����
9��7X�4N���Jm>p��+���/�%��B(?x��KB����W��V_��?��h����9@��0��	�ы��JCPv�4�e=e&-��(&_>3Mh%t'DS�%�t
�eMC8�!8[ �'�Sg^!g��?
l`;,B@�&���@&`��q���9f�@Q���4 7a����V]8 0�0"@
[V��
� ��O	��S�nw4����i1������!�=�(�?
\|���p�Ӭk���8��-ڰ�q��p~=�ŴP�k�jQR�c��% ����5��J��K]�x��6i�b$^�D+�Y��?��~F�3�M���S�_ҿv�F9M�_ƥ�#�(~�=���K�S�t����Ox�'˻���iut-�V��������w}K��<%>%�D��~�zZv�'D	'z;��� ���;Y7U�z�V]jM�������a=��?CU�3'0
?�A��i,Uk��/"�"�OEo&Xsx�6�.�^/�=�v�C�߄H�Ž��"�����D< �!���vK�
�b�Z�C���+v�Μ�#;܉�ߥ}AdASr�*���� �l��,�2�cR�1'�DX�����6�H��1b(�z{!og��C<L�}�(Ě<F�z�5K�f5
5^`���0�A4�`��
���[��%�[�2�Rͣ�k~�Y��$��>"�

�x߹�xhB��d,e��mݺ{ӝ��矾��;:�����ѣ�⿬{������p�e7����_����<޷1�k���VSs�Y*G�M�N�*�v
D��b�h�"�D�v�*T
A�*A}3����5d1���(ʑuL��A���Q3��t���2c2�i��)/¿c$3ؚ��AΡ�F8�'��,"��x�@D�jr���do����v{!�bA��
����f�zИ�~�����Yh]꿓���=��RaWl��&�I�k�ל
��c:��}K���C�m�PD�bD#�LF���g"�C�A���۳��Y�>�.zr/Vx������R[&�T�S��Á�O��TH��g����&:HkxC�ʄ
�o��ڧ�'�ݟ���g媙֜��ys������ώ��g�f[jFt�ɴۛJzRIo&D�݉��XN,$�1;C8L����4���4` 0a����A����̾�͜�?xp�Sۯ��W����G���z�Y9��x[>��,��޴���o\X�Tcw�:�|���P��b��`�|��b�l|Z�~9u7C���M�7���v��_t���{Vo��scjt3T"��w�������/ڻ��_�}Q��{�;�;�����ӛOl~c������R����f�qyw=Hy���� �_�B�.�?J.�[ǓHM�}H�|(I&
�֡5,��>�ܟ|.�$��מژ�AX�o
�N��Ǟ�I
�sH�O��c
mb9Z�<,7���<��r���DõMD�D�qBV�����0���rɏ��~��,���ȵ��ǻd^�_�.����ϔ1���u�ZŔ��RF��{˓e��
-[
%��Z�_��³�0���?Rܤ�[b�Yk&�`DZ��f	f�����:3��ΜȰ;�iyep�?F�F}sy��y~��f85d�V6��~i1ZL�8�;t/rxG�/cb?u�φ�D�YA0�{�N������Qfz�A��B�Y�I�BZ|U~�d��gd�޴�it3���'����L���%����I%���rΙ%��+'IY�e��f�QW�1TdS�x|0��^���1�;=A?0�|=�G�Z>���\a\�q���з(Q
�}�R�Ύ��J��V��������
͋���U:u>���y\=D
V���rku�P[B��Bh��p_�G��X��˫����g�C�҅!jM�B�Z�[2kW��V���G�����5 ?IR�NX�!�UE[ө'�f�j+&��t�����M����g+���,�<q��l�eR������k7�w��rv��G�Z�$��C�?;ox�5_���;WX�UaK%WC��[VW^����~�ܷ��C��<�;tA�ޡ��/�2�/?�N��N]`N��^���/l��ִ���eюh�z�M�|m��c�Ln:�ÿ�ژ,'��ZZ�zY��)&N�ks���&o�����	#��lk$@U+���8��ivR-�2
�X��.�k���b����(��Fq�=b�*�pw�5�)����d�jU�$��K��@0W�ر��T�γ`�*�@$�4��e�DhU��ة˙#DZ�xl�n���JV��b��/
�t�e�~e�re–妥�5m_Zo������~�S���Ο�����+z{�\�0�f�8]�)L��̀���k�W��,7;���x�D/{�w��D/���`�H�(�H�l�9�8g[!I/o��ey<�����Q�W�ŁJ����n�<%��NE�k	iBFd�G�I�e���H%T,Q�#��;^�(�
JLMN��H�û�"��H�s���@m�Zsn�&svB��'���!Aa`�MK1C� �c8���
�\f�W��	3�����onVjj�hնO\0t��ј�1:e&���q�rOmq�Ｘ[sD�����f/�e������۠k!�R.@�tI�����M$\r�z�<S{�L?^	_,T������I�
w[�X2b$�'��	sB�%H=%�|�������%�֢����CMt{��n�<E�Ms�oul[lf�m�0ÔsD�%Z;\�o�]X|����k�M��9�Q��x(�b�M'8#k�Ρ+���
�c�{z�u����4�(E�6�����3%)�|���6��d&>h������98`���_;^?n:+����H���hb"�/q*���m�*
���B��>�-��6�$�Q�*A\��lو��"��#��V��5��FQmV����j�E��x�
G��\k�����f�j�u�U&44�!��zBۧ��8�`��7���`�82G5nM1s^�ovv�/���n����?���g'��p�m�7���ާ���AI�B;rs�������Y}}
r����ߑ��3�5���^�Yt�I�-Q�\Q�~�
�&�&x���W
�	�&l�0l��{���;�Sp�_�)Q8E�S��M�Z3�2Yo�g
U�9V;��M���Z��{�.��@���M�{���AL���`n"�����������9& f��@:�Y�G�׹R�?�g��w
�
�BQV
��c��	���o7?����s>__j�����脎:��N錮��ԙ�`�l��s?��7'I�M��O&�=���B2�u��ǃ��͌
A���Ij�9	�Y�&�;�ɐ#B{���_�̵0s\Xޮ���L��?��c��}�7v�A��bZ�{z����������<?�	�>O�˹� D9)��b���<ׄ�\��?Y��N3g�L�����Ʋ�[F�c�L!�;]���x@j�x"0	�/z
��-9�ؒ�@I�E(�DR��
rFٔ�$3�@dK)��aO�&�Bw��[������a�j#����	�'���B�lnzz��C�ɧ_�T�t;�T+>����Ԣ5������+���Ϟ�������<�|P} :Y{R�k�Z`��Ź%z��͹-� -��������_d^t�M��q�Q�κV�����bǘ|�C,�튞�S�Z/�U��]���ٸ�
mp���E�9�F �@�d�'y�h8]D���-N����{�_ìc�pC�Z�Z�w�Ñ��QZ��L#���U��n�"�7dޟ�Z�O7�b���� 4:�;�I�x�X�='����
�u�avc�S�v�.��"�"U�m2-Ed�T���ti��^H�(�;	=���G�lXF�!��D]�M�YQ4���|S�]c�f���"���~M����V�����a�G������&5��5Tâ
�(���R<@й�"/N��Hom
��d��O��c�̓���1��
���sj���^�~xdP�0�(��$0�ު�a7���iM0'�n7�;&�>��vp��5���Y�A�h���J4�5/��
x	.=h�Y�q�f#�
8<ᬡ9��f���Ǭ�n�
���4]�ب5�dg�9i�귗[�X
}��Υm�~cA*�i��_\�(.�{,��;��}���_-T�Vw��u�8�׍�5V�ˉ�|]��Ɖ�^
%N�/v!s�䒠3��<,a90��Ϸ�+/�|��Hh���@�f +��M_��
���� hW�ԙ�>����ܳ�8�P
������>�Y�8��'���<k�3e�c`���5�]DJrg��)JhZ�L�a"pS��c5��B����~D��Д#�i�)�#Ʋ�h��ڼ
��m��!�7���&|����5���l�O�[�r|K/S(a�6/c��T�U&�hЊF���	�>�)+g=�#���{�����Ufb?#r�Ge�d��,i��ŀ=�2N��>�����0�C��%��L�_f�S�nr��6��
��$�ֹne�E���A��Ih,|�r����Y�:jq�Ť^�x`�9n��
���n�����V�����p�?
?�R�ˬ̑�s��\����Rz�b�H�fO.�C�`8��&�Iy�'���\�	
-�5�r����z;�N���a�Cu���C��/��K����@�/Y�΀cJ���u���ZǬ[�/�Вy�П��Ȏp��a,X�N�_�����>�m�:�S�)9ҾH���Fk�__�"p��u��c��@�S'T=G������
�5�?ǿ1]�{���=�=�t�L���l\	<W�0w�'{W���D�ٵ��,�(����u �z�V������[�"���R>��S
ͯa���
��pb�^f��h�9��J���hS��z���1,m+��%�ۜو�Շ�l�<�����Ÿc̏�K�XY�P���2jٌH	�%�7��I歲E�YNX������!,}*�D���Q�L�����'[�%z�=h��@�c�U+WFW
���WM���U�*z����U#���M�g�Ҧ�V2ʹ��Ӡ��4��V�,����U���"ĩ�{KgoKX�d<���B��h�'���c�H���9�}�����%Ī.�st��0G���ۅ���������s+�m�ymr�y�~׼�Of����kWҴ�oq�ce���򫻫k
���y���s�����nu�ڷn�yŊu}�5nZ�{���S��A��ѢQ]j�5V�s���X���4<����Dp�:tɗ�-y�JQ���)Y}��U	%+y��,Z#:�q 	E؊�Y���f�OBD/1�5��`�pz���ýT��&
�K��ĺ�%�s�% gM�t�k�Fc�&�Y*D'�@H���ut�`Z(d�f��)�Ht
��%V*��jI�X������
QL#�9�qI�K�����A��:��;"�"�"����_xɐW�!��Z����0��a�$B�E.�@L��l�Z��۰l�W5ګb�\��TG�U��"����ց*�z�J��<0]e¢7q���l6�X�&f#���p67
o���r�ca��wv�'N���]�y„���!�����"+��-��
'ڣ������Ndd*�diR�L����Ʒ�����j~�g�~�B�q���G��b{�-o0MĜ�sB@Z��/��N��-�7湌.�X�ɛ,v@D��G���3?X����Ǝ
Q?��9V�O����Fx�Ƙ�d+Z����\`�}�9���A�ik�BX4��8g�t
C[,�섎�A�����EIR&g4C�L�ù�
	��q
890`���V�Hp
�X"@�e#V�$AX�ET�
�H��G���/�K�¿�x�2Z*-�n�܉>+�q�:(D��*K�#&��EϏ�E���ݨd2���WcPd�	X�#�(;�`y�]�x�nX'��s6.��0�[q �fŁ�7=a�,{"�.�h��g!�b�=3
,p���Q
��b)7����vp�&�C窠u������d(%'����֩0
��+�&��˦�(������)?�W��ŚƠ�HCZ��p�H���"�b�E��{�vcHjNy,�g-�8j,��Lf͉M�)I�}�u�M�M��Ե7����[����5�kϟ���>������ױ�������Χ��Ɂ�ײԵ����}?<�����kc9�4��4U�ۚ���G��;�vh���ҙ���`�N��u�m��5Bw��Q�:�ɩ��<mN=eX��QLڻ�x���$�Pa
a��Kn3��~$,wZy��G�ێR�g>|
�S�$!j�<���[��.��
�z�F�k:>*�������X�n�H��bRFt6��D3�'P�)y@kMY�lV�8ٻ�h^�>oE~s��5�����;ć��ſJ��]C��*�1�D&�U]X�������U:N�c��j!��2[T��	-�=�5{gGT���y\�/3�;:MLxA]�����pO3ē���A@/QfHZ���,���X�3��S�饪`���5UNV�N�lx�%u��R��f��G� �$�<g'�'p�n	0]�9>	�$����thH-ٻ�3o�{���ݙN_mEC���]%ђ�"�?�f��/66�K	�6�ʎ�]w�/g��qo_��ⵖ��̥Ce;����x���8���h*�)6����0�C�l�r EHe�C�d{�*i��v�IHdf���C�`&rT�$�/�Ӧ�l(B�wD�xR�C�E��p�A�>Wy�&k�t�Hh��0�0p"��ȭk��m����+��@9Vo�ͭV��[ݾ4��1��6�o�mS.
\��~��=�+�=�+wg��s_u|)��ȗb_i�Z�Q�Áo���;��>������}�k��'���u}��e�tAX�Bm�k����(d<V<����T4j�+QQ4��4��#�D�'աx=�s��=�0	�Y�o�NB]����9QF�(�3�Y�G�Uw\Kd\��/�S^%�q��Bٲ�B,������Ω���O�ѓ��{gk�_�3�j]���ް[�|��;��?���������G�}��y3�?�bcg(�T,5,�^���?y%u=��-��b~���NwQ�ǘ>�!+�����J��G���4���Z5�����o�%�F���������<JD�(�xɁHa4�����`g_�ޖޕf�A�2�X
w��E*/��Qwo.���n�vI��/���N	�t
��?	���E�:$�*m�αp*�H���Y2hl�ꛣ��t���4+�hK;��#��]�tZHE�)���t�
b�q�D(VdbJ��<��v�N9�hTG���NS��5�i����#ه�f�:����c�2�c3��f�/5��4��;�8=ݭ����;�H���o��;z�V�
�S(�l��o���e�D�2�0����t�"w��Ʋ�i,�%�D��l�y!�0�l=s�����҄�t��.�3_)"�R�Ĵ��1G��8��v�����v�X5ǡ��C\��j�����"(��h$0�����2P	����l,���q�&'=�1GZd۽�����y���C�r�r4�lF���
:�T-���F������v�ŤUh���&�<f�� nv�ر�r�d]53a�Rޟ�U�hXj��������R*�%8Y�3rv�k�k��wtM!�؍��Ol?�KK�K��į�o�o��L������p�����h/����ƃ�=��E����ʇ��Km?��!��VCް?��/�/?���7aQs�L~y~uז���7��?����fȚ;"ԳtEQ�L��;H=[�B
�ٮE��#�h)
�9���;�T5�YXG�4\��*��;(
^j�S~�	no	^,�S!B���f�۰�:Јc�1�`S����bTDb~2�FH<9�t�i�S�HbE9��Q�f!
�L
�JX�<x�.�D�<M�h'�����R��������,��{Cf�ᱏ����f�|Q�l*7d֖�d���䅨3B|VQ0�&%d�jvн����{�{�2��#��6�I4IO2��l���Dp"tۗ�+)E��d�l4,�x)qO��ăynx�fgF�פ����F�%h��_��P�,RͪDԺ]�$�k���fXs�l�P��U�7�!T�k9T�*�	���U8��p��5F��߱�N�
��
��I��M���2s����ى�}�V>����j%M%�sK	���'/^�^�n��O��q�u1�����v�
k��Px���U]NE�2�/�{��Bo&[\r�7v��h�g?wam�%}�
ۿ�s�5L��g�D���SA4ۊ *�aa�B�X�
��q!�E�.��\�h)W˯�wa����y���B�0�x��fO/�k��ZYx���g���gN?^O"N�:~��{bԂ,� �\�F�܈���A��%�8�pĘ�.ȹL�O��?W���r�Cs�)$�>��������9����4��<J��
Xk[�����w����w���_��=
�ںڶź����5����G�+wpb<���2e�F��
7�}��:��.wJY���1�,���t�B�e��{Ѕ�]�pM�N��p�з��T���ç�!0�4d�Ξ4=yx�I�Y�A:3g/���$uy�N"S�t�+���d&�导ҕ��w�����?�s}��e�o�������f.��k�e�U1��KS�g�Ϝdf���$]nB�7Ml�bS,�虦G�)鑦�yҌ�����J�j�Ԗ.�;�Iؐ�h��v-�[t�Ƈ�v���O��)�T�D��"���ЌR+�j��A0SQ��͞H��U�KZ�2�l���WL�X��X
��UTQL��t��
�T���!j+J:�T5��k��+�����wP�0A˃$��ҠU�i��l���ӗF��\@t��3�:�L��4"�Bݒ�Sh�ᒩd�$x�l�-�I��S���(�D/#�9�H��k�E���
c��6�]��>*��</�P��5q%�����! ���rB��*�Pk"Ra��3�Zp��6�kB����e��7��7��p�m�Vmχz����z��+j���f5I��~0~��g����A��}p|�{%-\�C'�c�atèN?ߪ�'Q
�'�h;��f~�A3�[/a�P:gS��d)(JR[�gq���;���Ty��`��IG��ϝ�o��^;���:CR����~�O&)��
������q�M�9u5��~=�'��>&�,�I�E�"�����W���<�l{�zT|H����G����ˇ�#�����~��'��}(LJ��Ę�TH��0�H�l�,1�t�l�q�u:Ik�P��v5���Q�6��;�{ۤ>�"W�Z�E~:�j@�[ޣ��3=�R�vi
�J���wy)��5��lV�		I�=Q�9��H�R��D�
�E�B�=m��"'�I���K��wJAb��K�ģ��0���7�0�NI�~jEj����*4G�UJ����z�҆��̷������U�
a�+���"0��	���ӁhǴ����������(�w��V��7kP>%�^[����VJX ,�
,���,�j����4���]Ԫ*�r���f�+R���9��P:���+>�ҳմ���;��<�m�f��N�dJ��<m�
�%�%�d�����u�I���I�Ɩ<s��-�X�i��`�SRJ�L2�;x�z�T2kԵ
Ե�z)�=���Q)�Z#f�\k)��2��;�(OݘDIˍ���W���X�дK��x�u%?f�㐷|B%e@B��7�Lg2����F�o'�μ�|?c���丗��J�X�n����`\)�r*�ʧj�u�G|�h��DK�'ѓ^M�D��e�����̪��¸2����ݙ���������3�����sŗ�/e~��u�D1Jq��{X���R��V}��A�"a�vQv�e�r��ǿ'~w���xѷ[�˷;�ؤ!�I�N���ɤ����Q�x,�S�|�r���#�D�Zד88uf�ahɄ.
�$$�w6��АL�E�-��N����t�r2�H�5�[���T܏�u�2�Ϡw1EлOF��	[
eDz	悊�x��aQy|FR�t
��D�����f��E��q��u�'MS�g�5�1��A?��G��_�����%���#�#��ћ�"�g�B�(�p�!�������Bѻ�����4Fs�S�Ne�x���y?>5�O ��,��c���5����Y!;R8+5̀G���=����M��C
<�wk'X��e��
��Q b�����S�:[���,�Cȁ8w�]�b���H��1]i�O�`�$PL a�t"3$�m�М:�%��'<�*왔�Y(��4�F��4�Q�1�
�c6|셊����CK#n����t
�6d?��[�/��o½�����P4?�'����>;T��)q�g���n���I���C/�=��˺l��-E1����sSf��d��b�T	�b\
�!�T!�4	M�dVœm�Y
s��HF{m{�{��S�+�X^��&��.�QL�IK�:&�hy�S����b��+ugo���U�}�,����őe����o�}r��Fa�e��˹˻��EaR�t>�=���9��p:�Q%��r�Wꓕ�uҦ���V,b���^�rS	����&�T�!R�k�b_�E�J�f�O�h����)��>�7]�Te��ڥ���T�Z�&սޒ9�X,�Z�;��)%��w����8����b����l6�5����*�r���B��tW�I�7�.wY�]]V��5���J'���RJ�kE�:B(�_�T�π��	\��P���e+1���E�br
ٟ���tժT
�
��S~������.J@W�Ә<Iu��g���G�z2v|�Y��4D���`}�Ľ����}�ț�(Ql���~&���Β��rr��I�a��a<��M�wqO�~{�n�ҿ��1h���܈xԜc�;i�.Z0N������+��Ty@I�Bκ�*�`��xC#u4}�:>M
J�vC�D�f3�کÎZRwÇ�� �Ü�Іw��X'R:,N<��`^+�f�4E������ċ�Pk��9�7<0P�٨�
=`�8e�<�n�S˔ݵ,^��b/�ż���ċ��	�e�:^�9A������6�9;jB̉���:��嚴0��gO�9A�?�[�+���PwG�c�Γk����˸�ޅ�B�W�`j��w�_x&L!�֩�]u�e
O�%�m��Ԏ&�p�}��c�6;�4�Hp��'�|x]D�43�1e�<�;��i���nN�tk�����$](�}�&]����9�R&r3�w�z��p�d5)ED�Qa����uR*&�[�7nwEU��
=�
�z!�
�����b��g����)��STzYi��}[��@{�Y�U)z�v����Ӓĩ�_H9w %%�D ��E�j5�D�J�J��E��U�����'7o�����B}E�r�K�g����X&�����2"����|gS�O��?(��n|@>�#�}����XY��֏%
1��IP;��t)^;*>_��Bp��^�O��tT����;aj�-#�!"�{�
	
�:��ݒG�|=O��]�� l��[urx�����P%`�*�j�d�9�skq���γD���3��!�?��D��$3�&ۃ̊�V�mO�{��S�r�=��$����[�S��2rdIb�q��+�.��pzQ��g6�Jֵ����'�{a����?4I?-ƭ�՜
��C�=f�T���Iv�6i��b�I��n�utR�&���.�%�E����	�������s���C��Gse+�Ёnp�-�m�Q�e�>��$Y��ך�%�=E�D���0:9���v�#��n�a�:���������6+�lq GѲ�z>��X�������ʱ�?�ձ�І�6�6�᳦�􁒯���c��֢�Jш�{����7���#<
UEa����'��0-ɬ�U����Xw۽󘆔,�����O�尒F���	C�T�)�	`��À��b������f��}���Ǝ�Н8��X�ݷ{p�A�[��g�,U��&����=�Ŗ_�G��X�+�fx��}]p�
�bA��L�?޹�����~%��PS�e����ic���h��̬U�e��[]7�|�r�6ɲE�\�vRW!W�;�6�7�Є�X�����՞��K�ݺǜ�a��y�FI,l_��-D�6��i̬��<{��,3f�J��a�+�d���a��H�d�(2c�3��yqǵ��(���?^��މ/>޸:��ݞ��U��g��-�~�ݿ��C�V�{~��߯Tp����܅
����iRu�a��k��vO�	�����1$��0M��T�is�D��~E�u���Ĩe�;aB1C"�rƝ��p�{JX
R������
��goGq����s��H���Ssi$�4��:l˒o[���|a�66�,.c�B��n�
��1YH $dC �@�M ��$��
I��3��zf$�!�~�����������^��{ӯ�B�8(A��b�*�
oG��'6Q�t�CߖA�LO��!�&�&dߥ�;R����z�����˯)u�$�8Ŋ(��Rws��D7�e�$4MRu��U��J�؃8��]�6����*������={���������S�+�y�2ѓ�6�6)fUVlP�_Մ3��:�D�(W�
��g�]�Jm�<�@��<D��b8-A�D�A�4�������������S��@�T%�p��~�	E��W�����m]��n�Hl
�;m�j�حد�\}�~e�}���KDy��Q�@�����V�9���w%�e���� T��p
�	���0�N�Ј��Lf�zOL\�p43��ݤ6�lR
z��T�ɐ�K;Y����	5~g�y+�p��܋F��^�	/:�}�����K�v�')s��4��C0�D,�V@��=���^	�
��?�ղ��
��j��H�z�ֻ�.8�����A.��~�Vm����|G!G�@�d�~w���J��Htv�U=a�Ʈ)w��,�Rj�*�^$���e��zgR+�T�r�9����[��e7�+u:�t�6l���
m�m���HΡcS���Z"�
�%4��&�F
�ʛB�z�d��Sꯝ��;�	ތԝ�t�t���v������щ:�cş���霸��-���4N\�����F�G�t��_�~�w����9�9&�Ϝ��.y/A3�u�~��Oy��'���6�(g�[ZQk��&�=�J;)�"��%��յ�G:
]x���.t����+��	t�)�������Q�	��$}(�mqe����"u���#�#vƮ�.*��sJ剺k'��J����e���G�ь�~/\�1y�)O���½��+��r"i����l8�&��x��?-sݷ��`���"��eQ�X�6�������I�����Ch��A�C}�x�
���c��
�G6l#CN���r� R�Yx�r�{߸D�i<�8�x߁����������]�����B_�6�v�
��6�/�Ӧp�В���ns*��u@�F�w�݄
��
����:�Y@�BN���*S~��ډ�3����q�&�L����,���6(��MԾ<C��x����~�ix0���'�dݙu���D�p<\���a6��t���+Z�΃
o��B�=�����~��n
�2A��7p�Wre�@XԜ����֕?�_Xk�D�w�s�V�8�
BxBD�#�&b��	W�\񍔯���J�^����8����J��a��Y�)W ��)aUi1~����DFo�k�;�{ݘmii��y��EЄ�A�,b���"��@K�8Y2���$�&��a�pp�<��V�E��y�}KE�u�$0�<a��|ۃ�G'����u������������_�o��Sm7�>6�P�O�`%��L�Y��Q�;;u�h4qɽL�!��pmk�\s�b�-��@Ndʶ�Bbi7�ݲBm4%��#
� M&|����~�d�e��H6j�p��
������
uu�c]���p�P �K���������5�7�u@Fd��Inyμ2;j9by���ڗ�p�;@��'6П��TL?*9"yA�����’�̔`�>^�"e���&�Le&h�A���t,))�r4"�R��6�g�j˜sр��.�D��r����S'G�n�uh�m�����S�GOͣ�o[2t+y�[Jw�����,���"q}�vG���Ug���������
������x����N��ν���V#uH��&�袱Z�^���A
�X��vuNjUp&�&s;�ͨKD����.֋�i��`͈1�O�Ix5"�H<5�;P�Ȭq
o��x"����D�D
K�^oU4��|J�^�;��f:3�7N5��}D�,N�V��

w�P(�We!�I9�E�NpԨ溸S�|-�ϋ��2ϒ���W[�R��^��^�v��2ဠ�
'���s��[�+�:ץ�q��&�1
&�l��������]u����v=<ۓ�ڎC���=���&��V�(.�|�����lI�^�cu~���f���>;���ƻK���2��ɾ���4�m�Ǵ�Ƽ�U�糧�᳧�F��а���ʧg�L�ܽ�����5��뇵���*�j�'������u�#��(����w�vܪ�����:���[���������X��<^B::\t*����c��OK�k��L&��!g�����]y@����8�N;��lk.��?<�XX�X��20{�x�9oi%�D���q�"i��hl�`�W?/�������h��'-	����IH���ϵ�N����D|b��u_{j��@>�jM�
6�f�ɎY�N4��;%Z�D�N�b�
�s:zk�m�%�L�M��K�
��J���@��ZNq;	VN�W��h��3Ӻ�����c��I����lO�i�v�D�w��,��S@+}�I�
�̤��L�W���l�u�)~��'��q�V�N�]c��Xչ�ˁ�L�cI�&dE���(�9�����6�E&������"Qi�1d�&�Vg
=3.=������J��d����i��A��������������H������z�w�g�E����	��~��^I8�,���r
��Y�
C��1���z�;{�Ͼ������=�=���a��|{��ġ�e�����|oGo��/D�m�xg|V����v���z�R���>i�f���{>d.����԰�{֢��l��_��=���^��gf{��@�g{A/�lv{n>�ϟ�::r�|�Y�|��|L������G�՟�2
,�m�5q��-�p/p�s׼&ܐ��s��:x	kA+z��ړ���\t�+�Kg1=b%Gf`-�Qw9�]G�^�b�^]��l�!�
��4!	���CBBrS5%�d��	XpYB&!�0w94�U�*R<�l�2ϔ���)h�����9a`n�V(g��7t4>�cͭ��劈٦T漢�7���m��<�c����Q[���k퉛_�Lm��!o�����E����w�=�g�����|&}0���u�ݷu�U��L�i����E�T<PӦ���ִ���Xv��ً���.���y��Lbhw�=�iB��M�!�s��_<8��$�=)��t[�Thv�	Kt}b��	ׯy��5k���Ќ..u��ؙ@�"(C?�ej-sH�X�c�a��D�%2��ރ^��@�&�l�N?s'��Bf����.�ǩU�?&��/�N��;j�¿RJ��\�s���o�7}��G��z�3:���7v-_A�Iܗ�����4������?:`Ynٛ~��M���^�-;r(aM� `V�愙�!f�u`�K�rؽ��&���'yHx�q��J
��&�'樧���D�9��W�I
m�^o�76y8�Ҝ�O�3��D@�����5~q�xAp���2az���UvH˦sް�"���
��Z ed�Z�7{k��4FjaN���i9Y�,�Z6j+�O��-{;Q^OeZQF�n�����h
;�*�\�*IV��;�2
=��?eW�yיC׆=�0éTּ?����]�v����Ѹ}�5�g�]7=
����J�-oE���,�*����߾(m���=;F_��/�!z�oٷ�����nD��O�yYc=YRd	�%J�絕E�h�AfV�}e�qI�H�k���HP����UR�ij7�Ĭ;�F�,��h�}�f�	hL�,�F��8�ė�����?�����?�c4�w�ۏ:�f�G3G�%`"��D�F�?�P�88G���r"�Ų�|!3tG�X���K,ɀ4���8}o}�#�`����hF6�Fat����a�q��z{��`�r�z&��1s����[����y�'��k�^�P�����]r(��[���3	ε�-��Ж�-�.ѽ�p9$�¦'m�W�ȗ�/>$���Tr��Y��.Kt�:{�o���Z�3
ѨVo��;{]��P��/vX��$�d�R��#|���f�z�a�2��ׁ��@E>_9C+��3��l�-pr�&-a^���P�j��� �^ˤ�m&�<�S��H;7tk�@?�u�l%�����^~����X���^��N<V��s����O�̳ϕ~P�)��������W�s��~9��v��K$",�FǷ_۴y�/Ʈ?[z��X���ᜱsp�ٖ�Ko<�t�G��k=���mC3��K�f�r����Y�t���>$��0YJ���ffoT|�w��w�v�iw|wrg��N�Gsk��ks�#���;�~qbw���e���w����T�^��.�3��H{׀Fu��1��4��y���g�K����B�I	;)�&�gY�A@��a��a��UY{6�-d�쇄
�0/0�01���
ʆ��H>�>睊�(,�{u�V����P����5A��LEX�:�J�QV����u_�>W9��t��0��!�LCD�t�@%�O-�W�8��{��q�h�.p��W�y�t����A�/c-�,r�Q���
��~������?}�Q�?C|���[ŚZ*�!��4QM�>�w��C�k�[�[-ۢ;c{̷G��=}:&���-�1�i�f�Is��������u�c�Y�1����1(9�jy������ڽB!�Z�O8�x�=+�ɿ��@
|��y�]q�K�Z�����:̖�������yz��>_�t~���l�`C�\��DZ���h���F��Q`n�=XS�v��Z!@у�b0v�b�k5"qK>vty$RQ�C�gZ�@�>/�k�� 24e
��;�!p��<R���s�N�s�x��"����	
"L���]_QЕ���UI�_N���R)h��|��J�r�8eZv��I����i�lE�Lel/�0%��iP"Ce?����O~�S&�~ntI篘h/��枹l@�bVC
�@SΫ����4u�7�j�~O�G9�Vȱ3��V�ּ(�x���Y��F�5��B}���b<h���*nD�Ju�A�ǣM��23`r>�c@!�^#����!aJrO�ۑ��M|x�" ��ƇʞЭC��/\kiN=8Hy��Y�����E���`�<�ʬ�߭�Z��� g��'���}	�ܡ�6�a��v"�����P�>C}Tȧ1/S�Q�2⢅B4���
|$��F>Z�W�ҷ�����`������0Ͷ2��v���cXb+�"'�b�D�e*�+URҨ%
��q
��r:s(W �B���Nw���b�l��,FH�ш��4�L*��TJ�Cc���x��J����N�9&�$^zD��T-uH1�e�j�M�cʭ*�1�XpD��Ԫi��d�rq�L��"��+�{V��������|�1����:�US��HU�+'�t�R�ip
�[��8uN��_~o/-<����d�ǥ��S�����P�ϥ�{���HG�'
t��pH����~�>�L�ٱ���<�^�S�h׈\��Z�+���D8'B
l
��j��%&	��C��vԨ��D�+�jxBބU���v��=��m�
����ݘ��f�<�~‡�rG��������HX���h�Vl9�MX��n>����(��Y�Z�C��Ex	P�:\�������KW��h��x%� !�D����/��Qڟ��i�9
2W�uǫ�
����˻�����
�hŏ���Q*��x�I�k�Ey��G��p���y~��Y�A�Z�t��	_�V�˪)i>��9�<�X�֥b�GL��J����3�no��6|Υ��ͥ�vu�,/-��7�G�j\#�B�K�I�����0\Ţ��l*WN3�J��n�'ݹ�����q�����ڸ�녞��0ޟth-����p֯������~����F�	����&����nR�����Q*P�\*��z\&`����Z����*�[���,�ʡ��W���%`���T��D�vҽX�$L:�j-Ti�i��RO�d!�5�n�xm?
~C�x��SY5w�MԦ�(R�;���cAE�X0b���"I��f����N�GB�Y��(J�Qh�Y�0"
D+��0M�xGڴ1>LTS��ԉ�
>�8��r�8W��,H&d� -��x[�k�^|���>���ۻ�����ߗ�������������l��k�l����2�>������V��槏��<�-�}��O�����8�>?1Ǘ+��ѩ���6��ٝ�
R�<G:*�V�7),�;����R� �n�n���^�Y��q}l{_��7o��_1<exʄo7R����}��&��n�c8��h،3hZ��~�0���#[Vml
��	W(�m������ՄE�.Κ�v�,���@[���ԀF�=�t��S1�d\�j�j+�Mf�M�V��,����������X1?w5pÁ�ݸ��ggܿ��'��0m8d~���%���3��7�~�ߟ;;ޛxb׵?z���yd��x��/:o�o����wL�f�*����=q�q&�:��C�P�"��fX:":"�dXA�<���
�}�Ecx6/�dX*�p+?#��eGdHv^bt�)N8w�]�<B���b�v��A,CF�#���)�l�&x�g5M��T�i��C�(/h�B��|u�P�`.VB9��S
�r6�T9
���\R�?��%9��{f�G��?�TsJKgy�|i�������R�O��#T���BF*a�2���R�K�i@<��MZs��X��Q���&.f9���Fz���g�ABN�HҦ$��@Ӥ]��%�p���
�8��|�<�}D��G�Q/'����9̽����� ��JU"�(!›D�E��ڷDV~i���y����,� >n��V2*L)i�S|��B��J�d��3� A�t����b�?���|�#&��?�ߟ__]��t]i���v�S��_L;@iG>���C/�vq�I�!���(�Ș�crN����&��RQs���0Ta;.`|?��&���xY�X��/���1��i��#��>�#p�@.��
pb�D^!�@P�R��P�\�V\F]‰��ꠁ�R����>��tHi�����[jZ
���?��q��#�D����.���
93i{֕q�C��pf�}OH��� � ���]���D��lsC{�mw�$�m���S��?q1��k��?q����PX
��#a"\��g��z
�l�"�y���C�f��[5-�|8\Wg�ն
55�Z{m��P��Rݼ�
�X�>6�ɤ�f27�+�-�������V[k6?o���VS\<a��^F��0AF��y�VN�n�d�4f�j.
���n��m9哠=M"�G'za����7
���T�!R�?pV.+PDEr�M�)��ҷd�d�}��If���$mb��YZ �X��`���r�%Li|ZU�7�����{��c0(�-�*_�o+
��3�F�F�1��|�Uzxz�Gs��c=u��7�I�b�+�&�ե�^5�=�.��F�ߜM:Cc&x�*3��BR7A�ă�)��4�b�7B#�#�-���a�EU��$5f�_.���0�L&�U�8+��a\^�/�c��_���-9#�
^�hZ�4�4��4%B�1r��W��0
|��D95��-EˡJ�z
�t\]AI*O#n�W�I���pX��ji&J�p�ʐJ7����X�����ZEWp��'�"�Ϊ��B�
�g����җ�׺�K��y�6=�C���ޗ	$���[V��5F{�
��ƒ��	���HK8�ڔ�]?`��v	�A.�S/W'����Q/��9%���ī���;{��N�M�#oM3F^�׊"���1җI�.�A�D|;F:(��Jv�\�`:�P'Լ�����7x�Ô0�&l�$权�VI��'� D�/������U
�0�J�g(�0r
"H�q�:u��"z�ɿ��uw7��N�|ճk�z���G�ݻp�9w�kd����znt��GCon�=�݁����/��^����So��#�|!Z{`Ӗ]�7�r�ON
��ػٻ�
��7����w�=J&�Ê�x��nD�(\��]�ČB��+����	���2�U�1��3�!T2/�����5�?D��:j�l�������Bq��x\;I�,(%T#�N���`bg~��ZqS�	�o�X�E��p�kn�K����w�뽥���^�}~�F{��+uqkțy�(/��?�m�*/�����Sn˅v=-���BAq�],Ѕv�p��B��x���p�D1+�b��A�uY���!r)�QI}>.C~�-w�U+P
HS`:�4�B�@������L_�)>�^4�����k��/�>������ζ�퍹=>���<��s{�ޞ��6�x�xɃ��nKx���@g6uN>�-'9_�M��������o�%�������/"ݽ��_P_��飳��i'
� �k�T��<�5�1��E�����V�YK����A�Fc�x��9فt{�h�k��D�w�i_]����7z�6wpMi��]�OJ�X�љ�f�Zgh��W�ХO�
%�5�-s࢐����Q���F��
=������s�*���_4����<��~�����~���(k��P�UT<�S|_!�(�QnT�����`�[�t��?�f��D�),�Ս^ո�}c�;��8��G��
|PE��Q}�s::M��iw.GD�a$�ü2H��n��-�M_v���U�B6�Y=^ΟH��C�8�a��f
��=n�@(��@��
.1T?��:O��h���I�0��AȄV�`g�L&sZL��7,YQ����)#�I��/)l�df���O�X�����#�v�cѠ�ڰ��}�/3DU��C0��LD����.�<�J����aZAZE,�a��+�C�w�G�ό�in0#��lF-b]G��K�]טLV�K�a�᷁
>|Rb�֌�o�tR�N��ǫs�U�$�'8yY�����K�+N^�������6����p�t���׹�;�?�����i�B����]�N=v�]φ��������_[�J���ﱫ��	�ȧ��<O�!���pq�J�3z�qq^�$˛�慞E�EᅉaϚ���p�zώ�����}�}&�t�,������{k��UL�9�)oD'��P�	
kp�Q;s[�c��N	��?]�݂1<w�
�#��%Eފ|yCҡ�C�5�+����ؒ�7�}�7�ca�.](/�X/�$,L��W�7~T'�)#ұ�ؓ3&PR„
lje���u5=�Ɉ�+>��g{`���=
�o�f]w�0��f���c�[����7W�:�'
]���Y�[��?�:k,}p規��"���]p�� �̖�/���H�ft�5�ȷ���U��t�D���a�fe�7/�RL
> $i�8��!�,�P�CF2�]�ne����	��J���Tϗ�v��9�?Js�FQ����ތ(1����D,�`}}����(M
�'�l
��܂��e��3��!��旑u�[��B��4�Tz }�悐�h�F�)��幟l����[�.m[ھ�c`�h���fZ���j�n�h��7�pr޺�=��lo�c%zI7�/�M
�֦1�d���o9��Y�w�IeT��@Bi�!�M�2�M$xJ��N^�C����H/�7���<ó��%��J���T네��3"B�
����
nj�ݶ�
�],$?�„��.�b��É�p���x}���kg�/S�:�s��:�������ZH��Z�W���}�S��|���ٍ����v���E=��t:2�%N?�-�CaaDR6�����-��jj0q�YN�ϕ{��<��M�I.Ãf+y�i�N��L�U]�~�\ݟltx�_pˆ>�y�I_�[z��ݏ��h��4�����kkwݬOd��>p��:܉�6�l�޹y��v�BԐ2�����f�MWI\qY���w�
��lt8�V�#�^�ӝ��x�s���7�o�`hA�`�� �r������D���U O�C����k����jk�F��+�	?�����,�³vy�S@'%�������7ˆ��H�20o
1E��J��I�k��`�-3,WYG�ш��H`/�Y]����(7�|����qQ�c�˭P ��8�v��Uv���2F�٠�崨��k}H�H(����Ԇ�+�8)e������Xp��F��L����Z�����߄�ʶH��-.����ȍU�X-~My�����tN���|6��
����j0��&�_�-CD)L�e>+[���V5dR�qy�þ;bw����ѹ�3�ߓ���Ýs�p�V�_s�/]��fڊ�0�@���ǷoI����u��w��N;rn�]p�Ժdڑ��@���R��u��W��y5�9��Ūš����]�]��T���B���T����y�F�[*u(�(,f�^m�-#������S�R�喏(F/(�����F��˱�:�r@�ap LJX3�J}V��)Q	ٰ<�U(y=" 
���!(��7?�L���J�A�HG"�U
�4	�T���_&N舺�&<�'<˂X+�����bdq�Y���Y��5�v���7߰���㷄�d)=����[o?0�޾��ϝ����Νv�_�R�^(u���m�`�9��K������r8+�
eҊ�K��P"���)"��=��8�R�&���$�损X��^x<���j�e癩���|
� Γg�y�o����Y�#�7}�>7c-�͜i����,�
���ܔ8�<��'���D��VX�Q�i1>����D� �[��0���Mxci�Fe���N0â> �|AN$z���"�0Dzn��ȍ ��!�N�B�b�a����'�h�W:�({����ʃ�����Vsq�B��x>N���US�]�S=G'�	��))V/c�^�~I��Fტ�OV��b����pK�������̧%a;������?�"̶���v��F�`;�z�A��t��vF�2�xU�H@
*��(�� �8v�ݒ�D��@D�˳��6�	���G:��d:���@��;�	9/_.? ��:Ɛ�x9k,���6<.t���,zT
�g����`�"��L�+�	
� �tY�[(L�C)G�VR�p�����;�n�7�k��Y�J�R���5ٹ
�u�U+R����}v�@��k�H4�[V�׷��R�-=�anKğ��j�H��j��j����v���Z��|s{�r�^�L,2;S7P��a�5�

�;|}{U!�7�H�ZĪ�v��
[�YdPY�f�!,�h�#㍊�"Hg�uܱ�k�M{_$�E=�(�i�of�0�Ҥ� ]�ּ��p�ڃj��mClGl(a�mDuR�6l�6�4�87�O,DLS��Z�!
�K��G[�0��f]c܊*�@�7ҕ�p_t��
�/���y��ua�ys.[s���:���ˏ5�ck�_�D�1ʛ�[�/\>��CQ7R���Fv?`_\��:���J���W6�7	�#���ϒ	n
(��W�`��;�N����Ψ��>�2z�%_1�dC��eX�0`0{B eXE��iwU]����~�f"��.���Θ`^b��c�N	f��l]J�K=��O���y#}Z��'��$yVX�k%X$�R�-�8�1	uS��o�R�,<F����X���H�~�NA
�����m5 ?_ �:�0E�������M�Ƌh������1�9|�*��+�k�>�TEr���?�)dU\�`�����B��h��֕׈i���nj�X�i�w��7�?Y
�B�]���j^^� ���><n�+�8���<2'�f��N��d5����8�B�0Mg�r�;����뗈��so '�	��He�7�'f��e�%6��Y�M�d��Kޓ��t%���������ty�Mti��tl��|����|axkkC��������\9>e;K/D��c�;���C4Ζ��p�y����K�	����s!Ҳ���D�wI�!B�0Ցފ�Gt��1�T�]?Y[��.G��4��.�KjלF��0� /ԊN��'�4��Gܿ��@��5��v��-�-eG����b��z�C�gS/��g��&��_��X�����Ʊ�5�Ua�w:�;��2�����ޓ1��d�˰�&�"� ���8��Y�w,��:���V�֚��F�pJ�GE"���+p��2n7�r�Gca{��'����G��,�`�\~:�����=������1�/��j�Ë���+��;�I�-�*�0�� :[.��A ������'rJi(/�m�Ӂ���q�J9AIK�+��m���-~>
:\dU���h�tF���r9��H�����9e�)�9.����Q7�$�&r�t�S���D���٭ˡ�/����ޤj]�cYjF6��TsO���
�gJx��g`��ٻw�_�f�%��X��d߮o-�w���K�,*�a٪R���?�P����]��P�={_���"���v{����ֹz����|��ҿ>�ZB�I:.]`���מ��WU[K�jkI}��E��Wl-����­�r�~�Q���z��㵈�^�,(��]AA9��cB62�4������r��r�VׂD�2�Jb�һg%n~"�"LeU3�R+5��#\N��)�8湖��f�f�6p`��,w3��~���=ֻclcr�vYrmͺ�f憚�»�ۛoc�şt�q��Pa�D���k��)IF�rK%\mcJ�E݂	%�J	Ӄݙe�M�ݩ�)&��"�Q0~�E$�lyY.�"�_�Kn"�"d�)d�1�#	G�H��N�[Ti�)�;�?���t���RXv,�Q8jF��#-/�����
:�H���bicG��†�+���#�_v5����+/o; zahs�b�+v(�
e5��Ii+1��״>�l�+͘m�9��LCq��/�������Z�te3Mu�Z`��9ҵ�k:@�&c�i�P�*���Ygc-l�5�⌋�&��Q�k���8�"�Q��|%��2M
U�a��:iй2��<�9MF��AuŒ�Xg�_��,C����qzN�t�>w��_��__X��x�KX����ݳ�ƻ�u��;a
\-��a�bQ,�����i�}li��l���u͟�b�1؜��>X*}��/��4|��'w������e4HI�6�9�
�y)V3�=���������Ό��|�k�
��K��H��TO����^����s���x.�� 
n�(��[c��Y�w�1ix�`�lj���ڽ�^��!^U�t�􍯪�v�+�>	����-���nB��/	����B���8>��2=R���m0U��~�nصh�T�PD����
�@�W�2�\1[�r����냱��n�R�IL�n��c>_Ӓ�Z�R����2�1:�W�1x��\�
��#���D�E!LG�!��ë�ZY�B�	g&:�T
�f�z^q�ZJ"�]=��jB��l��RS�
'���"U:��]�
�եU�dp��Q�����L%��h��pc�E���pkƟq�T"I>Ź�m���j�����Y�,<k?o�X��ͪ%zpF�녧d�T&�i�fC����/xʪ_�RWi$���Lv2�V��*����^�L��i��CM���xKƗ��1Y��,<"&hb���7UD{�s����
���n=�4W��[��O)�0���YGsF������)/)��ʷ����HIUa$߫;nI�xR���%�^��_�+�Ֆ�6S��Z�y�ȚԅKh���E>���QғJyɂ��~�d�xSi�'M:���#,��9�����B%�8����K�}	�/]Iia�H@�bX=#3��\ރ���d0��e�0�Gb"#�D,�vY�k'P�
�IȖ�d��K�a'iy�<� �Y��H�2��ݪb�nf?s�y�y�y��#s�3��u�\���_�"���T\{&&���@I&AD�1I��GKK7�n�w6df�-6��w�W�a��B�,�%l���"15Va<�HL�y���hP�K�S��tD�~F�t�W0�%ol���B9��?�)LN)={��Yv
�<OF�Ex
ځ�Ɵ ���'�a
V
�iz~ȼ��H_L�$�}�����|p?Ů������å��%׎���:Ԛ���JHAᐩ�b��L�����4i�'�%�t ��tJ�Y�󠮎���u��X,���NxX���	���1��>
�q��+kT����G|���#���3V�����:�݂�A�Y�����Z��ڬ~w�]�C���T��qr���0P��_2��'�à�*����"gyrzʬ��!E>��B&�9�)ȉ����(��*�I<s�=We��tm�Ƈ7�V����y��>x���4��%�Fԏ~
���=�On��mZ��#�Y�:��XTz�=u�h�v��OPJП�@)fD�kɼ 5r���^�2��o/c�����4w����U��c+�G�p�f�AJ	o]~��*dG�#�^"��G�L^�X��Nм�^�oQ)�Z-�O�������D�3�I���Q@$;�ʤ�T�vy�AX��
�e�.}�{��2���J{0	g��,�&!
�)襉k�nR������SȺ����U2�rE_�[=�/��f5�����HM��ٻ�we��?�=�~:�z�BV��ay�H�d���o��D��!V�~��T�c��
�I�nө:�wЛ͙p�*�k�O������(0��?�����`p�T"���j��9�>�"�:����;���M�&�~��ﷴ����'��>���Š����&���6�<�ԡ�bn��o�4V�FM�D�^c���Z
TV�Gx(��P��2�oԁ)U	�JNė�5S�i,X&������Ƽ�͎3�Mp��3�*宩�K�ѝ��%�G�$�t�?���������Nom(�Jg�_�M�
��	�
��t*M���YS���ݎ��8����A�+�7��dzN�q�Dx� �B��=c0yG�C5��f����4��Lsѐ
8���}U~�M��Z[���2�Y~�Z��,��ݍ~C�إ���~&��o
!��[U��d��0%[çe�,:��#Y�+NՉ��|�:�߅NՉ����:�߭QD�&��V_ d��N�ϧ�?2��i�FM�I,�|�a��Vd��fSȣܤد@��U�L���GU.*öR?*�d���cI��>�HƓ���bz��$���	."�Ơ�<fl��+�%W�*�4ٯ��!�XRZU7��$	4v?.�w����04v���z�����e�帧���a�n�h�/o�>������u���
y����B�\E��/��xᓛ`#��w��F��a��s�z�iX�6�qB�+ڦ���F�V��E�5�dѐ�D=Уߞ��]�m:�
"����d�H�%dY@N �V��@��跼zz���íö��p�[�6
��"K�^>�`)������-0<sx��a����Ù��1�/ux�����o�=N:)v��2h��ܭ8.�$"W<n�,�2$Y]P��\�\�î�)�XTQ�e�$�M2���D�����;�H\�s����/�tMJ��וH_>E��8`J��0`�@`wҊ=�d$�NxI��_L���ZCP,U'�¡&��,���gz��L8�[_cK�ɘ����^Y�}W�/Y��OY�~��\�4��YY�5�L��P�?�o���{ׯ��l�9�ѝ��^��E-~��l4�3e�u"��U���*�[�oݾ0���jH���.r�����H[�lij�%fg�ϟt�Ȑ�C
p6��ū�'e�O$9m^4�zn	�u��:K��.=�|r@Et9/
#�s0�gš�Qz
��'}g|�oy���3�����s;��Lw)�01fK�@F����3!�#g��\V_�m�BU��⨠!CګL��`7����Y*K�~�bL�,"8m�!��*4Hㄻ�N�Н�nUڟ����*He
��h�����	W,�J�
�IC��l�;J���Z�,��-�>�	EW5��
��5���Fe@d��Ko��E�H��R����1��?<:���T<�y��d���S��ӊs�s���s����ߋ1BTaQA�1C�,*l�u��� /�uQ9�����ٖ�h�o~�4z�2��ׇ�,ޛ������点�O�>m�%���b�8��ԒSYVW#���!���:[P/���O6��2�Y���j�w��ۻҷ����[~���א�������f_�W��F���9���}5>���]0o�Vu]c�Kf��ҙ��I5�@����1Rj���^k�
��Z9)�IIiќ�6����������U�>m��
�j���"+�Zg�.YY�6pHl [W�0��U6��0���F*�E�T��O�0�p�eǽ��'N�N`^�<=����}{��y��/�Ϻ��N�������>�F�z��Ϻ�{�����M�Գ�̑�w�'����}��=�{����ͼ����Ɯ�:���ɳ�?���>����5�|������<� ��5��;כL�z�do��~���k���է�>� ���������/�Je>���>�z�ѹ�x�kg��:�m_�fWjr�N�ּ�A�$ỿ�`���̲e��=*UB�:�'��߁r�&�A\�4ڄ�F���M�����O~h�M���:��>m�|�,�=��n^���0�.��n7t��+��7O"2Zq��ۉV쥆���і-GZ�0ͧ�̦I|��":w��^
aFu���6L�����:w�G*���o!Zx�<�d#}K甛Lցu�!냠�$�_D}�V@�^���C/����!�y���q��iCL\Sx��5�t��w�$y�+�yA�qӫf25g��Y��~��tH��t:�c��lr�o�Z���������~;�+Z��_�'�C��������c�υ����q���^p}�������ZG��j�*O��jk&�]�5_p>�8��"y�m��C���(٧6e`�>����/�k|�zׄл&��e���y`��jjC�VH�*��z�QĊ�f���/�MP�5 ��SNߟ�W\�=B�K��l��l�j⩰&U���j��Qs�����dz����#3v�̈'���f�=�kJ�h��u{�-�X��`�h���~���W����
��Df�#��mJ��
9< �H���G�H~�t�r��-��j �v2ee�3�y(L'2����`"�jB���m���X�DTg�
(�?_t,h$Z�5?^�`�a�d
�3uh�p`��ɼΠmD.����ǯ�י�1�c$s��A�����H� xu|Y���<i�/ш�������.�s{E������ص���Џ�i�+�L`
���T���'ڣڣ��U�뾄�j�Nt��CkE+U����i�
Lkn�\OD�[F
�kT
�"���18r��+5�
���*Hf�b�b���2��������^���u0�f]�'�z������
C�,cz��Th�����e ��h���7Ѓl/��\����bhe
M�#S|X�r��ip����[��QR��ɢ��,��B*�@p@qD�y�q-`���
�A��.ER��|x��0���q�8>��QٺT�W�j�;�=�^۝�;%O�lz���b	�lM�y����2�����U4M��B
��I/�I	*}/po֜�5>x�h�@�W���E"7�� {@��M<�0�X&e�U�Y,Q�Y��ѯ@*%%�ɻ l���+�˧�.�jǰ䴄�6KH����p0@�y,!<ȗG����.aZ"Q�%w�˘����p^@J%���(��!���������M���Y�#��]ӺSɞ�d����|i'����p����*���8hXk@7�P��d@R��@�x���D4���
��L�j��I�F���i8����`�.�_����a���%B�g�X��	�,�V��_؛��\�3�"�6�,��X�m�է�b.�Zݯ����Vf:�u
�f1zt��!$��/��"�a*hB��:�!��
:�@Bg�^����!���i(�X��I�ۋD���>���� ^A�+M�3P)�d9p�_����t�KO«J4�V�7��8x�\���V.7�(��x2	��yS��d}«�"nrR8��c+n�ݵ�	D�I]B�
��z����7�o�J��9���i����$m�6m��em��R�]h
A\Pq
�t�+{
�q\�(�8�ΨU�}��%�wιI�"�7��}������ܜ��{��<�Y�y�<��7X�W�����e)�K~�+4<���绺��~�~9�
.b�s���&� BN�l;��"7�C��tHG#u�����P���reQ��R����:ࠓ'	%��S�|p����`)h.d9��>�v��U��v��!�:���I�����vf�{x��l��+U��r�̡��r$��;v�lu~{��KyG\���
���t�0�ŷ�R��B�����x%vG��r٣�����Az��g�<��R0��"%��;w�#�P����饖��7��=�VV0��V`��n#'N��^W����pn�s�@qI
�����j��� N�P�S���w�p����n�[D���V�����04n����
!�Ϥ�9�����pQI��WP`��x�PӑDո�,�J�r	�a^
�L����J).�1�5��[�t�1�S�d��̄�&][�?~��l2�דW��.i5�bY%i���ހ�cEVf���6z�x�z/Ij�#�#�؊��ݥl,m�B�����m�����7z���,D���
��l2"�Y��P�~�<�u�=�W� �����
�i��=�2)�mо�`P8��r�1��d�x��p'�Ѥ�뒽"߼��*�Qtp��Y�Q�MwV��vy���N�;�}�JC�~��!�5�H��꤄�
f�B�Y�}�4�}VS����=g0��D�s�J9�I�Aww|��Qw��O.��PN�*c��
�|N��guirn���ίX��ɥT������h�YUUpk��*TUxQ�T,<D*�O�<�>�YF�\_V��t������N�~��ȑ�T�v��`�+�Y�v�m�O�^O��V,��yK�i�HZ�y�h���>�DN^wB�M	6�mPms��*�V��Ty3e$�X�;e]��`�>V:W3���ɼ��2�g���X#�\q,
a#�]�G͕H�芒��d�+"
�ǿ-.�ɮ��W#F����o/=J��^�%_G%�\�?��_�_jb�v���p�}��$"g6p{��l��k��x�?,��"�'W�� [��$ġD�9�׈�@ /�6Z��0�c��y7/x�{ʴTV.�`@���А�Ɍ�jrp@N���V�[g���:�hh7���
&�褯�v�[�ɸ^ޒ(�SB�\�֠��Q@�sI�ot��p�-0$�ra,|-qOb�'�F#�w�ޑX�+w-�����\��
���'�J4O��~�-��=!Hf�O�f/�I'ȇ����B(�r�WT�Q>�%�ٸ�9���a.���E��&�ɳܱʏ���ղ�,��<��x�D�u��<O8��5p�b��	�^o��qc�j�^��V�\���@���l��2d�pň�90{A�\�He2La�r�6��PH���B*b���Z$��q?0��y媠AFft��Umm�2V��u�`[�=��0H���l �B4ʩ�*k����2�MP�K)���&z�Fh�t�~�����А�uac��#7i
�=�X2����М	�R���-�8ʥ��v!s�yj����k�n���z|��]�cr�`�!�y�uK{@���d(J؜:�ʌ&�)�v�P2ς��{R�o%1?����z�e_���W�.>�j��uK�(8#
S'�<lݠ	7>��s[ٚ�e9��;�nޞX|�ο��~�������O=~��o>��+�N�aPm�:��К�cp��c,@�-@���K�]t�!��c%Q���dT
�.
��L
s���
�)ߣ����6�=!gv�ۣvf�5bwf{������b;�.'Nj
��TNR}��^I�Zl�
�=v[��Ӗ�6KeU\�;��1SJ��%�n����{�yd�T��Rv�Y`y�)9+b�X{����T"��%
	+"��HT��QV�KLT�Ia48��ӌ�ρ�,��5��dH<d�֠I���x������aB���r��wd^�c��8�4��͏8����]3�&w
kV�&l�4�I�J��MC|�r�2f���|�ϔ�oچ����I�n쯔�x�����b@쟂B�"*�Dd��@F���ܐɪ*�<����@:١!�q�W*���O�*t��㹢����B_��t�H����OM� �x$yn|"y�,���7hV���0�W��r��3���
���e"�P��aK�"Hݤ
�9����4D�P
�q!]���#��Ⱦ:�$CH���T&�ޯ!V���R���"_�8�³�/Qi��] s17�c|Q��=!�����6aRQc�z��ɓ:�A��￡~�Ėۛ�X�1UJ�,e
�A�u�}0&ͺf���a��E�ζ(���)�ל�xx�AU��{c���Ch�O���+6��&�]�;t��Z���D��������!����A8�1��t"K�|K2�4fX�N �rh�p\�v��|��r�%�H
81#��XF����E�[R,��E�[rR�
@D�\���b�_��R)��%嘗�1="i�1bG�k��6��.\yJ�$�S��%�&g�*�;@q7k����,��ߒon<��q�H�]��O�O��&I�na,���2,7A(�p;���V	'���mpjE���VX��ɕ���Ķģ�pjb+���h����e��W%
�y��|��y��l��d
i-[���B$�������Z�e���X���/R�
$���<}��#i�"D3֕E��+�AK׎���xE�\]�8ī2�Q)�aN3&�bu����\b�X��7��zܴmA���6p�o� �U�$
X�a-��&s�,��V���զ[�ٍ�Fӽ�#����{���x�t�|�=͝6�6�6�e�rg�gMg�6��aM�a�Ȇ�a�.��L7H�TJ�$�@X8���4��&}
�)�d�2���T����y;.�5#_�B��T��^�,\3�9�4
d���Hh�9,2��b�� kՌ�k�}~pL��)�b?r���=FTUM]���נkw�I��|t�c���;m��.��R��H�Tt��
�S���m��A$
B�؃��o�VL"H<*#���G:R:]�D�Fz�T$���X
���O�Q`��<�G�ձ����B�A���8l�Iц���,�c�H��v�̮�$HMK��&�h��C �0�!]�� �M��O��ԮQYN
?j��9u�{l�������J��aǐ9��Fհ��'��c�R5�>�ƨ�՗W�l�z׌%�g�v�����T�
���_�H���-1��KY� d%�=���Kn)�����Xro��#�'<'�'b'JN��������.9]z�s�{6v�Ԟ���6�*�l�>;�Z��ۭ�l���S�e���b�\�E�ݰڴ��Z��*<�)�e�@�80&�����b}�.��n˖۹Ж�R�����w���
X��
�ӎ��a��+bڵ��A�4��
�9��ҙF���2�\�hA��Cm���]'�˗�_��D���	G�fa}l��5�#n��
�o�
`'Q�WXu�epht��w��bb'{I��#�D�4_ۿ��%�Ln,����"9��x�t�j�`"sn�y�`(ȜG�E���d.#6��f�g�
�1���|V����B9��C���P���������ӻ����7�FV\����s|����c�{m
�%:_
��^�/h�7�v��
�o<C'���j�&H�:O�:��ָP-�"���T%�D��$'L�
��‘��f�^�J`���Ӵ����x���M<�ym�򿜘���?�%Q����&�
����*>�^��*�,ʪ�\*[+�O��L*
���T����!�UTV�&M>��ɇ�K43�We�����r�r�r�r��>�H���r��z%:���|��`�}w�}:Jٰ�)�^	���6�2//�,/�#ee��)�F#�����z���n�(��Ң��6�ww���|�C��r�^S _�ʗ��m��^����g�D�L�țpb�[}F�����s��/�E�n�I70���(�^�bV��"�_p����Ӵ��Բ�ˍx/�}U
۲L ����$�Ƴ��25H�j��n2��eo�ن/Af֧��ۚ\M��U�U�U�
%�{��^2� t�ہ��Kݽ\������Ax���K�C��ȯ�z�v�*��Tç@/��7=��e.{���p����^�E��
�+�1�-�Dۘ�M$̾�D'��
�JI �]��^���6�hhC��.]ahKA�2g̉�vkmIS	*�{̬Ǭ�56��)!���s9C�������@r�ӳ�h�'�I��Y��hcڃT��mDӒ��m��y���ҝ���6�R��/*�,�7=�,bnSx��Θ���QC�rr`�_���ACf�-Z��W�Z>d:�֞�K|�4.7�à�������m���ϱV�Z���$��f�}��H�iƶ��J�{e��7{`}�3n(~s��&͆��hRcl(jbNj���HL���ؑ�����.!�a���B��[K�N,g9�{\�7���[�o��
H֠��hcŶ
T�o�|�&|�H�O�&��h�ha���<�щ�#�ETk>�����Ց��D�t�ю����6��<���\��᧢���.�#p3�C\��0�s�rQ��#/��Y��y�Hw4�%w4�ٽ���w؇�}0��!����I��m�n�K�
n���k�5p8�����{�T�;ڞ�n�K�YȀ
�s`�认�ʎL�q?~�;���@)�e'Rr�X���H�<��$�
���`~��M�7M6!�Eɷ˥E�,��PS�^�RO`�ϡ��>���UԀS�0}(�RS��:��n
�Jbiی�m81�V�M7ھhl|���+��"�N23Q�5u�*!YG�~��8�y�:O��VJWXW����E+ū$l���?���%�*m���t�t����z��ޑ����F�������P�ic��(
�C���Y*I�!��e�@C�l��1������0��Z-9j�J�5C�R9�ըU
�?�6����~v�j��Z�:�b\�X�U� f-�pa�*ޝߜ�' Ę����%\*�oifV��@����7a=d�9���)��{�.P���Bw����t���n�d��#����=yB�D
^�)3qޒ�i��x�h
S���L��a�nkH	5>�r�䉳��W|���Ǯ�UO��;�����������������4ޖ[���t�8�?$>~ܧ��~������?s�X�H&�Y &�������|A��3��8�r�F�<7h4|��r`��\�ɑ`�w@!�L�p�=jB��Ln��PMM(�G�FPt*m��1��C#:Ժ�\h��Յ\��Μ+c3P�8�����R�>�F}�@k�u��nC��u���:T�h�Y��A��i?1�{��Rھ	|��+[���j��OR�
�����v�S��S���|���i�����f�`q�J3�Sg�n&r>�Y1���JP�L�zb���)+���0�������˚�!_>��W���;�ܻ�6����s����z��P�b��|W�u���U$�ݞ��8��}���w2���Fީ�Z=�	0=���ɋɁ�,� Z-�����·�
~ඁ��V�+������>���n���jN�L����5e?T����έ&�ďɉ�/)z8
���{�9��T������<$¥���H����a������j�Zݮ�Y�u���WfgWUUcZQ|��ըfW�79&�-����Kܽ�>���P�ud�*�[��q!
�sݨ���~No/_Oo��ė�����g�@�>aZC���;�Œ�_K��.�IX�L�
X�A܀玭J�iz�r�b�&]��=�-,����7E%��C��K_������L�i��Z�2�:�:7{�A�Ė��K�
 QKx	#�M�q�U
E��)Ӓ�H�N�΃Թ��W1^�r���g������M�`�ď�F�@5�ۘjd��{b1����`L]F0/����ej��x�ry��\i�%n�Pȗ6��w��9&�I{��XAe����	���
�N��jv��|2�B���Щ�lv?���I��h��)�H�L��Νz`�G����;�IZ*�-Т�<�n͔�h�<`�`_����.�6W�ngv��SX�����qf纽�e��Va��>�STk��\T�fK0�T������[h~�2�J
e
���c����u_ ���n4�b�|�Z���ΔN�D%�_D’��R�LtV�T"������A��fm��{ɥo	fQ��9�K���2�g3���

z�T'���[<i���/��F�bK�y�|0�_��N���Z���B�-��6i�.��1aj#�+)��xGa�x��2��sl�I���@��$�F�#`!?m���3�@ R�uDv�p�;��N&�!�Yc\c>�y�@�-��xÁܞ��p�l���.h�
[�����
ܝd�4�9ٶ�@ �΅���w�isc�32_��
��B� $|RwY�6�K��ݬ7I`Q��|H�S�!��-�����Bk��l��@��i&��R���vj����'d3�j��O������m���%�&��Є�u�̕�6�&%+G�X��,�pv]`�Bh�_i$�t~��=�,]m�I}j
^m�{a�C�4��+(�c�?�&5,��7b��e.X_����*c�P[�)��P�M�n�K��C����pa67� j����e�_��۟�n�KpՅ��Uʗ��RX���)j���o��?����ͼ�A^�tL���҆�}1�;@G;\x��[��mR9�N|������Ο��Z�+���B��l�nIf���,.�ŢX�F�g��V�9�O�E���R@m�6���|���R�K�oLˑ�)�K��`S�O��2&\���F��ni�ڜ�n�K|#��m��)�ؑ�O�ҊK������x+W7U����hkuk��j�����P�mR�������\֖ԗ4�,,aW���`y9�9��ݚ�r�E�)�(�\���Q����rT;����2��~�q88.�L
^y��QYv;��&�B:�͞��V�1�u���puw�A@��f�����$��DT��ע�r)q�'��T!��V�Ĉa9�Xb1K�� ���ޠ'd����R[ќ0�a'�W�D�� lW� ��Z�����\"���u~C[��_�X��)�.,,/�8�G�5�嗀�hl<�~G�Zcm\��$t6�Z-V��0ٶ�ۊH�4|���i�EE��m6���t����X�Lw}_�z��������R��Wy}����6����),.�N.{N ���\Z���V}�C�H���3������9@*H�b�_�~AӦ��I;,
�X�h4�rE��?�[>�0�������
�S�����;\@�x�_��q5y�S�E����n�:�����1���)㭄Z"X_�W���XB��"V҆��S.*����0��sq
c���xmX���%?�����9�^��憢�"T�k�ni�3ZZ�n�s�l���=B[��֒`%ɥ�$�CwJ:4ȟ&\N�M:�#$�#1�h��B�C�
��Wʠ���)��	,�K��ư�
5�*4�R�͜A)EZ�H�d~B�y�ɂ��jA�ۢj���}[7�O,3p�s��c#y��XAy5�l��#qf+�$��"H�6Z�H�F�P�1džf�ģ�<j�vٚh���F`HFO$M�u���s�J�\�8oFbMߕ�7��w#78ql��_n�c}>��Vf)����+��4�	�o\��o��n��[�m�͌�
*�,���
U����·v�6��|�a@��z#M�J����D����!�1��K�L���6W$�ic&�f���Ʉ�&�
��q1E�p̀����U��r�K�6�T�$*_��QI�R$���HT�m�uK�|�L��%:�P@�J
��I
T�qI�j�Z�/��פv9�@u�"r(����R����lBL*��]�j� �k�Z
^2Q=����%I�<"���ܔX��G���x�������_$*��&
W���k1�����X�8�8�X��9���8�x7���f��lL,=p���}�����<�\)�P��	|�u�:[G_o�o�q�y�m�c���7G:S>�8Ǭ*
4VmD���Q��"�k��:B�$�o��bJ��u��9B��b��a%xX�1n�Z��8�h�].�VZ�b��g't:e9�NS��db�L�d�j6�6���6�L�i@�^M�"6Ș
2(�R
��O��r�3h㩍�.�0�ǣ�}�NUGWZ��K�ͺH:y��KSԱĉb�K��4x�������#���_�`/�(� ~�:` �Z�칣�#��<�������	d�(M|s��f����f��m�W.�;�F:���eZ1��
���i�0>�}Zۦ�nQݬF*6e[E&
"��$�	�HD�r�O#wen,
��l��(9"a%���l+��9*,���l����`��������9������WEH�b�j����MOnV�v%�#�����%Z����&��@��Ft���Yy���LSϗ��|��f��f���ߺes_�x��mŒ
��~v��o!ش}�c{#s�Lr����c��0r͕�b$N�z������
v��a=��-��t��n-f���f��|�ų�l��"P�geUŹ��5�g���ߥ�I`���ݻP�r��E��.��F�9�[��d�*�d"���k'bW!�m�kkc�����
�Sv�6�'�W��=�FGͥ:p.��n�z�`���w����P(��YG�b�-\��I�����n��1�
f�@*�-�-I�6V��m�?E�M��Ě5Nj\�5�c*6
}|dž��|��_N%���4m53�|��iUcg���G����-�p٭G潔���#~Շ�w�~��?�,Kx�*1���G��_�V_g�м��,W.ܩd�~Y.
�Ѽ�ݯ@�2�l6��gp.,R�8��W$Z,�[�Q	!"�f[L"q���� ��Ӝ#�HmJ�&�B-�J�
�b�Y���
<5p��5���-���6s�&*�E����-􀿢�R����I;?W�^N����/�q�_
^!��A/�H���^	������O�<�9���3_�[,=j��n��6-��<eo߳���~w7����:v�~V�
�EoO�����b��e[VmV
`7��ᖩ�����᠔����l3����$���5P��L��@%2�$r�֫�W1��V┤�Q��/��A���!����w�������6���-+�5!
��)�E6����M�X���%&
 -E76�X���D�_M���cOڼ�~��k��6
8����wڰ����$���}��I��I�G�
���p��i�p
���:�N�N��U/�.�f悹p��	�o7�)&�z��t�?d��V��m�\6�֍�0;���7�ɨ	h�[f���)˳��%<��J�6�xc�PA�CD��Z
F�4"��.?d�$s*D�׃�]*���;��ޡ�Z����Fߴ�9��
��G%�4hC����uѳ�U6b�M���Md��e�����ˢ����ؙe���w`!&g�j��#�@��Y����{$Z@f���k��h�}y�L��f�{H�1�(N�:���X,j�
K#�8�]��Zcv
E�	J(q�ɘ_Gx�Rs*�)%ʭ��Jƥ<��J�(�4�T{��Eo���"�:�-4�{��@l�p��3j|�Zj�!j|�Zv$X�F�ib�e���Əȁ^������/��u͐۾��y��Kg�Xu�w��iͩHlN\��]u���ۇ'
��a-�}����K�p��_��IX��9я�v�So�A;�;�>�j�	1b�0J&���"�
���%��q�$4��/T��Wn!F��b�CKC���|gF��H���8���~�R���?�3���_�"m��=�AauT��jL�F��D�*�jv	��|�**�/^U������.Y�+��W{)�{�^��Y���K�ޛ�j/�zo�z,��w�*ncL�2j�h$b�\���G�Z���V*��"��)�q���X�ه����<>�!��{!FR#>��gL��l0��%$���H�RE��фt�
�!�*d�vQ�v�M�EZ}oʤ���,{~�T�V)��/�8"�Sy�,N"����v-*.n��ؑ��#��/�K&��*���T���ٔ�����"���v,��
��S|��e�ːd�ڤ6;����ܑ�-u-#�Q�đ��f03�y#�Z�\��0r��[�5��Iޤ@aG��Gq���Ю��ڠ�W��9�lv`y��G�v
x��!h��x���5�}τ3�����<3�x?G$��3����x=� I)]]5�Y��T��~�e+1��bFc��ӛ/�+
���J|y6_�<q/���ÕY;r��6�Hw����k�i�s
D��d�-���q�d���u[������1�t�L�\�e0`�@�1U�\.��^>쭴ڗ�$�|�)"���;'��;�����<3fl����3������hƯK�����\G�|�|>�o�&��
;��3<�!�Q{���$˟�4�;�g�S�.�d6�,�����Qb���:��ֹ�U��iQ#lԹij�Rb���x(-+�:P2�dN ���m�_�8ɚ�8�8e!Q��
ވGY׎~ ���<�����!YQ����s*�N�/�ijE��yy����;?2�)WC9��W6�=�VT�}UxXԨ��W4��P_6t����}FM��>���~:����1u�#��+��3���c#F&���?TWh������Ȫ�HdKEE��,RY���EC�%E��x�a�V�Z9�gѬ�Ehβ��FC��������g�k�G�Ǵ��o��qj
[� ~���`>���f6�-g�ر�(K�Je�0r b�+,#߃�1KL��`�퀱��f�v�ߥ�Dm��}Y�Z
�R���I�9!�n�:T�Xh$;�M��K҄���WU
U]8>{�ЛNs����i��on����������f6W�����K�k�J�J�2�,S�W�V�&k���ed2%�a�Z�CvHb�.!�"#W���{��$������(�@�o���gՌz�F?�XMGp^�zr j��'�S9��h2`�j���g��0|��7�Ϙܴ�yt�����4dҬ�5����U�ཀ�v�~�RİJګ]2����ޥP(I�Z$�G
v�c�%�$Hr��l�����i�c�������)�����ix�
�t��]8.���c�����O����W�V�v�jA)�
��V��`Rf���"�l����O	�0�E���@D�G˕�x@���,B�-I0��E
ؠ��%d*��D5�et~���&	�.�mV����X3k��=��
��(��,a�̇�}�{A)�D5��F��o,����Lj��,Y���89Ez1�`�7���l��"���3���gw,�VaI��D�>�;KGz|�+KBmY�:�|�dY��0��Se���LX)�$)�� D&��G�at
���[B05o�Ղuq����'~qҾ������ʾ
7�$��,���6����w>ߦPA�=������lI�bfq�1l�
��̬X,��	��Rq�����q�xt
6tX�tb#�m�|�L�CF����!� !�β�[h^eFf<��X��@%( �<b4P �j]�"��Z[z�u?��7�#�ݩ��b�%���8(�8"z�w<�������'�@�7q�'�����7���y�$���ύ��F��Db��/	'��/:�27
AD �J�%FD`���P�Ŋ�� �ev8�{�ؘ�X��7��+0�v��@3霶�6
��:F���
t�2���:i��T���/D��pbZ�; M|�މG�%`��Tbq9�<����&�g����d���d�UIy�
����t�RUOM�It�(���s�����v^�1���8�����|esΛ�7������(v��L2���L��3�6ϳ�f��6���X���!5+�r�`}�	얪u�CL=
��=�0�����7�U�r�N-�db����5z7�t��n��9�p��3�H��+Q�&�Yϊ�%�%�"�-�nƺ����;��u���XY
�8V0��
��xc�p�H��վ���x{�H�����#�bDE��Z��މc7?�*�S�*��v�-�F�{�w��i����$�*�zr�{'��/��6IJWIY�!f0�����8B�X��d�A�>�����=����'���)�j�dЎd�!B'I��ep�l����T�MT_V,�H����|��\��N�tX�3#�?�(|��\���l٥7���s�FV���1�&��I�S�����]PZ!�%�Dr���DL�J!�C�e��AM�YJ���R<H��{Y Ð'
$S�a���=H�Q��΅ǽl�m���%�ed�
fύ��v$���0��ԌtX��j ����� |�{y���%�-G�����Ð>� G�x?f'��5;!"	9�,O�Z��[�;c#��s�ZDioJ����o�*��哝t�T�,�8�3�Ǚ�71?��:U#1��hH�f~�K�S%���K�`�/����y9��3���i�o^�إh�=�[z����ڰI�%c��X�ٗ=�sc*��D瞋W��ݴ�B��d��;Q90v�u�Ꭾ^D5����Bܵ��z��i�^����C�ZV'�\sIvd�^E�ɪ�`0��W��)� J�����'S�Q��^���}����
�ߋ��p
.�zU1(`c�n��d���M���������=?��n���ŭs ��!
rD*g�(�r	���T%��w�i=�i��絢㭗Vr��"~/�O�+��d8f��ba�ԝe�G�FF�x\/Z���n�C��.���Q<6Zp},!("���?"��>
���Ƴճ�?�$��������&�ְ�����v�c��
�����:��4%�D���/�����[��5�1&�ڶٰ��a
�<,7K�	)�=��YBҽVaۇ�,x-}ukho������^Z��h�~<C,#��x�K%"!��8�Y��\��i�5����{�[p�1
��)��A>��"!VʘY�l�J8QP,��ΥOF�=+a��	V[�# NGP��p�H��gIE�h�.�R\j4���Og
7�nE��A�T
�Z��9V"����)�<(�I��d���NL��u���@j���XI?�xQ���X�U���j��\�u�Oފ�
�J�n)f]�'��S���x��|z�k��.�����Gd�3?�uO�NCvE�f�sG(nt�X�Wrڳ[��gIR�$j�5��0դn�:t�x4R0p�D��X�Y:���%�Yr���X��+ Z�
gGG��>
���<�'>O@z�l�;����4��%)�[$xD,�ЉCL�C�K���&��.���&���:��'�9�?�Yl"���L����]D�̑�����A�h�&,����I$�c�X�.Ub�J���{1� ٮ1�I� �gS�E��T�$��
ha+/�W����5���%�iZJ!?8����X���D*H?�2�$H��n�������SI�֢�(��c1�/���~O!_Ǜ��)͡r��Je�#�%� ���i��爵���������<�c
t�]�x��f�c�^�J(�!d�$��8�
��+p�/���]�/�NI��d���/�0�A"��bt�z�3���E��^B�)ԥA1�M�����I$�Rym�u�ٮ�tW��h�4ݏ:{�
Ý�{��IA=o� (������èO�MX
�d�5��
�g�L�r�Rͣ��5�����#�ZQ�Hp>Y7��7�t��2�"��q'銢�����%�2�/u��0~C�����V
v	�>8�r;)څ�V
�
�g��H�p��.�'�����INi7�z�xR.���;�7wq���5L�i�d��Ȅ�Z��_�
��$���/u�qkINAd�)h���0V���^֍�(r��bz'&�ߧ7Q��
K���K�����
��V��9~��LIFF0�%`>��$0f)e���*4�W]
i9'%��U�	�@�iJ�%�)�\���T&ä�cK��>�{���\�ɟ���ş���.f%y�(���w�wS�Ǥ���P��{��A���O>�sx�����d*
�
n�T�����
r2��e�:D�I�9O�>��',uM.%��:����9B�o|9�w�ri�'�C��a�3(�Lˋ���W�7��d�$�P�1&i�,�+'��әBv�R
�-���!]M��D�$MO��D�N�� x���%�D�Q�N �Fc Haȱ�󩎟���7���*�]giW�c�t�Y]�G&*�:9qP!�T�ŧ�,�\� R�:%F�*V�
fe)�Dʑ��mVSsJW�/W��n�@�D�$'�?~I0GY� y��Nj3$
�IyS	^�e[6-Tz�&�I�L.�J� Ub���&T�<�!��9u��)^�6/�����م_T_���{�n����^�U�	&�-r@)��4#�c`a!ٛs]��n��/I��K�#%1p��Ҕ�&�h.dFo೔YY2"�\.������03�K�6K���Y���r3*B�tNi�(�/Wг����Z Hn�P�]J�I�+�r`x��:Mj	��ѸKST��!�AJ`��K��R�@�f)R�g�nEWO�T��q!eg5Y7]JKJ��JKR�`�_�"�D��FV��wr�+��@.hP)֐�
W���o��oY�����JD�$[�2	��
G3��ثTU�,� �!�{DB�Hp��T���l�� ��ߙ��8�A��g��
����ʌ�/��NC�Ll�IMT�0�hԤ�Y�@��9V�D��:�D�R)r�!I����%�I�L����h�:H�3�rfЙ�0�&E �^��Uе$��2�ٴFK��$=Oq�̑=ȗa���j4�*q��I�L�V�
�^��0�'�OH=U�x��:�V���W�����L����JF��oH@���nD$�iiJ�·�$�
6=>�w`�1MQ(�ZS�h4�(��y�4)�,�q,�Ǯ���j��hD�	Bh���#�p�a)Z���4P6�0=��T�F�PҜ9���q�j���*&c�;~3�D��?�J	�'����2���z(�a���ʅ�fH��
!vx�<~��P�!�m��6)-hRەװ�uq�k����ռgu��$ԣ#�]<c�f��0��+�B@i��A��i�U�Yy�

�m�
};Wx{7�,m������
x
U��V��k��ôt��Oꘅ+8_,�3Ihҽ��^�>��
f&$�Q�)��a\#�^!QP�@-�
��A��c����Y`X�e����&@.#/1�¤�e��v�ە�pz�9y���`�0\^+.�*-�D�{�}����ݯÐ��F�8h⸱�F6��0z����̞6s��yKZ����l��F��GM�k��rյ��,�Y��ÆO�*7g�W5��<M���k���E���{���"���t��3�6g�lp��YY�}��}�U~�O��c�/DnOqd��9s��(Z7h�< m�4���O�0��*Rt�,�V����}�~���*�++��اO������XW7�}��A�8rdc��IcHq��)�S��#���m_�ta���^w}�ai��e�6(�'�Nm�6MB�͢�ŋդ�q3�g�bIQ�\оp��$͖B8�}�<��uI��/�g@R�>����p����
�M���B������(��������3W����?��re\O�W� �/�\�P�O�ʕ��{�
��B���z�w��uW\���[�q]���[�o������>�7�ı����������ಹ��<��`7����x�����#�8�߁���|'�,RJi(}�Qz�����q��6�9���i��ӓ�Q]A�M�^�kj+)͡�e�7���T�R�9�gL�2�Й�s�͜5u��k�ܴz��w]ݝ��v�-7��{��6�߃[���c۶?q��z�ѭ���ɧ^:жw��w<��Ӈڷ��v<�ܑ㯽��w��ˉN{��?��n�{��я��7g�:���|���?|��_���ԧ����v�=�^=j*(����%��X��ޗ_9r��'m~�g����[�~���t���?����G�n^����68���>+7ԣf�k��������������k�
��𦛷<�wߟ���[YN���aĜ��o�ã{������nOyՐ��筼�;w����_E.oI���3W�z��w���_��Xـ��g��{�w�p��/�D6gq�nД�wm����|��)�b-�6N�<���O<�̳'?����M����s)�T�l.h/,��g��~���$���ɓ	y�F��]wG��u7��O�Ӿi�S����/����s�x���G�~D�����O��:��?f��;������������o��V��}�����J���zK����m������v����k��_�\�^��ﳬ��e��S6���˧�}f.=�������q"�����[�U_���+�|���������ʮ����8��=����~�*���c�/>?kŊ�ʰ.�����G�7-\����.=z�#ʽ�Ra���.gc�:U���-��M�+��g��5�]��,������<(����}�yr���0��@#�f�9���׃��&��
փ{���A����
;�N�/�W�q�&x�|>
_���7����}��(-�����X�(��
�x��
2p@���z��h�<����|��c�O��4u��3r��ƉS� �r��^��e�5s��d�[�dq����f�Zwǭko����7�w�~ۚ[V�Z�–-z��?<t���[�[�m�#�w�n���SO?�|닻�X�۟|��/�ܵ�l����񣯾�����z�cG�t�m���'�?��ǟ}n0���_����O>�B����O����o��՗��?���߾;���S��=��B���D�?>.����,Uٰ�#��nݝ�m{b��z����
�=n�;nt�SO��F��?�2x��k��z�y��㯝�KǏE�o\�x횇~�٣������&Lli�����{~ǫGN~������?iʂ�7��to�����o����4���7�����;_~��O�9�۫��s�-_���ݻ��ӿ~��O�j�
+�ٸgϿ��tNM��5s��v��y�~���SU��D�P�5�#�j2괾�6F���܋��*�(
�m�x���Q���3!)��v�c=)�uWv��ws�(�l�z�I���M���I�h?��o����k��K%.�U�O�k�m�Ǿ���X�F��UX[�UZz�|��s	��D~<�����¿�;�}W@���3����ȗ��|�:��5��zc����9z�x>�z.�7ٝ��N�9&2�S>�;���:��_���?c�P�5D3?d���{�'j���k�]�	W��#��s�_v�=�q㏸��n]	����s�����S��b^�X�R�sMOׯ��B����L?���K�C���X�QQ�+�q�%֭H�[)\W�kW�:�׮V^�G���;�j��x��v	 ����b^l����S��vV!%nm-1�ո71/^n b�
`q':L�����h>�Ֆ;��
����<�ߦ��4�+ٞw�
��čĂ��Kܝ��4Mڍ��o�?��X���Yx�`nr�0�V�Zܐ�{���y�Z����+�[�����Ux�a�D��j��I]���r�Lq�A���Q���x>�
��%n>�'����$:��ܰ³��l�J��x�𼒛ѱ<����� ��n('�̓�jҝB,�-�H r
�E�rq,:I�w�;X/s(A6��7�)yC��+�@o����耄�-ɪm����J���ť]�J�K�l�=�G}����j���j�|V�J���y�Kp�(�%�<k�0����
�/���e4�n#I�k�a�/��8馲��Ѽ'�&��'KO.l|aꇛ70��⢓��=��/~��I/N��ᇛ��j�{#��T`�
���{ح�T��>�V Sne�%�o��X�XԚ6�"��dZRǿU'HX*̯:~*."�A0#��j�d�8r�#�.eN^�G{�����ĭ��;XrN�
N0��v�m	ĴmL/eۡ�ǿ,�Lގ��'ȌĖ݆�Wg�#y¶Z���]I�v���"����#�A�C�Aq��׸4��e��K!ڷ���/��:���[>�J�EX�#`ݷ�$k���|�yr�$��-�w��c�`�:A����}�|�n�q��Cѧ�oD��ķ�n3�ng��Y�9���,�t-3�8�:���e�(Gj�����6f�����M�U~�$=�aQi /�Y߳�'�)Q�Đ����	�6I�55��5y%ǚ�0���[���)l�A?�g��>�����$;��!�S�ճ�4��4�O#9�������#�֠G�ד�������������F���%1��$ڝ0����������<�L���'y�9y�ĥ{7Bv�z�n�7q)q�'�����L(����Z�w��M��w�܎�}��?	���'.޽>߸2���=�}w������qcN����`��=t��AD�+����L[����5oq��dL�zc�-4�2"�D�ˊ�ߊ�t�Շ�C(�i�D>K��0zCna�/�F�$x���s[�[�C>y�rL�샾},uOZ���}��Lܫ�Ĉ�����uG��ې����~R��'�F"$LKc��PFr�+'��X���܂�.	,`K����Ix�7<aZ���4uʽ�ڡ>X�[�'����M̘ƨ;��~�Q j�~���A�&?�J���ʼnDN�F±fm^��΂�ݥ���sIتӆB��N�_��S�w:E�-����v�ι��"���}�в�(����Y>��gߎ�,ƯCnI�w�&�2]�A\��f��F�Ո5�PM0�ßE>����T���6x��2#Sش�j�@�`���z�˜� ~pw��/O\��sv������	���������3V���k�g��/VsUR�a�i��C�
qҦ��n�Z�Z�2\�M�e�_�N_^�%��9�1M��_������D4��?_�%���2XIzg��l�\��u�̭c�'�������N�
h�H|3uӼ��6$>�B{�>�ċ�Aګo�L̙�ޛ��q۹�k�ݾ�hT�U\��J�_��x��?|���2۫�I�ҮvW���*��"����a�m���l��flJ��(Ƅ7ldJp 	-
�&Լ�!q��E��5�Z}���U!����|~�ݙٙ�3�{�=��z;�zڞ�/��tv�jr�l}Sc��i�9�.�w���>joTL����r����9��ƫ����N�
�Х��6j�L��Ch�� j#��m<"<9�$��z��o#��ɷ����?�.�l�s#�M?�7��1����N�
L]���Lp����kh��œv��r����ͪ/n���7���M��7x
4��"4]�!�mn]}n|��~������M7}�7�����s�����B�v}�~��<`����B]M�����9���n���#O�����i��9(UBD%Ev��-E����I��Z�AJ��KQ�DA.�w�D��I�����x�c��
�T"�&��a�'���6�C�.���B�Q�$q'C�ޚ�ѝ���5%L�a�Bx���v�"��FV�Q����톯o&$z�\羪9>�P�&�#�&��A�K,���E�U��k|����j0r�C�G�=���2�Z��Q����g��
���ٜ<]��Ye�K�}nG�.���s��Lj��U2�lb��QK?��d��е��5�V+WXa� ��_����
�*���;/���m��tT%��n���D>�W�c���|e�%;[�7.y��]m��jKϿ�e�p���z{�[�Y?�᪹ב7��W�7O��{�	f�����b�Y��j�fL��=��O$��X�]4H+cE��Odm���k;h�6�R_ye�i�(G;�*�r�pDe�ih�H��FF>b�z��_��6]�s&q�����.Z�A6��k�V����Ī9D�V*���s���f��������KV�:�l��m�\��w�?д#�p��4��/��Wmx`��}鶎�K�w���yŽ/�1^��Dc���%;�	w-��dE�|t��2��p0�m�Qj�#@��oaGQ��{h?7��9<lKQ��)l��-lQx	�j]�t�wyɝ���n���^���[�^o�������M
��Uwi��;W����;VS~G?�o��3��g�l>by7<��t
��gQ�h
�z��
�9�cO7��i�
t��'�J���I�3Fɳ!���Z���
s\�ٗ;�]�o3���O��j���f�.��ťo�G+]��
���<`�q�۪R�
?G��]�&��
�Db�T�g�Pp	���2*�/��|�|ng��@)�$C���Z8���	�

�	,
?�<^��P�YV[3m�[�ɒ�[�rV?Wg�-���U��^���s[v;r��=��i�n�S�g�i/9����Ch�
ϰ��PQ/s?Ǟ��>"�/=�T�Ї'�����̐�	��ҷ���"�n��I/��؝��w�u?����m䉱7�����_u͜��-�MW�~�ܳ[vu_���Ey����p
(Oe�V��0�.����Jo�7�/y:�u'��ے���I>����1�kH��ώX��2ֳ!V��ܹ!׎_���;�`w��jȝ�8�P�셇�݋�mВ�IVB>)ЊzI�ZZqʞ�ϚI%|"VY����	0�X�
�29�{V߬�Y{g}0K�Q�xj
S�M94��)��j�1���v`����ڱ}���)iym���Q:`"�_��m~lt
{����+�Oy����TT3q	O|h����
��.���Ac�.���
��
A��	�ݭ����\�0���fP��Q�Qzёx#�;��@�������в=�K�kq���C�_�u>7��~%����D1=��^�������7��o�7U{m�赹���>���*T��\O��yB=ip��鈒'�<�}�	�b��їe��5>�������_���>��!>����ٳܱյ�<�����þg`����G��k1��)s�2�V�U�b7H�*ЈݢŨ��)�*�*��j�hqe��ʮl�S�0�f�]JLapJs(dK�~s �r)��hg!EC�r862|F����:hy�V���n�:CydX(���Ol�Z`��gJ�	ZRq�WVE]�zp�ƃ�ص�?R��LL/k�Y�pZ}I�>\����擋~һ�g�cM��gw�vU��w���vI�;]Z^3�ۗNMχO~��?8����{��{��w|�*�r����[nju��,=��&=�!��'1��J������w��F�B�p8nT�"�ڍ ����SD�A��zy�i�*��7�^#2҂.}�Mj籧
\��ߣ'�JBѫا�tN��4DwG�^���!�-E�
����ϝt��n��,
Ÿ�;\�C*�2i�~�y�gX=ƑZ�U��+&�z�뙻�c�[!.��-�`�TV�!��M-˟߿����ye�������;/Yx��~�@CWm]��~��//^t��?�������n�k�C�ZXvp�������N"�˹g����Ќ#���?��J��e�������C!UސVs�����N�A�G`�~���v']~�rr���sh�Mڭ82d�?߬���R2�8K��pI�F>�n��|v�\ޝK�7�[��M��2�
�`Z��������g������1�E��y�$R+���^%ѐ;#��Z�y���
�Ͻ������+�m��eǞҼ�A�YCFÀ#[*�D9�rE�?�1�'$��E+� �=]�lJH�0�op@5��"G��[I��� ��#���|�sb�61��;��;n_=m媎�U�%�K��X�1m��i��qĖ��x�o�.-(���CA���^���{�E�{*�،E�;�G���w6�����4���`�	�`"��%�!WDXko���p�z�>F ��>�a"d
E���Z�[hr;�����|�@ �T���'�A/�){b�����p#(���1��������,2,����0�~�X�����
��b�Y����,�
1��)ZD(ZJ����%������Us��*'-V��	-�gf�C��c�%-"���̄���i��c-���'�'��6j&��L�"�1N�8�5�λ[�Ԏ���3�1��c��G��<�
v7jD��bmC}���'R+�c���@��Z	Mz��x�4�#�I�
��z��՟����^����`���WG��$l��
��C)�tJ��qT.z�����R�R��R�w���CK1X�T&1�v�a�؛���|�UҷC���	�&�)لAS��CP�'t��sԎ=�{�9
0X֓mgmN�An�(C�c��a�vף�-(`vHw};W/�Wq2�1����^�^g��1HQR�e��黇З��6D�8cF�E���Ο^�a~̞������2��q"���vv/�ʳ�����>hC�m�m��v�[���:-�w�"��&�f� �b��mY(f��ȗMf�
پ,�fk|����x]v���Z��j�
q�K�pl���������eJ�|��G8u�d��5�8��m
�������Vk�����A�)���$=��Bd�M�e����T�������J�?0T
�MY��%
i����M%�
ٱ:�=R/�'y�=#� ~���кĐ�V�-�N��P�Q�����V�'^�U�9��3�D�Ɋif��	WG"9�l2�i��5��b�df���	l�V�Dm�N3F�FnB��kf�������s����p8\�����qÜ�3r�S}Iy�,+�B��K�K3$��,�ty�J9瑇�30#*
��J�����0�Ց�
�hT�?�0�E���3�-;;d��T�ˎ{٩^v�[^B+���d�_��yI
楤d�b��N��v�ń��@"A�c=ɵv͕�uUֈ����>mO�>�m��[��9Ys�ǔ������k�K���6�=�
Y�(�&���L��
`�㵗x��@I�'�Дx�Ao�'
��CF�L:U:*�q¡��hPA��e�x��R���C���k�i��p
>)���c��ޒ��n[��t����dɩ�����X�lƷ�t�Ձd,Ly��l�K��	Aٽ�10ֱ< |A<?Z"�e�(8]
�K�pC�ʩtC:��ص��J�<�-bk��^j�so��n
c��%�\�q�3a ��5;Z�+�i��-M)A���*GxA�nQ��(쵖롱��fNu����ܳu�P�������{�5
��č�9��֘�X[wɨ�3�F$,�I���2������rp�O���k���j��_L+�����۱hﶟ�c`�ǟ|�4P��!>1	l#w�
�����N,;-�Ж'�Z�����= �����Z�uB�	O:?p~��I���vb�t�v�cb���$<쿏����(���Io\6�s��:fH���E3C��l��l������;J�۹��rF+��?��y�ӆ$��@Β󷒳f0���3
�Z�z�����OY^��%�'$Z ��C�!Ba75�J��H5�,׎*��Ğ��:��k�M�j�m�s�/�w8��4V]�7��r0�}�nbWb!�7p*��#d�#�y^ƽ�'��-�zB�q�At�^d'e�seݲ>٠��y��f���*�*|r�a�D�Z.������A�®��Đ?`�9�r�c
�J+���*E�nw��Q������K!w`�c��;��o��<H��d��h�M��BC�3.������YmJ�UewC������<�d�
#=�	�=�3<��b�*=��)��IUƨ�!
�h����{s����:��y�e���JE�^�*�A3�:w쭷֟[��?�=����?E�<�X��0@,�w���-�=4lJƂ�UlE�5�L�"n�Ei�m�4�sfIW1{�B�����0�|
�r��;A9�GlT�+O+�R��Z�z�E!W�tH�&C�	����$%�ɧT��������0��Pxh�#�_���u��������x�]ԗ�[�{�\8_�/Ɗ�S]�R�l�l�lO�kL�K����W)JeRl��vs��^���B��͵�w�Y���]\X7�K����������*�X��i�D��Xxq�c�Yj��%7k�h���zy����	�2y�"n�"%��h�xb�@�BPR J_4���B.���rB�\n�өwAB(�ܪ�(���c�z����W)�X�>��ٓǣ�o�i�P�ڞ��β�\-�l�a�#7��z��OTCF²�����:��[�׋��e��#��\��8�:W���f	����k�}��+�s�,��}f�ðؚ��r�V���S.��k�#�b]�z��a"χEy�UQ�q�{�3��X�V8Lt@�a!�I�I6�n�V
� F ��"}��""%'11��	��|�jE��[I���Ĕ5e~A�s�&�Ő�g��[kK���ⱈ�"�[��e�M���|��q�C���pU|���O-�c��Aǽ��?�����`�ו����~�2�B��G�
cCB���
��vho�-�$z�H�@Yw�/���e��\XN<<`��F4��Ǧ$t�	�C�
R;
�hrU�*��($�w������}�GB���ο��tNDq-��GW<��ܙ��n���<;	��Z�{8w ��k��~ٌX�5ο���Vn?<��͖3��b�q���� ^�|$��ءԩRS���!ӟ�!}*��J�h���S��]H�ԊJMF�������4&7����"�Lf����Wb��!��L�x�}�
����8QԬ�b��jc��&���BA���z�^I6�%���}
�
dh+����@T�3[3���q�`�G7P�1B��T��G��`� �����M'�̒�Da>E(�ul%w4H�:�o�����	�ޘ�H[�I�����I�[�|���Wl��g�՛�R�
wDͱ������?���J�3����\ъ�p�}9<��|�@^x!w�M�E���\n��\ԣ~/^����;9.�N�U5'o�=6z�
���4آ�&[ƑT���G[n%V�{}NM��5%�#X�ꬱ��w��[*:9�|�m1�A��;1v����G�Ȋ�����ˊ�h�mu�1	�%�)&'�I���v����'�-��8�`J����}��B4 [OT)��I�	��FT�K��:o�>*�2Q=��f������C~+��S�8�8�b皢5�ر�h��m{؆�l�+��^���.�?�)r8!FSP@؀2�,A�]C�㓢����h�D_s�6]֨w{���n�=����s
��sR���?���u:9�3���I2H�<�Ӳ�p��<����Q�3��cg(��QT�Eu%�_8β�Xh�չ����O(�"���d,���<+}@=���o
��N����H��"y^C�!���.l�En�>b��y��ٹέS��9��و��υM��F�*���p�x[ނ����}b�~`2i=�J��:\��8�-�!�:���Z5�-?���t
����3͙j���d�,3v��7̙�w�3}귱ɐ�c4CJ��u������m(��|Pm�#����f�@��l6#�`0�'m�8]EV�3d�@t�%n�K֥�U!U%}vwQ�9�q�`{�z���[WX�q*)\v�OU�	�!�9].��Y��M�����)
A>����;�y���e���A���ì��ș	;��1֒��a+F��ʉ�Kz~�"HW��
�X��¦��l�m�53
mk�u�m��v���o��s�^Y1�����s��7�s�kC&��OF]�����R`�4�`��Or�(�D�䘬X%ߖZt��Q�i#uڢ�N�0HG����}����*h�LM�J�V���Zy<2z�$
�$,f��L��R+kE���M��M��Mf���n!rJL�$k =)F�����7�(�G�6o�e2�^%���#�Nz��Y��YS��1Y��P~5��u�lD
�Ql��H���H���I&"���!H'J������S�F�w���v�Ȑ�'�A�����%yy�\���q��׎ӃH	+������x›�"��k@�%����t�:��9�
'�0��
u��G�l�ac_>��ђS�j���t�a�|�
� �c9u$%G'&�d���7f:ȟ���
���`:�nj�� u2$B����5������(]/vV��ZB�Ьm�O�p}��r����~8�jNa6K�#�Yƨ�ފAXtr�������S�H�'Z�W����z��_���8�ђ������V�s�X���I��n�e?3`�oar!^8�W�
��i>
@v�]�W�Ց��\GG{E���zs�;����/����湳"�&q���7�-������#��t���ӓ�}���?���y����'�M�#��^|���Y��..9�M	�5B����Ή���xKsyys>�M�77�'��c'>6vZ����ħ��l�4~��Y76vZ��a痗����D���������_�{���$��?�/{|����
x)p�Ak�	�$���ڨk�V��I�La� ���a�H�?>6�[X�����%HHB 5ٞ����1)����{���R�qǤA��[I~�^
�F�BH�N�d�h42l���(�?��
+q���n �L�^�|I��t�g.�{qkŜV��eT���+bm����&U��7�.)#���^�&w��[���(�d4 ��iA
;ab2�ї#*��6�	�8�	~��dA4���05U,i��M��AL��X��H6����G�{)$2m� $�J"���BQ��A�P��S�p�h+9��ڞ�$�7p�T����!gl�=q�M��4�$�PU0���g���iz�4�&����vg��*����P��j��VV�jǴ�!x�Q�yK������#_�>{��0�%�I�:����
��$R��H�Ɨ�=ٳ�l��}��a�Ӊ<x���C�
,��1�<Ƨ�AQ���6�"$:�UUf��O�|�%��C��_q}�(��zk�6�5B�F��N�v 2�[�:p�̵��e;J�ܖ�F\�(���W~x�T_��y���=������Z�������;�(�H�?݋���_������F��X�upSl�;�`Y��C�W��j'B]��mJkX��J>,��&�h�F���p��
�i����!�^��O���g�<D�n�1��Z
LQsWa�Gs�;V��o8��0�?oä��m�܂L��[��ݺ�_|El�3��;aɖ+r��}���R#ѷeē��|����XQ���@�
���W[-�E�O|؃����W�8f��#��U�vw��\�n5'+���taYPV�"�H����@����%��MәMfb5۪�\Q���Pr�$�
����鋲E��i������j�����xxA�l1Y-j+O�+*�J
�O�6��•q���
���Ųq1�F�0M+۵��%f!��|�L���Mi��G���0�v�?"K��@��X��,��i�Tb,P��g	p��!�H�zL��<��X!�OH������0�4��av�6蜞{f�Co��s��-^�4����[uվ��nZ�����o�j�=���v*oX0r��
}>Wܼ d������}{ƌ��޾�E�f�_6kMKb��Sg��.�xj��̼ڲn�	�yN�+�i`.�K���T1y��s��@��

�2ȫL�~��~��:$��
�T<�9�����@�v�=�L#M�W�YT�3sE��q�
�^G����w;y���廪w6s�*Y��*R��M����*K5.).����F��h�����kh#�>�M�$�."��
�hq��X]���HS4EQs�����j*��Oi@8|��KA�1�Ij���S��sf����ڎxYٌ8�����s�bmw-���W��
�n�.L�+�:�/���x^�芣%n�y��꡹õ��b	R��D�͞�
����dp�l%�=�^������h��N���S�q�L�[�hb
�;l&��g��d�ʶ�{V���g����+j#ճ7��d/�L�k��8�h>�[�u����+)�m�
r׵��N�~�㞪��U]{��Y���Y=�|�yS�k>6��VTw�1��мd��Uͥ�G1E�����_	��ּ\�ɋT^y���������8s�8���S�P�*T�}8����(�������8����/g��b��3�+������b��Hi$�e|����!�m�!�li��c�ʆP�r[+�}uRM�>Rc��4�
��RTWFN��h��eb��O��|2A�d2@�z�O��rZ�x-E<kajsM<-k����q��ӣi.��˺�PYY�\V�9�[�9��\U*�"�p��Ƹ-��H2�{���3U,�b���F�nyypˌ�X�����Ozq�0��[�y��C���9����������x��ص+W]ն�q��S��i�˱�(���1޵��E1�kq���!t~{�0Ӵe}u��Uyf��YMɸ0#��&�h��g�'F2���9��d�����>�+���"�^x؊��"���I�F(#�0Fbz9�nɒ;M�\;#��)sY�g��K����iqQ0�!�JT�ef�\6���	g��2��d-�B�*C��7�T�g�i�%�h�I���&�JP!�
( ӂ%�nU]Q�ۋ��FcE��h��q���Q^�-�t:c���<����S��e$q�{��Ba}�H��� C܎��kŖg�o?�/��v}�^s�'�u/�_�j��}����$cZ[Z����.g4��al��2���u3�Ҿ83�>ƪ ��K�ã�Ԋ^$�d*=h�d �ɯ��$�
�]I��Dɤ�pXS�41�J���–�֋SWY�F�a^K$3{{.Y2�گ�-H&��Zsm������/���@�Q%dTj-@�bm�ZzD��Z��bf!����Ԁs�_&�h��FĆ�ڼ������q�ob�9�_*��[�A�������\�ZK}��x`�rTI<0+�l��'�'�ul��<%�o7a���8�x����
�m���ⷐ���\�'�
�Z� �d�Z�XkGq��e�5a�=h�>�0��������¥���T�����貹���:���k���R���>��ֆ?�t=<XI{�5�^$��i�c���
‡&������������/�\�|��E�_�;m��ٲ21[^��߅h�RCl�`����7�A��x>�<��#~,���W�)N�@%�ހ�,؉P��r�A��T��z�ƥV�e2�ҥ"�O�-�e|P/�rnq�
��t�N4��#�y������V��x��uA:�v�x"�V�
��epjW���gUPPui�9�xI�[� �����t���@B�$\u���ȗ=��:��=#t��)5m�\��VK/�~�æ�?���<�x�����k��4k����x�,����?�^`5�
�n<���KW�ގv|�i�ں�M�~�,��]���BԵb��=��|2��\���\�E������P�j<pug8��-s�= ��z SC���5&�K���.�?P�u�����&_ʼ.�?h���~�!�J����&_��	�M�1�FC�/�.WiiL�~���&s@��gC����SK0{�X����XH����,��Q�
y��i��H��tn��h�iz��U����3����M�34{���ФJ�%Qvd5��+�)�Ƌ���0yL�%�&��~������{L3Fe2LN���h�.�?��xP�u�&QS�0����KLpF265N�����_��{e<w����iv�fj�d;]M+���p�X\�/��=��.<w�9������'�����ܫ4�$ZQ�w�
�@?�J%�n\H
+p����c�ob�ֶІT
�Y�Y�9��JZ�s�AN�ve�*ȑ/{�<%��X��u��d<��b����	����V�����.��F"C�1�R�U��J�D6�����"�D��<�"$�:`;m���]k1�1�R�v���B���Xpfǜ��� Hi_^�˥t�<E�6%�N��)�Rw�!Վ�G�����k��n�*9��א��)���x����*n�:(���H����`3��ׄ��xhin:|`iم���Q"W���B�|o�$���#�G	[9Q2�[��ãg�.v���$F.�L�v"�$��"���4*+�$����Y^p�3�~����_��	2����_������x;���q�!�ŕ�Lo�� �J�i�!t�+�M�ߐW�.~!�):�ۭ2�,#���2.���"?ʰ��t(�!ċ��
�ø~n����pN��z��������=2
1��h��?ȟ�?�md�B�(h�����ۇ
,lG�)�j�Q�S�m��R\��|^��'
�0
a
�P�g�5�N~�7?��Ϝs��
F�bF7'���7��|V=ُ�}�����:�l:+ͦ#&���:;�F���5�Lx��Sޥ��ti;�o��+Ϳ���
����=%Ǘ�Ͳ�V��+��eX.�*���.�J�E5R��ڤ��qA�#"Hct�^'r:Ͱ�'�8��d6$��4�7R��ī5�(d<���I�hDF#o�fh6���\��\:��b������$�RW�)�uy|Y2(��`
��o�q��|~Q������K;����6�{�2�^�;��3�Nouy�@�dYͼ�f�%�u�^��
�Êd$q1v��lm��B�S^�/F�$�ѿ����z��ڇ4_�{��
TD�QY����W�W�W�󘐇�XX�֢"�Gا��!�q�z'$4+##�rȈ�`�ڱ�R��덄���2�)e��̽h��4)��(������y<�L
��ޒ�T,��G����`u���(/��R^�X��naDd�+�B��!=���)~l�`*���c��5=
��l���H��L~��	ȃ�4������zH���RMM����-\:"�[5����Pd��_6?�֟�vc[���t�Bt��#�n�g�͙~�5K�����-�3��3f9:W�s׏e	1��b���"�
�'^p���燧��Q�Џ�~�H��[�z�2Ӈ(�?`e��j:�aj��A�xm.�Sa���>�i/���~��>o����^��D�(��V���t�/�7�OB3x
�E
�A�?
�T��&i?�yFnn�:2tM{�5���s����<����\8�u��K[�����*����4����_J�b���-���B���5k44P �ؤT��J�R�
ґn$�]i态�+wT�S�����`�'���	����50Nu(�]J�S��F`&wp�

a�t��3��}��1e�,��T�L!V�(�e>�/M7ͬ!��!��m�~������W-]�� �Y)·���}�1R�|I��k�#�yk�ene]�~B��D�p�ѥ��Ա��O�_��~=����◀��x���tA�
��t�T��(Ujd�H�,�\�.�?PS�J�B����U�K�U
��x��NY)9
�B(�Br�*ꀏxq�A��bX\\�^/���n�Ⱥ�\[]{\�]��l|��.W]�$D�'�:R/��n�!%�I����������f���i4�JC9�q�J�yP�Z��'uȂϻawB.�y_m��o��?��E��c^�a�U�yy��]��K��%�]h��?z�@��}��7��s/nj+
�ax�e����Ư��+���{�����䦶bH~��o��n`v�P�Ŷ��{����o����ոC=͋f�g.��H�A�h�QUHqcWd�Q&��l���}E��Q�
;��h���5��2:��,j��m��N���wnsb��H�uE�����(��s����>WS�`���A/�bf�&�Y}�w���{��}���������c�>ؠW&�HT�*�^�S&�XI*�%!LS6��RxX8�����i�¼�pv�
uڳ����%�$�����5��^~���\.9�~S����*s6��!�͘
h_��F`��Ó*h�mD�SN�F=6|�]��S�vjM���\�;1�F�tMKGu�%X>�14��pf�չ��Yd��B��[GG�f�%#�%�|gf��=vM�t
|�\c#J��hiG�|����+����z�e�̇�@a�i�f#�It�|���3����ȟK!?��2]F�����u��ul˟�b�|��ȓ�}��k:9nM��/�϶�
r�}�٣ߐ�y��`�����٪�^J
���2}*��u�^�o
6�M���1�TC����3���ߋv���UV�j�}žȿ
SY�ڇ�����.QgRC����BEVm)K'(�g�K�J��RXJ
M���z�?.��hVP��8���C,?P�G������[,VDS��
������Oj�Lӗ=4�h/>��!O��1J�р�c�����,	�
�cD-��D���FD�QAV[��G�?��
�,èS�
�D-fC!�’Ҥ��}M�C��w���c��_y��Y��fnsCrżʮ��M]�u��F��ч��ѓ�^���KW?}���_����z}e�~��kvv���U�͵����
k�k���V�Tr��k�A�*���d����0di��Ng���HP*!@{T�PYd�T+w{RA+�(�B�`�zafɀ�z���0{��GK*Z��
fI'6��P*:b�dY�GOO~�I
S��<��*�Dc�A!�2��O_ϭׯ��o�;�e�����ڵ"���}��u�Yؙ�"�Lߺ��������X2W�\���V%zJ�kZ��R�[���.�z%v��D���9**�™Q(@�ZMF#Qw��^}� SpZ�?]:k�f�}�n�v���X�%hՉ"�]Sc�k�Z��i���L*b�%�}��}y$�ɦ|(�l���8^G��ґ
�2��N�q��3=�q��Q���VZ��:
Pw�^Dy/���ɯ݁���
{V�����[�=O�b1r�A`��Baٴ���MC��r���dž�6ǦU�7_�n�.5M�^b���~Cӗ�B%3*k����S�u��'wӏ~��{.�海m���M2����J��~)�&��AP^����C�ŞQA�
�hw8�V�\Gr�Q%W� W�*b��&{Fo�cGv:�c�9�+���|���7b���S���˪��M�Lv�!d4џ�C�-��SF��˸׈�Q ����(��xi�Y��'TN	���0c_�VU�7�����!�� %8��޻?��4 v_~��p|�2=1�B��_���8�r�7��U�v��F{�o��Q�&�x��jb.X���,�F�1Q�J��T�*Ɇ6N>�t�B6�������6���֧�-��ד����#���f��-���쬂�:4�o&�T�����**�ұؘ͸���.#�$������ǵ��A�<�1���m��ؠ���pJ$�9�����֝Q��fJqUIJ6�
"=�`j�(��`�d�,�1�2��?�䛇����?��b�i�ߒ۔{1�hn3�
;�4x��,t��
M��W�vL�����F���QV�uP}R��fh�7Vk^���\�<ݐ��N�P�5�0dϦ������
SUb��fK`��L�ȡO�-�s,KUm4ghvj?�N�I%-s��y "QaȘ(F@��ԴTvql�
�HCx�qA�=�ひ֗��2o5�>H�3��/b2!o�����
w~�D8`�mD��&�L�L@m4�lx����+/��[�WZ�bT,t���F���y����V�t�����0[,�1d�����C��a�F��q*'�&����|�/�X�v�C�w��P/��l#$�m6���kg	��>C�y2���s��K6�-��9	G�mu:p�=��ΑO�.,'b��P;���k�%�
�
Q�
�Vb���j{���M��4�I�r9��.,�h΃܏o�lN���Ig&{vο5�ln���r�E�`n:4=�*��;����.�����YPr�<�c��������<�}�Y��H�������0���|���v:(-�F��#���
�B��+JeH�6�Tj�9i��8q^���S�T 
�пD�3!�PaH�Ƨ�A�&�R�S�,&�xBψz�
}��s��}�|�9��;i�̳Nu��z`
l���m�$�ȣ�S�2�šaZJ
�0��z��l)��.�L�B�ff7��Ͻ�|<�7��Hq�^�S�O��N釾����
��,�?:�����8����r/�j���\;7
�IL���k�
���=EE�w��F2�C�@ �vƑ��	vXKF���`�P�d�cGLJz���&
Oj�x�܄��SB�C^2�����G|^���{�y��r^��j�*���$��cb��O�LEc�	�N�0	��&l��v���B̩J3!IKI8�9�Pk��Òi�$�&Vf�9ɩj�$3��$A��9������3N�~oWjѭ�b�f"P�/{��)�KzV���+BK/��<rp�y�W��G�-l��w�wD]I��Ŭ�}C�f�
#�4(� ���P)Uj�L��%r(�+Lr¯v�V۴Xe`�)���/|����l�ؕ
e2��V��˕D��A��*�R�g�hK��#�
���c,�j`fM��2�B��m�1��c��Cu�X�9j�C�{�h��zB���P�`�A��w{��n���mp�Q8sq���ʵl�oG���(���:
���.8W�L�A���.�j���kvzdW�\3
�D�9�q���9ŀMv��۵Ժt�<hT(�u�H�W��8
�Z^��Sh��5��ߊ[[qG<.V���A#:�Ej^�J�!t���"i�j�j!�*�J%
�>K�e�r��[,�[2@�^w��^��
�45!ÌP��f7EAb|S�`&HM�Y��A�
�`c�%6h�ؠ�ߵA��_IJ�h�;F
�
h��M+�m�MZ��2�$�LN�c��J!L����\�/��5���s���۸��������_Z�eݓ
�J�FS�uVC�����#�����7Gt��m��7��=f����#o-�
+���*J=!�y���L$?� O̾��B��5�� ��5��4XDl�!2Dr#֯u���RV;^s�)�#���!�)ۡ�[��h.��+�H_�YhŜ¬���z-�:5ƴjOS�����-�Q�B��>;�k�N��JNE����MS��Gx�W��O%�N��nU�j1�^�1rF��eTQ�dg�k�����j:,b %-%b'&X(y����(j	�4��T�e|&�|I�m�u�|Z�X�7�{,u~7w�񍫷-�t���/j�u^�7������;�_v^�&jز���o�]u�k����qY���:ؠ������iݫ�U���(zL�oD�+�5��[��^,��ë��^/(��:��i'�����dD�lHty� t�^ғ�+�QglC��1�����J[qm]�V\� �p�F���![9��+f#à|l0�H�4�&zb&��=ay�����Y��~{��2w�}N՞���'�,���8�c�h��&{י��E��W~	�Tx����������f�j��+��M"�Y,�P3��<q�:!�%BCX�5��.�)�r����T��dj!��
��
xa��|&��E�T�y�W���0�F�&���1�5�%�.�V��|�9�1T	MiH�,�	K)m���J�;�샕"L���c5|
��~�s/�
��XB��M����ھ������7��.wj�]7�鋧���8w]����f����=,nN��U����b�R	p
��v_�]��3�AP��b�Ĕ
r
o���M3AG��4*ʡ�/�R�Y*a��Oٯ�J%DAo�~���IR�2�s/[��l4�oB���
��Gc��>�Ιp@���WD�1��A�=�[
ʂ.86i�Zz�Q��S�u�'��b��l%[
��dTMK��F�,��l�'/%�d8?����DaZ�ב2�-�tiP*�lC���9ſ��vU��ν02%��Ax}��i�&w����s#|�H&���;��c��#c��������y�\'�W�e���i:C�'7;nq�)L�M�_��V�wpS�b���a�2���wr��4W{��X
̖���.�z.d�(UD�>)�{~�q,$1s�j�.��,N��+-��U�U��JhR�Єp�_�S
�̠�o-��9�x��Y+�%��*X�Vl�&ʥ�j
������5!g���Y[K���$:i�nA��b᪪�&D䁅�:L��X"{%c~��j3��S���/�NT���%=pC��nY��ZJ���Dׅa���o��{x����txѩ��=Ô������ǿ~a%����>�{�!7������3ܿ��(��t��Ap��`�n��լ
�D�/y���B��n�-	�ٍ��ZtI�1c�+�'\��HND䪄R9~>�Y��*�p�T9�:����)z��S�x��
���9iA�N�"���$���yK{K(=]���*E}��J��b'6h���ˑ�H�в	|7��x��.����D�����p���<��&f%�X��(�H�����3�xP�R�uZU]0&@M���zp�ѫ߼��G�|hʹĢP8{��S:vN_;����z�+;������������H]��w�~��}p�����_�C������4���c,v�sǀW4 8����4T<1��캀��>z�#84zLT��v�(M\����jE�CV+Bv����S$�Q�n�C?:bz'�9�9g����1��*Z�4<iF��;?�_9�p~E�/���G�O:S�����۴4�4}����6Qa�s~��
�/�э�G���G��rn3�]����s�_M�;��.�?�Q��*��O��I�e�ю<Hԙ�4�D@T��(M�Z� K��˭�$�[��X�����/�������ZIE�	b
�~������ϟ�#���0�]�潙|�w:_聅6rҜZ�,�Z�pmj��4� )�(a/lg�ϙ2�;?A��}�wC�{���3mu��v\v�zӢ�_�?ӽ��*c@�ɕAu۲M�W#����;��F^;���������Dž�(�݀�]�����^�V2�K�b��5��ºX��@��;���I�y-���W9�!����F[�7#<Ͼ\��~���B��|��WjVZ�������BT�T&���Ä�\�AWlR��0���z�SW�(�(��i'���`U(�rU��
?���K��,y�����X�Ti��C��f�xE�B��`$�d�l��}&���!cI�\u�{+���cσ�/-H�����@�s�_���>w�o`��K���~���r˽�y2��M�Or/���w`��:��B��9R��yW��4Ye;v�2��hG?�#c�T�řu���l��Դ�%�%U�S�6�7.]��zZ�/���P˪i!�DEq��V^]]lM�ԢFȨ�z=%��6��ebz[�`�e6����9F�f����A��y<��x��e}e�e����F�>������#uS����B�)�� ����h�i4�Wt�b��~�Q���0�w���g�ݙ���,�`]�5�{�<���_ٲ�����Y�Yt2�ꧏ=�����_�~:-����n��-�]�?[���yal�oy^��u�
*G
�'T���)ޝm�[�۰_x���Ӗ/�?�|j��W����!�7����������-
���ڛF]]���{��g�}�|g��d&��L�ɞ
��
¾C�QѤ�"`�֪��h��B-V��m_�R��ikm�h��j-*���{�3I@��{�?ʇ3�{��{�=w9��s�m��պ�u�I����F|���)_��y�T_{����J�"kh�%�4����iո���t�G�Z�lZ]�.�֖A=V�iu�V����'�e���\������D	�F�mll�ov����<��"~_���Yt�WY�$���U���+`���c�������d�k�h-|9��+�wN�,&c�$��8g]C'��7����}���zJsƖU��'�u�6G�$m�t���2�
=��r���)�w1rq�ɮs˯�5�&9�٘�*�F�Rfc����t�_~��]�!���e6�rW�3.��
Cƥy�̸<>��%�豹걲��j娞�<�WTVF��'�R�t(�cT�(��Q�	#�a���@�C&7��O�5[0^�JV���g�X4U^��������U�H��$ǃ�LiP�۾�䃷���&����s���ylT�U.�f�e#���$�_��3�o��M}ws��o�g��4�����w���-~i(����˷~���sw���H�+��L4� _�"_(x*��â�����rN����5��k"e��]��]�nZ�[eڥ�e�Ew���2��
�+s���:�����=u��S��(���ZmxXv�>�����
�����D�����6��<���h��vɭ�P*�O
{��M�j�峖��W&�ѝٺ�n��O�=�U�CM��z�ȿq.�.��Ӻ�����e_1eUޤ;�Ύ�4�*�qս�>z^~�݇6 �f�=Nt���?�^���0:��l2lb������hM��Y��>j��|���Y
ʉ���8î��x������>_"ִ���X�%
߾�����F��]3r�+o����%�XyC�ܻ,g��&����j���왟ʵ�d��'G/R���fC!��F���@c:T�|�_�p��sס�e���\%T�,/�,���_R���VuV�g��Uѡ��U4R�6��w�����Jv$�o�t�q=.�/aGQ*�K�l0I����tZ��I<c'�9񻳥�l)9Z�N5�얏�R��1�Lf������=�E��l�,lc��y�W�fn����~�6S�a��\FI�~�������N�N��C�C����ҧ�J�{�xH�y3�d�n��C1���Ā��Z���Л���Y�m'��of��IE^�%������"�;4�Qݬ�7���J�Na���ϗ	�H��[����L[�rEH�8��2e�Z��ڟgM�T��T�Wp4��L0�L��1�d5Q�e.��|_g&��ij��EY��a��a�Z�����
�@q��+������j�ޛ�q���?�y.���gn�pO�'��W]��3G+*��r�<<c����������NA�H����wݮ���"J�PcVnN�a����U^��+�ӄ�;8@9+Uk��YVv�\�7�aq�!m��bc�R��╬�F$��W�nj�a�{h�;-����+�vO�ЃfB�\�;�-�M�i�dK
���cu�;�K��/�/
��d6�h��S\X�"-I�TJ��Q������l���z}�|���8I��G�ɸT��
o(��n�re�+��f�D'h>v�`
΄�֢շ~�I�(��L��6`E�I�Pk4�]J���_%Kn�H��7?�3��k/Y�_~~F�}=�p|v'yo�t��QïV��>�X����7�dU~}�b�$4z,�ߟ��Dq�Y
௑��v�"n�L��}���赺��U������J^��G���9}}��͟?W�Vk%��/�V��*_��9C�t�`��\R����\0`^�`@�ӫ���}s.�=k@Y�]s��h�ėƻ��*n^j�&��7������45�7TO�Ï�S'M���`��_ʂKYpi�ߟ���n~��U�tV���F�G�x`���s��̞u��������"�J%���ҥ��:	i�l�����%�a�i	�$&��+��	�x�ia�+nܳ�*a&��S#Q}�`o�%�Uc��x
[�-,�xF���g��6���h��le;�����aڹ	�|�����������c��-����{�Or_���o��Н�Fa�N�3sf����'���ô���R{��DE�v���kc��Z�������jҎ�7l�}]}�K�ښ]���
�#���W��B���bS$�뛷LܩP��Y��;�,-#;�]8w�,���8�-J����<�3|�G�-!'����䖊��p1X>+�)��%���<��ʾ[�O�� Y�^�_o����������ޯ�[�U��>��%�B���e��]}�dW_(�"l�X/G��EP�o,�)��2sY��/+S���;J�V϶Ԉ���j5��K=G��0w�;�I8�03DBl�I��խ�ѵ'�Q��d��w��@6�x�!a�5�zC�@
	f�t
we`�dF�[���[�`{BOS���l��������m�ܘOCz����|��)�|x6���k�=������]z:�����g�n��{�������}���%&����r����}�7T�����黓���l��C&�)���6�1���3�H:͝����	�������D�Q��L�\��36�8�3��I~����N�D�F<ee^���IΖ�$E���~W����q}L�	������iaX�8�9k"g����9�5%MC&ބbN<Z^n�{g�(q_l�!�(��@}�Y���Z�B�(�p��o_v��@��)�w7���(�}�c�Vb��l�qx��;$��t�Y���yե_�k��+��3�;�
�$��ck�5�kb��}ʴ�|_L�Y��_>?&a��|wL�(��Wy4&93��d:4��dꝌ`���,�̫�2&�~�`	��YƘ�Df԰���yn���"c��Ĺ���466Ъd���z�Z^����Qr4z&z.�{���P��"c&�f�1��Rsߤ1ƌ~ƌ-����l����əg�T�|v�Ҡ���_���	�G���K��-��^��k����ղS��D�nwrgzoZ:5Ijk���=�I�L��=���,���Ij��t���?x���%�|M�$��[`I�ʣ�H�]+*�Q6�F����P��BK�
����lA9��<�.�'~�GO��e�}�C�]D#��t�S�C��f>����枳��.��!���p䪲��ܳ��&�g���f3�����+��;�ڰ��γ��0��s�}㜵�Ɋ����)�ܸ��V�?����<
-$dHn}�l�x������]S6���)��\��O�x���;ҩx{�uٞR�]I\[�k���2b�\���Y�1�!S!�)u���a�
'�L�y�ȸeLsXX���l�OU���U�G�EW���'�n�����	��s�UNj~�L�e�z����T�}�\�~9��ߗ��F���_��烤�w�����'�����'���R���KM�*�r�R)�M�\*'V]J�Ni5���)��KK�E]��kU:
�ά�ܫ���A�n�������*���0]�ܫ��&�P�Uȳ���e��_u����Y�2�'�0���j��Ea�ͶV�~��/t���|G�+�Uّ�&�0����`p}x}�`����I�)eԧ���H��벪Y�T�av �.���K���R��#
��M&/烦����ʭѨۧ��`6//W,
1���L8)��������:�g���T�LX%)�
ګ8����V��J�X.^P�e��[�3���B�G"��E)����n�
FG$0d.�`�� \Ig��b�`�������ťp�7��V�d����zi�[���M$��d�<ڵ�[�ˋ���6�5~�����ض���8����|"D�җ��~ޜZ�[/�՗O�~����n��wx����|mωC�v��*�'���(�xv�7Fv����3�s1�P�h�Fb8}��>H��2D5�8f�0)��gX�J�>�^�c� ����A��ך����/a\Tu_ya�/j�Rc�q5nUMT�WW}\$=�/}������yc�u1w���;&�r}��u�,�{I0��[P\:r+�r3�!�UuVŝʎ��5��(�v;��n���<����/n>�~����v��dءe{�e��5�d���#�
s�;�d2��ɤ�e�5U8�&�"�E�"G#|��zb�H�X�T�����*��8k'I;;����8����J�	��a��������o$��N�V�v�5v#�px�?P:w�3���;g���¥#�>rϛI��؄ES�'���&�٩Q��K���C!��n'�,���[�|�0ܳ��7mndm����@}6����GRG������zR�4�k�5KKӣڣ::�N�!퐎��9M�Z���R�4崜�z[ə�s�Tߚm=��{[�ZiC+6`�������~���`N5����?�q��
4x\�����n@�TP�P�4�׹�]���m=�".W��:����M����h�fP��o�'���l%�V��<W��+�V�l�P%�V&+i%6�V�ɯ���)����>~
=��H���������w��ϛ��5�,d,��t�+���͓6QŲ�.�J+��+Ȼ�k�CD��+3˩���fdW^���|�K
�zn������ ?p�L���Wo*7�w�{�A-�Zr�k�Ϲ�ϓ�5�ײY��z��*�����z��*�W�5�X�X=�>�����*:���D2QE�j��꒺*ʩ9
���3m��5�ٶ�m��m��ֵ!�Yp�����x\�w��$��gr�~�Rz�I�»
Q�mni�ZR��MMu��3��9����m=����d��*�G��v�%�ށɜ"S�����8��ي�׳g�yu�ƓqG���
~9�����2���t�?�zA�7���g�����췡j��������������W�`m�v
�4��fW��'����/�����W~��&�&��'�~�.�{�%LY*�>4���כ�٬�,.7�{��@��P���ŔJ�I��mE��r/LTY����q��˯�j�Q�q�9
�]RMb�a
�A<�X_����㊾&���y�����;G�th��~WT��=��s�kS����;�Ԉjt��1��Ļp5�3�K%:�dc�ϡ�l 7s?��.�$oyȫ�@���yϫ�bnvm�l��.��u5�h�+��p�]϶��
���1�W~���Ob�ڝ�:����5BuC�t
�&
��1���-�=�����M
�ǵ����&벚+�{ӿ�]�;��\��0Q�(�ܿp�E��+!N�c����Vaۻ�lkB����*=x\vwX�6{�'��D����v/�\�ֱ��5��/0��sY��0�ꮁORu�����u��V���IF���lZ)��S����Y;g�XV��A�֤5k�Z�L���`���.���E��+��~<{���������Z�+l������Vz]��K����˯�X�X��ׅV�����dܻ&�C�)|�R�򔹂	�PQUQ��|����
B,r���M��u�M��x��]YC�_�eJ��1'
̋���U*^�z!vy��+����9�0�)��i<�I����*�Ħ%��ȁ�-��~?��G��g����������V|���Z&C�����^�-<N�����r���}���T�����q4-�Ffs5ҹ�زJ��'	�kC5�wm�y�6ܱ��?��Zz�+�ʸ7�3�v�;��)%k�T;	�8�����6_Od����5F(G�������������&w�9x�B�S�l�rx:��O��z���3zi�O�J4��&�K��!)9#%C����R>+�)d~ż���kd�y�k%��Y��/��%ޒ�%��%�X��Z2%�K�G���3ш�;z`�����_U�E��W0�5�F���Ik�\ˇ�c~^�]ۈ�w�����my�{��o�[�ڶ��,Z1��5��D_��'�=�Y��1����j}��%�С?�y�ѿ^|�ߟ'j���\�?�Y��ĕ]�-�)�G�gCH�a�՘�M4h�����
}���~�����:y��6��L�&�Yi�9.jsĢoH�E�zX_��R�ʠ�q�U���v��
���e}Yz��My/=G��f��|%><y����|����N�+���O�������HRuNE�rYi0Ws�3�p���3�hG8���)Tԡ[+C��<��]KS��
UT�u��ZT�����Ԣ�y�?�
N:�*|�tz�G?{2�ԟ�Tt����Ҝ5��ݞ}թ�]���&��aOh�f�Ɔ�'��%Y�3oƥ�~ͬE�(vc���}!�o亹!�餜�	e��+�հ���8�L��q��ӛ	a&H�fC�)N���'��x/��z�0a8l�
�"��5=c���c�N�ƨ`�QA�ˣ��;+^�Gl�}���=o
����<cMt�j��Y3���}��y��uQH^���K3vƽ�<�_�R���\v��l��f��io1�Y���D��X�V�/d4��B�p2�YQ*�#�[�N���TrKDF��'pn��d��칋��Q��������O.ӄ� �<,W�U:��C�>׷���^ʢ���9�v��	����â�}����N8�8�)VP����Z�l��
�-p�bf�_�e5����W���ƚ�͢w����U8��%]�~kӞ��Ь�����GɜE���®�M��C���of]���YH�����RW&gydz��1w�����0�v���c��7��,�-QH���^I�Y�1��oߟ�?���T?�o��B'��v������m]]]�|�m�b��W���m�~�+��;i��p��"��;������+g�"�#�1��H���iӧw�4��Cxj �T��JEgw7��;8��<cF��P�����bͽ�����P_U�4
]�$����n�ƸI�I����No&�z�1��38�R9�S1�
�%�\�����-i���3z�;�;��

nwrvdv���$ؖyRrX���s~��an�Q�hc�S�&엋�Y����x�<V�PMKLg��Dž��������q
�ˮ�b��-���\"p�B�6����'=������:�U>���.U���,)��u�����:�VG����ɱ�ù�ut6�M5�:��S�(��H�Z^�0�f
�����
��5�͕e�
��-8k�����vv���p:6�qNHy�
g�e�!i��O�J�&E���p<��]�w}j�2VM��s׽m��p�Q�t�)��ۥ!2m�p�Ps	������c�c�J�R��u��T�@�zL$��
�V�W���0Z�V�=���eA��L!��K����Vw/���t�����a�X����؀{��̝��]X::�������ݰ�f��S�w5��zS��
s���c����������`����+�Qq#�w�ɖ�v���@qN
�]c1��h5�/i���o��7}}��kw�ِ�_�q`��
t�����V~���ٵ_�]�޺�'�OuOZ�g�[	�
'���/[���W��`���؟��J����^���`b$!���}����	f�
�]l7���\���,"#����T-�S�6[Z��D��<��V���Z��������?d=b=n=m�X�g�����>v7K��n�dO�xKtY1�GF|�}G}�|�
�x_�e�h�Șs��{�.ߪ�H� =�벶@ET(����.\uT0t�Q��N���B���4%����ef1�G�B&�~��Ӡ�	�օi}['�zS��Zf!��gi�d�)�N6׶Ϯ�m��\�Z9�<	��I���ɲy��p�r,Wӗ%�Ф-��>e�1�Wz
gᦐ;���Jr�to�+����R�UyO�s����Q�,K������u�lli�dTi��Z�u�^�JM����
vszc��<���ԝ��a#6+���HYY*�V��\--�2[��_���ƱEıE����&���8???�ŏď�O�%����[D%���`��"2��o2�u��H��>3��3��
�/���z��"�D��n&*������ġ�`���RWo���޷�����������y��o��p@���j4�����`k���Y(��������I�@lOG��cM�;��ݗ6}�V����.ZȲlV&����k���z�E��k%^��	Gk$ ⺔5�,�6�qRk����$mḦ�&���� O�<O��^?���ʎ�(Sl���x�?���o�H��>M$�Q�C����T58���!TW#��I>N��Iܣ4+�GS��[ .�`ĻY��{������3	s&BMc.p�}0Zƭ�
�@���$��0��c�@R0�����9*8������+��6�
	g��Oc��0�[&4�	��`��rn�p��E�o7��G�j��ij�Vl
�ώxm������Tm�2j��[+���ӵ�����S����}�큝'h�к�Duy�J��]XWv��n��Q�����b��jt�N*d��jA`W�g# ���:J����$~�J���ƣ���1�v=�!s���r�PT#�Q:�JZl�Y樨�q+k9e�	�6a��&�R�������E;b$^�9t7v����@�T�0{���R��[� Vd�I\#ɢ���'E�;X\0����e���b��}|�|�����ӑm�#Q_@��+�)_�w��tO��W�ݷ.X����M^��_�:.#�go���j��u��Lp��b�D,�TK�YVn!.K��
�9��2s�%���������.���[.)�Z,A���A�&�Yo����v5ԡ9�3�5�v8�Y�O	as<ǎk���lM�S�e}:-s���6�JEg?���n[��L$&����'����`�5�R!���
ҫ8�8��u�#��
^q��Ț9�զ78e}� ;�oKf�>��-H�
�_g5L��1i����N�YY��y�M2G���1֓��v60Ӈ
�20�����x/,�r�Nк�҂�/�ĉ�n�
/����vh2�8U(`��ʼn��Jwg8v&�\e����:=LR���؜k�U��~ �]sCs�+b���6�_lEK2�l���QJs����b/�(�Uov���`z$�.�p:c�
�^�J!��am��R��ղ�^mЎ��݊�Ĵ����a;M�[�v~�~�~�������K��*W؅ &�b��s�U�{�Uyq�������Щ���C�!>t��	�w��w���������Ө g3�!P��{�B�;`�
f�����ۯ�
��+*x'N�"���f�H;�)r�ј�p�Ly��ެk�,νH���'=3�&������[����Ӽ:?>��o�q��d��
�FB<	�G.W�LF���9�g�rG0�< �����4h
������(p$p<p: 	�P9�%B��"��x�ą��dD}X}T}J-��z���WO�,?ά���"��vV�~`��;�
�)jd�#*�
��	L)��p���L��ێ�v
��q9��]PZMi�v���\7�=���h��
����
5�>�ځ��Oʩ�����0#��#��H���[��ږj�ʴʒ���#�ʹB
�h����p��4%�N����%<[|R��L�t: �`�]hA\�T����r��M���L�7�q���`��Pe?JX�EL���
u]缙��9�`f�\h���.��r�޴*cdF
;�K���]���f�M�rݒ_J�P͵��삛UJx��I���&�,�84�5�
^�s���Ht�G\�s�3�����nFIIj����5m����ڠ=.i�*��#�����@�#������.4���5���)ldz~E~Ca
���S��g$�جVSH�*ȐbDAC
�W�dƐ	����J�)��}ZТ*R��{���(X�QPT.�Ei�IL��|��w�����1���z�[��`���8L=A�\`LYJOpK0�S���?D%�i�/R��^϶�I��?����.�ak̙V4������k�y�|��u���,�1��湑���ꑺ���8'w���~7?����-�������'�o��H�a�Ýg��O���Or�v�64�?`;Y(�ayZ�9���^�V�HB���B������3�*�yb8��p8���q8��Z�A�g��pD8.�f*a��ĆÙ�m?�+n?�[�~(g*2�:�:�:���+�U��۔N�f�q�m��b`+ڏ�"X��B�Q!��A?Ȇ6�#����I�������t��ag��������9Ϝ�8A����ov�l��h��?@F�d\��T�B޼�d
�/Oo\Y��1Q����&�h/&'"��=�{4&CMI�p�ZC42Q�kwb7����N��X��Gq��Q섞⚋Yc�L9�!�<�7LyX�����R\��m�hr&�6����56�0{Ȼ�^V�
qfa��^DKY�@<��M�-��f�,-p�Y}���D�,`��U�;�ڿ̩�ːcP��֍��U�(��e�z*'��΋�L����#��V��z��xt��I�x,f�YC�������i4j��{�_��8�/Ά#e�e�!�xV�eA�K�ؔlR��&�$M���FV��*�p�$�X�I�MH�$N%����[�HM��©�7e�g��XBf� 2��q�?����&�i�H0n5]v�lt�8��dT�a
)h�
��~#���c�-���&��+�
>}����X�YG-���y�ҏ>LϮ+���
�2
����z��݃F|��ՆP2.)ȗu���uQ!&�����Eא7�b�ܛ�F9���	Ӄ�C�Gۏ�KZX�ji�Z�YX�D�m��p��t�]�SR��e��--
�1���!�Cag�F��������A��_
QyR1��
dz���%#g+$G*NUPO�K**��
�^p���.g����PN����+G����cH�Y#�	���q�n��Q!��#P�����P��FUw@��������`Á��������'�/M��~���L#��G�?���Ĕ�j���K.j���›>��K«>~�p�������+B~?�w��t:���`r�
��
r�(+�`��ۉ=��V����і�<��Ŭ� �{����@PW���`�iq"�A���qf47K�L~b͸�7��=f�g�'�o��1K̅�������"�L�@�u�
�Ѧ�����M
���L��/n��&
�n�ި0%�C����i�ʨo��]�_�Ϊ۽�UA^�T�ظ{����\���D�u��d�=��F����={��ɩ0��p>�Փ�l�ߝK���߬�_�}���Z~o��ڧ��z�#��D=�TH�h��V�
��<*�+�
�EA���N�{ց�h?d:b:f�{M������5�'����bZ-7�?���α�}v{}}2�D�$����(r�?��6030��ń��c�����-����b�e+��D}�8���*X�h�2��
Q���
�lA���BT\���~|Ne]�d�W�[��D���r~%y���b��5=#�fF�J��ɓ�NQ�9��R��YqC��(�)v�.�9g��,K�XZg���v�6.��B;F�Ю��)��k��>�W����E	}Cr��M�Ax����[�Ox��o
GB�Anw�`i�2d�"ݢ��
�����''��|v�]V��Y�R%��1��<ɖ�O}��y5�]�]f�2ƛ���V�@ܚ*Ay�8��k�,��K.��d�<����12���7�Y�)9�U������+���g�߇!��*��'p����
�!v>�o]����-])�
��U}�U|M���#�;̣�QQ
�DB�z$��6E�l=�]/~������.�RoO�Y��"�hoP�Vnq�N���sEV��r���O;��j)v>��
�x��tX�L�ߟȵ���K}!+^b!���Nٵc�)�?
����e�A�\փ�I�k�>��#���������(;�ڱ���͵���&�'ۓ�7�����_�����ܵl�ȧ�%����1�DZ��#���������������Ĵ��?����������3����,ʘ=��<[��<`���שu����c�c���s���H����j0��X�$q=>���[}
��c�2��Ge�9��E�g��fu�#4[x�ڋA��}P*cm*Ę ��X2L���!�=-���1�S2
��/��w�:�)�i7��o���E������c�q� ��p>��%�-�-R�5�L(�˘l13/�J���r9m�U�p	��8�-[������N�gLh�a_��#-�F}sSQE��ܯϧ"5/�q�OVG+W�P��9�_�0眗	2��'�䖅\=�r������h���퀤u4�쀘�:��?�S��`���X�Ǹ��������Hɂ�XlK
�h�u�k�!����a[X��Um���LU��:J\�hIL;Tq��X�]�ݭ�u���<�K,ֲġ(9=�G�ǢOEyOtst8z(*�FceѨZ��.�^=?����e�1���*�q��\�t�4j��P��e�G�z0�K����qY�
=���H���O��%�Cz��Ǭ�Z������a�T��Y܆�VO�g�s�#9�!l1z��{�<��9������dH�̈́�Rl}��`��������T8|s���K8�֮j�	������l��uD�놉��3`�7�5��c�0
J��t�N2�ܛ[�z];�9�L�;k�zA.�0��/D�����z%s�ݚ��5��K���n��^ܟ��L�6R]����8#�l������s)]�J���[�'괣�I�?Q�e����o��~�Z���2�Ϋc����j����5��̒}�v�f���%�^oRȕ�J�0y]�y���W��C�
�JJ%އ�]‘Ann���a�0b�
�\�R��r����Z��k�#h3�E������=�,L=�ni}�:�yN+�NNʤEv��o�Έ��6�yC/��%�޳x�>���ܷ�[����Gs����-�0ݵ����O���#_6�@B/���
&�����%�9�Et�r�A�=
�ۮ������q�9v�����ޣ���S�s^��Z����~��7�6��/�u�C�C��t��V�ߑ�	�{9WM�f������o��'ެ�_�z)�J�7����o4����W��T�\���W.s�qGM�f�!�i�sy\	W�K�vv/�׭�}��%%��^ƛ#f2l&��y3=d>Ž���y��{Y7��US�c��2Yuu�XT
�� �$)�kQ�7d8j�G
��0?%#�ر{A�-�ĉ
��@�J�����&��9A�“��n��-
a�&���¶p��}��+��$�+*�-��?�9�.���
�,����*��tj>}$�^�'����˞FA��nr;��e�t�<����?�G×�E6�k���j�����x����7�3\4I�0�������W��������g�^���Җ�f�.��\�Ʉ��n d���D��(E}c�1�V6��1��y�I--5�F*-�A��]��R���:t�Et�^�[�Ts��-�����j��IϨ�b�
24[F�-;^v�L•�ˆ����zY��׉鯔�?���)ilO�:*$���Q��;�
��YC�,*EQmoqS��1�>�븏-��\�kh)f����o8fwN�
�^�FO�k�����r֩O�3���\Z��_��i��np�����G�,�s�æ��gn�tO�Z��������\��
�w�6���d�)v��]��k���L��F�����c�S��S�3�BFff3C,(�!.E�#��D�t�l�IK>��=����䡤$�L%�ɲhyyu:TV�s���II�K[��q�\t㧪��QF���VKQ�G�(c�%�P�Jn}�8XI�+�N9�<�<��(O�d��T)��J�
B�H�~�l�A���/��g��Ca�H�p�.��
�	Kƒ�l����_>��G'�ʼn�ؐ�6�O���4���C�?�}��F>݁Ҩ�+����)�f�6�Tn�ZK�Ln�9J	���ا>�&��0ݰ�M�c�4\vp���ش@o8�Y���7O�����ɜk���t��6�6�L�5���a�V�%y@2)wlW��=便�>
fzI��m�ɕ���P�m��iyLʽ��ځ�������V�4>���`�ɀ�;�h��D��Ξ*�ޗ���H�RU�����e�>�&��
#-|�����湖H���W�����^�,G`�h7J|�t�>R�`D����&�d
ʬ��u���B7[�-�x�h}�k����Z[��8s�s�Z�<��3�\,��������|ۣ��?��l%�O��I������
��@�ck��ڗ�y��mM�'��'��e��,� ���������^hp{��P0h�Ye��v���b(5���T���LB\w�'*�d��Y��y��No3�^!-���p�0��Tl�xQ���V���rn���P��meq���1{Et-:!�"ڬl���"�N�Y�6�
"z#��”W��2$��2aRZ��=�/�x�W�!ߴ�{�>o^D��5�ܭ�ߚQ7{�/U��n��{|Ҳ+�sw���R��d�6��θ����Uf���Go�O�eLC�4�f�f??R#�|K�֫m�E�d7s:�I�UUv$�!*�!�j󘼰!��M
G+A���?�${ņ����������-c�;���M�V�y7���'�k�!�\�	��nxv|DZ�����ɟ�+^�gWn���廎����
ʡn|���@�3�C6��r�dS�MD��}0Gr<�)��G=���l:��W�Lp�)n/����<�_Ꮙ9L�;r�Eo��6����K��8}ۖ�g��%-���-���lf2�*�Ifcw=g�;��H6�)�mQSt��)z����!�5G5���5�^3Qhaӊ�}���!-��a;��ȸr�*]�WŲe��/���ڶ�53�|ms�������B!�oXM�XVk'���P�I�y�)�VN�������X��DFvg�cJ]5O�DS"�ġ;'�kU��b�|�<��'�����I�,���q�ܟ��vr'�����6I���
��[��c����J*]�-�D������}j��lQ�B.�ϥ��S�e2��Z��c��T{gg���GR$�ʲ!����u��ё:RW�Wz�E2��M�bgB��#$�яʊ
�-Z���-k�6��i)э����ˆ7�o�qj�*�1o�UD4�a�4�Fet��T<t��&bB���w�������n'xm��q�XSMي���Eϧ�N��X��,aO���k?=}vos�,Ug	9K�fI?���n�ԓ�\�k}��Ź{���oH�]�L���on�VU���L��R2{t����3-�q	+��'��$�[q��n}�ۮ=�8�����Jȥ�������b��d�᎐L��A�A�opw�׹��<�������*�έT�a�n�Q��nzܼ���Su!�*�5����G���^�8xEv5���[	4%^�y�-�\.}0���!z4#�`h(4���s���1iI�S�s�wTtD�n���!%*��1)����L���7���%z`�(��@���8����̫-sq����1������n���_�ɥE�VS���%�����B����h�M�4}?�����oK��������Y�"A���{��ݑ;��pk�?oX��{��}.w|Ym��k��v��?P�V�.���k���b҉l탒�'%'��I����%5��/�q���v;�9�	wsw;r={��D�Y׳1=��N�R� �`4�/�ެ��A.�_�A/L���a7;v�#�����]��?~L�K'D����
A�]*�ʂ�.F@��Y�� �.F�g�]�3��jӣR�!�N���{�;���#���7se|3燿f.�G85�Ǚᯇe�T�z��Oˠ*!M��y���O��L6����2�m���9
���_xａ�7�x�K\�t�Q�v��\P|����������<�������j�TN269;�e�G�<®.�D2x!�U>~�;杇�^}����}�^vG��U���Q}����s_����//{���`�m7}��Oߞ9����P����ۍ�����v�tם����/�К�3r�_��8�b���<ӈe��#6 6�Op<y�=%?dH9D�C�,��93`���iRs��.6�
6����k ��1��t'��'
��@��a�7�Ӏ��+	x��Kc�4��4 !�޽�Ҭ�w
6!.����[�� ��Km����{
���t
�0f[~`b'��I�YH�!=��H/@z`=~���Am���9�n�b=|�aC� ���>�i��������!=��<m�4 �m�z�m��n��H�ac�A) M�Ӡ�
�gF�!=q�܄5ل���m�|6A�m�b�ۀM�&�i��&H�ѳ1��3�»�.�m����<P���
����i<������

��^��"�!}�;
5���\H�1n����5�34_|�� � ��
������������))���
�?�i�s?�0�%�c4u�O���?̿Hb�#���p/�0�O��
P����?gH%���P�{P�h�o��
�=L�=��{����[���iv��6�
(��Ie~.`2�La���q���;�h�:�EՈ:�/��6D�3��у1�^�����X��P�r�x�x�x�x�x�x�x�x��!��!�P�B �ɀZ�<��
0�X�?
X��DL1�w�)���C��vD
1�X�?Aa1��r,��c�d>D�@�' �JX�B�S	�y@(/ �<�Ak�B���T1;��T�_�
�O
a�
�C���3��������cX��X��@L"��M^�/�0?�*�[
@	{��P�bR=��n��vX��i�	 ��b�G�V�1
P�~@�=��<�9wCY��@�
�B�-0�!�
�R%k���k��:��@@#�%_hCځ��у��퐪���XXy�
�1��b_ah�Z*�B,C,T#��_-�]���B���i�tZ,�K���i�tZ,�K���i�tZ,�K��ri�\Z,�˥�ri�\Z,���o���]�J�$bU~`�ѐ>CC�8�i�v��[���tc��e��3���	_�`e��I���
,�e�Cax��@� MP�.���?:�v�_
���bP`=�1��b�z1�Q@� �����
+��)��.C�1�X�XX
��u@��a����Wp�L�hv/�F��F�i���TB�{0|�tH�f���b�����w.Ɛ�H�Cz=��
qc�Q�@�!~mF��4�6ĩ��
v#�`�=��8�̄t`c���p�W`�
@7B�À,�FL��g4K��\8�Yj��ڝ����
s�����wY6a6a6�}��P?M4˥
���!�&(�Ӎ�|�ǐ���&�"Y�_
�CV`�J�W!�Ɣײ�B�X�v�w 7���V3~��N��s�^�� �-��
�9iE.�b�Z!o{��B��8;�`?�/��[!�w�F��y���VH-i>8
�g�V��8�!�;S�[S�[S �/��[S >{:�6���֣��H���O��4��%�Bw��6H�����r� ����%���vg�C��!Hg*p�^�fD�N�B)�
9�
9�
p:�3`��
�dq��7@�]�*8@��.X�2|j����l��l��܅�߅m��NE����^��7�3�
���[��Rta)��NL7�wc)���؏�!��
g��ߍy�n���nl�t�z߀q���	�=�{�\��{���@{�[=�a�6�Y�
�2��M�[N�pg1�,Ő�+0|%ҫ�6z���q���	q+�lGz~}Ҭ����Ѐ��
�A�5� �À���蕻���i��_l�=
Ǻi��5�s1|>�/`�B)���Fr�\�W
.��Aĥ��0��H���V"�
q5��Az-�:Lg��4�C� nE܅�ޚ�c�ta�c����g:��
���1x����8��g`�
����d�q +���0��E�B��t�)φ�`�Ά�n�}H�Al���3�B�}��o
�#�>އ}��
p��>ț�}�Ҽ�΅t��~7��\Hgp*��9���\�;��d#�<�ɣ��g̓���8ߝ�u2����10d	>e)���p
��m�C=�
8�X��`�[\f�
ĕ0*.�x
p���6|�p!�`qDZ��,�t�\��B��BH�7��a�Zm�=]�17��㰔b�!���"����R���p�y7�J����s2c�����N��~D6v-Ƨ�a��8,�1d>e��,������_y~P��
�B��.Ad1!?�
���
B�/
n���[��5�z�t9���@j�Q~X�#�r�k��ȿG���k�1dd��8����ƮՐ��\�4��j��Ր�WYyWcj������,��du!��s-��Z,�ZLa-��;��Ho@d5�kx��:c����᜻c�ú]�u�k`~k=�t��!������z��zl{�o��k1d�a__�-d��p��#!�|�
[�����0�b�� ���x��
��
X��-mĖ�s�[�Fx��P�9@��M��&H�Q@��M��M�Y|ل�|��&�7A
�nC�qs3�z��;��
��~���wB^\	��N��N���,� �݀��0���D��k�0�.�����Xc7c���䠷@H
�
�
)�uȐ�&��l�( �&�M�<����C�Q�(�/�ȴܾ�s��]Z2!��sr�h�����O.W�\�i�Vr{�{Z���^�t���F��@N'�r���\v�@�S�x��L�#�4��hп-�rn�������YZ��
��~M~�@�p�����*U�ZC��]��\@�9!�Y>h6!-Z��i�@Z��w!�@�
���:i��EZ�s��\�%�u.�b���X�"-ֹH+�N�*�*i�����3㫹E����>j��@k�GҪ	�-aeq�eTO�2�q/�zV�X^�F�	���[0�#m���w_Fڅq�2�'��L���=����HW �g�bB�����.��!�˥�$�W�n
����m�6���ܵ��L�_[�f���b�Jv4�
��r� l5���ۆ�V¿+!�N�s<߈�^n��cm��������
)-�w&A���	�dix�
�ݿJa.��Vș���o&�*x6�����;�:E/<eO����Xn��������[��3��&LQ|�~��_����l���/�ˬ���^S����k<e�Z��+�RkW���s:g�jØ�0���w/�q�Z�O+�r�	8��˽k�����{!�Ӱ�V`����*��KC�c�&��*|�=ۆu����Y9Ɓb]��
P��2��r����n���\��uqe�-��m���/�������Lv�}�
;$�g��"$!����MY:3��6=�CwO�D	�

O1�QYd�!�EEDAdS� ((|U�5�����������dnwUu�nݭ��)��ЯD��i�f��X8�x��eD#
��~�ɓ�^�A�V��{�s�-M�����y�<�@,�)�Z��J���N�,q����+��ҟW�t�~�D}D
��%l��2�g�2p���������'}h�F��FR��G��6]��=��tN<���S<]��
G������g+�H�wty8�B߅Ģ=�Ո.)'���`)d�R2�G��S��;�̺��$F�U��Cl8st���6?�A+�[��ye)��U����<�����V��Y��
���7�M�$6Gt�5��TA)��y�GP�AB	�#{xo���K���:�SP���
�EE���D�̓>�Ez�Ȋ*˳��;��r�_rƊ^VC}�^Q�l��kh&���"+��z�!���"
jb5kA�'��P�&WDU�Ƴ�D����+N����T�%ύR/|�$���B�!����j,��	���/x8��_}U��
�׉X�
%���	J<[�Jܢ�͊[«�SPE�	�e�5֍ZT�*��#�2�@p�����/�DV$��zdĀ�w8U-�K�5֡dm*�
3������:�D��T�DPփ����@�B{Đ�"Ⴒ�e�k5��FyѤ^|��~���J5����Z�����|��YE"*��b�[�W��Ђ���ë�3�.,�I�U$dO������)�HdN�i����v�W�C�'h~�;D⽚�,��EvV�ʒ�U�2�S��Wx�,�M*[���;y�Q�Y^�P�$	�T\b�(�Z61������uɲ�E��ʞ2��p�) 
�U�@
d��(b��O�����" ��ЍL��:e�__"�K�L�9E�'�ez��XP4�5ѭi��]����$�������tyP6j|��f�H��e�BU.�J�ec�j)�%?q�E�
�pd��s����c�O��e܂D���L��2ZV�� %x���$�E�y�"X���٣����h��2�E�����j(�悭s��}x;ۡi�c�P$/�_�rbG"R�H�)�^��DY�]�0Z���1�n��\��g���S� ĜSF@�l&�FrH$f�����26�5l�HX�t�x��!����xbttva
7�MPRI@�g��#7D�Z,�p4w��ȳ(zh��'�E��r
9�}ՅXɠ��^�:i�}����r�u��h�2s��Q�!����8(��hg|�?�]5�ȱ�z�lXjxװհ�m2l6���)AIMV��Q��f"�R��Gz���T�H�y�>P�WIz�:���N�;yI�s���AYb	�Ձ>�̙%�J��d�.��l��ތ�:��U�L��<���_=�) �L8ӳ8���@.SBx���*��T���ѳ�����
��D259�JyHD�x\DNz>謱�7��ڠ���Վ����Q���D2�#(�ֳ��X<��W��e䥜z��������<X@�F3�@F,ҼW�QqP-�΀�,�Q��>�d!�j�X]CE�T�W���I'��[�\ͱn�buդ�#c�ʜ4�Ś��*6�s�Ϩ�곦B�Xx���W�e����.��*�3�ڙ�h���:oY�J�`��ID�U���j
�����N%�fEDs�$�׫d�����:	�Hd�g�ѯ���o
<�]���8'A(���j"H
y��V��!,&Tׁ��A!��LlB�k�qp����b`f�y*��ٜD~>���Z#����]���m���wE�$��Hd\w9h�H�M���@����z��A�����ߋ������":��~�����I��{
"�_6��{��Q�H
�R�	��]t)������%���\=���k����{b����w�����d�5C6�+�Ο㻒�;;�����O��]@��s�
�kj��'p
Ԯ�ZՁ���#�0�2����Y��3��LأK�{�n�n�.7�'���
�f���<��y���32���� �@(�H����=��wӠ.��X�4�@c�4��;
����#H��8��
mA;��v@q�茬&
ɦ�`�H����MH)�F�
���x����H����
Y�/��~�?ʈ�uF��P��$��Q�<�@Qqx<
F�1`,G�L�U!�zET�!Iy�t|����ɏdV�bH�d&�I`2���i�T����`:�3�L0�s�\0<�ρ�`
x,��bh/�%`)x	���PP��W�
��^�a`X
�o�5������z�
l��&�|��p�
l�`'�v���?��	����
����3�9��W��|�#�[p|����8���{�8
�	~g�YT������p
\��K�2�~W�5p�n�����	n�;�	�`4�c`]Xև��
l�ư	l
���l	[�G �q�5l��v�=�;�N�3��	0v�4C�B��$�S`*�
���|���`L��7̄}`��a?��� 8�Ca̅y0���8����'�h8��� �:������EP��2���P�*Ԡ�X
��8N���8N��>���a%�
g�Yp6���y��,|·��p!\���p	\
�_�/�e�X��W�
��_��o�Up5|�߆k�;�߅��up=�7���p�?�[�V�
n��p'�wÏ�?��	���������3�9��_ƒ�+x~
�����-<
����qx������x������'x��?�_�x�
/���
�
^���u�;�
o�[��'�
�0��2�Ȅ0&&�	c™&��b��r�.S����2
����7x�i�4e�1͙LK|R�a�G�8�5ӆi˴/0�LG�ә�g�D��1f��Xcg��d&�Ie�2���]�1|�Icҙ�7���a����\&��d1��!�P&��e��	6f83�Ɍbǧ��1�d�3��q2Sȸ7#2O��9���22�c�3
�2�g����)c&0�I�df
3��Ɣ3�S���t�����df1��9�\f��,�3�Y�<�,[C�^�C?���땽���u)��W��.���6�S��!�vL-fKR�s��L�"�^�٬�J�CG'��
�X0񄄦�.�+��:5�v���59	�sp��t�@Ge���~M0I:�7J�8e�(�� �۫�A�(o����l��):���*:��UB�'�,�ZMy� ���|�-ď?��#�l��3!h��tJ3B�x���so�Cx���C����O%4�*�<�A���[�&/�U���)\(uH�_yU?�J@VL>����Ӆ�"�H�������������锰����������0�7���@"�巡�������R���o���/��"��ʱ���C���~���Ś�����
땵<إ�櫾,Ј�u�C�Bi�Nʹ�l�4�R�o��zo��Vzo���͔���VJ�x���$J�)�x�TJ�(M�4�ӛ�LJ��4��'Q�$��D�(~�O��I?��'Q�$��D���@�E�H7���wR�N��k��w
!�3�YDhx�(I�j���
��)"���t��{�W�R��!*I��~����h��%�- 2�������
2
#�Q}���!n�GN���^g�ǯRc�]#kf��1ⓑ^�'��"�܂�#z�?⯕�z,�hL2S�Q��Q��Q�e�}�W�?4��;p0�u��W��JBi���ZwQ.����L���SS��=��!,���Ȭ�Y]w�j���b���5�o�s�kc�^1�ч)[%�`		ͦ\���l�+Q�*�TQ����f�n���{krT�"�+�^�蠍4f�ƙmvJ��^�A@�o0eE���Y��d����� VԠ���jx���B��B���~:{�>�_�=�.��:<h����A�e5�!(κԈ4�I�F�2p���S^ 4r�*�ȡȵ\s�c��7
G��V����P���EPE5�$pe�,#$z�̓W�B�n�5�(�
������E��*��Q��J�V#�7l�:JESxm4��!x��~���M��jt�r��w"r��oD�&,S�[óez5�#b��7�A�#{�>�����B!�t�W��&�1�»!�1b�����ǣ��S�䙁~f��!�RLf�h�q�!�d�����ߐ�
CT1*;7�v�#��E
����l��(i4`�]x7N�L�[
o�F�`Ha]�Y���R9�۠�e��Q�;��2D�B�
�W�]�Qr������%N<�ƙ)�Pj��F���$J�)M�4��4J�)͠4�R=��[8��Lq��Lq���L���)���)���)��7��L�ih���j���f���o���o���o���o���o���o��V�o��V�o��V�o��4�ڬ�J��J�i����k�R|+ŷR|ŷQ|ŷQ|ŧ��f��6�o��6�o��6�o��6�o��6�o��v�k��v�k��t'��)����)����)����)�������{?g�I�Iu|ڻ�w��s�d~�0������
�Q
��A?���y�p�������9�k�A����P�*��N�}+�G�P���aj�@h��E���&$p�L�M�+�h���p�A--^m5��N~��e�6
��}�rl���uϼ����{�����]���]UE�\�aW�TpE\7��77��Y��sg�m�z�!.��Y�y�5Gr�&C�����s
�MDl�a��@1��f{���\G�a��t��CS>g�+(Ţ	2#�k�8�K�P�E~F5�F	O���=՞:�{�!AQ��A;�+�\rv�M`�,\�+���!�P>p峘�r�{�圆[fV��ب��]��/�1��=o��܁�1s����X�r�'�:�~2�Z�����Y��x�U��Y�E���<�ˆ~s�
=�,����#��O������7�<�r�4 lQ��G/�N);�w.������p��
&�����(�͕��l�0����P��v\��=+����C�%�Yh���2
C~�X�pV|��1���u�jWզ2�>�P�Z�u�T5��'�v�~�-�"���¸:�=�
��#���gD�Y��3� �m��r��	��L�P
!�q�O�L;q:������]�,�"!ꩆ��u�׎j�o8r{��K��֬���lKI]�OҺ�8�t��%��-Jo�vӞ�y�O�<�4����W2pu�=�OU`R>U��?rO�?i�ql��ec�^���m�+��w����y����=���Vjء����9]f/=�%�ў���C7-�l�{�����?�ˬo�yޞF+�=q����䙍��g��/���=�u������5O�S�o����ɺ�1�]������N��M�7����x��o���||����Mٖ�V�}��_����M����'��QO�h�ʻ��|N�'�J37�b�MXl�p��	����}��
W7��F��+��o
}D }��M0�����z��O���P�\7?µ��׈v��p%�V䩶�ŷր��GbE���]+`@���U��[��~���ɳޚ��u��K'v�lw�[W8[|��}�7��f��2�hѱ�e1��\z���)r��Ͽ�����p�֜�7�������͙Wnv)j������7��95u@�u��ܫŔM��{�Yb�ֱ�4'��Ǿ��~fV��'�/�Y�_R�qw��?��s��N��<:�p�S#�����W��1z_݆�_y�\ގ����;�)��q��>��@�ҟ_1��c\ӣ��ee,m6���s��\�0���7�WF�"n�����Y�����+����ZӠۺ;>��(�´��ߌ��#���������İ�����.�K������*������J���"�$�<(�@␄d�+�r��m��B!ZJ�9�n�;��8ݯ�ƹ;{�0�*[�y������-�_;{��DX�c>����������Ŭ��հ����{��������{&?:�g�v����ʌ�ܲ�Ͼ������ʛ/�µ4������ڕ�����{��̱;���������ʲ��������<jٯ/��|�[N��)�����U���ԏ��/�Zz��l�0���λ�x�CzF2g�=41U�*ke��$��QPU����X6ͯ�eE�ʈk��ܜT���p����

���j|S�;H���cs7.U`�A�g;y����Å�LD��lGG��'����m�쁅f�N�l�8X8��0οm˅-S.>u�d��[��)�¾�;���6��Yt!=g��-�ƶ=��1��P����ݮ���η.~����W_�6MM��Ŋ�Vq��H)���t��泗�ٶ"�.wv��Ζ�z������������g�v�s��0����un{~����Y�*����ۮ�V��X��U�,��|���xh|��GoΌn��#	�;���/{�*N)zb��GV��9v�S�/�Ǫn��{�tݰe���1���W���gn��c {��kM�|ta�/��Ɛ�9}�s��J{?M��V!��t_G��Xc�-r\e_X�{&ml�A�1بŃ�Ǚ�p��PQW��U8�9x+q����7�T�?S}e�'�3��̥�؅�$��
q����܌k��N=b2֌@�@
�cldlvu��[�{�p&Mr�x�'6}�̕O����e\�r�J�?�u}�O��{��mcʾ��O7o�O[ӵ��&��t���k�/�i�-yi֖w[�+m}�EӘ���[,Gf�����Y�{�[����Q�Ilw��$�`�iA���n�hR�j��䇇N
Y��j�c'��O[!���ϟ�9�����3�8�'���h�#��Ǝ�6aW���
�E�����u�vm
7?z���C�ߓ��� 80&����Ǚ-)Ձq_�e��b�+,[�D�,�
����)�Y�\,��P�Ż�S��
�w����]_����5^b�{W����h�ao67p ~/�Nݜ�-�B��7�#{55g�?�+�C�߰�;�gF��q��^W���ls�}��~_:���1Y]��l\�ʁw�.J]����qht�:���ǡ�E��>fu�5cA�!�I/�8�Dz;ݦ���PT�yiII������w����)�폸p�=Ycި?gI TME�j"�x�XR�Ԋ�Ӹ^z�IE���Ze��ӌ��k�k�=Q������71�>����eX"�z��g�(��z�jx���Ր.��p���	�h��#����XUq5���;@R�_U�g˫�7���բ	�'�I���r�����_������6v���5W�)i���������G:����Ҷf�������Th6��:e�i�3ose���~u���Ѳ�|��M��q�,����'G���yc��K�L�7q�|�܎�B
����򏤿��Xv����X�
�6��M�wW��S���kG�����w~�\��0\3����^[���a��"cF}���G��鉎��X�#3G牛�6������^)���l�5?�c����L��s+������7���(nb ����/
u�	�^U��F{q8���j!�q�i�E��Q�/��Aw�$��7DfY���\�Xw�.������ʹ�Q�����
�2��ҫ�i���֗����A��g,��皮���P��'����җv�]�o�;z���K�Ҭ!������/�پ��/�6`�ٟ�wv�j���ʾ�+��u��z�u�����߼�hhn}�=�ή19�����0ӒMo;v��>�jl��9�1�u��x9
j5�0�+����ؠ\����>���²�!���f��գі��Ț����'����T.�b7����ŵ��)ʧ�����߯ϴ�����������[7��ܫ�y��2�]�z������7����������&�X�ݪ�a�ﰪ�����p�u���_��㼰�/�~���_�������Ʊ���]���ʚ�<�g���|/b�ދ/{�[;����\:rĺ?���l�iaa�o�~�����;�t/\�f-~���Lx
endstream
endobj
470 0 obj
<</Type /Font
/BaseFont /TimesNewRoman
/Subtype /TrueType
/FirstChar 32
/LastChar 255
/Widths 471 0 R
/FontDescriptor 472 0 R
/Encoding /WinAnsiEncoding
>>
endobj
471 0 obj
[ 250 333 408 500 500 833 778 180 333 333 500 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 564 444 921 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 333 278 333 469 500 333 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 480 200 480 541 778 500 778 333 500 444 1000 500 500 333 1000 556 333 889 778 611 778 778 333 333 444 444 350 500 1000 333 980 389 333 722 778 444 722 250 333 500 500 500 500 200 500 333 760 276 500 564 333 760 333 400 549 300 300 333 536 453 250 333 300 310 500 750 750 750 444 722 722 722 722 722 722 889 667 611 611 611 611 333 333 333 333 722 722 722 722 722 722 722 564 722 722 722 722 722 722 556 500 444 444 444 444 444 444 667 444 444 444 444 444 278 278 278 278 500 500 500 500 500 500 500 549 500 500 500 500 500 500 500 500 ]
endobj
472 0 obj
<</Type /FontDescriptor
/FontName /TimesNewRoman
/FontWeight /Regular
/Descent -216
/Ascent 891
/AvgWidth 778
/Flags 32
/FontBBox [-167 -307 1009 1007]
/ItalicAngle 0
/StemV 70
/MissingWidth 778
/CapHeight 662
/FontFile2 469 0 R
>>
endobj
473 0 obj
<</Length 115816
/Filter /FlateDecode
/Length1 181988>>
stream
x��	�\U�7^����}�}{�����>�,�0aHI�$v�.���PAAe�ɀ0�
�E��
�	�WeQ
y�߯N�L��{�����?�y<�O�{�:u��Tչ�4�x�ҽ���H�2A��>�WM|��?O�XC�\��������x�֯�g���1ރz��/[�ߺ��"r������7m8��SU�!(��?������ӾJd���'�I���x?�q�QN=�"d>�#�Qǟyd�́:�E��x�Go�tF��k�!J�h蒣�ذ�����!г�4ܷ[NE�B�sGo:�'OF��Bd�8�SN�9p}/)GF��;�?��
�'_G��a�wm�p�I�����Oذ�K���Hʙ�
�_N:�����|����L��t�'=���������ļ4=h�9�P��;����A7k�������]��2�,��b�B� �f}�8`Uv]����3} )����� �5�P;���V����j�I�=�u�:���|��HG*>�����j2���F����3�9������������<n�Q7���D7��+"�#s6
�����d��I:�p���]����Vz��G�(}b�r+��ڈ��]��i�B������J_�@���ҁbA�q9��(g��e�0g%�`���[�?ָ�)���"�㍻�>�w2>N�3�5T��5�B���W����0�A�oB�Q~��!é�_^��Qߊ�3'�}�_�6����#��n�3�������AG�_����,�YQn��k^c8���SR�v݅>�S�M�1�kc³fAg�E�-
�>�Ї���������$ ��'#X�8����yϳ{b�gi�/�id�>X���n�>R@ׇ
��Nw�	e)h}M�F�|�@�n6��N�b�ƿ�[���{�f��q9h��x'-@=�m�P�u�W�oӾ�k5]C�N�N�)GҔ)O-�W�Z�<k1��u7�j�mH����Bq���>�#�Ŵ�9����������1�ڲ(���ۙ�,�����_�g�����u%���6��+�����X�k����<gX�>Xfe3W����[�K(w��Z�(���@ݎ��k��e��}8��U���n�^��Ao���C�a�_/���:��l�#PN4�9[ ��i|VX_�Y���z��2�d�6��m�M�'�����ݿ�$u����{�c�gZ
��s]%JIz�k��R�j|�<�=w�n��8���a^z=�{��b��l�!S�N2�����Qʫ�5��Q��e��<_���Ǖ'�j�J9�r_�p�G�_�b~Vk�J;���F��Y0<�d�
���^[��)������h��O.�����+Ey�x��?�o��/��2�It���h�F9�li_�'f���z�6ʉ�C�q�z[i�!H��S�����G��ׁʰXd8N�g���U��}�Z�s����s�n}���}T�柳���'�{��sO�g>_��g�6���3�7�>�"��q�^���VQd^??����@?on�G��Ϧ_��͞S�s������l�p��s�?��=_
�p�������s}�e(?��!l��:�6� +
_�a�6M�B���y_jh\ϼ�4�C�G(����K�0/���5�
�gt��4I��k�!m
�P�Ay�`g��z����jZ�^[���H�I4Dq��*��|����n�_k�W���\u���q
�i|���a?���7]J_`;`�g�43�7.1?�x��)��q�w%�{y@� ���|�s?�2.�ƹ_�)#��O5.f~0�>��_K0�mt��Gp�O�Z��\LA�a~��k���q
Y,�6�0^�8K��]4�^E]�ۍ?��Q�u�|}����ռ�u!^�CNg7�7�<볥�n���p���a��G�9u:���\=4h��֪���l���+��$�+�v����u�<+�f����� ���?G�|1
Xcއ�G�)o�"ؑ�������!�V�B�]��M/��&$����`��h4Z[M�N���
`����m��#<x鎴̦�����g�7��&�;�}1�8��<�>��w�9I�Y;b�`�lx�x^`�y9!���}�]Bp�{��a�b���	O�w��a�ߘ�8OT#��[p�BT�j�h�@���a�D��d5�Ϩh�!Ν}�G<3,�(E�����r��/ D�F^en�V��d�l�o3��3�����v'�L%�����U�*��e����e�$��VE�K�-��	 �e��8��â d[��
a��>��%�QM�n�&%
���5�@<�GR
!Z�V@Q(T�'�;�� U��T�nTU���g�Vz�� Y��}���E6	�dG���N���EN@7�=����|�
�����-!
�
���\0J���q�&(��8`��%���C�4��
��7ޣ��y�(X����S�
�e	[���J�w�Be����vPk�ꔰFU�:�vI��:oS��=T�:`u5�F���A��p!�.���_	�
����48FC��ia�/4.�Z�
N�H�-ZJ��{��$-�G�e4�x����}ip����R��4�x�VI���
ܟ�5^���r�$\C�6�Lki���Z��x_G��Հ�Hx(�����7���$<��n��#h��EM��t,
x�<�6n����p���������d	O��O��
O���t��tl�w�	:�:�L�x�x6���-}R�O�I���Sϑ�\:���G�
�O�^ ��	����W�":�b	/��?Kg7~C�铀�ҧ/�s/�s
?�
}�������.��N��.�"}�j����KtI�e�2}�Z	��̀_���J�7^��Ix=}���F��&�������*�oH�M�bc}���6}	�	�C_nl�[�:���+�ߕ�{��Ư���5��%���
�Ѝ��tS��C�;��?��
�o�
�<��7
�o�+�}�����Ư�
�
�A	��n��
>���o<G�H�(��C��#�g�1�|��|�~�$�/��t�O�n��hp��?�{
������I���sz��`���K	������
E�>O�6��臀��
n�p=���H��DO�,�Nz��4�B?
�
=�����6���Ӏ��)��~�z�?���F�_���|��|C�7�W���-z�/��^�m|�^l��ޑ�]z��c�;����O	�A���~�����WO�.�-`�~8g�w�ۦ�ۦ�Ħ�����I��ڿm:l�u����o�ۦ�ۦ��Ц��ۦ�ۦ�;N��M���M'X\R��;�����h�[U��dR
��'n1��f�ق��`2�m*&�
*F�c�Q5�0U�6�
��d4p?�X,�_9����\�Vֳ͍�X1�+���h���b�7�2�/��)�=�,2��*���b�A���F���(���h@��l�tn����b@7��0-s50@n��vg��"��Z̖=Jf;'�lw�~��)�[T�Ոm`)�$Gfg�[��i6�Unl��t6��� #�3Z���u��e~XmحU��X��W�f1�7`ȑ���N��2[��b�0f��n���� ��X-�sX0�`4ڤI��F~ZA�oF��]S!
^�`���D��G���G�G���1co+~V�	����l�H}4��#&�U����f�$	�œ�Z��G���l��zN%~3�զ������s��jrH��>2yR���U��#�k�)��a��		�������9\k*�g�V��u���7

58&Π�)J�u����	N;�����[S���e��E&G^f��f*97�T7�b�|Fk�[87����k��nUy*�!;t��\6>�,$3�Yꣴ�HM�Yy>f�`�dka��\V��Zf0�Fy�X��GH�d��>Z��C���
r��&"��}dQ�m,=�G���0K}d��fQ���P�1H�1�������rĒ��2'���
E*��dl�͉f���l�١�6VK�>;�rM�\fA1x&�u�v�aw�� S��6��6�fw�l�R��Y��Y��S����0�`�5�6�5���t�9�&i��=�G��D�t9��Ϸ����!��qN��4�*
��|��znlR�t��#8�����rf�]A��6���X���9
�J�٤>Bw�|r�%���c�Cw����Id2@PX�Z�ln�
s�Y�*;���*͚t�pPF+|VH+k������:�`��-v�+\�q��5M3,����lV��n��xm'H
{ز����r�|�r��ŭ�	x�YO5�Yͳ~�y%�2���#� H5��M�����f��ȦʧԻx	k��v�q>Y
l
U�E�:k`R�Mφo1�p���5�
L5I�OdcÉ�KŰ;�Vh���v[8[�ͳ
��Q��9a���������3X���8��<��F΁'"������v3S�t6��-�����i�:�˂6��u ;��
k�C���6�������;ͦ�Qa�a��T@��
�:�9.�g�p�N��z���g�ޑc��af�����1�i�4������<>������G��݁�ю�X�����G��Gh����X�(=�!������>JE���q��G�Ãf����s8Y�1�B�q;,�&Y����G�2�����
�R,`�HF��)e��,�KJ�ᐒeE0I�b��Sa����	QZ��D��c�l�H9�@�::lN�������v���	��Rv�h�쐺�D���#9(l�Ê)��L��iVHŌ=
���s��h����*�4�B�p~Y��d8��V��9�lƋR�v�{�݉����8Y0�P��Z8>���캲��9�)��=��3��7��������<n����w6���r9���3��+�
������Gh
bP��$��d�G�)�f7h���>�z��Ho^e���N�x�#m����@�?X�@�{�,L���g�9��������=\l<��=P:�,[�4<��f��r
�h��G���5���l�0��ц��r�z�(a-{�l^N���y�Վ�9]���Y}�Ι;�eNќ����s�>J:�A*0?��&���]F� �q��[�G{S��G��-��Xe4�:anƉs���G�-��=��VB�p��N�����Y���ȸ������ �_���< M��zX�a7���������a�m>Ih��h����/B����)|1��`�Ǒ��f�p���V�l\P���>�6������sl�8���_s$��{Ê��!%n���e�3Y@�Tm ܎���K��u�dl�o���aa��0�uօ�7hv"�v��\.�ኂ��iw�]V1�谱�q��v��ҹۜf���4ɣ�r8�$��~N��x�_��cw�>6v��2�]6�n��>w��C��p�.+S�t6m����NLN�F��ř��]Hؽ����8�8�n����r�]�:ǔ��]�]�>*���\�3�����w��0�C�^ċ�IJԠ@�8�A���8�����/�����.���@�<6�,�Mގ�l`�d�{mV�`����������X�|��������A��w��.��̞�m&C}M�]8�9@Bt������:{՞5,���7�p{�X/�f�����P+�!��K�ۃ@pۃ�,������lK-dM�q�{�������i1��ND�8?@���h���,�������d!c'\2"#86�p]��������v������ޣ�r�fC~r����%�i��妑��5�}ұ�౜&��1�L��R�b>�h7�]�Q�Q���Ǐ�zL8�P0ltI��NsL	!�����cc��r��t���Z��^L���m�x=@
�<�H�p�B�2�$
��]ҥz�����x�ۑE�t����mD���`�as~Xg���g��+�(�\�����oux�A����A�D�fhd����J��甾G̓��>sީ�q�Û�)������ �
{�܆����a���"�44a�#�dA=�~B�,܃Ě.���_a�n�	�f�raa"/�:��($��y��6C��^����a*Z����Za;��88;"ͳ
��I�#����h��sz�}
����p�q��29��up�;���+���m�����tJ��!;�6:,Ag�!Xl�~x�A�x~�*��[=����3����nf3ǂΦ��K�z��^OZU
�����=������
G<��=QȍOnX�sc�[q:ا��C4j�'f�]0����NO	ѫ�Gn���OV���2_�����F
o�����(��-\8�!�.KЍyv�}8����̉@ ��8��P׬�t�ؗG �z�@��<.׼ ��`��v\q��\qI_~\X*f�$��
���$i����x���J����	�� bl�Շ s�������
���T�p�$� ����|�X����K�@{��8'��D�u�`c!����e�o��4s��9��9X���{-
4qW�NI52�����5�㌺��a���`�
Z|>����� X��/�qC��Ʌ�
�]��hs|!�WgW4����������>$>�?�R�`��K�,��:br�6���vC�B.����4������9�G�N��f}����0�������+6���0�_����b  ������:`�y�C#���m	{�o�x�ٝ[zX�N��j�Û�#�l�`�܌#JB�`�ۼ�@au�l>���v'�&t'�,x������\8f�~0(?�I`��Z�n�B�
�
�!H69n������� �|��g�V����ٹ�묝�����u�m����;`sf�(���p�RZ<E�b�O��8p�|6��ˬ�Aw����p�4�_��]M:��0�T��6�m1?g�!���ǰ۰����}aı� ���!hsx�{�\7�A������G|~\UܱlR���q�M �Q���P�����%����Sg[��3�NG�>�b�À�Aؓq��(��B���"������O+}>V�`���$@@8���` �0���=>+|\��/w>Wnq�U8nb�5�0\�ʌ�plc��#��Ra���	�,V[��~T3��&��%Y0(FI�Z�.�̖7,S�$C���a{`I�Mp��� ax�� b	�~�H�k
+l?\�'��h	�¾��#Q��E��kig��r����=J�4'�!=��D�8ߞH������p@�k.�&�=Q_�7w��Xqdְ7��&�L%gHŅ�`�ǞrF���s��6��n�� LZ �Х(�`,���B�N>�^�
K��J��1XE��������D�D(��P<��r-̄0�$��^���`+>o<�
A7=.�C��p8nG:���������>�t�|���"�`$���_ �"�d(���/C��
}�Z�>/G�V�;䅁4��|2��&ƹ�V_3�BBԃ`��F3P0-�6�'g}�4pɋ{�W-�ՙ,�ˠ��>�����!��2.�|X�
�2�)
�Fl�Fbވ��s��!�}��7�D#\k��rސ3�1h�>/$�h�!���i��ٛ���@ �g�	蜠�l*������c��4��r��9��p%��k
y�
x㘏��t6}s����'��kO�8��`<�~�b)�6f
���@�	�	Eb���X���zp]a}t����m�H(�p�N��p��C)o,
'c@�j8��(G6�e_�֜�N4��;��H}�]h,/� A첞�y���$!DE�J�Z��݁�(�װ�8~8�Ѱ����`8ѣ�0�"A?Ǵ~&�ؒ��~}AO���(A���&ƹ���֏��pL�x"Yd���ĸ��]Ӝ!T�~h�q�ɂ��$y�d�s�D�-�����k�U�6X�%�y¾PZ�H$�q?O�E,���X:ε�-���
���+���p=$�D2��V��g.�������C�x8�')�s�*3�ηߟH�@ڃcr�&�\��9'��`����$���d���tJ��!���z�3��N�Ѥ��&mQ��p����H<�3���"P":>�
�
��P�hm�x4�fr�h,�DC� �d8�@
Ǵh2Q.'r�H1����"�����	��$b	(��A7�1n��g� `��ʕ��D�v�`��:��`����s\.X�`[I��)�L��T,��R�|"CX
���+�~8t��;q��	,�[i��)��2ͪ9%8���A/G����.�\ᖔ�m�@*�k^�<Q���ePђ
��,�g���p��
�'�P|=�dr쾑�aO�cE���\��i=���+�O�<�إ��K6戅bpu���'�1����D�z8�
��	w��,%aZ�Q�dO�-s�jm+���w�`:N9�9_�n7h�'�MML9�a=�_8�`0�H����tJ��!?�����	Ψ��Q���^�uG"��tܧ�DJ�C��h�"G0��I�����!Z�U"�D���R&����h2^�z"�ׁ"K���ޞ.��m� ����	��`Яc+�P6J��Z����H��xʅp��ڕ#\�c�p!��5�om���
B�M�t�r���(�]�%�dIK$���ӆ�pԉ�5
s��p���E����(��Y��ʌ@ԃ`'�d��E��CN�xX/�z��4/“��*д��*�
��ׅ�w������K?�˯��� ��>�N�D�fs$|���f�ZX��k	g"��J��|�p���$��E#�h Ny+�	%�C"�N�{�2�*'���r6I���l!�;��@�n��LN3�&��\4���a'�l©GsQ�j��Tr�T��v�4Ψ�É,���J`tΩiI-��iZ	��c��3��3�'7���4I�Y%t��H�|�p����9��i�p.��K9��颖�tue+�Tg��L8�惄"��g ���"�B$�g���B���@,䭖�a�Zo�pUMD���AL�	��O^/����~ET��@@NO��AG�.h"�P4��.�����c'B�~�͛d	�rM������2#�����|�����s9x�h2�-�����S�h1C
h�s����4K���K��h��2[ޜL.M=2@�\	���ZH�G…��/@�0?zH������9�i.-��s	䨎�.-�u
HR�b"���Q��Q�r�v��/���ݓ�K�:�`)���B\OŢ�R"�J�S�t�@Sh.C���b��y�&��j�\��&��jdH%�#6F�m:gԽ�T
	�Ћ0���u���_�۠KEi2Z�~-���AC�+J��E�z�/��K)=
�[�,e�E=��2z5Z,f2mE�еl�^���:���Y��:�P,��&��l%+�c�p0G���
%"�Z5%�*����e�1.U��|��i�
D\į���bQ/�Rz1ӑ��>�O���A"�xʍ��\��!��#[j�!�b��q�C�;%���!�.��nȢ^,r�/Tp�+aZ@O!V�ǻ��^�w3Y�X$c���������/�$?y6�:��LD����T*Njq��\$At����Ŗ"�t7l��B��9v�n=�uH�Rk*��?������
ZZ����'��w/@����,���t"^jKݩj�J����\.�9�S�T��OLƑ���T9�]M:%�ȐJė���q_G�3�x��~���b����29���:�Klp2�֖`&J�c�P'7IE"�D$��p��\��E��\Ж/�y~>W����|G(rz��+�
��2پ<D�G�AH1A<����T�RI䣡"Q�?�sEt�����d���B������
����F0��O���'���2~�p���*���b:[.tsY��z1m,�'�ĬU�B|�INJIXbg@g
A���(�y��Ҳ�QM2��@2��6���{�%n��v��
���d:�L�MO9��d���-�`�۟�Z��_�ee��Y֓g��r2�&�:.�mmm�r2�c�p��d��̵�'�ʆ�i�d1\��h\�I���NE�X&Y��'9'�JzV�fK�Ҟ�r��	�r`hA[�VȤ�m�'���rM��\Nr��+�旟0�\L&��r��qW�NI52�Þz�pW�3��d�n?���d���)B
��p��U.�+�\6W���s�HړHEb�G��c�d*��˞.*��l
n8�����R)�ٖ�T�Rl����J��H[o�0�Q���0$�j���*��Nuth-�MD��,�Е����Dc�]k��3}]�P(S�"���'\�Lo�R���+���;:J�|��u�R*!,-dB�L
'+��f�ߝǼX̟OU2���
O��hb��<+J^V�����%���jc�P~QG����/PǴh)�ɗ2�1�Yԑc��Tɞ	�1��$����'�f*��R�Ց)�Jz����U�tdb�X%UI
W%S�t�:�V򗲥hG9S�U0-9��������R�L[xd,�93�Qh)������$u���"���,�k�V˵�`�=��;���D@Sj.wd8w�����10��ɔ��9�j�)�F�TR�ؘ	
V8�ʴ�R
?*]����*T�U*�m]|H*ݵX)��ަ�Y.��k&�ҵJ��JOK[>��tWڻ*���je!��Ju�(*���JWmr�>Rn۫��SQ=5��2U0���V����lUKt��#��u�+���
�u������'��¢�`4Zh�G��ݎ����Bl���d�V��v��(c�j5����+=Z�}�,c�ZY��$̉���&F�g-�*[��6�B��o2-���
�Z����P?�%+�B	a�$���]�d�Jy��,D��Q�Ab{�-Spw\
��դ��Pի�Jk(���/t`Wjz
n6R+�
ݽ�\���j���\�%k����_���
�
Z��V�/�,p.,]�
��-�.ؓ�S��	ghپ㽽-��B�wa�;XJW��J4�s������_�o>��Z�P
v�J�դSR����Z
l,D�j�Q�*�H�G����;���k��$l@wgw?߮j���*�?�|A�K�`�^�3-��Z7��ݵ�J'�Ua�ҡzW��V�������X?PԪ]õ��ի��vt��U�gy}�$$T���Al�\\���+�� �Kj��;���ML���D��`P���KF�	��`"8��8���^����o$]��=8X쩢��S�'‰�r1D9�(�Y�V1/�W�=�|:�K������&F��=kUV�e��y�<�hU"Q]>8�m�
X��0��k�r�^.����ULV�%_w�㸧����j^��}��L��|����z�7X����Z{4[�pQy����{�=�r9ރ `p� ���zk]�"�{�=��6�ׁ��h�ښ��;�=��ʜ��
�C����=IC�U+�p��?`��ۺ;�克����xǪo��4�`��Hu��7s9o\VG*�դSR���=e���ػ�3�rm!��3�wyh�H�����>����{��#��.L׫�j�Ԛ��w���|�5_*��K��`��ZO5�.O�7��?ҳ���׳Oyd��o������3�����Xн��\�k���iH��,�G��j��x[!3Ԛo�3���
tU�ڪ}*%�uGOP8��W��N�4���±�|Ҵ���겡��Q�&rաޕ����C�����C}���vU�j���U��#,�j.�����\:�^0��GG�e�Ğ�.�̈j/�{�u�V?`t��TF&Ñ�^���W���:�9`���ɪWK}�j2��a�z0/1�w�Q�b|_Lɏ@��z�7���z��]������h5W�
��J�jj�:T�Zo���7;ZG��0-�\���%K��Z��:�^��ʹz�HWOWo�H�Ȟ���u!�b�a��x�`O{u|��h���ث�:h*���*��D=k�jl�Z퍍�'j�դSR�����*�X�VqF]���#�C{�l��

��N䆆V�B��}�}C{����z��^(�;b��z�Tm/UZ��b�jelh�w���UW8�px��/Z�>1�p��	��^>41~��K��nXQg��5�z��}X--�V�˖u�c���\!=���ꭙu�kU��'/�h��[��\���Z_T�&j�I�v�V���M෼XZ;1141�;41�vl��}p*��Z�^�M$j�}��V,&z��jm�l(�7��'&�9�nc��+��Ej�dk��'����	غZm�����2L+��zfm�C&j���ζ�ޚ���^��K��fB�|
J������¶�Ρ�TJ��ܧ6Q+����ڀ�]���׆C]C��^��Xqcв��C@2�Ͼ=�Rw�@m4�ac�s������Z�מ���G�%?�u��F�ɕ=��U����`4������{���Zb�VJL�.��&��jdH�
{k��1��I$�cl������&���
-/����.-Z8�pl�dqaO�'�Y/��t%���Uj]����D���91�rp��X�t�~��,\<���|���ˁblh��c�'O>y�
�F���*�Zۡ���z}���[k�[��Z�j�x�����wd���^�������u=�򏀫�%�����)Ԅ��_��^:�L�O��/������iu�z�z��S�ð�a��PÕ�Ϥ���S�L���O����I#���wu����2�5��!���-%cʸ3�L0�h�R�53�ِ9"��^��)��yO>����\�
1�`�������/�_��)���t�������:�B�w���pa���px���q�T
�W�o��P�σ�A��ԛ
��2�g8�pE���_�~8ô������B�A��{A{׹&��3%������_��1�<�?�σ��yڏ(�O�h4^%j�ۉv��޿ϣXJ�J�Zvw����~�V��p�_9p�;�{��;O�yZ>�ӽ�;?�ʩ/��;�ٲ������ꗮ��馗.%���<���K'�tj/-z��Rv����;v��X����}G�}Gl�m}���~�k�_�Y�����l����ۿ�}�����۳�����I�R�f�_�?e���r�r+}()U��%�#����!)/qQv��v��8)w*wͿO���T�:]H�Q.�k�t}�.���-t3yh35���ޤ��r���0m�7�k��+���F7�m�8���K���tm�'�z���m�c�	=E��#�g�Sz��GG��t%�_��9M�?�g�X:���Mt<�@7Љt2�D�Щ�q:�N�O���:�Τ��S�I��n�s��8���ПhF\-��g2Ua��?ŗėŵ�:z��%��$̴K|E|U|M\/n7
��
�������zW�,�!�)�%�-n�����w������bJl��w�����,�w������!�bF�#\�-<�K/�N�~q��ODP\*���Cb�xX�D��O�����Gģ"&�"!���G��'�B�)�����c�q�xR�X�D<%���Ȋ�ȋ������3���t�(��h%z�^��g�%z�^�_Ӌ����7ěb�xK�E�U�-���DY������x_���]�m�EQTŠ�bV,�M�*6Ů8��R܊G�*>QQ�J@TE�TBJX�(Q%�ĕ��TR�fESҢCt*��)%�䔼RP�J�R�)ڢ\"�t'����4�A�����.�����Z�3t����>/�����JX���nq6�0��?���4�I�&t���l���������� .��X<�Lii=���ŖR���Rm��ջt����-\4<2:�x|�^K���g��}W�r���?v������C]��;|�Gu�1�w��N<��SN=���3�:�����9�w�~梋/���K/��s����/\�ū��җ�����կ]Í7}��o|�[߾�;���}�{߿}j��w�஻g����x�?�����O<��<���O�Ϟ��/~��s���޾�E����Ë
����,��:;ګ���r��X��=����x,	��
���q���?	�QAm��%��S��S�Bvb����4l�@���4��|x�Tz�����a�<�##��#��G
Oz�+m��lzj��lzF���_�8�6=��|_&߯��N��:&��#G/NO����%��y|�b��b��eǎ�U�h�͎W;ަ�ٓ���B!_��x��,N5�.��f3Sj~|�Ʃ��_�����)1vx��)ʎN�[���L�Ʀ�r��1��4��m���f<t��V����
��L����V��x*|�k��U �������qu�x�4W7o�8=u�~k>ث3\�80W�/Y�y	����i!L>o���#��ܲ����5;�=z��!���)Zy�>�
���I�����k��Ԣxv�ʼn-
ڼ��;����{*m[<�&7��ܳ/�_���or8�M��g�`��K�S��ӠdM�epD/m>�7.c���6B�LY��o������y��!�=���?ܲa�Ŕ��C���1�_�{�jm�*�Y/�c$h\(�*m��(/gO���h�L[����:K�ҙa:��s�[Ӭ���4
����R�s�ֹ����s�\����Y���h�,������?%B���#��������&=�y�,o'W�����}��Q���We/4q��`��qL����&o�1[���E��Ly�O4�Z���'�4��Y�{�,�S���|��!��Ul((��ܼ����%0;�7/ɦ�l^�y�L��òiOv�=�����O_?'љƽ�Ƨ�\��8Z�C[ݒ��eX\���5�x#_�z�4����ѵ[r�[sO�V�*�\Ks�&4}Z�Ȯ�=�D��^�l���g�6�\���g�f�G�!U�%c��c�����G�e�F�)#��n�PnGy��تn�c|�6<�gkU>�[J�{�c:V�=�nU��"ihxp:�=L��ξt�6_�(Wj/����ME}@}�Z���h��ޚQ����t�Y��q���tg}xFy�D���c��('����E�)����P��[;�"�}�'�oQ�Mo��
/��v��U����f\�m�N�.�-��.m�f|M{[Sn���~��Oo۾M�t�W�ݾ��m�m۶-۾L�t�W�}o��˖��c8Ǩ����*nU<�����6T�����ՇTþ���9���v�!�i���xZ54;>�4�]]���I�GBj'Jx���J�H�v	5	�6$|��z����)/�\�P^FQ�����DY�Ay�O�Gn@
eʡ(�E�'����� ��3�p����x�������bH�C�D��N%�P�v�ο]�<��SY@9tD$T�
���9�rΫs��s�s΃r�%9g&Ǔ�R
�]���,��ɔ�ݔ�/)�oR�SΟ��O9OJ9�H9W���)
�����=��8+=�d�sF	��^�&�}J������6��O/���^V��Wj�a��T������F�ȣފ���,�v��"�q�Ml��)�x^r���ŧ�#x����6#�^����eW�����m����J��i�(`DH?�k��P��1�-ԍ�&����ìۧ�oA�l��E��`�'��ִކ�oN���ƴ>���ק���IJѴ@.��6/���8����̧3
#������ĩ���x<O�]�D<�����1���x�#I��Ӏ|�5�,Ô���
P]�
�~��z�t��tO�U�^']b�M܆��E�C5�dQxZ���mxX�����iZ�
�t�)x���N����a��ko�۴7��u}m'���!������]ۦ�Z�K{����s���ش��|l[&O-��i�����'�aqNk��g��]{�>�=\������v��}|�؄�ߞ�w�ݬoӾ�`F\7��n�֮�/[��Ɍ
+���j��������hg�Ȼ����@���#����V[__�8p���`�S�@�E�@�{ܷ��>��k��yZ[:0�0�۴q���
_~8��.[������j}��kU�Ck���3�V���j����im�����,�C�x�j~�|��z����]�s�\0��is�������a�ɿ�b�(�f;����0y���̚ �|�(���H���P.����BQ���2�jt��ur��X9��:9e^qК-B|n����z8M��zwUvF�ࢍ�Q1囤�գ�R.�V�^3#<�3qv����q~~��kПJ��E�z��,�߀���uw��~(EZ�S�L�Z3ukr�T�_ɵ�S�U�uk�Q.Q._|�r1?֮�G�K�Wr��-^�ar�؄��<�����&�;L��`E.�0����0��x��a�rs\�DG���,_�n9���%9� ��S���-��rTj����v�E<h����x��l������z�{E�{����ݽ��}p��`t��?���?fը�\�f��F�"��ϐ礅R����L�^W_ ;�k.h��(-Zi����)�jV��T/�q���2a����O��5�q�Xhv�vUF*#܅S�].�
�vE>=�c�[�ڻ<h�b���1���ǩH���/>����&����꧞ڊ;���P����%��<��N�8�����S��q���sD�}HCI�_�8Q���P��k�����(����NՏC��li�<�M�����F���x����"��;�B:��b5�A�f���ޢl�Az��N�A^�.ZJ�K���]�9Y����O��U�6�:YXv5h:��J���D�&u?��[��0oD��AⓍG�7ަk
JR�^	q�a	�BX������k"���::�΢[�1�i���t���WR�EW��ax�q{��Ƴ�
h!fG��7iFlUtu�q���P���E
�ء��+G�;�t0�@w�V��=+���i��ʯ��n����щt!]EWc�-�]����~�*�[�q�E����k�)�=�A���zO�DQ��.��w��_}�p��f\ؠƗ���y��}�.�o���.��Y�S���n!�Ř�����T^�_W����O�D�lJCK@�2:��F�p
dz
�L?�g�7��0ç�"q�ة�ެ~[}����]�7�h|��J���<�Ok�����%t�y=B?_^�.��U#��&�__O���(��&�O+/�u�J�U�m��
���ozh�3����Qq��Xa~�>�>
NN�O��/�����`pl
r�]*��o���7�!e��+��|Q�C%5���
�5�M��a�p��׆?�i<�x��6�]�w]���N��ث�:E �E��q��3蓐��KX�.��y�58���AoB�&P�E�
��e:ʼn�Bq��C�#���ߊ7�Wьҭ(�e�r�r�ה*o�~������������?7�
�1!��q�q��jӵ�[�E��0x��U��K����:j�5����5F��7nn܍��Ə/6ޚ�o!���)l�	X�O�J:����!���f��/З��۱ϧ�������/�W���(�����EQ�z�+w;��+N��3����%�r��q�̷�q��
��Z�;�N܏=J@I*%�yLY����\�\�ܬܩ<�<�xQyE����Q��q��Z�{�T�R}V}U���7C
��3��F�q�x��f���G��L�fL0��1s��/�
K������'�qy���Q��,Õ�׋y	Q��h?�]e�U��: ��(g(6��7@/s�q=��dZ,�*ҵ�%�31�|X�T��K��+�0��T�QV�@O�A�kWR^9LyQ��ХڰVJ}�p���:�8�����T�B��UV�_W^V~F6z���&�8O��O(�,q��'p���r�`8H}C}�P���à��R����5�Q�+��ʕjA-0��Wt��P�����Y8p	XۻE�8���:�-�oO���t:U<nR��FhrN]��".3���*���|�[�$�\)+�O�nnQ�T��5"H�+ߤgv�FLA�T������5N����bĔ_�;w=�>����*����'�J�p5��������ނ�������0�����)�FϨ���>�����������B����İ�ϹW���I��ڤF�ҫ�?�w�س波��*:���:��ם���1�~�}���2�ɕt��>�k�I��丿���𙡋?�y8�m-<ҵb
����Y�<��ڛa�;u�8�^WN��xU�
�t��tŮapq���K��0�
.��p]	�O�yU<��ER�c��D���~"�V"��[!z���Nh��%"W����<���Z�i"���~H�I��(�yq�ED��(��ɣ�RhӺ���ejDY��{�����g�
 E���[U��ձ:V��g�'��f��a0�$73�� *bQ�fXׄb ����iͮowu]�-��ӎ��{�s�{��{���NUuUuս��N����#T�4B����E��Wy;B5��އP�����wJ-Bh���F�;Fþ�P�2�����W�B�{����e�����I��Ϛu�
�����@s���D��6?����b(�R��2(�rx�e_!��^��*Z	�
2���]�g"�&��u����7B�n��}�u��u�
�so���3n��u[�t�}=��f+��fx�ͻ��׷��[���soy
��
�n���{+�i���ްd�>oډ�Ϡ��}����\��e���6P���u�Ve;��>ЍAF����.��wLAh'���9�0���q����'���.��.x�3P�� �����_���o�{�z��L�
�W
c_�w�y�8�� ��L@൏�^�8{���a�����>� \B�W"���
����^�k��_?��P�7�#���-��[P�[o���ٽ���6��HT�
���{�����.��=�|߇2��x�}��x�!��C(��F
A�?\���P�?����
��G(�ǰ�|�Opϟ@����
B'��'�}X�Ox�_�g��;����g��~xV?<�����+��W�_=2�
��
|�[�����o�W߂l��~�~|���=�����T л3�3g�_?�>�u��9�8�:<<�:�B�R@��sP�s��AБA�� �m�12y�J��7C`o��C�NCVD�#���9���f^@X�a9��oV<�07a�n�U~��V�0Z��)��pM����]���1���M�@Y���@����;��
�{,<P�eY���\
Q�)@�|a?��
mz��6/�k��gD�^
��(�št#��
�w/�k��������C�
�����?ʁ�=��t �O����@p^�pD
����p-6�U��	���p��?.5

�J�,e�N�����$ (k� �\��U��:�Y�+���s����VB��YU���
@��*({�hµp�v*���5�=
d�w��@����@�P��
���n�p�v �]3Ա��2i�Aꇰ�	��8�G������������A�- �V�D+ȥ�n��@ �6�u�
d�����n^�Cy:���"<�
�:d?x0�=x5�40;�0.��x��x������\'|��9
��ߝ��|�e�Z
Ϟ<���
����������mDx���e�u��w�=�O@ �y��� ��? ������B��B��"(�b��b��x���2��r��r�˥��K�w�B}/}�y���{^��W@YV�w���+���\W��]���xw-�}
��:����7���P޵�������,���2Z�]�[u���r3���w�a�n��6x��@��;������;�,w�,�~�
t/�e��>���
��C��z?�~p5��A��p�!��#�;�@]v�����Kx�p�P�]n��>=��
�~�y0�<\{
����u�2���2��8�?�zd�`�\;e;�9�>�8�x��
��(�1����
�������߀�	��-��-��;P�w�������^~�
�>�߄?��?�~����{�Y���p�1���ק�3���� J_,s�H^Ǣ�=~	���ʽH�d�n?��,98��M!����q�Ǒ5ΟI�R��Tg.��p�¦���(�
v2h�Ke��2���}C���dˑ2��/S_!�P�";uB��p5���4�����2������8�9iT���UT((���I��6�nk�ߙ�L������}�I74`��� 4TV�nmim�h�
�!Y]e1��,EK��?\[��W�++N������BKO�薞|3VP���'K�ʿ�?&�l�\�H��\�ג6�=X��4�XZ����������4����gȁ�{��U��ܙS��&���ɺd�@�g����Jm�/kJ4)4U��J9�fZb��}�niY����%f��ᛶ���_<�:Eɖ �"'c�Qfq�I�8�^�8�W9�,��jX^'hY� h�z���MAK�mV
e�;����P�&�UC��V�\�q(�z��Az%8�A8�i�V��&A��
�����䤋,�Mk��x�VC~h����$S1M���l
���vX�����##
�J��>��{>��
�
<� ��y�r�
�I���:}@.��;r�	g]�7R���LfL���
�<r���@�a�S(�֋��l^�
P|�@�3w&70����)v����p�6g$��_"%�x"��A*}��_.m���o��o,��ݿ�[Y!��U�>�js@���G}F����m���L�e:�L�e�폧>?;�֩�Og������N�ԭ8���wZ��ӭ�����t�2vu
-t<��
5�[�t*���UW���j��]Z���n�y�jVg��ƃ��2w,XZ��M̈��cA�W��b�!�ǤRyx}���6<���R܋�p�^��s�v��z�:e�/��Z0�{Y��0^�j�V�=�
�C7��
�j�
{U�T�*KEN��zT���S
����R
.���6L��=���Ay0K�E���Ew1=��f^�ӐZW`���b��m��~ce�Y:p �T)�a*��`��|
X�D[��Ǐcs<%]9�ɵ
�y?��*=0R��������`h`���,�����R��(6�B�1
�
ԅ�c��"����Y�@��5�p$f�f�@[���D8B�;H�z�Rꌎꞑ	�#F�w����.���;M�2sª�cd������ml�;�$�_}�$��6�����uQJ{둹s���ǸS�OF��4�|��i�K1�����t�Uy3�;�(�^=�G�$NRS�Tj>�Om�tՋ�E�p՛Uj����"2D�JG�1m���4w�eq���H�޴W�
��K4;;T4��6��'�6mi��D7eq���'J��jQ�=�ֶŶ�F�����+X��Z�ر����̀�¦�R���\D%	g�$.�
��8�1��u�KE�����X!��H������s���ǃ�E7ݲ���n��n��mV�����gՋ�0���~`˲��x,^�nT0�
6��Ȗ��#{4�m��{��t����k��Z�7�j�1��!���
�hNq��W���U����Qoo�����@队�0�Y��\�$H���nl��:/_���$���C��]��	�4�8j�Ǎ	'5�n�����X󵢜�0���pwX~�ލz���bh=�P"S�V82�.X���"
�Ё^�Q@/x�
��8%�5��ͻ��
7�ލx���i>K}'�OP����t��*��6e��Fq���������𨉓�=c���d�g��~I���e�3�5�ٌ5a?m��s��Bb����}���J��ohH����������38|^� RЯ��>u>�G�@��B�U�I���dHsDB����-�1LQY��.�Y�ytUICU8���tɱ�Z�G�$=�>o�#�l���e��1~sr��m
��Ú�\9�����>�tr��ṷ�dy���ql����Bj�7�v�(q��������{�쭏���|Io{�L�U_�?��8�ʇ����|��>�n
(Q�tl�_F+�ݻ/���v,-G�
+D������V�h�>�7n��)^=�-Y�_C��'�K4��2E
Cc���' eA��?"8�(r�JQ%��֛R��_ė��B����rV�(
L��қ�k�*�k[�l=Х��s��vȖ�-��^���'Ո��E�y���P�![~
U
eңq����&���z�%(.�ʃj�HC��ԼC�.5V�a<���� )�4��\Tb/C�
$]������TmK�53���#��n�q<�U�O>���}��}��3�B�%�� ��˛ʛG4����ͣ��QMy���4���LZV�U*+U�~�%�z��=e�,J8D��ֆ�heM4�=����j^�
��`R#����Z��TN?s�֥pJ9R	u�"��:8n��D��h�gwjw蓺O��Y|��wB�i����?�x�/)Q"�o���|ʚQ�g�YP�Dj�M��r
��-��d�h*AI$�pSB1~����E�i��"�7U�o��֏�������D��4Ց2VY��q�l��X|�Fa��,
ͨ�XSٵ�˝�&KC{SYz��J�lL�(oY[5"%��F7F�h�T�R~[$��6�)YSۘ��R��G�K̈��=Ȫmb~μ�m�CSY܋1�J�	���28��V�88�*|ɦ�WU@r�s��J�=x��
�O_���}���׍?���ܜ�P�'��[�A�'��W�ŕȀF��^��:a�x7:�N�5Y��(��g�BQ�������gHF�ߐ�T3�~�a�ё�뉄��$ �r-�k�=�h�Pɴ�@ ��EF�Y�u�w�<������@侗�(4
����6fí��/���Ԋ�M�Z�s���C:��q)�-,B�*����+����ԩ�E]��,X�E�����mi��ť�dO�9�9=r5CҌ��I�Q��L��*���,�؏��l�a|���E$��b�,
�MO�~'�L��쵲���U�9x�	��WE>��5a����ƚ:����ޞzK�����D�maGi8��Vڪ쵎t8k���Ʊ:jt9�Q��c��*ȍ��5*�G4��ѠJ{���}:[Y��GQ~K��탋%Y��������R����T�Lg���������~)R!"/��U{P��CR�m�1H��	6����6b�3~yI�Mc'�y{W�]Zn�:Jc���쵁I7��ʖ���#�\�TojRov�;����u�{���md����R����zEu#`�!zpՎ��v/��iG��
��(�Q�i��8f�)D���JyE��ר�4%R��A�Ѥ��$���%��nG�(�PkQ#��&�[��k��u(���?��y����@��4��ߨ-��q=�yX����p��ݨ��x!��cL�cX_�$���.����C�KU�KT������(y]�m�z��9�j���C!��r���](�U��d�^|
�p��bի̯lTX]�T�k5B���i���[4�va��ݽ�mS��I
A�Z�~	?l��#��:�s{ܔ[��i�"[��&@0�X40��a(�F	&�‚M	P=�W�`	��B(�{�eX��,%5�c�I4��h��{W@�-��DPgR�����Ng�V�N;�23�

�B�HC�0O�~8���g�O#�{̿!Q}>_-�K��#`��G�'��
l�գ����y~�f�n}y����/`ٍK!�||���Y+���۹l�U�߸oU���Ȃ���Y��KbU5%�UtG�>��<V����[[��Uʒx���+J"����8�ӑ�*��+�����>
^�o'���?����f�Gx���E$US��^��A�m5b��8�$-�,�]ԉr,��kL{���^��R�+��2�}��4Oe���2���<'��ȓdD-���H�<�X)�c%/*�r�"�0��2��KV.��Z7�.:e��[�аfE�跞�|�����}U͉1�o�>��"U:G�il7�x�ϗLZS��W�f�x���e���_���~�c]`�C����\B�f5��!M]�$e��f�N]�i�������v�4f�z��^j��9���Q�Q�����5��#�#���i�i��aV��i�6�cT�R�&?n��HTl;�`8��
��D~�'��`�4��gi��d�H���`
gi�
�2ʩ�[�zX�`w�����AG{i������4Kg)���ȯbJ��X�JN�����ʗh��%��ڔڨ�W
J���v�hb$�I�ϩ��o2ؖ����–�V�p���=i�yv��o��i:����kڨ��8�qE����l�a_���,i�1b�Y~L%]zs���k���;����)���9O�_��IM�=Ol̈́��0
�x�\;�p���L��
5�iM�%��p�f���
��J3�J�E��|>�6`a�N��D]�V@�pn��V�Ē�a���h�,C
ʆ�@�� �	<Azg:�;\��E�B�;A���`]�2*_���F0#|r03�v+ Z7����x�����|(���U�O?�bi:t�/I6��i]��s�l�?����zk���kK�jŘ�QSo]�vm�&~�:@�Yv%�@�]�ƙ����ff|��¯�Y�du�C���VTFƪ�;�2�D�&�C���
nY�F�W�6�܃Z���.=��J�#e�r��V�t(^�� ~��Ÿt�����v5#y��dA�
f���M�`S��N��r2����{i��o���z��K���M�-�Ou阘�4 �2Rr�����z��'����÷a]k]�o�<~������[!(�xs9�H�n-	PX�0�h�D���)���%dr���S@�ሣF�}�Ҧb��6D�V$�+�c/��#�v0�A�XH�R����kV�}���r�kR�$�#gf�>0�
����n���7_W��/;{��[;
������6��G���x}]���)\�M���4Կβ�$��:��'�DU�,��W.���l�I��XO��X&�8�%�4��ќ�1�11%[i�>
[�P{����F�5����\v��L��0'j�bK���L�B[�Ev�B,\WlQnP�~,�(v8�O�������m�=������.iƗ���#b��ʚ���޺������������k��Wy����p(���=;G&�
��<2ob�����.�W��7gƨY�l��6��[�JdFQ��X���:���n��
C�N0q6�JX�tӠN[V0OY�(�hՕ0%
��(QO���д=@#Fnqɉ	�"��+"8�\��>�l1��^���Z������"'ϐLA
wIXB�{2tFh8�0}�M�6�+�o��A�qq��D�ȴ�1�l����~�ׇ���?��MxkK�kde�SS:��Sp�J����iIYN�.M���:�J�,�ƝW
M:Eu�C�#�2Q%�X�H��	��5��	s�L��X��U�}�QEjV�(��I��nH}���!�ṅlhnn����B8��J?ov�KDM�q��:�ƚ��C6HE-)�^ﴨ$���q�s�Ju�� ���>υRA�HB)L�/���R��\?�:wޘ�ys��]�Uҏ���Z��;g�w�e7z���ٌ��C�2�u�z<ɉ}��Ig���
��+��R�'�S4C#Z!���~j7�
_?�]G���c��
LMa����)H&�,��,<c������Fx[�t�@uI_12!\�͐��{��2���|�2�������ot��6z����
�1�b���*K?(r2�`���� Frv�B*'���B_'��\�B�g���5����s�	ћ֟X�N]+���~+��2�?p��"����a�ИƤmOT)��#�V*̀�5p�5��+}#p��n����sp�9?zR~�f܋g~;�l9
B���X���e岸-�
�&Y�m��	�
���/�����e
����h��*H��E��r�s��qU��e���֭֝Vb��E����
�Z�N�WEG�߁.���}�/,�Ž��B�����P:�U�_����[��5��+p��R�L~����7��ܳ4昘�W]��߸eŮK���̯�z{{{����{���t�%��FO:Q�yI��k�on[�u�'k���QC?�[�'�O��Tt��fx&d�M��)I5q��]��C���҉*�nD�����kE���Ա��A��5�b2W�:���v/D��}fzy��;�͆,���a��6-u��f��~>wJ���,t#���OK����/�ut���P�#���̰�"H��N���*�p>"���;�[�F�H���L�Ȅ�8�I��|�%�p�/g��/�K�
���:_�/�6��
���x����?0�ury�9Z�6w���N$�;4W�CU
�Bc�z�X��~X��}I�7�G��&<�o�����6\�c���k�[|�������n��_��LN����g��߿����:풒�[�����9���1AH�v���@B>��'�踲I�`K��*;43�˕�i�UnR>m�:�j�ƥ�Mr9��h�Ke��e���؁�!��z}�^t�@���1¤�N�R�h0��������3�=
�az�L�:���N�Ҿ�>ڗ��B;�&Y遁3 IH͋��w���I���Hh7�7H�Fa����6%�:� �.�I0���)\-���z����Έ����)�N���)�\�,�_J��������ig����7�K����C!��������-ͲPH!�θ|η"z�-�d1�(](�*�U�`�y��Ma:.r�D
l���\�D����F���2 �˅�h���*�Z�Ve�,�z��J���%C�;AQwEx�,"DBe�*�e�����r�]U��;�G��^%B���+�C�*�o�����I�1%��/�,��JM�s��:œ�
�I{"��C$^��RDg�I��BFk��Mf�E���O�OG��W�iTl���ޣk ���>��KM煝�WW�Z�"��T�e���0AY�u.\1��G���U�7��4����BM��M�̛T���*�gύ^&o�n�޾mn������	���Qk�r&�5���QT����ԏw�,�O�a�s�qI#v�y��6;���ӕؒ�Өx�K�@�/#s����@>���
�;�*�qФ��9�Y����6��(:�����`�S��Ƽ���భ�5�ҥ�"���<��Қ���/y7� m���Rđ�i�����I���I�s� �� Ɏ/��;�ݖ���s�=�_Pq}�������G?�r�h���-�O|����<ql��%Wކc_����
I�
��M(���?c� I�U�K�4AC۠�7�YR�O���U�Yf��UK�KU��6�vF�&3a� ԨD�X�r��#�p����@p�]H%#V�b�02��`�ad�2GTR0ᨌ�}o#��Q��G�	��l������#��OP)%���x�UV���
����B�m�����y}g��W��{x3�����`!�f��tNJ;>uf:4q=mJ���
��xy�ٓ���6�S/L��7��&�9�^
<���_D���ĥ�F?0�+��lB�-���=
_���2*IDPC�>����"]љ��HO��ȥ�k�����D�`���2x��D[yS�-�R�\Det��]��l�
�j^�萗���N`�K.��hw$��u���n�� ���e+X�&�i�0�ɿ��!���B~�GH����&?��珗d��b��c���3�� �ܰ�E�^�?��)��p���i��vE)��W��b|����%�9�D��޶ձ�A9�U���Ώ?�?5������T_&A��t��K=v)>���6��[I��	��k�Tazd/�G��\�`��[�R0-)�4� 
� ��]#P��!-�^~����}
nd����z�w�3�|u�s�Ջ愇��^�0-�8J6?$ù�z�侩�յ����KК�'{��fziGI8�zvALl*�o�:`(���r/�&�M�Od3����0'�([WF7�Fo:���6�+���L�������[WVW
+�׸�\�`����y����Xٗ��e�`��T ۦ�(V(h���R �g{�:��.��MZ���b�; (rۺ�v	E�^E�+l����`?c�fI�P@��G��=.��MP�r�#�Jz)��&�“ Y���� %�g��N?,Zl6��Uu�B|�-L�R��,=O��\��TY��0N�.��
��`���	:6���wt|C�J
�@�� �M��`%UL�3��i)�(�&���]+b��%��r*@�n��|ܚX�����{��̑����R͛�.LQ����2+$o��n�#J��;5�e��y���ϸ�f
D
u\G7�
T2��W\6�x�;�����r�܏��x(���tRѨ��4:�i�u���v�NΚX��)áW�h%Y�����8��&�YkQG�K�������hu&�˭���p�j
7�H�j#��Dx����p�
�}W�*݇�X��&�^,���mdi�+ �l��:�
���Pn<o����2�k�)�Br\���/xB~0%u�C���Ȑa1?��(^p��a?I�tIq�#[h�S�|(�nm���V<x������c�=ݩ�:��&��|��w�q�UxrSU(���F��v���o�3�|�C^4���i��ؕ��^����%�	�J�� $�+�r
ʼn���xӦms��g03�̈�H,Q\�\e^�&�Eq��f󭁍�M�+�%R���c��rO`[�Ķ�m��(~�=�����Q����]�G+�r�-�+^����[I%�qGsq�"	���N!gM���(]��rFC�`EM��BA�.�Yb���@"V�Jh�Z��2�[(�����m���A_����t
 "3ň6P0"�>�p:���)H�a�"j��R�X���ze�.D��cǞ(�
�h���AI��x&#ŏ$��C�%B���>ӷ1��@P��p_�PثM��9�.t��R_���埂���v#���8˓a��/��"\Qœ��C6j�j!������50&�!��}�5��H��١�{�
�P�xؙ�~�H�i�m��|�r��!�Qs�7�[��Uԣ�����6G`�2�\�;+|Uް�6b�2�J�;#<h�]����fωP��M�EK�Ph���]
�T(4�f|o����`��^0.#�t݄
}kEݯu�pv�"��n;u�#{�<ejc�L汖n�:;�CrH���^�;=x��e�6�0��]:J��?���b���.Jg�K�7iY�Kk2B��uQ9�z�&����h4Q��iF[��w�Q0ڔ�/�3��3<}T�R���$�R֒Y�G\������PQ�43{�?8���\�j��Y�^	���>4�4vv��t�B%��o�>g������򔢖�0V���5����������Y��Z�fͺ��]�_w�~a~²�V��;%�`/0��v{Y���!l�Z��S�-&�\��&/��Y�xp��&g��s��^7/���0]�x�
�_�!�a�Lk(����3ñt?q�8W쾒l2��զX-��o1�0�(��6&��T�����Ћ��z@5{����k>���
�k��v��Ӹ�go�����3��?�}�􎹣*J��F^e����t��*���D��+!E845<��)�1�>���ҳ�ۢ<^�H��5��I.in���56��:�6��<��a����\Vv�e�e�s����]���Gu������~�~�lW�Q�Q�~�~����,'\�t١���j����A�\&7��*��:0�Yʅy��Ż�n�+��p%P}��8�K�8\��p��<YWGlem(l
�Շ�u�u�z�0���
'��e#`K;�ِ"٣B
B�o�p�Q�%5��l1Y���fK����rR�NG��SQρ�u36?��̂9���`�;�<�W/2����F"zV�R��cm@�bۢ@:�
�R���/KZ0	/���7����p8UC�m=`�B�d�B�$����XD�*�zL6E��IC"�yc)�d6��0e��%"�i߯���1�P5�{�n�����]��P�=IOWQ7�D��蛍�.V��ZR5�*o����	SDŽd
%e��;y��PI5�bT���6o
��hbW�|��GpK���tC����Κ��ʫ��L��af`؁�!�7�l8joP4�����L��5��������i����?�~�~�z�zM�g��)8
g��Z!іc N�׺4j�ʥ���$'����BkԔ#KՋZP���{dX�#�ki�mȁv�L�9���2tQz�*�g�!r��f��}���E���K
��?��3��S/&/X�bV������)`�f՜L��Ҳ�'p����Ǣ��������3��Nl�K��>��[�l&#��nx��$��bS@5X�ZK}��jg�i�����VsGh1ZN]����1_�L�� �͈-ȡ��m����p�f-�&O�!�\��
�K(hLF��z �	����`�`
P6|��0Qu�����fS(�N��r�j �B��G4E!
,=�Mf�9��$j2
k��e����%���8t� N�{s�6/��=�����B[�t�ȕ�`��(�Td�p���t��v[�d��n�'��I�u�&��.�}#G�B��-�ddEW��{ڋ
��R�gL�
/�^d�0���CF|��w�8@�m�0��u4������(x֚���f�/[�!�&���LV�Enb|��JFw�e�gӏI�Ϥh��;���W�{�Y=x]]�j�.��_E���"Z:���@W/'��TL��D��'
(E5�5I}���I�S
��m�N?���ƴ	�@���{O�m[�6�U����%Q��jL
-FZ

��7� ��
���7������8
�)��

��^�j���׵i�KԏH�EN��.m�������;C8O�!����K�V�E/ӟrZA/h�Ae�C��(x>��&�������)����<=<o�"[pp@��:�bnM�Jq��)jX����M��"Y	��^c�ES㧎�ҝ*��r��P�@8w2���m�o��%�6�moW��WS[�%U)��Iן{��e�D(92R��lh�^�ˆNʎ�.E<��D��D��q�
x�o���5&2�'�+���P�5�2}����"N�d����K�fl~O���j�~�5d/r��Fm��Tj���:�$ͼ8���p�4�U&�_5�Bb�F��*�R%%>���<~���>�.���=ߵb���-�|y���Z��������u���/��W^"kl��c~ʖ57t�EU~�렮C��*�v��4��cJ�,�M
g���_k��v�bv��Z��懸���rϚ_�~�}��'�
-�R��9Hj)�Z�B�x���B]��ՙt������"dF܃\��*��5S`7�%Q��vڥ�4��IDž��^{�]�_a�i?ig���x�km	x*�/z��|.�K�|cpJj����a|�ۢ8����������bh��XEzPQ�)vF�,5�r!�L�[���*���죦�(ۧs��?ʍ�12~�#�f�Ԋ��n_y�
������P��
�O��|.��Yf1E0��*{E�EP=�TTU�ՐMi�q��	p"�H�|�n�q�i�q�I�T���Ѯ�1t�R�O*i0>�9f�݌�,�*#Mk��n�2b֋zc��5Z.���=�%9M?*��fĕw�vl�5$;���"r������
�6C��3<,�P�A��ő���iĿ!��E��^F�x1�x.A��A2b���ا���0?=
�f-���޽0��{W�_��1و�֏��d?��?�y.���>�X/<;MS��Z�u7����K����DO�k>[�/�1��t\V�o4�(h�K��x�������
���]���^���'�p��=1C7�7#�T�ĸı�y��Z�m��g�g�OGsorJ$�B=�6F��e�:=./V|�DYBe�P�~�p:Ic���O`���_��{�Ew�Vk�>�?({	Tˈ ���@w�7@X#��z!gP�}��)��+�5_�)%����
�@PՕ�`���V���C�,��,L�N��gH�9�'?		������5�݆�o�>C<��+�)���g��t���F���5՛}4�%���<O��R=o�5=J����+����$?�O��wY0�䠶�N���AS��B/�(!�%Oݲ�������[���j�^�w
��~��3��5�wbk�:�Td:i�.e���pY4�hO�W�	//Ml�l��
�~��5��o�ߌ��.��o�,uT�:~DM5.4D���]La�=�����/�Q�.����՚Qr�[x{RyKI����}��H�D��{�C�
��3���d�3 8,:b =�Q��rJ:7��ݳ���ـ��M���&}&�3}>��d��	WM�~��U��>5.�O��#׆5����0�ֱ����Գ��v�d���#�ڞ��t䜷����e땰�̽,����d��.�y��۰�������6���/��7�6�p�ظ���)���Q�h���<�[�Z��F�J�Q�$��&H���[�q��f�5`)ɅFA��
�dYa�G�&�n��3��1�����Ų�x��_������:g�׆�ٶ��1C���]56�0��&�栝3	&�2��{�g�gp"޷��ؓ�H�	,("&O$��ཤ�!���̂�(@=T��)[�b'{�<�'+�|�<0�|���؟�/R,'cKۙы�Ԛ��ؚ{�\�z�.�i���=.˒+��%�0��;7�9ٍ����cC��W�<x�8�3�}\<�cb�ru�s�cM��To��JǣV-$]���l4�4�:+��z�a�a�uS�A��g���0��rY��X…��e��,����3��n��`2�b��j�Q
2+D����h,j��,	������w��Dtk���+��*m��q�`��W�诬�×�{�7&J�0��sd��Eqp���%ڂ�����ŴG��:��XI��(b$��/�Z*�h#2���_��%+X�H8�<��u����Oɟ���fVDw
KT�c�y���o����U�j��J=se�Cro�U�����}�em��Iݑ���&���gNZ��ֳ�Z\h�	 ��d�d[�M�������m��������W�Kء5�=؄�.���������;�A!Kɝ'��P:�N�N�8A�BF
�Du�Ct�'�����Pߺ�Y
�S�
i��]N���t85N8�V;��	�1�6x�;K�9�f��ڌl����ISf�;E�:��Q�ఘ���EI�
�V.��Ti���T��:�z%lt\�A��������u��R��MM5�:�ɽ�~qEi�_]�.�=��0�ϗ��@22���j�5����2R�����\�H:uH,-*s'‰x2X��Ѝu�uw�ǖ�4�0O�Lf�f�f3�Y�Y��D�����AM��xpWV�\W�w1�r����Q$h5s��,,U&��	AfG,��/b"m�9���%i������e�p,t	���+�W��+��p
Hm�q�˕�N��I���t�N��?�D��\W���gq�~M\��I7��	qiYq�,~E�%�p�s��;�O�)��m�AZ|-BHڬ���s$�nD���������Sd`���)2<l�T4E-!�/H-I~��V���՘l��B@r���c�TJ@� �R���0<.BG@�G�O�rq3$Y�c�l��YGU��h�߯djG(����UQ�o[h՗�J��������iLn���T��%
�mss�T⦨��f��{s��*�@�9[`��y�=��A�rBr��7EQT4ף��w0�Ny[��r5��.��h�4�5K\�IӢ�4.Pm�Ve}I�$�N��]�;��z��^+W�.�఺�@,�
T�׸�e�q�,Z���w�\��x��*Y�� ���N:�˪�8�Au��T_�U�M�ad���[��lc9r�����\GU �W�|QR�v�20P{q,za�^���jV��)�1\A�&�>���,N�Gfh��p��'MT�u�"]���E�Ŏ&3�^QK>�3���J�V?y{D�L��K\U�������֪�=�N7�_~��H��Η(kÙMԕ���4iO��"���_���d,�#�5�'�e����`庡//�v�PV)��Hl�99"�$�.N���FGG��l!^�X�Yj���lSm�<�{����
��~�>��u8)V�p���C�+$'�,:0���*�u;��Z���7N�?F؄�:�!����	��(�NbJ������i������
�\��jt/N��` 4.݋8�w~����{q��d�F�z{o)�������4	��K;?'�Ȃ��r����L��_ܧ���C,��,R�0�!RTv��p(8qҒe� �^�y&����i��L)I�Tx{]���ڙ�Qª�X�����%�:��j}��+p���`0	8��v�ʿ:��׃��~����A�d6��,�V38*��c�rm��F�ޥThT:%ik�&�Sr
����W�_�*�����T��(K?�W�W�d�B��d$�&�a���r_sĿ�����!=iK�T����zZ�AnZOO*X�8Y)i�-�"K_�*�ɀk&so�>��Lq�U-.$>����9�8|Cɝ�N1���DW1X9��x~}���w��g�D~#Mx`Dk��R�Ju`��uܻԻ��F%$$�D��MQ��v�����w�0�dam��LQ�#dR�)-�!��œ��x
)i�uqK�PqK��_�S&h�?�=*_Gk�#�G���5#T���!O��s�K�Z���G��;�>�;����~���p݁�QYܲ�Y.-��+N���4�nZ�ax�?r�7R�J��G�QE����c�x�Iu����J�J��ʧ�3\e�c�1�����/\2�DE��;dĿ%��*�������O8D������WWMF���N�@��z5��w؃�f�l��M���̙�
�J�`CĦ�G=����h���^̠�������C"s=�[�EY���(�����[�{�.��1`���켴G�A(]e�W�v������;����z�z'WE�<���|+�2���H��d�&�6Ā�F2�����W��UV�>�o?>�q����\O�*�U��Y�J~�I+\��ӷS=�,V�y�0�#�C�~i)
c`��O��Y��:ED�@!T�q�ĩ`S�������WE��`IxJ���ƢqxBx�j�z�yS���k�O>���1'�A32}65���_Pa�c�a←�`�����H^��c����`��T"��S�!>�2�Cދ��0t쀱�y2��+Z�\��P���8�3Po������2}R&�:�ϭK;��i��Boa��;���*tS[��5_f��BcF���LIl=��������}dB1}aڨP�PW7<��P��Q��0���0�?����s搮!���LC�k]���u��ݷ_����N�<����Q�s�r�'�X����2����,�l�k�+��܁/[1{���^������V�������wP`Aa4(�hx5��M���*�Ѝ�{��L���k�������4�4�`z�l��S�/�a��jf��\b2��p����a�����-��Dp��֤Ri"Q^�{JYrK��g�Ky�
����>�e?cY��S	x�^Q��E4�&�\pAv�������7;�/!y�@qƀ�e��|�r02v�P/$� �¬^��_�l]O�)�b�6>۵�y�5ǟ���Y\e19TxB�H"\l�a�X�Z�ɖ����l_��߽4�	�sZ�&:�t�=�ٿw����-�[��H�݉�m��5Y$��6�-�Ѩ�!����=ZÆ��^��T�C,����e��F�t�DMi�y8���L���%�R����գ�1��K,��05�̈�PhT����3"�k�/�	�]�����	�����OѺ��V
�I��ιa��ͣ���}+�֖�H�t&�,���cU��ss�cxċƎ���%�N�Aŷ�̟�~�U�cC��`�����c�Xӈ�#5�FYUѲ&���P�$oGm�#�m4�/Y�����֒��!�0�,��՘��c�
 Gqm[�ݓSO�9�wv�7'm�*�E
$P")��MN��2�HhF6�Y`L0�'�qla�kl��m`gU�l��}�v��t�tխ���=�qZy4p4x��U�/���
�N�
�H�#vB
E\���(���'�G�Px��k�$��n�ʍ�ۭ����5[y9<�5Z�V2BBxX"R�cT�M��!E�R�c�C�M�b�g=�>��p�`�Ì3��0�{�r�;�Y�q�v>����Xee
��*��TYM�!�fw����+g��@�q�]{�,6,��5u_y�����v]�Z;+7�l6w����9�q��/[��rS��b)���7��-���5���B��Az�Go��ٙ���c�4x
�w��[��7��?L�h]`�����Ix*���Z����;I~R�Es	>!P�H�������+o!
&v���%��?���׋Z,���"�X쀎�bZ5���Y B2��쪒��2ŋEߗA�s|�ld�
�&�9;5xY�&l���,���|Ր�yw�]R1�"�
F����tB�
}�m\��
�m k�2�9�m{-����û^��O̜(]�y��%�-V]��nlt�o�e����+�����;[/�Ƣ
H—��d�5oA|�R��Q2��r���x��F��l�o���ue]9[!��:]��[����ƙٙ��s��v�wK�k|��&Ҋ4.�
3r)�l2�O�	��ć�0�ˀ,�%��2�
e#C	��1�n7UFvk�`�?�hv��p�7#���J�W5sd���h�AA���x���#c�2d�8�P_2��;
�e��
ZC^�5c�,���Yдq�0zapC����^Oُ�B��1��8��#�
����B�S���\
I��R�Ukkb:�t��Tf
��H{O��u���ݳ��2ᘅ��[�i�"������ڑ��)})�L\װ��NRZITNW~��1�/F�6+��QF�#/��렯���]u���S����׍^ȱ�}h�@�r<O?aD��*Y>/���>�t�63�9�{&�f�o����������&A]������w�IL;ܑn���:����?�V��jeo^���P�I�m*�YS�d+��,�pl��>g�Cq3�u�����43��P�y�y�xI��1Y�&la&L�����Gl���L��I�~ap�BUgg�a⏥�L����8���'�8� �
�ڮ��[C"��v�j�>YO�4���
{㜔����dSqH��]���ݡ&�XfH��8o����kf��W�W�X:g���jr�;2��
�%?3Sٵ��������-�ҵu�-�*�L!ъBF�������W�&��yy»u`ΣK�B�-��+�yS��KC�/W�g'W.�ϴ�,.���Ȣp1�Z���]n�L�����pv`V�?K��N�\:��gσ�h)YJu�N[{�5��/X�X��b��Mt�}WrW�a������'�����S��O�˞�MM������K����h�	�B�@0����\*�u�j���4H&��
�ҌũrVc��A2ѐ*��F����ԎtO���ڒ����hvI�F�%�sZ�!Zz�r�D&�%�B��E҆2�+N����@Uh���MP�B��qG����K�J&�0P �
X�*XwK��u���lP�$89�3��+�W>I:'�H�ʗ���TLv�vʥ������jmh�m�E�ҍ7��'�P����r�ۖ��0���9�@&�g�&�]��Xh:|*�ɋ[+����Z�a�K�H���O�j[
DH��}\,��%屋L��7�Z�֩-ڭ�;����	��~n�j2�^H�z�
2���~,+I��˼
��Zě�A�Ie��ܙ��H�9�s�<�;|$5�55��L��|<��g�����5�'��
A�Ujd�����Ԗ5��
�4y_o��*'�_K\:�H�y�a�����Y[ߐ+�ry�������*�]����ճ��g�Jj4_�)e�%�ʿ:s�<�m�S〾,�I+'+m�vLc�/�N��vzBѤ$�&n3vy;��"Ӣ3�+ū�+��"���{ܻ�j�T*��t�Q&�؍�h ��/EC��T��~ϔ�������<�C��Ѭ�y�>����Qy�_l�����H���?&-c���@�1�G��0�\Mb�ԑ-�D<LW�'����v��!ߗb�'|�_:޼���W�ʸ��0{N}Ü9�|�i �²�ӛS��Q$��l��뚐K$���s���+�/���g�M�@c�b6��<Q��s���V��'�F<�eDH�ۙ�~�����RB'��CT�4-�X4�1U.P���y�j�v�Ŧ��ic��bWŷǶ���W�Ҝt��e1Y��Ʃ��B��Tj��+�����r�����<��ͤ��

R,�
/�B��HZꕫ�x��@,�qh1�����*T�o�K@R䈝���'9/�3"��'����6�̤s9�~�C�Ӗ�fF���& &��p����b�a�>��^Q����QCed����
�%�� zK��p��5�	�i���|5�E!�O�UTgp\��ƻ��U��_U�FF�+{\OY�	�֬F��W�8@�M<\���iv	��#��;���4{��)ɜ1���}Y)�lq$�^1��UΔ�D|����N&Q�8�\#�����O�e"�vOg����/�<I���k�Rw
[��oC���δFn*��C��@C�h�[�@���zS��: �ڨ�i}V��
'�S���2�y!��
]J��T���J�p���b.�N�F�Zl4j�Hj�Va<o�a6 �Fb�~��L����4yX؏�C��
�$��
�om�6aMz��^���AlXd!�5���~�IQt[�Y.Tб:���^�j�؍���]��(��A�����{�|h�{/<8X5�w�kH�쇯0�S4�n���s"��>��� ��vy\wV��f;�um��\[k{�\�`�`�F�����}���U�_�Pq��!���'TO��,��^�g����
�!hw�
N�P� hs�����m'�<�62�hUw��B!Xנj�o��@[[��KՅ߶�w����џ<�h��$`�
n?������
B���d����G��a�(0�
4�u��e��S
�b��(�
FP8L���`~�i;������X�~z@[�m��_��T���ڊ�����jL�$q���C�q���;UG�PQ�j+�� _�s����
;
���?H�H����]*:ߎ鼮<��1����CN�3<���C���<�sB�A�\9��m�n���!�X0�o��m'��uz	_�w�
G��m�]�
Z)O"Q�ݓ7Տ��Ix��-WL{�D��B8�<Px�uYCo4��W����yfy��:��gΉ��65��s��U<	W8�[���؛V��K�;_���i���JДEsրtc��`s��޿�"��f�3��&
�2�3�[������W���?z��T�����ҩt�?�P0�j
B�~����D`6#9
2��*��F"Aw�������U�v�����6��i��	"�����\R���ǑcA}ڬ
j��i�x���vqd��������Y��"!	�3��*��䵉r	��
�Ia�Y�2�Ž&M�B�C�j��3����u�wr>8�moXps!ե�E��B�齞�������ؓ�ㆁ��Fڕ@��}��Wt�4��+�rr!�7��&�?�X`|:����͕/*?'n\䓳&@c�"�ʐmy����u&b�c���E�[]x�:��RPPL"����C2�=3�6�^�j�C]P��d:u@�9���96L�m[Q�a$��^���S1��a���������O��.�"�~�M� ��S<r�h����l?Qy����]��o{�ζ�9���5� t������g�}ݝ;�!m-U�g"E��ݑ���an���\ۉր븆as_d����$lS�V���k7�p7�t�h� iWJ.'RIIż)MR�\�h>��z�+&p:?6ry�dV��7����`Ҝbe��8�K��2y��x�%"�y��N+5�}f	p��b��,�A�-_�"C��g���8�F�C	َ禺�����|�4�!��PC��t�L�m��n��S�A�8��=��z�A�;ɛ�����צ��O��x�`w1��֦˖���[�T4e
M��A��r�i[�%f��ϟ��z��p=ye�;�������o�IuǗ&mn��M��@v^�k��޸ݹ��{��v4˽���ei��Ә�DĐ"w%�9Wr�f�(ڄA�
��'!Hc��,��%:@��a�p.���7w��g���'c��K�Ϛ��������v�>�S�SN.�p�N�\�P;\y�I�W�XIQ@,~�$��k�<M;]V�p}�W�Eb�y�@p^$���x�i�,<��(�&�X�-Yih��cAY�����@H���Z:#t���)��0�!=Io�`ew-J�Vn�?Q\^�y�vK�ᆚ9_U�x)�8]�;���Ȍ��MA��F������������O�u������:;Cuty���#�v��Z4����X���K�
c�bU�n��=g|���L�c�
�����c`��^��϶��j[7�lMk�]N����V�Om֘s.9G��\�Z�Y��DnT����%-�Pk0�H=�j3:�J_����y�gG�%1).�A&B8��2�ն�F�l@g��tB��V��E�������w�1-�3U:[ fe���c��:�CW5D�#�8t"x
�$b��LX[�3J:H�+��U6汆J�X5�����Ri
��EZ��������<Z����S,��W�Rm�,�]G���ʼ���6�rK���[�_&E���3�e��������HӾ����q�Ҏl�y`����E��ܒ�@��+���o�w���	��1do|����\���+��A*J(�8/Ru�b���/��WS��ۨm�{��O��W���z���СP!Kw���-S6c�9a�M���R�^a4
m��HS�"ɩ�l�
Q�]a%�I��;�yZڇ����L(�?o�a:���0~���oY`��X�	�������3�04^"�jD�9<X�Ne�/���.NI�DZ���v���v��k��^�W����)��Y��Sw�h�����¬�Io���6g��h�#:�:��ѻ懍^�^�tG�c�Ş��ٷw����`��+�[cѹ�;[�U�5";ZA^D�����<
8c�;��s�c�cv��~C�@���d�er�cD�����-�f�O�gh2�
su�s���2b�N�ΰش�|-q-�U�հ�z3q3y��N�����~�~�C���#���I�ep�|�|�7���=���dB��z�����\�[L�ˠ�<s�� &2)-��<dM��U�=�N]�2���sJzX�� �$\q�A614T���g���4�
ﰚ�aa�I��e�8u�}Ff���g,8�~���@�G'�D%z�ȂX
N�7
:�2hLT�J.��7�&�'$1p����N,=�����7�"�"R�l}������T��n������3&�Rꜣٴ�5]X@���;�
>mc(��61�*��p&�'&�%u���(�n�������U�U��­������O���OH���1�
�L�6�'��1��"!Й����)i���l� �Y�"Jl��=����ʼn�����3f�J\������TA��b�HJA�
�C*>V�I����'v$����� +����m��)�����aV��þ3)�֧5�RB�G���,��%�3È2X��=��W�3�4�}��k`x���L�>Ԫ������܁�R�@�٥
��������R�����T��;��<�,�o���U��<�(ҳv��u2�T�s�y��]��n��\�G��D���7:7�p�߃	��U3�|��<W�E)������.o�-&g��K2V�� ���;X��L�"�ڻ]�]�#�3�����ZE
!-N-��Rk�I�PJ�A�UAZ���
R-�@�-F��c"�.��G��j98
���d'Χ�k�qw�X2jm���c�A��l����ϐ}�Ex�[U�ͺڠ�]�8X���A7�(������;��֮�_㪵b��T8��ŝXq��捓i6b��K�$�[5�[YDK.4�H�FnRZ�Q^A޽�Uޒ�Z񍝷�W�#iM��U>����l!�ȧK�9�ͭ���
TG�ӋF:g1+F��O��"
�'m���O�w���~¯j#��=��ں@7٭ls��{���V6n��x�xHy �]�Iő��B&Q�u
.���½��4Z6+Ч�t��F�Ѫ���Z�!4@³�w|���Z��aGTa�:F��z!�/�}B(dY�.�:�pR�`���������]��Ҁm���]����$\;�������A\i���ȖςWn�E��J-�g32\��#U8\Pb�v��Ök����(k���.	���`U��W5DwR*"�#
8q�3O���Z$���u�BU�ⵥ���ە[}
���L.LZh=�k�)xZLM�~��	�
��d�+ղ��@�L,}j>�V�?@����ڛXN8���_刾�O���G��y��������<Zx��d�y��x^-�5 #2
��b�C������z�z����n�ܞ{��`��DžW�~�U��5Q�r����Nv5I�
:���G�&!_�gg�B����9�9�3�_�:����� R$`���CT
��W�(����|޲���m"F�^D�Me��s�U {����ȅ
,/E/� 9V��n��dN��*!���x�*��_��Ϛ|�K�������Q������K�s�ٺ��m��JZ����;�i`f5���en"Uߔ4:��1u/�8RF/yy�ޡoz��d�^k��Zy��+Q�T�U�o�����X��։e	�2xE[����T�X���3i�A]AP��
�H���;�?_�R�̻Y��p� ��a?Oݹ��c����0c���<�Z��9��IR.7�F(^�QC5@�hp��_F�d�d�eeGe/ʸ2�܎���Q&.2�p 
r�x�e�#	"�X�X�ؕ8��e��5&9|���U�~xC������W�_V�}�Dp6��W�5�����|�&���+S0�Ej��;Kt�����;�{jͭ�@~zg�>�@_k�p�r�����������?�������&�f曟�ye�'�6ؕ���4�
����G����(���&o^�u��
Z�J�0W3G��8I�D2�@��K�!���=9�ک>{�g!Xh��^�]�Z�^����o{ʫ������7w�S�-�{�1eQ��x%7{�ҧ�P��m��,�d.�ix�B�8x���
��2;�Άc��\��&4��w��Bi^�WUn�:�"T8�M$I�6��c=�k;�Ý��Q*�|�a0^Z��(�)��X�v-�5��7�&������U��W1��B�HɄm͐�Za�Q���Z�>}���\m������ښ�*L:3C��5���A�4�D�I�8mV(�fcnZsf�m�G�9q4�@\�rNe	�g5�����!3�n%��Aֳ��>H��l 
�Q�2|�+Ja�6�:��+�>\���Av�HQ{��A`c���<�	��j�
��^F���f����
kya(�ZUN)Ap'*S�g�[,`��EA>!�۸9%���w���~�a�d�������ۺ峷1�⽧9���Y�*����1���������������Q�0�ǝ5&�����y�����;�ڱ����l���������Z�k.<qݡǝ��q.@�w��C�J���}q�<)?pc�����p�zce)��s���G��92ǥ��=v;W��bb\���
� ����
���l}�
r3y}uT���J��Qc16X�[�k�V���x��5���{OW�F�37C��M^vLW�����1��Qӽ�?���o�V/�Nt�:���DP��$m���2,3*:Lh��(���荗ժ�b3�Z?9������V �jrgj�ؼx*��>�6��o6�,��w�L'�[��8ۗ/8�U?c�R󴀔������o�B�w�����@�V��s��W�$F��x�&�'Z���Q�>E⺑Y����>
">��	I_jQj]jgj_��R�ǎ>��K����[+�a,t�}��~�
�B������g�6�s����c���p?� 9/���=�B|,΍�����GR�>�F�Y�%��}�m�38�=��Ru�>��7�	~>��{�����#����F(˟ɎPj�U����j�k��v��%�c�����h��[���l�߰c�R�8��������`�]��
�N?���08��)-��)��x����<j��WZU���VP+'�&��a_�@����y*�7��l|�D����w�gQ�����M��tM4o�Kδ�?O��SD_�f��;��,�����D�_��i9I}���^{�jF
S��Q�Tn���v�r��J��q~�gV`|f�XeJʎDGm����i@���T(�v#r�&�=]mA�2�E3��V�,`@Y����d��
�-wO��w�x�q�M�E�+��-��#]mq�fL��$^l�
J!������!.���6�f�aD�!�}Jcoǽ�]B|h��͇��a�f�b��l_.�<��;O`j�>�zaQ��ɶr��Vﳽ���SD�л'м�D��gcwy�y3�6o0�����&����W~'�hJ�O7P��K���"����8/�v�q�������]����Ճ)YrAx
S���g����)k���$͔2D�Xj&�B������r�C�r�n�t�K�����O7���o�
�C���<�G�6ٯ<�W[5����9���ئ�4��-�
gP��i��
���2B1	�mi���UI0�=��s�}O��I�m_���f�����}�D�v��]��
���U�(�>��
�	�z�%��p6C�8�H)�(��ŗ`���c
���P%���W��]H��%[,.Ls�q����NƄP87@����Az^v��U۫�3�X:I�
��:��^��!#��A�P���TU�#�6_ũڀ+()�H;�j`"�))S�]b�"E�u�#+r�G�m�|�P,�m:464H��ꓥ'RCFK?��eb�'y�W�\{�͕.�xwx���+I5��r~�ߴ%�`Y}d�2M#��i�E�
�O��ZR�~Q9p�8N��`k�u�\��XPq���5[1� y�$H�^��Ӳ	���;��x��*�'��F�R�M똌�&��_}m߾�^�?��y�v��xu���^۷�����E3���xA�����i�4h��=�@���ꅑ�����	TklH�t�"�pء1�Һ�TL��2'�tة$�ۗ:ª7�u���3F�a�b.œ���۠�}E�wB!�s|���pF
㴉_�Aט>^$�QQ�h���M�{"��`�0���!8�l���2^ҫ�8����)	C��l@��
#&w������&2G�H��-��pB�nNdCm�-Yݲ�LAy5�X�q0�gb��h���EVSV�����0
�&���d��kҝs����S��I5��[��j1O�m��UmW
��9�΍w�9��Q����p�f7��r
�F.��Q����2xy��<�P5���mZ�膷U|�P�_���#Zv"�D�+�����F�>�_�P�\	��%[�ޒ,
��	
��������1��Z�B��R�/�#|Ou:8�2�#�c�?hax�X&a�M1>�'��H�:U*�H��h�;
�᳌�q��&0�����e�F8�2Yz�eH3E
eX:Uڬշ.}{��A����I�=����u��p�
�'����*����VLm2=�s�:E�D���s'JWf�٤B1iOM��qam_��X��ku����AO��UukM��Y[6���{*?Z��=u�2�D5+<��#��n��,�?�~��եݛ<�htvӼ
p���Ӡ{Q)�n7��
_(�l��4Z��M=�E�Pi��
�
f�2�$����gȆ\]OG�S�����q-��qU���MݻM7v�9 ���=���T2��t�1N�	J�B#��a�P~�_�Χ4�� M�˰���EL�6�I�
͛%�[@�\�[*�,�gl6h�9{�۬�8��{��GG���7E��ǡ���p��%�C'��xm;�]:SˉN
�fI᪦�T�G�Ud��b��Г?m�%�9��i�_�rAY6p��F��~���X��+���������om�a�@g��������7��%ZrC��7�io����g�5?^����g�e[����{W�5�r���{֦׃Wmh�vʹy�+�:n����+��
򇈇�̾�+ЋI�d:ks�
�K��+<޸���o<�����_����?���w�C%
\�!���t��e�e��=2�����x� iV&o:����,lFɛ0����	я�2�w��7��.���
��j=G\K����AE9K)�S��[ ϮƖ0W����8��͉5Ww-��CuE��r�Wy%���ܾ���ME���_���r��ܹ�^�ь]��͵�ș�$2�vI�����їĂ�h�
��tiv}���i鲩M2��o
��-�H2��*�n�!l4�As�H7�jVȂ}�m��!\��"���eQ˛-䢖-DK~�Qt��?X?VOX�ag=��;�
n>���RGR/�ȔaI0d3A��$D�TP�0�
.�	��)15�TȽz����n�`tnxx��D�c����xL��޸�<�����W��a�5�uI}u���I��
�_M�S*�`ǥ�y�&���U��w;R�R����˒�����S��Z���(�B�J�}���W6���e�
�V6�]uǴ9Y��a��u�C.�����:G��Mŝ#�TZwߑ��;+�Z�����pebc����������p塈M�n��翿�cVc��ksu��R��(�,I�,J1X;�
�_h����3����D��_�����2f���"��9���9�r�}�2\�hbQU,���1ʝ��}�X����L>:�g�0��f�F"�v�N��|z' u;���H�6�%wWcc<��O�T�n�X�vR�i��b}��2�{ȎaU����Lt,���!��/�;��u��=�����'�0�\
�,XM �[���K�ֿQPɄQ�pq�`�\�R;Ig�8b�Z�c��q�L'��3_x��l�\9��p�G*??|�>�����|�#��T��y�o��d��ވ��+�zgZ���9�=�է*O�.W�={�O�Y������c�_:��=��
�ַ���1J8���Y1��P�g�w���#��3�@^B�z�q�0^��곈��C����<�6$�p�	�ڝ�A��$�PdO�L�{"ع>c��)D2Q8��a�)L��on]?�I�P*�{���o��h���9z�Q$�F��i���&�n���V>��֒��m�L��c��k���U�l��������٤
=��1�/V���#���;�v�����u��(��Xi�g2k�&�2ƌ�8�5���x4NL�X!�d�s�
�*�c��G\�md�P��J�8�粒#N�ު'�?R�o�e��sY�G�\6p�Q:�-q0�Z��#.׹���3y.�?�,����2�c6��t�9�15Mf�H"�J$��x�L�#��-�X,�
�����$q�\}.�ehK$�2�R�T*��2�e$|Hl��GTJ�ߦ<K��?mčC�[������*��E,�0W.� �=Z����
�	(���f�8�yPW��@��'���pI�A��L")�H�cN�VX���b�]���H���Ň�:!~˾Ƿ�p�8��Wx�R�Pg�9/��ɍp�?�b.�L�PIv�+/�*���G��?�]r�+˙����GO�R��tW��O=*_W�7Me�"4~>z9�hE�Bkȶ"��v�v����oR���}�����eH]�h5��H=U�۟�˸�=8\ū�v�$0U92����m�2q�ʓN3k��x�����*SCu�|��HU��c��Vٯ���Ù�5d{{��>���ͻ����8�������L/֮�_���8�<�$ �H
p�$O��|Z &E2���ʄBN$�Bɕ 5I�᪅�X�
f��PI$�DL�P)�eg!4��w�	t�<zp����k��$	 ����T�MVæG���=��Qc��{r�#BV��E�Ib� �ϩ���J{���֭o�e�˶��'���&2��:z�\DУy���#�%d��:����{����1��#J�y%^A��������y�f��̃�GNI���M4B�`��h�R

�@*4pz����Z��p]@��4�dn�;�^�^���Es�cvW+�4fm&E_��v�����2?f��ʐ:� c���q99���Z�1G�1f_���GA�ȁГ+��tfs���r���V�H��D
��P���&Ӡ�
�V=�?�mϗav(�b��y��
�͌��A��$<8QWYYp�)E�����"�Vb��3�sq$mnx�E�-�~��Op�gFǓ���]REp�$��>W��v
��@���C��)b��j�D�鬊�*�8T�9��J[	���7�	4WV�r��|�\=_�� ���>���G��;���<��5;6#�B�v�_|O4�7���߅o���h��kp=���6��.�]yz����.�2��O�Jx,���oT�������K�Yc�s�B��� ���� ��w����9�Ū���J�
΂�����S\5)�R
\�׎�-�Ւm�+Eb1�	�
����$R�DLɝ.�A��
��F�T��A"���
����.��
I�b`IԤ7-��\e�yH����e�������. �f��,U������'�ٺHE�xN�h*=wx���.I�K"�Ճ�5P
`���q�{���r&8
�Tk�
�J�[�s���*���=}�[3�/���ʙ�ӯ��'��oI��]���+J;��6O�����t�ٖ-���o��/(��7W~�yQln�Ryq��˒W�
� ڤ�j��(�
H�Ō���K ���ڋ@l3mډ��3C��N
����I
ɵvr
�p�R�J�����}s�JQ��wU�����L
���̦t��(\��(C�m����~��-���-a�j���[g��t�7l}�٫Z��ވ�X�j��y�:��Ïn������������;��:���#������z�3׮�w�-f��LUpu�
�!�<�\�:�f
�L�'e\�$,��~\"�������
^�.@�>������u����2��|�2��.����������
�U�����ҌV��#,��<)G|�v�]n��n�T����!��X�����͕��|�؜�vjQ���9�K��\�P!Q��r(.�A
��L�'��=�=��Vc���c<���	��yz��OR�p_�1�W��#5���؃�^��L_4�G���w�W�j/�17LC��@]�6q�j��.��/NS_�
_�_���������Oψ��?޻���
�����i��!Qwx@�k��N����
��.��H��$�\�7l���X�����;��j���o�j�����}��+����Sp\���GF�� 9���0]��<��*��b��K���hgb�eAxA~�syp��!�Ҧt���F��D*o�$�7
�C4����W�6hy�'�N��ٔ\���]Vg֕'�IZ ��!*d��A�t	�Z9Ip
&��F��Zm�B#��
[��PL
ȫ@(��;Fft:�ش�D����NǢ��p1���$7�L��.���a���F�x�g��zuQ�������^
�l��ptd�Bt&�V��x�T�㡷�p��`����y�㨑���Z���8�4᪯Hp�y<|`K�&�`�Y;��E�q�Vn
�uJ>=	`������T6��|�pt���A��r�n��mj�t�֪N�	R؟�M���HFDV�5C|������횰����|]�����M���D�?�����Q�#�nB�@�gW��*�7�8�\�B�s�J�f�w'<R��7���FN��P��aЋ) ��tP"E��RT0T��I�YF�fA��c�e��z}��6�S7�m�BN��I��*�䅀��&P��h�,L.���C���`���0�����E��7E�L����j��$ɝR��7Y	�l/�t�#�ԛ��c:��7�[���[�
���
�9s�ކ�M}�ެW	D2�����7����s�m��%�׍>�Φ���3�[�.�r%M����ug�x}����}�����|������1��HAP��QplZ�MtB����,��c��9p>�_}PM�y��bxB߫%���v�~O	-C,+�Wٗ�d�"�6�puψ����pi�Wgf��C������l���Gb���@�Am�;���^H��恻޾y��%���a�P���ӗ��;ֵ�5;�Xw��'�߼���W���޾�n��s��?}Y�W\9���r�Kگ����JggP����%�2����HIJ"���v�TI�@"�@u��L0� ��N��v��ǠT�( ,�A�0��F֐��pr���<��f$�v��8��k�w����s��L/δ@ą��t5%����o��-�K-plj"&�,#le�!��U´�i��G<:z9U1��kGMDb�N2�6#߭�U���-�Fw��׏��|ΨX�����+m�o�p�MLH�Y���C�YV����Y�����,�{�)�,�|�i�,k}�i��x<�s��*%@"֝�J��Ư���f��p�#�x!�N�g`��(+����H�ݑc�hd�c�H���4�HWO�Α~�a�\���ι�]�܂snW�\'~��i��Oftx<�39/��p�;f|^W}��n�\D�׎�����xJ� 5sA����&�FF�r�h�%��6Ш(��f�s�e�cfƃUA��r
e(0�^S��G�.q"���g��G:R@��|p(��"zddd�:���a���/�����Q*�n�{k�;
��$�x�k;:^�+
~�xY$ѝ�:�Z�\+p���L�)��Tr�@�l��D�C˚�}ѼKev�WT�}�6���/V4����d���ѿ0w�C�O9+��O2��!l,��ӡ��yb�XQD�TЪ�#�A��v��K
%!�h�PX!mq���5q�e����D(|�<$$`_��������7!�w3�85V���xK'�a�#
L��V�G��I6�+_��f���T9�%�r�}�x��O��"�@��k�_H�����ҟWxB�RS�*_V��qU�MHx"�<!��k҆�흝M߆�;Ѧ
V��J��K})��d�h�$���4k������k
�ȐB%#�[^�ѿ�H�O���a	05
�Ϳo��|�K��]���6x��hR�W[9+O��˦
�����T>]ov+㐼���k�����#�3�$H�IIZ���O���F�JK��V�T��{�^��IH�����U'l��#��8�s)[����������������?���PD*�������p&f1B�?�\_7}<ZtdtG����H5�Q�Tu��/'\��
6sŭ��I-<��F�*Z%v.�/����t��	,�*�VC�	��1m�Zf���;W�����N@����z�;׈/k�6-��>m�Ι��w�~x�ƾ��o��
�� ��Û߅݇NU����ٴ|�� �-�<����/�MP�����/V~֖��g��,y�@	t�0n�^��"#Ŕ3�+P6����yq~J�v���|�HVY{;SH�D�q�� +:ΐ�
'Nܳ0U�Q����/��x�A�p`�@�le�j�H�;��X�[�@,@�@`��8H%(dF�Hm���D�{Z*��w�`F{����(K���
����NE�h�����F.@d�ն�'���5pQ�$Q[~U�;��~���gk�*
:��ɉ��('���%��]�\��m��*Rs�mL0ӳ�/�ȕ�.U��һ�ͭ|0�#�:M�0Y���)?�v�r�1ɬ��g�3�x�z����n�uZ�[��S?��퐬jM����9</�V�3�Nz���k;B�J�|ΉV��m#��u��
���@��o�\Ew�����GsXsR�Ǡ���S�81G�s�E[=���{�ax
E�X,
��F*��	�N'I���.R�Z�g�赬�&t����&.��:#H���,u*�����#��8	Pc#c$C.&ד�H.�)�-Л�W������
"
��*��>�)���������8�Ɍ����u�`��������6�(�LJ������&��v������֜�泧�3����ʯ��������ݝ�<��	7��4�s��eD�t6g̝���i�W����z��@����QȜ*xo_��|�ڪM��mmP�V���F:�7Y�����)�O��J�r����/�f�<��(?*?��#P�2X\2y4BI�f-��:�v�W2�m�Fr�x�

�1c!,�r�^�spq��2�m(���z>\+�4�Q6�i� :�g�Q+��,�]�S!���P��ql��+C�jY���e�"���~c1�T8�r��ܲ��Y���r���--��_e���ݶ�i�� lT�J�dϬ��wv�Ծ�o������6b7�S4B:pSH�Ҩ2�
k����(픮�l��$bIjU�F$��.!�!���TP�

�C����g�Z�a��4���h-v�5�.��#�x�Y�вhQK��E:O<�lz��1���O���E�%����=�ЪS��N�����ԥS8������81��`o��˥H|
.�-�ֿ�H�*�����.w�9�T�
_֑�V�@-f��������3���"U��H
�`7���p��x�D�@tE�|

%�r!5�<bs|�R���^��U?��G��U�?�x�x��BIy^7�]�W*�����z���]����Op��X�����@3x���9j.�E=ǃ8KɡS)hJ�q7�g�^'�J���e�Y�����tpd�5�d�
�
�@i
h|�iM�����q������
c�\&><�>���۞'������
��H��82R�f��hQ#��s?z��J�P���t�"}��z$Ɣɏ���q��F;���<���ZW�Z�5P�J@KLq.)1��K��՝W��h�xF-r҇t$]W����aoQ�tHD:._�Po�������m釶|�3�`vuF��K�[��
��-�[F��T'0�4�.���bQ�V�Q���D<J%rPQ*Y&1k�g2ƃ�
'��^���J�%�iF����y�ڐ/��G�Ɍ{L�g\y;}>��
_S�=�~F�S�(��ڎ�x������,�V����J�#54�ګj1�jF���e�(��:
%��r[_���i����ߔO_��1���2!���ܶ��65͕��6RW<�$�?�:�s�9�8}��R�4����2]�Q�����d�i
t�ԫ���,a�Z;�nH� $(���ndl�P�{!�K��Q:�� @2���yH�K���߇ߟ�L�%�]@R�~�O\�+*�՟�����
��H~F�C�!�E��q����q�R��#8��GO�{D'�e(��=$�
�5M�=���O�^���Z1"��U=�ץ�e��$2��詌������
��O��*�J
��?�瓢��^���3�����Y�|B
��_�O�>_����ũir?�������ɤ=%>�!�SVZ+&����.�o��+�Jr��5�#c�����
�\�h7*��ȍ[D�F{�|蘬�� z�˧YW@u�McP�O2L�?��/��նdik�%�_С��m1���Z[��%�K���1j�GO�5���l��GY��Խy|[��0<s�־˒�]�dK�lɻ���Y���w��Y���d!�5��
	NDh�By����B�Ҧ���,
It��̕d9I����}����Wҽw�9��93gx�X+/�*���O�����.b��1�GM,i�/i�u�`�u�2���Fъފ[*�
If�K����R`����'�)H�n�	�Ԃ:u����˫<
ձ�Q�Q��\=�W��$�]k���Ji�ʝ�������H��'� d/Au�,868;��C�7`Jd�<�Ĺ4	
J3pg���z<:[��--U�-Yc�����{�^�Uڜ�}9'Łzm�( ádM��JIs�Z���j���Ý�xZ��)� .{��a��Ҋ��bji�m�;���wgN<�A� ��xo�XB<��q76�������59[&�Ua'����� ږ?7N揍�~_>(E>�H��+�~�.�[ڝ}��ڏE�?^�
|��Q+S�S�����G�y`_�o�GZ��?��J�n������TC=�o\�7����wS�
�_�g���b�j���?�i���z�Z���S^�2�vK��s3��raQ%�#_D�}�W�Hu���
H;��n�VV*Q��YG���ʶ:`�(I��ޯM��u�"�E��ƍp�l�=�J�Г��V֛,Ú�Gۻ)H��Lk�� �Z�!��z�7�"�U���B 4�mz	. "�`�	S~KKI4��M�"�o�z^��ݓ�W}�ivK<������ێ@���KCK�]8c˟ycyd�޺Purԭ5߰mJ�9>|	����qوI��W�J;�m��7<_j�8���i�K+௃-��T7�'��_Q]�s���Q{��I}�c�>�=��Lp2@Mc�(�'a���3d���h�}̸�}kQ�����K����$
x/�#���0�h��
?����@��{����?���u?%���#��#�Ч�vȴ�b���Z��F
А�8���sX�w+qȬe-�c�
�Dzw�?����e�/�ۤ,v.
M��Qln�3��
>�6��Օ-Җ���۵�ĺͰ����35����밅�K�G�<����m����]77ҙ������y˺7,�1�߱��Z�����意��鎔��Q��
�l��YV%�!^
�I=-��R-��P�"���v�#���K����'\��T�M���H�3(G�)�=��m��ş�wT�-D��=z
�Eu��:2f���S
}u����0w+���P_Q'�\�q�/R/�^�^�1o�`�<ux�
��������PN��^䦆4�ғB=m��/Ҕ�io�7q	�)�no`���o��x���8���v�FƘ���R�j��k!ߒ\��n���x����|#.*l*j�q��d܄^�%�2kq�Ư1�3W33�6�tL�ǶW@E?Ε����uS,%��)���w�rX�[J�¾#[���HTF�@���U��S��h56�"������6523C�)�����o
	�1�E����PRP���24��h��d��H3T��)�"˛��V�)x ��B+�IJQ>�0?k9�n����D��ݝMe���s�wg�Q�0�@�������DܜR�n��z�v�^���b\lkH"���Ɯ��a��
�
��M��aHa���
f�5��NPo�8��4EaM��R4����$���R����P�:�R��md��cB��:ߴ�>�^v��}-)������x���L��bw"Ԛ�7���P�ҩ�)�fY��
���*���X,��/-ۢ��hg$,�H@"!	���+��jLV{#18�f�d�!z�7O�����3��$4u�7�e�#T��ب�y����WG��
�5	 ��K�Ͼ2
z�)�Tc%�P��I"i���B�E��[U
���oݵjN|�wm�
����f���^Ӣy���벑Ʊ������S�����d�F�6xv'��[f/�v������i�nm��6cY\3�-��ރஉ���H���@$�P��1�N3G�j�ȍٝ��z��h�^47Y��%��B��盚��/�{���o!i
{���J�:Ҝ.���@&F@>��#�
�����k�-���_�����v9b����ه��|Ӏ(�D��b�2Hw{�u����&��$F��4�d�5��hl
8*�Q�Ϟ枣�Z[_�`��f���\��Vkg2��1���di�@�4%*yz���:0�
U84�->~ܸ���]��m6UT;)h�Ƣj�1��m��Fh>l��:�/�z0��F3���NҚ�&mtRQ�
��oa��M�!�ﲧ{���6������hV�&!���w���D�E:���n�{*�/�$_� ƓX\�w'�x�h#$oX'��)&�lD-�j+Ӯ�3���#���WM���u3ƵTW$t2FZ�;���9q�oт��lX����
���1�TnK� �y6�@��}���?GwV�JU�m�
�����ƨ�aT��hL�+�|
��9S��m�n[�Q�,Q8�݉�5���� HyAJGp�9�7|�����A[����R_Y�	��F��z*��z��;��ܾ�c�p��9��cp[
y��+,��UZk�&i��i0�dJ
����J��e������15�E*y�
�
=.h6�-Kg��!-��+�����`�	�FL"�8
'���ob��;_؄�;,V�.�3i��&փ]\�P�B�ȣ��S,�
Ê��-v���đ7Ә�3E�#f��^��*��o���\��a�oWN�㝭3�r�XB/g�%�	wӯv9'���Z�nG�o���N-+R+�g77)Y�.9��=:�^��ߗ�h���FPӌ���?j��*.�����5���+C#vm�Q(����J
�z%���&O�
�5�����\�'9ã��g��N�(g{�|v�|%�R�ޱ��x��C>�eRcA�r���%cL�_��`4�$W²���E�ISc3���R2����._75v%��(�X_;��3����-}�S�	�@i�TT(�b�I�SGtSq�1�����j`ğ��P
3��3䤺�O7�s4L��Y��P��T�e��g��s�1�'�\���}��ňNL��A�.w�4����<NR�z�c}%uA���+6�;X=aL�.�86i���ܒ�K�k*�l����%3#������Ѯ�E��^<���r^��Dm��*�ŒJ���f��
GM���*�n��^��gU��\(:'��hJ}��p�N#I��>�%h�{�\��uNSe�^��R"q�4�E"���HG �5�d#���*Q��qml�\.�vÈV���k��[q<�Q,<M��'����?H-�%�chA+f.9|V�>{6=f�pl2�ե���B�t�~�:��N���X��o�/���2�^�Ȱ��-3��=���AKvO���]�S'�Yj�HhJ��S�RS?��i7�&r�
NG�FX$:�o
�fN�?
P�H��f�P��"���?��<CE���A�τF�d�aH$"Tg]���D(1�xM�
��Q
�-`4�
Nq֫k�k�k�ֶ�u��ǤO(�x�K�����a���s(X�6rDv���Z?��:����7T�d�-����U�����<q��=���8�S�:�>1r�Ԟ��t�ݾ;[|��Tɉ[L{H8�a�'���Cs�d�b�݃�����Nϙ,֖G㈯o�l[�&	���WI1����k~�=(,S��1�`/�}���\�0�?�l���n����e5�*��
���;6@U̾a��݋o���,Z�q8���^��뿹e��o�t��'d�4F��쒳��CY׎ͯB��k~�Q��-yuo�/ҵ��~�#���}�v^�S���KC��W׺+:w��]�ڛ��jo^���Z��>�������'<b/?�̛�W]/��}�w��ᝂO��N��K<l�􂇭w�s(=�/���ߠ�E;���\B
����<X��+h�@0��r \c;LA�V?"�V���v������:���P�%Z�.�h�7��e�J���������2���_���~E+B�(qmS:t碏�ш�|�<�F�J[���'���u��'����S�)�tY	+E*"Z�EK,��\�H�"9�;��>����*����2F�������.�	|J�Y�fz�Ѕ�E-��nD����nO���(2r�Y��X%ԥ.�m�����8%��t���R��w��<�FZX�k�k���#0�Q1$�^F�/q�|�������Z���j��T�%7C�H���Ue�P~�Uh崢V����~�R�Z�!�L�?���-~� 鋑��^y-��7j�8��f��\.�Kd�8�E�i�I�z�?\������+�)kJ�֓�M��@���j�N����W�K�&�]�P��O�E����#�s1r:'����E�)�	������E����R���14�A���|ɠ�����1=C��
|$o觶�hl�P?�Ed/y.����d!�6�O2_���`=��?-\x������7P+3I:�v
hy�0w	�V��(��J���~9��L�#�
���5kE��秭��6�?ϻNr�]�|���ٱ����\�*Y��}}��d�n��bU�����c��	�F�b>E��{�4ˀ��ϟ'�@�]�c�����l��#x�PŨ�z4�J�ɩ�CK ���qL����dP�'�P��,����
֮h�	�@�s|��B����j�+S͟��@���9��%�����x�������V�IE�Pb2Y��� �ܰam<7A�
�]�PNLs�dv��f��y2��X�k�Kv/9��hז�b"J�Uz4�����@�����s���Ղ}~�پe{K��o�@�MY�v��uk�`k��1cؽ�&O^��μ.�9#�
�@���3w0����)���l��<(a$�ST��{��S�cPL�g��9r0%��q%�]����8C]��7޴|����6��at�T�'�w,t8�M!OT����NFC���Yb0�ӥ@�Ak�"H1b�8�cq�0
h�� xP|>���B�A��Q��&׮��������(�r���{���F�����f����:�<
��+��_�hF�8$�L@ljL%
�f��x<
�g>zS��R��(����M(_��=���u�x����ウ��j�ߥQ'�b�es�48���$��nj��FhD��F6��**�Et���]�_B�`�l�� �2[(D,��Qh#�q�Q���!߀hV0�ʑ��=����a�5��E�~Ny�-����ھQ8�5J]%��)F�h�� 1Y��Y��$&+�!K١Ơ�k�2�]m6�V$b����'���)X���dez��y�
�gj���ޠ��$<�������k�&�+;
��
g5z0J+>�C�(���)���'�O�������%-�ź���0��R�"����>1;��&����������E����&ʨ��Ӵ�#��͟��$�ĉ����έ�������ۑ��������=���ʧ��{�z�����ځ���ɵ��-��'�#������5�2�β���=����<J�����[��
�0d��bX`�K�ve1ۭ4�.�N6�5C?w�LS�rd�(aѳk�*��H�lכ�v�I�&������ur�?h7��!�݀���\	���/5��~����y
"���($n:.,o?TWqHc��V{&|~�I$lK�ŗ�J̍�ss����7�lW˴�p�FOKG�Ӝ}�{����r�4{jj�4޷���*��
w�V���`ל9��?�,&��6 .���'̓bq+I­|�	���A�p���b�+�g�}6�O��8�ʘL�E>�����ʕ��I���֠<��z��/.� �
Rk�P+\�j�<�^������Oc��B=�:�
<�S���D���oi1Q�n��lH^��
�+�
��i�X��=̰,�H�C�M���`W�)lj�p؊O����u�Q�R�g�����>$�㓞'm0��|�m��C�^ꓖ[|�r�es���-5���o���|�r��áPk42�V�SZ��Ū��-2��.:��KmZ�Z%��"�:�R�x�%lW�Z-�L�uJu�M�,g`h�vd�H�RiR�dh%�H�DD��Bp�.��c	w�}�J0��������@�
��`��3-���*�X��H�'�HK#N%ߺ����p%1�~1�j���9��M��:[�����M�[u���<���l�.��K[�~��Z_�c���U0������jwE��O���o��W��K�T�?s�ɡ
�`��zXOUKG�Nj�A)ʥ�����b5L>��G�Xr�h�T,�!^¡P����:
��_�P��e
)��!VJ�28���)
qg���evyB)� -�!�5�D�
z���d��OF#Ne��RZB0H4�?���)L:o6$h�KrJo �����̭~}�Z�3I�X-���zE��aJ��F4�9�DC�ڟ:W�t��k���鴷�9���S#k�{{��{��#:T�Ձ�Q=5���hnV��ju��a��%9yu����/�m�3���0�<T1s�oݍ�
�_W�k?%����;��;wQ$��!|�Fґ�1f�a,:�c6>c}���̜�|-��K+G(CC1���V�� ��(��-(L�Zk��r�ϯP�������`חy]�2]�֮sZv�ߧL8VbV�-^'zKJ�fZ,��j4���)�ʜ�?�R8�?0��:Ix��Ze�-j�9&������e�s@v����λ7��X�8�A�|�w܄]�!��\?/�~�t<�s�G��O̻q�-���Y��f��������0SNm����D��+5~cs]c����0暷�x���a��G��'.���
;��/��������:�
��~a�a�ynS'
�A[�†z��4�m#a�h�z���2ҶHs��Q��rWA%���*�
��
�A��0��mM�U
����[I����*7� T�����:��z�
������&�
�"�HG�Q��A�~@u@u\E�Tq�/�M�`��<�����݅6٪0+ª\<#�zQ?l;����|�:g�
.��)�)��(r6s�r����o����2^Z1������jg��+�n��B���&j��
�=�YJ�s���"�Foc�3ʵ&<7���8��%D��`5��E�U�^X{��'2�D���cW=x�;gA4-��
s]������T$Y��k�u2����4�L�� #fD�%��/�G�-�����%�b?���>��~�/~��1*P`e���f��~�%x9"��T��[���K�@bZ���/䔼_v�:
����D���t9�͞Ɵ�Q�O���W��9�|�t� C������Spb��?=�����|�0������
�NB�\O�M��^���8ߕ��r�"���4%S�T�
z*����O.�#^���>N��@�Z-Eɤ�xm�K�%Ԩ)�������뾄�hx�W��e��_ }���3�f���Pj��
D�b��r"u�/�*�����c�+f��Z�^�}6��i�tRep�4���:�\/@�~��
�q��+K(�׊r)
z��Z-/�}��xo@ݨc*�f2Y 6�r6�
�q���/�V�:F�Ŵ��+���Z:�y������o��4��H�"�V�@K��U���j
~� ��[at\����!�n��Uw~�ud�VM�m�zu=W���:}^����*QϖS7QϠ����z3���e9b��᠟q�
#�c�g��Ê/U�|����k��$A!٬�㈦h�旓�].+W1F˱���e�w,�+T��q:�^��v����X�R����#����;��R��
�0���|O{e��v��/k�2?X��l�����Uc��ҕ��']�h\��/VV�j�5NL��kTvG�a�6�͢4�m����q�!�8��$ZDvPGrޫ�/��(�,��(_ޙ�K�j�&�V�ʔ*K�y��D8��h�{�e�h� �0�u�@Y�S�hF�����C��@�#M�Z٧VaT��}�&h�3C�Pf
�_V���=P{����/jjYgm�����b�z�a��T����JYV@/�.Ȩ��[���ML(��d�=ħkZ-8�	75��3�l�1�����x�D^˹/��]��D;z�+�����v�߀6�%�X�	�=C�~�o�^�F�s�d�_#�/M�[����}�_�3��v�f괹��8���=x�L�@�b����ɹ���e<�jg���pB���w�@�����.�'dwx���'d+U��)$q���NG�YV��՜�<�//���W�z�54
h�:]1�D�:VO3�������WPUQA��<�`�(�
z"�Bll�
RPݧ*�S)1 ��}G��@���P_r6����K�r:���^�r'�<
���\l�.-/H��/���dh-'�b���:]l�
6�S���X��!b��k����@���+��u��Dx��⛯!��~���H��&)@c#���!�g�*�E�ּ�s���2'-���*�fخf��7|b��BȽpS0���=)d'
���K.5��������L����S'�_�w@z�yv�4�A*��t.C����j���[nNE�"՜lN�5t����$���i�� oP5�Gh���k��.���ެ�֤`}SssW�N�45&����Zk��-i���%Ͱ�h$���ҪT��ʲ
&U[K`��U���Z���J�E���`�)�.��am� *ZZ��jj�uAU-����n�V�I����t����Q�E���at�xi�X��$Q�YG�d��C�A�k���֞���R��:��zoZZW��V.miIK������Z��C���dAbv�\�#'EWⳤۂ-�)�&�|0�yN\�r���KL*�W��d��{�@jF�xQ��g�T
��v��J������g�'����m�wzr� ���g����!�������ɡ18�-3�<��zO{�4�4k�mm�F���_�����A��h)�ڠ��AKyc��
��!:�^,�
�ruyY9]��7�*�c$2�.�����}�q�B0�]J�ҫg�B��o�\�E9S��W�a�l�dj�^�6PZ���r�֩��ژ�a��G��Rk_�{�-���U�(Y���O��K�UA�Z
�#��̌.�ݮ.U;����jK�ڤ���}�x�(l;��4�3HlE�H�J��oD�x!X;��N�Y�0i]���=�N�%���1���ͧ�+,HbN�L9'X�M&�F����@��=P����Cdk�(�ΐϝ��>m|�
c���`����ao��;['ǃ?
�z��]�[-��	�|#�7tQG��<U���gŲ&�ʓ�g�V�?��'��>aϊ
��Ȟ�{�e�	�g�d���Y��ͼ��`�d�c��l'�4�V��Q�G�N�E�*����Cu9�K!�A�,Ԁ�QN�72O��}���(g����E�B��
�Fq���
����q�ô��'��fB�U�t��ߟ��nwG���n�X\�w�&@r�4�KҖ�ܞ�.!2P��Kpl\C���@��G,��%���Z��ߓ8m��h�j�</D�U\I�EBBk9���.
	�+�������z��G%!sȒ�%)e���R]?\6\�i�L5O�\]����a-|�D!K�%b�ŬjIy�.�O���j��1�L%�%A������*���эg��HB�p&��t�;ћ%d��M*��
��ݖN�|�aAP���/�^�"i���hY�ll�X��6F�DzX��lX!�k/�t�O��Τ1&
�w�ق���V��'�?S;� �(��Y8�O�/��>�;�'Dp�J骇8���^�ס4���Ǝ��}�TK5F_�w��-V�ƙ����=u_W�)0��h~�F�7�Gn��3i?�.�4��@�W��߹�(WkJ��KWE�,�pdr�Uw@���"n�n�uq��m�ʲ.���=�Du���(���/B�v�R

���O�J��
������:b��������_�r'ۇ���_>{l���E�-�U�ѣ���]t��WN��cBA�9
��P
��h�'���!�>4����V����"Q�P��!�c'�8���'I
&�!u;��a
4��F.[+�w��"J�$��T�\��ZF�K5p��>������XrzC��"3��=P��BcL�Ē)
����e�Co�;�
{�#Z[�K��
�tmuSuG�n�~�}��-=�>��|��a�77%S�u����K�u��#��]�>j��O��w��z���ds�.2Է���$�m
q�%C?�9�:e!�ol0�Sÿ�؄��^�r�jZ��q:�_I�z�_��o���a��@�ux���+�<�C1�LgΨO_�h�x�
�u�-sy����J$xA����ڤ4��񪀈��b�6��.Ԗ��6��_���e�a"���.�	��k*x��n?����0醞����|�XR\g�˝���jɹ�pG�������p��y��]�v��~9\�B������<�W \����!���q=Up]�|d
���=���nY��x���!g8$���(R�G�!6h��g�":���=���UDs\��y��T��st 
8���ΥW��;L���M~8xN�Ϝ'T	^�k"7�n�<a�l�l�m3�W;��~fKm҈%B���"���1ܕT-�%t���K,f���E����>5�����M��1]��T�+*��Ts��ADJ����9{y|6�
LH/
��p�9�nL���g.:!"�vi�!�]���H\d;��U6����N��L�74N�S;�z��F*�š%���AϿ���J/Q�1>5v��?���{�qR؎���m��5;p0ej���J�#���^��ׇF ��i�tL�OwL+/�VvD����>V��F�:x�o��X���@U0P�e�`g�zNՋ�5խ�jk\��>����V��ˁ_��5U
S�J6�)O�����h=���2	��������2`Ac?QA���~�F�U��3��[ǘ��h(���q�(���̷�h����-��q�x��.�Y���
y� 18	F@���|��(��i4��hĦ>;" ��
�A}�fC��l9
A  �����6�a0J�B��]�7��(G��޴����BM]!R�B��]���fFRD43RC�R�'U9z�wDOH�N�P�1��A�֟��<��;q��z?"��G`Y*��R���w�����e
�i�Q���Z��a~�8�@?�C�;_�
~�[�X�O�)��z*����q���Cw.NF��dDB�B[�zQ$;��ܸ7�q'�\c0�gOim�Z=�
]Kj�$D��m7؄G{HLV�2�5����qjq}f`2�Ԫ�PU\~OQ�1$�,��;��z.��D���"�������X#���:Dck�.���!sM���U���{����AֵY�> �o�f����k3�f71��TS�Txg��r8���ꇠ��AF&�����e���G�V��
����;�
\��v��LyE}包]aw����2׻��5���Xl�y�k�{XdX���R���&�gֹ]F��"6�t�pP�.L��c�4�L�+�X�Ev̼�}�`U0Tt��M�
�P�9yU��`�]�����w�"x�J4�d��
��Y��
w��":xF��6(�:��Ź�K�CH_ ��u�<x�z������s�cj�\��l�?:vX����[��p1=�c�/Wg�%KKtJ��5+�k�gP�Q�M;z���^����J�H4�K�Qu���^Ǧ�e�X�Jf���{jjHH����{������`�[J�_Y�� �Lh�'G3��AE�auL��P;�B�
J]H3:��}.v1�#�Ǒ�}��ZX[���JȖ��Au���9�qM9��ٖh�V��{�֠��H�nW����c�C
����t�;H��&�j?^��wPW��.����2_��W��.���/�+/��/�U�I�GT��*�U��*$�l-� l�1.R'�3N��`d�
�P�mH���`o4���Xϲb�$��PA�Q�r`�r�r���Qv()Q
W�(�b�T�-~XL��A1��UB���d!˚�Rƒh�&���5;�g�S�F�:�{�1�|�0G�{r�^�5D?'�����D���^)_0%�^e|����Gu߼{;���N5�.�뇂�J����7��<r�um�,E�@p�"T���}�߂=6hq �F��4�YK�UA�썬�l�Б�ۮ
Dwp�M�9m�a���v�m8(������|�Y��_b
�X��`�?\p�\��b��p�����F6]y&�6��]8�g����DteX�IXP��9,�R�t�Uݵ�Ġ���$E,������3���B�����_�v����~�v?u=fv�o��􌠗�����ҷ���A�?�-{�������)����+fP�%�pM*���ZDaGx5
m������)n7��h���i�5%7��Y´*Fz:	F�i%
^�$�IPZ.7�1#��bՠכY��i���f�Y�a�!R#WԸ\���@MII��b�"�B�z��z��:�Q�m�f���:m�6Sfs�44Z�gEi@�.+�Q2YMlt)~$EUj6��
�Ms����p
V1���>ߙ<�*/�D<��[02,����!�������ׂ�^<:���E�L�o�{e��iN��~��o��Pd[��&z~��e���7��ݏ�w������v���V�_��5��x�x��k���ۗ�t�pu��8�<]�<v�k��=۹U*�V9�t�����Tg�.M{h
���nH�I7�]����"��F�D"�-��5��4���a9i6;JN��0%'�R���
�q-��b7�Q��{0P>v�gk�X��c��=@�F�t/FP\�P{�
�Kب��
�)�$��; ��� ;wV��d��g�?�ʹ��,��˿�T1g:��������|������=��Y?�랻g�x|�s:Ct�"`
g�ڎ�FZ�I��r���@P�7��,6�ʕ����.���I���i��_�-�J���ڪ�4��B���~�p�
A8���
��sjp��>����������k�+���h㰠�r�+��?����m��^�h�'��_��qͬ�Τ=��t�G�����s��l��V���ۻ�MhP���'�S���
��Q`�4
��!"�WG"
c����ɷRM�9;z�v�
"q�!.:_ii4ԭ|@y\I+3��T�z D��RNE�O*��Fku��s4�����_�L�ѓ3��R�'M�#��44�s�(T"n�����EA��ї�G�VLKf���T��s��a��¸l���:�wn��d_�S�k�܂�h��m�뎤U��<�i{M�m���;|�����Vz+P�d,'m0AS5<
^C���**��r�Q鐼iA��+0����WȠL���3�p�iH����b&y�c�5��@
����Q������T�uںGnl�[�z�{������>�ޛq��	����#h���˨�V��kZ�5�j��I�PTW�J_�.��fD���29PQ%?R�XE�U��(�I�~EɃ%TI��S^�MD���� �&H��h��f�-�(��0��(��J��Ԝ�򱝾�)Ͼ�^>�l���s��'5�������ʦ��<�����5بX���=��u�(��������V�`��FSn+Z-\R	Z/d���2�-�2�k�<���2=z�Y�z9סP� ��
Z�N�t�t@���Lݭ�/�^/���*�1�w8��:��U-ǚ�^NE�&�I�֋3K�rՙ��C���ՑPX���A�Oˉ��	��1���b%E�HC��z���WS
Ȣ@�ߧhk�����z��n���?^s��5�z���Jc>�������G�������;����������P�{����*��W��7���.����5��'���<�F 'S3eL���9J�
h�H��ڧ,KQ�*�&L|�@��J|��m!T�g���h�U1��@�?�Oz���έ�c�j�4K�����.C�}�*N���ˌ����-4�3T%��K�~=���pت~�ڳR�Ǣ1�R^j3�n�p�HLyP+�����s*WU�x2 �V	�Z�BE
��^J�Be�~�z��|@*�����V��lS*�*���t#hӽ�!�TK�
�YUn6T��A��O3Q��G�˕���( B����R��L#��X�De6�|� P�|Q�
{�(��2A�q�����|wD�D��j�L��)�WYd� p�9!�y��Ȁ�ߠ�X����N`�Spz�m
��r�T$2�u�*��n	�J��Ick�_����2f�?�/���*���*�zzk��=o�Jhǘ������؋���&~�~��Lp5��V��g-����lQe�|B����	3Kg6)zz䊞Y����S�k|
�7
K���lJ2��Kٮ��Ϛ��+8i2�Gl�̦�<��:����]��
�D#�D�ԍ;'L�W�C<sgJ��Tuh�8���_F�lW���*�H!�B��2��.[zE0 ��WD+��E/���>�᫼���g����1媉==�̡�7虴ʾ�2)�ѥ2���s���۾��2��¯�L�������)�����Y�����3���0���T'�ѝ����52Ӧ���-���դ<D`"��F4��7�*�)�;#������&�:�N�I�X��&��g@��S���������v�����]�0�nĮ��%���q̾b9	q")���:!�%�
�'U�� V۴c
q�5B�R�0��~
�`��S�(��w�tί���b�uV��}vO�-�,����W���+K�����Æi���ґ�����
y���^���H�:���/�1�q�R�Q*�n��tyMy2p�Bk`�&^;�{Y��˾W(��7�o���ȬC�6���f6E�Zw�9y��_��pFL�2T�C���Vj���L����E�o��j�:�X���k��A��2\BT��'~�^
p���H�	�ф0P�L�ϻF�~8q٬1��7�Uz�������X��nL�������_��
ǀ�4
*k߭w�*�w�y}�ٽk���u�׎���l3�jWc��~�W�M�S����+��ᄨ
堗�"+b��9����T�
@�@2EJ���]=Khl��w������}�l�Y�Q_&�*�~?��
`C7���O%�p��K�gf�nl�Ƴ��>��ó�;�B�Ҋ����v��}o�"r��������'ы�#�����A���0�
��ɝ;����.�����uU��짛�u_wd�����nB�Ak����s�;���å��O��M��5}�\��I�K�
$�D���3��`�-����{�{�\&�j4+�f)�Z��:-���ѨWQ.������Y��@۳9���8�(�T��挶]M5q��N#�T�7��g�=׊-����o�k�1[D����S�>uED�P~h��Gw�L���k���>EM���-+G��x���	�j��6�N&L�9��&��2��eJ h��)h�p�U1���`�29���b.qt@tI�S�l^@0����q��u'�4��`��k
��fh�4>�܇]7�?L��o�Q�(q���
�(1|��v-~x�YJ�i��*J����M�hD�G]�2���$(y.h[.�4��2K��o�o�B�G�/���,�+���Ҝ\�R��R����WT(���I��GQ����1�O{�"Lqh/4=E�P�顁:t롕m�>�M5i�2F�͊u|�	V�d#�k1�56����4-1J�:���@]5��C�� �QM�)_ߜ��DŭHh�E�*r�kj(��
��T[)�B���g�V�e#�Cn���(#�
�a��O
=��P��SQ�x���3O��+g��{��j���ۨ��Ă�"���m���:�-�){�**㐁D2y5��u����lט����ޣb5jcv)�v�|�-���UT6+��2P�Pw���s-�#��8������g���G����.
)!���qnc��T�
n*'{���:CR��ur�e��=2�E��0W�P,ܦ;H��5�T��T��HJ�H�K
�
Ne_A�#](�0	d"�9�}���\�'s��1��n�o�I!�T���X@Y42���ap�/�y�<^�p�d�i�,z�,3_~�M�.���\yn'�'�dI�<�jj����?
7��'����70Wȏ~�-�W58�n'�����U�R~�k��$�-9�r⦠�:�aJH[h	�U
���O30�.��G�¶��i�;	��q��"-��!sx`��/�7���Q�A&i5���L�z�G��o%M���g�@�<?�x��$����sT�ʮ? q��
R
s%�$8�@e����@	�D>��)�����<���	��#�RhI�g
�p��=��v �5D}n�O��y����cR��<.�qA#���s�9�p˗�`���@'�B�A%�ґ���z��jvu�O�ma�Du�=����i
�s8FB��; ����JsRh��0pD��+����<E�`K��-����T��C�H�@C�@�0�`r��yZ"`��cy�BPwm����i(�|�=

QCxH�"�3W���"�)�u�'̈́�
���)g��F'G��T�Ш�O�o�ħ��ɋ�P�d81^�`!]��%��sy`�&�
<��	�u(k�:�F��A:�+Ƒ��H�����<�-�
��r�����w�@�/L��
0��`�K{��'؞E�*��"�JE�"XGf�1G!�e�l�К�⻌��ˆ�Cm|��g���Ԅ_�Vf��z�����}����Zi�S��������Yӡ�b~� � 
R�
�A:��1
L
3@/��%`9X
�FrS����.���?xn��H�p�F�5���qcV��7l��?l�ȗ�K�q#��ް
��0���K>�7���0�T<b#����s��o��4|��`�׃�`+�v�[�m�.�#�x<��!p�����_�7���$�-�|����f*u����<?;�.������%.�)���L�hÆ��ij�����&wO~�{�T�� ����%��`QHvކ@n��N����xQ���49`+��`������P90��ɞB��Z@;	F�q`�z��\����*�lׂ��M`�܁����C`?x<���y�"x���7�����w�C�	�3�8����cH_���x.��K]���M������X�<u�3t��%�,[�~{.�.U���=����Ec�a����=x7~(�8��B��A�0n�XTP�݅����7o�o�(|n�WmDe>�����7� �ÿI���T���E ��J?��(Z���Ϝ�/�s
6�����$��C�8�	q�1D��X-��-�s��쎳Wa9�l���M����e�g'�7e#�·�c�
�DDz��zv�٫PIC�A
�����J������}��1�w+(�� ڢA'�~j�����Gx~�;�{��{ꮻޝ�4}v�;��3HY}rU׬gf�u��]�����D��`�	y}�B��'��z��5k�w�G���L�p5�E�C(�S�5x'-�e�-��K�X��=�l;���H>�5'��80�ݻ�ʷ�.���p���M<������z�ݻf���It;�
�Љ֫Z��(���8�����&7C�Z&���uo�q���zj0p3c|�����Q�׏?	��ğ�mdv��|�~�;u�b1J&�����}�Ƥ�͙��ٶ����(��0��Q��߳�?�{�ݳһvC�.�9�ߕ+}�{�x{��̠~=G�eC+q��^�Es�*�
ɾz*�����������%?�?��;�xz̾}�7��rqQ�zQ;|�\��$��bY�h4Aľ�g*C1�Ĉ%��0�'bR���D�9�č%�I�е����]��q��O�����
�^��y��%]+����O@{�09�+mm�OǠw�}3=�~w��o����o�N4�? N��5�{G��i�~��8���S��8Us�Y:&�xq��&Bg�iG�d���7�B��
��7�HV��	X��V�O�6��G�D0��C �.�o�5
8d�oo���M7�p3�ə5�l��W
u�>�o�W4�#��w빝7��y�7���5���?��)�~��kQ�����v�D`&v�&���[r!�P�&�!�3/{����s��7������L��e�b.+j�h�:�PE�gA'�?�@
���h��WM��f *W��Xļ
\����=:(�	�K�g?��:�.��Q[��;v��&����3o0�O�~]YŊ��k���>qn{{n{j���������M�0a��Upm)��T�u�H�r�b�*���u>�	���:��dr�"�t`ƕ�>�q���r�հ�=�>�ϳ���Ͽ������=�̴���=�İ�¨���=����#�WǨ��s���+�y�)����M����<=�W�Z�*+j�W��o~"��E"j�s������_�l\��{Oϲ��l��
�5o��`����w��_�y��g�����@�r�O�r�xl
�����HJ�A��Q?�q|x{�Xü}�cј?�3�ص��~�x��
|@�N@��B�Z�
��X������
~��Ku7VTϫ�9���w��w�3����ׅ�-\�k);������Ͽ��J\���-l�����+.�hҰCJ��ti���e�ݳ.�Ԟ}�P<����m�4~���*��;ϟ?�v����p
�Jj���V!���h�=��
*�����Q�c��;��D��ˍS���(�������To���x:�=iy|����[�_ƥqi��qfT8 =.}[��h�e�2SLJK�c�SXM�������>�
;���Ҷ��j췘�C��̈��8M�W�i�7�6�aWPk�8���Zr��Of����ķfT�a�����
r!z��T�1�0��飜T�mx�p�@2puY��� >�W����*���P�Vx5�G�Ut�v�:C��,�g�WwS˩��!�=�㨮��3�u�����m��jWڪf�H.�-ɲ-w[�.�
��q
6c�!�B(	`�)��B�$&���&$����_^J����;�*����=���? yˌ��=���;��99�@/VͲ�gY��W��cD��0�65p@�Lĥ:�~6(��gtނ��um�֎��h
��ϣ=��(��8E3&�O�{��}w��Y�5�N}�L�W3�z��Y�$^��+ͥ���sփs*�i�m�>��i��~ؓ�5_*x������Z����_�%���+_
�ޖ��P��[�:�t���%���OKO^8t��R��ޫbY�,0��D����j'�EZ�C����X���!��Ԅ�(7Њ~�.��l Br9��3��s�y�-�E�!<h�]�|�����ȋ���)���5&I��=O~�A%QlP���a��Q���F��5���'��|i�����n�pt,�T�}H�Q�-T���*�R)��6��S���
-�����Zݶrߢ��Z�+:.�=���͟_�����ȹ���/�6����
�<�hU���n-�l���Q<�c�7m�}�Y3��M�LO���\�!d���m�a��K�1\^y�o��e�fr��h�gK����pA��ޓOG,*����0j/(_�+a�4�vO����DL�>i���M��A'���9X{�}�_x���mZt��l�~r�E>�|�?�?
����]���ɳ�w[�$�	�Ud�7NFl1�<���G9�o? ����0���X��I�;0 ~G&�s2#-��D�8�q=f�O��w�[N0���S���rt�w��/�!�_;�%�>�����I���g��5��5���(������<S�(�)tGq�
p�<S��x{�2O��D�9�������#45�#��<���<��w�CuY��1
��_���.��>S�Ey���c\�gJ��nPF�g�N��\
I;�H{Q]��|"�F(Oa�JWC�w����X<��Id)��c�o!��.����¿�ot�w���1�-8�Ұ�_�S�1��ຑw0��,r���w@ϦLt�
���]"��mm}��/�ח(Jc$rh4pi��C!��������2���}!����䞜��n�$��I�J�of�U�J�������:Doc��?k9�������C~��p9H��������m���_Q�z��Ũ���Y�d�g��je����[�	�*|�{_�P�B�|�i��Z��ɽ5P�l�B�uMlofk�
����p[��
��2��(��S0��qj��t[_S��g}���=:y`�c��������������_������ړ��&I����6��@u��W�2���Ԣo��xn���-9���Kμ�Kz�G[n[<�����I:~SKx�����h_�u�����	���U��gAY�s�빭�ӝbWzF>�o�w��w�+�w�7g���qw������D��M�v�^"/>�'ɐ�\̠_��Ր���T�A����J�AccR���,D����a��o61���x[ʄ
����JIU�iJ��,˹����@��;�B��\��Y�eJ)�3UPC�'u�b2�k~�ZM� >��1E�/�U�s
u#is��
GD���(�
$�nM�����Eo(��mx��w��V��e�	V†�dC�d�s�k����o�k(��=��T�'
�ƈ�~���(��R@������������q�y��X�kK�pՆz�<�hv�JU�
ӯKg0�=̒������o�m��Z��$���[���eK��}��vc�t���<oI�#����K�x����γ��?;?���_	n���(����Ԯf_"�H�paJ���g�sZ
q_��~�>#��q�q�*F��D�(Mt>���y@�L 9�X��:?"�H��г��3۽��t�tS>mb!��|,V��pa���C[�h(��!$@B����4���o[�
��b�ڮ�����L��3
S>���
��
083@zɀ7��^�xQ�x/\��MrGP:�̶��@렞�>ؒk��~6XkAa���� ��ǯ�7Ğw����TU�tz�B�&LY�[���WX����u
�U,h�����k?x𭥓&��X\�������[���ߞ���e��"v�Z�
}���]�G�W4�R�V5[��;���s��3�W���殪�$�굽>V�
��oϣ:3H_�^@"}8�&�_b&���&����]RA;���d��0�.��T�.~�C���l����#�}�2B��G�4��.�<S�.��<B��Hl_�ީ�@L!q��4�9��3����2��ѣ�չ�?���C�o���<$W4I�̮�5�F>�_�ڹA��OԵ���O*L���|{�	�Ǣu�J�-4��P�V��P�IԘj�J��pp��Ϲ�1��:�F���
t�[H5�<*����-�#�������6��r�;�1k8] ���@�H*�?�\�}qn�ZKuP�}���8�;=�/�q.�P����T�Uk��W*jbsY�~4��\�t�o�n����V+����fJ-�9�=ˀ9rӬMǏJ׾ّ�O���Amx�"��Wp�i��XrYI�F~W�����7H�i��,$;��B����)�>�{����>�."
J�����$G��SB7�hD#�P(���v��T�մ�j��N��i�G� �'D�
j�(�;e<l0@ޱ$��Ж�j�TV���9���cw�<��NGI:nU;(��!�T(�9���8
8?�P���Y�邖��y���ؐX�)j��0��l�r��(Ly
����L�8݆:A�Ҏ*�:kI������Ҳ�ڭ/�s��ӗ�/����K/����a�ԤWl��)̹�B-GaRg�B��}f&���h��+�9���˯;}�Y�j(����9��v�}w������e�3�ϧI��
���6���kI*��++W2)�J&p�(+ ������v���
藯��\ˎ�w�K���&e59���ŀ����pD
�n4G�
媶��QYO#ώ�Q��;�D�+�=N�6�Z/�
A�&���`��X�X̥S)�v"�X��q��=��eb"�*�C(��@R�@�4�]%�.����\L����sC9:SN�2����b�O�����U�T�JU�d\����ef��ύc�ˤ�B����5��vm�82/\-9T�O�5�V;�$Q��'mvPG7���o��<�+��VM23~>�|�aޤ��O^�ݫ�
1g,���j[À���#}��$
Jo/�6m��P>i
w�%������j���@43{;��?Ϩx���P�	ws#�x	
%����7Jy��Ӧ5�:=mu8��`O�=��$m'I]�rV:��n�k��& �m.3��
=
H��"�BxW���>S��@���B�&Ys
�Ry2�"]�&~Xi]����G�Ϫ�?��Ё�������i��Ug?}�ⅸ�9W�d��^��U�3�w-��Gg/˩\�	4T&}��s�)���F��{s���k�H?�������~�ƶ�U�%[�^����(Y���1�y��D����=1�����$*�9�_�{vfG�x����$")y��IcP��}��F�'�1���hIx��Sj��E&P��vS�x�ϗ-��坟L�FQ���
����V�yu

'{u�fM/���T��WZ��������.�P�>t�:�t�q��Nc)��8�6`u�)��	`
�k��I��j�n�#�t`�n�n��Sm��tU]������n�#������ihi���x���4;\����#跐P-=aEu94����5�?Ғ�9��[�=�4��st���`(I���+�5��O��=�n�E�-_S�b�g�<�A�f�ۂ>�h+9��m��R�w~� ��[�n�};�~Kz��Zz�)}�-�I���3c��6dX9�$�KK��#�p��T�g��;/�M
�!�؍4
��6�F"D|�4�yK�r�o>��#W�Խ���� 
}#O�ʑ�"=6+g������8��w���X-�Gt��C�}Ю=�A�W}n��$��n2�I�]�|��Z5�<� <�Kz�Z��~=�W��vv�	�m�g�&�)�W"��:�������2a�[�_e��=W�ՠyE�^�d���Ntg�S��BȨbrAv/0rˣW>>��׳�vU�n���8���e�m�қeod��o���K��뭙3?����V׸>�e\��)d�7��)"�r��_)�͑z�U,ep��y����5:��$U�T
yy���ctcM�H�T��Ǩ��1*�k�fES�u_��"��z��vt�w�7Q�(��ct�0�4M�	�f���g
�(���:J�&M�cXS-R�:�\��ò����|����jU"P��ET5񓣝D���,�y�(�����mjHc�i��������c�j�#?Q�N]W�1����4�H��>ՉU}� :ځU"�my��
�b��WE�!�J�D=�k	�Sfu��QEo.2�=���e���JѺ���=@�=�dڜr
��t��}��n;����=�v:e:b9��PkA>�}&�)���%����9 
��ν�W{�R^�Q���l�K�A�LJ�%��빵D�9�ow��n�U��k�]R=�pE���z�������jF���t<�{��ɷ���"���-�C#�<)�</�WD��W�
+��zq�x����	�i�Ҹ��&�ϕ�"����9bM47�,= 6�,��5@��Dq@G������'7�e�sC��E�r��8@@_D�
���>�^����u�<e�ca�=u*���fO���p->���]ʧ��y�5+A��Y��|�$~�Ǹ^��#y���tG��18h���Ǹ[���$(�P����	�h�y�l��%����PS��2F�5���N�2e�
���S������ݏ��������¿ߏ�A_}?f����8�M�c�U"��7c/X�M�P�7:Ƶ���V�'I�uW� $9^�`m$�3yt�k�8�]�V<I��.�.Y�dG��dpm}�r�~��{�2٪|�v�Ep}�DW�G�ߨO8-Zه��Ք	U�1�tpݰ����t�T�&�t
*��
�hP��l\{���9הkȣ��X{���S�Č��uȑ$Π'S?�=��OR�
A�2
�}�o�����>�$1�̂����"^}-�c�n��8V����g�U����.j��"Ԅc��'�Gv�Ҏ���G퇨�ń8�lV��0������R1���]_��NSpj��es�C����ؔ�!���
�
�1g��c��JkN@�|�qdH�i
Jp� ��igk_GV9�=ZG}�7�5ܖ�G�:�7�:0��/�s�y����nb5K�s~���'S�3�_SyIy�e�u�Iݝ�kځ����MkJL7��ͽo'~|#!%\K���RY�|N���.�w�?�;���r�C�&�ڹ�riw���FrX2��%�t�Jx�^LC�D�Boew;=U�K9�f3U��*��f�Z}P���t�-��k����aȌXF��EB�D���߯];}�w�~�����x��f�&����p�@��K�!��:�6_,�C�pǦ�pO/����o����6�`P��F�3nb@θ�Y,J�%��F1N��Ta*�C�� ��xQ��j�ś�Ru\u����T��ۈؤ���7:[}�9���3 67�h�SL�6�E59I��Tj�E�RM
T(�ri<���8,uT���g��v��fn9��ʥAFpP#�][O�H&��e4;�?jOď�@�˼��6j�KEU�ܹ�?7��Էhn���`�������[�Yu��Sz]�^v�v���1�2�+>���H0�H��n�d�9��:�����ܱ������㢶�����m�!��ɢ��ߛ��������հ�Ĺ���樛�ijٲ�����<�@3%S�d2eՀ
��~�#(���,�'��zB4�i�T3�%��R�aQ�Uڌ�*�D�
&�8=0�JGu���h�z�bt�Y�Qc ��$v͞���{zfg���.1��
�9��ɥ�N���q/���J��	rCiSr7 ��Q��%�G��ե����*�(P��7ؗ�E{�ɶ���+��]߻���o*z�՜/VYH=���}:����^׍[W^���N���L[†���4뎾Vq!�?��Ӄ��oQ˴5`9)�߬�˫-+P~K�.�{�^n뢎ܔ�&_3��ы�w�����At��o8���Z��E��ؑݛq�2
hF[��tSk���\i�j%��fL�д�S��bD�|>�"���UC��bg紈8iR��LN���S�
g�אSX�+�� 5,2�%7*2$�R�q gLT��7�Yr����S3�_�y뚩3�|���Z��{�|���\�bZ����W��򲘲m��2]Q�y���8g�����yV��qX8b�R�B��n���c~5�7גB/��KP6��l�D��@��-Z�R�Z��T��"*�,*�Z�A���ή���*�V��Ѩ;$K����MɊ
K��I+��U)�T4m0jTFJ�ŋ
&!"�rEV���tE����!��tN!x![C�
�U���Y��7Ȃr�@�i��XY,o���h��莆�w��뇦�9o܊�\�C�ȵʢ�k3�df��"嶬��4ys��|o��E�������#��y��"��@KP�m6�3`
a������L?�K��)��j�'�vb�ny�`,�չ�
_����Pѣ(�Ċ
�u���FS���x{�
�7PM�9��K/���L-�
r=��?��(7�Fj�H�&(0�)��5�
�c�[T���>���KTk�{���G𽈛�XԳ�:���^O�D;A�^��V{�#ME��4��
��]��ќb\P.���f�u��L}U�#��,͞U���'_-�Ϫ�g�����-�Y�*-��_������A"B��4
Ӟ��o�#�È<�Z(d
��D
��au9�>�VK�u:��� H(
�Z��&��h2R>+��KЅ���h�Lf�����V�5u�9xK㓁���V��4�#��M~XC��ە��v�f�b�i�u�p��x�~pE9�K��!��ʃ�]��r�~6�
�ڀ
Mc��lޢ�s���I+���%~���3��P�ҮYx6�g�=#ӥ�yf�Fz�Wߟ����y�w����-VB�����X�
�'�z�����H�O�[:ԅ*�
�x4��6E;\8j��aG����h2����(a�Vz���E=��p7"�O���PQb�Z�d<� 	���L��02�k騝�V�K�{�t8���Y]�^o������tw�o7��{1�C)?�pV�~�_�Ƽ�����	�H��7���<"5�3���X��Yc2����]:Z�����@��3\���
��-��|���%��\x֬�,׃�&�~�ɰr8~�}��nY7����g��_��v���8��6�I����˩s�sU�����Y^��X^%�䉫�W��e�ɪ�d��rǍ{
��8�nʜ��b�\c����?�R��Kt1��l�Oc��4�l7)@�&$C>�P԰�\�F����8�M��>04���9=�x�Ͱ�ۍͰ����jҶ�ѿ0��������ѱ����r����l�W���(��"&��_'���ջ��(������J�|���������ݱ��<)Aj4C���%'��͇4T!�Ύ�^�77��C���'�C��F�|���z:C~�p���q��t���C��H�ܷ�k��Ə;�k�������ظ@H4�,��-�o� ����T�8zf\N��I��R}�*��>�W��8p�J#8q-,@kA���Y�@�U9UUE�Tn��b��^4�t���4t@E��
�V�2\�:W�5õ�E�}I��W�$��7>�8�|�j9E�����'O��s��S�G�:C�7.��C>n]9���/j�����˸�h�f�&��q�՛pFpF�ĹO��:C��?dE3�>�Yz�G�"� ����5\\:���~�X�P�����Q�Y���(��W��n
ZC�Q�*�*DB�z���E�2RN�,[-,�,�jI�H��{%�n���?����^}�xa$��x�#��g�_�.V�n�~&�_y���@T�G5�����u{?&���z�>��c�����Z�N
7=7|
��h���
�9�3[,������|�ZM8�K��T����6�J��T��y���\:�y^������[�J	'�����唎	+��U��*vBfDŽ�:n���5^:To;\�Ц(_T�M>
�3�y)�_npu3�5���Y��m
`ǜ��K}��Z�~hF4���L�ɪ�-<���ց�#��y^;���'���}Ky>�>J�J�
G�Ŀ�Ѕ�xu�(���{��h�S���Y�Ƅ�p}f\c�L�T�Q�`IkS9�P���y�&�E۳�5sA���@Y����*"�E@��Z�>��
��&��Tj5�'&@"���v�;l/ڎ�(���W�lv����a��d87�
�#�	
Q����
|�W�o�	�G��PV"ʿ8a�
�1�+��t!|V�)�aT)�%�!����a`8gi�����}���/�ܶ����qm�r��|t+x
t+`���סo�Dw�s�t18m8���
R����;���#�����`�I�_xE��Jw��122����Ʊ�:��
���tE�qfD���P��:�$����]ᔪ>�	T}�N�����Ě��|�-�;E!�2Ir��N�*�
:`��vRZ5MA�C�RA���r6>J��������ev�X�hw�_=O�j�Uk�u������L�	��hW�|A���s�����g���4'�J#��V�
_���C\+:�GR����fM&��=n�������
&��`r��v�LA�u6g@�вn�d"
�;'c���
B�¸��]�ퟟ��R;l��(AlL���['j/3s�62T�d�Y&����%�Vk��<OM�ʓ?��v`j���wѷ���,DQ��߽��ʄ�7ȿ�
��'T��ˎ��|
��=�f�*��*�!*;�^�f�h�:�D�4�G�2A�I�H,e�	m��db�_0����S�$	O�Q�����y�_��7՝4t��L�;�(�G�M��\:����)��hm�T�A�5��5Q���E��,�t��]��$���m噙kj�_8��Y��Ԍ��=g�7�'N_��5K|7]����𞎹��Ɉ�WZ�qTҝ+<R��T�7��؍���RRj//���)g�fߨΆ���+
�D����F+V�k���t�Fc��p�W���v�#�y=?��pf��l�X�v����~�o7k���Z�hM�!�H� �F�7`�hi��l��Y�~b�����r9�߲��{,=�R�R��Yt\�R�h�9���9?[5�3o7�3��P	q��ͱu��~�����w���QX�
'Vo�KO��J�6	� �	n���!('�5'��(H��X����~}m-�q�\�S�=S��Y�����T���ڇj�
�9P�^?ޙ�E�q��#����"4^�,����P.6b�c8lĉF�bg5Z֢�j�Z4�V3e�Z�j�֤aY��@ޜ�Z���4�ЖM�j��5YA7Aؘn��f4:,V�ٔkW��ZF?(ފ�7�#U����q�u4�S%+D��:l��9%Ja�-Fw���t��kד	@t��}u?�;�Ez����MR�v��Ғ���(U�{��s�=���۱&��M~ކ��j�8Ԋ`X�ܧZ�sF�v{�^����E�mpY?B�;"����29a/U�م"c�f[��buB�H��X֬9ݐn�n�i�f�ץ�N=��R�(�]�9΋zi������@QoMw��<�C�NZȜc�
c#Ev�
BZ�ͻ���6R�6�mq۞6:��&]�����E�����.]�:�����<���,�����?SK��7u��8�W&����w�^�
��G���q���L�f����ufr�R�ta�G�Lnc�O���sjz�/���[�2w�°}G�����ņ��l|f�M��B�~`��_����ap�5@s�k�v��{��O�����A3������a˓�O�����
d�#0_w�'p式����?[����<xU
8�%b�J$2'��x�
#�G�1|,L��_��ȟ�z̷��@���Q���}ctWG0W�>ʱ��x�QN�#IL������z���]��y�ӣw����;I�O�w�A(4(o�s3q'�}N�g��,��9|^�wf=?�E�>1?� ͤ��z�k��'�"��"!��"!���D
�_�${�Gu
�
Ge<E]���17�˸xAd�����ԉ#�R^/��b��K��7~�*\�n��^��#��<N��єʄ�<�x0�񀿠����F�K�T,��F*kJ9=*�sQv�j�|�6-��`jT��|RE��V�	�,jy�K�l
P|O�3J%�'��z���٫e�����4�u�lN��j2�~lahl>>�C�Q	��&�2�S~���JF�|idF'(V�~��+��曶��n����Ůs��XܱJ8�>�dJ�$i��;4����W�=�w�n��yŪ��t���iN����K����8Ui�M�Eĉ���
���4+n�А,A��8W4��
i6f}>)���]8Sd9NW5;9'�T! ��/Uw���ր�4�

@!��������F�C������QA�זRU�
%�"�i��I�9�|��vhp�2�jF('5,�A��I�����]l�s��Oy����gM���*f5�������U����<���7L�M�j��h�C:�f�/=L�V=��n1�̪L���/�T�*jVGhA2�ŚP'�:�MM�"(�L���"]���[8lc��!����a{��Rn����-'�[�|uPNc��(�#g�cvoy�v��@e�\�`��J������?e�M޽�#!<r["��t�0{������E˛R��i��I;S�s����v\�z<]>-pv_��v�f�4���|o\t鯦�C9O`N����g&��c��upr�V� ��[q;.;���L�‡C�z�	�k�N0�v�$�t{�n�W�$X�7���܆@8tTc+P���5�.�u�ulK~����\�.��e�ziS2ɚ��1=��h�az����6�Rn���2%�h���4&�~�atacoMʈ����Q6�(g�D��|���A͊�����1P�q�tH]����j~g�ܑy8k�����j?�;�~�Rs�2�{�|��[��I��Pz��v�?���`�8�˛�f�w&�E��U�oA�����6
ca��:4�7d�ݨ�T=p�̴��J�vg�.
����Uԯד�6R:�:Im2��&�
_�j-��)D�#n��W���Ç�����-銞��3-t5�;�Z��/��$=��[��
�������7|%��,]��}&h��\�&�.h{��8�7r�^�M��}a!\
S�p�\4S�[l�p(6�(Q�j�Y�`0�#aS�AHi6M�?�Q_9��"�%a�=L4�M��d�!;��!�<D�<��ZB�p�O
��aa[��d�(�!��5��r��g"Q��F�hM(�h�
|$�G�`0����7u"Y}�BĂΖᏜ�oEg�_�&�l~�&c�<�A^Ҡ�XU���hVnZ�Q�t���d�5�������zV��q�J�I
�����Nk�r�sW���9�l7�y���ꮖ6�]M�����S�=��ʜ�[g�&�)��8r��1j�ys�h��f�vh��h�͠sh-%>a���37%�� C=U!�?�0!`٦R������J8��0�!�ȉ���l�&[Q�{g�82����-@3)G�
aP�L-O��D���U����4(ĭ��'-W���S<���+H;u�4���k.�e���Z�罩g��׭�F��2i-P;!�������j+�	�d��R>��{�O��\�����mh�-�ێ��dR������{�>��0F����==܇p����!p.#��	�����p�_	0���=��OCR�!��9D�E��q	.��P�����Mc�B���*s�O�
��Lt�m��b�gp�RI����p��B"k�1��2m ���Д�z7|��������O��Ǧ�":���j�.�v���Z<��v�Μes]��g{�2wPz s��=E�-���ؗr^+u5���F�B�kS�!��gD�_�Q�d��D����OK,E�#b���$-E�	hA����	D/� ��hf���*��U�l�줦f2%n�b�
��.����32l<�;N��38d��sJ��Bϑ��<���71l�vw���h	�ؓr�-wT����������:���/-lt�{��VlZ}�=W߹dŴ�m[��1k�]~�y;�[��{�s�>_�'�[�k�s��k5�f'#�7U;���8�@KG�^v�ϧ�Yghނ���~��L���\�2W��Kb.�=K3�_A�l%8�ƃ����=o9k	T�bQеM����B���M�q�� ��,TAjO�s�Ca���
�	cTC���ɘ������ļ�~;�
A�z	+b4+��Z�J���s�MOo}�9�W_ۙo��Q�r[gk[w�4����?p��׽/��}�����>p��Ƀ+_��p��0�8��Yb���&U�H�&	7p�-p�=�d|>��=�洌���;���h�ٳ�ǰ����:6���5����0%�k������4���ٳ�����57ߘ���l<s�o���q������O�'�.�+��,P��ZS���ӥ���}4ŝ��Ɨ��\�h��R��û>���o��2�v�����f�����➌�u�����9��5��>�İ���0
��9,��.�4!�?���������I����ٶ������'���DZ�'�B�<g��&�H2��
�:	T�c��NY��+*�z���;��n�nl��s�K�kni��ߺ���s�K����3�-[��
l�I�r|0��s����3�=���s�Ŕ��O|K��F�I�,��o2��	��LI�O��44pn

�8�J
\Lo6�M Mfv��On3hkE=S�j���N'��4�ft�"g)�m^�
ne�ի	����.���vA�3�����x>��f�u�k����~���q�,����!��5��27V�j������}���BM��ց#W��y�4Su'^�_�ٛ��&I�f����� ף�H�5���]�Q	�T�|���8;�2i�5��M�!��6��a2iXU* x
�F�KjT����
�U�7T���@|���Q�hF�^p���p��q�A
:Ac�uc���
�"9��oܢn��U���P���H
�(�L�LH���>�gߑ�٧wT����
)UV����o��-?e��.�ɔϭX�Z�N�ݺ�������A�
i�;{������m����7�[��p�s]ʡm�j#B��
O�B8^�l>���/q�Оs��5ɚF��$B̎gϯ3Bc����q��KF��?��������՜S����a��Wu�9��~pTѺ9و	����ˁ�����aD�
5J� EwX@t�_.^�+z�����?ѻ->�Z\y�v��E�o�����(J��!�w��~��[����CR��y�u��9?�޼
\������\���k�}S���3�*=��۫�qB�F�$<���\�E��p�q7��4w��)�?�x��i�JT�z4�����鞆J��O�R��&܁��)<�}�7kj�D������q��V���d4~�*�q$Y�?D��G���U�pW$n�sW�H:9qZJ��l�χ�x
V!���n1��DH?1DC�M8��'	�T�Ӫ�6��̢�Z6�h������%�.�ĵ!���a�@�rI!�z�Lr�&"5�D��y��Ip;c\kJ��Ǔ�q[{�(R����u��^%�O�#�:�����&qM���R@�������8�z�������< ����������7���ŁmL�Zf�
DFn�U��㳷�k?�>��K~+]RJ�����m�4Y�������������6C�\iE���ʱX.h�l��Qb(�%#�>�>U�8�iB��	�W$H���n��сK�h�jvAʺí�C�d0C�b��#d7qs���H��?������r��zq|�"�Ҁr6!4aMX.�ƻԴ���zTTn�kw������$��=��7�|�a��^�y8���S���2��8o�����'�8�WC�o�˽`yw�%�2�q�C����>���0�]��	�Ҁ��n��_�뾁�/��j�pA*���@�j�x=W!7�f�a�d�L6@���*O��
h�n�e��Z�XB�DDVGT��Й�$�a�߫�dt��X�E�qe�G�6�l4�'$ʐ�z�˕���U�Gs��˂��$'�A��0\c*H�b���v�H�	陫�]���)�=mՆ�;{&�^�3�T��-�������磵���§��CO�k6�����C�w���RW��Ԝ�%<O
��j�sٮ�;~9�מ}���]۶:Bȕ�4��|�	���r��V�7��ʄ�G�Kb2AU �q��0���r���Kpq��6�I��P:���W*\�o/��.����aL&�?N[=U�к���A%����@�FԺ@��������b�1��'{L=�Ŧ�~Zg������.1�I	��R�i�kh����\��1��"?>�s4\x�����!:�	��T_�DV?f��;V"O���_�)�X���˙zKڰ&�^_��Y���^,{.Cnd���}���B=y�D��bf�)|����]������_t�<�%��<�zLz��gt'I����{u����~P��q/�y	*�7�:3�B�.�G��XCw5ӟ!38���T�?
��Z��,v;t(r~?��c�x�o���^B�dR�ФRd.��4�.�j���La�ڮ����=�=q��W�=��q:fiL�-�k�4�,���k�KV�Ս?`�,1��|]�D����ub�Ĩ$�E����ztj|F���7�<������gD61������POiӫ�|��
X��[�!�e(NK�?~��3G���Z��O��������ҋ���?�S�>�L�h7|�A�K�B_��d+T�(�*��	uֈ_�|��D}�p��?����Ls9��v������B>_nlj�2*�����D9�H4GZ3�+g�ʅP�z���\&k�4�d��r��nd�y>��ܔ*q:�*kK6�{R�1�l"���3
*���d���s�.�)]�T���=PTJ}��6����i��9Zw"
����9:�������m(���;E�}���3I�2�k��?��;IxK���y����[zZ7��-��.�sa�\���|�� l٧�.�=��T�2��ϼ�R��Sk�9~�֋6�m�����2j���8ό̫���ʠ�#�K���Ý�����I,�@�a����-�"A��X,�Fq�J���%;ԳIA�g.	y-�,��9���@��Zo �h�hU%m���s�������[Z�u��T�%:�oI�򜟵t[��uy��s�j�@���[Q�R��w���+��
�ԝZ��CKX����2�M*�
d=ciF�Epwh���!�W8�*O	Z$���ˤ߈ߪ��oڱs
�O;Kz�Y�(�a�v�ܯ_�[��)��qQ���0J�P���5\�ϋ7������bq��*xE%6���ּ��@�~ʹ���:1�Z�����RB,�D'����ir�j�b�
��:�9���n�O�p�d���I�b�0��O
@:a$3�����=>��U}3|�}�;���Y����!�wmմ��r��bp&��M����:D�L8�'�lT�)~�	f	�+ۨm��v��������?��ُ��
h~��7�iIg?ݹf�*�K7�
����1���S��t�ljṄ�cl�al8��?�(�"��<����/~�ņ"�(�%�	
vAh�
I2h@�#H���xI�^j�&=Q���
]C�aF��Z�&�a��/���5��n�%(���8�H��q���|~����wB\�rʃh�s���s��/��σ�e�[NM����J�P�/��ؽQQj�.�,�/�_������E[�n�.���Ë���oy��+Ad��җ6���U���5��«��aZ�[�ض���{�#3��tw$�������'��Bʹ"�7Tˈ���O�*=��Ʃ�ڋ�8�@M�{6N�w^� ��1q��*u*-���R�P��b�l.'�,�J\�J�njl,����;XO@Ow/Y0��{�g�^O�p�o[�`�q�8��={���*���|��҂��U;��	^h�P�vj�°U��7LkW6�fϘ1`;�?��7�\�z%��S/_N4(re� ������	����ت���pu�gx�0]X�.��f�|;ľU(�
��J
���
��׎|�!�s�s���#ݹ#�ɑ��nJI�S��3�-f=V�$1�
����T���>�yV��@ԓ@;�ʸD�@��ZMe(>�
WT�*
�k����B{��ʘ��K��,�Ӱ�m=�So�;chN�K��C�Bl���6a�dF�|�3�?#�����Y��ei�i��Kԯ>t��Ξe0�`�P�9���
����>��\׳f��������y���������=��Kڷ���H����C�M������HD�=W�V�o��_�Ub�3��Cۖ6l��4�z��'�:��_�ަ����P1�C�&�N�n�ӍQ6aF�-�C�!(����B�t�O���,�B�2��N?��S	p`t�Y���\1Y��Y|*����n�ʾ{
WGJ&�!�2zX����`M�a����'�_w���?H�}(r��w=��M����f��횸jm����=�ypՓ�
�?tx��-@��mw�i��P���~��+uy��f!4ET�����b��s��&�n;b�!�%�@eX[:E%�t��i��N��;���h���K�vVkK[.�Q�d6
1�1��
#.-���P�d f� ̒��%C���d����csl��X�	!"��8
���Q���?�����!��3�����0�������u>�.r/3eV%�w��v.�ry�Z�|��v3������3�f�P�y�U�mp?������8'�
�/�!y�q������wR���P���s��K�y�2dK���0�?x%RHο�"��rV,�NE���[ÑH�	��w9��X4o�.{w��f��mm-����\.�HvR]�X�:ҝ�T*,v�E��r�.{<�ՑN+�u���t<�����.���=��%�l%�W��派�`����)�t---��u%]W�T����iɮx)�r�t����� w�]����%�z6 �ȩ#99�-��sL�'K�2�"Sc�I�Sf�2����?
��Ѳ9�M��" ���
�8�-��OA���Ri-��y
p{#<�F�ƽp��"�P(���)�J	���\.o���5_"���b��dҸcH�ơ�)h��R�LS�@Hж��=��yR�2מ��XD���@1�oԿ������P.T
��C�I\�r�\�b����0�����
,-V9Q�E;v$-{0���$��L���鞸�ܿ���w�x3�|j�/go�9g��V\��BBz�9�f��n����θ×���6�k70��?EoA1�es�/�_�{��y��z�Dy�}i���|~���\ H�^�O��γ`3��, A[�=e�k�:�~�8(Z�Q�W�jK��a���a��)�R<�V+d���,�`�g>E�î@�������u���Dz�B��I���V�Y��f��5���S���P��'VG((�{9-(u夈�GT�1�%˄���2pSLh���t�F�mEa��3?��g�N�/����I8u|��wP&DN?�T3��ĩ�^Yq_�M">['	ZT�7g$Y���$Ӓf�DI�c��=ny��2�֙
gΙ��f�l������NJ��G�o�>���M=�Ӟ�zt"�޿
��q�|K�rdJ%A<+��j�8#!g9(	�� p��|n�%b�9�h�;5�]�tk�P$�9�vg$�t�C1��F�����l%��L�
�G�гt�ܱmp�
�z�e,V�~�g_������7�n��}�H���k�"n�+�^����Od�J���E?g
*�6��h��\��D�u�N��m2q.��rq.G��cZ-��r�)�B���:v-͙��@���-�~�Ѯb�c�p
���U��˧k��Dr9����v,Zm)���ǔ�@��\.W�^d@>-<
��O7�Pu ��������4X��;�r/V{G�=��JE"�$ከ匠���D��댽k<��m齝�鳘������/��`���7?p��y ݳ���"*,�߿}�?�;��ly��K��y���c��>i��+��fp綞'��F^P��%@��pPł~A�_,�r�R��A���r#Ŕm�g�MQh���;����M�6
��`�đF#���&�Bk�D}q��Ǜ�_O�R��&Z��5U}�&:�.'��>7�0�n�26)�����,�ͳ�87�貵�ղ��n�v������1�����Q�&�h(�h��ԭ��=�᳧(�_�6�}���ܰ�û��-<3o�Yǃzh����ݪ'od6OO~m���T�����Pb�Ӿ]3�υ���@���q>��;��2 �:m��?l��YWP�a~/s�߁R�_�U�-�@g-�9cШd�&������cY�v�%K$8���I�˪T�-�����YO:m"�.@�H�9`Ҫ�ZK̟���d���fi]��f���K!���=�l� r��R��=��e��R���S��qe�ZN�����
e7��y���V�V�p�\�KA�4 ��ϜS�~�X���1��N������Ő�0��5�;6�b82u!
�8����J��{o�Vq�����bK�,ٲ6[��Ȗwْ�=Vlǎc;��$N"�r�Ķ[JKH��ڲ�����(K!�Z(-���R�mJ������̹W��H�������K��͝�s�3sg�Ν��;~�N��N��pȹ�-)��y`�;����)v�ˈ8VN���F������@Ǘ�{��Ou����$kli���sfI��ȕ)
2�R�a)�jQ���4��k�s5*�ϡf����㦟@߷ldIWfȞS>��\��Q	֪z�`��U	F�R��9�5B�E����R��Xd�U��;R�ZŪ�:dU`=���A��Q�F�(�=N�"U0|����Q���}�YO�̫`
ũ����^M�v��5��(����QO�(x���m����mW����ڗ󼋿��WR��5ۮ��X�����jg]����.���N��������{�p���3-��L֔�f1/�@0;��A��O�='���:ŷ6����p'o:�8������9_���Bw�.l�"�vw���^u�g,���3y�>����m���߰Y�ߵ��4�������������@���0��=�Q����<�J
ɣ~W�«h���t![�R��i��s�3X�2]6+�����x�!��Ʒ���ږʈ��]�ܚ��e_)���VY��_&cN���]))��t���E���31g��!�ٿ��k��7�+p�c&�\pξz�oe-�8b�)�U��7�n<��+����3�ї��(Nٲ���c�N������o��$V ������&N�L���\^��$[��T��T��\E��
^���j�!+KzԔUV��>_�y���Ngm(���W)��w!��"��V�Ū�jߝ���Q��5TZu9�]OC���A�֩Zu�
2������ity}n�Ӝf�������[����Ic�8�_�	��G�ף�	(�t���gSE�? ��i/ꤗ�t�}ݙw�b[�^�-[�=V�`��]�^����}"��&{eYoW�lI�{e���ϭY�{�&gY����]�
ّ3m�U���@{x�d���E���
K&9g>�l'N
��e1�f��W��_�ԺV���Fry1��Ƥ)���9��gD��=4_�~6*f[>_�g�5>&M�1�Q��U��,��,>;+K�Ϸ[�\*�e6��H�`اM���K~N~~�7ټjuaZi�/�+?�hP�B�3W������X^~.�$�yu0p���/��Is���W���*c����㹗�Z��?-�����_��;�y�gbߚ�d/�z��f��z}�{�C�7Rơ�Ť��ï�慬�P&��V�g�=@XuHE.@[��2>��k��V���A����R��⪵	Y�L�-HU�B�j�
=�~-Sk[
|�ㆊ�e|�����՗CE����"S�Ծ9�A�
��E3�"#qQubk�O��B�Z,wu+���ߟ��Ge�`�^:o�7�����BR

����yw��]1�WaŦ;�ھqh�?a{c�N��N��3v>-��Ҷp4��u�\�.p��5��\�����
�磤�`���W��k�;�@W�/(2�+�!'NJ�Y��t��I7�
���te�A�����M�V���
�Jc���q��)�/d���B�^邧��eN��h,�;䠎tSzbC�w$�.;mB��|��
ǿ1��&I�T5Ѡ&��s�K�@}��B�Ǭ	�O��w�K=��)y+�z������̨����ۤ�.���دf��u�7?ҳe����C��|09XC^Ho��3�pʷ-x�����zg@���v8������V_AƏ���$��T��)��d癹����Y�*�I��nR)��{),%7�tQZب�g���,���4�����L�)�`'����:����L|/9@=
�VP�.��!�P�����‡κ؟w�/�X�����.|{���_޹�6v]K��u��;�iR�n������c[n8��ӬM��X�
�E׍��+��P�!�0�3x�8_w��?_���h���N�)?��b���Ҕ�&�ڒAG��̈́&ݛ���tG#���Ì2���1gvcJURY�Ľ��O��}��Kg��O�� 7g�A�3��w�}�7i��CO�~x�K��z:���9韭\�����B�}{���z���-��'7��f|#A�?�NB�d�Q�`��5��*kv�L�)�1��A	�w:P�B�ڪ�[iz��,cK���akT(�.���@iZ���T�wP�U���
Ar��ٽ������:�pOf}��=����a����/���o^?t�F�7���z�-�v�i��á���Vt��q>�d%��9�Ix�z�7����5zc�R�o�(I��B���8)���5� �&ҩ��u9��ê�T?S	����I|G.� �^��7�(.�@�	�	���нAYl�ko�{�W��o:��[�^�wo�]�߱��7_q�ޖC�b�ϼt�|���~�;u��[�qF��q%�Z�������&3)�%���PCI	����w�h4�<�wqeg����q��ŋ����������yy-�j�(Q5ɨ��R�W����ߨGר���JuvV75���<^�X�S��;���/a�Eu�%|'���:����T������j��Ĕx�)�`6S�ß�wt|�
�x<s�;���_���-�u�ߏ�}C��JhDg��II�
���;�6ϝ��7V��b̘w��RX���=��R����׷�5�y\�G�׮�n��];v��9��s���ס�m��卋�J�[����=r�������_+z�G���hʹ��?�cc��?����������%�C������\��ա���nڷx�[�7P�k��[�����Q$��a4�,ZGS�t�K.~������Z��RR���r�Z[��=�r�
����FqjuN�a�*���Z�I>�m��5�#Fj��H���'�CfB�J�w�2=n�>9��R1���NZ�PN��m���}�C�x�;�7��.��߽T;����w����SZG�.��Vz{7�_��@���nl�]1A�a�X�O�|�z�%��u�T���ׂ^�KFt�t��Ȍ|\�K�JSS5\	� ����c1+�W�I0�q}�!.�.$����A��{�S��dg��
���t����1�����.7�̏	��WX�cu{ӕ��<�㈃9�.4�P^^������=z����\�b���P�v?�Plr��݉E����nE��bK�ewuh=���'���a=?����C�1��8XG�|���x���^��g?�����^� N�|6z�S�EѮ�/i(ﬨh��{F�S�dd�̏�L��������R}�OW7�Yv�lS�5���҆U+O̬��0��W�&u��,ݲ�<|�y��y���5k�AGmQ[X��f�/#���Z���|��w
��������JX��E96��j�w� >q	�̠)*1R��,�Ц�|RXr�t/Q�5|�*�2��f��d�U�2������¢B�����9�~��`�WJg6Ն���yI촑����p@,���N�ڨ�
*���.oK�}/����D����
O����Ks��i[Yǒ��m���]S_U���'M#j�J8[�t���*+[���Ud/{ic��I-u�6v���:��Z�[���"RJ���~JK	?����T���P	R���A�'��n�qi#���� ��ZJ���E��P���ݭV�bQS��n(6j�ԙ^�ҧ�Μ�����9���r�MNS��,y�^|D$���������;cW�̝�����U��B{Ý�����n�v>&��ͫ	��Iv�,�k]�u�����9o�R�X�e�UKT��+��c�E3kM��Ov�:w��x�����׹��,���W������7W�&��h7�2��5��QicU�c�<ʷ߶	�V�V��ŵu%?��X��*U&_�����k��}��{.���Jb��$���
r� ���v"�e�FA����#Wi=��צt9)f�w��R�yE�&�96�P�?��t�|�(Ϭ��]�R���7�ՙ�&�	’�gI�Z�0ҋu�͒Š�j�*�i�����[^�t�.aIi�a_��P��w��h��ɤ�n"�cʢ�/6������֙��at�o7䷩��2z��O���k�m_�脂��Zܥ��-�t��j+P:[fd53CY��M';k]k�u���!��~q̯7f��1}�C ��L�!'[2^v�	+R�T�lv�K:b���`�e�YY&�`��r���e���#�4l����"��c9{mv�l5KSg�(��gY��a�<љ�t���=?H�./y��TeI[P����H��p����TI��ܧc��'���[-���'���X��x����-�����|4�٪���΅V⢙���%���-)+�|&��ܜg3A[CN�	���?�������x\["����>�>���߆�?������ߛ�>Ǥ!�D�Q���'�4��ź��,�X���T�䔥��*�������ϱ±�΄��1�B�?�%�t>�˸�6���"��������9��&�Ρ����i������Д�&���&�L�,��ҵ�z���Ղ������0?�����,3��������éO��,���褺����ۣ.���<�{$��\!�l2w$&ă��.�[-���z��;җ��*@�fl����f���q?�<i?��I��|�n<Z$���Ly�s{b��m|��݃�ƾ�PԲ���̛��E˶�^4z���r�h}�����ցkf�y����K�*g��w�ܺ/��ƅ�N�l�%4���.����	�7�cʍ��[�_�t=����o��{�>�b-��v����q�Lg��+�O��+/�cv>{�e�yH�����V?F�~Ucc�B�+8�%�~`�1�Y�������h������:LK�Vo�j�rm�E��U������cY{M�"R^";�:�b���yA��s�Mz�_���i��.�\��c_P�x�ܤ5ɵ͉���3��a��
f�΢�{'⮴��c�y�ޝ��@�>*��8ֵ-:���<��-����o��LϪ>��wZ?0�q�:�Ε�l�1{K-�`�!����r.�_�)�������1˼C+�^�#���	�4��gU�V� ����|�*_��v�1
z�P)�l';�y$�e�mT����S����nTotr���YK\j�k�w��j-ͷ��I_1%&��VvHFiNl�����z*jZ�9���z����b�=�Y��aO,��"��!���F27�.��)�)o��گ7wX��\5f���Z�U�Z�ue9�Q⁶�ֵ�֑
my����X��%��-��:�/�Iw���=fY���̲҅&>�rsH�5-Z��Z�1�$̑rLy+*�r���Χo���c>mT�Om��X=�Wi�Ϟݘ<s��YVS���ABjx��(�NJ�����y���n��Y���)�V��_�Ȩx��&-L멩5��J!�W��Ƙg������tR���i��ZY�֭�k��[��S��d4�MZ�}��+d��8my��}^x���ֿfݙ��g
ɤ�W��^G�_瞤�gS�͑�-��M����]ߴ����#�ˬn�ԯ�Ne�vqwxR��\��E>yP_h�{���wX���>׺b��;j�v.��@m�v��3�*Cq�Ǔ�>u���W�����}c)��_~S�M�{R�����S�u���N�����gu��N��I�����޸����)^�V��+J�>��X���R[�glo[r_}�OQkP(j�**|�R�R��5Z�{,�����Y�}��+�>��La;f��P�WX�ӨU�7��)�Z���hz3�/�T�2Ծ�zEYi��aɇX�\��R�Ũ�j���)��
�ӊ��\�[�WlU�����Qa⎣���'n����7R;�܌�9�#��k�Oi����-h;[����|k�>[N�.�����9V��G�+�&3��-Uٝ|^��?�Qj�%�9J2�����^��)g�E0�S
͂%S���3�!%�@R�l�\i|��R��	\�-JEv�N�$)	58\��7M��0_Η'��~�t�N�P� c���
�TyG��9h��b��#��,�/�����+UFŃ'����,�971|U��D�����/\�#���:`�7���s���o�jbv]0p���V����>ھ����0���h"y���<��s�������d��^���
���2S���mO�8�mC)���_`+��1�c���BiZK��||k�\o��B����*�
�����X�/��|A�.,��/+����֤Q�{
�L��m4l�2����&��m���8&��c�T��ݬw��&��4���3/GH�{�O�y3�\/I���4fkP�qi����Ti�%��=�Y�$jK���LB
��?|��_]���sLy�m�%]+�g�z)�^5P��o-��]�٭6i�j|�.ص'|t�y��;������wшm�:�7f��y_6�N�U�6�?.r4QW�=�Vh�l{�#�dȘd��$�J��lќ̐l�$�U����7Xg��;��w�AH�T>�aF�^o���~y'���ŵ7)��l���~�?Oc|N�����8�>�w�s�v3_r`n2�v�
7��U[�&������fGv�C�
R�����}���7�+WO��#z�?u
\�g�6$M�3�;3i�$��ŕ�*!Z�Lw����]���/���*�����XLC�����G�~j��f�p�����k/��j�-m�3o
-P�o��ZI9�O��40k�Eg*��*����Ʒ3	_y@��4�I���>3�hmJO���L{-��&A�ה�֫,�:}&��C�Tu�mI��������Ê�O)>�&���>!z*b�B�����f�8�)�xS��
ig�¤��usS���ύ�o]t��;c�����/]����|V��B�����\��7_|���?�m�+�����s||���^<��k��/�ۧ"|��
�A?�'G>)'o%i�?1�e�*�QM-
�|��?��#w�ӵZP\�Fm�h�9v�OY`P*����^��q}jj��ٔ�P�٩�9��[P��hUj���2�ؕ�]X9	]Ue���o�_�
f����V��scK{`'���櫮đ�;�f�
g��������/�l7�8_Z��p�L���
��5�����ioԕ�c�=�^�v������-=�t�1o�<`���'��8�c�0v�S芬]\m0�>�����6���*�ȺQ&�������δ��=%��0���������ٴʸ������=�����S8!�
#�W���ڰ��U&�K�����϶�2ط���2���5��򸿳�
��<Wv�/'ϐ����̕YM�4�Vv?�����ݮt������<J%���cZ�U�j4��s��z�X^��r
~��/��1�Γ
H'��vڸ��7RS�,�Ao��{aqCL�W�yʼĖp�@?+#sn�vZP�I����0#v��s�6޲�د^�G�X;lʭu�i�^�^���ϫ�.n��ړ��i�e������TK��-�s��|}췲���\���5���wHgd��(h�ӟ*�ٓ���� ��~x�<-{]���u~k�w�HL��s����^�ޠJK�͞�)X3�JU���L��qL�R�Ү4�l��$��2
:e�B!��$�9oa��ʤ����SS���ʤ�W�3��G��Y��<e�tm�¤b6���{���Q�x��)}�:6�.rXn2��^�����UiN�P��euf�k�'r����r�IՔ�Pk�y6Ɵ/�)S
����&h&�M6Q�_6��E��_�TL�x���5�`���ا.��).u��W
��&���)��!�0�^bpȗx��	�������Lm������gvޞۨ�ڊE}Y6�p8���܅+c_��vw��Cٿ�ꎯ�E��0�����8?��HK��������l���wb�,�y��n(_���gn<�هQ�����=�q���&��"!���j�\Mn��(�LV�%�����iu:"PmIe��T�;2^A �M�fDa{Ť&:z��j�.��
�ٗ5���(�(�#�\�V�I�M��H���4:q��w�㼎�ԁw�8�C�e�S_E,`�Li�l(<�?��_}����/��b�ꮃ�U�ܕ%uV�o����Ӿ��ek��\��3�؞V�lcrC��pqSU��|Æ����;ckb����ײ(�#���Q�i�C�̴��$]��Sr�����T�AeED�.�954�e�.3<ķu�R��B#������4�t�4��l�9u���ԥ1�7�6S�<U�,.�4��bn�v��PnH=���kJS�7��IgN�3�_ޯ�L~�N�q�rAU,��Hl[l�m����&��Iz%!�]Ͼ�H~/
����m
�,4w�A�����pYz�:;����{+Q7Kη�s�|�����?~���T㫊�*c.'}`����������a������W{����-n_�m�ˤ~쎣;���w��;���[�
����L��
������X�\_L��TuʩD�UU��DU�E*�T"�m�Ĝ[q�C3y�_q�:�Z�7�(�)�:���SQ�|,�m�NYqw5�B�Y�n.���2C������V�rk�]c;d;b{���Ma{L��pw�9�1��?�S�|Gz��u�]����Ww�N^w�N�݇;�<q|@7�;�[�a�nV�L:�6!㔵	��%P�ј����ىٵ:��{c�M��Q�%�M�ɣ^WQ^J友\�κ��Xe���V/q7{�e+�&csa�yv�B��
5�����i�&���Q�[���p�L{l�҆�^ٺ}�FVY���-�s��B3��[�ɕ���Y)�RaT��*�
F)|�K��;�ͤL(o�ML}���Q�W��t�P%o��lUUeM冦�����j3X�6')���r>�U[�p��[�4X�jj���G��{w}�����������h��^-�5Y[\�M6]�`�>��d�� �L�MNh���835��=�������5�o%�u7ܵD��ìv���S�����Ҧ
���
׈�M�e���kM1��w�4�����y
ݙ��p�׷NYx���B���b�F_���AK��k�,����d��L'��V��t���)j�*��dW�nӱT]�n�n�N�����P�(͑��g�-�>���?�������?���ڷɈg�����S���<�����f��g"i�W��+w�F}���'k�;�ۚ﨣N'�x�P����@�tOO𓶠���!��oM�ų!�����w���Lܺ��o~,�ЃO�i��23��J��P�T�zw�:;�x��5)X����w�n�+S��>����鳢������ʻ�`��?���ě�2�������ﳧ�2���ٱ���0��;�������󲜋��+Դ��/5����<��.��
�?�>�V��U�޴��y�]H_T>�6BoXw��� PЪ�2k�*/�/^{-8E�[�7�
�
��ԑv�EW�]n�jd���`(44g��ȴ���E6[Q4�Y]���z�>�oa���a0�_K��,sO��PT䢬H��HcF�Pf09
�jj:�m��])��~L���-�VX��?;��,Cj�EUm]]����eV���nv	El�K�\E��Tնֲ��TƊR�~PU�M�&�X������jV|��^Q҄���uUbGv���ow��:��F�,P�1sbk�M���-|M�Y�����V��<#�SA��O[�QTT,�
%��M�Zn>i�GW�Zz�w�/�~m�@G��
�>��{�(;V}�䒍=ukY��“��>���G��֖���]����yz�-���y^���G���^ط��w�#��'e3��޶���kC���@O=�����c�����x"�G{[6��u3�N~^�z�."��q�I�	ݺ>����(�6�Z,�����Q��9���)���dz��&ڗ�٦I��9$=���*�J�V�ʠv�����M���C����r�"���:�C̢��׼�a�^����Ԉǎ���Ĵ�"���<8�P5�����^ެ�!����j�S�4��Nb����7T�0��Y��f�/��no�R8��|բ���_<�$��mKv�7u֬��
]Ug��:�Tp4�o�>��~����15Ğx��eN_��_�>����[޷m!OɌ�+����C���=�(R6�ͮ���%�����S�p�f����!�,e��RZ��=�� PNH�����=HN��/�m�*�����P��5f<��8�7�H����3ǡW�2�J��X<�JY��+u�u�Le�8`�M�๢��u��o:�|g���K�_������Kο���}l��G�	�����+.=�o��������Eu^�tӥ<�c��(�` �����IU�ګ��À��W
�9�wy=��GH�D�sd)<�i
���
��!>
��lƐ~ـ�	��H�*`z쟀z�BHU����*ȍӍ�͈���=Ӄ9x0�0Jj!ի���͈��H:�_Gt�zDį#v�Bȳ��`��ۉ��xՑ�H�Az-��ހ�ek�r5�T
��@=ҜW�j@9��
p1b/�\����#r�5b�� ?�u����
�4B�1�q1b/�\����s`3j�uҌ:i�<�!ON�1�i.g3�ٌr6�Uxw5��1N?`7�i��#d'Y�_�G|���~yP�
�
HoBz��r~$�q�?���+�[��K��n\�%���g��x�Y�,NWƿBK�&
�c�9��W
?��x2v0�if�?L����<0�i��
5��x�B���JZ�3�dV�R�����B�ib%���#�"����ň%�5�g
�Y�y��k}���_,��De|=`J�
P�h�?�̏?A�����?
RuV"�k�NN@�F
O"�9��p���?�#͈�lD;�,�p��~�2�-H?B�?B�?B�?B�?B�?B�?B�?B�?B�Ob'!�+�$�����T'1U��X�bP��V"�k8BZ�e�t�	цhG,D,F,
�#�8JG��(s��9w�[λo39��0�f�u�x�y#��z�������4�8�
��]L	5�P��G�6��$y�����v�Bt#� ~ޯ�6���9
���L���1r�>hF�F�cx����N2X�t1�q
������)(y
HΑ���
�X�!��n�D�@@�@���+
��!-J���P�h�G
�H�-�و�%T
�+
+݈5!O�&��
�s���P�=P��Rh�,�K��Rh�,�K��Rh�,�K��Rh��_��kP~
ʯA�5(��
`e�^@7���5��<9���xȓ�&��H[s0Ď��K�=X��JD7b
G��1цhGt "#�Z!�W
�YF�
����m�:����"D�
��X��F���9f!���b@;o3������fB;�r���-`%��8��6
0i;���.F�րb���[!�\�!�ȱË1��K0�Cʡv\���ڈ��@���<������3x������UϺ�`H�S�z�U��g�׀���z����# � �wğC:
����?l&�V������@�ȟ�+�s�˟
7a�`���T�F��A���
@� �〝�#�݈K�4B�+
{�
��D���%�+��Ø<�F6��v�ǁo##��	5ل�lBM6�@�[I1`{|��4�$
\��C6��M����g
���6�!(Ep�0��#��
GAMP�Nc�載튟��7C�^
�
����/v#��N@y9��$ �gY+[%j��
\y���Yj�
�׆w� �M�k��R�A>��沵�e_b� C1��/
�I: >��`'h��f��	V{���倽 U'��+����:�͐s'\V���=��
�!O�<k
����l�o�X��X\€���
�ſ	��,�|pqq7��FO�f� [7���$丞h
�7#nAA!n�Z��Ɛ�.��|P�,���ځ��u(�@w����\�%l
O2p������BFA܆wG�DK�<d��#�D����.���r����A����@.aւ��}����=��
�����9���z@�#���=�m2�!�1d�Z=P�7xw�큲�ÈA�T۠v�@�8���Ǐ
N`�Iĝ��0�n�m���r��������0�'>�kM/��^��
�������$�
[�-�J��*[��j��8`3�]
>�<`+�5��`7�K ���Q�
.�g���W#�5��c+�y
J�b>(������P��a�ek����� �Հ\����K�툝�����<|��Z����
��u8nA�����A�	!�@C�r�Ki�0~i^�6��~��a��+�Ъo��7`�0�
��9��n����� �_�&�	�n�� g������H�q�!=�8�!!��c>�4�|3�s�r܂817c�Y��e؂��u�cnA�[���9n
�?#����C}�g� p�ȟ��� "%����8n��1�F�k`u2�!#(�j`�AyF�v#�7��a���`#��QL;�iG1�(�}���Q�>��F1�Q�8�9�b!(ˏ
��@܌���0�za)B���B�l'���ۉj�v�g;��U2��H���;�-݁m�����2��@�;�,?ƐQG�
u|�4�Z��ȥ�r��W����1�q,�8��8�e㏣珣N&@�	��"p�AE�D�\Q�-��E�{�G��Q��(�<��+�:�bmڅ��B��´�0�.L���������\���uu1��b���ت_����8/
�!� ���t��+�!d�l	~���ێ(ଟ	�}��\&��%�H���p����JޒhqS�D+�O�W�S��1�N%Y�Dk��|���U�&є�+~#ь�oJ�@��K��d+>�h9�(M� fe�D+�6e�D���v�N%��G%Z��P�*�j���P��H��f�ְc�I��h�
�P���5OI��,��
i9�[��-#��Z�nІ%ZF�ڋ�Vr=k�hЭ�%�Sx>�DC>�6�S%{��h/��%Ң�DZ��H��i�^"-�K�E{�t*Y�F%Z%_��N�դ�pX���&�o$Z#0�#�Z�i��*���2�]ew#�����K%ZF:���t/{��
e�IEZ��s�%�� �����$ZF�r�"��u��/�=��H <��%�2�lB:��c;,� ��Y��\~�R�A~�i�k�h�k��l.��y�9�o m�>��-���U���B�9�ɱ�e�>�<����I4ș�3�Ky|�Z�!���
^^�F���:vr:%I�)I�OI*WJR�Ғ�%�OK�KZ�.��!n��j5%A���0����C&1�~M
�1�!�Q	w�1�� +!l���i��kb������8�:�R���Xa@Nm@�A<�@���=
��Ø��T������S�Z�9LK�;H-���H�O�m.��ټ�s�<�!���j����M�&#���y����n
�
�� �sJ�d
���0�=*io~E�.�+��+Ϡ�3Kp���g���e���AGPWA�f���� ��=��⹖C�Z����E}
�\�]M�<��M������Q����g-���.�\p�;@�)H3�占<�U�V��8$y�4p��c�ݩ$k�ʼnb�p�,���HBbn�]�R�k4I�Di"�{�RsO��=!�;�\��\O��ם����8���I���F$]���
�����!b�A��%��:s�:NHýl�d�Ss�:9	�#�=��~I~^#y	D���9+����ĉT
����D���fK��.�m��i뎨��O��z��-"jj�Kõ�����&�|
�{��C��Xwز�-�8�p�������'��T=a��s�����Q�v��G����D8�g2�hOM���Px�ұpḻ2�m42�X�N�
W���K��+�ぉ��ذ�;
-�
N��S"9�b�
NMC��J�;�� ƪ��H��M;��T`88����|�ЎЄ#��L�"�aǪH 9&���S�0ܙr����Pp�rV� ��Xpd>����;ֆ�"��705��8�<5�GA�)�%08tp!FCA�Hhj:�LNS�d�����+�
��
O����ӓ���T�c8�

�:B����c88�6
�v���2�c{����x����x�w��Ɔ��a`::4�����h��� �mr�@Ѷ�&c�����Ķi���T�1�uDQ!�h�
M�PÃ{N�I 2W>Q`�h2���T8�mL��	NL�v��A�m�&��\TPѮ��.��1�B3A�v$�����Cֱld$4>m�iPr�gJ�਒Ġ�a���pt��At��\��F�
���c��H�~����t:�l:4�
@Z�-�vFE���<�Hر� x�Ppl��t,�-4E�p��H�C�QǶpx�
����
�ׅ��`��� ���tP`[���DpZt�� �d~������PT,"��c�����X`�8�+8	�V�F"��UU�w�Hn>^^	~S�Y���H�75
������������n�l^�YvƢX
��`
(88�*U��"܏''�B�9��C@ܩ���<�0��3�l��Xoh�������`�k��qf�h'�1�F��
������:

��]�Wr� Rt�gS�p���K梂�&��'G?�3@���"�K����-����|�3�b���ƒ��3�T�����\�@��00�t,o��
	j���qc�l�d<�nz�*��)G&	��“{� x�F�=2'
�&�Mc�R�?�j޺+�uR�s6´�z��R�8�Ky�G��D���\ J�t�{L7����3��|��K�Ns�`t,P�F����ы`�`�V��	|�@�SGH�j �Ýx�\��Y���)G��Î$N��ۙ�t�̼���o�t�T�e���焧�M���7������s��̔���T��on�D�@ؐԁ�Dbwl�f��/1J�N"����ء���(;����\yR�|7�:(R����.cu�M�z�8�;��!� v�v%5�N� v&�(��a�ʗ�6�F�{Z�NOK��(����#�k,Ik�S�P?��Ŵ$[B#��r�I�z��N#��y���\�=d-�4�<��:b�����
��헬aQG���aSرކ��:�����N>B�C�Ѯ�a���`��bNp���`͘�2-��	�����iC_=9<+�艡�
��i:�lX4p�DQ�����,���$��(�e�a�r(]�I
�y�+�eq
@�4�F?��l-����E�t��P5��pi8�J2o��@Pv�a��MǰA^!F��T�$�F!�=�-��1�!iRf҈�^�Þ�A�\2�iw̛��ɂ�щ!wr�0���0��x'<org=*:ϊ��y͛���bnè�I�ɞy1������Z�Ӊ��H���n�W��N�IS�R{S��K�0�[>����9���)��7�<U��i���ME�g���)�ϙ�"�¿n�����x��=��^J9J>�}�ϰ�<�]XWw��g�Ks|��GP���g�ٔ����dH�+>�ξ��i�����X�Ɠ�7bܳ͝�������>�)��f���v?1Z
I����h�u�Խp�'�1���lx��q8�<�P���^��^�y�z�N�A��C����S�����Y��>-e�۴4b�zE�,g+���$[���>/�3�Z�م����ɰ��Y���C<�5Q�����Hx�����l�H�ΰd�7�V(�o��i�e���&Y��'���e-�YqȬ�-�������rg����*>=e�`�3�������>u�֝��ק����;P��J�>C&��R��vǔ!�8��z�'�R~^����G)!�D@�
���o�Δ
�����~?�G�%g��]EpE��ȉ�(I
I�G�����CK҉��I�$�E��D��B�$����\`�G�I
)$NR|t�J����U�M夆x�:V>����I<R�H3i!H+�ã�
���tB�*�Py/k�°x9Y
E]*X��:�:��F����dيÃ!|,�HJ���L`e�4E����P�y�|r
�K.$��~r�\D.&����Rr��\A�$W����5���\G�H�D�L��
r#��|�|�|��B�����Fn'w�;�]�n�B�!��o�o�����
�m� y���C%����q�]�M%O���������s���y��y������D~J~F~N~A��_�_���o�o�+�w�U�{��G�y�ߟȟ�q��&�+�/x�E�&�U�o�]�y�|@�NN����#�Or�|L�E>!3$F�PU�4��Z�NuTO3h&5�,j�&j�j��4�ڨ��Rͣ���R'-���EKh)-�崂V�*��_�Q��Z�u��6�F�D�i]@[��.�m��v�E��v�Ŵ�.�=���ѥt]NWЕt]M�еt]O����n�t3�B���Ct���FGi�n�;��4L'�N:E�i�F�.���C��s�y�|z
�K/���~z�^D/��Ѓ�Rz��^A��Wѫ��5���^G�H�D�L��7��M�+�f�U�5z=L��[�m�vz���E�_���{�7�7��}�~��6}�>D�����G�c�(}�~�>A�G��Oѧ���3�Y��
�!}��@D_�?�?�/џҟџ�_�_�c�W���e��[�
�}��������F_�o�?�?���/�M�W�_���[�m�?��7�.}��O?��'�?��#�Oz�~L�E?�34F�0���ə�)Y
Ke*�fi�[+��tL�2X&3��afbffaV��r�7D,�9X�g��9�
��3+a�����
Vɪ��U��a^V�|��ճ�ȿ8a-l
ke~����v���N���n����g}l)[Ɩ�l%[�ה��l[�����m�k������b6̂l�mc�,�Wղ16�&X�M��l�M���]l7;��a�������]�������]�.a٥�2v9��]ɮbW�/�k�!v-��}��L���N���t��M�'�[��Ķ�`$:5��ml��h}u����_k�k|�Zw�lQt*�w����X;Ż5�u���S�]AE/ʅ�m��e@�*:�S�	�0^�L��ER��k�+(^zC�HP1&^z��1��z����b�x{B�,cM$�uK�j�J1ҔxY)Ɲ/���i��)|5�գX-F��E�f
�&�rc�I<��|�Mʧ�M��˻��
���`$ ,
�c��
�pp,P'�Cc��th�x@����hH�o���S������9Cc�qNMLG����b28
٥��»ǂ#%R�I^�����px��H
�#��R�ቴYjp:�
OEF�=ci�	��O|��vƂCA�h8:Ԁ��������pD�#o�
�E&g��zQ��wp�����Z
��J�z�*ݯ��k���G�]+�����R���*ů���>�Z']%~�
�u�tm��	>�u�t��>��O����$�>��O����$�>��O����$�>�?98ڡ��\�56"^�"����h`8(GT��k�Hhl�&|�J���ed*���S���	�:6�
M
�SC���(�))lz<4��G�1v�������8����|z�ˆƢ���`X���a�xtZr��6�of�KXh�z"0��L�'G�����G�aXl��R�T-�w������Jjk�T�'���ʅ�!�ī���&:>2<G=4G�UԽP��)I��U�Hl��b'6a>�Z��J�u۩��H�CM�t���zqR��9Z�x00%PtGBc�AE/�nI��$U�(UH��[jPC�U�$)���J呤�ԥ��o�'�á!)Pj�Ī���JW��hb���o�$JXe�(J8IA���:��$Q��
��4��F,hT,�)����1������Q���rߝD�'�{�h9��ۦUy�
5��	R�p�x
�^6=�
�tx�N
p���u�؁l���:�	�[��n8�
N��Sw'(E�q^4;��/4����=�dc��@*_�0�*�
��|4-2
��i5_�!�iӐń�C���&04���#��&!�R-�O$�����("��v�%*m�x��A��&)�j�xp�I���8ȑ��
�O�|�I|d���8yO`r2����닲�Q�>��x��!a�hX�
���Q��_h
	˧Ci�I|ӥ��ߪ�\!�Ʌ&
J���e�\�m��-;��F�\��w��c��QvN*�-L���0�j/I<)s��%�+��i�d�G�5��8�.��Z��HW�t�J�Z�ꓮuҵ^�6HׅҵM��K�EҵS���m�J|�%���j�o��Wj&�R��[-��VK|�%�����*��KͩWjN�Rsꭑ��H�k$�5���ĿF�_#���H�k$�5���G���{$���G���K
��#��H�=��_js�R���H�=���+��J�����+��l�W���{%�^��W���{%�^��W����J|k%���Z�o��Wj����Z�o�ķV�[+���J�j%~
Ry�罻:���2�����x��BH{s9#�E�����;i�o�pw�oeLZ��}K���9H���(~#Y��� g]�>��G�Zzp���4TɎ��A#��j�;M�"�ar9qoU��TF�1*;�ҽ�]��s�}_i��p�L_�W�?�c~~2݇w}m�s��g�?|�[�.}��
��}@8�}�
�(XW������ˉC-z��
�vkf��\�U�jw�BX#Sd�5��M�,�C��]hU'��C��e�~C��O�@��5��|Y��Ԯ�(�}��nҸ��>�����������6�6�����:������L�>��*����p��ո���.$�����Ľ�r�?����մ�=�����%�%�z�ݱ���]�������6�������̲�#�˳��C�s�Uֽ��������ұ�����=����ܱ��P�巴�쪿�_��寔ǭ��<p��W^j�{���?^���`��Xoʗ�|��moL=���-[���ӓ�ۇ�	��V��ݾ�9��﻽�0�\��T�r�����YZ��������B
��>��
���-�Ҹ��������ݥnב�#���ݳ����ұ�����+���6�D���Ě[�`*���<<����x�m��20��n}u:���X�jauE�)�$��,�A���^;�)|��o��n��@E�EY��T��l0��<v٫�_{�Ck���޾������H�ˎ�=~��/~������\����=,k�]J���B߽�����^V�w�9?�d��o����w\���t�O��٭o��-�o���g�w�go��7R~]���ʪ+���ʼ֎���G�9�O,>ֱ��[�#���g��7޾o��=�.��tKy�m/���-�6>��K��q�E'7�:a~h]����Ƿ�|Dk��s�}[�^6qP���'�)����n�|���Ծ��B�}]OY����+;�?zu|����Sk��+�j†��Y�L�#%3mt�S���d�������LuGtj00����P�=F�#�j�;��3
b���/���g� �:�m�g�nc×�JR��@M��U[�ӓ�����h����M'�bܣ�y��;~��~�����{/}���?�-�ۇs�O5g���qcƖ}+ˤi($�3c{
J�D��&[�q[֙,����[�K%��7TC)i�^mRMB�Jn)	���C��������yf���3综߯���}�;OjǛ�e	@�[lZ��A�t��W��O��L�WH�|�S�4_r�-�%�Դ�{�
�O����;�rK�;n�S���W�؋���7���/y����s�%$�m0D�U�%�͖˕���_��Ӑ���ځ��ޗ����B�MKW&�7�(��'l��(�q��}�E٣��v3�{j�����>�r{�9��1��C���衘�]���λ�-%�-����Y�ý�I߂r�s�Wkg��0�Cb��!
Co�0
���
c��
0I�׸���|�X[r)"ϥȷ�j�E��be`ɬ���B �tA]<�s�@���pk�A�)��:9�̳����-��n�]��E�[͇�_ �$ߐ4���M�7{�ޥ8fn�|c?t��|��������
��hn�[~��rx��MlrG�N�Y��jv����U�cG�H�=:��j⤪J�3���z�5�c���mF]w켼	Kׇ6|�c��t�!��9T��CPXԦ�]T?
jS0��G~�X�e(ݗ�G��Z��A�9kr��dT}g
f  .�x��!t(��s6��&��������tG!!3�E�D"�A�(-�6��A
w|W�}��ִ�^�i�������b������I������Yq�
��VNi��H[�W){��[KMF�9�3����Ɠ���@e#���Ea�jhM
*!S�y�]�jj��
�j���2��p{ǡW-����v�'`Q���t7h�&JM�h�>��$���&���f��Ӏ��ʣ>����8А�.����j���%�±�-���y
��������b�������<d�2�<Z��('�?�1���-ݸ��*O��8��y@k�Y4����7~R�ŕA� ��!['[a�Z?5�&a��LX
�#�4�
�
A8�&�3������8'"�5� l1�[��<@�PQ�NB}
AO,��Ky�_(��/�����b��YA�N	����4�*V��
��ӎ,W2X�Y@@9�aR������i"q�A���%]��xN�:"/�{��vd��z�ʰ�q5��(���Vn��}���n�Wů�,�O���[��>�T���˷�ް��|��ޚ����+3���x����γ�ݠ�"�b�,�۰�1�q�R���Ƴڶ���#����-�E�է���.�,�������).1�ᛷ��dz������<ȣ{�
&4/0�of�3��8��dJnMcm2�"�o�F��j�!����i�d
i^�%jG����Bf�'"/���"�¼P[��ӇR-RPXhwh�򚊷���{RQv6���8�4��A(���S[<�~�yr
�p3D��
Bki������~�73���^[ ݽҽ��`[g<�dI5�5z�p�L��@H�T�߫m|��6��eh�u�%WH�0b�t����R�(b�\�i��l�#��}�Mb����#��kd�|��"�k�޻݊p�e�����$r�܁�YT�A�����Ryn��		D�
k��_�-�fw�Y;[cu9��u�E\����@�B�EX~��wFX�����_�����+��Q���e<~)
��&���D�@Y��ځ*oF�zy��lm���Ud.��w,�&��p!f�:����d���Ɓ�b
��G�J52'�WO4���z?������Y��A�Ʊ׼��������=1s����ϕ�:�]�-�iuؗ%�r�-��Jk��ň���I�zH�;�)M���O/sh>Spa�6�8E��G�O�[V?���e�_�ս�xI�v���[�	�6x��-����z
f����(�h�����kܯ�Щ�Ҋ���ԋ���y5X����ue��N��Ԋ�_�K@&�
B�=A`4�GQ��?Y*`<��b�Mh�@����e�"����E(9�H����cEH���B�=��
�o&�]��*�w���V@�7�g��R���֖��ȇ`įT��}|uF�wl=��	��?�޺�R ܘĿ�H��*��s1FF�.�O��&B��jv�6ex)<s�|D�z�}Oib2Vûv%�]u��Dn]�6�M�u�����$YT����l�:�=��q��đ�5����u�0ȄQ�S����+��+zb�B:RpAH��T6o���&a�P�K�@ih�40x�7��
�����lG:;ꋵȮ`D��[�����
^�D�G���(���k꿌6lj/:[����&�
.�Pꤲ]�V/�tø�_�j�#���5uE0G���d�~��e��F�⬻Y
;�,��S�H��{)���8���ƈ��f���j�:�F��=Z���c3:���
B�#x
endstream
endobj
474 0 obj
<</Type /Font
/BaseFont /TimesNewRoman-BoldItalic
/Subtype /TrueType
/FirstChar 32
/LastChar 255
/Widths 475 0 R
/FontDescriptor 476 0 R
/Encoding /WinAnsiEncoding
>>
endobj
475 0 obj
[ 250 389 555 500 500 833 778 278 333 333 500 570 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 570 570 570 500 832 667 667 667 722 667 667 722 778 389 500 667 611 889 722 722 611 722 667 556 611 722 667 889 667 611 611 333 278 333 570 500 333 500 500 444 500 444 333 500 556 278 278 500 278 778 556 500 500 500 389 389 278 556 444 667 500 444 389 348 220 348 570 778 500 778 333 500 500 1000 500 500 333 1000 556 333 944 778 611 778 778 333 333 500 500 350 500 1000 333 1000 389 333 722 778 389 611 250 389 500 500 500 500 220 500 333 747 266 500 606 333 747 333 400 549 300 300 333 556 500 250 333 300 300 500 750 750 750 500 667 667 667 667 667 667 944 667 667 667 667 667 389 389 389 389 722 722 722 722 722 722 722 570 722 722 722 722 722 611 611 500 500 500 500 500 500 500 722 444 444 444 444 444 278 278 278 278 500 556 500 500 500 500 500 549 500 556 556 556 556 444 500 444 ]
endobj
476 0 obj
<</Type /FontDescriptor
/FontName /TimesNewRoman-BoldItalic
/FontWeight /Bold
/Descent -216
/Ascent 891
/AvgWidth 778
/Flags 32
/FontBBox [-184 -307 1206 1032]
/ItalicAngle -17
/StemV 70
/MissingWidth 778
/CapHeight 662
/FontFile2 473 0 R
>>
endobj
477 0 obj
<</Length 124851
/Filter /FlateDecode
/Length1 192588>>
stream
x��	x\��/Z}���}�3�hF�H����-ɲd�cۀ
��ق��a
��Y�  �@0	��"��	�-!�bf�!$!���~�#ن���{������w���>���������ȖI��ƃ��2�����ʥ�ف��ɰڴp�=潳�'��,%�龷�Ž�'���H<�Q���mѺ���%���{�>��/�=��;�ٮ�<��8j��C�P�D8�Lw�8�ؔ�z˾D�
�|�!�=J�w�%D?Dd|���kVS����X̧z䉇�tƒ������ի>�7��R�Ϊ��~����A�n��*4��i~�LOn�QǞp��+��-D��#V~��ߚs��\�|{y����Mw�G���'�6�N݌�`|��ˏZ��sN!�'�D������Bʣ�����o�\��#O
~ƿO�K#ђ��>w����8�X���}e���|q��cK')ا�#��9�u�������߰|La2�I��q?�>:k(�Q�
�}_YL*�U�I�b�X�Wk�&��M��Q�¨(F�h0ZU����>H'|69w�̅Ø=��b�p�lQ3�Žˈ�{�Y"�#s6�MqI�d���V���q)�>�[�b�T:H�%��;_���6���j����Q�6��I(�� Qf���r��(��Lǘ�Pr��
�G�F��楴��Z������Z�#���4�Ѕx�oR/h�cܧ�aM�
ӭ�����Oޓ�y��0�˰�.����a�F�7�6�q��	r*S�5Ѩ�˨n��_�[�*��D�Q/�6*�T�n�
��{	c��z�����2Jp���1w��E��6�'��Q����F(5z_�55,"�ľ���=O�I�ߤ���s�X��m/�i���?��?��J������AGh��&?����,�~��
�a8�"�D�2�8�xM�;�P�����4�V�A��k5]A�(]Я)4�|�^7�i�kYG����,y��N�h<�g~ϛ�6��k�/���{����}���8�5��=�kw��� ��>[�a��X�
�tJ�4^��>����K�d�6���;�O���X&d3Y^�,���V��Q>-�_���q�Qw�t��Ç�_c]�N|����#���ߣ��i�{�n�~5ό8I9�~�r4�Y&�&ʷ�#�
�+�91���W�/���^�ZY'>��d����{�����j[�3�z/�wp����va}�9�ՏH[��g��öz�>������gB��&�I^l�/h܅�SL!��P�ޏC��T?���3xx��g�p9]��M~�{�
Y��J}%�3�p̷	�|��]��J�3J���0�5�1�/6�)�����Z&q��c�ζ�_)ʟ���<�k|��0<C���2�':QR�5��PNG)[Zŕ�#ĸyoҠ7�@9�0Hӌ�йM4���;���M}4��CZ#6	���(��ё��8�XK��Ʌ�G�z�5um�d�_ti���ׯԏ��g�;Y˳�:Q/��{�a�l��7�}����Ə���%�����W�4��~^�L�����Wk�+l�ٯ`������&޿���ql����ϟ��j�m���~؇��
~���<�(|��F�nv6����h��iZ���|i���
�')%�τ?5�5n���iҏJ�L�m>4���i����旍�|>�τ�4^/|��(&���O�C>���4���zl��o��K��E��
�'��%]�&���?T�����6�Vg�9��Ơ�������$j���I�
�e�Ki�c!פ=fٛ�h�k>��+����qO�� z{yB�`����
5ڙ�E��Տ[��[Yx�����ю��~��	�i:�.���1g�[�ō׹W��O��2�×505�'m�	>�D�S�osP?���FC�������WOi�d�5n�J�E���p��������r�S��l4��P�^A��7�|�����7Βq�3Ԣ��� �i�&�-��э�Ǥm.I��}��A��}`Kf��k�bP����8b5!�xc���>��
��b�ض'��b��j��c�n�D�9������,���6X��5l����\�X���-��f��l[�4��&g��,�gD�a�s��f[y�~�~n3�V�wE���&,�?���z�TF�h�=h�L&�
�m�m�`W���
h�	��-V�?[��DEDѓC�"��J�/�Z�xh���#B&t�:Yi8��ـRmv��
��kP�T�DD)�Z��,�s��/�h��"&�I�+b2G����ӚHT�L)&�M"]0}�����y/�h����]�ZE<ƾ��DPD+��Bl@OtC@��B<{�"~��¸H%*Ђ�������
���)b�x�[��Z��Kݼp�CÐ\Ex="��b����Q��:AM�##��(+��T�dTU
5���/�M�A27��^f
��
�N��� �SB9
݀����H�%
���� /`���!�Oq�F(�0F�ƿ)NQ����)
���Ҕ�P
0Ki��(O�e
��P��1��X�����m���'�S	�Be�	;���꒰J�5�vSG��4�:
{$�.�:U"Q�i�
8��4�N���7�^�TD�8�C����8��
G�J�i��+�.4��
�JC��hp7�8�F���4p����{���_h
�
�P�E4poڭ��C�
��p1�
���܏�j�K�K��~�@��Ё�7�2�p9�x�۴������<�-:�����
&��t`�M:��
I�
����tP�
:�V���
����ߠC��:�X	��U���a�ߤ#��	�HG�DG
~���x�N��Z
x*x�+t:}�Z�m:�L:���΢�
Ϧo~�N�.��t�x.}p����ɍ��|:�:�B	/�������ѷ
/��R:�2:��"]Ng^A�
�>}���s�{��Wӹ�?�����s��?���
��L7�ŀ?��
��.
����.�	]x3]
x���S�>�t%�:�
��I�3�
Z~N��.�(]��~�x���:�
t=�t���#���ǀwK8N7n���#�ts�Y��n
��~��=�,����y݆�_����+	��>D���F��ô��Gz���
��I�8�������-�
���������$m���Oѽ�O�}���t?�%|�@���x~�6
>G�|�~�=��=m��Ez���k���Ɠ���[�Q�W�1�W�����5	_���AO�)�[����6=	���]z��[z��n���B|������g?�g
�&�G���N�����?%��^����8}B/
��1��^��g�ϟ�+�_Ы�[�5���x�?6�s������I������J������J������H������H������H������H�����oK�����oK�����oI�����oI�����oJ�����oJ�����oH�����oH�����K�����K�����I�����I�����J�����J�����H�����H�����[�M�"m�iӷH�����/K�����/K�����/I�����/��hӯ�����Ǧ�Ǧ��֦��Ǧ�Ǧ�ocӯ��eӟ��M���M'X\R.�;�����d�*�̪AUMے�`6�M6�XF�ɊG��d�����h�h�ɨ�7�����f�5��d�4g4rR���\�(�M`-V`�X�dB
���1�I��L��
�"�j�H�S1�A��4F����nĻs�17o��$�l0�
f<s�s��)3`a�i��8����̖�Jf;'��;x�f�'&W�#�af����oflGf�
֚T�Ds��mhf��e|KSVF�/�,1���%�,�ɯ�~P�捪,7Lbdia��h���h1[1�`0Zm<�Ǜ���sX����f3�Lf��9�&g�0ӌV��V�ɂ���h��h.c����pJ}���ji��>���8(�Z
�ɆG+����f�W����G#�Y���2[����>��ha}4ۭV���¬�H���2�vI
�v�G�v}�ǭ����`0UPk���~��9�I}�-��U�B��U*�I�X'�̒��lp8L�M��9��T2;8�f������P������5���o���haʚt2m�6�d�H}�[�/l`��(	��،V�u�2���b�d��*%�JMBe45��>��@e%7�v#��n�p�O�6���@eqX���R���>Z�r�����U�ap�x��e����j�j���a�$lv0�\�g��#a4B�`�;4��xN����I��X�y�M57��-.v�����h�C�p�y�$++Р��Y���h�<�Mqv�Gi�*�zT����,�҈�6��;�<���&D�#N K��N3g�Sr����H''��t9���1��J�"��k��yrO8�|&&��tN�I�Y�F�۬�٦�右��J}���h�حR�ls��(+%�A
ޱ��H�L�G��9D�0�~����a��N'���i�&��4J�o�e��x�&V>G�>4�q:�&rk��aq:��l�a�_1�O�,.�Ն�v#����
�`�v�M6��sΤE�5>�Ѵڶ{��8������/���ՙؗ`���2,�&&ߡ��Ό<%ւ��.�d񊪬yQM
�-��v���P[��3ؙ����O��b�zpi8����Ē5��Ma�"-�.���X�n����mg�c�}����	4�5f�1?��jr��
��T0^��A��P4l����l�9�����,�g�#��e�'V��d���ɵ؍6���H{�<�� \Y8�1�[2�)��m��Ň�.�ju���lN��
l�fsZmn�G�L,s�ؑ�H�i�7� ����ht�,f�<R��J}�UYzn��u@a���G�as��f������>�~Y�>ZA;v�������]3�.�C6����*Y��#&r��t��;�U�?b��G8�m��j`��T�),��M����f˄�Al�웍M�6��[]�B�m�GM�p�h��f�:: 4$Ьy��/�?P��B��8�̼��m}��i��@I�����y�(`C�p���Y꣍�ٝ&h)l'��n�C�l GՄ>Z8�d�!�@���hc�'���{�?�w�p�]�C�P�cwYm{S�;��̦�K}�4��O9����M���ju9��8�2��m|�m�b���1-���,�3�1��]�C�G|D�"��X���(C��Ѹc4%C:�ӡ�����6��,^��c-���@
��Ǚ�B�"�료���%�t�L�eB�(q���"�\l���2J}�JK�4PhqX���"؆������X9[=R��T�y8�f�Wc�f�n�f0k�h��(�?^��'N��M���t��&��H.pVύ���e��a���
j؅�
͓I�
}t��0��N�P8h����<CH��2�ب;xXC�G���dg��px�v�����E�1�����0���y��"ca���j!��M����F�`sr����ʘXz�u����i��{mw94@蛅���fd��]�k�|D�|�p2q|0�՜�2��;���m����41��s�I������]^��/RYtX�d�����5�%�q�E		�U6��&
o���"+o���j`r��gE��z�]N�t�6���q���l�0ڹ3�e�q�Y��y�Pj*�
!��0E �i�x�f���3��tZ]V���D�ධ'��e5iN�x7A^H���mq9]Ff��eb�B��qPT�� �%9h�pΉ6���
D|���y��+��S�业9����wBa��Y쒼f6�����>�F�e��'�f���Y)Ԉ�1v�G�Z�]|���X̰�`(n��ԋG7D�vz�Z�}lRLROLnǗrp�L�����ȩivM;,�c�94-`2;|nXH����� �D����p��L
n4ح�������;9�q��4yS��0��c�(A"f3%ܾ���fca�-!w�o6�M
��<E�oR5ܚ],���9�n�
�q�w*9������:��y�Z����8�̼|3�/,|�0��;L���&��HD�����qqƻ����C6��cq��&f��mv9�.��Y�,>�0�l��V;�Ph����9|>"H���!s���'j���
]^�+��[������i�~��K�Q8;�����18h��6
G|�`
f�ㅝvh|��W i�#�r#�q{<&?�8=n?t��,	���zH�,a@?L���挓��;z/^���yÐE!�G���Cy��9�`l?�ryB�#�S'��A!F�h�]ఛ-��ɯ��![��y��nK���z�t�U�^[b���DL�
���C���+���'5�p�������.�ߙ�u�9A��H��ya7�&�Ǟ��P0�dn~N��3k�9fm��I�$����f`�9#�D��m{�#n�g�h3���hn���|� `v�p��q�a����������s{��$�tx<��Ǧܰ�>��h
��X��2����=�;6
����;������C;�
��5�a�\^�e��%��pE�A�G���\����.l#��Q����<�Bf�3�A����'�ܲ�".�%V� ��7��CN.����N�
����=��
����r�� #�VwLJ�-�_&���Ή-4��L,���zv�*ಲ	�-�dqus[�./�y�F��� �w� k,������W��<��I~-�	g=��/�*�d��kZ��	sMf������u[�.��/)e:'� ���^�<���.����D�7`�{�8�0,~���z�~M�����W�[vF8�l���)����'����y��<����1��u{��/���5o��A���p�Dx�;|ҟcs�+�>��s�J�X�墄�>Z�O#A���
d�_�ٰ�;���^O `sz��{����a@��0�0�N� &�8��;9���0��j�������Z 
{
 '�_ �(&�s;m~� x������Q��jX����m�i	>�^;�L��q\�4�[P���X"�`0�`=�ba����N�)̒���
���C���+O [����&n����<0~��7�	4'����d��Q��ML�Wf^������B4��K@R�tN"��1���
?��"����u{�!G�@��T����}�����O;�<�Y].�����g�7����X,��C!��1W ��'�O�
R�G<�$�.�$g���D��A
2�s����sʖ��H��&bn7�2�Xl.��Z��
�mKv�栖��!�/����X ��0�|?TY���ra�1Y�DZ��Yu����`|�9�ٵƱ
��H(e�y����B�"
�� ^q�!�P2��q��âx�G]���MI�ȑ@H�ɯ�ؑת�Ҁ*A7K�G���_���+��Q�-�^�f��@��8c(ZBxcs�
�=n�����TJ���]AF�v*�R�`)әD8�	���*��w��ML\������Q:g���ZZ���2��H�
��x�?gD�v��
���`�
��&|P0���x�V�x���"���8Ԃ
�Chs��Qo<w%�@0�����
�1�S���C�t:�Ұ*�:\II�@�>��!T��u��e�*Z-���+�RIM�t6��GO���#�q{�#�ѓ���a?vd�!�q栉a_�
��y8��0��m
�8�!7�$�#�b|�9����8Q�Dì����-å,�hM}�xp,�zГh�#�	��pP�Mo�G�������
���H$�	�;�n�$����9Ғ�hz�@��c(Z�xcC�GX ΖN{8{R!�
��9}�Ӝ@s&��D��8���̮����A�{��f���7�>��`��D4��2��HQ8h�ߓ?���؎H���Qg8n�c��ǂ�p�����G�������� x�֓� +��k����t_���áL&��3A�DžK�����,��;�ى`sxrkpެ�a���mi��|1A�Di>_2�����큎�Bė	�"�P0sh����8��P2�{i>��Z�0�U��x��P(	�E�*��挓�wX����K�
v�?�AN8lѤ�f�G0Y[�	N�B�lė 2���H�#��R��T�e1���R�惥
U�y^��-��b>�EЍ-�6�b�ۖ�
.��E���C����@,��u�8G>����E#����L��p��L<��Ă��ŭ��Ng�	����o��[�/#h���ޘ���DJ��-�KG��s�]���v�H��l�P0�9"A=�!hB�<��k�}ˍ�ǫAZ>/T(�!D���x�e28D1���b���#�H2���T0\@��|Zƅ۸���cZ�a���h^��6k$
���g}^*��	�aJ�:��8bc��8���.�h4��F�I�/�Ɠ�d4JF2�Pȃ{a|
���<�q��
_$��ATq�O6g�Ps�� Et��E�=�O�Э@8����T<���/+��h�%ȇB.W(��AF�]���2GI��/J� SP�E��ဣ$�]Z��؄$��(�
9B�+�!
�a(Z�xc�'S0d
7�s��
΁R��� F'w&�2'��ֶb*�G��T l�f�\�� �Ee�囙o��}�8BG<��'%�L�$��sD�8�3Q�!��@�\-\�DړL�h4
%]�H6KB�B!��
z� �����Ӏ6_2���s_�"�E�d2�bS�x(��&mm�|$�G��|E-� �E�D�y�0�1��G"`��,�T��.Q0���ͭ�t�����X�n]�C�x\O�c�ۯGz:�����X�`�K��ɏa��y����|�rz#����ҳ�f��E��з���R:9�^�y�:�6�ae)O��R4
����c��v��s$ �`ڹ��u��Q/����!]��f��Pz���:l�l���?�:���[�@�㊈�hI�-�I��l8�E���*��P����c�xzgR&^��;:��l8��T�l��/�@'������73%��w�~Ъ�R�����D*&"~g<Tҁ_Lp����8������s�t2��c�hڭ�z"
���Siw$�
9!/.� ��x*�H�-���:x�o-�uV�x4/��i]/`S1=����Tg��Kv$!ko��
��	)�4r(����ʀ�q��By%W�5��"!XD#�]�D2�E\�m���d20=�ӓ��'���ӹdN��sɒ�#�����rGpa�r<��l�c}��0�s���d۵}��6�h���t�cm��$ɕpU*�ѕ�Ebz$Ҧ빎t�-�xb�`��+��ī:'Es2�&S�]XP��LQK�P��"8�`:�-�=�[�q�PKG�@�}:�6�����*�+Dq��HB�F8G��2I=�gw&��.$�ڔJ�K�؀��=�H����#L�.3/�����09��H6���2��H�JХG���/�c�"Il��q��i���9��'�xΓN�ө\F.�gs�X�q��B$�0�� 4�Y���zK<
�+��t
��Sz%�˥3e0=��gZ�\��;ӖLwCpA$؁�B��}9.�he�� ,�+�B$�U;"�Z&������zc9���mK^/�U��\1�*��\�=WLӱd1՞��ExC��1̍�����c�L8@X�Ӈ���'?��QD��X���s';�E�)�NJm.����璱$Npg:]��b�IY,���<�ty�S���o>E���f�
��U�p:��i�T*Ŋ�9��9ya�c�t1N���?���r@H㊈�h)�=�^,��"B��)=1α)�\*�N҅�I�t�$��;��TJdS�����`������̼|3�)�aw.Zs�B�()e:'��qcw�c�9�g8'pA����s$�o
sEx�$o.ݞ�4$�Bћ�b�H7�;��C�(T(S@[�����jk�"�g�]�b1�o�S8ԭ�b�^�w���l,��4\
���3R�ED��h�.D�Q�?�@��==�X����n7�d�����E�ϭ%�%b�bbJ6[,g3�/ZLu˙r6�*g:�z
qU8�O$��(�i���<�7ET�:�Q��rsF��f�"���)�����˭�t�D�SӼ��D"PL%R�D�;�-����$��6���n_j��:�ʸ��M~w����rB�fŢ��ikkK��D�-F��l"�(g��h6��R���}\9�
eC��2�R�$]n�cM@�w�����-�-�J;���iS�@���)mmz!�aW"�w���@6RA\Vf^��}Z3G5D�)��h��%�L�$RG^�j�Dw�y�:�D�nc�d��P�Xֲ�L6U����|��ɤ�l��ӓ����"�h$�
�Jh����t<��L�Y!��|vJ�\.;���TG����_�e
}�D"JD{ �X$/E_�����ڒ ��ƃ�X,%bP��D���t��D&�[u��vO���lK�`{{{f�Tj�,�:;���|���L��T/��1_4�	I��aS}�<.�e���dv�j����2�g]پH&��f�;�C�|_g���b��W�Z{&iϧ�L�$�h����4�J�� #=����2G�2��)��28���t{�?�V���L0m��b)S�𖒥$���|�mJg��a(Z:��$��ZVGL��C�Ι�J{K{KKG�cgRW��RKKˬ9��j��%�
UEw|Z�%n	�2L\If^���S'�����3�NI)�9�To�%}�L_;���sI��
3�T��l��J�R�3��Roo��,��s���`.M��t�_*�c�I��D�çg�ҔB;x��i���
���tgg{{L/���{J��ٳۧ����e2�h&9�d�Dk�E߉�I�jY�ߡ'S�w(B�3�'3����L���1�|�p�P�^��#�b��v���j��H�R��Tzz"�jy�=�B��2P)�����4���zx�Z!
7��,a4��4g���o[;�/�m���Ԟ��`i���Uh�O�BӪ�\�Vʗf
��9��0_LK�t�	�0�)ϖ��Qzd
L��ˁ��*�+�Z
:Z��=�H!Q��b�P)�ҕ4�̱r�Z����$0-=xc���3��M�c .����.ݵ�Z{��ʔ�I���vE�Y���H����^(��VM����b��J������7s$���X[TݹI)�9�4P-���p�U�e�r�vl��D#���dO�'P��U�=�j�@�����^.W��D��d>�ɰ�����!�̤;�2�̔J���<O��B�*����|OO�6�W��j_��{��k3ۺ�wA։Bzv�PȦ;�,����t!7u*�gzJ6���P�� ��ys
9Z��L
���H?��r=���R<�]�w��z�j���x��2�ǾZ��W�U�Tҡ\��,���<��B�P�K�B�|o>���1��9���Ʒ�틔�(��r�^�pe׾>�V��4}V ��d�J�R+�w	���w�i�%_q�<��+{�8��O�P��@�S����k%�Hd``��W��S��[��ke�R��Ǖ9Y���{�PK�R��>�U0IGߌ�b��q�˜�{M�W�������I�Յ�`���w������rTuz��d��D5Q+3q5�y�f�/
��!���-Ok铔2��H�z+�P��k/�g�r����*�=�<�Շ�}�}�Z��V��VGz���պ*�ڴ�x�-]
J�L�jɕ�rK���*��kCu�<?���:��:��v+����G��Zo�>\뛺���]=�@p�T9??��Rb�����-3f�����<.?)(B}zC>�p�r��.�K�P��Q�eğLVBz(Zٖt��,�������!��_��ǡz�6T�W���"d�)a‚���墕R	=��b4�5g���c��T�()�Y���ڂ�YЭʔ���‘Ĝ�J{n�V��+� a��ʂZM�k��n7��Ȑ^ۛ���C2E�fJ
1
���U�K�
K$622R��\?(��z�������k��J?�zC�2��&���ٚkO����K+�+�
��{gN��3i��t$�|��E##]}�P5�_�_����t����e��Y�6s)
�֢����!I)�9�4����W�^?���ԋm�0O�������zO�6�����O��ֺ�3����\%Z����h[K�T��A���D[yf}��
��޻�a|������P��|0��_ص>4cٲ�={��Ui�u���U*�-ӥ�J3K����΁rifk�-ے�"UZK����}+�t�a�S$�i�U�L��Ñt$^ݖ������������s�ۆ��8��Z�ۿW��z1�V�f�նj���m�<�X�Wۆ�ڊ-�������9�n�s�}�*�6���.��I�.��KooouZל��>�Zk��f-
	W��!�ޮ���ǿc.]_�ω#��2M~
�B��j�^�ͭNm��N��y��U���A!��_�������qhaj�:��bC�2ouL2u�nݕbW��:5���*��A��������ٙ�K��+�`T9l�yS��ת�jZ���ܗ��e��L\�̼|3�WR�mq�����+)e:'�����.�^Ü���O}���t:�G�ܡ]������s��}����^��?{nzjw��T�-ծxgk����	���ʜ�=���m_[���`z�����չs�f-�����{��Y�j־�g:�[x����b���6(E?�mN[�s޼�Y��9���B[�0k�m���v57^�ě���8�7!�
��P�C����ѩ�4q�h(�(�)VOUת�7��38{�4|/yv�︟&S�T!�	w7-՗H�J���1us궴1���2*�җ�o�(SƝ�f�hFǽ�537�<�2�d5\�(��y-��-#�����ݰ�G�Oϟ�?'~���
���c�{�����&�d������
�
�
+
���Li4�o3���<ڟ�g�����e��p�����ɏR>ܢS��jj�6��_h�?}�6�=�=��\��e��%���
�{n������[���8h�O�F���៉F��Q���L��E����W��������l-~�ז��a�n9k�e����-��r��܅���������W�}��Oزq�/����/]��
/�G��M<���K�_:o�/�x��R�őg�8����S^����bˋ��/�^���o~w�[�_��
�����l�3�����7�|��37n�nNoNmN�4.{�7&�I(g)�җ���j��$��o��e��ۋ����;���=���T��Eg+���}�.�����~L���I��_�C���O��/i3}@��O�#���n�u���n��h]L�c���G�	z�~C��7��=�����ѡ�>}��@O�Ӵ�ަw�\:��#�(:��N���t��o�:�������@'щ�-:�N���z:�N�)=�ޡ�h\\.�B(B��>�W�����9}!��$̴U�@\#�?׉�EX�M��
�G�O�X�X�(n?7�[�Oŭb��M�L�\�.F�z1F��?�s�Z�A�!�w���C8Ÿ�(\�Ϳ�^�-�+|�q����8O�'��_�M�"(B�s�]�ED�J<(�"&�"!��O���
�*�B)��Gģ�1�����xBdDV�D^�N<)~/�O�?�FQE�"J��.�H��K�=O/П�O���@�U|(6�������?���_��oQ�������*�²�"EQ�bTL�Y�(VѦ���P��Kq+��Q��O�+~% *�C	*!%�D��S�JBI*�r��RҢSt)QU�JN�+���(%�L��^9W����~%^�1�@ҷi}��!ޤ��/Щ�1@�Aq��X|��x�[|�H�h⿐@�(���aDŽN�`��n����<^�?�#�X<��S�L6�/[J�ֶ�JGgW��=���>u������3��g�̞3w�]��6�=��k��E{���%����k�l9�������Ï8����o�9���y‰'}��SN=��3�}�Yg�眻���/�𢋿wɥ�]~�����j��5����o�яo��'7���[�u���総��pǝw�=��{���_l��|��?��c���O��I��SO������{���/��p���}ӧM��N�U�:;*�m��RK���e3锞L�c�H8�}^��v9v�G+&�AU��dg/K���
ٹs��=�
�whX6�B��/㌦�I�ԗ1�y�W0����0��ꣾ���H65�Ĭlj\��b<_0+�$5��|�/�/��N<���	����R#���_�vd�,L��n������z��v<����׋Ѐ�Jhd�z�,N5���dg1�j~d���{�xdV,�^��6*�Wd��Ш�U�а\f�4<j�ˤ���y��m�֞?��A�Zg^�t�|	��iź�FC'����ɽË��coL];>,ůk�~75z�^�w�M3\�s`����l�l,}>31�
B�|�JsS+�#ܲ��Ԩ5;�]���e�Gt�(-81=�nll��Hj������Xv��Y��~Z���
��T��=�m�5O���]��sLJ����D�y��S0E�]���)P�8������������=b8l�:�l�6��y��1�`b�?	bϾ��/�,�h1�?�rl�/�O>�����ˬ�a4��)�mǏ+dWk)T`��ÖL���i��y�t^FO�kq�=E��h��uɨ��{6M����'{�
_����!�V`�R��ǭ}#�����ӽ��?oav�^�-N��]6��y�����o�x�
/Vc�ēSe/4q�6d~Y�5���$5��q��([Dj���ln.��������(Ym6A���/�O�����s�UA����[��ڵ�/�͆�Y�vv65{�������Miٵ�Qut��e�o�s^lt��K��Ub�U���Yq�^��9�[�QC�|΢�c���ˆ��ϡo���lU���[��h�����IrWl� ��� ���qA��2�&hŸ�l�dR;$�~�t��Q'� ��(�(��&��
##��qԭY����eG�P=}�O���C��I���:��ޫ�NEҁ�q,���dž�&z�͇
����3m�8�EQ�Ս�����R�p�
�W�&��Z�?���Z%�/�r��F�.���i�{fH�@�:F)�=QV�lA1��
�2�_Q(򪷌�z���z�8��^I�ZĠC?�p�Q9M9MU�W%��$Bc�C��MVF
ݧ�5�p�z�1A�M��c]��qTYm�d](6�t�Y�S��6�#����FQ�(�ߩ���hôB�>�ۜi�����Kk�q�s��@�`C�R��s����Z	]��Qոo����w߫��z������]����T����i�Z�1c嚗Q{���{1a?����k�����Z��]5��5�ol���k�i��U�Sݓ,o0�{�[�W#�J����p>�	�h�����38S�B���֙x�]��5��ot���9����{��v�r��v���
���:�������L5�m]�[:m�T�U��r�X2��޺;�Z�&�ִ���m�j��V�ik|��&_�'�[Q��!�j)��0cv5�uǴ��g���+�T�_��u�]��#e���Q
:�L��Z�ju��ɠ��ŭ�X���
,%��8S
�轺��4ä^�ܮ�ByR1\�ޮ�B}R5
��TUW;��ꁪ�=s����ف�ס���R�������!A{bF���3���b�s�Wz�|uLS�GE�,��^A����[�
�`(���L��-%K����J�v;/�v���\��\��\����l�v�t;gj�J�S�1�K���{J�6M9?L9H9/K9OL9O9������RΙN1 ��~	;%L0_���&�/�4���z�6@�+t���0�e,y�>3��(i�5��C1L�*�n��V@|FY�꟏����Y�Z�s��[����M�y�7�:��#��
��c�#1��fZ�(ˋ`��\���B�G�u}C��G`Mn^E9�6�z�İ�X��}"MI�_�‰���?��[Ę��ܸ�nL�0.�����_��۠]��u�ծs��㊸K�}�	����
�wwIğ�$�%��v���C����ks�L0sݠO�6�t\�u}5�98�
���T_�J
�~S�-=������<�O��u�>��N�zB��O��~�>5��ޛ�kU�rx9�́�Rv�^�Z���{�x��b-J�`�|���a�C��̃溹��nΘ�f��k�,.���u���@��,��Ɩ�V���MW&C�|��J���B�ҨO���[84��:o��X0Zo�7j�s��노p��7�i�;(5���츰!f0f�Ĩw�[4�r�����#Ύq�
'&Ͼ ����/X�������x�Ξ��M���)���N�^1o���[KF���H,�7:gaj���)ʷFfmTN�j��b�r��n�g-ن�:hPꓛh�Q�ѠݧI��h:F-���B�D��-�5c�����Y�u]�V�:��ΰ����8o�c��M��Q�˅$J.�����䀰>���{����6�O�����"������쾵ٰ�+�[���+����#�-�����޵��䰭��:���z๳���="�>������6����!�1#ܪ������&��������:���������@�s�������L�:�����ǎ���S����-���=���������<bd��Uv�
�6&�5H�wܚ5��	
��#P^_(�ʷl֒V\g���捖1h2�Gp��d͚V9�������ǯ�c�m�Z�lk<���U��㍗6$�����ZZk�g���y�X��a<fkαFλ����_���(q��]��WP��u���FX㭫��@�|�4S�n���N�o�U�Fz���մ�N}��x��@y�&�h����XN��"Kt!���g��;ʛ�7W��G��0�ӫE�rT��R�P����]��LfC7�D�5^ll���#zN����
ڗN���|eQ'S
4�@��&E��I���i-�C��8#�I��g�a����SĦ�mp�y�l���Gim�CI*åO�t6]FWҳ�"��.�F
aOˉ�4EF��q
���i)(�ﵷ�o�7B��u��[�&
O�������}�	ʸ���3�764��^�36�`}����M�K��9�{����_�����[����
Z��U�u:�΅l~H���u�D�Exį�N��e��1Ԡ�w�O :h&�u}��Aވ�)�"j�X�'�u�H�Te���\D��j7ni<��Cf�"h
�z
�vdw���qz�ޥ�����<�^�)�����)�>7>g��qm�s���yj�N�88�v
-_��!���	z�>�OELL���B�
�e���/�W�?ŝ�Q�0T
��3n1�e^����W7�aw>��
�WB�@'�
��n�h�}���ۜ�.����q��^<��UW�VV�BM�Y���c�
�O^0�d<oka�FE�F�a:�^�| �UNB>|���־m�'}���=; Ң(F������r�J�"~,։������r�r��c�i�-��R����VC�h7V���`����6�k2d����/�_<��K[[[�[n=k뽍ō��l�и����M?G��Яr�*89�h7:�A�@'����=䛱�
t=���D/#�)���?�s�),����+����!b�8I�o���?�������Y�؂,�t�k�C�Uf)s�=��
e����+�(?Q�V�Q~
)�IyVyC٪�!�u��5�p�D\�nP�V��>�>���~� ��!k��5�i�bl
�6n��W&��pܔ6�~cz�l2����4��<fn��N�������Tq�()��JU<��!.O(c���X"NRIi7�A��ӛʹj^�'������ɥ\�́vsZ�S\�.2��7#����=�I��<��C�P��y�{�#�N‰Zٸ
g�t1Ol�:T9Fy��AC_Q��޼���-�0���*�ж~�����!�EJ��~t�z$���
Ga��G��ܪ\�����x��_`��3�A��v����=�9h{\��r���`7�=@C\�@?��r-�T��t����ye����&>2t�*�	9�IK�{�B��+�O�_.N����)oб�w�P�P/RV�G�#"���!���*���@M�>0�f����Wo*����z���
�ջ� ���jJ�%�����7}�:�>��YJ�q����_��c���Cj�a�a�����I%$.Q�2.n|����b|��O'*ðO��Ne�W%
��h�N����%��?�qNG;Y�q;�w��}%}�[ͯh�z��]���d�v��~f�X�й"�\
m���0:�N���7]���񦭃�;ؽ}p7��p��*S
�i!|�)�M)W}�� �V"�����Bd����B�'���
�;�����eAY�2N�~�H{W0޷��A�{FQ���M���:��l���fK�MYX�!�w�m���R�**v,XQ@E�{���y�_�vwV�����ȩ����f7z�����|���ξ���{o!�g�,ه!���r� ���<�wO'B��B;
	��X0�p?�8B1B�� T1��
�ҏ"T�BB�O!T_�P/�~���h�����5�N�0p"B��C����&B���c�oc���;������^���M�r�yY9BW@����	��z��F!4gBs3Ϳ��_�?���%0ƥ���z�V�V�����`-Թp{��m�����5
ƿ���n��m���l�n�qn��l
_�
��o�{�
X����uo��9��[!��<w����m@�۠_���
�;��>��7�8���q��0Bw½�
WC_y�ǟEh����!��L�vC��@�4��Y�>�����C�-�?��Fh���A=���!����:�
�6����������
�xz��"��E��K@����^�\���x^����
}���Ї?@��?����:��
���)�ފ����<���]��w���B=�B�}���������A_���8}��}�����_��߀����>��V�w�h�
���@�� ���	���v����SЏS@�S0�π>����/B_��W@���8��NF��ɿ@n�:|u���?0��;?@]?�~�1��	B?��?½�@��0��Чs����
�Z�Z`<���^8�zx����}�'#L��3´	��R���@���	��k�Y/�x��'
���B0a�Q�oV���Z�;�3si��Ў���DX`؆0�*�&a�a�a��P��
�v:®��D�}-���xN8���Nh���CPW��"�S�>��
nx�(B�Ax&��`#@;�G�TUS
�;!h#��a�%u�x��#���#uGA�F3�����!�~�Fc��2h�l|^�)����Чr�S�!���NC��o�+
7����h����j"�����<�p
��f?µ�l-|���,��p^���:���l�aл8u���;�(�E���П>0��`l
��h�����M�/����SK��t�Az
�����7��
>�����B���� -ƒ�����
\
�~�z�
��
Cx���9
xi�5
�?
���	��%���+�6����A=�
く�����O�{$���D�D�k�y�e�e��$��dhs2�;�n��d��)�����7�<u�|�ץз�
�W�����,�l�d���U@�9�߹��y���� ��Z�^m.�~-
:.����K
�K��Kᙥ0����2xn�z��
P�
@ߕ��+
��al��@��P׍�#����Z��u�������:�:������@x3|o�y����6��V�ѭ0�ۡ�ۡo�� |��N����{A��q�4�
����z���
�?4~�y����C@����x�~��~|b�O��v���O�?
��i�g`��@]�C]-�f�p;�Cp������������v���c�G''�O�
~�-��%���
W�?�
���:�
�˛P�	2���/P����w`\�@{�A�>���з�O~��訏��O�
���t�Oal��>=��i��� _@���=�_�'�o@��ο�~tB��������
<���	�9c8�>�|�}�ٷ�Р�����4�������(�A��0�Ϫ���(����a��ԧ�ٍ�)������͔̈���Ϊ�����đS�`�豹<��{�o�8&ו�w�w�P#����P�&��	�
{t�O�pNb!��3/@$���Cj3x��*�Z�4���'q�nN��]�ø?x�bڅ�񼃎^g�i�#�������F��P��3���4��֙�j�j��lV�RA�ߊ ��������He�Y��$�aO�\����|S<����rxHۉ��fr�^.k�\x�.c}�A���x����!�-^�2)�܀5�����>�b��n��*��a�~�f�k��eD�x]�Je�B���KӁ^uuۻ_h���b�����������q���u��l4e�2� �Gyl�%#����/��������	�����>��<�<X����Bq�:�$:��+vUu�8����.�u�7�#k��ݧ��8��=$�v0�ˆ���h�8�Q�8%�q���֡S��^ɛ�z��l���]OY�eu�Ք��V����-^�Na���
���.C���n/s�,��h2y�>�*����wO�B�ө����!�d-eV���t�\v;v;�.y^�u���E���)�Ґ�¥���U�(�
��'S�K���v��A������=䖐7í6�Ŋ�.��ߙ�=b�j��yށ�"�;�$�3�^�ک1����8��3�3���ήB��������p8�����\*'��$�x��m`����
I)~�"\������6j�j�@�5���M�Z/��=ҿ��)c��K.s�C���/�Rx��k�A����h<a~��%0��{t�r�	�
�w/��dw�
T�����̡FJ�W��D��C��Z�ý/oX���#1Pkm����P���-�_��r�Z{c
N ���Q��C5��hS�&"���(L=�"�}5�'C"���J������O�(��	�!d��(�>����j���ڶ���B;��©�����ȗ~;��������K#�"�#t�04�uٽ��/G�کTK�^�a|-2�ْa
�0O��/���4ߎ�,#
��h�S#���Ʈ�Կ?�40���sq�<�3?�3�'ʉ0F�#���7v���?��\O�;s��:�wu4�2;͟��#7:�&{֔Ť� ����O�N�6�y���=y�P�h�F*Qe�.���V�?s����*{]��f�+��5�h$	��Ǵ���nE��v��7����)8jN��2͸a��|��7�풫��ڦ2&j�>�CÄg��~��>�e
�s�]:��ԢE|������.j�U{/��M1b�%��W�3�o�Jy���s��{��uD�ZXXt[�+�M�_hdW�z}Ú�5���$}UM�^��3nrH�5"P����pb7;������Ka�#į<�g6��éd��Fu
���
4m��W;.?P�\N"�#xؙr<d�"Q�xC�_�,�-�f�aI��d��I�}JV&/+c������ϔ��'����P�4���8@�1%��]T*(�{uU]�	��e����*6�4�Rv���m��4c���e�����7=�������;�#��Ł�e�9?]�>r��Å����a>m*������	G��7u��Yy��K��6��o.�k
4��E}������c��@��az�u2t��D��с�T���1q@�2EU(������"m:B߇�H�%��5��V7dM�>�!�{�[�K���U��_ގ��.I�v
h��>�x�͙�xJS*������k�*I#�pHP��9x�!\���h��t��w��w�
2��!Bn8D9şj�0eS9"8`7��|$��
+��%�s���h�u�ᒴ�(MvY0�`T�,
�R��)T[��|��k�^�w��q����^����W���tϕ8Ͳo�3s�����Hu7��f���A��w�f�#7\p���z9�t�m�^<z���c��u��Y�f�k_/7���ۯ������{��ҐU���Z�1��
�q�C�����Gu�Z�w����s��8��y@<׎�kCN�ѳEG�g_�2*.v��8��r���fpb�*�b>�'r#8m-�7�����T�06sF��Av���������6C3�46�xT�Ѐ&]<4�(7�T�י�]!�<�Q\���u�pZ��pa2��7�n\�c�M{��z�D/݁��'��|�������_ڗ��|,ź�{_<?���L�Wݨ#�WR8Z+K.�T���^�%w�]a��Q8V(�\x׷y�[�$���vj=�1�>�cs�!�9�O�\p��0���p4Ò�#M�Aky�x]*���\2�9�T
��e\�hH��O�C��*Fg|��v,�T�(^�L�4������w#+���-�]�����F�0<���c]A��<�]]�]�����ϝ��
8��R�s
�)�7�:����\��Y�춒W
V�h����tm������M�:�H��'�+C�d����_�H4�^��lh���Pև����ךԲ�+�]1]V澬�w��B"�
�����wEZ�J<�/X52���{	F�[ok�z+�WƳ͋�:��Lo����G����Yg�ZtN��e
�܉��@�0�����iP�Q��̫��h���{��0y�R��Д�����ڝg�Vax'�6�P�X������L������
k�H�
���������h��:��
ݘG�!�IIZd�|Өǫ�Xo<��G�v5h�ֹ�e��S(�_���R�V�*)��,֡���I��ޱ�ƭ�?3��ɠJsF[���j�
��WZN��ݠ�=�h-Q��K9���H+���0�. �2PG�(���w�_����%����=�������8�����U�ͺ��=�޹��޽[{�#���i��H�,��~���2��P9kN瑋�y��a�5`��H1iL,q�7��}bci]�b"��n�i��\�wA��F&B[�5���A�!��ޑ�a��������k�����ڮ�����d[o����v�C�Ǭ���������[[l��Ǽ'�!���Y�K�s�]C<���w
�'�C���fix���u��%�i������y� A�]$�rJ��l2f"��5�nZ<mVn�M�&�z�������5t��'�p�����?�]a�=Kj�oq�s��:53��ѧ�wޘ=+v
f�^��wPm%�j`��^�\JO͢S���t�
�x;��
Tf}�J��p�C��!�҃��k�p�7`�b���FA�a܉\�N��nD~��#t4��Ҵ���NG%
�=p۱G}���O/��g�r��dz��l��n�( ��E��B�Xtt`,{���E�b���h��P8���ҏv�[�V��\u:|	;���++�Qe8LiL��:<Xc1c��4��p��J@mR�V�͚Tw��V�՞P־�zݡ�����;��
�GN������U����ʹIA��5�%i�����8_�=A�����H�H����w����e�)p-O��+��u
� +h�Kv|
��_y^A5��(qZ��h7à���4x��@��{�Q���Y��~ە��]��̼eJ���u7>�K�x�p�}�=�'1^�v��
���>�j��E�P��_�غ~ I�^�菇���
FOc>17q}deb[bG�	�nǾ�ꈲM}�q"���.���"�R�A[F+h�<�ؓ8��ުd,e9Lo��;[1֋�i�6|M�[�9��Aj�B*�Գq�4�N��$#N��~���OC@[�[S>�;
*#�~OOE���e|�e'�J�����T��j�� �5?��y{f+��%�j�R���C������Ο�<v��훞�}�mg7����\��
�ɋF�N�9î9k���%�\3uOs��+�n��ƂU*v���ŗݝ�$
NO�Ð��)���l�T�jT��i�7���J��t��P/R3c�x��>�ݙ���`-�XF1�REk:-�Q ��L��q�_�I��h9�VS�9�$��4=w�f
i���h��E��;%�:�F�"���#ԓ�1EQ��D���!�e��X��7�;�WQ�M��i5�#t�>��Q�c^aW�IP��E"�_��@p��Uy���"q�|�T����� NTC��@F��w�N�`U2�^��ݕ�,�(�C�2H�u��
�t�����W�qu�VN��w·��έ��p'�f+}M��u3��`��_�"��4O!��@@���9�(v�b��r�
����B�M�M�u�ۙ�3�)ژC~�*�<O?壊�l�a��&L�Tw@���,��D�V���EQOѠJw;��^gr�{UG)���e���
�q�8�$�
�I��'X�o�w����8�(K����J��x�R�p��G'o�u׸����Dj��\Va����{�I��Eon��ފ\�7��	h����|n�����/�h���6��a���ٳ^ў��t���n�^�Y�I��y�o��N����>�#����t���v�s�jS��V����L2R�
���b�4����V�_n���u���Ax�4)������8�_�?a�]!�^�Q
� X�\���/���u
Q2ƪ�q�@	�@uZHYT����Z\�Ǧb��d��/������k-�>y��7�@�z̀�/_?:��Ύ�
ݯ$�����7�ߊ��b]����9+�ȿ/^c'���[Z���!���ֆQ���K���>򵤃�,����e�v����)MS���Z7� ���0X]�>�Sc�S��g��� �^���W=
b��LE�t�s��.	��S����UXƌ���8Gq@T(���.�(�����Ke�0��a�����F��|	�`�M���0��U|Vi��]o_�d�l/]6:X7$:O���E��x�cmh}�抝��u;<�G�*(����y,�;�/�>�=�;̟�|U�;�0R�\Ľ?����
]`/2��p�ÏJ�"O8+�{�����
�t��ˬk�Y���������Lń,���dj��A���g'��”@��L���TܢZ/��Á�����_��w�z͒��I�
��]�m����P��}`�c��n݂�g��6`���]��?5w�����cO5|�a����=�p�!�4�~s���Y7#6��b�k^u�J��a�ҽ١�L�
�ž�������f���1�u�����m>�8�).�������� ~4�D�$ҹ��3}d�L��
�0�ik�H���mm�@Ȝ���WB�����q�0�Ivbi!,"ɨ�x&E�*JZm�Y�6�3�O��{�u�v�9Z8��U��9�v�؈���ʇ������o��o�C���'�˨I���ܥ��.]a/z�������B
�U�R��IYZ��(�a�>+���vTiH�=n�A�E�F�d
`Oy��e�Л{�˷zwU�./�MnBB�n�Co�>�ʿ����
�K��׺���R/<$�3Pm�N�`��l��)���קHoRy莌�;Q���O���]�]��*%�`T�hy��&�\zc���U�;r�~����-�
M5�7fL�D3E��~�D
�I*���Д��uC�)X���,Dfe[͐��U>N��g~P�,������i�dȩdX��D7��J��Th ��RNWWGGG�Aw�b�{Nd�1c+��(�9w���ר�
����ߖ��_���Byf2�FV���vz��g�<�C�|;U���s��J�9�3Бʴ������������-��0�dl�!U�J����=M�hLS4C� <)��UXXV���VR,AAA
A�׏��>�p�0E1L1/�T6�(]�
`g8��0�
AKω���0�!̤���;�]�d�[
��x;�{J���;����s�6'�>ɨ��*������,�ڡ�3�ٵ��ۭ�1#ʥ�����#���y�}�G?�<I?���*=3��c�J��:�AS,���e�rZJhF
��J_�7�۱�ZQ���4����T�3��<��$sK�#Š��� ���d&.�	b������+'��<ӗ���I���4l��͟8��H��{��q��W���)%q��W�����sC�2�.&��&��̼IM�?�Sxd�wo�
���
�
vjBc�+�~���뾴|��6�(vl�[�/�?���Ϯ7����H��<V�c-��?n��Q���Ve�����
��3��*g��,ab����l_�oSSu9���/�
�*ٷ�b���(u5P�f��
��7QM�v���Ԥ��S��;����j��0�T��ԇ�N�)�LR[jգC�������k���r���%��u�φ
��~x0=�0�>2S0�Xt��z���1��u��q2��ѕ/zR@=�w�F��]@ɮ����FPN��NvŦ�$"��^�+��|���x�t���O��"Z��T����B
1D��&��	LC)3�3-"����"�f��#7v͢�����?Q������x�[X�w_�kr!Rx㟅ٟ��O����c�6
n�����k�=�pJ�$>����F�X�k�V�`�xa�GKC���xP�^,��}!��g����.l(��������
������C�=>�o��֫�³尨;��������ך�Ұ��ҳ��ұ�<8u������@��L��0�]���"�*QT��� N�#���W�w�?���k�dC�@������Ĺ�tqfh�e������/�w�o��1mI[+�U�S���D%g�LD2�ʘ�A�%Z��W�4�Z�)�4Dx��*��X݂���8 Z
1h
ZMޢ~�-��̉�<�{��h)VK�1E�Vl�'�ze��t���*Qr��B���tC"wP�j�M�K|��
��H���m�-A�ӓ�)r�ؙ�w�	�x�g�|���gr���dB�UY9�K6�qa�����_)�|N��2��C�<�/E0aK��٪��:�|��u��_'�j� ���R�}�k�����-x��/ܰ9���4�y�!�����q윳��tƬ�'��+|�>�X��'�p���ˌ(�v}���7�'A@��/-V26�2U�Í��)���WT��nMߥ~0�3���ٲ��V�M}4|"m_q��ĺD���f�F�H$�.���rs5�T�\��uI¶dJ�h&�1eV�u	W}���9.����d��w7�(��M!M$��B+��۲���������"�|�����.��k�.�j��s.��^}/�֞h_�1�Ǜ�GT�16�o�F�\�s��p-�����d���s��N�qHm�r����p'�����I�R\q�L����bc�>�����2�p�����������p�
�Զ��������8��iњ��(��ܝ<�T�.HA<�s�Q�R�R�
_p���S�O\��Ċ�g?�p���n�'ftľ��
7�+��7l������k�?�F��6[t,��wʌ��c��=��t���p��u�m㬅ڳS�GY��&>����G@�DѭR(�7k����Y��Ջ5K�7�w�d��~�n��w&Ja�T;.q��vUu�O[�)�A�t����j#練�F"��-Y�Iv�K&�4ph�#Y�;=�3#6cei6H��p
D��Tc��k���\���h�^���LPm"�r�}dF�aC��mn�y��>k��^>um��Ȯnt�?����rE��*g�_���?z��SG��W7ܸ�-�n�?�m�bI���-B�c O.�@B��/�j#p�������h�W���p�����b�X,�`RW�ĔNeIƬ��0�)�,�8��(�8g��O��-�a#+���`���I�b�$��d���C=���R��[$G��K~σ��e����=Ѹ���8p��I=����bZp*.��B���f�=4e�?��s׋���Y}������&W��n����S<����ן����0�5
����u���9�:7�e��R��W��<Λ�u`��vI��Nj��.�Nz����ݞ{O��La�Lm��	�,�b�͈f
�`']-�!��f�����rc
�G�
��R��B`������)!�DQ���½�n��%��
\���`�B�p]��J�
keO
�P},���R�ԘRb�g�[�;2n�����{{r{��Yl.Ofg��pe�= �{��}<!uX&u��s�=��!ײ��CE���"�/R?TTx��"�J\@J��B�0@�g��+>���<~*�������r�f��<�=���?)���n��tN�d�@2ea��r0,����͋�)X�ϯ������-1S��7�5;������|x��/t#�1�;�OO�p��~}lX����a�/��/X*�g�����7�-l�2y���UWf"�p�P�WJ:L��^���ƒڬ���PI���Vo��y2r�i3�(�^�0��E�#�b�-:;��<&D{��j�V&��ސF�W�Z��J���N���)�U%�c^
x)%%�'�JJݎ"��a#�J���p�̠�d|BJ��X ����N�?w
#�@(�_(�_�Q�_���[0H��<�s���t�5�7�W�T�5H�H�f�d6(QZ&�[�.i��3\2o�b�mP�3�����aZ�3=���ma��χ,+�r�>ͅYsC��X�Q������6��bM�y5X�m������E�������tYK�rp�d�L�����e���w��6��}��1�;��.���*Jc2�b�"
b��r���GQT;MIZeu�������Ċ��Y�Fty=Ҁ%3�A�eĚ�ͨ�1�g���bň�徆�F�k sz">����FD��F����,�
�����&�D5���d�^�ឹ���K��jդ�WZ]��<*�>�i�L��T��™�w���֗n_��9��~ㆆ������/|m����x�,D�X,s�T��;���>����qB�l� ��*B�� I}��ך���PF2}e#	����E�d�?��nV�Y��1��Ջ�豆������
rj�6B����gye\(�z�^}{�8
���.8ʂ1�,[U/d��]?e�/�
��U���*�4�"oq��f!����ʜN������U��������ȏ7� �W���	U�ή��TJ��Z�Ɍ\���R�k*�k����*�\�Q巕�JHI����ve�,��d�
-�j�Ĵ�R���8�ٕ��D�dɭ,In�S���r��)�=b\�Ƒ�������
����G�K��twt�ꈓ���t�"_ٙ-3��`F�_��_��喲���AA���2t��g	͡�@����+eDY�ڋ�C�S����uWz��ajJ��������f���[=��+��k�
!3]���n$(W�[�Y3\K�5�������#��%�"�
�@j�?ά��S�`&�k����ӓ�o��HWOϔ�*��W�!D^��;�cѐ�ޖ��������3���5~Lq�@q&lr�v�+hT���tz9����&#Ea狩9�q�	L����������c9�:G��kHq����"�9�챚5�ܟ���o�I�N3�K��8;�}�>�ݴڙP�b��ձ�2��9ɢ�������벹�ю�&�j����)�(�²����>��ܵh��%�찑#˕����6�e�ʾ^#���ʜ�ȟ>�����׎���ϖ�<�:�Wޔ�pA<��Sb5�Q���~���~�u��j$_"����śZFW�̸Bf��CV�{}��4�w�\����C���|c��X�5i,ol`u0�Ѓƒ�#a�r�ZսZ:�]�Inā1f)
�Ĩ�X���A��v��9
h%w����b��gW)�v<@R+���/�����vz���s�펧��!�'�<�2#�X�����:w�R"z)x"����S��^b��/p��o}Ѧ˩R(�P��8=*G[
T]�Qje���|�����[��ah&�u"�����wr����x���'-�6gXnTm���b��Us����HZ
x~<���
��C(I�ۺ�$�4M6I�-�34,E���듏��1�s[�U���)����z����/� h�;�Q蕂��u�h�����P�bF`m�U�E|a!R����^����
&S�$�ɔ>Հ0+�����ʸ�<�NFX�A�L�|���P_W�F(�ͦP�*oc����4��&��f^�7�?�~를��h�vo�zV�GG��&���[:o�xA'x	:,rQT���t�K2��?��U'U�$~��w 9�Z\������(�����)��ʙ7o���%����	�q?�t'Y�^L���������ϲ��	�h��Cmã&/�L�u��U��
����]rpZ�w��w�}�X�*��e^S8��-��˫
�i������ae&��XF�}��k‘�JZ6V.���u���A�.�Id�amTTo&�q��phsR5gv�(�8ۭ�-�-���At���ư
�\V�F���U�E���X;VH
���X4��rUY�S�h7��1���,w���n�
Tz����d����]fU�QT��� ����#?�-(����ОL��������m�x���l���Ř��$���(�M���Ur�=f^���jz�9�~����~�fTk�2U~��T���m̭�ulC�3�%���K���t��á2�-��25�B�Z���1��Ӂ����IaL�=m<��L��F� L�Lf���w����w5S�Y8 �
'D��(
/9+-y��+���B�{04�e�7A��%"LZ�4]I�*�w�/�D��ħ�=y�tUe��9F���i��lRS�G�D�4$JĔN���S�A=n���NTT}^���5�͞H8,U%�)
Q��.��*�vy}<p���IfS�v6?����!#_{{��-���_�3~�j��.�u�ڂ�
��Q�"�O����e|�
|�
I)�&ߪ*�
 _�:w���d�������b#a�_l6;���l#{�
��e��W]4�|�AN�<�� �
��L��"��dF�'@����v�A����G@�P�V�f<�s���掌vp]/���b�ʊ��}[�o_�lM���}e�?����%jv�٣L��R�1���C�Q���I�Ѧ��3#����V���߉e�p���+��e�
i��l7�,��^�
��i�u6��zܡk^����b�1i���*C��8A���a&�iĔ�JX�l��12�¡P�F�k�F�V�QY̜�\3��6���t�d�Hu�F�T�l�,�-k,[K;�h��}$%il�
y�F��L\�Z��Br)9]5����ն[m�l�mU9g���f[���DE�����;(��0li������E9ޏ��>��U�y�/�N��"�K�S��P�ا��@�N��k�Rv��P�ϿܕSՅ���,B뢓�i���Ѯ+j�DOɡŢ��2Kϵ^V�M��}�.���=.��ѳm~\m;�l�I����K���*��&��X�Y'Ӽ3�W{��-6/���[o�&ܣ����g���zB8�u+�*3e�F��Z��I2ݨ�,Y�4�F+
�������JF
�md �����|�H�����IV��32q�$�#�/{֩, t��((<A�`�
�E�ϙw9L�kßwf�����8X��5�O:u�=S�]�����E�W�_��rj�q��Ǜ�+?>�����:y�&��}�������{���f$���Q�w�?���?�l�j\N8�Rg���Q��N��?F�
�kl��E� ��j!Әl`���# �lrL���� v�J�E�HU��e2��B�V��� I�3��Z{KC2svʼߴƆm��Q&?o)���d�d�l+Ze[�*�J�MrȢ�f�������r=�yLf��i92���y���{����tc-��
�i��y�.�"Qs�.L2w$Q�7���p�i�_����:��zL��X���-�?�u�
�����vӬ���m����px�4�%L�]���_>c��+F��=QaT�C҈���m�[�o�w��c��נ���U�?9�rd�8��زq�$�VM��^~Y�����
��e۪��_y��p��jw
�
"�,�Zc=�H~9L�������5)u;�]���H���'ݒJ"#�]��r";y�K;~� B5�ݢ�0�S
R�s�,��,�f���r"9����H>��Q��,��JN�����:�[��yd��4HOW'�Ʈ��)9E�H�\a�%�C�.ӊ,�SFq��� �r�,e̿0jB��'S5�gϻp`V�'����`E��8~s����|��O�ٛ�����M[��v�m�����k�j�ٍ������0^zz�g��w�a�f3�spÛdU
�A~�1�*�fi���Es�а�!���j�-�-Kܭؑ�S~�~��DҸK�_I)<6ϦMG++�Y'h5�Zи,N�!ڪd��b1�-{	y�T�U�����VKvE�
��
sU�b�+�4z�@%�N7
���쀒P�WW��A�P�63Iq�K����Q4Kg����0����ב5ˉ���R�Z1�Z�?�V֘��H~6s�/�������	7�#?����PI�Mً2r�G۶���K�,@+�Eo�����(�J3ق}�D1=�a���\�w�!�2�?��:@�p�}�җ��tM�����ʕ�
��f��+w�T�0�5
�%t��DR��6�}O(,�>Q��ʝ�6o����?fƃ��I��Wܘ���������3��W�V�WV�kk���?`�c�\�I�M�
LOܠZ��.�Ius�͉��;�;����B�h�����H�N�ǵG�'���Tg�kK^������R(,v�� �~]RaH蒌2&�n�Ա���7������$B(7���Lq|ܤ~ڟN��4<��(�7��7���@��!E�ӝ!����T�1�&@\}�O��d��5j#�-O��D�.$�:xI�tע�}~ei Ov�tt��N���y�
�7:�����W	��uX^Ab/n��	�y#Ym_���̽Ȼ�Q�no�W����r�-k7�R�]�I�����7��Bo�=��"����7���s_[��}]��;�������#W������K&m{U����,4���v,5`u��G����ն�a��V��*��ǥ MdO&�M���Ǥ�ȇ�7R��
��
���*�F
��
��|�;Z%�n^
ֹ��ģv�֖,�
ÈR�M*�s�7Mr��t���r,+�^��8\�ծ��}d5	�=(�5$�z�ω�x��$���D�ɞu����<h27����|K�1w�l���z�4�W�'�KN�6���Ob�]<��I�8���Y��$�?�+ż�9!�2��Y-]��v�h\#ʅT9v^��։�0;�p�Ȇ�aϹ�ϕE*�a�q�m�osב�y�C���R��B�b�.o�'w�k�tGl�v�o�n}�Q%U���w��<�(����~��F�*
�
\�q�򄥼<�Š�b1�,n��6E���1dM��X��‹M�]����
&yׁ1�6I�Q&�7a�Qz�@g�Ν5�2�b��'�R2U����q��j��n�C�`�/�h)Q�$���������5�UJ-Θ1���$������B����zJΏ�dD�=�*B=ZO�����c-�G3qh��%������M
.M��k�>Ͱ�*�W}��k?iT��=م�0%�^�Iu˞�������S�C�)p����w�n���qz*\��HA|�,�yIBR��*�ʭ(�F��L��>��ά?�3�4�`�f�����
�1�~�o��z���񨑆�6(�
�R�5��-_�&{ɥTQ^�����
+�������:oD�������ۻK&�.���TTqd�];���_8L7�����F%|r�rX���v���_t��[��g:ɺ�R����"d������x��Qc�����8�UJ)����j���Y�I��?�*���*�-��櫚�Ԕ]3��Y�E���F-�W])��]������{9�2۬s�Po.J���3�Տ��7H���+o!y.��dTT`�1�z���H*t��leOHcȐk�'X�Ӣ֐�Kp�'k45$K(uhj�<`!���q~CX�`�le*��&��##őё�i�i�e��f�f�C�,w�[����H�H?�m�7VЍbc�1B7���
:�H�)�'�O�h��g�,z�`�UX��o�V�M��Yx%VJC$�����
&�d2��z���%����z�.X��TV��:��P:=��V��˿ƗРh$b�Z,*���$>���u��<D��vz|Krc����R)�8�4βy	��U��R�_�B���j���]��*��W�l1k%��zNz�8��9Ӌ���ȗV��!j#�k
*1����9�B~RP4��(��f����M�5��f�P�Px�i��
k.
8j*}f@(�K���kF���wM_�5��\�7�+G
�
����}}NI��������6j��^O�=��!���g��,�Yܽ�|�b#�*�61�3{�a��
<Y�VͪT*[���!�e�!�Wr�39@�v�����X,ZVF�H�`�jj�X��UW���6^0$kRB�H�v얮�6
H��}��(�eB"[�����,k�4�� �/c�Ѡ��@�u5eN��cU}%8%gJ$�wSb2
6�>1`Ы�PN`���	��p����o�ܠ_Y4�m��O�W��_xAɫr��^����|R<�T'{��^d
c���J>8	4����N?�#=�n�K�E�������������G��C4]_kF�ܮK/�M�~���G3�v������S����9�tL�˪���vG?i}���]��z�h
<��R<�p�R���5��pX�Km�[��c�O�A�cb��U��V��D~�xe<�J�$syH/��:l���V�U��A�3@�V�V�V�V�a'�I��w*v*w�T���������4�a�U���*q�W��jiK*���s�&���;I�W��2��q���eBLV2�A�#B4`�#�b���-.D7`�������N#��pkN
���L1�Eg,
���T��v��<g|S䊱A/�
��%.P�@�R�y�}K�*�F�0�$��̙r�
rN�Ӷ�A�
%{%�\�e���%�ْ���;(��q|�!j���0t,�B^�n�^����5ޣj����I����v!2B���v�'aCKn���D���N��<��ꖨM>Pq��Bm��Ui�_��rԛ\���
D�(Ye���J�M�!�|
b�v)h��
�-��ߥ~Bݦ~�l|�c�R"Y0�e�q��U	���`��$�ZGѴW��h�:-��t� �4��LR�Qx�CHM�:��|@Z\���q�(b�Y�p�P%B��Mk�P�������=�1�n��yt�('�dUѕ˖��oXy���9��&�`˓6����D1��E�g4��
{V�g���O��f^�byJ5�![dIDPK?s��`�-�Ȣs��7�����ԞuU�p]a��|�1�D��l�%�ʕ�wǨ.�:�q�Sm�8�TP%/Ȅî��TL��:d��X^�U�W�%�\%Ű��b��f�b�l]L�L���ک�V�y�a������5໩bjV�8���X*FtƇ�3��|����\|x�Ñ-����6���7���~f��@G��[�˂�,��J�����b��ߗ����,*_�B屋Ey����O�·��Q�q�А�������l�+{���0s_��ZcN��
g�Ɨ�"Ta�L�+�bJ��ݱ�5��f�;kMU��h*j�sk8
q���!t�!%V�P8�	�jj3�"��d��)�x9`<�|�'�����{�I����Az�(ms(b��u�W]�.��b��𕅝�CW�b������(PN��
�UЧ��#�=�N���&�۬S9��j��Bgـ����,o��A�G�x��£�G��}윮5�����0����K�Re�����4��o�Ϡ�p2E�	0��g��
c�[�f3"��.�o]r`) �BT;^�B#���`]
�*�v�x��@��&��9�Ҏ�>����Q���o�
�2�`��\�mvy�)<�����_п�7����Iί�]�ו߅�u�Q~o����eo Eu�
�S�zߪ��}������险�W`���MDW�wADqq%Q\g�H"�K�Kcn�Mb4�ƹ&��ī���Tu�����է��TW��=���1
��X���)�S5T.�禔^KV���3j�<�����XԔ�J�*9K����?�h�Lls�J�)��
Lt�1^���.NB~�H€�]Ơ�h�Jg�cܩkI�P�SY��˜��j��5�h

#~�J�y#��"�V���#cL�>�j��P����э�<8���8xo�`(��<�����A9jsF֘�׾1�
)V�S>6>+L�����Z��\97��RS��_�!(
��e�,Q����q�"с_LLy�1�����#Ѣ���
���dN��o��R�`��Z��]��W�ً��g�|���	�����D��d$�`�������Wa��V���]��o��\�TC���{�c1���u��k^�y����F��\ϊ��K6�oC[&-V���q,6��$��տ��fÚ��5s�����������yd�����T�~(��6(�C�l6X :j��E6)1;n�hEx���f�v��3lJ�3�*�B5�O_5�Tj�J����yO���NY�
�*V�����H�x�-yWB�$Pr��U<�X�*��h��B��Y��y�J���c��TQ!U	6�XU@^�\/W&LUwjbS��h�	L_c�`<<��r�$|�R��t�����U�v��2%�W�E��P��B
����붕��y�{1�ǰ	c,r�����\�<2m��qa߽�=^���(�n0ZU:I��Y#�ݽd�.�XV�}���0Tq]�xR��G�a,�7�fX5���ۨ;=[B����]�~�������!WX|knm
�� ��7n�iy]ؘ�/�z��
���x�Tm	�~�$@rlLK��SżE ���2KH�(�jQ
���h�ʥ�T�(� �9��O-�A�2�bz��1�K�c���"�%�/ã���dʤ��}�c�>\<�gN���(Y1�b�x�.�R�d��(����+N��Y3%��Y���z���{�Cϝ��
�#��&%�;���sŅ3X��uW>v�C0|xq[s�v��	�¨6l���W\=�"<���������ܣ'4x-�&�r|(�\1#'
s&�Qp�u��6��ɭ���Պ�����ˌ��賷y�\����8/y{�~���a�>p��2�Y�\��w*͸����oj��&���_�Y��k�P�H��%��\0�L�f�u�t�V��HO��Z�K4���:�[�/��p̙�ʭ0��
}1�3���x�E���y�g���V9��r����`N����S�]@��)�@��G0
��9���9`�/i�~>^	/W�;�T�s�Y�zV_��~��U�I���/��5Ɯ>���LL_���Vie��ïS�uǫ����&������#���Nb�i�_�d9�@�-׮��t�Yޞ��7��s�������޴273x�B��=l�֗���y[r^�ۿ�p�S�S��/�6�/������_��Y3/^�La�Q��&/�f����T�F�ڷ�(s9
��s�RFJ醤�eTX
4��=�^i��G�X����I?A?���G�5�2�]�"��-R�T&�
���[m�Tެ�9l)��>�N"
)�+b
�^�,kV��T�9<�E���K����7�Q��_NA"0*#���(
-Y��t�2LX��8!0Z9q,�K	)e�fr>�KaG&
Q}u=��X�1A=�ئNK�_�s��Ɖ_�{_	�v�YѶ��ˎ�7�iS�f��pC�g��Ƌ.]�6<?�qh����U��3��%I$��܅N��W�l�o�%Z�����Z��ʶ�
����AEm��2���x�wr&|��f2���Pe+l��Cӝ���������qݮ&0�l~���@%A��$�[�����y���Q�m��O���P�\!>�m���~UO~����#r1�f�KTy��Q�(�1i=���.��!��Ue���������Íߡ�`W���%���Ǐ���.b���S:�*F���/BDNΆ��ޢ��⊆�7���C>:��_1q��b�ć*@��s|��
DB��W/|���	����;�^��w]o��
K�����-`d$2}lY�G���꡶�xc��ɞ�%I�+d��,-��Y[m+����o��-aw�k2���H����蟩�����kچ�g$|i��II�y8;���xj��rC��hP���m\��~�����_ҽ�<�o���0k�70���_��h\�}���>����n��������c�
��\�u����o�贆*EK��\�G郻��k��As�4��de��6�Z����#LzA��h6�;��&ߋ���o
�x����N���O	��)
w-��.�zOc9dr�h"�)b+&�~�����_UK
����L�a�hei�0�V`��.Aw: +�ڕ����Cχ��1�w�����&k�����L݆O����1����7����w��'f���\ڞ��#\��*��w�[�kQ��\ꖕ+�8�5x��`&�9��fc#N}�?^�3n_��#�{Ϭ%�4��ŠG'�\��k>oF�ˤ�XS��0E��A��\��ȓ�Z�Zv�smh�l�sSpSH:.RCY�d���a4��!י\Φs3�/A�$J���6�ln��+�4$I_
-I��f��>�%�a���JI�]��1e�F��8��r?K�*%k&!���ž�b��/���t���	�����k�����-��E`m���%>�x�M� :�)�����Ψ�;��*E�K��cˑ��no�@��|r����
^}�}�*��ݑ�F�*��V��`=*�R��?��H��od�
�6���nX�
�|��,G�c�|G���{}1�.`m�:u��ۖ�G�j�*>S���&�_w��fSt��W]Co��\k
�Q�����J�L@
"�υ�u���BV�t���VB���H�gQ8���P���%���*%a�FѸ����)�Ѱ�ɰ[Mx@hd�!e	v�����Y�sr�,ob+4
NGx�|�M'�rgz�)�v�������uF�W�v�,PaN�$;��Si��Iŗw��}�TF��i� ������e�U�rJC���<�G�|=�ɳ�����oN�f����h����E�'z�Ƙ/�:�t4G2���.��Sd*d�����j��$��U�ٚ@`><��n�+���*wQ�"#�4��!]-�a2��ɶ_rUv�jY`qpqhgZd��tgpQ8�NO
�G)Q��i�+4AS��g4
ܮ@M8`�X��Q4�A�BZP�,���`bV{����`-�,���&�j�����ĎL�"O��cd���8^QS^�n~
*�E�J|����n�g�Xa�$(0��i�')�V7ʓ����Z�v�t5���ٗ'>��<*��"2Vѭ�W|}�_�/�])�Fo�+$"�^�0�Jsay����&���:x�K+��|�Si2YΘ�rLV��+�
�r�U�4#�g[�]�|��,AkU"a�$��"��a�@����(�a�W��PK��'*��|>�Y��@ �h�7�x����ҡpHN�J�N���"��+�J����O�f�?h������&�R�6d�jC0��A,�ⷩï3D"1�R	˝��!�"aT֬s��2�����C)<�a
�<:V��Hŗ+"�H%�7RY���,/d#�L���^�Ǔ�S�����ɉ��'x���O�����)‹)��K��f�m�i�D�C �$�@^!5\%�R�9/8��@Rq���E� � Lv�˖�+�Z�A���}
xP�I�E��&wN�7h�L��+�Q6<�e�n8`|l-&�����d�<�C�~�@ύ�����e�O#�������,z�[�ϬALw��3�
#\�@pAg��sퟻ�di�[�Vp�Y
Z��4.
�ӎ|>������ΨQ蜲���9�ڱ��<���)Q@t��=�+�FN��X�S~��Y-
�@��U��E���Ң#ѥ��Q�$\�����_%*�؄�k,���,��j4�u�)���ԉS�?�&!��]�
��
y��|�P��}U|�/�-�����Z�j�y��f5f�un���l
���
�62�u[6���/C�^�5�$
<�3�������b�{uC�+���4�F���Y�_mZߠ�`���������}zD�HnO�w�~����4����b��g;��<�p�p�'pqnU��4w̙�����x�]�ߘ����㪞'��0�Cݩy��y�C�~���礇fUA{[U������F":
$��I���
��fCcc3�
C=��~CooP��ӃI�<2o�͍���w���YC ]"��p����o#T�De]Z�/`�O�FΗm�l�̥��q����7��@��??�d����/�.��7��4�O96��\��y/�k�a�^62�,�6�����ӧ'F��O�����x6fz|��&����e�N�i؀PL���a�iU�k+�x��>\�H4y
���i���!�`+L�׫�>׉�rg3�It��X?�[�_�t��7��aA��S���՛4-[�-Զ��O�;{0٨[痉�rK��c�aQЗ�,vQH��DS[��|`���x��2���6K�.U�m)7�um����,ÚM-m����j�D�1��զ}�{`�J=�:ձ>~�3j�|��j�
W֗?���|J�rBxw|���[�~��]a�)�Q�=[2G6�9۽
nJlq�=>B	*��%��!Z$[�\�慍5NA�Ϗ�ή
�us���%�� i�C���X���d����+�0��x�*n$��B� �$k+Q�Ʋ'D����.�O��G�(����
$.l�q�Fb1��8�
$�@b3&N�:���/$<y����eΑC�1�h�F�}���[��N�:<ώ�z�Kj[��L�Ͷ�F�
�@�{�ɪ���N�j�?��Y�ΠO�<d_j�/,/�e�zUt���|(L_	��,�Ļ�ϻ�ij�(k��b?�7������V)%Cb9zJ���1ۘn��=�x�y�r�~�y�~��i�$�/X��������z�\���$�~Za J;�ds�PF��={�d���X�jr9ě����,�j�����|4"��M��U��D]/��	F�)K%�N$mUtr��X�:4��|�-�?m�ܲ�➝�X�{�?�Y��?|��;w��s/t�\P^�޲��I�,��ý�#�\�<x�r��y�*Q����]ƞ�<�E�+��υK_�����۽��|5J�����5�j50Yٴɨ6���N[	~�S��i���� �T	��y��5�]�Ox�/W�4Vh�# ��#�F �:���y�_pFwV¹���IfI.�<&9&I��F̑��|���]���'�3����#��,uV�J��/ϟRő��'s���fm�N5
x�|��V!��_����z��+I�,D��U	�?+��(�fT�a�7;/�?<|}�������5���rD>��d]nGf]���ڕsZ{k���m�d�F���7���
���t�
h��攄&�}���~t��y��Gd����h{@�Ǣ���M����G07%�e����gt�{��
=�؟<R�
�N���$����C�O4�� J��\=`��a�"-�A�=������cN&��G�f�~]���0���(�
�Lͤ��
���w�0^8�י���<�e� >\�#�:Rpn+�f�k�f2�f̶��ho^�fX&-�=?
U�0V�L��|:��!�7��g}��q�>��d�߳j�`�A��[��֌���U>lb
�Zy�#?��qn�e��Wy���KXW��������M3�܃�|u�L�*yW��K���g�?��
8�f�s�'�9�%G�gv��턗��EЄ�7��Z)�z�1�CKeK�s"Ϣ�4Ϛ���n���-�C4�t� ���g8�3 epS.
zR$*��y

�J�Wr�����q��a��I�8�,��8�w���I7�$�ws�����gݜ^|����ݑ
n�{ݯ��s�>��17��;��������<�s�g�$ax�e�����^՗B"k�h�թ�;�ժ�2�������]�	z�	�CS�B��f�΋:�b�C����؀f7��0vuG(�VL8]z�T�����6�����dmR�ddįeKRĽ��p�ZY��i�*h�Ya�B��§y�l��p��K���� -�#K	���	3�p��
j+8
I��,�Iu�=�G�
�q�s��Ǥ��.�V�	3��g��O����<f>f������B����d��S��Lbzw��OM��3����f�4US�����L�X�$U�~��L��) Z5���Qs����,��l�) ^��0c���R�U�Rs�-���6v�=���ܪǽ�$�x��y�ao��5��n��������F����@��Q��r��S�ϩ��h�m+�"������pS7��D9�Zi�Dv�
Z��Yd���IM���1
��
̚�LL�-&W�bb�^
r!��h��(�lU�H��ԙ�\>s����2񒫋��Α\y��D$U���D�m��(T����1�uJH��{����XT,B� Y "yi���#Ԇ2�ܣ����QX"�!ϒ9
�x��;��ݻ������ɱev��gXi��>���������W��������-҂�@�5�5���k��������c�Ͱ��m��#���ƹ`��@�H��‘<�_����`xY���/L�K�Ţ^&��+�3����)YWW�c�"�\��A�/��
��	s�E=#�*[���g+>��<��3[2zΘu����w���Ez,rʺ��K�d��Kg�a�xd�����P�3|�Y|�L����!��Ifc�,~���7�
�F�6��i�Da��e� �� ��_�h�#L�b�Y띰��<�'��Sh��u�ic6�ycE�k�GN|L� :k���;�s�g�$��?��&PN��!�Br�ׅ�*��ُ�Or�n���s���r�Txi�b��y��V�|�V�N�Z�^����
}�,�>W���^jSj��MW��R�ܝ��n��ٶ?��d&��L����}ŵ�a�c�aN�uv�Z�ѿ��{���B
^(�ɡR���%��c:g��[�ҥt-:����+����̄��E�<�����Ϙ)��3o6�0�k��a�V7��=���lKp0�,�z���|d7�
Ɍ[�~��"x/�?>˽ٽ��&�#�\�}<T��p�O�	��O1|t'os��D'���1����EP�}�W豂6���U^��xb��ަ���3�b�#u�(�X�?j�Q�<`)X����o��#3���we�N��#����K
�����ڰ�NV���^���	f��FI�2%roH�j^`�^d]��*�S���Ƕ̶$�ζֵ:�t�@L��-W�`�J�-�M	A����)��K���5zB3�n
������m6�Ŭ�-��[�jw)R�R]��&
�C��~l�j���
>����ܶ��/�S����E?���[��]ɳ���.���<ٴ��ϲ#�<�q��0D��<������<@��V� �T�9Uх+Pm�hZ���e�K�hUƴy���6o�
�����T�%�Ͱb|�0��d�/��Iob!Z��ª&9]oJ�#y�s����Z��%~��R�H@WQ'��#hˤ���S&��0�bMu���;�,�@������͊���)��K�#�ƫx�݂ǿJ�T�U�I4�f0A?�A§o�<	��<�nӋ-L^�{��r�I�[�̧���!�b�R�h��k.ra���Z]a�s�Q�yj�m[�N-a�]Ƃ\$��P2T�QK�g�^�^�{RE��<�
�c֛„}tXN5s���fΑmn�v�8�ݪU���Sk�.AJ������4B�7�u�p|�sz����+w���H&��Ⱦx�
�pz��
4$.Ӓ�	A�x�����.��wa���i�~#͞��s�V��^�Wl��v/mʇ=���������f���:іL���-��<�	�-2ƞ�U�M�鮚o	�H��3k��'�f���
��n�Q~2���]�6<�
P�-~�֘Y��j�X�,����p��:A���#���6l[mCtM:�9bNk�UK�S�D,l�I=5"����'e��ֆ 񟌅�O	��k��B��h]ZJV^�Ҹ�}��f��ٗX�f��b{
������e����|�������~z�c1q�Q�X��5hV���]���jP
!��*i�a��	��-���Z�-̧o�cx����#�C��.&ٳkP$��sU�J��e�ת���ϮQ�Ս��?޼���_=poƕj
TR�T$k�{�'�
mƜm)\t_�г{��YnF�P��<��^n���N�B�L����޾󛩍{:���Bh���u�ҙ�s:o!�$K9�7��C|�?㢞l�z�K��>D���qԈzU�U����*�G�G�4�8RU�Jf0�n�!2�3q,�N�Rȉ#.��
~��7�h��=2���mH�
��IV��ϰ�n�T�?ӧ
*��E|�-��$��uȥ�g�r���>N-+Q��d��� rI�Tp6w�E
;�d�;9+N���t���O&y���ϛ)����3�^��8:��!��f�4U6LM����j�_�y7ک����W���=W��̀8��qF�!���=F��t*�l̾�M��V5���WR�-���A4j�L3���_�{"q�C>*w�$���ʱ[tP��f3:���-+,WZ�ѤWAO9z���n��zaL.8��%�b�z��^���>>&����Ӎ�zvL~��/��d�;E$6L
OiY��G|�H��u�c<�BZ[��(��0B�t�C0�'�n��+n��Ȃ�ʕ�9
̺�#��6i�_�oŪ���>������<�DQ��LA�{��}ֵ����O�b;�/(���un���.p����u�+$�D������Iz*���Д^�Ӟm�gI�CpW�]ԗ����Y$Ȅ~Ġa�ŖMt;��rsn�9���Tz8p�Y���
�@�����>�}r�}5
��R�JD��w>w�i>���h����98X_�+v�����7�J���۽p�r�}.s��~t���)�ا{ⲕ�_W;2Y��t����,D]��NG��HO��vz
��Y0|�f��X��ӭ*��rf��D̦p?O�d�3��4��$U֒WZT{U�j��D��� LS'Hf���O@jr��7�W;nZ�n��9�0�":���]�\��[����;�ē��Pg�
�ɛv�q�ϻ�n���gΐ\D�E◨  ��l��
`!�%A6����a�E��h,��=�/Ň�����A�D1)w�J��j]�"p�j@�%�%��~����d)����0�Cؠ-��w�'a�� ~�SB"ǵ�|����I\�/&�σ�B
?0f��~��/{�SG���wx?������
�
�W �w�S��T~�@���j���<
�C����b9%�pgO���{�<�G�p�|��7aS��A� ��O{~C!*I���!����b���{/��
����>�������9��ԯ��/���s�l�~=�~�����/�����[����-/��뎿��O��
�<�(w;lOu��(�6u�п�[�5uχ�[y8~'Wex�&�a�<L���X�N�9�]�L�*3)(�9�Ϥ��L<���"!qbpו��Gt���9m�f����R�aPW:s�iK�m!�����p����q\ψ����o=�{|��_S�ߔ�����9���s�;�/��-��z@��Hk�ߪ��V��f�������V�W�����"~���ۗ�q�Y��|b�s�}�_��/|[�{�?˷������s���+���7'��:�wl�@��4�$��}o��[5��ġ(�^���o�o?��M�>pشZ�������?��œs։���e���l�e��/��9�։@C#>���г㒝�Gh��i���ky��ҙw������z|KNk9Q�X:s?�-�j��;�(�=�	l�̯�Q���?_��S�cm�5'�}{,��o��J���od���̵Oo:�.�G�	����r0'^�QsE�J$��� Z�`i(��9K$�T�f����܀އ>�
�w#5G�lL]�p�+��>��}��<^<�����B60��\�	�z%G\�X���CC��鴡J"��Y�"�
e�r���L	���uH�����{)�g��m�;Hx,���P��UO�\�`�Jw�[�K�W�h������QP��-�1���o`��nm�t�a���9j?��L ���c�����|Yu��rIJw>B�I�>{m#'?�>��4�e�u��@oJ��@ƫ0�v���*Y	���#����$�It��#�=���q����o�馑%7�$ZCNܰ��\r~󒑛�{�/ߎ���)�	�ޯ�SS9
P�F)���E4�V��b����D*�H�R�i�����<�Ĭ=A��%xt�UG�dF���J�_#��v�Bb1R�Ds8�C��.U�纥&�A�2�YD鰊�����۾N=csO�I:g�e8�2�e��"b*�:�8J|$5ST?^$�ǏWLN�
������'��[[/�W�Lh΂��-\�a+l��5
W\��9�	1
2U���ww�G>^�?����k�+�{�y��7������b_�it
9���St�)�ʎ����zދ�����Z�*�r����bm�_���̓�� �+s/�/�.W���W�y�(�2&j(ho t��ŀ��uD��&�V����[����i#��
FDj��U�hn)�=�V>OۙgY��m�j�Q����`�ڻ�#޻a�D���g�p_泖Ik�8Y��F�]Μ�d%���	R���LV��l��<lN﫯ӝ]�|�c���S
9��jK���C��+��
w<�����U�ũl��\M�5��h���m�{���������RQ]�	GJjZ=��'�N���D������9mm���Z����\��%R��^����[����a�~g4�3_����ՠ��s���_D(�T�H�S�����o��Ll��Cmy@�!�v���� ���z�y(���K�3�?�O
ٻ���M�L�s���
Љ<�,�G��,T�'F���;r��)&>�E!����iY��ܱ�s��V���d�Rn.ub��Z���zj[��T�eľce������[�E-��B�Lt-�=�O��|�E���a���R���v?prk�ˮo��nZ4��K[�Gw�.��}Ǐv.��ҭB�͋;�_�ݻ�_~�oA��?.hZ0��Q�,�=��b�a ��ƀӿ!�+�SFƙ��Þ�qQ|(T�J.x�/�g�B|��o��^�j��U�vދ#9�t��r"�u�JNM��X,AJ���%%�7T��R� ��%�kҤĄ[\B�`Ρ���d�J�8����\���G�x���~1:�/�I��X����M��	�����h��]+|7�\d��F��5�^:��u뺖_P`���_c�|����sLs(V��o*̡�*�"�E���ቶ-REZ�
q,�u;�5�?8��>J�N�JUq��$mo8�Z�-b
�$��E�����������ۨ���a�v�l�<8����)!۪Ȣp�����"�[��EU���
��
�=529)�>����q�U('!�pL ����%�v�<X�����0
Gb	��vP	��7SS9ӝT%��T��(�SG67.M8�_��W]�H�Q'�V��R&���g{Ǫ����蚥m׬\�~�����|��u��Dc_�|��绺��/(�\[���T��)/qG]z5�H��$�}�2��>{~�CW\�`�c�
�>ㆉ{��jȅ��Wc�Y�
��y�@���r�{��"��60Y.��:����3���o�(*�k����ާ�χ��y5�jX	��M��pK�����+A�Aoӆ6�;�O��D�Q� m�P8\�Or9�r%�J�Ba�_��f���}O�=�T��4L��� s�T6�e����Ȣ@ұ���%�8V�9Jј��5C��
	d��֘I)��2cf	~0��
��QfL�&(>�DoV���1!̐�	����S�Zާf�x�XO������JӕTl~��w����M��b�g�A��JFO��:g������F�q8��W�/�J�_}�{������w���_(�h�}x�=���'A��[*8 N���I�e$	$&���0�0�]�Jy��R���G��a8�O>���{��3�����<2p���A֠D�������&f��S����ɡ��u�ݟ>�������S�/���۰���ѭ�A��:��аڜ�����2�L.��'=����9�3���٣³ҵ������������̑=�9�<H3i*}r��Μϛ�A`�$��J����ѻ��XSBz�h�-���r9������?\z�0������
b��N��&Gm>5��S��B�-u��3�i�������P�z��ERI4��;���;h�����Ϻ9�#��]o\���������M3-JƤ��1r����ʎ|l���'�п��cP��J�v��9��� �WX��5ul���\��n���f9�cgQ����rvSjkJ�5�%'��W'.I��'W�Q��/>�D|=ˬ��IR�ҙ�ƒs��?9���&�!o�;Mm�|�w��|�w�����w���wrA_��C^�;M�C^�;M�C>�%�p�-i�;nas��E/`�?�^x3��D2�%�\��hp���J�X"����Q%��4���6;�h���╶6h�� �I��X�:�D�T������&ہgL�m�?�p����E3���xS��XB��I�>ʴ�mT#|\�6x\{ɱd�A]9��=��/N�p�|t^��>�Y�,V$�ld�!4�w��E��_��I�˕�
xEn �Y��1��92x>�%�g��L��0���d��������<YLE���6�Ǩ�����TV}PK�I�C(�1[G���+�wA�����7�l��K��Z(�lC@�-�o���o��?�B��;
!�6� 8��9�����ű9TG�̓�ǩb�]���(��CS�~6���RvvDL~�!�	:6�|��Q���Z]
!���>�H
H�G�J���/0�3��q|1���<
 5��}z�w��+E���X��J�"�%*�n�
הU�����t�Bl����m�6��eY��F�����
B���1aSH� �F����:ϴ�ԯ�͉xKs�d��i�"^9�%n���7�_�
��!��
oW"%���J$edJ��ȕH���(-#SQ:�XE
�U�A��D`D��1#r
��*���ˍh�+�@�g4��#*�(vcN��|aƓ�LGs������$T@�4��j�z�J=F����G�P�~:�xKy�*?���f��|��=���j)�䟗���LNP���x����S�N�������&��
��`w��S1_�Rq��V�����Ǟ��S��Pu�}����L�L���v[��>R8܍���������M
̪B]W�V���m��"����e2��9�ٹ����`SOC�yEGS<��~/�+�*���q:v��a1
�G/�n���7�z=���`0t� tj�
ZmwO��+�:FG�цd'�zO
��e�����P($I��;�e�Q��ǚf�iN56�f�3r�Ao�߫��b��e�wc����m���$�7����n�,��AHR��d�͘��ȴ��nF�j{�GТ�ɟy�6�q�_Fy �%
��Q�6~D.��0�O�Y~I4�ȣ�1DI12�*�3�/��3�7a�GF��1y�u�\�j%��"��x<��CZ��̨z�1�TQ�v
�6xNh�y�*8�H���u��5p����_[�#y�@y�=3M�ZNQ^'o^���aƬ֪ѯ��2���v�]�/�6?����<�������r]+kº�m
G�*��ϋ��0�Z��+��AcVʯ�xj�I�a�c�%e}g����>�n��LI��f`&z+����&Y�Aq��I�
�F̚�EbVX4&6��2��#����c�G�As��+8�Y��s}������������A�r�n����7�
k$�����<q�g�w{��Ta�@
�%�RA�Z
,� Q�|S+�:"�R�SAL6�*��i�(I!r��J���|A�đ�"�%��J����F^�G�Y
*���nNB��i�y�����FM���T<N�S�D��Y	�gXR��x�(�����n!@i,�Ud.Q����ϔ�����w7��F��[k5��u]Kϟuɛ{uh����zf�w����Z��އY�ˣ���k��e���^O"���|ٿ�����߻�s���}�\,ڈ^£u��\��'R/־X7K�Z�z��U
ZT@�J�pA��ͦ=(�|����=�fY��o3���\!+�f�$O��BVo�dK���K��BF�����y������}������ƌ��ЮLi�7���9�ys0�K�Sb�
����F����4�t��4�
���g�Z�9jK���Ϳ�z�������ai��[��߻x��/��\5�]s��5w�5��7E=�{ß�2ћ~��K�y��
���}�˻v뚑��nծ�n�;�
�n,���I�����89-��\��D�%��S("�_H��_�"49W�P�B��H�_��#���-�:3��\2�H�S �7��X ��bV�~5���G��'m�oUZ���+���f��e%�;�k6|b�kY3��t6�v�ό��/���{�_|�!�""@�:_��i_�/�����p�#��p�̎��h���F�
!J$���
����
P����!�vI�\.i�DC��k-�RȤ���4��TA��ۈ��i�5<��O�O�椬�ɉ�	�,��Γ
An
��F�{����]���>��諷��̰�?���<��|u���ґo���#�Lza3�ͤ�Ֆ�I?�Ֆ�I?�g����|@�O�NU��r#�|�^(�����@4-�+W}$��T����[��Ј	�b�k�z���Vӿ(7�+������g�7�0_R��q���~�a����]^�C�|�����v�f֠כk��M5J��I�	y�<�H�)���M
����.���z3��-��C8���o�C�r�ڑ
�#��(C���l#f���v�Ԥ)�B�Ywb�����Y�������Yf����8�Y�el����
2�&��^f6�����2}c���Y}������7������1
����O���)�{8U�V�,HN�)�w[�
;��O/�o�#���[�Y�<T3�W��*_�|G���:�@p+��]�2x�Xnr�ͮ�Փ��lЬ
�˳��r�>��_��������P��`�#�7)
��)��4���Ѷ�f|:��,�B�\{u�O���+;��`*��9�M�G�j~q�hyE�ϵ���� �οU���7�1�ߢ�U-�nPmQ�����S#��4x )1'�
>��D�,R�B
��R�ZM|�L!'ޙ�NEZ|�a��Vk	�1���'�A��f|��& �(�� 
��F[`}�F�J?Ո�J�����/�g�d�e*	T�g3�M����ГQX��S�ʈU묊��
�'�nP�)�(�
^��N�,��{!����E���O�������;��v�ݨ�5F<Z���)Ԡ�2uy�\l\�D������-s��!�sт;�5�/s
#��׭�z̙˸=����C�m'ь`��J�K>�<�!(�yAQ/�F�l��c%��d`�a.����,��w#x�d�H_"B�n�ń�W&�z��)kTE_\�}yW*��� �#���+�~W�bŢ=�����V��1v����~���ݯ�l_0z�[c6E葑E/l^7o��'��G{�9k�ѻ���H���'�7<r��v'��i�q��k�'Y��}���]�m�m�~�i����^E�R^C�%��D�8��!A�)�ZeP�UJ��O�6 �Ѩw�c��_)�>�� �-<5j'4��}��V
��p�[��P,�0ZY���R��R��l�`�o1�Vh$��A�r�Hl}�F�$���1���jNg 9<��'<��'�${��ہ6�uL*�^�V��@��ݴY������3y
]���M�&�T�䝨�k(�o	��x�:P~q�U���_���[��4K��īp���㪟4IK�:�����	�����~�$!_|�4��/֟4��N��F��햺Jh��@x�b�� ��Ze	��Y�~�$=@
�����dQ����� �l3�%Yg�#a�_������'����
���¾��>r�'j���PO0�=W��PO �3�?��9�S�g�TB�
�`kE�$s�S1H�*��K9�Ti�l<j2�J?3O���D]�iK�{�~�\fM?���	�Se�m��'^E��n7zv<����ӂg���3	�;��ӓg
�*Ɨᚴ^?L�bPduF���_�o������FmK���ِ/�j��,�H��fe��B�Ak�ieJt���E����T�op�"��}�5���/W�wd9��μ��/1�C��.^L)>��$(�2e �;_��!��x�:��^�{u�n0|y'(:Ȳ�A���{ S̖˯@2d�fMYkd�ln�ɺ�i+����ZP:Ģ�|�x0�o=���Pj�b,V�72d{'�~G݉PO������6��gS��Q8=F���� �SvY��g���e�,�������tm��ϷE��ھ��b��7b��˫��B�So��\��ʰ��e�O��';T��-R���i�ǧpp�\��k�2d�#����j��^l19���B��h�ْ�!�P��{�������j��m�]�8=�������Ց�♍
-_�U�
�跢X
�/΋4H��{/���I�/E����oJё�y�`J�)�.�36��*w�����H%��Ld(��V/&�c��U��
�͜�y�˥q��)7r[����Ԓɤ�V�R�Z��>sJ6�REYj���o�x�L`��߄�Zg�y%^i�VJ�����*3]����XP��'��,b�����C$�>H��|°�&�V��S^C��=��	�{��0�Ě�0՛3x'�tmj^��7޾��=i�-���;R��z���Ѓ���/�S��`yz���#�^�{�'Z�ę?���������)�
�"����p;��a�2�R�b���e�K�;W��ܕ{����y������|�z�|�z��`�˝��c��$��"~���{�S"�VM�U��Ew�`	��m~�����	�l�ƭ0��-�"D@e8�R�[��np���"ଯ��kc[kO�X�CnO��C{	a"�n�8�7��,]��RJa
f4Fh��i�yB�=U	V��Z�	���%<��0�G�(A(蠚��
�rT߀���ps@�eX���]����b��_oR.�زȺ��K/����x����'����A���\�h����l��
����ц�F4�[:Oי>�g�s����9b'R��=W��5�m_�ͅ��i+g�SH{�`�Ă@��>2΢3��Oћx��@��q1%VPj�F�"��iu2	���Lb�����
+�g9纖�._�B|����-�6�f���.��מؓ�']��^rp}/�a�]�ZM���Gt�إ��\�M)�
��Y�Oj&���i��	�U+(�-T�!%4�z�i��
%6�A�Kʭ*<� �,J
i�ci�V�������XRU�e<�$�+)_�	K�Up��fި���v�/3}\}�8Mu���x�^qV�oay=��D%j���}?��s��w��6�6v�ݷ�
e��M�C�{
�JL�!�\�a=z3|�k,��	o����/�
��9������û�U��_&�mx���bZ�[�BI���|� ���'�?F��zc�a�����HH~m	vsRn�]W�u����7
������}�̼��̛}��%3If&�e��$@HX�uX

Y4"�,*nT�
�"�-� �ź����k�Z�k�|[���m+���{o�m�߿8���-w;��s�=�sN��mo8�a�>{�:v����o�쏽�pB�p��0�/yY\�W!S�N��L��U
p��o�s�h.�
����w��9-��T�|՝;>�r�
�찿����ʌ5�Կ�á-�ݰ��������ɰڳ��]��ª�۳��?ۋ�Š�)�!6����-���������b��9�d�t<�z�}��Q��eb
�@B|
�����d�X���@��+��>�۳ܘ���ܽm=�7�V�������������\���oʄ5-����갥F��4��!�ճٱսD���6�8��ҋ�����#--������2�ݏ�Ï�����ڴ�:��Ӫ������ڥ�"��7���O��Ğ����<~�����\Y\���4ch?�D:
H�:���HIJzA�	����h2"�Ѹ�$
��,
�(��Iʤ#!%��9�F6��Y��B~M�ZN՗}'e�����#��C�� ���rt�,����J�C:�W��9�CN�Z�I��f��v���$��J���h8�ǵ��\}��������(ٔj�i�ӫw:�Nm��&!�T{���T�?�}�+��.���*��$�i-~��dT�
��MU�$pL�ZG
߫>�gi׮0V�
X1�}�q����o�8;�@�==����g����S#:�ԋJ�4�Ii�w�I�u̝�O�⃗)���#s6���$�@\z�V7ѷ_�BzݼUSgյ%�֐J�R�5���G��������lo��<.l���q[}
����?���+�4�C5~����ʔrͼ���N��M�1y��klK��>�)dR�'u=�7'�Pl �92��C�ֈ��Zy�8���p�ҏ~�Z��j����pE���Hf2��{���	���HDi�D�_����A�r
ēw�������@����SX����M��J�G�EaǮr�e)4⒋�W({��Ѣ���~�:f�.F5���%�[���[,y�
_���e
���x�s7c��kەΞ(+[P\��~ל��(��'���G}��z�9�8{!WM@�M�i���]@��N8-AOJ)��@��\��������x���m��IX�+#
K�CRo��!zaOqMq,���?��q���ԡ/�OȇQ=�)�[��%�e�0�X�T��,����H��0
AI
��Ke�$�B�
V��ּ$���J�2 �A�,��I_$���/�$ь�[q�z!��`��\�/˔�F���k����K�+>wU���}x��ܪ�?�oɇ��b�~Z��m�6>/��Q�9�tLS�
���`9!�#�b��8u��
a�RB���o��2��j�E#�w��U�=�(̗����iH�t�i�/|N[�G1V������
��,�J�H?��
���[b>��i�C����懜N�V��=�A��~�C�u�|����Rv��V�Q]��Ï��I�5�hm%Z.=x���φ}�b�����v�Ox�C�P��Qs|$�L>>Ox�B��j>J'��8�\�C,���G9.��X���pTO���m�o��虠t�k�+e��V"=���h���>f*�#��4�s	\%��iy絰7qm�V�ܡە}�u|R�|�<�;�>�<�}�����*���5��-w����Ͷ���������������W���N�Ͻ�����ՠ��j�;*��D,'�-	U?�3N��%�L'YG��'W���ý�&���u-:�[wN7��%�x{eC%�DЃ.���U��u�t-�Z��y��O^�ٙQA���3���u,J3Wt�7�]��qr��7�Ya� �̟�;�Z�;'
2*�-se5���/I�����Hz�R)��@[�o+�G���FP[r#�DX$cJL�^�,�*�fSa�c+�����`f�b�����3�Ҧ����c=�����tc��7m���]+֎Y�X�p�o�¾����߽�
^W���o�=�
�KK��Κ������E}�;��3fY�^�ɽ}9����T�����'��_�&��j��HW!�8��A����"i�6�[t-�N8>::5^	�����0��r�B�/��{�>�#�FW%i�NF�D�O/�� ��wmU׹�ud]��_��O�
��I�F�Q��CWI7��[�{8�gu���4�:=��⿬�B���ll�m�g!,ֶ6�4�+��]����
���ZJ"5�d�������,�Q�����;��s�4��+DoLb���3��(GN���&�-� @���]��֥O�Z�����<u�;��}���Ӝ��>�,[؞I�]���u74d�w_�EH^{3���_k��9��g��O�̿������̸��0
��+̞>��}��-ϼw�s�/���p���7|��*1?a���'������N�
��V���@��V��ei;<
� �ͷ�/RףY��`�4E��.ڪ:g$M��;�m�o]e%���!y`/A\(t�@�x�M�3aV�}�_�VD����7Ĝ ����/����d�D��F���K�W�I�J�m�q=����ҌR����foL����N�A-K�5�xKK�����-��l��,�p*S#���s�V?	Zu�&:��ơ���&u�&�"�:�D�7��Yv�k�?��cK���=��i���W�����$D�D�$4�ʢ�Ԭ�ϑ:��Ԭt�Fin��n����c�z�,Vknɾ�{9�'��ҁ�a�<��@3��W9�=�Z��~.N���g����n�p�d	YEIs�H�]���=y�N�A3��涚Y��t�E%B%�A���ϩ(
^CF��4+���1/~���k��_v
�w\�/��HicH~�Ʉ�YS�T"��g�&P)4&j��O��I���*�D_���gTW<��gQ?E�c����P��$�󕫔��b=�	�r�[����jqI
b���D�?�
�����-�
��~:E�R~?�)N�\���?H&Q�����p��i�KIb1�$()�ƌj��~�3�����ȧg�La2Y�/9��Ur2M;	�'�2��~IY�����-��Y��w�-�����p�=��
^?�j�Є��|�8oU�zx{}�98.��.d���Ʌ���K�&�~�cb�
��S
��Q���#3;�3��X&c;���I��
�f�H\>#7�!�1�y�9��V5lj �'|xmv8���g�N��KQ��p�0��Iq,��R+K'�"2k�G�H)�����Tt΅ijf�"F/�n!��$h��P/�7V�7q���h�B~�9�&���H��q�Z�R���.8�S�vZh3e���)?)_�c$$��d�⑁�jY0|R��j|�:u�
MV����.�E�On:l��ՆdZ�섳����xP��/cP�2�X'�Mi�o������sȡ[������“�f2���6��Hq̡���֤��l
�����m�~�������Xp�s�ʶ^ˆw?Q<h�g�M˔s�W,~��>-���񻮚D�/����?�FG�|�ኵYg`��G��,�__���n�5��ޡ/������U �W �ơd�3�$G��KͧRVd�B�X|vU쟼a�+�����(*��/!�KP�5�|�%% F���F0���x#%
�����&���CE/��
�1@|���K5��O<2�5���
��47�::\�g�O��L.{Po��GI���B���"���Q0E��a�K�v"�LU*��/Ϛ���['�;���@eߨ�v�>0���c/�(4�l��nB������H�`��c#G8M�Hr��1O�h��"�ʎ��'N�p`pNUr�����$˚Dja�ju8Z������t����&οM��j�#+��=5%S��=����J��'W3[����+���K_Y�ri���|�9ڳs~����r��j�1��3��&��l7H*t�f����q��W*�~��]�1�}2)-�����g�US�ޝ�&7D���!!S*4W��+F]hn2�5�+o����y�¿u�2���y���/F��&A=w��հ/
��O$�&/��"c�<�$���ToG�l=h5�s8�~
'��=$���6�?Q���(=Ǎ�}tMq�'I��	�P��2��#&?�3����*!�l��~�(��_Q�
��Gj<�a���p��'�;8Y�/ �*�1�m&�d�&��q�H��c��Ki����̩d�F��};]�����d���!	0b�O*-���R��
aΈ,~(��N7�|H{�5��x��#p�
��)�����Њe��	9�?=i��E���#,�Й3�@~:������,a֜��X�Q��bm�ц��Ƨ��4��,ܵ�J�"�	筅ҟ�f�5�o��Vh4��֛�Bա�8��n���
9��s��_!:�!:�����$�D����<]Cd(PU7g����=s�4���O.�/�*��ʧ����c,��3[[gN��ϴ���1猙7���=�&�M;Fx������s��u�:�~��8���kR?��+ߗ�Q�a���-�C�]��W,��78C�;(C$��A��a"D�_�5<�t��n���6<?|h�j�?Y���K2bX�EF⥙���%f�p%�NߌօF�l���]�'7���	{葹��������#�D�|l���Zb��S�8�����SX���^��I��]���B�[�eZ���Z�4��d-��oi���x.4}
]�p:*�ٽ�����{����^�!�#i4c����}$�����$��d�RU�U\�!
�
P��j��!���4��A^�-)��]
��ڄ�2��Zn��rM?�嶎Tr���
��U�u\8�ߑJpP�J�������Q���V�(ҋ���l�$��2�*���V	��VI.v�U���F�
)�(a��Q��a�D
6
�%@�	X���@'�
;����Ӽ
U�����G�o>k=���W=>��3�$uz�]We��M�M�c	9	h
D��V��StW}>�\?JYY�A��1SR�s��͍���-��H���g������^{>�i��_r��~��K������Nt���]��1�����7�$����/Ni����J�!^L�L
��#��-��b�bkp�o�lK�#h)�(X��W1	�G�4,�;��v���k�a��^���{gP��s��϶��]�ʴD�kuc��=��&�^��;o�ǎ���u���k���ݱ���~��j��ks������˿�O?��������~r}�?����l��&oɴ��;Z|��#P	����s�������6��������&�i,��t��&76������%g����/�
)�T��]y|5���x���U��fX���
��Fb��e�m���6B��^�A���.�Պe�+�q7*�G�CPG+[�!;����Kq��a*��頺��6��F�D։�7Hm
���v�?q���z
���I����<��"��X���֥q�a������-���G�Q�|�����ĦҺ�f3nY`x�~�~�`*��s���|��?�C�?S#�y
=Ïkx\#P���3��߇G-rs:�
��=��a
�����~��vB]*�*qI������׉}E�G�C�	�w���J��޵���U��{^�o3�L��ÏPm�0�_�%(��4~��S�Ӯt2=?M���a���զ�P���Bw
�P�NR,=�w�l5s����8��2me'*LP>,)�4�CY�[�/�c@�^�
H���X�'��7dX-ܭ�U��Z���Z�Bj�aiF�\�0P8=,9��t4#R�����N�I���S~BP����,����� ��:'(ᡖ�gBz�!���~b<N:���n>��̀�|)���]CFh��A�?��_��,��x⭷`���Dr=��9��h�S�B�Z�J
�ʴ���#�蠮���WZL�ލz˼K�-�J:��&�`�؁����2^�)8h���q��5�@��-]6��!��AO�x�z�,=��uwY=x���N�Wӣ�{�#�|	`��-���>���D�T2^�z����+��������|z#�]��zp' 
{�@R��H���2�R��Q#�~_qLV/�(�<�.9M�0U���>��}l>9��lm�I���){�ܷ���	��ר��C|����u?�~?�׃�����*��:b1.�c��-�t�E<�k�(�wz�����nIE7�nR���×_<o�%��
����p8��нr�ĉ�V��;;өα����W��ؽ��睩4���q�n88�
�9/��+"��2����B��
u +�)��z��~����
�
P����Q�Ox����I���'ؓRU�Qx�\�Vϖ�����l���/�N���s{�J�x��l{U��S�hM��'I�K>�ǽK�JNq��&h���H>89IIѨ��I?\u@*D� �cT?a�/�GqH<Rw�1&���Y�o: {�Gv��
E���]D��8Pރ���?�,#��o�W��OÙ����S�H4
'W��(PS&F&Q���55I�|�ӷ�_�TWx����4Q���'�M�71�����r���;�2oj�y�M�㭎�I�]�����j1�MF�bYIZ�$����g���x	I�������T ��%҂L�)w"i
[lœT��z�x��/��QE�G"��[D�)��q��R[�6�]��:"q�h���Y�x�z�#��P(�2�®ӡc��f��#s:]��f�;���
e���Po58���:t�-Ad?f�YQG�i�`���J�g�.hW(|r�^.wX]j%t9eJ�Ze2�î�S�8��&�^G@��V��a%+3���܉��8~B��)�"����'���īf~+�0,�*_
���d�K�
Gž�����f��"TJQK���/�@dS�3���!�=��W��6�s�_�gх&@����
v��is��I�P�f����zvu<�0�$
���^���5�*N��f4��<��:C,��A0�Ma�0N��� ��m����XI��a%U��h��p�*8
�V�����f��à�et�F�Na�F�F���U�&r��ȗ�P�#v��o[a=�N,y��ު�9���H�	�ߌ�����d�S���b�4�0��C�?�Q�bf�r�`���Ȁe7���pND<s/9����]v��u�4�'�l��\W?ky�V���6��w�^9eIѵ�a
F�T��\=�޺b�
��"�w1!�󨆾�����y>�H{��n�E^�m��:C��>��{�~!��VG��~��?;x��Ư����b	z��W�OXG��q�����[e�p�`����z��>.�/�|

�t4����$ ��8MS�TJ`<rY	�<W�
h)N��8��)��������]dU����d�o�N�gC����=J9�t�J��{�A'��3��W���ɏ	��D(@mBOT&����6�X������f�m��x�ߨ<�N���y/���T�h�a,ucb��G�5|dU){'ĩ�����<�ë%�C��Q(�<�Д�J@y����8�T���n1x@B�t$R_H1�]���^%�P����s�
Ӌ�;���S����E�O���1x����:�Acm�	�3����GB���-t5�q��(�"B�g���c���4Y����h�Y�e\k����g�8g���ފ�����[�,R>�I:)�I��>	㖴{'�󲵩��f��y�G�F/#���H+���!���d�!��(�r�ᰭ��<�����
)d4	h��!91��"�v?#�R�R	p�-Ґ_�����3p���ZU��9
�|�Q,-�B�xwWYI>�P@x
��J���\�?�E�o4aX���J/Yx �?�VY�X������^(����<mWU�Q�
c��X�1~�[P?��zݜ6���ק�~���ݯ��9t�m0��[z�����'�/m��4sqy?���r���[E�
�JoJi����%v>���G�+��7	��pS樟�gGr��;HR|�8,R`���I/���❚������c���
R�Z�9)
�)������J2���0C6�h,���e�ЅF�U�J�]�p=g1��wX,f�M������e�`�^^�'�j���/�L�],��B��0-��-��)O��P�-䃣��c@d814����h*°��ҋ�@V�]��h�
�y�G���	��¢�nV�m�Q��1Q���eonVZ�g�U�dc��[�<S�j�v��nr���:t��0�B��H�_鷄M0��J��k��}�����;��B.�1�H�zA�+W�J
�G+g�iʙ���#AiDW�D�}E��*�,�*�^���{G[q���aO�wH�* �VZ�+������bq)�=@�ZJ�����S�Zj8����d�J�~b"�(�ÀU*���p���&E��
�y��~-#����>��˓�
N6���NĠt�b�֑�Zˉ�Il�]��9�2�Κ^N�:�5�3�]�t���q/=�Y=c�M94��L�5��x�ɩ	�����Փ
6�,|^ٵ
���3m��_!Z
��9�oD_���KT���4{J�1@8�)T���ڑm�g��TN1
���<�
�(�
�}X.��D����s}��p���2z�D��nN.�*vr'
�m�@�}���Ox��
3��[��G��4��Oβg-�x F�`\��MH���paqw\�w��ꋏw��p!\Ѐ��wo��y߂���U�R`
os]R��Bl2m2o��J��Bo�[�*s��ܠ�dڪ��s����hR�!�$���#�=4�v�=�j4�ȝ ��,;
2M~�{*,W�����+	�@M�ma	�^��bYcb��[o
��m>�^��H���
�;X��.��<#>Q�!�&�����PZ�	�^c�ʀ\+/V��X�w�Y�*���%
Z��:T��cq�J%u���B��}:l`;�ȐS��ͺ�l6%�ư�!/�j�
�
�|z���С
��ΐ4��W��̯�i��e&�oY�ؐ���)��Ş��%O�o���(G{c%Xp,�N8��q�]cxm�Г�3ȗ6������+΅��cmٞlȵ�k�r����/δU��tKCK����s�(��[&�ϡvn!�$F팂M�^�t���@Qz���7
KR/p���n��!��v��N��JE����[I�Q��vv��=�����N���[)�o��x�2�(n��'���8�L��f��m�m���Ã��5��t�����=�9��l�����D[��,�4V]�_��Tl��Vk��W-��Mc�;��Pz��y�?뉡��M�ߎ4�ܢÎ/�_8�P*u���lR�H7���#T���o<�e>�=�>�9�?8�9U{�n�~���ֳMj�lR��!���_H*�Eݮ��qD$!DD	X}��P��6�O>��KJM��U��j�Q�&0@�~*��;��� I�;]��'�9X{�U��y��
Q����~��{��^m�Q4c�'d���I?E7�)���mߎ��x�6ƞ��c�A��9����\���
\�L����M�S��. ������背w��%o�f��ș�_T�?̿�
��D[��͎��z���zq�-)�R����I�����(�")"��g�;��|n�����s�D�V���-C��7 �h�O����ޠ��=�+�v�bQw�����I8I�$¡P6�G������#?O0��@��r{=��i6I��j!�H��C�<�
#�~�@T"���d�ɩ0O;N#\}ȇTs�Ϗh�Ӈ���ˈ?Ȅ��(�������`‰��0E�#,�#qy)�{q�d������{�Ϸ�B�"�B�XK�k�OI#����8%`��Z�8�i�\��H�������4VZ
�_�'�����,�0StՅٳɧ;~����K���6g����|���SaQ1�u�H|��⇈�n�(���z���q��j�h���D�_���]׻��z?�|�=��^٣��:K��������z�>�'Sٚt�6[�i�5Vg����lc����!�Nwd��LC��2����X�6S]S���I=��i@9��D�l���aC}c�2���T7�4f�G��#RHg2�p���K�DB	������`\nq���O)���	�ީ��L�ˆL��˫a�[�����Ɲt���|1�����9�n`3�&�J��m����'�
�����z����"���WO`�췼�H�E�rJC�x�K3�LD�DO.W�����&DK�u�˔C��I�mD9Z�Q��>�9<m%��C�Fi%��R���ɍ�b���c�g#�$�����"��e��b�v�9F�A
�!q�ʦ�Z�l|E�[�� 
Bhҹ��E�b)kblzk�-@�NV��7�.�a	�$$C��T��9����=��rFƦ��Fب& q4��F�����M�[���dܹ�q������~�1#���R���%��x��l2?�k����R�uaO�.\���ث��l�5Y�;
��G��@#7D�w/Ս��;W$��B��[�a��;���pF�Ӧ������Ú_AV_R�5��_��%xwX=iU#��y�;��Ù���8}y�5�
�6���ԅ?v]_��BM�x-����_�kyQު���eBV��d=^�k��w�8�����]�J�G7�9�H83�:6D�I#V
��m>;����;p�ſt����W����b� �/�W1�wS���Z1/�T��5^�?�6��kR9/�������_�
�ǜpo���#��1��_[�����W?��޹B�ц0���{�#v�qV�����q�c�&E��Z��<^�����)!��,�›ß�ɰ��(���׎J�l|�Lj�/�Y�ܑ�������29|������ȢOͫ�lC�������^��)�7$3���P43*U�TK�;5?E���~h�Ba$�'�ARi2LP�P�0�IcAS]s&��$�0��sȬ�D�QW�%���J��� -I�$.cұ:�O�\m�i��p�Ȇ;7E ���N�z'�	�@�j��;0���3�;8ec�ii5���򚋻��`��Bl���"Gb�a+��ya���2�]����+��1�N.����Ht��/�_��#�r�<YO)�:�"<zP����Ǯa�Zo�w���7��{��q�����7,��Wܡ����˘�3�ۺ�7ϵ%��j���.pʵJ�â���n�|z���;��e��)(��R�W꤁�B7�������XQZ��N�!|�j
^<��+q�@�c��CS�~�S�W�P�a0QB�����3��=H^�'<#���75���x��	��2�H�������_�j��� #9g�����Yq����՛�w7��?.N� ���n@�
�8DT��U���!N��߉�w��J�_��>��`H�$ޏ�/;a��˾���-�?�}���
L縶���T�D2ݚ;�0�u�aj�2�4���ׇ]����íUm�"cƷ�W�E�a0�
mfW�^F�~R��T`�?#_]Y�S����a�l��IŘ{4�5�4���X~�۽�u�30��C���m;˜-��*Kw���!�`g��)����H��#���=u;��pB&0C�C�H�`�2w�Ù��I߰�������S.s�
S�v�C���Z��}�<���1��e:�J#
�)��q����Ӏ�#+N��輖�#�4@ԣ:��듗���vN�'����l�p�-RY0�`JTv��ܧ�K�����u���K<�8$��rVH,���7' [<>2"�6�j���л�σN4��%Ϧ��#,��bIqV�Gi���g�a��=t��+�x?+z��|�_��E�-������Np�������lq7�c�䚌���;BAg�l����溦Le"�t8��釯�W�M�p3�d�P�0b,�6���S�F�UKee?Is:ư����h;Y����$��Lj�����϶KT^�t1�=	�0�A�#�_�$�;��p�="E>3��ut�[T��sf�k�DD��h�F��f��-ۧ6����E�]�

�#���_\��@��m���\�٨��j��U�9}"����2�������VMd�;�ˍ~�����`�]�YT�?5fW(���~E(��X����_��M����)$m0�9P���,��)��_7R ��k�6L����./�����C1�v�zї[�þܷŋ�Xt*�1]��Ә	��P�	�M�Ke�G$f�ҫ���t�m�`��_M>s���J�x]��g��-5��}+�F�~b�cC��	)�0�H f��%�Fl�m
��΅��;��~bA�
ͥ��<�U��k�9��D���8���9I�ͧĝ�dB��[���b�3�R>�?}T������>�b��2$��B�yo�}#�2��,Λ���0�D��z�ͪ���^{��.v���`?�=��V����K�@�_߁�EoT�,��H������6U�k
���q���P��'�.w?�����U|���C��$_���ߍ%Ռ�풹�����/{��7)^<:T)on��1�,�
�B�k+�/���(���~����zI��|IY+�^�����ʊ���o���PY�"i��
���C[+Rğ�ږ���%���-�ŷL���!��i H���Iiz����o��4�^����g�,?�}>�g;�^KY�z�X�S7��f�����/�{�n����mG3b
�CY�*g��c���%���^�͆=w国�����(�mH�M/K�8�y"5���ğ�)tn�X
5թ*c�j0���� U�
$	���O>̹�MF�+VT�TZcJf�%����C�G�.� )�M�;��a:i������t�@̒N�i�u_���#{�k�C�<ے��e
�8!���D����!�S����=�ţ�r�ĝ�?gg��y�g���x��g�W�7����ſ��Ϸk�>��m�`6V��h9���������{xn=�s��ʍ�K��ux[9+���!��LtwTu�;vuu��/�����/����}�9��;�8��q>�Y�V�<�z^�\�.C�l�X����������S�sg;/C.�E.�ޣ��W�(C�%mʤ���a��?S�/[�gBe��̫͛��;fhV��y�t	���S}�~Ix
�<�9^q�����J̕K��9a�x�	����Tp���nz<����tf��v� ��CJ)c�e^���Qc�:4�\�`����\�4�����p�.�dd?��y�u�1�
������8v��ڰ�@&�]��d>ϊ:�Ѥ��ْ;�ŀZ�_��'-B\�yక2�}	&(ϕ
��;����D^x���	�s��%���S�W�]��i�9���5�����4���Y%��j���㬓���Wz�
�-�v�.�"�k04ZG�`(TU��vU'�[���~�.��v;��6�������=�q���r{��ʼnx\�J
R��2!�_��{����݁}
�B}@ʞҎ���V�k����ի�7Uo��U�N������T�՜ڜ������8����˹�9��_Qcƿ�I���Br�37C�k$gɐG�Oab���.�$�!kQ�J�ߢ:��&����-B�֠�ϋg��0d5�I/S�x�
%��'O��Oš�՟������c���xx�z��bE@~�WLqn
*;��͜e�ˋ����)����kH�)�q���s'9Q��ͨ�^��dd�T4z;-��$3*�����ʭ�;�w��D~�;�;�;���X�\��mtuR2%2-�ʷ<�0� .IE������Iҍ�"��~ٝ��IH(B^�V��C������@ʛ�!5�}#!h�D��9��P8�8J"}
g�c�i��[���9tf��̲�1rP��n����a����]�>a���*�j�f�nջ���$�U����A��C�}�����v��ͮ{\�]�\�h��dK�UI����k��c��){-a�GS�X�E���0���t��VV��0��y��1!�a�h~�B숆��k@�
`���ɥ��"91O���w���l�REa��^ǹ��<8�4��:y�x:��M�c70��x�����]�	&�S��[0y�m}��{��&>�� �$��:a��f�9cnv�1�q����S������˂k��ۂ���ڟ<<n?8�+���B���8�7JeR�����}[�j�l�T
w`�ߛ5��%�*���U��f�=�}V�ju��7ح��d�,�B*��k
:�\a0�u�R�p��
y�q�eX[��-aX�W>����^CG�W9s�����[�-���=מ�=�w	��h*�m��������"c�w���CŖg��q{��7��	�O���bvU%��Xf{��Ŗ�e�M�;�[cY>�����˾�c'}�����3na�� �_�(۩Tj�R�;~PiPc��
�y#��(O�1�&4��ɛ8�����zll��Lty�{^���<�*,q�y�A�>;+"(���#����p�Z�����y�8!b��S����^��
7_�xw�]��|َ��kV����a��?{s�}��GNwMپ��U3s�H�D��LlҬ�_��tq��;
,�_k���������X���4�sr�q_��D���ѤG�[M?
?oBdh 3$�e��#��'�^:�P����:��*J����T�~c���W0�ϔis�;�g�9�$�F�R7$�0�l�σ���QG�I��8y�uyLfy�P&q�T��u����$�?İ1>����Ah3"�:V.S5}�_�$
'zy�ݏ�}�(�bZ�?�����}�M�)�+�A�;���w?�~ߺ���vo"啱r���+oa�
�D��+;�V���n���+G4Y�x��\Ԉ{�5Y+lJ�1^3�7�2�&V���x�ݫ������ʗ��M:VY
@-1��
��!ތI�:�c.�jj�ER��㦤��3����b�l�u����XL �T2��Ox9~�J=e�Ң�������m+�����\����҅w��$�f۵������7C��6���}p�3�Ř҉�h}\TmO�[�Ә��E�a��Jٕ�Uv�L&7[�F�\�2��F�@,g�L��h��b��$ZªՔ�Z�@rW���B��P�����r�-lf�5B4e��Vy(3j0j-:��-��xj(i_���Bt��#� ر�d~x%3��Y�V�{����99�y���u����5S֥�����m)L�O������*vQV^F{��[�$Uj�Ya��1*"Mh樧�3��Ҍ��V�b�Y���m�-ʭ���?U>�y�v�<J��U�b�26��FY�3��Z���V�2�q3=�f�f7#a��ê\!���e�I�7���	�*��T,���c�M/�VX��Sp*܌j7v��*ԭ��}4A���JbND�)L���)�(��
���1�3S���
4F��(���(�<m�J��
��xc�	.Y|������m�������F-XV|�xV���gf��������N�������
)|���3���o�[�Y%��?��� ���Pڡ:>Z��#uK�$�Cc��DH�DR��Ġ�Гd�����Y�[���g�6��M$�)L��Tdu=:�u-ң����B�?����(K(�^d"A�'b�*�����9�$E����f�:�䓓�Й
���C'~|�R�a8t��A���j�"D `��PX
���!�¸_�4��9%05"�Z7I�+��~�8�G,�9�2tMuc��kB��@r�^)�^Ӕ��(%�E��E_a)��7�D/;�I}Ü�&ݰ!�h'(����9t��N�R�����k
:�,&����s3b~�?c2���e��|��9�l��(ί\
�%W�F?:#}i�W�^�wu���w1�ҽ�D�T�,c�3�<}Yo�y��o�]��3�6�{g�p^�H����eB�~„S�y̲�3�O]v�dEs�T8u�< c���ӣ++�
��1UJޕH$�A��W[��"�	{=Ǎq�#c�l=�|ט1]��<y՞��d�%��r���:V���Ӳ������~��3+�,��c�S�
3i�$8�N��'R�3Tp�{U�*bU?)�j�h��̌�p�~����	�K�2�ML�[���~<B.տ公*�~���/-�~D���o1�����`~@���ٝ���xD�ǵ��D��|N{��> B����^s1�{��~@㖪p�4��v��ӂ?�M!E
�t�JP6U�
9�Y\�bTDt�+A�du>ך,��̈́h:��)%��	x��(&N��E�/�2��alE�Z5f������77E�.��γ��z�5y���̍u�Xo<�]vYЛѿ�h�j형���̪(|.o�r�������ؖ_\�������Mԭ��+LO�+T�ʥ-��:�%�x�E3o���_ݹ�=�k���\��]����g����c�W����ͤ�/�NYN��n�g��Q���V�������#W�sZ9#��F/A,FS�]��S��W#�ծ���i�4C���(���#N����¯�76N�4���&�t����+��_pŊ��쨪<�cK�Sȥt#*��cHJQA}��a�w��U*����KrE���M`��qi�ߢ�Q���
(���a�'4��!�O���Ƚ���\qł�k��o}}��Go�0o�w����s���[�*�2)� HY�!W� #�rHhT�j�rÿ-�~+6�o7.S�c�H£�Kt������D�@U��⫲p�Z0��-/)URJ�O\�YU0��0yy+P0wI�4�0�h��A>�Y��\l�)�*�T��,_�`���	��Lb�7��ӯ׼d�4�_�[�8j�Jdl���H�B"T��NSPM�
�
ʠ�K*�0�2�$�^;�u\���B,xi�K=P}��H=|��t߼C7�����7����<ጶ�g��2v����G�=p_�2~�|��^Tˇ���%�aT�I��If0�-:O}��'�M��.���
-ǵ5�w������������Ya�A
B)wZ(�:Q"�d�_�<{�]�>����Ž?��><�0����No�}��y�{�Fں��0��.< �����T;];V ��P�����N����&t���K�	��s@HA(�>�o
��Ѣ�'�ۅԿm�?v^ \�d95h�9�N��*h�蠐�Ot���D������Ǣ�ii�E����W,��*4��/�B5�Z�#}Ȭ���'�9�7��l����y��LX|��@m�A��L�mu�ǧIg��T��@�I�t(A��*Yb����
�wzW��ANN]%Q���;��G�7�,F��m�=|�ܙ=������oYu�5]�qݾ�����g�Qy���
0�B�g��GH%y}s*��C A����I�(�?6�b
����Ǽ҄uC\��
֞���������T�����8yp�7|��G������k����GF����@B�qIe�4"%�	-;E|$t�r�$BR]
��@`��]̻7l�
�"G%��ovMJ�&�A�o�__8D��xKq����Y�m!�����
�y|����q�c�R���T)ۊ���4HN(��CN�Bͻ`�&WN*�"� �����$288�N�"eF��U���SNdV31
����x�s���w���Q�F.��x�ā{�i�H�6mҤQ�)i� �}�ik<�V�;+d:�2](�:�u0�T:��OQͰ����'LG�	���"�Q���bҶ2�e��
U��ڄP�������*d�2��_��~�xѠ� �$���� ���e���34ѯ}�?"�}���'VI���+h�����g~;��������4:Ở~����x�����X�����q�i����l�Co����yT��ѻi�����؁~�9��O�1�����������-���ui�y��Ca9�#z��
�Z��]�z���nAoB����{G*�ekK�[d�ï*���.1g6�,\�|�J%�w).�Uz��J|3~-��ID��K�	<�A�⽾��}�>41~,J-�#r#�*
?0�G�B�c�hDy�!G�]C������@��"P�Kw�1DD#}o��jP����w
�l
�w��@��2�nd����P-�[�W�\h�z�ķ��B=p�2
<�{��8U�;V��
u�m��#�UA��ݯ�޽�&ˆ
�EN����ĭ�C�V�n�]|]�Lr�;��)�W�� v���˅FT|a��>����P��"�?h���0n���	�x�Ԥ���燈��pC�t�w����z�z���/�I�l�t�S�'�bM��;��P����"�K�'̌���9���9����p��o$�8W_�F����#�}�E�s��{�E^�~X���� ��3$j�Z(E�?	����,�'nCO��K�R����^A�S�N��D>
	� P��wW��P�"e�k�+w�@I|��Y~x-��Z�2��)�HS��7�D��u!��NDZ|�"���,��{//I��qӠ���R=
�(��H`?T�2���J�)���y���:_�	oĽ*�w�.�;E)S�Q.�$
/�DaC�q���g�iP�?�w'��K��2h�^|�KB"ue9�����pnT���NQ/��5�e%����ͺ�{ok/k�{�
ll���
�6.c8^�!T;�k�/! �!��K�ؔ�}�<
{g�{g$���|y��[[�ht��=�{Νs�������5�U�[�`��?��Y�y;*�Ҽ
�u`��`@+�/��ԅ�8���X
�����}[�Ybۋ�"��ރڻ�(D�C���K�q�$�5bӈ�u�P6)X���'�Quc����5��ߝ������}6�������7n0��	��jQ{Y��� � *A-ȁ�`8�"�I`�	Z�5`
X���`-�{�?���>K������緵��������v���][�F/M[�g�ݰ
��w�w?z�'���勤�
�m��޶
����A]�_�?���`���m`'��
����8x
G�	�x��^g�[�]�
��|
��%U�#/����t~���������%��r,���l���/�{������������u�gW��$�#ea�(�vفTn���X���U���䕭�
��f�)���������A��4�4��`&�)`h
W�y`XV���:�n����	v��rxO�g�/�1p<���
~�o�������9��#�ߔ���Ƶ��+c�������TH����GΣ���+������}e�g��+��=�~����G����6�?R<_��@u������ڊ���tV�
m�
�w�1����
��6�}��
�Q|������w�T軟8�c��?�O����C�!a�B#y��x���zi/�b�i�?!�"�Q�
}�
�5e//�۾�^�Yz?���;�7:y?����'�/|w�''�;zjzj��_�ʁ�����u�wP%���}?�8+x���\I~��b���A�Z҇��'�=��珟��5g��<;�={ޞ�,������1H�X�֪�W�j�;��A�l@�%Ϣ{DS�M���<˛'�Y;i�5���q��ɓ��]�'��La�P�Ƒ�oяA&
h#�J|�������O@b�[�g�����ޞ#�>�
W�Wx|�Yt�g�y��=�^hx_o���t},�*��ڀ��ft��"LF=%�
�S���3���2w���O�ox��`����ݻ �};�v��_�o�%�>o*E(�I^�0n�ޱ���WϹ��������>
���-���wl�{v���P��?*�ޛ/m���vZ���B�uT�/�3?�+��$��>��ѕ�Z-LU\q���W|I�C�K��\}w:7v��q?�h~��]_+�N��^i�d
�rBlg6[��'N��H�J$R䆆Ba��9�>����n
��X�5���}Y��w����_6@W5a�]KF��;��S�
Q��x�������7��7[.�z��۷~#����Cg9�u�얡�����4�7U���p�����k�'?�x����![�2�^6�o��oG�|{�Q����؄U�y�;�
��w2r�>�N�:_^�g��|}�v���V���5m��_�6~�_[ˏ�'j�]�/�q��[�}w������u����_�?�տ����"����`�AJBs
^�	d�Æ
�S��T���羭��a惱��žO��~� �����C{�(��ۿۆ.�}�v�$�my��
���}���wl6S�	F7a��ܾp�����ڗB��������^�L��:��uR�͞Ċ;�TQg�>yi�����~�y0��ۭ�7�Y;i��U�pm��j�PmH�ER��Lja	�����6��8��B��|Hv�b�Xp�u�sU݂���^����:�o���l�5��R3f5<���2���a7�zx�u�3C�����[>}N�����G�3���O�GY�*F
BWeGW�S�á�$���H� !���뜥�{�]6�>��eٞi��ͺ�̟:cî�[~�ؚ՛��?�W�g�[,�����H�d
).��3�u�ȟ�>1���y��Pg��������	����o��V���z��P���&4��~��_��OBOW��Kd���1��=8k٦�n;���1V�읿 6������-n��hg).}Jo;���J�/�l��J'̤3��u�������y�X<��?/=�a�Ķk�ީqgO^��-�o�׀W��m?=V�'dC@�0LX�z�q�����i
��J�1]L_b��7�j�a��F`?�"h3*a������P	�Z�5h��zN��i���M�;�I��{,^�P�e������t��^��� ��q�N9
����+�;�oȿ�K�3���_4�W&������+؎4c�وc�e�&�?��2JO#�i\�H4���V�T��P9�3_zeQ)PM�	�����+Oa���?�i<�����I�����
0\�2v�M��u6��X(��
�%+�u�L:S[��	:�nPIc��V��k��T8�E>��$�ϳ���e�ҹ�<��$���L�Dd�S0�䳜VF�X���\�9O�\������";���q�.�N��&F��4��F��`=��p�m��(����m�1=v+��]���mx����s^\�sX��-3D��n����XW�H	u���<�I1iQ�6ʧ�
�'E�ĺ*�3g��{��-��ON��2{��Ec)u���c�֌$�~~+}����\�d�-��`�m7�^����=MN~~��`jx&�{,���)tK?�a������8._s�'�u,]��m[*���'1
�eP�9P��F���*��-����"����ﱟ�R������*�:!`ݬ�M��ٔ1�z��0��D��&���f̏�pL0В��d�d��������t���ܤ����mq��PK�i��ߜg�n��c
(�k�[*����y�2�b�4��$4Yh�E��+�]��W垼it�U��kMC����'�nn���������Ҋxm�׃���7g
��y�s������nV?�}�����h��m|,����]H�	~��
ȃ��ޣI���Ͻ�iE�j3|��Hn�yu�D���Χ�TJ�w�M����V�獂����à��~�^4����<�[�R^
�$擝>�)�{�d��w/\x�]�F�_�Դ�����M#��Ѵ ��p�dn9�]�w�
%��h��vFE)��EWD)��}+�t��K�yM
�
��=윚譆��2F?�>I�(r%�����
s�@���<��
<�xuז"���7���K�(����%.'���A-'����j)�	������ԟ�����a��t\(�ܤ�/fnq���pj;�
���5��ښ`��9N�Z�^hvgAm5@Gb��}Uh�&��w���7.
Q�;LB��o�|ݗ�u�7�,W��j`݀;�5t������d�u$�:J�^����:އ���i!��F#
k
��a V�i���)߆@`I�F�$�F�z��@W�J����eT�B8���*ir�M	W(b�,�c�`>�{�]�V �ı�8G‰�%���d����?
���4`˯+b
�?/_���Q
�>i`��|�w����n�a�{@s���� ׄZ�_��"*�RY�YAI�|�͓����
д���	m˷�'��>�F��{�iGQ�L
�ʟoC�G8;��t欧.U�Ս�;TG�����
�y����T	j�2n����b��������'�P�WR�T{J<��*�N��b\��x�U�j���%Uҩ��{4�uTU��nΚ��J�T)sI�v���]�Le֕�JP��.�Ikt��.�˯M�t�̕Vj�n;0�_W�\�H��ģ�UJ]�JJ�.�b8K�d��-Sh��������35��Ƅ��L������"����#�v#8Ev�qص1������'2�,��B��\��D�-��gsd�#�"�#oD>�|�D���ᱷ��'�["���N1�W�F�����<k��g�r�N].¹�x��H�"n#���Zw.Ү�	GO$з��j�:��/N�"��:��osC�1A.O�g@�1�,^���u~*=��Y�-?�T���mA�-��Wh�
+
ɣ���
{��6���K{I/���z���VM4?a}�w�e�W��c���l��U�*��B�hl�g�O�J��	�j�81�gG+���%��`p����ߟs��`���篞�G�ވ��Č�_��2��Ĩ��O�;@��Z�!M���LU�����C��)����
�z���ae����)�C�`�E�����JqI.E��$�+ٙ$�I6�s��dkR��K0�Քd*5&My�T:��jY��h����´h�fB��D8L�t ��FT��L*
f�-qۢA�P�Px"�Hg��D��F�
�-P����?�������So}�A[�f	ZlE�$���V��/���"aL�\
W�nX��	�T]��`���|ݍq�ZV�d^҉eu����S� ��zI}��#�_
LQ��J�P�
�*C�`������3�*r��f[�jv��%%����,����Š'�O�9c#�sS�L�RW{�2J��b�Pዮ��FE���'NQ鉋�iY������"�;`��ex�_1��HZ��6��xo�q�iY9CX�>i�����:+��!�(\��Xo�D�����l����K�"�y�i�"�j}����k���ȴW��
4:T'��9�u�{�
a\h���y�nC���!��0�]߭�ʻ��1緃��	Ao��}n,���	|��ao��X�o���{��D6	Xqa�^Q**�����$��6�sF����JJ���9�z?�nƶD~l[��:pX"�8�����O1n��c$.B���#�Tp����8M�%#�φx5�Q*��d��m\�Z�&���;o��T,J�+q���qY�JL�^�h�?��G՚,�>O�@.n`��kvO��g>���.�+�H?^�s��'##�
������-v=��Y���
��6�1�\�^%
��
tg.�gP����e^gء�LX���d�@XS B�ݗo:�aM�w�mf�D�x	�92r�����
6�yOg��<��LΓ#P��h�����k���Sz:��]Ӎ|B�eE�\N�����W�� �p�ʉFb�f�v�s��𻑿�?�(vR�(4>�z�x�|�z�xY�
�7��K�c��:m��ٷ��F���^���sV3D3L;�i&$��Z��9]N�K�et:
�I����R�A8�E���
^$t(�r�/ڪ1�t*�I.���K��iT:��DN���,�5��7�:5���B;��re֭�k�w�b�t�Lb�[MX��U�fJ�xݬ�e<v�N��%,k�%��yI���9����uw�.v�byW}u�"C��\*C��}	����2x��o�7�P{�H�ԡ��i��>�a`F �+���R��W)Xg",%���I�Gnm��,�S,y`�T��,lK���:��:��c��2XKv������B�ɭ�����k��>���ck�}ĊՖ���!�;�!u�@ԏ�J[������Ղ�H�G�a��ǎ����DEE˜��U(�,��S�%�T� W�/��^>#�s�����D��ʡ��77(������������3�K���Z�ڻ�H�8�y�GΆ?(���<������/�?�fFYF9��͎f'-�*��l������+�N^�\�-)	=���ӓ��*N�dU*g���*���S���`��:r�2ȷȤB
?�H*�����~���a]��S��^��o��K�N�UgB��H&�8��ANӵ��%U#.�����}X�9 '��]��@�����BV'�U��W��j�����#�ыl�i��S"i��`��6bȻP����q���VIT.N����o�����,�4,R��Q3kh��w�E������7{.�n_Һ�><)cq��ꗉ�3k��s��w�tĢ����m%���e� �g���]��d�nq�{V|�s�k^�:�dJ����1���3�my�|\�ۤ-3�x<�z<��Q83�T��(�k�DR�1�������f��l��w@GY2��<��3z�>�G�8�|19��֜���>/�C��1�n��ҿ�^���J��8s��0G^�uA�a�n/&$�T�Y�¦F�)�f��? l;�Ü�f�~�^[�l�Z��"p)��ˇ���'���}��2u}�gV���'`������<$���#!���(Sp
�Շ�/vs��.K¬s�X�Os<���`���Z]�yt����ؚzbU�}�P��Y�U�����N\���Yw�X��R�4����谊�"���"?�(����":"@Hd�
������yol[�
�3������{T�Z.ky�0���b	�6b����ib�;&�Z�^�R�~������Â5+�[3:߂�D���Si�9������d���6E��n���R)���~�W?>��!�����4֛�ȓj8ゑ���1���q�"���+�����
�+�� �p����1�����b�H�؀�ź�ȱ2kM�d��N��T@F6p
��QJ%T*�H�0��"� �.r)����P�@�2[�d��0�VO(�B%�"	�Q���nY ��F}��L6ȇ����n���V{vS`�`�tnN�,([�"4wK1�pFU. �S�4��{�
.m��C��X5���,���x�f?R͂э�g�Jі�K��/��*�Dn_O�`�������Vz
􍡀X�/�e0L
��
'���S�`+%Y2Lܺd�h�΋?P�Vڗ��N$�wl���F�&����D����ӂ�9�����s�������?s�j�휶z��Q�q�q���/U5|G^�ɧH�*�Q�
Y�b����]~b����K?)W��J��ݐ���L7�VK�!<��)��%JZ*�{
(��k5J��EN�F��[ѩRJ�J��IJr�(��X�c61_2$�px=��U�j�W
�K���&�V�)�	9~*=�UTgO�o��}|�O�ZX_�oQ0�HԜ��"��9u�ͭ�	r� l��y,����!Ad�Q)Xl"8�Æ�3��D/Ř�[\v�PD|,���XO�T
�k
c?SF(ϯ�k��v����S���n�u�t��j���[��0�aW����&�o^����qMI��EV뷊hk�	d8*䮈
��,�
(*T.�6q�M1.Ķ�K!������y�0�!U�d0r�|�X��b��‹�B��$K�Dkr��|�`�E��wo<B��h��8n<��;�рk(��'�7a����K���#|�.��]V^�VVB;�K3[�5lM�fyͦ��	�oxe�/X��yK�@ᎇ4�։���$���*��q
ϰ2,`֡H�%
�wz�������IE��z?�n�w�h���œpe&e��ݖP���3Zd�l�[���k-K�q��\���'�_�?b���4�WJ'�·$�‡F���j� (̬���>���+�N��9��:.њ�ݞؔ8�8�������Ղ:�����#���ރc&���٫藒Z��<b51~|L�b]�]�.��K�
�%
(���g�&�)�x�8��u��t�#��9Ϝ/x7���u������5~	ǭ�����X�:B6������lt����aF�~}#\ϗ�WŃ1��dUJ��~�C�&8�)��ޮS�yu�)�*Y
I�A�ۉ;�㠜3R�Kq��!�+�n�|2����ĸ<�]� ��ڹ9�r��0��'r>i	�ŵy��Fx��*
�WQ�Q���x���|�t�a�o�����ɬ(k�1,�<�Qt)�t�J@ܟ/U�K�0g�#a�]j���?ʿ3�l �G�K�eB��O�� ?��̣�>U(�,�0����kC�H�ȭ@	\�\2`y�
�����ᑒ���"�֢Mm���ث�-�������噔�q�Gz��b��<Ƽ�'v��G��?R�vbO��l:�����.ϗ�\�������wCD�o����rr�XG]���������L��͆~��E�N�^D1F���'�o'"��u���S��UWCI��<�X�ϓO?Gq���(�U��U'���T'�2�tq�MS�c�'�f� ��L���/��)̻"Kv�\�����XO)A���10@�޹*�5�K���Sm���I%��xI�	�x��N>C�1���1��f ��kk,��ip��WK��E��I��v@ ��#*M/D�~�q��j��%�5��](�$}�+9
���r��~�w��PZ�ӽӻ5�߽�{��hZ:�5�=�=7�:��%y�����#��R��It����Q@i� �@:b�@�Թ��
W���[%	\n��.�k����Ub�x�Y�����u�*G���N�_�"�"1�O����#�(%�̘=f��P��G$Sw0Je6~�����zX���[�-�5rn��6Tց~��X�>l�@a�͘��B��Y��\]7�Z��-9�Mx����qT
�y=�I�K�U�"��-%R�4"�����	D5���$ս�?��V�#,U��A���Y_�r���S�F��N���X?�|`;{;�4~e%;ڬ����[��d��n�r/�SG�6bCԾs��5t��
�n�U5͡��:e*oZZ�xF��YC��T���C�҂��?S�&�6p�k8N���fj�f&�l�hYB-��^dN鞷�=�j5B7�D�A�!i����H�M��t��5��˕�F�)d�XRZ��#�$!$FC���=��3z<�D���6��)�*V�S�*�{��ω?��ɖn��xI&Y�M� XWLSBN0�u8Go8�oo������wa��w`J�鍿8��0���}��RX���`�1��H]������ 	���X�m�G��c$��t�6���LO��$��6��UP��.��9]u���Z�2`$iZ��ԫU��^%pl�V=��C����ԇ����
��z)E��uz�N��qSTIy����1���()!0˛��j�c�l�GvŶ�RjS���o93E#�TI�F� �5���W�s�Q��ɜu�[�y�� �$�Ļ�^��0�)3���n(�� h�}�ZAw��IÉ�Cp�[��o��L&��]l����Xw�
$���Jt�
����M�!������$OE��t?�Z<#S��"���BJ��},�̢~�u"ܐ��C�j���wS�̛����{W-���ʆe��G�U4N,��;>׹���K�9d��i��
3�Oؼd��[�����U%�����_��T���ׇՁa`<�p��H���8M*�leѲ�O��}�H�G��T�m&�X��Fw �:����J�
�ض|�
�7q��
;��s�.(��L�&oc��L���jRCϕ�;B�k
SCԼ;�5.�X�:�L���*�
c0`H�����G�`�7=�2V���^��Phℂ��Sz�G�)�D	Ck���3�����1��	>SY��V����T�h#�]9C�fB
e%�7����S۹)�������2���m����%�nX��7҃�¦tv�F����[؀�ۂδٳ�z�t��
�|��E�c��ٲd��[ʙ	�����ߎe>
�����p��á�󟎾�8J�%���&B)"&�=B6��,UZݡ
��˃;JK!�ˇe׹�Ǭ��n7��
^��SwM�)��TGN�):��f��p�9�N�tSF��;�59#Xҕ�h}���[+!0B���G�
�DK'�M�4#�(����`�Ð̅&���h*ʼ�bZ�Dl��	���<�z��[��vA�}2�BG��R?Q�I;���i$��/wC���ګF]�P��87:}>Y=u�|$�{V-]w�����G�p�^�\=*v��d�mr;�k&f&f�=�桃�N�j0��ˆ����V����u�S�ೢ|5�_'@%��sʭvk�Zc����c;Y��(w�Cx́��p�󂭕"{|�R�.���Qr�pr5%���4m�������M���2^��n�k�:N	|�:.j9W�'M�TZ)�e2�D~��5R%Sw0��@5���U�����X'>���`�K�g��Ȩ����d>���<���
�,Pq�^Ca��������_~>�W��>;�,TF����e�d�W/]ׯk'JLm�n'fX��i2r��'޼lH�#"9�8�r�G�C��À
�à��"|��{������$�>	��dwu�rô�tb8[��O`t��>���$��ھ�<&hw�݁����8���;~\���Q4��%;��#(��!Y)�r�*;�!K��J$2�`�@rn�2�
c�f�-<�ߒN
DT���J���}�9��d�n�"��9bҶ�
��^UM�X8����puo/�K���P�"��Hp���za}����&4 �
�j�Ti9�Pڞ0�
1� �.�vBK.'	��>OZ�� ��3
��/�%��Ljd��n���A���'B>�Z�T�@��2�k�O�P���\�/Eo�x����O�i7��

	�K�-�$�k�fw�
~��K�Le�*O�7ͻ���+�{l��'c�~����zM���V��.��e���N�CI+\J���{M&?�1��ǫ���n����7���G�&�[�s�$=��U*��c��&�����?��YtEd#���8�x]�d�.�Σ��	��������tػуwm�����Жl8F��<*"���4��d�q��s9�X`��Cy������7���Ob-�7����fĮ��sr�0Hm��>ם�����S?��(�b��0�+���	b�?_Q����,�b��^�,N¸@�ע�����5��a��J~�r�ɒG��p�(_���ƚn��W=����*��~N���|�3�[�0z� �,����s�����tr�[�=����c�S��t�q����]c\�Jh4L�&�q���
�6��2�׷�\JO���$�������I"�Z�R�o�ۿr�ܱ`�+F��@���wa�gKc�R�iE���zd���⏑
X���C�H�D�f�6�'w���>��X�Yw�>�+щ��F|�ѯ*E���� H9�v^P�.�|�?�)WW&��9�S.��'[�CPA�}����n�[��"{*����8�/��*���%��c�-�c�(2����1AZ�t��dp[D_�0��͆D�
��

�_�L�pt�]�*�����+w�����kycmiY���5:��Û�-A�;@��)M��ɸ��*֎HU�vT…�"����]�݊�>i��:>C6����.��b++=(�r�Q�w�±�+��@1{W
U�Ke�[\֐'�
	��:���я+�
�ō�X���4ź�I
R�5�ɨ�r�m6�,檊H\�X�f���kF��$��(9E�v�l�w�#9�
K�9E��e�Y\�*E>W=ΐ�'�f�e���)t�IX��Y�Bj�楗�Vz
�Y�D�/�c���������KĪk\
�p~��ى/�ɱF�n�ٶ!��pL�+W]���(M��zѳ������`������+���A�O����WZ�GgM�i�$��
q���L3�|�NJ�R�D�i��e����֫t.��ju+UF�RU��
K٠ǸyJWD���>/Py^��	�u�
m8�N�~�A%�TZ��<�8�Ɂ=�h���DK!�b��;��*�w�q��L��rY&�J9mj�olVl��¼ŭ���ҲP0X{���=��+��vҡXe3�Zjl5Q�������"�|�b�"�Z�z�f��{e�l�bCiqC�3i�(娑��΀�A�ަ�4P���DRr�`�M�&��)b{��T)�� ��ן`Fɏ.��
i�UHJ�����ܛǩcڣ��#�Cѷ5�G��u?w=�>�}(*Y�]'������i�J����Y�T�v�TRAW0�
v�v�N"gtHb+��1I�j��SE��y������~��`��[CgDC� �\�܄�;$�
Z� �+���(��E�-r�F�bh�������E���BѬ'�A_%�1M*٢`�X0,kS���`���d}�9BR�$r�q�\����]$<�ǞC��2G�,+w'c�E��D�g�����9�>ڒ�����5���"��ԑ��P!ů��b��%�ڴʨ���<XH�{�g� Y Q�����N�C���W1S	��]�z<t�{�tE�oT3��=k�t��V�o��\ys3
.�rڐQ�������,L�p���
϶�Dߤ��9x� /�MA�Rp9�L% ��X�Ɉ*h[�U�Zk��"����
�����5[��f��'%�fY�$���oQݒ�+�Ǹ׶��I�S�N�s꣦UJ&��@UbO+!U�L
S���a�k��dN'�
!D��v�!��qȎ����b�%�]�T�l�~*�U�)�J*sHI�l���X�?Nي��J���Z=��m�m�
)c���� ���������	�B���CZܻ�Ln┡ęԆ`(���y���A&O��Pa*
}bQA��%��he~�|O]?#�����!�|����݌��:�@&
0A�h*�y��-��|��ۿ>{�}��������j��>����>�
�Y���B\
�i��&��Ö_���������[�����8������#��{?#��(+�q�lzH��gDf�ƛjp'���2����lq��:�'˲Ѹ1�����H<�H�R����2�mLb$� �_At�P-�ӹ��䑨�-?avf�2Q������hg�t���ʣ�h�bm�
�~b�1�_���b$ן�TH��@�Bl�(�Q�� ��:	iy������^6����l,M�n�4��ڟ��]=���]��>�Tx�Z{V��I���24�1yR`,���D��h�#'�<���Db�̗Pbg�0(�%��6��Ii5�d)�Ôȉ�"*��Ī\��h	�&��  -��I�˓H�P�%)�6�������1�
I�� $rJ&L�%3�m������'G�cp�6#�y�
 ��o��oɹ�.��^����䷗����F@�Oد��k��~֎4	�qa�U����>r
�݉~?��
���PC���Bh�Ns�9�5��J��&�Q
%.��:�$�w�Z��b3f-�b��Uj��-NR�i4d2���Z�ʮ�%I5�g8�i��쏓p��CJ��$��׾Mm�Sd3�t�bK�Ŗo.~R`�.8��ܖ���?t�D�8��/�g)�
ɰ��ϕ�ь����*~�b��e�ezɥ=u����NF{J-�b�G�4�'�L�
-�ENYa���������h�!P�q��K���>+y$֙���O�?m���eڳ��ȵ�ޮ�b�\C/��5l�kޱ�
��&�k+��Xym���M�[��r��j�j�����'M�'�v�#Ԇ�ƒ����]���=�=㥽^yi�J�\
�8�P�27�I�#�짋�//M���L�gŠ
�
���6�����p�d>�j�I�'�X��!��Fb>E
"�X(nP���	UKd��+��Y"��j��r�������s?88�;b����t�?ϯ��W<f���O
|E6�|�V�rzc6��d80G[9�D[ �:����&�yMK�_�[$���6�oZHq�»�/�L�z->�鱫���5�������z̫�����A���İ��#���k/�G��;��)���Ǭ��b:?<�L����%�Ҡs�2~q!cW�ki�����UH������~b����e�k~Z�W��R���W͠���v��ZԵH.����ؠ�duـ7��T�f�F��L&�ۋ<N���G
�R�ѠO饌�kr3����-Y&'�(����}�M���¸C
&$��a���X�ŀUdT�9�u��z�,��A0���9EjK$�
�(F��:3rEO��M������)ꞯ��`I�.�Ϟ���?�F��A�y|3=:럺����d�g�I~}ٶ�l&��֑S�գ|�1��3�B�S��A'Q��G�0A	7t��Y�la��=����5?7��/h�r��3��hT(�&�R!W�
Fd�& WI�A�'ȳ@&p�2�.8�3�TJ�N/S��F%���h�
�y���-�X	�	�	���2;��+���
(=��Gu@��sZcV�����{�ʕL�'�O]�����)U�u@�\��S4�Ǧ�,�|�R�poRrb�>�Q���rt)U]$���GCSO;�:xou�K���O�^p�a:���yr�M�uAb��Ȁ,�u%(f��u��]�����Z,�bw�Zz����S�[(�����PSp�b�aF�b���
�򛫟�vV�?Wv,�A�I��%f��J����:��q���IW��|R0K��ùW U�lq��I0���`8^g�&�k9дka;^բO���t�[�4���LE�;3��1�ju��>_��&c����@J��\J#��nV�S�XEX�\�=L��1���7F��:�'��,r_c~�g}�,�N�L�!s3�9�o+Y�����a�N�X��.�
ܬ�Oi�趗�4uxQ�?���RQ�B�D����`6

!N:���%P7��݄��hΈs���`ٺ��}��M(�Zz몦����/ߛ�Kd��{���[��t�6�j�UC����{�f�~K�Y��-�����;�B���?����C�7R�����a@�b{j̆�%SCDpNݐm+�[4�/���H�~�<�8\�͢b�1��
Y��Ƙ	WD��ǨFG���3=���"c�dWk���S�fn��{����k���I��9P�������cP�	�2c&�7n&�Y�)g!���x,+,�C��9�n��ٍf�Tj2�eq��R��.��4''mEwJ�KJ_�ʥR	�6L�f�v�H�ԉ����$��m�rj�����I�l�)_@![�ѻD{OsZ�7=�Z�&ዖ��q�/z���V�7�I�1q���Q�hf\�呌�����:a�
�ob92�oGq��~�����*�3�
F���($���*1�5A0ҋل��ل;`�M�3��I
	��k���we���š��D>c�x~M
��].��_����)��y��|b�ބs�sή�G��	K��C�,�x	��0��ǫ������_����z�9�Y�=��񽗣��O�|��^��ID8I@mېlho��@���Z�A�o��gbb����H��w3�_�Z��K�,=�x�������o�Ni���1v�NYLfs�"�f3K�(ʢ����<����x��-�W�2t%ZO �V��V����h�R�Ĭ�6- ���,���sA&�$-d�B��S
@&Sf���(>	ǹ׺�$�����|�6��
�Ұ�/��b�#?���&���<'f���az���	�-yP(�����	n�Ѷ�����_�Y�lX�C�v�x
��**��<�a�
#��#������i����w�f�z�?������k�=0L��2�9e���a�?�4��K�97H᲻J\��)�O� du+vdn5
�*��Y�I�r&"�l�!ӗ��L��d8��*�f��G��Z�R�U�p��Y�Nk��������b�",�J�7e@��W`
M��
N���B �`Zz42���MF�$p��q�@�6%����Т�/����G��|}���.<��^�j���ϗ���þ��d�����5�Ϟ��V�A�U,����I�'�z3(p��ԝ�ǒdJ�n�ȋ4��<J���K
0�����t�hiE����V`�y�S�r��|�,
V<7é@f2L8n�[+��'̳�m"�R�Xu�H��y����b�ch<5��L�	$~	A#)7j��
/~/��J��zՌ�~���oO���u�����;��1撚䪎Ƈ����,_r5�9(i���Y�~�-��|φkf�ȁ�<b�S���Ss�'��p���ӃQ�	�iS��%Z�qd��J�0�tj��Yլm��p�d�z[c�U�������u�Z�X�����+��vJ;eO��x���o�;.FJe2�����>)P3ksm6��L��`�/)�}>�2��!�_a��J"N[��w�^���N�&��k.�m���v�F�l`�_��1��ow��m%6��b+Q��"����XD��B{���:���U������B�7�9I�zq+�,��A��������Zf؛�|�e��X#y��;�+m�?YU��
�;H<�z���B����z�����n�@�R�V���_w/y�04�D�l����VF٩��,�,�"�:�m���;�w�5?J=�y���Q�	ꗚc�W�W��j���i�1~c���Ԙ^f�f�>�# Q�M���25��F�N�&П3����)��6�کV-(�l#x
��Z�4�У+,������4�ԭ�$������m��|jO�i�ffM�0x�φ�;�͟�������p!\�u���^9�?ſ[��w�%��<�|��@Q�Y��"�?�����L��p��t<�<�{Y�����U���]E�8��fu�f>�����ӭ���<N�����rj}z���p1:���v9�Z4���n֭eA8�4y9��û}�x�K��9G���:����pr�ˈJѺ�]�1��F�f!	X������b6�lJ��
]:��3xz���� �
HY�B�r�_z�+����T/u*��8<�#�F�d�|
[\�HO���f�$K5^%_D_�]����|���z�(H���W���ϭ�-��M���^��x�r8IX�7PB�Tj(0��
��
�*;%�ҳ
Cp򾵶��ӽ7�W2�;y��{�̃`=��G������J3���c�F���+a�:�0�� {�2\%�\$#����a�{!�O�	���#��x

�&yH�Τ �[`FcH���%��D&�K�T�f��˜J�"��f�u��#$������O�†�6�ڋ����-����&`�h�M�H,����KВ��J!	�_1a(#�|�a�/��d}��P/����t�3Go!�d�{gܷf������G������rXQ
�D-t�G�1�{n��S�S�����[�8x�8@P��խ���T�H�P�P�Z5m0��Z֡D꫄$�ƀ1�T�T�C�.l�"լh=l��( �q��.�<�=� ��ᖓ����x>Tŏz���Ke��jll�
I�
�x?@�*f���Φ!s�6�B��V]���GM�����e���@�}�&P��Z�P˽e�P��E���7,�^�	/�t�K����٣
���}�U�e��us���#�w�`gfv&ȟ$�@>�0�gת��z��U�L�^�U-�7�H�U�a� �� 
�� ���T�P�k@Ft�A�ĤU(<����q����L���NH�C���[S��Kq��q�pMp|������ÃMK��n�`����v����т�����-8�d>���'kY���~~j�uDD�V��ĭ/8#�#&�sm��-���v�y�9�>�h]���/.�}���1�U�|���i��>���/�d������M�AYw�m,�i[��	���s���u
�PE�K�~��c5��KV���k[��(<�Y�|���H`�
W���
�`�*�2�&��>�A�aF)�Qh���)J�| V"3J���xQ�F�t�R����q(Q�aeP��$���hr
�np��K���ܣIi8M����ڷ_%�ī���^M$Z�
av�/��Q�aq̊����R*p���	,�>���X�j�Q����Z���M��_*[2�������Z���=m��N=���n����;g�
�>8q��W�F���B�^1�0W���db�hg��n�m
�w��=~2v*�B���V��)�*wINyZ'Q)
���7��x�5��4

 U�f�+�v�l����,9������u��:!�9AeE����L^S�����aad�ˑ8�$�<\J�g
Ѵ��<g��ڏ�j�ݲ����<���`�]S�E�X0�*T��/�f�C7���&���Q384A.�ڵ�K��
Q�\�B
�,g5���5Oj5�Ҟ�1ʕmh��t U���x� �K
R���rR�X�
���ǁF'�~�����`p0]&�^#�x5�;zB�ɚXx��:rM�a
ᙘ4�����n����a����"/�<I4&�pO�GW����?��Lfw�>ݱ�56}��$0����w&1nk�x��~s���NŨ��/�Æ��[��o[7��	�+m,����Иs�la�7nW�z? T@��da;���6�T�G駪'k����ի��ioQo��ܣ�Ss��Pwj:���#������P�P�g0�M5��V�7x}~I�Af�
+4ZFcw8,a�$��aX�Z���{�`�:�h���R�ڎ-��J�w�v�p�������~�jw�U�'1�6�I	��)�n늺4�ͅ;D�?a���8�%2���.��%J�6����?l�ms���D"G���MT��M~�,{x)���u�3��_v�a���01�!۲y�tN�\��j�N~$�@�X
۸����bR��:�ʢM9,	:���$�i��Q�(���)�)mն2ӌ�,�@����^�N=LRJ��x-�I��E���K�&�Hm\�R����z��h��	w��b"Π�/M�&
�UB2ΈD���T����^��!�M�*Ͻ��m�3˙�̙�3���ْ���$,!���@B@AUDD�]D
E�5��"�ڪ�bk��˽vQ+m�5�����%��}�̄������s�̐IB��Y~��{
�T�de�3�E���Ng���B���,l?	Dr'����ɳ$A�V��?5m�jŭ$g�H�XNu��֡�}<��4>�="������9*��'��:������,���Dz2��'��34�����:���N'�����K�ŨG�T���<j���K.)��#U�9���~9�]��WT�зr���v�S-��Ot�흩
w���M�o���k*������Tr����W���{�=��m�����.\
3�r��o^�]	��W.�O��
h�ԳS���~O���j|�W�E,	o���b5�o��66�2�5û0v��x��gy��|�u�q:i���K)t2��J��逹S
���'����C��S�v;ǂH�H�Q���0�a�w�T$w��0�KKX�#t�i��a�r��G�e�2�jPИ��2���~-74��B�DeP����cU95D��Y���4fk��ğ�����&�s3���|�����}�90P��w~�o�w탫��5b[NY�tt��_M�<�����<u�>���-�*���G�>r��ʔ����y�bvt�~�f�
8�lrf8pAvtz1;���0��E�Q�������.
����O�?�Sh��*��Z�b���/��f�et#ghg�a�HjL��0��;�fh���EnOwxMxK���A�������_,M��Vd�)��:�����wGY�w���.�5h�Ɣ@�B���<��o�=MsT�
�I�����ݚ]��1�v*W�Kl��=���g��ڞ�#�A�!�U�A�zm���N��<@>��\7�e[C^����ʸ��x,1R�T�=�ҭ)�
���^�i2��P,,����4Y
d��!M�ep�ƷK�"�b�u ������q���X,�܀�Y�V���T+p�H�ᯐAlKF4��'R)�OT<����b�H<�n՝���Č���l>llkX��eKm�}}è3��Y�M����Wjth���t��H�4ʹ�RTc��r.;'�Ly��N��K1Vlz���˫{�2U�K�dĘ��b�H���񛟘��g���_��k�m��ܲtс��A��w4׶W
׬�w\Rm�[�2��7ݲ��]~�
<vϊ��6~xgh6*[_!~�[=����v��b%9\\f�p9-���u��ӎ�ROSWb~�>�����*���
��j�V���l��T����͙	�2�
@�0
u�8�vT6s8X�$ާ�
��d�f��
V��,�.���}��)y��H[�Ca/1_�=�aL"̫����S�ýh(�����?��}�~i.���0/��+<���;#`Ϸ�\_ɥ����xך�
/�?j�h��F
_�o?
O�J47������X�!M���h�����%��.��GR����=����&�*0Y�<�RuwlM~K~m����|�?�����,4-4w�WD�a�����dͱ���J&I�Q/�"��a�+٬(���ɤ�h2�&�*GQ	8L,���0�SqD�K�bN��)u6�o�Me5N�X�&#�
��j������}��>��?
�l��1�	K�z�I�a��3r��"�"�F[�J� ���3w1,�)v�`�Im��V�T���,��D�Y�j���G_6��!����z&z�g�*V�<�[�2/R���xE�
��e�~Zͬ�\u�s���w᭑'��&��S����bbr�M�4�i������y㇋�٘@e�i��N�����ěv��kά-�~����$#{<t�߃��ѽqw�Yx���0�o���X8#=#5�m|�t����;�7�ožW-�o��E�i�~��	��mq[%c�i!1Ǵ0��z�ޢ��)7Mk**��� �p�|NV�\Ze�}P��$��?��*X��
��rN�+1������5�8QD�E>KU�bV�y)�H���
��;`0T�h�F��ތ9�u���Ĉ���a)X.��K���~X&����O�?��aD���T<���4:�3�;?����e��0b^����%��p�;?����%���V[u�ĝ.q�/��?5�yߩ��nx�XP]��z���������.����֕�����$�8�-��ΛB�#���C�ܠ^7B׶��WwĶ4����5#�4�ګ�J_�ƒ�K�"���g�����]�iPustn0H�:Z�����
^(t/H�� �;����Jw�jN�������߈���7�_�1��Jp��ƅ�7�4�����~(����-p[�>�Q��yz~hy���6��V���B���[\Lq�C��l0���KL�E1}��6`�le�Qp6[,��N����"JP�i:�Z�ĪHZdI�2��gq�(���V�`
��hĮ�d=XZ�;��va4�$iV���2&��lu����;�A�;�=.���
qP$��>T�9�jt�� ��C��|���7�S=��,���Ꮂ\A����{���-uTʜ��$�bLnUiC�EF��YZ���|��m�{���������T�e��j�m��c��
����񮨌1�m92��
�&^S���PH��o�����
{g桙�C�/&^2u�B��w�"ަ�8ѫ�4�E�Z�4i�؇g?�+�0V���^koW;B���C�!ߑ��_��.���A���{}
���S�MWNKS�{k8k�Z���@����
Tu�M�ڝ����3�CpJP`rBe.�qYk��L�Z����Vt�6k��Fz��d���,�*n�b
t�$^p:��qqYP��|�t҄�5��pj��a��lj����'p�0؈�\m1�!�Ik$b�x�'Q	��X����>��A�L$`�Ί#P�X�
��R7��y�p�Ab��d?�3��v�\��(�^���:0�LO����������C/���zc�sq�?�����W�?
�NV�`��L���B�+�׬��2>�ll��9�he�ߘ'�ԑM�b�y��)�����m|d!_�M�M#�7^_;1:q��]�u�Ϡ��n�g�.��7C�R
ޔ:��2���������c	JY	�P%dsrT.�@�H�D!%�,_-`NAp�3�`$���͹\^�I%��jKb�8<�L��>e����|�
��k�>⎈h��3'��b��c�c`�Oay��劾.}]���r%_�+�����r��㹓�r�stN^S�b���j�xYL9�\����˕^���re��C/Wrx9��r%��+9��E����*6�\|��rx��,6>>�m��<��W��w>��(�:�\������fAm.�+�m��w/�}⭸T���W/ȼz�)�[v�m��}·��ӣ��j���Xp��3�Ά�vܺ��Z(�w�}�.N�_=g�`�� ����?��3��P
�X�/�ܢ�O��n�0h<�������Kt[�4e�T��31�G-C+��0
'�0���b�=>��,�0���q�R#���K��%�����Մ<ւ#�:�i���g!��򒈲@�y!�nHx�ُ�f�#V�;�_�;�$w|I�xY��A�8���?��<���8�X|\=�
	���/���/	_6�,l<6�$l<6�$l|I����+D�P�����b|8^*�ȉ�:9Гѿ�\[G�!��7
�������a�`c�q"��đ˃Le����_��!]5+����t	
%��{�����:�	�A��G+�AD�61���)a���ʱ5z�bk(;���ԿC��B'�C�����l���{}]�~{����PS4�D͑H�ja�:J�k����A�RF���ͅE})�8�<��"��a�D��A��Gjz�0�8�9�#
�Ȋ�8(U�m_�.+eC�܇�^���N6�J�+J
�Y�jTW�+ǒzNw�WPTaSe�%8�.7����i/���������/)ԭڻ=ܸn�ko�w�y��!xtˬI@	�������]�t����W{��^Я���+<���P�i�$�ΟԂ^c�)ަ���wҍ�Q��T,�Nf�D��_��s��1f!��i{�=�=�WZ�pC�!ݐYHPnљSmѶ4e�9��3�NQ����>7�`�&J�~K|w�&����m��b�VE��v��M3�R*�ʧ
���2�5�:^�w��؂@���fЌ5��m�W��1�U�'�z%�'�j�k���i��y����5��<mZk8w���3�|�U��̘��5��6��)��
���8b޼ޮ�^"%��55�-J��'4��Ѩ��}�2��^ۍwwo�
��mk�6
�ׯ�����s�+KR/WR�De]j�(6$!�@B�.��E��E[�Ʌ�/��Ǝ��Y&�D�P4�L�P_|jt~y4t��C��Qb��	*Z�l�����e�tP�u)Uً��Xs�@g��E�s��WM����Ҍ���+�J���͸g�u��IS�h
�:�\���f�rUG��ٝ�[H~�T_��,�X�TD-�L�߸�����5��@����@0ع��{ҭw={ݔ�d]�=�hh�e���~������U�B�T�4&O����|l��uNRT��t�9���&����u�{�U)gg?$NSWB��5)��ƭ۝{��O��I�k�뜷���!8b������=��)�BfȠ��m���������0�I�ٷ�U^����z�`@^�`%��G�,�I(�d��\�+P�#�bQ>��cQK�iOIx�wl2�-�GY�ݿ�YԪl�
��m_P�Yo�x��ͅ����E��z�����=����m!	py�<�����/>P8�6˾
��\tO���/���w1��-w
��~:dr
K��
��{�{�!��"��/pvŻ��B���`uMsRQgH�ak���4����gyg���c��p

��NY
���Aqš����p���˕B-0X4%`���r8����N�@S��B������s�B�1�~A���(Q_��
���� h�8�m8�_��Q��k�
�����*���ݺCįV������b榘VG�@�s�r_��r{q�Kv�%�ڒc��m�4�ʹ�Q�p�ڇ���u�����8�G=�Gf��ʏ���4#�iV��/�.����w�#�q"T�~��ﶆg��_&�3�jU&�n$\���bHU��,�����C9�ܟۛ{9t(zt�+��]�']��6w{��	�d[C��ɹ� �1Y:�墡h�n�@V�愌3�r�D8.$`�V�C.�cK(β�&3)!);3�x��64�P8��d͙L��\֜s:rYG.�o0���
�cn!�O�^��\ΚH&�k�>����ͻL��C0�ޅ(�`��İpH2I�ϴD���z~��fTIB���%��(��P��K�^_������˒^?X��d�����zY�[T���Է|���#I�/Kz=�����ח$��,��H��K�^%��$��%I��BI�@�
��H��z1�G	���B��\<�@�k�@:�?���)�̘�b8��_ӎr�!6O�5\�/)(�д#�W)V��>����K���1,���(�S-�&&<dW�
�
'����RoC��4�]T8�	Ἐ�U���*04��
\�D�1J]5�暚Ze*�y�]o��	h�+��H$�4�Z��1R���p5�EP6�ɲ�9n:~mۿ��Y�V��B����.�(�y@*4I��1	�ш�
ZVu��|�hy���sg��0�#�v{]���&zw]��<���LYx���u�
���#hgJ����B7�p� ���Kӧ%bS��7���>�aUၥ�2�s�\��������6bn��*,�
���a�����`��ʽ��E��]�F���б�N��(an �u�E�F�tz�G%Ϊ2Q�n������sQ}�l?���v���
>��j'�X���@��hdaOn��|�HQ
�O�y�U������-�h-k|o&��_���Υ��Ԏ�]s�������Ϭ]��:�i�z���b)J�4=z��ęT0H��'N���W?��9Z}M�QbUw*J]���<������Iz��)����6v��!삉d��\0���iw/�����9�4Gd�v��:������̽H��*&�(��fW���
ԀW�����	^�7h�T��"�Å̘Î�Z��͈{H�Zk�������-�2�
W�z�q�ш.!��"a9y����R���E��/H�^�@�"i�2!��g��`ӗe[	l��y���02H��ґdГ�%�
tg��W��9�.�_".�~Eq=�%���/�+;(�|5t,2?�xI�����㓣dա�U17�r�<ƣ����һ�U�rS��ѐ�X�j��w@�
4�����t$��v�q��$Q�f-�#�E���l	H�.7и,n�.�8�
#��X��\@f{���y��o �c�V`��7o���0�WRbIb��l�\�Ւ��-�V+���V�]%)�*qL�VJʵ��q�I�£\��_�ʝv`�p��ZYx�C�&qc5G�M�ƣ�,8�>���������Cұ�6n�����ٺ^�uT1,%����,��x�P��1 o��XT��4��y��ρ�pu�m�<�ȟt+���Nn>
V�B��U(�T<T���O~ڈ���<�aaȐ��# MA�W?�{*ݱ ��wh��]`Q����ѫ_r��na5�U��Ai�ʤ�U��}�̋��}�)�S�UT�5�T\��m��?�}�%�	}D��Q.?�/��eZ
�TڜJ�}~o<�aR�9+m�:���d*��w��^�W��[1��+��� �2�ȧ�^,M4Bp�*����8L��a�S28L
���N�>H�N�)V�X.ű�
u�9p8.��B�0UƆ)�
S%l�*a�T�6L��a
b�T	�J�0u��uϘ��P�zΌ��x������Ȳ�y���\��"����(�󃩸N�b^��i���Z�Q������+z�?ڞ�4�X���r��v��d�,(h��9�8�p�f��[�R��������,��VJ��������z �	C?�h��r�[VZ�w0)�!��
�6G������N]币��������8�8xA�&��7S"n`
F6)���h�7�6��V�n�%�����X������`�Ǎ#d�P��`�e��6�f#I6y�h�T��P�����L���(����J����b�&��6[B�b�Z1��9�Ծ��S����q��6r��*�g�#���qN�+7X�qp�ii����LC���@�%�}��%~�~@=�撮���>��7nn\�ƭ�+�zl=��U�T-����aE�����w��lxt�7����q�Ofg��6-���0L�x��`����)�$5�#���ĵM�ʣ�A�hd0�Q�au=!6���h1
n�9��O���S)U��$*#�
��*Q;A�ꈃx(&�;��0���eb���٬�8��;�.����mO�D��'z=
㯬R&�q裠U���:E�_7)�tkس:���H~��=~�O�%�$����s:����j&�-,� ⇞>Td�w#%-�o粩�7��,� {j�X0�3X��b�:^���R��V��U�U�be�1��6�WU�\�H�׷ͩ��w~ȴv�jY����㟺�5�
s�����g��J�œ����;Q�bq���愽2����$:!�l����7��{�����-yhD���M��!��3�0�$��Z��i`���'Y'�&ULJOo�4O?/8�v٤�LG�/E��_j�3
���<ӥ�8Lj-�M�!<3i����o�P[-L`}����hp�j|+
�֎*e(8��Jd"Q[_��fQ�#�]0���ht�� �d"�Y��Z'TU��^
��G�FB����(�a$�ľ�~�N��$V�H�
�rπ��9�C��2�A"���!3��Şϑ�`�Ģ���."c����P�98����Ũ�}�W�f�X�"�n�&/��9ye�T<`m��˄�6O/Q���pɍ���Cl�CI�cA�mi�R2L�ԺZm�����"�J��u�-����]����^u��ÎУ���vE���d�A?t�Y�Tj��o��PD�c=��w+��i&$~�ǼŌ��z�>=����:�������t�.�մ�7����b�9������9���z-�ɶَOڔ�����'�����ٜ+��Ϗ+�����w�Ń��?��-�������r���1ߦ�������.�ɰ��:��<I`�1���.̳u{�U]�������>�}Ux�V��v>?�Bȇ��B(���\2+�к_T-����z�`�P]�J$͉D���K���c6��a�|��\�b���H2
Ϻzs�0n>�O�D��
P�}�b�\W�u:��t%\�+�:]	��d\��ם�}�;��ur3b�*
�9�9mF�!L�+c:�t��ӕ0����t��J�N1����t%L���C9q,��såfđ/����{r\q�ӎ8Fz��8�pN�Vw�N˭�L��	�r�a�\�X��ZƲjg?uK�$��n"UnB<#�l����mGB��rvQ��in�w'����c�Q�b�0W1Ƕ�{�����_T�.���pA���
#Qz��9
���/�p�^����5#�%���@����7��oe|\g?�|ԕ�����H�I�n~��_�K'�Q�BU����v������Q6G�t8�+ўɠb�$�ٮ$,��*;����}ٍ�r�Rn�b���hdl�;^!�1���/�|yT��l��ml`�
���I`$��98,�~.�H\�N��w��nj'4ԕ:)��'`c��0��I�piD��U^D�����y�	���W�X~Z8����u�S��-P�)8��=ś�
��'>
7����񿴥���ʯ����������ᛱ��q�C��<�Vސ���d6��H��Z���.Üļ�����ª%�eɥ�5٫��&7fw
w��Iܟ���W�z�?�H�"�r�V�+q�����J�T=��v/���WaQe��TJ�2��M '8
i�KE+��������Iӗ�}��}G�	Wc)h���ʜ��QC9�و���m��MP����CۆO��ay�%���ϩ�6:�-�C�??��|��E��ϱ���?�*℩��U������̭UW�����?�P�᧟��h��������[
��=�x�[�B�n7~��g��A�]���T�oB��1��ܩi엒OJG��<�<KGt�n��?U�!,�S�#�+�� ڥv�����G���}J�`1
��!8�Ë�����l���!3�4P`d6��7`��-�2�3��7	y�8�4�ֺ��弙"�k
�Gc㺙�˺.�8ͦb��r�<�Z\�PX�[�́܅�;`0
F�V�##�
?R�57���-}O��_��UK��&��G�[��)��YJ�����d`SU��Ȋ ��z;���SW��4�/{bĶ+&z����U�e�o>x�:�������Ќ�ϰig?&��̉E��R�@��V�#�~U���Yf_p �
�Y�Z�ީܩک�+@��`��Wի�eh�Z�,nк(���M��� �L4
l�ת����E7�Hs*Ќ��ֱ�
�qODC諴z��^=p���^����'b�����a;?����h������u��t ���P��b�qTx������CD!�_z��k��vc��j����_�~��xqAeᑽgV�<��<jG�ڀR��������v��u�[������p��V]
�����
�i�
�c�`OJ�*�!�:��Qw���W��W�L�!�QߧٯzRs��*vH{��"�N���g�3
;�16���m����4�ڕ��
 ���c� LG�Ɯ�<����T�JЯ��A4b��r7�̌S���"�$d�,6x��r�D�G�.��/��n���������F���?��w�z�oX�<������}��S�7WzlO�W{}�-������[��TL�T��]R\�7����]E��^N�����^���Ni��63�Q@�`�h0@����4IC��A��s�3�,�s�	�� r�bON���i�Wg�A�i04�
�F��+5	�%����˃������o�c��{e��mO:����;V��gl���{E{���7U�t�b������6];��	��D��u���)7ȃ��l���J���c\l�� )Z��l���Rت����*�����C���i��\K�"H��������~�q5���D{=K�~�zzFF�GUY1[�}x�N�}p��`/<��;�
������=]2��QW��
����^a�����m��ªB�w���������d�1U�ԟ=����������}ml'�sb?���x�y�2�3��?VCΊ͉/�]O(�'<
��0��a�c+��gD�oO#�@4:%�tfCa�MnwݪZD���)�-�n�� �/�����#9��|
�l����xkkh�����>&�k�'��T8���n��2�
lni�8��(�}�{�KS]��@Q]l9s��v,�Ttb�X�o�򄎡�5%sR�[�TZ��Ub��x�a'uU���O�4��G��S�$"O,��&��0����+f���~���w�v���fN=һ�1����������v�ÿ�t7{?�WX�u�,n�7�p�xCma�s�6?���Kw�5����~�;��)awx�=V�\��)��{�4����~����6(yo��l�OK��^��&�c�;�*4ϝ^��h�4
�k;ad��t5�IB'~S��{{��׫6�j����X��#-��C,ʖd��%5.���תw�Ԕ���h�Q�4�+O�`�V�r�LO�pqW�H�3b�1��T1NA�գVNQU~���OԹ��^uo��K_��>�-�}�_�Zmb>�>�HO��Uy����w�W[n�8���ؽt�e �bquۛ%���eMY �W����rh&�Sҍ��K�}ާm�8�*{}:S?�o��HӬ=����t�>��0�յ�&�f䩳���'��0��:�������Ѱ���������O�l�������k�S����W�������ղ��h1��-���ܳ����v�}�};��1Ԁ��7��)<���GN�N��PSEM�;7�B�b��6�Ln�$��3Ɋ�s�~'�4E�ICڪB\�8�4�
����8M��w�KL���rLz�#5Ux$��H�
���������P��x^��CA)�{�!�
��=��.?�-��D^~�x$�I���T!�������o_�d�0|H��o`d������(�yX~��bc���I��*�4�%�Dʎؼl�]
�'z�F���$?R����b���ȓVY�x�8�Q�.��XYUE</^��KnL��I{hZ����a+�t��ٓ����w���Wh�{��A1�8,�~g~�J-/���+#�}�)#_�-���~5�Ks��P����l����^x�l&�~�MfT�@��f�IW��k�=��l3�3���G�����������̫_�]ﻃ��W��{ԦP�3�4��?` L�Wyh�qn7�s� ��~���82���p3x���������W0,�t$�Z8�����x��3MB���xg����K�*��$(��A0�0Ë��_E��s`���2�ϼ>,���EN�S0�ښ�J4_evE�U̡�&D0J����[��ݹhK�rZ��rFGh��x����
�g�+27���i�u�6�Іo��9�����t�8;@_=�*�ǟj�+���>
m�D���愲V1y}|�g�g�ޯ�5`��m���C���8��Ǟ�C�e��"�|�U�a���Vx�q7h�;c4펮�~Vf��0̩"����X�Ȇ�,�X1
�l/��%X'�96+O�}�6�sE����d�)o=�����C�[gp(�Qqy����
�ũ���8��T\~QnhB,4��oX���7k����}������/
{\^��5���D�ȥ3x_u�u���w����m�
���I:W����B��)�5!
�I���Y�d[o����޳���?E|b�����g�OJf%�&�����F�-��H6�&{8ZL�Y�."�MV�q�bd�	E����f'V�����L�K�R�
.#�Y1^ѧx�M�a'9� �;��� H�;g3s��(��m��M&K���sBah��Z
�r�^�!C�t^�!ԉOk����aa��m���C�d�b
�X�`�	D
L\�3�����Ů���T�W��r��xˣK稱�+nG��n�-�vs&�]YU�d�'.�b�m�\,�}� �{��grs<���!Y}��E�D�3j����k�W��G���G��k<���7/���g~I4����t���mřPJ�^��[����R�An���p�¤t��ˁ����N�4���"���R�6Q�%�qn��l��I"�	��:����h�v��ɇ�ۅR�62\[����tJ���&O�2�m�݀�c:n�1��@���r{�m�
���q&O1Y%��?�P��b��_�dG6z!���Ԙ��X�C
B�K�*�*���>d���ܘ�a����t�A.p-�Z��	֚��׿if���w�߲6�<�B�>2���o1��'u�k��=�f�T`�C��a��9��,���Uh%�]~=+���z����cj���C~���d�6�u��g���J]#�8V�Ao'��	���}ǯ�a�U�S��hz#t%YE�9*Q{j���?/�S;���<ZA��lɯ��"��z�kV��Hd�4�f�D�q!XSQC*\����n/E�ĴV�Ã�I�v��%�7�Li����-�N�?��x�E�i@���d&��S$ޤ�U�Q��øS�U8�#!V����~'O�����x��D�XwL	�}fJRY�����p�n��K�A��vX�/7���B�����ҿ�-*.~�#f�^�N�/��LP!�"("E�����d�Β�=wz�<�
r�WWn]����7�
�puK��0��94g�ƍ��ڷo�_ml*����oi�����;����)U�|��S;�i˾�6]S�V�5���A��f�b��ׁ�
����_X8�y�d�׮*ly�g!^w�(5�B��E��Eri]a
���t��,}dZ��o���
?��,��=Y�m���"H��"��Ӕ�V�#@f���_�F֣�孴Տh��-K赴B��2X��#���Y�������p�a�la��n��a��r�p����n*l���2�`7�3�a�0�J����L�Be�L/��;�!6� 6� 6�N�R;�~���V���=��12E|͔�5S��L	_3�����
�`�6�Q��_������f�����5�a��r��})��!��Yc�T8��xP6I_�s� �B��b��O���ؠ��PW�g�,�`r��6K�e��T[�P�10W���2<]�ެ�5]��Y�i����.�L
��jA�7J�(}�R
�	k�]D�ط0��X�\�Ya\�ۈ_O\���߆o�?�?�7�켍�j�65�:j
��bc�m �P�P�p:qKd�14J����0�RN�=���>�&ܶhDmc��N�Q+�;��-���
�(���E˽�a;WjS-��#/� O��A��Afx��S�l?�c)u���]�4���\
����K���ﰶ�J�W���n�q�&��6�|��³S-s;��#Sk���̿�_����M���U|%a	z���6����m��Q
�1-��3�l�F�>��ȯi|Jw0H����̍�M̭�[ueT�6ƣ��X��ό*QG~
}}�N�cZCk�ڨ&m�Vp(�ћ����р��
�#�(��������(U�qچ�9�RT�0��4�deB�L�~���V��h�+q�ȐR���3V#����lh�A��|��D�{)G���s�Z#K0��ÿy@fE@θ[R��9�1J��B0Zh�BO����z�P�4�Ch�Lp�P�S��"kQQK�C
��4��P��"�uQ0Ө�+�).����g^V������ل��{l�w��y�5�t�4Ox�M�]}rE��cV�4���ϻ��)�����M��o�����p�RO�"�G�ϲg�
��k#k���s��.J�5��t�ۥ�W�^����Sс&j���S�Ϛ?{e��Z\TY?�;�yz��9�k�fe���]k���R{[�w �d���~�~�c��M�J�4��"�W���☤>��**g��okSs���{g�#�C�Ʌ,��Y�d��q�T[��=o��=������M�8r�$��s2������Ff�'�2IV�ɲ�#V��(<]�k�,<���u�t�C͗��u���zC;C�!"�*	�N�Nr�B�I�J.':E�)I�X�~N��/� ��vq���G���/��U�+�¥i�X,�J�v�q5	������$o��7�݂���ȸO��3Ƹ[��#I���-|F�(5�fV���O�	Zc�5YM���.��]�����
~��*q�9�`.S����<˕�
w�Y�'�,�'�V${i��ZIg@�X,���~׳�	�`
��g���n�V7p#�gS���Zŀ�diŠ⤂T�����~�������9��̣�X4�
�,����E
9��ދ�#�ΕE<P�!q��a�_��d���|Δ�\yj;x��]�,�Y���}w����dR<���|�s�eO�}�������ܽ0q)x8�:pl}�ҷ�4O���e�C�P�9̏Ձ%Ҍ���NB���B*��Bu�j��Y�̀�U���=���ۜobxH��
�'��;[a�f+8skY3�$�,t0.��R�f�kVվYW@�$�e���h��B�J�\
%�bs���C5[kAmmց�oՉ���
���$��,�r�g�#YV�Z����^�}����aѱ����6Z!ؐ�%�Q,��NS$��n���`̙��.�a=��LJ�r9�T���'�ꊁ>��44���J���<aD��y�E�(�a�?�2�pc5��zx���k�m� ��Z9��q�Sm��1k�o�4X%P�{p�2t��K@gқa�K��o�䭛�����-�FYz(DSI&���H�CNr��.��5�׸
�ێ�:�4���B�l���m�7�V�%`�(�͇囧�}��_t�����D��C�֋n/Mu�k\K
P��q�$���v�5�.I��_{@{VKj��6pN��Ʃ[�t2��El�����[��'�|����փ=%��oxNq��㈓�����)�A3���lsͷ�H�U����t����e��UZF8s@��(�4�x'�Q�A�5'Ԩ�`��N���A�Y��뀕�B��U��b��T�`�i�i�Sc:��)�\�����Q:	|}�%���j����
M���;u�k��_�f�?�����`6���C`�0���?*<��OwJYZ��$�X{[j�A�!�
b��������px�C��y�?�š��u؝٢l�N��� ��p�Yց9:�ޮr�I(���C�n�]DI��a
j˺
&��`�t>x&C�l��>@��.��}�G�"�FG��t9�9g$�iP�>mMmq)g@e w���?f�P��=�8�
&<q۾����x�2�����)���\G,{ꞿ������+��p��
��0ai�
#l����B�W�W�yg��y?{��
�$}X̔V~�-��:�
�ʣ�W�o*Ox楷Znv�Q>���y�K/q���uު��LM�t�;�K̗X����3Hf�Iٽ1���93�jA�է�f�d�ds����z�. q���h�B�� �S(�"FA��T3V�*Nmw:�f��l�b���f�uh�ѐB�c�w�W�5�J���u��-�~�1�D�V��t�H@�Z���h�U%	9�O�p;�����:N�,�y�ć�u���/>�9r���Dʫ��G�
uåzȹ�hF�[\d���,Oe���d*�,�Ć﫜�+�ޛH������g�첮#���~lyE��[N9�m#�W빓�y�%�*b�����>�y�X�@�\��g֮R��7d���E��
2�;Nࢱej>�ۜ�lK�0���ځ��R�j3ؤ����|"�P��=ԭ#1�$)��p:l'6瑊0vI����
�x�VxW�v��
,�3'��匹E��rj�c5�����
���,k���4/�<�w�TH���,�������X���A�0�O����UA�C�S�b��=�s��W�V
åT-R;��s��^��ѕ��{������͖�K{
0*�F��>L��UnTq��^?��
-�C�'��'~Иz�l�n�&z&@m$Ȏ��{���~��Ub�M
�9��K.�ζ���Z���1��Hm�xʅ�Q2o6o7�e&��^�36���i�Z�u�y�ђ�jXmZCRT�l�h���W�
PM%�����6����`/�X�5E���Hj��Xw�Ȳ<�S��'8��m�8��\2�����,1����Un���Q��#7��}~�\�Z9�Y���@Gv

uώ�u��o"�%@Km�EfB�����}�\�n]���l�m��P������>�9rt���]fHm^^Yd�
}�3H�+�<�{Y�_�l���(�)��e�U�;N2
�MZ��U��Iˈ��8`��壭�@���/�ru/�0v�MO�`
x�u�r��W�v�]��I��e�/��K�b�:�E{�?G�ܧJ��S�����g��[�s�t}Ԓ`�8�KX

��
C��}�}���������x�N]pf��mZ���lK�e���v`�o��&�������gϞ>�1�9�;+�"�S��n���/�(<U���S��3df���[k�.C���TS��k�3��y���*�r�U*����fd�(}�]'�c:2:F�1�,D����(лjP
�CþV$!,�·�l;�wǴ�VK��~��
D{Nn�LC08H�|��i�s�9yÀ�z����Y�h�U��cq_�߄�Ꭳ<����X��}��]ňK�]�|���b�d1+���K�m���d'.\9$aC��%�Ҫ��z��ui_ a1~����b
�F��6�O;��@���b�[g���^�g���:���o�U�,1`�SK*6���F�
���4�6���:k�nM@���a�#r8�N���t��m#�6Fc#�0�
j�n9�6)��HD�@�Z�[�R+�Ha2���`H�
��Sgl��S��N���#.'��m
�Y3�3��h!�/����%�Zv+7H�.�I'�G}9g˗jy=�����wD�W��ȁ�e�r�\���|��W���}
�"[��u��m������1�=����W���ߵ��"�w�{n��+9*����{+���`4���5�J&���u�����j�_�v�4�/k��{"�=���]���쌈�$2��eC��^��SUHiF��x:�-���Z���Ӧ��WC�3�iy��V@��kv�/(�%��r�t(�8-�LZRќ��>���G��y�mP$N��!=jzz	jwz�Fa���\�ĝ�9E�����>����
�h_g]ugCM{Mó�c5T��-����9)ב�Q�ø���!B(���{�2��m�T��#gʤ���W��7��t�����=G��&£]�6���H�ͬx͏�o�G}�ר��p	��e���
��ͅK6�3R8�Si\ߚ:A��n�R�V�K���V����'
����*��o	U̪�{�`��􅤤��R|�9t���q�\o�
$��n��ϋϛ0�zE僮C��2*]��p���
�
���*6?�bI�Z����1��B�!jWvWnW�8)�W��Lc�C�i����@��t{DQ]W�2�<eʄt"��:�^��of�8�E&L�:�;��S�M�drNB�d#Vm�i»�)�=�}JS���3���r�Nq4A�����-�v�%�䧩�pN~_u�X��-�����稹T,����+�]�2�3���������R�"��bj��.��oŏ^��񘊾�۴�ă
���&��-����o���!T�W,�YS�\w��M�w�?�H�c�ôu6b�&�(\���i���Xl�ܑ�����0r��
����]�
JOR��
:���z+�J�����+iE
�����X-��6Њc�S�����1Sq�$+L�i Si�T�2��@�Abg��t�D��4�Ce�L���ޙ�4��<
dB�@��4��4
d*O��4��4
d�j�6���L�i Ӆ�w#����͞Ȅ������ʹ54X�#��<
W���sm"xyaf�аH=��aZ䣌�PK�y6�Zx�vi,"�AE�6t"~<X�H��0��G0%�X���c���R.u���Kt������^�Pb���Z�Ѳ�jG���91��0��
#�2h�����9�$�N|G

�+���K�g���J{�Q� _��S=��P
���)����h�[J8��X<��%��f��)���B�
��=�M��K��KZ��b�Ȗ�&�.����<p|�'(�*�x����ޗ@GUdWUw���@�	
��K:A�!	 ����N�^B/	
Y�M@�QDE�mP�DQ�AqpW�
Ee\d��n�W	`�������s�����nݭnի�~�]J=Ϧ�q�[I8���n
4Ym?���X�W$��{�6��;�4h
=�v-���!�� G��GJ�ѹ%�
IPg�±>>)>=.#�����/�_zZ��hА���!��M2'��hNɆ�;Kv'n/�7$E������0pΉ��BM2&��=����԰����3ucj�\$$�+��2T�-EAa��t����2X!+K��TPs�h��eeÂSyeM���		�!�eÆ�+*r��bCCc���{�J/.�1R�����$P��g�I�lx��e�Gk���t����҇���w����ί&��]����s�>����
��
����q>�=j���3�)��8V��ww>_��9U�"���ho��Q�� ڇ^�ۍ��ן^|	�$�#+ʧ&�(C�h)
x���q��Q�2��GF'w�\x���w��W�Z1v����D��_�Ȯ_qᗵSn�
/o������~i�P�[{�zGYM����=�_��^���=N�T�/��CcT
cTv�q?q�����4�0�—h��������P��z�jI�ڒ�,:5����]�
�N��D�F�D��jX� ���=���E�V�R����kbb���{�B�$$�$&&��I�ç�%��$$&!x�����%�z��3�o�~驉�gp��E��BC�u����*�����}m��i��z�LM��d�'D��0g��1?ƨbR�P
�,&�����
�۰�gwg
�|�M��p�x����w��i|s|ُT�b�׽�/�������R�}ς]RP����߬��������X�-p�zhƏ^�.��пlk��dU`�k3+k+�U�T���ߔ/U�V_p;��
7��0�Z���8�q��_o���}���y�4���U_�W����+���b{B�G�Iܖ��wv(d�k�/&}B��Df�eF��֯g_MfZf���Ê#��r{�5�i��rD����>do��Qb`���塻�v�ݣZC�U�JB���dW�^����R��-O%h�j�)�M}%fy��kv%��f��df=M��n�6+g����������連D~b�J$��<��_��??��1����O�mM�-�-Ek�.����u�46�R�.wseŝ����;�׿���כW߸~���k,���_�}����o�*�Mywí�w�'�	�'�Hl5�*c8lЃ���8�wn'�!���`��5�4�:���v�6!]�[8�q*�Nh� Q�
� �
栜��>`!�䠜��k��>&��Ӏ(�����`b1�T�|��'Q`m>�F�AL
{�IO�\�4��#g��p��j��t-����t��
X��
ѶBе0��R�8O�<*])�#��~,ҵHOB�
���~���"���\f�_2g
�c�Dns�\�6��E(��c4�QZ1J+Fi�(����b����q����b���ɀ�d'�KjAr
`4�Z-H��0���G�8�
bU29=q'�&�q�&��!]��T���� ;@�N�6�	�d"�;
_d��d@#b�w��U��غ[�c�~6�G��6�
0v�
c8ҳd����b�o
3�A��Ct ��Y��`��1�H�L�Ʉ��H�l���>ձ8��Yw߻����z��4�#S#�v��&
F"���B��
�g�x�X|��i��1ӷ0�70���"�G<K
������i�h�}Y�a1�̀���LD:�nH��5
�B�~\K�zq��Sz}9���C_Ρ/�Зs��9���r}9��C���<���v��^n��5�� �>����E�s����p:
1	�'b/ľ��|/3�=:G�3�m�
�f@�n�0��0�L���#�y��p���x�ǿ}�Du�=,�������C+x�F01Q��G<K��q	��A�
�C_��9Y�o`<�&r-<�
{ �`}/��t֧cM�!��	A�C�fN���
��6���6���"�G������c!<���!hg�:@�:�x�}��X��5ݐ��m@kCx�
r;Ca4
�F�"�9��I�$p�/b:��pͷ#
#ѯH�+��D�"ѯH�+��D�"ѯH�+��D�"ѯH�+=�D�"ѣH�(=�D�"ѣи0���i�O�@�d�1���}
�N�� ���S����ELG��r�;K�}�z��G���z���cbO�^���
{�u��
	�f#j�A��^���"�#�r� fA�-��5�3�
�r
�Y!����$���%`9�*d�}�G�X���UXS
�
Y
ĿV~NO���ɾ��u���ę�6�^@;ҭ�E���*�`�8�*b%��ڷ�[G�=E���|_NC~��k��$�
9��n}�{�Cn�9V�H
�c
k|k
G�G�@��q0��I���b2�Ě����Á؂5�
�1���b�j1X4x��$�
�R�pz�d��6�i��������0��(�[
����h��Af3�x!�Ŭ�7p6�_^����[
G"VC���-�}H��JX�_�_�
9%�uwV�+�ak�j*�����2��
p&�ܞ2�C�89N*���q&�p��&���3�h`9�վ�5`�p���c�u`%D�0�g��9Pr��C 2���^�r�@�J�v%Hv�,��'!�d."��т�
vVB$���Q#Y9X5�0�p$��q2��C�G��8т8���HfG��
<��T�GՀ=AKy��"s��
����*�y��zD���	i3��hAl�V+�R��56�q �=X�ElC�
��`����j�y5ؖ�m�����o,�ܫ�h�
X�V
�XQ�k7N�!ڼ�k�c�D	ցjր�&��|��2b#�X�W�5x�������Bt!�!�lh�
k7F���Ȑ�
��G5�&�j_ �#58Ck���l�u�HȄQ�ۣ���
m��p��/�Z�kA��� �2�`	��_�
�D�
$�BFm��8
�Ԣ�	Зc	D{�<
8�
*�� �&@�q4�Nʐ�`EJa��Հ܆� �`9�p��B�'�^^?
rr"f�d��K��:#�3��YZ�
Z�f&�
ю���D_7�"�g��ޓ�<+�@&���q&�y�H���@��%��,І��˯�����z����1#-#Z�f&b3��Hs˧���(m:�*�����+�t��m��Y=c59g���qj��g��'
[��}M�!�5&��@#�zD.���$���&������ӂ4��֢d�:�z�3�B�� �D�!�i�ׂ>Z�~F̂z-h��ڂyn���@��[�����Z���Z��6@>s�h��ZQ��ZQ�%��_�C�q:�D�����L��(g&ư�D���$�j�84����� �G�p���jf�����=�N���oC�6��U@k�X�@lE�
k��c���q|���6v�͎�90�8���@��E�ȁ��/��D/�8�N�ʼn���qtb<]�c�G�.���%^����bT[q�Z��V���oE�[��V��V�ۊs�ǫgn�i�qiþmط
��a�6��
؂4�b	�|	�|	�|	�|	�G��}$�-�C�1P��2����2+��2E=?5���DT�l=�J��[N�ZE����&��A�n�=A�_V<!� �:Mt0I�_	:�,e���P�d�����1p��)�
|FЌ���|S�j�xD�
$"�'A����"��kL��B҂V:�m	zR�a�Gh���Iv�,AG��C�t$��K�Z�EF���dG܏tֿ%h^�)ҁ<����F&#������!�����W "�K���Rhe�Z/�V�K���Rhe�Z/�V�K�C�؝(th��ȝ�#��:�L�3
:"`[�ZAG�a�ʐ�1�B��n�#�q�^���v;�t8�Gw���h�� 	���k�&��k�����4���X��-h^�8�����<�O�{��N��=t���C�N�rz�
rz�#��4�ߎt���?��P�QAs9�#���$��Gz��
�כ���rR�
����`����?�ϯ`?����������%�c\&�'Z��j<i"2�5�I��C�I֔��h��[�#ZJ�
�4d,�Y�����J�R�V@3p��v;�j�((ې�	uH��~ȱHt�PkF	����QM	��[X�!F��}���(2.J��"�ϴY�E�������H3�9I�M.Ձ�~�pe�+?
��y�MF'%hPv���	������"w�"ze.�t|'U��mh��G���+Y��b�"(C/�oF�K̈́�	��VWc��h��u�� yܔ�6bO��Ƙz@?�#w�@G�Zq伀
�_V��O��A{�Q��X\c��l7hi�?F��7y������m�鰘�O+�T���gI�7��#�b5�4���CH�`�3��)[d��F��D3jv�Y���k�R��p��v	�	��
c�s�g��I<���,kcz�4�����6���~>#��������Ṫ)����^���?�H���ڧ����Z���;��<��f�1��W%RfDn
�B��\-�$��[l��ܕp�n��Ď9ܱ�(�ߑ�]������8�p�_e�����<��&YS�t8=�-����jq�$����֔�l��VK�ǭ+�eW�l�o��n�(�M3�i���f5��M��,�4Y�K�5
����c�V+!p C��pi7�[#i<.�,�%W����o��X��:�٬�< Ir�s�.�Z\���𸬲;��P?
��a��A���v:25�&���\f����

��M`�m�l���(�dM����h��Yr�v����۫x�W;f0�!��[�ٕ�i
mMVS���ѴIn�Yv[-��b�i����-��
�vM�lr�e��!sy��6��fvk�N0��5�d���kC�4&����A7\�X�McvImV�ŭi�]����x1 �D�?du�&�pC��1�<�S� ��)��ki�!�ȳ=��mm��I�G����
!ju�Z�M�ׅ�5w��x�E�b�ftc��$�������!���
�),���a�f�����{��]-��+�|Ќ�I�ت��]㴙5nO;���IrI��y�&�����d�Z�D�Sc�ȳM���=��k��f���k�
S��Ӥ�8�f
���io�'Z�2��׭$H��ٌ	
X�9V��V��%CJz�‰�j�N�Wq�3K6���Vw�MjW*ͭ��c�f7y<-E99mmmْHsdy6�M�����r��
���	����6�l>���J6/����
���񴳓�����=<�[ZlV�&�O�v��69�	>d(���A�㼑4�6@
���e�l͕��8N\0ȿ�a<���Ҁ��60'�����Jn0y[��&�F<�"+ī���q�LvX����r�@����M0�@xn�ʹ�M����#�=f?�]N�E��8�ek* [`BB�[d�G�A��������C*�d���MΖ�+�Q�x�>�Ѹ���を��<�i��j���O��1¾�z�ఘ�k����(�xW.0�L4W:`��X[q%ވ?�r�tY��^���b����+�/�]�,W>�t�nƫ9����ە��O���Tx���~~��ͪgT����v����~��vl*\~Ǯ�[���K#ԙ��ɊZ��P�J�[p���q���8��[�lƫq+cDZ�7V��De�m���V�r<��Ǎ�5�`�>�eS���ְ�рۭY@)�|e�ր�8'Z�lU�N�:6lmh�
d��F�-6`^�k�F���E�g��ӱ�w�:"��,'e�k�r8t�nYl���x����LJ��"BV�a�;b([�?>�ᴳ������9����:�Ծ�-8�����ʰ�������Ƕ�*6�J�Z����m>�E+��;͍����5�屹���c���P�%���+�h�<�/���ef�]�#�ŘvKݝ:Ǡ,.уG��1�����o풿��U�6���<��<k‘��^�6z��D�í��8�X�t��,<6���)�8G���u�/��`�5X1�\���(�$^�C%��ό�;��W�����%
;�%Xc;�����gN�	����e3f���(vH�3�-Ȋ43ƯǤ��Y���Ae\���:���kÿl�����$��b�����u�0]W>���e����}��_������;_p���E��β�}1�O^"$�Wb�_��;��#r��R2�r�]�(q��8W����W�K�*�Y�r�{����y�Zb��]��g��Ȕ]"����g��/Bޫ��y��u�k�?�ȸߔ`���[����3OWn��G����C:�\|Hɭ��I�/�����O�u�)#�aß���}1��s����g�v�ҫ=�)���b9�*B���n�2u��T]���Y�.�U�љ�7�v�Q����;�8�����*������|�ԟ���]
6���?�ԟ�5���G^����w�l5eTEՄ?���J7����a$&$�"�$���đx�@I�ҝ� )�'�
{�T҇�������7��%.&r��8>H.��H>)�uD��`r-BJ`1
�X�#��H��0\�p0�1�:po�]��d����2�L#�d:��<.,�"h3a�l�df�C��
nx����z2��'�B��,&7����,#��
rYIV���f���B֒u�VrYO6�@r��l$w���&D6�{�}�~��<@$���a�y���l%��'ȓd�Nv��dy�<Mv�=�������>�<y��H��������y��J���?�!�:y��I�"o�wȻ�=�>��&�#�#�1��|J>�I�9��#_�����8��˷�;H�ȏ����$����49CΒs�r��J~#���G	
�a4�F�HE�i����8Oh"M�ɴ�N{�ړ��ڛ��>4�������N3�:�f�,�M����ꨞ��.5�<�Oh!-��h1L��Ch	-�Ci-�tNG�J:�V�jZCG��t������xZK'Љt�L��:�N��t:�A%�@M�Le�H-��Z�L�Lm�N�I[�,�n�^�J��l�N�й�z:�Χ�B��.�7����.���
z]IW���f���B��u�Vz]O7����N�����E鍊�=t3���G�[��A�W�}�>B��ѿѭ�q�}�n������Oѧ�n��>C��g�st}��@_���K�e�wz��B_��k��}��Aߤo�ҷ�;�]�}�~@�����~B?��ѣ�s�=F��_ѯ�q�/�
��~G��?��	�=IOџ�iz�����/�<���F����An�bj�Yf!,���p�?3¢Y��Ų8�?�A�aI,�uc�Y��?}�4�7Ke}X�����Y��2�6�e�,��r��阞X.3�<��
X!+b�X1̮eCX	+eCY+gl�F�J6�U��(6��aױ�lϟ�e�$6�ձ)l*��?]�$����d2kd�Ĭl&~�ٙ�9Y��\��<��ZY����6�]���l
[����v#[–�el9[�nb+�*����ְ[�Z����n#!�yV-�ey�����Y����[{KS�._�j�^��S��|u����V�N�p�SZ�������*JX�:-N��$)e`�Ir9�f,�mP���W��%+E�d�z�@�RT+�6,��f�Gm�4;�b�����cԊR8Var)�X�ץ�J7J�<�(
��&
�.�[���‘/t���9s���eY�p�n��7�I5�� �Z���l�HAr��j�n��.�<�W��d��wj�&�K67�B��&�d������9]�-�ąH.���&7z���b��o*+�fg�C�����fv�wR
n9���4��l�V�Dyg2L�嵶J6�a���^�
#msZ�� �'�3[\����I6x0��J�A�e�R�D�.W���zQ��qm�F�ߨ��o4�R����e�(�>c�(KE9T�z�EY!�aJ�'��	�yB�П'��	�yB�П'��	�yB�П�[lNSs�
/�+[�R�<���n��rb��ːF��Y��P�=� ��*Y�-J��f�R�MV��&�X�
^��ᔨsۭ6|+���B��:e;���C����M6oC@�,�
�U�;�0��-�E���!�Y�Hf��Z�n����$ڭ����]��iŢ��-a/a+a+�l���A�v��I)�ʸ7^{�M�f�H+ST[*ʡA������'+����2?l��T˥R�by��D)�!l�_����zD��R7
Vz�6�h�"�RXeVU*VY�*łjUʰ�~�g^j�AXo�o��&:l��l5�J�f)SM��5�2OUᰨdX�FS�”ъ)N��
c~�8?S�~���z�����^��Z!�+��*ҽ��Z�W8:�Oz�=ُn�H�:kq���jX+;Ƞ�
��d,�F�mL(����'�M�J�a��ڔb�rhS�&���Kv[�!mT�d����Y^�ý��V�t��Bm����F�]�)^�|%o
�4�X)�;���-�p7�pt4��p��L&���*o�vVx��;���
-�w"$�+�^Wx�ڐJ���Gۭ|H��Z?���v٢0�X����Ԡ
���r��	=�:~7=j�"�Jji���oo0K���Fy�$k����XUc��
��9^�	���&�j��^�7J4v\�J�����;��v8���+�
�x����p������ռc@3�nSLwx�l+L�[�jr��a�	,2�Ƀ���K��;�#�����3�8�r�:Q�Eie�(���e�(DY(�RQe�(+D9L)�[8�B�N��	�:�W'�%3Wl4suB�N��	�:�W'���E)��~��报5W,��z�_/��~�Я��B�^���z�_/��~�Я�
B�A�7��� ��~����~��o�
B�Xs���k�
B�A���s��\�?W�������+��
��B�П+��
��B�П+��
�F��(��^��kzŝ �(��^��kz�B�Q�5
}F��P�[������=A��	���8����3�԰��Q�"th@@5\�=4Y��h|���]_3�R�%d!���y�?�8�:ޭ]��t�ҳ4�m^?��2Ju����`����Ё�TM�3��<V;F��W�㾞{�b��@8�e}�Vĵ�O��*O}be�9�<���M/����En^�]���]�6���8������I�o������|��]mD����4N�
	TժcY�8]�6�_��FN�����LM�Ô����
��Ԏ�r����'�Z�&dY��gb�6_�-�W�
�<LAc���N;�*�š�(�gJ��t�,�p�v�=�N��Z��h�`���v��w��	#��T�m^���q�$�7o��7Ԍ�.w֋sSV���f���?|�g�u[��ٺᧇG�*�g7��U5p��F�|'�X��s��t���SY�{?Y�聛S6ڪ�����ȏ���+_�4�����%�o�m����,��4��K�E/hs�a��(U�k�i�:��ti�xd�ir�d��"�A�����6%�R��i����z�3����mN[�*:�\�.�r<nw�Iʆzm�ԗ�׆v(Uk#y}�W�X��ڞ�:F
ó%V�����h�W���_�J�Ŕ�1/W�����ci/~���{ٽ.�
�!~Q~����'���\X~䧵k�O�V���+(|›�)�c���=w�8�~h��l^=����C���[��_�y����G�V���f���q�}�Yಏ�l�T~��<�o��3�~���<Pe��@�)�>V�nA꽆�97m�voP�!�!A;�i{G�]���{�x��{c����N����i�y�7e��wp����P���������R?����Z��z�o�7G&~�R���F
t,U���ϳ�����S�wW�O`�������/y����+;{�>"B���ٷh��L�+��kc�Epl�D���.��Lj�uq�kxuPlX��� 9Z��c<Ba<��6��K�v�a�qJ���?��J��u]/m�2~	����$��
fj��i�/
��d�XLS/���i��P�3��۶�����y+[�=�c�O����"={��LJ��r������:��qަ�}o}7�dۃ���n}<bO�϶�>;6���O�zw�����9�=�����^aGT��"r�w%=���dȁ�.{v����l՝�b�y]玘�uhv�a�5w^�����G���śV
ؿ����go�4���W�H�e�F��s�7�_u�t�����=��#�������ѽ��W��G^�>�l����{ũ�����4����ٲ��'�ǦN������˰ڷ��'�Ա�����ڼ5������/<#V�#�E��+�5�+F�6
F��TY7��ڼ͹��K��n�Pr�?U�Jq��U䏖���%Y�ؑߪ�pXB �
�tYFå	��#��fҋ�=t+���a����{=�=q�$ǧ��׿r��د�c#~�?�<q��[Gm|'�!���ޣ[tZY�l��㷓o�n��χ�����)��Ԁ׿~�p���\r�λw>:��܎��~#|Ӊ�/|{������2R�X����y\��޺�ٟ�Q)7�T{_�tO�ʙ��5*34�N�n�A3��`��4c\p�s�w���R����z�qj��\�wqj�Kc��\��*-�@Xl�Ź��=������i������֒G�3�-���"�I�nʀ-x6�hp|�vJ�p��i��6��V�{5����?���
�~�?�WUt�s��\5����$�����б�>��Ljؾ߼`���u���?2��������Ʒ��><{�Gra��7�o
��?�V����7Vn�~ӽ��]��=>����m#���C�N������5�?0�6m���̒��/2��|��볖.8>����,/�k��5�=�'�ԣ���Z����ʜ����~���Z;�k�ܰڲ��n�������橻�;�Ȣߧ�a���7�������P붛����ݱ)���o2�L�}�����w���[�<����?\גtW���#���?n�[~�����f��]W���N����6c���\
JT�A��d4����V�,�E��ͩK5�n9h1I��)��O��uN�I�.[bC���U��MֆT�fKOm]7m��;1�2���NT�,R���>}��_/lλ��)��t����Ey{u���^��|:.�n�s,%�pF�sU�س�
K�֢ħGέ=o���d������y׊��g�����Q�mګ?��������bǐ'o�iKݞ�������ABɖ�u1#BJ~��n���3�����ȏ?�^th������zkoړz�ߔz��j��_�~��ù���^f�N�b�/,V�(��ˊ�6���׮���jϘ�˶"�� |a�����Z�N_й0��V�6J�aW�lV����H��ؘ
[�f���*k&�K�tn�B����ݵ�b�Uc��b�H6Mey��Y��
�ąf\ǧR&H6�YI�V=�y���aN��ݡNueux�y��Czc�y��v�Ԯ9\rj�{�{"�(�|������s��#w���g^�0ս�pӝ�2곬�E�4޻�~7j����I=�n�T�t�����bj�|��4��n��v�]w�����m�����G�MZ������������Yyg�R�����X<�tY	�jK���N��͆ͺ���*Wf���u٪�لK���5�
����òj-W����Ŗ.�F�J��l2�.m/e�J�&,��
w�򩎆S����+wQ�ҩl�������}�s��;P�ʩ{���b�:e\V<�B�3E���q���mI��w���-�?�p�I�����g�G�u�n�ݨ\]4���޳���/V�s��i��E�������'������g�J��}�]?���z�km߼pK@㪱�r����mpZ~�-��UNć�}���S�2ߏ��9s��_�{����y���=�U�_��y�5!sBXT�{�׭9�";n�k�v�F~���ӞO����DT��_��E|f�.C���>T=Z���8���'�=�[�z
���R��W�?]ꮰ�wy9h�½8D�D:���Kk�ɝ�҅�����w�����xH�Ύj�5���O����oY�m����7��+Zằ�1��f�'�Zqoυ=��㑗�w�E��9xc؜w��yjⷕ+?��}g��}��{��As�yϓA��1x���'�M���#�F��3;����X�۫���>��܃�ʰ��d�>4�{�/���<����;�q!��_��[X��q�
��[_ڑ�d����ul�|y�>�-3�N}�9{&�^��]M�n1�AUO/���)�
���T�n0����7�a_��0��-
�(�Yj��F�ј���i��0��rJ��D�Zz0,�xՎ��N���|��|���������]������S~��/B[:}ݠ�^�=�h��_�ߒG��w<��&�
����sK�F�[aK�_n�.�Wڒ����<��o�n����c�����5�znyC���K�UA��>�Y�{���7<n:�ч�<�^�?�-
endstream
endobj
478 0 obj
<</Type /Font
/BaseFont /TimesNewRoman-Italic
/Subtype /TrueType
/FirstChar 32
/LastChar 255
/Widths 479 0 R
/FontDescriptor 480 0 R
/Encoding /WinAnsiEncoding
>>
endobj
479 0 obj
[ 250 333 420 500 500 833 778 214 333 333 500 675 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 675 675 675 500 920 611 611 667 722 611 611 722 722 333 444 667 556 833 667 722 611 722 611 500 556 722 611 833 611 556 556 389 278 389 422 500 333 500 500 444 500 444 278 500 500 278 278 444 278 722 500 500 500 500 389 389 278 500 444 667 444 444 389 400 275 400 541 778 500 778 333 500 556 889 500 500 333 1000 500 333 944 778 556 778 778 333 333 556 556 350 500 889 333 980 389 333 667 778 389 556 250 389 500 500 500 500 275 500 333 760 276 500 675 333 760 333 400 549 300 300 333 502 523 250 333 300 310 500 750 750 750 500 611 611 611 611 611 611 889 667 611 611 611 611 333 333 333 333 722 667 722 722 722 722 722 675 722 722 722 722 722 556 611 500 500 500 500 500 500 500 667 444 444 444 444 444 278 278 278 278 500 500 500 500 500 500 500 549 500 500 500 500 500 444 500 444 ]
endobj
480 0 obj
<</Type /FontDescriptor
/FontName /TimesNewRoman-Italic
/FontWeight /Italic
/Descent -216
/Ascent 891
/AvgWidth 778
/Flags 32
/FontBBox [-189 -307 1120 1023]
/ItalicAngle -17
/StemV 70
/MissingWidth 778
/CapHeight 662
/FontFile2 477 0 R
>>
endobj
481 0 obj
<</Type /Font
/BaseFont /Times-Roman
/Subtype /Type1
/Encoding /WinAnsiEncoding
>>
endobj
482 0 obj
<</Length 96795
/Filter /FlateDecode
/Length1 156064>>
stream
x��	xU��7����|�<�s����$7�\B!! * � �<U�UkնZ-N��Z��	g�
�����yj�Zg�V�����>��������������}������g����ڰ��}�����?����Ֆ�u�2'��<~΢���
��D��Dʺ���>�ձ��&"���-�?8����񉾱3�����=���]<�ă> ���I���ʰ���������̷�<��t�M�DߚDdZ�����C��V݁�c��XsEȆ�`<u�C��o4��{�Nz��)�Vz���[�D���N;`��U���N�3��?�Ō��(�8��c���-ཉ��~��#{y��I1mâ�9|�
��������O:t�1G��2`>q5��[q��C��ĬD��#_sԍ[3�H����w�G�>bx��������$���hx�Z�MO�'�(�!\~���������Ηo~���*��`�B� ��i��Ѡ�n��^E��A9�ۀ~D��s(�R큺��\�2o���j���I)��RÓ��Ⳛ�٨(�M1^Bʍ�t��cw�X8���_(����%:-��F,���PM��$��1V�)i��'4��o"hI���=�Rq�0*�ү�k����zڄ���&�)�_��O�kD�c��@��YH�!}�t>�Z��6��1&�a�jt�i�Ɵ0���t;��x^f|��a�>�=�/@7�{c��ki)�W��oQ���P^��u������r� �}��G}
㸐nߧ�A�5��kEc.E��9� ?� ��uL�zq?���V����.�?(ۯ�U�m�d���,Q>	ϗ�������0IjR����ݡ\�X����׍��ƚ'���x����xЎ	s~o��o��N��t��Sx�_�ԏ4My�5΁�^�]M��BNV�i)���qo�Ư��
���剴�F����1���8����
|���Rޡ���-���>�z�w���*�܄���9����H<oq\F,X�z˙�}���l���<�s�~aE"�?	s��f��=�|��6+�2�?\�5䀜n�N?���X��ap�W9-��DbƓ��X�r��E��A�͐�YH�x��4�ԏ�sG����*�¸��.��'�W}
�%�����1�/��1_O�E���y�m���|��͸b�����-����x�����?�j<g�c�s��S�sC'u1^k�9�E�[d{�ȿZk��e�,:����qYL��h/)�t3��3I�N�!�ӴJ�N��:typ�^��6}�z7���
���%�'˳� ������t�o�U��g��t]�&��SN�����kw��8�㻝���I�s��h?<�ez���z~�6ay[�#��s�oD:	�lm��,6Y� ��f��~�1�S��n�n�P��i+}�p&M5�M��I��AK��\��\�s�CN<>�#v���0��X�����9��1Lɜ��������ﹼ/�o�{��L���&�� �|�8>�����;����W���k.�����;�����?�F�q���)�����x�Ϳ�/:��'�K�(-��!���<n��~���yƼ�4�G��y)�z���;)�5�7����xgl���,#�g|�4��U��Gh/�k���?���+�Ks�,c}�g���-b��s�?m�k�����ƽ��Q��ƣ�}o�^h8G��UƟ7^3��q�}�����Si��x�9�1��;�/F��t���׍�bֻ���[�-X�=���7h�����@�嚖Ⱦ�5N�,{6~c�+�4݆:$�����c��sGYH��,0�y�ܫ�2=�w+i����e_��-��%�:��L辊���Cr�>	���څV>��8<����}�M��ￆ�as?l<o:��H�v����v�9�0߈s�#��ޞ�����X��t��3:��*�O���aCF<�j�9泇f�J+��F?�X�ϛ/��
I�|���g���R~C��Gv�^�,��Q��O�!��l6�L f���Ls�ߙ��b6��1[L����M&�����I���}�9c�d6�̾�z��1z��;��C�g~�[��AXfq]C
_(�)Ēo�g��
s�
�b6	n-0~c����2�N��W��	�?
�4��Yx�n��i4�H�QE�a��#B�D!�W%D"�O���	�ƯM" b,DOQ����PC�r�Y�1��R��;p��D�喆�SP�
��A�9e>�c�싄�)�%��Q��>{���(�D��A� 7���䥤II��"|"�!4Y�A�ρ]�_�"7>"��jBr^���,���_�)��ܢ����UVĔ��	
���/\
d�/MW�g�㸛>�6�J�Ɨ���@�du��INP�@ݒz�
��
��'�������
�4(i��P�B�I��Q4NQЄ�I�7>�%@5J��A?�0�%
4Gi�<e@�m|JEʁ�(�$i3�2A[�	�U�
57>�*�Aۨ��ZA;�Z�*h'��N����h��]�
�M5�:u�N���&�N��
��v��I:��A�S���6>���ʴ���><Ϥi�C�΢�߅�A�i�l��iW�A�94:�f�Γt7�t>
��N���6�t!��x���4tO��x���y��i7�%4t��{���h!�7h�>�~��h�E�i/��t_IWҒ�_i-]M{��G�@����聴�A��`I���Ҿ����ƛt��GЪ�_�[��H�t��G�
�ߦA���A�#�1tH�
:�=�������ߣ#��	�-����kt�
�>��6��hГ%=���x�~Dǀ�Jǂ�&�黠k���+t:}�IϤ@Ϣ/��t�:IB?�)����ΡS@&���G��ҩ�灾D���|�1����t:�t�E����ll���l�Kh襠/�e���駠����B�+�g�Wѹ�W�y��H���ut~c3]O��Z�藠7�E���+�
�n������2�[�r�[%�
��DW4����J��%�-]z]
�;��N­������z�{�נ���tC�9��nl<K��(�i����
�	�A��!��a���M�z�6�>F��>.�t;�������
������Oѳt�st7�$}��
�3���$�@�,���E�#�V����$�6z�ez�z�UI_�G@_�G���X�1�=����'@ߢ'����4�;��Kπ�Gς�Oρ~ ��'Џ�Ϡ���ǒ~B�A�N[ӧ�b�!����~N/�����~A/��S�/����*h�^���W������ӳҧ���?�>�S��h�����g>�U����U���ç3�g�>��}��;��{@gH�>���§(}��ҧ(}�ҧ }�ҧ�����OO����OW��w�OW��w�OW��w�O��|��ҧ�-}��ҧ�-}�[ҧ�%}�[ҧ�%}�[ҧ�%}�[ҧ��ħ$}�Aҧ,}�!ҧ���#�O_#}�Q��O?���O?Y����O?E����O�o����?,}��ҧ?,}��ҧ?,}��ҧ?,}���������?�>�c��������������������O�������O�����������������?�鰿�������O�������O����Ǥ������Ǥ�������������K�:�Ӵ�����6�-�ѳ�4��W���g�Ų��Z,6����1۬6<�'9T[��d6����`�����F��t2�8쎓�5'���U�|h��F��b1ʏ��
��nv
F7Y��_�]~"�Qm6�|2rDC�5X��MLc�&fW[�<��߃A����l�z��j��+�E6�o��B�lt:��-���T�88��v�U~��Z�"��h1y
fB��&#�
c��Hy�|2��ϱ��$��m����bR ],�� 7��6�����ZS'�Ufп��۪I>B���!'���Es�X8�#r�
�n���a�G��t��L�
(�
��M�"���1N����I<B2V��da<Z&���Zm̶�hfj�K���F��A67��
!�o���V�W��"?����j�I���N��9��l�Q6gk�l842�B������sK%3�l2����� yc!�MF��n����.1:Kr\���b��9mh�x䒮0;�f��i�hv��Ti۩`qr�5�6V3������h��D4�f�a�1L��|���~�@V�(C�X����&@� �=�cꄖ�(b}���}�I*�&�k�2� r�6�ba|�$(,V;�;�tZ�Q��I��D�v��7Kɛ�crع!,�e���v22�ƣT�WH
���%e��b��?"/��\��"ac0X�𨛸ģ�*�Ͳ#���X�݅�]�q<:�&� 4��H���rZ\cx�1�'�h�~�x4���Ѳ�`��AF#;&��2�I�\bo(�h�xD�U�%Z��	&<��.Gp+Mag�huq@G���
����0��&�(�˸#��EG�]�|�7wY�����]V�6ƣ�2��a�;�BFV��Չ8��-P�P:\�'k����|����a�D>HD�ѨqBg��>�M��k�7Ppm��ľ�#��rۀG��x�d��M��$18�ñz�v��	ۧՅ-Ɖ�Îj�@C����xd)��-P6M6��;���+��E��as8<Ѕ�)UCw�&'@h�I�3N���1
������ü��}����:��
���&��j��Z�[��d21�V�]�V�p`9Ȭ�m�z��a��Xc&.K]�v\hgR=V�V�C��w*�<�ѣ�YAX��f09M`�fҙ��蔑��x�5�W�O���}��������=6�(C�l&6p���rX`�x��T'���@�W �C{=����r�]V@�hU=.��Qtc��P���n��e6t�i���F+m�
!:����:n����Q�6"��d<b�p;&����Ϫ�
5۝N#�ƣ,9<�����4rs�G��=�c�aܓ��-�2a|�P������P3��U��zl*��l�G���~�����V��B`��x�9��u�`��&���g�,#���F�,K?��a����O�r��vlp;�v�T�z=X/����ێ��Ɏ�<��h6��D?�X�젌/$��%Vjt�T8�1<��0�G��m�S�]:D�v�N,���<��g3�
�0��H���^�m�Kƒ��
c0(���\��\9�4Z�[�o�籎��p�L&��y�.21m��|��
)�'��Wǣ��xt�s�#���k�xb2|u<�ٕ��b�xt9m;��kx��xt��؅�.y<\�8`���v����Um^\��H�:��x4�`�x�с/J�c�Mn��沚tEcb�s�Wx�p= �㡃[:�UA��G����6�6�S�fip;�^����X/�'���1��Ѧ���MW�MF=�l:]�S�s�^�����urD�Ų�����5�G�Q�Zr�L���u���ƛ����r9ܐ���y�s��T;������F���=̪�"�s��{7���v�V��#��X���x�݌G��^vG��+C֟.����^i�`:�%��ݣ�
��hj2B��l��x*��r{����q���.��H�t��Ѕ����!��s��넸������}?ߒ�\�o��d4\c�o�.��,��ata1A����pLp�&��\f�����h��
�zn3	4�p��{7�W�%�s�r.�kg���瀎����fg�X�F����8s̒�pd&Lc��5a�:��)��v���v���k�9�
�C6�����aÅ���B�px2�d(����}+��v���<.��B����¶�d|
P��	�����3���'<�t�6ȞU赫���=�ƒǹ[������A��(V���8�~7.V'+�+;֟�n7���*�8/�<*J7�]�kwZ���@l�o�����Lp�qC��ґ�Pw�V����q�
�-�~/�
���8��� _���N>;
���G��
ɉ�$��$M�[�*���|N��Y��
�lbȀ>�'Xx, �evY��۝8��#Y�Q,᠃�#�:��S��HC~�Ft�$�2Z���$МU��q<2N��'s�|z�z������.s��e��lV����pʼK@�ȼ�Nx/j�9E�~&&�v;dm�n�.��}N�=�~,܉10�脦�~���	���{��F�������������s��nQ$�#��C2*���";�?؎��׫z�^�Su�~Տ�W���	�	��p���
�'A�*n�V�~�>�t$츱��������<>_�ވߧ7������҂ƙ
$��Tj<U\�d�iau����:���Y�/J.�0{]�d��@ �5�r/�ĪKuy�d�>������JTڸ,���y�Rq��E��V�ǃ�;|�3
�|죜>h�d�>�#8s̒
V82��k�X�%:��)��u�R�{W$��X"*G�qjòV6�����.
"xY�pހϬJ�-�ބ���Y[~5��f�En�K�jwc��!�	���7
a�����V�B�ng ��>y���3�윝�HL��K������P�Ev"����
�7��}�P ���E}>/��p�ڴڝ����Ǚ6���a;�԰��m*�����>�[���I�k��0�C���۹�!���x�6�<� ��G=q~M�|&�����Ƭ���r��`��c���.��U,��=A��� ����<
,�njU8�l
�Z�v.KL�p�݇E*����)�'�L�q�HD
�Ou/N�����S0s̒�pd&�?y��&�Ǭ�ɜ2�
��~�{①��sD�x,;lc;�᠙���B
V���S�⃇5��!
����� �<A_�%x�d<����P�b������ 4
���	�>
�O���FC�0���0k�<��0�h�ĥ&��y���ģ���|���\�V+�YM�����Z<~5��(�	�߇�n�Yժj1�M���cU=@��p�C��&���&��B�&���XKw0��K(���a���l��q�,&���y<��lOI-�: i�_��'v���A�޽X��I
���%&�<U�g����!�A{�C��g�2�üa��x�걧���D��*���/�
*Mi�P~��	]>�]���vxb�%?X��L���`M8�|2��gP�c"��{5���G�q�g����?u��!�DG
uz}xB-�<���}ܥ����0k+쏨A٣%"^�@��X�7L@�>����?���b�ThR�F� z=�(�<w���l��X���۞��*Q:!���|� �N?�2}�fc�3� ����P\<
FQ
��E�	͇�p�6�P�%��q�6�ʻ(���r8���U}XL��\�l���"i�×�[z�p=�~	{�|�tʗ�/��g���S�WތT2{�h4�~�>~y�����j
��+�/���ڭ�.11��c9�|����a�a�
/��r�����n�3�S���Q�"����?�
3�d$�1���;`vd�������rd&���X-E�g��dN�ϰO�iس%�K����a�(;|~v�I0�P���@��`0fu�x�X��;�L�����Q��
G-�@4��!d5���
6{�X�?L@Ł@4%S�D0�	�
�sq
��B�	5�����������a߂Dӹ��(��2qzI��G����P(	b�7�KDb�J�P:���W��l�����o�j��\��;�E�%9_M���<f���XK5g<&%y��eB�XF�et<zCf��f<�8�X~�:�G������/�%��/泆�K���"�g>3�1⋠A�q��-��26t�?��c#uB��|��ћ�����Sp�2p���R�(�L�7��Ό#�t���+�	�Y�^���3�|2��għ�t$���L2<F8��b�	o8	W,3��k(��Y��P(�—Bp����PEb���B	_B���	?������a`*c�t*O��0FA�0FR����{8g�8��Qy���&���aAud�!Q�)A���e��ǺCv'm�n��B4�G�W��� ��&Q�Gs�E�	-��n������s��AP��*���x2���ׇ�qlM�k��x
�($���#����Nd�a'���6��\�,ր�5�N��V� ���pv�yW�����$�P�iZ0�G�qD�����$��XN�q4�;�H�a{��e�<���!w$�w5����4�X8�3!*p@�b)�H����D\
[\9g��
���c��`�#3a���k��:��)��1��}��I���G�����9��5w2��:�G��x���Q-a�b��}V�/�G�@<��@2�b����B�x4E1���0���#Ih:�Me"�b�Ox�`#x�Qt�S~
ۼ���~_����Ãd� v���
��i��p�����j���_2���D"�J�2)G0Υ2�J�DS"C�@�f����rЖ�~�3���n�;�މT&��ԇ�q���{�c�Vv��匦7L圪']��ܼ���F��.�d<��ۍ����jM�Y�^'�J9�.�ȉ�l�`��H��=E}.�gŽD0����D8�� ۰
o*�B��;�FWg����+��E�C���<�r�c�Y����;�h�:�����P�Kk��������
G`�YJ��̄c�yk
�m:��)�
�IK�}�\�ĜMG���(��s����L>�����Ÿ��,���8���)�H�ٴ��
)�6>�����ò�-���2�\8!+͹��<����D	�&�	�8�$�D��-ē-�0<h8��y ��
�!FB�|Lӡ0�#Al��\8����J"LT��Wo5k�pM�����W��r����4-����+�Ŋ���G)��jZ}C1O�����a{ݢ��+Ά�!����A��a}�'���y��l�
]T��)
g�.�7לHx�(&b����-14��Q����b.����_�Q��< ��k�����Z8rfbx��q(��|̥I]�U-��2�g1;V�C
2��]]	��|/��K�X �ME��Z5�1\�ơ���L�&����r.I���\6���O�n�9fI+�	��1�5�cv�O�����ؚ��>Vm�'\�Y�({b	,��[��/�
My;,�qiZ1�bu&�si�@����p�a>���f��R4!�;*�8��Jk�D&OPq"Y����Bs*�aF��X�G���=.��8�K�l$���bpC����X�F�ִ(Q��H�_"њ�{�����n76�D-����R��$��R��R>���o8�M$����:��qoԝ��#P��U�3�R^1���$	>�x�Z�P�z�R6��G��n���{�(Bb`�TkKԼ�#)Y8uEn�Z�Z�QK� ��M�?	��ބ#�®|"ޓIT�1%J	w&�G��p�	61d	V�'�h������|\���R9����D��]�r�v䓩d*��r;�Z<e��j��!\���.�>p春X��L���Ś�	��'s�|�zl�=;2�ZkIs��9��M��!C*�R���R�F��ݙL9��:S�8�;�%8��q�B�d$ϗ�@)S�� ���r2�f�bU��Y`*��M�|�Zmj��:q�IdÉD$���/Gˑd�ܢ�Z�G,��ڜ����ueD]S�	V�O���v�/��p_m,����|jΔK�x>U)��e�J�I)�M�p�E�Tʁ3W+���=�x)�⾖F�|�\�G����8I*�=����.被\�d���	�
z_el�`��ՙB#�#)٠�x<�q�&�9�: ��k�W^�S�|<u�Ry�N�]�TR�'/!b�|*�*eK���XE��*�A�W�'��2���-�����v�9�'7�3�L��-�L(e�&#@��S:����!ě�"�\w{3�t���c��`�#31�#Gk���:��)�YJ�q�ٙOu��3�I%�(�Ri,����[�������)y��J)u��q*͞���x4�tb�x$��R�C'4P�W�E9�3��Ε�<��L��.Pq&�M�j-��Bw
'<H�M�,S��o�WbZ�R�6a�0�.�NgG=.5]=�$Q��VRU5�NO*9��p��¥'��f����R	j�U�j��n/WJ�2/�^*��7����I�M�]���M~�H��ds"�{�Y�.�+e}Ĥ>쎓��H
-������{��Z���ʤ\ΟE9�N��J���tnI�t2Y����d2�����G��
I�a��@�UJ��r�޳Y�?��ޞ���R��VK�R�MYڅU���2��e?��� �s�\<S�Ȥ��P1�L�IrLN)gs�\�9߼3��뙂O9�ork�V̦��-��#X��8f�#0�,��
GfB�y�
!��n��'s�|��z�7��>�3��S��Q��sXv;DR�v������+��R{�����U-e��A&Ok.L���3�t�\qA�RG�BNN�ґ-�K�����l0
�
UhzrW[g�i*�4�6���x�Ij�-َ�G{G�EK�j86'�8aMnO�1S�gz)M48�F�2R(�V\�'����&�/�
��J{{�yR�?[)��'U&��^�T��W+඘E�B���z���1�/d;�Y-�
�л�>�]1���$�8R$���13*��̴w�������P�P�7��I���!\A�lŁj6[�{B�l�uҤI,�P@^{A�J�Y�*�TBe�^/L*�+�vD�Z)T
��v�
�"�^hG��P{]��.7k�ZqR�XH6E[����,��@G�����Vnۙ��48����4s��Z-�ڔ��:Rͮ�@�)i��#0�,U�
Gf�-ck�<:��)��^�cG�������Q���:V_�<%6�g�����T��-�:*M�x��W�IȠ��
yO6SȦ
�L��1��L���mrv��)���Jkž���R�訴7�L�tT�M��Z��9t���.V�滳�l1W�R��ej�B!��bG��.���Lxpv�@4��N�`0^.���h���z�'B0���Z�պ�j՞�`�V������U�ժ�ù�\D[>����ͱ,���\�mE�ZWO�>bQv�I�|��5U���D��#=]�A�����j5ڊ�j���٥<����B����X,����{kj<jOOOWWW0�D#�(��eo�X����5����ƦO�^�)k௫Xn��ʵrW[ge/V�CtE����ƹ\�Us-=�[ʙJ���_0R�X���
�T&�Mޙ�]�
����P���Q)�ݙ�;>���88s�R
�pd&�^=��b٫�ɜ2�]e=w��<2�S
wqD9Z�`��qQ�M�����e�U���Z_W�Y��jӦk-������+7{���b�����Bzjӛ'C����Nom�u�P�vu�vPq�����94�;�1in'v�BsyR�\Ε;ѽ\�V�^l)M�o�.�M8��8�ΜV�˅���f��{O#�œ���j"�n�Չ��Tuw��vw��
���3{gt�@��{~ww'����-�ѶZ��ʾ!ys,����r�	��v���ѫ�Xև�q�j)]�6mQ"Q]8ֲy�̰��ߵ�3�^�V:�Յ��3Ϋ.L�T��\�v�Z.Wþ� �3f����
�c8N�I:Q�u�;�B��n���O�����3��n��n���j�^Ϊ>�"�[�E��Do]ÝI.w6u6��j��kZW���{a�cy���Z{�6u�ԝ	}���=��3mZkWG�<��Щ&��k�d-	����
V82�?�)cM�O�9e>{�z��ۍ�Յ������r�Zò�p��1+=0����C���]Pg���{hz��-���Պ��\)��M�J�2�{Ve*�\^�`V����n���tN��1���;'t����ܵ�g�)ն��juJ�Z-�M��Blk�eR_k��jUk.�@;g�<.5��+D�VQ,�tv.��iZ���ztN�XަsY_��@_}x V��30�7��@�⾾:��tj��U�������O��:�pm-ZD�Bﾁ�
}Ī>쎓t�����o����2�e�20'��^׺:���N�ڳ����^�˴��׳۩���:5�Z��������#�����'�����z���堳�w�ܥ4���ܽ�Ý���"��������3�ı�:�`����5���p�޸�Ǚ4<wRgSw����Y��ʱ�tFW��^��3cg�`}���A�Y�hh�����:4�<śY��g2�8s�RX��L�z�bM���@��J�9Щ�Ń}x߹l�p=�x�#�Zg7�=WӴ��������������u��4+�7�	2�\m���Z��sr��68�F����f@��}���:��ۇ���@�t`b�o�>uv��=��uAo�>�;q�������2i���\���s�M��^����U��@`ќΖjgE[�jZ�hա#����K��L���z�'B"�
��jpp�N����
�Cixp��`B�g������Z��2�D��]�-������a}Ě>쎓��l���Y��y��l��,��r�LOwwW_�٘�j���L:��
z��Z�����G�7o �Ȥ�|�ՠ��`��-6\�==Z&�p����zb��v���`}x�0g�V�4\F���p]}9.����M��hJ���0���;tU�cm�]zz{z{w���΄ٽ�V"���w಑��S;k#�[������\�7���4V82�_�H@ȃXwH�9e>��z\>{�뫖��K,���L��^���n{�v�kn��7�\8<����Ӝ����z�{J�Z�
�:�k��������BPȼ�E]�@ȵ��]4�xp�`׬�e}��S��	�������e�v_2ch��������P�^o��{�����6e��=��:�cdr�^��p��{a��V�Ȯ:d�K�Zo�XJ���4���e��g�o���L=t�8Q�T4����
'��0\jx��4�f\f���'�SRKөt6]L��;�=������������gL&��f��jf���3Wg��9�����l,�e��-����꜂{m�@��,��@!RH�V�{�N*�\8�pF�¥����(�[x��x�υ7�����@qyqeq���_(���-旀�(�σ����Y�ˍ��6�n�Ǹ.uRꣴ_����Zz����{g�M����lj����U������	��.)\;��C��y��3����A_�F��*Q���L��M��K���Z�޼�i{i{�˿��������m?{y�n��嫶��VԜ�ͳ��ێy�K�t̶۶���U/�|�[/�z:��+��K��Gl����ӷֶ�m��e����[j[ڶ4m�l�m�o���n~k�_6���e����wn��f̱����7߰y����7�6g6�7'M���$k��c�8���k�kA�H���H��������mc�-��f�։��e3]F'�)��t.�N?���t�����I��Ԡ�9�>}@g�yt��ޣ����>��ѥt�O����/��u�����Gz����az�ޠ��	z��_���.����'�):�ޤ���tHӡtF���-:���5�m:���������X�.}���[�:�N��~��Jo�&�sq��=�a���<�q����I_
�0m���į���a6aq���>�����zq��R\%�׈k�u�z�kq��Q��
b#}Jψ���&q��E�*~#��%6�ۄ[x�*��m>���ߊ�����w�Nq��[�#B"L7Ѝ""����"&�"!��^q}F����H	M�EF�Q�/������Ȋ�ȋ�xL<.�O����t�(��h��*�&��gi+=O��Ez���w�{�}�Y| >���'���S�(���?�⟢E|)�÷�"E1(FŤ��b��M�+ũ���QTū�DE�+
QmJP	)a%�D��WJRI)kMI�vѡdDM�*9%���RR��f�
�i��n�[���5�H7��t7�J�7�|z����S1�����b��	�����]"a����
�����^�4Mf��fw8]��}�@0��9�H��t&������rKk����Q�4���>�gjoߴ��3g��ex��#s���m��.�cϽ/Y���o����+hߕ�V��
t�!�v��:r�Q�>�;�{�w���	'������S~t�i?^{�g�u�����������~q���/��ŗ\z��미򪫯��p�������
o���[���{����n�����?��C?��c��O>��3�>G�����[^����X�?}Z_�Ԟ)��ɓp�no�VZ[��M�b!��qDK%�X4~����
��U�mF�"�u(7kyz��|�X�
W��[��;T,M�j��ی���f鯷�G����e�޲��Pӽ�[iM�ң��̥7���/��3sKң�����X�
�z��"�L�����YG�vh�L���a�
��WZi�݁G�Fù#6��4!��P���.p5����f2���ЊU��w_<43��,�������}G)70�i�MhPN3j��i��r���ֻמ�I�}��8W�V�X�x԰b	��m��3G�ǽ����}��O��mܰv(r`��kמ��d��;��0]�c��R��|�,L}K1�F�}^���չ!�Y~PzԖ�����PHl�(-86�1뿭��bC鵋�2���%+f&6h�co����_Siݠzuinp{���VO��O�9?�,��`�r�
����48Y��B�LV�i��z\��t�@��UPÁ����k������Nk?!�=��;_�Y1Vc.��?28&���ϣ--��2��2E��i�<��z�&�+w��F����趤�
2�dX��o�}Q=i��z9M��7R[˒Qe9��{�Mp~s������s����kG�ʼn?5�:�gT���W��G�Fv_�8=�v��lG}����O�{�.6ĕ�'%n�o��e����9j,��Y"y�&�P�5"=kT]>��%�L�?촩�
���W����i�zy���_cϹ���Eed�ҵk�_{7~g��Y�����׮��8i�\Zͭ�M�B�b�C��5��q����Yg,�"=@�Br��7��.]|����-ވ
pp���
y�[|[�V�*�\Js�F��Q��W����N�o��B�Wn$��u�VnR�:U�!T�6,j�-Ά����7N��ߤ\}��q����knr�j'��*WҍHw!��d�v�ݐ��d@�+7������M��4o��I�ϙ[���a=����֣���n�MC�py�M��\�����W����}I=�mHӑND2b��7�z7[��]~S,^�ܥ\���������x��ͼ�EyF�x�],鉒~S�钶I�{��.�]��(i���%�M��%��q�yW���6�[�~�
҄��H���_���&'i?�$�ݓ�jzP�!u�w�Z�kH�-k�Ly��-0.��
�a�>�����7�Ou}y��l����9���ۍ<]�Hƍ�#�;�;-�@�r�F��&��F��&�ب}�mRD�_�L{M�T�������`�:�6��`��I�dD�Kʛ���=���0��v�v�vXZ�:$��ߡ�D����b�7�2/-g�E�0�jCx9��I�[�~��ZgEv�q�[��H����Z��uޚ8�U+a���eHۃ��x��-�uW[�]iYw�e�˺��u]�u�-��-��,�Z,�
�uIK�곪V��)���/�J���ƶ�>��*gf#S�|V��~�S�U�]i�oQF��ѻW�Ⱦ�ѿ/�mv�Sn@��Fhd�@d��2���X0��22j����
B�����i0�E�7�(W���6h5zʙq����d	������2k���,�-_�H�����co���d��,(.Dq�q1�=wd���k�KFk��H.=gaz���pݸ~h�m�w [��6C��ah
�Zg.Y2��v��
������M�v4���lgz��l���Bi��v�P�k�R��ܮ�څ�QJ�K����n�����r��n�mn���M4
M2�lS�dM(�ɬ��TƚT'�T�L�UMo�J��q�L-�QX=��2t ce��
VX��K�!��iR��+��S��Ɂ�ێӟ#7@ӧGZ�^�fv��QeA��S3������NT��^UfTf�+��_��9�*r��L�vq��+�^̱�G�m�8s�Ϛ�����(-/��Ms��2����%�k�s8�65��+����J�a��D��6�Ҹu�V��&��’�5`�(���H
5�NQ�����ȿð��79�~`�=~����+�+0�[ƒ����D�@*��p�?�����o�7��~��o��#h)n�a���@���x����	��Gң�'��q�𓃢4HG�m�j�'f���.�4�Э���yaT�LӚF�Ld�?ң���� u�l�G���U��>�,�L���(����3��������8�ڳۭ|�ڳ۴dz�����������ǐ�4��٫5������q뿳Ҽn�/��������Ѣ4������q3�>���������ɸ#Ը<'��+ͥ=h9O'Bb�|����n�ЀX
��ԃ�/����WDEA�İX(��/pw��|_Y�|j0���n1�hx��q�x��
����i�8�qq��ː�FM4c.�}hV��>��N��.D��.�+�V�D0tz�^���#�T�EML�b?q�8~���xJ���B�LyԐ3,���a3��k�Om����gl߰������q�Ɨ��� �
-�՘��	����i�v�L[诐�
Q
y�,*�Mt��bw�T�/�NJ���:q��P����͝�>�xS| >�d���t(�����J�R�Ϫ�<e�Te�r�r�r��3���f�u�C�s��@���aî�e��
��5�`��|ذ���cl2�O6^a�����m��&��,�9�_�^7�n&�j�3�7`��y����ew�~�,'Z~`��_�z=m�ul�Jw�Z��.��ŝ�U\i(׉��U�\�6D�`�/œ���ҫ���J��7q�8���k���1݊C���x����%���c􈽌��G�2���J�=��0^�َ��z������P����q�;��E��_�m�:��l**�4Y�f�(��۰��N�N����R.��T����RyIL5E�aG���I�gxX�˻x(Sľ�%�!.o({�\�t�q�3�E�"��ȸ�0۰��W~�o�(o��a	����L�����B����"���_�fq�q�
���(~[��n24@7n�;�Ն�D�h<F&�i}�
��|���S�1�xh�q�x�q��!u72�}q�1
�<�{$$����Bx�+Ɋ���,�5�f��ς�C���`1?���D�S�t�2Ò6�,%����|5��W�?�>�������&A3��L~��_,z�FdM ���?l��/Fz�	�t���0"W+��N�O��@�E[�v"?��"
�p��3���H/E�%�v����%�>���/X�Ye0f� ��ID�v��!�C�|
Q��V�+�U�'j 긛����X�4��R��BT/S�Aԃ�{���*�^�ջ����c>��iF�h�W
��Y'���h��D���h�{ѼMD�AV����{!���큝i/�k��h���>G��D� �o���Z�	>�C����r���j$�d�	2\q���Z�-#��}�B�=�X	Y�����W��ʷ�V�nd�����^#Z�9Vc-��w���s#�޸ߏ�!�����@�}Dt�~H�P��0�����DGn$ZBV��:��}�N�c�H��8��]�e��<��O��OĘ'A~��~=���\%��*�q��c��c�wm/������x&0v�
H��q����~R$�)�y�t����ϱ�_Ft.x>��:㜇]�<����������s�2����W����'�����KQtwƸ�^�.C�ˡ�ˁ�ˏA�	u�!��w=d��X�1��Ǖ��J��*�q�%H���\��kP-�u-��V���E&�����r�
x�mF!�Q���r�i9��|.;��V�t+�n�<n�\�~w!��Н�N�y'l�·����jHX�������`���k�r���=����^��^��^��>`�>`�>`�>�⏐���~�w������������� ��D������O<�yv���|�#��#���=�5=��>�v�B~���>�O�O'O����|�ƚ�9��Y����t�'��g��[x
|�ٿ=n�\7Ö7c����-��a'/Bn/�6�_[�v+��
m�N�†_^��^�z^O/������0�6�o��
��
v�
z�����}�|���_�J�
l����}:|:y2y2ykx��*��k��kX�k�����u��u�����
��
��d�|���_��[��;�ݻ��.��]��wA>ޅ.y~�������0��Շ�ɇ��G��#��o��7��7��c��!��!�O�C?����c~
}
�~
�~�����3��3��ϱ�����X�������
������u_���}��/��/��/�����9�m��I�����7
���րｵuUuWW�K��N'�N:!�=�b_��f�"
	�����!�(��(!pC�]ԙ��s����1�(2�ҝ���N߼��	�������Y�s&��n���? �@PČ���)h��R沠
��a~4�<�:�o����rhOA�a�m�-О���2\�H6͇v/�7�����m����A��A�k�GX�4�G\�R
�o�܇�g��ah���7��B�a܇
�k{܃c%�������K��̀�e����y¾��o@8��Y#����"�����V�>��Ihз�;�>��%��4��ܷ�6	�</4�gޟ�}�
��F�#p݂�Ѐnp�B74�w!���_؆pQ-�ݻA�����p�%��R�Eн�/��pа�UB�^������>�po�wo�]�
����:
�рv}i������w;���n��G
��
���ڣ�����P�����a�����G��\;�@Ñ7@�{	�	�y?4���@�Q K�[�
?�@�}�}��&�������$����
^�0��y
\{*�gZZ9�32�	��Y

d|��l��y�@Ϲ��yp��>����̃���1�f�<��N�rvS
‹AvC?���,
^�����O/��h�d�	��������t�@��@�5w@�^׹h��k��:��z��ۡ���С�h��?��A�,����c[q�S�zЂ���s�}�ܿY���;�^��Wת��k��(
�����N�(ȁ
F,��g�_�8�+����Ͱ�	�}QO�>�#>�Dz�e��E�ELy��K\+�Q��3��@�Xď���znqG�c5m�6kUQ;�F���vl��X��Gw����T�_,�~<������K�t\�x�J<q�ŋ��;�f��OI0+H�7��f�yԊ�������u���_�s��� ��A{��t;����LHd;9ނD��"Q�4�(�n�YP]����cw)N�p)�p��đ&�3�4)���M���m��4���P��4?�Z�&���R�.���v)&ID�A|v�A���T�I��in�˅$����Y\�(��@�*�%�j8e�*�-���6w��Q/l��;����]
O'��,+�����G�	8L�`l
[��	��6,�.���5����o
������%^����xŃ߇���ciۗط/Q�Oԑ(^@������ǧ�0�*�mv6�g��|�|�\nďt�t�����u�&�V�Zd��Gڧ�g��x�[����(�9�322{�r���ܬ���2�ņ��eQ�ߝk�v�fcr[qɩp�����fc<�5��U�HO�{�ك�lT�����lkz+�
��Z��0��l�LDIق`-�������l+���p�R�:����z�hQ�R5R��
 |�z�-������S�6�^�^�^�i��n�~�(�h�l���j�j�j�c8ƅB�N���
��J�K�]� pB�7��a��`V���B<�;m����4�_��%�`���e�j1y��Rgٶ�o9��ox���OwK���]�a��mng���	y���W�ux�?���Y�{ʼn�	q�K���'����t�����۹'��.
��ZǛ�@�dC
�E�2
l}OT�T�������Y>��I���OJ��➧0�*f�@�@��f����G�}M��G�~֣�8�ی��e�������K�j{�����p�G��K0.�Ô]�%Taw��S��x����L��#��@9C���۱{�c�o���hYtn�
=g�!m�}cN��F9/��_la��F�v�qs�e��q��P�H��+\s~�ڱ���w�8O����O�r�Z6hM/�j������3�r�8��KJK=99i��C�B���,x�-��bԣG0������3@�a��ܥ�YR��Di~{���!���l�'�Y"�Cn�T.��2
��=Ґ?�뙑��m�����r̳֜�z�⯚ygm^+���j͍���z��IN�_�?�ҥx���(o������C`���͊.�j��L�olV�T��>��H{7�r�0���W�W���A��/^p��+\t'�0��d��j�T�K���ל���K�'
�\*+S~7{����4�������eNbߞh�螃$��������9g�?N.=9���͹�ڸ�3�,������'��m��e'0+��,��5��v��?��U�[�� ˜e��U���Z���pd1�9����WaY�����aw3x	#�}�	�G>- ?y�i[
X�h�Z�/mj�<�N
r@��E?QE
z#���3�5��S��4c�O?%S���L-H���5�A�B��Y����Њj&���/��y��$3)'�U��1��Z��%<"Ն��u}�s;�%~]~sb4��~����5���a�$N'�t�I�&����,
ޣF�FQ
��W3ki2��0ī��O�7q9V�T<u1l�؉��rd-S���[�Oxv�R�/����ı���.n�`-~�|������o���mpnt�6Z��L�eLܴ(J@,cpYM��s�LJ��2e;}J�xNFHEv��3�5<��]|7nF�����c��W�c����3Ii��tף����
��B���\��������n�v��ދV�9�r������wV�������|�l���[v���~������HFQ�o`D­fV��Qx˰��Vqx�F�a<�g�*��V�5���"z�5��c
�o)��˷���F��q�3�؎�:F��7�����<t^�f�����X�A�|���?)"��ܫY	
�/1'�@|�H���щh�]�
��V!�
���U�@�E����9�rK�b��呁V���'��5�B�s/����%E�M��i�SC$��[[Z�=�<�Mp���wb�����t	��D~y�b
 G�ջ;�f��^��4�C,�+���x5`d��񏠬7�
���5}��.�W���^�����`�݀)7q�l�b�1�~��I`v�M�R�[;�n���ZlU7HHnR����$0�����2�<���M�(��EEo�i��?��E�����s�	l��>D���M�,Raw���(�&�"]�s��-w��;�����}��9Q�{EC��5M3���]]��r��r}�_����ė;`��#�n"ܑ��tk� .'�'襌�h���L&�Ö���8R/q�,C�b�y�V���0RX��02�Gh��IH�X���Z����U�:J���z5��T���E��W�cz��Cڊ�7s����l<WQ�M���_�O|�����
����像�?�7\���Y�{+�}>Sk�Mo�2Jk��Z�b)5�a�k���W1��*���/s"Y(ϳ��NK��>3cF�*�������I{�oe\>?�H��ç{y����v��^� ��rP=��z��'K�����O^�H0r_�1W�j��˞Kc%}H�x)�v�z=�`�4! �H�y��w��r�7�����_�Y�֜yZ��M�Ȯ��Oz���vxI��;���y�κk���R�(Օ� �ˀ��M)��v��R*R"8�$Ͱg(i\pP�*�H��,	�q��00��5K�8�엤�ßα�0-�F�y"B4砯ȃݔ��k��-��|�R{��,S�֦��t�"
%XP
�t]����1l���Oٷ.���]����}�ѭ3���<Y���>kj�����k?�u�{7�_}��{��w�-��Տ-=^U�+�J��hl�~\B&���������U�%#��I��s������1�e2@����I�8�$N�聮��L��Cs2,Dw,��$�2�n����\�eMB���w ��xJM
ۊ����xRd!a5�>>C����!�QD��[ �N�E0�H����+FЧ�g��)_�"}Ki�5J��aV�^�ǒ��K�D5訢��ٰ�쓀�3�lD�F�+0D�B�al��<Ĕ�}���;#����73���p8qq�Y�����	R��{"��Z�nq_kǟ�UK)Gˀ�@�L�����V�\9�A�i��8��iw�QVeFU���OWu�Y]^EGKs@�z��'��,�x�f�9�Q���
��#��Ds<�r4��llS��)�E���G�R�]�Ī����+�b-%%����R�IQ�5
��k
&%���������Y�䍻������O����������>؛��_��t��5��o�य़.\�w��|�hb[a�/>���{��>B#�Pn�kh�>��3}X:qS���Mn~ү|����R5}��)xK��|.`(���&u�kkPp9Qk��Z�l)��va?s�5��{������u0'�tz2�&O��lzz|
�S��}:�k���v�&��GOi+N�[w@e��G�1)
��k+|��Î~����O�X[��kk�?o:�,�}d��{��{��y+�a�D�m/���=X��'ߴ��g�To���_�~l��mz�����2ȓ	Mк-�7�$�����͑�rwr�A4�R&7�D��MQ|�Y�'�ྸ���K1=����ӣ��c��`T��3��y���v6�d�e}{��{��w��G�����!������򀔗��Z�� ��7
���ʤB����ͣoe��x��<����.\�cbp��qk�y�)J�����_�"~��5��rIn+.:�B�<���(
�^r���坘!}���X����WQۘ���RZq5�J�T��l��F��P�)�3f̴u���u����}}��l�������6���kE͞�C6޸�9&T�c���{�ݿ�w%}F��J���'�
L���M�e�n��ދ��q�9�ߤ����_&�Ҕ2~O6b�!���$��D8�A��� 8X�Y�m�^^xG6�&X�C��0�
"o�Y~�2�ߧ�̳�t>苚"OQ(��voJZΫ>:%���H��I��֓.)JZ;�X��%�@5���e��yo�3yǰM�?����ߏ��ІG�~�=���?��O�ҙ=�(˪y�6�k@�I�>���?^��o�o���|Ǒ9o-�k���AJ�e��!=�Pc 湁�~ɔ��@��li6��Y� ^�B��������X���x�╣���G��	���9r�Ld�$�"#A;�`^�/?C�#	(����	���/��N��g*Ip�5����nk��@WX�y?��gEގ$n�
R��&���_��ٗ�b��p<c �@�!"9��d0
MN�?���g����|<�����Of�f�Q�z��Z7oM;�s{U�'�1���ʰcG+�֕C�m��͉���J��A��x�����DDV
R5�_�!��=��p�
�^
n;�"�q�Ac�]�d^���r,~߱���%��u��i�N6���0�!��!?��0y�5p���K�_5`-���!�e�?{��2_�`�"�%�7�(�nN�
�`cWC���� �K<�=d�����2n��c9%s`Fzz�"u�`�	�ϐ��9<�T��
̼���&CGSu��Ӕv�-�������Ĩ'
D��/�]P�K}���w�Ɔ%<-�=��ڜa�o�&�D.F�"P��/vT�j�y,�O��x|��#bFb78A���?rD����e�xk��c_����T��a��2j$B�!t.�™Q~4�FA�X�j�uCfs�n���
͕�����&f>_r�ލ�_R�'S�
Ӛ�)��J�iݢ�����w"\V���,-�ne�����#��ԙ����X��ѕ����D�,@��\�̴%��fE�p�Z��)�T
,���UQ�$�czxH��Y,qحl�?����
�dg�v̊�,xU7d�!L�ԇ�lQ��'kx��%��jޕ��QV�d�����X��?�=?��Q�R�s��~�ؚ����Y+�X�o[2���o7%���U�n�y��8_{x��y�vGO����ݜ��{6�<����81��?%x쩵
ݺ�}�}|�l����8�V�ӿ�����#����[s��� u���~h@:�
2�<��
E����hx��>���?+���.Fbd�L�r'X0��^��_A�DC��[�3�B��0�`|�|�zwģ^B�Ը͸D��頌����l^�9.I)>�or.lַ�Z����A\b2
�*�c�_�������.~Q0O���2?��Dz��ߵ�8X��q���VD�Z��
Q�᠛���k�e��pFz8��\v�l���d�n����\Ħ��0K23a+2��
�d�fR�Q���i�����V�G-3C����Ō�U����Ayz?htg_�~�G�+k~h�?��q=��#3.��*?ͺq�����d,X�ŮL��8É�K
0�⊤L&�������m�z��m_�H<����L�����ڍ�bK��֒�Ν�,��Llj�{����&fȖ�}&���GTk���l﹎����C��
�F��
}��8D���P�ᦧz�`�v7	٣� f�ʪ����Vs�r���v�|k-�O!+"�d�f7�R���\V�4]�Qڟ��/��h��.����$f2BN�Po��~dQm�T[)���EG��tC��lj��}�>��7p��hٙ���]����2a��+xc�_��r��w�$��뷯R0$�$H���]�0�:�N7��w�?eg���'"��}8-��/�E~a0�����/�?�q�[�����o���bA�$egP`1� <Tv@Pb�p59L���6EU���XҢ��
B���1�Q��i����C�V<^���s��ؙ���Q>��ɫ�
ޟ�s�\�C��}:��'k2]�fX���f�z��>p�����{]�zGHӓh��Id��J��>[3�Q-�  �
��LHb ,#���1�J���8Vd^"༧j�g���a�*dL�Ђߪ��65W���t��Nz��T#}{�Q
�Y�8Ԃ�4�n�%lV��CӘ!�+����ܹ��ʣ	�g�b��!�s=�����M30%L9�A~�Y�s�>�����~��e�*�:~�4ǩ,t57˪⪥��)�K��t�묧"P��6���RY�뺘�E���5��b�l0.Og����6ڷ£�г�:����~��Y�	zk
U�Ù�
5����_7˩p�/��4�=��c��!��e|(#���R���i��ޥ��(@���B��(�E[���D��������w�p���RH�2L@*}�rmR�/�W�㫑Z5��@m�͝�>Ɂ��k�d\`�m�sC՚M�R2�n��y38H֯iJ��?q����3?���
�}/�s(��#����H�G�O�����a~�����vx�x��O?��Z܋�EB�A׈ϴa�h0p�$���k2Y�A�4pvx[�H! ID�9�}�L��EAXe��o6���C�DBDY�_:�8���5�w��*�^q��m.k��2�!mL�յ��'���j���o��8�`�0ӂ�:\����[/$޹�+.������"��J}-�0h�&�q�#��͡�R}��{-��(%�"���~3�a��H����Z�Y�*\�
V���.áo������8
�Z��eЅ�;;�@t=�ׁ�h��U�ݬ�G�������ZM�c�1)J�l�˲OC�d��ፄ/��&��(��8͸ �QO���D&?Y������dgب�.�)
jХ<�%��+H�p�:.�GA�;
-�K�����i�
pM��=�Ξ�w������ϊ����s�	�������dͿ���/��?����ou��Y�`E��JiLO�,Ið���U�e챙�d�8	L�`�ϔ���	g2J�.�cuqd�Zq�f2-�ƪ�����bI�Fs�թ�����aB��dg;�¹�(
�jȡ��i��W�ɼ�H3�F=�񞦀U���p�H7p��O�&���,�C�)6lu���D*��pc|�=L:��'�?NLL\��܇���}�+
�T��V)�Dz�i��E4:�A�_b[q��&��{���IWv��oF�|��Ft���1p����w���3M�ܗ��h�C^\�Tb�:X,R�Z'2��72�����`Zdm�-�6Yo�ne6Z�>f����7��3/IR��� ��F�h�Z���/��rz�C�
�P�e��L��?=m�gͨN;�����?�qq�X�� Â����F}x�j�(��MV���vlQ���cv3g��[qX���p\&}�g�:plQ��XQ�2e�Q���a�+p��DDe�!���>D[�B�pm��Q������r���v��@��]ʋ��{G��ת�T)��'df�|�����Eި�xߤ��[ھG�s�82����*��
���:{��|���ʿЭ�C�J5��"����P�<�|A?�QuLs�A�`#z�5����:Yq���l�=w�
���.��TYY�++'�y�% o6ZL���/���3	�so��{'!?%�y񞲙�X�����E��e�ܕa��no�����ᒝ�\����߽�xe"H�,�V�Նgj
K��\��T)�9\��N�r��Y���ry3�j�k�H�b��ִ�Tզ�l)�3�m�;�MT�)S �`5�pK�d���I$l2��&S+�E������0#��h4�*
��N ��6iyH��9��j'
�0F��+���t�R�I2�<U���.�פ�M��1}��CO^�@��_SlE:+U��h�~q}��+H��cYRa[T�d,�Ճ=�x��R.RǍu���%����_�8-���w^J�^n����ѕ��z��+̔_1#?b�{W6
�
|�
�|h���%a�4�6؉��=W =���L=sO��MLw����0�`�0�B���穆eW����,}��m��x<:`����aT꧐0Y���|��׎�we�U�h�.�AOV6�H�@�TN0=�_���O������ǞJ|����/k|���O��L&s��E���:����!�p���>X�����1f��ȯ��>=�����c�Q)�����m����5�TEu�و�k6��Ԣ��!�W�� ��V�����/��(~��_��|�K1��
W�e�_��w���q8K'�G��A���i�jg�=P�KȬC��
k\�oǮ��Շp�g��_9gwbwn��7M~ves ~��{���!�#p+�u������n�G�>1������e�=���� @��&��'2�4�qm����M�t�qa%ϒ�5�ą�r�*����_�z�j��[Xa��<�8�Yq��܂�H+.�,�L!�|�6&�P��)	r�$��%AN��=��݈���XZ�$(�R�B�r��f��f��B���d�U���l	5��.O�e%z�)��ak'l��o�ē3��~y�='��&�l��齉o�ܻb��	��
�۰�~��	��ys�pb�陼S�$�������s�'_��憬��+�k�N�o�A�F�i�h�%���	2�>U�Z�Nw�+�����/���v�R�Hܡ�v���,39J�'[]�&g�4w�Ł�ٺ���a3Ȭ!;[t�:Axٖї�����`fg�����@��#I���c�6��T�f�K�j׸��CW�\�ՏW�]z����F�u�
x2�>
$|��g�=�먼*�P5�x޲�-�a�U���9�1�ŝ�}l]�7�^U�ݑ�[��8�(������
#��YU�����
r_�><�
@�M��|*Ӵf�HI����<RΖ*�X�Y�f)w�	0�nr���ʌ�$�t�eU�
gd81.:��Lī�"��|����������JJ�+��T�%���e�{��ӗjV�ԟ�=�����y:��J�5W��P�q)~)bk�&MFk��ԶԸF,i2��V!�S�$���d�tװ�P��
�[�u���4��<�=����=�?;�9e�w��//����q{&�8�rh��T���݁�w����d���{g���6<�������x}��0�	�W2�br�����A��ny�)�;@Ώ��CZy�~���0�
�	�p:)�	@lr5~y�a6R��*�Gczfi��R�@�WNt4��.��U_�������Ī�+�t}�!�t"��cs�d���?9�ѣ��Ӟ���%/Rt��XTEKi���Nv48n�+�5A%�f:�����Ph�\z�(����Q)5y�L���V2WS��!6‹�wr�i����cwm�F�1�ym��DQ{ zug 	�$ ԥ
w|�'c���
��³�s;�������'.?��My�V-._�k��3�W��9�q�M/��y�!��v�_�
��8<b�.��ڱH�pH��
p&
�L��	��<�K�W4�e�9���9?^����gd�g�w_�þ����G��H���B�k`/�r�*�%�ė�=^��Ћ�o^�3�m��w={s�f�,"�Z�O&�As�]x�G=
��ӄ�<[�V��D`g\���RE�N�0�V3:� M���T����0�
�g*`�%&���MKs��"$�Y1�T�h���F�X$�A��>�.��Aqe��.����L��a2��v�4�5'U���ivT�>-�@�ĭ��( ���yH�hI{F���jz�G���V�|	��5�u�'ﶺ3D��1����.e�/l��@���3��,J������p�hMQ��"3*'�Pj��A*���5ɨC70�4�,F xe9~����mh?�z����;/�t��~�y-c~�Ì�rtϻ%����bɣ�j��U�/�t���Q����*?��tf���r�q�<�8@�o��댭���'�%�N�aB�ܸE�j<f�,��S	I!.��
Ѱ������j2�t-
bF]�LN��f=�'�H_�� )
C��n7���jU��F��F��QdP&��M��0�Cb��!C��0�O��p��e���0��vLB�I�&O2��IDS(�_Ռ~"R0}��o����Ќ��}/�М���v�u���%�
N���n��2|��
�[m�@g(��…�Z���(k�4s#A���	�$S��g�?xn���
���(����o���ks�䏉S�;{��0��=p4C�$�\H���hD_hc��$a���8,e�ؙp�%��2Et��1�E���v��E�0�b�y�H"������W�Whů�6�~��<�?�x2SE���I��W
��z���
59֪kⳳ���^�3��h��O�
��g!���_����������bH��D�?|0���u����
7�
��ĸ퇷<�O\�I�GF��=�z6�q��P�p�氅j�1}��X��n�Y�)<�S,�L��1�8�+Fn��b�d	��(ov@�ُ��.��~M6C@X�)�Sgq�9kQ�D�W_ƿ���%)1I��,)��D^�����ѫ�
L˅���@=*��Pl#���-��޳*
��G˕�ݹ&���,l�,���������Q�wSbБC���v%0X幀���ss�ş5s�	�s'9Z�ciF�ܳ�G����%�ޙxu4~5g�
!�K�
���8q꓌�"a��������_��z�|��&O���I
�3j%J3�P�i�~9鸺.ρ9�G.o��,�˵%����
Z8!�;`�%�	`+�xA�OpЙf� �?�Yt�mş�05��ݡPq:��z�c�d��V�;�8�<��xOb�6�l���$��G���	�?&\_�-�K�`�6�1��
�0��!�'�����{�lA���sɉ�x�M78t܁F�A���g���xf˿��W>#��k
ln�@?�f����;~M�P��LY���},Ѱ~=��|�(Y��@������Nt?��bD���n�̴"
�h��b�䐚x�s����h��K٣ؖh�lR��l9��2��6zr!Αr�1��'��"C�aB`n�--ȗ٢p�ĘQNf0al&���D
$�]�L�l����|^!$��Uo����e��P�ٟ����� 	vdjk)�T3e2�ϒ��`����"5�c@�d�P��1���CJ���4ߩ�8�Q�D�r}���ʋt�Lѡ+�񼠐Pd�)O��sj�����a�nѦ%�g*<�����^��3�ޡ	sX߯a��G�m=���[�Z�Jư����1��cS-�8��ڑ�SJ�fUT"S�F̘�8�s��h�
�m��gȤ602g���c��>�R���s�q�+�
��e�e;Lz6��l�1�p�/���[In�Y��h:F�E�����ߥs��43cD"!�Y@�{�G�sQQ4M��^���u���_���Μn���
�͋�qE$619�I�I��jv���cs<��i�[�Y9�0��H�	:����-붏��ڨ�k7�n8\����>�Мۦ�8R
x=~id�O����CS�-y���r�F�e�������v�<���T�4���Y��c<����Y�
i
�j�I����v�=O��I��7g+ce��MC�hl�Z}���2��������ts=RT�(�3*�w�f�+��5�W�9�R3x���dꃷ�d�tJ�@ˀ_��;0~��O⛧,<<yE}���v�k/~�Ɠxԉg/�#���-[6�D��|C���б�(#����^N�U������j:�NŞ�'��	
ow�"�
u��뉋�j�p�O���f�Q�����D��Hv�Mo+�ƷU�T�"�a3kn�٧���Cgq�Z;�O��k����kt��)�����.�	�k��¨�=v��C߭xu��S�w�&���j֦
��.hr����	�=���� �ܢu��=���;{n�հ�@���u�B�Ϣ��
A|4��T��T��Y���<��3�N���	1�-��^�Ϣ4/b��b�@�*��
V�(8`�X6�[`�e=l%V+��H���ܥ����P0�o�\�RdV͋͟
��d��$�#���T�1}D��L�����t��ŧ�֤�؅@*�ŁT�$3�P�疿2�A��=�?ʕح3c���nY���`�����m|>��۵c|�}W���-�'�?������Um~P�O����l��97Y˭&�u0V��i�c�e##����" 7R��_�vR��gY�w�5�-�3KU|�K��G"�c�P��r�omksM~���D�MQg9Hj�h{#5,���Z��!pj�@>�Q`^bV���\�nI:g%��C��%7�x{��>ev��o��ܻ�@㬾��f.�~e����vHP*�gQ(�Q=R��b*CQj�{�{�]%���+�r"��H�5�E�>��t��`{¦���	J.��.�M'����Z���g ���>���2�n���ԋ�9���Յ}�"�:׻.v�#�$��S0���N�;8���Jт��K�\R��z�H|�	������b�K�q��O���k���X�4�ٶ���)�UT��R��x�\�39����(a�[���j������Q{dHQغ�Ѓ>�͚�7f?�����6�;;�+G�
�Z�{A��*�Y���8�W�P����f\pϫO����s���:�C�.�����~���oR|:�t/���v��,	�g����sC� �f���0WXiX	~��3��Y��e;����;����4�v�I��o�^�-�p��$�T���E���Vӻ&V5�4M5-2�&S+Y�ziy��
�n�4e�G�1RM�kM��>�¨���d�D�o�]���ױ����<�(m�Ԍ΄�����b�%(�x�����s���PG�l��7l��{��!f���?����-���Anߞ]�on�k�J�ޠ$�:p�&e^e�b~bX�f$GU��׉O,�'���G�bH	!K�B��vzf&�-��B���j�p+�:���������X�B`V�.�N6E��"��F�H��t��_��(����_5%�*}p���5�|+�{r�^�ܻR��������@����'�/�ݶ_�Q�k�S�Q/g��0x`�T$1�ӖO������_?�vHP��]�oq�}͌Jf�&���[a���1����wt*ʼෘ��&�_1�!%:��ӲDI3WM3�JERT)�R�(�˜��T�|m���%��+k>O�?�>���q��Wk��(�~#��*�W$&�09�C����X:�	Dh��U��=�|��e�r������p��������+�
ͦ+��x�Y$u|���j��Ӹ��|v{7{/'�,63A�A��'�k70����j�E�h)��v��t�
IL2b'U��K3�p�j�:�s\ɼ ekTOy�i�@c���d����,��'*I��Q2�.<}�E�,���z=�$��V-"�3�8�m�ꖄ1���K��ڍ:#�`���P<Y��(�Zy�a��v����£�V!Y~d��H
{#Xv��uT����%��'�w�^����Ɲ�r3�wbi|	<�8H�n9n�.�	m�4���q�q�
��"�w�{����0���"Ā5Ջ�n�4�V�z�u�=Dg�BL8/Y
W7�k$4}IRё�FQ��#���+%�^��'�������u*6�����F)A�g��7��뵽K����;�nZX����vU��G�_H"�z��M�J<|��]��������'�N<��*u������^�Y�,��P�2���G��R&/���|JI�W���\>�����v?=��>��l�mv����c�͞��=>�Q�d|�/������n��v�T��p�f�e���1|����"j~�u�
��U�]�QC�4ɖ��Ϊ�X2��ut
'�:����{I�3JJ8�?���"ԑEޕ�s�Ggv�q�O[rf�����<s�F�Ζ�l��G�olٯ�-�yl~V:�X�0e�̵Kz4�Ǒ��rJ�gz$'��J�'JH)tQ�t��Q�
A�m('�ud�qi2��<ny
@�ۆ7,
�t�q`�˥�JS��J
N,Qq
_0�8�Y�|��2��Q����Ic�
;
��
3�!k �!��IW=���v
o�W�E�jk��Y�-�,��Mu$Z�<j�[G
)�Sܐ��^t�TBW)~�
7|z$w�����nn��:pۇ%s��م��/�uk|
ypFQY��LXA�gAT6�� ?ZqYC���/� �iY��ϥ9��D�$G]f�o�c������r�*���S��c�e�i�E�(����
�F�9+4���j9
5j{�g6��ڹ��	N]Q�3~:������~kAˮE=������i���2�W�}����$^96�����+��j��ɻ���]���h`�@�,(�~Ѳ���)�I�f����7��1up9l7s�Q�V�9�����
#�Lt��M���9�{�!c%���ܼ!���d��Œ2���d$1)��)�%���Eީ^�m%
-�fzD���ݲ��b4BDYajNQ��V��]}��C��U�S�2�ܱ@45���!�G���mt�
�'�2���;p�Q_lϘ�_���V<m�,~��ۦ
\>�_��{n��៼�h�Gk_�����[�Qx��{����Q�y
���V���*�V�&35��k��^g/T��D��|�gQ_XRJ��PWz)��̜��WU�ӈb6U�^҄�6�4�ҊE4��Uq�	����jT�NU��x���?Ra���Ԁ:�C��Bh�:�E���Gگ�.���G��†kr&tV��4銬�dI��}w�}����~�G���wZw��>��Mӧ���W��˻�b��›^��?3���-X�u��>�,MEO�d��]�V��&q�a���&��Q�k���_>D�l%.'Cpފ�L��R!S���S�iN�w���T���R�u��4�������{��\�Suo��Y\}M邎Ai��Y����@ʉ+.��&g�y����̔ߞ�©��']%t���y�4rɜ
��pᘃc�G+���z�$6���Dz�O�'�(�j��1@��C��o���R��i��恃}���g1˙����>#+SU���T/*�m�#�&v�$o��|cv +Xid�F��{���cl(�<��&p�<9�.��.�4�$�z�����5���߿7�Q��Cr��k�,�y�ȩ:��N�|�[݋Ic�������pI;8�Ʈ���D�J&�Q2�ǩ���5��򚫫?в1�>#?���mu+Vd�$��?��S���}�]�lʼ��5��Mms�m��r�M���-��_��[4d���������J��2��ɓ'�Y�o�]�1�E[��a�9����滕{lGŧ�ϧmg��1#�\`1�ad���'ե�s8�l$��^/[I�I�R�Y�š�D ��]ª�;EFl%;��*��ſ"��.�9y�mK����'*=9B�Z4�d��II���?2���Q��mg�ΊwG��|z�+'�z�^KYx`p-i؎�5����-���,��:���l�{B[�1x�}�i���������ɽO�'=�<�r�
�ra��Ը���"��2��:<n�N��	(�V`��Cag���0`Z�b�8E�����y��
;=Nu�;)�0���zFz�zyXO+YӜN�H��ߝ��q�s�sLG'�x\���J�/�_-U��nz�VgM1�M�5;I�A�GrVD,�G%Jל�N{�G��u<z�d</���@ֺ�;�C���pfLk����v���0��8������uw� ���!�nM@S	Ԇ[s�q��G�
[�u�G��L�-IN6W�Dt��&蛁�$�Z�e<�A[=2��pl�G���"��!��5�U���G�|���5	�s���ꢓ7�#��8��S�����x���l(~fڇ�w�[��������}������I�g���&f��ɸ޶ѽ�{@���+�k�k����:�z�]��Upl�Q���岻=^�������)6�]�g��)I��6e����gz�d;Gf!;�}ƛ�ry���s�,�ɬ���Z��fR�
��j����EM4��خ�m6�\n�R�_�%<��qO����tר��Z��I���d���9t���?��� !B+�t����b�,O�(���n#lf~��+A)nlk����0K�*_��D0q)s򜅳I~����M����Y��؂���t�:�T�7cE�[U��Br͚e�e��I���[t�Qث��"�sDxA��1��
�dT�,Q�y�Ǭ� Cx	��l/͔id *#�y&2�Α,���f|�)��ޢ�E���w������z�6��]= ��n!a���4$k[�
�E8ST4�	�:�Ї�h����e�֎���R��֏5��*��V�BdZf_O�r1��I���I�a\�I�6�>?+��@҈����xK������XC�ib4�hjGwkc���fԜ�%N4�&����Jo0�&Ev 60fU-� (&ET�d��$�7H��F���"Ջ��9�8 |j[Q{�:=u�*�K-�y}K?��պ�Z*Ryn]E��ԷɕeY�=�>9�m�?�<���Ĝ�UO`�<6/�աC̄_k�ZBC$���bAg�Q��&�����Ji��k���K�(K��!���a�-I��KK����#J<�6�UD��E��\�Eu��Ɗ
�N
Ku3
ϙ��R���;}x�RD�/�Ѡ�R[�JEk�))ڢ�=���S��I�Q�q�T`Z�rM!K8���=����2?S掟�1�@%~(���>�������泧�4��ǂij���_�����'���̳Ռ51��=?���n��<�B&�ׅ=z�9fs�HWi%4����<�O�2�t�0g��g��2A����=�
��q_B�p���C+�z��qZ1�^��k\v���Tu�腣Jj����k
K��g��
BrE�����K����w�,�NjO^�'8�2�7~x8�?d�!�f�"�U1%Գ_��Z2�Ԏ�k��έ4�M��ꉅ�@c��ݻB!��v�d�Z;�Gz��?
���h<Q���=� �`D���Dfv�AnD�E�S+U�,%�g&F�^K�ո�hҤS��f�S��9�M��v6߃Y��Y`uڭVg��HgA�ߞ����{p����(�%�~�'��<�g1{��8�N�k�\j)�>�s:r�>����-*�p���%�[w�`�h��E0��^м1P���W��P:����
�iW'��)8�fm�5}Ą>YI~�,���ܕ��h����Gҫo��(2�aR�=�t��yU�����
��:;�ajͻ�sK
�SF�����Qc��GH!�0�9�h��ɺ�JXYv��4�rn�g���2��s�<�ɋ��q������qF�_�
x\7��ɾ@E�D�.�V����Z���
. zG���z�ʁ�}��k���^�>Rk$�WK3���ޯ.O�_�::�+��!!D�t
�N�E.�Hb1�!�����O���������>
��<L3�v<F�N&ѿ��������Q��xU�5==G�}gf2IfrN�IB �@9D	hDENA7�*"�^ȡ����T�`]]u�{wQ�#�~Dփt�U�=�$�~������O�=]]�S�S�<�78��'��z�ǰ��g�l��Hj�ppD1u7�S����{#֍�
��̶�Z�ݦ��h�s�w8E?���>\��q��ܟ��~�Ek\����q~3.tV�F݅�A g%��<p����ɟL�B���S��Oy?%Sq"���؀�Ո|�P�;���r���Kq�qڡZ�;��@1"X�7�h���)q���@[��*�����߼�}�7|Lq!P]\���_T[�T��G�#Xݝ����'���ԛh��߯������bnow��7x�z��o뺵��p�yJ�Yw���I�����p�W[i.���,Rg�D
�����ݣ�>���r����_S-�e�D���������9���s~�����������0nj!
�N����f[w�M�]�&���&���l&�$���I�����~������w�6�9x�7۫l��iw�B?�
��:l�\6��Ri�LK���q!�
"BC��zy��D�{�KZݡ ��J��>��_���)��#�3@K��B�M=KKUا���/-��_H�J&;��J�W���?��^Y��|�4镬>5��}�G�&����lX�=6e�[I���DK��;�&Z:,
TSbkbo��k�=�ݧG��{��~��C��bl�`ۺ��1Tѧ��Ƨ���[���HqÀ�/����c
��L��ц�����`��!q%Tʆp�?P)�ն}S�>�)
p
���Q����V�-2`~�]ό����|�u?e��	��x��y�!�����9D��߃֟��%�K�n�	n��������uh/���0s��O�q(*��-R�� �F$J<O������#J?.a`���<O�
���F^���
�
O/9�s{����x��^h,g�J�!�t�R`���;"U��%*	t`����Q��R��ɭ��ư������	����ژ}L
ֿ$�
�[�q B�
=�]q��V��3��?@��!�^����%���b�LG�즬�A9m�.~d�����MV7mZݰi��ydѢݏ,6m�0��u�X�����l���>a:lc�(�%����e�8������͌D��h��.�
9����ɐi������w�#�H�5ė��df����z3"6B�����[����$#�6�|&_��8(�Ća��>b��R�A�sJ;��)G_�~��iZp��z_c����P�c��sl�w����™�����'���_�	m�C�hFxߜ����s��<�����Gf2�{��Z^���\h$n�,��P]����rq��v�m��^2�˒(�~ؠ~u�F2ƕ���Op�W���7��+6H(����4J�p0���pF�(� bv��좲e ���H�-�"l	9#[б*��m�_dnCW4������X7�a�b��W��v]�<CY�`]���v��g�g:h���D �־Z�'�!jűJ��k�kO7*�<Nb�P_Mi>H�_�n ����ۡ돏����u��UO9af�8uI�w|���ƹ��D6M��m�g�7{�����ˏB�c�5�<���U��|�^�V��i4p�o�A�x��`�RJ��k*Ɩ^[�LJ��+�3��r�\p������x�S���-l�vB��$Ԇ�W��?F�|P�A���
#؆���c
s넒��X��
~�X��/ɭ��-�����9H<��:���Pܪ4�;���V�	
O7�yOje߽r=�T����fqm}��}3�����������?�D�S�[���/s��n�TR���Gs�^��r_�ˮ�)y��,.|s\�z�2ﱋ��s��5�f4�Q�j��\>�eH��
7=�)YQ�?|��1�ݚ�SN0���?�Y�Xj�^�Ȣ�����V�I��i�I7�0G���w����;{ֽ����3�h�X}A=��4K&����J�X-�
�%�)�(�bc߷�C(�v��C;��+k�r	m��զ;D]1��2�=��i�b���|\���җ���r�џ.�y����v<����J2+��i��x6:"FC^n"+�f����PYy�~�U� ���#������{���c�!�׆���HN���eebyy��D���B;��G������)6R����ߐ���=�4AG�i�C'�Q�n���F��W���f-�������	L��l��3�۴��ꒋ�f��/�����G�9D�{���S�^R���1�P�I7̬����N�z�ͣ�5K'M�-���)�?��7�	�����q���
��w��܈h*�-�,���d&#�ja���#�og2��Le8@�]�!?.$�%�ἰ̻�{��1��^�ks+���6����$�$J&(eeo����伝�r*?���T��Ց#��#L$'š�,{��d<��6��9��,�A�4y���VL6|��XC_�K�uV�=��H��&)J%��8c��v�g GlO
A�$�"�B��O��=�����l�:he�������ǎ��_�ya�����‚ݻa���껪z6��zv����i���,�n̮�'�_y/���꽯U����u�x��v��<�[}�^���Q����ߙ��������]k��	�{���������C��ϊ��C�q�mO>�lJ��|/�%����G�j˖�_������%J	���%����������K����)��$a��(������,G3�ay<�=U�{j���6���=u�aa���ƅ��;	��H�5T5����t��$��량+3�nx��kڗ��tdYƒ���ݸ`�����锳n������z^h��G�o`^ՠm�h��T�5�	I6��"�n�%��`��𱈸6X�XX�����,0cݩ
�k%A�г-�1��N|I1��+E$�p[|�lAV*��_FO|��l
7g���,�1S�@�w�LP���=�$x#h�.BY�p�b1����?��Y8���^;��ݕ�
����#�d����;��Ή�`�H�v/��z�)�K��hb�05���p-(������'�f,?}l��[d����
�s��>wJ=����L��"s�WDA��)����ɶ��[�N�č
[�n�	�7LT���4Z'�uZY*������[��c�8���kǪ�S�P�e�?+S
�&�u�C;��IFт$�h�&�`�&g�&��1��Ი \�$'B�U��e!�f��$
��m6{���f5�ѴR:��+��?�-ܽ�7�?���D`�7�G�f�;�����4�>'΂�:w-"��g�:����׋��{O���Mτ���߃���EI#�$|�����+��P���Gկ�5׫�(~l�Q�W�_
?��C����k|N�O��>��~�a2]�I;���!b�H{Y�3�qm���&�찲v�pt��Q��	��
�S0Dy��#�G�l���IK�e����f��(FM	�JÞ_6Tc��2��2�Xr<"4�e���}��/�@xL��S�ω/���t��"e�8sF7k�Up{6Ј<v�:+��-'am�UC|��
��!���d`���Y���:MSQg���������?���������Q���z�� ́Oum�+�Y����f���m3��f�+-�3�*p�&��c���Ve�9���7GH��z�e�x�����r�~3nn)�
L9�!��Ŋ�B�DV�8�2�pܛ�â/��.!�æ����8y�o.�Å"cf��k�+=b,���y<"-�q�4�"�L~��D�!C��q��
V�_���&X(M�n�}�/#Q�A�\�'�O�6*�Tzw7�V\�C���B��Ԃ�츰���O����&?����7n��ޮ����y�]w��~���iXq/A�:p��<�坪�K^{�i�/o��Z�%G��z�+�R�^lG/���

�������`���.�����#�H ���.OY�0\�i��^)ז�aXܷ�8M�@�b�
k���1�R#Űض3(��yJ;.�yv�X�eu�n��k=����+��
�R<�`y��������Nߏ�xa�*@�_ZhuB����
nj��;M��Ɯ�f�	�f�Ti�.��'ΜX(w��ƅ�
�ܸ4b�
������+ni���	U�|�z_���
�&�>4t�����^�}��wN�~b҈���3g_�/���+�nj����ͫ޶����>�}a#^�n-�.�1gA0~�5UF�����8ʞ�֋�S�f@&����20+E�*IQf�(N�e��l4��V!��+�^A9���>�@?w�>���N��9 ��Rn&���w�%_����s�hy�ù�#X���(x�aL� DD,��4���+Efa2�	��O�KZ3��L
���fq6%��I-\�U:�))�y�Ѣ�������>�ܠ8�r&
�3�x�RD�l$�L�,�ϢX���V&B8*��a�D�NA�Z$�7ie�j��U�\��M
���w4P���@>�'KQO��X�ތ�ݬZ
4�
-�s���k�(�K�*�&�6�s�}����ex��h2[�A�I�,��]��֢p^���?�q�3���3��G��`P�l�:V�#�nu�'�C����4�V&#�G+}�97��%�a7� �F�\ɑh�	��ZC��R
��,4=ӛ�A18�����)�H�����,-%�4Ydұjh�����z K(��@�0����auf֫�\|����Æ/:O��B�0܊_����};zS}�o�1�V�/:�����I�������>��h�a�m�s��z�F?�0�6�0�6�y���6�i�%���B��
-fs�d�K���1pz<@Ƃ̃U'`�B�.Y-F�7a���;U`fxX`0�Ç"Vh���
�#M���&w=�o�����Z�X�T�|�f�!ޒ�����y�o��$S��o$��g��y��jk���T&�0�U[�`�uW���q&�4ωϹ|�J���>l_����s���|��q�'}�����y5�UD�X������ ��̉���d�6g����8,r��X�E;a4��^���"G�]w�F.��H,�H�䳸vg���)��]GO��
�R���<9aϦ{|P�H�����ov��+���߫m�����cl����������CG]��nva��ǖ������������
���:M-����wϭ
�]������C��R}��
���D�'[L�dtJ������N�=�FI䣂�R��-�D�6sSD�0%��A��`a��� �L����&�gɛ�/�|���B]����6���8���`���}�\�ڹ������Ǹ?=z�sx�Y����:�'��NN^�L�nք��T�g����
?T�m�"����n"��Y�D�lН��0�b+�}�M8r��%�O?����ҕ����\�X��A��*z
��N6���&��o��+����YY1�g��̀rg9���(R��>���1L���tvvt�<Ui��A��S;~q}�[��F���rj.��M�
L-,U��zl6��-&T�+��4��v��b6ӂۧ<$���r�by3�]C:����5dhya���]D��؋�`��6��"pT�?]�R�$/���������SK �ĜܬLc
�h�d�de�D� ��i33mq/��,�3NWQعٹ�I��G)�hW.�mE�@�eV2\>>f÷���	��Z�F%�x��֪7a�"�i
Y����UC��`�X^�!�T��zPJ��
� �&e֊���Ϫ�^���ߘ���;*B��_�DZ����0���K'
��������55�Y_<�9��X*;C��D�Fܞ��_�Q�=� ʔ�f��|a����NwX�gX„A��ժ��)��֑"�FZX�'�U}�C�6<�jӌC���\8j각���76�m����_Qp���w�%t��Y��vq��<�Rk���$��
�����9K�묜��f2��l����
���a�l[�l�=a�*����p=�_�|V��@.�� �e���6QW���u�r	������3cQqp
ևw$ȕ�<��䢫A~7aVN�A�)Iv���-�B�BZ�@9��U�5^�l,:*(�'�ʰ�i��K�`nդ+v��18��湓ʯ�s;_W0��i�7�}���:�<4��J�<p^��zX�y���P]��y&�3p�3o�����W�;�Ѳ
������ւR0������t�u�m%� qQ��q�ߋ	��%V[�(��T�����#�Z*`k2ˁF
v��.V^Y0H1���a��(6��fs��!��G��������d���Ͽ�����a6�(�z�8�0TFr�c�"n�`*��>zL�>Ԇ|��"f�h
B�2�S�qr�B�"�	�܈�&�4%.f���Rҫ[sҐC�Q��Ú�f���J����ho$��26/�����Ф��,>>���<���%W��Q#<W^���xs���㝕/Ͱ���];c�u ,�`����ޘT;�a��9p���}��+>~Ǥۇ;L
��ґ�Wϰ�|������5Wgdl�o�1jwS�?�,F����qWO�Pv����2@Z�y��|)⪑��FK�]�
�zˣ�QKl����DEbxb��x�����b��a�	Y@�یL�
f�4�aF؝`sL�	�
�A̙pg����
��0|�����k��(a{�.�
3��YΉP���`�p2G���s�r<��F�eE'��YY��/�
2�L�
v<�O:�6Ւ��{����X��w���C��ɡp��pC�w�%�mDžx����
y<�-��e�eK�R�}����,��w�!�<��������e����#�^����+�k7�mY��
x��֪?��>xJш;O^1�K�'Ջ�,ʵ
˔�
�By�a�a�a��/J
��:����!����4�؁%��ۍ��E$u&��4�������K3�H$�$��U;3�Ǖ���{B���(l�nÓ"�Ӝ+���O�/6��V����Y�(��3�	�ޑ�cmlΉꝗm�0�ˍ�]�����������^>���Kչ���R�����6�����7���ڳ�<��^l��+n���S̠$S���a#g���F�b��v~����*A��
�s8Pc���S��d�{�l�ΝR߃uC�#�>��ȁr�Y��ހ��6�������N�Y���Mcj|��_�U�$,����k�1X�ۨT� �
N
�*1��1N�B��
�I��8�� LB�)*c��W)����!
e�ƥ���J��[�� ��J1Ra���=����B(ij!����ʯf�Bx�0���L�e�}玓v(Rdz��@kM3�f�
#(�@0J���f>l���#�h`�]vyC�/9y^
y%���!#yEWD��`P���#��L8b��c�a�a��1�2c��D�g�&�J�d�l^���LNM"w��n�{��[�"���:�
��T�t�2��b�K+��g�{�{ݞ�q��f����p��{���W���t�����q���A�r�{+gϼ���!Z�*��]��
7(�)ހ;PH�}�L�����/ZȘ�Lm��&y%V��o�Εx�ިx`9jC��7�._�_���ycϣ���Wt�b
^ً����w��W��!��-_�*�Ns��|7i��%�����9w��d��: �[�X;���~��۽Cw���b���W�y���=�s�=Vi�x���'�g�gبr��J��|OsKF���?p��O��#�5�c��`��`��9�A�X��&A�,�3�Q�M�t�j
u_<�~�ѨȰ�eZǩ���ڟ�f^;WE���`;�y�x���Jx&����f���%�he�,b�3@��p/���g
O"��YE�G�p?b��,
^lf|�yih��K���5gj��K�^�k�{��͉��z�݉�j�P�����q�.��3��L���x$Xa"���r��l+���@�x���\�q�ɉ��7/��?�Z��cL}��-/��w����K����
5�N���Oj@�LP$s���DM����6PL�q�T'�ă������[�bh'Sw�����(���_@����VY*��`N����r�K���n/u!���>���Ӵ����������<^��u��
���>���0���Ǐ���?���"Њ���a9��5�z�薧�~�q�h�W�)�f���+������4�����
�R��'�ʹ��<�Lf���fW22|f�f��8�E�=�r9�>KN���mфՂ2��;�����}���5��/;ڠG1��b���Q�g}Y�W�m6���ְZd_|^q��|�G��(+J⫯�Zd.��:&�v�8������
�
�,M��|���g��mM���	4o;��2�KC������9�?�k��N�����j<:,����\{�)ֹzz5vni�
��N�t����ucn]V40�x���@X��'Oθꩽj�����|�}�������\[w���𘽱�0��A�|�֐n�hP�I��^�s|&�U�!���ں�$���"zS�%@���$>������}���W���ܝ��+< ?4PΊ��-J�]Q^��x��q@�f3
�a&��)�,v�DE�oP6p��G���
Nى��Z�-)�…��j��ݞN��Ӝ#�~����cc��IS�����k���&=��n�R�L���nt�W����_�̃׿\y���k����b�.����ّ��l[�\gźyW=;s�ʋ�[̔b1q˵Ӟ?4c��?��u�59��y��qY�-7϶�u:���}�����\���¶u����;]��/Ԏ�m�b�
q�_�_��,����;ɮ��
�T^��@�I(�	�ܴ�@�G�C�S�"<sE�It��fO��e�V
��<>W��o��[m{�=�y�J�&�9�&(�
�1lD�6t��	�92�WP�`m�#��R�����\p�.�|Jä`���~������u��xvĺ?1r�[9��W�Kr����>�ʢ��ʣG�ޱ�>������&��-�^�J<�ϖ+�
�%ew��"�V#
X	�<�jې�P��E�C�Mc�I�?�*�$���R�vD"a��6V/���Ҁbs�����������V�n��%Be��G�����Y��vo�i�nN��vx�N�4���K�׸����F�S��
̧����$%��w������3
K
����Ҧ+g����J3���g��PZ����z2��֧�����ͼ�*i?�R�Y|^�y�!�R-��nu���u7l@����n�Q���n�ے�Y��CBzI�y70��hpPwS�4�Xk��L}=����J�7��M<���Xg,��	+gs�l�,�5�վ
�q9�~�G<�ɺ�
�����4�{X^�"������9��l=����ٗ�T/ee_��j�ۄuLSb�ٓ�I�4�#É����`\S�Xl4���Y�׀Gk�D�1����@D��of}�jMI��'��)���AD1="B�O���
xk��$�gr�:+;�W��:�unG3�^@c�i���z��Z����C�c~�ƅ��D�P�DE��1e[�0T,��B+?����G�
�y��(+�X�a���)0mpg3��l��xt�
�j����,6����)��V�d���럝���~^=������]_s�8�\�@kV��A4X}���� �J	��~)`ģ"��ٮB��.b4�c2"�_	�3���#ϧ�A�hb2�B�e�	ɎOk�Ŗ��%��ت�x���'��*���ɗ���F�����^�OL>oR�l�"�v���"Jm��uX��/��#U�e�=�k�ciE�wnz�˝_~X�~Oi-	u�6shy�s���M�/+\��z7�
U����������딡�Zg/��A�X�W��f���)�,v9���s���oV�a�|���dZ���*��T�z7�S�f@�C�߆�E���$�(��"�� �:�]ʮ�9A+
#�HF2��dĴ���%4��<Ҕ�
[�|]�?��q5�^�G�|<�.�Zj[��*'����u� 
��eB�h4�gd\^��I
~�&3c2Z������XF��o�
	��D��6B*`�.���%�ѽ��,F����g��Dk��hC.�
D�b
�V��Tm�hK�H�V~8���/y��$��t�����f5������
�p���v�v�����SgD����*��o��|	M*h-P�>k���q�օ9�u��Ѩ��9w���~��{��u���~�fe�(���^��z ��N�?@�?���j�c�M�?���2m~��/Sp0�������X2D�2��=�z�/��;�C�{^���X������W; �'���x��Kp<�]<O�S(FB;��f[�=X;�V}
P�.�p�5��M��7�_�"$K��@�x3
�	���5#ov���0ڑ�a4:@��":�@��	��Ά�&�,\Ǔ��L̫,�!�WqC�*;�ZL0�~��0��!��	<��8�wxZ
CQNcI'�r����A�8�+XM��$��4`�'h�:}��H]������ul�X�!�.�7D�%����'����:�P)�G;��c�M[!�:�u�uC��j��ෟ@��ٮ��a����ŝM�&��M�[���*4�����Ӻ�+���u��0��<�rN4-,�Pׇ���7� �
gam���E6Iu���y�a\P�h�nט>ڰ�9s��O�)�_��*å�Q��ݵ�@�$/����]
��:n�nk��`�L�)Y����a�����ᬓ�����|��Nz�lF(��P�n�Ȉ���%Z�d���/r�Ȣ����
EE�"0r��H��R|��R�R�$t��,��:+Y�Ǥ�(�OgG-�8&t\�Ow&�P�h`*�1u��S$��������_�����.�=k٭wV�^V~AMq�Tesh۹�����2.{�q�~y@��e�/3_^��
+��o�x뤡�Ｕn�e���������?��i��IuK��L��6u'�ڳ��ޥz���@ˤ��؁��Zr�"O=�
z�r_d���6�6�
��P�m���
���U��q#lé�>�l�@vŬ�v�h.T�M�:�n��f��p�%iA�X�?�V����L+e�;�����d+.��42�w�K��
��1�1��$>~������$�6�c
0i�5�5`�4iC�6$i�Rԇ]�7jh�.<��3���sC��>Z�!�V���i}���W��+�[��T�GC�H�G~�����~�^����z�{z��i�i��xjw4�|��#��A�.h��2���("�߾ޘ���|xy���7c�Ah������y����I|CC�!�m�p��H�7~w�Dw�!X�Z2���-�)5^w��L��U<�5��8�:��8N'Ť�����ޝ�2���l-�Bͧ�PcU�rX����Y6���@
>i�e����o�M�C��j
~c~/Zs8 ��
>�"��`�2~�0��%�+�:~?�_έ�l@�����A�+����ɵ����շ�ЏSg�>�+rh�y����S�P����	(����q�i�3MM8��W�k�^�«tq�HS=�g�F�M�9���,�k����+����Ja	I�]q�s_��h_:�s-��LLQ�:*�pa���)?1���UFk�y�L+��#o�D�D��[.��E3�kr�?�q�s1W���_�Mm?
�ŋF@�p�B{Yh٫�O-�dlj*"�Q�x��'6����ۙn^�[
�	P��lX2�u�Q��]Qf����mYpH��:�A���h^w�i���x�4�n�����楋��6]8d���؈��Ml;��F"ec�U8�pbm�0����g��G�E�R�bS��b���ϱ�>�]�Z��(^��&����25�Ǽo_�Ko���&����ڎO:Mb��
��L/�{&�h��kG��s��Q׎�-(��-,�����9sFk�kɬ�NBc�	����Qy��Y1=ż����.����d5�ɔ�M&<,�a�0
�|�ݾ�($�f�[�����-�a>�x��Z�ݳE'���"oxwS��O
����E3��C�Q�����?�0X��\����ֿtՅ�ʿ��)����dZ�"�b�=�g����Nq,B�y(�ɥ����X���˼�ޱ�IHt���9�ȴ���a^;4��������ޘ��Z-��� 4�����_�g�;�w�m^Ұ6u�+�V,�	˸l2{2 Y�QR�o�|v?����P�(XZ��S���w���>f\R�aM�2�lb}m��%��_��>�J�	��l�����Y<�%
���Q��y`�at�ty3�Y��z"o�y��G����6���]	��z*���^_���=�aR3*s�X��5�&���C
f�1��@@�����qFc��u�ͬPh�?�B�\�E�1�0�
���ɂ^��bzYjCW)+ljF�J�Ȳ"�b٦���͞o�����q%lUI��pJg�&Һ;�_��)�PIܺ��Rz6��ǖ�u1��%�ع�hʬ��С�c'�~���=d.���FX�$pR���0��f�Zb�o�c�$��
���KcE����F/�Ј�H	�QXl0p&�����M�wBf!�J�)�E))M��Kn����,y����54T�n~��J��R���%����7�i��ԛ�R��ۢ�6��x0���V4����ӝ�M�9�3�h!���jT�.��C��5o�t�05w��P�����s�@�k.�R�烈���{�;�»���4��z^f��on�|����ґ(J#ͣA�c��qqC7�
�i��>X�� �	`(�"�d��9ނ���9�B��?����4_���F�B[���p�<����?�/���;�!�]�ku�''.�QEID!VgH,Kp9Lܕ����l�K�\�3��V#�솬�(we€�U�h[������Rl�n�G�S2���-�\+����<1�g��sX�yp�6|��e�����u�~?�gԩ��3x^�`�d�xj��]G�ē�P�x,βi��GB����܍wm�����pE��'����-�_?p���FOY5uĽ]`�'��E;֡FyҮw�>�~�٪Ϟ�=V8��_j:���u���k�
ƒ�����O�n��Yy��`u``�;�B��ح��y�16�|)�ʜY�|t����@���� �{!�^{3Q��3��(�r����7����G(i��D%x��Sf����RND��#D(��zQ��_������"'=UinS��R�)tw>h$��ni��f����ɡ~��|���h�s��������jǶ��'��{��ݺ��_������;K��z�z�_��;vw��{8��w����\3uʹ�nݺ�ܺ��}��	��5�%�#e�Y�ɬ4����i���Ә��<+�M�zN�N��hQ��!t��jhS� U��0b�fR�����]fXOZ*�M;vأVY� ���te"[<y�m+�A��h�� I|�B�6�;Oc�����S9z
h��6�M߭�Oq�)��R�a4P	
|e���܌�����Z�s׮Y#�\�q�zw�4�<�����w���P���g�������Q����{.���⨠-��5U��c��[�[YF���� L=�k"�3�p���Y�%r�?�♠�Ȕ���ߠ�8�6����)qQ/�	=�W�ecz(�~�^������+���Ύ	u��/A����,F�V�J���E�����S�P��z [v�����Ra��6x+��m�p��?�����3%s!3�YƬc�3V�p���4��!�B�ޢ�=�	� �b$��X��6�o�&2��<��&��5�pE0YtO��ӝvz�L�)�DT�WC��A*4@}�zX
��������W�W�v8�~�U+�����+�5΃>Epo,W+�)�0�b��߆v*\�!!@i���YX	��]e�&�H1
#8�h<1�7>'rg�)�
H�o�'N/�a���/wϟyO`����b9Gd�vϫ��=l��)���9��u�5
b��c|�&����M d9��f$(��Ic�C�;�"�?ln����V�˘w(��k1͖�A�S9\.*�t��q=dC7*lo;0��8�"����޾�����C\p�}:��Ӫ|�y9�����6��<~h�)�e��.��L)�Kܠ��<��r��aD� E��?���`
�DB3���n$�9��a^��`�D8*����&w�����rSu�V�Y�סWMCcK6th�ᄠ~�)�2V�)�[�`���=�/;xT�':�e@�����+n�}\��
��X�(�\U1�������2Qٯ�q��E5�2&���c9��+���R-���e�a�
�v6	V4,ȅ�y�i2����|l���d6���a,'%$�b��<�<�G�ے$M�����'��jfO�$� o��(��@{�*��gl� k36�$��n5�q�vn��XK
�3�SdԒ�B��A}�S��5ɚdgj��o�ʷ�
,���U
t
��v�C��=c�7��Jz���{:��d�y���c��3���
�֓��.��g�t���o��c��'��{���p:}���ں>T���e���6�6�Ʋ�03V�Ev;ހ����n��p	��bf�6ۆ����
���-�������`Og��
�;���-6W`�[&�E��b&=�p��
B�b�WD܋����������
<�[��-?�3��g�_��C��s�`_p��U��3�;�çw,�z�|�1츟���C�o�2�tr-
�"P!M��P���a�̀�9r��`i�sr��ߧ�+��x
,b�O�����oD�����i���	_��;O�n[
?S���A	��H_��}�/ڗ�TÅ��X��bҗ���,�,^<���͂EU��r��W�U�T&��WV�e�,f�d-�W�췡��YUU]YRRPU�?2x�(Ђ#���U��K���p���Uo(O��sWb
X�����-i�jH����PB���Y�i���Z�x<�3`�Ⲳ�ؐ�?P���}[�,|	T�JBm^XR_��Rua�k��a<,-�Ѱ�0��+��b����]���mk��Y��! 9D�5��h$�����v0��

2����
h�g����ؑ$s�v�����pC
[�L�Ԇ������ �=��A���&\�ͩ�1͗>6>�M�{nG���N�!��"?Pr*M�db�Z�n��@1�&��P��X�5Jm���D�vu�b�6�N	�E�"^s������~~�j�Et��+# ��%���j��6��]de�gW;�����h���A�O����r
��{G猎���Y����Y�A�j&l����vLN������	38�y�UhC�sI9�(�6��a/��W-�۹�b����5<�Fɣ6ʇ�x�kȴ�u=D�
zY5�i�ۄS��R@��@�������=��C=�����$��x��lD0�{N�Ȏ�u<7���k{-��t����p���k�A��bL�c�VC�/����AX1�dmm�C�/ֲ�����h�"c�Y�ᮯ��E��[t�HYt!iX�S��u�uS�nX�~�U��i5�����S�<9A��륾�M�|�i�|���s�#��:�J�k?gn�i�
�r�����l�3;: 0��y�����ѡK�׸�Bsԝ՘��unD$�n�1$�g[��	�T��B���K��� ���7��%z4,�Z����h1^��+.�MYZ-!ɟ�$m��H�%r�a6H�&(�g:}��g�1*�h�T�[�J��K�S �R�SKg�ּ�������C����5��kod��[�?�q���7���uk�r��٣���2pG����ʮ#��k.Y��Ͽ�T}�XOm�3�+�]xu�m��sU���U��.k�
Hsﮑ�I�����3n��h)*b��'8!�T@��=p��"�D
Zz�D�I�����C���Br�����S�^#QC��ԍb�!�^����T���c�����<�*h�)3��"�����}.��Ϥ
�\|���|ANv�.���D�u\�#�%�٨�k�=3�<�
�������V.c-l���̈��M���@�x�q���#_�Ƥ+�?�y��jʉ�r��t��H�S4
Bwh�	�aΛ���(Ȭ�F�GWG7G�(�
s��M�zӛ�*[�[W[�X9+�%�ˑ��|n5����q�	l,�p���m�Ҡ��S��2ыN�ÓL�Dŗ(<t���3�����XӇe��3����[Է�������̸q�uNV��D~�O���G�\g��������Ѯ*��P'p��ّ���sx�[ڱ���$E[����1�Ώ�}0�Ϗ�R�M͏��.���4���e$C�&���_�P~>nM�S߈8%DI� �O�r����ף=��K@�d=�{I
�z���������z^AcP�^=IJ�^�� 9���K�3w���1������0JN�Q«@��+D���,�h�j4��+D�J�$Z_��o3�D�y�Q�$�hŶ~�,J�ѳyHo�̾']�`U?R�V���L�q랕�i>-��"F1k��ʎn�ڶ,~�*XrL��c;4ϳH�/�����Cы��*��fЬd
�?X�`��#Xƀ���	��{�1�m(���z�)�p���r����W����j�S�|�x"�D�F^�߈�
�!��m��芐�Þ����pz�&T���R��Gj���F���~6��1:�EA�G������S��S�5�qӑ��M��g-,��;m[��O�m�k��t��%�|˅5�/i��^��X�r������r�����h
oo>�>y|���uo��/�Em�N'���y�k`Z^�Ѽ��9�8�94��;F_O�OP�ԉ2��\N�)��w��p�Mc���)��,{
Mћc�J,U�L�(����wV��Y]:�n5�2��%w�H]W�1o��������:�s�~�)��#�H����H�z	@#*"-e�ì��$u#\��YU�+H�����M;?�v�t�"���W=����(��TB��փt������	#+�k��
>~K�'r�S�t�y���Ro�k4�6x�M0Nj'������o�8��Y�1��"�L�2���F)%9%���
�MP� V��R�Up�~>��������ֿ8��8��(М���p�W�b�a����ف��5��/⧇���ѷ>����'薕���따����h���="�}�g��,���+�ٱݞt9ݞ������W$��04)����䭷�����t3�|����������<�-�4��^�Yi�� �>C!

w��|�F�wC��'�4_|����
u3���C=��=��]8�,�=
^^�z6{��ֆ�T��{��7���o�u��0��W���������NB��I
�<JS���=�Mσ'�����
[Gx�p�����J�q)��q�@�Xȍ��r�x)�2P&!3�(��a<���J8a���V�,�p��~��N�%��NA��;���bEP)Kq�� nQ�*t��ly���E^�7~�P���_��Y݅c-�` ������?��e�]�=ekxȏ���|��b���,D�\:K���'�q!�H��l� ��t� 
6��p���X�ĝ�Y��s`�Z���~��{	������F��AEbh5����N=�nUe8F�~��4��I��~�g�wK�k���߀�;N(��W.#�Ve'9������>�h�v��$A�1CNI�.��
��|�"���,���$B`�"	 Kd<J�5�G]P��+j@sQU����Qw^�
�e�#E�䨔F��MA����Sܭ��4��QU��:��	t@�ԑ1i@X*���qB�2���lrA�藜8s�X�#��E���X�������[c�W�wp�1��/r{ޣ~�ڃ��۾��

��o4?�UhS��� �=s����3�~���2l�CR�E��c�C��h#��_(�������7B�`X���%�hG>�w�"�H�A�I�[�����洳�������p��&:����,���b���|-��³�25/���@�ݱ�#��ҿ-�ε������6�?�����V�մ�ߟ�|�-6������<8��N�N�9���_]��Jmīq���|u౳^��J�K�[�� �
N|���

�m�',I$p�{+���3��0��͉ �GJ8RF8�â�gĒ��.�fy�e�vV�Y���D�]N�D��+qW�����ÝO^���	�����|{d�����9y�‡���oզ;���:���õbK�)�vB��U����[�u�ُ�9
�~�����aQ�1�`��@� �NH�Ng���B��/'�ւ�^)�@R��=��:����
�6��#)t�CS�!��j����ۧ,�|�7�lǚ�W�ݺ��'?j}�k?������YC7ZףU����%��,{���W�����i.�k`
pe;@��D2�ɴ����O�i@a+��GX�k�q������a��1'HQV�nѫS��cw����=.V�3w��
��/�<�~i�۷,l�3�s߂=�9uQNj0��v.��Q8����C�M���k�0^)��1�\���3,Ӡ�>��32<��_�S̖2���A������=��^�XLQ�舽�n�|u���׸(���4VQ�ͅq�@68�%H<Y���'͇����GQd�l&������#�%:].QpN��
���`�!e�r�K��|b8b���*[X�8�M�����D"99�|��t��ۛ��[-�يJ�եZ�`e�R夈s��c���y�h먵�7͛�5zc��/~sdl��ކU0﵏��*C��A�?Z������y��~\=����W���
W��(�_�z�*���Ιl\�'��"{���i�='PV;��E�A~�9���h���!�@�
/ҽ�}ѯhĘ
��M��_&����7ݤ�7�H����QD-J��+,|�����QUi�8~ιm��)w�L2��!�L�	�$!�R��j��$@�*(�� EĆ�u-Q)��"�몋�+�W�uWו27��{g2A�w��������;s�s��s�BO^h>NU܇��8��""qE�cȇ��U�*2O$���b��!��G�ˇERj����ѥ�b�XU�ժ��)�$��ܾ�T,qI�}d�^UV-��*:j*���	V�e^��Ȋ�~s7ݷ�:�f�+?��o6���h��t��{ds!e�M,vܸ]3".3;j)s�
��9��X��?���)��7M��v{m���α
MCbC���n��H�
�kT2�}e�����&�T}�����O߾&1QY)ɢ0��bn���:l������vEUBcI�AUG����,T� �Se�J�d�ԧO"Qe��ā��͵uݻU��u=�����K����gH9�1
�9O��'^6��S�:�m&��dd��%$x�$�L��5�#��Pϒ�!{W����2R����˞X�����ǿ�?��Wi�x�2����O�;��fX$��F2�D�	���ǴF.��)�n��.�:�QS��j��G]Z��!�e��y�XR#>0hF�L(�2
cq&t6�EXc� Rs~=�6�S�����>{�`��Q�n�_�;q�E���;޹o����C�*g�tݐ*�6o���W��?\��[�]3ye�\^VP��V�?�"2��Y�����p��j��IW\�jʈ�Op�=��%9�*�ƒ&�n�Θ?�*xӟ�6NX�B[�n���M�G�
��S�M=�Ke����/l�{l�Cz���T�85��<�QR[W��ܽ����/?���/:��^8a��ٯl�^UQt�vj��˅�>� �
�z�K1���E���_�=u℅ܝ�3��5C�O?�K84�GwtV��.T���Gk�0ѕ�q�E�;��fC�U����/�ؿ��ʼn�`;����,ڡ��c�p�T����\��{�z��™��ӧ>
��������W
����e���zz��$�	Vķl{d��G�m�W�ߴ�~�Nc�ܢ]�M���3����+J��Z�ް��m7�Ӷ��-���{��姾Z�wت���iX��B�r�t/p�[�ی���K�4����>"�����c����1���Ͷٱ�ŷ!��ݴ�	<s
ǩ6����)0��AC\��6^�����*gAʁ���34R��9��l�c>��Z�ڇ���<<:ʏ�V�@a���h~��d�mT�%eȗ,�@�H��s4�P�{qt��@�dI%����+�J���?\�轻�)��\;��K/}jA�đ9X���'5�������V��E���_}��uoP��W�_qhƤ�f��<VL�[�I�(fj-�I�);�"Ф�8`�1�d�$Y���\	��M�a�t#�̋��`�����T���eW���2B5�EQ�{~����䤶Z��\M�����D�I]a=����
,�h��``	?ڃH��,�ͭI���|�ӆ�Y����^m��!�`8��ߑ��!L
�i�
��h�U�ӥ��������_S�w&|����i���'��K�v�@���I�P�i��h����Fb��h�u��Po�S8��[_��ޒj`�<h��o�+����hU����S����K#��W`i���߀.�WZ�[�=?_@�*���
���g�U/J�j%/��^&T�v�[�r�w�F1�,=���
M��3��������,o%������Z�qq���,W~�Y����Wg��ߥL������E�m�^�E���х��Io�WCK0V��@����ާ3�Ҧ2�2�2��Ph�1mg����J)��2���z��0m���
��ȭf;e0Z_�o���iE?3���Ef���z�_�Eac�ړٌ=�?��7=K��C��g(�m�5̔e	6��<�:���U������?��fc�f(𐹭<>�^�J�c�kמ�η�f�o�fU�����C9�%�1F�b��Hb�3��P`�N��A��e�#a��c���c<N�����(Boh������L�E����9
��3�a4*f�Qӳ6�҇Nk�3~O�P6
�zK�)�pԐ����m$��M/i��:��:�[&�+s�b�7��Ec|�^R
���6�.1	��#VRI
�g-׽�t7R��5����܋�7���!%&�}��K.�0:�{��F�{Zgj�t�����}(��b5
h=Ϡ���������|�y�  ���.6�T�	��c�̠SC��te
�c]v�������[���K�r�;�Ƚ #��g;�g�����3�¶4�Z;�Ɍӓ�����6��f�!�Ӌ>N�G,���uZc��K)T��No��iP�,t��:�F��{�LwJ|rh����:�c����E�\��e�2��lO�

�VnT�j��펎Qﲝ��r�HE�TĠ���(��׎m�`A(�ς:3�Vc.|�:��H�����a�SB�[������r���
�b����A!��6㾎����ō9�1~�33�����g���wr~#ߵs�w���R+y7�cM�LF�[5̕��1T��(�jP=�Qt>�$�Q�"t	���t4�E�"�aj<�"�%�|����}��-[��	��-K���ҥ���e�^�e��O��ҥ��d{����7�8���4`��4�ﲥ�߲��{ԣ��@{	Z�V��h=ڄ���6�݋D�V��E@��e�*:��B�ѧ�t}���
v��՟�%�������ˬs�9^�o���?���t�I��-�)������xfN��(E#[�L> �$�7�
�yٯ���_�1�-�~�Y�Ҵ�9���^�ʶ���]�՞�7���!����C���24�@���<t%Z���k�uhڈnB��Nм�F���У�	��GϢ?��+�u�&zE���_���	�J�b���%����^5�s�b��s|�FJ�zI�('���g�(�����]�9v��\����w3�?�9�K���/]z����#:���p�e�2P/�B
�.�i(���h7,�nX��]��\md���;����(t�7
C��*��uƁ�4���)�r
���=~f8}!���F�ߨ,!����Am9��U���A�GQ��%��ԕTӉ�}&�*����G��O](�K���i=��a����L�[��0�ԕ�R�z؁�Wi�Sc���\�I���q�X�5��/�"�Nȗ�����d�ܷj��{5m��s�����Lz�;5����&{�5�����x���m���ކY���Ʌ�
���ּ�.5z�B��3�䩅�G-��P�j>�S��Aϵ��P�T���b�:�`BGZƯNl~k!�iL�5���I���IL�C\�4��ކ!�N���;;&��GH������ײ61�XTTϹ��z�����+�|�����Fܪ��~��n��	���R폟��7~�9nLwOF����	��̧��^�v��X���I[�u��+�������
����hx�^#S3�m�ys�	S���>��t���l� _��둂��s���챟��\í�2鲭ՍCw�v�p��}�ހ�M�A6�mQ��x�
�����>L|�$*JX¢(�Z\\�K0������S�A��ܚ��v�ŅI��b��kO��������ܼs��A
.8���=�����Ӿ���q)餽����۸���q�x��*5������Ml������8o@�Ek�#�zj������f���k47h_��iJ������[�����"|��"ސʩ8�����
{� ~U���%�k��u��_�]���?[�]�^����׵+�k���x����?u���׿��ɽ���_��i^�������VͲ4#�sI�)��؍..qu��ӽ
7j�n�冓�k\��б���q$g�h5=�N����Mן\8���9N�wm�����
PP䏠Bv����$D|�h}u]&IKo]G�y��g��K���/��t�i߫|�u�/�&Z񧪁}�#�zM��+/k���d���w&LXu���#��
����k��j�NF
#�l&4��؜��M�LT\�(�:�����q��KZ��6��������o�#�p�ֻ�5^�%���]����Xa���UCK�߳�eWM��;Ͽ��9�&�
�;Z���gM��]�{v�i۾毁Qat���=��";
zDJ&�ܿ8X�yۜ+F�,��5g��c��wAw��#��e��7��`^��ۧ_�G��A��ھ�ޅ֩{8�m�uR�yܪ�/���G�'F\�w��]�#;���C�=�9��]�?.x�Nh���C�Ca�J����.����>�p��U�H����
]��n�tΊ[��(����vN��;!9���#�L�������m+�j�����ּ>�Сu�傍;&�Yu�ե=���6����ӏ,]>r��)7�
����<�x��%�iԫ���X��u��
�	BȻc?ڇM�J`yW���8��]��˃5Z~~�צ���	�Q�$���GN����|��O������Þ�����T��}�S�ވ��=m�
�������{đ
Dn��P�z}�n��n�dQ�̈>{���ltfbia/�V������K'CH��G���$���_àauEk�
���L�Ѯ}DJ��O��MG�a����ε���D���ۭő�}��'�#��De~�ݠ�f�=eC��9#.���ϋ(�Ȥ�
�1�h���X�6�:���xS�4K�*���˦"���'N�0����D��������W=6���wϻ�%x�y��6��٫�|����~s����O���)��O
c��l7��m���,^s�|�����l�����c�����{�L��ݵ��N�Cit��D�Y0掔id}�\�����TŤ�.݇|J�~Z@JEݿ�)4�/)��;p�p�����wA
��h	��K�p��r��$���੊+�X�ԋ^Oq�M���=1R;���‘��kBM�zW.��2iO2�������w}U͐��G�r�&����t��b}/��o�<2�n�����\1���W�إ�5�|��
�tH��}�G[7u-*�/��j�Y%]ju���$����	�S�|��a��ϒ�����H��Q��G������ 8��^�����r`�h�]�<K�$��h�7;J�t����dw�vhͬ0�ˑ1�˷n���[f�6}���P�>����N�6p�t��⡬��{�N<���dwb�ʍ7[k��u�f}��������|]�n�6��N�������RV|0�Q0L��rN�7B�㴎y�Bt���xEpW����6��I�1��Q�=��y�����^n��r�占�����=���{x�/hS�^K�^t鈴Yߩ��xŊ-��;�
^��/�����:�}7k�w��o̶�>��/N��}5FV�pk�`⬳��kM�����lG����|n��w�y���|t_k��e�Z�"X�~����G;��{Zӵd�}���1?���u�l�z�G�+3����-������a���]$F�~&б�ZR�:��I�#JZ�M�kf!�^{�1��S�ѡ����^���v!�^M#�U[���Ғ�Py�]^R\WQeIyQ���4\l����qE�r粲�`Y~~i����4���ýR�.�e	v%��}�U�&�;;j��`�j��_N�Ԗ�
dq+��5�LW3��4���W��\�#s�DYo$D��B���>�,~h�z���S���j4
�֎{��No~x��bש����C�Y{��>�Ѳ��y1�j��������<���f��ܦ
������O�a�g��K�����r����ÏP��Nb)2
^&�/mq�T�)�)d�{t��t���k6U�
�-�����L�̢���~[k#�ES?B��		
&N���ٙqaG$�9�n�#rU����xP�$e�V��m�N�HX��H8��af��IGmiXu�l�dʁ�ᨳDJJ:G�ŵ���X+ò�i�n,o��F2k.jD��b&p*�����l�X��D<]�5�����,�����X��a�z���p4e.<�r,[�nEo��M-MO܋_���{й��߹�̦�4wz�ݞڿ�~����/��-S�z�^��y�J朚ఙ6�]�n̦�u�=��c�۴��a����{�xv�N��1�&������A󑅑�Y���@���\`�qu
�%�B&r��g"���A�;���n�8�N�L�l��,�n�a����� �) lq�Q\�ŮLP���6�"$��:\�I����t�d�-աm���x����&��;]���&r�?f"���&2�c"a>l"&;�R'�q����RրݕpW�������WMꗀԄ���<zU��C`!?���/j�GS�������j2�#r�b,A6n�+��0<�����~�����.���zxsڴ�0~���R͟���[sz?ٝŸ���T�a+�
cg�R4�
):F�O0��|�	���` �����y��@(
Y����P]I����bM�X���ߟ��9)��d��k�d9f���fK�0o�ڕ,r0��}ło�<d�o�dK��o�c��9�9߫6��jf�`�k���Ȳ�3:���F�0/�1�jǠܤ��
�l�
s�l�?
�x��̚,�mjS#�"�~e��l�
�K�Ǟ{�]�=�z�ڂA�f�allžS+
��� �������ۖ�HVo(��}�������k֮]cD�_)�{���wQ�y��䎱CzByIx��?��{�^�v�J>�·9���0�I1�T)���E�Hgu�d�B~�����{w�s�ȕ�h/�,Sn�&�A��K���7���f�J�f;������o��s��ϛ??3����c����@�|
���0ؒ͢E������mi#�,&W���ߎ���A����f(Ӊ������1��]��h}A�ČRU��x��y���Ś�u6��I�I����4_7:�R��҂
„@�SH�'yt�0�Tgr�8�T_=��0ff�8UĢ:6��Ƭ6��j3YU�&�'��v�(�Lv�jcnN���h[���zJm�5��I��g�0~d�,5�)�6\�29�u�SHА�jց'�O�ԃ�7��c#�s
��<�Z��9ҽ�O���=_�����L����1�^��t���x�E������z�m��(��v��`��꥘��b|�Tȡ�R��2<_:ё�"���9z�*�e�Y�8ެ����"���a�DA��d��$���
�PwQ&fF
�
�
2�|�+�z�b�HP"l�N�>s�h�+c,�ŏ�/ilf����i��?�=z֥3#����$%3�_j5?�ZiS�'q�?�3����u�Η��h_�I��֒�F��iw���j��
�/
�z$d0�
��V�z�{�w7"��M	ƾ���
�R��򯍕�b�ҍF{��d����"D�0z��Q���(k4��+a��!toJ�E�18#��yT��
�{a�MM�	b�6�Ճ
B!�W��%���VU�W�#�V(rA��)�0*��D�UC�4"b%B$�?��6�",��.u1�����j0a�aD0|��;,�����N������P���'��6q��aW/���e�./x��p��?ioh'�i�o���3n���g��t�
Z��^(�~L�mqa3�_n�GE�'Km��-���D�D�-��G�yG8_��D9�ہ�m���x��^��[l���8Ŗok�q>J��
��5������Y"�6�ا�<�2�2��Y(��t�P�g�=3\�`��j4�sxiGx�H�FpD��^u�#Z|�(1(0O�s1pK�;��nň��5�~�"=�W\;}�'��������ȿ<Rx�g����)eW:�9���o��շ=G4�kՆv~���)�+BZ#Eb����g;��	F2=}���zm��C�h�S�}����>qo+�zw$Y�io�ЛJp��.��l��wc���ѿ���T��Q���������(����ݗ���O��ۙ����dp�d�ev:��%lg^������`���@^��12p��)�Z���+�c�
(��/sj���ݝ�TnȂl�w��g���?�C��*՛ʍY@)�w4���tGj\��d�΃�n�-���$#�)a�&�8W��W��P΃P�[0V��|Ty�$�0��?�s�:�
��'U;����׸:�\G�i����k�� �!^S#u='���-F.�v�Z8Ư�i��xzP�y�a�h
�>�`��5�ut��۾��`A�Ƈ�X�ò[.,��@		8"!p�U��q���p
�l� ��������QD��H$��P������|���x����������~��_r�s�Yq8<��@z�!lV��=Z�W��z|y�f��6;��7ډ��Gu�:�uߣ��`H�&&��6]a��1�׮��-��2���(��Zh�P#��!ߨn�޽.�:�ӭ�[S�
6��D���W����s�{Y�9.�_t�ckp�aA{uM&�
�����2�[FZtB�jc{d��Y�*]��Ӽ"���u��z������?Ϝ������l���_�[�3J��8��(	=�l
��N:u�mz/7f{y�Z�:<:*du��_�F�2ۡ]�8N?\�sg�3��Wj#��|q�叱f�**��R�2-g��q��&P:j&(\���pG-h��lt��l�Cfzܚ�
6���u,�<-�@��Ъs*7�TmN��:}�Ҡ�
��䗁ĵ���9���TbCW�*�jD%���6�!J�	���l�b��ǒO�7hfj��>��jJq��(eq$b���y9��'��q����O]yi�/��j$���ҁ�E#�\�8ի��g�ٖ��������噼p'��0��lfq�R2�J��_B�#ْmIT����%w���,1o~�o�O�/i.���f���xz�0h�
��j��i�CG��H�C���Pc-�mۣ����Zl�Ks&}-r���C�;��E�!�ck�K/O�����a�S�a�k�)ֱ�o2�'�JT�':����V���]���w.w��|�\~�K�q$̲��?��a��l9�6n?H�(q�:Zf�<��_�s�h��_�yr$���B�saxƕ���F���S�����ϲ���d�ꠃb�
!9=0����%�Ǎl��u�i'����ꜽS���ٝj�/vj�SYy��mJW��{�4O!�W�i�,�ت=��B���?�*��Y�$�އX��
�ns�$������8��4�!='ӣPfTC,͎�����?�ǻįP��vW
~��v�s���f��QgL@�H��-��e;�_3��Rm�����ԡ���ڶ�R*��aW��E�x7��C��:O
�"Qw�Ä�+�\yku|tQeu����jJQ�ds�zQmR�\�gg�q��H^~~$$J��9^^�Vi�P�T����lUsrsIT�W��PKj���A]����1����&����?KA�X�e�f<M�~��O�Ț��{��/.����~M�܈i��vQb Fx�UN*�����;Z��9~��]��7N[���#ڇʩ�ץw��W^=�~��[�
�b��;o����us�eG8|s��s�X��?�cZ��m�:4�;��n�wU���~)?9Q���Ht)ל.0���K
({g�%n����t��~�-)���$� X��+zB��dG��
��#W��Nρ{_�dۆ
S���Z{�>N��/}����K���㛮�=�7j�i�_�����Q%�]����~yHx�Bv
;-d�0�B�	�,$.�-D�犜��~A$��	R	��Ec���J�ZL�S�@���Ky��h���a�dxT�T���UNU��Ε^�r�ʼ�n���%�`���RA]̯�	�s���
��H��c�.
����8
Ra��: v�|��yTo�q�iv�7��v8��c��
��n��~�k`���G����?m{~����;�c+�\���Go������ק����1r���3�<9�}`�
���mk�YO�<j]Qѵ��_z��y[#�ɚʊ��ʹ�?o(��6X��l����G��?Sc�����.JUq��^��e�A���a�V�K*�u��
-9���^�]�^��-�XR[ˡ�ރ��Ǥ{eiv�J#��K����+����$]+�����#C��j5je0h��x*7{��*�b�5:A��D"��FF9{������:���M'2�`�e3§�z|tc�u{�l��L`��~ᶱ�۰�li�a#��^�\P��w��e���'�-y�/]q�U�l�r��d�^��Uх�7���dB����V>���f�����.�۰ښX<u�����efVu�⛂�k�+*��0o��VXէ
�#�� �cjTΒz|��n�%XKk	�a��-�u�8�e]�Ȁ�#]?�J��%�ڵO����}J	�u��Ime!]ҞtI#������հн+�Iu)׿��|���4W湑;Z<�z�����*Vռ��W�;/���̲2�����%�Y[�~L�0DV�����]��M���-���yFNZ3�µ��ڊ��1s6�m��f��+��|h;[�>�G���>���!���;��y��������ŷɳܱճ����i�.�F͙<�ڲ�kg�[2�X�xU��b�}��k�1�ƢgR���4��Q��D� ��I.)�Mdif���"�<%�e�$��t�� +����5���͗Y�/����4/��a	&�%�\��%y�!p�_
�b��+7ԷmڨC�_U�є�1���x"�/�\��.��;'ڕ�@G �vL�k;|�oʁ��4�J��b���,!��ew����F���fŎΙ�Q��O�D<�s<M8�;���	�����
�k���ҡ/n�Ր)c�M���R�����gqm;沈�M 0Q�
�2��H{�����G	*�A0�I�\5P�/���Kj�p��Cx���r��)
���$�v3U$��dj�f2a�e�M��o�4J�畭Iq%
��>%x-�DD�wt�M�`�M���D%3�������"���+
A�^D�{��w��8Y�g�o���O�۠��#�
���=��N�N�%��8���t�)�
X�0p���]u��T��$l����L�$Y`x!���"YxɈwh9
c�MQA܇��
�R&"'�0g�9	Fc�`�e��X0�zB�">�����ݲ�0(7=�Z��<�7vJt
��j4�6�.1z��E9�KD��>*�s��������oq#�kCL�������]�?�]Lz��/nX��?���g�~�vt�~���ؒ�LMH���p�%c��\D�-V���!]���x�
��Mv�b�lf��`���<PKx���l�'E���x�]'g� �ۃ*g��هi7eg}"����3��Qi�~��;W�g���;�&wk������a���Z�5�";_��db�L�蝽��q�b��бM�)[�������
���6�e�I�̊BB&�
�DQ�f3QD
 Do�L� ы��0_�\��x>�s�	#�D-l�P��3��/��K�4n�s����Nt̮��m0�hsA����=�4��+JS��B\sx�e�a�����&m�p ��\v�?�o@���������G<��`��@��$��E���z��T1��(Rva@ �
��̤�Z����L��=p�p�|�
GYk�����cȧ���r�$�?�-h4hc
vm&��B���k���ųӋ4=>������'yy�t.��A����T(n0�h�P�B�]e,h�Z�@�:ɐn_֤�4":@T�x�=ha'R�v�"�Hv��N�-�*N�Nx�V�|F�`���}ǃ����־�I;�fJ����cm����S������hi�0����K�!���ۉ�ˇ`�,HE�l�lR-��"�>c[��UUmt�6[�a0���NDY��L�vN���n`�"��f>(�l1W$
z_[�I��=���%汚@Uԝ�GQ����d&�=�2+M��
k+;^�	X8z�N�%��E��Y�����A����}���r�ub��jm�֝�ߍ[�\�~��	�^lb�E���(_��G6��Zxi$�PAB��I(��)�����|(��
�ڬG�j
2Y�*)�sl��f��Jpe
.���W*o(�N�+K�O�3�~��T�}7
h,#
��Ά�[}���L
�������
��P~'<���������p�N�;cG���_jOc�0�&׻������}�ݬ���<���~x�ןaE���M{l�N�����"t��ؗ��7R{`G0RlԬ���s�U��b" ^j?�ֆ�!$�d�E�F��\<�2f4/e���N�d"�3��^�$h�FAq��q�������Q ���` �*H�b�q�����Z�7v�gc
�q��1�"�Y�)�<��K��ꉔ�<�IG�\�H6wu)��Sf�=�3��c�q��n4�=��Ln���s%�`����-Ju]�c��I��!$����3����-�f!�`�d��̠JɄ�J��{����&�W��	5��m�{�q�ԜN�0�9�{��],�vO��O��0un��5��9��!�sp��)6�*���Ϟ� *
�`vk
N��4[�G%��E1E�<A	g6��8��qa%��jb�
[�,�O/�=�W�R���!�DZ3�C����E���>��dn���`4�ȈDMoq`,[S0)�I%�W�
e�����6�����>&��"�1"cz�
��V�4��
)��g��o��������p�4�y�5c
 ���k����'mҾeI\�NP�����tk�|*�y�R�zq���B�Y��B:���-f�@�.DM&�0x�Y�EIAH6I��D�,Fe�?��e6�-˿�;3������O= �D��ؙ��s�u���[1Y�]��~%����n�db�ԣ��7{�A���s	{��f����a�	���2Sj�"����2�E�䱩jH���
=@�@���Gr{<R�S8U����E�&	#���lVU��ܞf	��R���GmV�B�y�PRQ<+8�rz����@s��yVx�y8���<>%�O����ĩ�Ĺ���������3+�9��.���6���?�^?����ضُ[����.��8�S돱��d=�x8dz�������������k���^��×���DŽ�k���ˍ<�jz������.h��Kq|��{)�A������~�R�t�~����&����=��D�*%��T�,�l.rcs�������y�����˹��G����e�|x�12Ÿu��p���a��l�:);���Y������=��,N�q�n
�����	�j�����[>���O0;̍3�[�¢��4�Vnimߍ�&^���2�D��uC�o;X’�Xy�Bt�zD��]�a)!$��P��K��X�8���|�>GY���x���\�O�0���� *C��G:�u�R8����^H�-L�:����̎�ߒ��	s!�R�-K
�++�<�lk���uy�eeE�����Ńl���T�1ӝ���P�m���9i[P"�fq����Z|����,>�B���I�p�%9
�hXlы'�
ʘ����Ej�.	u)�2>y�{�jԇ�ک_�~ן~�x�ҟ�]��q)~���!-O���{��Oh[
v���^�������/�~D��i\�U���F���{��#�����8;�N(}%_���R#dE�Y��bA *�tkN�$s�bA�[,�4�����$�/�f��̘�@� �RNm&�!4�6���#���rL`z��Πr��_�з8��WBH���2z��}�_b�&G���x_��;��y[�
���"~9p�K5�c�J�#I
� a��f5l�0�`�v�!A$
!pF,��	d��0���Άxn�y`p4��8�c,O���D�Q��-H��[�4��a�W���Z�ͷi+�K?J��
�x��C6<�]�T�����߁g�FS��v*���ǩ
-.����b������f�#L
D�b� �lS��s�0R	0Շ�0R�$��Y��6��ђ��p���򃅣���-���˵��Z@��x������{d�5rS<g]Wu�����a�OOV�~�<�E;����禫�Z?�%����W|ש�K��NkN*K�J�Hx�
�+�#u[Ri�{�_7����8�I���ú�G�lX�O�3�ἰ�x,n+�GD��ԜŐ/��tL�����ge�`ʺP�G�'�(۸���s���~�=�}��їdp��˵6�x�I��3�~�/#���v}z)VI���k�N_�v���p��y�
f_11�8LX)�!p�@�L9�I�^��'��GT�����̠&�ؒh�'K�w��]�g&�=?��	_|��8?��~�)�""(���ޗ�2o�2/��]�D 1��
^0�D�fsLO"`��B36S�b�&/2���4WH3���4��7X'(8�4*�@cQ���yY��-��R����olX}cjk�3��O��<�}�i��X��w���[��X[��\ۘV���j���ĉDB!1]��x��5z�K�Y�Q��AϤ�@�����'	����$�;�8u�����.�n�8v�8�t�'�سL��!��cW�3�b��j�_����E_�^����t%y#3�@3s4*TD�'E���0TB�5�-;������"+�QuKa�b��=^��b�c�Bt_�P'K������B�(�����Z�ȫ6ڱ=e�'�����R��Ӡ>�b$�Ie���%��o#M��+��lА��Ѥ��|�:J�T�%����3K�;���CW���n��&�~ֺw��I�6m$=N0z�RM�����/)h�(�0���'�J�kT��d.̺���J�ò��0�h8d���"Y���fYFn!RRRBn~�����F
��۳���ì1l
�dO%��Kz�o�T��[��<
�QI�G����9�잖�[	}�=:k�œ��|�!����W|��W}���ֶ���W�m�~�?cb���e��[�	�-��6���,z�z�����1Y�i�@d$;g�pj��G���k�O���
��G�6;B1L`/��
ۈ�s¢�[�m�+��p4)�{���F����v�P�vF�+�����v�Q�ҕ.�3x����؈
�&W��q�"��i8��{v'W�ص�텯�\p��IS�N�n��h3������ڜؼv���Z|�w��\���0�B4{�9���-Q�0S1�jx�i$�h�s..����j7��\N�T�'��E��NR��8f�5Y�h�I7�	9�m�L��l��v�-@����6��oo�ȝM�vĐ��#'7n��8���/_���6N�x��9���k��
������� �������Rs�v��.�A
�������H��b݀�k�sA�`��������@���~��
3Q�w�0s���f3gn�b��0�����u�\��y�F�N��sܦ�J/�߹��F�gڳĿ�Q���-�sye��7�{!!�4�{A���^��ѬǾ]y����Ұdms�0�/53��aŬ 3�(�Fq)�VA�M�؅ 
S�J�ř���&�mNj�h�����ͼ�4�DTS#�q�D�<�wx9ڹ@V�Oi�Z�2��&����K�T��]5co�?�I��S����> 
0�=�t(]Df���4����
x;���X��9��
���L��+�M>��Y�n��N�!��� ��ޘ����LA��9%�9�Q�v����l��	�,'���fS��}�P�݊��Zʺ����S�?XI�u�u���ڃ���A.��}s}����|>k�b��$�1DǑ�8+����=(��yz�X6�͍�{��6\��o��.��U����#����`� ���>^�83���q|P�[dѮ��m/oX�Kk@?�|���]�*gɾ\�>)"�$$:�b8��}6_����dR�E0�.�@��KDQ8O�y�y\ނ2.R\��ȷ�RF5ě�`Lפ ��
�
!`���#4#�.�:�%5:a,�D�r��{�O'5��~t�oOe��>�%�TkG�2yG���o���"��3�|%=��{�͞�/���[_�C{G�x��E/?��7�ޠ֭����
��'�$����'��zQ�T��}�&xB�aj�aG$'S�Q[��9���و����Ezo��mD��I"�*�S�� ׯ��*��ɰ~����|�3A�ˑju>WL�ϲ1@n��fϋ,.���"���m�ŭLc}2U�ʩ������AE��p(��B������C�ء ��3U�Ƌy����B�\A"�
��4y�d� ?XP��*�U��r�*��Az�Fœ_��1ãϩ�e�1ڽR�.h,WWa)�2�h�e���������Әs�O�^��Ӳq[_ۺ���v�
-B��{]��൚vK�cݿ�w���鑂�Z�,S��t7V�g�Z��5-����t_���Yn�������O��^��)4�D����
Y�q����-3��RV$�IUpBjY�3����+eU>��a�ԝ��yY�?j��ڏ�þ,'�B^x��q�D��8�>8������E?�/M���p?�������K{�E<��78�c'���?�.z��8�+�;`�i���_O3v�QwΛ%z�9��Yf�=���v��ڨ`��7m�M��b�?5#F���)�Qq~0h�[l��?�
��]��:PEq�T,y$Xa6y+����G˄|%h���.P�Ҝ��%��9ϯ��~�-X(��}~���P"(�Q�����̥Pc�G6Yb�0a(Y���~��(�2y"�C�5vW�
a\���W?��vB�q^��G#�O��$�8:�n�v��}�2��-��ܠ��_��)���G�qf`�禗�����~���B�,� �Fat(5�)��x�Xx\��:l��	)nТ�꘧��v;+�V+Bn�J<
�g��2�=�C�}�s�yj���հ��ծ*�J���v{�N��#�Ϯ_AQl�e)4�\�����1#�Xf�7a��,2��ځ�����w1���Yn>�k^X��\1�,����k�j�	қ{?��F�K_J�H��v^�MCD=�ūf
�Hj�8v����yQ"�+@
?���3[,!]z�ސ�2�:�y��u
E�q~����g2�-V����������*��Y��3�K
6��g�R�&B5�}�ex���p��ibǠ:94�+��~���|Z0���7<����	a�K���p���k��I�Y:8����:�۠��c1L�`��?���D"9���\^��Mg�|A�y�6C��[�3�	a9l&a!,���L
E3���%d��K�q[J�Ll&)� ����,+� ��2	���1�;&�	Ӝ�+�1
��qB������#4F�
�Gn�l"U&�,�\V;��	��B|&�#&K�j�^��h�w��u
�%3�`��>_�޴2�xz�L�苜��E��{Ҿ!i�9��H����ܧ������-�P�
��M��Ҥ�좌pv{Ȇ�6�i>a��^a��n���F-ЀM��|�-a#��y6��[����sع�\&ܾ�۷!���Oĝ?zz	���4�8%ZW��&�u�s�:�z���M�`����B�לb����*魲�܂��%�����!�"6�kAR�B�wQ��
7�;O3�-����Xڦ}��������>>aJN�V�
���Gm��C���p��<��,%�ӪHF�i`�@0U��
��(s"/`'��&�ى��*��,�B�M
B���r˂��}�Cv�k&l�3��sk&trq q��	F#���-|��v,�����GIQ�s/i[3���N�8��S��7�m
y��:�I��	��������-M@�݋��^D���g�U���c����A���+q~e��%�.@���^ao~ �{�c{KcEE��Rwqq)
�B�^�p�Wi,��{�p�hA�ۣ�\��P/���E�&�zf%=ؓ����4VV� ����_S]]�zAKa5�/*.���>��BA����=��54ő�絫9Թ%�r�jǶ��l[�Q�ӣNpT�C���SJ`�+..
Ѓ�E����Bf�ӗ���.^�����ݩ_a��u��~�l��sZ���G]{Ֆ?n�~�M����\�x���5�}^�_lԴ��ev�:`gWw�r�ٵ�{y~��۶�{�������	�a�	�qF�����9%�}.�5U�y��d
�� w}�lgt�~d����Z��Z��\v�
x]H��KU�;y����C�p�^"G�
��Ve/��N����T�-eVk�,�qa�ʯ
�^3.j��½(��u2���6#\�3��x��&x���S�V�lo����~|����k�І^�P�o�{�
Kjɽ���W\�j��;���[�_ Pqߢ��4�W��7�–⌕�@F{S㹈bI���DM�ȏI�x�Dh>ِ(�3SJ%d�	'#	~�N�a/	�QK-���H�8���$�nTE
́�(JB�r�D�l��_Y�:ۃ��J���d߰�|v
s
�m��߹����p���p�����S����A:�9ƹS��[�s���s{:rn*��/D�Sd	�
c��@D���;??����?����P!r�@(=V��'��A*"P�Qa���FME�
�
U��L����N��D!)�+��(�A�rS�I߸99��9~�m�6��[��qYpS���=E�g]�=�7�������̺�>�̵����ʲ��ڲ����Űڧn�������1�ǰ��ط����b���������y�����J�j�<��߶� �`�4�	aP�H��J����n���pT�VUdP<^�"z�y�	H����:Ɵ����'c@�Aa~ϩ�R��Z�a����R9��S����(�*&�s��f�~��0XF�t�0�]ۮ'"wH{�EH��X������v�W�[���H;�������s��m���B��H��Kx�+��L�XV��=w��bg �2Hߞ:o	Y� ]IW(�3v�	�x��p��p��B��p�� ۷y�lw�~G�çRaz��-�7�?�����#�4�]�
‘;n�S���:Ka�퀕���VX�����W��`:����_��.o�99h�����b۬#'��g&qw��p�M|ȿ���B�3�>�tw�6Å��
I�Hy�ݔ`�y�#y�ٌ��L�l����p:ɳ*dY��gF ��ʪ@�z^���0��[��c{2�����?�P�z��5�����;M=���� �>�~�&yy����/�T��" �D�׉��/�Z��;�+��=�e�Pɻ�1�/�����]�a����p�r���]��w?d��g؆�>d֞����%����a9���E�G���?�Ƈ�a��ŰDZ�-
i[��)��{OAȰV9/��~��P�q�1��BŌ$@���f3.���l>f��YN��"���f��9�I�����o���j�������OM�g����-����_u���v�o[wك��;p�aP.4�:��t݂��C�C��<���H���.��V��f�s�Ԫэ�n7��m3l�m�M�J�
^
��I1[��|��z�?��0��R�Z(�̟�v'��m��}nò#єC��M����n����5u��Xgnj�'���|a���k�M��*����-�%�t'������l��@�@�¾�5�N��4t�M/	��
wGq�QdSGeF�}�eF��]T:߭�^w:��ߜ���w�/9}�z��޺u�[�[wݑS7����7�?�f��P���d�2{��l���[f�,�����|X�G���/��X�(�vc��墑��ZhB�	E�A�J����т� ;�;�$�%Q� �qJ*1�)�SD�ňR��V�$�R�%�5��z�Fa��FH��\��{��zkę���
��)��=����~N?��G�Ϟ�\�n
]Nl?(�[����N@�l:1�t�
��\؈�wY���RL4
�Q�ӎh�9zI�)�e�φFtJ.�*%:hG�ZlI�R)S�2b�`�F���6%�R�>E�-ܢB���ѬB",����2���|�&�����.�kD[�#����{��ڑ	1���N�t���0
�w
v��Q�Z�
G�Uʉ&Fm�85L����)j��M�oh�d�Z��XM����l��<}�����3A�ͤK������#1w����2���c�lEM��^GR����Y�[�-�6
J%O��C@c���:)8:RyaJ
x�2��'�P�0P�]gi���!���,�f�h	oFD"�.vv�i1�bӍN�>Oȃ���E/�φ�q�3�ʞ�v�ш�F0&|��R#�[�>��/�����xA|���0�0^#�1#��v|7x#\>:.f�Z�IX�
�F
R�j�������Nឱ�ˁhtDA
ЌbP�щ��W���*簚K�}ٯ
��z�.,؆������b*Y]�N�c�2�4V!�}$�
�!�(���4>!!�w��IRa�2�w,Y*%$A2����N5E
T*���Y<�c	;e�9�Q����$���pxU	�`�9�i?�3����ؿ�?qY�!x�|�_яE?u�a�7����S�V���C�ׂ�����.���^s��F%AY��o|ttlk��ċ��x_x��ߌ��,��Ӧ�A��ڌ�+C!��5�8}��8Ъ��y��s=%qz�]�r�י��cʠ��ʿ�L����t�Qt��`m��o���<��j+>���Z|=C����W�#[h�0�Oi~pz�����/n>*���ӽ�~���
^z]��$xCPC���\Vl
���g蘣�AX�	����ه��TaA�诏�-7�^�I���+�Do2ăw�2K�
3��A����8�N�$��Z�\��O���x�$^g�� ����gu��kB]�I�U�bS�\�w��PP!<�8�ዞұ�Z!�.��_9���<O������_R-<�M~��A��uO�bv�q�/8��;����uW��ȻC�re�N��UO#q�����V���t����dq��F*h6w�qS_ �$�Rc����4�+f�|�9N�L��S��w�*�HfO�$Ɨ�a�����CS��LU_�8�^\��^x~̇��
k��\�$��K�����=ּx��E��,x�����MJ��k�5�G����u���H/k�ۜ��{�`p�ٿ���$��}����'��O��^>�'
��42�,�U��/�[��|!�@���O!�f�)3Ŭ�g��jhTK�E"I��u:�؈|�*�ԏ���8bmĂ�з�����cI"�X���Jf�$����+�>�AGS�=]y~o}ŋ/����1��+:��
2�;��E���z�MnǕ��ys�L�S���+owO�vrR�iɛP��� I�bM�ѕ�5TiNK+P+�5�T�)��XZ̗p
0�2���Q��6+��K||��V�3"���ܗ��>ڒ�U�me����|�M��'>�ShN�Px�����#K��ĿI&���vӁO>3��;�~m몞���?�R����WT�hQK�Ĥ��{�M_6*���`L}�ݧ	�oOÎq9�Vk��@�y��@�H�$I`0��|�(���b%_5�L̔Z�ъds�:�ϼŦY��=��y�/�Pj��qy[Yq/���B�3�qCZ�ס��Ó�ʋX&���}.㊟�_
~|�G:��֫R�_�:�����_]׵�UY��??
>�өw���1�������_����S�-�'�������y,��?���ϴ��ɸ��ܳ�ۘ2�'�������<�LL�ɉ���x���������m��ʦii��
����h}�����xilN�a�vNL�f������j��4Sf�*DƧb�}h͹>9^b��W5И�T5�$;=Gb�Ro�P��h�-�%%Y4��WC�t���,���ՙ&����܊�cđr�L򣠖���x�r>(���}c��xN
?o�X�o��o��{�X�?�>O������'6�yvx�?�V&�����ۦ̺jBUu^Vba]e��Y�Wr�L�ڳ�j���wi��55ɚظc��Z�40/-m�ivp0]x�Ωq.�Ѕ��N��L�W�Qc�7l���i�-�][G'�}���WNٙ�E�	-:�\]�3D��ff>�/�����T�)К�RcI܎8gH5����R���V�����E�I�����&��)|��I�YV�B������#ܲq%g��x��y#
�$N���O��ΌL�M~���,\������>���c���lLضm��!�����kzl̟�m�I:\{�c��Ɇ�Xӂ�zk�S\�<��3M��8��GR%��zၦ|$y!�<\'�hmqPC�ј�`���a|�c�(� ��%����4bHK#1r5���̼#e?I����*.LMS�U*c%�\��t$���;A�ДF�ӆ�MN��5�҄��:$�W��:̽�_?� ���DE�-S����m&(l�#����X4#=���td딺���o�p�k/*�����ޙ���HKnn	>��������%������v�M,����<t�2��Ù���N#S���R�JB�$*�Z&V+<RC<���%|��;K+j5z������%.��2ѥ�.����(�W�YňC��[b�h�_�#6ev����f����{=$��o�sM���Q��P��M|W-�MS�E�]J�����̢V�K,#�(��ϼ�cX�TG�K�9ʢ�0��P���V�7]U ��*��@8b�J�TL��Ie�La�Fބ�T
~�
H�Oר5*�B�"j�Z�U05�:�:9����O��]4
Z�Q�}M���RG��[f+�8,'_����\Ya�g��jX�*��ֱ-*9i�r�Ѝϧ�z;͔��eRm=C�>�{0}��IЬ_�Ly���^I�/Ķ�W!�W;�R9Z�$QR�?#��SH�����a�Ɓ;��.�TN����� ���u���F���Us��4
�Z̙��%���\�VH׋s�4c�Bzf�#����[y�E��m�Np�E�	�J� W��h=���J�f�$P:h22"Wx�T�%��!-%��h�
^2E����d�/�U/�(�d�}O�ދ���_\���_�ұ��t���e;���u��W���ƳW�����
��N���>.�T���A���5�i�<���
��i�n�1��f��m���v�y6��BX�c��nj�D�L��M�6993EcHIѐ$u���T�a�f���%7�J�L����${44�2W�s�<�2���S���y+�A{����-���cJe�3[���E�WMœ(�{����jb�����:ƾ	cl&pXp��V��V
�ϋܭ������c�n���y���v/�޽���W_Z�3�g/u,k�}���[�Xw�쫎���1ճ��c4���Y�rϟ���+����<#ο$�-�xM����������;��r?u}4s"��<�������L���u�u���V�5.�|��U��CA|�!>>!��J
���W��)1�7N���	j�٤����t@�V��[)�i<	7YF�02L�2R�r5)$Cה��dҥKّ"IIP�є�ɐ˘��ΐd�3�)Y})p�e�N��H=v7����!�񚈎�|��Xr��
~�<o�8p:d���*��~���%��L���0bR5���>A�}������ן�o���i��iƔz]r��{��A�7���A���ډI�b&32��	�sa0bP�ePE+@�U|C��B"��*�
��v"QiuZ�8���Vi���<F��󂽨 C��Bx�YZ4�;�BS����Z�hMGǾ������U��羑���^0y7n^U�
������a(�@0V�I�d�\�\˖�e��S�R��K2T�䔔��$CjjR��7yĐ�G�el�`iyU�\��$��lV��SRU�I)��uR?yw�Iay��ܤT����T�<e*O*�����G����T�ʘgT��O������RYDs�wh�8��o��ŧ�^�S��m��F���^k�����y��7�V
|��X�#��ɾ���m�f���]P0x�s��z~�����'^�}���{N���p,w��s+z���z��3��`{�������7Ûɖ�/O`˔�T���Y]Y�$VS"�k�,�/0���^a�	�)
���x�^��Ȗ�-��h�
����H�W)�y�u*t
uf�z �10OZ��1 !>Q�Rj�4ޤ���x�V&)�J�I����0��
�^�PZMSL̄�m�&��L���١�&�^x���ei���K.��#��*�I�&���5ya�k�o��\�6�o�p؄@:L�>jq�U��>��={�F,]xè�tѡ1�������k�����Wx���v��rnan�I��ʿ]��e�9�����/�*�Ҁ��C�����F[��II1Z3�ǘ5*�E�k���P�Pm�L��� Y�82�~��
.ƈ+��(G�3��T�8��y3cs�������<�M���?b��E�UW�^|l8��4�id�=x���}�y����+_׎�b�+ ��d�gm2�Y�8k#��	}J��!�ա��"N�$X����j�N�߫J�q�J����GK��u&ҷ
��
���i��~}©��lȣ�<�ˋ��=x��e\>/��=�n��E�q�Tn���؈�p��A:����
#	$F�M1�F�e�36�^�gl�Z�a���b�nC�P�:��$�� ���c=�'�~m���JC�.]�AIE�iɫҡP�[y	N՚���x�:�O<)c��<�@�i||"5���4�o�(7���X5K!�FI,�hꉦxfI�Y�eQ*�-��րӟ�}���	�q~�PEcx�.�J8��"q�N���.���t�l�w
�������$�#��sO
}w�d�5����S�?
��=Ϲg�W�i٧�:b r� �k�?��-TYZh}Lm#wk��^�),l`�8��j4��
�A�h֨%�1��
B�t��ژ�2��6���-N�D��0��54��z�2�3}�,j� �S_z�+���U&�o@��˔��.q�#����R6M��c��d�7~�����s�s�!�ڶ�+A��,����?�a��k�o�]ϬX���v>
�k赁�Ȏ��&��<���'����x�F�5�%o&��4�6	�@Q��x�c؞�i�|\��d��:U1��3�u��Lj��;��
K��A��_=���S�"gh6�̈_&��d��N�YP�d����wO���x�������������
���2,�1��Zlڰh�ݓ�/�<9�_����"|C��?-a��_���QfIk�w�K�j����46Oݚ�#�~T�re��F�sdLAr��Hr�L���ڽ�8ሚE�����cNB�A��Q�J3��LJ�̆��\��k�	|5�,''3Wj�͕�L�2iN��&z��>�A�DiJ2yL�4��$5/ה*��
K���ɩM��Ti��lHr��in�a���<� �3��׊�
/��jtėUe��v��_W�*}�6�
�]���j7�oL�o�����C=�q۞a��ƷZ����)m̘��
�M���o��n���Ζ����/����b�l�2x�_n	��v\s�$�������GD3�q��	��m#�"���r3܉Rɕ
��*�	3e�٨T���
9�Ae�C;�y����0����ce���k�j��g�GQ�q����{>��^s�/��(��.R��id��$���e�EJ����'��@�EIif��f�\a֪qb��4&%���%!Ai!*�W��]��� �K�D+i���A�To�K��3��
a�5[nQt:�]�wT���>�f����k�Ng���o�
�sO��U��٭�p�*�M9�h���w7W�M_�%r/�r��������X31���7����
	�3�d�����ԯkG@c�Y���8#IN���B�Fc��-����9+K��њI�<٬Vśuj�IVk����D<���x��Ìr5�$��,�ۣ�s{�W��Qm��
���Ы=tNQߚ�3��Ta�x�U�!G����$�#|>�?f}�Vt��6
}|kfYɨ����V�����a��+��l`���H��5���;�LN�)4�	ÿ6�u�L(m"�;b6�ǩ��X�Nk���T��R�ׁ+c�pĚ���������*�6Ze���.F��{�L�azUL�.�"92Yz4ot����т3�'�_sϦAx�FJ0S/�*�IO��Q��^��m����Y�P�#�?�~3�Tl� 6�SP΅H����=��fr�6#Y!�HY�<��d�f���R���R�T*��1�Y|�g[@E�f�UHtR�Yf2)A��JE��޼���g;��.<�����0���|�1�q����8�DIS��J�t4U7�Tb��I��Iu�g��rѦ6Xt�԰��;?�
��E�_x�g�/��6m������G�CF����1���n�����D/�8K�{�ŝ��Cg��	�2����{��T��_�z�<B��/S�ᗩ,�f�V�RZ��k�`GN�h0&�b���Ɗ�
}}q�&Qo��7��~w��L��z�!j�z���0�����10-t��)%
��k0J����+��@������Q�P0��m��0���7t�x����Oj�k�m.�c��gR�:�}�����co�X}`{�U�'�g,���=���/���Nws��3�d���n����#�B��������V[�&MS��$�¡a}�e��2��;d�Z|�L�ݤb���\�S����G!!Q��(�:xu��������"F��D���7-��m~�q��
�X�I�!��TZP�@�������r�!����4haA�R�	eq�UR�(�'(�rn������
=_�L*��d�ۅf'�!s&l�\�|i�p���L��	��V}���󜯩��k6��A���}��M�(VY艝;����?�^�x�NЕ�����V�wQI͓��$R�D��d�,}Gy}]�H�-�ZT|B�@Ώ�����eef�R,M�[m�2p{A:#y%�8�ґ��m�(�<j$�#�wH�sF�^f6k��$�^/�I�c�Z]x�D� �q��� \1���L��Š�Sx��e��ԡ�
�+��<��3�2�#9J�2���̨4�lQeЩM3D���\�'����t&4#ua[
�vg7F���75
_X��C'���	�2x\��z�=�7>I_9w8x�`��O��:~�m���ȃs�,Y7~�M/a�Y�ϖ��'���h閟�ϏӼ#+�O޷vƌ�7
u|q����1B�܇���5D�j�D*��*�šm>�'���Vߺ���*�
2��_�&s�
��ex@�pd�v28�2ܻ&���sc��j����I����Lq�j�_���O�$8���O��f����v�O�.�t����;_[p���=q�J��{<}]tL��SR	KH��ՖS��x�}l<��c�4��"6�MfML�x�L!��6e�E�~�FY3,frLS�4fc�%z�j��1���4ՒlL�VZK�P)ݘ��lܞ|[���O%��,+N�<9�)ٝ�*Y���+S�����z�2���8�����q�'�|�?s��O�2I7�1�d����5:~㼈�ܚ�s�9U��:�*#_�0*rx�K���m3F�T�ߖEW�sn�o3�s�� j̝7.^|�
��7J�n��2v�+Vvn��Z_��+V�n���H�XC��9~hwؠ��}kz߁��W��#~�s{y�B�h ��v��%p7�T!^ݻ�`����9��E8��K��!}<����
�"̂��_��cnŐ�>�5�#
�ǻ�!��ae�C�P
Ͼ��`�5����@UD�0a��"&�YK!}�wG#�pp^E�!>S6 >���*�b5P�x�Y
T8�Ϋ!~w,�	?
��F�K:r�P�x,�Y��D8!��V�e����cO��j�:��z
<��E|>5
��g �����'���7r��s29���s��s��s1�\�������c�>����������<��{��{��~	pr�
��z��@�ٟ�rH$/<�{�s{9d��� h>���9������Xww��c
0������E������gn��bf�}����ޏ
!�",�E#�GhBhA��0`)�\�9�bΥ��W\c�W4��z����WL�q���7@-B��W,a�������Z�"����lo;�s{9��.���0
a"�$�)M�rY0���H�,���=��8��8��8��8��8��8��8��8��8�9��g��S��s��9|*woX�{���O
!�",���4P.��#4"LChB��0a�^�Fh/R�E�H���r�[���{�C��!��vo'�q��!�6�sA�L��$S����C��
@���;�P����",Eu
�,>u!����Y�F�S2�����^�	�'�~
0�T�7a�t�������Ўfc|��<
�ŭ
�X���4qȵ`B+�R���(�<
9�BΣ�6m�Ѐ0
a"�$�)M�t �$SB;0�
����a)�@�C�,�9���6�X�Z�_��k�-�E��ȿ��"�Z�_��k�g-�E��ȳy�"�Z�9�[�nX�����+Z1��w�R�C���@e@O�8nD<�T�M���c�,|vY0�\��C|3PI�m
`B+�Ryky&A;�Є1ij�A��%s	��ai�[,�[H�q�
�����ЄЂ0�f!��x⹈�ei�柆��q��0�4�9
sN�0�4����ze��f�1s�������=�E�K9��9�GhBhA��0a�,�-�d!�,�9�s0>�s0>��0>��0��W�X��B������MceDZA�A��
��hH3���}`=�� �Al<O�&��p2�3�vlkD؊Љp1B�j6�P5�
���P���a�h�����8�V��
N�4�1fޝ�y�����y5���v>i
FZ��LJ!^�p4�z���`�5h񘉘~r�!�Ӡԃ�
��e�:�������Z'
� ������d!����
�by��#��a�����#lħ"�#lA�@؊��#�����B�
����� ��D

.�2�g��L��L�Bz�A��X�a��a�C�!��a�a û�G8
c��a��
矱���z��NG`
���G��:6
(ֱ9G"#�l�#tcL�� Փk��h�j4r5x�8��gaJ��h���l,�a��E��c���B}fc���B�y�E��w�SBy�
��e�1���|��[v�G��GI֣���z̳�S9������I����z��z�F=J��14p�X��,�,��8��ql(<5)�C���H��w'`�L�;�gc�\�oD�a3B;�����#t"\����>�~�]�
���E�[�x� �?e5�
��c�����<�|��y���F� ބp!�f�vЙ��?�[1}���Ӂx'B�%��:�|nX�3
8��H�%���rj�lP''�D���P��#�u1����l��H���f'�V�S!��F�s*��ihɧ�%�
�����
�k��6���]�����Ѡ�3�.�� ��o<�d�f3@x�Ypw&�������0f4Н	�*8��r�;�c����7 ?
��6���6��P��&4�n���<��fCݝ�[�l��٨W�A�
r�1-���9(�9(�9�{s�J�a^����n�ŷ�\��7"\��	!��!oE�D��Z�w]�R̅���
1� ���G؈�	�a�V�N����آ��F|�KԈ�6"?��l#>Ո�4"'��nm�����-�,@�X�Vb
�ބ�7aٛ�Jr؄��PzMH�	9l�R7!�&�҄�7�<��J7#?�H�iٱ,v�|�߂iZ0��i��kE��b�V�ފ�Z�J�Bw
Rr)�#�혾ӷ#���T;�x;>ՎO�c�;�)'Rwb�N��	�8	|�@�"�?Q>�P2��EHk�Z���d��X��Z���).B��!�n����

��u`1��\(=�b�����ň�Rt ?XG�IR�@���bJN���X�K_x!�C�q,�%
 ���e���.����.�a�J�
`,�����{!�zxW�d�ыތ^�f��7������EoF�y3�ϛ�'��=pB�<�8ܛ��!���
�$��YC�".!Ed��KI"�^�e$�<$�r�N������(�Koq%�L���V�-�0J��
�P�D&��8#r�R��|��K�F�I�eD+�N����+H��!�"�Nĕd�"K�U�I�q5IU>'�R��Dĵ�*NģI���	�J���(��dm�2���8�����S;[�A����\�y�Fģ0~����W��%�B}	�P_.ԗ��%�B}	�P_.ԗ��%�B}	�J������ɠ��"�!����V�G� ��dt���*BV�Y�����h�KR��<]���Ԥi�GC|TR��K��.�u<���"�'݈����8�?��!B���c��E��?�x�Of"��:ēx>����I�D<�Oq�~>�it�"�1�.�����|nq�Ͻ���c"����x!���|~�xT���"�Q���ri"�k"�k"�E������+�W6�����t��Oz�c���8�6�wb�"�3����B�A\<�'>�r@��][ �p����C:�b}�W���B�3���/u���-����"�(� ����ș
~~,��
��,�87i�/$�s����f•�x�-d:r�GYpʼ�Ř��n�l����#�<u�%$si.�tF�)���6��elE�8DIO�'��2L�;�ェ|�� %/�q������*!�dh�� �V��������Zɫ�&�B�tn�ߋe
���Džrv��*�w���5җ&�:k
^8���Ǽ���I�n��J���L/p�%�%�)�n���p�s���D�����cRvGp,���%�*�Jxދ� Ȉ�Z���e���ki�̄���C�pM����ܸ4; > �̇2�#��[%/���}4��KF'�q�)�X����:v�K�.ϭK�Ԍ-\�G˯�w+jt�%kD�TB�
��(�Sy�|6Q{9Ǽ
�׆V�'\�����?����)�(Ʌr�c�����.��Rj�VZf�;,ݝn��a�s{=n���twY��\�iζv��2��sx�-EýN���os9��}vGg��k)�`�E�npx}𸥢�j��B1=�����Z6�b���W�[<.���hs��������!���)6�%�2c�erkk����bq�|��vHV�("�p�38�u;;���N�8��n��'9��n��W���:�N�e�-���YJ��ֹ;�������u�, g����s�u��C*�nv��K{���	�[��6������uZ�^���:���
�x�l���nq�Y��:�n�����v��9l��;H���w;:�N���ޞ"�����A���������T����[�K�5�r
���7�pv�|~,����rD
������ى	��Ő�
����P-N[����n�[�.��misv90
��b��@�H��i��6��
B�;�,���\T�R(K���c�����]<�����9���f�%��BY:�8�
;����
%��L~?�(��
��ŀJ��P����f���	Y;��Af�x���q�z8	�t����y�5H�,��>�1O��;ܘ[Q���\\���]dU�\dww��=^>A�������倚�������d�l����t�!?
�R
�3WE��x<.�CTK���c�qx�v�Q Ll*���B%B��6�����+���pM�C��d��{-\��F���j8�D
Ϧ’�
:�ח��	���,s�FT|�1W�N��a��̠䨫��v(����(K_�[���
̵��P�e�R������q؝�\�Ao=�
����
��O
	�mw{z.�x�V[���
72K�����y]NGwd�}u��z�A�[B�B*!A�g�_����:�v}'T]��^*��7�\�u��;.[��<��س��כ�\pg1^]N�\�����O]�J��+i"�%�$�K���<��_|���v��"�v^|�����>݊ކso�{���b^�O���G�_�#��i��|�W��^�M��x��͇<n��O;�C���7���wN-�
�q���`oǏ)C�O�Ƽ�}~�M,�@�&J��t���t�s�1
�tQD�1�K���b?�ɽ퐷�ߎOw�4�b9K�C2h��.�D����{�B9��>�W}u��~�л��F�b
:D/|Fأ�ȁ����=YA�v��CwH^-H�-·�FoR�?����{�ma�<�C���?��;���E���۰_�5����\���9u��-�KrӃ=Q���E�0x��B�Of��gi4c�p�O/d	�x]a���K��E�z�#OB^�s/���Gz�BK�:�׻�v`���>��n�׎w��L�ނ��`��	����x��G	���R���!�C�{�~�;��"1�ý��c/�|���Ȟ�]��������P�EZ�P�[��G2�w$��HF�rãy�?���8�ߑ��0�A�D��z�����f�%w�>��������������]�V�������>�^�?�������9��<ْ>?ώO���'��r��+��uD��io�<�g��?�����l��X#�~�G�F	~�3��mt��s½�t*\���	�Չ���w�H䝾��A.�S�wB���\���㇢6�/�>���Қ,���J�K����#���������ʷɨ5,�ſ��Ű�!����Ö�y
�����⬓��������ɹ�ޗ��+�ϳۻ�<#��{����El+eTB���ˈ�(HQ�Ϊ�t7���%qDO$�$#I$I$���T�FL���I�$Yd�&9`���@�-��������2R���T�A�tz�!���d��G@M��G�1d,��8��2�L"�A6S�42��3I�Ef�h.�G�F��4���ر]���Y�v��w��\���5��c)h��dYNV��dYM֐��
��\I֓
d#�D6�-d+�F�"����\M�!ג���TFn$7���-��V*'����r'���M�!�
r��F�?����d7y��!{	ߑr�<J#�!�89L��I�9B�Ry�'ϐ��g�s�yr������@^$/�����I�*y��N� o������.y��O> �@�?"�O�?�?ɧ�4�4��/��/�W�k�
��|G�'?��Y�or�����BΓ 饄ji4��:K�!6O��&�$�LSh*M�&j��N3h&͢h6͡�4������"ZL�|�
-�崂V�*:�V��t���ѡt����ZGG�Qt4C��z:����D:�N�S�T:�N�3�L�@g��t�K�����.�Mt!��fj�-�A[im�N��.�.�A;��z��>�
�E��R�C/���r������j����W�u�J��n��&��n�[�6z�Nw�jz
��^G��7��M�f�z�#���Fw����Nz���C�D������A�g�}��=t/�G���Q�=H���a�}�>E�У�}���п�g�s�yz������@_�/ѿӗ�+�$}��F_�o�7�[�m�}��Gߧ�S�C���~B�A�I?���g�s��=C��_ѯ�7�[����@�g��9����B�� �e�w�I��ɘ�)Ƚ,�)������0`1L�bY�3_�ό,��ƒX2Ka�|�;33Kg,�e�
,��X.�cY>+`���3++a�����
Vɪ� V����2���ղ�l�c#�(6��ac��V���Md��d6�Me��t�֐5�Yl6����s|�kb��53;ka���X;s��V��:X's3[¼���,��X7[�z��l[�V��l[�ְ��
��]�ֳ
l#��6�-l+�Ʈb����]ͮaײ����6W���*��\�n��#P"��ޡt:KK��
����9}�Q
�[��bkksx[�]����f�SQ�����e��ؽn�_��}v��!�p�@2��f���!�a��nsw:+lB(i�yݝ�0#1�(1�CL4J���	6{��`���@:
(J]��$�v�LRub����l�y.[��uG^ɧ	x�`��W��>43��� �?�B>CH��@6���l�8���G9Џ�\!��1P�
�Xuy���
ٌv��&����\�v�������*��9�:l�- �;��d��8�c��e��X�/�qx�n����AvJ����v9Z�
��^>(�lqww
X��߮��tj�X�ϡr{��n���8;�P���GzՎ%
g����;d��ϡ�p����w�ۯ�ۼ6��F����V���a����%�b8H���b|�x]&^�����%b(�_Q&�b��
1��*1�UT��p1!�!:#�p���J�~�H�R�_)ү�W��+E��"�J�~�H�R�_)ү��f�۾X
u�C�p�jB�_����m-BE�b��ЮAk�KU慚T�y���G��uK��Z�v���r(��]�|*��11���t�(FW�B�t�[�Rd>�ڱՁf�ۻ�$�ܜ��ɲ���#�����6����̹���i�����[�����;<��(�
b,)�;\�pQl�E�ՍV�=�N���X�N�M�u�4��V�c��އ����=�*F�O;�P>J��T���q�Q��
m���n��1�f�-�B=6"��>\:��敶������܉��^��)�Z/��,w�h��B����>\3>����.�\S�����k&D�qE^L��茸���l�8:��EF�"��F�h�E>����}�����)$ d�H' ҙ)�	�)
$ 
dVD���������n����`�maT1|���'�\6h����p��7��i���	�u�,�]�-����tx�"Wv�0�!a�%
7_o��ݎ����H���ڔ|��
M	�t��A���u)�>5�$q�2�/t
a�.\2����ӆ��+�p�CT3Jx��E�(���w��fr��W�p13"�jr��MH���(Ȑ�t��"�\�
R��l��㱁c���bclR��v*Djl�S2��-������B�,�kwJ������1��е��W<Gd���9C�3�?���fH(k��}��i~����?([����;l���-�����9�ǀ��\\�HI�\@\㎔u R�����[KİT�İ\+İR��p�V��p1!�ub8JG��ڇP�["�-閈tKD�%"��n�H�D�["�-閈tKF��H�D�_*�/闊�KE��"�R�~�H�T�_*�/闊�KE��"�R�~�H�T�_&�/闉��D�e"�2�~�H�L�_&�/闉��D�e"�2�~�H�L�_.�/闋��E��"�r�~�H�\�_.�/闋��E��"�r�~�H�\�_!ҭ�V�t+D�"�
�n�H�B�[!ҭ�V�t+D�"�
�^�X�j�_�����Jq��5Kho/_�M�D�T
��Y־͏̚^&g���^~~[op��	�V+!�D܁Aq���� 4��Mֵ���ʁ�Ǯ?��
�km���(-��j�Q�&��B�*_N�tm��]ӬS�1�w�V����L�q�م�2��[-���~�vAV��럝�rJ�nCʮ���Z��ֵ�y����u���ӿm����O���>�5�6�,�<M/Q[�r�L�\�fN/1Z���J���鸌���^T�o��7$���
�g��2�o����S��.'_�U7�j2j�U����Fm	tXK�
VTWTϵ���D�h	D������RhSj]s[d!��H�l#�5�ؚ5���o��޸~a^¸y��w.ް��+>�r���ľ���˗��֚���������;��������澱��Q������4>뗳dz��Ⱬ�I������?���󴥰³�$�����*Τׄ�볢��Uۇ�c�DzԱճ���Ұ�&�i���4,�s!?�޹渳��Q��<
*_&SP*͵f[�B�V�>�ϰ�����<E]|�"�/�
��L�S�+eVb-�Wfi�u�5wW�����v���s�~���n+�xkh�BcU��J���<>��K%L~�j�ױR�����ؒ+ֆ|���%����d-�d�3��Z��'ڬc�'?r;������+��T��F�k��S���7;w�mH��狫�T�;P�|��O�ݴ��u#�v|v׶Y�~z�E:�b}���s��y���O`�&^��/�L?��)�������?��ɧ�^���?�s���=���gS�=�`u�k�2n/�R���/+҇��T�w�f{r��/n�y���Ҍg�\=�\��F�[��81����8p�c��%ww��h<�`���{g�x����?_�+���������\/����,{���y֗~[��8�
��7橤�>�6mt��w:�jK�����/����E�^3����vZ�lG��ǣz�Ȁ�����{|��PA}�ۺ���4k
�P�
B���/m�+�x��lM�/A��ے/Ԕ�f[-�����˲P���kiƅ�u-�!�b\��;�箿�`yX�bӃ_���Gc�j�=qgK�ۏ�;Q��:��+������[c�z�_K���g���k�j��u�'�>0���ֲ��n����鮳���|���s�ñ��}��嵩+�����6<�t���"�Mk�����X���*|aiy�uq7�|����~|l�ցOoI�����g�O�ܟ���.��u��8��<|f�{�7d,gh�˦������o������c�nNn�e��ɂ�\�͊���&���{Fý׽��Ʈ��<��o���}�C�!{7}\��X׼�_Z���ň��!`�X�vc�u��rW�����_���D�J�p�"z�"�eB�8D�yW���o�^&mPaIaEم������>�}ldjɦ���j����	/��<�󃨼;<w����iگ���A�?y��I7���vXU�dO��o�ڰ���H��O�z徜I�?��m�w_������x��C��q�[��}r�3+xIs��7�O���2(��qֵҧ��+���;o�[������&�]؎�~g˨�V-����>K�eJ���[�x�����b-��v������	�yIe_�����f���@4j}B_��|~�$����]\2�Z-$(�Z4�W����!>��9��?�z���\���෡�Ѹ���*��Ł�i�����������<���_]�ũ��?Kt���ze�?�t��$ͱ�_�������c�>?����TǗ'�����ޒ�󷭯f�}���:��+��ή(���󱷖k�Μ���?������謧�<�{�{��o��¿��������o�ٲ;�pRΏWF;>λ�+�,/\�����n;VV�So��L���֍�j�����1���������ҙ����]��[��x���לoz�C�?�=����p�j����n�Yp��[r�O��������?=��TOՇdc��u���Ӯe#׉�-���
y$��H/��zS/\?����(�0J�Gj��&��V�YKs�X��ؕ���k��c��a�O���n�,�I.2�r����]E(�$�6dX-w���%��DAwbQe��B�TH,Z� 5D�0�����.k�\��Ҽ��~p�*���~����}��.��xs\���$M�V^��A'�I�v�K����l�O-3�U{י��;n�e�ᇋ�N,�<�����åom����Nn�7쑵�s��Cg��O���v�K~u�Xe���Ğ�̬S���ᔇR~�~�TњV��6yg`��C߾�����b���s��s��5G��x�~�Zx/��|%�����)�J�N휭���\���iA�a�,)��jX�%��†�D�b�Zc+���rv�����)���\�-c��.���Ϛ��]*��p��%C�5BQ+F:ۜ~ލ��2�������-
6��EP��R�!��
���N�/DNrir�ٳy�콥y��ݍ�[��U����{E�������
{�)n�F�w�ˏ;�w]��7��[P蜪]q�z�k1����g�(m��h�]��u�kc'^�Ϟ�!+oI�,���g�����q�|2oĠ�_P}���ώYpoܖ�B�j��e(�4=vQ�Y�jk�`k���X��lW���f���ue��^/�:�[hz���y��_$�@��崶�NkX8[_vQilNۯ�o�^�Y�_�ք՗�p�O�zq}c)����/�+}��G�uOޱ��+���w��N����
5�Y��|z��@�{�;���O���O�r��5�n}�t��'Ɯ�q�ԫ�:�Z"�6x����wۡ��_}����6j��k��t�{�}p��й�p�g���^=��i�N=��yEԶeGw�>?�Cֺu���T����m�)�򎤫�g��y��
ވ�=��[>+:���_���嗏�w����z
�1s_x�d�[^�o�2���Njw��x$�#c���+�y>�.�e?�z�l昼�7�?0�w����
��>��ޒ������e�Z�<������	�7�k͓�.V�:�KK*bM
k�RR�����F\���]ǃZ����Iu�n;u���}�s��w�<�g�uBDr
����W'��I��V��־�l�t�ꊃ��udׄïe���M�p[�2�[0ɸ��O������T������o�y����[����?$?�ue�G�w�*���ڏ��IݛS����G�ݖ�H�{�W����n������ݯ4~�������c7>p�z��g����n�Y��%k��ڹ*����/1f����%,*�^V���z�P��;��x1V[+K+J**�?ךY��I���񖅎2�?���wߓ����算.���׷�r���s���4���7Wr�yչI/��{���z����-7�������ޫ�:3���X�q�v艖��?w>{���߮x������l�ݵ�+�.�`Z�����_w����|gb��o��ᇦ���'Y��j�L�����:�N�c��
endstream
endobj
483 0 obj
<</Type /Font
/BaseFont /Arial-Italic
/Subtype /TrueType
/FirstChar 32
/LastChar 255
/Widths 484 0 R
/FontDescriptor 485 0 R
/Encoding /WinAnsiEncoding
>>
endobj
484 0 obj
[ 278 278 355 556 556 889 667 191 333 333 389 584 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 584 584 556 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 667 944 667 667 611 278 278 278 469 556 333 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 334 260 334 584 750 556 750 222 556 333 750 556 750 333 1000 667 333 1000 750 611 750 750 222 222 333 333 350 556 1000 333 1000 500 333 944 750 500 667 278 333 556 556 556 556 260 556 333 737 370 556 584 333 737 333 400 549 333 333 333 548 537 278 333 333 365 556 834 834 834 611 667 667 667 667 667 667 1000 722 667 667 667 667 278 278 278 278 722 722 778 778 778 778 778 584 778 722 722 722 722 667 667 611 556 556 556 556 556 556 889 500 556 556 556 556 278 278 278 278 556 556 556 556 556 556 556 549 611 556 556 556 556 500 556 500 ]
endobj
485 0 obj
<</Type /FontDescriptor
/FontName /Arial-Italic
/FontWeight /Italic
/Descent -212
/Ascent 905
/AvgWidth 750
/Flags 32
/FontBBox [-262 -325 1082 998]
/ItalicAngle -12
/StemV 70
/MissingWidth 750
/CapHeight 716
/FontFile2 482 0 R
>>
endobj
486 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
487 0 obj
<</Type /XObject
/Subtype /Image
/Width 1454
/Height 992
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 131601>>
stream
����JFIF



��C	!"$"$��C
����
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�(��(��(��(��(��(��(��(��(��+��i/�xK�g�5�9LWQX�`�uI&e�X{� ?�xg��[?����|8�������u�]+<BA�,H݃��q��#��������l� � բ�I
���)�����v���C�	��3_���x�S�������$Pʓ�϶L���9�}�s76�[\��ʅ$�E��`��#�xW���C�|Xitb�-+�����8��.�3G�T���'��O8���3м��x���ah�e�s�cAݘ�?3�	��{�-xw����Λ�}N6������R8��%��,�nx'ڼ��
I�;��'��"�2�Cf�������1����bx������-zM?�掚llI�����u�'�nVR~�1�U����h�_��7Ӧ�)X������;�(��Ǟ����w�=+��tMB��!�k֑��[~y�|K��2�t���ץx�š/��'�~�;�؊6����dOFS�>��9��Ŀ�;�s����*�z����4��ٖ̲����F�����Ĵ�����o�?�)�'��������>�ԑ���޳�Ҵ󩳾�F�>�ղό�������<�M��8�)w5Ɠz�~Y�����
;�%�F��n�)��W���5x���<C���cT���+��,0�Eb��ݪ����Ӛ����������α�ދ-j��;	�I&�-���O���#����K�
�����i�խ�?�u����`&o�v�o�(~�q�x��������x�F�w��lo��8����w�ms⟄�MS�_h��5�;[���-̊I�]w,@��# �_G��?|a���.���_�2��U���h���#mĊ�r���|�e�[�����+0���;+H�1�Gs��W��R/�%~�������h_�k
{L�S��ĺ�����l�+�1��*[�㷃5���k�(wMa�i+g+&{lD*x88#�׸~ƞ?���E�5�xoJ��{�%��2�3��0##�Ƽ���������w��ojvZ֩gq$��Z0�8beǗ��`����# _�5����~,�Y�ǨC�#�|N	WF��+?
�������
|T��w��o�&��>�����_�S#cS�]���~Ų7��e������y���ce��a��;{�����ߋ?�-ߍ��|�l�Y�
�*��l���2�=#�\���8����5���Z]J�m��N��BB+m�v�ތ���W�u���'���ʆ�Oҵ�T����{�)?說҈�]ѕ��U��#ր>	�����~���~�.(5ym4�}"�y�E&w?�5	���dIӼd��l��\ω5�3ß��������N��kOs6�.5�$�PX����Oڏ�Z�0�9!F�y���T
�?
�k_�>3�E��mƜ�.��ٮ��8��0����8����ڳ����~j�%�,u8&��c�y�[�ue9R{W��Ee���מ�.&�[�Z)�l�r*��W�zs�*	�A���h��`�y�m�Y��Vh�Jw�M��|
�j�2����-�So�f���Q��F�,y<��L~�ڗ��]uே�vs^ؿ�}�ܩ�,��
*x,��#o���M��%~"�����W�-�E�_����5֗��f]Z�ܩ1]�$��
�ḩ#��tw_?j�յ�V�\�J_����Gl=��W��}
�+~Щ�a�|=�X���$���g'ɻ�`3(9(�Hʒz��exK���]��-|M��ʻf�.��x#re�}PU���~�-����������g�$i���F�cuX���V �����P�ց����~(��Eiʑ�̓�s�4���0I������Q�ƚ��t��щ6��~������"������(��.n<y��	���K8�2�e���܅�c���_G~�Ҽ�kC{[X�R����n6��G�7��聶�ӂ{��j�������B<s��:Hs�}gE�:��Qc?�
}}�3⿇>-xP�.�k�K�>V̶�zd������ ���3��7���xc[��k{�YQ�r�I��D=�N
|�k�����4}�!�c����[ �F�N;��B}h�mO��~�S�tOx��2�}+�"�
�ۥi�Rۤ��|����?��ń����+�����M"�U���,�FW�
�
Ҿ^�����oѿ�[��Jnk��]�/~��ΰ�}�x�[�L����+��;��{�/�}U�n|F�ß	�z�����]����;����� bU`9����]�N��O�^�7���߫^}��JG�eԨ�**�ª�j�_�(�ݵ��__YOŭ����r�#C�`}9�Q���ؼ#�o��[={5y��?���K�/��h=����,"lIu �
?uFAf=2:�
�����5����ך*���oockx�貱ǩi1��G��
y�i_��:���}=�T;�ˣh�mt^ۋ�����
�����<��c�F��چ�����U@?T"���S�}�߁��h��D��/�%U�\M��V=��`t�oړ��W����;�X��M�������!|�.��}�u_�w�����?��|�D�[�>�n;0�Ђ� ���g����ߨ�g�^'k->(���6˧�L��<JO/1�=3Y_�N?��|E��,]���M�`L�,�Ȫ;eel��V�_�Jh��jk뉛lq%��c8$&�6�e��?�
�����5zO���o�?Z�����l�I�^��{ᴴ�0��fQ
����C���O�?�I���5�|2���O�_���k�ڿ��W���&���7��Z���~����ұ<y���^��*�f��`����f�ߥm׏~�:��gOH��n��9�|�Q[�/@�Q�v����)6_�f��n���o��|5������]��-��ֱ�a�$A�*:\�����L�5�-Z�xV�[��+���oĨ��\��_�
Ӛ���/��������o>��*��Ea2�X����rF
�N0	�g����O�>�,~0�q�,c�I�մPO��&_26#a��8�s�'>�P^�[���gws��G,R.UцH��>y���7���Kþ/�K�X�$�(�7V�q����p��k���>*¬�e=����Qck�#�_4�H ��,T���ĝ\��?h{][D�rNot�rv�jć�s܀Y��dU�k��A�C�i�*\[iZ,�?c�^e��8�NO�ȹ�h������i��x�K�
smam��m�%�rD��~��'����>�v��'��'�o]N���喟cm�Z�)H�uDQ�bG���𞃥�[�Z�t[am���,F;(�Orz�ܒk���:�l=o�Z�73Yi�/�&�;eV�����3('��Pi�/����o����������
��sU���i�9��D~�Y�]xa-��9]�o���u��ڿ?�
�?�����~
�О��⛯xwL��ݵ�޻��
FQd�%c�2/o^h�+�ڣ�����|b����x��iv�ʥ�I��$lȌ@U`�Ư�<s�?	x7X�-��L����~��$(�'{��o�(���7�4�K{
�3�ݗ�\��\b�1��@��|f�'�u���]Yubȥݬ�g��7��5Q��H��=�����U{q�G��M2�WKKMVM&��=���dol�����'���S�����~ j^�ψ�o�[��m,��KY�d���TBY��O~
&�[�w��$��b��s�t`
���\w���^��W��&���g�j_h��^M���E,ṛ�޾ǟ���L��G��DM*�'�ր<g�}��|M�x����������m��m�fڢE)Rp�
^�����������{������G$	�HԮ���+H�SֿO(���i��b�ᮢ�𵝶��DPnZr~�e��.���dd��|���?��-^Q��me�a��_�߲������G[�x�WP�=Ʊ~�V�@w
ú�����Ҁ:!������>%������#����5�_���<{�c���jC���;�6V����c{j
�r��͔���b���~�ETEDP�
��ş����ϊ�>9������1�%��oyS�	�]�\n�ޤ�U�\��Ğ�5u�
j_�ښ^���G.�6Ȭ��e��~=�g�O�����W�N�n[X��<P�`���5Q���q�~�W����w�������X�N/�"������5�{OƝgR���Ok�=��u
*���m��$T%[k���^	��Z�����"��?� ���[u��fr	�H���^��G�������Y�������9�������@	�Q�z��࿎�"�φ|W�&��g��ϵ�f�X��g��噏'�{�O�[�?��E��QukL�\� ��yS�clj���^q�_.��@7�s�+A�Ӂ�d����T��9���K�	�skz�v0��LLe��ձ��{���_�_
<)���Pi�Χz������|�l���I8�kǿeϏ_<i��þ�7��ݤ�}��������k+�̑�2�������������7�$̶vZXN��vN���?�W�#?k�
�.��-�}�q|V���}O°�/^�ˎ���d�m�=��Q��Ǧ:׹|�u/|$𮻬\��Q�ҭ�.fة�F@Y��
9�����C^��k��
*�g�q���o�
���@_����|;�Y��~��/��ⵒ_��6�	خ$Vy���V�c�����95�j��Z���y��*�@������ࣿ�D4o� ��k������/������>|n���_چ��z߉�ՠ��Bֿ`�L�P�э�~
/~q�}�_�?�'��͏��5o�'���j++��嗆|/�x�R}��m��Sc�TR���Z���
�_�?��^��e߈n�z
���ᛧ�����@7\~�?�y����nd�U�m
G���0��d����ϋ�������ZK�47
z,��J���
����o�N�\kQ���_�#-�yx�w��'�?��	��Sq�x��7Se�$���d�o��G��d4
[�ώ�i�+�޿����xvc-kᄹ������`m�1o�5�z���F�������/��J2�K;��)����@d0#�A�G_��������_Zo����I�/����o������������4|O�}�D��-�6�-�<?��&��Bgi�Vl��(�N:W����w�K~��b��Ss@��W���w�~x?�~�إ¤:��
���X��O�6�ʸ��Z�c��z��υ?n���k�}䖷���3 8x�j�m`�
�������ٺ��K�ss�B����8����T}	����^.:?�MG�Wm�^�-��/e��fe��}��_�P�#᾿⹊�M��X�tyq���r��?c?��&�E�_���t
.��s��cJ�lJY#V��୏�(����~��
���7f�����FB?�5����
�%�q
K�\5��+�D>����P�|[���O���?�Sė���}���k<�¢�;�̚��_��@����#W#�oYxK���|O�Eq-��⧺�-�ZFD�$(b
?R+�O�m_�����
��Eq_|y�Qj<?a�+�����ߵυ��!���.ќs�_gW������Sů�i~!��KW�/})�ee%c��v�d�7��u_h�	5-C��W���9`�gb.�*eP���g��c���[���Y�z\ڦ�|M�XA�ͺ��0��
���Œ�g��B��m��6/ۗ���@'�k��C�x��Z���%�f��5op#'8
���8=}+����?5����v������'Q�V�n&O3i&��?���_���}Z�2װ~�>#������[�)Z+��㱍��g���z�_���ݞ�>�����(�&�t�A3gɏ m��;�`�
o���V�ju�J�\�J9�����_����*�?������[�i̚;Eo�	���LyT(���
���2�`#��>k���j?�Z�񅝮�����O
"����Q�
$7l���� �����|(�զ�����i�J�0�&F�1�ѻ�|��cxF���Ƕ��(4�om���c���u;1�~x���8�ПkM�?x�.�T���Y�e�_��|�?�ߵ?�m#��%潣[�'������N��n
8�ڥ�>3~�� ӗR�%��d�Unl�-�F�#"���
E�$�ÿ��"Z�?`o�7{/���t
��'k����W�����֓V�(�LR}�C	R"ew��6=Fx���h��C�>ʪ�[�~���Z���߱��㰷���.�ڴ��l�6������׿�]�>��,�����f��G���)����G�_�����ߴ����O�׳ճ����O��%多��ۻ帿������렠������.��</�Yx�S[�{K�W�|���o"��**�C#���s_B��칭��+���ڴ�Twr�7�$.��Q���'�5�;@����'�������O���ٺ�����G)�$j�;����������C�E�_��QE
�����Oÿ�zn���fXO�Eu$_a��t�<�[t���c8������$�Yx�X�P����ʲ�A[r)��Q��-�7��p�M�}�o�g����4�;��s�gR��]��ʀ�:���O���:�'_���V_j�k-WIS<y�EB���8�k��
��O�ÛO�R8���k�w��6�[�ܬ
�� ��߶����N������׋���k�-� �f�"�
��	9����?f/�~��4}7W�H/���u�D��ȪA�v��;E|����������=��:��C!������c-� '#�q]�,��'���3��6?�F�?��>%h
�&K�o�j7Vo�Kj�4y7�F���F>C޾�����Y�@����$P?���>��o��*Zx�4�%���>�Q��MPB�m�'˟S�+�����ڣO���;
Xx��(5	SOk
��C|�d6��c�Nk����3�z�T��Ն�h�d��0�"�Fݒ?�O\W�P�����F��B��%���`62h6�p$8
<���#�g��4����v�u�x�@� �w��n�~���r���f�����FE_�T
�����Oÿ�zn���fXO�Eu$_a��t�<�[t���c8⾬����ү.�̞{8e���d�:���Q��-�7��p�M�}�����?�[�赠��>%��ᾑ�y���eI}qp�-�Xf�P���61������q�o�|[�;��+����f�Ɩ�Ɏ=�;��>TP�
�8���ॿ��O�}]��1W�~�?�i��mG�J�(�/~П����Ο��Q�/>��@�m�
8��ޗ��g����jA�!���`x��`~"�?�����jmw�ڧ�n��T��o��.dg���5f觜c����������u����7����hͿe�ڃY�m|��,���SO�m��J
>\���68+�p1�Gu�l�A�ïh���u��˝T[�'٢�t~T��+
ʎG5�_�K+��_����x~�K[G��m^-m�s>��c	��}�"��W����-K�|{�� ]��֥־�����c��
�ǵWr}�J���z���-g�?<K�?^}�T���)$�L���pT�OQ_��U���
�>&i�a��if��\��)G������_o�b�ƙ��1׼[���XE�BNL,�#?�y�0{�_�i�kŞ4����^ �h�)Vf��^\�!��.xL��X��i�a�q���K��s������k$P1��j����,��z���U��C)���F�j��>
��⯏��Ǫ��J�<5�n�xv+�X���ѳH.�F�d����/����E׵}�:��˥$o4�&H�V,3�
W��|ˌ����ْ��v?	�ؼg�/BՔl�!X�H�<Ȋ$=��c�%G�P
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
^]�Wh�����>�IV�n��R �&?�f�F�"+�#�ea�R2�������"���<5<�ΫiŲ�����nQ�v�[�}+�b@��+�ύ����|1���o�:��M��imq�]�>zFI�v��:`�5����q�2O
j:�䴙L2�Ѿ�$S�V�F�S�/�=��~����|
�z�w�����(&��!���~e
�;H�@�
���h����x�c�.���
�!���\O�W�~�߳���5d�ώ��,,#�H-7.݇L�) y$����ᶉ�O���KBۼ�;�P^�`W���	��a~�)��U���YΏ6�c�u?4R@�<�*��مz/���;��
���\����
=ĬxTQ���w�������-�+��[���}�Cj��Fq�q���<Rk�'�O�|E���L�D�~`�������Jƭ���=q�d~���^,��4}J����N~�$
���	�~�+������oѿ�[��Jnk�o�{�]��{����<M����1��c�1g������'���G�<I�I���<A��G�C�a��q���%"���ր2�n�����OSɢ�fd�c�hI�?�l��Y_
�i>5�����'�a��dz���#������C"/����o����߳~�c�闚���ɲ�<Vֶ�$�a|�UE�#��j���'���{�~%�'�|5�h�Ge���l����|���yI���yW�����1��6rs���M�k���_�J�;�a���%�1���s?���!�g���Nj�n��d��D�DZO3nݠ��+��o�
��Ŀ
tOh:��q�$�+I.ɐn*��2@Ͻx_���g��k��u����&O��d��<�3��\�nzW��7�*𖝨�s�o�:�Q���6��99��s�:t �ף�ƚ6����t�sJ�ү���/myn�ʠ���
ײP�߷G�-<�.���:Cd�̉c�  �� �x�1���W���'�Cm�E�@�}M�k�����j����cӽz�����?>9ǧh�
�,�6��i�wcK��39
$�f͡w6���#�}������Ҽ9�-4�H�b$rU.O��O���������*�Ě����_Gj���>)#IY�,ܖ���GW���_�M�h�J$�җ�.�Ѐ��&3�Mk���|��mn�ߋ�X��Oު�킟�:�������<Y��wĞ
�>����˱��������G����?�Պ(�<m��/����5)n"��<V��=�*Ȩ���,�
wߴw���7�<
��z����iz�H�ʌ�����o'<g� ~9���������c��]����ɾ��y��<ͻv������x���X�H�J�8ʰ<A�(���ſ�����Ι����ci��K��/.O��y�`0��}�����m�����J�c���?�_~/����@׵
0̺��q��Kp�N>SlS���z�:�_A�w��Gğ�k���[x��~ӣ�6ar����m���t�ހ0���l�?��!u�'
X�����]}��߁�|Km��k/��t�In��"܋��gë�@�k��߈�5��^������H⿴���<���
# ��W�|���m�����`���k�y���;�	Kn�
#r��J�æ8��_���
5d�O�k�9ة/�`_�I���W�_�{�/�Km�(us��е��*�ZO(9_�X���kp���ú����'��1y��������$7��^��(�;&Ѽko��<kiqf�5���	fy�}+) c9$��� g�kF�����k�[��@�X��"����H�:���h�^���>���$��O�����Gv���مY���E���y|=�9������\����lwSї��8#�~~�u���!i���n4E�d t-	$����������oj^"�'X,4�v�wc�t���H���i�~ ���mB�KCu�\�����9�ּ7�R|c�
;Ěg�e�Y
٨�.�l���cVǮ�}+�/ٓ�����ó���"�B����:Cy�Nx,y8���(�����Ÿ?��潃���N|u�;C�N�k�x���TRmE����`��_��� 9j�����4�'�&�þ��i�O=��5�j����,�@l2�{�Z�#�0��t{{��9#��$���F��C�@����k�w�֋�S̙�-E籜�qn�G��o����h�ޟ�/������Kg���j�&���ۛ�xSW��
W7p&�c%��r~xX"��W<m`�5��셤����}+Z�/t��>����@��빙w#FT��b(֫�o���.�?�J�����-o�Y�AZ��7����J�/�cঝ��P�w�� ��>��(���ѱ��v���䲵�@=�>$�<_�-3ĺ<�5��n��T�nG*�S�#���7��w��
x�R�%D�t�-��2�*D��O�'�|[��W���3wsc�7�Il�Ie��6���{]A>�Cz����o�J|i�m�Ŷz���ҋ+{l�e����d�ڀ6����E��ŽgZE�E���)��K*l_�G!���=�k@�_��k!`�Gc�
�}���f���+�i����Ͽ�t��2�?�@�W�Ԓ~O��|�k�����ox�Rӛ�8���&��4
��<�@��U����3���o�G�L��S����?��5���#��3F�|�3nݑ�?�6s���zmW���v��A�|R��I�f�Y!h�dw�U��bp�b�J�����eo�_�φ��k�E"�i���P@ݎv��)��y�r�����W�д�i�O*ij���y
�#� 1��
��y�OȾ6����	�x9�+m;^�kDV,S�;E�@.��a�ixC��>�}��h�(�����~�/흺y��P���mnzq音�����į�qMo-���-�.�\���"iy;B��
��
�@>͢�(����E�u�wZ�ժ��{��th̒,n3�U��¸��&捦��|M�
l�R�Q[39�+8Q�71'�ҽG��ѵ}{���hzU��}%ũKk;v�Vt$�@I��?��~"���]z��z���K�#���Kwt�c����3�@HW浦�������|=�Z}�L���>cG�|�N7!:v"�Jk�oǞ�����^'�����q�/��/�Х�6
<�]s#� �h���eρ?�#�Z���WM�����o�z��߃�7��=�Z�/ۮ&�2�]�H���Nq�+��Y�O�|g��l��]O�_~����X����I�O�D��\xU �B[�� �]��1@��?ƿ�?4��Lƻs�\(?��	
���Ǐ��e�'��ş	4+�#�Z?�nR���3O}o3�HP�r���0H�kѿh��F���I�0�;���Q�C�Z߾�8�8�$�aP�7���8ۊ��H���t�=.�!
��	oc�"(U��?(~-x�T���I�Y�i�e��qq�,#t�M��X�v;��:�Q_����?�=�1��~YD���Z�z��|�O���aX��<y�?V�Ӭ���t�MB�(�/#�yUG,�HI�_�
��|0�"���|#�=#O�.�g5��4�F#�w:����@�a����
Ҿ"~ӯ��n����P�56K7U�|��U�YX}�A�5�~���;|3�S�^�/�m
7ޥ�V��q¹d
Y	�I��+�<i��>�Η�����뚟�<Ge�.���_\isGW��)�v��P9�"���t�cJ�ҵ;X��!h. �edFe>��k��g���6���>�4?[���y5r2��Y��o ���
���G�o�_>7���O
��Z�ӮV�L��Ӧ��H[?��Ƥgn�u�#��+���x��v�&��Iw��W�43۹4n�
���<a����=cGF�_X�l�8�x��~z~������m5�,��3�lf�|��T���'Յ~��ȿ�/�éx��7>9�l����3_�m ��/S,,HP��T��H<�>�����?�O�S��>�i�Ȗ�\r�j&�%a�FN��n㜌q_6���Zy�ж�ل/�$?��t���-����f���F�/����Eg0��Ӟe�k���b	
A�nw1���n���q���^�H��@�>�+���p^�'�oi��n �Zy7!d��T���ߑ����"�SL�ǂ5o
j��ũ@bvLnF�eq������~~�_�Wq�]Z�R;�>з1��|���e ����?ik�m�
x�I�X����	��.��?���	�u�O��e��o�M�1�}����x�O��>-�z���\ZoV�n���m����F�������s�
�#�$�7�1]�z��q���� acL�UA<���Ҁ>D��_�տGP�ڞ�# ���WK�\,��kM�v��ȳ���&�O�"\���O��������>���C�7:D����a�&��"�n��`]�R���6�J���(�5��g�:χ4=GX���%��W�_*T
��v�����@a���j�x��&+n�����˒w��?w����~�_�/J�V,!��#�8�����k�^
���=P��F�!H/�^	L1&Cmp�Ҹ��^O�<��:_�yg�j~�������}q��
^���eۂY@眊�?��H/�s�ݴW������f�}C��T��+�zTP6��1���*j��3���
L71��2��6�@vۃ㐬1�:8������E�zk�/�ZG�-�䔳%���6��7���A#�
鞔
��Q��_�Z�H�i<C��ʭ��c�_η�`�|�������n�t��7��s��q�W��������{9�ee��e~׭��8m���8^�"d�g�G����x�:G�t�g�Ӡ��7Y]�gs�ٛ�@�̟�{6?�տ���E��4�[�W��-�>-���<_m�A�ݽ��x~Y�l�D$���G=�\����e��?�
�����5}�_�?���2��%��K

.��c'�?��g�^��[�/��/_��C�M�О]"�_
}���.�������A8⹟�{�O�m�,_x�ƞִ��Z��mN�Xk�����v��:Z����� ���8��W�dvb�`��<��6��M�W�~�>5���O���e��^��Ĝ"_���.C��+�B�&��~x�U���x��~յ��Yy7˧X�p�,$g�7#*���3@l����s�'y���֛�����O�M[\�~xv���^��kQZ-�����1�/��U�?>���j�;��|
�c���u�#�>$�4�.l/-t�����@�C��8*A�
}�_�G����-���75��|A�{�#ƞ$�ä�xw� �m#�!���f��\\\��H
�S�q�@c�#�D������-k������k�Kx��uh�{UA�[���1�̑��#����Z<��K���U��j#����o��z߉��ߊ�/�����>�w
���)��H�jv�	ze�x���?�Oڊ
A�[�C5��a2|�s#��;�O���f���h�5��a�gco�	���B�����?a���'���u��_V���,��ƣc-��yr�M�7mO38�k�J���&��x��׾�u�o�i��-h.a���F����C��__��.|	���*׿�z�J�������?xS�^+y`�e����I����W\�����?�e��?�
�����5}y����?���k����n��5�����6*J�Iz���� �m�������?��,M}^�-E��E�i�K���6.��l�uȯ�������ؼ]�n_�[{5y/�{������+E�/u;����Z���K&۸Y���N�`h����_���}Z�2ת~�5α�:x���Kb�^^蒮��Y�
����>�?�4_��_k+�\ڴ+�YInd
d�]�3�����������Wp$���SD�*���wP��M�X[�����3$w�F+�5c�(PVP=��q�C_i���?e��C�/�?�-s�i�7�k�ϗ}bz���ve;�Gs�w�O�W�o�i㥉��]t_��?��D���@߷��4��{��K�n��C�J��̲I#(�S.��W��t��᷅�+����t{KIߎF�T��_�/쵫�%���Ԇ)l��iE��Q��3)+�p�A9?{*~Ǡ���_�J�;�a���%�����w�������Y����E�_��
��4WZ��XI������7@H g޺/؟D�|?�&�M״�CI�[��kk�g�P��;\�@c��ٴM�6�bK�N�z��#L�J}����b�#�����^xoC����\�Գ^[��I#^J̣�������o��jI.5Ox��÷�Y��Ɨ<P�c�_{(r�8��ϊ����$	(TU
A@��|m���Ƿ�4���ӵ+�#�E���]T2�f ���z������߅��dl�K�5k��u�%_�Յy�����|y4m:�P�4{���`����U?��T~V݁���`e��s��-�txm���]GO�a �$jΠpU[��h�?cO�:�_���+�V�14|q�_��<O�/x��Q�i�7+��f_r����J�?�e��?�
�����5}�E|��#��㇈<A���b�\��+X���ة��ݵ�I��5�}|
���ߣط����i�?��D��q���{Xmu��-u���1�TR��s�>���{�#ƞ$�ä�xw� �m#�!���f��\\\��H
�S�q�_d�B)`��R�a::�ea��h��U�'��!�B-7�?�le�K�&J�>�2pp7��`]Ö*9���sZ ���m'��k���w�N�y�(��]
�R�Pq�cal���c�Q
8`0�@?�Mz���/�.|;���L�tksmڎ�4?m�i�gQ��XrxS�T
�7�m��A��6���/�KN]*k��$�+�
�+tc�q�}����'��o��^��������=�?כ]���<g��-[����\���d��U�<W�������?�#c��j�;��?�7����z'�Tw̏r>�4���k�1���ƾQ��|g�Dk�����g�8�g33_xu,��@?x!Nz�k�������'�7����2*�"��~#��w_�����|I>�|Ok8��K��1����`]�F9���|
���~1hWl?u/��O�Kq9?����o��O��m]^�*�D*s��k��k?���o�6w<��x�I.m��c|L{}�U���$|�ᨿj��v��xG�u��v+����s���W'�����R����@4�Z��^H�б�f��^���������\>ݸ��%l�9��_*h��;|e�:��"լ!!V}GZ_)��9�
ܐ�Us�����M�l�;�(|7�B��OӅ��}�*��_�~&�?7�e����O���g�7z���i����M�Ѩta�����������]oE����5r�SM:6�^�!\��
� �ݧ�-�_xs�T��!�w�t{3�����&�2�H�]Πd���_hx��zG��-��k]�:~�	�d=Fz2�08 � P����-�}�x*�N�߆t�
���/����fk����ZGL�a��<w���H���w��DK^�|_�!��j��I�[i�F7���'�
Bѱ�܊FJ��;\�׿��:>��_�~xo]��SK���M��!F�O���܄���������Mg�{�.;���k��=��&��rU��f��t���~kv����	�[���R���*�N:���}��hھ��E�5�*�J���轵�C*�;�J8ds^E�t��5�N����;�J�r�ڵ���K+�b9� $�6�������_���}Z�2���������'�Ƌ���K��cE{��V�u)-̀,�+�Fq��־���(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��+'�����o�~#��h�4�g����Q�(�Ǡ�
�Eq��$xw◄��6.�m$7h�4R.+0�9�EvtQEQEQEQEQEQ_<�����o�j���<Y%ޕ}5��
����'db��	\��@�Vg�6����x�����"�>����w�j:e����u
L���0Ͽ5j�
(�ox���~�|M��q-��k%���#")$(b
<w"�6h�/
x���~��S��s
����UYO����	��(��ꗑi�e֡:�Ek��,UT�ǿ
j���x�H����Ohv���7O"$w��((�B3��]eQX>��|���Ǩܳ�쳧�R�����������޺0���d����ϰ��ϰ��ϰ����<_��XA{�-N+�n��6KM3�**�I�C$�P���L����?�����k������u���$�@�2�y��]�QEQEQ\W�?������Ai�]Y��Z챍M���u�Oz�h��(�����t?�����jW6�ڌztKe;�]�m�n#ns��PkEP
EP
E`�����5�E�58�Ե��}�&I��tQݏ;�Y&�����W��{k�ɩ��%{Ib�(#�0�:q�4
��EQEQ\���
�w��r������G���%� �vQսj��<W�x���w�t	�m>�!${�FG�X#'�@�W�����{�j�����^D����Lg�%���5v�Q^o���?�|y��x/Ckѩheį:"�p�'��	K(lrB��^�@�>>���xKZ�H�N��\��c��V�$hè����d�]G��>(\���5)����O��ʜ��W����X�=:����#��SӴ�i��ܺ�/4'O�'UUl��Ny���?l�7I�o�,���YBQ}�I�� h�*+��&м_��_xoS�Q�n�1O��H<��S�)�8�6����)�^E��-�y�`ltU�Y�G$r(n��>|A�~&�2xp]%���Ct��B�pU³q��WUs46��\��0ą�F
��d�'��KE|���������cm6��ثͦZ�E���:n�]�����&� 𾳺�5�%��f�_�<0�Rqހ=�*��yi�X�}s
���fI���$hK3
b���ğ���-'R6vϯk*���,,��8�+�#�^��⇂�'iS_�KU�I�!nm�C��rǜ0�8<�h���(��(��(��(��(���{�#C�g��%�R�Q���WRZؽ�h���c�Y����Ct4
��X���;�x�G��kz�����ZGX�wg8���nN2Fo�
EP
Eq>#�-�k�r�Q�M_R�N�q��� ��\/�}����(����l�'�-W�ڌW��v�]N�(22"�B� �r*?
x���~��S��s
����UYO����	�
�(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
�����.�����"G�/���e:�gf?�,7�&��+�K���������7���=:��V�g<����Hʃ�s�I�����C���ּ	_x��5*1�#�@ېzgl��ڻ�ڗ�v����W�tkm:�K�j��N谴R�2�e;�v;�׊�?���"xÐ�M��ε�;��Ew7��|����<�B��9<W_�`��N����Y*����+�����{�ʟ��	|[��������	���t���ۙ�ӌ.�+�~�FG��7�g��>._X�����+{�
�+�ڞ�H��$����S��k��� z�z���b��������U��<>@��۞sd��zOƟM�
�ڌ2�i�ؼ�����Ć/%zd�
8��8�6�h�KJ1�~���F�ώ7���H�����f��	�lך�Vw�_�N�.[Tv��[i�6���2�O��J�3F�/��l��9<?�q7ڌʑs���W�S�#
��|e��'���P�b�O�����2�
�I���H,9S�FU��5�~��������|�N���,_^\nX�%_�-�3+���r;'�a��٣㟈,�x�}V�R�O�A���B���qڽ��W�8�g�,h����1�f$�$�@�|a�����������K�11�b@�����Ny�r9�O���~8��\x���KK��+�Ky!7*���W'������Es�l����N�����X�P���1eP;�\c�J���[�����|5%��f��zz�ߩ�W�Ҡ�������=Cg�e������ߌ������=����'S(��YIb���_q���G샫i:��?�ھ�cm:�U����e�� �c���W��
���O��
�o�c�4׿���e���O6�����:�װ�����+��{O���Q'�]���@Q�'�y����	���Ʃ<K�}Z{ΰ��a���2z�g��{���߆V��[�9��3D��=�Y�L�
q_�Ž_�&��KN���������6w���V�P����w���{�e�?��:�]�r��n�F /��L�9/��+���cIu_�1H���]���Ae��ڙU�g��P��1�#<�R
E�W�>�����ܳ�-���ܰ���kʽ��������<é����K�l_<E�iZ���km{`ْ�I�~z�X���1�犧�˕���2��Xf��Ҥ�[�[����h����H�5���ϊ<1c�>����R���TҦ���̬.f�6����኷�J��c�����k�F��ң	|�4��"/�?���\b�h����?�3��ƞ|(S�X��o8�����c��N1�r�m����qz�4֖�7�G��t�t ����W�����Rx4x�?i�@�|�y�"U�pOf�g�x�h��O���c��I;�X%��%S����{��������\趯��!v�o�]Z�L��Muq��F��m�rA����q���z����?�[P�~ɚ��'�x�ͪD����K(%�$�A�G8"�_|{����P_��n��\[]J�b��<�؄�^u$�1��c���n~�_�c���
�����~�q�~̾dUV����#��� ?*����'�~#|&�-���'k�
u��I�b�<��'{!^�)`AN������!"kO�i���n��L�'��ʇ1
��fЇ;S�zv߲�+���+��5�w:g��~��?c�k�����>��7�|��6;�B���,��x���kQ��gÛ=kE�g0I�j�m����̱
��s6$.q]����W~8ֵ_��Òx_�zB	.��Y�8��y�
�x�R	������� Ӽ!��
���%΂|3ks5�����`wd�9_��ῇaO�qu-g�e���]a�IՍ���n�I4,bVVu8?7�1@Zwǯ��)��K��F��}X��Y��6�Y��yy�4���F�<�[�gǏ�/⮓�h�c����%��7��M�y+��v���D���q��ܡH�.�Y��
��?��q���������L�H�ӺQ��?���t��ᯈ��~1|=ӴM?�+mew`�;0U�D�+`��R
�;W}�����mcE����3'��_�{K%}�k��?|p�p0�Ks����Ǧ|:�>YS��}��X��ʵ�/|C�\��o�>
ִ�]�i���Z��[�Q�11����u�lr
�j?�7�<���0�3�t�]ܭ�]��h��'+4�N
!N��85��wj^>��������M�ԭgӯ�̛Q��!o��ۃ��s�������C�����?�-W�z���4zKC
�*�_t�}1���8�8���%�<��݂���ȒN[Pߋ�*|N��>���6"�������E��1��1�����d�����3���-�������;/���𬩵���=��<��>99��#@�߶o��~��o��%R����_�ﲿ�%�VVz��E��spq�����
N�V���?��i����͞���3�T�r[�oIJ���r��WY�L�g�>k�M+I�լuɮE�^[�ìf
�
W3y�r��?n�h6�
�
����mZ{eӭ���ΎΪ9۱Xn��
�B����|���f�3TM�6�^\��oާس�;�G��_<��$���k
;��3�d�)k�U�oa#n�<i����.�|=𦏨i�T����	��F��%Z���N��YG|��mU�fO�*l�$t?l�Z��q�;_�τ��;÷zv��x���6��!�4Xb���vg�c�@;�/��w�,�&���]��絭�f�Y�]̳ɷ�d$t�����e�O�{F����Z�����d�Hˑ���+���4
ß�9|q��T�/n�4��a��������c�%�FX��{O����O����C��5������O�5��%�����u]E��������v���Y��p�8�h���l�KK��k��V�6��&{��ucV��#��;�
GZ����¡<[����YxY�.Rom�b2~��nz<h	�"�~��Ɵ���t��ņ��k�y:nG��a�8=;W�~Ѿ(�Տ�^^�/m���6�����e��?/��3)��{W����3�.�Ii����oYK���x�:����{��ߋ��Դ_
xWï�Ok����b���Hề�$�_��Ə�w�}#�<
g�ۍ{+�^�I���6�䀓�8l�˕�dS�����n�jZ��vvZ������s�������
����ޯW���Ox;Ş���_�>!�K{K[�G�3��dy?{����;�(��>2��uo�~�~:g�4�䲹��0�(�H̾w�0���i�z�^�៍_�U�mYu�ti^�Lӆ�k�"*`��k�-�v����uOڃ�v
>�t2N9>X��I?l?�"�
�`���?�
��|}���MsM�����O��)�\�	=���
���#�`�;J�m��W���r��f��$:Mƹ�
bso�i�g�8�Q�	%����o�V��n�(%u+R��8������?��x�|)k.�%�:��iw��s4r�7��nj��׺�����)��G�-�����e��%����
���z��	��Fk�]R��t�=_L�K����d?,���VPk珊�ݯ��J_~�v1�j�١�2xB�F�Sc�f9�g���z��m2�G�;�;O��\���~�~�mjg��do)�eH�f�8_ۧ�M�]���O�(J�߃ח?
~&i��g��?�
ޏs+e,�Y|d��$)�1��W�~�?�m���|��BV������>�+
��u��}�\�{��lo��V�e�q_����?����Qפ~��7_��5�$�oR�<��>H�����M|���^,������-���WQ��uS �R����B�}J��½����~.�h��]R:|6PI�j���-�i�������^�
���F��F��������?de�;���r��/�ʕ��m�5�v�U��q{a,v���]�!#܃_4���\���h7Z~��@x�[��p���w�g_��`>`9��Z���>#x���^Ն�g׌|o5�Y]���»��C�l�A,��9?٣�g���� i�>�e�Ģ�����o7J��@Ĩ]�	�p�潂	�)����W�5�YumS!�D��}�w�\����Ꮤ���	�{�����O�[������v�zT�L���Rn;7)�9�5�?t|:����_�M���j;mOL�f-ٻ�6 H�O���@c��O���{�路}�t�7Xӥӵkk�9���\D$Fc+��3���|��{����ƫ�h����i��D����U���|��4Z����S�W�M2Y_D��k(��2!;FٹE'���l~�7s��_�G�]5���.��Z���YBr���.�Xk'�h�O����.�G �%�=&�v]�p� X�ͼm�O0W��/�_�ů�K�<{��?O�N�ye��EႲIU ��NL�v���C���ڛ�_
YV�C�dC[�c"K�2"���(ǤK�V�m�cS�A���}"��'񦲖2ȧ�dR�v/,y��^]����/��]�ʼn>)k6����,W�K����;O!ۻhe�I9��ڶY|G����ƿ
ۛ�;}�#y`��rO^8�zrOJ�o��𯀼?��"���,�,c͸8�~��޾}����x&=�O�-���E�j��ɷ_-.��`����?�W`s�^��M�����x���|Ba�3�:�E�W��>��.�ʹ��?���������▗������
����ڪ����ѣ��28�����;�R����@���7���v������.������2�ξ����/���DZ���������/���R<j=Fd/�X�}��Ca��Xۂ!��a���@����g}�]�ⵕ��0�KYW��I�G�������(���
�?A�C�ޏi�XqF2���]�r�&�x>i:g�_����Z�����kQ�ߖ�"w
��O\��g�<5�-sÚ͞�c"/�����^�øl^m��imK�ƃ���Qi��,����r�g��:�� ���x9�ߋ��Mc�
��(�z������^f"�� ��\�˒]@ܣ$�
��8����&��������vi��o�i��}�$�2�p̠��5��TӼ?�S�`�5�m5mZ���NY�)�!�Tc��#�u�v������c�?��]Cq�c�X.D0�i-��R͎PA����
l�Y���o|t��:_�!ע���{+[tqw=㳅]��,`.�%x
�k����>"x+ţD����-$_�K6�4�f�i�CĒ+�&A\3.FF��o�����d$d��(�������R*�ǯ���Xmܜ�D��~�
��||����W�����u[���h�7�o���$e�smdBB�t�����Ӫ|+���4�}CK�����`y.���A����~`�Eb��B����a�o�Z��Pj�6��E�ռ@�G�[�]e��"$Ʃ#�\�g�(�����W�.�����	���\̩�YM���X�d>c
��Ǔ����3i?<%��Zu���T�*hv6̓w�)�	��@I.��Fo�{�OX~�~!��P�f�-V>=���Fe*Pݑ�.k��B��������se��i��Y�R�s
<&���i=�:+ߎ?�^"�����¯*����~��Y���L@��p23^��{����
��o�:h�
��� ����|��iT2���9^:��$K�Lx��ZW�_˩�V~^���Z�/��n&�6X�c���7'��'�@�u�/|3�wŭ^�D�ԢY4{�YC+ɗ�ȋ�UI�Ǧ܀�� ~�������#YѦ�Xf󧻷S�f=�\
��q�]G�O�:�~&�3�֗i�Mg�Bkk繉̑�4ʲ�?�o����>.�����@����[I]7W%����������p	�]��a�C�+�l��{7���߬FAd��ݏ€8��z��Hl�J�q��Aw�-��Dw�{'IO�0���NT|����`�׭�KS�<�
�@��y,#c�ZdrX��!��Q�Ì��LuOۯ�if
?��I�a����x��������������.��L��.#­��T,�HF:��S��t�<�]3N�������f�p��j�t���F�$Ē������_JW�?|�/�#�~+�Җ�I����l|
�Y
�J,
柪��Z��I�Km*�	gk�#��d�d!@,W�z�x��� o���7���/]�E�oW�I�xgRӬ,�m��?"�'���!w7����q�"��ۏ�@�?�o���^��hƒ�
b����e# ���s�'������1����t����y��Č@_1��Br^% W�|U�Ϣx'�V��{9�W�#���2�r�G�&x%F�O��j_ڙU�g��P��1�#<�R
|��˕���2��Xf��Ҥ�[�[����h����H�4
s��/��|,�_���h֛5���fKI$F��dr
b���{�+����E�m�!�_Śᑭ����8c�Y<�HX�ܞ��'�t�ϊ<1c�>����R���TҦ���̬.f�6����኷�J�����俱/����㲱����E�J!B���P��3
�԰��O����i���[O>)�|��i��q�o�����z�?u�|o�'���ՌFH��J'|ȇ���#��:�9��{6k���>)^xm|Km�Si�h�/7���vHLg%��~=*�엧xc¿5��#Ǒ��D}V��mE���b��q�B��Pmr��@�h!�Gx|~������$���
����V>����]��W�|*���m;Q�宙g�]G�KkaƖ�ܬm�ܗ�s���'�Y.-_����W�@�3�Ă=�6Y���g��]M�^���yi��[���\ijA4m�dFV� ��(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��*j�gQ�o4�uqi��qn�K�#z3��FGC\��o���?��Sæ���IZk�V�Wv�g*�	�`W]ESִ�=cG��u{;���&��a��kɇ������L�y.��it�3Y����rI�Ǘ�'o����9c�j�Z(����7�~	Լ%��w���4���*���)ea�GPj]#�_���o-����Zi���c�"H݁��jݢ�8���
<5�φ����n5Ml�"jE%iVVfu}��G�GN�����	u��!�6������(d������9]C�^��kw�����Z
ŋ��VXV�7��|ܓ�'����/Xx3��_����f�� B�,�#(��P����Eyφ���-�<i��Z�S�/�Y�5w���A�\mf�ce��~Q�ǚ���e�x�ĭ�?��+����A�q�W�
��+���5_
�V���5O�v��v�\��.}w2����_D�1��i:4�?���J(�Ki���x<�7�������8��j8�H�H�EH�B�(�P:;T�
�ϋ?do��%�V��+�oű���^ΐ�[���vv
��d��f�|,������2�����(�<C�w�:ށ�}��WK�m&��KyL��nc!�gh^�+���,<g��S�ڤ�0�jp&{fU�T�t�`�ݢ�8��o�Y~Z|8��U�m���T�`de@������LW�h��G)�7C�ܽ������o�1"��D<�7���Z���9�O��
�~�/��pY���}��h�����y�y
��>�d���Bܾ�����vy����޾���(hZN��h��>�c��i�xSjF���5.�g��]i�WP�.P��YJ�{�V���4�+��Λw�ˤ��
5Ĉn�[̨#y���ִ�x+J�w�];��%��ņ���R]����J�⪣�9����@W���~�w�|M��j3^x��;�乑8��¨ ~���n�����7��'���O����&��*m���7�<�_�j���������}v�
SF��s%��S�k3�����	�J��ɮ���|-�g����rA����̞lt݀��;�5��@_�?������h�Z��k���7B�D`��$�ګ��O�$�
�9~/��=��!�æ�g,D�1�$�n�۾c�X��֊��*|8��#�h���֣n�F��nl�E-*m��^{`��GƏ�~���Y�Moy
������G:�Nv��˜��q��dץ�@
k�$|"����-��'��?��F��+����q�vd�Ez����������$}B{[(���2��<q�ě��,T���Nzp1�Q@I�/G��c�W�-e�=H�Z{��FG��d�!��S$�O�t���;�v����4܈	kk���5�d�\��p8�WiEx��O��w��A�m���[8���Y�E��FTDE$u���Wu�߆���]�/j�Z�7�����-�E�Fs"@�I�_�W��֊�>(�+J���]G���������y�Z:���ʒ����� �A�5���~	�ǁt�����km���%	sTT�`1��]��=���H�E�X_[Io�js][�	u{t�%���E@�,��]g���[^�=��.��u��r#�p��.N��U���@�pz�WͿ�5����൅��w6�>)�ᧆ��ܒ#�Ѳ�������+�*����ݻ��մm;�ʸ���K���ᒽ���2���������<cC��>�~(�ص[��Q,Zu��{X�9hP̾��|ע|\�k��L�����:�����ŨBl]����T�Fq!�x�mEq���C�v����8�$^��'��cԣ��d�����O������Ꮈu�GQ�JCu�̒��6�����7c8��&�~���>�Z���
��;]Dɣ�q�냴ZG� �&f�A��*�����(�8���k��-4��O���y�]X̱ʁ��S�YH;W��2i �9�|A�}s�GZ���v?aӃ�Yc��fo���+��H��8���to���º�֡mc$���e"$�������S���>�DŽ���(�P�@�^�VH�F�lw�t8��������=Z�R�u�]#�:Z_ݣA�r
	��H=�^�iiH�(UE
@j����+�H������7��7O��n�((�����]�g��Z��3�V��(\��UB���V��6���k?���2�M{O�qm",7,����P�0S�!�zV��~�>�������Ƿɩ_��>"��72���ጰ"�#�*)�����8��箵��(���<?�/��$�w��s�<5��J���ݟ1Wf���yb?x�t�yExo��g�G�5��f��tK���1�n$v=N�GU�� V��/�~�jh:u�ު���y�"��p�UPq�J�J(�~7|	����ON�<I�떒��0�>h�YY�wo���+���c/���K4ڏ��Qz�=�!�o���4P5k��L��
��
�iRZIj���$��R՘7�9'sn9���[�m�ς��'��5��v\���3�fg*�8�+���3�G��x�@�4-R:�P����3���U�{�������E�>�P�����Sx�`�Z?�J������ſ�7�-{S���gA21g�L�E�'�dG�=�����������Z�|/�K)���wM+��6�p�}�n{�q_BQ@4�.mt�Kk�ǽ��I�]Zg
9Uǜ
�iڕ�����i���7vw1�S�2I�
��"��@<x��>�E�j
wj�!�ј�ocz�>{67 ~5�
~x+᎝-�����y����\�<���a�с�]�
�>x⬐�����F���DS��v�C+���q��d�?��>|/ԛU���/�]��R�e�%=BmUU�8�\���W��8���r�_��{]�CY�M��X��cI�ݛ�|����G�~�~3�w��M�]j0�xV�K���9�d�)$~�~�^��Z(�����C����Lj.�+[5�K��2"I�2��1�^=�OiZv��D|��{8�,/��%Y�
}-Y�����:����h�u桧�lI&�'����g�
���>xg�����j����%���nVKxX�*��ǣ��R���
x��r��Zdz���p��Z7
ч*�'��GBk���<¿�G�M]�U�=gY�$��Q�G�H9T�Kf$��W���?�@��o�j]�W�)���֍�*@$}		�Q@>�o�C�G��i�̺殱����.Ѡ�9�F���|ץ��ᦃ���C�z�ơos�;����tH���H�$��J��;z(��6�
�WŻ��6�kyb�W:|��2s���)��O5o�/��x���f��k+������߬�n�
B���͜A�+�h��k�/|-�7� �m��5��Y�Ϫ�$�����n���Q@_�O��{m�\��m�Hԣ�m͜���@@
�[+�lz>&|7�� \�z�Y��m�@ԓQ��"��H >�l��}봢�0�{��;T�5�6Z�	�ٕdU?�,���῅e�]i��S�mWA����R񁑕
۔.c;�=1]�
����$|(қSt:����Ko\�F�c++4C�pp\>:�������ļ;�|6����-���c1�����?������+����>������������`ݻ�"�|�z���泦������*����?�6����<>�Pã����ϖ���R�3�İ��������(���i<<4���ŏ�~�yV�u뻾��T�Q�[�>�º^���V�3[�JX�HU�|�(���$	�8�mQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW���ÿ�󥷋�Ue�\���y��z7��
�Wo_,�|�>-x��x��ߊ.��jH�\z������UDay�Fй�4
��'x�N|�[]U��i�Ux�E�7�Ulg�1U����t?kZ��K
GD�9��#�K"�&��b~T,y�������pxLi���{m�i7
.����ɹ>�������h�l��=�v����������F��e�i������3���հհ�%
��<����_�|B����*��o"B�n�I�GV	*�`29֯��?�:bj>/��4�$$E��JG]��,��d������/��s����=�E}Z����>!L�@��N���S��oG���f��/YG�i��m���.>hr�Y���/!����R���y��W����k���Sdx�r���2��3_WW����S���Q�}"�D���ֶwV�q�������5�A\0$w
�ހ>e���1��g�O�|5g⫝:;
v����C��Hd]��]��D'=�*/�~ �<I�c�{��x.t��V�k{��d�k�a�a��K�^�{@������=2Y�O�o�H��Z�!-���$~�pH��$U/���ZF�����-���4��F���d��{@�p*H�ր=�L����R�@�ݟ���5&��E+"�#���1QN�WԴ�#M���[�{+d2Mqq �8�u,ǀ+����/ý�}����zV��=�[�Y۬r0y㉕�|���O�O W?�Sk��?��
�6�桤�qG��:Jyח�c��E���<���{~��@�����t��5뿖�h��7n�d�	=�y�P��|y�����?f_�ZM�ٙ,o��"�B���,��g[#5��-׉���m|ac�YkVн��z��c��6e|71�����@k��6��׬_�>:�ث�ڦ�mk��d�y����靸���1(�ԨbG^��W�~���m�1��X��|u�^3�s����o�o�O��ƾ���y���ɣ[x���k�T�_�4
��[��P��c|_�>ڽ��z����j�/�e��Isp��Q�~��J���M��{���["�>-�B�6M���m��F_Ua]�����o��w�t.o5�݈ŵ�m$�Xf
��K?�1�n�+�'�x�¿|3�cIJ�i_o/m.��Vݼ� �ݴ)?���}�u!��Y�4�4-�z�A_
|Z�o��a�n����~1���m>��ğd���}�s��	�>�k鿂�����������-�������%��9���ڐ��8��ր<�7�I�i]���km���k�鳢�d������Pq�KWk�|����Ǿ��a���!���íi��@A
 W%U�RHء���@�~	x'�8�����Z��Y�2�����ۘ3N�_�0+�G^+7R������s�X���Z��v���ɼ�w�sОK��I� ��<;e�<1�Kq���^���2���ր�,�
X��1���_����a�k�F޸X��L+G��������W_��}@;~��.��|�������q��>�Ggk�c��7-đ�����x�k�\xg��查�:ψ�M�48vi�r?��{Z�4���PmDٰ�i�vW�Y���������@x�W�j=$hռsa�Ka�G#
y ݽ�#�hR"�z6
��ȳ����/��]y�:�P��y���-��F��ޕ���Ķ�[���\��.5{���L��CN����UY��df�`���/C�����~%�E���O�&��v���؍����&:���z���qV�|K4�&�i�Hd��F�*�][>���
��~�ڧ�t��ߍ>�&��ݨ��,�EKB�.��0��:�9����e�iZͯ��/|6��K[�K��%�9�GEm��˴1X}�_\��	j�O<i���,�wg�1�k��n�B�?gKȚx�MB��;0�>ky�O���V4
�V��qw:��rO ����
�$/�
[�׷�
��M�6���)[�]2����*��
x��+�H_����%�
�*�[�5�g���������ğ
�h�s����|A���hi�]1i-��q��!�8$+2j�B�lg�׃·��y��
�?�_�����3�o�$�?�5u��/YHX���]ܜ�^x�U9�������-�c��ݶ�f�2�Dyr��;Qc��(5�ÿ��
��e5߃�Ck�G
d@�$Y�7
�	������o	x��7���:=���^$������K[�vw���f8A�8��[~���?ۖ�G�Ōzv��x\�Iio�C�ڽ�Y�m�
�>*��>�|����ϱ�O"Х���ۊ����>:��������o4���5��4+�H6<R����[nO\c�^%�h~
��O|��O�]J�o��L�Q���X�eTN_��.�2��5M?���%ޕ���p_�L�b�}�|�����a��
�@N����ÿ
j��������;���_��!P�!p��_�	nzu��_�������J�G�i���s�q$l���|�.�/�s�k�.<�����׭<G���V:~�
���A$2ȩk��NR~��
Ю� |�U������jw��ma���Z�0v��wbhڼ=��_�|\<)�x�O����G,�%a�)!_-ϲ��C��u�I�x��1�x�M�SI<�l�oЫ�Ƥ,1�⟶����;�6��/�sO�����$zl+�+!��yb
�<�:����������u��|-�E�X	���+�Ǖ
�_�۹�'��>��uM7I�fյ;�k->�ɮg�$H��,x������'>�4��������m:E���фǾ�W	�X��~ɿ����
b�L[;i�;R�aڐ����������'��xCU�Q���ٟXѡ��yc�/��4�-B�wd��`����ր>š������?5�y�&3��Lc�םi?~�$OX��N�P�A`���8
���ؓ��s_=��\�����O���}&�@y+N�~��A�J�Mw�r�G�x)|.��Ӗ4EMF�4K�+���T�'��9<P�j����i���{ocel�I�.$�����yօ�@�����t��5뿖�h��7n�d�	=�y�����'�Y����MoC�bڌ6('�5�D����\��'8�|y�����?f_�ZM�ٙ,o��"�B���,��g[#4
���e�xvOx�R���#�bi��%�1��7�Z�_�åɩK.�X�3��I��N:����.]x����W�:���mw��z��c��6e|71�����_PkΩ��݂��I��4
�~6xJ��-��<5ↈ�p�Y�w�e6d�U|(W���Cˀ�u�[Ꮞ|��Z�to��P�i�Di⛵�cqneg!�<m�1�ܨ~���6�t�O�	�K�i�W�ee�\ڵ�!�P��D,>V�Ú��t=L��o�7G��5
+�\[�$r]2��der767g4
����C�G�KxZ�J�����f�Pm�Bʛx��/�V7�~;�%�'����7��n5)d��,K+�������ׁ�R�{�ٓ�����$>!��mo�M�h�/���o����~Ο	����pxf
�]
CHD��
��U����޼����7���uj��e�8�..e�=Os�^{�~�u�b=&��Vf�W��Oo<���"�_z���4φ���H|IռA|�WD��5��%�&
A�#T��eJ
���W�~ѩ��K��w�~κ��c�hu��6�M{pf�~h��v�9�l�
z���� o���7���/_D��?�/��	����������仵�$��5��|��f��g�7����W�x��~�v��X��W]>�[��xhdq,���YT��ז sּo������o�-��$��ۓF�����z�-�O)YNI^l~
@�e�@|���~�ǚk�<�Z��&+���]���I����B�O��M�\\H4����W����?����h>Ҵ��!�����$��QX;��
Va��=Es�e�Ƕ_�ׂui���;k{�M|Ӿr����p���g�v_>1|5���O���]���#s���FJ	w���k��g�-?g��]O�h6�$��TE�X��ּ����+��/�:�_Iе
ͮ����X����G�.W��$W�|iծ����xn�]w���b���7���LX��P(� ���ͮc'��ߵoٽ��`��w)�c�v+��׍|3��
��QkM :!���[���>R�
x��H�W�w��"��
����'���%�~Qx������'����R�u�g�x���t
V�����f�I-�Ud¿;G�UOm�v�=��ĺ
���ŗ��hii��{�1�J�1�#�99��W�t?�r��^���L�-�N����H$,�����0k��6GU��m�0_x��o�k�0�W>���J<ų�8�r㴙�v���Ze����[i�}�V�v�,0C�H�F@��,�EQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW�Z�h���,�-��M��'����I~�_J��3��X�p���q_V�@)xO�_ƫ�7�?|j�:܌'MDY�G����q��)a�����ݒ���'�<�;����ot�+�ڶ�koew���l����z������{M
��|��]�K�hz_����ϪM�ƟgFkr�k�f�V�t�Ҳ>3�4����Q_��nl�]��Zj�]�U��(S� 
���_@Q@"��������+Ş5Ӵ��K�`��N��"��WV�wf���m\g �8�����<7����<U�g��
ig��_V���J��H(�r̪@h�Aa�x5��	�M񯊾��V�ŵ���{=Lj����˳��`��	pDlp���_CQ@e�Q�[]���xg�6?oկ>��{9#߲�'o��TaU�'�s_�k^0�O�������m�+ki��݃,s�H$��r,�w
�(:��*(�����<Ab��Ҽ/���_&Mz)�K��u�+�lwXԎ�5�'��+��?LЮ��C[���d���4�\9$��1'�88�v����;úϋ�
x�Þ��n�{%�jG��Q���(���>�w���	h��g���K+[����r�+��$FA"�z(䯈��׈�iO
x��w�<56�i��-�q-��:4��w+.X��`
��}'��)�j�K�'�t��hz&�,|9��9��.�bW�K��?:�v���B
�k���6�/��"|@�Ά��9������Dgh|��`�>�J��#�k�h��tχ���{��7�L�?�|),�5�������� �x��W�c;A8�V�
�6�\�F�}�M#A�ޑv����̮�ʽ2U��2	.HR@�5�
���_��狾x��LJm���
]]]H�1E�s`�!`|����n+_~�:���|>�~�d��<Lb�����A5��
��~���/��Y����ǚҽ�܈�D������G��;G+�R�ʟu�xKWռgl�x�Ě����$�>f���=]�'f+�(�G��m� |3�|%8@���-��G:��?�����u���P|7���K�^�Dl���)�$x6�F̠�ڸ'��#�o��>����S���7�.<��xg�7����u	B:[���blm�n���W��>1�'Rмe��Fh�%����[MRI��~m�FK)
K�Tn�_x�@4A�]
�Tk����skt�f�r�������%���⏈��|#��ij#S�����ȫ 't���C�k�h��(�����j����$�<G5���΅���#�G
��E߂|Q'�{g���3���8l��Ϗ��9۳v�㝸��h��>V��3���W���|0�4�^#�_P�N��wfo�4����� �r*���ㄿ|�Cƍa�L�<w���q�6�J�����]���A副�h��߂<Qi�_x�Ƿ^�_xq,��<����[�o�ߒ��J><�#�'���^�������'�T�ύ>Ό�屷�`�����'������
�߶?�<Q��z�t��-Djp�|���d�w�v�W��|Q����z���Cm����nr~&��(���ޭ�O�h/mc�/%��Y�Ȇ7�2��Wr�k�v�y�h�O�O_xo�^�~�$
�-����RV<��aY���g���YE|���<Q�$i��[k�����2���4�0*��89�q\�������>?<E�,�[�[k�G24����&���n����Š���X�g�=�:��W�|待{(�YUC q����zc5�O/����Ε��*�2k�N�]���\�c�Ƥv���h�"����������6����Qբ�7�U��y^{�0��Ř+���R1���8�tڋ����>+�B�t5�k[�N	#��� �|�"FU.R̉���WԔP��'�e�/��᾵i����j,R̒"4�!�s�X`�\�8�N��x;�_����Y���ӭ��KK?���%��,��F>����&����<�?�o���u��D�^�ik=��@��Q�*̄��$n\��q��k����&i|?񵷇�/I$cQ��6��5`�udl��p0H䁚�Š���Ÿ����)�mS�����N�eT�
�il.B������������/��Y�wöV����3.�Fe���u<��8������/Ï��>���'�����;�����#�-�q����)'����(��������:��ɼ9�}�4в�ʴ����a�հ����w�����R����G�|��𫳧�����M�q��������B%�������㥵���
矴w�����/�<=g��R�Kx<ԏy���Q�=Mp�8�5�x����;�мu��>��fw�\GK$E�p�����Pu����3ƞ���$�V�ϊ��H��؝�D'��R
&�5������8��Z�7�ٗ�������&�gk-������(�����*N8#8�P�����F����|(�o��	K��f�{���+��t�^�
<=�;�Sƾ6�%��5�Gy9y�$j�w�ֽ����P��4ؾ
��WL�S�VRj�����	���C���
�xW�|%������������8�ʼ�M�+/j������z�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����M�e��P�v�܋m��6�<�p��ù=�=zW�P~�_�ϯ���֭Ᏹ�]K�D�Z��v")ę/��|�/��w�%�E�9o�?5[��m|].l���X�
���.GL�b�F�wď��~'_�Y�g��l�˶�EHج$L�$p7`�ps@O|h��x�^��[V՟_�I�/��V@���*��9��y�������:�ŏ�6w�5Y�5�2�#w ��8^v8Bpzs��,��$�CI�Ɠ�kZ]հ��mB�9|�`p��<a��ھO���y?��i���hX�_y���Ȫ�������"x����O�a��c��K�7�"�u�R�8�E�;D�4o!�
�z*��*��/�/���Y�����J�H�����o�a��}���$�i��c����?��/��?�kL���Ba�^��6Ɗ�*�J�g�Fwkͼo�|V��~!�oS��}G��֦e���>T���c����c����^��oh��O���������P�1U,
�*�nP�H��_㇊uo���)�Z�þ*�������c{�,]��Â9�5v2��J4���T�!s��%���9�||f���~Mk�I5�������6��x��袩kW�ٺl��c�������/2V�
�|g?@h��Z���MB���B��.�X"���ˌ��us���~�5��
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP�~�~�w��^Y�\�t��J�V�ez��9\���Yxec�N7�L����>2x���&�|�.��F��X�:��9AqI���`o���d3�~�U(t�.-^}b-6�=J�5�kŁD�"��Y��	�>]����@�'���O���u�j{�W�X�Ҭ&�$c
$yE;D�#z���\���x��7�SJ��f\j*�GRu�Yn���C�GdܒO�tP�|rվ9E�x_ſ�����ց%�rN	
�>uG,�k��S�-��%��E��w��!�������T��Tf,*��\�I��h���h�x�B�������9<A=�k���	��WB�,7)�%H3��c��i>0x���~Ҵ�a����3�FU\2���Q��g����(���>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�C�o���1Z����!�7�e���?�z����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����2���V��=u��|M��c��+O����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�C�o���1Z����!�7�e���?�z����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(ʿj���o�����*�RY�����r���<(lg���_,xSß$��ψ|!㋍sŇC�ui�{�	w��!̌#eA���r�pq��_��o�������-_O�tmD�swy�ɇΆ7s��a`;�9f�+���_�>�%�Ï&�g��շװ��.٬���_,�W���H#�+��[���o��;�>�<�=J?ꨧT���E2*�ܹ.�U��1���ߊ6�?g�3B���Ż��ն��/�I Y
4�;��!nQ.=���W��'S�#�|N��H��O�U�c��ԕu^�Ru9�|��������[O��8�n1��7s�s���`�.
韴���å�¿nN��x�C*ܓ��x�(���pY���2u�Mc�g���|W�
�ƞ�3,3=�vh\�F+�;��.���`O˜Q�S��e�W�X�X-"�ӣ���Á��ࠪ�~1�Uam��=��X�\���2
o��9����>��x~{��ڎ�
"d]��/̡cB�)�
�g�,�G������o��iZ������q��2�Y��,��K0��1�g��b���i'ȯhJ�w�Ke_�1N���y�x�4���;# T-�̍���@]�ER�n/�t�gӴ������y����7'�w�o���1Z���יx�S������/��׭Yf�|s�l�˵Fzd�ڽ6�
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
��h��丞T�����
�I'��K_.~�4�KF��U����^��0���ˌ��ß�Ƭ8y
��P�
>/x���ͯ���x�x��}/Á��XX��� �N[�E}9^o�#᎛�?���="��eiџ8k[�@0����a����V�x�O�6�կPìڳXk�mho"�dR;g��`€;�(��
(��
(��
(��
(��8����ω���%����r�[ܪnky��\���#��OG��~0�8�|��ŭ�
�Z[\��H���F��n�Qw2w]�
�,+�
(���w��W��Ÿ>�zN��h�E�z�̨Ӳ��G�q��~�q�0=�����ڿ�������$�"�L��Eo[!
�SdKrI$�NO5�e
����|S�/���[���z$h��!��b��)
΁� `u�x�?�-S⎑�ό�5���_��[$�7)܌߻�
��p������
�?�/�=G�^#Ѽu�~?��G
�\ʤ�2+P������$F1��_�������~*����~)0�mE�br�gb`�ʅTP71���(��(����2���V��=u��|M��c��+O����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���x����ί��r�I���y�������g>�	���o�~2������ښY�ŭ�{������d�{^���i��׍��?�zƙ��sX��d��d���C�Tn�u����cc��2薺���swrח��M̳0
��;G�;��Mq�����3��_�l,�-��-�[h�72���b�b��Nr<���ᯇ�<o⫯�~6�{����-�4	e���7�&�?zF�p�`pq_d�@3�
��>�������U��&�d�����s�s��0����|�D���<����Ĭ|��]FB]��}1EQEQEQEQEQEQEQEQEQEQEr�X�����g������,��i���_@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@G<���4�q�gw8U�I=p��(��G�]�b��k���gkl�y��X.O
0I�O�|Ծ#|PмD�<!c��WX��4�;2%�B�������<�-��
�k⶝���'�yJ]�6+�kU_w�����-ҫ]�Ξ��*j^9���%�ɧ�wCe��yȈ��z�a���MzG��
xK�������L�c�B�i&>��s�s�j��+xb��;{x�(�P�ƊQG:8�h��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��+��⯀�~#�����6�^"�d?f�V�P��eimV
�v��>�
��Z���n.u�k(7�'�c]����Mx��}k�n����@:e�ź�u�{�q�$2�`�#�??(�q?�Ax�������&���\��t=.GKa~]���gq�����P�*�
�
��3��߆��h#�n|W�Y��MCP̎�,
�,F��I$�~��EQEQEQEQEQEQEQEQEQEQEQEQEQEQEr�X�����g������,��i���_@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@s�y�_��k~,�����!�����]��:�k��4|r��<m?��^���P(��H���ê�'���Qr9nEwM��N�|+s�sDҵ����-�gۼl+�ڹ
�t�o�~/���>����L��������<ˈ�t�1�v��1
��t_>�#�]������M�:���_P�/�+���O5�PCG�QF�B���K@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@�����?�b���믮C�o���1Z����
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
Eb���^�v�.��}^�J���,����:����^sy��[�O�����:��Wr_O��6��2l�l�0�z���=6mwL�֓mgu�[ۛ�ӣ�O�l�Jg*	��x�|���⟍�|K�-J��߆4�Ś�F����������&N?��9���G����ƹ.�y�x��2�������.N
 X�u�^�@$0��2D�$�p��L���h��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��+��W�`��f���F�?jH(t�.�e����gf�
�݁�4
�Wϟ?h�O��o���c��1Ee�����a�`��Pu�j_����x���?�h|1�ď��f�9�Y_4s���1l�mZ��@дI�'��];N��S=���$M<���P77=Mp>>�/�O�~&мU�5	nt�5�����C,Is�
�C2�w\�
�/O�Ҵ�4�2�����C�b8�_EQ�j�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��C��r����jVrjV�Y��f���ɝ�ObG4
v�(��(��(��(�C�o���1Z����!�7�e���?�z����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��u�ZF�����ki�H��[�&�e����ǭkP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
E�2zW#��z_����h|U��
�i�ʷ���c�s����p2q@uy7������y�N��$�u�;���%�[��v��p�w�5�|&������_�l|��×�'�5��*vgp��9��������
~h.��n��k(�������MҸ��Y�y"<�OɎ�
��]�W��/�{��^0��v�}j'լ^ݖ�E�U�6�*2���'���u���W�_�_F��N�K���7�p�`3����ɮފ(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���������~jz��&�����Cu�ۣ���{6��w�|�������s�����KmN�R��m<���3Ƭ��r�7_�������Q|M�c����`��L�Q��fS��9�+��9x����O�6:�g��1�������u

��������&�?�i:������Ap�i��&�%�h���2��tRy���z�����b�R����k���,����og�ERIP��?0��9��>ko��/��W�>�MFX�/
�������	��@�t�����In��^�����[�
;�O���8GԵF�a�nHc ��������	f�oƺh�ĭS��ۈ����%�H�?��K�W���w�_C|X��?�:4?��6��� ��|�vvUM�s(��1_7~���<[��^�}��h���HR�N�a�M��&w1�j��i-GY���H�o�e��y�hRB&�ųmi���0=��m#sA��������Xk����<Eh��1;��q�w�.T.U�������C���1\�f&n��O�5���_�;�_���uge��ighү��5����s@]�ERֿ���f���۸�׻���;���?�(����2���V��=u��^-����������۶�>�����q��m��ҽ6�
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��8bif�#�
,�pz�@Q\Ή��k�!���/��}GU�3+��ݤ��OL����gğ��������
�Y�_�ܽ��ah�][����(��B@��+�>&�Ɲ�~����7��{��]Z-L�^Դj|�o-��b���p1޼���|����|K&�?�tm.�v�h�=�l)
#���1�7��/��.������i��l�^y.�%�ki�N7��O�\��^��/����a�x��z���F6�H.f�s�4j��;[ۡS�W���
,�7�^"����~�")�˟�����ؼ�_
Y_xG�H��[��l�U[�Cg���ܓ�P���������KĶ���1�.#�6!8���3�f������)�%���<��f�ׯ*�^���C�0𷆴�����V6����=�W�>YZe����3�gt;�z�oZ�>'�i�ë
��w�bj&�����!�),zm�׃�4|&���O������n�}>%�t��h���p'�Ͼk��t�7R�a�t�KȐ�xVES�
M3I����M�l섘�-�X�c�v�h����>=Ʉ��h��	L��y��}+��S���Ӯ�E�3L�SO2��&
'\�}Fy��뿇�ݤ��/�.�{4�LKu�+֓����{{H<W�
U,�o:>a
��#�x�Ҁ-xK�~�j�|/�m'Y�0fWi+G��������{K�;��e��}�
�Hi��r>
�U�
�}7��7�-�b+�I�r�?����s���߱������ڭ�&�����ڳ����ؼe�����–����o���h����ׄ$�������޵��2��$���������k��</m���Yx�^%��V���@&G����g���E|Ծ:���;�Mg�O���S&7��
�{9��vJ��4�jӾM��o¾"���&�K�H�� lff��zP�Q^o��O��&i:������ţ�I~/����b�+�#��sڵ|9�W᷈fH4xz�wm���ec�Cʀ;:(��
(��
(��
(��
(��
(��
(��
(��
+��g㮥i��th��o���������j��2���T�F�>bOݯ�r3��@Ex�ſ�?����Z�A�k�g^��}?O�qG VvŽ��X�J��j�> ��������wR�4�k�6�]Nѱ�̈́e%~��q@�_;x����?� ��s῅5�j�M�-�������6=v��|�=�?�����1���x�Z��6����5,Fb[��תh���$ɣi~����L�������@��4
�����Γ�'Z���:-��6��rsˆ
��p۔m�5��(�o�_�>:�,�	$�g�iL��&������Ɗ(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���>#�;E���o�+�^K�
�g
�����_/h��>�|}��^.�e�Lv�y2�"#^mrE�/��BuSn��(�
:�a�h�z6�l��P$�DE(��yu��O'������	.�>!�_�q��`ϝ����wǽz�
���xs�児����SN,l�l@�ʲ�r
�A��7����k�x���>9�α�SN*l
�2�EyBw�#6�ʍ�ھ���<�����麧����-,��j��s����A 7̸e*s�ɬ�_�>����Z�5/x��?(�W�T��
 3� �X�01��h��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��($
�Ҁ
+�<S�C|&���o���x�+��Xzdmt#f |̟/���g|n���/|So�|-��t�[Uy�˹#g�R�v���u�ڀ={S����&�ԯm��]�\\J����7}k��������+C�ꚝ�2F���<
�Kc������:���k�|X��7mF��u$���FX��
�]7�\`
]?��x#����)�}3J;v�a���+e��&�<��N��K�6�t
h��(%��y,r4�@��Kc��"$w5�x��M���z?��(x���Q��.oot�[aq*�•(T�td�o�ש�@���ÿ��
x~;{����H�N�q������zP
^/�#�O�uϋ���1��"{=;�6p]it-��2�lnl����J��(������h��LE��W?�_�|e���{J�i��_�K�9`�?��������j��c4�(��(��(��(��(��(�
gN�ͽͱ��0]��K�PFa��#�k�u?ٛ���]�m"8l[^O6;�A^�Ey7�߃s|G�,5�/����V�Ō��?1m�)��	
�Ҭ|2�'��3�m�ę�]�\#"�U��Z�#`��wvR�I�:��(�U��4�r��V�ׄ�A�<�7Q�E#��0"D#��}+����{��Eicc��'��M�ؖ��m�<�,l2�+ֽz����/|?��gw�k~����忶9
{۝���������C�Z�־*kk˩V(b���=��o۰r{�z���##��0�)zW2��uu#����A,7J�H�9nA��Ğ9�_����x�A��%��H/��vL��Ì�3�kKEִ}j���6�a�Y�W��	,yF�$W����_�Z�j�.��Z��B![����	 -�8��I�
��h�L�Z>�$ȷr���6;1#�z~f�;�{�.}��ʿ�G?J��|�����A�F��
?U�Z�i�)sf� ����lqمt?�g��P�D>"�|C�M>�e�H�PD�Cdly���b��(eR�3t�^c�_��/�>k~��^#���|�:�{��B(��p3����ⸯ
~��
�=�=?^�Y�]�ݍ�\�&��!t`�;"V�Gf�q��C�hJ���f��2���!���	���{�[x�I��t������g�-��<��:�=k����#���O��Oi�wW�n��˽�4dRJ�)�h��t>�i�o�^����-�{����R�q�v��ib�<Pa�M�ԼK�hV�wu�]GkE�L�$v
�.�q�9��+���?�c�xQ���$��X�p��D��H�!8#�� ��?�'���d�<'�iR/G��ⅿ5Pk��L�.��Q��|C���"֐��.�91�©�%鞌���u��ź�졪|:�N�e��v����F/#y�(�m�q#d��(S׊����Ykz�x��>)�.��
j��^Y]ݖKY�+�9wR�w<�W���H������
�?��y}��������x'Ķ����H�K�-��D��ԅ���(�wϠ�{����Ϳ�g��b�n1�_��b�Lɍǀ^ճEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE
�|M��c��+O�����>&�̱������]���Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ��Ϸ���$�
����<��s�������=/�-%��F}ʻ~S�A`[=Mu�����^�>���x��I����'�$��#g���^O��'ƿ�>9�ԧ�k�
a�Ϩ�T���S;I���M��'�ڻ��~j�?x��R����������xO�UTt
ŀ��|}�S�Y�7�h|^u���$�
�eAGdb��d�+�o5_࿆�.4���/i��:�(��H�%����tU��wf�Z�����++hm��A04
UG
�T�
��=�;���N��g�v6�jr.�{���B̿��QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQERm;O�V�{id=Y�V'�5n������2���/�S��t�dY"���וe�A�*�QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE
�|M��c��+O�����>&�̱�c���]}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW	�3�����17�%^"���ٹlb>m��#_���������9����#������V��3Y�G%��3�;��uw� ��`�Y��{W�:��K����?�0�����@���L��*�G�*�}خ��o¯xK_��g��"�~(֯���-��� ��ʬ~b6��-��^���Z&�l����iPH�G���!VcՈP
>�
�>k��������]-�w�=�\�I����`�2�x��~|9��
6��KI���S4�M)�I��]�ztQ�qһ
(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����2���V��=u��|M��c��+O����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����S��M��?iW:��%���7�5̀�$u�f���zu����pZZĻ��y"Rǁ_:k_�1x�]�о|'��Kk��MW^F�1��~S�T��s��k����cG��|=q�mOT��؏�c��쵚F�ᔰ���@v�<;��_�Z��n`��������idElr7���������5񮗯k��^���>��,�p� �p�dd��8�~
�7���6���J�v
 ���v%��I���<�����MCǷ~8��+i�kwL�$�l�G�T(a��W�����8�8�Q��J}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE
�|M��c��+O�����>&�̱�c���]}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEr~!xW�充��!e
��Y�v%���G,ݿ]X �A�5�U����p���?x�h��~���4��`"�S&n��<,c
ӄn՗�G����m�>'��uMz���";�o:;���C>I��}X�'��TW�|j�G��/���	co5��Mb�u��r�
�.�s�����g�|$��-�{��ϩj����lm
��PNCg�9�vw7�m����97��T�n\�
����f�ٜ��ו|U����7Ʒ��u�W��;]����,Բ�`��7A�kk���������h�_궬�Fs,���
1>�r+�h�u�x���};C������!�ɺ6@\O�r�YI
�ܣ�����������nn5g��&�{7�1BA 
�\��*�z}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE
�|M��c��+O�����>&�̱�c���]}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEVL�#Т�L>�U�Mn{cw����;K���#�kZ�
(��
(��
(��
(��
(��
(��
(��
*��흄���XA��i/�j���/�2�i�
,v�q��=X)$P��z�����Eܶ��>��x\�"G?�U��fz���߀�	��/^���a���>������.�ۗ`?.���"��;�+̾����������D����v������=�F���������8<�k�uoڢ5����O�5im�hNm�d�8���G��@G�^[�S��4�
h��>�������$����#���������[,��ı������Ŵ�6뚶���'��+����k���L��+(�N1Ϋ���{����e���차�ڸ�K�+�z����������n���c�ס|���_���������ıհ���O��/�Ӱ¼���ʠ,ʬ��݁��
�5�k���4��$�۰�8��ڰ���7��7�?�:'���K�ʴ�����ʬ7�ʝZ<��s�I��i�7���WI�϶����v.�����[����_,���{�F����Y&�
�eEۖ�̫��{��>�_��}��q��#]Ң��^�]EDq^3«t g�5�d��#�����@�������ǥO@5é���#�A��#��Q/ޞD����a�'�U���4Mj�E�g��g��_�\G�Yh.��s+}�!��s��9��k̾-�"����m�O��h7�"H�o�̈���nRC���
��o�?|.𖡢��s�ɬ���x�✄eeX�����	8�+������+�+�z-������a��R8RV�7X���7R0;�E�
C^����3�)��Uw�{��t��'Z���P��f�����dT�<�
�0A��ik7�Jh>�4H������"�I�\4�P���
c�N+J�
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(���Y㿈^=ռ��R������-���l.$�O�[[��#2�fn��n��+��
��Vͪ�O��߈o">c�Z��F������=���5�|�ݧ�?E�Ei%��S=����s%��|Ip:pG�:t�ʊ(��(��(��(��(��B@��+���&�?�<a7�t�iWZ�*�ֱ�s�*�u��T�����+%�I����m��(kl�b��?��w���8�
j*˫k+Yn�.!���wI,�}K��
���&Y_Þ#�������^�p뱎(f����^��ɨ����e̗s�Q�՘�*���l����7W�
��ct����$f�4袊�>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
*��c��=ޣyogn�zY�X�}X�Y�7�<+�_����mR�E��Z_�,���Ubq�@tW�x��gQ�ӵ_��]���O
�dh�NH@y�;��_>�沵��>&�<Uh4�@)�hM$��B -��� F4
��^A��?�/�5��4�5��#(��#mFF���=+��W���F�ﴛ]�Z��s�&x"�A)S���L�=��@HQ^[⯋wv?
4O�g�>"�(����m�VV;����@#$z��?�.���_����
��k�nu�PB�C`
���<�M���TW�^'���'���+Y�.:tW2%��߉-O�c��n�d�c�1]��>(�ڟ����f��1�Yd����S�DK0��~�x�	�
��W�����s�6�㿈^�'���e��HX�̻�H� ����N��x���
W�Z����%����]HֱA�b��*�IeG٠�j���Y�:Mޫ�Ζ�vp����c��1�k��o��ƿ
4O	�|C�wo���R�P�_2��e��^��_+k_���k�>+�-�ۭV?_]̤%�RvE��NY���d��7Z��}�I6�ki�����t�*{�Gm b�1L��#,��z��?����j#Ӵ�U�%���u�>�ݷ���9^�ҼWW����i�ǧ�%��e>Uėʪ�d�7��>����~�&������ލg�O���ԴO0�F��-�iޮ?����
�g�~'��:��G��W���Dfh �-�9���W�/ڃ�މ�]i�x�����V�U���`I*�:������>	���¾�t��"�^����鳢�����ư�8°���ײ�7��<n�s$��61؜�fےsހ9?����h�7��W�4�oa�66����xf2�9��Y�~=�{⯈��mþ$�k{Srn/m�B@e]���
�p;��W�"�"�(UQ���@:x����=��}���i��[���1ț������^���E����_h:��>jZާ�,mu���d��G�RI��1�qҽB����8���][���x_IKS$7F��2�\&�rr��p1�޹/x���}v��G�w���u����v���9�?�z����/���n����_�V^&dF֖|�J�Xܰ�mߟ��1�R�)��z�����?�v�Ik]���0�*͹p�X��ۻ9'��v���^�k�JjZ���i��4�.��M����W>00>���{�+�獼Y�]C�~*j��,��enQ��F��H�2�l�?B=>��?�_	<E�
z�V�>*���������8��o3����0��p�\���&��´�֯5���^5�7����>�+���捳���t�����࿃<s�
�!��z$vn��%!c	��d�sG¯�>����g�P���Iq=Ԓ��YX�v��^��zE
��/������
���H�9tfRǯ�N�����o���m��{��wV6�V��kH�(B��H��p1ڵ��
:^��iQ�ize���7-�8��@��Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@W?�x_�B��,��t�&��I''�|�TX��;PAE|�����.��)��~bv���(��R��5��
�sĿ/�>��6�Ww���㨿��}7Ey���ߌ�z��ŝ#BҤg����s�uo0>�s1?{=�[����~>�u}[K�k���Ӧ��ll�N����Oj��/�Å����Mu�R�P���-�
�����ʾ)�R����Y3�b�?�����/�֕��i:���ѯ�?H�ҽÿ
�xi����Y���6���`[���_�;�j�T���.�i������)w0���wj��W>3��]���irx�L�mຏQ%C�����L�'�;{��芈*����>M���|s�]xG��5�kȢ��Ľ�!_��Gp���B��ݦ��I�cZѵ��F��O�/��z�Prv�0y9����S�?�/�C��K��')+�����%f�#�)��~3x�ݴ��Q��tG�.����a�����\�=���;W�xG��?�<7a���,���PB����y$��O$�MkQEQEQEQEQE
��iֱ߳.���%�o���ݟ
��lS�ƾe�Q�����ˡ�_������u������Oڔ�̻���p�>�ٿ<q��xmcź%����L�WV�����ȭ̋#��8�׫+⟊~�}.���S:���Z~��,w��O&yf,��~V�}k���5�c�A�B�>2�U��:J`pf��#��$�(����g8�_��c�
?�ێ�}���k,��6֖�J��F�u\/�1�������>!�%�=����j�´ܳ���?ޗ�����ʭ���������������슀.��������#�9�﷓�����/���<�6�aL���t���c�/��O���Ï�
.4�;Q����̒���F�d�w$���� q[�>4o�G�'�u�P��y��
�E�I!'�\?n6�����GL�'�{�fX�qU��F t�s�@h
�"?lo
�*�g�_Y���m���Ip�ݕU3����v�c�;���<7�C=���Mc�bӼ�<�24bX�X��#s��x�����SÚ��"���Z��+�+���FO��o�N��������1�Y4{K��;��Or�������
��|a��:�����^�F�4�����f�l��+,J���0
�$��g��_|}s������>�f止XZ��;q1k�-�ǃ�#y�����/�����]����5
�2�e}wqu�{���X�(U��H��;�Ww�8���|��{5톥��_��iq&�J�HG�D�ʒ#���;���}S�9�]�΋�|q-�[�����+�[t����ߡN�#�����o��~<�«�nj��u��KK��$�4I�HԮ⍂�q�9�@�nʊY�P9$�W�5:ͯu�kKU�駕Qze����Oٟ�^�ޣ�I�d�I�աwo��ۏ��S�{�Zυt��;��
�!�W!7�z��(Y	*�!���H���Z��L��;dz�|Y��ܤfW��Q�GTX��@��k��h���j>>�R��"��7�T��������C�:�ְ±��������������2��$���~��6���9�ӎ��c���������,<Y����ƀ>�ֿh��V��7�t��d۲+I�����U_�_�/�?x��¾ԯd�nQ����Y6)v��C}+��4�����o��n����x�O�{}�3�RMK���4���4�oaI���m��PG��j��O�z����>*��ҧx.;X�"�ԩg�W���#��`�?����4H�ڋ�u�� D�̙o�O�_EXx�Ú���]үC�]� #�5b�IҬ�6Ze��<�?���4?�&�Q�!���lW*�w������*1�ӗ�����p�x?���϶����:���E�z�;W�tP�x���L�	t��
�~����Ԭ�f�	�����ά@�<��/�?��^�d�f�r�)��R59��Vuc�Ԏk��(�[�~�������;G�V%`���!��(����zsZr|5����}/Z���i�*��Kc#Gt�;��;������?�k���g����w�,gx����!r����8�=�ם���F���u�~���A���t���cv,q�/|��8�M
򬟱�^i�iڿ�_Y��ɷ0��,
��0\d����W�;yVI|[�a�!��~Y����4>����6�yu!�,�*�4���'��rNk��'�_k�k�5դ�qyV7FUcEE
��ª�8�h��<?�/�[DԤ�Pڔ��F���*|PCxV�C�ڥ�������𾃤�c��Z�f�Zm�B+x��V$�\����!| �q�W�W�w� �[��ybo,B�-�<���]�
��~�]J�D�:��?��ZO�g�c����?���s��^�Es����r?xSN~��<�/5�%��1g%��\�Ə������*:���d6�gs��m� ���x�E��>h��/�d���0��}�[��?�y��?j�_5���
ߥ�wzUܱ��S�a���Eɍ��;�$>��7���C���\���'�4�N�_&������t�898
��Q���|�V_��N��i&��㢴�3
�W�Y�'��>/k^?����}cV��6�
f��_:��c�(e`��1<0n�+���!�jq>��/��8��FZ�$��;����u=N+��'��š����6
;L�]���s�I<�O$�I�@=~��7�<1���y��A!���r��i��_/�>��L����6�c�������澛��<���Ə	�\�Q��r�V��M���7��w�ۂ��~�wϵz-�����3GK��`�?OH��"�s� c'޹�^��ď	K��r�O*J
��7G^�N���Y]C)A
:�c�WR��>�_�W�����ѽ�������7�����y���>>����ēo�|�'�ߍ}=Eyg�ψ~9�Ƨa�o�z��n,
�M�ȹ,NBnQ��b��w�mcT�4k�5}F�N�����L�F���I�.�PX��_[%Ս�V�2�� to���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
�����{G��5�F�N��t�ES߶;���'�<�&���zm�@-��Q*�22�xdzW���.�#���6?x����~��\�i4��jL�~uTmʑ���s���O�i_����ӯe��S���������z����#�Z5���jV���r�����:0����;׊]��?�_�Ūj7�ۈ����0~W�eމ�ώVx)����>�kb!��Ȋ�x���<�:��>����?�࿅>&���"�����ܳ�=�ܫ�����,ˍ�H�?)��ᵴ��������
���D��¶������ճ���=������<i�
/��Qn���X�2GQ�(����|��M>/�3�ɨ�6�
��J�71�80�V����q�|fac�]2�~�^(�(�0���>
��0�����?�ؼ_���<1�O��NmG�zޝ�Z+��k+����%I��{��Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@��x���^n��izRc;�.�c��W�x����1��Y�mk{*�Kd���dR��z���)����~����&�����ȹ��p���r9�V�=W��o����:F�-�H/���W��m�UZD�~n~n�9�K��("i��"�Yݶ�=�|���W��>)h���c�G���R5?�����4�Ze�����x�prKL#��C+~�
�f��麵����K��m%��*�W*H���#��]7�f�a{}��:ĺ���:|!�`3�1?/�R}85���ׅ>�~���v2���M7�3��3���ɶĻ��DZ���������������
�-����ܰ�2:�����<h��k���_:���9��W��Z"���*��%}7Ey��?x���%���|�����q0����p#��pz��s���^�nj�!��N�c��A0�(���##�&���ox[�>���<;��*1eg?��EQEQEQEQEQEQEQEQEQE
��H�?��t
z�;�2�?.�	3�^��#�@"�t�c���I�ԯ���
�1���������q&s1�������m-വ����X�5ڨ�0
�
^{��������zh�mne�����T���H��9O���/�#�O��i�j��$�ѶK������G�>��_>x�x�H�R�uHՖ��R�$6�����8�A8'�M{
��b�K�ϊ�]�����3Z�mo-d��w�
� ���Vo�����Qqsy��{۝F�?)��Y&�;j��$�s���B�+��ګ��|W���_�|1��i76v��ksn7Ol�]�\Q�䎵��
��<5�HEa�iڕǏ
�^G�ͨ�d�B�K�63�<%��o�<G��wC�6�ך-鸁f��5�9e�ѷ>�	bp+����,��i���_@
BJ�W�JuPYC)V���ޱ�	�WR����t[����"�?����
��?>_��|0	�aӣ����
��ٓ���Kx"8X��1��c��b��>y�?c��Y�_�����
����Y��~�?�$�猴�t�H����E������|oe� ?��6 tS����/�������/���8��ؤ?�z�j����?��ӆm�&�OQ�tIm�1���j>��d���n����\��H��(�_�Yߵ6��!_��U�:��|��i(���������^'�>���9Q�������
�/�5ō������M���Ҷ?ｕ��~؟.����-??��`���ھ���OA��@��]:�=~�j�g��
�Z_�-�KP�#�ͼ,����,~-�u�O�/���ѧx������!����*���{�V����0Y��zlQ���"�\���.|�w2�E�?�k�\'�:\��@�gwk{�����G���T��U��o��&7:�|Y�\���F��7�=P������τ�hp���{��ƿ�����诙�?l_�î�GŨ�u#��zR/���wǟ
��/��w���&�䑑}O�&��~4
����`|<�H��&��]��qh���|���r�+��>��h��{����b����P���Z*+yṅg��9�q�t`��؊��
(��
(��
(��
(��
(��
(��
���x��Sxw�:p��fes����*��A}J�h����:�G�}C��o�J��|�$d�Cc�Z�g����t��t}��8O����ƾ���<��W�-{�ڝ���k~�4�C'����wdaY�Nx�0x�^�쨹fz��ur�h_|/��D����*L�ZK�Ȏ����~�
��_0Š���Q��o�K����4�iI�G�F|���qh������'ď��YG���
��<���P��W�|���/�v�����k�;��]��
=����ea�n�<rz=QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQ\��~$x�{Lj�a���'X%�O;����
��^	s�X|*mz�Fч�u鮧Xc{
8��t���^�M{�WR�,4�V�ԯ�����Kq*ƃ�X���?h���RY>,����I�(���ݱ��n;���۶�?�<�i��/����2�O��G�y�Dh�\��~�=]��~
�Kky��*I��o�P}�%e��P�Ҽ�Ÿ~�a�J�&��FC$�q�������^�@?x��_�t�1�4_�*��mp�[�:��"x�IW2�9돛��O��k�s�|@�߆���Ci��V"���n���ٟƚ��?��<��PbA1[�������E}%��;{A4ӈ"Xē6�h��=��5b����Y�\��^�m���tT�;� P��8�W�|P�Oះ�6�~ �
4�x^+F�״H����]oaG��_������z(�m>)�̶�������۟"=)Vn�ǔ#ݟ­|%�ּu�B��ޯ��hZ5�����>�!�0y.d_�݀t�޳�������������~~ʞo���֝QE6DIk���0ȥUTP���h��cF���RcI��cC�K�t�T��
s�
�]���:������=��ʊ�;�/
�<��LF/���~��_������V�y�"H�]�K;�3����W���X������V�[�����m�i^C+)�gЎk���mc�"��o�����p�}3E|�g��o͡��~"�r+Ę���f��zg���S��z�?�qg��1��ʃkÍ��6�'?/��^�Er_��^���}��k��H�+K���(O�ܲ��p����v~�:O��?g��ݿ{�6IN~�VZ�n�����m?�F��1�1��B����:���|�c[��|?i������#��T*�2;��u�׭Tkk#H��w������
����h=α�_�a�ڦ��'}����p>���/����O����c�T���Y���_�4�G����{�>�<���@�"��}F~���T��>��'��l�����#���m�(�4�_JԔ6���^)�`�d��5v�r�c��,Z�������2���~��Zo���3��)��(�1asp�L��o�
�g c��{eKZ���F��ӯ��{5����ybO"B�,�O
�����|�~���i'J�ɡ^(���'����@L�_2�?�M������,F���ԭ��ߵ#x�M��<(�������D�Eݔ	ؒ=6�u�}������'��K눏��"I'�r�|��yA
�
���7�/�?�n�������U�'�ƛ�R����y֣�Y�$q<��I�9h��{�(�����5����_𽬭�h-��[����b�"|lULa�a�*�ǹ_^��-|}�K���%���p����jKz�Iȓ슢8@�ɴ�����z����z|�h��[�X
�N��@�s0��f5=2�"���.�ge��~ �#��Y�]}�Y���"1�,d��E����O�����/>K��,�77g�kϼ���^ ���
g��/����"����+Z����p�(�m�v�84
��WJ��]��������~ϟ/��7��;s�g�W�|Y�]�g��5��4���ФH�XZ���v[-�s�c��o��[^��N��i�w��H��"+�c�+j��NJ�7x�YS���\���d�+�;�IhC^M�=L�?i�U����Ж�6���]ZOż�9bp��zG{ך�Z����Ꮁ��k�éI�ֶ�#�!Ind��9��
�:W��;c���Zi��m�[b�v$��jK�G�����I����v$�[#�.s��d��~�z&��/�9�%�`T��3!�*3�s�������KW��X��_����*�eQ"�P0�@��	�i?�le��i�Z������1(�vw<�ۜ3\������/��O� �핬m�v��	9�~a�v�7���(��4/���5��mQ�A�HN_�����T?�z7�~
|'��Ӧ|?�C�ݒ��\:�]��נ�@����[���A
$q�UQ��SQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEr�X�����g������,��i���_@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@�m+Lխ����Y��z�sʇ�`Ey��?g?�^!������I�3�m�,d/�+�(��n�d�]V��s�7�~�'p_1s��g\�5�?k��=O��lc��ϵf��[�b�o_O�@2��R�^�m~*|(�/��pSs
"s��8�u��W��~��ˏC���8�Nm�'�$�K�s^�s70<�,.0��Xzzד���q�C��2[�
å]??iқ�	�vO�Mz�Z�-o���t�j����i�Ϥ�5���^������pn�>��m��πs7�?����.cҵ~bǧ�FO��_�p_�7x��n��Q�����7~"�M[R��1���Ux����|�z���h}������&�����������w��ҼC��v�v����m��-�r�O���7���߆^=1C�x��_I���?g���Џ����¹�#�O;\��&��J�{5Q@Q@Q@Q@Q@Q@Q@�mo��G$�t��
s�}k�����_�^���<c��J�.R�/��`�ha��V*wg���WkE|����Zx��j��M:?��՟o�o-����Mi�UK����>*|1�/�.��������K��
ݵ���]��q��X{���[�ď�G��/|�E�%�U�@�������0����ӎ���'�<%���xo��^�o^�Xڤ"V�m�g?��/���<'��|^���Y��ЇY����%N@?w�;�+��Hko��Dž�/٧
qe�eo�B����Oe�[�z]��|D�s�
]�1A�!�m�)��(�7���|J����v����(.�1<RB_;C+�y��#����P
EP
EP
E�խ��ח�0�Z���g����ǀ�OEx���#�\8����;8����:=Ķё�/���O���^6У��+���q�BNQ���p����7���(��(��(��(�o��<�O�w�x�C��3��o�I3����
^[����֋�m���nU�u��ɤا�4
��WΞ��<U��i�~�+�[�*��#�Q�sE`qA��/ھ��M$p����(�;=�y��>7�'��ռw�y���������V-��y���.�������:���ͱ�ҥ������…���.�>���帿+���������_̽��ԝ���������Q�����_�����ֳ��<+��<��oh�����qc�p�Z��izn��Z-��akcn�v+hV4�U����_>!x��z�Nj~5�'E���
6��E��#x@B��[�[����%d�ѯu�פ���0����⦽Ҋ��߅�7�<�hV�0V��8A��5�EQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW��U�ck�;�iz��|Y��M?Y��IɎT<K?�}O<�}
��Y���V���S�Ɖ��0���^���E=q������ӭz'��?�/��=�n��M,�y�\L�~Y�����
����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
����<�_�WӼU�}I���7r$��2�3��2��kQ�_��+�o�	�7�R��=Ɲ�9��2����<7�&��e�_x[E��y��[�>����W>������~3jR�$�5��e����ye�	��ԯ�3�
���{W�_�|�B?��U�Z��=���h�����	��8K���f�<W��7�5MHh>:ӯ����I����)�Uֽ������;�I⸂U�8eu=#�+�������?�
��4=M�r�m�/�$\2��
��ş�7rj�<[&��2I��Y�
�8F>�˴Dz������ϳ�?�;��<;}�|H�n��D"9#�V[fo��z��/�F��#�$�H�C+��`z{���(��(��(��(��(��(��(��(�������{k�hn`q��d���S�@�𷆼4n��|=�h�������8<��m�g=}O�a�d�E����a��W��+r�	{��J�R��g�*��v�P̋������e�@���DK����K�����?���?�+��þ#�^��J�F��?��}7Eyo���/��ƥg�φσf�T+5��&�9]���{����/���J��$��
:ّdh�i�0U
G���7��ז�Z���q�k�*F�
x��Q|�Q�W?�q�\���G�\�?��
>#����o���-,���$.�$�-��ݙ��Y�X{�W�j?
>j^���es���a�������h�-�O��?P:E�6���!��N���51�q�'�
@=���1�}�ƚ7��G��մ�l��nb&��1�G�9�>>�Ҿ�v�4�-�m'�rͦx�/�;wu�����
��nL��q�x��W��Ğ'���w��o$�q
�\-�?<~\������늿kj?h?�~�y��E��C��[3}	������Ϋ�U3��9�B�zK|c�N�X�H���B�jͼ���r�>���-��<�i?�k1f���<G����ڵ�i��ըW����=U��И������^'��ށ��/u[����$*���8�5�w�kg=�G,�m!H�s�p���s~�q�
ߦ��x+��m�`��m���e���dZ����j]^�V�Ÿ�i��HP�g�P��L?jM{�E��n��1��,��_MQ@>�+I��/�Y�����ҴH��K� I$� ~h��23�u�����<CO��>
��s�z��,Ҵ�o5	YT���J����|>�/�6��CC�d^���Ʋ~/���5��@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@�����?�b���믮C�o���1Z����
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP)�#�߃�"h�L�f�o~�*b6�
��A�/�=�����Ư���{��S��
F/&�z7\@��(�}��OT5�e
�_�h�H�4ŝ�/��M#P;$.:�ہ'~8n9Q^�^U��G��'D�w���Z��W�P�<��Aӯ>�k�l� �]�
w��R����#���^hW�v=O�2`�u�
�����	�?x�B�[�m��?�7�u�����
���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��3/t
��/�4M6��?�<֨�/шȭ 
KEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEr�X�����g������,��i���_@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@A{km}i5���76�)Ia���꬧��OE|�����W�'�~kR�wY_�m��E�v.쁟�>S�f+s�������!_4��o��a�tv��c7�c�X󑵛5�u��a�I�ϊZG��K��ƥmu0�6��u�e����;�+��_|X��nbӼkǎ>���n,��V���s��W+�?x��~8��:���k}J�^�~h�����a�@4
�EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP!�7�e���?�z�����2���V��=u�QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE

ݼ�����ż�c�)P2:�
�<Fx5�W��x�� ��߳���m�߼��{��UpG�
�?+/����<[�w�
�x����Z���gyS�W�A,���[?���k�k�>9���;?���t�@��Ū�d#�y�c����^��㿃����;Z�y�H�^��H���ze�O��� ��U]'Q�մ�}KK�����A$7H9�*Â*�QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEV_��A�xcE�Z��k�i��qp�Tzr{
ɮ���^?�Ɓ��m���6�^G���
����)烵�?-z��|F���hp�^0Ն�a5��G)�IwHU�.�՛�1�1�q���g\�,4M/�_h��.c����2�|�d`��h���$�@�Es?|{�iq�^/׭t�yX�^f�R:�E��3P�;�����Vs]�;�6��@@�4rE���pA��J�(���>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
��g��/�7���}KN��	�#=�=U�f#�k�@%j����6�W �u-ϋ>����Iش���L0;�h��� f�����_�Rп��3���}��l-ų̽ǣ���Ewu�������O��j����2��o.��:#7~67�KPдW��hU�5��@�+i���x�݄'�]��v�O�f�2U��y_@�
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP��P�]L�g�ڛ�Ou�-QέD�łyE���TW��|��O��#�<�Voj���K��c,V�e�DUuu`��� �z��?i���/��?�<5�k3����pm��pј�I�K���ȯ��%��
��ǂ�����Z
��'bc�i�@�n�9$s���ࢷ�7sx��ַwQ�q5��[�YݾD�W� ˁW�|K�[7�
?��)�	��;��6�g��aY<�ߺ'0��1`6��͎{׬x��_��_�gB��Z�W���E�a�V����Fv,
p[j�/������3�'�?�=�l��V�]i�	��D�� �G<���(C����~�=�_��-�������h���/ ���x��4��_�Α��b�7I��Ug��@�(�7\*�y�+�{�x��������^'�l4mf�Lw���G�O����
���`O���L��4�G�pjzV�b�q{j��"8��\p�̕S#���*��c����e���/3o�%��\0?+v�1�&�9߉��,��i���_^e��
�c��n��]�7k���Wמlc�;������k�h��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(������4Ac�;-��)z�-ű�o�_U9��xV�㟉���oᯉ�������
z�K�l�­�x�͎G�3
��ҩk:f���w^�eo}cr�9��<r)�A��
��D�N�m�x{S�Դ���6�>��;���Z��~�����s�_��3�$��j^����pupL~�{��_~6xK⭁�O������"倚2:�?��3�C�p�
�QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEe����'��Y�_�v���8Ė�	�O��#���/�߳�~��T׭��;빯��Ky`b�d$
�!wm�s����(��
𿍴���v���mꓧ(��F2�pEb|;�G����䗞𭦝w"�k��O0S�C���p�+���9��������<_����ѱh�����(�C&�"��u���?l��o��t�� ���$����`2p	�&��(��(����2���V��=u��|M��c��+O����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��+�>9~��O�5
��޷�|on�t:��1���n�C�E��wt�o��>k�i��Y�ψ���ǫ�
r<-�����zr>������띘��b�%�%���p�۱���Ѓ�W3�+������<Y�G}oɆO�-��~7�~��q_9�+��7��O����S�j��c������j+��c���>�ׅ5H�!��,���D��=��P
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP!�7�e���?�z�����2���V��=u�QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQES$Etdu�0T��)�P��g��+�-��ڷ�"�$L��z6�;��@����P����_
?h�k�lx⾖|��XF�i;[��U���T��_AW�g��~'h�پ*�g@~�{�؞����NT��;`A(��#����5H �����h��3��>?~��c�L⾂�]�+��to�?	�]�϶��ܞ�Fy^T�&�;(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��9���,��i���_\�����?�b���믠�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����WPT�FA��~(~Ͷ7���mU�⸉�E��������=����澄��>g�_���C[���	�=��fskr:n`��m2�<��}��6������_YN�⸷�I�������<9�M�5��c'X�;O��������V�%�/��?�>x�k�9�͹�֢��A�.p���>:3����?���ׅ��@�oǖsx��kmG)?�va�e��0Z��7Y]20ʰ9z�袊(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��8��|
�&���+Р��l7i���ݐs���}ExK�.���VF��K�s��Fw6���"���?X�1�鯪��q�P�7Y�:�l�	��$���+���@���/����_��8_��?�~i��$��_Vk�J�AF%�����9�{o��
���[x�ÖZ�U��'��*���+�
g�~�vz7�O�o~���)��:�~vǃ;
��R7(���@����Mй���n�:���x��v>8��׳�����������̌���?�=�옱���Y�k����5-���]���я}����O�G���j���߾����'��>$�԰�?��<����mq���`3�q��Z�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�C�o���1Z����!�7�e���?�z����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���q�/~�:'�l|�/i��t��ȷ�J��l������w��<N��&�{k%���_��6�E.���B`׉x�ᮍ�'������x�5%��l��� �e@�5e8<(�OJ�f��x|4��~��>"�x�K��i��c��0����N_�[ƾu�����X�N��4�Z?���)���"H�� ua��2�.�W���Ł��v6W
���#�G�̘V?�^�m<70$��G4.2�F����#�y��~
�$�s<�����.[$�`
�����?�^i?���w��⟊|/1;����F>��c8���h�+�E���|���xc�։�D�#�o�>K�oƚiOxg����?�ti����{E�ɷ�"PӴW��k���5����_R�$n�`�ދz��ף��Í|(��s���K�F$��	
�PcE5]�V�N��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�C�o���1Z����!�7�e���?�z����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��'�������h:���[��O����:���[V���bm6V�;+�Efe�{e
�3~�VZK3x#◌|:s������3!�C�H��-�x]Go��օ�~��j�j����?�V������(��[��w�=
�i-'�C��o��͕�~�ZZ�n���~Ԟ"��ğ�c�~l	�C�*[�3��H!��7��	{�����Ƞ����Eq7��9��WP��4
�V?���{��Ƨg�����q�|��O�k�}�6x�$'��I���*���*��{����=��_��c���Su�/�
d�)�B���*(:����ۯ��%����� =+^���������F�o��vk
��|�3u��������̏�AaY���댑��jwC��q@�k�	]m|S��O.�&���~
WK�Ǒ��˞F�ճ��������z~�o��稹�����?�m�L��<?�_F�(�}�AR<�;ӫ�s��5BM��|e
=qwnx��"��D��/�>3�=s���
�f����[S��<~5���w�c��H(��i��?���Fx��w��=z\��f������,���Ix�Lp<䟧�p�—�������̀q�ؤ<~%���h����X�Զ�5���.V���n����~�֟s�W��tV���$΀>���7��)�|]��>h^��B����m^�dg3�a�g���\���d���
�1�������ik�~3����S�i`���̋q�o!���2Fs���s������\�g���U�|�R�����B�Z����i;!����8�}������V[���}o����v��_~/��~�5���Qk:}��Yi�;��ID�0�~A����h�����&�q�~��/���pG��Z?�/m��'�c�V���#�Q�j�f������_��v��߳D~�dԫ�i|/o��'�ٳ����|��
���|_�_�g��Ǐ�X���)�Q��_�n��y�O~O@CQ^�s�e�Sգ�M�s��f��
m�[����e�
��+��᭾�cS��l��G�5��o�j�-��(�h�����-�A�O���������1���_�y��
_����cn��ɟ�����o�5�������\��@�E|�/��u�>�&z���~mQI�b|!U�"s�����+�#�d�$"�����1��ʋ�?�?��[��P����J����mO�����z�;n9�?���ͷ��g*w?d����ƀ>���f����L���:��C�����axe�X�x�����<|���
���7�5ޗ�D����h����������-}3E|��
km'6�
|g0O�? h�����C�?������4W����_�H|g�~��?�t���x�[���@LׄZ�A���x�����[i������73�w|�`����{�����s���p��}�>6��	?iO
�KX����OO��)�(��d���>\a�?Z�?��k��φ�uV>���
��]S�4oY����E.�4��Z_/ko����	�
���>i�+�8���d���
����o��~�Z�����E�u�ش����fYV}��n;��j�V���/����|E���ո�k��NN�KW��ӟ�ʀ=����j�2cw�n���ݥ�q����G�.L�M�1��]���B�{=�q~�d_ڎ�5���8��_���3���1����ր=B��~9| ��|E���?=���|[�W1�|!���ۂ�
�Q\��q�#��=6j�7�j�o��?q�-"\��^��lQUཱི��E��q�H?�X��(��(��(��(��(��(��(��(��+�a���#v�>��?����-Ֆ���!F*v�ny
�TW���C�_�O�&�6��Uu�
�&�F��=��as�̑^Z�vf�h˩e;rz��(���(��(��(��(��(��(��(��_��|�H�P�]��L�kko�<�q�j��� r9港�?���~(jI�5���!s
�ĂD�W$yr
m�1R
��f�=���ό�����_]\���M���BK�Tc-�B��Ո�l��<�\\�᫛�/�TI-��B9�g�Vee�+q�dd�袊�>&�̱�c���]}r�X�����g���
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
��UռM��#ƾ"O�^+����i��O�ډT�*ۉ#����%
�?����!�?�\��]`�Z���}�Dx+�O���~�tKB;��kQ�,`.�	�#��}	EQE�Uu*����N��*˧i����>:n�N?J�/�t	wy������D9�+R�—���g�t'�M�|G��3���С�������AEs���x/�����&��B<�B����[�]
�����<?�����?��_�
��l?�MtP^��Y��+��z�����i����W����"��kj�ȋ��>W����P�Q���,z�n�Fӑ�V�
�U�ESV�#M���
�얿����5���@t�-P
EP
EP
EP
EP
_7�C�~*�k��v�?
�i�C���}F��L�Y!x�T/�Xs�}!Ex��.�{��o���'�Y?ι���\��-wúK�j-=WY�X�IV}��~_���|��3�дINeѴ�O����r�;�2�%���O��쵻Er��:�0"_�b@NN�&��|�I�|.��'��=I�m���Ί�e�/�C��q�q�>��65�B�K���������������<�o��ି{�p�?$�/�z�?���6Qρ�N1����������e�rgg�/a��59�?�5Fo���r�\���@�榾���>m��2�O �5/C�>K�O��	�?�|	�x���v�p?�a<zq��h���m�����2�����:K���O�ǿ���C�^���f�����⽿�y�Ҟ,+�e[�
��'�Q�
O����z~�W���{�'�f��h����X~�v����M�<�=:u��ϭ��~ؖ��*xB�Gg�L�����h�����l�o��x6��F3�����~��b�6��w�?��_L�@3�_�b�s'��ܯRR�<�?���Q�3��������L�q������_L�@3����-��W��y |�d����C|\���٫�Rv&�?�٫�(��i�C��|gl:�%<v����x��M�;c�?���
�b����'����x;ƖÒO�!<~2��o�f|&��<UO�c��e5�W����?h��l�w������ן�����?����k����?�+�w»m�~ ���;۹Y>�<�l����#�E}Cq�
\g���.�e�k_2�����/�PX��o&����lz�V�`�h}��3��ǵ}���W�>$[^\x3]MV;'T���і�ܬ��k`��~	�u���a-;�IMhxs�7�
�4>�?�4h�}�%���,���	���`���|^��������s���
ͻ��@-�אE{�Q@Q@Q@Q@Q@Q@Q@&~ٖ׆�.���Ф׼;�"�yl)������pq�#�g�rd�ς�/�öZ���H����ZIf�v
p�VFT�n~�g�� ��/����|E���:6�s��TQ����{�d�PC��R�
\�;W�>���]�_�zO�t�[�����֭w,�-�ؒ's�v f�`B�
������(�vZ�Iuo�Z'�#uWm����IY��)�1�_�
�ۍ-?�Vi�ԌmY�K'��Z7�f���r�	�mm/�o� ��m�Iv�X�[}����cr:�n3L���i��ڶ�V{��n�w^�-}��N	�C�pJ�P���յ��\�\�mct��W'$��=A{km{l�ז�������V���<u�p�����߳kZt�N�k,�]�6��̓Z��)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@��5�
_�N�-kN��yҭ��t@.���������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4
���_Х����bִ� ��g�*�!H�D�9�����)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�%>���G������?�)���z?����Q����\���
?�&��E�3�B���Q��4�S����
��������ǣ��l�U��xg�������h��[�?�.h���@�����k���Zo����?�I���Fv��7c�WS�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(����|7��Qx�ŗ2�Ztp\}�ɕ��$�b!������u_��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����Q�	O��c���6?�*��E�3�B���Q��4�-��4���������ǣ��l�U��g��=�c����[�?�.h���G�"���sG��(���?�)���z?����W9q�� ��I�4��4�]�xmY���$�ɮ��o�й����M��xg�������h��g�
�C�	�����_ۗ"�΅���
�;~�<c��MC�t($�D�4�2){���B��2B�	�VV��V�mgm
�	��EE\��
�\��QEQEQEQEQEQEQE
SU�t�Z�K
V����Q� ��d�����\�Ÿ���k���r��id�K��?>���[��2"�.�����ձ��DZ�ҵ�=���쳢������p,ѷ�X��=���<?e�G���L��,�����^i��W�~jZN���B��TlCoarI�1ú�RN\���z]��h���濯��a��G�O<�g$����
��l�WZ�Ӥ�ߴ���5������
����u�2��%{����{�qV�PɽOB6��Y_�o�|C�=��4�;�=>����"���v����ո�����h�4�o���<{��?�cP��FFy�4�*�Bb`囓ԨW��
Eyo��~
���V�G��S��K�Y���ZL�ȑ����l�	P�gԨ��(��(��(��(��(��(��(��(��(��(��(���O|j�o�>*��
nF�w��c���[4���pT��
�0{���+����o
|?�Ծ!�V���5;K<�z"(���=	�+ɼ�Z|&��"��]cFi��u�["@�NY$m���g�P��\��_�^�V���l\6��D$�`U26X*�� ,�rGZ�@�>��x"��%Ӵ˻�3{�6�M�Ɇ!p�'�@�W������1��b�T�-*d�W��#�ݵ�k���~�#�����@x+�/�l�/�k�w�v���N2�v��Q�g�z���h��T�k�g��_�mo���A
G�YAIX����(��(��(��(��(��(��(��(��(��(��(��(���A������˨]k���<1�mat��hݷ��:<�=p
�tW�S�G���)�x�Q6�J�;xcC$ӿRG\���\�_ڋ�w�|I��e�t����F�n���z*�;�Om����=Š�>.|A��x2o��;ɬ�8DV��,��(fQ�O=
�mk�zf���Q�J�~�mi����
��Ӄ�ݰ'�@4W�W�~��c·>#�垧kim|�N��ƒX��
��H��+��uҵۛ��T�w�ӡYe�OB��Ur9�l�t�W��?����WH�����KVU����˞�۹rF
�8<��(��(��(��(��(��(��(��(��(��(��(��(���O	�j�w�~-j�
�U�.5-29$��$f�����>��>ߺ��������������Ű���{�Ͳ����<�z��
��@�o�'����V���>��겂`���X�|����2;)8�������������4?����ֳ���>��ǧ�[�Ə+�������'=���>!���������v���2쩃$�ѳ�������
�ר��䷡�����$���8�l<}���0�'*�4Y�	`�+��	���W���j�,��������(�+˾�p���V��Z~�h�bD�B�0��vH��=q^�@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@�eDgv
�	$�+��|h��ğk���j2I�����b�u�P4L�Y���J�
�TW�|d���/�R�i�K˩���c���K1L��䪨$7�t5���?�*_K�x~���S��a�"X�tYv�+c�
��@�Eq^>���x3�>�֡k��j>'�6�)i0B
y7:�A���T��!�sᏄ&�7�d���"��<���Ƭ�	�X�8S@}��?i�2�n��2+�,u+qq
\������X�x�Mx牿k���&�.��z��C�XZ�ۂ	�)a�4
���h>5�ͧ��5�%��v	�UH ᕔ�ܠ�(��(��(��(��(��(��(��(��(��(��(���wk���}{q���m,���R4Q�Ğ�
���_�Ř��|1m�E�2E+�‘�w��ɵ���?{��z%�?hO�_u�]n���UUW��N�d�%nF�̪��q�8��"�~
�f�7�xn��n���ay����e�U�3���z5�k�t-⦁��kmF�Z�-乀�������|��t��>+�S�6�m�x����T�M���#�)�Y��(ڼd������ҵ��Z���6�}Œ_o�!<����p0��p=kĦ��~��#����-��:�������n?�
�
[M�����}CO�����5�	�p�"0ʲ���Y��(��(��(��(��(��(�_.��ד�
�]m6�i�*1s�7����o��ֿ?>>�-���S�zߌ�G.���O.�!s"G�5��ܱ��d�>�'�v�B������w�}^��v�
�oſ��'��	x��P��Γ���F���IVd��|��d^x�_ttPM���|;U��"p^�ʀ>�R��7��=�����o�����.�����e�p��������>�k㿶�������7�ߍ^:�����2ܙ������!��ʳ۱Ւ2�x������T�}��i���<Z�ޗ���w�F}
�Yq��jx��'�]g�ï��׿�4H4����o���~w������J���|G��T�W���r��GF������[G�i;\/�9�}E@~ĺ-���i?���Ymt�yp]�+�E-�3��?����=7H��x0��a���$)a����y	ww*���^s�)���`���G�N�㟂g���L�_�</a5��d�-4��lU���������p��w��?j��\\������Wo�R���l����~}|�>.���ճ�˱��N�o�س�3���H�÷���'��ǒ��,��'��ȯ�Z(��(��(��(��(��(��(��(��(��(��(����6���ױ��e�X�<��'�g�#��z���%m���^g=��b�/����ڻᦍ�kR�Z������v��]L����FynI��8�����'����l?���=��O�O�Z���]j�ç��¶3�yfe�+gq�5����x^�����1cmu�+;�)�C6�4e�c�r�vȤ��?��Ź�|=��%�x�Yg�ә�"�y�`��p?�˜�����c��_Ⱦ9�ߎ��㋲fc>�y(�g��o(����'��0�~�K�C�_������� Ԭ4�Xrd��C7��|��������5���=�6�"�D�gc�[��R
���e,B��z�H"�|_k����sca/ڴ�D}w~
�2����ly��Z�>A��i�����i���U>-ig���^
�}y�&�n����b��}��1������8��M/�x����?�kѼ[�Ih�	��w��r�BӢ�|:���&D���FAe-�qԀ|��x��:�ß�~���.�F�Go�E(\]��U����`�'#����_.�m~�z��Z\����
}�X�	����A�m��u
�8<WشQEQEQEQEQEQEQEQEQEQEQE
�?�&���]�Ʃ����^��٘E�[}�vv�ϛ���>�/�߷/��'�6��ֲ�=ԋ��,�t��˒p	'I��k�O�R[��׫�Z����%�/�&��i5'}�[��2$��dVF�hV�ǥ|��fj�O��0x3�������-mquj���=��|����9��W���/~xZ��>��������������~U=�ǂy�������n��֫���_u�M�i�m��(�u���Ê���>%��¯����込Lg�0���+��|�o�'��<O�[[�,�^�4Ƽ���@Z��;r��
�9g�c!FF����ݩ]�^��~[x�<,�q��������K�Y�`[���
��N/�"������5�x�������^;�d��<k⋫ˈ��E.�/���pWe
��0��$p+����_�D5��'��kj�Z֑�?~�^3���\Xi������y��y�p��V+m�z�
�_�g��x�W���7��XY�X��wr��n,�;v��hU�x�g�Z��PI|c�Ox��~�i5���[�"��('�Yc`>�!��Q�s�5��QEQEQEQEQEQEQEQEQEQEQEy7�%�O��6�t�x\�ŷ��e�.��^-����9?¸�s����V𵯂?loxN��[�4�.xi@
&��I<v��k�?���/�ץ��t������v��\mB�R҄koneCjV2̡�d9��r|��wW��&~ٞ	�����F����n�V�f�d;��X�Hݜq�]W����Ñ����w���R����`�bTF�y�K��
����d�7����]+E���*՞;Y��I�F�݀X��#M�w���`��ٟ~�_<7=������*�і��@�޸��s�W��H�9�猼I*xoC�I|?�� m�*>T�yv�q]��3�	g�i�O�d����B�9ʩ,��P1���ס~ԟ�o~6��[�1@��-�&ۡ�����=E�i�H��/���Y�M{�r5���>dqq���eQ�s =�_�[�M�B�����(z�_��������>m��S<G�WH��-���=x�j���Y�-�ke�5�c[�E���,���?�L����kԨ��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��<S���}��U���x��~�9����(�lM��|��.B�����t�}�GĽ��{}?6�4�,R;�PN;�W�u��a�'�s����ҹ(�o~x.O��ޡ-���+��3#ZG�!`�~]�2����tmSN���zX���[Lң-{�B�I�q:<�ዬ@�=*����~{�'�'X>�!�
Ck��^1�0f
	c�� �?�7��g�Ec�����K_�Rk�t��徘՞0�����rI j���ݦY�^��~k�*�0��x�������U�<3�ω�|K-ɴ��45$���r���6��~��N�W�~ȹ�7�>+|Jc�G�k����CH����|�����&ۮ��ͧ��%k�ӟW��|9��p��{�5�̝c.�����k���5�{��>�o�Ǭ�׳M^��Aqm>a��M��Ձa��.��"���Kg�j?�����˪�xVxl�[i�R�{�s_;~������<�6H�ɮ.�2X3��1�,L�p�Y[� �����o·^�n�w֗GX��R�[N��(�a) ��@�[A�v�����zN��|�.�8���P��}9$܂4V��f\�
}+@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@
�@|+���o�Zn��	,�Gè�b�Q�)���4��Pr�`���W��W��4��
�o�����e�����&���<m�_V���
��w�o
�G�N��v����Fx���mF�3oj�i*
mU���^
�<�[�����G�|!j���	ZGX���4i�;4��.<����,E���o�$�Þ�.��^�ɒa,���$ygTa�S��x�����=���=�G���^ ��H%��g���[�e�I$�W;T��P�y�~��;�	�ퟅt�t�s��#��<��hυ~<о[�I���Yu?�Z�6+j$%�&܂����\*|��u�F����x�~:�L^x��7���(?�3-e��G�h��2A���4
��O�Q���n!��g�>�b�}��#'�>}�^��|3�uo��0�fĕotnKE*�� G�o�J�}e�F�G��j�zT���~��,cm�q��N����95�|w�>k
�C�h���|}���v��L�	<��B�i'
��p8����;V���g�.��>���"�'f� A���u��/�/��/F�uh�Q�i/�aa���U>�&Gc�ڽr�
(��
(��
(��
(��
(��
(��
����1�I-d��4}a��5�_�G9����7�۝��zJ٢�2|I��x��;O�:^�o���i�#���\	�5��
��g�O������Ί���o�4���
�V�Zt-��i�$������)����7���(�m'���u��gJ��a��7w��Q�=�f��GU�o���y��(�m;���uۭ{N��g��[��,���p��ȫ��B�����P
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
Xڏ��1�k�������W�
����G%�
X����r��#�I��(ľ���K�}Z{p��,"�1�B�S��t����T�?�x3�v��EvtP>��
隫j�o���-E��ծ���f�B�����D
s��}lQEcxg����s��h�*\�.�e����E�O_Z��^���-���:��@�r�i���Z(���i�5�z~��Y��q����b�~��
W(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
�oxa�J�'oh���ں����J6���n��J��q[4P=�?x3ķ��?xY��!
O��<���3�!r�q�}k7�?���&�����]�
���:��_jzn��Y_�����#�����
r2z�]�����k[�"���9b�C$��X#�����߇�
X���4=3F�yL���[��@���F}��7�~��-���Z���ܑ���p�}@p@�j(����iV1XivV�6���Ao�@��*�P
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
X�~�ş�'���4�mf��P��5��d4�w6p:�¶h�k]��5�I�=w�>�/�
^��K�iX
�2�p8V���KK�n�>�F��	H��F�W���YX&A"��(7D�t=�EӴ�w1��얩�!��
��y��M>�U��ӵKk�+��=��K$r/�+d��tP~�������V:U�d����XbRNN@'�����x��N���]q��1eژmك.��t��b�h��(��(��(��(��(��(��(��(��(��(��(��(���_xgD�n�-úF�}zK]��YG��Ļ*�ܒy�kf��u_�5mF}KU����m�\��K,����I?ZM3�ý.�-CL��lo!m�\[����VT�?J���hZ'�t���FӴ�=�O��ڤ�=[j2p9��k�>��i�i��c���A{k�u�& �eXpy�
(����iZ|:v�cmcen� ���c�5�U\>���x'��֤����R�Lm���a�U�L3)5�Q@�Q*�¨zS袀
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
(��
��υ�1���^��T�!�]>�;q!�`�3�����Er�]��ww���7��K,�5�<��,��2I995&����ޛ4�i�𭜲D�������WBBr���:pk���(�V��i�iz.�g��A�*���(�K��
�I�5�<=�x��,|G��ͪJ&H/��5p�
��3�}kR����KXmm`���X�%
���P80+<���N���WW,\ߍ:!p[��ۻ?�o�@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@�^"���q�3Ğ
�?†�SxtZ}����,�|��H��pO���'�,O���n��z��
��W
�K�
��MX�Լ8��4}j�G��7�u�hBĊ�/�8�Ew�QEQEQ_�:��o�Zߵ�<%�����Q���O�|�lo��r��\ץ��Q���tPٔW�G�x_���M
��� ��.4�}�9� L���;I��T��>� Т��S�_o���H&�O*T��Z<�)Å<��QY~���
o�ڝ���\c���r�pG��"�mo���
�M��G�Ztw�'��$����J�c\t9a���+�o�s�s�{x���X�Y5�H�2�� �����ǎ<k�Oi�Q�f�e�[1چ�L4��|�}��h�;�'�υ�8��K�׌�����;ic��I\"ʪ_���J(��ॿ��O�}]��1W�w�7��������O�7N6��	��%��DcV?�{b�;�+�u���4(�$��og�����	��ʕ�:"�*�p�O5���O�N���_��M�;��B��J�gy�q�
��_���T���u�O��,a�k76�
�Y��$g�YF�S%����I�E�D���������Y�ʻ��k�1\�7��m��1�v�W+�����g%ׄ<Ge�,@c���0z��uϸ+7_����@�
�|O
��
q$[�#XLŌ�<�����n�PyEyd��	�;y��^��Y\Gmq:��G˒@�o���#�>Z�_����B��MO��q}��+� �Y<�P:3�!h��@�Ee�_�'�4H5�jv���p	���M�q��<��<e���'�5���{Ɩp�B�%�f�1�uo)i�<���\^��O�����K��O��/tm.&��hU���
ļ{|��<m������}n>;x�P���>�ഴ��G�|��h��b��!c���2G�}�E|��ി�v���~.֡���@`Ғ&6��&[�#���`�ӥ{��|G��[G�W��g�XE�Ou(E�`3ԟAɠ
j+�</�����5��t�ص�DK�f�18
ZTUbO`y����</��A?��8̰	��%��@��觶(����_����B��MO��q}��+� �Y<�P:3�!h��]φ<C���D�\���k�i��c���2u�<��
�EyN��E|ѵGӯ�ydn#r��ki��߉Z�#�m��,z׆u{]WO�����T�V��hb����	��%K�����{WڴQ^u7��#�<?u��k]GEYPK�&�!�ʍ��@�w2��$���5|/�α������;-�)`y1��%U��?.hШ���nO�8������K����<=�
��j��M�0S5ěAc�Tuc�2hf��?�y�G��f-B���0H�����O
�TP�}&�2�
(��
(��
(��
(��
(��
(��
(��
(��
+˾>|d�~���y�M�\�W%~��^;d�~�!8�9�0kҬ.���`���'���e�T9WFV�@�EQEQE|��"��W����-}KE|��������M��Y��}�!�Jg<�m��<�(� u����R^���?����>آ����)��O��s�w[Ji�o2�y�c��	ʯ�_��"x��x_���[�~wW��#I��I�U��5~��Y�Z���� ״��M�͚�[���FɽH��+���6��3�X��╶�6�{>���-���.�������H<����>�y�������d~����X��>��FlI�%�+"�̬��2rV�?����G�{^�QP�Wŷ���in�:7ĸe���e�Z-�>u���v����~'��j��wsy{c�9nd�%�X[�\��,��m<��}sEy��E�o�@�	k��3yW���ă���A_u]����~���_�oïk��x��ΐ�Z�#D۽v��7�
�[EC{s���w2,pAI#���2O�+����'��_u=3B֥�<%`7����	l!�S�lςpxl}�E|��}���CA��>����ܷ���M��,�����dzܑ�۱�ӟ����������8����6���G´���E�+�DZ��@�E������6>���⳾��&�L���E����՝�ܞ���|៊?�f�������a�<5mq�*H#|EeUJ�f �{}�E|<�	~:|	�q��Q��v�r��omE�`Z9�fdM����?{����`�ѿ�5V�L� \��UV�c-��c��8��W�'��Q����
>��������ױ���݊�����'�.<W��Q&�oo��.�
2y]�v,9t٢������;i��-~����c|\[�Nf}�U�������s��u��"�5�Ƌ+���33��PD��	]��(���?�_���{����UKrȊ��zn�°�V^��ᦝ�+�j>*��ǫ�ڰ��g�h�%��Ą�Y<��A���׊�
+�<���O�����vWZ��H��)a2��C�e'5�x�[�<=�ͫ뺝��a̷R�h�����@4W�h��7��cX]*�ǚx�fڦ�)��'��"���Ӯ'���K��("C$��T@2X��s����;��K�����x���n��.$�?��c(G�q]7�u����}�+xN�L��Z���R�m!�
�e�<m'#�ڊ���P�7��ඹ�x3ź���MQ濿�����T"ŒWWD<����?g��R]_�v���Y�Xވ��KH���C��
V4b	~g=���4W!��_�~���ĖzSNE�Yu+r=�O��|�e>�5��$K�HWts"�x��\|b�;
(��
(��
(��
(��
(��
(��
(��
(��
*˘,�&���;{x#i%�Fڨ�2�I���x�|w��$����W��&(uH�m�����&Nd��P��\���^�������x�N�ѵK&�
�7m��r>`OQ�dWy@Q@Q@���v^]i�����{{�k9��7\��>��k����~(��מ!
Ԣ�g��!Q�*�b;�;+}�A�^��A��i�����i���]����S��1xf�m��#��V�}�<<��o-~�h��+��U������|J|�����p�v�g�����c_L~վ6�|�SV�|>�I�+X'#>G��K��qz�������6�/����셞kW���``�k4��z�#�	�{��t���_�D����1�ͦ��\�\(T�̂7\��n������W燍~������O���쟵^M'ھ��������9�:�A��b��
^x���?��M*?�܋x^�t�ygR�0m��	g�B
�}㿲G�ϊ�YemoL�6WΫ�LB�Ip8���ҷb�����
�w���#���/�xչ9o*8�]���}gE|k�j׾
���O��ܘ�&�kpxS<
�ɷ�����:�+�������������R��0H~Y'~?쁹����
+���_�'~�k��ƞ;��M����g���N�1�8�x#�<w1k���e/i3��d�|+x�X����U���6-�Ƀ���p�@}�Y�������'�g�Z�u���e�
|��'��Ÿ���EP�4WÞ�����i����X������+yt����)�LO��
����{��u�|*�6�=���m�Le6��*�$h��;���ox���WŸ�O�4	�p���x�V������=āW&�p��c�M}a����Ï�7����U��y�ks��TueYUK
���wtW;�xS��Zj^-�l�Ydm;|�7���1�\��~>|"�f������k��$1Oo5���ES*($�h�h�;ƿ|�i:�����:����M ��>dB��>b+3ß>��Q�,4OAq�Z�yx"���A�u}�]G���z��Q^[��u�0|I�	Ţ�ikP�o:J�*�0X�y��>���sִ�>2�/����/�񮖳ٰ������Ѳ9����$�@$.ܜ������?��*�>��,��;��ڜ��X<�!�W8ݲEV+�@�5c�į|>��l���KE�Yu+�{�:�+ϼ�ᇎ�1��[�֗����E,>NՕT����׍�'�])u?붚M����f;�`2B(�1�@�����Z�Ҽ1�;��'˶�)-�'bʪ_�~\�>�ճ������Ӭ�{��&�)���Ѡ��:��4
�E��ς>8��)񦮚�҇<geu#m��X��yO�	Uw�e�l�I���χ6��3�����1@�f�m�H�J�q�@m������g���wڇ��-�޵ד!�,+l��mϵy��><���Ƨ��x�+���a�K-��I��,�J���hP�Q_,����O{���Œ]��U��֭j�|�
��(�ZU�$;���E�/�|W�U���kZLj&�Q���D�
g��y��}������������[���O�e�eI'�)�Y"Ve�V����^����~������X�Y"�q�6
�8=@�h���O�?�x�X��Ŗz}�P�f	$�=	H���*o�_��Ayb���59�]�@�W8��Ȫ���(���*���)��w��#_j���i��>�^*���Y���+�ݫϱ�2����@�
����#?���<�7�&_�O��T��_L�@3�e�d��'�g�G����e�d��'�g�G�����
�?��K�J���-މ���7^%����߳�tZm�am埵�$៟�����/�'��?�?�*?�N��X�O�M���c����R���Xb�Z�͈�A�
��Ic�=�w��O�Tg�*T
�<K�KY��k�w���>�o��>�p����y~t)���/˃�u�ƻ��L�l��$������:�;�}�O���x���"}_^�޷8�̆�38�*�`
�Cױ���t
�7�&_�O��T��G�&_�O��T��_L�@�O~ԗ~/�-�]��–:�
��6�h$�/�e�Ԅ�;m9��^�E
�թ�_ƾ.��|g���_��j7�-��f��j�2�Ks��zO�(/ڟ��W�]����|*��4_��'��í�7��-iy�����ɜ�#T�����?ش
��ݰ]Z��Ze���}�Z��sK���H�y99��_�?������/|3��j�����3@�s�$d1�y@�P�s��������_?e�A�4��/����a��b�L�;��/���O��������0��2�O�����mk�#bf��Wxm�H�8���?g���~+_i�2�5��@��14��l�{0�
�b��~��?�kN���ɠ-}n��cL(X�}Ӝ��
�^+o�U�1�M�?�|�Dm6=zO-Qn���f-����#=�s|
�M|�Լ+�kk���2�yw2�b���"�U]ˇ\�3Ԁs��w�l|%�ox�Úa�A�[譆��#�J�=ʃ���l ���vj�VK�Fi���؄h�_�:��s��䎕�~��(x3����_��MB�{Y��XK���\L�̈́��cyq���8�o�p��E�����z�� VW���m�W	��X��:|����ݓ@��������}�x��z���K=N+}�l"�dFW`J��dR�_l}�3_�<Q�º����4Ȟ�����?���5�ω~�пu-+O����/
�N&�Q�V�����M����FI�c�_�t�
A����:}�v�񃝱��Q���
����@	�����*������<=�_Z��z���>�������<�j�cqp�+��a�P)��s����_�{����g�>���ޑ��b�{7���1G�G+���N	
q���>��?�X��Οy���7����r����!��@�q�rk����~	��G��-5=9oĢ���-�H;��#9E?P+�<�?i��
��/��+^O�f־r6&h�Uw��Ԏs�z��b߆~0��|K���G:\ڍ�J.���y{I�l�s�@S������_x��W�4�F�M�M��{�D�KW���0%(�+��=+����g�_�<]��%���y<�0�Uyc�B�d�@EW�|
�a���珯t�'�����R��uJK����F�D�b��I�F�=+W��,�1������Zf�e��k�*�U�g���fEd
ʲ�a���<�wm�[_�w��1���_xF����Q�K��H�>\�XŠ�૑�)M�I�9�z�������X�����>�dbf_��ƽ�����5ɩ|H>�4$��I,�v�,M�ўIws��w�>��������!�h>���`�٤��\���67����7�������χ<1�<�O
hV�o.�l�Gai
���70@2q��_��M�ˬ^�gO���t���f�Z�9BH�c��p��8�95�_�?�<Q��z�t��-Djp�|���d�w�jx�~ �f_i�V���ͭ|�lLѺ��
����
��N�
�U�o��6
�>�(����������6����'��l2���ڷ��ʱ��)������<a�}�G�M��	�1�<q�>�.��E.a�����Xyl����|&�m�J�!�5�x;E�����̥�[��ƅA _1d�Q��Z��aH���8x�A��E��y�]y�=�y���*!�\|�C���׊w��ok?�W�t]cÚ>��Z���{+�(��Ъ�FR��%F�^��3��������u�X.���6��!f�Ib�����da�G'ұ �S���ǟx��΅��v���,w�1���Y��dFޥTdd9�
_�#/�w���QK�L���l
�6֧�<?n��aV ?�<�Xz3(T�m��x��_�
G���~"[�{>��Zk�yɶ
��p�p��~ӟ��x�K����Xt��*��Ug��|l���=F�
��[��uc�+Vִ?iz.���R�Ocl�3�"#,�q����d���*���u_~����g����]K?>����$�ʳ�����\/�������/ڛ���<g��w�:��yuѱ�
��$��
q�n����mK��H�i��K�S�N��]�\E�1)�ViW%�8�~`|3�G��o��]b��:}�{�\߾�4
�1�FC���.
�9ɬ��6}5�x���7��C[�7r�Oo�z�S�A����4�ن������'�g�k_94n���l�G9ǽy�_�^5����
x��x~�]�
���)�ʪT�����P|f�8kO��:f���g��x����ay>��<;�E+)�5���On��	�u;���ɤ&����g
��*_�����᛿��^��+D��Fmny��HD�h�>�q��x�+�������v��K?�f��
���V�Y���}�ve�%
�
�ր8/�'���/�����_j�����¯�Ǿ/�<]��gZj1���pK�5��n�p{⾠��|!�����_���Z-��}v���&d?*���G|`�Mj��~
����c��.�>�m��BI�4���cx�TPX<������O��O�Wŭ�MN�O�
��}wh�jZ��'�@��3���D��|q����&�������LG��n��J�*�#}�;c��w�¼}G�o½BU	%֝c3(�\��_���x����?�u���k8��X��t��x�YB�{m�����M��d�N��O�Aw2��"�.F�uc����?jo�:�5������ź/�&m�:�'�+t�O����`d�������w�m��b$�d�6٬��f�� �y�Z�(�5,B(s?�<����.4��������&��+K7̷vW1���gD�S!�p�*�Ө���m�m�湒�H�Ty�<�6�O^
b�(��(��(��(��(����~��oIӴ��Q�m_��W˨N�@ �9;��q��<z-
���ߎ����o����%���yw���_�nN~^��x�����W��+�kڬ�!sx��3�ɻRx���t��h�/���|iӼ+��|>�v���s�:Ž��ھ�8�t�����8犿|A��R�5������lV���,���I�eYD���rrv��x���>2�����_�=���~���Ͱ��Ϸ�:������0���7.�ҳ���z�ա���‹�/��7������,��Э���巡�Z��+(�=�l�������9��1Һ���㟃�>�	<-�MY�G���$z����:UV��L�	6�4lA�p����#�Cx_�Zw��mo�~�n��'خ�ڣ'���$�M'���;�������A��m2-.��op�]Z�I���p�r�0Ny�������U�/����A�Kp֓�\+;˸|�D����\���>0��S�K/�>{E��LoQ�L�w������_HQ@]�S[�է�W@��}��V��@u�{��#�m�vǙ#�7��q�|�~9j���?���6	n�{�gyw���^1�����=b��~���Q�g�Ǻ���k{*C�Ϝ���-���`p3����R/�%~������Ե�����|E���x7H�Ӽ��Eı��(v��H��#(<��s@?|S�n����
�:�-����h�j\X»
��(���R� �]��?o=/Śb�Z�^lʎ0ѷ�[�C�s�⾺�ςb�>
�
�u���N���څ��c�+�����Y�����̿�����+�����������ɲў�?�#��#�ڲ����o����܌��4
���F<m�
h���js}��T��G�)�g$�b�-����>��5�������T6�cu=��S�d��b@p���^��| �ki|e���<d̖�sqo<wD�bSvm���C/r+ݿ�S�,��i�����
�����MW�4�ZΡ�xRG��{��;R���pB�\���	���o��oo�M��:/�,����2���1����1���6q�_�	�cǿ�3x�K����>백վ��\��������沵�Գ�����s�����/��!�$�;�-�����U���G*���q������3��l�a���j�N�����]���w�Ա��K��.�����<�?<l��
�2�*k����ȓj��6܏kv�}AhjΑ��_�/����
ib�l��7<���h�H?w�r��N8�m���<����Q���ç�r���
cщsž��
�|7�]C�
5{sdD���:����M�r���?���Y�n=F�����)�V�&Ң*=wE��^��*|��_��I�[�u/j1yL`%����̡������H���B�mm�x���
k�V�KQ{�wK��Yb�8�[ֹ_�����
�t_h~ ӵ
UK7���"[cǏ)+�b#��\�?�S�z�ǯ|B����1ew��cc}%��n�� *��ĻF{�GJ��k����KF�ӗ���-
ռ��}�%�r�� *�9A
��1�]�����f�Y_^is����
��i����י��5u
?�7�ZN�]Cζ�*[�x���En���?b���>�^#мa����w�n-nV�	W�C���!a�9+�,�J�%��~<�Ǐ�����el�wy>������-3���?��������<	y���%�"�n�t�.����J<Đ�D�uː��I�y�^����w٤� �>xޱ�on���������Z���k~ҭ/�Zg����$�K�{��rz��?��.!�}}໿_xr���>]����2��0(\�@]�=(���-���f��e��m����O���+W������5��'�m5y�ʃ�YQ���x����R��Դ�:������Y�VS�A"�8տg��?
�Y{����Ɵvx�7G*�rD��Rm��g=x9�K��ſ|,])�[ss��t�ȋ�*��v��2
����
�;����J�t�5ՓQ��h�ʋ�YN�X����|�<|T�������DkkR�����,�NDAb��q���}N;����_��/x2�O���N�4�]:�D&1�Ѹ�m���������
��Q?�S�x�+�VX��eO��o���;s��1_6��.����<3y3�c��E5��ϖ'�7��.�c��ֽM+����i�u&������m���?<Í���n��n���y��J�
s��ُ�>�@�|O�ڳ\Ȯ�,�`��g��I�8{�|/�/��x�_��,5mB����Mw��D�|����1ܸn��+���x��0��S���E��J��;{{�Vh�Ld�l`T�E�zf������|��ߊt���R[ۙR�E.U�ES���z��a���;�k�	��&��W���~����g����ꝱ���~�
�_�m����m�h,e�S�F�-���Ȭ�=�Q��ex���G�?��^נ�F�q}�Op$X	B�	1�}��S�[�Ǻ/��O�z����o����p6�#
�"�q�u�!�֕�=g��Ԭ|!�A����ϱ��wF�E`%
ß��<��@o��������W������>��ٱtq��_j`R�0�z
�hoj��q�g���ܰi�Ε�^]ym��ްI$�BUx_L�����_�h?��)�l>'�ܳ����!,�|�� <3�	$f����h��C���g��ޛ�j^	��G��-����fT���7��d9*�=N}@?�W��V�5��	�M�`�v�v���cv��H�z�p_��ŏ�w^�w$����i�%����/"q	c��ь�`(<U�x�������?i��4�J���@�ˑ�3�D�C�E{��P����W�<S>��ƾj��%&i�˗;U���ʀ�q��^�&��	
�^��K֖�A��ĝ�$������8<���;/��� x���w��˦�=�7ұ��v��������|��5�o탦�f�xsþ$��7��׷P�)W'��e݌�3�:֧�����^����I-���i�����dr��Al��c���@#��~�n��?��f���j63��a5��+,R
ojp�����J��G�~־'x�5�JԖ�KAwg�݄͆�p;O��^���ş�jZ'�t������n���M�&�
�6a���3�>��?���y�I�c�ܺ𱹁���.�q�ɰ��������/��������ֶ�<�o���?���[����-.n��Ѣ�"���(ݕc�r*��+���׮Ŝ>5?��<u��*��7PGim�N��!�l��"5Ehة��g�'����
��w�[��u캉��t��<��W�eVF`�)
]w��?i�WƑ�<�����#���4�ʎ�#�C�<�
�QEQEQEQEQEQEx�ſ~њo���o�
kFa���Q+9_�2��X�dt<`�G�/�'��?�?�*?�N��h����2����3���������~(��n�w�M.�K��}ik/�O��+ݰz�����E|��uj���	.����2x:�(WX�^�dѹ�Bō�Dm��9A+��ҼO�]Xiv�Zg�Ae)�p��#Q��ޘ�������B����D���h.!~��0~�ߵx�����'�-�D�'č.���|�px�������,�����q@!�~ѫ��Ʃ����w����Ң��L���$sb��Xd����~�?u?��z���hu6�3	#1mc�p	;��z�����7�n<Y��M����83�*�!���O=2����ڿŭ'Nӟ�G�t}~�I\^��p#�iPe�9;��q��<y_�&_�O��T��_L�@3���l|��	�������k�]Bm�mZ�+]E��k�b}��F�V�dޮ�@�{�����|/c{w�
��4N
Y�R=8�|�}�3�o��.����;c��,N�!�ݢrQ�Ac�V�s�¯�_����{�h>�,��k�ϵ��lw����=�����O�S������"�	�ҙ�]폞�u n
O����4��
�o�����e�<���%h��mc{�����F�;v��VG��m��ʼ��7#�O½��I�w�3�o��vuyz��G.�i��w2�rmR�!T�rX����?���"�~0�GL�����jIm|,��gg�\����x7�7��_<w���[�5�)B�%�F� �]�>Hb��?�����A��ǿ�n�m�i��Oe
}��]���0�Эc�i��|/״���zv���M>{-6��_9uA U��Ó�1�y�Ï��3�'��|-����N�~۠^�nH")�� 9�q�(����>h|A��6�����y&6��eʴsG�|�0�  �W�-|\��i�n_�^[���o-�W��X��J4�Ċцmē�rs\��o���r�c�ڊ�i~����X�=܁"�=�A���
x��>>����/V��Ē��D)1���^I$�[i*r=z
��>���k_����IM}S��?��/���b�=�1�����~"�*��4��'���>Y������'toF����dr����k��v�þ7Ԣ���u3y�6q����i�|�q�t_�Mx��¾3�t+^[ sЕ���2�u���c𼟵���C�0�z��c,��QX��B/�a�@]���������u����F����rj�!��t2�c�i��	,۝�����9�sְ?e߀G���������7w�K,z����[F0���2�����>��������0�������>-��&�V��9-�Բ���8�F���(�Վ��Z�����+�_�=�����ϱ�3'*����#�>��?�U������<M��X>�#A����Sۭ�����.v�l�Q��[�A[�
�����l����}�b�kAq��#f	U�fP�6c'�t�Y��<M��?ه�z�װ�i�^�~�.I�w	K
�r��9�Ey���?
x��υ΃��j�m�~�o%���pȲt�a������_��4�6� �ޤ�Ml�[��^>i-�v����9�:�g/���!�f���+{���L��Y'��"��BJ��h�ٮ��~��w�txn';Yw/_�H�����ȉ�O�
K���诅~ _|;�<A�>����
��I�>���m*
8#�^C�n|9��o	�z���7��ŝ��:}�v!L�YA�Ҁ<�ö�}��t�=&i!�%��l�m.&[s��pD���?{�[��~����O⻻{��P�q���3���ʄぷ��{W�,n��
�L��ɻ�����=��:D��#��N+v�>������>/���L��-��ws��a�y
�@]Of��d�J��ƅ�x/��𵟅l ѭg�����O.52��Q«.A�^��*�*��~4���^'�~��jQN����	|��!��Gf(� Q�K�W�u����~=�4?ÖRص����]�6;�Fp��@����-������έf�[=7O����I�W����F�ī0�x�g����5�K@ռ����v��.�m�
��(\�v��03��9�k�&��{F����+-R��@M�̑�Ia}���*���� �:��|u�Q�G|VҴ�ĚV���r4��qb�7]�L�$�I%#\n��(��dԼa����w��f����?�g\��<���_�Z^�"�z����y�`o��
��y������|F�����T����a��"�1���i7#%����r8���cw���e�^u�ޗs���&U<�:�@��_|���߉�?a�O
�v�%�4q!B�U[��#��1�9�k�D�}��о%����mCJ�"�����|ȋ���7+d8
[��8�}������τ�Cc�=�.���&�>���&	�L�s�X���¯�'�O��E�}�f��i?����-r~Tva��yމ�i�������H��8\`Z�6F�.��:��ā�q�^��F�_�ދ�v�\񵶭�/�G�G�i�ԡ$��Dc��H$ܻR�S��n$������h���k����	���3wߧ5��?���
��3|Z�a�� k����X�������2��+�;d�x��5�2����V���x������[����83�UUX|�\�����o[��'������#7z%�b�rv�ͮH#Ѥ�}A�5?��_�I�;Ÿ�C������/qa�]Cz|L���,�qb�`�'�^��C|���
;��»�U�-�����2���]�������h�տg�W�0�|Q�Ɠw��h�ҟ�p��nY
��pF{�q��5��K���߇ntk��l��m#+^��Y�mV`���/��f��W����e��5+��U��:i�� �	��<���y
yǡ���~��ƞ"�> ��O��X	3���|l��V'�pA�1�ο-u�X�����#�.�ap$[�6����
�J��6��9>���ۗ���������ܴ����$���#�9�����<�ݞ
wZM�퉭�V���Ŝ?�2N;�*K#�c���]�Y�X�����MҮ��t˅���8�²'S�9d��'�������Q���1ג|�t�[�����e�1�]����ȝ,�ISp;]rpÑ��?�?j_�%��ֹ��zF�c��)"�Dך�™��r��2��m�}�y�?gO��(ѿf�|>�u��6����@�bO�1�/��
���:�=�^x#Xׯ4=2�W��Y-o��G��|��Iܣ�n����s�)����%\m/�Z]���jq]W��_�|D|-}�xF�P77����C���ʼn7`�N<�ڴe_�^=�OƟ�����4�J)����/�Z�:������
��؃�z'�x���=���A�D��*_B&�}�L��+ǖ�d����߁���{��j�����z�Kr���Y1�� 8���>1����x�୞��蚰����R?)wT`�vB��py��	�������>(��l���:��ї+�7,H����f�,
��5�ٿ�_�]Z�B��o�ɤ��2(E���d��຅۵K�mq�?������
��:���P�4�ch�� ���o��q��q�^�c��¯��>�:'��w�D��F�8��I����)P�qӜ	|9�{�>��O��Oei�-��q��X��V��h|�Gev�Ϻ� `d�oƿ�H��뾛���V�_���Ǻ�������)lZ���p.��#8s�e��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�<��������J�����/����������8�tgڽ��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(�����]�3��U�2;�e�g��Z�|y�g����^�EQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE�|E�ރ�_
�z֭#�f�-��V��tbg�cf_�vy$�u5�>���M�M��'+��-�u	 P�8����f;�:;�
�:���;�h�����v�zR���V6�u“���I#�xޟ�S�.�m{����`�-v�ń
�*��H�ߕ��C
��x��n�췪xD�Ѥ�#���i���j^L��~��hP��s����[���M'�n�u�}gÖ:D�f�o%�����z��LH�]�~P�PK��H��"�GFʲ�Au��|F�Ρ�Z�ᵌ�\�v:i�.�0�:'�ͻ>�����=���.��������ݻq���W�̲����Y2�����2ݑ���<��>�������������I5�Ʊ�����������
���"�g�Ƌ��;���0�����˱��)��u?���������*�\���Ҵ����}����k�����Ұڄ$��0��
8�p��������m*�<�4�
\�V�܁4�$E����қ�a���Y��PӼgiR
�yr+���F��>(�Y����GO����m_\Ԕ����ٛ��Pg,#������~|X����
[I�4�y�j�f��8��x��8��Q�ხ��_�R�.�<�N����e�1Dчpl����k.��a|/ԭ,�Ɲ��2D��@~���
�u��#���Y�\��=��c��������$��61��&��|7�t�G�~(x���v���˭s��t-n��M��,#Ȋ5���	����`O<���W�E�����_��w�i�Ǥ-�z0�c��A=���.��cP�pv�⟋�+O��
~.Z�-��s>(�H�ᑌm"�+:�dm�X�g4
�e���Ǎ��x'K��e�A����f�/���gpY��*Fѷ�q���ϋ�u��K��?ýN����MK�w���1�V�E���1���b�=���;��>�I��~#x��ź��{[
b-=l����H��*�c�~0q��a��W�oxg���[�j��Ai&����]��+)��8)؏��R��Ӵ��B�e���&�i�"����
5��oi>3𭏉t)$�M���$e�]�;O#%O^q^S�'��_���<_qg�z�;���0�C�Y�lIX�~��^p��`�ĺ����5�}�/�oIjt}Y$�O>�����˴�$�����ۇ��>���4�ڸ�����w�E����<*4D6�7y?h��n�L�zf��������|M�
&�Q���Ҵ�)����RB�2�W��ܤ��o�>5Ҿ�Q�o{qa��^lv��+y��K�3(��3�8�n�w�j:e����u
L���0Ͽ5�g�I��h����\x��zW��mI��T���M5��4L��P�;��u��|�"^��`���
�Ex���x�_�Z?�
ei��ٶ��j��y������T��Xc�9_�n\Y<U�;�O��5�|B�-���1�[�ӡ�c�R������q��ׯ�
�W�~"�Ž_����?��}���ןyb�
=v�^D�ٜ(Wm�c�l|;�Gď
�t?<�Y����HmSN�����Q�ʔtO��[�O��=ҹψ�3м
���x���ah�ژ2L����7;Ϲ k����k���^�3��E�KV���?�=4��k��x��Q�ݾc���t8}�k6Z��l�B���7Viz�Sl��nH�q^Mq�Jx/d����q�h0;,�펆ϧ��C1��8��w���|д=Zq���v���!#'�۪��B�$pEY��<%��ᤒN�i���v,D�5U�K�/9,ǹ4
��}{H�?����;�6�?2�x�^��A�A�x~*�L��+���,4�\�]J��B���=�Y��U�PK05�~ʑ]x�g}�0=���f���p`� ���U�8�1�I�/�΍���N��Zh�O�/_�w�y�D��4�Hٶ0,6y|:P���F�&���u-���5)Vί��{��wd��Ԁ=q^�_3~�^.}C�_
d�ƭ��7�ֶ�^*�l�t�E���37 '!G��׳x��מ&�ym�����42�>�dU��(���\c�3�zP�;��> ���x��k�G��9/�E��3<���u�!��9
�x�N���u_��o�t�W��b��Fv�$��2@�����p��o��g�<?�i�^��	d29-N��z�ff�����L�֋�_��_�� ���@�?c�����ڟ�z����j>���˧��٥�-�Գ��?�0���P���̃Ͳ��.��������<4n^���[,��h�~B�P+#����#ϥi���u/�nk���K�6W`�A�E�~Q�9H�?�B(��9�A�?^"/�0{�����]�M0B�$�H�UFKz+��A�/ÿ��s�1�-���&�^�%�����?!.7`���|[����㘾�sȚdI�o!r�+Rr�jã���3�dV7�1�񝭴K���8�F���=�@�<�T2K��b�ڃ,p:
�X���%^�[���4/9�~Ŭ�}��6�\�y8��=VW�L��&�$p�)�pB�Wʷ�"����CO���jf���)��Ly{<����
����MK������7�4#�q�]�U4�0�0~�O�̡��88>���Q5�
�z�D�g���%���iQ^#����t��~�u�wK��r�6��@�,
3�8����F0ު;��è�2�~8:/�5xb{O6Ao
��M����[�wPz�z�c�����Ǎ5�i�O6��G�
#!"2�Qw���:WI_'|������ �w��r��X��'�,)���ظ�o�g5��[ğ~4O�����0��?�m/d��%:Lw����H�a�)'�zt� CQ^/�⮰���ÿ൷���77�6@�o-<��fE?t����^���i��	��V��C�i�I��g��H[�un��V��g�ʼ�ď��e���F�u��Z��k�\E�j��p8љe�]��s.�9#'��W�ߵ&�q���g�j:Mމsu��6[�+��9-�ʟz0p<�29��B�׊�*|I|?�I��p��zз�Gէ����F1��8<���(���ş~'|I�/�~��������.���7|�#s�*� ��@�Ex�¿x�N����T�Z���Դ�f�
_�n�w�8I
�ӏ��
n�/�~8|VӮ�A��FӴ}^K9�	��p���V6EVPI$�>���&��������������ʳկg�y'������6�ǻ�+���<+�C�7߳��/]k�f��kwֺm��aDQ�hM����y�>���h�/?h�|���o�M�=!ocц�����/,��yv��������T��z���	�S�bӴ�O���fB�s�b{�'�z��oi��N���^��t��I��UiXU�C2��:�Z~��ִ-?Y�IR���+��P�H��l3�ؚ�k���>7����v�u��,ү��-���=)-�屷-"�����?֨���w�ı�����^����߇�<��[;���N��ɯ2`��;tigp:�S���q��{��׌���,-�g�i�9��\��n4x짲�G	�Bџ��|�r8�#c���M��⏇�E�j�m�e���
J�U�c˛�
��g�b��Ƞm��[�Ǎ<Y�7�'�<Se�=�Ë:~�j-cΥ2���#.�R*:�g�h��w����������м�E�{�j�����w$U/k��n�Z��մ�!o�j��E�8b��<�����EC���+�~ ��%�n�4����hm��3)����׊���?�"i�����Xj�w��mn+{�>��\���?�۳j���б�<}h�+�ϊz�ǯ�>��Z���-���޳��<;���
Hꘊ|��r�u�=+����Ėz߄|���Ğ+g�;����am�B��63���>�
��x�����B�-�n|3|,�Z�RG;���1+�O�q^����?�6^��7�ukG�Z���X΀�� QU�
I<�=��G}w�x�����%�n����M��:Gp�px8 u�>�����q�����o>۪^��q?���"WQ�
8��-���i����� ����Z�[�O���H��Lk��,I�@<���<Y���k�ڿ���KM*�k��FH�.�A œd��s�l/���~�F�e�9���Y��W��n�1���lW��Pӿh
/�ψ�C���7�5�z���JHV�bev�u;��
����<�*����I�����w�#��ؿ�uk->�������'Χnq�p}��+珉>4��ߴݷÏj��7�ܱ��I#�m�ぽ�
Svܰȫ��/���w�~����~0�<Mis5���dvS[�m#)H�]�_���9
�TW�K����%��A�y�{xs��a���M��{����Q�P�A��y݅��s��i]{�ߏ�m���"Y["Cq'�K�v��B
��<q���U]VW�L��&�$p�)�pB�W��n��⇅t�^>�Ӵ�;�ͺ��I.�ɺFg�8V��b�
&�>��/��-��^L��1��T)�G�������'��*|a�5�G�~.��G����,,�Ε�΢�����X�c�ʴ���1����������Úi���l����!+.�²�P���8�Լ��xb�]���tO���A��~�w�d���۝��<��mWʚ�ſ�0~ĺ7�h�A��7���c��Qy4x��yc�U/oZ����~�^����b��;��
����f��	��0��G��
+�|Y��?����_�|�aiud��~�w*��ͻ���q�n�;֗��x�������G�:���4��,1��a
�aՀ�	��~C@�Exv�⯈�~%���5�
��t��u���i��d�Nvm\���*���x�ÿ�gĭF�[�����]n��[����K�U��^0;�g��x�H🆯�G�]}�M��͸�c1Q�p�I `z��<[�o�ψ�-�+A���e���o��s!T��������T��v��hs�#\�����'�Z���C7Q߯���d�P'k����zs@C�Z����Xkaŵ��w0�m���G����������?d-?^������#X=���M�_d��(��l!���x�qϵZ���O���+m�KV�N�>��C‘�j���#ط'2;�@'���P��W���I����_���(��'����k���Ȩ����ǐy�GR:`�_>#�����Ä�����?�V���<���,p��r�t��|��Ex��/�|A�\x���6𦳨G��]�.;�>��3����|��ӽ����ޯ�N��ៃ��>�M�J��ϼ�����c/"����+��1�>����þ5�<A���cJ��}C���vBF�o*��� Fs�G=q��7��|n��O��Cg�h�
�=3Z�NKY#*�J�i�q�����y���|?�xh��f��ڗM����ƅ?�KG?�x?��Oɝ��>��������k��p$�z*��?�|��k�O�M*�ƾ��?
�q$z5�����wlT�����/���
�%ı[�%���w<Q�&����}�&��>�ߋ_MC�>���Ҕ�*����z�\N���C�c�
����DžekmZ���n���c�Ȓ�J��=��c8�šG� �=�j��.�g��`�K�68����@���wɸ��0���(�����<��S�:�73Yi��KeV��t1POԊ�?h�7?<u]2�5
j��-7I�rv�u.v��`�gdg5������#��^&��>�̰�i����������9�+��>�����������~�a��6�*�3����"�尤ꬲ]���(�繁������ξ����<+���v��5/���͢������@��2�J�����k���>#���>9�q⽳����)��3���������*��̫��7&��=�ڲ�<�d�c��-�X�tֱ��?�J�7����h^s:��Y��5�mb�h�p29�^q����� ��|a��z���_	��+l&�e��+��]�h8�t港	|o�U�짥x�Ud���}JM/MG�"Y�i0�Q�T'�23���������<S�Cs5��
�d�UiG�C�H���|K�m#�v���c
�	2�"���P�a�pO־i����u���wR�7��i��b[M�JKc`�@��̡X�w��溣��kŸ��o��V��-�F�ai���"Umb2���^=��0@>���{�����8����h�G���
;)m�w����~��s��D���|:�,>��-�^[�¤����v�;Qw
 ր>�����?>|b���|i���~,y���4����h�6���2��I�c�z���#|@�����ƻg�M/�)�ܶ	y,�
�q�ˀ��zd�o> �ֿ���m�b�J:�s,i�qwLݻvP�9�¾T�kx�?m�7O������������/)/��$t���6]���)�k�_��>,���q�[�F���tV[m���.nV3�6_0�Uc��a���})Eq��w{�?�[]+_�w�O�̒Cr���&�m���[ �
�P
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
���+�_Ë��GI��nl%�[�i�wͮz���Q��@
�+�� |H�E�][��֥�隶���>�->ٰ�u��lh�y%Vd���x澻�'N�[�{^x��@��T��(���$L���L&呷�<�_J��7i�Ə�/�n��ji�$�\�I%�T*1�����~~!��?��޽����4h��5���%���_���� �fLn+���@����?���~%kM�}���B��*J�1�$E�س�{cڳ�9��ß�q����5k/���ֵ)t�D�[[@����v�C���g�J��R���R�����m���H�zn
g�o¾��ʾ�ޏ�,����v���f�<5u��w�m��U{����K�����m�	�7����6N���V��?����|)w���+L����-�}��u1�k �X���$7�M{ƽ�h� ��������wy��<y����4D����tO�m3�Ȳ�H#Ϯ�P�|o�o�4���2j��}�X�xS��i�<���u	^k�D��a�v���v;W$��
�
�&�������k��xR��V�o�Ll��f蒋��6�T��%��co�ǥ[�[C�����"U�"�F
�B���I��=./D�,��7yV�p,1G��6�P�$�ܚ�/�q��?�?�&����7)/}E��Vl�1"���j���{e�U�:��+��ϊ4���Ks4[�EDѻ�ˌ�y��W܏��_h%��΍�i�l�����ZZ$-r�'|�@.�f99<�Z�XҴ�f���cM��l����P,���Xh��xg�_����'�����-�.�=�y���i��l
|�1��^2�৏�$x�G���Y��ZM�KmM��>�o���,��8� c�>���|7�^�I������;uc��~%�|Lb>$�΋��hX�q����q@9�Ե���`�m�K����e����y�$����dh��q�
�第�����|-{m�k�4	ws�[J�<an�;Y�	@�68��4�+=:�;=>����!��1 �
8��x_�^����|;�iS�n������H�QAn������-�3��D>%��Ҭ�$����o�O��?'�����{U��^�>|0���kz/��;���鷁��;Y\o� �!��ԏ�������D��֧�o�e�7o�k鐴��w�ݟƺ	]C+2��G�|��a|\���Q�|5�+
v�W6Ωc/�m�I��(�U\>\q_Fx#�D������-j�^�$vW�Qx'�Ik�o ].
�y���
�l�
������(�P���UQ���>{���[|3����x����|E�󢶢�LV�K(p��A�'ՏE$Q���ⷌ�
���ڝ��g��k:�Ν(�;hC+�r�"F�=@�~��4�?U���T�����bH.aY#q�U�
S�熼9�w��h��w<vq۫Rh�<�'�����?��6������w�^��F�\��`�,"ծc�|��.%A�+I�̣�{
&�ti��}v}"�]Z�3�l��$9ʬ�ܪrx��
����M��?������b���f��i�i���i���15��+,Rs�F@<�P)�oM����_������v���Lgj-��������0�������o��/�x?L�g��'s�A�.����c��>���4k��W�M�ΒbXM����yk��呷h���s����4�g��������?Ś?�>�����M�$�^�k�خ4��6���� b1�z����)��]��5����:Y��h'����
�U�v�+�9V����Ij�_�<?b��
ul-��c���M�6�UU,9 
[졔�A �4
�>.�2�~	k�ZO�4�v�[�$����)�k�'�
ǘF]Hf
�F=k�>蚟��xWBֲ5-.���l|����V����iz����	h:�Mݾ�s��������<�������i��M
jÏ~�S�6�g�]
c���oNXW���&�k�^kv�F��z��w��"�p�P�
��
��>�I��/oolt�+[��^M
�\2���ː8�/W�~���H�o�/��{�ghZ.��Z=���Xiv�+L��[$(��y��q�ɠ���/�>�զ��dz�����������v��,�z�����p88���s��ލ�ċ���4�t��<K}mw�eĿj��n���L�~�|�{�ԕ���6��h�E����s:Y�$+,���0P71��NK��������M|7�(����2��J��DWFGP���d�Xm������M�=�E1t�E�`�ݸE�nrI�:�'�Rɽ����o��l|	��!�?����&���SO��t���R�����6Oos�����}i���6����[D��(8�FUG
�(�?h�[�m�
�S⯄-�<-�$�g��M����D����C�x�“^w���~О����:���7Ěޖ��{ga
���"���?�w⾫�4�3Y��O���=F�_���P����Xj��|3�
���w��N��.�q۫p�f�<ឫ�iߵ���#Y��t��[�:+(g�c��:F�8`x�\�?���7���ڇ���6�|9�\+&�0�K�]ˬ����s���{���
j嶻��"�V��ٯ����!���!]˃���/�S�r�/�|1��C����"����u8�(�iW?�W�ƚ3.��hg@Ю�C�Ȱ�g��|k�>:���?��O���WW���'��氛D�m�mu(�!$3n!y�����-mശ�����%	Q�UE�=�&����S^��q��AK�l"k�#�$+�~t
�w�1?�<U�;�6��z}����x����Z��,K$w8M����
�'�g�J�������/��f�{���SN�T��O
�(�W�^��h�6�kzE����s^[$����(`v���FM7���+4����j���&Xo�Rx�� 8W�}�i�͟|I�|(����>9ԭ��Mn]sI���Eݼ݄��ܸPy�������G����-�E�iZ�(w$w�qΪ}@p@��i�C��Ox]�'�=�ꑃ�\]�͘�n���t��n����H�o�/��{�����M�vU����C�m�}@�д]@�{=H���V�ᲶHQ���@こ@5񿁿���7�ɩ����Eb��OA�^��xkG�M�%y�m�5����D���\�p(�������J�����4m>����mm'���%mR�Ws}�o�.�{_��ھϷ��m����{+ht���ڤJ�$Av��
�(^6���t}'EҢ�tm.�NӢ#���b�1f�(
2I'�I4
��Y����=WJ�׈�u�CZ�%���_2Hc#�ʣ��U<>H�c㟆�V��x��zD���l�5Չ�_���G�H�"(c��
�X?NE���x+Ñè^ƺ\!nFw~�m���kml,WM]1l���ba�`` ^�q�:b�>R�7��c�&�Ѵ�_�L��i��sww3�
������|Wc�F^�⻝�|��1%ޯSj�H�h�4芰'9��Q�s����{>����{������Ү�;�ӡ�F�\�(&���:����Y��u�������j�=������ڀ<k�a��+}���9�=g�E���T����nI7
�7~y�V5�F���w֚N��j|�حn�W��
H���a����u�hWz宽u���ֈc�����9ʤ�nPw7�5�|=�g�#~#�$zl2��T�P��
$j�T��/+��;y�^���_�%�,��-���z�;_��<�)�cu���w_h]��wk5��\[̍�J��Da���
d��
I��h�xcE}2�a=�����m ݇�6�F��
���y����&����r���+���<~����n�$���H�.�Lvo$'�f��~��k�oI���.m/[�,�;	�����,�I��.�`A���
}Ɲaq���qck5��Dm��Z"���#�y[|\>"������9�Ѵ�������<G��M�v�<��X� v`Aw�^�5����U�W��Č�^jr۪���Π�k�xw���{Oh:^�n��ⰴ�f�!Ԛ^��iwwךf�acs�I�^�ol�����H�2���穠��f�������i��,�u�g��Ҥ|^4�i
�C�ܰ+�A��yo��
k�߱F�s�Y<�����5f��N����+3c��_e�xLx��!�}�k9���_i��uۻ��z��h�g��]���<6V�
3��b��p2hþ0|u�q��
�e�|Eg�����d2��兕�ȇ́
ff`
pO�$��{���dӿ���	������xC��s�D���4�C���k���.�9T��S����~�'��g��%Yl-��3���h�n�x+�P����܏��|m����-�q/�+��4_���H?�4��#��o�2}���|�3�睹��&�}�Y���F�s��n�����[no-�ܙpFh�σ%��¯��|�}Z�B��[�\�n�	D������p3�ݏ�qK��4�~�~*�t9}-<(���;H[�ŰgL�]��=��<]���/�u���.��������lu�J%�Hs���C*Ǔ§`�w��^�E��5��6����ST��O������i>BÆbB��:��ms�@����'��k�ao�6���n������Etdu�0�FA�KB��M�L���*�2J[Y۬1)''
�
��|]�o����*�]�G�}:�L�V��J#���i�⼵?��F$g���Ǩ|-���s��xb��D���][����:�0���ۘRHN6���w�'�</�Q���mdE����1�l�oS��g�i�ZXҬ��;k�>�
�m=W`p}(��Q�������.+�ړ�M�����+������q�fO
�o��ۣ�[O�ڣn-�݀�%�u$֞���j�|�v�cm}ep�'���d�E�el�>�
�~6�,���=��i^�ukO��Al����Sz�v��ٗW����g^��}%���Zh�tm�c��Yn���I+��++;->:��{("Xa��0��������8�U����xr����t�ͤ2,mR˜�P
�
ϰ��#�?�M7�����L�ݵ}E�mS��&���)��H�������#�>��B����>2������7���Z�p�ͅ��������<�3+3+6����8���A���������wo�Rt�k�)����B�B�,4�Pr ��Hc��Pʂ��7�;�_Z�z��Ƕ�%�p�B��%S��w����9T�I<�
Eg�x��?�'�	u�F�\����R���זQ��[?1�6O���Z�j�V�<l��ӡ�E�L3)"�ͥ��6&�jc�%�S۷�1�(�?�]�u�ؓJ}V��R�t�k�m:��̱���u�FT�+пn��6�w��m?��+�c����&У�_�J�a<�K�� �Q��۴��3�j�>��i�i��c���A{k�u�& �eXpy������<A�^�w���ז�c� �����?t�/<��f�L��K,q�ݨ,��+!���?�_Zk6���h���c�i��Z][���Rr�
�q����t��4�w6�X�f�HU�(:.�1�:P˗����|E�i^���V��^$V���qx�w�d?h��NN@�����<}�bݧ�Яa�߄|)᧑�9�Fi����v(�[�EѠ�.5�4��k��3�%��Pc
�cs(���€<O���|
��n��k���kHҿiߌ�N��ZYj��a�i�	-���f��������ɴ]}r�]�H��V�����!��r�&7*��
�j��j�_��~�.5�~ �%���"��d+�z���%�V�u�j�8��7�S[o���+�ּ�c���?�+���;֬<-�?�5����:��<�ux���>�O�W?GV������+�{º�u���t��t�3�#��&&�5��o��Z���%0i,f3q
�2!����C��~Ŀ�l^����-����[���kx����1
cv��8�W�4�/C����M2�L��w�kg�{��mE�Oɠ����B
h^)��&���W_��.m�\��C�{d�5���~k��?x��Z�5�?*���M�Ƥ�w��DN�:b�� A��|�x���x3ñ�h�Kݺd#�*NH����������!�˟�п�T��ԓ��<{�O�C$�i�/��胗��X�q�O��e�m��χ'�������4:CF�dog-�G��G�ʀ1���X�t}'^�d�5�*�T�������&��9V�@7�-hw���W��ϋ����H�>X��
���GúN�7�c�_���^��)⃬\�Ĺw�;�C��~���6֖��1�[��
�Qc�#FЁG
@�1U�=Gд���M&�K���K[;t�%�r�E�M|��I�i�y�|�,�9�;kP����k+I7���T4A1;���.�sK���ox�H��|!��ֶ��P�����m�1��)RN]��}K��ۼ�xv?�){�L�}�I�|�8���[V�6�dZ]���6B-㵎%X� �Da
B�(��k�9���/,t�]]H�Z��uw{;9(�\
���+�p+�֭-���ᝅ����[xJxa���4H�0T''$
����k�t?�3B�P��#�iw���,��a��rʠ��6��O�[����ј`�{d7!�Ud��S��=�x��9�%w��������3����������x�P�E��M�:���^H"��a����VV|s��}W>��h�6�wcy���:|�u���#�?4l�(�F:
o�|?����Yx�D�u�Um��T�0޻\�����4�<q�sX��zu��屎�
�J�#3��ġ����(qT5{���W�_�X�v��q�߼2κж��@.Q�R7-���$_L�x_�VZ���g��"������1YF��I��S,�h�P������w> 𮇫��r�i�N�=��"��<�I�&�/�|_6�⋭k�z6�,z6����5�a��H�Q@s2À0=�H���cM�S�5MF�q�nmfYb���� ��ґ��1�4y4�6�d���0���a�B��T�A��H�4�M�L�4�M:�
�m�aX���*(rI�ր.QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW�|n�����^������Ju?Is�?ڋg��nte9�R���5�u�w�e�`|e�/��eꚯ�/u>Ǧ���3|��,i����@_�,O���n��z��ܮ��3�h[�x�ԭ��n�x�M/��ی�|Ħ���=
q��O������o�ʱ���glq�8����FrO�g�^����[�&�e���}����-!�t��l@����|�
��W���%2���?
������dߋ]M�o�NI��l�+)?�1��t�_�~
��[�޻�x�M'�H���=�������-��H���+�7��5�v���&����Z������ҙ_cas��q`3�ס�M_�ǂ<=$>#���(�_���r������[�<�,7�����@�\���|y���co�f�uo���f$�<�+g?��w~��_�/��
u��_�=��ƷSj�A��:����2[��ee]���?8 �^���??؎��Qq@�EG4bX�&.�ԩ(�HЎA����|O���7���Mn�P���Γ__N��-�n�)]�$�+�-{���G�^��u��wڍ����<A$~�S�&�O�ݖ ��TX�~88\��G�-��ỏh����<emn�?f��v�i�R��1-�p���:�=(��+�.<Q��+���H�]�����;�6��h�9V�r�ݽ[��
�5��<k�|0n�������uD�Ay����V�����؜�=p�t��(��?h[��~П��o�:ݕ�wmk+` �<�3��[kv�{W��:��;A}%�M�f�[�j��܀�
��>Q�S@5��O�+�/xoល�+���j������֪YU"iP�������t����?��+��O�2_�m�hڦ�o���?
4%N����;�q��Ҋ���
��~���	мs��:3�n9�V�b�Ta�sB��IY�/���f�	�|4��4_O�w���=�]�0Of!d�[��00Ǐ�4
�=p����P�[����zտ�~ӝ��4�������ݺW�i+⿍��a��~ ��1�6�i�r-�.�c�Y$�����1��[஛�m���.��i�˛O	��d�$��h�h̀p\d�=��>��.��M_H�����f�n^4��Ў�|Cdހ
�����t�/��]⹿ck���Z�W�������7��$ݹ@�s[m���a��u���&�B]R����Gba�)"���
���$�~����?�Y�|
�t�խ��|w=���@Rُ�4�zd68�˸�v���'���|!�|G�ϋ�4Ԕ�ꫨ�u
2
%���j����>�XW��f���x�>�|�	V��%�6�j���RF�FS�I䎝�^��	e��z<����%������jI'�����'Y�[��_�$P�G����Yɫx��&�����^��N���	bAռ��$�b�_��$Ѽ_�x~�/4����%^3؂ � �"��C)V�0A�k���8_�_�5�Z��Y�kŷ�i��U�ʍ0?�0R@���+��u/C�S��~4�
9�٦��dDms�U'i<g�jи���}s�z�����v�6����
7���:��:�d@������◀|K��g¾5�G��g�X<G��Z�M����+��#�RǑ�f��/x�Ms�D��ċ_���`�Z��/�����@-�C�aX��'ڀ>���_���`�y�_º��|E�n��=���{��6R	P�(��p@�4�Ox������H�!��C�͇�d��"t���6�1,�ʹ;Tw��(��|��J�~/x���<A���޾��+j��#%�����Y������lW]�.������?�:��u_�Zu���w����G�fQ��}����"�;߀��j|;�������m̰}��>~6g~������5��~�������'��/�Cy2閺�l�I��i���;Bp>��¤���Ğ�y�/����Z��<q���dz��pv�;�>�-�v�y LQ_(�Ek�xrꟵ����	�0x��4�%#"#k�2�;I�8�;T~/����Ϳ��u)���j���ͧ\4A��L6�]v����J�ʰ|����|S�����o��˱$*����B��k��O�=w÷M�x��� ��5�w�Y��f*�`�"��+�״]�si���a�ػkk�d�"G �pFEx���I�i��%��
sA�e��X7�O$)!
$��F�ב������r���H��$���"�����Ϧ+���U��υ5o��$��#�ھ!��;����-w+(VKxV<����[���7�����"�vv�L�W9'�@�P�3�U
��84
��_�~�ŭk��D���,Eĺ�W
��_0+F�̣p��`��1�������tO
~�4�<9���m��mxFԒI<�'��$��_IP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
EP
^�D���	������[׿Q@x���:ς����"�������|�2��7�F�;J������=�Ť��uf�ھjou�ң9�c��'��KĿ
�-h���|��'���ftc*vu
��ϳ�=F3��_]Q@0i���>��Oҵ��֚biV�7�[��r��-�,�3��O�1U�?Yk62�%Ծ.Ew�	���*kX
�_4Cl�G� aq�0�,����i���x@A�m/Y��Ե�]��+|�cr+;#�s^í�?����FVV�;`r�E�5��P
_%~�v�!����E�č xj�G��4j��աs��Wֵ�Wÿx�⶗�?����n,�8g����hfT/&�7���|���@3�h_��z����xW–j^�����D�.ź��"��p~�����g)tQ�ɼZc��#+���W���e���n�vs�v���h��~<�5���Q�7�������k�x{IQ$62>/1bT���a@�q�a����?��I�x���j`��Cu�k6z)���ѤydFw.�<c�������4�]~���m�Y!�KԞ7^���b�_AQE|��Kxi4ϋ����x:?xf����r��-�[Ź�9�L;ZF9���5��~x�TӴ���?�]F��#������c?zI��ߍ�����;Ex�����C�b:�E�/���=������j��(�o
x�N���:?����|9�
]��#Y��I�v�����q�v$� ���Q/�m/���W�m��+`������n-�ed<�r�q򕯩(���)�&%�#��W?�:޾���_��+�l��h��t�Z��`�A����מ
�?�f��fI����B������jO�����_C�D���5���=��ǦF��B�Πoij����>���ᴟ�7�C�j�F�t����=������Ă)�ȱ����<���~|c��ko�ϊ^#�}���x�����\}�P�`��� $��:P�x-Y|��)V]>A���x�7�M�?�?�O����Z]��-q?��l5Pv�,y`8���Q*�¨zS��5/�s�Ō��2}[���C�m7N�nC���	x��S����R�����e�hZ���	���_^��8ڷ>bH��8�	���k�(��x��{��実���Z^��8 X��#��{�gQ���u�� ���^kS�/���S�τ<k�߅��Լ7����O1�F��T���Q��,�^+��(�w�U��]OÞ�-w���>����^��,�5$�)�獹�p"��,�'��h���^:�M��|�->n������.�%T���T�c�9���

󷂼I��4k?�_�=j�)������f�]����(�rR-�������p��kߨ��a�'��s���g��CG���<}�bݧ�Я}��>7���6xg�?`��r���n�S��x�RM
�f�F��q"��9�K��'�����׋g�gҵ�[ϢXݏ._��6跏�i�Ϡ='�J(��x��{��実���Z^��8 X��#��{�gQ���u�� ���^i��j���
��c�#w��9ѭ�+2`3��vP	��xYQ@q��O��������աYE��;�����N�r9��$WcE|��o���)���Yk���u]>K(���x%�
4�7e�n��K��o<��~�eY/l,�n
�UdbY��K�WiEx���<}�bݧ�ЯZ�O��/�A�u�S욏�&h4�|�ϑJ�J�2'� s����(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(����
endstream
endobj
488 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
489 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
490 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
491 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
492 0 obj
<</Type /XObject
/Subtype /Image
/Width 350
/Height 96
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 7775>>
stream
����JFIF



��C	!"$"$��C
��`
^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�&y���[$��XZ����d�ģ�"�zW.+��C���W��*5+>Zqm��W��x��-,��z�ŏ銢�5�	��_a|�^6ʠ웗��;�2<\��K�zu���XC�Ŷ�{���Ň�-�`���C��w˭m�����;����5rl]5~[��SN�l���K��{��>��Z澒�XU����.Qqv���(�QEQEQEQEQEQEQEQEQEQEQE�|g�/ĺ���mi�S���T�13
�T`g��=Z�4�.��O�o��E�J�B�V��I��r������3�d�).<O����U����l�$?�}^/�&��O��]H���>�W5����ER((��(��@j���Z�֏sw D=X�z���+[i.&m�ƥ��J����i	XT�(��5�|E��)���%��_��zYn_,d��+w��C�k�U�4f���#S����ElxgB��nx�v�y&?A�_��x���ns������J�
���Q�ceu}8����`:}Oj�ygi`Lw��pc���}ۿ�ƶ|G����6���K�����g���k\m6�1|�[���d���<��:������]_�oE��NN@�RQK^C��4�)p��!�ubJ��q�k�G�z-�X���'��+�3�~�����b�R����Z�������֣ua1H�o,�yA���:W�`q�1Խ�uv�kF��)R�,�QE�fQU����W�����i%p�?@(�7�~5xLܰ��Rᴄ��}6
��
�ho
v蚹���5;
��z+�to�
��Ev��������c�W��zΕ�ح[�۟��}��4�	�_�����S�xGKMK[�x`yDI�2圂q��
7(� ���<!����.�"���?�z��v/��[��.!IDo�˸���4
�-QX�%�>��a>��[�)���,�E��W��_�!op�ZX귊��bƨ�鹁���`m#ר�"��?x>��b���lT������'��L�5�'^���G���ݎ7����#�>ƕ�;�4QE
)��Q��ȱ���1�Ԛ�<E���1hƦڌ�pc�O3�8_ր��TW�7�
ᬜh�����B���k�6��9��4�	���S�R@�H�f+�o�5������ལB�W!?�j��W���ާ�+��9c���C#B�d�eE|���;=ϯ?g���S�]�?�9�3�~�����g���M"�6�P�G���j[�奍�����m���UQ�My�����Y+�>� ଡ଼%����S�s��o��Y;tM\�S����4��>
���ҷ�������2ㄟҝ������ղԁ�����������{�O��Ў��������������<�����p��m{��\��i_��~��W�Y�>���}�����/����?����X��<a�w�˚E�����=\��;��|Ks�<8�vCd�<���=X��SU>���-&�ﴥ�-3�G����Ǯ�.����������<��+鰔���9c?��]�o������O��G�CW���k�-W��BQI@��7>#�đ���8�H�M�𳾭%���oʹ�Χ���ݾ����"��6�������w��t���������a��e��?�K�±����/7�W�����c���r�6���ʰ��,�«v�D���޽>��.졹��ȡ���������ǀ�<�2Kry�N=����[ü�p�O'�E��5��ΰ��UO��h�Uj��&�y��>�{H�W>�t�~�|��|X����L\��jw
~�k��}�?�n�|�����+�
�%����#�ʽ��_��x��7z֠妸|���e�W���?��v>+��Ķ�ɶ�++��}B��ϥ^�m�3��wŸx�(�m���A�./Ƭ=@�c�P1�]c~�~(�u� �: ���\<̮T|S�����֬J���;������}�
T�g��
k1jzE�F�@�<���yV���_U|r�MO�����R��A��g�Ǿ��5���T��j���֭�E��n�b�D�I�S�O�9�x��ozL�t���4��������ŗ­!.A
(y���J�c���o|�����-�����*V彏+�-��R���y�H�z� �_K�c����LJ�ڸ�+���dwl`�����D�%ҵ�MNG��U�0�7)����ρ�
N�)�ծ��C-���y'�_�g8�^��d/#����<{���yc�e��o�ܪ�ӂH�WAw�?x�+v��SҮ$"0�+����(D
�
����/�kzV���si�����p�I�G���WQ�o�w~񽔑��b��m��-�1��z�r?�滿������D�[��X#���ґ��-#����,*�Dlϼ��fx�\Ӽ;�\����h$�c�@�I�TaFz�]��|c&�ⳠZ���-���'�t~>�	\��s�>$��5�t�W�ҕ������㱲��M�z��/�|!�/��4���-�B�����ǏíY�i�;���۱ሲ������������
�E�������������ձ��»R4�=���<�7bR����◌�}&6?�F�㶳���^7���j,5 :���?��־�����ʏ�5�u�-B�#��Xʶ�
�+��\ui|b5/i:{V�����?�w_�ޠo>'�o����P��.�:����?�>+i!�R�̸om�q�⫡����
���P���m�7#Ͻ�+kj��!�>�;��5�,l'���G��1�Q�!_�B�E��Uw��3v�o�@���>�ԥr��7�~0׼]~n��בC
q@�U��O�i�3់�W\i�w�f������#�wa��o����>(�$����U��H���/\�@�>�־��5�#UTQ��0�n��}Ϛ�ូQ���gI���ɏ�mp�9�y���V�h[j�@��'��~ W�WU��������{i��,n2M.fW*> �ֽ�xsT�S��$�����u�B����x��ƾ�T�V+�>]� �ːq�z��|��=�?�OEf-�K��X��*Ez���&ѼC��J���B���u�N�ڹ1vgbIbI�EK{Ay40cr��5
5N.q{����h��
°�v�c0�~'��^k�[�W���f���Xp
��"����4&��ݑ������~���r�?'š��t>[%��/���cQIZn���������m_����hU�.JQr}����*F��ݑ�]_��4�����em��D#�a��Z�7�,t�[�bx�u�i8�O�֦��Uha�W{caQ����9F)�/7�V�Cv�W�����f517��W����5��b*�
p��q�S�^y<�O;�3��X�Z'�[��Y�i$nK1�W��'VΫ&�-8�1�_��i�����º��g�׋�j3\�v?!a
��2��2O���RΩ[�7���͚XY_��:��ګ[{?	X���U��ҁ�8�q�}���E|��W�;��M�$�O�i?���H�|l�<r�����
+A���������Kk(r�ub��I�<��'��o���H�.ˋ{���]�
��p}q^����<������OE���+T�Ԉߡ�Ǐ:ns������D�v��Axnw�������J$�NI�+���u�
���2���H?�Z���9��I��a�������+�<�����ޤ����G0�C�{��>������_èj�k��۞V3��S�О�Z��
��N�$s�i.�p�!�r�����`עGF����(ª�=(�`Q�6���㷂5�(�""�P0�����W]����`���_b��l�p�	'�W�Z������ ��\I1���~�Gp����M����;+���̹e����g�Ԋ�F����cX�B�(�P8W���ZH2kzۯ Gk����W����
(��G��u�ƚn�~�e��s�W
�OmS�>�f��oc���C��E5����_|V�[r�������j~�vF��O�"��Ys�'��W�˩���54�|3�j�@�%����!I�8������Kq;��������k�O�2���A[i"��2A_$v���O�T���������g�Q���A����B�����։g�@�7ډO�rX�:�)2��A8��|u�E�	j:ܛsk
hՏ�_ň�|��_Q�čz�NP�<h}U>A�-w����f�v�����و��Ԍ�C^7,�,�,�Yܖb{�־���,L^�51����{�\���茖�������>Ki�%�gK~;>�~\~5�{��spL�����G�`�׉h6�y����2�\���Z#�Ks�o�Z~����I�u�l�2?���N?
�)`R��R9
���94
��Ǣ��޼W���|��S�[m5׈'�CF'�ҳ|w�
k�z���)sw#���/�zw쭢}�[�5IT �[q����	���dd�=�
���
®"�]���8?���7^��%u})�'�zOǥyD��R4R�GC�R9���Xs���=W�U����ص_�߽?��]��@3�C�����T�sjBŨ�nS�rn�6cϿ������mg+b+�
��q����W�\�ͻ�*�IW�e���C��4�~Ҏ���x8��9��=~Os���i��Uof�t"�
�U4�!��]�j���Pkzl�e�A&Jc��5�'2Ͱ���YE�F���{С����S�$�M3n�Y$>���tQ^,�)�i;��E-QE#
��Y-�a�oq�k����o���<''���W����Y4��y�Ek�N���Ϝα*MQ�MXW�_�d�,���.��>��?�Wӵ�����.<A�h�m>2�K,�2�	��z��~������-���ţx�G�.!���I��L���:�B
��W���_	�5�b���(�k�XT$q|�"�����=G?Z�"b�}#Ep���E�|Gx��"��?�Cy��ݱ*u�9�h�eo�n?Z�2�w�W��?��픍3N�o��X,I��O�]��o������W1YG�������{�On�X.�O�W�K�>�~[i��R��m ~�W�'�}k�G^�?�Z�{��RE
���覾J=*�D�>������e�۹f@B�ר�/����
|?lWk}�9z���]EK--��&���k|t�k��=���/��?\R�w����V�����is���k�?d� g�����?R�G�+�NI�9&����,E��w���^_I&q�(T��ή[Gr��-I���Y�B��־O�_qx�D��^ԴY�J�dB����_jw}��7�47��F�������W|?,L-�Dqٓ�#�����)C��E֒Wҥ�������wS���k�[���Ŵ?�DT��R�����i���ݓ_6~Ҿ9MZ�|+�K�ZY?�y"rQ�\�.3�S|N��.�m.�����PRK����}߯_�sǃ'��f��x�jz��QG}������*	�����w<�}q�;�}��F��6��K;{����G�_q�&�i�����,�B=����!A)�\۰����iI�'�AC�Mx��t,u�+�	��G�����>5�JOx{;ES}l�����A�� ���|},o���Ȅ�+#�"��J����h�-㸂E�):2��R2�+�߃���t�tE4�p
��Q���V^�v#���V�����$�q$R+~EsR�-I�y����\E�uAM����.G��@?R+�?<'aj�؂�W�< �Q��X�_;x��ڷ���5mb2fDQ��{*�šD��k��>o��;��^ޟ�\�K
��\׌��	��񇈭$�̂U��P^�R� �8���^�|A�.���Si�WI%k^��d�0ppN

�Q������#Q����^�A�5Պ0+��2��B��z}יՇ�T��U)�O�%�b�+�"A*k�<���ŭˁy��-����
{@��e���,��~>����t��g�
�x�~����W���%աkI�m�滮���ⰹ�.J��kk���:����l`�L�c�O��Z�o4�g
f���:}Gj��<Z����!�	b����]lAq�RX���5��򼫊i{HK�������U�&y����e�%x�ўQEz-�����]���?���t���7���?�5��7��ք�t�ד����S֥�a��?�#��-G��&�AH
��#���
?�G({���F�~���pƱD���
T`
�2�Ԛ����_f��V�_��ό�"�-_r;Xl��
�??z�(���_�J��d�H��ܝ�PFF(���>h��̚��8�/dm�G�t���q�^S��������Z� ��\���O�_YQN�|x>|C-��F����c�B���� ��6����>?"k�j)�1r#�
�x�e�ڶ�cl;��m)�����ܼ	�/�j�C��Y���%��f9$�
��U�E+ܤ�y��o�4�l4��TErf�ϐ�8R��Ƽ�?��6�|�N̍ظn���}GEhnGk�mH�"��
���)+�����z���-H0���b52�U��$�5�ъ�h������?�!����ះ����vF��3�9R�ś���ttSn�J�k�~+�&�<f��ZL�~���s�t=��zU���$j_� Y���⃁%��߃JM3���ٕ$�b�By�����J���|�\��4oO��J����r��#�z�s�
��ǂ|C�k].�E{5���a<�r���=�ν>�.;#�;�/��ݯ%Ҿ�%S.�؝����_N��@���P��+
���h>/�MB:f���%�J�N��~��RW>R�>���f�Y�1�x'
H���Y_�>!�����_>,�U���d�#�'�w��%U�����=^{��D�z���xD�;�jc�ݡܨɶ?���8��Z���(�3^��O�+W���I��/�zb28�⸛�������]��1Hg�y#��V�Q6���\����}&�
C���
endstream
endobj
493 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
494 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
495 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
496 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
497 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
498 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
499 0 obj
<</Type /XObject
/Subtype /Image
/Width 350
/Height 96
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 7775>>
stream
����JFIF



��C	!"$"$��C
��`
^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�&y���[$��XZ����d�ģ�"�zW.+��C���W��*5+>Zqm��W��x��-,��z�ŏ銢�5�	��_a|�^6ʠ웗��;�2<\��K�zu���XC�Ŷ�{���Ň�-�`���C��w˭m�����;����5rl]5~[��SN�l���K��{��>��Z澒�XU����.Qqv���(�QEQEQEQEQEQEQEQEQEQEQE�|g�/ĺ���mi�S���T�13
�T`g��=Z�4�.��O�o��E�J�B�V��I��r������3�d�).<O����U����l�$?�}^/�&��O��]H���>�W5����ER((��(��@j���Z�֏sw D=X�z���+[i.&m�ƥ��J����i	XT�(��5�|E��)���%��_��zYn_,d��+w��C�k�U�4f���#S����ElxgB��nx�v�y&?A�_��x���ns������J�
���Q�ceu}8����`:}Oj�ygi`Lw��pc���}ۿ�ƶ|G����6���K�����g���k\m6�1|�[���d���<��:������]_�oE��NN@�RQK^C��4�)p��!�ubJ��q�k�G�z-�X���'��+�3�~�����b�R����Z�������֣ua1H�o,�yA���:W�`q�1Խ�uv�kF��)R�,�QE�fQU����W�����i%p�?@(�7�~5xLܰ��Rᴄ��}6
��
�ho
v蚹���5;
��z+�to�
��Ev��������c�W��zΕ�ح[�۟��}��4�	�_�����S�xGKMK[�x`yDI�2圂q��
7(� ���<!����.�"���?�z��v/��[��.!IDo�˸���4
�-QX�%�>��a>��[�)���,�E��W��_�!op�ZX귊��bƨ�鹁���`m#ר�"��?x>��b���lT������'��L�5�'^���G���ݎ7����#�>ƕ�;�4QE
)��Q��ȱ���1�Ԛ�<E���1hƦڌ�pc�O3�8_ր��TW�7�
ᬜh�����B���k�6��9��4�	���S�R@�H�f+�o�5������ལB�W!?�j��W���ާ�+��9c���C#B�d�eE|���;=ϯ?g���S�]�?�9�3�~�����g���M"�6�P�G���j[�奍�����m���UQ�My�����Y+�>� ଡ଼%����S�s��o��Y;tM\�S����4��>
���ҷ�������2ㄟҝ������ղԁ�����������{�O��Ў��������������<�����p��m{��\��i_��~��W�Y�>���}�����/����?����X��<a�w�˚E�����=\��;��|Ks�<8�vCd�<���=X��SU>���-&�ﴥ�-3�G����Ǯ�.����������<��+鰔���9c?��]�o������O��G�CW���k�-W��BQI@��7>#�đ���8�H�M�𳾭%���oʹ�Χ���ݾ����"��6�������w��t���������a��e��?�K�±����/7�W�����c���r�6���ʰ��,�«v�D���޽>��.졹��ȡ���������ǀ�<�2Kry�N=����[ü�p�O'�E��5��ΰ��UO��h�Uj��&�y��>�{H�W>�t�~�|��|X����L\��jw
~�k��}�?�n�|�����+�
�%����#�ʽ��_��x��7z֠妸|���e�W���?��v>+��Ķ�ɶ�++��}B��ϥ^�m�3��wŸx�(�m���A�./Ƭ=@�c�P1�]c~�~(�u� �: ���\<̮T|S�����֬J���;������}�
T�g��
k1jzE�F�@�<���yV���_U|r�MO�����R��A��g�Ǿ��5���T��j���֭�E��n�b�D�I�S�O�9�x��ozL�t���4��������ŗ­!.A
(y���J�c���o|�����-�����*V彏+�-��R���y�H�z� �_K�c����LJ�ڸ�+���dwl`�����D�%ҵ�MNG��U�0�7)����ρ�
N�)�ծ��C-���y'�_�g8�^��d/#����<{���yc�e��o�ܪ�ӂH�WAw�?x�+v��SҮ$"0�+����(D
�
����/�kzV���si�����p�I�G���WQ�o�w~񽔑��b��m��-�1��z�r?�滿������D�[��X#���ґ��-#����,*�Dlϼ��fx�\Ӽ;�\����h$�c�@�I�TaFz�]��|c&�ⳠZ���-���'�t~>�	\��s�>$��5�t�W�ҕ������㱲��M�z��/�|!�/��4���-�B�����ǏíY�i�;���۱ሲ������������
�E�������������ձ��»R4�=���<�7bR����◌�}&6?�F�㶳���^7���j,5 :���?��־�����ʏ�5�u�-B�#��Xʶ�
�+��\ui|b5/i:{V�����?�w_�ޠo>'�o����P��.�:����?�>+i!�R�̸om�q�⫡����
���P���m�7#Ͻ�+kj��!�>�;��5�,l'���G��1�Q�!_�B�E��Uw��3v�o�@���>�ԥr��7�~0׼]~n��בC
q@�U��O�i�3់�W\i�w�f������#�wa��o����>(�$����U��H���/\�@�>�־��5�#UTQ��0�n��}Ϛ�ូQ���gI���ɏ�mp�9�y���V�h[j�@��'��~ W�WU��������{i��,n2M.fW*> �ֽ�xsT�S��$�����u�B����x��ƾ�T�V+�>]� �ːq�z��|��=�?�OEf-�K��X��*Ez���&ѼC��J���B���u�N�ڹ1vgbIbI�EK{Ay40cr��5
5N.q{����h��
°�v�c0�~'��^k�[�W���f���Xp
��"����4&��ݑ������~���r�?'š��t>[%��/���cQIZn���������m_����hU�.JQr}����*F��ݑ�]_��4�����em��D#�a��Z�7�,t�[�bx�u�i8�O�֦��Uha�W{caQ����9F)�/7�V�Cv�W�����f517��W����5��b*�
p��q�S�^y<�O;�3��X�Z'�[��Y�i$nK1�W��'VΫ&�-8�1�_��i�����º��g�׋�j3\�v?!a
��2��2O���RΩ[�7���͚XY_��:��ګ[{?	X���U��ҁ�8�q�}���E|��W�;��M�$�O�i?���H�|l�<r�����
+A���������Kk(r�ub��I�<��'��o���H�.ˋ{���]�
��p}q^����<������OE���+T�Ԉߡ�Ǐ:ns������D�v��Axnw�������J$�NI�+���u�
���2���H?�Z���9��I��a�������+�<�����ޤ����G0�C�{��>������_èj�k��۞V3��S�О�Z��
��N�$s�i.�p�!�r�����`עGF����(ª�=(�`Q�6���㷂5�(�""�P0�����W]����`���_b��l�p�	'�W�Z������ ��\I1���~�Gp����M����;+���̹e����g�Ԋ�F����cX�B�(�P8W���ZH2kzۯ Gk����W����
(��G��u�ƚn�~�e��s�W
�OmS�>�f��oc���C��E5����_|V�[r�������j~�vF��O�"��Ys�'��W�˩���54�|3�j�@�%����!I�8������Kq;��������k�O�2���A[i"��2A_$v���O�T���������g�Q���A����B�����։g�@�7ډO�rX�:�)2��A8��|u�E�	j:ܛsk
hՏ�_ň�|��_Q�čz�NP�<h}U>A�-w����f�v�����و��Ԍ�C^7,�,�,�Yܖb{�־���,L^�51����{�\���茖�������>Ki�%�gK~;>�~\~5�{��spL�����G�`�׉h6�y����2�\���Z#�Ks�o�Z~����I�u�l�2?���N?
�)`R��R9
���94
��Ǣ��޼W���|��S�[m5׈'�CF'�ҳ|w�
k�z���)sw#���/�zw쭢}�[�5IT �[q����	���dd�=�
���
®"�]���8?���7^��%u})�'�zOǥyD��R4R�GC�R9���Xs���=W�U����ص_�߽?��]��@3�C�����T�sjBŨ�nS�rn�6cϿ������mg+b+�
��q����W�\�ͻ�*�IW�e���C��4�~Ҏ���x8��9��=~Os���i��Uof�t"�
�U4�!��]�j���Pkzl�e�A&Jc��5�'2Ͱ���YE�F���{С����S�$�M3n�Y$>���tQ^,�)�i;��E-QE#
��Y-�a�oq�k����o���<''���W����Y4��y�Ek�N���Ϝα*MQ�MXW�_�d�,���.��>��?�Wӵ�����.<A�h�m>2�K,�2�	��z��~������-���ţx�G�.!���I��L���:�B
��W���_	�5�b���(�k�XT$q|�"�����=G?Z�"b�}#Ep���E�|Gx��"��?�Cy��ݱ*u�9�h�eo�n?Z�2�w�W��?��픍3N�o��X,I��O�]��o������W1YG�������{�On�X.�O�W�K�>�~[i��R��m ~�W�'�}k�G^�?�Z�{��RE
���覾J=*�D�>������e�۹f@B�ר�/����
|?lWk}�9z���]EK--��&���k|t�k��=���/��?\R�w����V�����is���k�?d� g�����?R�G�+�NI�9&����,E��w���^_I&q�(T��ή[Gr��-I���Y�B��־O�_qx�D��^ԴY�J�dB����_jw}��7�47��F�������W|?,L-�Dqٓ�#�����)C��E֒Wҥ�������wS���k�[���Ŵ?�DT��R�����i���ݓ_6~Ҿ9MZ�|+�K�ZY?�y"rQ�\�.3�S|N��.�m.�����PRK����}߯_�sǃ'��f��x�jz��QG}������*	�����w<�}q�;�}��F��6��K;{����G�_q�&�i�����,�B=����!A)�\۰����iI�'�AC�Mx��t,u�+�	��G�����>5�JOx{;ES}l�����A�� ���|},o���Ȅ�+#�"��J����h�-㸂E�):2��R2�+�߃���t�tE4�p
��Q���V^�v#���V�����$�q$R+~EsR�-I�y����\E�uAM����.G��@?R+�?<'aj�؂�W�< �Q��X�_;x��ڷ���5mb2fDQ��{*�šD��k��>o��;��^ޟ�\�K
��\׌��	��񇈭$�̂U��P^�R� �8���^�|A�.���Si�WI%k^��d�0ppN

�Q������#Q����^�A�5Պ0+��2��B��z}יՇ�T��U)�O�%�b�+�"A*k�<���ŭˁy��-����
{@��e���,��~>����t��g�
�x�~����W���%աkI�m�滮���ⰹ�.J��kk���:����l`�L�c�O��Z�o4�g
f���:}Gj��<Z����!�	b����]lAq�RX���5��򼫊i{HK�������U�&y����e�%x�ўQEz-�����]���?���t���7���?�5��7��ք�t�ד����S֥�a��?�#��-G��&�AH
��#���
?�G({���F�~���pƱD���
T`
�2�Ԛ����_f��V�_��ό�"�-_r;Xl��
�??z�(���_�J��d�H��ܝ�PFF(���>h��̚��8�/dm�G�t���q�^S��������Z� ��\���O�_YQN�|x>|C-��F����c�B���� ��6����>?"k�j)�1r#�
�x�e�ڶ�cl;��m)�����ܼ	�/�j�C��Y���%��f9$�
��U�E+ܤ�y��o�4�l4��TErf�ϐ�8R��Ƽ�?��6�|�N̍ظn���}GEhnGk�mH�"��
���)+�����z���-H0���b52�U��$�5�ъ�h������?�!����ះ����vF��3�9R�ś���ttSn�J�k�~+�&�<f��ZL�~���s�t=��zU���$j_� Y���⃁%��߃JM3���ٕ$�b�By�����J���|�\��4oO��J����r��#�z�s�
��ǂ|C�k].�E{5���a<�r���=�ν>�.;#�;�/��ݯ%Ҿ�%S.�؝����_N��@���P��+
���h>/�MB:f���%�J�N��~��RW>R�>���f�Y�1�x'
H���Y_�>!�����_>,�U���d�#�'�w��%U�����=^{��D�z���xD�;�jc�ݡܨɶ?���8��Z���(�3^��O�+W���I��/�zb28�⸛�������]��1Hg�y#��V�Q6���\����}&�
C���
endstream
endobj
500 0 obj
<</Type /XObject
/Subtype /Image
/Width 94
/Height 78
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 747>>
stream
����JFIF



��C	!"$"$��C
��N^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���
endstream
endobj
501 0 obj
<</Type /XObject
/Subtype /Image
/Width 82
/Height 94
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 771>>
stream
����JFIF



��C	!"$"$��C
��^R
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���
endstream
endobj
502 0 obj
<</Type /XObject
/Subtype /Image
/Width 350
/Height 96
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 7775>>
stream
����JFIF



��C	!"$"$��C
��`
^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�&y���[$��XZ����d�ģ�"�zW.+��C���W��*5+>Zqm��W��x��-,��z�ŏ銢�5�	��_a|�^6ʠ웗��;�2<\��K�zu���XC�Ŷ�{���Ň�-�`���C��w˭m�����;����5rl]5~[��SN�l���K��{��>��Z澒�XU����.Qqv���(�QEQEQEQEQEQEQEQEQEQEQE�|g�/ĺ���mi�S���T�13
�T`g��=Z�4�.��O�o��E�J�B�V��I��r������3�d�).<O����U����l�$?�}^/�&��O��]H���>�W5����ER((��(��@j���Z�֏sw D=X�z���+[i.&m�ƥ��J����i	XT�(��5�|E��)���%��_��zYn_,d��+w��C�k�U�4f���#S����ElxgB��nx�v�y&?A�_��x���ns������J�
���Q�ceu}8����`:}Oj�ygi`Lw��pc���}ۿ�ƶ|G����6���K�����g���k\m6�1|�[���d���<��:������]_�oE��NN@�RQK^C��4�)p��!�ubJ��q�k�G�z-�X���'��+�3�~�����b�R����Z�������֣ua1H�o,�yA���:W�`q�1Խ�uv�kF��)R�,�QE�fQU����W�����i%p�?@(�7�~5xLܰ��Rᴄ��}6
��
�ho
v蚹���5;
��z+�to�
��Ev��������c�W��zΕ�ح[�۟��}��4�	�_�����S�xGKMK[�x`yDI�2圂q��
7(� ���<!����.�"���?�z��v/��[��.!IDo�˸���4
�-QX�%�>��a>��[�)���,�E��W��_�!op�ZX귊��bƨ�鹁���`m#ר�"��?x>��b���lT������'��L�5�'^���G���ݎ7����#�>ƕ�;�4QE
)��Q��ȱ���1�Ԛ�<E���1hƦڌ�pc�O3�8_ր��TW�7�
ᬜh�����B���k�6��9��4�	���S�R@�H�f+�o�5������ལB�W!?�j��W���ާ�+��9c���C#B�d�eE|���;=ϯ?g���S�]�?�9�3�~�����g���M"�6�P�G���j[�奍�����m���UQ�My�����Y+�>� ଡ଼%����S�s��o��Y;tM\�S����4��>
���ҷ�������2ㄟҝ������ղԁ�����������{�O��Ў��������������<�����p��m{��\��i_��~��W�Y�>���}�����/����?����X��<a�w�˚E�����=\��;��|Ks�<8�vCd�<���=X��SU>���-&�ﴥ�-3�G����Ǯ�.����������<��+鰔���9c?��]�o������O��G�CW���k�-W��BQI@��7>#�đ���8�H�M�𳾭%���oʹ�Χ���ݾ����"��6�������w��t���������a��e��?�K�±����/7�W�����c���r�6���ʰ��,�«v�D���޽>��.졹��ȡ���������ǀ�<�2Kry�N=����[ü�p�O'�E��5��ΰ��UO��h�Uj��&�y��>�{H�W>�t�~�|��|X����L\��jw
~�k��}�?�n�|�����+�
�%����#�ʽ��_��x��7z֠妸|���e�W���?��v>+��Ķ�ɶ�++��}B��ϥ^�m�3��wŸx�(�m���A�./Ƭ=@�c�P1�]c~�~(�u� �: ���\<̮T|S�����֬J���;������}�
T�g��
k1jzE�F�@�<���yV���_U|r�MO�����R��A��g�Ǿ��5���T��j���֭�E��n�b�D�I�S�O�9�x��ozL�t���4��������ŗ­!.A
(y���J�c���o|�����-�����*V彏+�-��R���y�H�z� �_K�c����LJ�ڸ�+���dwl`�����D�%ҵ�MNG��U�0�7)����ρ�
N�)�ծ��C-���y'�_�g8�^��d/#����<{���yc�e��o�ܪ�ӂH�WAw�?x�+v��SҮ$"0�+����(D
�
����/�kzV���si�����p�I�G���WQ�o�w~񽔑��b��m��-�1��z�r?�滿������D�[��X#���ґ��-#����,*�Dlϼ��fx�\Ӽ;�\����h$�c�@�I�TaFz�]��|c&�ⳠZ���-���'�t~>�	\��s�>$��5�t�W�ҕ������㱲��M�z��/�|!�/��4���-�B�����ǏíY�i�;���۱ሲ������������
�E�������������ձ��»R4�=���<�7bR����◌�}&6?�F�㶳���^7���j,5 :���?��־�����ʏ�5�u�-B�#��Xʶ�
�+��\ui|b5/i:{V�����?�w_�ޠo>'�o����P��.�:����?�>+i!�R�̸om�q�⫡����
���P���m�7#Ͻ�+kj��!�>�;��5�,l'���G��1�Q�!_�B�E��Uw��3v�o�@���>�ԥr��7�~0׼]~n��בC
q@�U��O�i�3់�W\i�w�f������#�wa��o����>(�$����U��H���/\�@�>�־��5�#UTQ��0�n��}Ϛ�ូQ���gI���ɏ�mp�9�y���V�h[j�@��'��~ W�WU��������{i��,n2M.fW*> �ֽ�xsT�S��$�����u�B����x��ƾ�T�V+�>]� �ːq�z��|��=�?�OEf-�K��X��*Ez���&ѼC��J���B���u�N�ڹ1vgbIbI�EK{Ay40cr��5
5N.q{����h��
°�v�c0�~'��^k�[�W���f���Xp
��"����4&��ݑ������~���r�?'š��t>[%��/���cQIZn���������m_����hU�.JQr}����*F��ݑ�]_��4�����em��D#�a��Z�7�,t�[�bx�u�i8�O�֦��Uha�W{caQ����9F)�/7�V�Cv�W�����f517��W����5��b*�
p��q�S�^y<�O;�3��X�Z'�[��Y�i$nK1�W��'VΫ&�-8�1�_��i�����º��g�׋�j3\�v?!a
��2��2O���RΩ[�7���͚XY_��:��ګ[{?	X���U��ҁ�8�q�}���E|��W�;��M�$�O�i?���H�|l�<r�����
+A���������Kk(r�ub��I�<��'��o���H�.ˋ{���]�
��p}q^����<������OE���+T�Ԉߡ�Ǐ:ns������D�v��Axnw�������J$�NI�+���u�
���2���H?�Z���9��I��a�������+�<�����ޤ����G0�C�{��>������_èj�k��۞V3��S�О�Z��
��N�$s�i.�p�!�r�����`עGF����(ª�=(�`Q�6���㷂5�(�""�P0�����W]����`���_b��l�p�	'�W�Z������ ��\I1���~�Gp����M����;+���̹e����g�Ԋ�F����cX�B�(�P8W���ZH2kzۯ Gk����W����
(��G��u�ƚn�~�e��s�W
�OmS�>�f��oc���C��E5����_|V�[r�������j~�vF��O�"��Ys�'��W�˩���54�|3�j�@�%����!I�8������Kq;��������k�O�2���A[i"��2A_$v���O�T���������g�Q���A����B�����։g�@�7ډO�rX�:�)2��A8��|u�E�	j:ܛsk
hՏ�_ň�|��_Q�čz�NP�<h}U>A�-w����f�v�����و��Ԍ�C^7,�,�,�Yܖb{�־���,L^�51����{�\���茖�������>Ki�%�gK~;>�~\~5�{��spL�����G�`�׉h6�y����2�\���Z#�Ks�o�Z~����I�u�l�2?���N?
�)`R��R9
���94
��Ǣ��޼W���|��S�[m5׈'�CF'�ҳ|w�
k�z���)sw#���/�zw쭢}�[�5IT �[q����	���dd�=�
���
®"�]���8?���7^��%u})�'�zOǥyD��R4R�GC�R9���Xs���=W�U����ص_�߽?��]��@3�C�����T�sjBŨ�nS�rn�6cϿ������mg+b+�
��q����W�\�ͻ�*�IW�e���C��4�~Ҏ���x8��9��=~Os���i��Uof�t"�
�U4�!��]�j���Pkzl�e�A&Jc��5�'2Ͱ���YE�F���{С����S�$�M3n�Y$>���tQ^,�)�i;��E-QE#
��Y-�a�oq�k����o���<''���W����Y4��y�Ek�N���Ϝα*MQ�MXW�_�d�,���.��>��?�Wӵ�����.<A�h�m>2�K,�2�	��z��~������-���ţx�G�.!���I��L���:�B
��W���_	�5�b���(�k�XT$q|�"�����=G?Z�"b�}#Ep���E�|Gx��"��?�Cy��ݱ*u�9�h�eo�n?Z�2�w�W��?��픍3N�o��X,I��O�]��o������W1YG�������{�On�X.�O�W�K�>�~[i��R��m ~�W�'�}k�G^�?�Z�{��RE
���覾J=*�D�>������e�۹f@B�ר�/����
|?lWk}�9z���]EK--��&���k|t�k��=���/��?\R�w����V�����is���k�?d� g�����?R�G�+�NI�9&����,E��w���^_I&q�(T��ή[Gr��-I���Y�B��־O�_qx�D��^ԴY�J�dB����_jw}��7�47��F�������W|?,L-�Dqٓ�#�����)C��E֒Wҥ�������wS���k�[���Ŵ?�DT��R�����i���ݓ_6~Ҿ9MZ�|+�K�ZY?�y"rQ�\�.3�S|N��.�m.�����PRK����}߯_�sǃ'��f��x�jz��QG}������*	�����w<�}q�;�}��F��6��K;{����G�_q�&�i�����,�B=����!A)�\۰����iI�'�AC�Mx��t,u�+�	��G�����>5�JOx{;ES}l�����A�� ���|},o���Ȅ�+#�"��J����h�-㸂E�):2��R2�+�߃���t�tE4�p
��Q���V^�v#���V�����$�q$R+~EsR�-I�y����\E�uAM����.G��@?R+�?<'aj�؂�W�< �Q��X�_;x��ڷ���5mb2fDQ��{*�šD��k��>o��;��^ޟ�\�K
��\׌��	��񇈭$�̂U��P^�R� �8���^�|A�.���Si�WI%k^��d�0ppN

�Q������#Q����^�A�5Պ0+��2��B��z}יՇ�T��U)�O�%�b�+�"A*k�<���ŭˁy��-����
{@��e���,��~>����t��g�
�x�~����W���%աkI�m�滮���ⰹ�.J��kk���:����l`�L�c�O��Z�o4�g
f���:}Gj��<Z����!�	b����]lAq�RX���5��򼫊i{HK�������U�&y����e�%x�ўQEz-�����]���?���t���7���?�5��7��ք�t�ד����S֥�a��?�#��-G��&�AH
��#���
?�G({���F�~���pƱD���
T`
�2�Ԛ����_f��V�_��ό�"�-_r;Xl��
�??z�(���_�J��d�H��ܝ�PFF(���>h��̚��8�/dm�G�t���q�^S��������Z� ��\���O�_YQN�|x>|C-��F����c�B���� ��6����>?"k�j)�1r#�
�x�e�ڶ�cl;��m)�����ܼ	�/�j�C��Y���%��f9$�
��U�E+ܤ�y��o�4�l4��TErf�ϐ�8R��Ƽ�?��6�|�N̍ظn���}GEhnGk�mH�"��
���)+�����z���-H0���b52�U��$�5�ъ�h������?�!����ះ����vF��3�9R�ś���ttSn�J�k�~+�&�<f��ZL�~���s�t=��zU���$j_� Y���⃁%��߃JM3���ٕ$�b�By�����J���|�\��4oO��J����r��#�z�s�
��ǂ|C�k].�E{5���a<�r���=�ν>�.;#�;�/��ݯ%Ҿ�%S.�؝����_N��@���P��+
���h>/�MB:f���%�J�N��~��RW>R�>���f�Y�1�x'
H���Y_�>!�����_>,�U���d�#�'�w��%U�����=^{��D�z���xD�;�jc�ݡܨɶ?���8��Z���(�3^��O�+W���I��/�zb28�⸛�������]��1Hg�y#��V�Q6���\����}&�
C���
endstream
endobj
503 0 obj
<</Type /XObject
/Subtype /Image
/Width 67
/Height 94
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1530>>
stream
����JFIF



��C	!"$"$��C
��^C
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�(��(��(��(��(���.~|,�<ei�ŨMd�(��B��d��F7g��io�ڝ����W���A$��rG*���A�����G�뭟��E]g���$������x��4G�?�7m�o������ݵ��
���U�e
��4G�?�7m�o������ݵ��
���U�e
��4G�?�7m�o��thx�����/��n�줹�&yVt+���n��������k���E�e�`���ִ
�uQ@%�q�ɴx������TU�~Ϳ�@��`[o�W'�q�ɴx������TU�~Ϳ�@��`[o�P��EQEW�>���x���C�I�k���G���o�(�5�}]EP�~��m%����Uu��o��?����@����m%����Uu��o��?����@
�4QEQE���"�2��P��kZ���Q�?��[�_�
�Mk@WQE
�_���G�뭟��E[����?m�+�P\k�\3G�[��%�j�v' �Y�W��O�_xC\�����h�I,�RQ�ȲVTg��x�1W������-���>�����?�1i����	O��b�?�6?�ኾ���m����|,������2�����/�J|3�C��������g��-#�c������g��g������G�1W������-���>�����?�1i����_?ࡾ/�����ҾI"p�ط�py��U����3���o�G����������/>'����+��l��/�!x��RN%9�Gz�Z(��
(��
(��
(��
(��
(��?��
endstream
endobj
504 0 obj
<</Type /XObject
/Subtype /Image
/Width 350
/Height 96
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 7775>>
stream
����JFIF



��C	!"$"$��C
��`
^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�&y���[$��XZ����d�ģ�"�zW.+��C���W��*5+>Zqm��W��x��-,��z�ŏ銢�5�	��_a|�^6ʠ웗��;�2<\��K�zu���XC�Ŷ�{���Ň�-�`���C��w˭m�����;����5rl]5~[��SN�l���K��{��>��Z澒�XU����.Qqv���(�QEQEQEQEQEQEQEQEQEQEQE�|g�/ĺ���mi�S���T�13
�T`g��=Z�4�.��O�o��E�J�B�V��I��r������3�d�).<O����U����l�$?�}^/�&��O��]H���>�W5����ER((��(��@j���Z�֏sw D=X�z���+[i.&m�ƥ��J����i	XT�(��5�|E��)���%��_��zYn_,d��+w��C�k�U�4f���#S����ElxgB��nx�v�y&?A�_��x���ns������J�
���Q�ceu}8����`:}Oj�ygi`Lw��pc���}ۿ�ƶ|G����6���K�����g���k\m6�1|�[���d���<��:������]_�oE��NN@�RQK^C��4�)p��!�ubJ��q�k�G�z-�X���'��+�3�~�����b�R����Z�������֣ua1H�o,�yA���:W�`q�1Խ�uv�kF��)R�,�QE�fQU����W�����i%p�?@(�7�~5xLܰ��Rᴄ��}6
��
�ho
v蚹���5;
��z+�to�
��Ev��������c�W��zΕ�ح[�۟��}��4�	�_�����S�xGKMK[�x`yDI�2圂q��
7(� ���<!����.�"���?�z��v/��[��.!IDo�˸���4
�-QX�%�>��a>��[�)���,�E��W��_�!op�ZX귊��bƨ�鹁���`m#ר�"��?x>��b���lT������'��L�5�'^���G���ݎ7����#�>ƕ�;�4QE
)��Q��ȱ���1�Ԛ�<E���1hƦڌ�pc�O3�8_ր��TW�7�
ᬜh�����B���k�6��9��4�	���S�R@�H�f+�o�5������ལB�W!?�j��W���ާ�+��9c���C#B�d�eE|���;=ϯ?g���S�]�?�9�3�~�����g���M"�6�P�G���j[�奍�����m���UQ�My�����Y+�>� ଡ଼%����S�s��o��Y;tM\�S����4��>
���ҷ�������2ㄟҝ������ղԁ�����������{�O��Ў��������������<�����p��m{��\��i_��~��W�Y�>���}�����/����?����X��<a�w�˚E�����=\��;��|Ks�<8�vCd�<���=X��SU>���-&�ﴥ�-3�G����Ǯ�.����������<��+鰔���9c?��]�o������O��G�CW���k�-W��BQI@��7>#�đ���8�H�M�𳾭%���oʹ�Χ���ݾ����"��6�������w��t���������a��e��?�K�±����/7�W�����c���r�6���ʰ��,�«v�D���޽>��.졹��ȡ���������ǀ�<�2Kry�N=����[ü�p�O'�E��5��ΰ��UO��h�Uj��&�y��>�{H�W>�t�~�|��|X����L\��jw
~�k��}�?�n�|�����+�
�%����#�ʽ��_��x��7z֠妸|���e�W���?��v>+��Ķ�ɶ�++��}B��ϥ^�m�3��wŸx�(�m���A�./Ƭ=@�c�P1�]c~�~(�u� �: ���\<̮T|S�����֬J���;������}�
T�g��
k1jzE�F�@�<���yV���_U|r�MO�����R��A��g�Ǿ��5���T��j���֭�E��n�b�D�I�S�O�9�x��ozL�t���4��������ŗ­!.A
(y���J�c���o|�����-�����*V彏+�-��R���y�H�z� �_K�c����LJ�ڸ�+���dwl`�����D�%ҵ�MNG��U�0�7)����ρ�
N�)�ծ��C-���y'�_�g8�^��d/#����<{���yc�e��o�ܪ�ӂH�WAw�?x�+v��SҮ$"0�+����(D
�
����/�kzV���si�����p�I�G���WQ�o�w~񽔑��b��m��-�1��z�r?�滿������D�[��X#���ґ��-#����,*�Dlϼ��fx�\Ӽ;�\����h$�c�@�I�TaFz�]��|c&�ⳠZ���-���'�t~>�	\��s�>$��5�t�W�ҕ������㱲��M�z��/�|!�/��4���-�B�����ǏíY�i�;���۱ሲ������������
�E�������������ձ��»R4�=���<�7bR����◌�}&6?�F�㶳���^7���j,5 :���?��־�����ʏ�5�u�-B�#��Xʶ�
�+��\ui|b5/i:{V�����?�w_�ޠo>'�o����P��.�:����?�>+i!�R�̸om�q�⫡����
���P���m�7#Ͻ�+kj��!�>�;��5�,l'���G��1�Q�!_�B�E��Uw��3v�o�@���>�ԥr��7�~0׼]~n��בC
q@�U��O�i�3់�W\i�w�f������#�wa��o����>(�$����U��H���/\�@�>�־��5�#UTQ��0�n��}Ϛ�ូQ���gI���ɏ�mp�9�y���V�h[j�@��'��~ W�WU��������{i��,n2M.fW*> �ֽ�xsT�S��$�����u�B����x��ƾ�T�V+�>]� �ːq�z��|��=�?�OEf-�K��X��*Ez���&ѼC��J���B���u�N�ڹ1vgbIbI�EK{Ay40cr��5
5N.q{����h��
°�v�c0�~'��^k�[�W���f���Xp
��"����4&��ݑ������~���r�?'š��t>[%��/���cQIZn���������m_����hU�.JQr}����*F��ݑ�]_��4�����em��D#�a��Z�7�,t�[�bx�u�i8�O�֦��Uha�W{caQ����9F)�/7�V�Cv�W�����f517��W����5��b*�
p��q�S�^y<�O;�3��X�Z'�[��Y�i$nK1�W��'VΫ&�-8�1�_��i�����º��g�׋�j3\�v?!a
��2��2O���RΩ[�7���͚XY_��:��ګ[{?	X���U��ҁ�8�q�}���E|��W�;��M�$�O�i?���H�|l�<r�����
+A���������Kk(r�ub��I�<��'��o���H�.ˋ{���]�
��p}q^����<������OE���+T�Ԉߡ�Ǐ:ns������D�v��Axnw�������J$�NI�+���u�
���2���H?�Z���9��I��a�������+�<�����ޤ����G0�C�{��>������_èj�k��۞V3��S�О�Z��
��N�$s�i.�p�!�r�����`עGF����(ª�=(�`Q�6���㷂5�(�""�P0�����W]����`���_b��l�p�	'�W�Z������ ��\I1���~�Gp����M����;+���̹e����g�Ԋ�F����cX�B�(�P8W���ZH2kzۯ Gk����W����
(��G��u�ƚn�~�e��s�W
�OmS�>�f��oc���C��E5����_|V�[r�������j~�vF��O�"��Ys�'��W�˩���54�|3�j�@�%����!I�8������Kq;��������k�O�2���A[i"��2A_$v���O�T���������g�Q���A����B�����։g�@�7ډO�rX�:�)2��A8��|u�E�	j:ܛsk
hՏ�_ň�|��_Q�čz�NP�<h}U>A�-w����f�v�����و��Ԍ�C^7,�,�,�Yܖb{�־���,L^�51����{�\���茖�������>Ki�%�gK~;>�~\~5�{��spL�����G�`�׉h6�y����2�\���Z#�Ks�o�Z~����I�u�l�2?���N?
�)`R��R9
���94
��Ǣ��޼W���|��S�[m5׈'�CF'�ҳ|w�
k�z���)sw#���/�zw쭢}�[�5IT �[q����	���dd�=�
���
®"�]���8?���7^��%u})�'�zOǥyD��R4R�GC�R9���Xs���=W�U����ص_�߽?��]��@3�C�����T�sjBŨ�nS�rn�6cϿ������mg+b+�
��q����W�\�ͻ�*�IW�e���C��4�~Ҏ���x8��9��=~Os���i��Uof�t"�
�U4�!��]�j���Pkzl�e�A&Jc��5�'2Ͱ���YE�F���{С����S�$�M3n�Y$>���tQ^,�)�i;��E-QE#
��Y-�a�oq�k����o���<''���W����Y4��y�Ek�N���Ϝα*MQ�MXW�_�d�,���.��>��?�Wӵ�����.<A�h�m>2�K,�2�	��z��~������-���ţx�G�.!���I��L���:�B
��W���_	�5�b���(�k�XT$q|�"�����=G?Z�"b�}#Ep���E�|Gx��"��?�Cy��ݱ*u�9�h�eo�n?Z�2�w�W��?��픍3N�o��X,I��O�]��o������W1YG�������{�On�X.�O�W�K�>�~[i��R��m ~�W�'�}k�G^�?�Z�{��RE
���覾J=*�D�>������e�۹f@B�ר�/����
|?lWk}�9z���]EK--��&���k|t�k��=���/��?\R�w����V�����is���k�?d� g�����?R�G�+�NI�9&����,E��w���^_I&q�(T��ή[Gr��-I���Y�B��־O�_qx�D��^ԴY�J�dB����_jw}��7�47��F�������W|?,L-�Dqٓ�#�����)C��E֒Wҥ�������wS���k�[���Ŵ?�DT��R�����i���ݓ_6~Ҿ9MZ�|+�K�ZY?�y"rQ�\�.3�S|N��.�m.�����PRK����}߯_�sǃ'��f��x�jz��QG}������*	�����w<�}q�;�}��F��6��K;{����G�_q�&�i�����,�B=����!A)�\۰����iI�'�AC�Mx��t,u�+�	��G�����>5�JOx{;ES}l�����A�� ���|},o���Ȅ�+#�"��J����h�-㸂E�):2��R2�+�߃���t�tE4�p
��Q���V^�v#���V�����$�q$R+~EsR�-I�y����\E�uAM����.G��@?R+�?<'aj�؂�W�< �Q��X�_;x��ڷ���5mb2fDQ��{*�šD��k��>o��;��^ޟ�\�K
��\׌��	��񇈭$�̂U��P^�R� �8���^�|A�.���Si�WI%k^��d�0ppN

�Q������#Q����^�A�5Պ0+��2��B��z}יՇ�T��U)�O�%�b�+�"A*k�<���ŭˁy��-����
{@��e���,��~>����t��g�
�x�~����W���%աkI�m�滮���ⰹ�.J��kk���:����l`�L�c�O��Z�o4�g
f���:}Gj��<Z����!�	b����]lAq�RX���5��򼫊i{HK�������U�&y����e�%x�ўQEz-�����]���?���t���7���?�5��7��ք�t�ד����S֥�a��?�#��-G��&�AH
��#���
?�G({���F�~���pƱD���
T`
�2�Ԛ����_f��V�_��ό�"�-_r;Xl��
�??z�(���_�J��d�H��ܝ�PFF(���>h��̚��8�/dm�G�t���q�^S��������Z� ��\���O�_YQN�|x>|C-��F����c�B���� ��6����>?"k�j)�1r#�
�x�e�ڶ�cl;��m)�����ܼ	�/�j�C��Y���%��f9$�
��U�E+ܤ�y��o�4�l4��TErf�ϐ�8R��Ƽ�?��6�|�N̍ظn���}GEhnGk�mH�"��
���)+�����z���-H0���b52�U��$�5�ъ�h������?�!����ះ����vF��3�9R�ś���ttSn�J�k�~+�&�<f��ZL�~���s�t=��zU���$j_� Y���⃁%��߃JM3���ٕ$�b�By�����J���|�\��4oO��J����r��#�z�s�
��ǂ|C�k].�E{5���a<�r���=�ν>�.;#�;�/��ݯ%Ҿ�%S.�؝����_N��@���P��+
���h>/�MB:f���%�J�N��~��RW>R�>���f�Y�1�x'
H���Y_�>!�����_>,�U���d�#�'�w��%U�����=^{��D�z���xD�;�jc�ݡܨɶ?���8��Z���(�3^��O�+W���I��/�zb28�⸛�������]��1Hg�y#��V�Q6���\����}&�
C���
endstream
endobj
505 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1579>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.������t����G�ux�K
G�op���*��:U��d���	��e%{��w��
~̾���z^�S֣�h�}'�������,���#��=��2?����2��=���B��?f�w�z��t{��]+m��V���s���q�
?�x�n��ڃ���9�鶺E�D��d`\#��y<���������_��s���{�xg�)�%G�����AZ�:��
I��}�~.�r��Զ2���D9���U������u����4����ag�������ޖA����|c�?�~3���������Vxg���	�����Ա�5����|b��5]�ˡY�;v�)K�{��?R��}a�/�#��]�H~�sx�QQ>�t@.��%[���NOz��{�'��7���w����ڼ'����g���i��.:�)�%G�����AZ��;�LҾ|?��.�����"��v
������$����;��5M?D���_V������m-��,hr�گ|P���?|E�}׆<C��KIʲȒ��S��HẌ�@4|�[��+�
��<uwr��7]܏�ܰ�o�UF
#�'"��m������Er|>�<+rS"��\|��d;K
�I�⾸������l�=���Ӭ�ArG���I䓚��O������ȴ�x��:��S���;���Ƕ�A �(�-���;�$Y"����e# �¼3����g���i��.:����f4X����"(
Ue ;+��'�-�_���}oú����M��,w�DV�� �€=�ľ�׉��wH֣��B���w<���>Շ�
��g�O������Ί�?�S�,��i���[�§�Y�D����"���+���8��T�?�x3�V��Ekxk�����O�
�Z,�(Id�����E 1E�kv���
endstream
endobj
506 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
507 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
508 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
509 0 obj
<</Type /XObject
/Subtype /Image
/Width 48
/Height 62
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1191>>
stream
����JFIF



��C	!"$"$��C
��>0
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.��������<M�É���U�����ԺmɆ]��ѹ��=�o�e���L��������{���������G����?ᗼ;�E3��c��4
�TW���/xw��g�����k+�}�d�w�%����XӴ�&�HV���@�܀�c�8�n~ҟ�T~�����s���?�������+^�@Q@xO���<ω��ӿ�\u���?��>&��N��q��iO�*?��g?�
׹��������:�C���qY�Zx����C���X�Wm�����=����J��������(z��?�G�/����P�?��€=*�'����g���i��.:�?�}������������E�x�������wR�Դ�{���b���>���������<0��_��p1hSP���c'�T88'ڰ��S�,��i���[���@g�*���M<��+o�"��T�?�x3�V��EvtP�
��g�O������o
x7��i�7�]E�e	,�~��H��(�#=�n�@��
endstream
endobj
510 0 obj
<</Type /XObject
/Subtype /Image
/Width 55
/Height 78
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 1739>>
stream
����JFIF



��C	!"$"$��C
��N7
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�(��(��(��(���5�h��~����j#��K�9Yc�'dd�����P?���<O��2�MK�s�ȱ�/�-?�	+���R�!�;L���Q��5�+X�2Oql�ƙ8f�rEO�O�2"��5�gF�-��{�����l-
]�v�T9Y- K��VG���⼫�	��JM[�w�u�����}�N�W��æOh،z�E���ſ�9������T�ρ����R����<�d��/�r.��[�I�qָ���|I��M��?�����H�� b��)��p�@��|����Go�#��S��
��,k�p�Ͷ&��>�΀8���]�|I�D���R�S�&��Isu)�F;��xŠ���?���?�]�?��J(����c�_�8Z�W�����"ǀ��p���$��(��c���i�J���U#9WR�~F�!�X5��V�#��)����堐��Cu8<��C����lߏk��._�N��ŋ����A���+���Z�;Rҵ[[+�B���
B#=��Dʷ�e'��2(�#�'�H�
�~�$խ���_�%�0������9����j����Z����?�[V�oZx�ᯇ�Kf�c����T��@�t㺰e�+C��%k�����m@O�ɵ�����L�Q�ɵ�����L�P?���"ǀ��p���$�h��s�K?
kw^���_��F��B6�����$
޼{��ҼC�x'³xsÚ��s����-l-���$r���Fp3�����*ѱ�������J��s�v��[�w<��.���w��jw
�e9�`?x����>����i<o�ڛm/S��}&q�1:F�
�L)�����D�N�%��{�F�>���?�?����﫟�D�	a�|L�e��|�&K]O�a�F�3�_ވ�F�2Or�{�?�J�?�q��ھ~������F��?�����*���@�T��[�7���q}��H<���ٽJ�d�zPk�ɵ�����L�U���G����C�5�*�K��k�%���*q!F��㡢�=��(��(��(��(���
endstream
endobj
511 0 obj
<</Type /XObject
/Subtype /Image
/Width 350
/Height 96
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Filter /DCTDecode
/Length 7775>>
stream
����JFIF



��C	!"$"$��C
��`
^
"

��







	
���

}
!1AQa"q2���#B��R��$3br�	
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������










	
���

w
!1AQaq"2�B����	#3R�br�
$4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
?�.�&y���[$��XZ����d�ģ�"�zW.+��C���W��*5+>Zqm��W��x��-,��z�ŏ銢�5�	��_a|�^6ʠ웗��;�2<\��K�zu���XC�Ŷ�{���Ň�-�`���C��w˭m�����;����5rl]5~[��SN�l���K��{��>��Z澒�XU����.Qqv���(�QEQEQEQEQEQEQEQEQEQEQE�|g�/ĺ���mi�S���T�13
�T`g��=Z�4�.��O�o��E�J�B�V��I��r������3�d�).<O����U����l�$?�}^/�&��O��]H���>�W5����ER((��(��@j���Z�֏sw D=X�z���+[i.&m�ƥ��J����i	XT�(��5�|E��)���%��_��zYn_,d��+w��C�k�U�4f���#S����ElxgB��nx�v�y&?A�_��x���ns������J�
���Q�ceu}8����`:}Oj�ygi`Lw��pc���}ۿ�ƶ|G����6���K�����g���k\m6�1|�[���d���<��:������]_�oE��NN@�RQK^C��4�)p��!�ubJ��q�k�G�z-�X���'��+�3�~�����b�R����Z�������֣ua1H�o,�yA���:W�`q�1Խ�uv�kF��)R�,�QE�fQU����W�����i%p�?@(�7�~5xLܰ��Rᴄ��}6
��
�ho
v蚹���5;
��z+�to�
��Ev��������c�W��zΕ�ح[�۟��}��4�	�_�����S�xGKMK[�x`yDI�2圂q��
7(� ���<!����.�"���?�z��v/��[��.!IDo�˸���4
�-QX�%�>��a>��[�)���,�E��W��_�!op�ZX귊��bƨ�鹁���`m#ר�"��?x>��b���lT������'��L�5�'^���G���ݎ7����#�>ƕ�;�4QE
)��Q��ȱ���1�Ԛ�<E���1hƦڌ�pc�O3�8_ր��TW�7�
ᬜh�����B���k�6��9��4�	���S�R@�H�f+�o�5������ལB�W!?�j��W���ާ�+��9c���C#B�d�eE|���;=ϯ?g���S�]�?�9�3�~�����g���M"�6�P�G���j[�奍�����m���UQ�My�����Y+�>� ଡ଼%����S�s��o��Y;tM\�S����4��>
���ҷ�������2ㄟҝ������ղԁ�����������{�O��Ў��������������<�����p��m{��\��i_��~��W�Y�>���}�����/����?����X��<a�w�˚E�����=\��;��|Ks�<8�vCd�<���=X��SU>���-&�ﴥ�-3�G����Ǯ�.����������<��+鰔���9c?��]�o������O��G�CW���k�-W��BQI@��7>#�đ���8�H�M�𳾭%���oʹ�Χ���ݾ����"��6�������w��t���������a��e��?�K�±����/7�W�����c���r�6���ʰ��,�«v�D���޽>��.졹��ȡ���������ǀ�<�2Kry�N=����[ü�p�O'�E��5��ΰ��UO��h�Uj��&�y��>�{H�W>�t�~�|��|X����L\��jw
~�k��}�?�n�|�����+�
�%����#�ʽ��_��x��7z֠妸|���e�W���?��v>+��Ķ�ɶ�++��}B��ϥ^�m�3��wŸx�(�m���A�./Ƭ=@�c�P1�]c~�~(�u� �: ���\<̮T|S�����֬J���;������}�
T�g��
k1jzE�F�@�<���yV���_U|r�MO�����R��A��g�Ǿ��5���T��j���֭�E��n�b�D�I�S�O�9�x��ozL�t���4��������ŗ­!.A
(y���J�c���o|�����-�����*V彏+�-��R���y�H�z� �_K�c����LJ�ڸ�+���dwl`�����D�%ҵ�MNG��U�0�7)����ρ�
N�)�ծ��C-���y'�_�g8�^��d/#����<{���yc�e��o�ܪ�ӂH�WAw�?x�+v��SҮ$"0�+����(D
�
����/�kzV���si�����p�I�G���WQ�o�w~񽔑��b��m��-�1��z�r?�滿������D�[��X#���ґ��-#����,*�Dlϼ��fx�\Ӽ;�\����h$�c�@�I�TaFz�]��|c&�ⳠZ���-���'�t~>�	\��s�>$��5�t�W�ҕ������㱲��M�z��/�|!�/��4���-�B�����ǏíY�i�;���۱ሲ������������
�E�������������ձ��»R4�=���<�7bR����◌�}&6?�F�㶳���^7���j,5 :���?��־�����ʏ�5�u�-B�#��Xʶ�
�+��\ui|b5/i:{V�����?�w_�ޠo>'�o����P��.�:����?�>+i!�R�̸om�q�⫡����
���P���m�7#Ͻ�+kj��!�>�;��5�,l'���G��1�Q�!_�B�E��Uw��3v�o�@���>�ԥr��7�~0׼]~n��בC
q@�U��O�i�3់�W\i�w�f������#�wa��o����>(�$����U��H���/\�@�>�־��5�#UTQ��0�n��}Ϛ�ូQ���gI���ɏ�mp�9�y���V�h[j�@��'��~ W�WU��������{i��,n2M.fW*> �ֽ�xsT�S��$�����u�B����x��ƾ�T�V+�>]� �ːq�z��|��=�?�OEf-�K��X��*Ez���&ѼC��J���B���u�N�ڹ1vgbIbI�EK{Ay40cr��5
5N.q{����h��
°�v�c0�~'��^k�[�W���f���Xp
��"����4&��ݑ������~���r�?'š��t>[%��/���cQIZn���������m_����hU�.JQr}����*F��ݑ�]_��4�����em��D#�a��Z�7�,t�[�bx�u�i8�O�֦��Uha�W{caQ����9F)�/7�V�Cv�W�����f517��W����5��b*�
p��q�S�^y<�O;�3��X�Z'�[��Y�i$nK1�W��'VΫ&�-8�1�_��i�����º��g�׋�j3\�v?!a
��2��2O���RΩ[�7���͚XY_��:��ګ[{?	X���U��ҁ�8�q�}���E|��W�;��M�$�O�i?���H�|l�<r�����
+A���������Kk(r�ub��I�<��'��o���H�.ˋ{���]�
��p}q^����<������OE���+T�Ԉߡ�Ǐ:ns������D�v��Axnw�������J$�NI�+���u�
���2���H?�Z���9��I��a�������+�<�����ޤ����G0�C�{��>������_èj�k��۞V3��S�О�Z��
��N�$s�i.�p�!�r�����`עGF����(ª�=(�`Q�6���㷂5�(�""�P0�����W]����`���_b��l�p�	'�W�Z������ ��\I1���~�Gp����M����;+���̹e����g�Ԋ�F����cX�B�(�P8W���ZH2kzۯ Gk����W����
(��G��u�ƚn�~�e��s�W
�OmS�>�f��oc���C��E5����_|V�[r�������j~�vF��O�"��Ys�'��W�˩���54�|3�j�@�%����!I�8������Kq;��������k�O�2���A[i"��2A_$v���O�T���������g�Q���A����B�����։g�@�7ډO�rX�:�)2��A8��|u�E�	j:ܛsk
hՏ�_ň�|��_Q�čz�NP�<h}U>A�-w����f�v�����و��Ԍ�C^7,�,�,�Yܖb{�־���,L^�51����{�\���茖�������>Ki�%�gK~;>�~\~5�{��spL�����G�`�׉h6�y����2�\���Z#�Ks�o�Z~����I�u�l�2?���N?
�)`R��R9
���94
��Ǣ��޼W���|��S�[m5׈'�CF'�ҳ|w�
k�z���)sw#���/�zw쭢}�[�5IT �[q����	���dd�=�
���
®"�]���8?���7^��%u})�'�zOǥyD��R4R�GC�R9���Xs���=W�U����ص_�߽?��]��@3�C�����T�sjBŨ�nS�rn�6cϿ������mg+b+�
��q����W�\�ͻ�*�IW�e���C��4�~Ҏ���x8��9��=~Os���i��Uof�t"�
�U4�!��]�j���Pkzl�e�A&Jc��5�'2Ͱ���YE�F���{С����S�$�M3n�Y$>���tQ^,�)�i;��E-QE#
��Y-�a�oq�k����o���<''���W����Y4��y�Ek�N���Ϝα*MQ�MXW�_�d�,���.��>��?�Wӵ�����.<A�h�m>2�K,�2�	��z��~������-���ţx�G�.!���I��L���:�B
��W���_	�5�b���(�k�XT$q|�"�����=G?Z�"b�}#Ep���E�|Gx��"��?�Cy��ݱ*u�9�h�eo�n?Z�2�w�W��?��픍3N�o��X,I��O�]��o������W1YG�������{�On�X.�O�W�K�>�~[i��R��m ~�W�'�}k�G^�?�Z�{��RE
���覾J=*�D�>������e�۹f@B�ר�/����
|?lWk}�9z���]EK--��&���k|t�k��=���/��?\R�w����V�����is���k�?d� g�����?R�G�+�NI�9&����,E��w���^_I&q�(T��ή[Gr��-I���Y�B��־O�_qx�D��^ԴY�J�dB����_jw}��7�47��F�������W|?,L-�Dqٓ�#�����)C��E֒Wҥ�������wS���k�[���Ŵ?�DT��R�����i���ݓ_6~Ҿ9MZ�|+�K�ZY?�y"rQ�\�.3�S|N��.�m.�����PRK����}߯_�sǃ'��f��x�jz��QG}������*	�����w<�}q�;�}��F��6��K;{����G�_q�&�i�����,�B=����!A)�\۰����iI�'�AC�Mx��t,u�+�	��G�����>5�JOx{;ES}l�����A�� ���|},o���Ȅ�+#�"��J����h�-㸂E�):2��R2�+�߃���t�tE4�p
��Q���V^�v#���V�����$�q$R+~EsR�-I�y����\E�uAM����.G��@?R+�?<'aj�؂�W�< �Q��X�_;x��ڷ���5mb2fDQ��{*�šD��k��>o��;��^ޟ�\�K
��\׌��	��񇈭$�̂U��P^�R� �8���^�|A�.���Si�WI%k^��d�0ppN

�Q������#Q����^�A�5Պ0+��2��B��z}יՇ�T��U)�O�%�b�+�"A*k�<���ŭˁy��-����
{@��e���,��~>����t��g�
�x�~����W���%աkI�m�滮���ⰹ�.J��kk���:����l`�L�c�O��Z�o4�g
f���:}Gj��<Z����!�	b����]lAq�RX���5��򼫊i{HK�������U�&y����e�%x�ўQEz-�����]���?���t���7���?�5��7��ք�t�ד����S֥�a��?�#��-G��&�AH
��#���
?�G({���F�~���pƱD���
T`
�2�Ԛ����_f��V�_��ό�"�-_r;Xl��
�??z�(���_�J��d�H��ܝ�PFF(���>h��̚��8�/dm�G�t���q�^S��������Z� ��\���O�_YQN�|x>|C-��F����c�B���� ��6����>?"k�j)�1r#�
�x�e�ڶ�cl;��m)�����ܼ	�/�j�C��Y���%��f9$�
��U�E+ܤ�y��o�4�l4��TErf�ϐ�8R��Ƽ�?��6�|�N̍ظn���}GEhnGk�mH�"��
���)+�����z���-H0���b52�U��$�5�ъ�h������?�!����ះ����vF��3�9R�ś���ttSn�J�k�~+�&�<f��ZL�~���s�t=��zU���$j_� Y���⃁%��߃JM3���ٕ$�b�By�����J���|�\��4oO��J����r��#�z�s�
��ǂ|C�k].�E{5���a<�r���=�ν>�.;#�;�/��ݯ%Ҿ�%S.�؝����_N��@���P��+
���h>/�MB:f���%�J�N��~��RW>R�>���f�Y�1�x'
H���Y_�>!�����_>,�U���d�#�'�w��%U�����=^{��D�z���xD�;�jc�ݡܨɶ?���8��Z���(�3^��O�+W���I��/�zb28�⸛�������]��1Hg�y#��V�Q6���\����}&�
C���
endstream
endobj
2 0 obj
<<
/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]
/Font <<
/F1 465 0 R
/F2 0 0 R
/F3 470 0 R
/F4 474 0 R
/F5 478 0 R
/F6 481 0 R
/F7 483 0 R
>>
/XObject <<
/I8 486 0 R
/I21 487 0 R
/I15 488 0 R
/I5 489 0 R
/I9 490 0 R
/I12 491 0 R
/I26 492 0 R
/I10 493 0 R
/I13 494 0 R
/I20 495 0 R
/I17 496 0 R
/I14 497 0 R
/I18 498 0 R
/I24 499 0 R
/I2 500 0 R
/I4 501 0 R
/I25 502 0 R
/I3 503 0 R
/I22 504 0 R
/I11 505 0 R
/I6 506 0 R
/I7 507 0 R
/I19 508 0 R
/I16 509 0 R
/I1 510 0 R
/I23 511 0 R
>>
/ExtGState <<
/GS0 463 0 R
>>
/ColorSpace <<
>>
/Properties <</OC1 461 0 R /OC2 462 0 R>>
/Shading <<
>>
>>
endobj
512 0 obj
<</Title (Cover Page - 10K)
/Parent 615 0 R
/Next 513 0 R
/C [0 0 0]
/Dest [3 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
513 0 obj
<</Title (Table of Contents - 10K)
/Parent 615 0 R
/Prev 512 0 R
/Next 514 0 R
/C [0 0 0]
/Dest [5 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
514 0 obj
<</Title (Forward Looking Statements)
/Parent 615 0 R
/Prev 513 0 R
/Next 515 0 R
/C [0 0 0]
/Dest [7 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
515 0 obj
<</Title (10-K Only - Part I )
/Parent 615 0 R
/Prev 514 0 R
/Next 538 0 R
/First 516 0 R
/Last 537 0 R
/C [0 0 0]
/Dest [9 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
516 0 obj
<</Title (10-K Only - Item 1. Business)
/Parent 515 0 R
/Next 533 0 R
/First 517 0 R
/Last 532 0 R
/C [0 0 0]
/Dest [9 0 R /XYZ 0 742.23 null]
/Count 0>>
endobj
517 0 obj
<</Title (10-K Only - Overview)
/Parent 516 0 R
/Next 518 0 R
/C [0 0 0]
/Dest [9 0 R /XYZ 0 721.23 null]
/Count 0>>
endobj
518 0 obj
<</Title (10-K Only - Our Strategy)
/Parent 516 0 R
/Prev 517 0 R
/Next 519 0 R
/C [0 0 0]
/Dest [11 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
519 0 obj
<</Title (10-K Only - Our Competitive Strengths)
/Parent 516 0 R
/Prev 518 0 R
/Next 520 0 R
/C [0 0 0]
/Dest [11 0 R /XYZ 0 502.23 null]
/Count 0>>
endobj
520 0 obj
<</Title (10-K Only - Products Overview)
/Parent 516 0 R
/Prev 519 0 R
/Next 521 0 R
/C [0 0 0]
/Dest [13 0 R /XYZ 0 502.23 null]
/Count 0>>
endobj
521 0 obj
<</Title (10-K Only - Select Development Projects)
/Parent 516 0 R
/Prev 520 0 R
/Next 522 0 R
/C [0 0 0]
/Dest [17 0 R /XYZ 0 352.07 null]
/Count 0>>
endobj
522 0 obj
<</Title (10-K Only - Major Customers)
/Parent 516 0 R
/Prev 521 0 R
/Next 523 0 R
/C [0 0 0]
/Dest [19 0 R /XYZ 0 514.07 null]
/Count 0>>
endobj
523 0 obj
<</Title (10-K Only - Competition)
/Parent 516 0 R
/Prev 522 0 R
/Next 524 0 R
/C [0 0 0]
/Dest [19 0 R /XYZ 0 270.07 null]
/Count 0>>
endobj
524 0 obj
<</Title (10-K Only - Seasonality)
/Parent 516 0 R
/Prev 523 0 R
/Next 525 0 R
/C [0 0 0]
/Dest [21 0 R /XYZ 0 262.07 null]
/Count 0>>
endobj
525 0 obj
<</Title (10-K Only - Patents, Trademarks, Licenses and Proprietary Property)
/Parent 516 0 R
/Prev 524 0 R
/Next 526 0 R
/C [0 0 0]
/Dest [21 0 R /XYZ 0 214.07 null]
/Count 0>>
endobj
526 0 obj
<</Title (10-K Only - Governmental Regulation)
/Parent 516 0 R
/Prev 525 0 R
/Next 527 0 R
/C [0 0 0]
/Dest [25 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
527 0 obj
<</Title (10-K Only - Service Agreements)
/Parent 516 0 R
/Prev 526 0 R
/Next 528 0 R
/C [0 0 0]
/Dest [35 0 R /XYZ 0 304.23 null]
/Count 0>>
endobj
528 0 obj
<</Title (10-K Only - License & Collaboration Agreements and Acquisitions)
/Parent 516 0 R
/Prev 527 0 R
/Next 529 0 R
/C [0 0 0]
/Dest [37 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
529 0 obj
<</Title (10-K Only - Environmental Matters)
/Parent 516 0 R
/Prev 528 0 R
/Next 530 0 R
/C [0 0 0]
/Dest [37 0 R /XYZ 0 604.23 null]
/Count 0>>
endobj
530 0 obj
<</Title (10-K Only - Employees)
/Parent 516 0 R
/Prev 529 0 R
/Next 531 0 R
/C [0 0 0]
/Dest [37 0 R /XYZ 0 496.23 null]
/Count 0>>
endobj
531 0 obj
<</Title (10-K Only - Information about our Executive Officers)
/Parent 516 0 R
/Prev 530 0 R
/Next 532 0 R
/C [0 0 0]
/Dest [37 0 R /XYZ 0 424.23 null]
/Count 0>>
endobj
532 0 obj
<</Title (10-K Only - Available Information)
/Parent 516 0 R
/Prev 531 0 R
/C [0 0 0]
/Dest [41 0 R /XYZ 0 616.07 null]
/Count 0>>
endobj
533 0 obj
<</Title (10-K Only - Item 1A. Risk Factors)
/Parent 515 0 R
/Prev 516 0 R
/Next 534 0 R
/C [0 0 0]
/Dest [41 0 R /XYZ 0 496.07 null]
/Count 0>>
endobj
534 0 obj
<</Title (10-K Only - Item 1B. Unresolved Staff Comments)
/Parent 515 0 R
/Prev 533 0 R
/Next 535 0 R
/C [0 0 0]
/Dest [99 0 R /XYZ 0 256.67 null]
/Count 0>>
endobj
535 0 obj
<</Title (10-K Only - Item 2. Properties)
/Parent 515 0 R
/Prev 534 0 R
/Next 536 0 R
/C [0 0 0]
/Dest [101 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
536 0 obj
<</Title (10-K Only - Item 3. Legal Proceedings)
/Parent 515 0 R
/Prev 535 0 R
/Next 537 0 R
/C [0 0 0]
/Dest [101 0 R /XYZ 0 436.23 null]
/Count 0>>
endobj
537 0 obj
<</Title (10-K Only - Item 4. Mine Safety Disclosures)
/Parent 515 0 R
/Prev 536 0 R
/C [0 0 0]
/Dest [101 0 R /XYZ 0 388.23 null]
/Count 0>>
endobj
538 0 obj
<</Title (10-K only - Part II)
/Parent 615 0 R
/Prev 515 0 R
/Next 552 0 R
/First 539 0 R
/Last 551 0 R
/C [0 0 0]
/Dest [103 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
539 0 obj
<</Title (10-K Only - Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities)
/Parent 538 0 R
/Next 540 0 R
/C [0 0 0]
/Dest [103 0 R /XYZ 0 742.23 null]
/Count 0>>
endobj
540 0 obj
<</Title (10-K Only - Item 6. Selected Financial Data)
/Parent 538 0 R
/Prev 539 0 R
/Next 541 0 R
/C [0 0 0]
/Dest [107 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
541 0 obj
<</Title (10-K Only - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations)
/Parent 538 0 R
/Prev 540 0 R
/Next 547 0 R
/First 542 0 R
/Last 546 0 R
/C [0 0 0]
/Dest [109 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
542 0 obj
<</Title (Executive Summary - 10-K only)
/Parent 541 0 R
/Next 543 0 R
/C [0 0 0]
/Dest [109 0 R /XYZ 0 575.23 null]
/Count 0>>
endobj
543 0 obj
<</Title (Critical Accounting Estimates - 10-K only)
/Parent 541 0 R
/Prev 542 0 R
/Next 544 0 R
/C [0 0 0]
/Dest [109 0 R /XYZ 0 233.23 null]
/Count 0>>
endobj
544 0 obj
<</Title (Results of Operations - Consolidated Results - 10-K only)
/Parent 541 0 R
/Prev 543 0 R
/Next 545 0 R
/C [0 0 0]
/Dest [123 0 R /XYZ 0 526.07 null]
/Count 0>>
endobj
545 0 obj
<</Title (Results of Operations - Segment Results - 10-K only)
/Parent 541 0 R
/Prev 544 0 R
/Next 546 0 R
/C [0 0 0]
/Dest [131 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
546 0 obj
<</Title (Liquidity and Capital Resources)
/Parent 541 0 R
/Prev 545 0 R
/C [0 0 0]
/Dest [137 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
547 0 obj
<</Title (10-K Only - Item 7A. Quantitative and Qualitative Disclosures about Market Risk)
/Parent 538 0 R
/Prev 541 0 R
/Next 548 0 R
/C [0 0 0]
/Dest [143 0 R /XYZ 0 254.85 null]
/Count 0>>
endobj
548 0 obj
<</Title (10-K Only - Item 8. Financial Statements and Supplementary Data)
/Parent 538 0 R
/Prev 547 0 R
/Next 549 0 R
/C [0 0 0]
/Dest [145 0 R /XYZ 0 496.06 null]
/Count 0>>
endobj
549 0 obj
<</Title (10-K Only - Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure )
/Parent 538 0 R
/Prev 548 0 R
/Next 550 0 R
/C [0 0 0]
/Dest [145 0 R /XYZ 0 448.06 null]
/Count 0>>
endobj
550 0 obj
<</Title (10-K Only - Item 9A. Controls and Procedures)
/Parent 538 0 R
/Prev 549 0 R
/Next 551 0 R
/C [0 0 0]
/Dest [145 0 R /XYZ 0 412.06 null]
/Count 0>>
endobj
551 0 obj
<</Title (10-K Only - Item 9B. Other Information)
/Parent 538 0 R
/Prev 550 0 R
/C [0 0 0]
/Dest [145 0 R /XYZ 0 142.06 null]
/Count 0>>
endobj
552 0 obj
<</Title (10-K only - Part III)
/Parent 615 0 R
/Prev 538 0 R
/Next 558 0 R
/First 553 0 R
/Last 557 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
553 0 obj
<</Title (10-K Only - Item 10. Directors, Executive Officers and Corporate Governance)
/Parent 552 0 R
/Next 554 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 742.23 null]
/Count 0>>
endobj
554 0 obj
<</Title (10-K Only - Item 11. Executive Compensation)
/Parent 552 0 R
/Prev 553 0 R
/Next 555 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 496.23 null]
/Count 0>>
endobj
555 0 obj
<</Title (10-K Only - Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters)
/Parent 552 0 R
/Prev 554 0 R
/Next 556 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 460.23 null]
/Count 0>>
endobj
556 0 obj
<</Title (10-K Only - Item 13. Certain Relationships and Related Transactions, and Director Independence)
/Parent 552 0 R
/Prev 555 0 R
/Next 557 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 226.03 null]
/Count 0>>
endobj
557 0 obj
<</Title (10-K Only - Item 14. Principal Accounting Fees and Services)
/Parent 552 0 R
/Prev 556 0 R
/C [0 0 0]
/Dest [147 0 R /XYZ 0 190.03 null]
/Count 0>>
endobj
558 0 obj
<</Title (10-K Only - Part IV)
/Parent 615 0 R
/Prev 552 0 R
/Next 597 0 R
/First 559 0 R
/Last 573 0 R
/C [0 0 0]
/Dest [149 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
559 0 obj
<</Title (10-K Only - Item 15. Exhibits, Financial Statement Schedules)
/Parent 558 0 R
/Next 562 0 R
/First 560 0 R
/Last 561 0 R
/C [0 0 0]
/Dest [149 0 R /XYZ 0 742.23 null]
/Count 0>>
endobj
560 0 obj
<</Title (10-K Only - Schedule II - Valuation and Qualifying Accounts)
/Parent 559 0 R
/Next 561 0 R
/C [0 0 0]
/Dest [149 0 R /XYZ 0 571.23 null]
/Count 0>>
endobj
561 0 obj
<</Title (Item 6. Exhibit Index)
/Parent 559 0 R
/Prev 560 0 R
/C [0 0 0]
/Dest [149 0 R /XYZ 0 374.03 null]
/Count 0>>
endobj
562 0 obj
<</Title (10-K Only - Item 16. Form 10-K Summary)
/Parent 558 0 R
/Prev 559 0 R
/Next 563 0 R
/C [0 0 0]
/Dest [155 0 R /XYZ 0 513.40 null]
/Count 0>>
endobj
563 0 obj
<</Title (Signatures)
/Parent 558 0 R
/Prev 562 0 R
/Next 564 0 R
/C [0 0 0]
/Dest [157 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
564 0 obj
<</Title (10-K Only - Certifications)
/Parent 558 0 R
/Prev 563 0 R
/Next 565 0 R
/C [0 0 0]
/Dest [159 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
565 0 obj
<</Title (10-K Only - Index to the Financial Statements)
/Parent 558 0 R
/Prev 564 0 R
/Next 566 0 R
/C [0 0 0]
/Dest [161 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
566 0 obj
<</Title (10-K Only - Management's Report on Internal Control over Financial Reporting)
/Parent 558 0 R
/Prev 565 0 R
/Next 567 0 R
/C [0 0 0]
/Dest [163 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
567 0 obj
<</Title (10-K Only - PwC Opinion)
/Parent 558 0 R
/Prev 566 0 R
/Next 568 0 R
/C [0 0 0]
/Dest [165 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
568 0 obj
<</Title (Consolidated Balance Sheets - Endo International plc)
/Parent 558 0 R
/Prev 567 0 R
/Next 569 0 R
/C [0 0 0]
/Dest [173 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
569 0 obj
<</Title (Consolidated Statements of Operations - Endo International plc)
/Parent 558 0 R
/Prev 568 0 R
/Next 570 0 R
/C [0 0 0]
/Dest [175 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
570 0 obj
<</Title (Consolidated Statements of Comprehensive Income - Endo International plc)
/Parent 558 0 R
/Prev 569 0 R
/Next 571 0 R
/C [0 0 0]
/Dest [177 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
571 0 obj
<</Title (Consolidated Statements of Shareholder's Equity - Endo International plc)
/Parent 558 0 R
/Prev 570 0 R
/Next 572 0 R
/C [0 0 0]
/Dest [179 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
572 0 obj
<</Title (Consolidated Statements of Cash Flows - Endo International plc)
/Parent 558 0 R
/Prev 571 0 R
/Next 573 0 R
/C [0 0 0]
/Dest [181 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
573 0 obj
<</Title (Notes to Consolidated Financial Statements)
/Parent 558 0 R
/Prev 572 0 R
/First 574 0 R
/Last 596 0 R
/C [0 0 0]
/Dest [183 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
574 0 obj
<</Title (Note 1. Description of Business - 10-K Only)
/Parent 573 0 R
/Next 575 0 R
/C [0 0 0]
/Dest [183 0 R /XYZ 0 725.23 null]
/Count 0>>
endobj
575 0 obj
<</Title (Note 2. Summary of Significant Accounting Policies - 10-K only)
/Parent 573 0 R
/Prev 574 0 R
/Next 576 0 R
/C [0 0 0]
/Dest [183 0 R /XYZ 0 632.23 null]
/Count 0>>
endobj
576 0 obj
<</Title (Note 3. Discontinued Operations and Divestitures)
/Parent 573 0 R
/Prev 575 0 R
/Next 577 0 R
/C [0 0 0]
/Dest [199 0 R /XYZ 0 580.07 null]
/Count 0>>
endobj
577 0 obj
<</Title (Note 4. Restructuring)
/Parent 573 0 R
/Prev 576 0 R
/Next 578 0 R
/C [0 0 0]
/Dest [201 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
578 0 obj
<</Title (Note 5. Segment Results)
/Parent 573 0 R
/Prev 577 0 R
/Next 579 0 R
/C [0 0 0]
/Dest [205 0 R /XYZ 0 588.07 null]
/Count 0>>
endobj
579 0 obj
<</Title (Note 6. Fair Value Measurements)
/Parent 573 0 R
/Prev 578 0 R
/Next 580 0 R
/C [0 0 0]
/Dest [211 0 R /XYZ 0 594.07 null]
/Count 0>>
endobj
580 0 obj
<</Title (Note 7. Inventories)
/Parent 573 0 R
/Prev 579 0 R
/Next 581 0 R
/C [0 0 0]
/Dest [217 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
581 0 obj
<</Title (Note 8. Leases)
/Parent 573 0 R
/Prev 580 0 R
/Next 582 0 R
/C [0 0 0]
/Dest [217 0 R /XYZ 0 554.63 null]
/Count 0>>
endobj
582 0 obj
<</Title (Note 9. Property, Plant and Equipment - 10-K Only)
/Parent 573 0 R
/Prev 581 0 R
/Next 583 0 R
/C [0 0 0]
/Dest [223 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
583 0 obj
<</Title (Note 10. Goodwill and Other Intangibles)
/Parent 573 0 R
/Prev 582 0 R
/Next 584 0 R
/C [0 0 0]
/Dest [225 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
584 0 obj
<</Title (Note 11. License and Collaboration Agreements)
/Parent 573 0 R
/Prev 583 0 R
/Next 585 0 R
/C [0 0 0]
/Dest [231 0 R /XYZ 0 227.07 null]
/Count 0>>
endobj
585 0 obj
<</Title (Note 12. Contract Assets and Liabilities)
/Parent 573 0 R
/Prev 584 0 R
/Next 586 0 R
/C [0 0 0]
/Dest [233 0 R /XYZ 0 322.06 null]
/Count 0>>
endobj
586 0 obj
<</Title (Note 13. Accounts Payable & Accrued Expenses)
/Parent 573 0 R
/Prev 585 0 R
/Next 587 0 R
/C [0 0 0]
/Dest [235 0 R /XYZ 0 518.87 null]
/Count 0>>
endobj
587 0 obj
<</Title (Note 14. Debt)
/Parent 573 0 R
/Prev 586 0 R
/Next 588 0 R
/C [0 0 0]
/Dest [237 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
588 0 obj
<</Title (Note 15. Commitments and Contingencies)
/Parent 573 0 R
/Prev 587 0 R
/Next 589 0 R
/C [0 0 0]
/Dest [243 0 R /XYZ 0 203.47 null]
/Count 0>>
endobj
589 0 obj
<</Title (Note 16. Other Comprehensive Income)
/Parent 573 0 R
/Prev 588 0 R
/Next 590 0 R
/C [0 0 0]
/Dest [259 0 R /XYZ 0 161.06 null]
/Count 0>>
endobj
590 0 obj
<</Title (Note 17. Shareholders' Equity - 10-K Only)
/Parent 573 0 R
/Prev 589 0 R
/Next 591 0 R
/C [0 0 0]
/Dest [261 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
591 0 obj
<</Title (Note 18. Share-based Compensation - 10-K only)
/Parent 573 0 R
/Prev 590 0 R
/Next 592 0 R
/C [0 0 0]
/Dest [261 0 R /XYZ 0 413.23 null]
/Count 0>>
endobj
592 0 obj
<</Title (Note 19. Other Income \(Expense\), Net)
/Parent 573 0 R
/Prev 591 0 R
/Next 593 0 R
/C [0 0 0]
/Dest [269 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
593 0 obj
<</Title (Note 20. Income Taxes - 10-K Only)
/Parent 573 0 R
/Prev 592 0 R
/Next 594 0 R
/C [0 0 0]
/Dest [269 0 R /XYZ 0 536.43 null]
/Count 0>>
endobj
594 0 obj
<</Title (Note 21. Net Income \(Loss\) Per Share)
/Parent 573 0 R
/Prev 593 0 R
/Next 595 0 R
/C [0 0 0]
/Dest [279 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
595 0 obj
<</Title (Note 22. Savings and Investment Plan and Deferred Compensation Plans - 10-K Only)
/Parent 573 0 R
/Prev 594 0 R
/Next 596 0 R
/C [0 0 0]
/Dest [279 0 R /XYZ 0 450.23 null]
/Count 0>>
endobj
596 0 obj
<</Title (Note 23. Quarterly Financial Data \(UNAUDITED\) - 10-K Only)
/Parent 573 0 R
/Prev 595 0 R
/C [0 0 0]
/Dest [281 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
597 0 obj
<</Title (Section 1)
/Parent 615 0 R
/Prev 558 0 R
/Next 598 0 R
/C [0 0 0]
/Dest [285 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
598 0 obj
<</Title (Section 1)
/Parent 615 0 R
/Prev 597 0 R
/Next 599 0 R
/C [0 0 0]
/Dest [311 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
599 0 obj
<</Title (Section 2)
/Parent 615 0 R
/Prev 598 0 R
/Next 600 0 R
/C [0 0 0]
/Dest [365 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
600 0 obj
<</Title (Section 3)
/Parent 615 0 R
/Prev 599 0 R
/Next 601 0 R
/C [0 0 0]
/Dest [367 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
601 0 obj
<</Title (Section 4)
/Parent 615 0 R
/Prev 600 0 R
/Next 602 0 R
/C [0 0 0]
/Dest [373 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
602 0 obj
<</Title (Section 1)
/Parent 615 0 R
/Prev 601 0 R
/Next 603 0 R
/C [0 0 0]
/Dest [375 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
603 0 obj
<</Title (Section 2)
/Parent 615 0 R
/Prev 602 0 R
/Next 604 0 R
/C [0 0 0]
/Dest [425 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
604 0 obj
<</Title (Section 3)
/Parent 615 0 R
/Prev 603 0 R
/Next 605 0 R
/C [0 0 0]
/Dest [427 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
605 0 obj
<</Title (Section 4)
/Parent 615 0 R
/Prev 604 0 R
/Next 606 0 R
/C [0 0 0]
/Dest [433 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
606 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 605 0 R
/Next 607 0 R
/C [0 0 0]
/Dest [435 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
607 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 606 0 R
/Next 608 0 R
/C [0 0 0]
/Dest [439 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
608 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 607 0 R
/Next 609 0 R
/C [0 0 0]
/Dest [447 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
609 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 608 0 R
/Next 610 0 R
/C [0 0 0]
/Dest [449 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
610 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 609 0 R
/Next 611 0 R
/C [0 0 0]
/Dest [451 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
611 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 610 0 R
/Next 612 0 R
/C [0 0 0]
/Dest [453 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
612 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 611 0 R
/Next 613 0 R
/C [0 0 0]
/Dest [455 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
613 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 612 0 R
/Next 614 0 R
/C [0 0 0]
/Dest [457 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
614 0 obj
<</Title (New Section)
/Parent 615 0 R
/Prev 613 0 R
/C [0 0 0]
/Dest [459 0 R /XYZ 0 792.00 null]
/Count 0>>
endobj
615 0 obj
<</Type /Outlines /First 512 0 R
/Last 614 0 R>>
endobj
616 0 obj
<<
/Producer (WebFilings)
/Title (ENDP-12.31.2019-10K)
/CreationDate (D:202004261121)
>>
endobj
617 0 obj
<<
/Type /Catalog
/Pages 1 0 R
/PageLayout /OneColumn
/ViewerPreferences << /HideToolbar false /HideMenubar false /HideWindowUI false /FitWindow false /CenterWindow false /DisplayDocTitle true >>
/Outlines 615 0 R
/PageMode /UseOutlines
/OCProperties <</OCGs [461 0 R 462 0 R] /D <</ON [461 0 R] /OFF [462 0 R] /AS [<</Event /Print /OCGs [461 0 R 462 0 R] /Category [/Print]>> <</Event /View /OCGs [461 0 R 462 0 R] /Category [/View]>>]>>>>
>>
endobj
xref
0 618
0000000000 65535 f 
0000000009 00000 n 
0003942060 00000 n 
0000001839 00000 n 
0000001957 00000 n 
0000017281 00000 n 
0000026756 00000 n 
0000047719 00000 n 
0000047980 00000 n 
0000055017 00000 n 
0000055279 00000 n 
0000069976 00000 n 
0000070239 00000 n 
0000083857 00000 n 
0000084120 00000 n 
0000106199 00000 n 
0000106462 00000 n 
0000123635 00000 n 
0000123898 00000 n 
0000140488 00000 n 
0000140751 00000 n 
0000155373 00000 n 
0000155636 00000 n 
0000170399 00000 n 
0000170662 00000 n 
0000186167 00000 n 
0000186430 00000 n 
0000201663 00000 n 
0000201926 00000 n 
0000220175 00000 n 
0000220438 00000 n 
0000237608 00000 n 
0000237871 00000 n 
0000252569 00000 n 
0000252832 00000 n 
0000266646 00000 n 
0000266909 00000 n 
0000281473 00000 n 
0000281736 00000 n 
0000298289 00000 n 
0000298552 00000 n 
0000315780 00000 n 
0000316043 00000 n 
0000330470 00000 n 
0000330733 00000 n 
0000349481 00000 n 
0000349744 00000 n 
0000366707 00000 n 
0000366970 00000 n 
0000380470 00000 n 
0000380733 00000 n 
0000393538 00000 n 
0000393801 00000 n 
0000407526 00000 n 
0000407789 00000 n 
0000422447 00000 n 
0000422710 00000 n 
0000438760 00000 n 
0000439023 00000 n 
0000455332 00000 n 
0000455595 00000 n 
0000470709 00000 n 
0000470972 00000 n 
0000485822 00000 n 
0000486085 00000 n 
0000498226 00000 n 
0000498489 00000 n 
0000509998 00000 n 
0000510261 00000 n 
0000525078 00000 n 
0000525341 00000 n 
0000540725 00000 n 
0000540988 00000 n 
0000555626 00000 n 
0000555889 00000 n 
0000567499 00000 n 
0000567762 00000 n 
0000584968 00000 n 
0000585231 00000 n 
0000600303 00000 n 
0000600566 00000 n 
0000615746 00000 n 
0000616009 00000 n 
0000629204 00000 n 
0000629467 00000 n 
0000643230 00000 n 
0000643493 00000 n 
0000658090 00000 n 
0000658353 00000 n 
0000675767 00000 n 
0000676030 00000 n 
0000691521 00000 n 
0000691784 00000 n 
0000704208 00000 n 
0000704471 00000 n 
0000722156 00000 n 
0000722419 00000 n 
0000738521 00000 n 
0000738784 00000 n 
0000753500 00000 n 
0000753764 00000 n 
0000765061 00000 n 
0000765326 00000 n 
0000775306 00000 n 
0000775571 00000 n 
0000788767 00000 n 
0000789032 00000 n 
0000800602 00000 n 
0000800867 00000 n 
0000830096 00000 n 
0000830361 00000 n 
0000849833 00000 n 
0000850098 00000 n 
0000860853 00000 n 
0000861118 00000 n 
0000882044 00000 n 
0000882309 00000 n 
0000894090 00000 n 
0000894355 00000 n 
0000908098 00000 n 
0000908363 00000 n 
0000922632 00000 n 
0000922897 00000 n 
0000936689 00000 n 
0000936954 00000 n 
0000955850 00000 n 
0000956115 00000 n 
0000975809 00000 n 
0000976074 00000 n 
0000996188 00000 n 
0000996453 00000 n 
0001015161 00000 n 
0001015426 00000 n 
0001030595 00000 n 
0001030860 00000 n 
0001055101 00000 n 
0001055366 00000 n 
0001074908 00000 n 
0001075173 00000 n 
0001092872 00000 n 
0001093137 00000 n 
0001116451 00000 n 
0001116716 00000 n 
0001145419 00000 n 
0001145684 00000 n 
0001161704 00000 n 
0001161969 00000 n 
0001175638 00000 n 
0001175903 00000 n 
0001190649 00000 n 
0001190914 00000 n 
0001211194 00000 n 
0001211459 00000 n 
0001234252 00000 n 
0001234517 00000 n 
0001258365 00000 n 
0001258630 00000 n 
0001265171 00000 n 
0001265436 00000 n 
0001267893 00000 n 
0001268158 00000 n 
0001274686 00000 n 
0001277149 00000 n 
0001282731 00000 n 
0001282996 00000 n 
0001289337 00000 n 
0001289602 00000 n 
0001301297 00000 n 
0001301562 00000 n 
0001317356 00000 n 
0001317621 00000 n 
0001330603 00000 n 
0001330868 00000 n 
0001336428 00000 n 
0001336693 00000 n 
0001357770 00000 n 
0001358035 00000 n 
0001382102 00000 n 
0001382367 00000 n 
0001396216 00000 n 
0001396481 00000 n 
0001463296 00000 n 
0001463561 00000 n 
0001500486 00000 n 
0001500751 00000 n 
0001517557 00000 n 
0001517822 00000 n 
0001532787 00000 n 
0001533052 00000 n 
0001549939 00000 n 
0001550204 00000 n 
0001564247 00000 n 
0001564512 00000 n 
0001577906 00000 n 
0001578171 00000 n 
0001591101 00000 n 
0001591366 00000 n 
0001605543 00000 n 
0001605808 00000 n 
0001622393 00000 n 
0001622658 00000 n 
0001642282 00000 n 
0001642547 00000 n 
0001659864 00000 n 
0001660129 00000 n 
0001678681 00000 n 
0001678946 00000 n 
0001698498 00000 n 
0001698763 00000 n 
0001728102 00000 n 
0001728367 00000 n 
0001754374 00000 n 
0001754639 00000 n 
0001771231 00000 n 
0001771496 00000 n 
0001792224 00000 n 
0001792489 00000 n 
0001822052 00000 n 
0001822317 00000 n 
0001838523 00000 n 
0001838788 00000 n 
0001854375 00000 n 
0001854640 00000 n 
0001866439 00000 n 
0001866704 00000 n 
0001899463 00000 n 
0001899728 00000 n 
0001917917 00000 n 
0001918182 00000 n 
0001951020 00000 n 
0001951285 00000 n 
0001968456 00000 n 
0001968721 00000 n 
0001984845 00000 n 
0001985110 00000 n 
0001999057 00000 n 
0001999322 00000 n 
0002015491 00000 n 
0002015756 00000 n 
0002042946 00000 n 
0002043211 00000 n 
0002060877 00000 n 
0002061142 00000 n 
0002079410 00000 n 
0002079675 00000 n 
0002098430 00000 n 
0002098695 00000 n 
0002114081 00000 n 
0002114346 00000 n 
0002133411 00000 n 
0002133676 00000 n 
0002151032 00000 n 
0002151297 00000 n 
0002165543 00000 n 
0002165808 00000 n 
0002183084 00000 n 
0002183349 00000 n 
0002200154 00000 n 
0002200419 00000 n 
0002216322 00000 n 
0002216587 00000 n 
0002236479 00000 n 
0002236744 00000 n 
0002251262 00000 n 
0002251527 00000 n 
0002268073 00000 n 
0002268338 00000 n 
0002289958 00000 n 
0002290223 00000 n 
0002308205 00000 n 
0002308470 00000 n 
0002327038 00000 n 
0002327303 00000 n 
0002349442 00000 n 
0002349707 00000 n 
0002368516 00000 n 
0002368781 00000 n 
0002376255 00000 n 
0002376520 00000 n 
0002393653 00000 n 
0002393918 00000 n 
0002408282 00000 n 
0002408547 00000 n 
0002448867 00000 n 
0002449132 00000 n 
0002455257 00000 n 
0002455379 00000 n 
0002462732 00000 n 
0002462854 00000 n 
0002469856 00000 n 
0002469978 00000 n 
0002476611 00000 n 
0002476733 00000 n 
0002483974 00000 n 
0002484096 00000 n 
0002491193 00000 n 
0002491315 00000 n 
0002498028 00000 n 
0002498150 00000 n 
0002505020 00000 n 
0002505142 00000 n 
0002511124 00000 n 
0002511246 00000 n 
0002519469 00000 n 
0002519591 00000 n 
0002527292 00000 n 
0002527414 00000 n 
0002534810 00000 n 
0002534932 00000 n 
0002542316 00000 n 
0002542438 00000 n 
0002548712 00000 n 
0002548834 00000 n 
0002557024 00000 n 
0002557146 00000 n 
0002565741 00000 n 
0002565863 00000 n 
0002573876 00000 n 
0002573998 00000 n 
0002581408 00000 n 
0002581530 00000 n 
0002590287 00000 n 
0002590409 00000 n 
0002598234 00000 n 
0002598356 00000 n 
0002605577 00000 n 
0002605699 00000 n 
0002613129 00000 n 
0002613251 00000 n 
0002620025 00000 n 
0002620147 00000 n 
0002627462 00000 n 
0002627584 00000 n 
0002634318 00000 n 
0002634440 00000 n 
0002641959 00000 n 
0002642081 00000 n 
0002649627 00000 n 
0002649749 00000 n 
0002656892 00000 n 
0002657014 00000 n 
0002664511 00000 n 
0002664633 00000 n 
0002670895 00000 n 
0002671017 00000 n 
0002678054 00000 n 
0002678176 00000 n 
0002685325 00000 n 
0002685447 00000 n 
0002692897 00000 n 
0002693019 00000 n 
0002700882 00000 n 
0002701004 00000 n 
0002708332 00000 n 
0002708454 00000 n 
0002716247 00000 n 
0002716369 00000 n 
0002723212 00000 n 
0002723334 00000 n 
0002732241 00000 n 
0002732363 00000 n 
0002740674 00000 n 
0002740796 00000 n 
0002748618 00000 n 
0002748740 00000 n 
0002754544 00000 n 
0002754666 00000 n 
0002756974 00000 n 
0002757096 00000 n 
0002767116 00000 n 
0002767238 00000 n 
0002775100 00000 n 
0002775222 00000 n 
0002781487 00000 n 
0002781609 00000 n 
0002784714 00000 n 
0002784836 00000 n 
0002792782 00000 n 
0002792904 00000 n 
0002801077 00000 n 
0002801199 00000 n 
0002808764 00000 n 
0002808886 00000 n 
0002816062 00000 n 
0002816184 00000 n 
0002824611 00000 n 
0002824733 00000 n 
0002832849 00000 n 
0002832971 00000 n 
0002840822 00000 n 
0002840944 00000 n 
0002847639 00000 n 
0002847761 00000 n 
0002854496 00000 n 
0002854618 00000 n 
0002862568 00000 n 
0002862690 00000 n 
0002870278 00000 n 
0002870400 00000 n 
0002877585 00000 n 
0002877707 00000 n 
0002884805 00000 n 
0002884927 00000 n 
0002891423 00000 n 
0002891545 00000 n 
0002897429 00000 n 
0002897551 00000 n 
0002905470 00000 n 
0002905592 00000 n 
0002912379 00000 n 
0002912501 00000 n 
0002921089 00000 n 
0002921211 00000 n 
0002928588 00000 n 
0002928710 00000 n 
0002936426 00000 n 
0002936548 00000 n 
0002943594 00000 n 
0002943716 00000 n 
0002952165 00000 n 
0002952287 00000 n 
0002960774 00000 n 
0002960896 00000 n 
0002969012 00000 n 
0002969134 00000 n 
0002974126 00000 n 
0002974248 00000 n 
0002976676 00000 n 
0002976798 00000 n 
0002986713 00000 n 
0002986835 00000 n 
0002994446 00000 n 
0002994568 00000 n 
0002999975 00000 n 
0003000097 00000 n 
0003003260 00000 n 
0003003382 00000 n 
0003036947 00000 n 
0003037069 00000 n 
0003054521 00000 n 
0003054643 00000 n 
0003062769 00000 n 
0003062891 00000 n 
0003071490 00000 n 
0003071612 00000 n 
0003080441 00000 n 
0003080563 00000 n 
0003083985 00000 n 
0003084107 00000 n 
0003095732 00000 n 
0003095854 00000 n 
0003097427 00000 n 
0003097549 00000 n 
0003102930 00000 n 
0003103052 00000 n 
0003111839 00000 n 
0003111961 00000 n 
0003120589 00000 n 
0003120711 00000 n 
0003125927 00000 n 
0003126049 00000 n 
0003130999 00000 n 
0003131109 00000 n 
0003131218 00000 n 
0003131297 00000 n 
0003255936 00000 n 
0003256114 00000 n 
0003257039 00000 n 
0003257290 00000 n 
0003257393 00000 n 
0003397851 00000 n 
0003398024 00000 n 
0003398944 00000 n 
0003399193 00000 n 
0003515100 00000 n 
0003515284 00000 n 
0003516205 00000 n 
0003516464 00000 n 
0003641406 00000 n 
0003641586 00000 n 
0003642504 00000 n 
0003642761 00000 n 
0003642861 00000 n 
0003739746 00000 n 
0003739918 00000 n 
0003740841 00000 n 
0003741089 00000 n 
0003742834 00000 n 
0003874606 00000 n 
0003875963 00000 n 
0003877708 00000 n 
0003879453 00000 n 
0003880810 00000 n 
0003888752 00000 n 
0003890109 00000 n 
0003891854 00000 n 
0003893599 00000 n 
0003894956 00000 n 
0003896313 00000 n 
0003897670 00000 n 
0003905612 00000 n 
0003906524 00000 n 
0003907460 00000 n 
0003915402 00000 n 
0003917098 00000 n 
0003925040 00000 n 
0003926785 00000 n 
0003928142 00000 n 
0003929499 00000 n 
0003930856 00000 n 
0003932213 00000 n 
0003934118 00000 n 
0003942670 00000 n 
0003942800 00000 n 
0003942951 00000 n 
0003943105 00000 n 
0003943281 00000 n 
0003943452 00000 n 
0003943586 00000 n 
0003943739 00000 n 
0003943905 00000 n 
0003944063 00000 n 
0003944231 00000 n 
0003944387 00000 n 
0003944539 00000 n 
0003944691 00000 n 
0003944886 00000 n 
0003945050 00000 n 
0003945209 00000 n 
0003945401 00000 n 
0003945563 00000 n 
0003945713 00000 n 
0003945894 00000 n 
0003946042 00000 n 
0003946204 00000 n 
0003946379 00000 n 
0003946539 00000 n 
0003946706 00000 n 
0003946865 00000 n 
0003947043 00000 n 
0003947287 00000 n 
0003947460 00000 n 
0003947724 00000 n 
0003947869 00000 n 
0003948040 00000 n 
0003948226 00000 n 
0003948407 00000 n 
0003948554 00000 n 
0003948763 00000 n 
0003948956 00000 n 
0003949191 00000 n 
0003949365 00000 n 
0003949519 00000 n 
0003949698 00000 n 
0003949889 00000 n 
0003950062 00000 n 
0003950307 00000 n 
0003950531 00000 n 
0003950706 00000 n 
0003950884 00000 n 
0003951089 00000 n 
0003951264 00000 n 
0003951401 00000 n 
0003951569 00000 n 
0003951709 00000 n 
0003951865 00000 n 
0003952040 00000 n 
0003952246 00000 n 
0003952399 00000 n 
0003952581 00000 n 
0003952773 00000 n 
0003952975 00000 n 
0003953177 00000 n 
0003953369 00000 n 
0003953556 00000 n 
0003953715 00000 n 
0003953907 00000 n 
0003954085 00000 n 
0003954236 00000 n 
0003954389 00000 n 
0003954550 00000 n 
0003954699 00000 n 
0003954843 00000 n 
0003955022 00000 n 
0003955191 00000 n 
0003955366 00000 n 
0003955536 00000 n 
0003955710 00000 n 
0003955853 00000 n 
0003956021 00000 n 
0003956186 00000 n 
0003956357 00000 n 
0003956532 00000 n 
0003956700 00000 n 
0003956863 00000 n 
0003957031 00000 n 
0003957241 00000 n 
0003957416 00000 n 
0003957555 00000 n 
0003957694 00000 n 
0003957833 00000 n 
0003957972 00000 n 
0003958111 00000 n 
0003958250 00000 n 
0003958389 00000 n 
0003958528 00000 n 
0003958667 00000 n 
0003958808 00000 n 
0003958949 00000 n 
0003959090 00000 n 
0003959231 00000 n 
0003959372 00000 n 
0003959513 00000 n 
0003959654 00000 n 
0003959795 00000 n 
0003959922 00000 n 
0003959988 00000 n 
0003960094 00000 n 
trailer
<<
/Size 618
/Root 617 0 R
/Info 616 0 R
>>
startxref
3960555
%%EOF